PN 	 TI 	 AU 	 AE 	 GA 	 AB 	 TF 	 EA 	 DC 	 MC 	 IP 	 PD 	 AD 	 FD 	 PI 	 DS 	 FS 	 CP 	 CR 	 DN 	 MN 	 RI 	 CI 	 RG
WO2019093347-A1;  JP2019552824-X;  JP7227615-B2	New mutant polymerase basic protein 1 of influenza            virus RNA polymerase used for screening mutant            influenza viruses, used in epidemic strain prediction            system for predicting antigenic mutation site,            comprises specific amino acid sequence	NAITO T;  SAITO M	KAWASAKI GAKUEN EDUCATIONAL FOUND (KAWA-Non-standard);  KAWASAKI GAKUEN EDUCATIONAL FOUND (KAWA-Non-standard)	201943545A	   NOVELTY - A mutant polymerase basic protein 1 (PB1) of                influenza virus RNA polymerase, comprising an amino                acid sequence of SEQ ID NO: 2, is new. Sequences                not defined here may be found at                ftp://ftp.wipo.int/pub/published_pct_sequences/publication.    USE - The mutant PB1 is useful for screening mutant                influenza viruses (claimed), which is used in                epidemic strain prediction system for predicting                antigenic mutation site occurring in pandemic                strain.    ADVANTAGE - The mutant PB1 predicts antigenic mutation                site in advance in an accurate manner with high                sensitivity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) RNA comprising a nucleotide sequence                complementary to the nucleotide sequence encoding                the mutant PB1;    (2) mutant influenza virus comprising a                genomic RNA comprising the RNA;    (3) mutant influenza virus library obtained by                propagating the mutant influenza virus; and    (4) method for screening mutant influenza                viruses prevalent in future involves contacting the                neutralizing antibody against a pandemic strain                with the mutant influenza virus library and                selecting mutant influenza virus in which the                infectivity is not neutralized. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-C01D;  B04-C01G;  B04-E02E;  B04-E99;  B04-F11B;  B04-G08;  B04-L04A;  B11-C07A;  B11-C10;  B12-K04G1B;  D05-H06A;  D05-H12B;  D05-H19B;  D05-H99	C12N-015/54;  C12N-007/01;  C12N-009/12;  C12Q-001/04;  C12N-015/34;  C12N-015/56;  C12N-007/06;  C12Q-001/6869;  C12Q-001/70;  C40B-040/02;  C07K-014/11;  C07K-016/10;  C12N-015/44	WO2019093347-A1   16 May 2019   C12N-015/54   201943Pages: 40   Japanese;  JP2019552824-X   07 Jan 2021   C12N-015/54   202104Pages: 24   Japanese;  JP7227615-B2   22 Feb 2023   C12N-015/44   202318   Japanese	WO2019093347-A1    WOJP041262    07 Nov 2018;   JP2019552824-X    JP552824    07 Nov 2018;   JP7227615-B2    JP552824    07 Nov 2018	JP2019552824-X PCT application Application WOJP041262;   JP2019552824-X Based on Patent WO2019093347;   JP7227615-B2 PCT application Application WOJP041262;   JP7227615-B2 Based on Patent WO2019093347	JP214983    07 Nov 2017	WO2019093347-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      		WO2019093347-A1 -- WO2017011620-A2   UNIV ROCHESTER (UYRP);  COX A (COXA-Individual);  DEWHURST S (DEWH-Individual)   COX A,  DEWHURST S	WO2019093347-A1  LI, C. ET AL.:          "Selection of antigenically advanced variants of seasonal          influenza viruses", NATURE MICROBIOLOGY, vol. 1, no. 6,          23 May 2016 (2016-05-23), pages 16058,          XP055608045,relevantClaims[1-10];  YANG, X. ET AL.:          "Motif D of viral RNA-dependent RNA polymerases          determines efficiency and fidelity of nucleotide          addition", STRUCTURE, vol. 20, 2012, pages 1519 - 1527,          XP028936091, DOI:          doi:10.1016/j.str.2012.06.012,relevantClaims[1-10];  LIU, X.ET AL.:          "Vaccine-derived mutation in motif D of poliovirus          RNA-dependent RNA polymerase lowers nucleotide          incorporation fidelity", J. BIOL. CHEM., vol. 288, no.          45, 30 September 2013 (2013-09-30) - 8 November 2013          (2013-11-08), pages 32753 - 32765, XP055608046, ISSN:          0021-9258, DOI:          10.1074/jbc.M113.484428,relevantClaims[1-10];  NAITO, T. ET AL.:          "Generation of a genetically stable high-fidelity          influenza vaccine strain", JOURNAL OF VIROLOGY, vol. 91,          no. 6, 4 January 2017 (2017-01-04) - 28 February 2017          (2017-02-28), pages e01073-16, XP055608050, ISSN:          0022-538X, DOI:          10.1128/JVI.01073-16,relevantClaims[1-10];  CHEUNG, P. P. H. ET          AL.: "Generation and characterization of influenza A          viruses with altered polymerase fidelity", NAT. COMMUN.,          vol. 5, 2014, pages 4794, XP055308637, DOI:          doi:10.1038/ncomms5794,relevantClaims[1-10]	2356802-0-0-0 A K; 2356802-0-0-0 CL DET			RB8ZO7 A K		CN109796531-A;  CN109796531-B	New porcine delta coronavirus N protein monoclonal            antibody secreted by a hybridoma cell line useful for            preparing product for diagnosing porcine delta            coronavirus	TONG G;  ZHOU Y;  LI H;  ZHANG W;  CHEN P;  LI X;  YU L;  JIANG Y;  GAO F;  LI L	SHANGHAI VETERINARY INST CHINESE ACAD AG (CAGS-C);  SHANGHAI VETERINARY INST CHINESE ACAD (CAGS-C)	201947431S	   NOVELTY - Porcine delta coronavirus N protein monoclonal                antibody secreted by a hybridoma cell line (CCTCC                NO: C2017257) is new.    USE - The monoclonal antibody is useful for                preparing product for diagnosing porcine delta                coronavirus (claimed).    ADVANTAGE - The monoclonal antibody has high                sensitivity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) hybridoma cell line secreting monoclonal                antibody against porcine delta coronavirus N                protein;    (2) kit for detecting porcine Delta                coronavirus comprising monoclonal antibody;    (3) bispecific antibody comprising antibody or                an antigen binding portion, and second antibody or                antigen binding portion;    (4) composition comprising monoclonal antibody                or antigen-binding portion and vector or                diluents;    (5) use of monoclonal antibody in preparing                product for diagnosing porcine delta coronavirus;                and    (6) porcine Delta coronavirus N protein                epitope. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-E08;  B04-E99;  B04-F05;  B04-F11B;  B04-G01;  B04-G21;  B04-G22;  B04-G23;  B04-G24;  B11-C07A;  B12-K04G1B;  C04-E08;  C04-E99;  C04-F05;  C04-F11B;  C04-G01;  C04-G21;  C04-G22;  C04-G23;  C04-G24;  C11-C07A;  C12-K04G1B;  D05-H06A;  D05-H09;  D05-H11A1;  D05-H15A;  D05-H99;  S03-E09F;  S03-E14H5	C07K-014/165;  C07K-016/10;  C12N-005/20;  C12R-001/91;  G01N-033/569;  G01N-033/577	CN109796531-A   24 May 2019   C07K-016/10   201955Pages: 19   Chinese;  CN109796531-B   11 Mar 2022   C07K-016/10   202228   Chinese	CN109796531-A    CN11127879    15 Nov 2017;   CN109796531-B    CN11127879    15 Nov 2017	CN109796531-B Previous Publ. Patent CN109796531	CN11127879    15 Nov 2017			CN109796531-A -- CN104744572-A   UNIV NORTHWEST A & F (UNAF)   LI S,  WANG X,  ZHAO Q,  ZHOU E,  SUN Y;  CN105440132-A   SHANGHAI VETERINARY INST CHINESE ACAD AG (CAGS)   SHAN T,  KONG N,  LI G,  TONG G,  TONG W,  ZHENG H,  YANG S,  PAN X;  CN106518989-A   JIANGSU AGRIC SCI INST (JSAS)   LI B,  PANG F,  HE K,  GUO R,  FAN B,  YU Z,  MAO A,  WEN L,  NI Y,  YUAN W,  WANG J;  WO2016007576-A2   ZOETIS SERVICES LLC (ZOET)   BALASCH S M,  CABANA S M,  DOMINOWSKI P J,  HARDHAM J M,  MARX J G,  PLAJA D L,  RAPP GABRIELSON V J,  ROMERO G O,  URNIZA H A;  CN109796531-B -- CN104744572-A   UNIV NORTHWEST A & F (UNAF)   LI S,  WANG X,  ZHAO Q,  ZHOU E,  SUN Y;  CN105440132-A   SHANGHAI VETERINARY INST CHINESE ACAD AG (CAGS)   SHAN T,  KONG N,  LI G,  TONG G,  TONG W,  ZHENG H,  YANG S,  PAN X;  CN106518989-A   JIANGSU AGRIC SCI INST (JSAS)   LI B,  PANG F,  HE K,  GUO R,  FAN B,  YU Z,  MAO A,  WEN L,  NI Y,  YUAN W,  WANG J;  WO2016007576-A2   ZOETIS SERVICES LLC (ZOET)   BALASCH S M,  CABANA S M,  DOMINOWSKI P J,  HARDHAM J M,  MARX J G,  PLAJA D L,  RAPP GABRIELSON V J,  ROMERO G O,  URNIZA H A	CN109796531-A  HUI HU :          "Experimental infection of gnotobiotic pigs with the          cell-culture-adapted porcine deltacoronavirus strain          OH-FD22", ARCH          VIROL,relevantClaims[1-10],relevantPassages[3421-3434];  : "-N",          2017,relevantClaims[10],relevantPassages[357]CN109796531-B  Hu          et al. The invention claims a method for preparing the          cell-cell-culture-cell-cell-cell-cell-cell-cell-cell-cell-cell-cell-cell-cell-cell-cell-cell-cell-cell-cell-cell          OH-FD22; Hui Hu et al., "Arch Virol"; 20160912; 161 (Day          12); pages 3421-3434;;  Li          Huichun and so on. preparation of porcine -coronavirus N          protein monoclonal antibody and antigen epitope          identification, Li Hui-chun and so on, China Animal          Husbandry Veterinary Society 2017 year academic annual          session set, 20171102, 357 page						KR2018201-B1	Kit useful for detecting bat-derived coronaviruses using real-time PCR, comprises combination of primers and probes including pair of forward and reverse primers, and probe having specific base pair sequence	KIM Y K;  JHEONG W H;  HYESUNG J;  SON K;  KIM J;  MEONG K W;  WOO C J;  WANG S J;  PARKJUNGYEUN;  HONGYUNJI	KOREA PUBLIC (KOPU-Non-standard)	201980815D	   NOVELTY - Bat-derived coronavirus detection kit contains (a) a first combination of primers and probes including (i) pair of a forward primer having SEQ ID NO: 1 and reverse primer having SEQ ID NO: 2, and (ii) a probe having SEQ ID NO: 3, (b) a second combination of primers and probes including (i) pair of forward primer having SEQ ID NO: 4 and reverse primer having SEQ ID NO: 5, and (ii) a probe having SEQ ID NO: 7, (c) a third combination of primers and probes including (i) pair forward primer having SEQ ID NO: 5 and reverse primer having SEQ ID NO: 6, and (ii) a probe having SEQ ID NO: 7, (d) a fourth combination of primers and probes including (i) pair of a forward primer having SEQ ID NO: 8 and reverse primer having SEQ ID NO: 9, and (ii) a probe having SEQ ID NO: 10, and (e) fifth combination of primers and probes including (i) pair of a forward primer having SEQ ID NO: 11 and reverse primer having SEQ ID NO: 12, and (ii) a probe having SEQ ID NO: 13.    USE - The kit is useful for detecting bat-derived coronaviruses as mentioned above using real-time PCR (claimed).    ADVANTAGE - The kit enables simultaneous, early and accurate detection of 27 bat-derived coronaviruses in a cost-effective manner.    DETAILED DESCRIPTION - Bat-derived coronavirus detection kit contains (a) a first combination of primers and probes including (i) pair of a forward primer having SEQ ID NO: 1 and reverse primer having SEQ ID NO: 2, and (ii) a probe having SEQ ID NO: 3, where the first combination of primers and probes is capable of detecting bat severe acute respiratory syndrome (SARS)-like coronavirus RsSHC014, bat coronavirus 273/2005, bat coronavirus JTMC15, bat SARS coronavirus Rf1/2004, bat coronavirus Rp/Shaanxi2011, bat SARS coronavirus Rp3/2004, bat SARS coronavirus HKU3-1, bat SARS-like coronavirus Jiyuan-331, SARS coronavirus ExoN1, SARS coronavirus MA15, SARS coronavirus Sino1-11, SARS-associated coronavirus Tor2/FP1-10895 and SARS coronavirus urbani, (b) a second combination of primers and probes including (i) pair of forward primer having SEQ ID NO: 4 and reverse primer having SEQ ID NO: 5, and (ii) a probe having SEQ ID NO: 7, where the second combination of primers and probes is capable of detecting bat coronavirus A613/2005, bat coronavirus A620/2005, bat coronavirus A701/2005, bat Coronavirus A897/2005 and bat coronavirus HKU6-1, (c) a third combination of primers and probes including (i) pair forward primer having SEQ ID NO: 5 and reverse primer having SEQ ID NO: 6, and (ii) a probe having SEQ ID NO: 7, where third combination of primers and probes is capable of detecting bat coronavirus A632/2005 and bat coronavirus A633/2005, (d) a fourth combination of primers and probes including (i) pair of a forward primer having SEQ ID NO: 8 and reverse primer having SEQ ID NO: 9, and (ii) a probe having SEQ ID NO: 10, where fourth combination of primers and probes is capable of detecting bet coronavirus SC2013 and bat coronavirus 16BO133, (e) fifth combination of primers and probes including (i) pair of a forward primer having SEQ ID NO: 11 and reverse primer having SEQ ID NO: 12, and (ii) a probe having SEQ ID NO: 13, where fifth combination of primers and probes is capable of detecting bat human coronavirus EMC (HCoV-EMC), (f) sixth combination of primers and probes including (i) pair of a forward primer having SEQ ID NO: 14 and reverse primer having SEQ ID NO: 16, and (ii) a probe having SEQ ID NO: 17, where sixth combination of primers and probes is capable of detecting bat coronavirus B15-40, bat coronavirus B15-41 and bat coronavirus 1A AFCD62, and (g) seventh combination of primers and probes including (i) pair of a forward primer having SEQ ID NO: 15 and reverse primer having SEQ ID NO: 16, and (ii) a probe having SEQ ID NO: 17, where seventh combination of primers and probes is capable of detecting bat coronavirus 1B AFCD307. cca/taaa/gtgtgacagagcca (SEQ ID NO: 1), cta/gtagaaacggtgtga (SEQ ID NO: 2), tcttgctcgcaaacata (SEQ ID NO: 3), cctaagtgtgacagagcat (SEQ ID NO: 4), cctaagtgtgataga/ggcat (SEQ ID NO: 5), gtgaca/gtgcttagaaccca (SEQ ID NO: 6), cctaatatgattagaatga (SEQ ID NO: 7), cctaagtgtgatcgtgcta (SEQ ID NO: 8), catgtttgcgtgccaaa (SEQ ID NO: 9) and tgcctaacatgtgtaggat (SEQ ID NO: 10). INDEPENDENT CLAIMS are included for the following:    (1) a method of detecting bat-derived coronaviruses using real-time PCR, involves (a) preparing a genetic sample, (b) amplifying the genetic sample by real-time PCR using the kit, and (c) detecting bat-derived coronavirus based on real-time PCR results; and    (2) a primer set comprising (a) pair of forward primer having SEQ ID NO: 1 and reverse primer having SEQ ID NO: 2, (b) pair of forward primer having SEQ ID NO: 4 and reverse primer having SEQ ID NO: 5, (c) pair of forward primer having SEQ ID NO: 5 and reverse primer having SEQ ID NO: 6, (d) pair of forward primer having SEQ ID NO: 8 and reverse primer having SEQ ID NO: 9, (e) pair of forward primer having SEQ ID NO: 11 and reverse primer having SEQ ID NO: 13, (f) pair of forward primer having SEQ ID NO: 14 and reverse primer having SEQ ID NO: 17, and (g) pair of forward primer having SEQ ID NO: 15 and reverse primer having SEQ ID NO: 16. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03B;  B04-E01B;  B04-E05;  B04-E99;  B04-F11B;  B04-L04A;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  D05-A02B;  D05-H06A;  D05-H18B;  D05-H99	C12Q-001/6851;  C12Q-001/70	KR2018201-B1   06 Sep 2019   C12Q-001/70   201973Pages: 27   	KR2018201-B1    KR051099    01 May 2019		KR051099    01 May 2019										KR2019092776-A;  KR2234745-B1	Inhibitor for spatula MERS coronavirus helicase            nsP13 activity, used in pharmaceutical composition for            preventing or treating viral diseases, comprises            icariin, 1-isomangostin, isovanillyl catalpol,            friedelin and 24-methyllanosta-9 (11)	JUNG Y J;  PYO S	UNIV KOOKMIN IND ACAD COOP FOUND (UYKO-C)	201970428H	   NOVELTY - Inhibitor comprises icariin, 1-isomangostin,                isovanillyl catalpol, friedelin, 24-methyllanosta-9                (11), 25-dien-3-one, imperatorin, ledebouriellol,                methoxyeugenol, cinnamomum, taraxerol,                sec-O-glucosylhamaudol, 4'-O- beta                -D-glucosyl-5-O-methylbisamiminol,                prim-O-glucosylcimifugin, galangin, amentoflavone,                24-methyl-5 alpha -lanosta-9 (11), 25-diene-3 alpha                -one, ursolic acid, oleanolic acid, steigmasterol,                beta -cytosterol, gypenoside XVII,                5-O-methylvisamminol, gallic acid, gamma                -mangostin, spatulenol or mariolide or their                salts.    USE - Inhibitor for spatula MERS coronavirus                helicase nsP13 activity, used to inhibits                double-stranded ribonucleic acid (dsRNA) unwinding                activity or adenosine triphosphate (ATP) hydrolytic                activity of middle east respiratory syndrome (MERS)                coronavirus helicase nsP13, used in pharmaceutical                composition for preventing or treating viral                diseases, in food composition for preventing or                ameliorating viral diseases, in an antiviral agent                an in virus growth inhibitor (all claimed).    ADVANTAGE - The inhibitor relates to a MERS coronavirus                helicase nsP13 activity inhibitor comprising a                naturally derived compound. The inhibitors can be                used to effectively and safely prevent and treat                viral diseases by efficiently inhibiting at least                one selected from the dsRNA unwinding activity and                ATP hydrolytic activity of MERS coronavirus                helicase nsP13. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)	B04-E99;  B01-D02;  B06-A01;  B06-A03;  B09-C01;  B09-D02;  B10-E02;  B14-A02;  B14-E11;  B14-L06;  B14-S18;  D05-H99;  D03-H01T2B;  D03-P	A23L-033/10;  A61K-031/19;  A61K-031/34;  A61K-031/352;  A61K-031/56;  A61K-031/7048;  A61P-031/12	KR2019092776-A   08 Aug 2019   A61K-031/352   201967Pages: 20   ;  KR2234745-B1   01 Apr 2021   A61K-031/352   202131   	KR2019092776-A    KR011915    31 Jan 2018;   KR2234745-B1    KR011915    31 Jan 2018		KR011915    31 Jan 2018					97523-1-0-0 K M; 95641-1-0-0 K M; 97742-0-0-0 K M; 705237-0-0-0 K M; 1890022-2-0-0 K M; 155037-1-0-0 K M; 95827-0-0-0 K M; 109956-1-0-0 K M;  K M; 1958539-0-0-0 K M; 135565-0-0-0 K M;  K M; 107488-1-0-0 K M; 3171091-1-0-0 K M; 615899-1-0-0 K M; 367876-1-0-0 K M;  K M; 2770191-1-0-0 K M; 1890022-2-0-0 CL USE; 1958539-0-0-0 CL USE; 3171091-1-0-0 CL USE; 2770191-1-0-0 CL USE		06384; 02987; 05186; 08220; 03544	RA0QF9 K M; RA4FXU K M; RA99C5 K M; RAAA6O K M; RBZFNH K M; R17281 K M; R08508 K M; R18626 K M; RCN0TO K M; RB0L6I K M; RA2PQV K M; RCN0TP K M; RA2VEY K M; RBQN2V K M; RA8LWH K M; RBEMJI K M; RCN0TN K M; RBIO55 K M		KR2019119391-A;  KR2047072-B1	New expression vector useful in useful in vaccine, medicinal composition and diagnostic kit for preventing and treating middle East respiratory syndrome coronavirus infection, disease i.e. respiratory disease by producing antibody	GWIN J D;  KWON K H;  YUN S W;  DUJIN K;  HYOUNG K Z;  PARK S;  SONG D S	KOREA RES INST BIOSCIENCE & BIOTECHNOLOG (KRIB-C)	201990915A	   NOVELTY - Expression vector loaded with polynucleotide encoding full-length protein or fragment of MERS (middle East respiratory syndrome) coronavirus nucleoprotein, is new.    USE - The expression vector is useful in vaccine, medicinal composition and diagnostic kit for preventing and treating MERS coronavirus infection, disease i.e. respiratory disease by producing antibody which specifically binds to MERS coronavirus (all claimed).    ADVANTAGE - The expression vector can be mass-produced in Escherichia coli, and provides protective ability against MERS-CoV when inoculated with antigen in animal model.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:    (1) vaccine composition comprising the above expression vector;    (2) producing an antibody which specifically binds to MERS coronavirus, comprising (a) introducing the expression vector into an subject as an antigen, and (b) recovering the antibody from the subject; and    (3) medicinal composition comprising the above antibody. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-E08;  B04-E99;  B04-G0800E;  B11-C07A;  B12-K04G2G;  B14-A02B5;  B14-K01;  B14-S11A;  B14-S11D3;  D05-H09;  D05-H12E;  D05-H17A1;  D05-H99;  S03-E09F	A61K-039/215;  A61P-031/12;  C07K-014/005;  C07K-016/10;  C12N-015/63;  G01N-033/569	KR2019119391-A   22 Oct 2019   C12N-015/63   201987Pages: 12   ;  KR2047072-B1   20 Nov 2019   C12N-015/63   201996   	KR2019119391-A    KR042778    12 Apr 2018;   KR2047072-B1    KR042778    12 Apr 2018	KR2047072-B1 Previous Publ. Patent KR2019119391	KR042778    12 Apr 2018										CN110314228-A;  CN110314228-B	Binary inactivated vaccine useful for preventing            and treating pig epidemic diarrhea and porcine delta            coronavirus disease, comprises porcine epidemic            diarrhea and porcine delta coronavirus	DONG J;  CHEN R;  ZHANG L	SHAANXI NUOWEILIHUA BIOTECHNOLOGY CO LTD (SHAA-Non-standard);  SHAANXI NUOWEILIHUA BIOTECHNOLOGY CO LTD (SHAA-Non-standard)	201987678M	   NOVELTY - Binary inactivated vaccine comprises greater                than or equal to 107 Median Tissue Culture                Infectious Dose (TCID50)/ml porcine epidemic                diarrhea and greater than or equal to 107 TCID50/ml                porcine delta coronavirus prior inactivation.    USE - The binary inactivated vaccine is useful for                preventing and treating pig epidemic diarrhea and                porcine delta coronavirus disease.    ADVANTAGE - The inactivated vaccine is cost-effective and                provides a new method for domestic aquaculture                enterprises to simultaneously prevent the                occurrence of two diseases.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for method                for preparing the inactivated vaccine, which                involves (a) inoculating porcine epidemic diarrhea                virus at a dose of 0.2% in Vero cells with a dense                monolayer, adding maintenance solution containing                trypsin and culturing at 37 degrees C, (b)                inoculating porcine delta coronavirus at a dose of                0.2% in ST cells with a dense monolayer, adding                maintenance solution containing trypsin and                culturing at 37 degrees C, (c) when the cytopathic                effect is more than 80%, harvesting the virus                separately, repeatedly freezing and thawing 2 times                and storing at less than or equal to -20 degrees C,                (d) performing virus content and sterility test on                the harvested virus liquid, and selecting the virus                liquid with the virus content of more than greater                than or equal to 107 TCID 50/ml and sterilizing by                the sterilized test for inactivation, (e)                inactivating the two kinds of virus liquids using                binary ethyleneimine (BEI) respectively, performing                inactivation test and mixing virus liquids in a                volume ratio of 1:1 and (f) emulsifying the mixture                obtained in step (e) using Montanide ISA 206                adjuvant in a mass ratio of 1:1 to obtain binary                oil emulsion. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C02 (Heterocyclic.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-F11B;  B11-A01B;  B14-A02B5;  B14-E02;  B14-S11A;  B14-S11D1;  B14-S12;  B14-S18;  C04-E99;  C04-F11B;  C11-A01B;  C14-A02B5;  C14-E02;  C14-S11A;  C14-S11D1;  C14-S12;  C14-S18;  D05-H99;  D05-A02C;  D05-H07	A61K-039/215;  A61P-031/14	CN110314228-A   11 Oct 2019   A61K-039/215   201988Pages: 13   Chinese;  CN110314228-B   28 Oct 2022   A61K-039/215   202289   Chinese	CN110314228-A    CN10342197    07 Nov 2017;   CN110314228-B    CN10342197    07 Nov 2017	CN110314228-A Div ex Application CN11087386;   CN110314228-B Div ex Application CN11087386;   CN110314228-B Previous Publ. Patent CN110314228	CN10342197    07 Nov 2017;  CN11087386    07 Nov 2017			CN110314228-A -- CN106636011-A   CHINA INST VETERINARY DRUG CONTROL (CHVE-Non-standard);  SHAANXI NUOWEILIHUA BIOTECHNOLOGY CO LTD (SHAA-Non-standard)   CHEN R,  QI W,  SUN F,  XUE Q,  ZHANG L;  CN107050447-A   CHINA INST VETERINARY DRUG CONTROL (CHVE-Non-standard);  SHAANXI NUOWEILIHUA BIOTECHNOLOGY CO LTD (SHAA-Non-standard)   CHEN R,  QI W,  SUN F,  XUE Q,  ZHANG L;  CN111073863-A   WUHAN KEQIAN ANIMAL BIOLOGICAL PROD CO (UHZA)   XU G,  ZHOU M,  ZHANG H,  CHEN B,  HAO G,  JIN J;  TW201613558-A   ZOETIS SERVICES LLC (ZOET)   BALASCH S M,  CABANA S M,  DOMINOWSKI P J,  HARDHAM J M,  MARX J G,  PLAJA D L,  RAPP GABRIELSON V J,  ROMERO G O,  URNIZA H A;  US20170202951-A1   ;  CN110314228-B -- CN106636011-A   CHINA INST VETERINARY DRUG CONTROL (CHVE-Non-standard);  SHAANXI NUOWEILIHUA BIOTECHNOLOGY CO LTD (SHAA-Non-standard)   CHEN R,  QI W,  SUN F,  XUE Q,  ZHANG L;  CN107050447-A   CHINA INST VETERINARY DRUG CONTROL (CHVE-Non-standard);  SHAANXI NUOWEILIHUA BIOTECHNOLOGY CO LTD (SHAA-Non-standard)   CHEN R,  QI W,  SUN F,  XUE Q,  ZHANG L;  CN111073863-A   WUHAN KEQIAN ANIMAL BIOLOGICAL PROD CO (UHZA)   XU G,  ZHOU M,  ZHANG H,  CHEN B,  HAO G,  JIN J;  TW201613558-A   ZOETIS SERVICES LLC (ZOET)   BALASCH S M,  CABANA S M,  DOMINOWSKI P J,  HARDHAM J M,  MARX J G,  PLAJA D L,  RAPP GABRIELSON V J,  ROMERO G O,  URNIZA H A;  US20170202951-A1   	CN110314228-A  VOLKER GERDTS ET          AL.: "Vaccines for porcine epidemic diarrhea virus and          other swine coronaviruses", VETERINARY          MICROBIOLOGY,relevantClaims[1-4],relevantPassages[45-51];  : "PDCoV-PEDV", ()          ,relevantClaims[1-4],relevantPassages[A006-306]CN110314228-B            Volker Gerdts et al .. Vaccines for the disease virus and          other antibody coronaviruses; Volker Gerdts et al., "          Veterinary Microbiology, 20171231, 206, 45-51;            Hou linn. PDCoV-PEDV secondary inactivated vaccine for          primary development and immunogenicity research of the          mouse; Hou Lin, China excellent Bobo degree thesis          database (master +) basic scientific album, 20191215          (period 12) A006-306 the page	200757-0-0-0 K M P; 109563-0-0-0 K U V; 107370-0-0-0 K U V; 107860-1-0-0 K U V; 88707-2-0-0 K U V; 200757-0-0-0 CL PRD USE; 107370-0-0-0 CL RGT USE; 107860-1-0-0 CL RGT USE; 88707-2-0-0 CL RGT USE; 109563-0-0-0 CL RGT USE			RA00GT K M P; RA0426 K U V; RA01J8 K U V; R00149 K U V; R00222 K U V	0149-U; 0222-U	CN110079637-A;  CN110079637-B	Multiplex-reverse transcription (RT)-PCR detection            method for bovine rotavirus, coronavirus and viral            diarrhea virus, by collecting RNA of sample to be            detected as RNA template, performing RT-PCR            amplification, recording and judging results	SHI L;  LIU K;  MA D;  GUO S;  YIN J;  WANG Y;  ZHAO Z	UNIV INNER MONGOLIA NATIONALITY (UIMN-C);  UNIV INNER MONGOLIA NATIONALITY (UIMN-C)	201969206X	   NOVELTY - Multiplex-reverse transcription (RT)-PCR                detection method for bovine rotavirus, coronavirus                and viral diarrhea virus, involves collecting the                RNA of the sample to be detected as an RNA                template, where sample is bovine rotavirus having a                597 base pair sequence (SEQ ID NO: 1) fully defined                in the specification and bovine coronavirus having                a 624 base pair sequence (SEQ ID NO: 2) fully                defined in the specification, and bovine viral                diarrhea virus having a 504 base pair sequence (SEQ                ID NO: 3) fully defined in the specification                specific upstream primers and specific downstream                primers designed as primers for the genetic                characteristics of the three viruses, performing                RT-PCR amplification to obtain an amplification                product, then subjecting amplification product to                1.5% agarose gel electrophoresis and recording the                results, judging whether the sample to be tested                contains bovine rotavirus, coronavirus, bovine                viral diarrhea virus according to the results of                electrophoresis detection.    USE - The multiplex-RT-PCR detection method is                useful for bovine rotavirus, coronavirus and viral                diarrhea virus.    ADVANTAGE - The multiplex-RT-PCR detection method ensures                accurate, rapid and efficient identification and                diagnosis of three viral diseases. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01B;  B04-E05;  B04-E99;  B04-F11B;  B11-C08D1;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  C04-E01B;  C04-E05;  C04-E99;  C04-F11B;  C11-C08D1;  C11-C08E3;  C11-C08F8;  C12-K04F;  C12-K04G1B;  D05-H06A;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/686;  C12Q-001/70	CN110079637-A   02 Aug 2019   C12Q-001/70   201970Pages: 14   Chinese;  CN110079637-B   20 Jun 2023   C12Q-001/70   202355   Chinese	CN110079637-A    CN10517811    14 Jun 2019;   CN110079637-B    CN10517811    14 Jun 2019	CN110079637-B Previous Publ. Patent CN110079637	CN10517811    14 Jun 2019			CN110079637-A -- CN101063176-A   SHANDONG OX BIOTECHNOLOGY CO LTD (SHAN-Non-standard)   YANG S,  WANG C,  GAO Y,  YANG H;  CN103397107-A   NAT CONTROLINST VETERINARY BIOPRODUCTS P (NACO-Non-standard)   XU L,  WANG Q,  ZHAO Q,  CHEN K,  ZHU Y,  ZOU X,  FAN X;  KR2010058222-A   DAEHANMINGUK GWANRIBUSEO NONGRIMSUSANSIKPUMBU                  GUKRIPSUUIGWAH (DAEH-Non-standard);  REPUBLIC KOREA MANAGEMENT MIN AGRIC &                  FI (REPU-Non-standard)   KIM I,  HYEON B,  YOON S,  LEE H,  YU J,  JEON S,  GANG S,  PYO H,  CHO S,  CHA S,  CHO I;  CN110079637-B -- CN101063176-A   SHANDONG OX BIOTECHNOLOGY CO LTD (SHAN-Non-standard)   YANG S,  WANG C,  GAO Y,  YANG H;  CN103397107-A   NAT CONTROLINST VETERINARY BIOPRODUCTS P (NACO-Non-standard)   XU L,  WANG Q,  ZHAO Q,  CHEN K,  ZHU Y,  ZOU X,  FAN X;  KR2010058222-A   DAEHANMINGUK GWANRIBUSEO NONGRIMSUSANSIKPUMBU                  GUKRIPSUUIGWAH (DAEH-Non-standard);  REPUBLIC KOREA MANAGEMENT MIN AGRIC &                  FI (REPU-Non-standard)   KIM I,  HYEON B,  YOON S,  LEE H,  YU J,  JEON S,  GANG S,  PYO H,  CHO S,  CHA S,  CHO I	CN110079637-A  : "E2RT-PCR",          ,relevantClaims[1-4],relevantPassages[1-62];  : "NSP5ART-PCR",          ,relevantClaims[1-4],relevantPassages[258-264];  :          "BVDVBCVBRVRT-PCR",          ,relevantClaims[1-4],relevantPassages[61-64]CN110079637-B            Lin Chu-wen and so on. BVDV, BCV and BRV triple RT-PCR          detection method for establishing and application, forest          and so on, livestock and veterinary medicine, 20130710,          the first 45 rolling (07), the 61-64;  Li          Jiao. The establishment and application of prokaryotic          expression and nested RT-PCR detection method of bovine          viral diarrhea virus E2 protein, Li Jiao, China excellent          master's degree thesis database (electronic periodical),          20081015, the 1-62 page;  ,          and so on. A general establishment of A group rotavirus          fluorescence quantitative RT-PCR detection method based          on NSP5 gene, Zeng Yuan, virus, 20170331, 33 (second          period), the 258-264 page						CN110499391-A	Recombinase polymerase amplification primer and            probe set used for detecting respiratory virus,            comprises upstream primer, downstream primer and probe            for detecting Respiratory syncytial virus type A,            Coronavirus NL63 and Adenovirus-7	SONG H;  HAO R;  GUO X;  QI H;  ZHAO R;  ZHANG Y;  YANG Y;  WU F	CHINESE PEOPLES LIBERATION ARMY DISEASE (CHPE-Non-standard)	2019A2033N	   NOVELTY - Recombinase polymerase amplification (RPA)                primer and probe set comprises (a) upstream primer,                downstream primer and fluorescent probe for                detecting Respiratory syncytial virus type A, (b)                upstream primer, downstream primer and fluorescent                probe for detecting the Coronavirus NL63 and (c)                upstream primer, downstream primer and fluorescent                probe for detecting the Adenovirus-7.    USE - The RPA primer and probe set is useful for                detecting respiratory virus e.g. respiratory                syncytial virus type A, coronavirus NL63 and                adenovirus-7 (claimed).    ADVANTAGE - The primer and probe set has excellent                specificity and high sensitivity and rapidly                detects respiratory virus.    DETAILED DESCRIPTION - Recombinase polymerase amplification (RPA)                primer and probe set comprises (a) upstream primer                for detecting the Respiratory syncytial virus type                A having a 31 base pair sequence (SEQ ID NO: 1)                fully defined in the specification, downstream                primer for detecting the Respiratory syncytial                virus type A having a 31 base pair sequence (SEQ ID                NO: 2) fully defined in the specification and                fluorescent probe for detecting the Respiratory                syncytial virus type A having a 44 base pair                sequence (SEQ ID NO: 2) fully defined in the                specification, (b) upstream primer for detecting                the Coronavirus NL63 having a 31 base pair sequence                (SEQ ID NO: 4) fully defined in the specification,                downstream primer for detecting the Coronavirus                NL63 having a 31 base pair sequence (SEQ ID NO: 5)                fully defined in the specification and fluorescent                probe for detecting the Coronavirus NL63 having a                48 base pair sequence (SEQ ID NO: 6) fully defined                in the specification, and (c) upstream primer for                detecting the Adenovirus-7 having SEQ ID NO: 7,                downstream primer for detecting the Adenovirus-7                having SEQ ID NO: 8 and fluorescent probe for                detecting the Adenovirus-7 having a 44 base pair                sequence (SEQ ID NO: 6) fully defined in the                specification. cttccacgaagggagacaatattactaagg (SEQ                ID NO: 7), and ccatcaatatcagtccatgattcttctcca (SEQ                ID NO: 8). An INDEPENDENT CLAIM is included for                kit, which comprises the above-mentioned primer and                probe set and detection reagent. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03B;  B04-E05;  B04-E99;  B04-F11;  B04-L04A;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  D05-H06A;  D05-H12D1;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/6844;  C12Q-001/70	CN110499391-A   26 Nov 2019   C12Q-001/70   201998Pages: 15   Chinese	CN110499391-A    CN10769954    20 Aug 2019		CN10769954    20 Aug 2019			CN110499391-A -- CN105473158-A   CUREVAC GMBH (CUEV)   KRAMPS T,  SCHNEE M,  VOSS D,  PETSCH B;  CN106399590-A   INST MICROBIOLOGY & EPIDEMIOLOGY (JSYX)   KANG X,  YANG Y,  LI Y,  WU X,  JIANG T,  LI J,  HU Y,  CAO X;  CN106754752-A   GUANGDONG SOUTH CHINA UNITED VACCINE INS (GUAN-Non-standard)   PENG T,  XU Y,  MA S,  WANG Y,  LU Q,  HUANG Y,  SU W,  DING D,  CHEN L,  NA R,  YIN H;  CN108060266-A   BEIJING ZHUOCHENG HUISHENG BIOLOGICAL (BEIJ-Non-standard)   WANG L,  WANG Y,  ZHANG Z;  CN108300803-A   BODITAI XIAMEN BIOTECHNOLOGY CO LTD (BODI-Non-standard)   ZHANG R,  LI B,  ZHAN E,  GUO Y;  CN110055353-A   INST BEIJING VIRAL DISEASE CONTROL &                  PRE (CCDC);  JIANGSU QITIAN GENE BIOLOGICAL TECHNOLOG (JIAN-Non-standard)   MA X,  SHEN X,  WANG Z,  YING Q,  ZHANG Y,  WANG J,  LI X,  WANG R	CN110499391-A  ZHANG,Y. ET AL.:          "Human coronavirus NL63 isolate GS05_2009 nucleocapsid          protein (N) gene, complete cdsGenBank: KM055611.1",          GENBANK,relevantClaims[1-9],relevantPassages[];  SONG,J. ET AL.:          "Human respiratory syncytial virus A strain CC09-01          fusion glycoprotein (F) gene, complete cdsGenBank:          KY296721.1",          GENBANK,relevantClaims[1-9],relevantPassages[]						KR2005685-B1	Producing isolate MERS Coronavirus clone useful for producing fluorescent protein-expressing recombinant vector by preparing cDNA different fragment, preparing cassette bacterial artificial chromosome, and inserting fragments into vector	LEE J Y;  KIM S;  YANG J S;  CHOI J;  KIM J M;  PARK W J;  OH J W;  KIM M W	UNIV YONSEI IND ACADEMIC COOP FOUND (UYIA-C);  KOREA DISEASE CONTROL & PREVENTION CENT (KODI-Non-standard)	201968367J	   NOVELTY - Method for producing a full length clone of Korean isolate MERS Coronavirus (MER-IS-2015001) involves (a) preparing cDNA fragment of the Coronavirus chosen from (i) fragment between restriction sites recognized by restriction enzymes BamHI (807) and StuI (9075), respectively, (ii) fragment between restriction sites recognized by restriction enzymes StuI (9075) and PvuI (18776), respectively, (iii) fragment between restriction sites recognized by restriction enzymes PvuI (18776) and PvuI (25760), respectively, and (iv) fragment between restriction sites recognized by restriction enzymes PvuI (25760) and SacII (29157), respectively, (b) preparing a cassette bacterial artificial chromosome (BAC) vector, and (c) sequentially inserting the cDNA fragments into the cassette BAC vector.    USE - The method is useful for producing clone of Korean isolate MERS Coronavirus, which is useful for producing fluorescent protein-expressing the Coronavirus recombinant vector for evaluating the efficacy of therapeutic agents and vaccines in cell lines and animal models while maintaining infectivity and replication capacity, and for developing large-capacity assays for development of therapeutics and developing attenuated vaccine strains.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for producing a fluorescent protein-expressing the Coronavirus recombinant vector, which involves performing the above-mentioned method, and inserting a fluorescent protein gene into the cassette BAC vector. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E02F;  B04-E03F;  B04-E08;  B04-E99;  B04-F11;  B04-L05A;  B04-N02;  B12-K04E3;  C04-E02F;  C04-E03F;  C04-E08;  C04-E99;  C04-F11;  C04-L05A;  C04-N02;  C12-K04E3;  D05-H17A6;  D05-H99	C12N-015/65;  C12N-015/66;  C12N-015/86;  C12N-007/00	KR2005685-B1   01 Aug 2019   C12N-015/86   201961Pages: 68   	KR2005685-B1    KR161360    13 Dec 2018		KR161360    13 Dec 2018										CN109207639-A	Kit useful for detecting respiratory pathogens,            comprises detection reagent pre-packaged and            lyophilized in microfluidic chip well, control reagent            containing negative control and positive control	CHEN F;  WU H;  YANG Q;  YANG G	NANTONG INT TRAVEL HEALTH CARE CLINIC (NANT-Non-standard)	201909523E	   NOVELTY - Kit comprises detection reagent pre-packaged                and lyophilized in a microfluidic chip well,                control reagent comprising negative control and a                positive control, where the detection reagent                comprises reverse transcription polymerase chain                reaction (RTPCR) reaction solution, component                buffer, 2 mM dNTPs, 1 U/ mu l and the primer probes                are detected by Taq DNA polymerase, 2 U/ mu l                murine leukemia viruses (M-MLV) reverse                transcriptase, 0.3 U/ mu l RRI and 16 respiratory                pathogens.    USE - The kit or primer probe combination is useful                for detecting respiratory pathogens                (claimed).    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a primer                probe combination, which comprises microfluidic                chip containing 16 reaction wells each of which can                detect a pathogen type and pathogen detection                primer probe and an internal reference gene primer                probe, where the 9 respiratory pathogens comprises                influenza A virus, type B Influenza virus,                parainfluenza virus, coronavirus, respiratory                syncytial virus, respiratory adenovirus, human                metapneumovirus, human boca virus and rhinovirus                and the sequences of the 16 types of detection                primers and probes of the nine respiratory                pathogens comprises influenza A upstream primer:                cgaggtcgaaacgtaygttct (SEQ ID NO: 1) and influenza                A downstream primer: ggtcttgtctttagccattcca (SEQ ID                NO: 2), influenza A virus probe P: 5'-fluorescent                reporter group-ccccctcaaagccgagatcgc-fluorescence                quenching group-3' (SEQ ID NO: 3), influenza B                virus upstream primer: cttgttgccactgatgatctta (SEQ                ID NO: 4) and influenza B virus downstream primer:                actcccaccgcagtttcag (SEQ ID NO: 5), influenza virus                probe P: 5'-fluorescent reporter                group-ccatcggatcctcaactcactcttc-fluorescence                quenching group-3' (SEQ ID NO. 6), Parainfluenza                virus type 1 upstream primer:                actaggtgtgacagacacagcaa (SEQ ID NO: 7),                parainfluenza virus type 1 downstream primer:                tcccctatcagcrgtgtcc (SEQ ID NO. 8), parainfluenza                virus type 1 probe P: 5'-fluorescent reporter                group-tgccacttctatrgctccacca-fluorescence quenching                group -3' (SEQ ID NO: 9), parainfluenza virus type                2 upstream primer: atgggccacaatcaatcct (SEQ ID NO:                10), parainfluenza virus type 2 downstream primer:                gcgaccaccatatacaggaa (SEQ ID NO: 11), parainfluenza                virus type 3 upstream primer:                ggaccacgcgctccattcatct (SEQ ID NO: 12),                parainfluenza virus type 3 downstream primer:                ccactcccattgcataactcc (SEQ ID NO: 13), secondary                stream sense virus type 3 probe P: 5'-fluorescent                reporter                group-atagttgcctggtgcgaactcacca-fluorescence                quenching group-3' (SEQ ID NO: 14), parainfluenza                virus type 4 upstream primer: cccactggatctgaagagag                (SEQ ID NO: 15), secondary stream sense virus type                4 downstream primer: aattttcctkgcatctgtttg (SEQ ID                NO: 16), parainfluenza virus type 4 probe P:                parainfluenza virus type 4 probe P: 5'-fluorescent                reporter                group-tcyaacatcctrccctgctgcttgt-fluorescence                quenching group-3' (SEQ ID NO: 17), coronavirus                NL63 upstream primer: attcccaggaatcttgtcccta (SEQ                ID NO: 18), coronavirus NL63 downstream primer:                ctttaggaggcaaatcaacacg (SEQ ID NO: 19) and (SEQ ID                NO: 20), coronavirus OC43 upstream primer:                accgtatgctaaagaccag (SEQ ID NO: 22), coronary                disease poisonous OC43 downstream primer (SEQ ID                NO: 23), coronavirus OC43 probe P: 5'-fluorescent                reporter group-ctgatgtcaataccccggctg-fluorescence                quenching group-3' (SEQID NO: 24), coronavirus 229E                upstream primer: tgaaggtgttgtctgggttgct (SEQ ID NO:                25), coronavirus 229E downstream primer:                gattgaagtgtggtatctctg (SEQ ID NO. 26), coronavirus                229E probe P: 5'-fluorescent reporter                group-cttgcgcctaacaccgtaacc-fluorescence quenching                group-3' (SEQ ID NO: 27), coronavirus HKU1 upstream                primer: acagctgatggtcaacaaaag (SEQ ID NO. 28) crown                Virus HKU1 downstream primer: cgtgggcatcaccatagga                (SEQ ID NO: 29), coronavirus HKU1 probe P:                5'-fluorescent reporter                group-ctatctcggtaccggyccatatgcc-fluorescence                quenching group-3' (SEQ ID NO: 30), middle east                respiratory syndrome MERS-CoV upstream primer:                actaatcgccagtaccatcag (SEQ ID NO: 31), middle east                respiratory syndrome MERS-CoV downstream primer:                gtagtaccaatgacgcaagt (SEQ ID NO.32), middle east                respiratory syndrome MERS-CoV Probe P:                5'-fluorescent reporting                group-agtccatggctgcaactcgtg-fluorescence quenching                group-3' (SEQ ID NO: 33), respiratory syncytial                virus upstream primer: atggggcaaatatggaaaca (SEQ ID                NO. 34), breathing TC virus downstream primer:                gcacccatattgttagtgatgc (SEQ ID NO. 35), respiratory                syncytial virus gene probe P: 5'-fluorescent                reporter                group-cttcacgagggctccacatacaca-fluorescence                quenching group-3' (SEQ ID NO. 36), respiratory                adenovirus upstream primer: caccccctcgatgatgc (SEQ                ID NO: 37), respiratory adenovirus downstream                primer R: ctcaggtactccgaagcatcct (SEQ ID NO. 38),                respiratory adenovirus probe P: 5'-fluorescent                reporter group-tacatgcacatcgccgg-fluorescence                quenching group-3' (SEQ ID NO: 39), human                pneumovirus upstream primer:                aarcatgctatattaaaagagtctc (SEQ ID NO. 40), human                lung virus downstream primer:                cctatytctgcagcatatttgtaatc (SEQ ID NO. 41), Human                metapneumovirus probe P: 5'-fluorescent reporter                group-caachgcagtgacaccytcatcattgca-fluorescence                quenching group-3' (SEQ ID NO: 42), human bocavirus                upstream primer: gaagagacactggcagacaac (SEQ ID NO.                43), human bocavirus downstream primer:                ccactgtgtcggatcgg (SEQ ID NO. 44), human bocavirus                probe P: 5'-fluorescent reporter                group-ctgcggctcctgctcctgtg-fluorescence quenching                group-3' (SEQ ID NO. 45), rhinovirus upstream                primer: gacatggtgygaagagyctattg (SEQ ID NO. 46),                rhinovirus downstream primer:                aaacacggacacccaaagtagt (SEQ ID NO. 47), rhinovirus                probe P: 5'-fluorescent reporter                group-ccggcccctgaatgcggctaat-fluorescence quenching                group-3' (SEQ ID NO. 48), human reference gene beta                -actin gene upstream primer: cgagcgcggctacagct (SEQ                ID NO. 49), human reference gene beta -actin gene                downstream primer: tccttaatgtcacgcacgattt (SEQ ID                NO. 50) and person internal reference gene beta                -actin gene probe P: 5'-fluorescent reporter                group-accaccacggccgagcgg-fluorescence quenching                group-3' (SEQ ID NO. 51). 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03E;  B04-E02F;  B04-E03F;  B04-E05;  B04-E99;  B04-F01;  B04-F11;  B04-L04A;  B04-L04B;  B11-C07B3;  B11-C08C1;  B11-C08E3;  B11-C08F8;  B12-K04F;  D05-H06A;  D05-H09;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/6851;  C12Q-001/70	CN109207639-A   15 Jan 2019   C12Q-001/70   201933Pages: 29   Chinese	CN109207639-A    CN11231737    22 Oct 2018		CN11231737    22 Oct 2018			CN109207639-A -- CN105463129-A   SHENZHEN INT TRAVEL HEALTH CARE CENT (SHEN-Non-standard)   GUO Y,  LIU J,  SHI L,  XIN B,  XU Y,  YE Y,  YE J,  LEI X;  CN107475446-A   JIANGSU MOLE BIOTECHNOLOGY CO LTD (JIAN-Non-standard);  UNIV FUDAN CHILDREN HOSPITAL (UYFU)   JIA R,  LI Y,  LIU P,  LU L,  WANG W,  XU J,  XU M,  ZHONG H;  CN107488748-A   SUZHOU SYM-BIO LIFESCIENCE CO LTD (SUZH-Non-standard)   DONG W,  HE X,  ZHANG P,  LIN M;  CN108588285-A   NANJING LANYU BIOTECHNOLOGY CO LTD (NANJ-Non-standard)   XU H,  CHEN J,  WANG L,  YU P,  ZHANG R	CN109207639-A  : " ", 31 July          2017,          ,relevantClaims[1-10],relevantPassages[212-214]	201562-0-0-0 D K M; 204644-0-0-0 D K M			RA0124 D K M; RA031J D K M		CN110144422-A;  CN110144422-B	Simultaneously detecting four kinds of human            coronavirus quadruplex fluorescent quantitative            detection kit useful for detecting four human            coronaviruses of MERS-CoV, HCoV-NL63, HCoV-OC43 and            HCoV-HKUI	GENG H;  ZHU N;  CAI L;  SUN Y;  XU C;  YANG Z;  WANG S;  WU H;  TAN W	WUXI CUSTOMS DISTRICT PEOPLES REPUBLIC (WUXI-Non-standard);  INST BEIJING VIRAL DISEASE CONTROL & PRE (CCDC-C)	2019755042	   NOVELTY - Simultaneously detecting four kinds of human                coronavirus quadruplex fluorescent quantitative                detection kit, is claimed. The human coronavirus is                specifically MERSCoV/HCoV-NL63/HCoV-OC43/HCoV-HKUI.                The detection kit specifically comprises a specific                primer pair and a probe four groups, a positive                property control product and a negative property                control product. The each set of opposite primer                pairs and probes comprises a pair of specific                primer pairs and a probe sequence. The positive                control product is artificially synthesized target                sequence. The negative control is deionized water                or sterile water.    USE - The detection method is useful for detecting                four human coronaviruses of MERS-CoV, HCoV-NL63,                HCoV-OC43 and HCoV-HKUI (claimed).    ADVANTAGE - The kit has strong detection specificity and                prevents and controls infectious diseases, and                guides clinical treatment. The method has fast                detection time. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E05;  B04-E99;  B04-F11B;  B04-L04A;  B04-L04B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  D05-A02B;  D05-H06A;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/686;  C12Q-001/70	CN110144422-A   20 Aug 2019   C12Q-001/70   201973Pages: 16   Chinese;  CN110144422-B   11 Aug 2023   C12Q-001/70   202368   Chinese	CN110144422-A    CN10520231    17 Jun 2019;   CN110144422-B    CN10520231    17 Jun 2019	CN110144422-B Previous Publ. Patent CN110144422	CN10520231    17 Jun 2019			CN110144422-A -- CN102732638-A   UNIV SUN YAT SEN (UYSY)   CAO K,  GUAN L,  CHANG Y,  FENG F,  HE X,  LI M,  WU J,  XU L,  ZHANG D,  WANG Z,  ZHENG Y,  XU S;  CN103993101-A   CUI S (CUIS-Individual)   CHEN M,  CUI S,  DAN W,  HUANG F,  SUN Y,  TIAN L,  WANG H,  ZHANG X,  ZHANG Y;  CN104846125-A   SHENZHEN BIOEASY TECHNOLOGY INC (SHEN-Non-standard)   ZHU H,  HUANG C,  LU H,  YOU T;  CN105543409-A   SHANGHAI ENTRY EXIT INSPECTION &                  QUARANT (SHAN-Non-standard)   TAN W,  TIAN Z,  ZHANG X,  ZHANG Z,  LI S;  CN110144422-B -- CN102732638-A   UNIV SUN YAT SEN (UYSY)   CAO K,  GUAN L,  CHANG Y,  FENG F,  HE X,  LI M,  WU J,  XU L,  ZHANG D,  WANG Z,  ZHENG Y,  XU S;  CN104846125-A   SHENZHEN BIOEASY TECHNOLOGY INC (SHEN-Non-standard)   ZHU H,  HUANG C,  LU H,  YOU T		201562-0-0-0 D K M; 204644-0-0-0 D K M			RA0124 D K M; RA031J D K M		KR1969696-B1	Antibody or its antigen-binding fragment is            specifically binding to CDRL1, CDRL2, CDRL3, CDRH1,            CDRH2, and spike S2 protein including variable domain            of heavy chain including CDRH3 having sequence of the            MERS coronavirus	KIM D Y;  KIM Y J;  PARK K W;  KIM S S;  LEE J Y;  LEE H S;  WOO H M;  KO H	KOREA CENT DISEASE CONTROL & PREVENTION (KOAD-C);  OSONG MEDICAL INNOVATION FOUND (OSON-Non-standard)	201936491G	   NOVELTY - Antibody or its antigen-binding fragment is                specifically binding to the CDRL1 having the                sequence of (SEQ ID NO: 1), given in the                specification, the CDRL2 having the sequence of                (SEQ ID NO: 2), given in the specification, the                light chain variable region including the CDRL3                having the sequence of (SEQ ID NO: 3), given in the                specification, the CDRH1 having the sequence of                (SEQ ID NO: 10), given in the specification, the                CDRH2 having the sequence of (SEQ ID NO: 11), given                in the specification, and the spike S2 protein                including the variable domain of heavy chain                including the CDRH3 having the sequence of (SEQ ID                NO: 12), given in the specification of the MERS                coronavirus.    USE - Antibody or its antigen-binding                fragment.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a nucleic acid, which is coding the                antibody or its antigen-binding fragment;    (2) a expression vector, which comprises the                nucleic acid;    (3) a cell, which is separated it is                transformed to the expression vector; and    (4) a kit for diagnosing the MERS coronavirus,                which comprises the antibody. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-E02A;  B04-E03A;  B04-E08;  B04-E99;  B04-F0100E;  B04-G01;  B04-G08;  B04-G23;  B11-C07A;  B12-K04G1B;  D05-H09;  D05-H11;  D05-H12A;  D05-H12E;  D05-H14;  D05-H99;  S03-E09F;  S03-E14H5	C07K-016/10;  G01N-033/569	KR1969696-B1   16 Apr 2019   C07K-016/10   201931Pages: 28   	KR1969696-B1    KR008913    23 Jan 2019		KR008913    23 Jan 2019			KR1969696-B1 -- KR1828794-B1   CELLTRION INC (CLTR)   YOUNG L S,  SOOK Y K,  MIN K C,  SUN Y J,  HEE R S,  JIN L H,  SONG H,  JIN B Y,  JOO L H,  YEONG S E;  KR1895228-B1   KOREA CENT DISEASE CONTROL &                  PREVENTION (KOAD)   LEE H,  CHOI J,  GRAHAM B S,  MASCOLA J R,  KIM S,  LINGSHU W;  KR2016036178-A   IBK SECURITIES (KOIN)   HAN J K,  LEE Y K;  KR1782862-B1   UNIV WONKWANG CENT IND ACAD COOP (UWON);  KOREA RES INST CHEM TECHNOLOGY (KRIC)   PARK H,  SHIN H J,  YEO S J,  KIM M H,  CHONG C K	KR1969696-B1            Scientific Reports. 2015, 5:13133.;  (          4) Lingshu Wang et al. Nature communications (2015)          6:7712						CN109609691-A	Detecting porcine delta coronavirus TaqMan            fluorescence quantitatively by reverse transcription            polymerase chain reaction comprises e.g. fluorescence            quantification of porcine delta coronavirus primer and            probe designing, and performing	ZHENG L;  WEI Z;  WANG S;  ZHU J;  WANG P;  LIANG Q;  LI B	UNIV HENAN AGRIC (UYHR-C)	2019357846	   NOVELTY - Detecting porcine delta coronavirus TaqMan                fluorescence quantitatively by reverse                transcription polymerase chain reaction (RT-PCR)                comprises (i) performing fluorescence                quantification of porcine delta coronavirus primer,                and probe designing, (ii) performing quantitative                RT-PCR detection using standard plasmid with                concentration gradient of 1 x 101-1 x 109 copies/                mu l as template, using quantitative primers of                porcine delta coronavirus as primers, and adding                reaction system comprising TaqMan probe, 2 x Premix                Ex Taq and deionized water for fluorescence                quantitative RT-PCR, (iii) detecting Ct value by                fluorescence quantitative RTPCR as Y axis,                establishing standard curve with concentration of                standard plasmid as X-axis, the standard equation                is y is -3.272x + 42.37, and the correlation                coefficient R2 is 0.992, (iv) replacing standard                plasmid in reaction system of step (ii) with the                complementary-DNA (cDNA) of the sample to be                tested, performing fluorescence quantitative                RT-PCR, and recording.    USE - The method is useful for detecting porcine                delta coronavirus TaqMan fluorescence                quantitatively by RT-PCR.    ADVANTAGE - The method: is capable of efficiently                amplifying 1 x 101-1 x 109 copies/ mu l of PDCoV                standard plasmid and other positive samples;                exhibits excellent linear relationship; detection                sensitivity is 1 x 101 copies/ mu l; and has                excellent specificity and repeatability.    DETAILED DESCRIPTION - Detecting porcine delta coronavirus TaqMan                fluorescence quantitatively by reverse                transcription polymerase chain reaction (RT-PCR)                comprises (i) performing fluorescence                quantification of porcine delta coronavirus primer,                and probe designing, (ii) performing quantitative                RT-PCR detection using standard plasmid with                concentration gradient of 1 x 101-1 x 109 copies/                mu l as template, using quantitative primers of                porcine delta coronavirus as primers, and adding                reaction system comprising TaqMan probe, 2 x Premix                Ex Taq and deionized water for fluorescence                quantitative RT-PCR, (iii) detecting Ct value by                fluorescence quantitative RTPCR as Y axis,                establishing standard curve with concentration of                standard plasmid as X-axis, the standard equation                is y is -3.272x + 42.37, and the correlation                coefficient R2 is 0.992, (iv) replacing standard                plasmid in reaction system of step (ii) with the                complementary-DNA (cDNA) of the sample to be                tested, performing fluorescence quantitative RT-PCR                according to system and reaction conditions in step                (ii), recording Ct value, substituting the standard                equation gives the concentration of cDNA of sample                to be tested, which is the concentration of the                porcine delta coronavirus in the sample to be                tested. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01A;  B04-E05;  B04-E99;  B04-F11B;  B11-C07B3;  B11-C08E3;  B11-C08F7A;  B11-C08F8;  B12-K04F;  C04-E01A;  C04-E05;  C04-E99;  C04-F11B;  C11-C07B3;  C11-C08E3;  C11-C08F7A;  C11-C08F8;  C12-K04F;  D05-H06A;  D05-H18;  D05-H99	C12Q-001/6851;  C12Q-001/70	CN109609691-A   12 Apr 2019   C12Q-001/70   201953Pages: 9   Chinese	CN109609691-A    CN11575572    22 Dec 2018		CN11575572    22 Dec 2018			CN109609691-A -- CN107557497-A   LANZHOU VETERINARY RES INST CHINA AGRIC (CAGS)   LIU X,  ZHANG Y,  WANG Y,  FANG Y,  ZHOU P,  XIAO S	CN109609691-A  JIANQIANG ZHANG:          "Evaluation of two singleplex reverse          transcription-Insulated isothermal PCR tests and a duplex          real-time RT-PCR test for the detection of porcine          epidemic diarrhea virus and porcine deltacoronavirus",          JOURNAL OF VIROLOGICAL          METHODS,relevantClaims[1-6],relevantPassages[34-42];  : "PCR",          ,relevantClaims[1-6],relevantPassages[95-100];  : "(PDCoV) RT-PCR",          ,relevantClaims[1-6],relevantPassages[1631-1638]						JP2019028687-A	Server device e.g. computer for performing pandemic prediction of infectious disease, has pandemic estimation unit that estimates number of infected persons from cough sound resulting by infectious disease	KOROGI S;  SANO H;  KONISHI T;  SAITO T	NTT DOCOMO INC (NITE-C)	2019180155	   NOVELTY - The server device (200) has a receiving unit (202) that receives sound information, positional information, and time information from the communication apparatuses. A cough classification unit (204) determines whether the cough sound resulting from the infectious disease is contained in the sound information. A pandemic estimation unit (205) performs pandemic prediction from the number of infected persons, the positional information, and the time information, and estimates the number of infected persons from the cough sound resulting by the infectious disease.    USE - Server device e.g. computer for performing pandemic prediction of infectious disease.    ADVANTAGE - The server device improves the time resolution and the surface imagery when performing pandemic prediction of infectious disease by using the sound information and the positional information and the time information acquired from a communication apparatus.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a pandemic prediction method.    DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram of the server device. (Drawing includes non-English language text)    Server device (200)    Control unit (201)    Receiving unit (202)    Cough classification unit (204)    Pandemic estimation unit (205) 			T01 (Digital Computers)	T01-J05B2;  T01-N01A2;  T01-N02A3C	G06Q-050/22;  G16Z-099/00	JP2019028687-A   21 Feb 2019   G16Z-099/00   201916Pages: 13   Japanese	JP2019028687-A    JP146944    28 Jul 2017		JP146944    28 Jul 2017										KR2019122283-A;  KR2051052-B1	Monoclonal antibody consisting of light chain comprises any one polypeptide sequence selected from group consisting of polypeptide sequence, or functional fragment, which are CDR1 region, CDR2 region and CDR3 region	JU K H;  PARKBYUNGKWON	UNIV HALLYM IND ACADEMIC COOP FOUND (UYHM-C)	2019923284	   NOVELTY - Monoclonal antibody consisting of a light chain comprises any one polypeptide sequence selected from the group consisting of the following polypeptide sequence, or a functional fragment, which are a CDR1 region (SEQ ID NO: 1), a CDR2 region (SEQ ID NO: 2) and a CDR3 region (SEQ ID NO: 3), heavy chain comprising the CDR1 region (SEQ ID NO: 4), a CDR2 region (SEQ ID NO: 5) and the CDR3 region (SEQ ID NO: 6), given in the specification. The monoclonal antibodies that specifically recognize a protein of MERS-CoVa or a portion of the protein.    USE - Monoclonal antibody.    ADVANTAGE - The monoclonal antibody, which is important for diagnosis.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:    (1) a method for preparing a monoclonal antibody that recognizes MERS coronavirus, which involves injecting an MERS coronavirus derived epitope peptide and a CpG-DNA complex co-encapsulated in liposomes into an animal;    (2) a MERS coronavirus diagnostic composition, which comprises a conjugate conjugated to a monoclonal antibody;    (3) a method for providing information about virus infection, which involves contacting a sample with the monoclonal antibody, and detecting the antigen-antibody complex formed by contacting the monoclonal antibody with a sample sample; and    (4) a virus diagnostic kit, which comprises monoclonal antibody, and MERS coronaba comprising a container. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-E99;  B04-F11B;  B04-G08;  B04-G21;  B04-L03C;  B04-N03K;  B11-C07A;  B12-K04G1B;  D05-A01A4;  D05-A01B1;  D05-H06A;  D05-H09;  D05-H11A;  D05-H99;  S03-E09F	C07K-016/10;  G01N-033/532;  G01N-033/569	KR2019122283-A   30 Oct 2019   C07K-016/10   201986Pages: 30   ;  KR2051052-B1   03 Dec 2019   C07K-016/10   201995   	KR2019122283-A    KR045651    19 Apr 2018;   KR2051052-B1    KR045651    19 Apr 2018	KR2051052-B1 Previous Publ. Patent KR2019122283	KR045651    19 Apr 2018					220514-0-0-0 D K M			RA0F7A D K M		CN110468237-A;  CN110468237-B	Mixed solution useful for preparing kit for            detecting Middle East respiratory syndrome coronavirus            gene, comprises upstream of envelope gene and            nucleocapsid protein gene-specific forward and reverse            primers, and specific probes	LI M;  HE W;  JIANG X;  ZHOU Q;  GAO X;  XIA Q;  YOU H;  YE A;  WU J	UNIV DAAN GENE CO LTD (UYSY-C);  GUANGZHOU DAAN GENE CO LTD (GUAN-Non-standard)	201999010N	   NOVELTY - Mixed solution comprises upstream of envelope                gene (UPE) and nucleocapsid protein (N)                gene-specific forward and reverse primers, and                specific probes. The UPE gene-specific forward and                reverse primers have base pair sequences of SEQ ID                NOs: 1 and 2, respectively. The UPE gene-specific                probe has base pair sequences of SEQ ID NO: 3. The                N gene-specific forward and reverse primers have                base pair sequences of SEQ ID NOs: 4 and 5,                respectively. The N gene-specific probe has base                pair sequences of SEQ ID NO: 6.    USE - The mixed solution is useful for preparing the                kit for detecting the Middle East respiratory                syndrome coronavirus gene (all claimed).    ADVANTAGE - The mixed solution ensures simultaneous,                accurate and rapid detection of UPE and N genes of                the Middle East respiratory syndrome                coronavirus.    DETAILED DESCRIPTION - Mixed solution comprises upstream of envelope                gene (UPE) and nucleocapsid protein (N)                gene-specific forward and reverse primers, and                specific probes. The UPE gene-specific forward and                reverse primers have base pair sequences of SEQ ID                NOs: 1 and 2, respectively. The UPE gene-specific                probe has base pair sequences of SEQ ID NO: 3. The                N gene-specific forward and reverse primers have                base pair sequences of SEQ ID NOs: 4 and 5,                respectively. The N gene-specific probe has base                pair sequences of SEQ ID NO: 6. tttccactgttttcgtgcc                (SEQ ID NO: 1), gacccatagtagcgcagag (SEQ ID NO: 2),                cagttcctcttcacataatcgccccgag (SEQ ID NO: 3),                gtgctgtttcctttgccgata (SEQ ID NO: 4),                ggtaagcccagtgtaccaag (SEQ ID NO: 5) and                acagtgttatttggtgcagctcgtggtt (SEQ ID NO: 6). An                INDEPENDENT CLAIM is included for a kit, which                comprises the primer-probe mixed solution. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-B03A;  B04-E01B;  B04-E02;  B04-E03;  B04-E05;  B04-L04A;  B04-L04B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  D05-H99;  D05-H09;  D05-H12D1;  D05-H18B	C12N-015/11;  C12Q-001/686;  C12Q-001/70	CN110468237-A   19 Nov 2019   C12Q-001/70   201997Pages: 13   Chinese;  CN110468237-B   30 Jun 2023   C12Q-001/70   202357   Chinese	CN110468237-A    CN10821266    10 Mar 2016;   CN110468237-B    CN10821266    10 Mar 2016	CN110468237-A Div ex Application CN10147784;   CN110468237-B Div ex Application CN10147784;   CN110468237-B Previous Publ. Patent CN110468237	CN10147784    10 Mar 2016;  CN10821266    10 Mar 2016			CN110468237-A -- CA2910533-A1   XIANGXUE GROUP HONG KONG CO LTD (XIAN-Non-standard)   ZHENG B,  ZHAO C;  CN103554244-A   XIANGXUE GROUP HONG KONG CO LTD (XIAN-Non-standard)   ZHENG B,  ZHAO C;  CN104846125-A   SHENZHEN BIOEASY TECHNOLOGY INC (SHEN-Non-standard)   ZHU H,  HUANG C,  LU H,  YOU T;  CN105039598-A   HEILONGJIANG BOTENG BIOTECHNOLOGY CO LTD (HEIL-Non-standard)   SUN J,  ZHANG W,  ZHAO H;  KR1593641-B1   BIONOTE INC (BION-Non-standard)   CHO Y S,  HA G W,  JUNG S K,  HAN S H,  JANG S G,  KIM J H;  WO2014180180-A1   XIANGXUE GROUP HONG KONG CO LTD (XIAN-Non-standard)   ZHENG B,  ZHAO C;  WO2014045254-A2   UNIV ROTTERDAM ERASMUS CENT MEDICAL (UROT)   HAAGMANS B L,  BESTEBROER T M,  VAN BOHEEMEN S,  FOUCHIER R A,  OSTERHAUS A D,  ZAKI A M,  RAJ V S,  BOSCH B J;  CN110468237-B -- CN104232593-A   INST VIRUS PREVENTION & CONTROL CHINA                  DI (CCDC)   YANG Y,  WANG Y,  TAN W,  GENG G	CN110468237-A  XIAOYAN LU:          "Real-Time Reverse Transcription-PCR Assay Panel for          Middle East Respiratory Syndrome Coronavirus", JOURNAL OF          CLINICAL          MICROBIOLOGY,relevantClaims[1-10],relevantPassages[67-72];  : "",          ,relevantClaims[1-10],relevantPassages[];  T.S.SARASWATHY          SUBRAMANIAM: "Sharing experiences from a reference          laboratory in the public health response for Ebola viral          disease, MERS-CoV and H7N9 influenza virus          investigations", ASIAN PACIFIC JOURNAL OF TROPICAL          MEDICINE,relevantClaims[1-10],relevantPassages[]CN110468237-B            and so on. Study on the Middle East respiratory syndrome          coronavirus (MERS-CoV); plum; Chinese Veterinary Surgees;          Cases 30 (days 8); 848-854;            Middle East respiratory syndrome coronavirus real-time          fluorescence quantitative PCR detection method of          establishing, , China pathogenic biological magazine, the          30 (th) (eighth), 848-854	1525931-1-0-0 D K M; 201562-0-0-0 D K M; 1525931-1-0-0 CL USE			RARECG D K M; RA0124 D K M		CN109161613-A;  CN109161613-B	New multiplex ligation-dependent probe            amplification detection kit useful for detecting e.g.            detecting viral nucleic acid diarrhea syndrome            pathogenic nucleic acid, comprises e.g. reverse            transcription and pre-amplification mixture	WANG X;  SONG H;  HE H;  ZHOU Y;  LIU Z;  CHEN L;  SHAO C;  ZHANG X;  CHENG C;  JIANG S;  SUN J;  ZHOU B;  SONG Q	UNIV ZHEJIANG A & F (UZAF-C);  UNIV ZHEJIANG A & F (UZAF-C)	201906265E	   NOVELTY - Multiplex ligation-dependent probe                amplification (MLPA) detection kit comprising e.g.                (i) reverse transcription and pre-amplification                mixture comprising reverse transcription and                pre-mixing amplification primers (SEQ ID NO: 1-12)                as shown in the specification, where the reverse                transcription primer is a 12-base random primer,                (ii) multiplex ligation probe mixture comprising                sequences of probe (SEQ ID NO: 13-24) and sequences                of an universal primer (SEQ ID NO: 25-26) as shown                in the specification, (iii) MLPA buffer, (iv)                ligation buffers A and B, (v) ligase-65, (vi) PCR                reaction mixture comprising universal primers (SEQ                ID NO: 25-26) as shown in the specification, (vii)                SALSA polymerase, (viii) negative-control, and (ix)                positive-control comprising porcine epidemic                diarrhea virus, porcine transmissible                gastroenteritis virus, porcine Rotavirus, porcine                delta Coronavirus, porcine bocavirus and porcine                virus positive-control plasmid, is new.    USE - The kit is useful for detecting viral nucleic                acid diarrhea syndrome pathogenic nucleic acid, and                detecting pathogenic nucleic acids of six porcine                viral diarrhea syndromes (all claimed).    ADVANTAGE - The kit: has high throughput; is economical;                and has excellent specificity and high                sensitivity.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for                performing MLPA amplification test for                simultaneously detecting pathogenic nucleic acids                of 6 porcine viral diarrhea syndromes using new                multiplex ligation-dependent probe amplification                detection kit comprising (i) extracting magnetic                particle extraction of sample DNA/RNA by                simultaneously extracting DNA and RNA from a sample                by using a magnetic bead DNA/RNA co-extraction kit                and a fully automated nucleic acid extractor to                obtain a 200 mu l sample, (ii) performing RNA                reverse transcription into Complementary DNA (cDNA)                and pre-amplification for one-step reverse                transcription (RT)-PCR reaction comprising                preparing 25 mu l reaction system comprising 10 mu                l One Step Ahead RT-PCR master mix, 1 mu l One Step                Ahead RT mix, 5 mu l DNA or RNA, 1 mu l random                inversion A mixture of primers and 5 mu l                pre-amplification primers (final concentration of                0.5 mu M per primer) supplemented with 3 mu l                water, and the reaction conditions comprising 50                degrees C for 10 minutes, 95 degrees C for 5                minutes, 95 degrees C for 15 seconds, 55 degrees C                for 20 seconds, 72 degrees C for 20 seconds, 40                cycles and 72 degrees C for 2 minutes, (iii) MLPA                amplification and detection comprising performing                DNA denaturing by taking 0.2 ml PCR reaction tube,                adding 0.5 mu l DNA solution and 4.5 mu l tris-EDTA                (TE) per tube, denaturing at 98 degrees C for 5                minutes, and dropping to room temperature at 25                degrees C, performing probe and sample DNA                hybridization preparation of 3 mu l mixed probe                mixture comprising taking 1.5 mu l MLPA buffer and                1.5 mu l probe mixture, adding the probe mixture to                the above PCR tube, incubating at 95 degrees C for                1 minute, hybridizing at 60 degrees C for 1-16                hour, and incubating at 54 degrees C, hybridizing                probe ligation 32 mu l liase mixture comprising                taking 25 mu l distilled water, 3 mu l ligation                buffer A, 3 mu l ligation buffer B and 1 mu l                ligase-65, dropping PCR instrument temperature to                54 degrees C, opening the tube cap, adding 32 mu l                ligase mixture, incubating at 54 degrees C for 15                minutes, heating at 98 degrees C for 5 minutes to                inactivate ligase, and incubating at 20 degrees C,                performing PCR amplification of ligation probes to                obtain 10 mu l PCR mix comprising taking 7.5 mu l                distilled water, 2 mu l PCR reaction mixture and                0.5 mu l SALSA polymerase (substitute of Taq                polymerase), removing the PCR tube, adding 10 mu l                PCR mixture at room temperature, starting the PCR,                where the reaction conditions comprises 95 degrees                C for 30 seconds, 60 degrees C for 30 seconds, 72                degrees C for 60 seconds, 35 cycles, incubating at                72 degrees C for 20 minutes, and dropping the                temperature to 15 degrees C, and performing fully                automated nucleic acid analyzer analysis comprising                analyzing 20 mu l PCR amplification product by                using a fully automated nucleic acid analyzer, and                (iv) performing description and determination of                results comprising a quality control criteria                comprising the positive control with specific                amplification bands at 102 bp, 110 bp, 117 bp, 124                bp, 131 bp and 138 bp, the negative control with no                specific amplification bands, where the positive                condition does not meet the above conditions, and                the test is considered invalid, determining the                result to be positive, when there is a specific                amplification band at 102 bp, indicating the                presence of pork bocavirus in the sample and the                specific amplification is at 110 bp band,                indicating the presence of porcine Norovirus in the                sample, when the specific amplification bands are                at 117 bp, indicating the presence of porcine delta                Coronavirus in the sample, when the specific                amplification bands are at 124 bp, indicating the                presence of porcine epidemic diarrhea in the sample                virus, when the specific amplification band is at                131 bp, indicating the presence of porcine                rotavirus in the sample, when the specific                amplification band is at 138 bp, indicating the                presence of porcine transmissible gastroenteritis                virus in the sample, sequencing the product and                further confirming, and determining the result to                be negative when there is no specific amplification                bands, indicating no porcine epidemic diarrhea                virus, porcine transmissible gastroenteritis virus,                porcine rotavirus, porcine delta coronavirus,                porcine bocavirus, and pig Norovirus. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-E01;  B04-E05;  B04-E08;  B04-F11B;  B04-L04A;  B04-L08;  B11-C08E3;  B11-C08F7A;  B11-C08F8;  B12-K04F;  B12-K04G1B;  C04-E99;  C04-E01;  C04-E05;  C04-E08;  C04-F11B;  C04-L04A;  C04-L08;  C11-C08E3;  C11-C08F7A;  C11-C08F8;  C12-K04F;  C12-K04G1B;  D05-H99;  D05-A02B;  D05-A02F;  D05-H06A;  D05-H18	C12Q-001/686;  C12Q-001/70	CN109161613-A   08 Jan 2019   C12Q-001/70   201928Pages: 22   Chinese;  CN109161613-B   22 Oct 2021   C12Q-001/70   202191   Chinese	CN109161613-A    CN11091224    19 Sep 2018;   CN109161613-B    CN11091224    19 Sep 2018	CN109161613-B Previous Publ. Patent CN109161613	CN11091224    19 Sep 2018			CN109161613-A -- CN102943129-A   BEIJING ENTRY EXIT                  INSPECTION&QUARANTI (BEIJ-Non-standard)   SHI X,  MA G,  GUO Z,  ZHANG W,  QIAO C;  CN103555861-A   UNIV LIAONING MEDICAL (UYLI-Non-standard)   ZHOU T,  ZHA E,  CHI Y,  DONG X,  GAO S;  CN108220479-A   UNIV ZHEJIANG A & F (UZAF)   SONG H,  ZHOU Y,  WANG X,  SHAO C,  CHEN L,  ZHANG X,  CHENG C,  YANG Y;  CN105002301-B   BEIJING ENTRY EXIT INSPECTION &                  QUARANTI (BEIJ-Non-standard)   BAI Y,  HAO J,  LI B,  MA G,  LI Y,  LIU Q,  QIAO C,  SHI X;  EP2373819-A1   PATHOFINDER BV (PATH-Non-standard)   HOPMAN A,  REIJANS M,  THEELEN W;  CN109161613-B -- CN102943129-A   BEIJING ENTRY EXIT                  INSPECTION&QUARANTI (BEIJ-Non-standard)   SHI X,  MA G,  GUO Z,  ZHANG W,  QIAO C;  CN103555861-A   UNIV LIAONING MEDICAL (UYLI-Non-standard)   ZHOU T,  ZHA E,  CHI Y,  DONG X,  GAO S;  CN108220479-A   UNIV ZHEJIANG A & F (UZAF)   SONG H,  ZHOU Y,  WANG X,  SHAO C,  CHEN L,  ZHANG X,  CHENG C,  YANG Y;  CN105002301-B   BEIJING ENTRY EXIT INSPECTION &                  QUARANTI (BEIJ-Non-standard)   BAI Y,  HAO J,  LI B,  MA G,  LI Y,  LIU Q,  QIAO C,  SHI X;  EP2373819-A1   PATHOFINDER BV (PATH-Non-standard)   HOPMAN A,  REIJANS M,  THEELEN W	CN109161613-A  : "(MLPA)",          ,relevantClaims[1-3],relevantPassages[74617521]CN109161613-B            chrysanthemum morifolium and so on. multi-connection          probe amplification (MLPA) technology simultaneously          detecting five kinds of virus research, chrysanthemum and          so on, agricultural biological technology report,          20130730, the 212 (th period), summary, 746 page 1          section to 752 page right column 1 section	201106-0-0-0 K M			RA00R0 K M		RU2702834-C1	STRAIN OF INFLUENZA VIRUS A/UNL/HK/2:6/2017 (H5N8) FOR PRODUCING INACTIVATED AND LIVE INFLUENZA VACCINES	GRISHCHENKO V I;  TSYBALOVA L M	SMORODINTSEV INFLUENZA RES INST (SMOR-Non-standard)	2019946572	   NOVELTY - Invention relates to the field of biotechnology. Influenzavirus A, subtype H5N8, strain A/UNL/HK/2:6/2017 (H5N8), deposited in the State collection of viruses FGBU FNIZEM of N. F. Gamalea of Ministry of Health of Russia under No. 2885, for production of inactivated and live influenza vaccines against potentially pandemic influenza virus A/H5N8.    USE - Biotechnology.    ADVANTAGE - Invention provides enhanced protective action of vaccines against pandemic influenza virus A subtype H5. 1 cl, 6 dwg, 5 tbl, 5 ex 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-F11B;  B14-A02B2;  B14-S11A;  B14-S11D1;  B14-S11D2;  D05-H06A;  D05-H07	C12N-001/00	RU2702834-C1   11 Oct 2019   C12N-001/00   201989Pages: 0   Russian	RU2702834-C1    RU145880    21 Dec 2018		RU145880    21 Dec 2018			RU2702834-C1 -- RU2464309-C1   AS RUSSIA MED NORTH WEST SCI RES INST (ASME-Non-standard)   DESHEVA YU A,  RUDENKO L G,  ALEKSANDROVA G I,  SMOLONOGINA T A;  RU2664460-C1   SMORODINTSEV INFLUENZA RES INST (SMOR-Non-standard)   POTAPCHUK M V,  SERGEEVA M V,  PETROV S V,  VIDYAEVA I G,  TSYBALOVA L M		200757-0-0-0 K U			RA00GT K U		RU2702833-C1	STRAIN OF INFLUENZA VIRUS A/HK/HK/6:2/2016 (H9N2) FOR PRODUCING INACTIVATED AND LIVE INFLUENZA VACCINES	TSYBALOVA L M;  POTAPCHUK M V;  VIDYAEVA I G;  GRISHCHENKO V I	SMORODINTSEV INFLUENZA RES INST (SMOR-Non-standard)	2019946573	   NOVELTY - Invention relates to the field of biotechnology. Invention is presented by Influenzavirus A, subtype H9N2, strain A/HK/HK/6:2/2016 (H9N2), deposited in the State Collection of Viruses of FGBU FNIECEM of N. F. Gamalea of Ministry of Health of Russia with No. 2884, for production of inactivated and live influenza vaccines against potentially pandemic influenza virus A/H9N2.    USE - Biotechnology.    ADVANTAGE - Invention makes it possible to intensify protective actions of vaccines against pandemic influenza A virus subtype H9. 1 cl, 3 dwg, 5 tbl, 5 ex 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-F11B;  B14-A02B2;  B14-S11A;  B14-S11D1;  B14-S11D2;  D05-H06A;  D05-H07	C12N-001/00	RU2702833-C1   11 Oct 2019   C12N-001/00   201989Pages: 0   Russian	RU2702833-C1    RU145879    21 Dec 2018		RU145879    21 Dec 2018			RU2702833-C1 -- RU2507256-C2   EXPERIMENTAL MEDICINE SCI-RES INST (EXPE-Non-standard)   ALEKSANDROVA G I,  DESHEVA YU A,  RUDENKO L G;  RU2563351-C2   EXPERIMENTAL MEDICINE SCI-RES INST (EXPE-Non-standard)   ISAKOVA S I N,  KISELEVA I V,  KUZNETSOVA V A,  RUDENKO L G		200757-0-0-0 K U			RA00GT K U		KR1957040-B1	Vaccine composition useful as feed additive for preventing pandemic diarrhea, comprises N-terminal domain of a spike protein isolated from porcine epidemic diarrhea virus	JANG Y S;  LEE K Y;  KIM S H	UNIV CHONBUK NAT IND COOP FOUND (UYCN-C)	2019255085	   NOVELTY - Vaccine composition comprises N-terminal domain (NTD) of a spike protein (S protein) isolated from porcine epidemic diarrhea virus (PEDV). The NTD comprises a fully defined sequence of 1386 amino acids (SEQ ID NO: 3), as given in the specification, from the 231st to the 501st amino acid sequence of the S protein.    USE - The composition is useful as feed additive for preventing pandemic diarrhea (claimed).    ADVANTAGE - The composition is absorbed into mucosa through administration of mucosa. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)	B04-C01G;  B04-E99;  B04-N03K1;  B12-M12N;  B14-E02;  B14-S11;  B14-S12;  C04-C01G;  C04-E99;  C04-N03K1;  C12-M12N;  C14-E02;  C14-S11;  C14-S12;  D03-G01;  D05-H07;  D05-H99	A61K-039/12;  A61K-038/00;  A61K-039/00	KR1957040-B1   11 Mar 2019   A61K-039/12   201921Pages: 20   	KR1957040-B1    KR121180    20 Sep 2017		KR121180    20 Sep 2017										WO2019220150-A1;  AU2019270582-A1;  CA3099643-A1;  IN202037048349-A;  BR112020023354-A2;  EP3793593-A1;  CN112654364-A;  SG11202011122-A1;  PH12020551944-A1;  US2021299241-A1;  IL278830-A;  ID202102347-A1	Vaccine composition or preventing or treating            viral infection e.g. caused by a zoonotic virus, or            pandemic viral infection, in individual, comprises            immunogenic peptide comprising cluster of            differentiation (CD)8-positive T cell epitope	PHILIP R;  PERRINS R D;  HUANG X;  RADEMACHER T;  UPTON C;  PERRINS D R D	EMERGEX VACCINES HOLDING LTD (EMER-Non-standard);  EMERGEX VACCINES HOLDING LTD (EMER-Non-standard);  EMERGEX VACCINES HOLDINGS LTD (EMER-Non-standard);  EMERGEX VACCINES HOLDING LTD (EMER-Non-standard)	201998271L	   NOVELTY - Vaccine composition comprises an immunogenic                peptide comprising a cluster of differentiation                (CD)8+ T cell epitope from a polypeptide encoded by                an open reading frame (ORF) encoded by portion of                the genome of single stranded RNA (ssRNA) virus in                the opposite sense to positive sense RNA capable of                translation.    USE - The vaccine composition is useful for                preventing or treating a viral infection in an                individual, preferably human, where the viral                infection is caused by a zoonotic virus, or a                pandemic viral infection; for identifying an                immunogenic peptide comprising a CD8+ T cell                epitope from an ORF encoded by portion of the                genome of a ssRNA virus in the opposite sense to                positive sense RNA capable of translation; and for                determining the pandemic potential of an influenza                A virus (all claimed).    ADVANTAGE - The peptides encoded by the conserved ORF in a                vaccine composition may confer protective                capability against multiple human influenza virus                strains, overcoming the problems caused by their                tendency to antigenic shift and drift. Each peptide                capable of binding to a different HLA supertype, in                the vaccine composition may provide a                broad-spectrum vaccine that is effective in                individuals having different HLA types.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) preventing or treating a viral infection,                which involves administering the vaccine                composition to an individual infected with, or at                risk of being infected with ssRNA virus;    (2) identifying an immunogenic peptide                comprising a CD8+ T cell epitope from an ORF                encoded by portion of the genome of a ssRNA virus                in the opposite sense to positive sense RNA capable                of translation which involves: (a) identifying an                ORF encoded by portion of the genome of a ssRNA                virus in the opposite sense to positive sense RNA                capable of translation; (b) predicting the sequence                of the polypeptide encoded by the ORF; and (c)                assessing whether a peptide that binds major                histocompatibility complex (MHC) class I molecule                comprises a sequence present in the predicted                sequence;    (3) an immunogenic peptide comprising a CD4+ T                cell epitope or B cell epitope from a polypeptide                encoded by ORF encoded by portion of the genome of                a ssRNA virus in the opposite sense to positive                sense RNA capable of translation; and    (4) determining the pandemic potential of an                influenza A virus, which involves: (i) identifying                a 1st ORF encoded by portion of segment 8 of the                genome of the influenza A virus in the opposite                sense to positive sense RNA capable of translation;                (ii) determining the number of codons comprised in                the 1st ORF; and (iii) comparing the number of                codons comprised in the 1st ORF to the number of                codons comprised in a 2nd ORF encoded by portion of                segment 8 of the genome of a known pandemic                influenza A virus in the opposite sense to positive                sense RNA capable of translation, where a                difference in the number of codons in the 1st ORF                compared to the second ORF is indicative of                pandemic potential. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B04C;  B04-E99;  B04-F04B1A;  B04-F11B;  B04-H05C;  B04-N03K;  B11-C08E;  B12-K04G1B;  B14-A02;  B14-S11A;  C04-B04C;  C04-E99;  C04-F04B1A;  C04-F11B;  C04-H05C;  C04-N03K;  C11-C08E;  C12-K04G1B;  C14-A02;  C14-S11A;  D05-H06A;  D05-H07;  D05-H99	A61K-039/12;  A61P-031/16;  C07K-014/005;  A61K-039/145;  C12Q-001/70	WO2019220150-A1   21 Nov 2019   A61K-039/12   201992Pages: 91   English;  AU2019270582-A1   26 Nov 2020   A61K-039/12   202096   English;  CA3099643-A1   21 Nov 2019   A61K-039/12   202098   English;  IN202037048349-A   05 Feb 2021   A61K-039/12   202115   English;  BR112020023354-A2   09 Feb 2021   C07K-014/005   202118   English;  EP3793593-A1   24 Mar 2021   A61K-039/12   202126   English;  CN112654364-A   13 Apr 2021   A61K-039/12   202138   Chinese;  SG11202011122-A1   30 Dec 2020   A61K-039/12   202149   English;  PH12020551944-A1   16 Aug 2021   A61K-039/12   202177   English;  US2021299241-A1   30 Sep 2021   A61K-039/145   202180   English;  IL278830-A   31 Jan 2021   A61K-039/12   202343   English;  ID202102347-A1   05 Apr 2021   A61K-039/12   202363	WO2019220150-A1    WOGB051386    20 May 2019;   AU2019270582-A1    AU270582    20 May 2019;   CA3099643-A1    CA3099643    20 May 2019;   IN202037048349-A    IN37048349    05 Nov 2020;   BR112020023354-A2    BR11023354    20 May 2019;   EP3793593-A1    EP726124    20 May 2019;   CN112654364-A    CN80047427    20 May 2019;   SG11202011122-A1    SG11011122    20 May 2019;   PH12020551944-A1    PH551944    10 Nov 2020;   US2021299241-A1    US17054104    09 Nov 2020;   IL278830-A    IL278830    01 Jul 2019;   ID202102347-A1    IDP08594    16 Nov 2020	AU2019270582-A1 PCT application Application WOGB051386;   AU2019270582-A1 Based on Patent WO2019220150;   CA3099643-A1 PCT application Application WOGB051386;   CA3099643-A1 Based on Patent WO2019220150;   IN202037048349-A PCT application Application WOGB051386;   IN202037048349-A Based on Patent WO2019220150;   BR112020023354-A2 PCT application Application WOGB051386;   BR112020023354-A2 Based on Patent WO2019220150;   EP3793593-A1 PCT application Application WOGB051386;   EP3793593-A1 Based on Patent WO2019220150;   CN112654364-A PCT application Application WOGB051386;   CN112654364-A Based on Patent WO2019220150;   SG11202011122-A1 PCT application Application WOGB051386;   SG11202011122-A1 Based on Patent WO2019220150;   PH12020551944-A1 PCT application Application WOGB051386;   US2021299241-A1 PCT application Application WOGB051386;   US2021299241-A1 Provisional Application US673647P;   IL278830-A Based on Patent WO2019220150;   ID202102347-A1 PCT application Application WOGB051386;   ID202102347-A1 Based on Patent WO2019220150	US673647P    18 May 2018;  CA3099643    06 Nov 2020;  US17054104    09 Nov 2020;  BR11023354    16 Nov 2020;  CN80047427    15 Jan 2021	WO2019220150-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          EP3793593-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR              		WO2019220150-A1 -- WO1994009035-A1   ;  WO2013034726-A1   MIDATECH LTD (MIDA-Non-standard)   RADEMACHER T,  WILLIAMS P;  WO2002032404-A2   ;  WO2006037979-A2   MIDATECH LTD (MIDA-Non-standard);  IGENEON (IGEN-Non-standard)   HIMMLER G,  MUDDE G C,  KIRCHEIS R,  RADEMACHER T W,  PENADES ULLATE S,  MARTIN LOMAS M,  DE PAZ CARRERA J L,  OJEDA MARTINEZ DE CASTILLA R,  BARRIENTES A G;  WO2007015105-A2   RADEMACHER T W (RADE-Individual);  BRADMAN G (BRAD-Individual);  PENADES ULLATE S (ULLA-Individual);  OJEDA MARTINEZ DE CASTILLA R (DCAS-Individual)   RADEMACHER T W,  BRADMAN G,  PENADES ULLATE S,  OJEDA MARTINEZ DE CASTILLA R;  WO2007122388-A2   MIDATECH LTD (MIDA-Non-standard)   RADEMACHER T W,  WILLIAMS P;  CN112654364-A -- CN1810961-A   INST MICROBIAL EPIDEMIOLOGY PLA (JSYX)   WANG X,  LUO D,  YANG P,  WANG D;  WO2018127689-A1   EMERGEX VACCINES HOLDING LTD (EMER-Non-standard)   PHILIP R;  WO2007061969-A2   UNIV RUTGERS STATE NEW JERSEY (RUTF);  UNIV TEXAS SYSTEM (TEXA)   MONTELIONE G T,  KRUG R M,  CUIFENG Y,  LICHUNG M;  WO2011046996-A2   UNIV JOHNS HOPKINS (UYJO);  UNIV SINGAPORE NAT (UNUS)   AUGUST J T,  TAN P T,  TAN T W,  KHAN A M	WO2019220150-A1  ZHIRNOV O P ET AL:          "Structural and evolutionary characteristics of HA, NA,          NS and M genes of clinical influenza A/H3N2 viruses          passaged in human and canine cells", JOURNAL OF CLINICAL          VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 45, no. 4, 1          August 2009 (2009-08-01), pages 322 - 333, XP026469069,          ISSN: 1386-6532, [retrieved on 20090708], DOI:          10.1016/J.JCV.2009.05.030,relevantClaims[1,4-20|2,3,26-36],relevantPassages[&lt;pp&gt;322&lt;/pp&gt;&lt;ppl&gt;323,          326&lt;/ppl&gt;];  CLIFFORD MONICA ET          AL: "Evidence for a novel gene associated with human          influenza A viruses", VIROLOGY JOURNAL, BIOMED CENTRAL,          LONDON, GB, vol. 6, no. 1, 16 November 2009 (2009-11-16),          pages 198, XP021064306, ISSN: 1743-422X, DOI:          10.1186/1743-422X-6-198,relevantClaims[1,4-20|2,3,26-36],relevantPassages[&lt;figure&gt;1,          3, 4&lt;/figure&gt;&lt;table&gt;1,          2&lt;/table&gt;];  CHU-WEN YANG ET AL:          "Uncovering the Potential Pan Proteomes Encoded by          Genomic Strand RNAs of Influenza A Viruses", PLOS ONE,          vol. 11, no. 1, 13 January 2016 (2016-01-13), pages          e0146936, XP055610357, DOI:          10.1371/journal.pone.0146936,relevantClaims[1-20,26-36],relevantPassages[&lt;figure&gt;11,          13,          14&lt;/figure&gt;&lt;table&gt;1&lt;/table&gt;]CN112654364-A  : "", 30 April          2013, , pages: 117 - 119,relevantClaims[1-35];  WEIMIN ZHONG:          "Genome-wide Characterization of a Viral Cytotoxic T          Lymphocyte Epitope Repertoire", THE JOURNAL OF BIOLOGICAL          CHEMISTRY, vol. 278, no. 46, 5 September 2003          (2003-09-05), pages 45135,relevantClaims[1-35];  MONICA CLIFFORD:          "Evidence for a novel gene associated with human          influenza A viruses", VIROLOGY JOURNAL, vol. 6, 16          November 2009 (2009-11-16), pages 1 -          12,relevantClaims[1-35]	105730-0-0-0 K M; 184611-0-0-0 K M			RA012P K M; RA00H1 K M		CN110452884-A;  CN110452884-B	New anti bovine coronavirus nucleocapsid (BCoV-N)            protein monoclonal antibody hybridoma cell strain            useful e.g. for preventing bovine coronavirus and            preparing bovine coronavirus antigen diagnostic            kits	ZHOU Y;  REN Y;  HU L;  CONG Y;  MENG Y;  DI H;  JIA W;  WU R;  HOU X;  ZHU Z;  LI C;  REN D;  LI N;  GAO W;  LI X;  JIN G;  WANG M	UNIV HEILONGJIANG BAYI AGRIC (UYON-C)	2019979983	   NOVELTY - Anti bovine coronavirus nucleocapsid (BCoV-N)                protein monoclonal antibody hybridoma cell strain                produced by cell fusion of mouse spleen cells and                SP2/0 cells and having a preservation number (CGMCC                No.17693), is new.    USE - The monoclonal antibody is useful for                preventing bovine coronavirus (claimed) and for                preparing bovine coronavirus antigen diagnostic                kits.    ADVANTAGE - The monoclonal antibody: can specifically                react with bovine coronavirus in western blot and                immunofluorescence experiments; does not cross                react with bovine rhinitis viruses, bovine viral                diarrhea virus, infectious bovine rhinotracheitis                virus and bovine parainfluenza virus type 3; and                has good affinity with active bovine coronavirus                virions.    DETAILED DESCRIPTION - INDEPENDENT CLAIM are also included for:    (1) a monoclonal antibody secreted by                anti-BCoV-N protein monoclonal antibody hybridoma                cell line; and    (2) preparing the monoclonal antibody. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-F05;  B04-G08;  B04-G21;  B12-K04G1B;  B14-A02B;  B14-S12;  C04-F05;  C04-G08;  C04-G21;  C12-K04G1B;  C14-A02B;  C14-S12;  D05-H11A1;  D05-H15A	A61K-039/42;  A61P-031/14;  C07K-016/10;  C12N-005/20;  C12R-001/91	CN110452884-A   15 Nov 2019   C12N-005/20   201993Pages: 15   Chinese;  CN110452884-B   29 Mar 2022   C12N-005/20   202231   Chinese	CN110452884-A    CN10734259    09 Aug 2019;   CN110452884-B    CN10734259    09 Aug 2019	CN110452884-B Previous Publ. Patent CN110452884	CN10734259    09 Aug 2019			CN110452884-A -- CN108318686-A   UNIV HEILONGJIANG BAYI AGRIC (UYON)   ZHOU Y,  FAN C,  NI H,  ZHU Z,  HOU X,  SHAO H,  WU R,  REN Y,  GAO G,  JIA W,  WANG M,  HU L,  MENG Y,  CHENG S,  WANG X,  BAI B,  HUANG X;  US5672350-A   VETERINARY INFECTIOUS DISEASE (VETE-Non-standard)   BABIUK L A,  PARKER M D,  COX G J;  CN110452884-B -- CN108318686-A   UNIV HEILONGJIANG BAYI AGRIC (UYON)   ZHOU Y,  FAN C,  NI H,  ZHU Z,  HOU X,  SHAO H,  WU R,  REN Y,  GAO G,  JIA W,  WANG M,  HU L,  MENG Y,  CHENG S,  WANG X,  BAI B,  HUANG X;  US5672350-A   VETERINARY INFECTIOUS DISEASE (VETE-Non-standard)   BABIUK L A,  PARKER M D,  COX G J	CN110452884-A  : ".",          ,relevantClaims[1-4],relevantPassages[3-5];  DREZE F:          "Production of monoclonal antibodies to study the          molecular biology of bovine viral diarrhea virus.", ARCH          VIROL          SUPPL,relevantClaims[1-4],relevantPassages[239-244];  : "",          ,relevantClaims[1-4],relevantPassages[83-86]CN110452884-B  Xu          Wenzhong and so on. bovine coronavirus monoclonal          antibody research, Xu Wenzhong et al., Nanjing          Agricultural University Xuebao, 19920401, No. 15 (first          period), the 83-86 page;  Dr          Sze F et al. The molecular biology of the molecular          biology of the invention is the molecular biology of the          molecular biology of the molecular biology of the          molecular biology of the molecular biology of the          molecular biology of the molecular biology of the          molecular biology of the molecular biology of the          molecular biology of the molecular biology of the          molecular biology of the molecular biology, Virol Suppl,          19920201 (Phase 3), pp. 239-244;            Chen Huanchun and so on. The bovine coronavirus          monoclonal antibody study I, the establishment of hybrid          tumor cell strain, Chen Huanchun et al., "China          Veterinary Medicine Magazine", 19931215, No. 19 (No. 12),          3-5	184587-0-0-0 N			RA00C8 N		CN109364083-A;  CN109364083-B	Use of conivaptan hydrochloride in preparation of medicine for inhibiting feline coronavirus and treating feline infectious peritonitis	PENG G;  LI H;  LIU Y	UNIV HUAZHONG AGRIC (UHZA-C)	201920704J	   NOVELTY - Use of conivaptan hydrochloride (Q) in the preparation of a medicine for inhibiting feline coronavirus, is claimed.    USE - The compound (Q) is useful in the preparation of a medicine for inhibiting feline coronavirus and treating feline infectious peritonitis (claimed).    ADVANTAGE - The compound (Q) reduces the toxic effect of feline coronavirus while having reduced toxicity to normal cells, and inhibits the proliferation of feline coronavirus in a dose-dependent manner when tested using indirect immunofluorescence assay. 			B02 (Fused ring heterocyclics.)	B06-D17;  B14-A02;  B14-C03	A61K-031/55;  A61P-031/14	CN109364083-A   22 Feb 2019   A61K-031/55   201927Pages: 7   Chinese;  CN109364083-B   18 Aug 2020   A61K-031/55   202069   Chinese	CN109364083-A    CN11307771    05 Nov 2018;   CN109364083-B    CN11307771    05 Nov 2018	CN109364083-B Previous Publ. Patent CN109364083	CN11307771    05 Nov 2018			CN109364083-A -- CN102885892-A   TIANJIN JIHE SCI&TECHNOLOGY CO LTD (TIAN-Non-standard)   LIU Z,  SU Y,  WANG H,  HUANG J,  PEI Y;  WO1992008487-A1   ;  CN109364083-B -- CN102885892-A   TIANJIN JIHE SCI&TECHNOLOGY CO LTD (TIAN-Non-standard)   LIU Z,  SU Y,  WANG H,  HUANG J,  PEI Y;  WO1992008487-A1   	CN109364083-A  SAEED SHARIF ET AL.: "Diagnostic Methods for Feline Coronavirus: A Review", VETERINARY MEDICINE INTERNATIONAL ,relevantClaims[1-2],relevantPassages[1-8];  PAUL GAGLIOKWAKU MARFOJOSEPH CHIODO III: "Hyponatremia in Cirrhosis and End-Stage Liver Disease:Treatment with the Vasopressin V2-Receptor AntagonistTolvaptan", DIG DIS SCI,relevantClaims[1-2],relevantPassages[27742785]CN109364083-B  Saeed Sharif et al .. Diagnostic method for Feline Coronavirus: A Review, Saeed Sharif et al., Veterinary Medicine International , 20100622, the 1-8;  Paul Gaglio Marfo Chiodo III. Hyponatremia in Cirrhosis and End-stage Liver Disease: Treatment with the Vasopressin V2-Receptor AntagonistTolvaptan; Paul Gaglio Marfo Chiodo III; Dig Dis Sci "; 20120626; the 2774-2785	165983-0-1-0 K U		74905	RA3XUP K U		CN109112111-A	New hybridoma cell line 1A11 (CCTCC C2017107)            capable of secreting monoclonal antibody against            porcine delta-coronavirus N protein useful in e.g.            preparation of kit for detecting porcine            delta-coronavirus	FANG L;  XIAO S;  DONG N;  WANG D;  LIU H;  LIU K;  SUN Q;  JIANG X	UNIV HUAZHONG AGRIC (UHZA-C)	2019039398	   NOVELTY - A hybridoma cell line 1A11 (CCTCC C2017107)                capable of secreting monoclonal antibody against                porcine delta -coronavirus N protein, is new.    USE - The hybridoma cell line 1A11 capable of                secreting monoclonal antibody is useful in                preparation of kit for detecting porcine delta                -coronavirus and in intestinal immunohistochemical                analysis of piglets infected with porcine delta                -coronavirus for non-diagnostic purposes (all                claimed).    ADVANTAGE - The hybridoma cell line 1A11 secretes                monoclonal antibody 1A11 having good stability and                specificity. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  S03 (Scientific Instrumentation)	B04-E99;  B04-F05;  B04-F11B;  B11-C07A;  B12-K04G1B;  C04-E99;  C04-F05;  C04-F11B;  C11-C07A;  C12-K04G1B;  D05-H06A;  D05-H15A;  D05-H99;  J04-B01;  J04-B03;  S03-E09F;  S03-E14H5	C12N-005/20;  C12R-001/91;  G01N-033/569;  G01N-033/577	CN109112111-A   01 Jan 2019   C12N-005/20   201924Pages: 18   Chinese	CN109112111-A    CN10819106    12 Sep 2017		CN10819106    12 Sep 2017			CN109112111-A -- CN102533666-A   UNIV SOUTHERN MEDICAL (UNSM)   LI H,  HAO W,  LI M,  LIAO X,  LUO S;  CN104630151-A   UNIV CHINA AGRICULTURAL (UCAG)   FAN S,  XIA C	CN109112111-A  : "", 30 June 2016,          ,relevantClaims[1-3],relevantPassages[369-374];  FATEN OKDA:          "Development of monoclonal antibodies and serological          assays including indirect ELISA and fluorescent          microsphere immunoassays for diagnosis of porcine          deltacoronavirus", BMC VETERINARY          RESEARCH,relevantClaims[1-3],relevantPassages[1138-9PDCoV10711];  DONG,N.: "Porcine          deltacoronavirus isolate CHN-HN-2014, complete genome",          GENBANK          DATABASE,relevantClaims[1-3],relevantPassages[accession          NO: KT336560.1];  NAN DONG:          "Isolation, genomic characterization, and pathogenicity          of a Chinese porcine deltacoronavirus strain          CHN-HN-2014", VETERINARY          MICROBIOLOGY,relevantClaims[1-3],relevantPassages[98-106];  QI CHEN:          "Pathogenicity and pathogenesis of a United States          porcine deltacoronavirus cell culture isolate in          5-day-old neonatal piglets",          VIROLOGY,relevantClaims[1-3],relevantPassages[51-59]						CN110124027-A;  CN110124027-B	Bovine rotavirus and bovine coronavirus            inactivated vaccine used for e.g. preventing calves            diarrhea and immunizing cattle, comprises inactivated            vaccine containing inactivated antigen of bovine            rotavirus and bovine coronavirus	BI Y;  ZHANG D;  GAO F;  SONG X;  LI Y;  JIA A;  QIN X;  WANG L;  XU L	QILU ANIMAL HEALTH PROD CO LTD (QLPH-C);  QILU ANIMAL HEALTH PROD CO LTD (QLPH-C)	201972842K	   NOVELTY - Bovine rotavirus (CGMCC No.17686) and bovine                coronavirus (CGMCCNo.17687) inactivated vaccine                comprises inactivated vaccine containing an                inactivated antigen of bovine rotavirus and bovine                coronavirus. The inactivated antigen is prepared                separately from bovine rotavirus JY strain and                bovine coronavirus YQ strain.    USE - The bovine rotavirus and bovine coronavirus                inactivated vaccine is useful for preventing calves                diarrhea caused by bovine rotavirus and bovine                coronavirus infection, and immunizing cattle                produces immune protection.    ADVANTAGE - The vaccine has no adverse reaction, immunizes                pregnant cattle does not cause miscarriage, newborn                calves obtains high levels of maternal antibodies                through breast milk, and is safe and                reliable.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method                for preparing the bovine rotavirus and bovine                coronavirus inactivated vaccine, involving (a)                passaging cell culture Rhesus monkey kidney cells                (MA-104), culturing by adherent culture and                microcarrier culture, subculturing human colon                cancer cells (HCT-8), and culturing by adherent                culture, (b) inoculating the strain bovine                rotavirus JY on MA-104 cells, cell propagating to                obtain the virus antigen for vaccine preparation,                inoculating the strain bovine coronavirus YQ on                HCT-8 cells, and cell propagating to obtain the                virus antigen for vaccine preparation, (c)                inactivating the prepared virus solution using an                inactivating agent, and (d) adding the seedlings to                the corresponding adjuvant to obtain the                vaccine. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-B04C1;  B04-F11B;  B14-A02B;  B14-E02;  B14-S11A;  B14-S11D1;  B14-S12;  C04-E99;  C04-B04C1;  C04-F11B;  C14-A02B;  C14-E02;  C14-S11A;  C14-S11D1;  C14-S12;  D05-H99;  D05-H07	A61K-039/15;  A61K-039/215;  A61K-039/295;  A61P-031/14	CN110124027-A   16 Aug 2019   A61K-039/295   201971Pages: 15   Chinese;  CN110124027-B   26 Jul 2022   A61K-039/295   202264   Chinese	CN110124027-A    CN10546787    24 Jun 2019;   CN110124027-B    CN10546787    24 Jun 2019	CN110124027-B Previous Publ. Patent CN110124027	CN10546787    24 Jun 2019			CN110124027-A -- CN106729692-A   QILU ANIMAL HEALTH PROD CO LTD (QLPH)   WNG L,  XU L,  BI Y,  ZHUO B,  GAO F,  JU H;  WO2002062382-A1   ;  CN110124027-B -- CN106729692-A   QILU ANIMAL HEALTH PROD CO LTD (QLPH)   WNG L,  XU L,  BI Y,  ZHUO B,  GAO F,  JU H;  WO2002062382-A1   		200757-0-0-0 N P; 200757-0-0-0 CL NEW PRD			RA00GT N P		KR2019008-B1	Detecting Middle East respiratory syndrome (MERS)            coronavirus useful for diagnosing MERS coronavirus            infection by reacting sample with antigen, reacting            monoclonal antibody with detection antigen, and            measuring level of detection label	LEE H;  KIM S;  LEE J Y;  KWON K H;  GWIN J D;  NHO J Y;  YUN S W;  AHN M J	KOREA RES INST BIOSCIENCE & BIOTECHNOLOG (KRIB-C);  KOREA CENT DISEASE CONTROL & PREVENTION (KOAD-C)	2019783768	   NOVELTY - Method for detecting Middle East respiratory                syndrome (MERS) coronavirus involves (a) reacting                sample to-be-tested with a detection antigen                immobilized on a solid phase support using                nucleocapsid fusion protein comprising an amino                (N)-terminal domain fragment and a carboxy                (C)-terminal domain fragment of a nucleocapsid                protein of MERS coronavirus as detection antigen,                (b) reacting the monoclonal antibody specifically                binding to the nucleocapsid fusion protein and                conjugated with detection label with the detection                antigen immobilized on a solid phase support, and                (c) measuring the level of the detection label of                the monoclonal antibody that is antigen-antibody                bound to the detection antigen. The nucleocapsid                fusion protein has a 276 amino acid sequence (SEQ                ID NO: 8) fully defined in the specification.    USE - The method is useful for detecting MERS                coronavirus, which is useful for diagnosing MERS                coronavirus infection.    ADVANTAGE - The method enables early detection of MERS                coronavirus.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a MERS                coronavirus detection kit, which comprises (a)                nucleocapsid fusion protein, and (b) monoclonal                antibody specifically binding to the nucleocapsid                fusion protein. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-B04C1;  B04-C01G;  B04-E99;  B04-F11B;  B04-G08;  B04-G21;  B04-L03B;  B04-N03K0E;  B04-N08;  B11-C07A;  B12-K04G1B;  D05-A01A4;  D05-A01B1;  D05-H06A;  D05-H10;  D05-H99;  S03-E09F;  S03-E14H	G01N-033/543;  G01N-033/569;  G01N-033/68	KR2019008-B1   05 Sep 2019   G01N-033/569   201971Pages: 32   	KR2019008-B1    KR012840    31 Jan 2019		KR012840    31 Jan 2019			KR2019008-B1 -- JP2017145246-A   UNIV YOKOHAMA CITY (YKHM);  KANTO CHEM CO INC (KAKA)   RYO A,  MATSUNAGA T,  YAMAOKA Y,  KUROYAMA H;  KR2018124584-A   REPUBLIC KOREA ANIMAL & PLANT                  QUARANTINE (REPU-Non-standard);  MEDIAN DIAGNOSTICS INC (MEDI-Non-standard)   KIM Y H,  LEE K K,  OEM J K,  KIM S H,  LEE E Y,  SO B J,  JANG S H,  LEE E S,  CHEONG K M;  KR236470-B1   LG CHEM LTD (GLDS)   MOON G D,  PARK G W,  CHUNG H H;  KR1593641-B1   BIONOTE INC (BION-Non-standard)   CHO Y S,  HA G W,  JUNG S K,  HAN S H,  JANG S G,  KIM J H;  KR1782862-B1   UNIV WONKWANG CENT IND ACAD COOP (UWON);  KOREA RES INST CHEM TECHNOLOGY (KRIC)   PARK H,  SHIN H J,  YEO S J,  KIM M H,  CHONG C K;  KR191782862-B1   ;  WO2015057666-A1   UNIV NORTH CAROLINA (UNCR)   BARIC R,  AGNIHOTHRAM S,  YOUNT B;  WO2016080701-A1   BIONOTE INC (BION-Non-standard)   CHO Y S,  HA G W,  JUNG S K,  HAN S H,  JANG S G,  KIM J H		97055-0-0-0 D K M			RA02YE D K M		CN110063954-A;  CN110063954-B	Use of FHPI for preparation of feline coronavirus            inhibitor, where chemical name of FHPI is            4-4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-dihydro-imidazole-2-subunit            cyclohexan-2,5-dien-1-one	PENG G;  MAO J;  LIU Z	UNIV HUAZHONG AGRIC (UHZA-C);  CLOUDPET BEIJING ANIMAL MEDICAL TECHNOLO (CLOU-Non-standard);  UNIV HUAZHONG AGRIC (UHZA-C)	201968450E	   NOVELTY - Use of FHPI is claimed for preparing a feline                coronavirus inhibitor, where the chemical name of                the FHPI is                4-(4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-dihydro-imidazole-2-subunit)cyclohexan-2,5-dien-1-one.    USE - FHPI used in the preparation of a feline                coronavirus inhibitor and used for the manufacture                of a medicament for treating feline infectious                peritonitis (claimed).    ADVANTAGE - The FHPI has anti-feline coronavirus activity,                and has good curative effect and high safety.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a feline                coronavirus inhibitor comprises the FHPI. 			B03 (Other heterocyclics.)	B07-D04C;  B07-D09;  B14-A02;  B14-L06	A61K-031/4439;  A61P-031/14	CN110063954-A   30 Jul 2019   A61K-031/4439   201973   Chinese;  CN110063954-B   06 Aug 2021   A61K-031/4439   202167   Chinese	CN110063954-A    CN10285547    10 Apr 2019;   CN110063954-B    CN10285547    10 Apr 2019	CN110063954-B Previous Publ. Patent CN110063954	CN10285547    10 Apr 2019			CN110063954-A -- CN107073123-A   UNIV MUENSTER WESTFAELISCHE WILHELMS (UYMU)   EHRHARDT C,  LUDWIG S	CN110063954-A  NAVAL P.SHANWARE:          "Non-specific in vivo inhibiton of CK1 by the pyridinyl          imidazole p38 inhibitors SB 203580 and SB 202190", BMB          REPORTS,relevantClaims[1-3],relevantPassages[142-147];  TETSUYA MIZUTANI:          "Tyrosine dephosphorylation of STAT3 in SARS          coronavirus-infected Vero E6 cells", FEBS          LETTERS,relevantClaims[1-3],relevantPassages[187-192];  ROBERT A.JOHNSON:          "Inhibitory effect of          4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole          on HCMV DNA replication and permissive infection",          ANTIVIRAL          RESEARCH,relevantClaims[2|13],relevantPassages[101-111]	112085-0-0-0 K U			RA104S K U		KR2019035542-A;  WO2019066389-A1;  KR2103857-B1	NC fusion protein used for MERS-coronavirus            diagnosis, comprises N-terminal domain fragment and            C-terminal domain fragment of nucleocapsid protein of            Middle East respiratory syndrome coronavirus	JEONG D G;  YOON S W;  KIM H K;  SONG D;  NOH J;  AHN M J;  GWIN J D;  YUN S W;  KWON K H;  SONG D S;  NHO J Y	KOREA RES INST BIOSCIENCE & BIOTECHNOLOG (KRIB-C)	201932050E	   NOVELTY - NC fusion protein comprises an N-terminal                domain fragment and a C-terminal domain fragment of                a nucleocapsid protein of Middle East respiratory                syndrome (MERS) coronavirus.    USE - NC fusion protein used for MERS-coronavirus                diagnosis.    ADVANTAGE - The NC fusion protein can be mass-produced in                E. coli.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a monoclonal antibody that specifically                binds to an NC fusion protein;    (2) an expression vector, which comprises a                nucleotide encoding the NC fusion protein;    (3) a host cell transfected with the                expression vector;    (4) a method for producing an NC fusion                protein, which involves obtaining an NC fusion                protein from the transfected host cell;    (5) a method for manufacturing MERS                coronavirus, which involves injecting a fusion                protein as an antigen into an experimental animal                to induce an immune response; and recovering the                antibody from the experimental animal;    (6) a kit for diagnosing a mers coronavirus                infection, which comprises an NC fusion protein;                and    (7) a method for providing information on a                mers coronavirus infection, which involves adding a                sample isolated from a diagnostic object to a                diagnostic kit. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-C01G;  B04-E08;  B04-E99;  B04-F0100E;  B04-G08;  B04-G21;  B04-N03K0E;  B04-N08;  B11-C07A;  B12-K04G1B;  D05-H09;  D05-H11A;  D05-H12E;  D05-H14;  D05-H17C;  D05-H99;  S03-E09F;  S03-E14H5	C07K-014/005;  C07K-016/10;  G01N-033/569	KR2019035542-A   03 Apr 2019   C07K-014/005   201930Pages: 31   ;  WO2019066389-A1   04 Apr 2019   C07K-014/005   201931   ;  KR2103857-B1   27 Apr 2020   C07K-014/005   202037   	KR2019035542-A    KR112836    20 Sep 2018;   WO2019066389-A1    WOKR011155    20 Sep 2018;   KR2103857-B1    KR112836    20 Sep 2018		KR124394    26 Sep 2017	  WO2019066389-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    		;  WO2019066389-A1 -- EP3045181-A1   UNIV MUENCHEN MAXIMILIANS LUDWIG (UMML);  UNIV PHILIPPS MARBURG (UYPH)   SUTTER G,  FUX R,  VOLZ A,  SONG F,  BECKER S,  EICKMANN M;  KR1593641-B1   BIONOTE INC (BION-Non-standard)   CHO Y S,  HA G W,  JUNG S K,  HAN S H,  JANG S G,  KIM J H;  US20160264647-A1   ;  US20160296617-A1   	WO2019066389-A1  CHEN, Y.: "A novel          neutralizing monoclonal antibody targeting the N-terminal          domain of the MERS-CoV spike protein", EMERGING MICROBES          & INFECTIONS, vol. 6, 24 May 2017 (2017-05-24), pages          e37, XP055586083,relevantClaims[1-11, 13-14]						WO2019121513-A1;  CN111491663-A;  US2020330585-A1;  EP3727444-A1;  BR112020012049-A2;  JP2021506835-W;  RU2020123612-A;  RU2787596-C2;  RU2022133854-A;  RU2787596-C9	Immunogenic composition used for preventing            disease due to influenza virus, comprises first            alpha-virus RNA replicon particle encoding first            neuraminidase and second alpha-virus RNA replicon            particle encoding second neuraminidase	MOGLER M A;  KITIKOON P;  PUTTAMREDDY S;  STRAIT E;  SEGERS R P A;  NAGARAJ B;  STREITER E;  SEGERS R P A M;  NAGARAI B	INTERVET INT BV (IVET-C);  INTERVET INC (MERI-C);  INTERVET INC (MERI-C);  INTERVET INT BV (IVET-C);  INTERVET INT BV (IVET-C);  INTERVET INC (MERI-C)	201954071U	   NOVELTY - Immunogenic composition comprises (a) a first                alpha -virus RNA replicon particle that encodes a                first neuraminidase (NA) or its antigenic fragment                and a second alpha -virus RNA replicon particle                that encodes a second NA or its antigenic fragment,                or (b) immunogenic composition comprising an alpha                -virus RNA replicon particle that encodes two or                more NA's or their antigenic fragments. The                immunogenic composition does not comprise a swine                influenza A virus (IAV-S) hemagglutinin (HA) or its                antigenic fragment and a nucleotide sequence that                encodes the IAV-S HA or its antigenic fragment, and                the first NA and the second NA comprise amino acid                sequences having 98% sequence homology or                less.    USE - The immunogenic composition is useful as                vaccine for preventing disease due to influenza                virus, and immunizing a porcine against IAV-S (all                claimed) to elicit immunity against IAV-S and other                diseases e.g. other swine infectious                diseases.    ADVANTAGE - The composition is produced in a                cost-effective and rapid manner.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for vaccine,                which comprises the immunogenic composition, and a                carrier. 			B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-E02J;  B04-E03J;  B14-A02B;  B14-S11A;  B14-S12;  C04-E99;  C04-E02J;  C04-E03J;  C14-A02B;  C14-S11A;  C14-S12;  D05-H99;  D05-H07	A61K-039/00;  A61K-039/12;  A61K-039/145;  A61K-039/193;  A61K-039/295;  A61K-039/39;  A61K-009/10;  A61P-031/12;  A61P-031/16;  C12N-009/24;  A61K-047/06;  A61K-047/22;  A61K-048/00;  A61K-009/107;  A61P-037/04;  C12N-015/56;  C12N-015/63	WO2019121513-A1   27 Jun 2019   A61K-039/193   201953Pages: 74   English;  CN111491663-A   04 Aug 2020   A61K-039/193   202066   Chinese;  US2020330585-A1   22 Oct 2020   A61K-039/145   202086   English;  EP3727444-A1   28 Oct 2020   A61K-039/193   202088   English;  BR112020012049-A2   24 Nov 2020   A61K-009/10   202002   English;  JP2021506835-W   22 Feb 2021   A61K-039/145   202118Pages: 61   Japanese;  RU2020123612-A   20 Jan 2022   A61K-039/193   202293   Russian;  RU2787596-C2   11 Jan 2023   A61K-039/193   202312   Russian;  RU2022133854-A   10 Jan 2023   C12N-015/63   202315   Russian	WO2019121513-A1    WOEP085198    17 Dec 2018;   CN111491663-A    CN80081694    17 Dec 2018;   US2020330585-A1    US16954583    17 Jun 2020;   EP3727444-A1    EP830436    17 Dec 2018;   BR112020012049-A2    BR11012049    17 Dec 2018;   JP2021506835-W    JP533132    17 Dec 2018;   RU2020123612-A    RU123612    17 Dec 2018;   RU2787596-C2    RU123612    17 Dec 2018;   RU2022133854-A    RU133854    17 Dec 2018;   RU2787596-C9    RU123612    17 Dec 2018	CN111491663-A PCT application Application WOEP085198;   CN111491663-A Based on Patent WO2019121513;   US2020330585-A1 PCT application Application WOEP085198;   US2020330585-A1 Provisional Application US607101P;   EP3727444-A1 PCT application Application WOEP085198;   EP3727444-A1 Based on Patent WO2019121513;   BR112020012049-A2 PCT application Application WOEP085198;   BR112020012049-A2 Based on Patent WO2019121513;   JP2021506835-W PCT application Application WOEP085198;   JP2021506835-W Based on Patent WO2019121513;   RU2787596-C2 PCT application Application WOEP085198;   RU2787596-C2 Based on Patent WO2019121513;   RU2022133854-A Div ex Application RU123612;   RU2787596-C9 PCT application Application WOEP085198;   RU2787596-C9 Based on Patent WO2019121513	US607101P    18 Dec 2017;  BR11012049    15 Jun 2020;  CN80081694    17 Jun 2020;  US16954583    17 Jun 2020;  RU123612    20 Jul 2020	WO2019121513-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP3727444-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN            		WO2019121513-A1 -- WO2005007689-A1   ALPHAVAX INC (ALPH-Non-standard)   CHULAY J D,  DRYGA S,  REAP E A,  OLMSTED R A,  MORRIS J S;  WO2014005958-A1   NOVARTIS AG (NOVS)   BANNERJEE K,  BARNETT S,  OTTEN G,  GEALL A;  WO2017123976-A1   ETUBICS CORP (ETUB-Non-standard)   BALINT J,  JONES F R,  RICE A,  GABITZSCH E,  LATCHMAN Y;  WO2006078294-A2   CHIRON CORP (CHIR)   PERRI S,  POLO J,  UEMATSU Y,  GREER C;  WO2008033966-A2   ALPHAVAX INC (ALPH-Non-standard)   SMITH J F,  HUBBY B,  COPP L;  WO2009014919-A2   UNIV IOWA STATE RES FOUND INC (IOWA);  US SEC OF AGRIC (USDA);  UNIV MINNESOTA (MINU)   GRAMER M,  LAGER K,  MA W,  RICHT J,  VINCENT A L;  US8460913-B2   ALPHAVAX INC (ALPH-Non-standard)   KAMRUD K I,  SMITH J F,  MAUGHAN M;  US8597662-B2   INTERVET INT BV (IVET)   JACOBS A A C,  SCHRIER C C,  SEGERS R P A,  VERMEIJ P;  US9084768-B2   INTERVET INT BV (IVET)   JACOBS A A C,  SCHRIER C C,  SEGERS R P A M,  VERMEIJ P;  US9441247-B2   ALPHAVAX INC (ALPH-Non-standard)   RAYNER J O,  SMITH J F,  HUBBY B,  REAP E A	WO2019121513-A1  MARTHA I. NELSON ET          AL: "Evolution of Novel Reassortant A/H3N2 Influenza          Viruses in North American Swine and Humans, 2009-2011",          JOURNAL OF VIROLOGY., vol. 86, no. 16, 15 August 2012          (2012-08-15), US, pages 8872 - 8878, XP055564910, ISSN:          0022-538X, DOI:          10.1128/JVI.00259-12,relevantClaims[1-26],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;&lt;figure&gt;4&lt;/figure&gt;|page          8877, column 2, paragraph 3];            WEBSTER ET AL., MICROBIOL REV, vol. 56, 1992, pages 152 -          179;            TONG ET AL., PROC. NATL. ACAD. SCI., vol. 109, no. 11,          2012, pages 4269 - 4274;            MEHLE, VIRUSES, vol. 6, no. 9, 2014, pages 3438 -          3449;            NELSON; INCENT, TRENDS IN MICROBIOL., vol. 23, no. 3,          2015, pages 142 - 153;            HOLTKAMP ET AL., THE AMERICAN ASSOCIATION OF SWINE          VETERINARIANS ANNUAL MEETING, 2007;            KRUEGER; GRAY, CURR TOP MICROBIOL IMMUNOL, vol. 370,          2013, pages 201 - 225;            GAO ET AL., J GEN VIROL, vol. 98, no. 8, 2017, pages 2001          - 2010;            ANDERSON ET AL., INFLUENZA AND OTHER RESPIRATORY VIRUSES          7, 2013, pages 42 - 51;            ANDERSON ET AL., MSPHERE, vol. 1, no. 6, 2016, pages          e00275 - 16;            WATSON ET AL., J. VIROL., vol. 89, 2015, pages 9920 -          9931;            VANDER VEEN ET AL., ANIM HEALTH RES REV., vol. 13, no. 1,          2012, pages 1 - 9;            KAMRUD ET AL., J GEN VIROL., vol. 91, 2010, pages 1723 -          1727;            PUSHKO ET AL., VIROLOGY, vol. 239, 1997, pages 389 -          401;            BREDENBEEK ET AL., JOURNAL OF VIROLOGY, vol. 67, 1993,          pages 6439 - 6446;            LILJESTROM; GAROFF, BIOTECHNOLOGY (NY, vol. 9, 1991,          pages 1356 - 1361;            PUSHKO ET AL., VIROLOGY, vol. 239, no. 2, 1997, pages 389          - 401;            LEE ET AL., CAN J VET RES, vol. 71, no. 3, 2007, pages          207 - 12;            VINCENT ET AL., VACCINE, vol. 28, no. 15, 2010, pages          2782 - 2787;            KYRIAKIS ET AL., VET MICROBIOL, vol. 144, no. 1-2, 2010,          pages 67 - 74;            MEMOLI ET AL., MBIO, vol. 7, no. 2, 2016, pages e00417 -          16;            MONTO ET AL., J INFECT DIS, vol. 212, no. 8, 2015, pages          1191 - 1199;            MURPHY ET AL., N ENGL J MED, vol. 286, no. 25, 1972,          pages 1329 - 32;            BRETT; JOHANSSON, VIROLOGY, vol. 339, no. 2, 2005, pages          273 - 80;            JOHANSSON; KILBOURNE, PROC NATL ACAD SCI USA, vol. 91,          no. 6, 1994, pages 2358 - 2361;            KILBOURNE ET AL., J INFECT DIS, vol. 189, no. 3, 2004,          pages 459 - 461;            HESSEL ET AL., PLOS ONE, vol. 5, no. 8, 2010, pages          e12217;            BODEWES ET AL., EXPERT REV VACCINES, vol. 9, no. 1, 2010,          pages 59 - 72;            TRIPP; TOMPKINS, CURR TOP MICROBIOL IMMUNOL, vol. 333,          2009, pages 397 - 412;            VANDER VEEN ET AL., VACCINE, vol. 30, no. 11, 2012, pages          1944 - 1950;            NAYAK ET AL., J VIROL, vol. 84, no. 5, 2010, pages 2408 -          2420;            PAVLOVA ET AL., VACCINE, vol. 27, no. 5, 2009, pages 773          - 785;            SYLTE ET AL., VACCINE, vol. 25, no. 19, 2007, pages 3763          - 72;            BOSCH ET AL., J VIROL, vol. 84, no. 19, 2010, pages 10366          - 103674;            KLINGBEIL ET AL., VIRUS RES, vol. 199, 2015, pages 20 -          30;            KITIKOON ET AL., METHODS MOL BIOL, vol. 1161, 2014, pages          295 - 301;            SANDBULTE; EICHELBERGER, METHODS MOL BIOL, vol. 1161,          2014, pages 337 - 45;            KUMAR ET AL., BIOINFORMATICS, vol. 28, 2012, pages 2685 -          2686;            KATOH ET AL., NUCLEIC ACIDS RES., vol. 30, 2002, pages          3059 - 3066;            KATOH ET AL., MOLECULAR BIOLOGY AND EVOLUTION, vol. 30,          2013, pages 772 - 780;            PRICE ET AL., PLOS ONE,, vol. 5, no. 3, 2010, pages          e9490;            NELSON ET AL., J VIROL., vol. 86, no. 16, 2012, pages          8872 - 8878;            ANDERSON ET AL., INFLUENZA OTHER RESPIR VIRUSES SUPPL,          vol. 4, 2013, pages 42 - 51;            KUNTZ-SIMON; MADEC, ZOONOSES PUBLIC HEALTH., vol. 56, no.          6-7, 2009, pages 310 - 325;            KUMAR ET AL., MOLECULAR BIOLOGY AND EVOLUTION, vol. 35,          2018, pages 1547 - 1549;            MOLECULAR BIOLOGY AND EVOLUTION, vol. 18, 2001, pages 691          - 699	105730-0-0-0 K M			RA012P K M		CN109765384-A;  CN109765384-B	Canine coronavirus antibody fluorescence test            strip, comprises sample absorption pad, conjugate            release pad a, conjugate release pad b, nitrocellulose            membrane, absorbent pad and bottom plate	HE F;  WU X;  SHEN L;  WAN Y;  ZHU L;  LU X;  LI B;  FENG C;  CUI H;  LIU Y	BEIJING KWINBON BIOTECHNOLOGY CO LTD (BEIJ-Non-standard)	2019463593	   NOVELTY - Canine coronavirus antibody fluorescence test                strip, comprises sample absorption pad, conjugate                release pad a, conjugate release pad b,                nitrocellulose membrane, absorbent pad and bottom                plate, the conjugate release pad a is coated with a                chicken anti-canine antibody-biotin conjugate, the                conjugate release pad b is coated with a                streptavidin-fluorescent microsphere marker, the                nitrocellulose membrane has a detection line and a                quality control line, the detection line is coated                with canine coronavirus N-expressing protein, and                the quality control line is coated with a goat                anti-chicken anti-antibody.    USE - The Canine coronavirus antibody fluorescent                test strip is useful for detecting Canine                coronavirus antibody (claimed).    ADVANTAGE - The test strip: is economical; has high                sensitivity, strong specificity, simple operation,                and practicality; and can realize rapid on-site                quantitative detection.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for                preparing Canine coronavirus antibody fluorescence                test strip, comprising (1) preparing nitrocellulose                membrane having detection line coated with an                Canine coronavirus N-expressing protein and quality                control line coated with a goat anti-chicken                anti-antibody, (2) spraying conjugate release pad                with chicken anti-canine anti-antibody-biotin                conjugate and conjugate release pad b with a                streptavidin-fluorescent microsphere marker, and                (3) fixing the sample absorption pad, the conjugate                release pad a, the conjugate release pad b, the                nitrocellulose membrane, and absorbent pad                sequentially on the bottom plate.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic representation                of the sectional structure of test strip. 			A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	A03-A03;  A12-E13;  A12-V;  A12-W11L;  B04-E99;  B04-C02A3;  B04-G08;  B04-G27G;  B04-N03J;  B11-C07A5;  B12-K04;  C04-E99;  C04-C02A3;  C04-G08;  C04-G27G;  C04-N03J;  C11-C07A5;  C12-K04;  D05-H99;  D05-H09;  D05-H10;  S03-E09F;  S03-E14H	G01N-033/531;  G01N-033/569;  G01N-033/68	CN109765384-A   17 May 2019   G01N-033/68   201954Pages: 11   Chinese;  CN109765384-B   18 Nov 2022   G01N-033/68   202295   Chinese	CN109765384-A    CN10083502    29 Jan 2019;   CN109765384-B    CN10083502    29 Jan 2019	CN109765384-B Previous Publ. Patent CN109765384	CN10083502    29 Jan 2019			CN109765384-A -- CN103675261-A   UNIV NANCHANG (NANU)   LAI W,  PENG T;  CN103687615-A   DECARO N (DECA-Individual);  MARTELLA V (MART-Individual);  ELIA G (ELIA-Individual);  BUONAVOGLIA C (BUON-Individual)   DECARO N,  MARTELLA V,  ELIA G,  BUONAVOGLIA C;  CN107831317-A   HANGZHOU WEIRUI TECHNOLOGY CO LTD (HANG-Non-standard)   WU J,  ZHANG J,  WU G,  WANG Z;  CN108414748-A   SHENZHEN BLOT BIOTECH CO LTD (SHEN-Non-standard)   XIONG Z,  ZHANG Y,  MA W,  ZHANG D,  WANG H;  US4567042-A   AMERICAN HOME PROD CORP (AMHP)   ACREE W M,  EDWARDS B,  BLACK J W;  CN109765384-B -- CN103675261-A   UNIV NANCHANG (NANU)   LAI W,  PENG T;  CN103687615-A   DECARO N (DECA-Individual);  MARTELLA V (MART-Individual);  ELIA G (ELIA-Individual);  BUONAVOGLIA C (BUON-Individual)   DECARO N,  MARTELLA V,  ELIA G,  BUONAVOGLIA C;  CN107831317-A   HANGZHOU WEIRUI TECHNOLOGY CO LTD (HANG-Non-standard)   WU J,  ZHANG J,  WU G,  WANG Z;  CN108414748-A   SHENZHEN BLOT BIOTECH CO LTD (SHEN-Non-standard)   XIONG Z,  ZHANG Y,  MA W,  ZHANG D,  WANG H;  US4567042-A   AMERICAN HOME PROD CORP (AMHP)   ACREE W M,  EDWARDS B,  BLACK J W	CN109765384-A  : "IgG",          ,relevantClaims[1-2],relevantPassages[128-130]CN109765384-B            Zhuo Guorong and so on. fast colloidal gold immune          chromatography test strip for detecting dog serum          toxoplasma IgG antibody research, Zhuo Guorong et al.,          "Heilongjiang Animal Husbandry Veterinary"; 20100630; No.          6 (No. 11); No. 128-130	133921-0-0-0 K U			R01861 K U	1861-U	WO2019151632-A1;  KR2019093110-A;  KR2019093114-A;  KR2019093107-A;  AU2018405442-A1;  CA3090327-A1;  IN202017033401-A;  CN111727199-A;  EP3747902-A1;  BR112020015475-A2;  JP2021512599-W;  EP3747902-A4;  US2022177552-A1;  HK40029535-A0	New neutralizing binding molecule that binds to            spike protein on surface of Middle East respiratory            syndrome-coronavirus, useful for diagnosing and            treating infection caused by Middle East respiratory            syndrome coronavirus in subject	LEE S Y;  YI K S;  KIM C M;  SONG K M;  BAE Y J;  KIM W J;  CHEONG H J;  SONG J Y;  PARK M S;  NOH J Y;  CHUNG H J;  PARK M;  JIYUN R;  LI X;  LI G;  JIN Z;  SONG J;  PEI Y;  JIN Y;  ZHENG X;  PIAO W;  LU Z	CELLTRION INC (CLTR-C);  CELLTRION INC (CLTR-C)	2019685974	   NOVELTY - A neutralizing binding molecule that binds to                spike protein (S protein) on the surface of Middle                East respiratory syndrome-coronavirus, is                new.    USE - The neutralizing binding molecule is useful in                composition or diagnostic kit for diagnosing,                preventing and treating infection caused by Middle                East respiratory syndrome coronavirus in a subject                (all claimed).    ADVANTAGE - The neutralizing binding molecule does not                cause adverse side effects, and has a superior                ability to bind to the S protein of MERS-CoV and                excellent neutralizing effect on Middle East                respiratory syndrome coronavirus.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) an immunoconjugate in which at least one                tag is additionally bound to the binding                molecule;    (2) nucleic acid molecule encoding the binding                molecule;    (3) an expression vector in which the nucleic                acid molecule is inserted;    (4) cell line in which the expression vector                is transformed into a host cell to bind to Middle                East respiratory syndrome coronavirus to produce a                binding molecule having a neutralizing ability;                and    (5) composition comprising the binding                molecule. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-E02A;  B04-E03A;  B04-E08;  B04-E99;  B04-F0100E;  B04-F0200E;  B04-G01;  B04-G08;  B04-G23;  B04-Q01;  B11-C07A;  B12-K04G1B;  B14-A02B5;  D05-H11;  D05-H12A;  D05-H12E;  D05-H14;  D05-H99;  S03-E09F;  S03-E14H5	C07K-016/10;  G01N-033/569;  A61K-039/395;  A61P-031/12;  C07K-016/46;  C12N-001/15;  C12N-001/19;  C12N-001/21;  C12N-015/13;  C12N-015/63;  C12N-005/10;  G01N-033/53;  A61P-031/14	WO2019151632-A1   08 Aug 2019   C07K-016/10   201966Pages: 44   ;  KR2019093110-A   08 Aug 2019   C07K-016/10   201966   ;  KR2019093114-A   08 Aug 2019   C07K-016/10   201966   ;  KR2019093107-A   08 Aug 2019   C07K-016/10   201966   ;  AU2018405442-A1   20 Aug 2020   C07K-016/10   202068   English;  CA3090327-A1   08 Aug 2019   C07K-016/10   202070   English;  IN202017033401-A   18 Sep 2020   C07K-016/10   202081   English;  CN111727199-A   29 Sep 2020   C07K-016/10   202083   Chinese;  EP3747902-A1   09 Dec 2020   C07K-016/10   202000   English;  BR112020015475-A2   08 Dec 2020   C07K-016/10   202003   English;  JP2021512599-W   20 May 2021   C12N-015/13   202142Pages: 37   Japanese;  EP3747902-A4   01 Dec 2021   C07K-016/10   202198   English;  US2022177552-A1   09 Jun 2022   C07K-016/10   202247   English;  HK40029535-A0   19 Feb 2021   C07K-016/10   202295   English	WO2019151632-A1    WOKR015141    30 Nov 2018;   KR2019093110-A    KR138228    12 Nov 2018;   KR2019093114-A    KR152779    30 Nov 2018;   KR2019093107-A    KR108125    11 Sep 2018;   AU2018405442-A1    AU405442    30 Nov 2018;   CA3090327-A1    CA3090327    30 Nov 2018;   IN202017033401-A    IN17033401    04 Aug 2020;   CN111727199-A    CN80088236    30 Nov 2018;   EP3747902-A1    EP903480    30 Nov 2018;   BR112020015475-A2    BR11015475    30 Nov 2018;   JP2021512599-W    JP541701    30 Nov 2018;   EP3747902-A4    EP903480    30 Nov 2018;   US2022177552-A1    US16966248    30 Jul 2020;   HK40029535-A0    HK6019026    27 Oct 2020	AU2018405442-A1 PCT application Application WOKR015141;   AU2018405442-A1 Based on Patent WO2019151632;   CA3090327-A1 PCT application Application WOKR015141;   CA3090327-A1 Based on Patent WO2019151632;   IN202017033401-A PCT application Application WOKR015141;   IN202017033401-A Based on Patent WO2019151632;   CN111727199-A PCT application Application WOKR015141;   CN111727199-A Based on Patent WO2019151632;   EP3747902-A1 PCT application Application WOKR015141;   EP3747902-A1 Based on Patent WO2019151632;   BR112020015475-A2 PCT application Application WOKR015141;   BR112020015475-A2 Based on Patent WO2019151632;   JP2021512599-W PCT application Application WOKR015141;   JP2021512599-W Based on Patent WO2019151632;   US2022177552-A1 PCT application Application WOKR015141;   HK40029535-A0 PCT application Application WOKR015141;   HK40029535-A0 Based on Patent WO2019151632;   HK40029535-A0 Previous Publ. Patent CN111727199	KR011776    31 Jan 2018;  KR108125    11 Sep 2018;  KR138228    12 Nov 2018;  CN80088236    30 Nov 2018;  WOKR015141    30 Nov 2018;  BR11015475    29 Jul 2020;  CN80088236    30 Jul 2020;  CA3090327    07 Aug 2020	WO2019151632-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA                EP3747902-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      EP3747902-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR      		;  CN111727199-A -- CN104447986-A   CHINESE ACAD SCI MICROBIOLOGY INST (CWSW)   GAO F,  LI Y,  YAN J,  WAN Y;  CN106414496-A   KYRATSOUS C (KYRA-Individual);  SIVAPALASINGAM S (SIVA-Individual);  STAHL N (STAH-Individual)   KYRATSOUS C,  SIVAPALASINGAM S,  STAHL N;  WO2015164865-A1   DANA FARBER CANCER INST INC (DAND)   MARASCO W A,  TANG X;  WO2016080591-A1   BIONOTE INC (BION-Non-standard)   CHO Y S,  HA G W,  JUNG S K,  HAN S H,  JANG S G,  KIM J H;  EP3747902-A4 -- WO2015164865-A1   DANA FARBER CANCER INST INC (DAND)   MARASCO W A,  TANG X;  WO2015179535-A1   KYRATSOUS C (KYRA-Individual);  SIVAPALASINGAM S (SIVA-Individual);  STAHL N (STAH-Individual)   KYRATSOUS C,  SIVAPALASINGAM S,  STAHL N;  US2022177552-A1 -- US20170158752-A1   	CN111727199-A  KRISTEN E.PASCAL:          "Pre-and postexposure efficacy of fully human antibodies          against Spike protein in a novel humanized mouse model of          MERS-CoV infection",          PNAS,relevantClaims[1],relevantPassages[8739]EP3747902-A4  KRISTEN E. PASCAL          ET AL: "Pre- and postexposure efficacy of fully human          antibodies against Spike protein in a novel humanized          mouse model of MERS-CoV infection", PROCEEDINGS OF THE          NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 28, 14 July          2015 (2015-07-14), US, pages 8738 - 8743, XP055692240,          ISSN: 0027-8424, DOI:          10.1073/pnas.1510830112,relevantClaims[1-13],relevantPassages[&lt;figure&gt;5&lt;/figure&gt;];  X.-C. TANG ET AL:          "Identification of human neutralizing antibodies against          MERS-CoV and their role in virus adaptive evolution",          PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol.          111, no. 19, 13 May 2014 (2014-05-13), pages E2018 -          E2026, XP055162782, ISSN: 0027-8424, DOI:          10.1073/pnas.1402074111,relevantClaims[1-13],relevantPassages[&lt;figure&gt;2-4&lt;/figure&gt;|&lt;table&gt;1&lt;/table&gt;];            See also references of WO 2019151632A1						RU2694558-C1	METHOD FOR GENOME DETECTION OF CORONAVIRUS INFECTION CAUSATIVE AGENT IN CATTLE	CHERNYKH O YU;  BANNOV V A;  MALYSHEV D V;  MISHCHENKO A V;  DONNIK I M;  LAYSHEV K A;  SISYAGIN P N;  LYSENKO A A;  KRIVONOS R A;  SHEVKOPLYAS V N;  KOSHCHAEV A G;  CHERNOV A N;  KULAKOVA A L	UNIV KUBAN AGRIC (UKUB-C)	2019714568	   NOVELTY - Described is a method for detecting the coronavirus infection pathogen genome in cattle. Method includes isolation of RNA from biological material in form of extract of excrements or fragments of abdominal cavity by sorption method, synthesis of cDNA on RNA matrix by single-step staging with addition of internal and positive control samples of multiplex reverse transcription reaction and polymerase chain reaction - with 45 cycles of amplification with real-time detection using oligonucleotide primers specific for the virus genome region of fluorescent-labelled probe. Fragment of the coronavirus infection agent genome has the following nucleotide sequences: BCoVF 5'-GATCAAATTGCTAGT-3' - forward primer; BCoVR 5'-CAGTCTGCTTAGTTA-3' - reverse primer; BCoVP 5'-FAM-GGATGCCACTAAGCCA-3'-BHQ1 is a probe.    USE - Biotechnology.    ADVANTAGE - Invention extends the range of methods for diagnosing coronavirus infection in cattle. 1 cl, 4 tbl, 1 ex 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01A;  B04-E05;  B04-E99;  B04-F11B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  C04-E01A;  C04-E05;  C04-E99;  C04-F11B;  C11-C07B3;  C11-C08E3;  C11-C08F8;  C12-K04F;  C12-K04G1B;  D05-H06A;  D05-H18B;  D05-H99	C12Q-001/00	RU2694558-C1   16 Jul 2019   C12Q-001/00   201965Pages: 0   Russian	RU2694558-C1    RU101642    16 Jan 2018		RU101642    16 Jan 2018			RU2694558-C1 -- EP2780477-B1   US DEPT HEALTH&HUMAN SERVICES (USSH);  VINJE J (VINJ-Individual);  GREGORICUS N (GREG-Individual);  CHHABRA P (CHHA-Individual);  BARCLAY L (BARC-Individual)   VINJE J,  GREGORICUS N,  CHHABRA P,  BARCLAY L;  RU2435853-C1   UNIV RUSSIA MED FEDERAL AGENCY HEALTH CARE SOCIAL DEV (UYRU-Non-standard);  RUSSIA EDUCATION SCI MIN (RUED-Non-standard)   KAFARSKAYA L I,  EFIMOV B A,  SHKOPOROV A N,  KHOKHLOVA E V;  WO2016034610-A1   INTERVET INT BV (IVET);  INTERVET INC (MERI)   PETERS C M,  MELLENCAMP M W,  XUE W,  WASMOEN T L,  TRIGO E							CN109913423-A	Recombinant vero cell line stably expressing PDCoV            N protein used for preparing porcine delta coronavirus            reagent, and monitoring the specific antibody-positive            reaction contains PDCoV N protein gene and resistance            screening gene	ZHANG X;  QIAN B;  WU Y;  CHEN Y;  GUO M;  ZHANG C;  CAO Y	UNIV YANGZHOU (UYYZ-C)	201957248A	   NOVELTY - Recombinant vero cell line stably expressing                the PDCoV N protein contains PDCoV N protein gene                and resistance screening gene.    USE - Recombinant Vero cell line stably expressing a                porcine delta coronavirus N protein is used for the                preparation of a porcine delta coronavirus reagent,                for pig group un-vaccine immunity, and monitoring                the specific antibody-positive reaction that can                determine the herd virus infection (claimed). 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-F0200E;  B04-F11;  B04-G08;  B04-N02;  B11-C08E;  B12-K04G1B;  B14-G01;  C04-E99;  C04-F0200E;  C04-F11;  C04-G08;  C04-N02;  C11-C08E;  C12-K04G1B;  C14-G01;  D05-H99;  D05-H06A	C12N-015/50;  C12N-005/10;  C12Q-001/70	CN109913423-A   21 Jun 2019   C12N-005/10   201966Pages: 11   Chinese	CN109913423-A    CN10237539    27 Mar 2019		CN10237539    27 Mar 2019										KR2019063512-A	Testing and detecting coronavirus using real time PCR involves amplifying N gene using pair of primers, and confirming fluorescence value when one fluorescence probe hybridizes with amplification product and disassemblling	KYU Y H	KYU Y H (KYUY-Individual)	201951317F	   NOVELTY - Testing and detecting the coronavirus using the real time PCR involves amplifying N gene using a pair of primers, and confirming the fluorescence value when one fluorescence probe hybridizes with the amplification product and disassemblling.    USE - Method for testing and detecting coronavirus using real time PCR.    ADVANTAGE - The method enables to test and detect corona virus using real time PCR, which confirms the presence or absence of corona viruses in a simple and prompt manner. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E02;  B04-E03;  B04-E05;  B04-F11B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  D05-H06A;  D05-H18B	C12Q-001/68	KR2019063512-A   10 Jun 2019   C12Q-001/68   201947Pages: 4   	KR2019063512-A    KR162353    30 Nov 2017		KR162353    30 Nov 2017										CN110616198-A;  CN110616198-B	New recombinant adenovirus obtained by            transfecting adenovirus packaging cells having            adenovirus E1 gene with recombinant plasmid and            carrying out cell culture used for e.g. coronavirus            vaccine and medicine for neutralizing coronavirus	ZHANG L;  ZHOU D;  JIA W;  ZHANG C;  SHI X	UNIV TSINGHUA (UYQI-C);  CHINESE ACAD SCI SHANGHAI PASTEUR INST (CHSC-Non-standard)	202001788K	   NOVELTY - Recombinant adenovirus obtained by                transfecting adenovirus packaging cells with                recombinant plasmid and carrying out cell culture,                is new. The recombinant plasmid is obtained by                inserting a specific DNA molecule into a Delta E1                region of chimpanzee adenovirus vector AdC68. The                specific DNA molecule has a full-length MERS-CoV                Spike protein coding gene. The adenovirus packaging                cell has an adenovirus E1 gene.    USE - The recombinant adenovirus is useful in a                preparation of coronavirus vaccine and a medicine                for neutralizing coronavirus (all claimed) and                providing a possibility for radical cure of middle                east respiratory syndrome.    ADVANTAGE - The recombinant adenovirus protects the                recombinant adenovirus expressing the full-length                MERS-CoV Spike protein and provides the vaccine                which is against coronavirus MERS-CoV and has                important theoretical guidance value and wide                application prospects.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a recombinant adenovirus expressing                full-length MERS-CoV Spike protein, where the                starting strain of the recombinant adenovirus is                chimpanzee adenovirus type 68 or non-replicating                chimpanzee adenovirus type 68;    (2) a kit for preparing the recombinant                adenovirus comprising the recombinant plasmid and                the adenovirus packaging cells;    (3) the recombinant plasmid obtained by                inserting the specific DNA molecule into the Delta                E1 region of the chimpanzee adenovirus vector                AdC68; and    (4) a product comprising the recombinant                adenovirus as an active ingredient, where the                product is coronavirus vaccine or a medicine for                neutralizing coronaviruses. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E08;  B04-E99;  B04-F11A1E;  B14-A02B5;  B14-K01;  B14-S11A;  B14-S11D3;  D05-H07;  D05-H12E;  D05-H12F;  D05-H99	A61K-039/215;  A61P-031/14;  C07K-014/165;  C12N-015/50;  C12N-015/861;  C12N-007/01;  C12R-001/93	CN110616198-A   27 Dec 2019   C12N-007/01   202005Pages: 27   Chinese;  CN110616198-B   19 Feb 2021   C12N-007/01   202118   Chinese	CN110616198-A    CN10628239    19 Jun 2018;   CN110616198-B    CN10628239    19 Jun 2018	CN110616198-B Previous Publ. Patent CN110616198	CN10628239    19 Jun 2018			CN110616198-A -- CN102719478-A   IST RICERCHE BIOL MOLECOLARE ANGELETTI (ISTR)   CIRILLO A,  COLLOCA S,  ERCOLE B B,  MEOLA A,  NICOSIA A,  SPORENO E;  CN103937835-A   CHINESE ACAD SCI SHANGHAI PASTEUR HEALTH (CHSC-Non-standard)   YANG Y,  ZHOU D,  DING M;  CN105273067-A   INST VIRUS PREVENTION & CONTROL CHINA                  DI (CCDC)   DENG Y,  CHEN H,  HONG T,  LU Z,  TAN W,  GUO X,  LA J;  CN105543248-A   INST BEIJING VIRAL DISEASE CONTROL &                  PRE (CCDC)   DENG Y,  CHEN H,  HONG T,  LU Z,  TAN W,  GUO X,  LA J;  CN106414496-A   KYRATSOUS C (KYRA-Individual);  SIVAPALASINGAM S (SIVA-Individual);  STAHL N (STAH-Individual)   KYRATSOUS C,  SIVAPALASINGAM S,  STAHL N;  EP3045181-A1   UNIV MUENCHEN MAXIMILIANS LUDWIG (UMML);  UNIV PHILIPPS MARBURG (UYPH)   SUTTER G,  FUX R,  VOLZ A,  SONG F,  BECKER S,  EICKMANN M;  CN110616198-B -- CN102719478-A   IST RICERCHE BIOL MOLECOLARE ANGELETTI (ISTR)   CIRILLO A,  COLLOCA S,  ERCOLE B B,  MEOLA A,  NICOSIA A,  SPORENO E;  CN103937835-A   CHINESE ACAD SCI SHANGHAI PASTEUR HEALTH (CHSC-Non-standard)   YANG Y,  ZHOU D,  DING M;  CN105273067-A   INST VIRUS PREVENTION & CONTROL CHINA                  DI (CCDC)   DENG Y,  CHEN H,  HONG T,  LU Z,  TAN W,  GUO X,  LA J;  CN105543248-A   INST BEIJING VIRAL DISEASE CONTROL &                  PRE (CCDC)   DENG Y,  CHEN H,  HONG T,  LU Z,  TAN W,  GUO X,  LA J;  CN106414496-A   KYRATSOUS C (KYRA-Individual);  SIVAPALASINGAM S (SIVA-Individual);  STAHL N (STAH-Individual)   KYRATSOUS C,  SIVAPALASINGAM S,  STAHL N;  EP3045181-A1   UNIV MUENCHEN MAXIMILIANS LUDWIG (UMML);  UNIV PHILIPPS MARBURG (UYPH)   SUTTER G,  FUX R,  VOLZ A,  SONG F,  BECKER S,  EICKMANN M	CN110616198-A  ZHANG ET AL.:          "Current advancements and potential strategies in the          development of MERS-CoV vaccines", EXPERT REV.          VACCINES,relevantClaims[1-10],relevantPassages[761-774];  : "DPP4MERS-CoV",          ,relevantClaims[1-10],relevantPassages[593-600]CN110616198-B            Yao Yanfeng and so on. Clinical and biological          characteristics of MERS-CoV infected mouse model after          different doses of DPP4 is transduced; Yao Yanfeng, et          al., 20151130; the 31 volume (the sixth period); the No.          593-600;            Zhang et al .. Current and potential for the development          of MERS-CoV, Zhang et al, " Expert Rev. Vaccines,          20140426; the 13 volume (the sixth period); the 761-774          page	200757-0-0-0 M N; 200757-0-0-0 CL NEW USE			RA00GT M N		EP3431101-A1	Composition for vaccinating general population during pandemic, comprises one or more non-live antigens derived from respectively relevant pathogen, where one or more antigens are Herpes zoster, Polio, Hepatitis A, Seasonal Influenza	ARWIDSSON H;  MALTAIS A	EUROCINE VACCINES AB (EURO-Non-standard)	2019074159	   NOVELTY - Composition comprises one or more non-live antigens derived from the respectively relevant pathogen, where one or more antigens are Herpes zoster, Polio, Hepatitis A, Seasonal Influenza, Influenza A, Influenza B, Respiratory syncytial virus (RSV), Human metapneumovirus (hMPV), Human papilloma virus (HPV), Rota-virus, Norovirus, Human immunodeficiency virus (HIV), Herpes simplex, and/or Parainfluenza virus (OIV), Rhinovirus, Severe acute respiratory syndrome (SARS), Coronaviruses, Herpes zoster/varicella, Hepatitis A-E, Hanta-virus, Cytomegalovirus, flaviviruses or mixtures or from Pneumococci, Meningococci, Haemophilus influenzae b (Hib), Bacillus anthracis, Chlamydia trachomatis, Pseudomonas aeruginosa, Mycobacterium tuberculosis, Diphtheria, Escherichia coli, Streptococcus, Neisseria gonorrhoeae, Bordetella pertussis, Tetanus or adjuvant.    USE - Composition for vaccinating the general population during a pandemic.    ADVANTAGE - The composition is effective in naive subjects such as children against seasonal influenza virus strains.    DETAILED DESCRIPTION - The adjuvant comprises one or more carboxylic acids, aqueous medium, and optionally one or more mono-glycerides for use as an intranasally administered vaccine. The vaccine is for immunization or treating of pediatric subjects from newborn to 18 years of age against a pathogen infection. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B04C1;  B10-C04E;  B12-M12Q;  B14-A01;  B14-A02;  B14-A04;  B14-S18;  B14-S24;  C04-B04C1;  C10-C04E;  C12-M12Q;  C14-A01;  C14-A02;  C14-A04;  C14-S18;  D05-H07	A61K-039/00;  A61K-039/145;  A61K-039/39	EP3431101-A1   23 Jan 2019   A61K-039/145   201909Pages: 37   English	EP3431101-A1    EP193418    17 Dec 2013	EP3431101-A1 Div ex Application EP805935;   EP3431101-A1 Div ex Patent EP2931307	EP197522    17 Dec 2012	EP3431101-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  		EP3431101-A1 -- WO2012042003-A1   EUROCINE VACCINES AB (EURO-Non-standard)   SCHROEDER U,  ARWIDSSON H	EP3431101-A1  PETERSSON P ET AL: "The Eurocine&lt;(&gt;R) L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination", VACCINE, ELSEVIER LTD, GB, vol. 28, no. 39, 7 September 2010 (2010-09-07), pages 6491 - 6497, XP027267112, ISSN: 0264-410X, [retrieved on 20100715],relevantClaims[1-17],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;table&gt;1&lt;/table&gt;|&lt;pp&gt;6497&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;|&lt;pp&gt;6492&lt;/pp&gt;&lt;column&gt;r&lt;/column&gt;];  FALKEBORN TINA ET AL: "Endocine(TM), N3OA and N3OASq; Three Mucosal Adjuvants That Enhance the Immune Response to Nasal Influenza Vaccination.", PLOS ONE 2013, vol. 8, no. 8, 2013, pages e70527, XP009172690, ISSN: 1932-6203,relevantClaims[1-17],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  SUSANNA ESPOSITO ET AL: "Different influenza vaccine formulations and adjuvants for childhood influenza vaccination", VACCINE, vol. 29, no. 43, 4 August 2011 (2011-08-04), pages 7535 - 7541, XP028306518, ISSN: 0264-410X, [retrieved on 20110802], DOI: 10.1016/J.VACCINE.2011.08.012,relevantClaims[1-17],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  HAILE M ET AL: "Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine(TM) L3 adjuvant protects against tuberculosis", VACCINE, ELSEVIER LTD, GB, vol. 22, no. 11-12, 29 March 2004 (2004-03-29), pages 1498 - 1508, XP004500396, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2003.10.016,relevantClaims[1-17],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;1499&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;|&lt;pp&gt;1500&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;|&lt;pp&gt;1499&lt;/pp&gt;&lt;column&gt;r&lt;/column&gt;&lt;para&gt;4&lt;/para&gt;|&lt;pp&gt;1501&lt;/pp&gt;&lt;column&gt;r&lt;/column&gt;&lt;para&gt;5&lt;/para&gt;|&lt;pp&gt;1503&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;3&lt;/para&gt;];  BUONAGURO ET AL: "DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity", VACCINE, ELSEVIER LTD, GB, vol. 25, no. 32, 20 July 2007 (2007-07-20), pages 5968 - 5977, XP022162332, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2007.05.052,relevantClaims[1-17],relevantPassages[&lt;pp&gt;5969&lt;/pp&gt;&lt;column&gt;r&lt;/column&gt;&lt;para&gt;4&lt;/para&gt;];  HINKULA J ET AL: "A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations", VACCINE, ELSEVIER LTD, GB, vol. 24, no. 21, 22 May 2006 (2006-05-22), pages 4494 - 4497, XP028010738, ISSN: 0264-410X, [retrieved on 20060522], DOI: 10.1016/J.VACCINE.2005.08.015,relevantClaims[1-17],relevantPassages[&lt;pp&gt;4494&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;|&lt;pp&gt;4495&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;1&lt;/para&gt;];  SCHRODER U ET AL: "Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants", VACCINE, ELSEVIER LTD, GB, vol. 17, no. 15-16, 9 April 1999 (1999-04-09), pages 2096 - 2103, XP004165061, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(98)00408-3,relevantClaims[1-17],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;table&gt;4,5,6&lt;/table&gt;];  GLUECK T: "Vaccinate your immunocompromised patients!", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, LONDON, GB, vol. 45, no. 1, 1 January 2006 (2006-01-01), pages 9 - 10, XP002460594, ISSN: 1462-0324, DOI: 10.1093/RHEUMATOLOGY/KEI237,relevantClaims[1-17],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ESPOSITO S ET AL: "Vaccinations in children with cancer", VACCINE, ELSEVIER LTD, GB, vol. 28, no. 19, 26 April 2010 (2010-04-26), pages 3278 - 3284, XP026997103, ISSN: 0264-410X, [retrieved on 20100310],relevantClaims[1-17],relevantPassages[&lt;pp&gt;3281&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;6-8&lt;/para&gt;|&lt;pp&gt;3281&lt;/pp&gt;&lt;column&gt;r&lt;/column&gt;&lt;para&gt;3&lt;/para&gt;];  HANA HAKIM ET AL: "Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults", VACCINE, ELSEVIER LTD, GB, vol. 30, no. 5, 25 November 2011 (2011-11-25), pages 879 - 885, XP028436167, ISSN: 0264-410X, [retrieved on 20111205], DOI: 10.1016/J.VACCINE.2011.11.105,relevantClaims[1-17],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;884&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;3&lt;/para&gt;];  REED, L.J.; MUENCH, H.: "A simple method of estimating fifty percent endpoints", THE AMERICAN JOURNAL OF HYGIENE, vol. 27, 1938, pages 493 - 497;  RIMMELZWAAN GF ET AL., J VIROL METHODS, vol. 74, no. 1, September 1998 (1998-09-01), pages 57 - 66;  VAN DEN BRAND JM ET AL., PLOS ONE, vol. 7, no. 8, 2012, pages e42343;  MUNSTER VJ ET AL., SCIENCE, vol. 325, no. 5939, 24 July 2009 (2009-07-24), pages 481 - 3	87667-0-0-0 K M; 88534-0-0-0 K M; 2021-0-0-0 K M; 2068-0-0-0 K M; 95874-0-0-0 K M; 3222-0-0-0 K M; 102701-2-0-0 K M; 114178-6-0-0 K M; 5855-0-0-0 K M; 7117-0-0-0 K M; 7434-0-0-0 K M; 103159-2-0-0 K M; 8400-0-0-0 K M; 896-0-0-0 K M			R04038 K M; R03770 K M; R00122 K M; R01147 K M; R04255 K M; R00121 K M; R00954 K M; R04471 K M; RA7AF3 K M; R01143 K M; R01356 K M; R00206 K M; R04540 K M; R01226 K M; R01061 K M	0122-S; 1147-S; 0121-S; 0954-S; 1143-S; 1356-S; 0206-S; 1226-S; 1061-S	WO2019143955-A1;  CN111629751-A;  IN202017031357-A;  EP3743107-A1;  US2021093711-A1;  US11369675-B2	Composition used to e.g. elicit immune response to            influenza virus comprises inactivated first, second,            third and fourth influenza A viruses comprising            hemagglutinin of first, second, third and fourth            subtypes A respectively	TAUBENBERGER J K;  SCHWARTZMAN L M	US DEPT HEALTH & HUMAN SERVICES (USSH-C);  US DEPT HEALTH & HUMAN SERVICES (USSH-C);  US DEPT HEALTH & HUMAN SERVICES (USSH-C);  TAUBENBERGER J K (TAUB-Individual);  SCHWARTZMAN L M (SCHW-Individual)	201965247G	   NOVELTY - Composition comprises a first influenza A                virus comprising a hemagglutinin (HA) of a first                subtype, a second influenza A virus comprising a HA                of a second subtype, a third influenza A virus                comprising a HA of a third subtype and a fourth                influenza A virus comprising a HA of a fourth                subtype, where the first, second, third, and fourth                influenza A viruses are inactivated.    USE - The composition is useful for: eliciting an                immune response to influenza virus in a subject;                and immunizing a subject against influenza virus,                where the subject is a mammal or a bird, preferably                a human, the human is an adult subject or a                pediatric subject (all claimed); mitigating a                future pandemic. Test details are described but no                results given.    ADVANTAGE - The composition serve as a pre-pandemic                vaccine.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a                container comprising the composition; #eliciting an                immune response to influenza virus in a subject or                immunizing a subject against influenza virus,                comprising administering the composition; and #a                kit comprising the container 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-F11B;  B11-C06;  B14-A02B2;  B14-S11A;  B14-S11D1;  C04-F11B;  C14-A02B2;  C14-S11A;  C14-S11D1;  D05-H08A	A61K-039/145;  A61K-039/295;  A61P-031/16;  C12N-007/00;  A61K-039/00	WO2019143955-A1   25 Jul 2019   A61K-039/145   201960   English;  CN111629751-A   04 Sep 2020   A61K-039/145   202076   Chinese;  IN202017031357-A   18 Sep 2020   A61K-039/145   202082   English;  EP3743107-A1   02 Dec 2020   A61K-039/145   202098   English;  US2021093711-A1   01 Apr 2021   A61K-039/145   202128   English;  US11369675-B2   28 Jun 2022   A61K-039/145   202253   English	WO2019143955-A1    WOUS014220    18 Jan 2019;   CN111629751-A    CN80009484    18 Jan 2019;   IN202017031357-A    IN17031357    22 Jul 2020;   EP3743107-A1    EP717381    18 Jan 2019;   US2021093711-A1    US16963718    21 Jul 2020;   US11369675-B2    US16963718    21 Jul 2020	CN111629751-A PCT application Application WOUS014220;   CN111629751-A Based on Patent WO2019143955;   IN202017031357-A PCT application Application WOUS014220;   IN202017031357-A Based on Patent WO2019143955;   EP3743107-A1 PCT application Application WOUS014220;   EP3743107-A1 Based on Patent WO2019143955;   US2021093711-A1 PCT application Application WOUS014220;   US2021093711-A1 Provisional Application US620051P;   US11369675-B2 PCT application Application WOUS014220;   US11369675-B2 Provisional Application US620051P;   US11369675-B2 Based on Patent WO2019143955;   US11369675-B2 Previous Publ. Patent US2021093711	US620051P    22 Jan 2018;  CN80009484    21 Jul 2020;  US16963718    21 Jul 2020	WO2019143955-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW      EP3743107-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      		WO2019143955-A1 -- CN101732711-A   INST MICROBIOLOGY & EPIDEMIOLOGY (JSYX)   DUAN Y,  LIU K,  LUO D,  WANG C,  WANG X,  XING L,  YANG P,  ZHAO Z;  US6194388-B1   UNIV IOWA RES FOUND (IOWA);  COLEY PHARM GROUP (COLE-Non-standard)   KRIEG A M,  KLINMAN D,  STEINBERG A D;  US6207646-B1   UNIV IOWA RES FOUND (IOWA);  COLEY PHARM GROUP INC (PFIZ);  US DEPT HEALTH & HUMAN SERVICES (USSH)   KRIEG A M,  KLINE J,  KLINMAN D,  STEINBERG A D;  US6214806-B1   UNIV IOWA RES FOUND (IOWA)   SCHWARTZ D A,  KRIEG A M;  US6218371-B1   UNIV IOWA RES FOUND (IOWA)   KRIEG A M,  WEINER G;  US6239116-B1   UNIV IOWA RES FOUND (IOWA);  COLEY PHARM GROUP INC (PFIZ);  US DEPT HEALTH & HUMAN SERVICES (USSH)   KRIEG A M,  KLINE J N;  US6339068-B1   OTTAWA CIVIC HOSPITAL LOEB RES INST (OTTA-Non-standard);  UNIV IOWA RES FOUND (IOWA);  QIAGEN GMBH (QIAG)   DAVIS H L,  KRIEG A M,  SCHORR J,  WU T;  US6406705-B1   OTTAWA CIVIC LOEB RES INST (OTTA-Non-standard);  QIAGEN GMBH (QIAG);  UNIV IOWA RES FOUND (IOWA)   DAVIS H L,  SCHORR J,  KRIEG A M;  US6429199-B1   UNIV IOWA RES FOUND (IOWA)   KRIEG A M,  HARTMANN G;  WO2015195218-A1   US DEPT HEALTH & HUMAN SERVICES (USSH)   TAUBENBERGER J K;  US11369675-B2 -- US9278127-B2   GLAXOSMITHKLINE BIOLOGICALS SA (GLAX)   HANON E J,  STEPHENNE J;  US10130700-B2   US DEPT HEALTH & HUMAN SERVICES (USSH)   TAUBENBERGER J K;  CN101732711-A   INST MICROBIOLOGY & EPIDEMIOLOGY (JSYX)   DUAN Y,  LIU K,  LUO D,  WANG C,  WANG X,  XING L,  YANG P,  ZHAO Z;  US4522809-A   INST PASTEUR (INSP)   ADAMOWICZ P,  MULLER L;  US5698432-A   RETROSCREEN LTD (RETR-Non-standard)   OXFORD J S	WO2019143955-A1  LOUIS M.          SCHWARTZMAN ET AL: "An Intranasal Virus-Like Particle          Vaccine Broadly Protects Mice from Multiple Subtypes of          Influenza A Virus", MBIO, vol. 6, no. 4, 21 July 2015          (2015-07-21), pages e01044 - 15, XP055386099, DOI:          10.1128/mBio.01044-15,relevantClaims[1-32],relevantPassages[page          7 left col., Table 1, Figures 1-4];  KARL-HEINZ          HERBINGER ET AL: "A phase II study of an investigational          tetravalent influenza vaccine formulation combining MF59          ?", HUMAN VACCINES AND IMMUNOTHERAPEUTICS, vol. 10, no.          1, 20 September 2013 (2013-09-20), US, pages 92 - 99,          XP055222167, ISSN: 2164-5515, DOI:          10.4161/hv.26495,relevantClaims[1-32],relevantPassages[&lt;pp&gt;97&lt;/pp&gt;&lt;column&gt;left&lt;/column&gt;&lt;coll&gt;right&lt;/coll&gt;];  ANONYMOUS: "ANNEX I          SUMMARY OF PRODUCT CHARACTERISTICS", 1 January 2017          (2017-01-01), XP055587595, Retrieved from the Internet          &lt;URL:https://www.ema.europa.eu/en/documents/product-information/aflunov-epar-product-information_en.pdf&gt;          [retrieved on 20190510],relevantClaims[1-32];  ANONYMOUS: "PACKAGE          LEAFLET: INFORMATION FOR THE USER", 1 January 2015          (2015-01-01), XP055587597, Retrieved from the Internet          &lt;URL:https://www.hpra.ie/img/uploaded/swedocuments/2154348.PA0919_001_001.edac2ec8-a54d-42aa-9a76-ae241135d10c.000001PIL.150304.pdf&gt;          [retrieved on 20190510],relevantClaims[1-32];            BENJAMIN LEWIN: "Genes V", 1994, OXFORD UNIVERSITY          PRESS;            "The Encyclopedia of Molecular Biology", 1994, BLACKWELL          SCIENCE LTD.;            "Molecular Biology and Biotechnology: a Comprehensive          Desk Reference", 1995, VCH PUBLISHERS, INC.;            BONNAFOUS ET AL., BIOCHIM BIOPHYS ACTA, vol. 1838, no. 1,          2013, pages 355 - 363;            DELRUE ET AL., EXPERT REV VACCINES, vol. 11, no. 6, 2012,          pages 695 - 719;  E.          W. MARTIN: "Remington's Pharmaceutical Sciences", 1975,          MACK PUBLISHING CO.;            COTTEY ET AL., CURRENT CONTENTS IN IMMUNOLOGY, 2001,          pages 19.11.1 - 19.11.32;            SANDBULTE ET AL., INFLUENZA OTHER RESPIR VIRUSES, vol. 3,          2009, pages 233 - 40;            CATE ET AL., VACCINE, vol. 28, 2010, pages 2076 -          9;            GAUGER ET AL., METHODS MOL BIOL., vol. 1161, 2014, pages          303 - 12;            LARSEN ET AL., VET MICROBIOL., vol. 74, no. 1-2, 2000,          pages 117 - 31;            STEITZ ET AL., PLOS ONE, vol. 5, no. 5, 2010, pages          e10492;            GAUGER ET AL., METHODS MOL BIOL., vol. 1161, 2014, pages          313 - 24;  WU          ET AL., PLOS ONE, vol. 7, no. 8, 2012, pages          e42363US11369675-B2            Anonymous, Annex I, Summary of Product Characteristics,          AFLUNOV suspension for injection in pre-filled syringe,          https://www.ema.europa.eu/en/documents/product-information/aflunov-epar-product-information_en.pdf.,          Jan. 1, 2017, downloaded May 10, 2019, 30 pp.;            Anonymous, Package Leaflet: Information for the User,          AGRIPPAL 2014/2015, Suspension for injection in          pre-filled syringe,          https://www.hpra.ie/img/uploaded/swedocuments/2154348.PA0919_001.edac2ec8-a54d-42aa-9a76-ae241135d10c.000001PIL.150304.pdf,          Jan. 1, 2015, downloaded May 10, 2019, 8 pp.;            Herbinger et al., A Phase II Study of an Investigational          Tetravalent Influenza Vaccine Formulation Combining MF59,          &lt;xhtml:i &gt;Human Vaccin.          Immunother&lt;/xhtml:i&gt;., vol. 10:92-99,          2014.;            International Search Report and Written Opinion from          PCT/US2019/014220, dated May 23, 2019, 11          pages.;            Schwartzman et al., An Intranasal Virus-Like Particle          Vaccine Broadly Protects Mice from Multiple Subtypes of          Influenza A Virus, &lt;xhtml:i          &gt;mBio&lt;/xhtml:i&gt;, vol. 6:e010445-15,          2015.;            Vemula et al., Vaccine approaches conferring          cross-protection against influenza viruses,          &lt;xhtml:i &gt;Expert Rev          Vaccines&lt;/xhtml:i&gt;, vol. 16(11): 1141-1154,          2017.	200757-0-0-0 K U			RA00GT K U		KR2019078174-A;  KR2033773-B1	Kit useful for pretreating sputum to detect middle east respiratory syndrome-coronavirus, comprises first component containing reducing agent, and second component containing neutralizing agent	YANG J S;  KIM S S;  SONG D;  NA W;  KANG A;  YEOM M;  HA G W;  KIM J H;  KIM D H;  KIM S;  SONG D S;  SUNG N W;  JOO Y M;  HA G;  KIM D	KOREA DISEASE CONTROL & PREVENTION CENT (KODI-Non-standard);  UNIV KOREA RES & BUSINESS FOUND (UYKR-C);  BIONOTE INC (BION-Non-standard)	201960270H	   NOVELTY - Kit comprises first component containing reducing agent, and second component containing neutralizing agent.    USE - The kit is useful for pretreating sputum (claimed) to detect middle east respiratory syndrome-coronavirus.    ADVANTAGE - The kit quickly and accurately detects middle east respiratory syndrome-coronavirus in sputum by eliminating mucus without damaging antigen of virus contained in sputum by sequentially pretreating with reducing agent and the neutralizing agent.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for pretreating sputum, comprising (a) treating reducing agent to sputum, and (b) treating the neutralizing agent to the sputum. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.)	B04-B04D2;  B04-N02;  B12-K04G1B;  B12-K04G2G	C12N-015/10;  C12Q-001/68	KR2019078174-A   04 Jul 2019   C12Q-001/68   201957Pages: 10   ;  KR2033773-B1   17 Oct 2019   C12Q-001/68   201982   	KR2019078174-A    KR179939    26 Dec 2017;   KR2033773-B1    KR179939    26 Dec 2017	KR2033773-B1 Previous Publ. Patent KR2019078174	KR179939    26 Dec 2017					90158-0-0-0 K M; 297125-0-0-0 K M			R24040 K M; RA20EO K M		RU2694499-C1	TEST SYSTEM FOR DETECTING CORONAVIRUS INFECTION PATHOGEN GENOME IN CATTLE BY MEANS OF MULTIPLEX POLYMERASE CHAIN REACTION WITH FLUORESCENT DETECTION IN REAL TIME	CHERNYKH O YU;  BANNOV V A;  MALYSHEV D V;  DROBIN YU D;  DONNIK I M;  USHA B V;  PLEMYASHOV K V;  LYSENKO A A;  KRIVONOS R A;  SHEVKOPLYAS V N;  KOSHCHAEV A G;  MISHCHENKO A V;  KULAKOVA A L	UNIV KUBAN AGRIC (UKUB-C)	201971456S	   NOVELTY - Described is a test system for detecting the coronavirus infection pathogen genome in cattle using a multiplex polymerase chain reaction (PCR) with real-time fluorescent detection. Test system comprises a PCR buffer, a mixture for its carrying out, consisting of deoxynucleoside triphosphates, primers and fluorescent probes specific for coronavirus A and for an internal control sample; mixture of enzymes from DNA polymerase with antibodies inhibiting enzyme activity, TAQ POLYMERASE and reverse transcriptase MMLV REVERSE TRANSCRIPTASE. Mixture of recombinant plasmid DNA containing a fragment of BCoV virus genome and a fragment of bacteriophage MS2 genome contains the following nucleotide sequences: BCoVF 5'-GATCAAATTGCTAGT-3' - forward primer; BCoVR 5'-CAGTCTGCTTAGTTA-3' - reverse primer; BCoVP 5'-FAM-GGATGCCACTAAGCCA-3' - BHQ1 - probe; MS2F 5'-TGGCACTACCCCTCTCCGTATTCAC-3' - forward primer; MS2R, 5'-GTACGGGCGACCCCACGATGAC-3' - reverse primer; MS2P Cy5 5'-CACATCGATAGATCAAGGTGCCTACAAGC-3 BHQ' is a probe.    USE - Biotechnology.    ADVANTAGE - Invention extends the range of means for detecting coronavirus infection genome in cattle. 1 cl, 4 tbl, 1 ex 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03B;  B04-E01;  B04-E05;  B04-E08;  B04-E99;  B04-F11B;  B04-L04A;  B04-L04B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  C04-B03B;  C04-E01;  C04-E05;  C04-E08;  C04-E99;  C04-F11B;  C04-L04A;  C04-L04B;  C11-C07B3;  C11-C08E3;  C11-C08F8;  C12-K04F;  C12-K04G1B;  D05-A02B;  D05-H06A;  D05-H18B;  D05-H99	C12Q-001/68	RU2694499-C1   15 Jul 2019   C12Q-001/68   201967Pages: 0   Russian	RU2694499-C1    RU101637    16 Jan 2018		RU101637    16 Jan 2018			RU2694499-C1 -- EP2780477-B1   US DEPT HEALTH&HUMAN SERVICES (USSH);  VINJE J (VINJ-Individual);  GREGORICUS N (GREG-Individual);  CHHABRA P (CHHA-Individual);  BARCLAY L (BARC-Individual)   VINJE J,  GREGORICUS N,  CHHABRA P,  BARCLAY L;  RU2435853-C1   UNIV RUSSIA MED FEDERAL AGENCY HEALTH CARE SOCIAL DEV (UYRU-Non-standard);  RUSSIA EDUCATION SCI MIN (RUED-Non-standard)   KAFARSKAYA L I,  EFIMOV B A,  SHKOPOROV A N,  KHOKHLOVA E V;  WO2016034610-A1   INTERVET INT BV (IVET);  INTERVET INC (MERI)   PETERS C M,  MELLENCAMP M W,  XUE W,  WASMOEN T L,  TRIGO E		1525931-1-0-0 K M; 204644-0-0-0 K M; 201562-0-0-0 K M			RARECG K M; RA031J K M; RA0124 K M		CN109593889-A	Detecting porcine delta coronavirus based on            real-time fluorescent reverse transcription            recombinase-mediated strand replacement nucleic acid            amplification technology comprises extracting PDCoV            viral RNA as template RNA	CONG X;  WANG H;  YANG Z;  YANG Y	GUANGZHOU DONGBAI BIOTECHNOLOGY CO LTD (GUAN-Non-standard);  UNIV ZHEJIANG (UYZH-C)	201935210V	   NOVELTY - Detecting porcine delta coronavirus based on                real-time fluorescent reverse transcription                recombinase-mediated strand replacement nucleic                acid amplification technology comprises (1)                extracting PDCoV viral RNA as a template RNA, (2)                designing Real time RT-RAA primers and probes, (3)                establishing Real time RT-RAA reaction system,                performing Real time RT-RAA reaction on viral RNA,                and real-time fluorescence detection results.    USE - The method is useful for detecting porcine                delta coronavirus based on real-time fluorescent                reverse transcription recombinase-mediated strand                replacement nucleic acid amplification                technology.    ADVANTAGE - The method is economical and has good                specificity. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E05;  B04-E99;  B04-F0100E;  B04-F11B;  B04-L04B;  B04-L05A;  B11-C07B3;  B11-C08D1;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  C04-E01;  C04-E05;  C04-E99;  C04-F0100E;  C04-F11B;  C04-L04B;  C04-L05A;  C11-C07B3;  C11-C08E3;  C11-C08F8;  C12-K04F;  C12-K04G1B;  D05-H06A;  D05-H18B;  D05-H99	C12Q-001/6844;  C12Q-001/70;  C12R-001/93	CN109593889-A   09 Apr 2019   C12Q-001/70   201951Pages: 17   Chinese	CN109593889-A    CN11640249    29 Dec 2018		CN11640249    29 Dec 2018			CN109593889-A -- CN105483290-A   UNIV HENAN AGRIC (UYHR)   HU H,  LIANG X,  WEI Z,  ZHENG L,  ZHANG J,  ZHANG L,  CAO B;  CN107557497-A   LANZHOU VETERINARY RES INST CHINA AGRIC (CAGS)   LIU X,  ZHANG Y,  WANG Y,  FANG Y,  ZHOU P,  XIAO S;  CN108624720-A   ZHEJIANG INT TRAVEL HEALTH CARE CENT KOU (ZHEJ-Non-standard);  JIANGSU QITIAN GENE BIOLOGICAL TECHNOLOG (JIAN-Non-standard)   ZHENG W,  WU Z,  MA H,  HUANG L,  YANG Y,  GUO L,  TANG S,  WANG Z,  YING Q	CN109593889-A  LEI MA:          "Development of a Conventional RT-PCR Assay for Rapid          Detection of Porcine Deltacoronavirus with the Same          Detection Limit as a SYBR Green-Based Real-Time RT-PCR          Assay", BIOMED RESEARCH          INTERNATIONAL,relevantClaims[1-10],relevantPassages[1-7];  : "TaqManPCR",          ,relevantClaims[1-10],relevantPassages[1080-1086]	201562-0-0-0 D K M			RA0124 D K M		KR2019134578-A;  KR2136954-B1	Middle east respiratory syndrome-related corona virus epitope protein comprises amino acid sequence	YONGSEOK J;  KIM J	UNIV CHONBUK NAT IND COOP FOUND (UYCN-C)	2019A2418R	   NOVELTY - Middle east respiratory syndrome-related (MERS) corona virus epitope protein comprises the amino acid sequence of (SEQ ID NO: 2), given in the specification.    USE - Middle east respiratory syndrome-related corona virus epitope protein.    ADVANTAGE - The middle east respiratory syndrome-related corona virus epitope protein, which induces innate immune responses, inflammatory cytokines, and inhibits the proliferation of NOd2 and RNA viruses, has antiviral activity, enhancement of innate immunity and immune booster effect.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:    (1) an antigen of MERS coronavirus, which comprises the epitope;    (2) a recombinant vector, which comprises a gene encoding the epitope protein;    (3) a transformant, which is transformed with the recombinant vector;    (4) a pharmaceutical composition for preventing or treating MERS coronavirus infection, which comprises the transformant, a protein extract of the transformant, or a recombinant MERS coronavirus epitope protein isolated from the transformant; and    (5) a health functional food composition for preventing or improving MERS coronavirus infection, which comprises the transformant, a protein extract of the transformant, or a recombinant MERS coronavirus epitope protein isolated from the transformant. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)	B04-B04C1;  B04-C01G;  B04-E08;  B04-E99;  B04-F0100E;  B04-N03K1;  B04-N03K1E;  B14-A02;  B14-G01;  B14-L01;  D03-F06;  D03-H01T2B;  D05-H12E;  D05-H14;  D05-H99	A23L-033/18;  A61K-038/17;  A61P-031/12;  C07K-014/005	KR2019134578-A   04 Dec 2019   A61K-038/17   201997Pages: 22   ;  KR2136954-B1   23 Jul 2020   A61K-038/17   202062   	KR2019134578-A    KR154546    27 Nov 2019;   KR2136954-B1    KR154546    27 Nov 2019	KR2019134578-A Div ex Application KR171343;   KR2136954-B1 Div ex Application KR171343	KR171343    13 Dec 2017;  KR154546    27 Nov 2019					184616-0-0-0 M N; 200757-0-0-0 M N			RA00H3 M N; RA00GT M N		US2019351049-A1	Composition comprises a first anti-Middle East            Respiratory Syndrome-Coronavirus spike protein            (MERS-CoV-S) antibody or antigen-binding fragment, a            second anti-MERS-CoV-S antibody or antigen-binding            fragment	KYRATSOUS C;  STAHL N;  SIVAPALASINGAM S	REGENERON PHARM INC (REGN-C)	201997416N	   NOVELTY - Composition comprises a first anti-Middle East                Respiratory Syndrome-Coronavirus spike protein                (MERS-CoV-S) antibody or antigen-binding fragment,                a second anti-MERS-CoV-S antibody or                antigen-binding fragment, and a pharmaceutically                acceptable carrier or diluent, where first                anti-MERS-CoV-S antibody does not cross-compete                with second anti-MERS-CoV-S antibody.    USE - Composition use in treating MERS                infection. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-E99;  B04-G08;  B04-G23;  B14-A02B5;  B14-K01;  D05-H11;  D05-H99;  S03-E09F;  S03-E14H5	A61K-039/12;  A61K-039/215;  A61K-045/06;  C07K-014/165;  C07K-016/10;  G01N-033/569	US2019351049-A1   21 Nov 2019   A61K-039/215   201991Pages: 149   English	US2019351049-A1    US530140    02 Aug 2019	US2019351049-A1 Provisional Application US002233P;   US2019351049-A1 Provisional Application US004971P;   US2019351049-A1 Provisional Application US051717P;   US2019351049-A1 Provisional Application US072716P;   US2019351049-A1 Cont of Application US633589;   US2019351049-A1 Cont of Application US717760;   US2019351049-A1 Cont of Patent US9718872;   US2019351049-A1 Cont of Patent US10406222	US002233P    23 May 2014;  US530140    02 Aug 2019			US2019351049-A1 -- US20170158752-A1   		184587-0-0-0 K M			RA00C8 K M		KR2019070629-A	Pharmaceutical composition for preventing or            treating congenital immune enhancement or viral            infection, comprises human beta-defensin 2, and healthy            functional food composition also comprises human            beta-defensin 2	JANG Y S;  KIM J	UNIV CHONBUK NAT IND COOP FOUND (UYCN-C)	201956726K	   NOVELTY - Pharmaceutical composition comprises HBD2                (human beta-defensin 2).    USE - Pharmaceutical composition for preventing or                treating congenital immune enhancement or viral                infection.    ADVANTAGE - The pharmaceutical composition comprises human                beta-defensin 2, which has antiviral activity,                innate immunity enhancement and immunity                enhancement effect.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a healthy functional food composition for                preventing or improving congenital immune                enhancement, which comprises HBD2 (human                beta-defensin 2), and viral infection;    (2) a MERS coronavirus epitope protein                consisting of the amino acid sequence of (SEQ ID                NO: 2), given in the specification;    (3) an antigen of a MERS coronavirus, which                vomprises the epitope;    (4) a recombinant vector, which comprises a                gene encoding the epitope protein;    (5) a transformant transformed with the                recombinant vector;    (6) a pharmaceutical composition for the                prevention or treatment about the MERS coronavirus                infection, which comprises the recombining MERS                coronavirus epitope protein separated from the                transformant, and the protein extract or the                transformant of the transformant; and    (7) a health functional food composition for                preventing or improving a corn virus infection,                which comprises a transformant, a protein extract                of the transformant, or a recombinant maize                coronavirus epitope protein isolated from the                transformant. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)	B04-C01G;  B04-E08;  B04-E99;  B04-F0100E;  B04-N02;  B04-N03K1;  B04-N03K1E;  B14-A02B5;  B14-G01;  B14-S11A;  B14-S11D3;  D03-F06;  D03-H01T2B;  D05-H12E;  D05-H14;  D05-H99	A23L-033/18;  A61K-038/17;  C07K-014/005	KR2019070629-A   21 Jun 2019   A61K-038/17   201952Pages: 16   	KR2019070629-A    KR171343    13 Dec 2017		KR171343    13 Dec 2017					198683-0-0-0 M N; 198683-0-0-0 CL NEW USE			RA16R3 M N		RU2685121-C1	VACCINE STRAIN OF INFLUENZA VIRUS            A/17/HONGKONG/2017/75108 (H7N9) FOR PRODUCING            POTENTIALLY PANDEMIC LIVE INTRANASAL INFLUENZA            VACCINE	BAZHENOVA E A;  KISELEVA I V;  ISAKOVA S I N;  MATYUSHENKO V A;  KRUTIKOVA E V;  REKSTIN A R;  RUDENKO L G	EXPERIMENTAL MEDICINE INST (EXPE-Non-standard)	201940451Y	   NOVELTY - Invention represents a strain of influenza                virus A/17/HongKong/2017/75108 (H7N9), deposited in                the State Collection of Viruses of FGBU                "N.F.Gamaleya Federal Research Center for                Epidemiology & Microbiology" of Russian                Ministry of Health, D.I.Ivanovsky Institute of                Virology under No. 2860.    USE - Biotechnology.    ADVANTAGE - Declared strain is used for production of live                intranasal influenza vaccine for adults and                children. 1 cl, 6 tbl 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-F11B;  B11-C04;  B12-M12Q;  B14-A02B2;  B14-S11A;  B14-S11D2;  D05-H06A	C12N-007/00	RU2685121-C1   16 Apr 2019   C12N-007/00   201938Pages: 0   Russian	RU2685121-C1    RU121381    08 Jun 2018		RU121381    08 Jun 2018			RU2685121-C1 -- RU2416640-C1   AS SIBE MED EXPERIMENTAL MED RES INST (ASIM-Soviet Institute)   ALEKSANDROVA G I,  KISELEVA I V,  LARIONOVA N V,  RUDENKO L G	RU2685121-C1  ..          : , , -, 2017.						CN109371174-A	New kit useful for specifically detecting a middle            east respiratory syndrome coronavirus in a sample		JIANGSU EHCHUANG BIOLOGICAL TECHNOLOGY (JIAN-Non-standard)	201921594X	   NOVELTY - Kit comprises PCR reaction solutions, enzyme                mixtures, negative control products, and positive                control products, is new. where the primer sequence                for the nucleic acid amplification reaction in the                PCR reaction solution are: P1: 5-                tgctaagaatagagctcgcactgtt-3, P2: 5-                tagtaccaatgacgcaagtcgct-3, the sequence of the                oligonucleotide probe for fluorescence signal                monitoring in the PCR reaction solution is Probe1:                5'-X1-tcgccagtaccatcag-Y1-3', Probe1 fluorescent                reporter group X1 is FAM, and fluorescence                quenching group Y1 is MGB.    USE - The kit is useful for specifically detecting a                middle east respiratory syndrome coronavirus in a                sample (claimed). 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03B;  B04-B03C;  B04-E01B;  B04-E05;  B04-E99;  B04-F11B;  B04-L01;  B04-L04B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  D05-A02;  D05-H06A;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/686;  C12Q-001/70	CN109371174-A   22 Feb 2019   C12Q-001/70   201943Pages: 8   Chinese	CN109371174-A    CN11566975    20 Dec 2018		CN11566975    20 Dec 2018					201562-0-0-0 D K M			RA0124 D K M		WO2019027501-A1;  US2020171060-A1;  US11253529-B2;  US2022133756-A1;  US11980630-B2	Preventing, treating or reducing effects of            filovirus, flavivirus or coronavirus comprises            administering acyclic fleximer nucleoside analog            comprising e.g.            2-(((4-(2-amino-4-methoxypyrimidin-5-yl)-1H-imidazol-1-yl))            methoxy)) ethyl acetate	RADTKE K L	UNIV MARYLAND BALTIMORE COUNTY (UMBA-C);  UNIV MARYLAND BALTIMORE COUNTY (UMBA-C);  UNIV MARYLAND BALTIMORE COUNTY (UMBA-C)	2019139020	   NOVELTY - Preventing, treating and/or reducing the                effects of a filovirus, flavivirus or coronavirus                comprises administering an acyclic fleximer                nucleoside analog comprising                2-((4-(2-amino-4-methoxypyrimidin-5-yl)-1H-imidazol-1-yl)methoxy)ethyl                acetate (I) ,                (R)-2-((S)-(2-(2-(4-(2-amino-4-methoxy-pyrimidin-5-yl)-imidazol-1-yl-methoxy)-ethoxy)-ethoxy)-phenoxy-phosphorylamino)-propionic                acid 1-ethyl-propyl ester (II),                2-((4-(2-amino-4-methoxypyrimidin-5-yl)-1H-imidazol-1-yl)methoxy)ethyl                triphosphate (III) and                2-((4-(2-amino-4-methoxypyrimidin-5-yl)-1H-imidazol-1-yl)methoxy)ethanol                (IV) and their salts, isomers, hydrates, prodrugs                or solvates.    USE - The method is useful for preventing, treating                and/or reducing the effects of a filovirus,                flavivirus or coronavirus, where the coronavirus is                severe acute respiratory syndrome (SARS) or middle                east respiratory syndrome (MERS), the Flavivirus is                Dengue, Zika or West Nile and the Filovirus is                Ebola, Sudan or and Marburg.    DETAILED DESCRIPTION - Preventing, treating and/or reducing the                effects or binding to natural and/or mutated                polymerases of a filovirus, flavivirus or                coronavirus comprises administering an acyclic                fleximer nucleoside analog comprising                2-((4-(2-amino-4-methoxypyrimidin-5-yl)-1H-imidazol-1-yl)methoxy)ethyl                acetate compound of formula (I),                (R)-2-((S)-(2-(2-(4-(2-amino-4-methoxy-pyrimidin-5-yl)-imidazol-1-yl-methoxy)-ethoxy)-ethoxy)-phenoxy-phosphorylamino)-propionic                acid 1-ethyl-propyl ester compound of formula (II),                2-((4-(2-amino-4-methoxypyrimidin-5-yl)-1H-imidazol-1-yl)methoxy)ethyl                triphosphate compound of formula (III) and                2-((4-(2-amino-4-methoxypyrimidin-5-yl)-1H-imidazol-1-yl)methoxy)ethanol                compound of (IV). 			B03 (Other heterocyclics.);  C02 (Heterocyclic.)	B04-E99;  B05-B01J;  B07-D09;  B07-D12;  B14-A02;  C04-E99;  C05-B01J;  C07-D09;  C07-D12;  C14-A02	A61K-031/506;  A61K-031/66;  A61P-031/12;  A61K-031/675;  A61K-031/683;  A61K-045/06	WO2019027501-A1   07 Feb 2019   A61K-031/506   201915Pages: 43   English;  US2020171060-A1   04 Jun 2020   A61K-031/683   202046   English;  US11253529-B2   22 Feb 2022   A61K-031/683   202218   English;  US2022133756-A1   05 May 2022   A61K-031/683   202239   English;  US11980630-B2   14 May 2024   A61K-031/683   202441   English	WO2019027501-A1    WOUS015352    26 Jan 2018;   US2020171060-A1    US16629057    07 Jan 2020;   US11253529-B2    US16629057    07 Jan 2020;   US2022133756-A1    US569804    06 Jan 2022;   US11980630-B2    US569804    06 Jan 2022	US2020171060-A1 PCT application Application WOUS015352;   US2020171060-A1 Provisional Application US539034P;   US11253529-B2 PCT application Application WOUS015352;   US11253529-B2 Provisional Application US539034P;   US11253529-B2 Based on Patent WO2019027501;   US11253529-B2 Previous Publ. Patent US2020171060;   US2022133756-A1 Provisional Application US539034P;   US2022133756-A1 Div ex Application US629057;   US2022133756-A1 Div ex Application WOUS015352;   US2022133756-A1 Div ex Patent US11253529;   US11980630-B2 Div ex Application WOUS015352;   US11980630-B2 Div ex Application US629057;   US11980630-B2 Provisional Application US539034P;   US11980630-B2 Previous Publ. Patent US2022133756;   US11980630-B2 Div ex Patent US11253529	US539034P    31 Jul 2017;  US16629057    07 Jan 2020;  US569804    06 Jan 2022	WO2019027501-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          		WO2019027501-A1 -- US20070060535-A1   ;  WO2016123318-A2   UNIV MARYLAND BALTIMORE COUNTY (UMBA);  UNIV KATHOLIEK LEUVEN (UYLN);  UNIV LEIDEN MEDICAL CENT DEPT MEDICAL (UYLE-Non-standard)   JOCHMANS D,  NEYTS J,  PETERS H L,  RADTKE K L,  SNIJDER E J;  US11253529-B2 -- US10058516-B2   UNIV MARYLAND BALTIMORE COUNTY (UMBA);  UNIV KATHOLIEK LEUVEN (UYLN);  UNIV LEIDEN MEDICAL CENT DEPT MEDICAL (UYLE-Non-standard)   JOCHMANS D,  NEYTS J,  PETERS H L,  RADTKE K L,  SNIJDER E J;  US10226434-B2   UNIV MARYLAND BALTIMORE COUNTY (UMBA);  UNIV KATHOLIEK LEUVEN (UYLN);  UNIV LEIDEN MEDICAL CENT DEPT MEDICAL (UYLE-Non-standard)   JOCHMANS D,  NEYTS J,  PETERS H L,  RADTKE K L,  SNIJDER E J;  US20070060535-A1   ;  WO2016123318-A2   UNIV MARYLAND BALTIMORE COUNTY (UMBA);  UNIV KATHOLIEK LEUVEN (UYLN);  UNIV LEIDEN MEDICAL CENT DEPT MEDICAL (UYLE-Non-standard)   JOCHMANS D,  NEYTS J,  PETERS H L,  RADTKE K L,  SNIJDER E J;  US2022133756-A1 -- US10226434-B2   UNIV MARYLAND BALTIMORE COUNTY (UMBA);  UNIV KATHOLIEK LEUVEN (UYLN);  UNIV LEIDEN MEDICAL CENT DEPT MEDICAL (UYLE-Non-standard)   JOCHMANS D,  NEYTS J,  PETERS H L,  RADTKE K L,  SNIJDER E J;  US11980630-B2 -- US10226434-B2   UNIV MARYLAND BALTIMORE COUNTY (UMBA);  UNIV KATHOLIEK LEUVEN (UYLN);  UNIV LEIDEN MEDICAL CENT DEPT MEDICAL (UYLE-Non-standard)   JOCHMANS D,  NEYTS J,  PETERS H L,  RADTKE K L,  SNIJDER E J;  US20070060535-A1   ;  US10058516-B2   UNIV MARYLAND BALTIMORE COUNTY (UMBA);  UNIV KATHOLIEK LEUVEN (UYLN);  UNIV LEIDEN MEDICAL CENT DEPT MEDICAL (UYLE-Non-standard)   JOCHMANS D,  NEYTS J,  PETERS H L,  RADTKE K L,  SNIJDER E J;  WO2016123318-A2   UNIV MARYLAND BALTIMORE COUNTY (UMBA);  UNIV KATHOLIEK LEUVEN (UYLN);  UNIV LEIDEN MEDICAL CENT DEPT MEDICAL (UYLE-Non-standard)   JOCHMANS D,  NEYTS J,  PETERS H L,  RADTKE K L,  SNIJDER E J	WO2019027501-A1  PETERS, H. L. ET          AL.: "Design, synthesis and evaluation of a series of          acyclic fleximer nucleoside analogues with          anti-coronavirus activity", BIOORGANIC & MEDICINAL          CHEMISTRY LETTERS, vol. 25, no. 15, 2015, pages 2923 -          2926,          XP029160589,relevantClaims[10-14],relevantPassages[See          abstract; and figure 1.];  SELEY, K. L. ET          AL.: "Molecular chameleons ''. Design and synthesis of a          second series of flexible nucleosides", THE JOURNAL OF          ORGANIC CHEMISTRY, vol. 70, no. 5, 2005, pages 1612 -          1619,          XP055572460,relevantClaims[10-14],relevantPassages[See          abstract; and figures 1-3.];  TAN, E. L. C. ET          AL.: "Inhibition of SARS coronavirus infection in vitro          with clinically approved antiviral drugs", EMERGING          INFECTIOUS DISEASES, vol. 10, no. 4, 2004, pages 581 -          586,          XP055572465,relevantClaims[10-14],relevantPassages[See          abstract; and page 582.]US11253529-B2            Peters, H.L. Design, synthesis and evaluation of a series          of acyclic fleximer nucleoside analogues with          anti-coronaviurs activity, &lt;xhtml:i          &gt;Bioorganic&lt;/xhtml:i&gt;&          &lt;xhtml:i &gt;Medical Chemistry          Letters&lt;/xhtml:i&gt;, 25 (2015) pp.          2923-2926.;            Seley, K. L. et al. Molecular chameleons. Design and          synthesis of C-4-substituted imidazole fleximers,          &lt;xhtml:i &gt;Org.          Lett&lt;/xhtml:i&gt;., 7 (2005), pp.          63-66.;            Tan, E.L. et al. Inhibition of SARS Coronavirus Infection          in Vitro with Clinically Approved Antiviral Drugs,          &lt;xhtml:i &gt;Emerg. Infect.          Dis&lt;/xhtml:i&gt;., 10 (2004), pp.          581-586.;            Yates, M.K. Flex-nucleoside analoguesNovel therapeutics          against filoviruses, &lt;xhtml:i          &gt;Bioorganic&lt;/xhtml:i&gt;&          &lt;xhtml:i &gt;Medicinal Chemistry          Letters&lt;/xhtml:i&gt;, 27 (2017), pp.          2800-2802.US11980630-B2            Peters, H.L. Design, synthesis and evaluation of a series          of acyclic fleximer nucleoside analogues with          anti-coronaviurs activity, &lt;xhtml:i          &gt;Bioorganic&lt;/xhtml:i&gt;&          &lt;xhtml:i &gt;Medical Chemistry          Letters&lt;/xhtml:i&gt;, 25 (2015) pp.          2923-2926.;            Seley, K. L. et al. Molecular chameleons. Design and          synthesis of C-4-substituted imidazole fleximers,          &lt;xhtml:i &gt;Org.          Lett&lt;/xhtml:i&gt;., 7 (2005), pp.          63-66.;            Tan, E.L. et al. Inhibition of SARS Coronavirus Infection          in Vitro with Clinically Approved Antiviral Drugs,          &lt;xhtml:i &gt;Emerg. Infect.          Dis&lt;/xhtml:i&gt;., 10 (2004), pp.          581-586.;            Yates, M.K. Flex-nucleoside analoguesNovel therapeutics          against filoviruses, &lt;xhtml:i          &gt;Bioorganic&lt;/xhtml:i&gt;&          &lt;xhtml:i &gt;Medicinal Chemistry          Letters&lt;/xhtml:i&gt;, 27 (2017), pp.          2800-2802.	 K M;  K M;  K M;  K M			RC1N0P K M; RC1N0Q K M; RCJ81Y K M; RCJ81Z K M		WO2019067671-A1;  US2020299359-A1;  US11230592-B2;  US2022112271-A1;  US11981724-B2	New nucleic acid molecule useful in composition            for preventing or treating disease, preferably Middle            East Respiratory Syncytial Coronavirus infection in            mammal, preferably human	WEINER D;  SMITH T R;  MUTHUMANI K;  SMITH T R F	WEINER D (WEIN-Individual);  SMITH T R (SMIT-Individual);  WISTAR INST ANATOMY & BIOLOGY (WITA-C);  INOVIO PHARM INC (IVIO-C);  WISTAR ANATOMY & BIOLOGY INST (WITA-C)	201933088T	   NOVELTY - A nucleic acid molecule encoding one or more                synthetic antibodies is new, where the nucleic acid                molecule comprises at least one chosen from (a) a                nucleotide sequence encoding anti-Middle East                Respiratory Syncytial Coronavirus (MERS-CoV)                synthetic antibody, and (b) a nucleotide sequence                encoding a fragment of an anti-MERS-CoV synthetic                antibody.    USE - The nucleic acid molecule is useful in                composition for preventing or treating a disease in                a subject. The disease is MERS-CoV virus infection                (all claimed). The subject is mammal, preferably                human. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E02A;  B04-E03A;  B04-E99;  B14-A02B5;  B14-S03A;  D05-H12A;  D05-H99	A61K-039/42;  C07K-016/10;  C12N-015/63	WO2019067671-A1   04 Apr 2019   A61K-039/42   201929Pages: 55   English;  US2020299359-A1   24 Sep 2020   C07K-016/10   202079   English;  US11230592-B2   25 Jan 2022   C07K-016/10   202211   English;  US2022112271-A1   14 Apr 2022   C07K-016/10   202232   English;  US11981724-B2   14 May 2024   C07K-016/10   202440   English	WO2019067671-A1    WOUS053044    27 Sep 2018;   US2020299359-A1    US16651435    27 Mar 2020;   US11230592-B2    US16651435    27 Mar 2020;   US2022112271-A1    US560727    23 Dec 2021;   US11981724-B2    US560727    23 Dec 2021	US2020299359-A1 PCT application Application WOUS053044;   US2020299359-A1 Provisional Application US564177P;   US11230592-B2 PCT application Application WOUS053044;   US11230592-B2 Provisional Application US564177P;   US11230592-B2 Based on Patent WO2019067671;   US11230592-B2 Previous Publ. Patent US2020299359;   US2022112271-A1 Provisional Application US564177P;   US2022112271-A1 Cont of Application US651435;   US2022112271-A1 Cont of Application WOUS053044;   US2022112271-A1 Cont of Patent US11230592;   US11981724-B2 Cont of Application WOUS053044;   US11981724-B2 Cont of Application US651435;   US11981724-B2 Provisional Application US564177P;   US11981724-B2 Previous Publ. Patent US2022112271;   US11981724-B2 Cont of Patent US11230592	US564177P    27 Sep 2017;  US16651435    27 Mar 2020;  US560727    23 Dec 2021	WO2019067671-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          		WO2019067671-A1 -- US20150284448-A1   ;  US20150337029-A1   ;  US20150353638-A1   ;  WO2016138160-A1   US DEPT HEALTH & HUMAN SERVICES (USSH)   GRAHAM B,  JOYCE M G,  KANEKIYO M,  KONG W,  MASCOLA J,  MODJARRAD K,  SHI W,  WANG L;  US11230592-B2 -- WO2016138160-A1   US DEPT HEALTH & HUMAN SERVICES (USSH)   GRAHAM B,  JOYCE M G,  KANEKIYO M,  KONG W,  MASCOLA J,  MODJARRAD K,  SHI W,  WANG L;  US20150284448-A1   ;  US20150337029-A1   ;  US20150353638-A1   ;  US2022112271-A1 -- US20150284448-A1   ;  US20210188947-A1   ;  US11230592-B2   WEINER D (WEIN-Individual);  SMITH T R (SMIT-Individual)   WEINER D,  SMITH T R;  WO2016138160-A1   US DEPT HEALTH & HUMAN SERVICES (USSH)   GRAHAM B,  JOYCE M G,  KANEKIYO M,  KONG W,  MASCOLA J,  MODJARRAD K,  SHI W,  WANG L;  US11981724-B2 -- US20150284448-A1   ;  US20210188947-A1   ;  US11230592-B2   WEINER D (WEIN-Individual);  SMITH T R (SMIT-Individual)   WEINER D,  SMITH T R;  WO2016138160-A1   US DEPT HEALTH & HUMAN SERVICES (USSH)   GRAHAM B,  JOYCE M G,  KANEKIYO M,  KONG W,  MASCOLA J,  MODJARRAD K,  SHI W,  WANG L;  US20150337029-A1   ;  US20150353638-A1   	WO2019067671-A1  LI, Y ET AL.: "A          humanized neutralizing antibody against MERS-CoV          targeting the receptor-binding domain of the spike          protein", CELL RESEARCH, vol. 25, no. 11, 22 September          2015 (2015-09-22), pages 1237 - 1249,          XP055587421,relevantClaims[1-8, 9/1-8, 10/9/1-8,          11/9/1-8],relevantPassages[; entire document; DOI:          10.1038/cr.2015.113]US11230592-B2            Kasem et al., Cross-sectional study of MERS-CoV-specific          RNA and antibodies inanimals that have had contact with          MERS patients in Saudi Arabia, 2018, Journal of Infection          and Public Health, vol. 11, pp. 331-338.;            Elliot S et al, 2017 DMAb inoculation of synthetic cross          reactive antibodies protects against lethal influenza A          and B infections, NPJ Vaccines.;  Li          et al., 2015, A humanized neutralizing antibody against          MERS-CoV targeting the receptor-binding domain of the          spike protein, Cell Research, 25(11):1237-1249.US11981724-B2            Elliot S et al, 2017 DMAb inoculation of synthetic cross          reactive antibodies protects against lethal influenza A          and B infections, NPJ Vaccines.;  Li          et al., 2015, A humanized neutralizing antibody against          MERS-CoV targeting the receptor-binding domain of the          spike protein, Cell Research, 25(11):1237-1249.	93605-0-0-0 N; 105730-0-0-0 N			RA00NS N; RA012P N		US2019117702-A1	Treating acute respiratory distress syndrome comprises administering agent comprising adult stem cell or adult stem cell condition media	MARCH K;  BOGATCHEVA N	UNIV INDIANA RES & TECHNOLOGY CORP (INDV-C);  US DEPT VETERANS AFFAIRS (USGO-C)	201936751X	   NOVELTY - Treating a patient afflicted with acute respiratory distress syndrome (ARDS), comprises administering at least one agent comprising adult stem cell (ASC) or adult stem cell condition media (ASC-CM), where the patient comprises human or animal.    USE - The method is useful for treating a patient afflicted with ARDS, where ARDS is caused by an upper respiratory tract infection caused by at least one coronavirus comprising severe acute respiratory syndrome-related coronavirus (SARS-CoV) or Middle East respiratory syndrome-related coronavirus (MERS-CoV) (claimed). Test details are described but no results given. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.)	B04-F02B;  B12-M12F;  B14-A02;  B14-K01;  C04-F02B;  C12-M12F;  C14-A02;  C14-K01	A61K-035/28	US2019117702-A1   25 Apr 2019   A61K-035/28   201933Pages: 67   English	US2019117702-A1    US177103    31 Oct 2018	US2019117702-A1 Provisional Application US077824P;   US2019117702-A1 Provisional Application US989459P;   US2019117702-A1 Cont of Application US705895;   US2019117702-A1 Cont of Patent US10143709	US989459P    06 May 2014;  US177103    31 Oct 2018					200757-0-0-0 K U			RA00GT K U		KR2019129525-A	Composition comprises: cell membrane target            ligands; hydrophilic polymers; and nanoparticles            comprising a hydrophobic polymer as an active            ingredient	HAAM S J;  YUN D Y;  KIM J;  KIM H W;  LIM J;  HAEJINCHUN;  SONG D S;  JOO Y M;  SUNG N W	UNIV YONSEI IND ACADEMIC COOP FOUND (UYIA-C);  UNIV KOREA RES & BUSINESS FOUND (UYKR-C)	2019A3485K	   NOVELTY - Composition comprises: cell membrane target                ligands; hydrophilic polymers; and nanoparticles                comprising a hydrophobic polymer as an active                ingredient.    USE - The composition is useful for inhibiting virus                infection (claimed).    ADVANTAGE - The composition has good biocompatibility,                mucosal permeability and stability in the body,                inhibits infection and proliferation of the                mutation of the virus at an early stage, and                efficiently prevents the outbreak of the pandemic                virus. 			A96 (Medical, dental, veterinary, cosmetic.);  A23 (Polyamides; polyesters. (including polycarbonates, polyesteramides); alkyds; other unsaturated polymers.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.)	A12-V01;  B04-E99;  B04-C02E4;  B04-C03;  B04-H01;  B12-M11Q;  B14-A02	A61K-031/69;  A61K-009/51;  A61P-031/12	KR2019129525-A   20 Nov 2019   A61K-009/51   201999Pages: 19   	KR2019129525-A    KR054314    11 May 2018		KR054314    11 May 2018					97115-1-0-0 K M; 444-0-0-0 ; 5938-0-0-0 ; 7560-0-0-0 ; 7447-0-0-0 			R03231 K M; R00351 ; R01295 ; R00448 ; R00009 		US2019274967-A1;  US11110065-B2	Pharmaceutical composition used for inhibiting and/or killing virus includes sintered ferrous amino acid particles prepared by sintering a ferrous amino acid chelate which includes ferrous ions and amino acid	LIN T;  CHEN M;  WANG K;  JAN H	PROFEAT BIOTECHNOLOGY CO LTD (PROF-Non-standard);  PROFEAT BIOTECHNOLOGY CO LTD (PROF-Non-standard)	201977967K	   NOVELTY - A pharmaceutical composition comprises sintered ferrous amino acid particles prepared by sintering a ferrous amino acid chelate which includes ferrous ions and an amino acid. The sintered ferrous amino acid particles has an average particle size of 500-2600 nm, and has a weight average molecular weight of 1500-600000 Da.    USE - Composition used for inhibiting and/or killing virus including porcine epidemic diarrhea virus, porcine respiratory and reproductive syndrome virus, influenza virus (swine, canine, equine influenza or avian influenza viruses), transmissible gastroenteritis coronavirus, feline coronavirus, canine coronavirus, and/or equine arteritis virus. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  C01 (Organophosphorus; organometallic - i.e. compounds containing other than H, C, N, O, S and halogen.);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.)	B05-A03A2;  B10-B02J;  B12-M12N;  B14-A02;  B14-C03;  B14-E10;  B14-F02;  B14-S12;  C05-A03A2;  C10-B02J;  C12-M12N;  C14-A02;  C14-C03;  C14-E10;  C14-F02;  C14-S12	A61K-031/295;  A61K-009/00;  A61K-009/51;  A61P-031/14;  A61P-031/16	US2019274967-A1   12 Sep 2019   A61K-009/51   201972Pages: 7   English;  US11110065-B2   07 Sep 2021   A61K-009/51   202173   English	US2019274967-A1    US223426    18 Dec 2018;   US11110065-B2    US223426    18 Dec 2018	US2019274967-A1 Provisional Application US639064P;   US11110065-B2 Provisional Application US639064P;   US11110065-B2 Previous Publ. Patent US2019274967	US639064P    06 Mar 2018;  US223426    18 Dec 2018			;  US11110065-B2 -- US20170224727-A1   ;  TW287856-B1   INTERUNIV MICRO-ELECTRONICA CENT VZW (ITUV);  KONINK PHILIPS ELECTRONICS NV (PHIG)   PAWLAK B J;  US20150065569-A1   ;  US20170007568-A1   ;  US20190358168-A1   ;  US20200138726-A1   	US11110065-B2  Demetrio et al (Materials Research, 2013, 16(5), 1030-1038). (Year: 2013).;  Saif et al., Park Gateway, Aug. 29, 2013.;  Fenner's Veterinary Virology, 2011.;  The Center for Food Security and Public Health, 2009.;  The Winn Feline Foundation, 2017.	349617-0-0-0 K U			RA33B6 K U		CN109206501-A;  CN109206501-B	New cat interferon useful in preparing antiviral            medicine for treating or preventing viral infections            including Feline coronavirus and feline parvovirus in            cats	XU Y;  FAN W;  WANG L;  WANG Z;  ZHU Y	UNIV NORTHEAST AGRIC (UNEA-C)	201909509H	   NOVELTY - Cat interferon omega including fully defined                196 amino acid sequence (SEQ ID No: 2), is                new.    USE - The cat interferon omega is useful in                preparing antiviral medicine for treating or                preventing viral infections including Feline                coronavirus and feline parvovirus in cats (all                claimed).    ADVANTAGE - The cat interferon omega has antiviral                activity and is superior to existing known cat                interferon, provides a basis for further                development and application of cat interferon                products.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) nucleotide sequence encoding cat                interferon omega ;    (2) recombinant expression vector, comprising                nucleotide sequence;    (3) host cell, comprising recombinant                expression vector; and    (4) preparing cat interferon omega . 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-C01G;  B04-E02B;  B04-E03B;  B04-E08;  B04-E99;  B04-F0100E;  B04-H05;  B04-H0500E;  B14-A02A9;  B14-A02B5;  B14-S12;  D05-H12A;  D05-H12E;  D05-H14;  D05-H17A2;  D05-H99	A61K-038/21;  A61P-031/14;  A61P-031/20;  C07K-014/555;  C12N-015/20;  C12N-015/70	CN109206501-A   15 Jan 2019   C07K-014/555   201929Pages: 15   Chinese;  CN109206501-B   04 Mar 2022   C07K-014/555   202224   Chinese	CN109206501-A    CN11125211    26 Sep 2018;   CN109206501-B    CN11125211    26 Sep 2018	CN109206501-B Previous Publ. Patent CN109206501	CN11125211    26 Sep 2018			CN109206501-A -- CA2019803-C   TORAY IND INC (TORA)   YANAI A,  UEDA Y,  SAKURAI T,  SATOH M;  CN1730491-A   INST MICROBIOLOGY CHINESE ACAD SCI (CWSW)   LIU W,  YANG L,  YANG F;  CN104788554-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   CHEN X,  LI Y,  LI H,  ZHANG Z,  YI Y,  HU X,  LIU X;  CN107569516-A   BEIJING JINGMENG HI-TECH STEM CELLS (BEIJ-Non-standard);  BEIJING JINGMENG CELL BIOLOGICAL TECHNOLOGY                  CO LTD (BEIJ-Non-standard)   BAI G,  DING W,  DU Y,  LI Z,  LIU J,  MA R,  NIE C,  RUAN Z,  TIAN Z,  WAN X,  WANG Y,  WU L,  YANG H;  CN108276486-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   HU X,  LI Y,  ZHANG Z,  LI H,  LIU X,  YI Y,  CHEN X;  CN108314724-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   HU X,  LI Y,  ZHANG Z,  LI H,  LIU X,  YI Y,  CHEN X;  JP2003339261-A   TORAY IND INC (TORA)   ASAOKA R,  MORIYAMA H,  YAMADA M;  US20020013452-A1   ;  WO2010016525-A1   TORAY IND INC (TORA)   OKANO F,  SHIMIZU M,  SAITO T;  CN109206501-B -- CA2019803-C   TORAY IND INC (TORA)   YANAI A,  UEDA Y,  SAKURAI T,  SATOH M;  CN1730491-A   INST MICROBIOLOGY CHINESE ACAD SCI (CWSW)   LIU W,  YANG L,  YANG F;  CN104788554-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   CHEN X,  LI Y,  LI H,  ZHANG Z,  YI Y,  HU X,  LIU X;  CN107569516-A   BEIJING JINGMENG HI-TECH STEM CELLS (BEIJ-Non-standard);  BEIJING JINGMENG CELL BIOLOGICAL TECHNOLOGY                  CO LTD (BEIJ-Non-standard)   BAI G,  DING W,  DU Y,  LI Z,  LIU J,  MA R,  NIE C,  RUAN Z,  TIAN Z,  WAN X,  WANG Y,  WU L,  YANG H;  CN108276486-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   HU X,  LI Y,  ZHANG Z,  LI H,  LIU X,  YI Y,  CHEN X;  CN108314724-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   HU X,  LI Y,  ZHANG Z,  LI H,  LIU X,  YI Y,  CHEN X;  JP2003339261-A   TORAY IND INC (TORA)   ASAOKA R,  MORIYAMA H,  YAMADA M;  US20020013452-A1   ;  WO2010016525-A1   TORAY IND INC (TORA)   OKANO F,  SHIMIZU M,  SAITO T	CN109206501-A  : "",          ,relevantClaims[1-10],relevantPassages[34];  YANG,L.M :          "interferon omega 9 precursor [Felis catus]",          GENBANK,relevantClaims[1-10],relevantPassages[ACCESSION          N0.NP_001082776];  : "",          ,relevantClaims[1-10],relevantPassages[186-190];  YANG,L.M.:          "interferon omega 9 [Felis catus]",          GENBANK,relevantClaims[1-10],relevantPassages[ACCESSION          N0.ABD78712];  : "FeIFN-FeIFN-",          ,relevantClaims[1-10],relevantPassages[1556-1560];  U. TRUYEN :          "Antiviral potency of interferon-omega (IFN-) against          selected canine and feline viruses", DER PRAKTISCHE          TIERARZT,relevantClaims[1-10],relevantPassages[862-865];  LI-MIN YANG :          "Cloning and characterization of a novel feline          IFN-omega", J INTERFERON CYTOKINE          RES,relevantClaims[1-10],relevantPassages[119-127];  WEN-LU FAN : "Use          of dual priming oligonucleotide system-based multiplex          RT-PCR combined with high performance liquid          chromatography assay for simultaneous detection of five          enteric viruses associated with acute enteritis", J VIROL          METHODS,relevantClaims[1-10],relevantPassages[80-82];  XIAONA WANG :          "Cloning, Prokaryotic Soluble Expression, and Analysis of          Antiviral Activity of Two Novel Feline IFN- Proteins",          VIRUSES,relevantClaims[1-10],relevantPassages[1-16]CN109206501-B  U.          Truyen et al. " Antiviral agent of interferon-omega          (IFN-) against selected canine and feline "; U. Truyen,          etc.; "Der Praktische Tierarzt"; 20021031; No. 83 (No.          10); pages 862-865;            Liu Po-chun. "Effects of feline interferon on canine          parvovirus infection"; Liu Bochun; "Animal Husbandry and          Veterinary Science and Technology Information"; 20030430;          Section 19 (Phase 4); page 34;            Wang Hongbin and so on. " New-type interferon FeIFN - []          and interferon FeIFN-alpha expression and antiviral          activity comparison, Wang Hongbin, et al.,          Bioengineering, 20080930, 24 (ninth period),          1556-1560;  Li          Hua and so on. The clone of the cat interferon gene and          the antiviral activity analysis of the expression product          thereof; Li Hua and so on; China Prevention of Veterinary          Medicine, 20210228; No. 43 (the second period); 18th to          190 pages;            Yang, L.M and so on. " interferon omega 9 [Felis catus]          "; Yang, L. M and so on; " genbank "; 20130417; ACCESSION          N0.NP-001082776;            Wang, Wang, and so on. " Cloning, Profile Soluble          Expression, and Analysis of Antiviral Activity of Two          Feline IFN - [] Proteins, Wang, Wang et al., Viruses,          20200319, 12 (th period), page 1-16;            Wen-Lu Fan and so on. Use of dual priming system-based          multiplex RT-PCR combinable with high performance The          invention claims a method for detecting and detecting          human body, wherein the method comprises the following          steps: using the method for detecting the human body; Fan          et al., "J Virol Methods"; 20170206; No. 243; page          80-82;            Yang, L.M. and so on. " interferon omega 9 [Felis catus]          "; Yang, L. M, etc.; "genbank"; and 20070305; ACCESSION          N0.ABD78712;            Li-Min Yang . Cloning and characterization of a novel          feline IFN-omega;Li-Min Yang ;J Interferon Cytokine          Res;20070228;27(2);119-127	 N P			RCCX0H N P		IN201741038086-A	Preparing virus-like particles (VLPs) by            transfecting vectors encoding four influenza proteins            into host cell and expressing influenza virus proteins            to allow VLP formation comprises e.g. amplifying H1, N1            and M genes of influenza A virus	GOVINDAKARNAVAR A;  JAGADESH A;  SALAM A A A	UNIV MANIPAL (UYMA-Non-standard)	2019406333	   NOVELTY - Preparing a virus-like particles (VLPs) by                transfecting vectors encoding 4 influenza proteins                into a suitable host cell and expressing the                influenza virus proteins under conditions that                allow VLP formation, comprises (a) amplifying H1,                N1 and M genes of influenza A (H1N1) virus and N2                gene of influenza A (H3N2) virus, (b) adding                restriction enzyme sites into H1, N1, M and N2                genes, (c) cloning individual genes into different                pFastBac vector, (d) constructing pFastMN1N2                vector, (e) constructing pFastBacMHAN1N2 vector,                (f) transforming pFastBacN1N2MHA donor plasmid into                DH10Bac and (g) transfecting Sf9 cells to generate                VLPs.    USE - The method is useful for preparing a VLPs by                transfecting vectors encoding 4 influenza proteins                into a suitable host cell and expressing the                influenza virus proteins under conditions that                allow VLP formation which is beneficial during the                emergence of new pandemic influenza virus that may                carry a heterologous N2 or N1 NA, e.g. H2N2 or                H5N1. No biological data given.    ADVANTAGE - The method: provides robust protection against                widely divergent viruses; is efficient in                situations of pandemic influenza outbreaks; and                provides drift variant, homotypic or heterosubtypic                protection against influenza by administering to a                subject an immunogenic amount of an influenza                VLPs. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-F11B0E;  B14-A02B2;  B14-S11A;  B14-S11D3;  C04-E99;  C04-F11B0E;  C14-A02B2;  C14-S11A;  C14-S11D3;  D05-H99;  D05-H12F	A23L-033/00;  A61K-035/76;  A61K-039/00	IN201741038086-A   03 May 2019   A23L-033/00   201940Pages: 25   English	IN201741038086-A    IN41038086    27 Oct 2017		IN41038086    27 Oct 2017					200757-0-0-0 K P			RA00GT K P		CN110079541-A;  CN110079541-B	Constructing coronavirus infectious clone useful            for preparing infectious bronchitis virus infectious            clone for preparing vector vaccine, comprises e.g.            extracting RNA of the coronavirus, and performing            reverse transcription to obtain cDNA	XIE Q;  FENG K;  SHAO G;  ZHANG X;  SHAO Y	UNIV SOUTH CHINA AGRIC (USCG-C)	2019692092	   NOVELTY - Constructing coronavirus infectious clone                comprises (i) extracting RNA of the coronavirus,                and performing reverse transcription to obtain                cDNA, (ii) fragmenting the cDNA obtained in the                step (i) to obtain each fragment comprising the                entire cDNA gene, where the first fragment of the                fragment includes T7 promoter, the overlapping                fragments of the fragments contain 50-70 bp                overlapping regions as recombinant homologous arms,                and the fragmentation method is PCR amplification,                (iii) ligating or assembling PCR-amplification                comprising terminal fragment including hepatitis D                virus ribozyme sequence and T7 terminator with each                fragment of the step (ii) using linear plasmid                vector, and screening to obtain a recombinant                plasmid comprising each fragment in the step (ii),                where the plasmid vector comprises a resistance                screening gene, (iv) randomly selecting one of the                recombinant plasmids obtained in the step (iii) as                a nonsense mutation to obtain a labeled                fragment.    USE - The coronavirus infectious clone is useful for                preparing infectious bronchitis virus infectious                clone for preparing vector vaccine (all                claimed).    ADVANTAGE - The method: successfully constructs an                infectious clonal virus infectious clone by using                medium and low copy plasmid vector; opens up a way                for the construction of infectious clone of                coronavirus; solves the problem that the selection                of the coronavirus vector is difficult and the                virus large genome is unstable in the bacteria; and                has high the positive clone rate. The infectious                clone: has completeness, passaging stability,                infectivity, and high salvage efficiency; and                provides an tool for studying the pathogenic                mechanism of coronavirus and developing                vaccine.    DETAILED DESCRIPTION - Constructing coronavirus infectious clone                comprises (i) extracting RNA of the coronavirus,                and performing reverse transcription to obtain                cDNA, (ii) fragmenting the cDNA obtained in the                step (i) to obtain each fragment comprising the                entire cDNA gene, where the first fragment of the                fragment includes T7 promoter, the overlapping                fragments of the fragments contain 50-70 bp                overlapping regions as recombinant homologous arms,                and the fragmentation method is PCR amplification,                (iii) ligating or assembling PCR-amplification                comprising terminal fragment including hepatitis D                virus ribozyme sequence and T7 terminator with each                fragment of the step (ii) using linear plasmid                vector, and screening to obtain a recombinant                plasmid comprising each fragment in the step (ii),                where the plasmid vector comprises a resistance                screening gene, (iv) randomly selecting one of the                recombinant plasmids obtained in the step (iii) as                a nonsense mutation to obtain a labeled fragment,                (v) digesting or PCR amplifying the recombinant                plasmid obtained in the steps (iii) and (iv) to                obtain a fragment set including each fragment and                the step (iv) labeled fragment in the step (ii),                homologously recombining the target plasmid vector                and the fragment collection, and the termination                fragment of the step (ii), and obtaining positive                clone by screening, where the target plasmid vector                is a stringent plasmid having a capacity of 1-60 Kb                and the homologous recombination is homologous                recombination mediated by RED/ET recombinant                technology, and (vi) co-transfecting the positive                clone obtained in the step (v) with the helper                plasmid to express a cell line expressing T7 RNA                polymerase, where a positive clone that                successfully rescues the reverse strain of the                coronavirus is an infectious clone comprising the                entire genome of the coronavirus. INDEPENDENT                CLAIMS are also included for: (1) constructing                infectious bronchitis virus infectious clone,                comprising (a) extracting RNA extracted from avian                infectious bronchitis virus vaccine strain, and                transcribing to obtain cDNA, (b) PCR-amplifying                four fragments of A, B, C, and D containing the                entire gene of the T7 promoter and the infectious                bronchitis virus vaccine strain by using the cDNA                described in the step (a) as template, using the                gene-synthesized pUC47-HDVRT7 ter as a template,                and amplifying fragment E containing hepatitis D                virus ribozyme sequence (HDVribozyme) and T7                terminator (T7 terminator), (c) using the linear                plasmid pBR322 as template, and homologously                recombining the four fragments A, B, C and D in the                step (b) to obtain recombinant plasmids containing                A, B, C and D fragments, (d) selecting the                recombinant plasmid containing D obtained in the                step (c), subjecting some of the bases to nonsense                mutation, and recording the mutation fragment                vector pDt, (e) amplifying linear vector p15A-cm                for infectious clonal assembly using plasmid                p15A-cm-ccdB as template, digesting the recombinant                plasmids in the steps (c) and (d) to obtain A, B, C                and Dt fragments, co-transfecting fragments A, B,                C, Dt, E and linear vector p15A-cm into competent                cells GBdir E.coli, and obtaining positive clones                by resistance screening, (f) using the cDNA                obtained in the step (a) as template, and                homologously recombining the amplified N gene with                the plasmid pVAX1 to construct an eukaryotic                expression plasmid pVAX1-N expressing the N gene,                and (g) co-transfecting the eukaryotic expression                plasmid pVAX1-N expressing the N gene and the                positive clone obtained in the steps (e) and (f)                with BSRT7/5 cells, where a positive clone that                successfully rescues the reverse strain of avian                infectious bronchitis virus is an infectious clone                containing the entire genome of the infectious                bronchitis virus; and (2) infectious bronchitis                virus infectious clone obtained by the above                mentioned method. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E08;  B04-E99;  B04-F11B0E;  B14-S11A;  B14-S11D3;  B14-S12;  C04-E08;  C04-E99;  C04-F11B0E;  C14-S11A;  C14-S11D3;  C14-S12;  D05-H07;  D05-H12F;  D05-H99	A61K-039/215;  A61P-031/14;  C12N-015/66;  C12N-015/86	CN110079541-A   02 Aug 2019   C12N-015/66   201969Pages: 21   Chinese;  CN110079541-B   20 Jun 2023   C12N-015/66   202355   Chinese	CN110079541-A    CN10373562    05 May 2019;   CN110079541-B    CN10373562    05 May 2019	CN110079541-B Previous Publ. Patent CN110079541	CN10373562    05 May 2019			CN110079541-A -- CN102382812-A   JIANGSU INST POULTRY SCI (CAGS);  ZHOU S (ZHOU-Individual);  TANG M (TANG-Individual)   CHENG X,  DAI Y,  LIU M,  SHEN X,  TANG M,  XU L,  YOU S,  ZHAO B,  ZHOU S;  CN103497967-A   UNIV HUAZHONG AGRIC (UHZA)   LI S,  JIN M,  ZOU Z;  CN107190022-A   UNIV ZHEJIANG (UYZH)   LIAO M,  ZHOU J,  SHI T,  CAO S,  YAN Y;  US20160060303-A1   ;  CN110079541-B -- CN102382812-A   JIANGSU INST POULTRY SCI (CAGS);  ZHOU S (ZHOU-Individual);  TANG M (TANG-Individual)   CHENG X,  DAI Y,  LIU M,  SHEN X,  TANG M,  XU L,  YOU S,  ZHAO B,  ZHOU S;  CN103497967-A   UNIV HUAZHONG AGRIC (UHZA)   LI S,  JIN M,  ZOU Z;  CN107190022-A   UNIV ZHEJIANG (UYZH)   LIAO M,  ZHOU J,  SHI T,  CAO S,  YAN Y;  US20160060303-A1   	CN110079541-A            LAUROVELAZQUEZ-SALINAS : "Validation of a site-specific          recombination cloning technique for the rapid development          of a full-length cDNA clone of a virulent field strain of          vesicular stomatitis New Jersey virus", JOURNAL OF          VIROLOGICAL          METHODS,relevantClaims[1-9],relevantPassages[113-116];  T NOLDEN : "Reverse          genetics in high throughput: rapid generation of complete          negative strand RNA virus cDNA clones and recombinant          viruses thereof", SCIENTIFIC          REPORTS,relevantClaims[1-9],relevantPassages[111311];  : "H120cDNA",          ,relevantClaims[1-9],relevantPassages[231262161]CN110079541-B            LauroVelazquez-Salinas et al. Validation of a          site-specific cloning technique for the rapid development          of a cDNA clone of a virulent field strain of vesicular          stomatitis New Jersey, LauroVelazquez-Salinas et al., "          Journal of Virological Methods, " 20190115; No. 265;          pages 113-116.;            Chou Sheng and so on. chicken infectious bronchitis virus          H120 vaccine strain full-length cDNA infectious clone          construction, Zhou, Chinese poultry, 20101231, 32 (the 23          period), summary, page 23 left column 1 to 26 page right          column 2 section, FIG. 16, Table 1;  T          Nolden et al. Reverse genetics in high throughput: rapid          generation of complete negative strand RNA virus cDNA the          recombinant viruses, T Nolden and so on, " Scientific          Reports ", 20160405, sixth volume, abstract, 1 page 1 to          the 13 page last 1 section, supplementary material, FIG.          1	200757-0-0-0 K P			RA00GT K P		CN109206502-A;  CN109206502-B	New cat interferon-omega useful in preparation of            antiviral drug for preventing or treating infectious            disease caused by virus, preferably intestinal            coronavirus and parvovirus in cat, comprises specific            amino acid sequence	XU Y;  WANG Z;  WANG L;  FAN W;  ZHU Y	UNIV NORTHEAST AGRIC (UNEA-C)	201909509G	   NOVELTY - A cat interferon omega comprising a 203 amino                acid sequence (SEQ ID NO: 2) fully defined in the                specification, is new.    USE - The cat interferon omega is useful in                preparation of antiviral drug for preventing or                treating infectious disease caused by virus in cat.                The virus is cat intestinal coronavirus and cat                parvovirus (all claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) nucleotide sequence encoding the cat                interferon omega ;    (2) recombinant expression vector comprising                the nucleotide sequence;    (3) host cell comprising the recombinant                expression vector; and    (4) method for preparing cat interferon omega                . 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-C01G;  B04-E02B;  B04-E03B;  B04-E08;  B04-E99;  B04-F0100E;  B04-H05A;  B04-H05A0E;  B14-A02;  B14-S12;  D05-C12;  D05-H12A;  D05-H12E;  D05-H14;  D05-H17A2;  D05-H99	A61K-038/21;  A61P-031/14;  C07K-014/555;  C12N-001/21;  C12N-015/20;  C12N-015/70	CN109206502-A   15 Jan 2019   C07K-014/555   201933Pages: 16   Chinese;  CN109206502-B   04 Mar 2022   C07K-014/555   202224   Chinese	CN109206502-A    CN11126498    26 Sep 2018;   CN109206502-B    CN11126498    26 Sep 2018	CN109206502-B Previous Publ. Patent CN109206502	CN11126498    26 Sep 2018			CN109206502-A -- CA2019803-C   TORAY IND INC (TORA)   YANAI A,  UEDA Y,  SAKURAI T,  SATOH M;  CN1730491-A   INST MICROBIOLOGY CHINESE ACAD SCI (CWSW)   LIU W,  YANG L,  YANG F;  CN104788554-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   CHEN X,  LI Y,  LI H,  ZHANG Z,  YI Y,  HU X,  LIU X;  CN107569516-A   BEIJING JINGMENG HI-TECH STEM CELLS (BEIJ-Non-standard);  BEIJING JINGMENG CELL BIOLOGICAL TECHNOLOGY                  CO LTD (BEIJ-Non-standard)   BAI G,  DING W,  DU Y,  LI Z,  LIU J,  MA R,  NIE C,  RUAN Z,  TIAN Z,  WAN X,  WANG Y,  WU L,  YANG H;  CN108276486-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   HU X,  LI Y,  ZHANG Z,  LI H,  LIU X,  YI Y,  CHEN X;  CN108314724-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   HU X,  LI Y,  ZHANG Z,  LI H,  LIU X,  YI Y,  CHEN X;  EP88622-B1   GENENTECH INC (GETH)   CAPON D J,  GOEDDEL D V;  JP2003339261-A   TORAY IND INC (TORA)   ASAOKA R,  MORIYAMA H,  YAMADA M;  WO2010016525-A1   TORAY IND INC (TORA)   OKANO F,  SHIMIZU M,  SAITO T;  CN109206502-B -- CA2019803-C   TORAY IND INC (TORA)   YANAI A,  UEDA Y,  SAKURAI T,  SATOH M;  CN1730491-A   INST MICROBIOLOGY CHINESE ACAD SCI (CWSW)   LIU W,  YANG L,  YANG F;  CN104788554-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   CHEN X,  LI Y,  LI H,  ZHANG Z,  YI Y,  HU X,  LIU X;  CN107569516-A   BEIJING JINGMENG HI-TECH STEM CELLS (BEIJ-Non-standard);  BEIJING JINGMENG CELL BIOLOGICAL TECHNOLOGY                  CO LTD (BEIJ-Non-standard)   BAI G,  DING W,  DU Y,  LI Z,  LIU J,  MA R,  NIE C,  RUAN Z,  TIAN Z,  WAN X,  WANG Y,  WU L,  YANG H;  CN108276486-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   HU X,  LI Y,  ZHANG Z,  LI H,  LIU X,  YI Y,  CHEN X;  CN108314724-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   HU X,  LI Y,  ZHANG Z,  LI H,  LIU X,  YI Y,  CHEN X;  EP88622-B1   GENENTECH INC (GETH)   CAPON D J,  GOEDDEL D V;  JP2003339261-A   TORAY IND INC (TORA)   ASAOKA R,  MORIYAMA H,  YAMADA M;  WO2010016525-A1   TORAY IND INC (TORA)   OKANO F,  SHIMIZU M,  SAITO T	CN109206502-A  U. TRUYEN :          "Antiviral potency of interferon-omega (IFN-) against          selected canine and feline viruses", DER PRAKTISCHE          TIERARZT,relevantClaims[1-10],relevantPassages[862-865];  : "",          ,relevantClaims[1-10],relevantPassages[34];  : "",          ,relevantClaims[1-10],relevantPassages[186-190];  YANG,L.M.:          "interferon omega 2 precursor [Felis catus]",          GENBANK,relevantClaims[1-10],relevantPassages[ACCESSION          NO.NP_001095910];  : "FeIFN-FeIFN-",          ,relevantClaims[1-10],relevantPassages[1556-1560];  LI-MIN YANG :          "Cloning and characterization of a novel feline          IFN-omega", J INTERFERON CYTOKINE          RES,relevantClaims[1-10],relevantPassages[119-127];  WEN-LU FAN : "Use          of dual priming oligonucleotide system-based multiplex          RT-PCR combined with high performance liquid          chromatography assay for simultaneous detection of five          enteric viruses associated with acute enteritis", J VIROL          METHODS,relevantClaims[1-10],relevantPassages[80-82];  XIAONA WANG :          "Cloning, Prokaryotic Soluble Expression, and Analysis of          Antiviral Activity of Two Novel Feline IFN- Proteins",          VIRUSES,relevantClaims[1-10],relevantPassages[1-16];  YANG,L.M.:          "interferon omega 2 [Felis catus]",          GENBANK,relevantClaims[1-10],relevantPassages[ACCESSION          NO.ABD78705]CN109206502-B            Yang, L.M. and so on. " interferon omega 2 precursor          [Felis catus] "; Yang, L. M, etc.; " genbank "; 20130418;          ACCESSION NO.NP 001095910;            Yang, L.M. and so on. " interferon omega 2 [Felis catus]          "; Yang, L. M, etc.; "genbank"; and 20070305; ACCESSION          NO.ABD78705;            Wang, Wang, and so on. " Cloning, Profile Soluble          Expression, and Analysis of Antiviral Activity of Two          Feline IFN - [] Proteins, Wang, Wang et al., Viruses,          20200319, 12 (th period), page 1-16;  U.          Truyen et al. " Antiviral agent of interferon-omega          (IFN-) against selected canine and feline "; U. Truyen,          etc.; "Der Praktische Tierarzt"; 20021031; No. 83 (No.          10); pages 862-865;  Li          Hua and so on. The clone of the cat interferon gene and          the antiviral activity analysis of the expression product          thereof; Li Hua and so on; China Prevention of Veterinary          Medicine, 20210228; No. 43 (the second period); 18th to          190 pages;            Li-Min Yang . Cloning and characterization of a novel          feline IFN-omega;Li-Min Yang ;J Interferon Cytokine          Res;20070228;27(2);119-127;            Wen-Lu Fan and so on. Use of dual priming system-based          multiplex RT-PCR combinable with high performance The          invention claims a method for detecting and detecting          human body, wherein the method comprises the following          steps: using the method for detecting the human body; Fan          et al., "J Virol Methods"; 20170206; No. 243; page          80-82;            Wang Hongbin and so on. " New-type interferon FeIFN - []          and interferon FeIFN-alpha expression and antiviral          activity comparison, Wang Hongbin, et al.,          Bioengineering, 20080930, 24 (ninth period),          1556-1560;            Liu Po-chun. "Effects of feline interferon on canine          parvovirus infection"; Liu Bochun; "Animal Husbandry and          Veterinary Science and Technology Information"; 20030430;          Section 19 (Phase 4); page 34	127225-0-0-0 N P; 127225-0-0-0 CL NEW PRD			RA04O9 N P		CN110468234-A	New multiple fluorescent quantitative PCR kit used            to detect 19 human respiratory viruses e.g. human            parainfluenza virus type I comprises PCR amplification            kit having respiratory virus detection amplification            solutions and reference kit	CHEN Z;  WANG W;  WEI C;  WEI S	XIAMEN AMPLLY BIOTECHNOLOGY CO LTD (XIAM-Non-standard);  NANJING ANPU PRECISION MEDICAL TESTING (NANJ-Non-standard)	2019994490	   NOVELTY - Multiple fluorescent quantitative PCR kit                comprises PCR amplification kit having 1-8                respiratory virus detection 19 (RVD19)                amplification solutions and reference kit, where                e.g. RVD19 amplification solution 1 includes                influenza A virus (IAV) primer probe, human                coronavirus NL63 (HCoV-NL63) primer probe and                internal standard primer probe, RVD19 amplification                solution 2 includes human adenovirus (HADV) primer                probe, human parainfluenza virus II (HPIV II)                primer probe and internal standard primer probe,                RVD19 amplification solution 3 includes human                coronavirus OC43 (HCoV-OC43) primer probe, human                bocavirus (HBoV) primer probe and internal standard                primer probe and including primer probe sequences                (SEQ ID NO:1-57) e.g. mycoplasma pneumonia (MP)                primer probe comprising upstream primer: (SEQ ID                NO: 1) and downstream primer: (SEQ ID NO: 2) and                chlamydia pneumoniae (CP) primer probe having (SEQ                ID NO: 3), upstream primer: (SEQ ID NO: 4) and                downstream primer: (SEQ ID NO: 5), is new.    USE - The kit is useful in detecting 19 kinds of                human respiratory viruses including influenza A                virus, influenza B virus, human parainfluenza virus                type I, human parainfluenza virus type II, human                parainfluenza virus III, human adenovirus, human                respiratory syncytial virus, human coronavirus                229E, human coronavirus OC43, human coronavirus                NL63, human coronavirus HKUI group, human bocavirus                virus, human metapneumovirus, human rhinovirus,                rubella virus, measles virus, mumps virus,                mycoplasma pneumonia and chlamydia pneumoniae                nucleic acid.    ADVANTAGE - The kit: adopts 8-well combined detection                method where each well contains three fluorescent                channels that corresponds to a pathogen which                qualitatively detect and distinguish 19 kinds of                viruses in the human respiratory tract                simultaneously; is the most comprehensive detection                method for pathogens of viral respiratory                infections; provides a basis for                laboratory-assisted diagnosis and clinical                testing.    DETAILED DESCRIPTION - Multiple fluorescent quantitative PCR kit                comprises PCR amplification kit having 1-8 RVD19                amplification solutions and reference kit, where                RVD19 amplification solution 1 includes IAV primer                probe, human coronavirus NL63 (HCoV-NL63) primer                probe and internal standard primer probe, RVD19                amplification solution 2 includes HADV primer                probe, human HPIV II primer probe and internal                standard primer probe, RVD19 amplification solution                3 includes HCoV-OC43 primer probe, HBoV primer                probe and internal standard primer probe, RVD19                amplification solution 4 includes human                parainfluenza virus I (HPIVI) primer probe, human                rhinovirus (HRV) primer probe and internal standard                primer probe, RVD19 amplification solution 5                includes human respiratory syncytial virus (HRSV)                primer probe, CP primer probe, MP primer probe and                internal standard primer probe, RVD19 amplification                solution 6 includes human coronavirus 229E                (HCoV-229E) primer probe, human metapneumovirus                (HMPV) primer probe, infectious bronchitis virus                (IBV) primer probe and internal standard primer                probe, RVD19 amplification solution 7 includes                human parainfluenza virus III (HPIV III) primer                probe, measles virus (MeV) primer probe, rubella                virus (RV) primer probe and internal standard                primer probe and RVD19 amplification solution 8                includes mumps virus (MuV) primer probe, human                coronavirus HKU1 (HCoV-HKU1) primer probe and                internal standard primer probe and the kit                comprises primer probe sequences (SEQ ID NO:1-57)                e.g. MP primer probe comprising upstream primer:                5'-accccagaagggcttacttat-3' (SEQ ID NO: 1) and                downstream primer: 3'-catttctcgatcaccagagtca-5'                (SEQ ID NO: 2) and CP primer probe having                carboxy-X-rhodamine                (ROX)-5'-cccgcgccactggggagaac-3'- black hole                quencher 2 (BHQ2) (SEQ ID NO: 3), upstream primer:                5'-ggtttgtagcgttccttgg-3' (SEQ ID NO: 4) and                downstream primer: 3'-cacagagtcaccagaagcatag-5'                (SEQ ID NO: 5). 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03E;  B04-E05;  B04-E99;  B04-F11;  B04-L04A;  B04-L04B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  D05-H06A;  D05-H18B;  D05-H99	C12Q-001/04;  C12Q-001/6851;  C12Q-001/689;  C12Q-001/70;  C12R-001/35;  C12R-001/93	CN110468234-A   19 Nov 2019   C12Q-001/70   201996Pages: 31   Chinese	CN110468234-A    CN10733306    09 Aug 2019		CN10733306    09 Aug 2019			CN110468234-A -- CN102586475-A   SHENZHEN PURUIKANG BIOTECHNOLOGY CO LTD (SHEN-Non-standard);  RADIOLOGY & RADIATION INST PLA                  MILITARY (JSYX)   CHEN S,  LIU Q,  LIU Z,  PENG X,  WANG S,  ZHANG M,  ZHU K;  CN104561377-A   HUAMEI BIOLOGICAL ENG CO LTD (HUAM-Non-standard)   JIA X,  PENG Z,  ZHANG S,  WAN D;  CN107058622-A   DEBIQI BIOLOGICAL TECHNOLOGY XIAMEN CO (DEBI-Non-standard)   TONG C,  QIU Y;  CN107365876-A   NANJING LANYU BIOTECHNOLOGY CO LTD (NANJ-Non-standard)   CHEN J,  XU H,  YU P,  ZHANG R,  ZHU T;  CN109055607-A   CHEN S (CHEN-Individual)   CHEN S;  CN109207639-A   NANTONG INT TRAVEL HEALTH CARE CLINIC (NANT-Non-standard)   CHEN F,  WU H,  YANG Q,  YANG G;  CN109487008-A   CHONGQING ZHONGYUAN HUIJI BIOTECHNOLOGY (ZYBO)   CHEN W,  DONG L,  OUYANG X;  US20140127671-A1   ;  WO2012100370-A1   BGI SHENZHEN CO LTD (BGIG);  INST MICROBIOLOGY & EPIDEMIOLOGY (JSYX);  BEIJING GBI BIOTECHNOLOGY CO LTD (BGIG)   CHEN W,  GUAN Y,  JIANG Y,  LIU L,  PIAO J,  YANG Y	CN110468234-A  : "PCR",          ,relevantClaims[1-10],relevantPassages[];  : "RT-PCRAB",          ,relevantClaims[1-10],relevantPassages[];  : "15PCR",          ,relevantClaims[1-10],relevantPassages[]	201562-0-0-0 D K M; 204644-0-0-0 D K M			RA0124 D K M; RA031J D K M		US2019358168-A1;  US10881621-B2	Inhibiting and/or killing virus by administration of composition including sintered ferrous amino acid particles prepared by sintering ferrous amino acid chelate which contains ferrous ions and amino acid	LIN T;  CHEN M;  WANG K;  JAN H	PROFEAT BIOTECHNOLOGY CO LTD (PROF-Non-standard);  PROFEAT BIOTECHNOLOGY CO LTD (PROF-Non-standard)	201999428J	   NOVELTY - Inhibiting and/or killing a virus comprise administering a composition including sintered ferrous amino acid particles prepared by sintering a ferrous amino acid chelate which includes ferrous ions and an amino acid. The sintered ferrous amino acid particles have an average particle size of 500-2600 nm, and a weight average molecular weight of 1500-600000 Da. The composition is in the form of pharmaceutical composition or food composition.    USE - The method is used for inhibiting and/or killing a virus including porcine epidemic diarrhea virus, porcine respiratory and reproductive syndrome virus, influenza virus (swine, canine, equine influenza, or avian influenza viruses), transmissible gastroenteritis coronavirus, feline coronavirus, canine coronavirus, and/or equine arteritis virus. 			B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)	B14-A02;  B14-S12;  C14-A02;  C14-S12;  D03-H01T2B	A61K-031/295;  A61K-009/00;  A61K-009/51;  A61P-031/14;  A61P-031/16	US2019358168-A1   28 Nov 2019   A61K-009/51   201995Pages: 7   English;  US10881621-B2   05 Jan 2021   A61K-009/51   202103   English	US2019358168-A1    US527648    31 Jul 2019;   US10881621-B2    US527648    31 Jul 2019	US2019358168-A1 Provisional Application US639064P;   US2019358168-A1 Div ex Application US223426;   US10881621-B2 Provisional Application US639064P;   US10881621-B2 Div ex Application US223426;   US10881621-B2 Previous Publ. Patent US2019358168	US639064P    06 Mar 2018;  US527648    31 Jul 2019			;  US10881621-B2 -- US20170224727-A1   ;  TW287856-B1   INTERUNIV MICRO-ELECTRONICA CENT VZW (ITUV);  KONINK PHILIPS ELECTRONICS NV (PHIG)   PAWLAK B J;  US20150065569-A1   ;  US20170007568-A1   ;  US20190274967-A1   ;  US20200138726-A1   	US10881621-B2  Demetrio et al (Materials Research, 2013, 16(5), 1030-1038). (Year: 2013).;  Saif et al, Pork Gateway, Aug. 29, 2013 (Year: 2013).;  Fenner's Veterinary Virology (Year: 2011).;  The Center for Food Security and Public Health (Year: 2009).;  The Winn Feline Foundation (Year: 2017).						CN209669259-U	Canine coronavirus fast detection reagent box            comprises e.g. packing box, clapboard, micro-fluidic            chip A, micro-fluidic chip B, reagent tube base,            reagent tube, specification, the clapboard divides            packing box into left, middle and right three            chambers	QIN T;  CUI S;  LIANG L	INST ANIMAL SCI CAAS (CAGS-C)	2019A00696	   NOVELTY - The utility model claims a canine coronavirus                fast detection reagent box, comprising a packing                box, a clapboard, a micro-fluidic chip A, the                micro-fluidic chip B, reagent tube base, a reagent                tube, , specification, the clapboard divides the                packing box is divided into left, middle and right                three chambers, the first chamber is placed in                parallel micro-fluidic chip A several along the                vertical direction; the second chamber is placed in                parallel micro-fluidic chip B along the vertical                direction, are provided with a sampling hole on the                microfluidic chip, a micro-flow channel, DNA                separation chamber, a waste liquid chamber,                triangle valve, PCR reaction zones and/or                fluorescent detection chamber, the third chamber is                the reagent tube base is divided into upper and                lower two layers, the reagent tube containing the                DNA separation bead is put in the hole of the                reagent pipe base, the reagent tube base lower part                is placed . The utility model can further realize a                canine coronavirus with high sensitivity, fast,                fluorescent quantitative PCR detection, the                operation is simple and fast. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01A;  B04-E05;  B04-F11A;  B11-C07B3;  B11-C08C1;  B11-C08E3;  B11-C08F8;  B12-K04F;  C04-E01A;  C04-E05;  C04-F11A;  C11-C07B3;  C11-C08C1;  C11-C08E3;  C11-C08F8;  C12-K04F;  D05-H06A;  D05-H18B	C12Q-001/6851;  C12Q-001/70	CN209669259-U   22 Nov 2019   C12Q-001/70   201993Pages: 7   Chinese	CN209669259-U    CN20129822    25 Jan 2019		CN20129822    25 Jan 2019										US2019255085-A1;  US10695361-B2	Treating Coronaviridae infection caused by            Coronaviridae virus comprising severe acute respiratory            syndrome and middle east respiratory syndrome in human,            comprises administering substituted nucleoside            compounds	CLARKE M O N H;  FENG J Y;  JORDAN R;  MACKMAN R L;  RAY A S;  SIEGEL D;  CLARKE M O H	GILEAD SCI INC (GILE-C)	201971794G	   NOVELTY - Treating a Coronaviridae infection in a human,                comprises administering substituted nucleoside                compounds (I).    USE - The method is useful for treating a                Coronaviridae infection in a human, where the                Coronaviridae infection is caused by a                Coronaviridae virus comprising severe acute                respiratory syndrome (SARS), middle east                respiratory syndrome (MERS), human coronavirus                229E, NL63, OC43 or HKU1 (all claimed).    DETAILED DESCRIPTION - Treating a Coronaviridae infection in a human,                comprises administering substituted nucleoside                compounds of formula (I).    R7 = e.g. H, -C(=O)R11, -C(=O)OR11,                -C(=O)NR11R12, -C(=O)SR11, -S(O)R11, -S(O)2R11,                -S(O)(OR11), -S(O)2(OR11) Z1-P(=Q)(Z2)- and                -SO2NR11R12; either    R11, R12 = H, (1-8C)alkyl, (2-8C)alkenyl,                (2-8C)alkynyl, (4-8C)carbocyclylalkyl, aryl,                heteroaryl, -C(=O)(1-8c)alkyl, -S(O)(1-8C)alkyl or                aryl(1-8C)alkyl; or    R11R12N = 3-7 membered heterocyclic ring,                where any one C of the heterocyclic ring is                optionally replaced by -O-, -S- or -NR1a;    R1a = H, (1-8C)alkyl, (2-8C) alkenyl,                (2-8C)alkynyl, aryl(1-8C)alkyl,                (4-8C)carbocyclylalkyl, -C(=O)R, -C(=O)OR,                -C(=O)NR2, -C(=O)SR, -S(O)R, -S(O)2R, -S(O)(OR),                -S(O)2(OR) or -SO2NR2;    R = H, (1-8C) alkyl, (2-8C)alkenyl, (2-8C)                alkynyl, 6-20C aryl, 2-20C heterocyclyl or                arylalkyl (all optionally substituted), where each                (1-8C)alkyl, (2-8C)alkenyl, (2-8C) alkynyl or                aryl(1-8C)alkyl and each R11 and R12 is optionally                substituted by at least one halo, OH, CN, N3,                N(R1a)2 or OR1a and at least one of the                non-terminal carbon atoms of each the (1-8C)alkyl                is optionally replaced by e.g. -O- and -S-;    Q = O, S, NR, +N(O)(R), N(OR), +N(O)(OR) or                N-NR2;    Q1 = O, S or NR; either    R1y = H, halo, OH, R, -C(=Q2)R, -C(=Q2)OR,                -C(=Q2)N(R)2, -N(R)2, -N(R)3, -SR, -S(O)R, -S(O)2R,                -S(O)(OR), -S(O)2(OR), -OC(=Q2)R, -OC(=Q2)OR,                -OC(=Q2)(N(R)2), -SC(=Q2)R, -S(=Q2)OR,                -SC(=Q2)(N(R)2), -N(R)C(=Q2)R, -N(R)C(=Q2)OR,                -N(R)C(=Q2)N(R)2, -SO2NR2, -CN, -N3, -NO2, -OR                or    2R1yC = carbocyclic ring of 3-7C;    Q2 = O, S, NR, +N(O)(R), N(OR), +N(O)(OR), or                N-NR2; either    Z1, Z2 = (R1x-(Q3-P(=Q2)(Q3-R1x)M2-Q3-);                or    Z1Z2 = Q1(C(R1y)2)3Q1;    Q3 = bond, O, CR2, NR, +N(OR), +N(O)(OR), S-S,                S(O) or N-NR2, S, S-S, S(O) or S(O)2;    M2 = 0-2;    R1x = R1y or                -(C(=Q2)-Q3)M1a-(C(R1y)(R1y)M12c-(Q3)M1c-(C(Q2)-Q3)M1d-R1y);    M1a, M1c, M1d = 0 or 1;    M12c = 0-12;    Z3 = Z4 or Z5;    Z4 = R, -C(Q2)R1y, -C(Q2)Z5, -SO2R1y, or                -SO2Z5; and    Z5 = carbocycle or a heterocycle (both                optionally substituted by 0-3 of R1y). 			B02 (Fused ring heterocyclics.)	B04-E99;  B04-B03D;  B04-B03E;  B04-J02;  B05-A01B;  B05-C07;  B14-A02B5;  B14-C03;  B14-J02B1;  B14-J02C1;  B14-K01B;  B14-K01D;  B14-L01;  B14-L06;  B14-S18	A61K-031/7056;  A61K-031/706	US2019255085-A1   22 Aug 2019   A61K-031/706   201969Pages: 107   English;  US10695361-B2   30 Jun 2020   A61K-031/706   202054   English	US2019255085-A1    US265016    01 Feb 2019;   US10695361-B2    US265016    01 Feb 2019	US2019255085-A1 Provisional Application US219302P;   US2019255085-A1 Provisional Application US239696P;   US2019255085-A1 Cont of Application US267433;   US2019255085-A1 Cont of Patent US10251904;   US10695361-B2 Provisional Application US219302P;   US10695361-B2 Provisional Application US239696P;   US10695361-B2 Cont of Application US267433;   US10695361-B2 Cont of Patent US10251904;   US10695361-B2 Previous Publ. Patent US2019255085	US219302P    16 Sep 2015;  US265016    01 Feb 2019			;  US10695361-B2 -- US4816570-A   UNIV TEXAS SYSTEM (TEXA)   FARQUHAR D;  US4968788-A   UNIV TEXAS SYSTEM (TEXA)   FARQUHAR D;  US5663159-A   BRISTOL-MYERS SQUIBB CO (BRIM);  ACAD SCI CZECH REPUBLIC INST ORG CHEM &                  BIOCHEMISTRY (CESK);  REGA STICHTING VZW (REGA-Non-standard)   STARRETT J E,  MANSURI M M,  MARTIN J C,  TORTOLANI D R,  BRONSON J J;  US5792756-A   BRISTOL-MYERS SQUIBB CO (BRIM);  ACAD SCI CZECH REPUBLIC INST ORG CHEM &                  BIOCHEMISTRY (CESK);  REGA STICHTING VZW (REGA-Non-standard)   STARRETT J E,  MANSURI M M,  MARTIN J C,  TORTOLANI D R,  BRONSON J J;  US20030050229-A1   ;  US20040006002-A1   ;  US20040023901-A1   ;  US20040063658-A1   ;  US20040067901-A1   ;  US20040138170-A1   ;  US20050187180-A1   ;  US20050209166-A1   ;  US20050215513-A1   ;  US20050250728-A1   ;  US20060058303-A1   ;  US20060142238-A1   ;  US20060241064-A1   ;  US20080107628-A1   ;  US20080161324-A1   ;  US20080280842-A1   ;  US20090004138-A1   ;  US20090221524-A1   ;  US20090233879-A1   ;  US20090317361-A1   ;  US20100015094-A1   ;  US20100016251-A1   ;  US20100021425-A1   ;  US20100035835-A1   ;  US20100035836-A1   ;  US20100203015-A1   ;  US20100234584-A1   ;  US20100298257-A1   ;  US20110070194-A1   ;  US20110084230-A1   ;  US20110230654-A1   ;  US20110257122-A1   ;  US20110293563-A1   ;  US20120009147-A1   ;  US20120020921-A1   ;  US20120027752-A1   ;  US20120071434-A1   ;  US20120107274-A1   ;  US20130034521-A1   ;  US20130143835-A1   ;  US20130281686-A1   ;  US20130315868-A1   ;  US20150111839-A1   ;  US20150133395-A1   ;  US20150152116-A1   ;  US20160058779-A1   ;  US20100291031-A2   ;  US20130344028-A2   ;  US6312662-B1   METABASIS THERAPEUTICS INC (LIGA)   ERION M D,  REDDY K R,  ROBINSON E D;  US6476030-B1   MERCK SHARP & DOHME LTD (MERI)   CARLING W R,  MITCHINSON A,  MOORE K W,  RUSSELL M G N,  SCOTT G,  STREET L J;  US6656915-B1   BIOCRYST PHARM INC (BCRY)   BANTIA S,  MONTGOMERY J A,  OMURA G A;  US7368437-B1   AVENTIS CROPSCIENCE GMBH (AVET)   BOJACK G,  LINDELL S,  ROSINGER C,  DUDFIELD P,  EARNSHAW C;  US6909011-B2   DSM FINE CHEM AUSTRIA NFG GMBH & CO                  KG (STAM);  US7105493-B2   NOVIRIO PHARM LTD (NOVI-Non-standard);  UNIV CAGLIARI (UYCA-Non-standard)   SOMMADOSSI J,  LA COLLA P;  US7125855-B2   MERCK&CO INC (MERI);  ISIS PHARM INC (ISSP)   CARROLL S S,  MACCOSS M,  OLSEN D B,  BHAT B,  BHAT N,  COOK P D,  ELDRUP A B,  PRAKASH T P,  PRHAVC M,  SONG Q;  US7176203-B2   MERCK SHARP & DOHME LTD (MERI)   CHAMBERS M S,  GOODACRE S C,  HALLETT D J,  MAXEY R J,  RUSSELL M G N,  STREET L J;  US7268119-B2   BIOTA INC (BIOT-Non-standard)   COOK P D,  EWING G,  JIN Y,  LAMBERT J,  PRHAVC M,  RAJAPPAN V,  RAJWANSHI V K,  SAKTHIVEL K;  US7285658-B2   BIOTA INC (BIOT-Non-standard)   COOK P D,  WANG G,  BRUICE T W,  BOYLE N A,  LEEDS J M,  BROOKS J L,  PRHAVC M,  ARIZA M E,  FAGAN P C,  JIN Y,  RAJWANSHI V K,  TUCKER K D;  US7390791-B2   GILEAD SCI INC (GILE)   BECKER M W,  CHAPMAN H H,  CIHLAR T,  EISENBERG E J,  HE G,  KERNAN M R,  LEE W A,  PRISBE E J,  ROHLOFF J C,  SPARACINO M L;  US7429571-B2   BIOCRYST PHARM INC (BCRY);  BABU Y S (BABU-Individual);  CHAND P (CHAN-Individual);  WU M (WUMM-Individual);  KOTIAN P L (KOTI-Individual);  KUMAR V S (KUMA-Individual);  LIN T (LINT-Individual);  EL-KATTAN Y (ELKA-Individual);  GHOSH A K (GHOS-Individual)   BABU Y S,  CHAND P,  WU M,  KOTIAN P L,  KUMAR V S,  LIN T,  EL-KATTAN Y,  GHOSH A K;  US7514410-B2   BIOCRYST PHARM INC (BCRY);  BABU Y S (BABU-Individual);  CHAND P (CHAN-Individual);  WU M (WUMM-Individual);  KOTIAN P L (KOTI-Individual);  KUMAR V S (KUMA-Individual);  LIN T (LINT-Individual);  EL-KATTAN Y (ELKA-Individual);  GHOSH A K (GHOS-Individual)   BABU Y S,  CHAND P,  WU M,  KOTIAN P L,  KUMAR V S,  LIN T,  EL-KATTAN Y,  GHOSH A K;  US7560434-B2   BIOCRYST PHARM INC (BCRY)   BABU Y S,  CHAND P,  GHOSH A K,  KOTIAN P L,  KUMAR S V;  US7598230-B2   BIOTA INC (BIOT-Non-standard)   COOK P D,  WANG G,  BRUICE T W,  BOYLE N A,  LEEDS J M,  BROOKS J L,  PRHAVC M,  ARIZA M E,  FAGAN P C,  JIN Y,  RAJWANSHI V K,  TUCKER K D;  US7608597-B2   NOVIRIO PHARM LTD (NOVI-Non-standard);  UNIV CAGLIARI (UYCA-Non-standard)   SOMMADOSSI J,  LACOLLA P;  US7713941-B2   BIOTA INC (BIOT-Non-standard)   COOK P D,  EWING G,  JIN Y,  LAMBERT J,  PRHAVC M,  RAJAPPAN V,  RAJWANSHI V K,  SAKTHIVEL K;  US7807653-B2   BIOTA INC (BIOT-Non-standard)   COOK P D,  WANG G,  BRUICE T W,  BOYLE N A,  LEEDS J M,  BROOKS J L,  PRHAVC M,  ARIZA M E,  FAGAN P C,  JIN Y,  RAJWANSHI V K,  TUCKER K D;  US7842672-B2   GILEAD SCI INC (GILE)   BOOJAMRA C G,  CHEN J M,  HUANG A X,  KIM C U,  LIN K,  MACKMAN R L,  OARE D A,  PERRY J K,  SAUNDERS O L,  SWAMINATHAN S,  ZHANG L;  US7973013-B2   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  METOBO S E,  RAY A S,  XU J;  US7994139-B2   BIOCRYST PHARM INC (BCRY)   BABU Y S,  CHAND P,  KOTIAN P,  KUMAR V S,  WU M;  US8008264-B2   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  PARRISH J,  XU J;  US8012941-B2   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  PARRISH J,  XU J;  US8012942-B2   GILEAD SCI INC (GILE)   BUTLER T,  CHO A,  KIM C U,  XU J;  US8071568-B2   MERCK&CO INC (MERI);  IST RICERCHE BIOL MOLECOLARE ANGELETTI (ISTR)   NARJES F,  GARDELLI C,  DONGHI M,  ATTENNI B,  DURETTE P L;  US8119607-B2   BOEHRINGER INGELHEIM INT GMBH (BOEH);  BIOTA SCI MANAGEMENT PTY LTD (BITA)   BETHELL R,  BOND S,  DRAFFAN A G,  DUAN J,  FRANCOM P,  FREY B,  HARDING M,  HUFTON R,  JAHANGIRI S,  KUKOLJ G,  LILLY M J,  TYNDALL E;  US8242085-B2   BIOCRYST PHARM INC (BCRY);  BABU Y S (BABU-Individual);  CHAND P (CHAN-Individual)   BABU Y S,  CHAND P;  US8318682-B2   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  PARRISH J,  XU J;  US8415308-B2   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  RAY A S,  ZHANG L;  US8455451-B2   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  RAY A S;  US8853171-B2   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  PARRISH J,  XU J;  US8871737-B2   ALIOS BIOPHARMA INC (JOHJ)   SMITH D B,  DEVAL J,  DYATKINA N,  BEIGELMAN L,  WANG G;  US8889159-B2   GILEAD PHARMASSET LLC (GILE)   CLEARY D G,  REYNOLDS C J,  BERREY M M,  HINDES R G,  SYMONDS W T,  RAY A S,  MO H,  HEBNER C M,  OLIYAI R,  ZIA V,  STEFANIDIS D,  PAKDAMAN R,  CASTEEL M J;  US8980865-B2   ALIOS BIOPHARMA INC (JOHJ)   WANG G,  BEIGELMAN L;  US9090642-B2   GILEAD SCI INC (GILE);  CLARKE M O H (CLAR-Individual)   CHO A,  WOLCKENHAUER S A;  US9243022-B2   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  WANG G,  SMITH D B;  US9249174-B2   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  WANG G,  SMITH D B;  US9278990-B2   SMITH D B (SMIT-Individual);  DEVAL J (DEVA-Individual);  DYATKINA N (DYAT-Individual);  BEIGELMAN L (BEIG-Individual);  WANG G (WANG-Individual)   SMITH D B,  DEVAL J,  DYATKINA N,  BEIGELMAN L,  WANG G;  US9388208-B2   CLARKE M O H (CLAR-Individual);  DOERFFLER E (DOER-Individual);  MACKMAN R L (MACK-Individual);  SIEGEL D (SIEG-Individual)   CLARKE M O H,  DOERFFLER E,  MACKMAN R L,  SIEGEL D;  US9393256-B2   GILEAD SCI INC (GILE);  RAY A S (RAYA-Individual);  WATKINS W J (WATK-Individual);  LINK J O (LINK-Individual);  OLDACH D W (OLDA-Individual);  DELANEY W E (DELA-Individual)   RAY A S,  WATKINS W J,  LINK J O,  OLDACH D W,  DELANEY W E;  US9481703-B2   MEDIVIR AB (MDIV)   KALAYANOV G,  TORSSELL S,  WAHLING H;  US9487544-B2   GILEAD SCI INC (GILE);  CLARKE M O H (CLAR-Individual)   CHO A,  WOLCKENHAUER S A;  US9504701-B2   UNIV TEXAS SYSTEM (TEXA);  CASOLA A (CASO-Individual);  ESCAFFRE O (ESCA-Individual);  FREIBERG A N (FREI-Individual);  GAROFALO R P (GARO-Individual)   CASOLA A,  ESCAFFRE O,  FREIBERG A N,  GAROFALO R P;  US9540411-B2   MEDIVIR AB (MDIV)   KALAYANOV G,  TORSSELL S,  WAEHLING H;  US9542154-B2   RUBANOVICH S (RUBA-Individual);  PONS T (PONS-Individual);  GRADSTEIN A (GRAD-Individual);  SPERBER Z (SPER-Individual)   RUBANOVICH S,  PONS T,  GRADSTEIN A,  SPERBER Z;  US9549941-B2   GILEAD PHARMASSET LLC (GILE)   CLEARY D G,  REYNOLDS C J,  BERREY M M,  HINDES R G,  SYMONDS W T,  RAY A S,  MO H,  HEBNER C M,  OLIYAI R,  ZIA V,  STEFANIDIS D,  PAKDAMAN R,  CASTEEL M J;  US9605018-B2   ALIOS BIOPHARMA INC (JOHJ)   WANG G,  BEIGELMAN L;  US9616076-B2   UNIV TEXAS SYSTEM (TEXA)   CASOLA A,  GAROFALO R P;  US9701682-B2   GILEAD SCI INC (GILE)   CLARKE M O H,  DOERFFLER E,  MACKMAN R L,  SIEGEL D;  US9724360-B2   GILEAD SCI INC (GILE)   CHUN B K,  CLARKE M O N H,  DOERFFLER E,  HUI H C,  JORDAN R,  MACKMAN R L,  PARRISH J P,  RAY A S,  SIEGEL D;  US9828408-B2   MEDIVIR AB (MDIV)   KALAYANOV G,  TORSSELL S,  WAEHLING H;  US9949994-B2   GILEAD SCI INC (GILE)   CHUN B K,  CLARKE M O H,  DOERFFLER E,  HUI H C,  JORDAN R,  MACKMAN R L,  PARRISH J P,  RAY A S,  SIEGEL D;  US10023600-B2   GILEAD SCI INC (GILE)   BUTLER T,  CHO A,  GRAETZ B R,  KIM C U,  METOBO S E,  SAUNDERS O L,  WALTMAN A W,  XU J,  ZHANG L;  US10034893-B2   ENANTA PHARM INC (ENAN)   LULY J R,  MA J,  WANG G,  OR Y S;  US10059716-B2   GILEAD SCI INC (GILE)   CLARKE M O N H,  DOERFFLER E,  MACKMAN R L,  SIEGEL D;  US10065958-B2   GILEAD SCI INC (GILE)   MACKMAN R L,  PARRISH J P,  RAY A S,  THEODORE D A;  US10251898-B2   GILEAD SCI INC (GILE)   CHUN B K,  CLARKE M O N H,  DOERFFLER E,  HUI H C,  JORDAN R,  MACKMAN R L,  PARRISH J P,  RAY A S,  SIEGEL D;  US10251904-B2   GILEAD SCI INC (GILE)   CLARKE M O H,  FENG J Y,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  WO1991019721-A   ;  WO1999045029-A1   ;  WO2000056734-A1   ;  WO2003093272-A1   MERCK SHARP & DOHME LTD (MERI)   BETTATI M,  CHAMBERS M S,  GOODACRE S C,  HALLETT D J,  RUSSELL M G N,  STREET L J;  WO2003093273-A1   MERCK SHARP & DOHME LTD (MERI)   CHAMBERS M S,  GOODACRE S C,  HALLETT D J,  MAXEY R J,  RUSSELL M G N,  STREET L J;  WO2006121820-A1   VALEANT RES & DEV (VALE-Non-standard)   GUNIC E,  CHOW S,  RONG F;  WO2007065829-A1   HOFFMANN LA ROCHE&CO AG F (HOFF);  PHARMASSET INC (GILE)   CHUN B,  CLARK J,  SARMA K,  WANG P;  WO2007135134-A1   NOVARTIS AG (NOVS);  NOVARTIS PHARMA GMBH (NOVS)   MUTZ M,  VOGEL C;  WO2008055870-A1   BOEHRINGER INGELHEIM INT GMBH (BOEH);  BOEHRINGER INGELHEIM PHARMA GMBH & CO                  KG (BOEH)   HIMMELSBACH F,  ECKHARDT M,  EICKELMANN P,  THOMAS L;  WO2008079206-A1   MERCK&CO INC (MERI);  IST RICERCHE BIOL MOLECOLARE ANGELETTI (ISTR)   MEPPEN M,  NARJES F,  PACINI B,  GARDELLI C,  DURETTE P L;  WO2008141079-A1   BIOCRYST PHARM INC (BCRY);  BABU Y S (BABU-Individual);  CHAND P (CHAN-Individual)   BABU Y S,  CHAND P;  WO2009009951-A1   UNIV ZHENGZHOU (UYZZ)   CHANG J,  BAO X,  WANG Q,  GUO X,  WANG W,  QI X;  WO2009131926-A1   BRISTOL-MYERS SQUIBB CO (BRIM)   COOK J H,  IWUAGWU C I,  KING D,  MACOR J E,  MCDONALD I M,  OLSON R E,  WANG N,  ZUSI F C;  WO2009132123-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  PARRISH J,  XU J;  WO2009132135-A1   GILEAD SCI INC (GILE)   BUTLER T,  CHO A,  KIM C U,  SAUNDERS O L,  ZHANG L;  WO2010093608-A1   GILEAD SCI INC (GILE)   BUTLER T,  CHO A,  KIM C U,  XU J;  WO2010099458-A1   INTERMUNE INC (HOFF);  ROCHE PALO ALTO LLC (SYNT);  PHARMASSET INC (GILE)   PORTER S B,  BRADFORD W Z,  SMITH P F,  YETZER E S,  DE LA ROSA A,  ROGERS M D,  SYMONDS W T;  WO2010135569-A1   PHARMASSET INC (GILE)   ROSS B S,  SOFIA M J,  PAMULAPATI G R,  RACHAKONDA S,  ZHANG H,  CHUN B,  WANG P;  WO2011011303-A1   GILEAD SCI INC (GILE)   CANALES E,  CHONG L S,  CLARKE M O H,  DOERFFLER E,  LAZERWITH S E,  LEW W,  LIU Q,  MERTZMAN M,  MORGANELLI P A,  WATKINS W J,  YE H;  WO2011035231-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  METOBO S E,  RAY A S,  XU J;  WO2011035250-A1   GILEAD SCI INC (GILE)   BUTLER T,  CHO A,  GRAETZ B R,  KIM C U,  METOBO S E,  SAUNDERS O L,  WALTMAN A W,  XU J,  ZHANG L;  WO2011123672-A1   PHARMASSET INC (GILE)   CHANG W,  NADUTHAMBI D,  NAGARATHNAM D,  PAMULAPATI G R,  ROSS B S,  SOFIA M J,  ZHANG H;  WO2011150288-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  RAY A S,  ZHANG L;  WO2012012465-A1   GILEAD SCI INC (GILE);  CLARKE M O H (CLAR-Individual)   CHO A,  WOLCKENHAUER S A;  WO2012012776-A1   GILEAD SCI INC (GILE)   MACKMAN R L,  PARRISH J P,  RAY A S,  THEODORE D A;  WO2012039787-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  METOBO S E,  RAY A S,  XU J;  WO2012039791-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  METOBO S E,  RAY A S,  XU J;  WO2012051570-A1   BANTIA S (BANT-Individual);  KOTIAN P L (KOTI-Individual);  BABU Y S (BABU-Individual)   BANTIA S,  KOTIAN P L,  BABU Y S;  WO2013084165-A1   MEDIVIR AB (MDIV)   KLASSON B,  ENEROTH A,  NILSSON M,  PINHO P,  SAMUELSSON B,  SUND C;  WO2014033617-A1   NOVARTIS AG (NOVS)   ANANDAN S,  AULAKH V S,  FENAUX M,  LIN X,  MAO L,  SAUNDERS O,  SWEENEY Z K,  YOKOKAWA F,  ZHONG W;  WO2014078463-A1   MERCK SHARP & DOHME CORP (MERI)   BENNETT F,  HUANG Y,  WANG L,  BOGEN S L,  KEREKES A D,  GIRIJAVALLABHAN V M,  BUTORA G,  TRUONG Q,  DAVIES I,  WEBER A E;  WO2014116755-A1   MASSACHUSETTS INST TECHNOLOGY (MASI)   ESSIGMANN J M,  LI D,  SILVESTRE K J;  WO2015069939-A1   CLARKE M O H (CLAR-Individual);  DOERFFLER E (DOER-Individual);  MACKMAN R L (MACK-Individual);  SIEGEL D (SIEG-Individual)   CLARKE M O H,  DOERFFLER E,  MACKMAN R L,  SIEGEL D;  WO2016069825-A1   GILEAD SCI INC (GILE)   AXT S D,  BADALOV P R,  BRAK K,  CAMPAGNA S,  CHTCHEMELININE A,  DOERFFLER E,  FRICK M M,  GAO D,  HEUMANN L V,  HOANG B,  LEW W,  MILBURN R R,  NEVILLE S T,  ROSS B,  RUEDEN E,  SCOTT R W,  SIEGEL D,  STEVENS A C,  TADEUS C,  VIEIRA T,  WALTMAN A W,  WANG X,  WHITCOMB M C,  WOLFE L,  YU C;  WO2016069826-A1   GILEAD SCI INC (GILE)   CHUN B K,  CLARKE M O N H,  DOERFFLER E,  HUI H C,  JORDAN R,  MACKMAN R L,  PARRISH J P,  RAY A S,  SIEGEL D;  WO2016069827-A1   GILEAD SCI INC (GILE)   AXT S D,  BADALOV P R,  BRAK K,  CAMPAGNA S,  CHTCHEMELININE A,  DOERFFLER E,  FRICK M M,  GAO D,  HEUMANN L V,  HOANG B,  LEW W,  MILBURN R R,  NEVILLE S T,  ROSS B,  RUEDEN E,  SCOTT R W,  SIEGEL D,  STEVENS A C,  TADEUS C,  VIEIRA T,  WALTMAN A W,  WANG X,  WHITCOMB M C,  WOLFE L,  YU C;  WO2017049060-A1   GILEAD SCI INC (GILE)   CLARKE M O H,  FENG J Y,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  WO2017184668-A1   GILEAD SCI INC (GILE)   CLARKE M O H,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  WO2001032153-A2   ;  WO2001060315-A2   ;  WO2001090121-A2   ;  WO2002008241-A2   ;  WO2002018404-A2   ;  WO2002032920-A2   ;  WO2002057287-A2   ;  WO2002057425-A2   ;  WO2003100009-A2   BIOCRYST PHARM INC (BCRY)   BANTIA S,  BABU Y S;  WO2004046331-A2   IDENIX CAYMAN LTD (MERI);  UNIV CAGLIARI (UYCA-Non-standard)   SOMMADOSSI J,  LA COLLA P,  STANDRING D,  BICHKO V,  QU L;  WO2005009418-A2   IDENIX CAYMAN LTD (MERI);  CENT NAT RECH SCI (CNRS);  UNIV MONTPELLIER II (LIER)   STORER R,  GOSSELIN G,  DUKHAN D,  LEROY F;  WO2005123087-A2   MERCK&CO INC (MERI);  ISIS PHARM INC (ISSP)   BUTORA G,  MACCOSS M,  BHAT B,  ELDRUP A B;  WO2006031725-A2   PHARMASSET INC (GILE)   CHUN B,  WANG P;  WO2006050161-A2   BIOCRYST PHARM INC (BCRY);  BABU Y S (BABU-Individual);  CHAND P (CHAN-Individual);  WU M (WUMM-Individual);  KOTIAN P L (KOTI-Individual);  KUMAR V S (KUMA-Individual);  LIN T (LINT-Individual);  EL-KATTAN Y (ELKA-Individual);  GHOSH A K (GHOS-Individual)   BABU Y S,  CHAND P,  WU M,  KOTIAN P L,  KUMAR V S,  LIN T,  EL-KATTAN Y,  GHOSH A K;  WO2006064033-A2   BOEHRINGER INGELHEIM INT GMBH (BOEH);  BOEHRINGER INGELHEIM PHARMA GMBH & CO                  KG (BOEH)   ECKHARDT M,  HIMMELSBACH F,  EICKELMANN P,  BARSOUMIAN E L;  WO2006065335-A2   MERCK & CO INC (MERI)   MACCOSS M,  OLSEN D B,  LEONE J,  DURETTE P L;  WO2007027248-A2   VALEANT RES & DEV (VALE-Non-standard)   GUNIC E,  HONG Z,  GIRARDET J;  WO2007056170-A2   BAYER PHARM CORP (FARB)   OCONNOR S J,  DUMAS J,  LEE W,  DIXON J,  CANTIN D,  GUNN D,  BURKE J,  PHILLIPS B,  LOWE D,  SHELEKHIN T,  WANG G,  MA X,  YING S,  MCCLURE A,  ACHEBE F,  LOBELL M,  EHRGOTT F,  IWUAGWU C,  PARCELLA K;  WO2007064883-A2   BAYER PHARM CORP (FARB)   DIXON J,  MAGNUSON S,  PHILLIPS B,  WANG Y,  LI T,  PARCELLA K,  NEWCOM J,  KLUENDER H,  HONG Z,  CHANDLER B,  ZHANG Z,  ALLEGUE K,  LIU Z;  WO2007064931-A2   BAYER PHARM CORP (FARB)   DIXON J,  PHILLIPS B,  ACHEBE F,  KLUENDER H,  NEWCOM J,  PARCELLA K,  OCONNOR S J,  MAGNUSON S,  HONG Z,  ZHANG Z,  LIU Z,  KHIRE U,  WANG L,  MICHELS M,  CHANDLER B,  O'CONNOR S J;  WO2007065289-A2   BASILEA PHARM AG (BSIL)   BARBIER P,  HEIM J,  SCHMITT HOFFMANN A;  WO2007097991-A2   PHARMASSET INC (GILE)   ERICKSON-VIITANEN S,  LEVY R S;  WO2008005542-A2   GILEAD SCI INC (GILE)   BOOJAMRA C G,  CHEN J M,  HUANG A X,  KIM C U,  LIN K,  MACKMAN R L,  OARE D A,  PERRY J K,  SAUNDERS O L,  SWAMINATHAN S,  ZHANG L;  WO2008082601-A2   UNIV MONTPELLIER II (LIER);  CENT NAT RECH SCI (CNRS);  IDENIX PHARM INC (INEM)   SOMMADOSSI J,  GOSSELIN G,  PIERRA C,  PERIGAUD C,  PEYROTTES S;  WO2008085508-A2   MERCK&CO INC (MERI);  IST RICERCHE BIOL MOLECOLARE ANGELETTI (ISTR)   NARJES F,  GARDELLI C,  DONGHI M,  ATTENNI B,  DURETTE P L;  WO2008089105-A2   BIOCRYST PHARM INC (BCRY)   BABU Y S,  CHAND P,  KUMAR V S,  KOTIAN P L,  WU M;  WO2008116064-A2   BRISTOL-MYERS SQUIBB CO (BRIM)   LIU C,  LEFTHERIS K,  TEBBEN A J;  WO2008121634-A2   PHARMASSET INC (GILE)   SOFIA M J,  DU J,  WANG P,  NAGARATHNAM D;  WO2010002877-A2   BOEHRINGER INGELHEIM INT GMBH (BOEH);  BIOTA SCI MANAGEMENT PTY LTD (BITA)   BETHELL R,  BOND S,  DRAFFAN A G,  DUAN J,  FRANCOM P,  FREY B,  HARDING M,  HUFTON R,  JAHANGIRI S,  KUKOLJ G,  LILLY M J,  TYNDALL E;  WO2010036407-A2   BIOCRYST PHARM INC (BCRY);  BABU Y S (BABU-Individual);  CHAND P (CHAN-Individual);  KUMAR V S (KUMA-Individual);  HU X (HUXX-Individual)   BABU Y S,  CHAND P,  HU X,  KUMAR V S;  WO2011123645-A2   PHARMASSET INC (GILE)   ROSS B S,  SOFIA M J,  PAMULAPATI G R,  RACHAKONDA S,  ZHANG H,  CHUN B,  WANG P;  WO2014042433-A2   KAINOS MEDICINE INC (KAIN-Non-standard)   CHOI M,  OH S;  WO2014078778-A2   BIOCRYST PHARM INC (BCRY)   BABU Y S,  KOTIAN P L,  BANTIA S,  WU M,  KUMAR V S;  WO2014169280-A2   ACHILLION PHARM INC (ACHI)   DESHPANDE M,  WILES J A,  HASHIMOTO A,  PHADKE A;  WO2010111381-A3   BIOCRYST PHARM INC (BCRY)   BARTLEY G,  CLEARY T,  LANG J F;  WO2011123668-A3   PHARMASSET INC (GILE)   ROSS B S,  SOFIA M J,  PAMULAPATI G R,  RACHAKONDA S,  ZHANG H;  WO2012142523-A3   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  KIRSCHBERG T A,  MISH M R,  SQUIRES N;  WO2011080568-A8   DEV CENT BIOTECHNOLOGY (BIGY);  DCB-USA LLC (DCBU)   KUO M,  LEE Y,  CHEN P,  CHEN L J,  LU Y Y,  HUANG Y,  HSU H,  TSAI P	US10695361-B2            Cho et al., Bioorganic and Medicinal Chemistry Letters,          2012, pp. 2705-2707.;            Alessandrini, et al., Synthesis of Differently Protected          1-C-methyl-ribofuranoses Intermediates for the          Preparation of Biologically Active          1-C-methyl-ribonucleosides, Journal of Carbohydrate          Chemistry, 2008, pp. 332-344, vol. 27, No. 5.;            Ali, et al., Quantitative structure-activity          relationships (QSAR) of two series of O-aryl or N-acyl          O-ethyl phosphoramidate and phosphorodiamidate fungicides          incorporating amino acid ethyl esters, Bulletin of          Environmental Contamination and Toxicology, 2000, pp.          415-420, vol. 65, No. 4.;            Arimilli, et al., Synthesis, In Vitro Biological          Evaluation and Oral Bioavailability of          9-[2-(phosphonomethoxy)propyl]adenine (PMPA) Prodrugs,          Antiviral Chemistry & Chemotherapy, 1997, pp.          557-564, vol. 8, No. 6.;            Asbun, et al., Synthesis of 5-substituted Pyrimidines.          II, Journal of Organic Chemistry, 1968, pp. 140-142, vol.          31.;            Ballini, et al., Enantioselective Synthesis of the          Lactone Moiety of the Mevinic Acids using D-Xylose as a          Chiral Precursor, Journal of the Chemical Society, Perkin          Transactions 1, 1991, pp. 490-491.;            Balzarini, et al., Inhibition of Feline (FIPV) and Human          (SARS) Coronavirus by Semisynthetic Derivatives of          Glycopeptide Antibiotics, Antiviral Research, 2006, pp.          20-33, vol. 72.;            Bandini, et al., Indium tribromide: a highly effective          catalyst for the addition of trimethylsilyl cyanide to          -hetero-substituted ketone, Tetrahedron Letters, 2001,          pp. 3041-3043. vol. 42.;            Barker, et al., 2, 3, 5-Tri-O-benzyl-D-ribosyl and          -L-arabinosyl Bromides, Journal of Organic Chemistry,          1961, pp. 4605-4609, vol. 26, No. 11.;            Barl, et al., The halogen/magnesium-exchange using          iPrMgClLiCl and related exchange reagents, Heterocycles,          Jan. 2014, pp. 827-844, vol. 88, No. 2.;            Belokon, et al., Optimized catalysts for the asymmetric          addition of trimethylsilyl cyanide to aldehydes and          ketones, Tetrahedron, 2001, pp. 771-779, vol.          57.;            Benksim, et al., A Novel Stereospecific Synthesis of          Glycosyl Cyanides from 1, 2-O-sulfinyl Derivatives,          Organic Letters, 2004, pp. 3913-3915, vol. 6, No.          22.;            Benzaria, et al., Synthesis, In Vitro Antiviral          Evaluation, and Stability Studies of          Bis(S-acyl-2-thioethyl) Ester Derivatives of          9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as Potential          PMEA prodrugs with Improved Oral Bioavailability, J. Med.          Chem., 1996, pp. 4958-4965, vol. 39, No. 25.;            Bio, et al., Practical Synthesis of a Potent Hepatitis C          Virus RNA Replication Inhibitor, J. Org. Chem., 2004, pp.          6257-6266, vol. 69, No. 19.;            Bobeck, et al., Advances in Nucleoside Monophosphate          Prodrugs as Anti-HCV Agents, Antiviral Therapy, 2010, pp.          935-950, vol. 15.;            Bojack, et al., Design and Synthesis of Inhibitors of          Adenosine and AMP Deaminases, Organic Letters, 2001, pp.          839-842, vol. 3, No. 6.;            Boyer, et al., Pathogenesis, diagnosis and management of          hepatitis C, Journal of Hepatology, 2000, pp. 98-112,          vol. 32.;            Bozza, Zika Outbreak, Brazil 2015, ISARIC, 2015, 28          pages.;            Brown, Progress towards improving antiviral therapy for          hepatitis C virus polymerase inhibitors. Part O:          Nucleoside analogues, 2009, pp. 709-725, vol.          18.;            Bullard-Feibelman, et al., The FDA-approved drug          Sofosbuvir inhibits Zika Virus infection, Antiviral Res.,          Jan. 1, 2018, pp. 134-140, vol. 137.;            Burns, A Glimmer of Hope for Fatal Feline Disease,          JAVMAnews, Dec. 15, 2017, 5 pages.;            Butora, et al., Synthesis and HCV inhibitory properties          of 9-deaza- and 7, 9-dideaza-7-oxa-2-C-methyladenosine,          Bioorganic & Medicinal Chemistry, 2007, pp.          5219-5229, vol. 15, No. 15.;            Cabirol, et al., Robust and Efficient, yet Uncatalyzed,          Synthesis of Triarylsilyl-protected Cyanohydrins from          Ketones, 2008, pp. 2446-2449, vol. 73.;            Caira, Crystalline Polymorphism of Organic Compounds,          Topics in Current Chemistry, 1998, pp. 163-208, vol.          198.;            Cales, et al., Treatment of liver fibrosis: clinical          aspects, Gastroenterologie Clinique et Biologique, 2009,          pp. 958-966, vol. 33, No. 10-11.;            Calisher, et al., Antigenic Relationships between          Flaviviruses as Determined by Cross-neutralization Tests          with Polyclonal Antisera, Journal of General Virology,          1989, pp. 37-43, vol. 70.;            Camps, Studies on Structurally Simple--butenolides-II,          Tetrahedron, 1982, pp. 2395-2402, vol. 38, No.          15.;            Carroll, Robust Antiviral Efficacy upon Administration of          a Nucleoside Analog to Hepatitis C Virus-Infected          Chimpanzees, Antimicrobial Agents and Chemotherapy, 2009,          pp. 926-934, vol. 53, No. 3.;            Chapman, et al., RSV604, a Novel Inhibitor of Respiratory          Syncytial Virus Replication, Antimicrobial Agents and          Chemotherapy, 2007, pp. 3346-3353, vol. 51, No.          9.;            Cho, et al., Discovery of the First C-Nucleoside HCV          Polymerase Inhibitor (GS-6620) with Demonstrated          Antiviral Response in HCV Infected Patients, J. Med.          Chem., 2014, pp. 1812-1825, vol. 57, No. 5.;            Cho, et al., Synthesis and antiviral Activity of a Series          of 1-Substituted 4-aza-7, 9-dideazaadenosine          C-Nucleosides, Bioorganic & Medicinal Chemistry          Letters, 2012, pp. 2705-2707, vol. 22.;            Cihlar, et al., Design and Profiling of GS-9148, a Novel          Nucleotide Analog Active against Nucleoside-resistant          Variants of Human Immunodeficiency Virus Type 1, and Its          Orally Bioavailable Phosphonoamidate Prodrug, GS-9131,          Antimicrobial Agents and Chemotherapy, 2008, pp. 655-665,          vol. 52, No. 2.;            Clark, et al., Design, Synthesis, and Antiviral Activity          of 2-Deoxy-2-fluoro-2-C-methylcytidine, a Potent          Inhibitor of Hepatitis C Virus Replication, Journal of          Medicinal Chemistry, 2005, pp. 5504-5508, vol. 48, No.          17.;            Clarke, et al., Discovery of          beta-D-2-Deoxy-2-alpha-Fluoro-4-alpha-Cyano-5-aza-7,          9-Dideaza Adenosine as a Potent Nucleoside Inhibitor of          Respiratory Syncytial Virus with Excellent Selectivity          Over Mitochondrial RNA and DNA Polymerases, Bioorganic          & Medicinal Chemistry Letters, Apr. 29, 2015, pp.          2484-2487, vol. 25.;            Colacino, et al., Synthesis and Biological Evaluation of          Some 5-Nitro- and 5-Amino Derivatives of 2-Deoxycytidine,          2, 3-Dideoxyuridine, and 2, 3-Dideoxycytidine,          Nucleoside, Nucleotides & Nucleic Acids, 2003, pp.          2013-2026, vol. 22, No. 11.;            Dai, et al., Synthesis of 2-C--Fluoromethyluridine,          Organic Letters, 2003, pp. 807-810, vol. 5, No.          6.;  De          Clercq, Antiviral Drugs: Current State of the Art, J.          Clin. Virol., 2001, pp. 73-89, vol. 22, No. 1.;  De          Clercq, Molecular Targets for Antiviral Agents, The          Journal of Pharmacology and Experimental Therapeutics,          2001, pp. 1-10, vol. 297, No. 1.;  De          Francesco, et al., Approaching a New Era for Hepatitis C          Virus Therapy: Inhibitors of the NS3-4A Serine Protease          and the NS5B RNA-Dependent RNA Polymerase, Antiviral          Research, 2003, pp. 1-16, vol. 58, No. 1.;  De          Las Heras, Synthesis of Ribosyl and Arabinosyl Cyanides          by Reaction of 1-O-Acyl Sugars with Trimethylsilyl          Cyanide, Journal of the Chemical Society, Perkin          Transactions 1, 1982, pp. 903-907.;  De          Lombaert, et al., N-Phosphonomethyl Dipeptides and Their          Phosphonate Prodrugs, a New Generation of Neutral          Endopeptidase (NEP, EC 3.4.24.11) Inhibitors, J. Med.          Chem., 1994, pp. 498-511, vol. 37, No. 4.;  Di          Bisceglie, et al., The Unmet Challenges of Hepatitis C,          Scientific American, Oct. 1999, pp. 80-85.;            Dolzhenko, et al., Pyrazolo[1, 5-a][1, 3,          5]Triazines(5-Aza-9-Deazapurines): Synthesis and          Biological Activity, Heterocycles, 2008, pp. 1575-1622,          vol. 75, No. 7.;            Domingo, et al., The quasispecies (extremely          heterogeneous) nature of viral RNA genome populations:          biological relevancea review, Gene, 1985, pp. 1-8, vol.          40.;            Dondoni, et al., Thiazole-Based Synthesis of Formyl          C-Glycosides, Journal of Organic Chemistry, 1994, pp.          6404-6414, vol. 59.;            Dudfield, et al., Synthesis of C-ribosyl 1, 2,          4-triazolo[3, 4-f][1, 2, 4]triazines as Inhibitors of          Adenosine and AMP Deaminasses, J. Chem. Soc., Perkin          Trans. 1, 1999, pp. 2937-2942.;            Dudfield, P. et al., Synthesis of C-ribosyl imidazo[2,          1-f][1, 2, 4]triazines as inhibitors of adenosine and AMP          deaminases, J. Chem. Soc, Perkin Trans I, 1999, pp.          2929-2936.;            Dymock, et al., Novel approaches to the treatment of          hepatitis C virus infection, Antiviral Chemistry &          Chemotherapy, 2000, pp. 79-96, vol. 11, No. 2.;  El          Safadi, et al., 5-Modified-2-dU and 2-dC as Mutagenic          Anti HIV-1 Proliferation Agents: Synthesis and Activity,          Journal of Medicinal Chemistry, 2010, pp. 1534-1545, vol.          53, No. 4.;            Farquhar, et al., Biologically Reversible          Phosphate-Protective Groups, Journal of Pharmaceutical          Sciences, 1983, pp. 324-325, vol. 72, No. 3.;            Fukumoto, et al., Viral Dynamics of Hepatiis C Early          After Orthotopic Liver Transplantation: Evidence for          Rapid Turnover of Serum Virions, Hepatology, 1996, pp.          1351-1354, vol. 24.;            Garcia, et al., Synthesis of (2, 3, 4,          6-tetra-O-acetyl-alpha-D-glycopyranosyl)thiophene          derivatives as new C-nucleoside analogues, J.          Carbohydrate Chemistry, 2001, pp. 681-687, vol. 20, No.          7/8.;            Gardelli, et al., Phosphoramidate Prodrugs of          2-C-Methylcytidine for Therapy of Hepatitis C Virus          Infection, Journal of Medicinal Chemistry, 2009, pp.          5394-5407, vol. 52, No. 17.;            Gleeson, et al., Prediction of the Potency of Inhibitors          of Adenosine Deaminase by QM/MM Calculations, Chem.          Commun., 2003, pp. 2180-2181.;            Gordon, et al., Control of Hepatitis C: A Medicinal          Chemistry Perspective, J. Med. Chem., 2005, pp. 1-20,          vol. 48, No. 1.;            Greene, et al., Protective Groups in Organic Synthesis,          1991, pp. 118-142, John Wiley & Sons.;            Gudmundsson, et al., Synthesis of imidazo[1, 2-a]pyridine          C-Nucleosides with an Unexpected Site of Ribosylation,          Journal of Organic Chemistry, 1997, pp. 3453-3459, vol.          62.;            Gudmundsson, et al., The Condensation of 2,          6-dichloroimidazo[1, 2-a]pyridine C-nucleoside with an          Unexpected Site of Ribosylation, Tetrahedron Letters,          1996, pp. 2365-2368, vol. 7, No. 14.;            Gunic, et al., Cyclic monophosphate prodrugs of          base-modified 2-C-methyl ribonucleosides as potent          inhibitors of hepatitis C virus RNA replication,          Bioorganic & Medicinal Chemistry Letters, 2007, pp.          2452-2455, vol. 17.;            Hamann, et al., Synthesis and antiviral evaluation of 7,          9-dideaza-8-thiapurine C-nucleoside derivatives,          Collection Symposium Series, 2008, pp. 347-349, vol.          10.;            Hamann, et al., Synthesis and antiviral evaluation of          thieno[3, 4-d]pyrimidine C-nucleoside analogues of 2,          3-dideoxy- and 2, 3-dideoxy-2, 3-didehydro-adenosine and          -inosine, Bioorganic & Medicinal Chemistry, 2009, pp.          2321-2326, vol. 17.;            Han, et al., Synthesis of 1-Chloroacety1-1-dehydroxy-2,          3, 5-tri-O-benzoyl--D-ribofuranose. A Potentially          Versatile Intermediate for the Synthesis of          C-Nucleosides, Synthetic Communications, 1992, pp.          2815-2822, vol. 22, No. 19.;            Haraguchi, K. et al., Stereoselective Synthesis of          1-C-Branched Uracil Nucleosides From Uridine, Nucleosides          & Nucleotides, 1995, pp. 417-420, vol. 14, No.          3-5.;            Harki, et al., Synthesis and Antiviral Activity of          5-Substituted Cytidine Analogues: Identification of          Potent Inhibitor of Viral RNA-Dependent RNA Polymerases,          Journal of Medicinal Chemistry, 2006, pp. 6166-6169, vol.          49, No. 21.;            Hayashi, et al., C-Nucleosides, A Synthesis of          2-Substituted 7-(b-D-Ribofuranosyl)-Pyrrolo[2, 14]-1, 2,          4-Triazines. A New Type of Purine Like C-Nucleoside,          Heterocycles, 1992, pp. 569-574, vol. 34, No.          3.;            Hecker, et al., Liver Targeted Prodrugs of          2-C-Methyladenosine for Therapy of Hepatitis C Virus          Infection, J. Med. Chem., 2007, pp. 3891-3896, vol. 50,          No. 16.;            Hoffmann, et al., When, in the context of drug design,          can a fluorine atom successfully substitute a hydroxyl          group?, International Journal of Quantum Chemistry, 2002,          pp. 419-427, vol. 89.;            Itoh, et al., Divergent and Stereocontrolled Approach to          the Synthesis of Uracil Nucleosides Branched at the          Anomeric Position, J. Org. Chem, 1995, pp. 656-662, vol.          60.;            Jasko, et al., 5-Phosphonates of Ribonucleosides and          2-Deoxyribonucleosides: Synthesis and Antiviral Activity,          Nucleosides & Nucleotides, 1993, pp. 879-893, vol.          12, No. 8.;            Kabat, et al., Nucleosides, CXLVIII, Synthesis of          6-(-D-Ribofuranosyl)picolinamide: A Novel C-Nucleoside          from D-Ribonolactone, Chemical & Pharmaceutical          Bulletin, 1988, pp. 634-640, vol. 36, No. 2.;            Khamnei, et al., Neighboring Group Catalysis in the          Design of Nucleotide Prodrugs, J. Med. Chem., 1996, pp.          4109-4115, vol. 39, No. 20.;            Kim, et al., Reversal of the Progression of Fatal          Coronavirus Infection in Cats by a Broad-Spectrum          Coronavirus Protease Inhibitor, PLOS Pathogens, Mar. 30,          2016, 18 pages.;            Klumpp, et al., The Novel Nucleoside Analog R1479          (4-Azidocytidine) is a Potent Inhibitor of NSSB-dependent          RNA Synthesis and Hepatitis C virus Replication in Cell          Culture, Journal of Biological Chemistry, 2006, pp.          3793-3799, vol. 281, No. 7.;            Knaggs, et al. A QSAR Study Investigating the Effect of          L-Alanine Ester Variation on the Anti-HIV Activity of          Some Phosphoramidate Derivatives of d4T, 2000, pp.          2075-2078.;            Knutsen, et al., Synthesis of Imidazo-fused          Bridgehead-nitrogen C-Nucleosides : Coupling-Elimination          Reactions of 2, 5-Anhydro-3, 4, 6-tri-O-benzoyl-D-allonic          Acid, J. Chem. Soc. Perkin Trans I, 1985, pp.          621-630.;            Knutsen, et al., Synthesis of Imidazo-fused          Bridgehead-nitrogen C-Nucleosides via Dehydrative          Coupling Reactions of 2, 5-Anhydro-3, 4,          6-tri-O-benzoyl-D-allonic Acid, J. Chem. Soc. Perkin          Trans I, 1984, pp. 229-238.;            Kobe, et al., Use of Distance Geometry Approach for the          In Vitro Antiviral Activity Evaluation of N-bridgehead          C-nucleosides, European J. Med. Chem., 1992, pp. 259-266,          vol. 27, No. 3.;            Lefebvre, et al., Mononucleoside Phosphotriester          Derivatives with S-Acyl-2-thioethyl Bioreversible          Phosphate-Protecting Groups: Intracellular Delivery of          3-Azido-2, 3-dideoxythymidine 5-Monophosphate, Journal of          Medicinal Chemistry, 1995, pp. 3941-3950, vol. 38, No.          20.;            Lefebvre, et al., Synthesis, Decomposition Pathways and          In Vitro Evaluation of Bioreversible Phosphotriesters of          Azt, Nucleosides, Nucleotides & Nucleic Acids, 1995,          pp. 763-766, vol. 14, No. 3-5.;            Lindell, et al., Synthesis and Biochemical Testing of          3-(Carboxyphenylethyl)imidazo[2, 1-f][1, 2, 4]triazines          as Inhibitors of AMP Deaminase, ACS Medicinal Chemistry          Letters, 2010, pp. 286-289, vol. 1, No. 6.;            Lovelette, 1, 2, 4-Triazines. Synthesis of selected          members of the s-triazolo[3, 4-f][1, 2, 4]triazine and          tetrazolo[1, 5-f][1, 2, 4]triazine ring systems, Journal          of Heterocyclic Chemistry, 1979, pp. 555-560, vol.          16.;            Lu, Chengping, Veterinary Microbiology 5th edition, Jan.          31, 2013, p. 431, China Agriculure Press (No English          Translation available).;            Martell, et al., Hepatitis C Virus (HCV) Circulates as a          Population of Different but Closely Related Genomes:          Quasispecies Nature of HCV Genome Distribution, Journal          of Virology, 1992, pp. 3225-3229, vol. 6695.;            Mason, et al., Polyadenylation-dependent screening assay          for respiratory syncytial virus RNA transcriptase          activity and identification of an inhibitor, Nucleic          Acids Research, 2004, pp. 4758-4767, vol. 32, No.          16.;            Matulic-Adamic, et al., Synthesis of          3-(-D-Ribofuranosyl)-2-Fluoropyridine and          3-(-D-Ribofuranosyl)-Pyridin-2-one, Tetrahedron Letters,          1997, pp. 203-206, vol. 38, No. 2.;            Matulic-Adamic, et al., Synthesis of          5-(-D-Ribofuranosyl)-Pyridin-2-one: a Deletion-Modified          Analogue of Uridine, Tetrahedron Letters, 1997, pp.          1669-1672, vol. 38, No. 10.;            McGuigan, et al. Application of Phosphoramidate ProTide          Technology Significantly Improves Antiviral Potency of          Carbocyclic Adenosine Derivatives, 2006, pp.          7215-7226.;            McGuigan, et al., Intracellular Delivery of Bioactive AZT          Nucleotides by Aryl Phosphate Derivatives of AZT, J. Med.          Chem., 1993, pp. 1048-1052, vol. 36, No. 8.;            Meppen, et al., Cyclic phosphoramidates as prodrugs of          2-C-methylcytidine, European Journal of Medicinal          Chemistry, 2009, pp. 3765-3770, vol. 49, No. 9.;            Meppen, et al., Medi-404A Prodrug Approach for the          Treatment of HCV Infection, Abstracts of papers, 236th          ACS National Meeting, Philadelphia, PA, United States,          Aug. 17-21, 2008.;            Metobo, et al., Practical synthesis of 1-substituted          Tubercidin C-nucleoside analogs, Tetrahedron Letters,          Feb. 2012, pp. 484-486, vol. 53, No. 5.;            Migliaccio, et al., Characterization of Resistance to          Non-obligate Chain-terminating Ribonucleoside Analogs          That Inhibit Hepatitis C Virus Replication in vitro, The          Journal of Biological Chemistry, 2003, pp. 49164-49170,          vol. 278, No. 49.;            Mitchell, et al., Bioreversible Protection for the          Phospho Group: Bioactivation of the Di(4-acyloxybenzyl)          and Mono(4-acyloxybenzyl) Phosphoesters of          Methylphosphonate and Phosphonoacetate, J. Chem. Soc.,          Perkin Trans. 1, 1992, pp. 2345-2353.;            Mitchell, et al., Synthesis of C-Nucleoside Isosteres of          9-(2-Hydroxyethoxymethyl)guanine (Acyclovir), J. Het.          Chem., 1984, pp. 697-699, vol. 21, No. 3.;            Moennig, et al., The Pestiviruses, Advances in Virus          Research, 1992, pp. 53-98, vol. 41.;            Moradpour, et al., Replication of hepatitis C virus,          Nature Reviews Microbiology, 2007, pp. 453-463, vol. 5,          No. 6.;            Moscow, et al., Reduced Folate Carrier Gene (RFC1)          Expression and Anti-Folate Resistance in Transfected and          Non-Selected Cell Lines, International Journal of Cancer,          1997, pp. 184-190, vol. 72.;            Murakami, et al., Mechanism of Activation of          Beta-D-2-Fluoro-2-C-Methylcytidine and Inhibition of          Hepatitis C Virus NS5B RNA Polymerase, Antimicrob Agents          Chemother., Feb. 2007, pp. 503-509, vol. 51, No.          2.;            Murphy, et al., The Nucleoside Analog GS-441524 Strongly          Inhibits Feline Infectious Peritonisitis (FIP) Virus in          Tissue Culture and Experimental Cat Infection Studies,          Veterinary Microbiology, 2018, pp. 226-233, vol.          219.;            Neumann, et al., Hepatitis C Viral Dynamics in Vivo and          the Antiviral Efficacy of Interferon- Therapy, Science,          1998, pp. 103-107, vol. 282.;            Nishimura, et al., Synthesis of pyrrolo[2, 1-f][1, 2,          4]triazine C-nucleosides. Isosteres of sangivamycin,          tubercidin, and toyocamycin, Carbohydrate Research, 2001,          pp. 77-82, vol. 331.;            Ogura, et al., Reaction of Ethynyl Compounds with          Lactones, Journal of Organic Chemistry, 1972, pp. 72-75,          vol. 37, No. 1.;            Otter, B. et al., Conformational Properties of          Purine-Like C-Nucleosides, Nucleosides & Nucleotides,          1996, pp. 793-807, vol. 15, No. 1-3.;            Pankiewicz, et al., C-Nucleoside Analogues of          Nicotinamide Mononucleotide (NMN), Nucleosides and          Nucleotides, 1988, pp. 589-593, vol. 7, No.          5&6.;            Pankiewicz, et al., Efficient Synthesis of          5-(-D-Ribofuranosyl)nicotinamide and its -Isomer, Journal          of Organic Chemistry, 1988, pp. 3473-3479, vol.          53.;            Patil, et al., C-Glycosylation of Substituted          Heterocycles under Friedel-Crafts Conditions (II):          Robosylation of Multi-Functionalized Thiophenes and          Furans for the Synthesis of Purine-Like C-Nucleosides,          Nucleosides & Nucleotides, 1990, pp. 937-956, vol. 9,          No. 7.;            Patil, et al., Synthesis of Pyrrolo[2, 1-f][1, 2,          4]triazine Congeners of Nucleic Acid Purines via the          N-Amination of 2-Substituted Pyrroles, J. Het. Chem.,          1994, pp. 781-786, vol. 31.;            Patil, et al., Synthesis of some new thieno[3,          4-d]pyrimidines and their C-nucleosides, Journal of          Heterocyclic Chemistry, 1993, pp. 509-515, vol. 30, No.          2.;            Patil, S. et al., 4-Aza-7, 9-Dideazaadenosine, a New          Cytotoxic Synthetic C-Nucleoside Analogue of Adenosine,          Tetrahedron Letters, 1994, pp. 5339-5342, vol. 35, No.          30.;            Perrone, et al., Application of the Phosphoramidate          ProTide Approach to 4-Azidouridine Confers Sub-micromolar          Potency versus Hepatitis C Virus on an Inactive          Nucleoside, Journal of Medicinal Chemistry, 2007, pp.          1840-1849, vol. 50, No. 8.;            Piccirilli, et al., A Direct Route to          3-(D-Ribofuranosyl)pyridine Nucleosides, Helvetica          Chimica Acta, 1991, pp. 397-406, vol. 74.;            Pierra, et al., Synthesis and Pharmacokinetics of          Valopicitabine (NM283), and Efficient Prodrug of the          Potent Anti-HCV Agent 2-C-Methylcytidine, Journal of          Medicinal Chemistry, 2006, pp. 6614-6620, vol. 49, No.          22.;            Poduch, et al., Design of Inhibitors of Orotidine          Monophosphate Decarboxylase Using Bioisosteric          Replacement and Determination of Inhibition Kinetics,          Journal of Medicinal Chemistry, 2006, pp. 4937-4945, vol.          49, No. 16.;            Porter, et al., Zika virus, drug discovery, and student          projects, ScienceBlogs, Mar. 9, 2016, 7 pages.;            Puech, et al., Intracellular Delivery of Nucleoside          Monophosphates through a Reductase-mediated Activation          Process, Antiviral Research, 1993, pp. 155-174, vol. 22,          No. 4.;            Ramasamy, et al., Synthesis and Antitumor Activity of          Certain 3-B-D-Ribofuranosyl-1, 2, 4-triazolo[3, 4-f]-1,          2, 4-triazines Related to Formycin Prepared via Ring          Closure of a 1, 2, 4-Triazine Precursor, J. Med. Chem.,          1986, pp. 2231-2235, vol. 29, No. 11.;            Rao, et al., C-Glycosylation of Substituted Heterocycles          under Friedel-Crafts Conditions (I): A Two-Step Synthesis          of the Thieno[3, 4-d]Pyrimidine C-Nucleoside Analog of          Inosine, Tetrahedron Letters, 1988, pp. 3537-3540, vol.          29, No. 29.;            Reddy, et al., Stereoselective Synthesis of Nucleoside          Monophosphate HepDirectTM Prodrugs, Tet. Lett., 2005, pp.          4321-4324, vol. 46.;            Sacramento, et al., The clinically approved antiviral          drug Sofosbuvir inhibits Zika Virus replication, Nature,          Jan. 18, 2017.;            Schul, et al., A Dengue Fever Viremia Model in Mice Shows          Reduction in Viral Replication and Suppression of the          Inflammatory Response after Treatment with Antiviral          Drugs, Journal of Infectious Diseases, 2007, pp. 665-674,          vol. 195.;            Schultz, Prodrugs of Biologically Active Phosphate          Esters, Bioorganic & Medicinal Chemistry, 2003, pp.          885-898, vol. 11.;            Scott, et al., Interferon-a-2b Plus Ribavirin: A Review          of its Use in the Management of Chronic Hepatitis C,          Drugs, 2002, pp. 507-556, vol. 62, No. 3.;            Shekunov, et al., Crystallization processes in          pharmaceutical technology and drug delivery design,          Journal of Crystal Growth, 2000, pp. 122-136, vol.          211.;            Siegel, Discovery and Synthesis of a Phosphoramidate          Prodrug of a Pyrrolo[2, 1-f][triazin-4-amino] Adenine          C-Nucleoside(GS-5734) for the Treatment of Ebola and          Emerging Viruses, J. Med. Chem., Jan. 26, 2017, 51          pages.;            Silverman et al., The Organic Chemistry of Drug Design          and Drug Action, 1992, pp. 19-23.;            Silverman, The Organic Chemistry of Drug Design and Drug          Action, 2nd Ed., 2004, pp. 29-34.;            Srivastav, et al., Antiviral Activity of Various          1-(2-Deoxy--D-Iyxofuranosyl),          1-(2-Fluoro--D-xylofuranosyl),          1-(3-Fluor--D-arabinofuranosyl), and 2-Fluoro-2,          3-didehydro-2, 3-dideoxyribose Pyrimidine Nucleoside          Analogues against Duck Hepatitis B Virus (DHBV) and Human          Hepatitis B Virus (HBV) Replication, Journal of Medicinal          Chemistry, 2010, pp. 7156-7166, vol. 53, No.          19.;            Tapia, et al., Combination of a Mutagenic Agent with a          Reverse Transcriptase Inhibitor Results n Systematic          Inhibition of HIV-1 Infection, Virology, 2005, pp. 1-8,          vol. 338.;            Uchiyama, et al., O-selective Phosphorylation of          Nucleosides without N-protection, J. Org. Chem., Jan. 1,          1993, vol. 58, No. 2.;            Vaghefi, et al., Synthesis and Antiviral Activity of          Certain Nucleoside 5-Phosphonoformate Derivatives,          Journal of Medicinal Chemistry, 1986, pp. 1389-1393, vol.          29, No. 8.;            Venkatachalam, et al. Effect of change in nucleoside          structure on the activation and antiviral activity of          phosphoramidate derivatives, 2005, pp.          5408-5423.;            Warren, et al., Therapeutic efficacy of the small          molecules GS-5734 against EBOLA virus in rhesus monkeys,          Nature, Mar. 17, 2016, 19 pages.;            Wu, et al., Synthetic Methodologies for C-Nucleosides,          Synthesis, 2004, pp. 1533-1553, vol. 10.;            Yamanaka, et al., Metabolic Studies on BMS-200475, a New          Antiviral Compound Active against Hepatitis B Virus,          Antimicrobial Agents and Chemotherapy, 1999, p. 190, vol.          43, No. 1.;            Yoshimura, et al., Synthesis and Biological Evaluation of          1-C-Cyano-Pyrimidine Nucleosides, Nucleosides &          Nucleotides, 1996, pp. 305-324, vol. 15, No.          1-3.;            Zhang, et al., A Practical Synthesis of (2R)-3,          5-di-O-benzoyl-2-fluoro-2-C-methyl-D-ribono-y-lactone,          Tetrahedron: Asymmetry, 2009, pp. 305-312, vol.          20.	184620-0-0-0 K M; 114-0-0-0 K M; 2157647-1-0-0 K M U; 2629612-1-0-0 K M U; 2629613-3-0-0 K M U; 2629614-1-0-0 K M U;  K M U;  K M U; 2629619-1-0-0 K M U;  K M U;  K M U;  K M U;  K M U;  K M U;  K M U;  K M U;  K M U;  K M U;  K M U;  K M U; 2157647-1-0-0 CL USE; 2629612-1-0-0 CL USE; 2629613-3-0-0 CL USE; 2629614-1-0-0 CL USE; 2629619-1-0-0 CL USE	216122101 K M U	61435	RA012O K M; R01706 K M; RB4RFE K M U; RBEZ9V K M U; RC7QJW K M U; RBEZ9X K M U; RCN5DX K M U; RCN5DY K M U; RBEZA2 K M U; RC3GID K M U; RC4G8L K M U; RC3GIF K M U; RC4G8N K M U; RC3GIH K M U; RC4G8M K M U; RC4G8O K M U; RCHNPG K M U; RCN5DZ K M U; RCN5E0 K M U; RCN5E1 K M U	1706-S	CN110468113-A	Expressing and producing transmissible            gastroenteritis coronavirus (TGEV) AH virus useful for            rescuing TGEV AH virus by using pBeloBAC11 as vector            and linear expression construct for reconstructing TGEV            AH virus particle	FENG L;  CHEN J;  ZHANG X;  ZHU X;  SHI H;  SHI D;  LIU J	HARBIN VETERINARY RES INST CAAS (CAGS-C)	201999013R	   NOVELTY - Method for expressing and producing                transmissible gastroenteritis coronavirus (TGEV) AH                virus involves using pBeloBAC11 as vector and                linear expression construct for reconstructing TGEV                AH virus particle.    USE - The method is useful for expressing and                producing TGEV AH virus and rescuing TGEV AH virus                (claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) method for rescuing TGEV AH virus involves                analyzing TGEV AH virus sequence and pBeloBAC11                vector sequence, determining cloning site of TGEV                AH virus genome, amplifying in sections, inserting                into pBeloBAC11 plasmid vector to obtain                full-length sequence of the recombinant virus by                transfection and culturing to obtain stable passage                for rescuing virus;    (2) a recombinant porcine infectious                gastroenteritis virus attenuated strain (rTGEV (v)                AH), and its microorganism deposit number is CGMCC                17498; and    (3) a rTGEV AH- expressing green fluorescent                protein (GFP), and its microorganism deposit number                is CGMCC 17496. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-F11B0E;  C04-E99;  C04-F11B0E;  D05-H12F;  D05-H18;  D05-H99	C12N-015/65;  C12N-015/85;  C12N-007/01;  C12R-001/93	CN110468113-A   19 Nov 2019   C12N-007/01   201997Pages: 35   Chinese	CN110468113-A    CN10728644    07 Aug 2019		CN10728644    07 Aug 2019			CN110468113-A -- CN1402780-A   CONSEJO SUPERIOR INVESTIGACIONES CIENTIF (CNSJ)   ENJUANES SANCHEZ L;  CN1616670-A   CONSEJO SUPERIOR INVESTIGACIONES CIENTIF (CNSJ)   ENJUANES SANCHEZ L;  CN101423836-A   CHINA ACAD AGRIC SCI HARBIN VETERINARY RES                  INST (CAGS)   HUANG L,  LIU C,  LU Y,  WEI Y,  YUAN J,  ZHANG C	CN110468113-A  : "TGEV",          ,relevantClaims[1-8],relevantPassages[61811]	200757-0-0-0 N P; 200757-0-0-0 CL NEW PRD			RA00GT N P		WO2019078600-A1;  KR2019044006-A;  KR2017217-B1	New binding molecule useful in plate and kit for            determining antigen of Middle East Respiratory Syndrome            coronavirus for determining antibody titer on sample,            comprises specific amino acid sequence	LEE J M;  LEE H J;  PARK P G;  SHIM D H;  KIM N R;  LEE J E;  PARK J E;  LEE H K;  KIM H R;  PARK S;  LEEJUNGEUN;  HYELIM K	ATGEN CO LTD (ATGE-Non-standard);  UNIV YONSEI IND ACADEMIC COOP FOUND (UYIA-C);  NKMAX CO LTD (NKMA-Non-standard)	201937030P	   NOVELTY - A binding molecule specific for Middle East                Respiratory Syndrome coronavirus (MERS-CoV)                comprising a 258 amino acid sequence (SEQ ID NO: 1)                fully defined in the specification, is new. The                binding molecule is an antibody or a binding                fragment of binding molecules.    USE - The binding molecule is useful in plate and                kit for determining the antigen of the MERS-CoV,                which is useful for determining the antibody titer                on sample (all claimed).    ADVANTAGE - The binding molecule measures antibody titer                in a simple and rapid manner.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a method for determining the antibody                titer on a sample using the binding molecule or                antigen, involves determining the antigen of the                MERS-CoV;    (2) a plate for determining the antibody titer                on a sample using the binding molecule; and    (3) a diagnostic kit comprising the binding                molecule or antigen having amino acid of SEQ ID NO:                1. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-B04C1;  B04-C01G;  B04-E99;  B04-G01;  B04-G23;  B11-C07A;  B12-K04G2G;  D05-H09;  D05-H99;  S03-E09;  S03-E14H5	C07K-014/005;  C12N-015/86;  G01N-033/68	WO2019078600-A1   25 Apr 2019   C07K-014/005   201939Pages: 23   ;  KR2019044006-A   29 Apr 2019   C07K-014/005   201939   ;  KR2017217-B1   02 Sep 2019   C07K-014/005   201971   	WO2019078600-A1    WOKR012226    17 Oct 2018;   KR2019044006-A    KR123551    17 Oct 2018;   KR2017217-B1    KR123551    17 Oct 2018	KR2017217-B1 Previous Publ. Patent KR2019044006	KR135754    19 Oct 2017	WO2019078600-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      		WO2019078600-A1 -- KR2016091350-A   UNIV PENNSYLVANIA (UPEN);  INOVIO PHARM INC (IVIO)   WEINER D B,  MUTHUMANI K,  SARDESAI N Y;  KR2017005133-A   KYRATSOUS C (KYRA-Individual);  SIVAPALASINGAM S (SIVA-Individual);  STAHL N (STAH-Individual)   KYRATSOUS C,  SIVAPALASINGAM S,  STAHL N;  US20160264647-A1   ;  US20160296617-A1   	WO2019078600-A1  LI, YAN: "A          humanized neutralizing antibody against MERS-CoV          targeting the receptor-binding domain of the spike          protein", CELL RESEARCH, vol. 25, 2015, pages 1237 -          1249, XP055587421, DOI:          doi:10.1038/cr.2015.113,relevantClaims[1-14]						CN110468112-A	Expressing and producing transmissible            gastroenteritis coronavirus (TGEV) H165 virus useful            for rescuing TGEV-H165 virus by using pBeloBAC11 as            vector and linear expression construct for            reconstructing TGEV-H165 virus particle	FENG L;  CHEN J;  ZHU X;  ZHANG X;  SHI H;  SHI D;  LIU J	HARBIN VETERINARY RES INST CAAS (CAGS-C)	201999013S	   NOVELTY - Method for expressing and producing                transmissible gastroenteritis coronavirus (TGEV)                H165 virus involves using pBeloBAC11 as vector and                linear expression construct for reconstructing                TGEV-H165 virus particle.    USE - The method is useful for expressing and                producing TGEV-H165 virus and rescuing TGEV-H165                virus (claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) method for rescuing TGEV-H165 virus                involves analyzing TGEV-H165 virus sequence and                pBeloBAC11 vector sequence, determining cloning                site of TGEV-H165 virus genome, amplifying in                sections, inserting into pBeloBAC11 plasmid vector                to obtain full-length sequence of the recombinant                virus by transfection and culturing to obtain                stable passage for rescuing virus;    (2) a recombinant porcine infectious                gastroenteritis virus attenuated strain (rTGEV                (a)-H165), and its microorganism deposit number is                CGMCC 17495; and    (3) a rTGEV-H165- expressing green fluorescent                protein (GFP), and its microorganism deposit number                is CGMCC 17497. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-F11B0E;  C04-E99;  C04-F11B0E;  D05-H12F;  D05-H18;  D05-H99	C12N-015/12;  C12N-015/63;  C12N-007/01	CN110468112-A   19 Nov 2019   C12N-007/01   201997Pages: 24   Chinese	CN110468112-A    CN10728643    07 Aug 2019		CN10728643    07 Aug 2019			CN110468112-A -- CN104830875-A   UNIV NANJING AGRIC (UYNA)   FAN H,  LIN H,  YUAN X	CN110468112-A  : "TGEV",          ,relevantClaims[1-8],relevantPassages[4118113.21]	200757-0-0-0 N P; 200757-0-0-0 CL NEW PRD			RA00GT N P		CN110420274-A	Pharmaceutical composition used in preparing medicine for treating canine coronavirus disease, is prepared by following traditional Chinese medicines comprises Ajuga decumbens thunb, Castanopsis delavayi franch and Ampelopsis heterophylla	SU Z;  CHEN W;  HUANG L;  LIANG J;  CHEN J;  CHEN Z	JIANGSU AGRI ANIMAL HUSBANDRY VOCATIONAL (JAAH-C)	201996271J	   NOVELTY - Pharmaceutical composition is prepared by the following traditional Chinese medicines comprises 9-28 pts. wt. Ajuga decumbens thunb, 30-80 pts. wt. Castanopsis delavayi franch, 5-15 pts. wt. Ampelopsis heterophylla and 10-30 pts. wt. hedyotis lance.    USE - Pharmaceutical composition used in preparing Chinese veterinary medicine for restraining intestine propulsion, and in preparing medicine for treating canine coronavirus disease (all claimed).    ADVANTAGE - The pharmaceutical composition has the traditional Chinese medicine composition which adopts the specific compatibility, and the four drugs are used in combination to complement each other and coordinate the functions, the composition has the advantages of addressing both symptoms and root causes, high overall curative effect, short treatment course, not easy to produce drug resistance, less residue, less toxic and side effects, which is effective in treating canine coronavirus disease.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for preparing pharmaceutical composition, which involves:    (A) performing a step involves mixing Ajuga decumbens thunb, Castanopsis delavayi franch, Ampelopsis heterophylla and hedyotis lance, adding water to extract for 2-3 times, combining the liquid extract, concentrating it to thick; and    (B) carrying out an another step involves adding the ethanol until the concentration of the ethanol is 60-70%, freezing and settling, filtering, collecting the filtrate, and recycling the ethanol in the filtrate, after the recycling ethanol in the medicine liquid, adding ethanol until the ethanol concentration is 75-80%, stirring uniformly, refrigerating, precipitating, filtering, collecting the filtrate, and recovering the ethanol in the filtrate, then concentrating the filtrate until there is no alcohol taste, and concentrating the medicine liquid. 			B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.)	B04-A08;  B04-A10;  B04-A98;  B12-M07;  B14-A02B5;  B14-E10C;  B14-S12;  B14-S18;  C04-A08;  C04-A10;  C04-A98;  C12-M07;  C14-A02B5;  C14-E10C;  C14-S12;  C14-S18	A61K-036/87;  A61K-009/08;  A61P-031/14	CN110420274-A   08 Nov 2019   A61K-036/87   201993Pages: 10   Chinese	CN110420274-A    CN10864717    12 Sep 2019		CN10864717    12 Sep 2019			CN110420274-A -- CN1644199-A   REN Q (RENQ-Individual)   REN Q,  SONG X;  CN103720932-A   ZHOU G (ZHOU-Individual)   ZHOU G	CN110420274-A  : "GC-MS ", ,relevantClaims[1-10],relevantPassages[130-134]	200757-0-0-0 K M			RA00GT K M		CN109554508-A	New real-time fluorescent quantitative PCR detection primers and probes useful in reagent for identifying variant porcine epidemic diarrhea virus (PEDV) and transmissible gastroenteritis coronavirus (TGEV)	CHEN Q;  ZHOU L;  WANG L;  CHEN R;  WU X;  CHE Y;  HOU B;  WANG C	INST ANIMAL & VETERINARY FUJIAN ACAD AGR (IAMV-C)	201932466G	   NOVELTY - Real-time fluorescent quantitative PCR detection primers and probes to identify variant porcine epidemic diarrhea virus (PEDV) and transmissible gastroenteritis coronavirus (TGEV), are new.    USE - The real-time fluorescent quantitative PCR detection primers and probes are useful in reagent for identifying variant PEDV and TGEV (claimed).    ADVANTAGE - The primers and probes rapidly enable to identify variant PEDV and TGEV in less labor intensive and cost-effective manner with strong specificity, good stability and high sensitivity.    DETAILED DESCRIPTION - Real-time fluorescent quantitative PCR detection primers and probes to identify variant porcine epidemic diarrhea virus (PEDV) and transmissible gastroenteritis coronavirus (TGEV), are new. The primers and probes for detecting N gene variant PEDV comprise upstream primer PEDV-F (5'-3') having base pair sequence of ctcccgagtgtagttgagattg (SEQ ID NO: Not defined), downstream primer PEDV-R (5'-3') having base pair sequence of ctccacgaccctggttattt (SEQ ID NO: Not defined) and fluorescent probe PEDVP (5'-3') having base pair sequence of FAM (RTM: 5-Carboxyfluorescein)-caacccaacacacctcctacttcacg-Black hole quencher (BHQ) (RTM: Not defined)1 (SEQ ID NO: Not defined) and detecting S gene variant TGEV comprise upstream primer TGEV-F (5'-3') having base pair sequence of tgagggtgctggctttgat (SEQ ID NO: Not defined), downstream primer TGEV-R (5'-3') having base pair sequence of caagagtgacaccacccgtt (SEQ ID NO: Not defined) and fluorescent probe TGEVP (5'-3') having base pair sequence of VIC (RTM: Not defined)-cactgtggcacccttacctgattgt--BHQ (RTM: Not defined)1 (SEQ ID NO: Not defined). 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E05;  B04-E99;  B04-F11B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  C04-E05;  C04-E99;  C04-F11B;  C11-C07B3;  C11-C08E3;  C11-C08F8;  C12-K04F;  C12-K04G1B;  D05-H06A;  D05-H12D1;  D05-H18B;  D05-H99	C12Q-001/70;  C12Q-001/6851;  C12N-015/11	CN109554508-A   02 Apr 2019   C12Q-001/70   201954Pages: 16   Chinese	CN109554508-A    CN10097009    31 Jan 2019		CN10097009    31 Jan 2019										WO2019135003-A1;  AU2019205602-A1;  CA3087214-A1;  IN202037026806-A;  CN111565743-A;  KR2020107958-A;  US2020353060-A1;  EP3737407-A1;  BR112020013790-A2;  JP2021509809-W;  RU2020123357-A	Use of polypeptide having protease activity in            preparing medicament for treating or preventing            coronavirus infection e.g. common cold, pneumonia,            pneumonitis, bronchitis, or severe acute respiratory            syndrome in mammal, preferably human	GUOMUNDSDOTTIR A;  STEFANSSON B;  SANDHOLT G B;  GUDMUNDSDOTTIR A	ENZYMATICA AB (ENZY-Non-standard);  ENZYMATICA AB (ENZY-Non-standard);  ENZYMATICA AB (ENZY-Non-standard);  ENZYMATICA AB (ENZY-Non-standard)	201960780L	   NOVELTY - Use of polypeptide having protease activity is                claimed, in preparing medicament for treating or                preventing coronavirus (CoV) infection in a                mammal.    USE - The polypeptide is useful for preparing                medicament for treating or preventing CoV infection                in a subject, preferably mammal. The CoV infection                is an infection of the respiratory tract and/or                gastrointestinal tract. The CoV infection is chosen                from common cold, pneumonia, pneumonitis,                bronchitis, severe acute respiratory syndrome                (SARS), Middle East respiratory syndrome (MERS),                sinusitis, otitis or pharyngitis. The CoV infection                is the common cold. The CoV is chosen from (a)                alpha -CoV, (b) beta -CoV, (c) gamma -CoV, and (d)                delta -CoV. The CoV is a human CoV. The human CoV                is chosen from (a) human CoV 229E, (b) human CoV                OC43, (c) SARS-CoV, (d) human CoV NL63 (HCoV-NL63,                New Haven CoV), (e) human CoV HKU1, and (f)                MERS-CoV. The mammal is a human (all                claimed). 			B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  	B04-E99;  B02-C04;  B02-P04;  B04-C01;  B04-L05;  B04-L05C;  B04-L05C0E;  B10-B02D;  B10-B02J;  B10-E04C;  B14-A01;  B14-A02;  B14-A02B3;  B14-A02B5;  B14-A04;  B14-C03;  B14-K01;  B14-N04;  B14-N05B;  C04-E99;  C02-C04;  C02-P04;  C04-C01;  C04-L05;  C10-B02D;  C10-B02J;  C10-E04C;  C14-A01;  C14-A02;  C14-A02B3;  C14-A02B5;  C14-A04;  C14-C03;  C14-K01;  C14-N04;  C14-N05B;  D05-H99;  D05-A02C	A61K-031/407;  A61K-031/43;  A61K-031/47;  A61K-031/545;  A61K-031/7036;  A61K-031/7048;  A61K-038/06;  A61K-038/48;  A61K-047/10;  A61K-009/00;  A61K-009/20;  A61K-009/68;  A61P-011/00;  A61P-031/14;  A61K-045/06;  A23L-033/18;  A61K-045/00;  A61P-011/02;  A61P-027/16;  C12N-015/57;  C12N-009/64	WO2019135003-A1   11 Jul 2019   A61K-038/48   201957Pages: 58   English;  AU2019205602-A1   09 Jul 2020   A61K-038/48   202056   English;  CA3087214-A1   11 Jul 2019   A61K-038/48   202062   English;  IN202037026806-A   07 Aug 2020   A61K-038/48   202067   English;  CN111565743-A   21 Aug 2020   A61K-038/48   202071   Chinese;  KR2020107958-A   16 Sep 2020   A61K-038/48   202076   ;  US2020353060-A1   12 Nov 2020   A61K-038/48   202092   English;  EP3737407-A1   18 Nov 2020   A61K-038/48   202094   English;  BR112020013790-A2   01 Dec 2020   A61K-009/00   202002   English;  JP2021509809-W   08 Apr 2021   C12N-009/64   202130Pages: 43   Japanese;  RU2020123357-A   14 Jan 2022   A61K-038/48   202266   Russian	WO2019135003-A1    WOEP050266    07 Jan 2019;   AU2019205602-A1    AU205602    07 Jan 2019;   CA3087214-A1    CA3087214    07 Jan 2019;   IN202037026806-A    IN37026806    24 Jun 2020;   CN111565743-A    CN80007479    07 Jan 2019;   KR2020107958-A    KR719596    07 Jan 2019;   US2020353060-A1    US16960387    07 Jul 2020;   EP3737407-A1    EP701577    07 Jan 2019;   BR112020013790-A2    BR11013790    07 Jan 2019;   JP2021509809-W    JP536869    07 Jan 2019;   RU2020123357-A    RU123357    07 Jan 2019	AU2019205602-A1 PCT application Application WOEP050266;   AU2019205602-A1 Based on Patent WO2019135003;   CA3087214-A1 PCT application Application WOEP050266;   CA3087214-A1 Based on Patent WO2019135003;   IN202037026806-A PCT application Application WOEP050266;   IN202037026806-A Based on Patent WO2019135003;   CN111565743-A PCT application Application WOEP050266;   CN111565743-A Based on Patent WO2019135003;   KR2020107958-A PCT application Application WOEP050266;   KR2020107958-A Based on Patent WO2019135003;   US2020353060-A1 PCT application Application WOEP050266;   EP3737407-A1 PCT application Application WOEP050266;   EP3737407-A1 Based on Patent WO2019135003;   BR112020013790-A2 PCT application Application WOEP050266;   BR112020013790-A2 Based on Patent WO2019135003;   JP2021509809-W PCT application Application WOEP050266;   JP2021509809-W Based on Patent WO2019135003	GB000274    08 Jan 2018;  CA3087214    26 Jun 2020;  BR11013790    06 Jul 2020;  CN80007479    06 Jul 2020;  KR719596    07 Jul 2020	WO2019135003-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA              EP3737407-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        		WO2019135003-A1 -- US20020141987-A1   ;  WO2017017012-A1   ENZYMATICA AB (ENZY-Non-standard)   ASGEIRSSON A,  GUDMUNDSDOTTIR A,  STEFANSSON B;  WO2018138292-A1   ENZYMATICA AB (ENZY-Non-standard)   BERGVALL K,  CLARSUND M P,  LINDBERG F;  EP213303-A   EKMAN B M (EKMA-Individual);  MAGNUS E B (MAGN-Individual);  NORSK HYDRO AS (NHYD);  LINDAHL A R (LIND-Individual)   EKMAN B M,  LINDAHL A R;  EP1202743-A2   BJARNASON J B (BJAR-Individual)   BJARNASON J B;  EP1202743-B1   BJARNASON J B (BJAR-Individual)   BJARNASON J B;  US4235871-A   PAPAHADJOPOULOS D P (PAPA-Individual);  US5851451-A   TAKEDA CHEM IND LTD (TAKE)   TAKECHI N,  OHTANI S,  NAGAI A;  WO2015150799-A1   ENZYMATICA AB (ENZY-Non-standard);  SMITH S E (SMIT-Individual)   CLARSUND M P,  RASMUSSEN P B,  SVENSSON B R,  THORSTED P B O D,  WALSE B U;  CN111565743-A -- CN1356907-A   BJARNASON J B (BJAR-Individual)   BJARNASON J B;  CN104017787-A   FANG F (FANG-Individual);  MALAKHOV M (MALA-Individual)   FANG F,  MALAKHOV M;  EP3121272-A1   ENZYMATICA AB (ENZY-Non-standard)   ASGEIRSSON A,  GUDMUNDSDOTTIR A,  STEFANSSON B;  US20060134641-A1   ;  WO2017017012-A1   ENZYMATICA AB (ENZY-Non-standard)   ASGEIRSSON A,  GUDMUNDSDOTTIR A,  STEFANSSON B	WO2019135003-A1  SZELAZEK BOZENA ET          AL: "Structural Characterization of Human Coronavirus          NL63 N Protein.", JOURNAL OF VIROLOGY 01 06 2017, vol.          91, no. 11, 1 June 2017 (2017-06-01), XP009512578, ISSN:          1098-5514,relevantClaims[5-7],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  BERTRAM STEPHANIE          ET AL: "Cleavage and activation of the severe acute          respiratory syndrome coronavirus spike protein by human          airway trypsin-like protease.", JOURNAL OF VIROLOGY DEC          2011, vol. 85, no. 24, December 2011 (2011-12-01), pages          13363 - 13372, XP009512575, ISSN:          1098-5514,relevantClaims[1-49],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];            GRALINSKI; BARIC, J. PATHOL., vol. 235, 2015, pages 185 -          195;            CAVANAGH: "Coronaviruses with Special Emphasis on First          Insights Concerning SARS 1", 2005, BIRKHAUSER VERLAG          BASEL, article "Coronaviridae: a review of coronaviruses          and toroviruses";            STEFANSSON ET AL., COMPARATIVE BIOCHEM. PHYSIOL: PART B -          BIOCHEM. & MOI. BIOL., vol. 155, no. 2, 2010, pages          186 - 194;            ASGEIRSSON ET AL., EUR. J. BIOCHEM., vol. 180, 1989,          pages 85 - 94;            "GenBank", Database accession no. AC090397;            STEFANSSON ET AL., COMP. BIOCHEM. PHYSIOL. B, BIOCHEM.          MOL. BIOL., vol. 155, no. 2, 2010, pages 186 -          194;            ASGEIRSSON; BJARNASON, COMP. BIOCHEM. PHYSIOL. B, vol.          998, 1991, pages 327 - 335;            "GenBank", Database accession no. CAA55242.1;            GU6MUNDSD6FTIR ET AL., EUR J BIOCHEM., vol. 217, no. 3,          1993, pages 1091 - 7;            STEFANSSON, COMP. BIOCHEM. PHYSIOL. B, BIOCHEM. MOL.          BIOL., vol. 155, no. 2, 2010, pages 186 - 194;            STEFANSSON ET AL., BIOCHIM BIOPHYS ACTA., vol. 1865, no.          1, 2017, pages 11 - 19;            GUDMUNDSDOTTIR, FOOD CHEM., vol. 111, no. 2, 2008, pages          408 - 14;            ASGEIRSSON, EUR. J. BIOCHEM., vol. 180, 1989, pages 85 -          94;            "Genbank", Database accession no. AC090397.1;            "Genbank", Database accession no. AOX15769.1;            "Genbank", Database accession no. AOX15770.1;            "Genbank", Database accession no. AOX15771.1;            "Genbank", Database accession no. CAD30563.1;            STEFANSSON ET AL., COMP BIOCHEM PHYSIOL B BIOCHEM MOL          BIOL., vol. 155, no. 2, 2010, pages 186 - 94;            GREEN; SAMBROOK: "Molecular Cloning: a Laboratory Manua",          2012, COLD SPRING HARBOR LABORATORY PRESS;            THOMPSON ET AL., NUC. ACID RES., vol. 22, 1994, pages          4673 - 4680;            MEZIERE ET AL., J. IMMUNOL., vol. 159, 1997, pages 3230 -          3237;            VEBER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 75, 1978,          pages 2636;            THORSETT, BIOCHEM. BIOPHYS. RES. COMM., vol. 111, 1983,          pages 166;            GREEN; SAMBROOK: "Molecular Cloning, A Laboratory          Manual", 2012, COLD SPRING HARBOR;            "Remington's Pharmaceutical Sciences", 1990, MACK          PUBLISHING COMPANY;            "handbook of Pharmaceutical Excipients", 2000,          PHARMACEUTICAL PRESS;            ASGEIRSSON, B.; P. CEKAN: "Microscopic rate-constants for          substrate binding and acylation in cold-adaptation of          trypsin I from Atlantic cod", FEBS LETT, vol. 580, no.          19, 2006, pages 4639 - 4644, XP028061322, DOI:          doi:10.1016/j.febslet.2006.07.043;            ASGEIRSSON, B.; J. W. FOX; J. B. BJARNASON: "Purification          and characterization of trypsin from the poikilotherm          Gadus morhua", EUR J BIOCHEM, vol. 180, no. 1, 1989,          pages 85 - 94, XP001105360, DOI:          doi:10.1111/j.1432-1033.1989.tb14618.x;            ASGEIRSSON; BJARNASON: "Structural and kinetic properties          of chymotrypsin from Atlantic cod (Gadus morhua).          Comparison with bovine chymotrypsin", COMP. BIOCHEM.          PHYSIOL. B, vol. 998, 1991, pages 327 - 335, XP025794920,          DOI: doi:10.1016/0305-0491(91)90050-N;            BACHOFEN, C.; B. BOLLINGER; E. PETERHANS; H. STALDER; M.          SCHWEIZER: "Diagnostic gap in Bovine viral diarrhea virus          serology during the periparturient period in cattle", J          VET DIAON INVEST, vol. 25, no. 5, 2013, pages 655 -          661;            BELOUZARD, S.; J. K. MILLET; B. N. LICITRA; G. R.          WHITTAKER: "Mechanisms of coronavirus cell entry mediated          by the viral spike protein", VIRUSES, vol. 4, no. 6,          2012, pages 1011 - 1033;            BRADBURNE, A. F.; M. L. BYNOE; D. A. TYRRELL: "Effects of          a ''new'' human respiratory virus in volunteers", BR MED          J, vol. 3, no. 5568, 1967, pages 767 - 769;            FEHR, A. R.; S. PERLMAN: "Coronaviruses: an overview of          their replication and pathogenesis", METHODS MOL BIOL,          vol. 1282, 2015, pages 1 - 23;            FORNBACKE, M.; M. CLARSUND: "Cold-adapted proteases as an          emerging class of therapeutics", INFECT DIS THER, vol. 2,          no. 1, 2013, pages 15 - 26, XP055249597, DOI:          doi:10.1007/s40121-013-0002-x;            GALLAHER, W. R.; R. F. GARRY: "Modeling of the Ebola          virus delta peptide reveals a potential lytic sequence          motif", VIRUSES, vol. 7, no. 1, 2015, pages 285 -          305;            GRAHAM, R. L.; R. S. BARIC: "Recombination, reservoirs,          and the modular spike: mechanisms of coronavirus          cross-species transmission", J VIROL, vol. 84, no. 7,          2010, pages 3134 - 3146;            GRALINSKI, L. E.; R. S. BARIC: "Molecular pathology of          emerging coronavirus infections", J PATHOL, vol. 235, no.          2, 2015, pages 185 - 195;            GREEN; SAMBROOK: "Molecular Cloning: a Laboratory          Manual", 2012, COLD SPRING HARBOR LABORATORY          PRESS;            GUDMUNDSDOTTIR, A.; E. GUDMUNDSDOTTIR; S. OSKARSSON; B.          BJARNASON; A. K. EAKIN; C. S. CRAIK: "Isolation and          characterization of cDNAs from Atlantic cod encoding two          different forms of trypsinogen", EUR J BIOCHEM, vol. 217,          no. 3, 1993, pages 1091 - 1097, XP055200930, DOI:          doi:10.1111/j.1432-1033.1993.tb18341.x;            GUDMUNDSDOTTIR, A.; H. HILMARSSON; B. STEFANSSON:          "Potential use of Atlantic cod trypsin in biomedicine",          BIOMED RES INT, 2013, pages 749078;            HEIKKINEN, T.; A. JARVINEN: "The common cold", LANCET,          vol. 361, no. 9351, 2003, pages 51 - 59, XP004772755,          DOI: doi:10.1016/S0140-6736(03)12162-9;            HULL, D.; P. RENNIE; A. NORONHA; C. POORE; N. HARRINGTON;          V. FEARNLEY; D. PASSALI: "Effects of creating a          non-specific, virus-hostile environment in the          nasopharynx on symptoms and duration of common cold",          ACTA OTORHINOLARVNQOL ITAL, vol. 27, no. 2, 2007, pages          73 - 77;            JIANG, J.; W. CUN; X. WU; Q. SHI; H. TANG; G. LUO:          "Hepatitis C virus attachment mediated by apolipoprotein          E binding to cell surface heparan sulfate", J VIROL, vol.          86, no. 13, 2012, pages 7256 - 7267;            JONSDOTTIR, H. R.; R. DIJKMAN: "Coronaviruses and the          human airway: a universal system for virus-host          interaction studies", VIROLOGY JOURNAL, vol. 13, no. 1,          2016, pages 24;            KARBER, G.: "Beitrag zur kollektiven Behandlung          pharmakologischer Reihenversuche", NAUNVN-SCHMIEDEBERA'S          ARCHIVES OF PHARMACOLOGY, vol. 162, no. 4, 1931, pages          480 - 483;            KRAAIJEVELD, C. A.; S. E. REED; M. R. MACNAUGHTON:          "Enzyme-linked immunosorbent assay for detection of          antibody in volunteers experimentally infected with human          coronavirus strain 229 E", J CLIN MICROBIOL, vol. 12, no.          4, 1980, pages 493 - 497;            LIM, X. Y.; L. Y. NG; P. J. TAM; X. D. LIU: "Human          Coronaviruses: A Review of Virus-Host Interactions",          DISEASES, vol. 4, no. 3, 2016;            LO, Y. S.; S. Y. LIN; S. M. WANG; C. T. WANG; Y. L. CHIU;          T. H. HUANG; M. H. HOU: "Oligomerization of the carboxyl          terminal domain of the human coronavirus 229E          nucleocapsid protein", FEBS LETT, vol. 587, no. 2, 2013,          pages 120 - 127, XP028975221, DOI:          doi:10.1016/j.febslet.2012.11.016;            MACKAY, I. M.; K. E. ARDEN: "MERS coronavirus:          diagnostics, epidemiology and transmission", VIROL J,          vol. 12, 2015, pages 222;            MEZIERE ET AL.: "In vivo T helper cell response to          retro-inverso peptidomimetics", J. IMMUNOL., vol. 159,          1997, pages 3230 - 3237;            PARK, J. E.; K. LI; A. BARLAN; A. R. FEHR; S. PERLMAN; P.          B. MCCRAY, JR.; T. GALLAGHER: "Proteolytic processing of          Middle East respiratory syndrome coronavirus spikes          expands virus tropism", PROC NATL ACAD SCI U S A, vol.          113, no. 43, 2016, pages 12262 - 12267;            SOKALINGAM, S.; G. RAGHUNATHAN; N. SOUNDRARAJAN; G. LEE:          "A study on the effect of surface lysine to arginine          mutagenesis on protein stability and structure using          green fluorescent protein", PLOS ONE, vol. 7, no. 7,          2012, pages e40410, XP055215573, DOI:          doi:10.1371/journal.pone.0040410;            SPILLIAERT, R.; A. GUDMUNDSDOTTIR: "Atlantic Cod Trypsin          Y-Member of a Novel Trypsin Group", MAR BIOTECHNOL (NY),          vol. 1, no. 6, 1999, pages 598 - 607, XP009187291, DOI:          doi:10.1007/PL00011815;            STEFANSSON, B.; L. HELGADOTTIR; S. OLAFSDOTTIR; A.          GUDMUNDSDOTTIR; J. B. BJARNASON: "Characterization of          cold-adapted Atlantic cod (Gadus morhua) trypsin          I--kinetic parameters, autolysis and thermal stability",          COMP BIOCHEM PHYSIOL B BIOCHEM MOL BIOL, vol. 155, no. 2,          2010, pages 186 - 194, XP026805399;            STEFANSSON, B.; G. B. SANDHOLT; A. GUDMUNDSDOTTIR:          "Elucidation of different cold-adapted Atlantic cod          (Gadus morhua) trypsin X isoenzymes", BIOCHIM BIOPHVS          ACTA, vol. 1865, no. 1, 2017, pages 11 - 19, XP029823711,          DOI: doi:10.1016/j.bbapap.2016.10.005;            SUZUKI, T.; Y. ORBA; Y. OKADA; Y. SUNDEN; T. KIMURA; S.          TANAKA; K. NAGASHIMA; W. W. HALL; H. SAWA: "The human          polyoma JC virus agnoprotein acts as a viroporin", PLOS          PATHOQ, vol. 6, no. 3, 2010, pages e1000801, XP055030303,          DOI: doi:10.1371/journal.ppat.1000801;            THOMPSON ET AL.: "CLUSTAL W.- improving the sensitivity          of progressive multiple sequence alignment through          sequence weighting, position-specific gap penalties and          weight matrix choice", NUC. ACID RES., vol. 22, 1994,          pages 4673 - 4680, XP002956304;            THORSETT ET AL.: "Dipeptide mimics. Conformationally          restricted inhibitors of angiotensin-converting enzyme",          BIOCHEM. BIOPHYS. RES. COMM., vol. 111, 1983, pages          166;            VAN DEN WORM, S. H.; K. K. ERIKSSON; J. C. ZEVENHOVEN; F.          WEBER; R. ZUST; T. KURI; R. DIJKMAN; G. CHANG; S. G.          SIDDELL; E. J. SNIJ: "Reverse genetics of SARS-related          coronavirus using vaccinia virus-based recombination",          PLOS ONE, vol. 7, no. 3, 2012, pages e32857;            VEBER ET AL.: "Conformationally restricted bicyclic          analogs of somatostatin", PROC. NATL. ACAD. SCI. USA,          vol. 75, 1978, pages 2636;            WENTWORTH, D. E.; K. V. HOLMES: "Molecular Determinants          of Species Specificity in the Coronavirus Receptor          Aminopeptidase N (CD13): Influence of N-Linked          Glycosylation", J VIROL, vol. 75, no. 20, 2001, pages          9741 - 9752;            "Emergencies preparedness, response", 2 February 2017,          WHO;            "Handbook of Pharmaceutical Excipients", 2000,          PHARMACEUTICAL PRESSCN111565743-A  BOZENA SZELAZEK ET          AL.: "Structural Characterization of Human Coronavirus          NL63 N Protein", JOURNAL OF VIROLOGY, vol. 91, no. 11,          pages 1 - 14, XP009512578, DOI:          10.1128/JVI.02503-16,relevantClaims[1-49]	129500-0-0-0 K M; 129502-0-0-0 K M; 129503-0-0-0 K M; 490-0-0-0 K M; 8182-0-0-0 K M; 8188-0-0-0 K M; 90915-0-0-0 K M; 109563-0-0-0 K M			R00480 K M; R00116 K M; R00114 K M; R00113 K M; R01654 K M; R01628 K M; RA0DRC K M; RA0426 K M	0480-S; 0116-S; 0114-S; 0113-S; 1654-S; 1628-S	CN109439799-A	New nested PCR primer for detecting porcine acute            diarrhea coronavirus, comprising coat primer comprising            upstream primer and downstream primer and inner primer            comprising upstream primer and downstream primer	SONG D;  ZHANG Y;  ZHANG F;  YUAN W;  TANG Y;  LI K;  YE Y;  DING Z;  WU Q	UNIV JIANGXI AGRIC (UNJA-C)	201924853X	   NOVELTY - A nested PCR primer comprising (i) coat primer                comprising an upstream primer having SEQ ID NO: 1                and downstream primer having SEQ ID NO: 2, and (ii)                inner primer comprising an upstream primer having                SEQ ID NO: 3 and downstream primer having SEQ ID                NO: 4, is new.    USE - The nested PCR primer or kit is useful for                detecting porcine acute diarrhea coronavirus                (claimed).    ADVANTAGE - The nested PCR primers or kit is easy to use                and has high detection sensitivity and                specificity.    DETAILED DESCRIPTION - A nested PCR primer comprising (i) coat primer                comprising an upstream primer having SEQ ID NO: 1                and downstream primer having SEQ ID NO: 2, and (ii)                inner primer comprising an upstream primer having                SEQ ID NO: 3 and downstream primer having SEQ ID                NO: 4, is new. cgttctcgcaatcaaagtca (SEQ ID NO: 1),                ccaccatctcaacctcctc (SEQ ID NO: 2),                tgagttgcttccgacacaag (SEQ ID NO: 3) and                tccaccatctcaacctcctc (SEQ ID NO: 4). An INDEPENDENT                CLAIM is included for kit which comprises the                nested PCR primer. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03E;  B04-E05;  B04-E99;  B04-F11B;  B04-L04A;  B04-L04B;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  C04-B03E;  C04-E05;  C04-E99;  C04-F11B;  C04-L04A;  C04-L04B;  C11-C08E3;  C11-C08F8;  C12-K04F;  C12-K04G1B;  D05-H06A;  D05-H12D1;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/6848;  C12Q-001/70	CN109439799-A   08 Mar 2019   C12Q-001/70   201946Pages: 14   Chinese	CN109439799-A    CN11313618    06 Nov 2018		CN11313618    06 Nov 2018			CN109439799-A -- CN103243179-A   GUANDONG WENSHI FOOD GROUP CO LTD (GUAN-Non-standard)   WANG D,  PAN Y,  SONG Y,  ZHOU Q;  CN107630109-A   UNIV SOUTH CHINA AGRIC (USCG)   JINGYUN M,  LING Z,  YUAN S;  CN108315490-A   XIANYANG VOCATIONAL & TECH COLLEGE (XIAN-Non-standard)   ZHU X,  WU X;  CN108411040-A   UNIV ZHEJIANG (UYZH);  GUANGDONG LAB ANIMALS MONITORING INST (GUAN-Non-standard)   WANG H,  HUANG R,  CONG F,  ZENG F,  GUO P,  WANG Y;  EP3261668-A4   UNIV IOWA STATE RES FOUND INC (IOWA);  ZOETIS SERVICES LLC (ZOET)   BANDRICK M,  CALVERT J G,  CHEN Q,  GAUGER P,  HARDHAM J M,  MADSON D,  STOEVA M I,  THOMPSON J R,  VALDEZ W,  ZHANG J	CN109439799-A  LING ZHOU:          "Development of a TaqMan-based real-time RT-PCR assay for          the detection of SADS-CoV associated with severe diarrhea          disease in pigs", JOURNAL OF VIROLOGICAL          METHODS,relevantClaims[1-10],relevantPassages[1]	201562-0-0-0 D K M; 204644-0-0-0 D K M			RA0124 D K M; RA031J D K M		CN109628494-A	Preparing coronavirus-resistant cloned pig based            on CRISPR/Cas9 gene editing technology comprises e.g.            obtaining gRNA sequence specifically targeting the exon            2 and exon 3 of the pAPN gene, and preparing            CRISPR/Cas9 targeting vector	YANG H;  ZHANG J;  SHI J;  WU Z	UNIV SOUTH CHINA AGRIC (USCG-C);  WENS FOODSTUFF GROUP CO LTD (WENS-Non-standard)	201938569D	   NOVELTY - Preparing coronavirus-resistant cloned pig                based on the CRISPR/Cas9 gene editing technology                comprises e.g. obtaining gRNA sequence specifically                targeting the exon 2 and exon 3 of the pAPN gene,                where nucleotide comprises sequence of                5'-gggctcctggcagatgaag-3' (SEQ ID NO: 1) and                sequence of 5'-gatgttgaacgtggccttca-3' (SEQ ID NO:                2), preparing CRISPR/Cas9 targeting vector                corresponding to the gRNA sequence by digesting the                PX330 vector with the restriction endonuclease                BbsI, separately synthesizing gRNA positive and                complementary strand DNAs of the second exon and                the third exon, carrying sequence matching the                viscous end formed by the digested PX330 vector at                both ends, mixing gRNA positive strands of the                second exon and the third exon with the                complementary strand DNA, boiling mixed mixture in                water at 98-100 degrees C for 2.5-3.5 minutes,                allowing to stand, cooling to 20-30 degrees C,                annealing two complementary strand DNAs to form                double-stranded DNA.    USE - The method is useful for preparing                coronavirus-resistant cloned pig based on the                CRISPR/Cas9 gene editing technology.    DETAILED DESCRIPTION - Preparing coronavirus-resistant cloned pig                based on the CRISPR/Cas9 gene editing technology                comprises (i) obtaining gRNA sequence specifically                targeting the exon 2 and exon 3 of the pAPN gene,                where nucleotide comprises sequence of                5'-gggctcctggcagatgaag-3' (SEQ ID NO: 1) and                sequence of 5'-gatgttgaacgtggccttca-3' (SEQ ID NO:                2), preparing CRISPR/Cas9 targeting vector                corresponding to the gRNA sequence by digesting the                PX330 vector with the restriction endonuclease                BbsI, separately synthesizing gRNA positive and                complementary strand DNAs of the second exon and                the third exon, carrying sequence matching the                viscous end formed by the digested PX330 vector at                both ends, mixing gRNA positive strands of the                second exon and the third exon with the                complementary strand DNA, boiling mixed mixture in                water at 98-100 degrees C for 2.5-3.5 minutes,                allowing to stand, cooling to 20-30 degrees C,                annealing two complementary strand DNAs to form                double-stranded DNA, carrying viscous end that can                be ligated to the PX330 vector cleaved by BbsI,                digesting double-stranded DNA linked to the PX330                vector with BbsI to obtain targeting vector                PX330-pAPN2 and targeting vector PX330-pAPN3, (ii)                transferring obtained targeting vector PX330-pAPN2                or targeting vector PX330-pAPN3 into porcine fetal                fibroblasts, obtaining positive clones of biallelic                pAPN knockout by monoclonalization and screening,                and (iii) providing positive cells as nuclear                donors, implanting into enucleated pig oocytes,                obtaining positive reconstructed pig embryos,                implanting reconstructed pig embryos into the                uterus pregnancy of the surrogate sows to obtain                the cloned pigs. An INDEPENDENT CLAIM is also                included for coronavirus-resistant cloned                pig. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  P14 (Animal management and care (A01K, L, M).)	B04-E01A;  B04-E07;  B04-E08;  B04-E13;  B04-E99;  B04-F0200E;  B04-L05A;  B04-P01B0E;  C04-E01A;  C04-E07;  C04-E08;  C04-E13;  C04-E99;  C04-F0200E;  C04-L05A;  C04-P01B0E;  D05-A02C;  D05-H16A;  D05-H19C;  D05-H99;  P14-A05;  P14-E01A;  P14-E02A	A01K-067/027;  C12N-015/90;  C12N-009/22	CN109628494-A   16 Apr 2019   C12N-015/90   201940Pages: 16   Chinese	CN109628494-A    CN10062079    23 Jan 2019		CN10062079    23 Jan 2019			CN109628494-A -- CN104593422-A   UNIV CHINA AGRICULTURAL (UCAG)   HU X,  LI N,  LI Q,  ZHAO Y,  CHEN J;  CN105543257-A   UNIV ANHUI AGRIC (UYAH)   CHEN J,  HAN C,  LI Y,  ZHANG Y,  PAN K;  CN107034218-A   UNIV ZHEJIANG (UYZH)   ZHANG K,  WANG S;  CN107893088-A   INST ANIMAL SCI CAAS (CAGS)   LIU Z,  MOU Y,  LI K,  LI J	CN109628494-A  JIANWEN CHEN ET          AL.: "Production of porcine aminopeptidase N (pAPN)          site-specific edited pigs", ANIM SCI          J,relevantClaims[1-9],relevantPassages[366-371];  KRISTIN M.          WHITWORTH ET AL.: "Resistance to coronavirus infection in          amino peptidase N-deficient pigs", TRANSGENIC          RES,relevantClaims[1-9],relevantPassages[272];  : "",          ,relevantClaims[1-9],relevantPassages[89-94]	200757-0-0-0 K P			RA00GT K P		WO2019189827-A1;  JP2020511128-X;  US2021189386-A1;  JP7113395-B2	New nucleic acid construct comprising guide RNA            portion binding to target RNAs and RNA cleavage            clustered regularly interspaced short palindromic            repeats associated protein expressing portion, used for            providing e.g. antiviral effect	ITO T;  OGINO K;  TSUJI M;  BANDARU S;  SHIMIZU Y;  HIGASHIDE M	UNIV OKAYAMA (UYOK-C);  UNIV OKAYAMA (UYOK-C);  POIRT SYSTEMS CO LTD (POIR-Non-standard);  KUROBANA KK (KURO-Non-standard)	201983298S	   NOVELTY - A nucleic acid construct comprising at least                one guide RNA portion capable of binding to one or                more target RNAs and an RNA cleavage clustered                regularly interspaced short palindromic repeats                (CRISPR) associated protein (Cas) protein                expressing portion, is new, where the target RNA(s)                are derived from a mutation in a vertebrate cell, a                virus or a bacterium.    USE - The nucleic acid construct is useful in                pharmaceutical composition for providing                anticancer, antiviral and antibacterial effects.                The virus is any one chosen from influenza virus,                HIV virus, herpes virus, Ebola virus, avian                influenza virus, foot-and-mouth disease virus,                severe acute respiratory syndrome-related                coronavirus (SARS coronavirus), Middle East                respiratory syndrome-related coronavirus (MERS                coronavirus), papillomavirus, hepatitis virus                (including type A, type B and type C), measles                virus, rubella virus, mumps virus, rotavirus,                respiratory syncytial (RS) virus, norovirus, herpes                zoster virus, poliovirus, dengue virus and adult T                cell leukemia virus (all claimed). The cancer is                chosen from synovial sarcoma, brain tumor,                leukemia, malignant lymphoma, lung cancer, prostate                cancer, renal cell cancer. The nucleic acid                construct is also used for treating Alzheimer's                disease. The bacteria are chosen from Shigella,                Serratia, Aeromonas, Bordetella pertussis,                Brucella, Bartonella, Legionella pneumophila,                Coxiella, Neisseria gonorrhoeae, Campylobacter,                Helicobacter pylori, Streptococcus aureus,                S.pyogenes, Bacillus anthracis, Clostridium                botulinum, Listeria monocytogenes, Mycoplasma,                Chlamydia pneumoniae, pneumococci,                enterohemorrhagic Escherichia coli, Vibrio                parahaemolyticus, Salmonella, C.perfringens,                Meningococcus, Pseudomonas aeruginosa, Citrobacter,                Acinetobacter, Enterobacter, Klebsiella, and                Clostridium.    ADVANTAGE - The nucleic acid construct is superior in the                degree of freedom in selecting a target gene and                specificity for the target gene as compared to the                existing technology, performs indiscriminate                expression suppression of mRNA expression in cancer                cells, virus-infected cells, and bacteria, does not                substantially act on normal cells, and exhibits                fewer or no side effects. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E08;  B04-E13;  B04-E99;  B04-L05A2;  B14-A01;  B14-A02;  B14-H01;  B14-J01A4;  B14-L01;  B14-L06;  C04-E08;  C04-E13;  C04-E99;  C04-L05A2;  C14-A01;  C14-A02;  C14-H01;  C14-J01A4;  C14-L01;  C14-L06;  D05-H12E;  D05-H19C;  D05-H99	A61K-031/7088;  A61K-048/00;  A61P-031/04;  A61P-031/12;  A61P-035/00;  C12N-015/09;  C12N-015/113;  C12N-015/55;  C12N-015/63;  C12N-015/31;  C12N-005/10;  C12N-009/22;  C12N-015/11;  C12N-015/85	WO2019189827-A1   03 Oct 2019   C12N-015/09   201981Pages: 32   Japanese;  JP2020511128-X   08 Apr 2021   C12N-015/09   202130Pages: 24   Japanese;  US2021189386-A1   24 Jun 2021   C12N-015/11   202153   English;  JP7113395-B2   05 Aug 2022   C12N-015/55   202265   Japanese	WO2019189827-A1    WOJP014183    29 Mar 2019;   JP2020511128-X    JP511128    29 Mar 2019;   US2021189386-A1    US17043138    29 Sep 2020;   JP7113395-B2    JP511128    29 Mar 2019	JP2020511128-X PCT application Application WOJP014183;   JP2020511128-X Based on Patent WO2019189827;   US2021189386-A1 PCT application Application WOJP014183;   JP7113395-B2 PCT application Application WOJP014183;   JP7113395-B2 Based on Patent WO2019189827	JP067565    30 Mar 2018	WO2019189827-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        		WO2019189827-A1 -- WO2016205764-A1   ABUDAYYEH O O (ABUD-Individual);  BROAD INST INC (BROD);  GOOTENBERG J S (GOOT-Individual);  HARVARD COLLEGE (HARD);  JOUNG J (JOUN-Individual);  KONERMANN S (KONE-Individual);  KOONIN E (KOON-Individual);  LANDER E S (LAND-Individual);  MAKAROVA K S (MAKA-Individual);  MASSACHUSETTS INST TECHNOLOGY (MASI);  MINAKHIN L (MINA-Individual);  SEMENOVA E (SEME-Individual);  SEVERINOV K (SEVE-Individual);  SHMAKOV S (SHMA-Individual);  UNIV RUTGERS STATE NEW JERSEY (RUTF);  WOLF Y I (WOLF-Individual);  ZHANG F (ZHAN-Individual);  SKOLKOVO SCI & TECHNOLOGY INST (SKOL-Non-standard)   ABUDAYYEH O O,  GOOTENBERG J S,  JOUNG J,  KONERMANN S,  KOONIN E,  LANDER E S,  MAKAROVA K S,  MINAKHIN L,  SEMENOVA E,  SEVERINOV K,  SHMAKOV S,  WOLF Y I,  ZHANG F;  WO2017219027-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  ZHANG F (ZHAN-Individual);  ABUDAYYEH O O (ABUD-Individual);  GOOTENBERG J (GOOT-Individual);  LANDER E S (LAND-Individual)   ZHANG F,  ABUDAYYEH O O,  GOOTENBERG J,  LANDER E S	WO2019189827-A1  ABUDAYYEH, OMAR 0.          ET AL.: "RNA targeting with CRISPR-Casl3", NATURE, vol.          550, 2017, pages 280 - 284, XP055529736,          doi:10.1038/nature24049,relevantClaims[1-13],relevantPassages[,          supplementary information, abstract, page 280, right          column, line 8 to page 282, right column, line 2, fig.          1-3];  COX, DAVID B. T. ET          AL.: "RNA editing with CRISPR- Casl3", SCIENCE, vol. 358,          2017, pages 1019 - 1027, XP055491658,          doi:10.1126/science.aaq0180,relevantClaims[1-13],relevantPassages[,          supplementary material, page 1019, right column, line 37          to page 1021, middle column, line 15, fig. 1,          S3];  KONERMANN, SILVANA          ET AL.: "Transcriptome Engineering with RNA-Targeting          Type VI-D CRISPR Effectors", CELL, vol. 173, 15 March          2018 (2018-03-15), pages 665 - 676, XP055529705,          doi:10.1016/j.cell.2018.02.033,relevantClaims[1-5,          7-13],relevantPassages[, right column, line 20 to page          672, left column, line 21, fig. 4-5, S5];  AMAN, RASHID ET          AL.: "RNA virus interference via CRISPR/Casl3a system in          plants", GENOME BIOL., vol. 19, no. 1, 4 January 2018          (2018-01-04), pages 1 - 9,          XP055639663,relevantClaims[1-6, 12],relevantPassages[,          abstract, page 3, left column, line 4 to page 4, right          column, line 12, fig. 1, 2];  EAST-SELETSKY,          ALEXANDRA ET AL.: "RNA Targeting by Functionally          Orthogonal Type VI-A CRISPR-Cas Enzymes", MOL. CELL .,          vol. 66, no. 3, 4 May 2017 (2017-05-04), pages 373 - 383,          XP029999996,relevantClaims[1-13];  GOOTENBERG,          JONATHAN S. ET AL.: "Multiplexed and portable nucleic          acid detection platform with Cas13, Casl2a, and Csm6",          SCIENCE, vol. 360, 15 February 2018 (2018-02-15), pages          439 - 444, XP055538780,          doi:10.1126/science.aaq0179,relevantClaims[1-13]	93605-0-0-0 N; 105730-0-0-0 N			RA00NS N; RA012P N		US2019232279-A1	Microfluidic device useful for detecting human            pathogen and/or its genetic material, comprises            reaction module, liquid reagent module comprising            blisters, housing having open areas over the blisters,            and label affixed to housing label	JENSEN T D;  FORD S;  VILLARREAL E;  FISH A D	GENMARK DIAGNOSTICS INC (HOFF-C)	201966264C	   NOVELTY - Microfluidic device comprises: a reaction                module; a liquid reagent module comprising many                blisters; a housing having open areas over at least                one of the blisters; and a label affixed to the                housing the label comprising a chad formed by                perforations in a serpentine pattern over at least                a portion of at least one of the open areas.    USE - The device is useful for detecting a human                pathogen and/or its genetic material, where the                human pathogen is a respiratory, Gram-positive                bacteria, Gram-negative bacteria, fungal, CNS, or                gastrointestinal infection, preferably the human                pathogen is e.g. influenza A, adenovirus influenza                A H1 subtype, human metapneumovirus, influenza A H3                subtype, human rhinovirus/enterovirus, influenza A                2009 H1N1 subtype, Coronavirus 229e, influenza B,                Coronavirus HKU1, respiratory syncytial virus A,                Coronavirus n163, respiratory syncytial virus B,                Coronavirus OC4, parainfluenza virus 1, Bordetella                pertussis, parainfluenza virus 2, Chlamydophila                pneumoniae, parainfluenza virus 3, Mycoplasma                pneumoniae, parainfluenza virus 4, Bacillus cereus                group, Staphylococcus epidermidis, Bacillus                subtilis group, Staphylococcus lugdunensis,                Corynebacterium species, Streptococcus,                Enterococcus, Streptococcus agalactiae,                Enterococcus faecalis, Streptococcus anginosus                group, Enterococcus faecium, Streptococcus                pneumonia, Lactobacillus, Streptococcus pyogenes,                Listeria, Pan Gram-negative target (at least                Enterobacteriaceae, Acinetobacter, Pseudomonas,                Bacteroides, Stenotrophomonas), Listeria                monocytogenes, Pan Candida target (Candida                albicans, Candida glabrata, Candida krusei, Candida                parapsilosis), Micrococcus, Propionibacterium                acnes, Staphylococcus, and Staphylococcus aureus                (all claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) a fluidic cartridge comprising a body                comprising a recess comprising a fluid filed                compressible element disposed within the recess,                where the body comprises a label comprising a                hanging chad that is at least partially within the                recess where the chad does not separate from the                label; and    (2) a microfluidic device comprising a label                comprising a chad formed by a serpentine separation                line which allows the chad to separate but not                detach from the label upon compression. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).)	B04-E01;  B04-F01;  B04-F09;  B04-F10;  B04-F11A1;  B04-F11B;  B11-C06;  B11-C08C1;  B12-K04F;  B12-K04G1A;  D05-H04;  D05-H05;  D05-H06;  D05-H09;  J04-B03;  J04-B04;  J04-X04	B01L-003/00	US2019232279-A1   01 Aug 2019   B01L-003/00   201962Pages: 36   English	US2019232279-A1    US881486    26 Jan 2018		US881486    26 Jan 2018										CN110128510-A;  CN110128510-B	New polypeptide used in pharmaceutical composition for preparing medicament for treating middle East respiratory syndrome-related coronavirus infection or infection related disease, where disease is middle East respiratory syndrome	WANG C;  LI Y	ACAD MILITARY MEDICAL SCI PLA (JSYX-C)	201972744G	   NOVELTY - Polypeptide (I) is new.    USE - Polypeptide used in pharmaceutical composition for preparing a medicament for treating and/or preventing middle East respiratory syndrome-related coronavirus (MERS-CoV) infection or MERS-CoV infection related disease in a subject, where MERS-CoV infection related disease is middle East respiratory syndrome, and subject is a mammal, such as a human (claimed).    DETAILED DESCRIPTION - Polypeptide of formula (I), its stereoismer, mixture, or a pharmaceutically acceptable salt, is new, where formula (I) is (Z-Ile-Glu-X1-Ile-Val-Lys-Lys-Ile-X2-X3-Ile-Glu-Arg-Ala-Ile-Glu-Ala-Gln-Gln-X4-Leu-Leu-Gln-Leu-Thr-Val-Trp-X5-Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-B)n, where n is 1 or 3, and when n is 1 then formula I represents a monomer, and is referred as a monomer of polypeptide, and when n is 3 then formula I represents a trimer formed by covalent crosslinking of three monomers, and is referred to as a trimer of polypeptide, X1, X2, X3 and X4 are selected from L-form amino acids, X5 is selected from hydrophobic amino acids, Z represents an N-terminal group which is a group obtained by modifying -NH2 or an amino group with an amino protecting group, and B represents a C-terminal group which is a group obtained by modifying -COOH or a carboxyl group by a carboxyl protecting group. INDEPENDENT CLAIMS are included for the following:    (1) a pharmaceutical composition, which comprises a polypeptide (I), or its stereoisomer, mixture, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier and/or excipient; and    (2) a method for inhibiting fusion of middle East respiratory syndrome-related coronavirus with cells in vitro, which involves contacting cells with polypeptide, or its stereoisomer, mixture, or a pharmaceutically acceptable salt, or pharmaceutical composition. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.)	B04-E99;  B04-N04;  B14-A02B5	A61K-038/16;  A61P-031/14;  C07K-001/06;  C07K-014/16	CN110128510-A   16 Aug 2019   C07K-014/16   201974Pages: 26   Chinese;  CN110128510-B   26 Feb 2021   C07K-014/16   202122   Chinese	CN110128510-A    CN10427530    22 May 2019;   CN110128510-B    CN10427530    22 May 2019	CN110128510-B Previous Publ. Patent CN110128510	CN10427530    22 May 2019					184611-0-0-0 N; 184616-0-0-0 N			RA00H1 N; RA00H3 N		CN110540954-A	New porcine ileal epithelial cell strain IPI-FX susceptible to three porcine intestinal coronaviruses useful in culture, research and development of e.g. porcine epidemic diarrhea virus and porcine transmissible gastroenteritis virus	FANG L;  XIAO S;  WANG X;  LIU K;  WANG D;  FANG P	UNIV HUAZHONG AGRIC (UHZA-C)	2019A4371J	   NOVELTY - Porcine ileal epithelial cell strain IPI-FX susceptible to three types of porcine intestinal coronaviruses comprising a preservation number (CCTCC No: C2019115), is new.    USE - The cell strain is useful in culture, research and development of porcine intestinal virus, preferably porcine epidemic diarrhea virus (PEDV), porcine delta -coronavirus (PDCoV) and porcine transmissible gastroenteritis virus (TGEV) (all claimed), preferably in research of porcine intestinal coronavirus immunity and pathogenic mechanism and mixed infections.    ADVANTAGE - The cell strain: enables the proliferation of PEDV, PDCoV and TGEV with proliferation titers of more than 106 TCID50/ml; and depicts the actual situation of porcine infection after research. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-F02;  B04-F11B;  B11-A04A;  B12-K04G1B;  C04-F02;  C04-F11B;  C11-A04A;  C12-K04G1B;  D05-H08	C12N-005/071;  C12N-007/00	CN110540954-A   06 Dec 2019   C12N-005/071   202001Pages: 12   Chinese	CN110540954-A    CN10420946    21 May 2019		CN10420946    21 May 2019			CN110540954-A -- CN101491673-A   TIANJIN RUIPU BIOTECHNOLOGY CO LTD (TIAN-Non-standard)   YANG B,  ZHANG G;  CN105462931-A   SHANDONG ACAD AGRIC SCI ANIMAL SCI INST (SHAN-Non-standard)   CHEN L,  CHEN Z,  CONG X,  DU Y,  GUO L,  LI J,  LIU S,  REN S,  SUN W,  WANG S,  WU J,  YU J,  ZHANG Y;  CN108676780-A   UNIV HUAZHONG AGRIC (UHZA)   XIAO S,  FANG L,  ZHOU Y,  LIU K,  WANG D,  LIU H;  RU2306334-C2   VETERINARY RES INST (VETE-Soviet Institute)   DYAKONOV L P,  SAVENKO N B,  SIMONOVA A S,  BELOUSOVA R V,  KLENOVITSKII P M	CN110540954-A  KWONIL JUNG : "Susceptibility of porcine IPEC-J2 intestinal epithelial cells to infection with porcine deltacoronavirus (PDCoV) and serum cytokine responses of gnotobiotic pigs to acute infection with IPEC-J2 cell culture-passaged PDCoV", VET MICROBIOL,relevantClaims[1-3],relevantPassages[49-58];  XUNLEI WANG : "Susceptibility of porcine IPI-2I intestinal epithelial cells to infection with swine enteric coronaviruses", VET MICROBIOL,relevantClaims[1-3],relevantPassages[222.2];  : "DeltaRT-PCR", ,relevantClaims[1-3],relevantPassages[11-16]						CN109988865-A;  CN109988865-B	New probe set useful for preparing the kit for            detecting the presence and level of the respiratory            virus in a sample or for diagnosing infected            respiratory virus, comprises a detection probe and at            least two media sub-probes	LIAO Y;  LI Q;  XU Y;  XU H;  LIN M	UNIV XIAMEN (UYXI-C)	201962032E	   NOVELTY - Probe set comprises a detection probe and at                least two media sub-probes, is new. The vector                sub-probes independently comprise a vector                sub-sequence and a target-specific sequence from                the 5' to the 3' direction. The target-specific                sequence comprises a sequence complementary to a                target nucleic acid sequence or a control sequence                specific for a respiratory virus. The vector                subsequence comprises a sequence that is not                complementary to the target nucleic acid sequence                or the control sequence, and the vector                subsequences of all of the vector sub-probes are                different from each other and a capture sequence                comprising the detection probe from the 3' to 5'                direction, complementary to each of the vector                subsequences or a portion thereof, and a templating                sequence.    USE - The probe set is useful for preparing the kit                for detecting the presence or level of the                respiratory virus in a sample or for diagnosing                whether a subject is infected respiratory virus,                preferably influenza A virus, influenza B virus,                respiratory syncytial virus A, respiratory                syncytial virus B, rhinovirus (eg rhinovirus B),                adenovirus (eg adenovirus B) ), parainfluenza virus                type I, parainfluenza virus type II, parainfluenza                virus type III, parainfluenza virus type IV, human                metapneumovirus, enterovirus, rotavirus, boca                virus, coronavirus SARS, coronavirus HKU1 ,                Coronavirus OC43, Coronavirus NL63 and/or                Coronavirus 229E.    DETAILED DESCRIPTION - Probe set comprises a detection probe and at                least two media sub-probes. The vector sub-probes                independently comprise a vector sub-sequence and a                target-specific sequence from the 5' to the 3'                direction. The target-specific sequence comprises a                sequence complementary to a target nucleic acid                sequence or a control sequence specific for a                respiratory virus. The vector subsequence comprises                a sequence that is not complementary to the target                nucleic acid sequence or the control sequence, and                the vector subsequences of all of the vector                sub-probes are different from each other and a                capture sequence comprising the detection probe                from the 3' to 5' direction, complementary to each                of the vector subsequences or a portion thereof,                and a templating sequence. The detection probe is                labeled with a reporter group and a quenching                group, where the reporter group is capable of                emitting a signal and the quenching group is                capable of absorbing or quenching the signal                emitted by the reporter group. The detection probe                emits a signal that, in the case of hybridization                to its complementary sequence, is different from a                signal that is emitted without hybridization to its                complementary sequence. An INDEPENDENT CLAIM is                also included for the kit comprising probe sets,                where the kit further comprises: an enzyme having                5' nuclease activity and/or nucleic acid                polymerase. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E05;  B04-E99;  B04-F11B;  B04-L04A;  B04-L05A;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  D05-A02B;  D05-A02C;  D05-H06A;  D05-H12D1;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/70	CN109988865-A   09 Jul 2019   C12Q-001/70   201966Pages: 72   Chinese;  CN109988865-B   05 Mar 2021   C12Q-001/70   202122   Chinese	CN109988865-A    CN10004952    03 Jan 2018;   CN109988865-B    CN10004952    03 Jan 2018	CN109988865-B Previous Publ. Patent CN109988865	CN10004952    03 Jan 2018			CN109988865-A -- CN105734167-A   CHANGZHOU GENMAG BIOTECHNOLOGY CO LTD (CHAN-Non-standard)   XU Y,  ZHAO H;  US20020081589-A1   ;  US20030032029-A1   	CN109988865-A  FALTIN: "Mediator          Probe PCR: A Novel Approach for Detection of Real-Time          PCR Based on Label-Free Primary Probes and Standardized          Secondary Universal Fluorogenic Reporters", CLINICAL          CHEMISTRY,relevantClaims[1-10],relevantPassages[1546];  : "",          ,relevantClaims[1-10],relevantPassages[91-215-182.2-2.3];  FRIEDRICH:          "Simplified development of multiplex real-time PCR          through master mix augmented by universal fluorogenic          reporters",          BIOTECHNIQUES,relevantClaims[1-10],relevantPassages[123-12815473-715481          PCR]	1525931-1-0-0 D K M; 1525931-1-0-0 CL USE			RARECG D K M		WO2019067884-A1;  US2020231630-A1	Chimeric epitope comprises conserved donor receptor binding site or neutralizing epitope or functional fraction, and acceptor molecular scaffold or fragment	SCHMIDT A G;  BAJIC G;  MARON M J	CHILDRENS MEDICAL CENT (CHLD-C);  CHILDRENS MEDICAL CENT (CHLD-C)	201933085R	   NOVELTY - Chimeric epitope comprises a conserved donor receptor binding site (RBS) or a neutralizing epitope or a functional fraction, and an acceptor molecular scaffold or fragment.    USE - Chimeric epitope is used to elicit an immune response in a subject. The immunogenic composition is used to prevent an infection caused by a pathogen in a subject and vaccinating a subject, where the infection is an influenza infection (all claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:    (1) an immunogenic composition, which comprises the chimeric epitope and a pharmaceutically acceptable carrier;    (2) a method for inducing an immune response in a subject, which involves administering the chimeric epitope to a subject; and    (3) a method for vaccinating a subject, which involves administering the chimeric epitope to a subject. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B04C;  B04-E99;  B04-N0600E;  B14-A02B2;  B14-G01;  B14-S11A;  C04-B04C;  C04-E99;  C04-N0600E;  C14-A02B2;  C14-G01;  C14-S11A;  D05-H99	A61K-039/12;  A61K-039/145;  A61K-039/295;  C07K-014/005;  C12N-007/00	WO2019067884-A1   04 Apr 2019   A61K-039/12   201929Pages: 92   English;  US2020231630-A1   23 Jul 2020   C07K-014/005   202060   English	WO2019067884-A1    WOUS053402    28 Sep 2018;   US2020231630-A1    US16648475    18 Mar 2020	US2020231630-A1 PCT application Application WOUS053402;   US2020231630-A1 Provisional Application US564775P	US564775P    28 Sep 2017;  US16648475    18 Mar 2020	WO2019067884-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    		WO2019067884-A1 -- US20140370032-A1   ;  US20150010566-A1   ;  WO2016109656-A1   UNIV GEORGIA STATE RES FOUND (UYGA)   KANG S,  LEE Y,  KIM M;  WO2016100615-A2   UNIV CHICAGO (UYCG)   WILSON P C,  DUNAND C J H		184602-0-0-0 M N Q			RA02DV M N Q		CN110257557-A;  CN110257557-B	New multiplex reverse transcription polymerase            chain reaction detection primer useful for detecting            transmissible gastroenteritis virus, porcine epidemic            diarrhea virus, swine acute diarrhea syndrome            coronavirus and porcine deltacoronavirus	HE D;  LI J;  LI G	UNIV SOUTH CHINA AGRIC (USCG-C);  UNIV SOUTH CHINA AGRIC (USCG-C)	201991661K	   NOVELTY - Multiplex reverse transcription polymerase                chain reaction (RT-PCR) detection primer comprising                transmissible gastroenteritis virus (TGEV), porcine                epidemic diarrhea virus (PEDV), swine acute                diarrhea syndrome coronavirus (SADS-CoV) and                porcine deltacoronavirus (PDCoV), TGEV-F, TGEV-R,                PEDV-F, PEDV-R, SADS-F, SADS-R, PDCoV-F and                PDCoV-R, preferably primer TGEV-F comprising fully                defined 24 nucleotide sequences, primer TGEV-R                comprising fully defined 25 nucleotide sequences,                primer PEDV-F comprising fully defined 25                nucleotide sequences, primer PEDV-R comprising                fully defined 24 nucleotide sequences, primer                SADS-F comprising fully defined 24 nucleotide                sequences, primer SADS-R comprising fully defined                24 nucleotide sequences, primer PDCoV-F comprising                fully defined 23 nucleotide sequences and primer                PDCoV-R comprising fully defined 24 nucleotide                sequences, is new.    USE - The multiplex reverse transcription polymerase                chain reaction detection primer is useful for                detecting transmissible gastroenteritis virus,                porcine epidemic diarrhea virus, swine acute                diarrhea syndrome coronavirus and porcine                deltacoronavirus (all claimed).    ADVANTAGE - The primer: adopts one-time PCR reaction;                quickly distinguishes and identifies TGEV, PEDV,                SADS-CoV and PDCoV; has good specificity, high                sensitivity and repeatability with good stability;                and is very suitable for pathogen diagnosis,                pathogen purification test and epidemiological                investigation, preferably at e.g. laboratory, entry                and exit site and farms, etc.    DETAILED DESCRIPTION - Multiplex reverse transcription polymerase                chain reaction (RT-PCR) detection primer comprising                transmissible gastroenteritis virus (TGEV), porcine                epidemic diarrhea virus (PEDV), swine acute                diarrhea syndrome coronavirus (SADS-CoV) and                porcine deltacoronavirus (PDCoV), TGEV-F, TGEV-R,                PEDV-F, PEDV-R, SADS-F, SADS-R, PDCoV-F and                PDCoV-R, preferably primer TGEV-F comprising                5'-gtatgaagcgtagtggttatggtc-3', primer TGEV-R                comprising 5'-aataggttatgacaggttcacaatc-3', primer                PEDV-F comprising 5'-tttcacatggaatatcatactgacg-3',                primer PEDV-R comprising                5'-atgaagcactttctcactatctgt-3', primer SADS-F                comprising 5'-tcctgaggaagaggttgagatggt-3', primer                SADS-R comprising 5'-cgtgcttaccattgtgtatgagac-3',                primer PDCoV-F comprising                5'-agacactgagaagacgggtatgg-3' and primer PDCoV-R                comprising 5'-cttcttgtccttagttggtttggt-3', is new.                INDEPENDENT CLAIMS are also included for:    (1) multiplex RT-PCR detection kit comprising                a multiplex RF-PCR detection primer set of TGEV,                PEDV, SADS-CoV and PDCoV; and    (2) detecting transmissible gastroenteritis                virus, porcine epidemic diarrhea virus, swine acute                diarrhea syndrome coronavirus and porcine                deltacoronavirus, comprising (i) using the sample                RNA to be tested as a template and randomprimer as                an amplification primer, preparing a reverse                transcription reaction system and performing                reverse transcription reaction of sample RNA to                obtain cDNA, (ii) using reverse transcription                reaction product cDNA obtained as a template to mix                the primers TGEV-F, TGEV-R, PEDV-F, PEDV-R, SADS-F,                SADS-R, and PDCoV-F and PDCoV-R as amplification                primer and preparing multiplex PCR reaction system                to perform a multiplex PCR reaction, and (iii)                subjecting multiplex PCR reaction product obtained                in the step (ii) to agarose gel electrophoresis and                determining result comprising confirming                determination of the target band at 801 bp by TGEV                positive amplification, determination of the target                band at 616 bp as PEDV positive amplification,                determination of the target band at 368 bp by                SADS-CoV positive amplification and appearing                target strip at 250 bp, judging band to be                PDCoV-positive amplification, determination of the                target band at 801 bp as TGEV-negative                amplification, where target band at 616 bp is not                determined to be PEDV-negative amplification and                determining the target band at 368 bp as SADS-CoV                negative amplification and absence of the target                band at 250 bp to be PDCoV negative                amplification. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03B;  B04-E01A;  B04-E05;  B04-E99;  B04-F11B;  B11-C08D1;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  C04-B03B;  C04-E01A;  C04-E05;  C04-E99;  C04-F11B;  C11-C08D1;  C11-C08E3;  C11-C08F8;  C12-K04F;  C12-K04G1B;  D05-H06A;  D05-H12D1;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/686;  C12Q-001/70	CN110257557-A   20 Sep 2019   C12Q-001/70   201985Pages: 26   Chinese;  CN110257557-B   13 Oct 2023   C12Q-001/70   202385   Chinese	CN110257557-A    CN10496100    10 Jun 2019;   CN110257557-B    CN10496100    10 Jun 2019	CN110257557-B Previous Publ. Patent CN110257557	CN10496100    10 Jun 2019			CN110257557-A -- CN102943129-A   BEIJING ENTRY EXIT                  INSPECTION&QUARANTI (BEIJ-Non-standard)   SHI X,  MA G,  GUO Z,  ZHANG W,  QIAO C;  CN108315490-A   XIANYANG VOCATIONAL & TECH COLLEGE (XIAN-Non-standard)   ZHU X,  WU X;  CN108715906-A   UNIV GUANGXI (UYGU)   OUYANG K,  ZHONG L,  HUANG W,  WANG R,  LU Y,  WU Y,  LIU X;  CN108950083-A   UNIV HENAN AGRIC (UYHR)   WANG C,  CHANG H,  WANG A,  CHEN L,  ZHOU F,  LI Y,  WANG X,  YANG X,  CUI D,  DU J,  LIU H,  ZHAO J;  CN109439796-A   GUANGXI ZHUANG AUTONOMOUS REGION INST (GUAG)   HE Y,  LIU L,  LI B,  LU B,  QIN Y,  LIANG J,  SU Q,  ZHOU Y,  DUAN Q,  CHEN Z,  BI B,  ZHAO W,  LU J,  JIANG D;  CN109439799-A   UNIV JIANGXI AGRIC (UNJA)   SONG D,  ZHANG Y,  ZHANG F,  YUAN W,  TANG Y,  LI K,  YE Y,  DING Z,  WU Q;  CN109517926-A   UNIV JILIN (UYJI)   LU H,  GAO F,  HE W,  YANG Y,  LV X,  LI Z,  GUAN J,  ZHAO K;  CN109666766-A   TECH CENT INSPECTION & QUARANTINE                  ZHUHAI (TEIN-Non-standard)   LUO B,  LI R,  SU H,  DENG X,  HUANG Z,  ZHAO F,  LIAO X;  CN110257557-B -- CN102943129-A   BEIJING ENTRY EXIT                  INSPECTION&QUARANTI (BEIJ-Non-standard)   SHI X,  MA G,  GUO Z,  ZHANG W,  QIAO C;  CN108315490-A   XIANYANG VOCATIONAL & TECH COLLEGE (XIAN-Non-standard)   ZHU X,  WU X;  CN108715906-A   UNIV GUANGXI (UYGU)   OUYANG K,  ZHONG L,  HUANG W,  WANG R,  LU Y,  WU Y,  LIU X;  CN108950083-A   UNIV HENAN AGRIC (UYHR)   WANG C,  CHANG H,  WANG A,  CHEN L,  ZHOU F,  LI Y,  WANG X,  YANG X,  CUI D,  DU J,  LIU H,  ZHAO J;  CN109439796-A   GUANGXI ZHUANG AUTONOMOUS REGION INST (GUAG)   HE Y,  LIU L,  LI B,  LU B,  QIN Y,  LIANG J,  SU Q,  ZHOU Y,  DUAN Q,  CHEN Z,  BI B,  ZHAO W,  LU J,  JIANG D;  CN109439797-A   GUANGXI ZHUANG AUTONOMOUS REGION INST (GUAG)   ZHAO W,  LI B,  QIN Y,  LU B,  CHEN Z,  BI B,  LIU L,  ZHOU Y,  DUAN Q,  LIANG J,  SU Q,  HE Y,  JIANG D,  LU J;  CN109439799-A   UNIV JIANGXI AGRIC (UNJA)   SONG D,  ZHANG Y,  ZHANG F,  YUAN W,  TANG Y,  LI K,  YE Y,  DING Z,  WU Q;  CN109517926-A   UNIV JILIN (UYJI)   LU H,  GAO F,  HE W,  YANG Y,  LV X,  LI Z,  GUAN J,  ZHAO K;  CN109666766-A   TECH CENT INSPECTION & QUARANTINE                  ZHUHAI (TEIN-Non-standard)   LUO B,  LI R,  SU H,  DENG X,  HUANG Z,  ZHAO F,  LIAO X	CN110257557-A  FANFAN ZHANG: "A          simple and rapid identification method for newly emerged          porcine Deltacoronavirus with loop-mediated isothermal          amplification", BIOLOGICAL          RESEARCH,relevantClaims[1-10],relevantPassages[1-7];  LEI MA:          "Development of a SYBR green-based real-time RT-PCR assay          for rapid detection of the emerging swine acute diarrhea          syndrome coronavirus", JOURNAL OF VIROLOGICAL          METHODS,relevantClaims[1-10],relevantPassages[66-70];  : " RT-PCR ",          ,relevantClaims[13-526-10],relevantPassages[29141];  :          "PEDVTGEVPDCoVRT-PCR",          ,relevantClaims[13-526-10],relevantPassages[757-7581          1]CN110257557-B            Ren Yu-peng, etc. The establishment and preliminary          application of the multiple RT-PCR method for          simultaneously detecting PEDV and TGEV and PDCoV; Ren          Yupeng and so on; "Chinese Veterinary Science"; Volume 46          (Phase 06); Abstract, pp. 757-758, part of "1 material          and method", Table 1;            Yang Yannan. The establishment and initial application of          the four pig coronavirus multiplex RT-PCR detection          methods; Yang Yannan; "Chinese Master degree thesis full          text database agricultural science and technology" (Phase          01); abstract, page 29, paragraph 1 to page 41;            Lei Ma. Development of a SYBR green-based real-time          RT-PCR assay for rapid detection of the emerging swine          acute diarrhea syndrome coronavirus;Lei Ma;Journal of          Virological Methods;265;66-70;            Fanfan Zhang. A simple and rapid identification method          for newly emerged porcine Deltacoronavirus with          loop-mediated isothermal amplification;Fanfan          Zhang;Biological Research;50(1);1-7						KR2007161-B1	New antibodies specifically bind to spike protein S1 of Middle East respiratory syndrome Coronavirus, useful in medicinal composition for treating Coronavirus infection and kit for diagnosing Coronavirus infection	LEE J Y;  KIM S;  LEE H;  HYE-MIN W;  KO H;  KIM J	KOREA PUBLIC (KOPU-Non-standard)	201970352T	   NOVELTY - Antibodies or its antigen binding fragments specifically bind to spike protein S1 of middle east respiratory syndrome (MERS) Coronavirus, comprising heavy chain variable region including CDRH1 having sequence of (SEQ ID NO: 1, 4, 7, 10, 13, 16 and 19), CDRH2 having sequence of (SEQ ID NO: 2, 5, 8, 11, 14, 17 and 20), and CDRH3 having sequence of (SEQ ID NO: 3, 6, 9, 12, 15, 18 and 21), and light chain variable region including CDRL1 having sequence of (SEQ ID NO: 22, 25, 28, 31, 34, 37 and 40), CDRL2 having sequence of (SEQ ID NO: 23, 26, 29, 32, 35, 38 and 41) and CDRL3 having sequence of (SEQ ID NO: 24, 27, 30, 33, 36, 39 and 42), is new. The antibody is antibody comprising heavy chain variable region having amino acid sequence (SEQ ID NO: 43) and light chain variable region having amino acid sequence (SEQ ID NO: 50), antibody comprising heavy chain variable region having amino acid sequence (SEQ ID NO: 44) and light chain variable region having amino acid sequence (SEQ ID NO: 51).    USE - The antibodies are useful in medicinal composition for preventing and treating MERS coronavirus infection and kit for diagnosing MERS coronavirus infection (all claimed).    ADVANTAGE - The antibodies have novel complementarity determining site having high specificity due to no cross-reaction with human Coronavirus and high neutralizing ability against spike protein S1 of MERS Coronavirus, maintains a constant monomer form and high stability at high temperature conditions.    DETAILED DESCRIPTION - Antibodies or its antigen binding fragments specifically bind to spike protein S1 of middle east respiratory syndrome (MERS) Coronavirus, comprising heavy chain variable region including CDRH1 having Gly-Gly-Thr-Phe-Lys-Ile-Ser-Ala (SEQ ID NO: 1), Gly-Gly-Ala-Phe-Asn-Thr-Tyr-Thr (SEQ ID NO: 4), Ser-Gly-Tyr-Phe-Ser-Thr-Tyr-Glu (SEQ ID NO: 7), Gly-Gly-Thr-Phe-Ser-Ser-Ser-Gly (SEQ ID NO: 10), Gly-Phe-Thr-Val-Ile-Asp-Tyr-Tyr (SEQ ID NO: 13), Gly-Gly-Thr-Val-Ser-Ser-Tyr-Ala (SEQ ID NO: 16), and Glu-Asp-Thr-Phe-Arg-Arg-Phe-Ala (SEQ ID NO: 19), CDRH2 having Ile-Ile-Pro-Ile-Phe-Gly-Thr-Pro (SEQ ID NO: 2), Ile-Ile-Pro-Leu-Phe-Arg-Ser-Ser (SEQ ID NO: 5), Met-Asn-Pro-Lys-Ser-Gly-Ile-Thr (SEQ ID NO: 8), Ile-Ile-Pro-Phe-Phe-Gly-Thr-Thr (SEQ ID NO: 11), Ile-Tyr-Ala-Gly-Gly-Ser-Thr (SEQ ID NO: 14), Ile-Ile-Pro-Leu-Phe-Gly-Thr-Val (SEQ ID NO: 17), and Ile-Ile-Ala-Phe-Phe-Gly-Ser-Ala (SEQ ID NO: 20), and CDRH3 having fully defined 17 amino acids (SEQ ID NO: 3), fully defined 19 amino acids (SEQ ID NO: 6), fully defined 14 amino acids (SEQ ID NO: 9), fully defined 19 amino acids (SEQ ID NO: 12), Thr-Arg-Asp-Tyr-Leu-Ala-Ala-Gly-Gly-Leu (SEQ ID NO: 15), fully defined 16 amino acids (SEQ ID NO: 18) and fully defined 21 amino acids (SEQ ID NO: 21), and light chain variable region including CDRL1 having Asn-Ile-Gly-Ser-Lys-Asn (SEQ ID NO: 22), Ser-Ser-Asn-Ile-Gly-Gly-Asn-Tyr (SEQ ID NO: 25), Arg-Val-Ile-Ser-Thr-Tyr (SEQ ID NO: 28), Gln-Ser-Val-Cys-Thr-Ile-Cys (SEQ ID NO: 31), Gln-Gly-Ile-Arg-Asn-Asn (SEQ ID NO: 34), Gln-Ala-Ile-Tyr-Asn-Ser (SEQ ID NO: 37) and Gln-Ser-Val-Ser-Ser-Thr-Tyr (SEQ ID NO: 40), CDRL2 having Ile-Asn-Asp (SEQ ID NO: 23), Lys-Asn-Asn (SEQ ID NO: 26), Ala-Ala-Ser (SEQ ID NO: 29), Gly-Ala-Ser (SEQ ID NO: 32), Gly-Ala-Ser (SEQ ID NO: 35), Gly-Ala-Ser (SEQ ID NO: 38) and Gly-Thr-Ser (SEQ ID NO: 41) and CDRL3 having Gln-Leu-Trp-Asp-Gly-Ser-Thr-Gly-Val (SEQ ID NO: 24), fully defined 11 amino acids (SEQ ID NO: 27), Gln-Gln-Thr-Tyr-Asn-Thr-Pro-Gln-Thr (SEQ ID NO: 30), Gln-Gln-Tyr-Gly-Gly-Ser-Ala-Trp-Thr (SEQ ID NO: 33), Gln-Lys-Tyr-Asp-Ser-Ala-Pro-Leu-Thr (SEQ ID NO: 36), Gln-Gln-Tyr-His-Ser-Thr-Pro-Pro-Trp-Thr (SEQ ID NO: 39) and Gln-Gln-Phe-Gly-Ser-Ser-Pro-Gln-Tyr-Thr (SEQ ID NO: 42), is new. The antibodies or antigen-binding fragments are an antibody comprising a heavy chain variable region having fully defined 144 amino acids (SEQ ID NO: 43) and a light chain variable region having fully defined 127 amino acids (SEQ ID NO: 50), antibody comprising a heavy chain variable region having fully defined 146 amino acids (SEQ ID NO: 44) and a light chain variable region having fully defined 131 amino acids (SEQ ID NO: 51), antibody comprising a heavy chain variable region having fully defined 142 amino acids (SEQ ID NO: 45) and a light chain variable region having fully defined 129 amino acids (SEQ ID NO: 52), antibody comprising a heavy chain variable region having fully defined 146 amino acids (SEQ ID NO: 46) and a light chain variable region having fully defined 129 amino acids (SEQ ID NO: 53), antibody comprising a heavy chain variable region having fully defined 136 amino acids (SEQ ID NO: 47) and a light chain variable region having fully defined 128 amino acids (SEQ ID NO: 54), antibody comprising a heavy chain variable region having fully defined 143 amino acids (SEQ ID NO: 48) and a light chain variable region having fully defined 129 amino acids (SEQ ID NO: 55), and antibody comprising a heavy chain variable region having fully defined 148 amino acids (SEQ ID NO: 49) and a light chain variable region having fully defined 130 amino acids (SEQ ID NO: 56), as given in specification, respectively. INDEPENDENT CLAIMS are also included for:    (1) nucleic acid encoding the antibody or its antigen-binding fragment;    (2) an expression vector comprising the nucleic acid; and    (3) isolated cell transformed with the expression vector. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-C01;  B04-E02A;  B04-E03A;  B04-E08;  B04-E99;  B04-F0100E;  B04-G08;  B04-G23;  B11-C07A;  B12-K04G1B;  B14-A02B5;  D05-H11;  D05-H12A;  D05-H12E;  D05-H14;  D05-H99;  S03-E09F;  S03-E14H5	A61P-031/14;  C07K-016/10;  G01N-033/569	KR2007161-B1   07 Aug 2019   C07K-016/10   201966Pages: 46   	KR2007161-B1    KR136210    07 Nov 2018		KR136210    07 Nov 2018						215970803 K M Q; 215970804 K M Q; 215970805 K M Q; 215970806 K M Q; 215970807 K M Q; 215970808 K M Q; 215970809 K M Q; 215970810 K M Q; 215970811 K M Q; 215970812 K M Q; 215970813 K M Q; 215970814 K M Q; 215970815 K M Q; 215970816 K M Q; 215970817 K M Q; 215970818 K M Q; 215970819 K M Q; 215970820 K M Q; 215970821 K M Q; 215970822 K M Q; 215970823 K M Q; 215970824 K M Q; 215970825 K M Q; 215970801 K M Q; 215970802 K M Q				KR2019111505-A	Producing Spirulina Lactobacillus culture useful in feed additive composition, comprises forming Lactobacillus culture medium comprising MRS medium and barley sprout extract, sterilizing, seeding seed in medium, and culturing	HAN M H	SPIRULINAFARMS CO LTD (SPIR-Non-standard);  ESPEEDBIO CO LTD (PEED-C);  HAN M H (HANM-Individual)	2019845994	   NOVELTY - Producing Spirulina Lactobacillus culture, comprises (a) forming Lactobacillus culture medium comprising 95 wt.% MRS (de MAN, ROGOSA and SHARPE) medium and 5 wt.% barley sprout extract, (b) sterilizing the Lactobacillus culture medium, (c) seeding the seed in the sterilized culture medium, (d) primary culturing at 22-28 degrees C for 3 days after spawn seeding, and (e) secondary culturing the obtained product by adding 2 wt.% Spirulina.    USE - The culture is useful in feed additive composition (claimed).    ADVANTAGE - The culture increases productivity of livestock, improves blood characteristics of livestock, and swine pandemic diarrhea, and can replace conventional chemical antibiotics.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (I) Spirulina Lactobacillus culture produced by the above method; and (II) feed additive composition comprising Spirulina Lactobacillus culture. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-A08;  B04-A09;  B04-A10;  B04-A98;  B04-F10A;  B11-A04A;  B14-S18;  D03-G01;  D03-P;  D05-A04D;  D05-H08A	A23K-010/18;  A23K-010/37;  A23K-050/30;  A23K-050/75	KR2019111505-A   02 Oct 2019   A23K-010/18   201980   	KR2019111505-A    KR033706    23 Mar 2018		KR033706    23 Mar 2018										CN110331171-A	Efficiently and rapidly constructing a porcine            intestinal coronavirus recombinant virus comprises e.g.            designing two sgRNAs scraping the ORF3 gene of porcine            epidemic diarrhea virus AJ1102 strain, amplifying and            homologously recombining	XIAO S;  FANG L;  PENG Q;  WANG D;  FANG P;  ZHOU Y;  LIU K	UNIV HUAZHONG AGRIC (UHZA-C)	201986816E	   NOVELTY - Efficiently and rapidly constructing a porcine                intestinal coronavirus recombinant virus comprises                (i) designing two sgRNAs scraping the ORF3 gene of                the porcine epidemic diarrhea virus (PEDV) AJ1102                strain, and in vitro cleavage of the BAC plasmid                pBAC-AJ1102 containing the full-length cDNA of PEDV                AJ1102 strain using the CRISPR/Cas9 system, (ii)                amplifying a fragment containing the upstream                sequence of the ORF3 gene of the porcine epidemic                diarrhea virus AJ1102 strain, EGFP gene and                downstream sequence of the ORF3 gene of the PEDV                AJ1102 strain by fusion PCR, (iii) homologous                recombination using the fusion cloned recombinase                to cleave the plasmid pBAC-AJ1102 and the fusion                PCR product at a molar ratio of 1:5, (iv)                transforming the recombinant product into DH10B                chemically competent cells, and screening positive                clones by PCR, and sequencing the PCR products, (v)                extracting a large number of plasmids after the                positive clones with correct sequencing are                expanded and culturing.    USE - The method is useful for efficiently and                rapidly constructing a porcine intestinal                coronavirus recombinant virus.    ADVANTAGE - The method has wide target selection, high                specificity, simple operation and short                experimental period, and recombinant virus can be                obtained within one week.    DETAILED DESCRIPTION - Efficiently and rapidly constructing a porcine                intestinal coronavirus recombinant virus comprises                (i) designing two sgRNAs scraping the ORF3 gene of                the porcine epidemic diarrhea virus (PEDV) AJ1102                strain, and in vitro cleavage of the BAC plasmid                pBAC-AJ1102 containing the full-length cDNA of PEDV                AJ1102 strain using the CRISPR/Cas9 system, (ii)                amplifying a fragment containing the upstream                sequence of the ORF3 gene of the porcine epidemic                diarrhea virus AJ1102 strain, the EGFP gene, and                the downstream sequence of the ORF3 gene of the                PEDV AJ1102 strain by fusion PCR, (iii) homologous                recombination using the fusion cloned recombinase                to cleave the plasmid pBAC-AJ1102 and the fusion                PCR product at a molar ratio of 1:5, (iv)                transforming the recombinant product into DH10B                chemically competent cells, and screening positive                clones by PCR, and sequencing the PCR products, (v)                extracting a large number of plasmids after the                positive clones with the correct sequencing are                expanded and culturing, (vi) transfecting the                extracted plasmid into Vero cells with                Lipofectamine 3000 for 6 hours, replacing the                serum-free Dulbecco's Modified Eagle Medium                containing 10 mu g/ml trypsin and observing the                cytopathic effect day by day, where the upstream                sequence of the ORF3 gene described in the step                (ii), and the nucleotide sequences of the                downstream sequences of the EGFP gene and the ORF3                gene are as follows: upstream sequence of the ORF3                gene is fully defined sequence of 1104 nucleotides                (SEQ ID NO. 16) as given in specification, EGFP                gene is fully defined sequence of 740 nucleotides                (SEQ ID NO. 18) as given in specification, ORF3                gene downstream sequence fully defined sequence of                519 nucleotides (SEQ ID NO. 17) as given in                specification. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E02F;  B04-E03F;  B04-E08;  B04-E13;  B04-E99;  B04-F0100E;  B04-F11B0E;  B04-L01;  B04-L05A2;  B04-L05C;  C04-E02F;  C04-E03F;  C04-E08;  C04-E13;  C04-E99;  C04-F0100E;  C04-F11B0E;  C04-L01;  C04-L05A2;  C04-L05C;  D05-A02;  D05-H12F;  D05-H18;  D05-H19C;  D05-H99	C12N-015/50;  C12N-015/65;  C12N-015/85;  C12N-015/90;  C12R-001/93	CN110331171-A   15 Oct 2019   C12N-015/90   201984Pages: 29   Chinese	CN110331171-A    CN10626337    11 Jul 2019		CN10626337    11 Jul 2019			CN110331171-A -- CN109321571-A   WUHAN KEQIAN ANIMAL BIOLOGICAL PROD CO (UHZA)   XU G,  SUN F,  ZHOU M,  ZHANG H,  HAO G	CN110331171-A  BI J: "Complete          genome sequence of porcine epidemic diarrhea virus strain          AJ1102 isolated from a suckling piglet with acute          diarrhea in China", J          VIROL,relevantClaims[1],relevantPassages[109103];  WANG G: "The          N-Terminal Domain of Spike Protein Is Not the Enteric          Tropism Determinant for Transmissible Gastroenteritis          Virus in Piglets",          VIRUSES,relevantClaims[1],relevantPassages[2-5112134];  : "PEDV",          ,relevantClaims[1],relevantPassages[112593]	109563-0-0-0 K M			RA0426 K M		CN109666070-A;  CN109666070-B	New immunoglobulin G antibody useful for the            preparing of drug for preventing/treating middle east            respiratory syndrome coronavirus comprising of heavy            chain and light chain	ZHANG L;  WANG X;  JIANG L;  ZUO T;  SHI X;  ZHOU P	UNIV TSINGHUA (UYQI-C)	2019408540	   NOVELTY - Immunoglobulin G antibody comprising of heavy                chain and light chain, CDR1, CDR2 and CDR3 in the                heavy chain variable region of the heavy chain are                in turn, the sequence from amino acid residues                45-52 of the N-terminus comprising a fully defined                sequence of 461 amino acids (SEQ ID NO: 1) as given                in the specification, amino acid residues 70-77 and                amino acid residues 116-120 and the CDR1, CDR2 and                CDR3 in the light chain variable region of light                chain are in turn, the sequence from amino acid                residues 45-52 of the N-terminus comprising a fully                defined sequence of 235 amino acids (SEQ ID NO: 3)                as given in the specification, amino acid residues                70-72 and 109-119 amino acid residue is new.    USE - The immunoglobulin G antibody is useful for                the preparing of a drug for preventing/treating                middle east respiratory syndrome coronavirus                (claimed).    ADVANTAGE - The immunoglobulin G antibody has broad                application.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for gene                encoding the immunoglobulin G antibody comprising                heavy chain is as follows: (1) a DNA molecule                represented by nucleotides 49-1383 at the 5' end                and (2) a DNA molecule comprises defined sequence                of 1386 base pairs (SEQ ID NO: 2) as given in the                specification, the gene encoding the light chain is                as follows: (3) a DNA molecule represented by                nucleotides 49-705 at the 5' end and (4) DNA                molecules comprises defined sequence of 708 base                pairs (SEQ ID NO: 4) as given in the                specification. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-C01G;  B04-E02A;  B04-E03A;  B04-E99;  B04-G27G;  B14-A02B5;  D05-H11;  D05-H12A;  D05-H99	A61K-039/42;  A61P-011/00;  A61P-031/14;  C07K-016/10;  C12N-015/13	CN109666070-A   23 Apr 2019   C07K-016/10   201950Pages: 22   Chinese;  CN109666070-B   19 Feb 2021   C07K-016/10   202118   Chinese	CN109666070-A    CN10951002    13 Oct 2017;   CN109666070-B    CN10951002    13 Oct 2017	CN109666070-B Previous Publ. Patent CN109666070	CN10951002    13 Oct 2017			CN109666070-A -- CN104447986-A   CHINESE ACAD SCI MICROBIOLOGY INST (CWSW)   GAO F,  LI Y,  YAN J,  WAN Y;  CN104628848-A   UNIV TSINGHUA (UYQI)   WANG X,  SHI X,  ZHANG L,  ZUO T,  WANG N,  JIANG L;  CN104628849-A   UNIV TSINGHUA (UYQI)   WANG X,  SHI X,  ZHANG L,  ZUO T,  WANG N,  JIANG L;  US20140161822-A1   ;  CN109666070-B -- CN104447986-A   CHINESE ACAD SCI MICROBIOLOGY INST (CWSW)   GAO F,  LI Y,  YAN J,  WAN Y;  CN104628848-A   UNIV TSINGHUA (UYQI)   WANG X,  SHI X,  ZHANG L,  ZUO T,  WANG N,  JIANG L;  CN104628849-A   UNIV TSINGHUA (UYQI)   WANG X,  SHI X,  ZHANG L,  ZUO T,  WANG N,  JIANG L;  US20140161822-A1   	CN109666070-A  : "MERS-CoV          RBDMERS-4", ()          ,relevantClaims[1-10],relevantPassages[E059-32];  SENYANZHANG :          "Structural Definition of a Unique Neutralization Epitope          on the Receptor-Binding Domain of MERS-CoV Spike          Glycoprotein", CELL          REPORTS,relevantClaims[1-10],relevantPassages[441-452];  JIUYANG XU :          "Antibodies and vaccines against Middle East respiratory          syndrome coronavirus", EMERG MICROBES          INFECT,relevantClaims[1-10],relevantPassages[841-856];  WANG,X.Q. : "Chain          H, Heavy chain",          GENBANK,relevantClaims[1-10],relevantPassages[ACCESSION          No.5YY5_H];  : "MERS-CoV", ()          ,relevantClaims[1-10],relevantPassages[E059-7];  :          "MERS-CoVMERS-27",          ,relevantClaims[1-10],relevantPassages[70]CN109666070-B            Wang, X.Q., etc. " Chain H, heavy chain "; Wang, X. Q. et          al., Genbank, 20180813, ACCESSION No. 5YY5_H;            SenyanZhang . Structural Definition of a Unique          Neutralization Epitope on the Receptor-Binding Domain of          MERS-CoV Spike Glycoprotein;SenyanZhang ;CELL          REPORTS;20180710;24(2);441-452;            Jiuyang Xu and so on. anti-body and anti-hernical East          Asian syndrome virus, Jiuyang Xu and so on, " Emerg          Microbes Infect, 20190606, eighth volume (first 1), the          841-856 page;            Zhang, Sen-yan. MERS-CoV RBD protein and neutralizing          antibody MERS-4 and its variant action mechanism          research, Zhang Senyan, Chinese PhD thesis database          (electronic periodical) medicine health science and          technology, 20200415 (04) E059-32;            Wang Yan-shuang. "Middle East Respiratory Syndrome          Coronavirus MERS-CoV receptor recognition mechanism          research"; Wang Yan-shuang; "Chinese PhD Desertation          Full-text Database (Electronic Journal) Medical and          Health Science," 20150915 (Day 09) E059-7;            Zhang Lin, and so on. MERS-CoV surface spike protein and          neutralizing antibody MERS-27 mechanism research, Zhang          linqi and so on; the eleventh national virology academic          seminar and the sixth Wuhan modern virology international          seminar discussion set, 20151031, page 70	184587-0-0-0 N			RA00C8 N		CN110105348-A	New heterocyclic compound useful in pharmaceutical            composition for preparing drug used for treating            infection caused by enterovirus and coronavirus, and            cysteine protease-induced disease including common            cold	SHANG L;  MA Y;  HE S;  SHANG C	UNIV NANKAI (UNAN-C)	2019706811	   NOVELTY - A heterocyclic compound (I), is new.    USE - Heterocyclic compound is useful in                pharmaceutical composition for preparing drug used                for treating infection caused by enterovirus                including poliovirus, coxsackievirus A,                coxsackievirus B, Enterovirus 71 (EV71) and                Echovirus, and coronavirus including SARS virus and                Middle East Respiratory Syndrome Coronavirus                (MERS-CoV), and cysteine protease-induced disease                including hand, foot and mouth disease, polio and                common cold in mammals (all claimed).    DETAILED DESCRIPTION - A heterocyclic compound of formula (I) or its                optical isomer, metabolite, salt, solvate or                prodrug, is new.    R1 = -H or 1-12C alkyl, 2-12C alkenyl, 2-12C                alkynyl, 3-8C cycloalkyl, aryl, heteroaryl, aryl                1-8C alkyl, heteroaryl 1-9C alkyl, aryl 2-6C                alkenyl, heteroaryl 2-6C alkenyl, aryl 2-6C                alkynyl, heteroaryl 2-6C alkynyl, -O-alkyl,                -O-cycloalkyl, -O-heteroalkyl, -O-cycloalkyl,                -O-heterocyclyl, -O-alkenyl, -O-cycloalkenyl,                -O-heteroalkenyl, -O-heterocycloalkenyl,                -O-alkynyl, -O-cycloalkynyl, -O-cycloheteroalkynyl,                -O-aryl, -O-aralkyl, -O-heteroaryl,                -O-heteroarylalkyl, -S-alkyl, -S-cycloalkyl,                -S-heteroalkyl, -S-heterocycloalkyl,                -S-heterocyclyl, -S-alkenyl, -S-cycloalkenyl,                -S-heteroalkenyl, -S-heterocycloalkenyl,                -S-alkynyl, -S-cycloalkynyl, -S-aryl, -S-aralkyl,                -S-heteroaryl, -S-heteroarylalkyl, -N-alkyl,                -N-cycloalkyl, -N-heteroalkyl, -N-heterocycloalkyl,                -N-heterocyclyl, -N-alkenyl, -N-cycloalkenyl,                -N-heteroalkenyl, -N-heterocycloalkenyl,                -N-alkynyl, -N-cycloalkynyl, -N-aryl, -N-aralkyl,                -N-heteroaryl or -N-heteroarylalkyl (all optionally                substituted by halo, -OH, -SH, -NO2, -CN, 1-8C                haloalkyl, 1-8C alkoxy, 1-6C alkylcarbonyl, 1-6C                alkylthio, 1-8C alkoxycarbonyl or -CF3);    R2 = alkyl, cycloalkyl, heteroalkyl,                heterocycloalkyl, heterocyclyl optionally having O,                S or N, alkenyl, cycloalkenyl, heteroalkenyl,                heterocycloalkenyl, alkynyl, cycloalkynyl,                heteroalkynyl, cycloheteroalkynyl, aryl,                heteroaryl, aryl 1-8C alkyl, heteroaryl 1-9C alkyl,                aryl 2-6C alkenyl, heteroaryl 2-6C alkenyl, aryl                2-6C alkynyl, or heteroaryl 2-6C alkynyl (all                optionally substituted by halo, -OH, -SH, -NO2,                -CN, phenyl, 1-8C haloalkyl, 1-8C alkoxy, 1-6C                alkylcarbonyl, 1-6C alkylthio, 1-8C alkoxycarbonyl,                -CF3), and in which aryl is preferably phenyl or                naphthyl, and heteroaryl is 5- or 6-membered aryl                having 1, 2 or 3 hetero atoms chosen from N, O and                S;and    X,Y' = -H, alkyl, halo, -CN, ester, amido,                carbonyl, aryl, preferably phenyl or naphthyl, or                5- or 6-membered heteroaryl having O, N or S. 			B03 (Other heterocyclics.)	B06-H;  B07-D05;  B14-A02A;  B14-A02B3;  B14-A02B5;  B14-D07C;  B14-K01D	A61K-031/4439;  A61K-031/444;  A61P-031/14;  C07D-413/12;  C07D-413/14	CN110105348-A   09 Aug 2019   C07D-413/12   201975Pages: 32   Chinese	CN110105348-A    CN10174469    08 Mar 2019		CN10174469    08 Mar 2019			CN110105348-A -- CN1311793-A   AGOURON PHARM INC (PFIZ)   DRAGOVICH P S,  MARAKOVITS J T,  PRINS T J,  TIKHE J G,  WEBBER S E,  ZHOU R,  JOHNSON T O;  CN103130710-A   TIANJIN INTERNATIONAL BIOMEDICAL UNION (TIAN-Non-standard);  UNIV NANKAI (UNAN);  UNIV TSINGHUA (UYQI)   CHEN C,  CUI C,  LOU Z,  RAO Z,  SHANG L,  WANG P,  WANG Y,  XU M,  YANG C,  YIN Z,  ZHAO Q,  ZHAO X,  ZHOU H;  CN103145608-A   UNIV NANKAI (UNAN);  UNIV TSINGHUA (UYQI);  TIANJIN INT BIOPHARMACEUTICAL UNITED RES (TIAN-Non-standard)   ZHAO X,  YANG C,  YIN Z,  CHEN C,  LOU Z,  WANG P,  ZHAO Q,  ZHOU H,  RAO Z,  SHANG L,  WANG Y,  XU M,  CUI C	CN110105348-A  SHENGJUN FU ET AL.:          "Target-guided screening of fragments (TGSOF) in the          discovery of inhibitors against EV-A71 3C protease",          CHEMICAL          COMMMUNICATIONS,relevantClaims[1-8],relevantPassages[2890-2893];  YANGYANG ZHAI:          "Structure-activity relationship study of peptidomimetic          aldehydes as enterovirus 71 3C protease inhibitors",          EUROPEAN JOURNAL OF MEDICINAL          CHEMISTRY,relevantClaims[1-8],relevantPassages[559-573]	 N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N	216520901 N		RCNR86 N; RCNR87 N; RCNR88 N; RCNR89 N; RCNR8A N; RCNR8B N; RCNR8C N; RCNR8D N; RCNR8E N; RCNR8F N; RCNR8G N; RCNR8H N; RCNR8I N; RCNR8J N; RCNR8K N; RCNR8L N; RCNR8M N; RCNR8N N; RCNR99 N; RCNR8O N; RCNR8P N; RCNR8Q N; RCNR8R N; RCNR8S N; RCNR8T N; RCNR8U N; RCNR8V N; RCNR8W N; RCNR8X N; RCNR8Y N; RCNR8Z N; RCNR90 N; RCNR91 N; RCNR92 N; RCNR93 N; RCNR94 N; RCNR95 N; RCNR96 N; RCNR97 N; RCNR98 N		WO2019113462-A1;  AU2018378832-A1;  CA3082191-A1;  KR2020071119-A;  CN111372592-A;  IN202017019418-A;  US2020276219-A1;  GB2581936-A;  EP3706762-A1;  SG11202004403-A1;  BR112020010581-A2;  JP6804790-B1;  GB2581936-B;  JP2021505530-W;  JP2021042235-A;  PH12020550607-A1;  KR2248165-B1;  KR2021050594-A;  AU2018378832-B2;  AU2018378832-B9;  GB2590198-A;  AU2021206866-A1;  EP3706762-A4;  CA3082191-C;  JP2021165280-A;  US11147826-B2;  US2022016153-A1;  GB2590198-B;  US11331331-B2;  RU2020116571-A;  JP7179372-B2;  HK40037053-A0;  HK40038030-A0;  IL274155-B;  ZA202002849-A;  IL274155-A;  JP2023082213-A;  IL284100-A;  JP7305205-B2;  ID202101279-A1;  MX404855-B;  KR2626210-B1;  KR2024011880-A;  RU2023133687-A;  US11903959-B2;  SA522432673-A;  AU2021206866-B2;  BR122022008466-B1;  US2024189335-A1	Pharmaceutical composition used in pressurized            container which is e.g. inhaler for treating or            preventing e.g. human coronavirus and Venezuelan equine            encephalitis virus, comprises excipient and            N4-hydroxycytidine derivatives	PAINTER G R;  BLUEMLING G R;  NATCHUS M G;  GUTHRIE D;  PAINTER G;  BLUEMLING G;  NATCHUS M;  GEORGE R P;  GREGORY R B;  MICHAEL G N	UNIV EMORY (UEMR-C);  UNIV EMORY (UEMR-C);  UNIV EMORY (UEMR-C);  UNIV EMORY (UEMR-C)	201951069A	   NOVELTY - Pharmaceutical composition comprises a                excipient and N4-hydroxycytidine derivatives                (A).    USE - The composition is useful in pressurized                container which is a manual pump spray, inhaler,                meter-dosed inhaler, dry powder inhaler, nebulizer,                vibrating mesh nebulizer, jet nebulizer, or                ultrasonic wave nebulizer for treating or                preventing a human coronavirus, severe acute                respiratory syndrome coronavirus, middle east                respiratory syndrome coronavirus, eastern equine                encephalitis virus, western equine encephalitis                virus, Venezuelan equine encephalitis virus,                chikungunya virus, and Ross River infections,                Orthomyxoviridae virus or Paramyxoviridae virus or                respiratory syncytial virus, or influenza A virus                and influenza B virus, or filoviridae virus or                ebola virus infection and alphavirus in a patient                (all claimed).    ADVANTAGE - The composition utilizes (A) that exhibits                improved pharmacokinetic properties e.g. maximum                serum concentration (Cmax), half life and area                under curve. The pharmacokinetic property of (A)                was tested in male Cynomolgus macaques using in                vivo assay. The result showed that                (2R,3R,4R,5R)-2-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)-5-(isobutyryloxymethyl)tetrahydrofuran-3,4-diyl                bis(2-methylpropanoate) exhibited Cmax value of                16.3 plus minus 13.2 nmol/ml.    DETAILED DESCRIPTION - Pharmaceutical composition comprises a                excipient and N4-hydroxycytidine derivatives (A) of                formulae e.g. (I)-(VI) or their salts.    X1 = CH2, CHCH3, C(CH3)2, CHF, CF2 or                CD2;    Y1 = N or CR1a;    Z1 = N or CR2a;    R1a, R2a = H, deuterium, halo, OH, amino,                thiol, alkyl, alkenyl, alkynyl, aryl, heteroaryl,                carbocyclyl, heterocarbocyclyl, cycloalkyl,                heterocyclyl, or carbonyl, where R1a and R2a are                optionally substituted by at least one R10;    R1-R3, R5 = esters, branched esters,                carbonates, carbamates, thioesters, branched                thioesters, thiocarbonates, S-thiocarbonate,                dithiocarbonates, thiocarbamates, oxymethoxy                carbonyl, oxymethoxythiocarbonyl,                oxymethylcarbonyl, oxymethylthiocarbonyl, L-amino                acid esters, sulfenyl, imidate, hydrazonate,                oximyl, imidinyl, imidyl, aminal, hemiaminal,                acetal, hemiacetal, carbonimidate,                thiocarbonimidate, carbonimidyl, carbamimidate,                carbamimidyl, thioacetal, S-acyl-2-thioethyl,                bis-(acyloxybenzyl)esters, (acyloxybenzyl)esters                (all optionally substituted), H, D-amino acid                esters, N-substituted L-amino acid esters, N,N-                disubstituted L-amino acid esters, N-substituted                D-amino acid esters, N,N-disubstituted D- amino                acid esters or BAB-esters, where the R1, R2, R3,                and R5 are optionally substituted by at least one                R10;    R10 = deuterium, OH, azido, thiol, amino,                cyano, halo, alkyl, alkenyl, alkynyl, carbocyclyl,                heterocarbocyclyl, aryl, heteroaryl, heterocyclyl,                cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy,                heterocarbocycloxy, aryloxy, heteroaryloxy,                heterocycloxy, cycloalkoxy, cycloalkenoxy,                alkylamino, (alkyl)2-amino, carbocyclamino,                heterocarbocyclamino, arylamino, heteroarylamino,                heterocyclamino, cycloalkamino, cycloalkenamino,                alkylthio, carbocyclylthio, heterocarbocyclylthio,                arylthio, heteroarylthio, heterocyclylthio,                cycloalkylthio, cycloalkenylthio, allenyl, sulfmyl,                sulfamoyl, sulfonyl, lipid, nitro or carbonyl,                where the R10 is optionally substituted by at least                one R11;    R11 = deuterium, OH, azido, thiol, amino,                cyano, halo, alkyl, alkenyl, alkynyl, carbocyclyl,                heterocarbocyclyl, aryl, heteroaryl, heterocyclyl,                cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy,                heterocarbocycloxy, aryloxy, heteroaryloxy,                heterocycloxy, cycloalkoxy, cycloalkenoxy,                alkylamino, (alkyl)2-amino, carbocyclamino,                heterocarbocyclamino, arylamino, heteroarylamino,                heterocyclamino, cycloalkamino, cycloalkenamino,                alkylthio, carbocyclylthio, heterocarbocyclylthio,                arylthio, heteroarylthio, heterocyclylthio,                cycloalkylthio, cycloalkenylthio, allenyl, sulfmyl,                sulfamoyl, sulfonyl, lipid, nitro or carbonyl;                and    lipid = 11-22C higher alkyl, 11-22C higher                alkoxy, polyethylene glycol, or aryl substituted by                alkyl.    Provided that, R1, R2, R3, and R5 are not all                H in (II), (III), and (IV). An INDEPENDENT CLAIM is                also included for a pressurized container                comprising the composition. 			B03 (Other heterocyclics.);  C02 (Heterocyclic.);  A96 (Medical, dental, veterinary, cosmetic.)	B04-E99;  B04-B03A;  B05-A04A;  B05-B01D;  B10-H02B;  B14-A02B;  B14-K01D;  B14-S18;  C04-E99;  C04-B03A;  C05-A04A;  C05-B01D;  C10-H02B;  C14-A02B;  C14-K01D;  C14-S18;  A10-E01;  A12-V01	A61K-031/706;  A61K-031/7064;  A61K-031/7068;  C07H-019/06;  C07H-019/067;  C07H-019/10;  A61K-009/12;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-043/00;  A61K-009/72;  A61K-047/04;  A61K-047/06;  A61K-047/10;  A61K-000/00;  C07H-000/00;  A61K-047/54;  A61P-031/18;  A61P-031/20;  A61K-031/64;  A61K-031/68	WO2019113462-A1   13 Jun 2019   A61K-031/706   201949Pages: 249   English;  AU2018378832-A1   14 May 2020   A61K-031/706   202041   English;  CA3082191-A1   13 Jun 2019   A61K-031/706   202049   English;  KR2020071119-A   18 Jun 2020   A61K-031/7068   202051   ;  CN111372592-A   03 Jul 2020   A61K-031/706   202059   Chinese;  IN202017019418-A   14 Aug 2020   A61K-031/706   202071   English;  US2020276219-A1   03 Sep 2020   A61K-031/7068   202073   English;  GB2581936-A   02 Sep 2020   A61K-031/706   202073   English;  EP3706762-A1   16 Sep 2020   A61K-031/706   202076   English;  SG11202004403-A1   29 Jun 2020   A61K-031/706   202083   English;  BR112020010581-A2   10 Nov 2020   C07H-019/06   202002   English;  JP6804790-B1   23 Dec 2020   A61K-031/7068   202004Pages: 237   Japanese;  GB2581936-B   10 Feb 2021   A61K-031/706   202114   English;  JP2021505530-W   18 Feb 2021   A61K-031/7068   202116Pages: 292   Japanese;  JP2021042235-A   18 Mar 2021   A61K-031/7068   202124Pages: 236   Japanese;  PH12020550607-A1   15 Feb 2021   A61K-031/706   202128   English;  KR2021050594-A   07 May 2021   A61K-031/7068   202140   ;  GB2590198-A   23 Jun 2021   A61K-031/7068   202152   English;  AU2021206866-A1   12 Aug 2021   A61K-031/706   202168   English;  EP3706762-A4   01 Sep 2021   A61K-031/7068   202172   English;  JP2021165280-A   14 Oct 2021   A61K-031/7068   202186Pages: 288   Japanese;  US11147826-B2   19 Oct 2021   C07H-019/067   202191   English;  US2022016153-A1   20 Jan 2022   A61K-031/7068   202208   English;  GB2590198-B   23 Feb 2022   A61K-031/7068   202217   English;  US11331331-B2   17 May 2022   C07H-019/067   202241   English;  RU2020116571-A   22 Nov 2021   A61K-031/706   202256   Russian;  JP7179372-B2   29 Nov 2022   C07H-019/067   202297   Japanese;  HK40037053-A0   04 Jun 2021   A61K-031/706   202200   English;  HK40038030-A0   18 Jun 2021   A61K-031/706   202200   English;  IL274155-B   29 Jul 2021   A61K-009/12   202166   English;  ZA202002849-A   25 Jan 2023   A61K-000/00   202317   English;  IL274155-A   31 May 2020   A61K-031/7068   202335   English;  JP2023082213-A   13 Jun 2023   A61K-031/7068   202350   Japanese;  IL284100-A   29 Jul 2021   A61K-009/12   202356   English;  JP7305205-B2   10 Jul 2023   A61K-031/7068   202358   Japanese;  ID202101279-A1   01 Mar 2021   A61K-031/706   202363;  MX404855-B   01 Aug 2023   A61K-031/7068   202389   Spanish;  KR2024011880-A   26 Jan 2024   A61K-031/7068   202410   ;  RU2023133687-A   10 Jan 2024   A61K-031/706   202415   Russian;  US11903959-B2   20 Feb 2024   C07H-019/067   202418   English;  SA522432673-A   09 Jan 2023   A61K-031/64   202421;  AU2021206866-B2   18 Apr 2024   A61K-031/706   202433   English;  BR122022008466-B1   05 Dec 2023   C07H-019/06   202446   ;  US2024189335-A1   13 Jun 2024   A61K-031/7068   202449   English	WO2019113462-A1    WOUS064503    07 Dec 2018;   AU2018378832-A1    AU378832    07 Dec 2018;   CA3082191-A1    CA3082191    07 Dec 2018;   KR2020071119-A    KR714737    07 Dec 2018;   CN111372592-A    CN80073278    07 Dec 2018;   IN202017019418-A    IN17019418    07 May 2020;   US2020276219-A1    US16755779    13 Apr 2020;   GB2581936-A    GB008628    07 Dec 2018;   EP3706762-A1    EP886104    07 Dec 2018;   SG11202004403-A1    SG11004403    07 Dec 2018;   BR112020010581-A2    BR11010581    07 Dec 2018;   JP6804790-B1    JP524817    07 Dec 2018;   GB2581936-B    GB008628    07 Dec 2018;   JP2021505530-W    JP524817    07 Dec 2018;   JP2021042235-A    JP195927    26 Nov 2020;   PH12020550607-A1    PH550607    08 May 2020;   KR2248165-B1    KR714737    07 Dec 2018;   KR2021050594-A    KR712910    07 Dec 2018;   AU2018378832-B2    AU378832    07 Dec 2018;   AU2018378832-B9    AU378832    07 Dec 2018;   GB2590198-A    GB020498    23 Dec 2020;   AU2021206866-A1    AU206866    22 Jul 2021;   AU2021206866-A1    AU206866    22 Jul 2021;   EP3706762-A4    EP886104    07 Dec 2018;   CA3082191-C    CA3082191    07 Dec 2018;   JP2021165280-A    JP106296    28 Jun 2021;   US11147826-B2    US16755779    13 Apr 2020;   US2022016153-A1    US465344    02 Sep 2021;   GB2590198-B    GB020498    23 Dec 2020;   US11331331-B2    US16755779    13 Apr 2020;   RU2020116571-A    RU116571    07 Dec 2018;   JP7179372-B2    JP195927    26 Nov 2020;   HK40037053-A0    HK6026557    02 Mar 2021;   HK40038030-A0    HK6026723    05 Mar 2021;   IL274155-B    IL274155    07 Dec 2018;   ZA202002849-A    ZA002849    15 May 2020;   IL274155-A    IL274155    07 Dec 2018;   JP2023082213-A    JP062657    07 Apr 2023;   IL284100-A    IL284100    07 Dec 2018;   JP7305205-B2    JP106296    28 Jun 2021;   ID202101279-A1    IDP03494    13 May 2020;   MX404855-B    MX005392    13 Jul 2020;   KR2626210-B1    KR712910    07 Dec 2018;   KR2024011880-A    KR701358    07 Dec 2018;   RU2023133687-A    RU133687    07 Dec 2018;   US11903959-B2    US465344    02 Sep 2021;   SA522432673-A    SA5432673    27 May 2020;   AU2021206866-B2    AU206866    22 Jul 2021;   AU2021206866-B2    AU206866    22 Jul 2021;   BR122022008466-B1    BR12008466    07 Dec 2018;   US2024189335-A1    US390347    20 Dec 2023	AU2018378832-A1 PCT application Application WOUS064503;   AU2018378832-A1 Based on Patent WO2019113462;   CA3082191-A1 PCT application Application WOUS064503;   CA3082191-A1 Based on Patent WO2019113462;   KR2020071119-A PCT application Application WOUS064503;   KR2020071119-A Based on Patent WO2019113462;   CN111372592-A PCT application Application WOUS064503;   CN111372592-A Based on Patent WO2019113462;   IN202017019418-A PCT application Application WOUS064503;   IN202017019418-A Based on Patent WO2019113462;   US2020276219-A1 PCT application Application WOUS064503;   US2020276219-A1 Provisional Application US626998P;   US2020276219-A1 Provisional Application US595907P;   US2020276219-A1 Provisional Application US760434P;   GB2581936-A PCT application Application WOUS064503;   GB2581936-A Based on Patent WO2019113462;   EP3706762-A1 PCT application Application WOUS064503;   EP3706762-A1 Based on Patent WO2019113462;   SG11202004403-A1 PCT application Application WOUS064503;   SG11202004403-A1 Based on Patent WO2019113462;   BR112020010581-A2 PCT application Application WOUS064503;   BR112020010581-A2 Based on Patent WO2019113462;   JP6804790-B1 PCT application Application WOUS064503;   JP6804790-B1 Based on Patent WO2019113462;   GB2581936-B PCT application Application WOUS064503;   GB2581936-B Based on Patent WO2019113462;   JP2021505530-W PCT application Application WOUS064503;   JP2021505530-W Based on Patent WO2019113462;   JP2021042235-A Div ex Application JP524817;   PH12020550607-A1 PCT application Application WOUS064503;   PH12020550607-A1 Based on Patent WO2019113462;   KR2248165-B1 PCT application Application WOUS064503;   KR2248165-B1 Based on Patent WO2019113462;   KR2021050594-A PCT application Application WOUS064503;   KR2021050594-A Div ex Application KR714737;   KR2021050594-A Based on Patent WO2019113462;   AU2018378832-B2 PCT application Application WOUS064503;   AU2018378832-B2 Based on Patent WO2019113462;   AU2018378832-B9 PCT application Application WOUS064503;   AU2018378832-B9 Based on Patent WO2019113462;   GB2590198-A Div ex Application GB008628;   AU2021206866-A1 Div ex Application AU378832;   CA3082191-C PCT application Application WOUS064503;   CA3082191-C Based on Patent WO2019113462;   JP2021165280-A Div ex Application JP195927;   US11147826-B2 PCT application Application WOUS064503;   US11147826-B2 Provisional Application US595907P;   US11147826-B2 Provisional Application US760434P;   US11147826-B2 Provisional Application US626998P;   US11147826-B2 Based on Patent WO2019113462;   US11147826-B2 Previous Publ. Patent US2020276219;   US2022016153-A1 Provisional Application US760434P;   US2022016153-A1 Provisional Application US626998P;   US2022016153-A1 Provisional Application US595907P;   US2022016153-A1 Cont of Application US755779;   US2022016153-A1 Cont of Application WOUS064503;   GB2590198-B Div ex Application GB008628;   US11331331-B2 PCT application Application WOUS064503;   US11331331-B2 Provisional Application US595907P;   US11331331-B2 Provisional Application US760434P;   US11331331-B2 Provisional Application US626998P;   US11331331-B2 Based on Patent WO2019113462;   US11331331-B2 Previous Publ. Patent US2020276219;   RU2020116571-A PCT application Application WOUS064503;   RU2020116571-A Based on Patent WO2019113462;   JP7179372-B2 Div ex Application JP524817;   JP7179372-B2 Previous Publ. Patent JP2021042235;   HK40037053-A0 PCT application Application WOUS064503;   HK40037053-A0 Based on Patent WO2019113462;   HK40037053-A0 Previous Publ. Patent GB2581936;   HK40038030-A0 PCT application Application WOUS064503;   HK40038030-A0 Based on Patent WO2019113462;   HK40038030-A0 Previous Publ. Patent EP3706762;   IL274155-B Based on Patent WO2019113462;   IL274155-A Based on Patent WO2019113462;   JP2023082213-A Div ex Application JP106296;   IL284100-A Div ex Application IL274155;   IL284100-A Based on Patent WO2019113462;   IL284100-A Div ex Patent IL274155;   JP7305205-B2 Div ex Application JP195927;   JP7305205-B2 Previous Publ. Patent JP2021165280;   ID202101279-A1 PCT application Application WOUS064503;   ID202101279-A1 Based on Patent WO2019113462;   MX404855-B PCT application Application WOUS064503;   MX404855-B Based on Patent WO2019113462;   KR2626210-B1 PCT application Application WOUS064503;   KR2626210-B1 Div ex Application KR714737;   KR2626210-B1 Based on Patent WO2019113462;   KR2024011880-A PCT application Application WOUS064503;   KR2024011880-A Div ex Application KR712910;   KR2024011880-A Based on Patent WO2019113462;   RU2023133687-A Div ex Application RU116571;   US11903959-B2 Cont of Application WOUS064503;   US11903959-B2 Cont of Application US755779;   US11903959-B2 Provisional Application US595907P;   US11903959-B2 Provisional Application US626998P;   US11903959-B2 Provisional Application US760434P;   US11903959-B2 Previous Publ. Patent US2022016153;   US11903959-B2 Cont of Patent US11331331;   AU2021206866-B2 Div ex Application AU378832;   BR122022008466-B1 Div ex Application BR11010581;   US2024189335-A1 Cont of Application WOUS064503;   US2024189335-A1 Cont of Application US755779;   US2024189335-A1 Cont of Application US465344;   US2024189335-A1 Provisional Application US595907P;   US2024189335-A1 Provisional Application US626998P;   US2024189335-A1 Provisional Application US760434P;   US2024189335-A1 Cont of Patent US11331331;   US2024189335-A1 Cont of Patent US11903959	US595907P    07 Dec 2017;  US626998P    06 Feb 2018;  US760434P    13 Nov 2018;  AU378832    07 Dec 2018;  EP886104    07 Dec 2018;  GB008628    07 Dec 2018;  WOUS064503    07 Dec 2018;  US16755779    13 Apr 2020;  CA3082191    07 May 2020;  CN80073278    12 May 2020;  RU116571    21 May 2020;  KR714737    22 May 2020;  BR11010581    27 May 2020;  GB008628    08 Jun 2020;  KR712910    28 Apr 2021;  AU206866    22 Jul 2021;  US465344    02 Sep 2021;  US390347    20 Dec 2023;  KR701358    12 Jan 2024	WO2019113462-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA                EP3706762-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                      EP3706762-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR                                                  		WO2019113462-A1 -- US20030008841-A1   ;  US20090105186-A1   ;  US20140235566-A1   ;  WO2016106050-A1   UNIV EMORY (UEMR)   PAINTER G R,  GUTHRIE D B,  BLUEMLING G R,  NATCHUS M G;  WO2017165489-A1   UNIV EMORY (UEMR)   SCHINAZI R F,  AMBLARD F,  COX B D,  BASSIT L,  ZHOU L,  GAVEGNANO C;  CN111372592-A -- CN101253190-A   DELBRUECK CENT MOLEKULARE MEDIZIN MAX (DELB)   MATTHES E,  WILL H,  SIRMA H,  FUNK A,  VON JANTA-LIPINSKI M;  CN107427529-A   UNIV EMORY (UEMR)   PAINTER G R,  GUTHRIE D B,  BLUEMLING G R,  NATCHUS M G;  WO2017165489-A1   UNIV EMORY (UEMR)   SCHINAZI R F,  AMBLARD F,  COX B D,  BASSIT L,  ZHOU L,  GAVEGNANO C;  GB2581936-B -- US20030008841-A1   ;  US20090105186-A1   ;  US20140235566-A1   ;  WO2016106050-A1   UNIV EMORY (UEMR)   PAINTER G R,  GUTHRIE D B,  BLUEMLING G R,  NATCHUS M G;  WO2017165489-A1   UNIV EMORY (UEMR)   SCHINAZI R F,  AMBLARD F,  COX B D,  BASSIT L,  ZHOU L,  GAVEGNANO C;  US11147826-B2 -- WO2016106050-A1   UNIV EMORY (UEMR)   PAINTER G R,  GUTHRIE D B,  BLUEMLING G R,  NATCHUS M G;  CA2743451-A1   PHARMASSET LTD (GILE)   STUYVER L,  WATANABE K A;  EP2615101-B1   HENAN ACAD SCI HI TECH RES CENT (HENA-Non-standard);  UNIV ZHENGZHOU (UYZZ);  ZHENGZHOU GRANLEN PHARM TECHNOLOGY CO (ZHEN-Non-standard)   AN H,  CHANG J,  GUO X,  YU X;  RU2264409-C2   VEKTOR VIROLOGY BIOTECHN RES CENTRE (VEKT-Soviet Institute);  CHUGAI PHARM CO LTD (CHUS)   POKROVSKII A G,  ILICHEVA T N,  BELANOV E F,  VOLKOV G N,  KUKHANOVA M K,  ALEKSANDROVA L A;  RU2322989-C2   HOFFMANN LA ROCHE & CO AG F (HOFF)   DEVOS R R,  HOBBS C J,  JIANG W,  MARTIN J A,  MERRETT J H,  NAJERA I,  SHIMMA N,  TSUKUDA T;  US5349947-A   BAINES W D (BAIN-Individual);  NEWHOUSE M T (NEWH-Individual)   NEWHOUSE M T,  BAINES W D;  US5691319-A   SANKYO CO LTD (DAUC)   KANEKO M,  HOTODA H,  SHIBATA T,  KOBAYASHI T,  MITSUHASHI Y,  MATSUDA A,  SASAKI T;  US20030008841-A1   ;  US20030087873-A1   ;  US20040171860-A1   ;  US20070031824-A1   ;  US20070196824-A1   ;  US20090105186-A1   ;  US20090220950-A1   ;  US20110269707-A1   ;  US20140057863-A1   ;  US20140200277-A1   ;  US20140235566-A1   ;  US20140273023-A1   ;  US20150011497-A1   ;  US20150105341-A1   ;  US20150366887-A1   ;  US20150366888-A1   ;  US20170143749-A1   ;  US20170143751-A1   ;  US20180044369-A1   ;  US20180079774-A1   ;  US20190022116-A1   ;  US20190054108-A1   ;  US20190083520-A1   ;  US6369086-B1   GLAXO GROUP LTD (GLAX)   DAVIS S T,  DICKERSON S H,  FRYE S V,  HARRIS P A,  HUNTER R N,  KUYPER L F,  LACKEY K E,  LUZZIO M J,  VEAL J M,  WALKER D H;  US6369087-B1   APPLIED ANALYTICAL IND INC (ANAL-Non-standard)   WHITTLE R R,  SANCILIO F D,  STOWELL G W,  JENKINS D J,  WHITTALL L,  MEYER G A;  US6372733-B1   MERCK & CO INC (MERI)   CALDWELL C G,  HAGMANN W K,  MACCOSS M,  SHAH S K,  SHANKARAN K,  FURMAN K L;  US6372778-B1   VERTEX PHARM INC (VERT)   TUNG R D,  MURCKO M A,  BHISETTI G R;  US7718790-B2   PHARMASSET LTD (GILE)   STUYVER L,  WATANABE K A;  US7919247-B2   PHARMASSET LTD (GILE)   STUYVER L,  WATANABE K A;  US8686045-B2   UNIV NORTH CAROLINA (UNCR);  UNIV CALIFORNIA (REGC);  US DEPT VETERANS AFFAIRS (USGO)   LONGO F M,  MASSA S M;  US9073960-B2   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  WANG G,  SMITH D B,  DEVAL J,  PRHAVC M;  US9211300-B2   MAYES B A (MAYE-Individual);  MOUSSA A M (MOUS-Individual);  STEWART A J (STEW-Individual);  GOSSELIN G (GOSS-Individual)   MAYES B A,  MOUSSA A M,  STEWART A J,  GOSSELIN G;  US9422321-B2   HENAN ACAD SCI HI TECH RES CENT (HENA-Non-standard);  UNIV ZHENGZHOU (UYZZ);  ZHENGZHOU GRANLEN PHARM TECHNOLOGY CO (ZHEN-Non-standard)   AN H,  CHANG J,  GUO X,  YU X;  US9603863-B2   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  DYATKINA N (DYAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  DYATKINA N,  SMITH D B,  SYMONS J A;  US9603864-B2   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  SMITH D B,  SYMONS J A;  US9809616-B2   UNIV EMORY (UEMR);  RFS PHARMA LLC (RFSP-Non-standard)   AMBLARD F,  COATS S J,  SCHINAZI R F;  US9862743-B2   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  US9877990-B2   KRYSTAL BIOTECH LLC (KRYS-Non-standard)   AGARWAL P,  KRISHNAN S;  US10052342-B2   ALIOS BIOPHARMA INC (JOHJ)   BLATT L M,  BEIGELMAN L,  DYATKINA N,  SYMONS J A,  SMITH D B;  US10100076-B2   PHARMASSET LTD (GILE)   STUYVER L,  WATANABE K A;  US10307439-B2   ALIOS BIOPHARMA INC (JOHJ)   BLATT L M,  BEIGELMAN L,  SYMONS J A,  SMITH D B;  US10370401-B2   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  US10464965-B2   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  WANG G,  SMITH D B,  DEVAL J,  PRHAVC M;  WO1990015065-A   ;  WO1992009705-A1   ;  WO1993010820-A1   ;  WO1995007919-A1   ;  WO1995007920-A1   ;  WO1996026933-A1   ;  WO1998017647-A1   ;  WO2004064845-A1   GILEAD SCI INC (GILE)   DAHL T C,  MENNING M M,  OLIYAI R;  WO2004064846-A1   GILEAD SCI INC (GILE)   DAHL T C,  MENNING M M,  OLIYAI R;  WO2005028478-A1   GILEAD SCI INC (GILE)   JIN H,  KIM C U,  NELSON P H;  WO2005042772-A1   GILEAD SCI INC (GILE)   MCDERMOTT M;  WO2005063751-A1   GILEAD SCI INC (GILE)   FARDIS M,  KIM C U;  WO2005064008-A1   GILEAD SCI INC (GILE)   ARIMILLI M N,  BECKER M M,  BIRKUS G,  BRYANT C,  CHEN J M,  CHEN X,  CIHLAR T,  DASTGAH A,  EISENBERG E J,  FARDIS M,  HATADA M,  HE G,  JIN H,  KIM C U,  LEE W A,  LEE C P,  LIN K,  LIU H,  MACKMAN R L,  MCDERMOTT M J,  MITCHELL M L,  NELSON P H,  PYUN H,  ROWE T D,  SPARACINO M,  SWAMINATHAN S,  TARIO J D,  WANG J,  WILLIAMS M A,  XU L,  YANG Z,  YU R H,  ZHANG J,  ZHANG L;  WO2005066189-A1   GILEAD SCI INC (GILE)   CHENG X,  COOK G P,  DESAI M C,  DOERFFLER E,  HE G,  KIM C U,  LEE W A,  ROHLOFF J C,  WANG J,  YANG Z;  WO2005072748-A1   GILEAD SCI INC (GILE)   CIHLAR T,  DOUGLAS J L,  GIBBS C S;  WO2006033703-A1   GILEAD SCI INC (GILE)   KIM C U,  NEYTS J,  OARE D A,  PUERSTINGER G;  WO2006091905-A1   GILEAD SCI INC (GILE)   JACOBSON K A,  MACKMAN R L,  JOSHI B V;  WO2007011658-A1   GILEAD SCI INC (GILE)   CASAREZ A,  CHAUDHARY K,  KIM C U,  MCMURTRIE D,  SHENG X C;  WO2007079260-A1   GILEAD SCI INC (GILE);  JAPAN TOBACCO INC (NISB)   KEARNEY B P,  KAKEE A,  KAWAGUCHI I;  WO2008005555-A1   GILEAD SCI INC (GILE)   CHONG L S,  DESAI M C,  GALLAGHER B,  GRAUPE M,  HALCOMB R L,  YANG H,  ZHANG J R;  WO2008013834-A1   GILEAD SCI INC (GILE)   DESAI M C,  LEE C P,  LIU H,  SWAMINATHAN S,  XU L;  WO2008077649-A1   GILEAD SCI INC (GILE)   WATKINS W J,  CHONG L S,  ZHANG J R;  WO2008077650-A1   GILEAD SCI INC (GILE)   BONDY S S,  WATKINS W J,  CHONG L S,  HERDEWIJN P A M,  DE JONGHE S C A;  WO2008077651-A1   GILEAD SCI INC (GILE)   BONDY S S,  CHOU C,  WATKINS W J,  CHONG L S,  ZHANG J R,  MISHRA R;  WO2008103949-A1   DESAI M C (DESA-Individual);  HONG A Y (HONG-Individual);  HUI H C (HUIH-Individual);  LIU H (LIUH-Individual);  VIVIAN R W (VIVI-Individual);  XU L (XULL-Individual)   DESAI M C,  HONG A Y,  HUI H C,  LIU H,  VIVIAN R W,  XU L;  WO2009005687-A1   GILEAD SCI INC (GILE)   GRAUPE M,  HALCOMB R L;  WO2009005693-A1   GILEAD SCI INC (GILE)   HE G,  KIM C U,  MITCHELL M L,  XU L;  WO2009006199-A1   GILEAD SCI INC (GILE)   KEARNEY B P,  MATHIAS A A,  RAMANATHAN S;  WO2009006203-A1   GILEAD SCI INC (GILE)   KEARNEY B P,  MATHIAS A A;  WO2009009001-A1   GILEAD SCI INC (GILE);  LEUVEN RES&DEV (UYLN);  PUERSTINGER G (PUER-Individual)   DOWDY E D,  KENT K M,  TOM N J,  ZIA V;  WO2009088719-A1   GILEAD SCI INC (GILE)   DESAI M C,  HUI H C,  LIU H,  XU L;  WO2009132123-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  PARRISH J,  XU J;  WO2009132135-A1   GILEAD SCI INC (GILE)   BUTLER T,  CHO A,  KIM C U,  SAUNDERS O L,  ZHANG L;  WO2009143011-A1   NOVARTIS AG (NOVS)   BUECHE B,  KUO M,  LALONDE G,  SAHNER D;  WO2010002998-A1   GILEAD SCI INC (GILE)   CANALES E,  CHONG L S,  CLARKE M O H,  LAZERWITH S E,  LEW W,  LIU Q,  MITCHELL M L,  WATKINS W J,  ZHANG J R;  WO2010005986-A1   GILEAD SCI INC (GILE)   GRAETZ B R,  POLNIASZEK R P;  WO2010011959-A1   GILEAD SCI INC (GILE)   AKTOUDIANAKIS E,  CELEBI A A,  DU Z,  JABRI S Y,  JIN H,  KIM C U,  LI J,  METOBO S E,  MISH M R,  PHILLIPS B W,  SAUGIER J H,  YANG Z,  ZONTE C S;  WO2010075127-A1   GILEAD SCI INC (GILE)   LINK J O;  WO2010077613-A1   GILEAD SCI INC (GILE)   DESAI M C,  HALCOMB R L,  HRVATIN P,  HUI H C,  MC FADDEN R,  ROETHLE P A,  YANG H;  WO2010080389-A1   GILEAD SCI INC (GILE)   LINK J O,  VIVIAN R W;  WO2010093608-A1   GILEAD SCI INC (GILE)   BUTLER T,  CHO A,  KIM C U,  XU J;  WO2010132601-A1   GILEAD SCI INC (GILE);  KIM C U (KIMC-Individual)   BACON E M,  CANALES E,  CHO A,  CHOU C,  CLARKE M O H,  COTTELL J J,  DESAI M C,  GRAUPE M,  GUO H,  HALCOMB R L,  JIN H,  KATO D,  KELLAR T,  KIRSCHBERG T A,  KRYGOWSKI E S,  LAZERWITH S E,  LINK J O,  LIU H,  LIU Q,  MACKMAN R,  MCFADDEN R,  METOBO S E,  MISH M R,  MITCHELL M L,  PARRISH J P,  PHILLIPS B W,  PYUN H,  SAUGIER J H,  SCHROEDER S D,  SHENG X,  SQUIRES N,  SUN J,  TAYLOR J,  TRENKLE J D,  TSE W C,  VENKATARAMANI C,  VIVIAN R W,  WATKINS W J,  XU L,  YANG Z;  WO2010135569-A1   PHARMASSET INC (GILE)   ROSS B S,  SOFIA M J,  PAMULAPATI G R,  RACHAKONDA S,  ZHANG H,  CHUN B,  WANG P;  WO2010151472-A1   GILEAD SCI INC (GILE)   DELANEY W E,  MO H,  ZHONG W;  WO2010151487-A1   GILEAD SCI INC (GILE)   DELANEY W E,  MO H,  ZHONG W;  WO2010151488-A1   GILEAD SCI INC (GILE)   DELANEY W E,  MO H,  ZHONG W;  WO2011005842-A1   GILEAD SCI INC (GILE)   MACKMAN R L,  SPERANDIO D,  YANG H;  WO2011011303-A1   GILEAD SCI INC (GILE)   CANALES E,  CHONG L S,  CLARKE M O H,  DOERFFLER E,  LAZERWITH S E,  LEW W,  LIU Q,  MERTZMAN M,  MORGANELLI P A,  WATKINS W J,  YE H;  WO2011031669-A1   GILEAD SCI INC (GILE)   CHO A,  CHONG L S,  CLARKE M O H,  DOERFFLER E,  KIM C U,  LIU Q,  WATKINS W J,  ZHANG J R;  WO2011031965-A1   GILEAD SCI INC (GILE)   HALCOMB R L,  ROETHLE P A;  WO2011035231-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  METOBO S E,  RAY A S,  XU J;  WO2011049825-A1   GILEAD SCI INC (GILE)   HALCOMB R L,  ROETHLE P A;  WO2011079016-A1   GILEAD SCI INC (GILE)   HALCOMB R L,  SWAMINATHAN S,  TUMAS D B;  WO2011088303-A1   GILEAD SCI INC (GILE)   CANALES E,  CHONG L S,  CLARKE M O H,  DOERFFLER E,  LAZERWITH S E,  LEW W,  MERTZMAN M,  MORGANELLI P A,  WATKINS W J;  WO2011088345-A1   GILEAD SCI INC (GILE)   CANALES E,  CLARKE M O H,  LAZERWITH S E,  LEW W,  MORGANELLI P A,  WATKINS W J;  WO2011106445-A1   GILEAD SCI INC (GILE)   JIN H,  KIM C U,  PHILLIPS B W;  WO2011143105-A1   GILEAD SCI INC (GILE)   BAKER W R,  CAI S,  KAPLAN J A,  KIM M,  LOYER-DREW J A,  PERREAULT S,  PHILLIPS G,  PURVIS L J,  STASIAK M,  STEVENS K L,  VAN VELDHUIZEN J;  WO2011143106-A1   GILEAD SCI INC (GILE)   BAKER W R,  CAI S,  KAPLAN J A,  KIM M,  PHILLIPS G,  PURVIS L J,  STASIAK M,  STEVENS K L,  VAN VELDHUIZEN J;  WO2011146817-A1   GILEAD SCI INC (GILE)   BJORNSON K,  BONDY S S,  CHOI Y,  CHOU C,  MISHRA R,  TRENKLE J D,  TSE W C,  VIVIAN R W;  WO2011150288-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  RAY A S,  ZHANG L;  WO2011156416-A1   GILEAD SCI INC (GILE);  KARIM Q A (KARI-Individual);  KARIM S S A (KARI-Individual);  KHARSANY A (KHAR-Individual)   CIHLAR T,  KARIM Q A,  KARIM S S A,  KHARSANY A,  ROONEY J F;  WO2011156757-A1   GILEAD SCI INC (GILE);  DELANEY W E (DELA-Individual);  LEE W A (LEEW-Individual);  OLDACH D W (OLDA-Individual);  ROUSSEAU F (ROUS-Individual)   DELANEY W E,  LEE W A,  OLDACH D W,  ROUSSEAU F;  WO2011163518-A1   GILEAD SCI INC (GILE)   BABAOGLU K,  BOOJAMRA C G,  EISENBERG E J,  HUI H C,  MACKMAN R L,  PARRISH J P,  SANGI M,  SAUNDERS O L,  SIEGEL D,  SPERANDIO D,  YANG H;  WO2012003497-A1   GILEAD SCI INC (GILE);  BABAOGLU K (BABA-Individual);  BJORNSON K (BJOR-Individual);  GUO H (GUOH-Individual);  HALCOMB R L (HALC-Individual);  LINK J O (LINK-Individual);  MCFADDEN R (MCFA-Individual);  MITCHELL M L (MITC-Individual);  ROETHLE P (ROET-Individual);  TRENKLE J D (TREN-Individual);  VIVIAN R W (VIVI-Individual);  XU L (XULL-Individual)   BABAOGLU K,  BJORNSON K,  GUO H,  HALCOMB R L,  LINK J O,  MCFADDEN R,  MITCHELL M L,  ROETHLE P,  TRENKLE J D,  VIVIAN R W,  XU L;  WO2012003498-A1   GILEAD SCI INC (GILE);  BABAOGLU K (BABA-Individual);  BJORNSON K (BJOR-Individual);  GUO H (GUOH-Individual);  HALCOMB R L (HALC-Individual);  LINK J O (LINK-Individual);  LIU H (LIUH-Individual);  MITCHELL M L (MITC-Individual);  SUN J (SUNJ-Individual);  VIVIAN R W (VIVI-Individual);  XU L (XULL-Individual)   BABAOGLU K,  BJORNSON K,  GUO H,  HALCOMB R L,  LINK J O,  LIU H,  MITCHELL M L,  SUN J,  VIVIAN R W,  XU L;  WO2012012465-A1   GILEAD SCI INC (GILE);  CLARKE M O H (CLAR-Individual)   CHO A,  WOLCKENHAUER S A;  WO2012012776-A1   GILEAD SCI INC (GILE)   MACKMAN R L,  PARRISH J P,  RAY A S,  THEODORE D A;  WO2012037038-A1   GILEAD SCI INC (GILE)   CLARKE M O N H,  KIM C U,  LEW W;  WO2012039787-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  METOBO S E,  RAY A S,  XU J;  WO2012039791-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  METOBO S E,  RAY A S,  XU J;  WO2012068535-A1   GILEAD SCI INC (GILE);  JANSSEN R & D IRELAND (JOHJ)   MENNING M,  OLIYAI R,  WISER L;  WO2012078915-A1   GILEAD SCI INC (GILE);  SELCIA LTD (SELC-Non-standard)   APPLEBY T,  FLIRI H G,  KEATS A J,  LAZARIDES L,  MACKMAN R L,  PETTIT S N,  POULLENNEC K G,  SANVOISIN J,  STEADMAN V A,  WATT G M;  WO2012087596-A1   GILEAD SCI INC (GILE)   DELANEY W E,  LINK J O,  MO H,  OLDACH D W,  RAY A S,  WATKINS W J,  YANG C Y,  ZHONG W;  WO2012088153-A1   GILEAD SCI INC (GILE)   DESAI M C,  LIU H,  XU L,  YE H;  WO2012088156-A1   GILEAD SCI INC (GILE)   DESAI M C,  HUI H C,  LIU H,  SUN J,  XU L;  WO2012088178-A1   GILEAD SCI INC (GILE)   CANNIZZARO C,  DESAI M C,  HUI H C,  LEE M S,  LIU H,  SUN J,  XU L;  WO2012138669-A1   GILEAD SCI INC (GILE)   LI Z J,  LI Z,  LUO L,  OFFERDAHL T,  KIM S,  YANG B;  WO2012138670-A1   GILEAD SCI INC (GILE)   LI W,  DE CROOS P,  FANDRICK K R,  GAO J J,  HADDAD N,  LU Z,  QU B,  RODRIGUEZ S,  SENANAYAKE C H,  ZHANG Y,  TANG W;  WO2012145728-A1   GILEAD SCI INC (GILE);  MITCHELL M L (MITC-Individual);  ROETHLE P A (ROET-Individual);  XU L (XULL-Individual);  YANG H (YANG-Individual);  MCFADDEN R (MCFA-Individual);  BABAOGLU K (BABA-Individual)   MITCHELL M L,  ROETHLE P A,  XU L,  YANG H,  MCFADDEN R,  BABAOGLU K;  WO2012151165-A1   GILEAD SCI INC (GILE)   KOZIARA J M,  LUNONG A,  SUJINO K,  YU R;  WO2013006721-A1   GILEAD SCI INC (GILE)   DELANEY W E,  CHENG G,  MO H,  XU S,  PENG B;  WO2013006722-A1   GILEAD SCI INC (GILE)   DELANEY W E,  CHENG G,  YU M,  MO HONGMEI,  XU S,  CORSA A;  WO2013006738-A1   GILEAD SCI INC (GILE)   BONDY S S,  CANNIZZARO C E,  CHOU C,  HALCOMB R L,  HU Y E,  LINK J O,  LIU Q,  SCHROEDER S D,  TSE W C,  ZHANG J R;  WO2013010112-A1   GILEAD SCI INC (GILE);  WATKINS W J (WATK-Individual)   WATKINS W J;  WO2013025788-A1   GILEAD SCI INC (GILE)   LIU D,  SHI B,  WANG F,  YU R H C;  WO2013066748-A1   GILEAD PHARMASSET LLC (GILE)   BERREY M M,  HINDES R G,  SYMONDS W T,  RAY A S,  MO H,  HEBNER C M;  WO2013075029-A1   GILEAD SCI INC (GILE)   BACON E M,  COTTELL J J,  KATANA A A,  KATO D,  KRYGOWSKI E S,  LINK J O,  TAYLOR J,  TRAN C V,  TREJO MARTIN T A,  YANG Z,  ZIPFEL S;  WO2013082003-A1   GILEAD PHARMASSET LLC (GILE)   CLEARY D G,  REYNOLDS C J,  BERREY M M,  HINDES R G,  SYMONDS W T,  RAY A S,  MO H,  HEBNER C M,  OLIYAI R,  ZIA V,  STEFANIDIS D,  PAKDAMAN R,  CASTEEL M J;  WO2013090840-A1   GILEAD SCI INC (GILE)   JIN H,  KIM C U,  LI J;  WO2013090929-A1   GILEAD SCI INC (GILE)   CAI Z R,  DU Z,  JI M,  JIN H,  KIM C U,  LI J,  PHILLIPS B W,  PYUN H,  SAUGIER J H;  WO2013096512-A1   GILEAD SCI INC (GILE)   LOPATIN U A,  TUMAS D B;  WO2013096681-A1   GILEAD SCI INC (GILE)   BOOJAMRA C G,  HUI H C,  JANSA P,  MACKMAN R L,  PARRISH J P,  SANGI M,  SIEGEL D,  SPERANDIO D,  YANG H;  WO2013103724-A1   GILEAD SCI INC (GILE)   BABAOGLU K,  BJORNSON K L,  HRVATIN P,  LANSDON E,  LINK J O,  LIU H,  MCFADDEN R,  MITCHELL M L,  QI Y,  ROETHLE P A,  XU L;  WO2013103738-A1   GILEAD SCI INC (GILE);  BABAOGLU K (BABA-Individual);  BRIZGYS G (BRIZ-Individual);  GUO H (GUOH-Individual);  HRVATIN P (HRVA-Individual);  LANSDON E (LANS-Individual);  LINK J O (LINK-Individual);  LIU H (LIUH-Individual);  MCFADDEN R (MCFA-Individual);  MITCHELL M L (MITC-Individual);  QI Y (QIYY-Individual);  ROETHLE P A (ROET-Individual);  VIVIAN R W (VIVI-Individual);  XU L (XULL-Individual);  YANG H (YANG-Individual)   BABAOGLU K,  BRIZGYS G,  GUO H,  HRVATIN P,  LANSDON E,  LINK J O,  LIU H,  MCFADDEN R,  MITCHELL M L,  QI Y,  ROETHLE P A,  VIVIAN R W,  XU L,  YANG H;  WO2013106732-A1   GILEAD SCI INC (GILE);  CULLEN A J (CULL-Individual);  YU R H C (YURH-Individual)   CULLEN A J,  YU R H C;  WO2013115916-A1   GILEAD SCI INC (GILE)   RAMANATHAN S;  WO2013116720-A1   GILEAD SCI INC (GILE)   RAMANATHAN S;  WO2013116730-A1   GILEAD SCI INC (GILE)   RAMANATHAN S;  WO2013138236-A1   GILEAD SCI INC (GILE)   CLARKE M O N H;  WO2013142525-A1   ALIOS BIOPHARMA INC (JOHJ)   WANG G,  SMITH D B,  BEIGELMAN L,  DEVAL J,  PRHAVC M;  WO2013158776-A1   SIEGEL D (SIEG-Individual);  SPERANDIO D (SPER-Individual);  YANG H (YANG-Individual);  SANGI M (SANG-Individual);  PARRISH J P (PARR-Individual);  HUI H C (HUIH-Individual)   SIEGEL D,  SPERANDIO D,  YANG H,  SANGI M,  PARRISH J P,  HUI H C;  WO2013159064-A1   GILEAD SCI INC (GILE);  BABAOGLU K (BABA-Individual);  BRIZGYS G (BRIZ-Individual);  CHA J (CHAJ-Individual);  CHEN X (CHEN-Individual);  GUO H (GUOH-Individual);  HALCOMB R L (HALC-Individual);  HAN X (HANX-Individual);  HUANG R (HUAN-Individual);  LIU H (LIUH-Individual);  MCFADDEN R (MCFA-Individual);  MITCHELL M L (MITC-Individual);  QI Y (QIYY-Individual);  ROETHLE P A (ROET-Individual);  XU L (XULL-Individual);  YANG H (YANG-Individual)   BABAOGLU K,  BRIZGYS G,  CHA J,  CHEN X,  GUO H,  HALCOMB R L,  HAN X,  HUANG R,  LIU H,  MCFADDEN R,  MITCHELL M L,  QI Y,  ROETHLE P A,  XU L,  YANG H;  WO2013173488-A1   LINK J O (LINK-Individual);  COTTELL J J (COTT-Individual);  TREJO MARTIN T A (MART-Individual)   LINK J O,  COTTELL J J,  TREJO MARTIN T A;  WO2013173492-A1   LINK J O (LINK-Individual);  COTTELL J J (COTT-Individual);  TREJO M T A (TREJ-Individual)   LINK J O,  COTTELL J J,  TREJO M T A;  WO2013185090-A1   GILEAD SCI INC (GILE);  SELCIA LTD (SELC-Non-standard)   ACIRO C,  STEADMAN V A,  PETTIT S N,  POULLENNEC K G,  LAZARIDES L,  DEAN D K,  DUNBAR N A,  HIGHTON A J,  KEATS A J,  SIEGEL D S,  KARKI K K,  SCHRIER A J,  JANSA P,  MACKMAN R;  WO2013185093-A1   GILEAD SCI INC (GILE);  SELCIA LTD (SELC-Non-standard)   STEADMAN V A,  POULLENNEC K G,  LAZARIDES L,  ACIRO C,  DEAN D K,  KEATS A J,  SIEGEL D S,  SCHRIER A J,  MACKMAN R,  JANSA P;  WO2013185103-A1   GILEAD SCI INC (GILE);  SELCIA LTD (SELC-Non-standard)   ACIRO C,  STEADMAN V A,  PETTIT S N,  POULLENNEC K G,  LAZARIDES L,  DEAN D K,  DUNBAR N A,  HIGHTON A J,  KEATS A J,  SIEGEL D S,  KARKI K K,  SCHRIER A J,  JANSA P,  MACKMAN R;  WO2014008285-A1   GILEAD SCI INC (GILE)   BJORNSON K,  CANALES E,  COTTELL J J,  KARKI K K,  KATANA A A,  KATO D,  KOBAYASHI T,  LINK J O,  MARTINEZ R,  PHILLIPS B W,  PYUN H,  SANGI M,  SCHRIER A J,  SIEGEL D,  TAYLOR J G,  TRAN C V,  TREJO MARTIN T A,  VIVIAN R W,  YANG Z,  ZABLOCKI J,  ZIPFEL S;  WO2014028343-A1   HASHASH A (HASH-Individual);  WOLCKENHAUER S (WOLC-Individual);  SHI B (SHIB-Individual)   HASHASH A,  WOLCKENHAUER S,  SHI B;  WO2014055618-A1   BROWN B H (BROW-Individual);  CARRA E A (CARR-Individual);  WANG X (WANG-Individual)   BROWN B H,  CARRA E A,  WANG X;  WO2014070771-A1   RFS PHARMA LLC (RFSP-Non-standard);  UNIV EMORY (UEMR)   AMBLARD F,  COATS S J,  SCHINAZI R F;  WO2014070939-A1   GILEAD SCI INC (GILE)   BORNSTEIN J D,  ADAMKEWICZ J I,  SMITH V,  LYMAN S K,  CHIEN J,  LI X,  SHAO L;  WO2014074620-A1   CHENG G (CHEN-Individual);  DELANEY W E (DELA-Individual);  PENG B (PENG-Individual);  YU M (YUMM-Individual)   CHENG G,  DELANEY W E,  PENG B,  YU M;  WO2014099941-A1   PARSY C C (PARS-Individual);  ALEXANDRE F (ALEX-Individual);  DOUSSON C B (DOUS-Individual);  DUKHAN D (DUKH-Individual);  PIERRA C (PIER-Individual);  SURLERAUX D (SURL-Individual);  MAYES B A (MAYE-Individual);  MOUSSA A M (MOUS-Individual);  STEWART A J (STEW-Individual)   PARSY C C,  ALEXANDRE F,  DOUSSON C B,  DUKHAN D,  PIERRA C,  SURLERAUX D,  MAYES B A,  MOUSSA A M,  STEWART A J;  WO2014100323-A1   GILEAD SCI INC (GILE)   JIN H,  LAZERWITH S E,  MARTIN T A T,  BACON E M,  COTTELL J J,  CAI Z R,  PYUN H,  MORGANELLI P A,  JI M,  TAYLOR J G,  CHEN X,  MISH M R,  DESAI M C;  WO2014100500-A1   LINK J O (LINK-Individual);  COTTELL J J (COTT-Individual);  TREJO M T A (TREJ-Individual);  BACON E M (BACO-Individual)   LINK J O,  COTTELL J J,  TREJO M T A,  BACON E M;  WO2014100505-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  WANG G,  SMITH D B;  WO2014110296-A1   GILEAD SCI INC (GILE)   BONDY S S,  CANNIZZARO C E,  CHOU C,  HU Y E,  LINK J O,  LIU Q,  SCHROEDER S D,  TSE W C,  ZHANG J R;  WO2014110297-A1   GILEAD SCI INC (GILE)   BRIZGYS G,  CHOU C,  HALCOMB R L,  HU Y E,  LIU Q,  SOMOZA J R,  TSE W C,  ZHANG J R;  WO2014110298-A1   GILEAD SCI INC (GILE)   BONDY S S,  CANNIZZARO C E,  CHOU C,  LINK J O,  LIU Q,  SCHROEDER S D,  TSE W C,  ZHANG J R;  WO2014124430-A1   UNIV EMORY (UEMR)   LIOTTA D C,  PAINTER G R,  BLUEMLING G R;  WO2014145095-A1   GILEAD SCI INC (GILE)   BJORNSON K,  KARKI K K,  LINK J O,  PYUN H,  SCHRIER A J,  STEVENS K L,  TAYLOR J G,  VIVIAN R W,  ZABLOCKI J,  ZIPFEL S;  WO2014169278-A1   ACHILLION PHARM INC (ACHI)   DESHPANDE M,  WILES J A,  HASHIMOTO A,  PHADKE A;  WO2014186637-A1   RIBOSCIENCE LLC (RIBO-Non-standard)   KLUMPP K G,  SMITH M;  WO2014209979-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JIN Z;  WO2015023893-A1   GILEAD SCI INC (GILE)   DVORY-SOBOL H,  HEBNER C,  MO H,  XU S;  WO2015038596-A1   UNIV EMORY (UEMR)   LIOTTA D C,  PAINTER G R,  BLUEMLING G R,  DE LA ROSA A;  WO2015054465-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  WO2015069939-A1   CLARKE M O H (CLAR-Individual);  DOERFFLER E (DOER-Individual);  MACKMAN R L (MACK-Individual);  SIEGEL D (SIEG-Individual)   CLARKE M O H,  DOERFFLER E,  MACKMAN R L,  SIEGEL D;  WO2015099989-A1   CASTEEL M J (CAST-Individual);  DASHNER K (DASH-Individual);  JUNG H (JUNG-Individual);  SEO M S (SEOM-Individual);  SHI B (SHIB-Individual);  WANG F (WANG-Individual);  ZIA V (ZIAV-Individual)   CASTEEL M J,  DASHNER K,  JUNG H,  SEO M S,  SHI B,  WANG F,  ZIA V;  WO2015100144-A1   GILEAD SCI INC (GILE)   BRINGLEY D,  CHAN J,  FUNG P,  KEATON K,  LAPINA O,  MORRISON H,  PCION D;  WO2015108780-A1   HURLEY P B (HURL-Individual);  LAPINA O V (LAPI-Individual);  SHI B (SHIB-Individual);  WANG F (WANG-Individual);  WANG Z X (WANG-Individual);  WOO J C (WOOJ-Individual)   HURLEY P B,  LAPINA O V,  SHI B,  WANG F,  WANG Z X,  WOO J C;  WO2015120057-A1   BEGLEY R R (BEGL-Individual);  CUSTODIO J M (CUST-Individual);  KEARNEY B P (KEAR-Individual)   BEGLEY R R,  CUSTODIO J M,  KEARNEY B P;  WO2015130964-A1   GILEAD SCI INC (GILE)   BONDY S S,  CHOU C,  LINK J O,  TSE W C;  WO2015130966-A1   GILEAD SCI INC (GILE)   BONDY S S,  CHOU C,  LINK J O,  TSE W C;  WO2015179448-A1   GILEAD SCI INC (GILE)   BABAOGLU K,  MCFADDEN R,  MITCHELL M L;  WO2015191726-A1   CAI S (CAIS-Individual);  DU Z (DUZZ-Individual);  KIM M (KIMM-Individual);  LOYER-DREW J A (LOYE-Individual);  NADUTHAMBI D (NADU-Individual);  PATEL L (PATE-Individual);  PHILLIPS B W (PHIL-Individual);  PHILLIPS G (PHIL-Individual);  STEVENS K L (STEV-Individual);  TREIBERG J A (TREI-Individual);  VAN VELDHUIZEN J (VVEL-Individual);  WATKINS W J (WATK-Individual);  YEUNG S C (YEUN-Individual)   CAI S,  DU Z,  KIM M,  LOYER-DREW J A,  NADUTHAMBI D,  PATEL L,  PHILLIPS B W,  PHILLIPS G,  STEVENS K L,  TREIBERG J A,  VAN VELDHUIZEN J,  WATKINS W J,  YEUNG S C;  WO2015191743-A1   EVARTS J (EVAR-Individual);  KAPLAN J (KAPL-Individual);  PATEL L (PATE-Individual);  PERREAULT S (PERR-Individual);  PHILLIPS B W (PHIL-Individual);  PHILLIPS G (PHIL-Individual);  TREIBERG J A (TREI-Individual);  YEUNG S C (YEUN-Individual)   EVARTS J,  KAPLAN J,  PATEL L,  PERREAULT S,  PHILLIPS B W,  PHILLIPS G,  TREIBERG J A,  YEUNG S C;  WO2015191745-A1   DU Z (DUZZ-Individual);  EVARTS J (EVAR-Individual);  KAPLAN J (KAPL-Individual);  KIM M (KIMM-Individual);  NADUTHAMBI D (NADU-Individual);  PATEL L (PATE-Individual);  PERREAULT S (PERR-Individual);  PHILLIPS B W (PHIL-Individual);  PHILLIPS G (PHIL-Individual);  STEVENS K L (STEV-Individual);  TREIBERG J A (TREI-Individual);  VAN VELDHUIZEN J (VVEL-Individual);  WATKINS W J (WATK-Individual);  YEUNG S C (YEUN-Individual)   DU Z,  EVARTS J,  KAPLAN J,  KIM M,  NADUTHAMBI D,  PATEL L,  PERREAULT S,  PHILLIPS B W,  PHILLIPS G,  STEVENS K L,  TREIBERG J A,  VAN VELDHUIZEN J,  WATKINS W J,  YEUNG S C;  WO2015191752-A1   CAI S (CAIS-Individual);  DU Z (DUZZ-Individual);  KAPLAN J (KAPL-Individual);  LOYER-DREW J A (LOYE-Individual);  NADUTHAMBI D (NADU-Individual);  PHILLIPS B W (PHIL-Individual);  PHILLIPS G (PHIL-Individual);  VAN VELDHUIZEN J (VVEL-Individual);  YEUNG S C (YEUN-Individual)   CAI S,  DU Z,  KAPLAN J,  LOYER-DREW J A,  NADUTHAMBI D,  PHILLIPS B W,  PHILLIPS G,  VAN VELDHUIZEN J,  WATKINS W J,  YEUNG S C;  WO2015196137-A1   CARRA E A (CARR-Individual);  CHEN I (CHEN-Individual);  KEATON K A (KEAT-Individual);  ZIA V (ZIAV-Individual)   CARRA E A,  CHEN I,  KEATON K A,  ZIA V;  WO2015200205-A1   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  DYATKINA N (DYAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  DYATKINA N,  SMITH D B,  SYMONS J A;  WO2015200219-A1   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  SMITH D B,  SYMONS J A;  WO2016007765-A1   GELEZIUNAS R (GELE-Individual);  HESSELGESSER J E (HESS-Individual)   GELEZIUNAS R,  HESSELGESSER J E;  WO2016018697-A1   CLARKE M O H (CLAR-Individual);  MACKMAN R L (MACK-Individual);  SIEGEL D (SIEG-Individual)   CLARKE M O H,  MACKMAN R L,  SIEGEL D;  WO2016028866-A1   GILEAD SCI INC (GILE)   CLARKE M O H,  MACKMAN R L,  SIEGEL D;  WO2016033243-A1   GILEAD SCI INC (GILE)   BRIZGYS G,  CANALES E,  HALCOMB R L,  HU Y E,  KATO D,  LINK J O,  LIU Q,  SAITO R D,  TSE W C,  ZHANG J R;  WO2016036759-A1   GILEAD SCI INC (GILE)   BABUSIS D M,  RAY A S,  WANG J;  WO2016096116-A1   GILEAD SCI INC (GILE)   GEGE C,  KINZEL O,  KREMOSER C;  WO2016105532-A1   GILEAD SCI INC (GILE);  ORGANIC CHEM & BIOCHEM ACAD INST (CESK)   JANSA P,  KVASNICA M,  MACKMAN R L;  WO2016105534-A1   GILEAD SCI INC (GILE)   JANSA P,  MACKMAN R L,  HU Y E,  LANSDON E;  WO2016105564-A1   GILEAD SCI INC (GILE);  ORGANIC CHEM & BIOCHEM ACAD INST (CESK)   JANSA P,  SIMON T,  LANSDON E,  HU Y E,  BASZCZYNSKI O,  DEJMEK M,  MACKMAN R L;  WO2016106237-A1   GILEAD SCI INC (GILE)   BACON E M,  CAI Z R,  COTTELL J J,  JI M,  JIN H,  LAZERWITH S E,  MORGANELLI P A,  PYUN H;  WO2016134054-A1   ABBVIE INC (ABBI)   CHEN H J,  DEGOEY D A,  KALTHOD V,  KRUEGER A C,  WAGNER R,  RANDOLPH J T;  WO2016141092-A1   GILEAD SCI INC (GILE)   AKTOUDIANAKIS E,  CHIN G,  MACKMAN R L,  METOBO S E,  MISH M R,  PYUN H,  ZABLOCKI J;  WO2016161382-A1   GILEAD SCI INC (GILE)   CAI Z R,  JIN H,  LAZERWITH S E,  PYUN H;  WO2016168349-A1   GILEAD SCI INC (GILE)   AGUAYO E,  APPLEBY T,  BIRKUS G,  CHENG G,  DORNAN D,  KOBAYASHI T,  MELLO C C,  SCHMITZ U,  WILLKOM M,  YU M;  WO2016186967-A1   GILEAD SCI INC (GILE)   BARTLETT M J,  CODELLI J A,  CORKEY B K,  COSMAN J L,  ELBEL K,  LOYER-DREW J A,  SPERANDIO D,  VAN VELDHUIZEN J,  YANG H,  YEUNG S C;  WO2016205141-A1   GILEAD SCI INC (GILE)   SHI B,  SU Z,  WANG F;  WO2017004012-A1   GILEAD SCI INC (GILE);  JANSSEN SCI IRELAND UC (JOHJ)   KOZIARA J,  SPERGER D;  WO2017004244-A1   GILEAD SCI INC (GILE)   KOZIARA J M,  MCCALLISTER S;  WO2017035230-A1   GILEAD SCI INC (GILE)   BONDY S S,  MCFADDEN R;  WO2017040895-A1   ABBVIE INC (ABBI)   CHEN H J,  DEGOEY D A,  KALTHOD V,  KRUEGER A C,  RANDOLPH J T,  WAGNER R;  WO2017048727-A1   GILEAD SCI INC (GILE)   GELEZIUNAS R,  HESSELGESSER J E,  KAUR J,  MURRY J P,  SLOAN D D;  WO2017049060-A1   GILEAD SCI INC (GILE)   CLARKE M O H,  FENG J Y,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  WO2017059120-A1   GILEAD SCI INC (GILE)   YU H,  CIHLAR T,  STEPAN G,  SLOAN D D,  MURRY J P,  HU Y E,  GRAUPE M;  WO2017083304-A1   GILEAD SCI INC (GILE)   HONG L,  COLLMAN B M;  WO2017106556-A1   GILEAD SCI INC (GILE)   DU Z,  DORNAN D,  GUERRERO J A,  KAPLAN J A,  KNOX J E,  NADUTHAMBI D,  PHILLIPS B W,  STINSON S Y,  VENKATARAMANI C,  WANG P,  WATKINS W J;  WO2017156380-A1   UNIV EMORY (UEMR)   PAINTER G R,  GUTHRIE D B,  BLUEMLING G R,  NATCHUS M R;  WO2017165489-A1   UNIV EMORY (UEMR)   SCHINAZI R F,  AMBLARD F,  COX B D,  BASSIT L,  ZHOU L,  GAVEGNANO C;  WO2017184668-A1   GILEAD SCI INC (GILE)   CLARKE M O H,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  WO2017205078-A1   GILEAD SCI INC (GILE)   GAGGAR A,  SUBRAMANIAN M G;  WO2017205115-A1   GILEAD SCI INC (GILE)   AKTOUDIANAKIS E,  CANALES E,  CHIN E,  CURRIE K S,  KATANA A A,  KATO D,  LINK J O,  METOBO S E,  SAITO R D,  YANG Z;  WO2017223268-A1   UNIV YALE (UYYA);  GILEAD SCI INC (GILE)   TURK B,  CALDERWOOD D,  SCHLESSINGER J,  SHI X,  BATES J,  BRECKENRIDGE D,  KUSAM S;  WO2019173602-A1   UNIV EMORY (UEMR)   PAINTER G R,  PERRYMAN D,  BLUEMLING G R;  WO1994003467-A2   ;  WO1994024144-A2   ;  WO2002100415-A2   ;  WO2003090691-A2   GILEAD SCI INC (GILE)   BIRKUS G,  CHEN J M,  CHEN X,  CIHLAR T,  EISENBERG E J,  HATADA M,  HE G,  KIM C U,  LEE W A,  MCDERMOTT M J,  SWAMINATHAN S;  WO2004005286-A2   LEUVEN RES&DEV (UYLN);  GILEAD SCI INC (GILE)   NEYTS J,  PUERSTINGER G,  DE CLERCQ E;  WO2004006843-A2   TRIANGLE PHARM INC (TRIA-Non-standard)   FURMAN P A;  WO2004031224-A2   GILEAD SCI INC (GILE)   DELANEY W E,  XIONG X;  WO2004035576-A2   GILEAD SCI INC (GILE)   CHEN J M,  CHEN X,  FARDIS M,  JIN H,  KIM C U,  SCHACHERER L N;  WO2004035577-A2   GILEAD SCI INC (GILE)   CHEN J M,  CHEN X,  FARDIS M,  JIN H,  KIM C U,  SCHACHERER L N;  WO2004050613-A2   TRIANGLE PHARM INC (TRIA-Non-standard)   SZNAIDMAN M,  PAINTER G R,  ALMOND M R,  CLEARY D G,  PESYAN A;  WO2004096286-A2   GILEAD SCI INC (GILE);  BOOJAMARA C G (BOOJ-Individual);  CANNIZZARO C E (CANN-Individual);  CHEN J M (CHEN-Individual);  CHEN X (CHEN-Individual);  CHO A (CHOA-Individual);  CHONG L S (CHON-Individual);  FARDIS M (FARD-Individual);  JIN H (JINH-Individual);  HIRSCHMANN R F (HIRS-Individual);  HUANG A X (HUAN-Individual);  KIM C U (KIMC-Individual);  KIRSCHBERG T A (KIRS-Individual);  LEE C P (LEEC-Individual);  LEE W A (LEEW-Individual);  MACKMAN R L (MACK-Individual);  MARKEVITCH D Y (MARK-Individual);  OARE D (OARE-Individual);  PRASAD V K (PRAS-Individual);  PYUN H (PYUN-Individual);  RAY A S (RAYA-Individual);  SHERLOCK R (SHER-Individual);  SWAMINATHAN S (SWAM-Individual);  WATKINS W (WATK-Individual);  ZHANG J R (ZHAN-Individual)   BOOJAMARA C G,  CANNIZZARO C E,  CHEN J M,  CHEN X,  CHO A,  CHONG L S,  FARDIS M,  JIN H,  HIRSCHMANN R F,  HUANG A X,  KIM C U,  KIRSCHBERG T A,  LEE C P,  LEE W A,  MACKMAN R L,  MARKEVITCH D Y,  OARE D,  PRASAD V K,  PYUN H,  RAY A S,  SHERLOCK R,  SWAMINATHAN S,  WATKINS W,  ZHANG J R;  WO2004096287-A2   WATKINS W (WATK-Individual);  ZHANG J R (ZHAN-Individual);  GILEAD SCI INC (GILE);  CANNIZZARO C E (CANN-Individual);  CHEN J M (CHEN-Individual);  CHEN X (CHEN-Individual);  CHO A (CHOA-Individual);  CHONG L S (CHON-Individual);  FARDIS M (FARD-Individual);  KIRSCHBERG T A (KIRS-Individual);  PYUN H (PYUN-Individual)   CANNIZZARO C E,  CHEN J M,  CHEN X,  CHO A,  CHONG L S,  FARDIS M,  KIRSCHBERG T A,  PYUN H,  WATKINS W,  ZHANG J R;  WO2004096818-A2   GILEAD SCI INC (GILE)   BIRKUS G,  CHEN J M,  CHEN X,  CIHLAR T,  EISENBERG E J,  HATADA M,  HE G,  KIM C U,  LEE W A,  MCDERMOTT M J,  SWAMINATHAN S;  WO2004100960-A2   NELSON P H (NELS-Individual);  OARE D (OARE-Individual);  PYUN H (PYUN-Individual);  RAY A S (RAYA-Individual);  SHERLOCK R (SHER-Individual);  SWAMINATHAN S (SWAM-Individual);  CANNIZZARO C E (CANN-Individual);  WATKINS W (WATK-Individual);  ZHANG J R (ZHAN-Individual);  CHEN J M (CHEN-Individual);  CHEN X (CHEN-Individual);  CHO A (CHOA-Individual);  CHONG L S (CHON-Individual);  FARDIS M (FARD-Individual);  GIBBS C (GIBB-Individual);  HIRSCHMANN R F (HIRS-Individual);  GILEAD SCI INC (GILE);  KIRSCHBERG T A (KIRS-Individual);  LEE C P (LEEC-Individual);  LIN K (LINK-Individual);  MACKMAN R L (MACK-Individual)   CANNIZZARO C E,  CHEN J M,  CHEN X,  CHO A,  CHONG L S,  FARDIS M,  GIBBS C,  HIRSCHMANN R F,  KIRSCHBERG T A,  LEE C P,  LIN K,  MACKMAN R L,  NELSON P H,  OARE D,  PYUN H,  RAY A S,  SHERLOCK R,  SWAMINATHAN S,  WATKINS W,  ZHANG J R;  WO2005002626-A2   GILEAD SCI INC (GILE)   BOOJAMRA C G,  CANNIZZARO C E,  CHEN J M,  CHEN X,  CHO A,  CHONG L S,  DESAI M,  FARDIS M,  GIBBS C S,  HIRSCHMANN R F,  HUANG A X,  JIN H,  KIM C U,  KIRSCHBERG T A,  KRAWCZYK S,  LEE C P,  LEE W A,  LIN K,  MACKMAN R L,  MARKEVITCH D Y,  NELSON P H,  OARE D A,  PRASAD V K,  PYUN H,  RAY A S,  SHERLOCK R,  SWAMINATHAN S,  WATKINS W J,  ZHANG J R,  ZHANG L;  WO2005012324-A2   GILEAD SCI INC (GILE)   KRAWCZYK S H;  WO2005039552-A2   GILEAD SCI INC (GILE);  CHO A (CHOA-Individual);  KIRSCHBERG T A (KIRS-Individual);  WATKINS W (WATK-Individual);  FARDIS M (FARD-Individual);  CHONG L S (CHON-Individual)   CHO A,  KIRSCHBERG T A,  WATKINS W,  FARDIS M,  CHONG L S;  WO2005047898-A2   GILEAD SCI INC (GILE)   MCDERMOTT M;  WO2005063744-A2   LEUVEN RES&DEV (UYLN);  GILEAD SCI INC (GILE);  PUERSTINGER G (PUER-Individual)   PUERSTINGER G,  BONDY S S,  DOWDY E D,  KIM C U,  OARE D A,  NEYTS J,  ZIA V;  WO2005070901-A2   GILEAD SCI INC (GILE)   JIN H,  KIM C U;  WO2005117904-A2   GILEAD SCI INC (GILE);  PASTOR R M (PAST-Individual);  CAI Z R (CAIZ-Individual);  CHEN X (CHEN-Individual);  FARDIS M (FARD-Individual);  JABRI S Y (JABR-Individual);  JIN H (JINH-Individual);  KIM C U (KIMC-Individual);  METOBO S E (METO-Individual);  MISH M R (MISH-Individual)   CAI Z R,  CHEN X,  FARDIS M,  JABRI S Y,  JIN H,  KIM C U,  METOBO S E,  MISH M R,  PASTOR R M;  WO2006015261-A2   GILEAD SCI INC (GILE)   BOOJAMRA C G,  LIN K,  MACKMAN R L,  MARKEVITCH D Y,  PETRAKOVSKY O V,  RAY A S,  ZHANG L;  WO2006017044-A2   GILEAD SCI INC (GILE)   DAHL T C;  WO2006020276-A2   GILEAD SCI INC (GILE)   CHAUDHARY K,  FLEURY M,  KIM C U,  MCMURTRIE D J,  SHENG X C;  WO2006047661-A2   GILEAD SCI INC (GILE);  WATKINS W J (WATK-Individual);  CHO A (CHOA-Individual)   WATKINS W J,  CHO A;  WO2006069193-A2   GILEAD SCI INC (GILE)   BONDY S S,  OARE D A,  TSE W C;  WO2006110157-A2   GILEAD SCI INC (GILE)   BOOJAMRA C G,  LIN K,  MACKMAN R L,  MARKEVITCH D Y,  PETRAKOVSKY O V,  RAY A S,  ZHANG L;  WO2006125048-A2   GILEAD SCI INC (GILE)   CAI Z R,  JABRI S Y,  JIN H,  KIM C U,  LANSDOWN R A,  METOBO S E,  MISH M R,  PASTOR R M;  WO2007009109-A2   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  SHENG X C;  WO2007014174-A2   GILEAD SCI INC (GILE);  LEUVEN RES&DEV (UYLN);  PUERSTINGER G (PUER-Individual)   BODDEKER N,  NEYTS J,  SHIH I,  VLIEGEN I,  ZHONG W;  WO2007014352-A2   GILEAD SCI INC (GILE)   CAI Z R,  JABRI S Y,  JIN H,  KIM C U,  METOBO S E,  MISH M R,  PASTOR R M;  WO2007126812-A2   GILEAD SCI INC (GILE)   CRAWFORD K R,  DOWDY E D,  GUTIERREZ A,  POLNIASZEK R P,  YU R H C;  WO2008003149-A2   GILEAD SCI INC (GILE)   HERDEWIJN P A M,  DE JONGHE S C A,  LEE W A,  WATKINS W J,  BONDY S S,  CHONG L S;  WO2008005519-A2   GILEAD SCI INC (GILE);  LEUVEN RES&DEV (UYLN);  PUERSTINGER G (PUER-Individual)   BONDY S S,  DAHL T C,  OARE D A,  OLIYAI R,  TSE W C,  ZIA V;  WO2008005542-A2   GILEAD SCI INC (GILE)   BOOJAMRA C G,  CHEN J M,  HUANG A X,  KIM C U,  LIN K,  MACKMAN R L,  OARE D A,  PERRY J K,  SAUNDERS O L,  SWAMINATHAN S,  ZHANG L;  WO2008009076-A2   GILEAD SCI INC (GILE)   HERDEWIJN P A M,  DE JONGHE S C A,  WATKINS W J,  CHONG L S,  ZHANG J;  WO2008009077-A2   GILEAD SCI INC (GILE)   GAO L,  HERDEWIJN P A M,  DE JONGHE S C A,  WATKINS W J,  CHONG L S;  WO2008009078-A2   GILEAD SCI INC (GILE)   GAO L,  HERDEWIJN P A M,  DE JONGHE S C A,  WATKINS W J,  CHONG L S;  WO2008009079-A2   GILEAD SCI INC (GILE)   HERDEWIJN P A M,  DE JONGHE S C A,  WATKINS W J,  CHONG L S;  WO2008010921-A2   ;  WO2008011116-A2   GILEAD SCI INC (GILE)   CANNIZZARO C E,  CHEN J M,  DESAI M C,  MITCHELL M L,  SWAMINATHAN S,  XU L;  WO2008011117-A2   GILEAD SCI INC (GILE)   CANNIZZARO C E,  YANG Z,  DESAI M C,  MITCHELL M L,  XU L,  SWAMINATHAN S,  CHEN J M;  WO2008016522-A2   GILEAD SCI INC (GILE);  KOREA RES INST CHEM TECHNOLOGY (KRIC)   GUO H,  KIM C U,  KIM H S,  LEE C,  LEE Y,  MITCHELL M L,  SON J C,  XU L;  WO2008100447-A2   GILEAD SCI INC (GILE)   CHEN J M,  HUANG A X,  MACKMAN R L,  PARRISH J P,  PERRY J K,  SAUNDERS O L,  SPERANDIO D;  WO2008133669-A2   BONDY S S (BOND-Individual);  OARE D A (OARE-Individual);  PUERSTINGER G (PUER-Individual)   BONDY S S,  OARE D A,  PUERSTINGER G;  WO2009005674-A2   GILEAD SCI INC (GILE);  KOREA RES INST CHEM TECHNOLOGY (KRIC)   GUO H,  KIM C U,  LEE I Y,  MITCHELL M L,  RHODES G,  SON J C,  XU L;  WO2009005676-A2   GILEAD SCI INC (GILE)   CHO A,  CLARKE M O H,  KIM C U,  LINK J O,  PYUN H,  SHENG X C,  WU Q;  WO2009005677-A2   GILEAD SCI INC (GILE)   COTTELL J J,  LINK J O,  SCHROEDER S D,  TAYLOR J,  TSE W C,  VIVIAN R W,  YANG Z;  WO2009005690-A2   GILEAD SCI INC (GILE)   CAI Z R,  CHO A,  KIM C U,  XU J;  WO2009105513-A2   GILEAD SCI INC (GILE)   BIRKUS G,  RAY A S,  TUMAS D,  WATKINS W J;  WO2011156610-A2   GILEAD SCI INC (GILE)   CAI Z R,  DU Z,  JI M,  JIN H,  KIM C U,  MISH M R,  PHILLIPS B W,  PYUN H,  SHENG X C,  WU Q,  ZONTE C S;  WO2012068234-A2   GILEAD SCI INC (GILE)   BACON E M,  COTTELL J J,  KATANA A A,  KATO D,  KRYGOWSKI E S,  LINK J O,  TAYLOR J,  TRAN C V,  TREJO MARTIN T A,  YANG Z,  ZIPFEL S;  WO2012142523-A2   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  KIRSCHBERG T A,  MISH M R,  SQUIRES N;  WO2013040492-A2   GILEAD SCI INC (GILE);  RAY A S (RAYA-Individual);  WATKINS W J (WATK-Individual);  LINK J O (LINK-Individual);  OLDACH D W (OLDA-Individual);  DELANEY W E (DELA-Individual)   RAY A S,  WATKINS W J,  LINK J O,  OLDACH D W,  DELANEY W E;  WO2014134566-A2   GILEAD SCI INC (GILE)   BRIZGYS G,  CANALES E,  CHOU C,  GRAUPE M,  HU Y E,  LINK J O,  LIU Q,  LU Y,  SAITO R D,  SCHROEDER S D,  SOMOZA J R,  TSE W C,  ZHANG J R;  WO2015084741-A2   DENNING J M (DENN-Individual);  MCHUTCHISON J G (MCHU-Individual);  SUBRAMANIAN G M (SUBR-Individual);  SYMONDS W T (SYMO-Individual)   DENNING J M,  MCHUTCHISON J G,  SUBRAMANIAN G M,  SYMONDS W T;  WO2015191526-A2   BACON E M (BACO-Individual);  COTTELL J J (COTT-Individual);  LINK J O (LINK-Individual);  TREJO M T A (TREJ-Individual);  ZIPFEL S (ZIPF-Individual)   BACON E M,  COTTELL J J,  LINK J O,  TREJO M T A,  ZIPFEL S;  WO2015191754-A2   KIM M (KIMM-Individual);  PERREAULT S (PERR-Individual);  YEUNG S C (YEUN-Individual)   KIM M,  PERREAULT S,  YEUNG S C;  WO2017059224-A2   GILEAD SCI INC (GILE);  ONO PHARM CO LTD (ONOY)   VENKATARAMAN S,  TUMAS D,  TANAKA K,  YASUHIRO T,  YOSHIZAWA T;  WO2017106346-A2   GILEAD SCI INC (GILE)   BALAKRISHNAN M,  CARR B A,  CORBIN J,  PACE C S,  THOMSEN N D,  ZHANG X;  WO2017184670-A2   GILEAD SCI INC (GILE)   CIHLAR T,  CLARKE M O N H,  JORDAN R,  MACKMAN R L,  SIEGEL D;  WO2002032920-A3   ;  WO2003090690-A3   GILEAD SCI INC (GILE)   ARIMILLI M N,  BECKER M M,  BRYANT C,  CHEN J M,  CHEN X,  DASTGAH A,  FARDIS M,  HE G,  JIN H,  KIM C U,  LEE W A,  LEE C P,  LIN K,  LIU H,  MACKMAN R L,  MITCHELL M L,  NELSON P H,  PYUN H,  ROWE T D,  SPARACINO M,  SWAMINATHAN S,  TARIO J D,  WANG J,  WILLIAMS M A,  XU L,  YANG Z,  YU R H,  ZHANG J,  ZHANG L;  WO2007022268-A3   IRM LLC (IRMI);  SCRIPPS RES INST (SCRI)   OKRAM B,  REN P,  GRAY N S;  US2022016153-A1 -- US11331331-B2   UNIV EMORY (UEMR)   PAINTER G R,  BLUEMLING G R,  NATCHUS M G,  GUTHRIE D;  GB2590198-B -- CA2743451-A1   PHARMASSET LTD (GILE)   STUYVER L,  WATANABE K A;  WO2016106050-A1   UNIV EMORY (UEMR)   PAINTER G R,  GUTHRIE D B,  BLUEMLING G R,  NATCHUS M G;  WO2017165489-A1   UNIV EMORY (UEMR)   SCHINAZI R F,  AMBLARD F,  COX B D,  BASSIT L,  ZHOU L,  GAVEGNANO C;  US11903959-B2 -- US11331331-B2   UNIV EMORY (UEMR)   PAINTER G R,  BLUEMLING G R,  NATCHUS M G,  GUTHRIE D;  CA2426187-A1   PHARMASSET LTD (GILE)   STUYVER L,  WATANABE K A;  CA2449572-A1   HOFFMANN LA ROCHE & CO AG F (HOFF)   DEVOS R R,  HOBBS C J,  JIANG W,  MARTIN J A,  MERRETT J H,  NAJERA I,  SHIMMA N,  TSUKUDA T;  CA2743451-A1   PHARMASSET LTD (GILE)   STUYVER L,  WATANABE K A;  CA2889171-A1   KONINK PHILIPS NV (PHIG)   JOHNSON M T,  KROON B,  VAN PUTTEN E G,  VDOVIN O V;  CN105288635-A   KUNMING JIDA PHARM CO LTD (KUNM-Non-standard)   FENG P,  WANG L,  ZHANG X,  ZHAO Y;  CN107427529-A   UNIV EMORY (UEMR)   PAINTER G R,  GUTHRIE D B,  BLUEMLING G R,  NATCHUS M G;  CN101862345-B   PHARMASSET LTD (GILE)   STUYVER L,  WATANABE K A;  CN104114568-B   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  WANG G,  SMITH D B,  DEVAL J,  PRHAVC M;  EP2615101-B1   HENAN ACAD SCI HI TECH RES CENT (HENA-Non-standard);  UNIV ZHENGZHOU (UYZZ);  ZHENGZHOU GRANLEN PHARM TECHNOLOGY CO (ZHEN-Non-standard)   AN H,  CHANG J,  GUO X,  YU X;  GB1325798-A   UPJOHN CO (UPJO);  GB1386334-A   K K KOHJIN (KOJK);  GB1480120-A   KOJIN KK (KOJK);  JP2006519169-A   ;  JP2010522705-A   ;  JP2013518076-A   ;  RU2264409-C2   VEKTOR VIROLOGY BIOTECHN RES CENTRE (VEKT-Soviet Institute);  CHUGAI PHARM CO LTD (CHUS)   POKROVSKII A G,  ILICHEVA T N,  BELANOV E F,  VOLKOV G N,  KUKHANOVA M K,  ALEKSANDROVA L A;  RU2322989-C2   HOFFMANN LA ROCHE & CO AG F (HOFF)   DEVOS R R,  HOBBS C J,  JIANG W,  MARTIN J A,  MERRETT J H,  NAJERA I,  SHIMMA N,  TSUKUDA T;  RU2327701-C2   HOFFMANN LA ROCHE & CO AG F (HOFF)   MARTIN J A,  SARMA K,  SMITH D B,  SMITH M;  US4096324-A   UPJOHN CO (UPJO)   KELLY R C,  WECHTER W J;  US5349947-A   BAINES W D (BAIN-Individual);  NEWHOUSE M T (NEWH-Individual)   NEWHOUSE M T,  BAINES W D;  US5691319-A   SANKYO CO LTD (DAUC)   KANEKO M,  HOTODA H,  SHIBATA T,  KOBAYASHI T,  MITSUHASHI Y,  MATSUDA A,  SASAKI T;  US5736531-A   PRO-NEURON INC (LLST)   BAMAT M K,  VON BORSTEL R W;  US6086376-A   RTP PHARMA INC (RTPP-Non-standard)   MOUSSA I,  PARIKH I;  US20030008841-A1   ;  US20030087873-A1   ;  US20040121980-A1   ;  US20040171860-A1   ;  US20050043268-A1   ;  US20060014709-A1   ;  US20070031824-A1   ;  US20070037773-A1   ;  US20070160554-A1   ;  US20070196824-A1   ;  US20080260826-A1   ;  US20090105186-A1   ;  US20090220950-A1   ;  US20100189772-A1   ;  US20100298256-A1   ;  US20110269707-A1   ;  US20140057863-A1   ;  US20140200277-A1   ;  US20140235566-A1   ;  US20140273023-A1   ;  US20140294769-A1   ;  US20150011497-A1   ;  US20150105341-A1   ;  US20150366887-A1   ;  US20150366888-A1   ;  US20170143749-A1   ;  US20170143751-A1   ;  US20170253628-A1   ;  US20180044369-A1   ;  US20180079774-A1   ;  US20190022116-A1   ;  US20190054108-A1   ;  US20190083520-A1   ;  US20200276219-A1   ;  US20210060050-A1   ;  US20210252033-A1   ;  US6274563-B1   PRO-NEURON INC (LLST)   VON BORSTEL R W,  BAMAT M K;  US6369086-B1   GLAXO GROUP LTD (GLAX)   DAVIS S T,  DICKERSON S H,  FRYE S V,  HARRIS P A,  HUNTER R N,  KUYPER L F,  LACKEY K E,  LUZZIO M J,  VEAL J M,  WALKER D H;  US6369087-B1   APPLIED ANALYTICAL IND INC (ANAL-Non-standard)   WHITTLE R R,  SANCILIO F D,  STOWELL G W,  JENKINS D J,  WHITTALL L,  MEYER G A;  US6372733-B1   MERCK & CO INC (MERI)   CALDWELL C G,  HAGMANN W K,  MACCOSS M,  SHAH S K,  SHANKARAN K,  FURMAN K L;  US6372778-B1   VERTEX PHARM INC (VERT)   TUNG R D,  MURCKO M A,  BHISETTI G R;  US6846810-B2   HOFFMANN LA ROCHE & CO AG F (HOFF)   MARTIN J A,  SARMA K,  SMITH D B,  SMITH M;  US7439344-B2   ROCHE PALO ALTO LLC (SYNT)   SARMA K;  US7718790-B2   PHARMASSET LTD (GILE)   STUYVER L,  WATANABE K A;  US7893037-B2   HOFFMANN LA ROCHE & CO AG F (HOFF)   BIRUDARAJ K,  BRANDL M T,  HEGDE S,  SANA F,  STEFANIDIS D;  US7919247-B2   PHARMASSET LTD (GILE)   STUYVER L,  WATANABE K A;  US8236779-B2   HOFFMANN LA ROCHE&CO AG F (HOFF)   MA H,  SARMA K,  SMITH D B;  US8686045-B2   UNIV NORTH CAROLINA (UNCR);  UNIV CALIFORNIA (REGC);  US DEPT VETERANS AFFAIRS (USGO)   LONGO F M,  MASSA S M;  US9073960-B2   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  WANG G,  SMITH D B,  DEVAL J,  PRHAVC M;  US9211300-B2   MAYES B A (MAYE-Individual);  MOUSSA A M (MOUS-Individual);  STEWART A J (STEW-Individual);  GOSSELIN G (GOSS-Individual)   MAYES B A,  MOUSSA A M,  STEWART A J,  GOSSELIN G;  US9422321-B2   HENAN ACAD SCI HI TECH RES CENT (HENA-Non-standard);  UNIV ZHENGZHOU (UYZZ);  ZHENGZHOU GRANLEN PHARM TECHNOLOGY CO (ZHEN-Non-standard)   AN H,  CHANG J,  GUO X,  YU X;  US9603863-B2   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  DYATKINA N (DYAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  DYATKINA N,  SMITH D B,  SYMONS J A;  US9603864-B2   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  SMITH D B,  SYMONS J A;  US9809616-B2   UNIV EMORY (UEMR);  RFS PHARMA LLC (RFSP-Non-standard)   AMBLARD F,  COATS S J,  SCHINAZI R F;  US9862743-B2   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  US9877990-B2   KRYSTAL BIOTECH LLC (KRYS-Non-standard)   AGARWAL P,  KRISHNAN S;  US10052342-B2   ALIOS BIOPHARMA INC (JOHJ)   BLATT L M,  BEIGELMAN L,  DYATKINA N,  SYMONS J A,  SMITH D B;  US10100076-B2   PHARMASSET LTD (GILE)   STUYVER L,  WATANABE K A;  US10307439-B2   ALIOS BIOPHARMA INC (JOHJ)   BLATT L M,  BEIGELMAN L,  SYMONS J A,  SMITH D B;  US10370401-B2   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  US10464965-B2   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  WANG G,  SMITH D B,  DEVAL J,  PRHAVC M;  US10874638-B2   LIGAND PHARM INC (LIGA);  ZHI L (ZHIL-Individual)   ZHI L;  US10874683-B2   UNIV EMORY (UEMR)   PAINTER G R,  GUTHRIE D B,  BLUEMLING G R,  NATCHUS M R;  WO1990015065-A   ;  WO1992009705-A1   ;  WO1993010820-A1   ;  WO1995007919-A1   ;  WO1995007920-A1   ;  WO1996026933-A1   ;  WO1998017647-A1   ;  WO2002088159-A1   ;  WO2004064845-A1   GILEAD SCI INC (GILE)   DAHL T C,  MENNING M M,  OLIYAI R;  WO2004064846-A1   GILEAD SCI INC (GILE)   DAHL T C,  MENNING M M,  OLIYAI R;  WO2005028478-A1   GILEAD SCI INC (GILE)   JIN H,  KIM C U,  NELSON P H;  WO2005042772-A1   GILEAD SCI INC (GILE)   MCDERMOTT M;  WO2005063751-A1   GILEAD SCI INC (GILE)   FARDIS M,  KIM C U;  WO2005064008-A1   GILEAD SCI INC (GILE)   ARIMILLI M N,  BECKER M M,  BIRKUS G,  BRYANT C,  CHEN J M,  CHEN X,  CIHLAR T,  DASTGAH A,  EISENBERG E J,  FARDIS M,  HATADA M,  HE G,  JIN H,  KIM C U,  LEE W A,  LEE C P,  LIN K,  LIU H,  MACKMAN R L,  MCDERMOTT M J,  MITCHELL M L,  NELSON P H,  PYUN H,  ROWE T D,  SPARACINO M,  SWAMINATHAN S,  TARIO J D,  WANG J,  WILLIAMS M A,  XU L,  YANG Z,  YU R H,  ZHANG J,  ZHANG L;  WO2005066189-A1   GILEAD SCI INC (GILE)   CHENG X,  COOK G P,  DESAI M C,  DOERFFLER E,  HE G,  KIM C U,  LEE W A,  ROHLOFF J C,  WANG J,  YANG Z;  WO2005072748-A1   GILEAD SCI INC (GILE)   CIHLAR T,  DOUGLAS J L,  GIBBS C S;  WO2006033703-A1   GILEAD SCI INC (GILE)   KIM C U,  NEYTS J,  OARE D A,  PUERSTINGER G;  WO2006091905-A1   GILEAD SCI INC (GILE)   JACOBSON K A,  MACKMAN R L,  JOSHI B V;  WO2007011658-A1   GILEAD SCI INC (GILE)   CASAREZ A,  CHAUDHARY K,  KIM C U,  MCMURTRIE D,  SHENG X C;  WO2007079260-A1   GILEAD SCI INC (GILE);  JAPAN TOBACCO INC (NISB)   KEARNEY B P,  KAKEE A,  KAWAGUCHI I;  WO2008005555-A1   GILEAD SCI INC (GILE)   CHONG L S,  DESAI M C,  GALLAGHER B,  GRAUPE M,  HALCOMB R L,  YANG H,  ZHANG J R;  WO2008013834-A1   GILEAD SCI INC (GILE)   DESAI M C,  LEE C P,  LIU H,  SWAMINATHAN S,  XU L;  WO2008077649-A1   GILEAD SCI INC (GILE)   WATKINS W J,  CHONG L S,  ZHANG J R;  WO2008077650-A1   GILEAD SCI INC (GILE)   BONDY S S,  WATKINS W J,  CHONG L S,  HERDEWIJN P A M,  DE JONGHE S C A;  WO2008077651-A1   GILEAD SCI INC (GILE)   BONDY S S,  CHOU C,  WATKINS W J,  CHONG L S,  ZHANG J R,  MISHRA R;  WO2008103949-A1   DESAI M C (DESA-Individual);  HONG A Y (HONG-Individual);  HUI H C (HUIH-Individual);  LIU H (LIUH-Individual);  VIVIAN R W (VIVI-Individual);  XU L (XULL-Individual)   DESAI M C,  HONG A Y,  HUI H C,  LIU H,  VIVIAN R W,  XU L;  WO2009005687-A1   GILEAD SCI INC (GILE)   GRAUPE M,  HALCOMB R L;  WO2009005693-A1   GILEAD SCI INC (GILE)   HE G,  KIM C U,  MITCHELL M L,  XU L;  WO2009006199-A1   GILEAD SCI INC (GILE)   KEARNEY B P,  MATHIAS A A,  RAMANATHAN S;  WO2009006203-A1   GILEAD SCI INC (GILE)   KEARNEY B P,  MATHIAS A A;  WO2009009001-A1   GILEAD SCI INC (GILE);  LEUVEN RES&DEV (UYLN);  PUERSTINGER G (PUER-Individual)   DOWDY E D,  KENT K M,  TOM N J,  ZIA V;  WO2009088719-A1   GILEAD SCI INC (GILE)   DESAI M C,  HUI H C,  LIU H,  XU L;  WO2009132123-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  PARRISH J,  XU J;  WO2009132135-A1   GILEAD SCI INC (GILE)   BUTLER T,  CHO A,  KIM C U,  SAUNDERS O L,  ZHANG L;  WO2009143011-A1   NOVARTIS AG (NOVS)   BUECHE B,  KUO M,  LALONDE G,  SAHNER D;  WO2010002998-A1   GILEAD SCI INC (GILE)   CANALES E,  CHONG L S,  CLARKE M O H,  LAZERWITH S E,  LEW W,  LIU Q,  MITCHELL M L,  WATKINS W J,  ZHANG J R;  WO2010005986-A1   GILEAD SCI INC (GILE)   GRAETZ B R,  POLNIASZEK R P;  WO2010011959-A1   GILEAD SCI INC (GILE)   AKTOUDIANAKIS E,  CELEBI A A,  DU Z,  JABRI S Y,  JIN H,  KIM C U,  LI J,  METOBO S E,  MISH M R,  PHILLIPS B W,  SAUGIER J H,  YANG Z,  ZONTE C S;  WO2010075127-A1   GILEAD SCI INC (GILE)   LINK J O;  WO2010077613-A1   GILEAD SCI INC (GILE)   DESAI M C,  HALCOMB R L,  HRVATIN P,  HUI H C,  MC FADDEN R,  ROETHLE P A,  YANG H;  WO2010080389-A1   GILEAD SCI INC (GILE)   LINK J O,  VIVIAN R W;  WO2010093608-A1   GILEAD SCI INC (GILE)   BUTLER T,  CHO A,  KIM C U,  XU J;  WO2010132601-A1   GILEAD SCI INC (GILE);  KIM C U (KIMC-Individual)   BACON E M,  CANALES E,  CHO A,  CHOU C,  CLARKE M O H,  COTTELL J J,  DESAI M C,  GRAUPE M,  GUO H,  HALCOMB R L,  JIN H,  KATO D,  KELLAR T,  KIRSCHBERG T A,  KRYGOWSKI E S,  LAZERWITH S E,  LINK J O,  LIU H,  LIU Q,  MACKMAN R,  MCFADDEN R,  METOBO S E,  MISH M R,  MITCHELL M L,  PARRISH J P,  PHILLIPS B W,  PYUN H,  SAUGIER J H,  SCHROEDER S D,  SHENG X,  SQUIRES N,  SUN J,  TAYLOR J,  TRENKLE J D,  TSE W C,  VENKATARAMANI C,  VIVIAN R W,  WATKINS W J,  XU L,  YANG Z;  WO2010135569-A1   PHARMASSET INC (GILE)   ROSS B S,  SOFIA M J,  PAMULAPATI G R,  RACHAKONDA S,  ZHANG H,  CHUN B,  WANG P;  WO2010151472-A1   GILEAD SCI INC (GILE)   DELANEY W E,  MO H,  ZHONG W;  WO2010151487-A1   GILEAD SCI INC (GILE)   DELANEY W E,  MO H,  ZHONG W;  WO2010151488-A1   GILEAD SCI INC (GILE)   DELANEY W E,  MO H,  ZHONG W;  WO2011005842-A1   GILEAD SCI INC (GILE)   MACKMAN R L,  SPERANDIO D,  YANG H;  WO2011011303-A1   GILEAD SCI INC (GILE)   CANALES E,  CHONG L S,  CLARKE M O H,  DOERFFLER E,  LAZERWITH S E,  LEW W,  LIU Q,  MERTZMAN M,  MORGANELLI P A,  WATKINS W J,  YE H;  WO2011031669-A1   GILEAD SCI INC (GILE)   CHO A,  CHONG L S,  CLARKE M O H,  DOERFFLER E,  KIM C U,  LIU Q,  WATKINS W J,  ZHANG J R;  WO2011031965-A1   GILEAD SCI INC (GILE)   HALCOMB R L,  ROETHLE P A;  WO2011035231-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  METOBO S E,  RAY A S,  XU J;  WO2011049825-A1   GILEAD SCI INC (GILE)   HALCOMB R L,  ROETHLE P A;  WO2011079016-A1   GILEAD SCI INC (GILE)   HALCOMB R L,  SWAMINATHAN S,  TUMAS D B;  WO2011088303-A1   GILEAD SCI INC (GILE)   CANALES E,  CHONG L S,  CLARKE M O H,  DOERFFLER E,  LAZERWITH S E,  LEW W,  MERTZMAN M,  MORGANELLI P A,  WATKINS W J;  WO2011088345-A1   GILEAD SCI INC (GILE)   CANALES E,  CLARKE M O H,  LAZERWITH S E,  LEW W,  MORGANELLI P A,  WATKINS W J;  WO2011092158-A1   HOFFMANN LA ROCHE&CO AG F (HOFF)   MA H,  SARMA K,  SMITH D B;  WO2011106445-A1   GILEAD SCI INC (GILE)   JIN H,  KIM C U,  PHILLIPS B W;  WO2011143105-A1   GILEAD SCI INC (GILE)   BAKER W R,  CAI S,  KAPLAN J A,  KIM M,  LOYER-DREW J A,  PERREAULT S,  PHILLIPS G,  PURVIS L J,  STASIAK M,  STEVENS K L,  VAN VELDHUIZEN J;  WO2011143106-A1   GILEAD SCI INC (GILE)   BAKER W R,  CAI S,  KAPLAN J A,  KIM M,  PHILLIPS G,  PURVIS L J,  STASIAK M,  STEVENS K L,  VAN VELDHUIZEN J;  WO2011146817-A1   GILEAD SCI INC (GILE)   BJORNSON K,  BONDY S S,  CHOI Y,  CHOU C,  MISHRA R,  TRENKLE J D,  TSE W C,  VIVIAN R W;  WO2011150288-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  RAY A S,  ZHANG L;  WO2011156416-A1   GILEAD SCI INC (GILE);  KARIM Q A (KARI-Individual);  KARIM S S A (KARI-Individual);  KHARSANY A (KHAR-Individual)   CIHLAR T,  KARIM Q A,  KARIM S S A,  KHARSANY A,  ROONEY J F;  WO2011156757-A1   GILEAD SCI INC (GILE);  DELANEY W E (DELA-Individual);  LEE W A (LEEW-Individual);  OLDACH D W (OLDA-Individual);  ROUSSEAU F (ROUS-Individual)   DELANEY W E,  LEE W A,  OLDACH D W,  ROUSSEAU F;  WO2011163518-A1   GILEAD SCI INC (GILE)   BABAOGLU K,  BOOJAMRA C G,  EISENBERG E J,  HUI H C,  MACKMAN R L,  PARRISH J P,  SANGI M,  SAUNDERS O L,  SIEGEL D,  SPERANDIO D,  YANG H;  WO2012003497-A1   GILEAD SCI INC (GILE);  BABAOGLU K (BABA-Individual);  BJORNSON K (BJOR-Individual);  GUO H (GUOH-Individual);  HALCOMB R L (HALC-Individual);  LINK J O (LINK-Individual);  MCFADDEN R (MCFA-Individual);  MITCHELL M L (MITC-Individual);  ROETHLE P (ROET-Individual);  TRENKLE J D (TREN-Individual);  VIVIAN R W (VIVI-Individual);  XU L (XULL-Individual)   BABAOGLU K,  BJORNSON K,  GUO H,  HALCOMB R L,  LINK J O,  MCFADDEN R,  MITCHELL M L,  ROETHLE P,  TRENKLE J D,  VIVIAN R W,  XU L;  WO2012003498-A1   GILEAD SCI INC (GILE);  BABAOGLU K (BABA-Individual);  BJORNSON K (BJOR-Individual);  GUO H (GUOH-Individual);  HALCOMB R L (HALC-Individual);  LINK J O (LINK-Individual);  LIU H (LIUH-Individual);  MITCHELL M L (MITC-Individual);  SUN J (SUNJ-Individual);  VIVIAN R W (VIVI-Individual);  XU L (XULL-Individual)   BABAOGLU K,  BJORNSON K,  GUO H,  HALCOMB R L,  LINK J O,  LIU H,  MITCHELL M L,  SUN J,  VIVIAN R W,  XU L;  WO2012012465-A1   GILEAD SCI INC (GILE);  CLARKE M O H (CLAR-Individual)   CHO A,  WOLCKENHAUER S A;  WO2012012776-A1   GILEAD SCI INC (GILE)   MACKMAN R L,  PARRISH J P,  RAY A S,  THEODORE D A;  WO2012037038-A1   GILEAD SCI INC (GILE)   CLARKE M O N H,  KIM C U,  LEW W;  WO2012039787-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  METOBO S E,  RAY A S,  XU J;  WO2012039791-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  METOBO S E,  RAY A S,  XU J;  WO2012068535-A1   GILEAD SCI INC (GILE);  JANSSEN R & D IRELAND (JOHJ)   MENNING M,  OLIYAI R,  WISER L;  WO2012078915-A1   GILEAD SCI INC (GILE);  SELCIA LTD (SELC-Non-standard)   APPLEBY T,  FLIRI H G,  KEATS A J,  LAZARIDES L,  MACKMAN R L,  PETTIT S N,  POULLENNEC K G,  SANVOISIN J,  STEADMAN V A,  WATT G M;  WO2012087596-A1   GILEAD SCI INC (GILE)   DELANEY W E,  LINK J O,  MO H,  OLDACH D W,  RAY A S,  WATKINS W J,  YANG C Y,  ZHONG W;  WO2012088153-A1   GILEAD SCI INC (GILE)   DESAI M C,  LIU H,  XU L,  YE H;  WO2012088156-A1   GILEAD SCI INC (GILE)   DESAI M C,  HUI H C,  LIU H,  SUN J,  XU L;  WO2012088178-A1   GILEAD SCI INC (GILE)   CANNIZZARO C,  DESAI M C,  HUI H C,  LEE M S,  LIU H,  SUN J,  XU L;  WO2012138669-A1   GILEAD SCI INC (GILE)   LI Z J,  LI Z,  LUO L,  OFFERDAHL T,  KIM S,  YANG B;  WO2012138670-A1   GILEAD SCI INC (GILE)   LI W,  DE CROOS P,  FANDRICK K R,  GAO J J,  HADDAD N,  LU Z,  QU B,  RODRIGUEZ S,  SENANAYAKE C H,  ZHANG Y,  TANG W;  WO2012145728-A1   GILEAD SCI INC (GILE);  MITCHELL M L (MITC-Individual);  ROETHLE P A (ROET-Individual);  XU L (XULL-Individual);  YANG H (YANG-Individual);  MCFADDEN R (MCFA-Individual);  BABAOGLU K (BABA-Individual)   MITCHELL M L,  ROETHLE P A,  XU L,  YANG H,  MCFADDEN R,  BABAOGLU K;  WO2012151165-A1   GILEAD SCI INC (GILE)   KOZIARA J M,  LUNONG A,  SUJINO K,  YU R;  WO2013006721-A1   GILEAD SCI INC (GILE)   DELANEY W E,  CHENG G,  MO H,  XU S,  PENG B;  WO2013006722-A1   GILEAD SCI INC (GILE)   DELANEY W E,  CHENG G,  YU M,  MO HONGMEI,  XU S,  CORSA A;  WO2013006738-A1   GILEAD SCI INC (GILE)   BONDY S S,  CANNIZZARO C E,  CHOU C,  HALCOMB R L,  HU Y E,  LINK J O,  LIU Q,  SCHROEDER S D,  TSE W C,  ZHANG J R;  WO2013010112-A1   GILEAD SCI INC (GILE);  WATKINS W J (WATK-Individual)   WATKINS W J;  WO2013025788-A1   GILEAD SCI INC (GILE)   LIU D,  SHI B,  WANG F,  YU R H C;  WO2013066748-A1   GILEAD PHARMASSET LLC (GILE)   BERREY M M,  HINDES R G,  SYMONDS W T,  RAY A S,  MO H,  HEBNER C M;  WO2013075029-A1   GILEAD SCI INC (GILE)   BACON E M,  COTTELL J J,  KATANA A A,  KATO D,  KRYGOWSKI E S,  LINK J O,  TAYLOR J,  TRAN C V,  TREJO MARTIN T A,  YANG Z,  ZIPFEL S;  WO2013082003-A1   GILEAD PHARMASSET LLC (GILE)   CLEARY D G,  REYNOLDS C J,  BERREY M M,  HINDES R G,  SYMONDS W T,  RAY A S,  MO H,  HEBNER C M,  OLIYAI R,  ZIA V,  STEFANIDIS D,  PAKDAMAN R,  CASTEEL M J;  WO2013090840-A1   GILEAD SCI INC (GILE)   JIN H,  KIM C U,  LI J;  WO2013090929-A1   GILEAD SCI INC (GILE)   CAI Z R,  DU Z,  JI M,  JIN H,  KIM C U,  LI J,  PHILLIPS B W,  PYUN H,  SAUGIER J H;  WO2013096512-A1   GILEAD SCI INC (GILE)   LOPATIN U A,  TUMAS D B;  WO2013096681-A1   GILEAD SCI INC (GILE)   BOOJAMRA C G,  HUI H C,  JANSA P,  MACKMAN R L,  PARRISH J P,  SANGI M,  SIEGEL D,  SPERANDIO D,  YANG H;  WO2013103724-A1   GILEAD SCI INC (GILE)   BABAOGLU K,  BJORNSON K L,  HRVATIN P,  LANSDON E,  LINK J O,  LIU H,  MCFADDEN R,  MITCHELL M L,  QI Y,  ROETHLE P A,  XU L;  WO2013103738-A1   GILEAD SCI INC (GILE);  BABAOGLU K (BABA-Individual);  BRIZGYS G (BRIZ-Individual);  GUO H (GUOH-Individual);  HRVATIN P (HRVA-Individual);  LANSDON E (LANS-Individual);  LINK J O (LINK-Individual);  LIU H (LIUH-Individual);  MCFADDEN R (MCFA-Individual);  MITCHELL M L (MITC-Individual);  QI Y (QIYY-Individual);  ROETHLE P A (ROET-Individual);  VIVIAN R W (VIVI-Individual);  XU L (XULL-Individual);  YANG H (YANG-Individual)   BABAOGLU K,  BRIZGYS G,  GUO H,  HRVATIN P,  LANSDON E,  LINK J O,  LIU H,  MCFADDEN R,  MITCHELL M L,  QI Y,  ROETHLE P A,  VIVIAN R W,  XU L,  YANG H;  WO2013106732-A1   GILEAD SCI INC (GILE);  CULLEN A J (CULL-Individual);  YU R H C (YURH-Individual)   CULLEN A J,  YU R H C;  WO2013115916-A1   GILEAD SCI INC (GILE)   RAMANATHAN S;  WO2013116720-A1   GILEAD SCI INC (GILE)   RAMANATHAN S;  WO2013116730-A1   GILEAD SCI INC (GILE)   RAMANATHAN S;  WO2013138236-A1   GILEAD SCI INC (GILE)   CLARKE M O N H;  WO2013142525-A1   ALIOS BIOPHARMA INC (JOHJ)   WANG G,  SMITH D B,  BEIGELMAN L,  DEVAL J,  PRHAVC M;  WO2013158776-A1   SIEGEL D (SIEG-Individual);  SPERANDIO D (SPER-Individual);  YANG H (YANG-Individual);  SANGI M (SANG-Individual);  PARRISH J P (PARR-Individual);  HUI H C (HUIH-Individual)   SIEGEL D,  SPERANDIO D,  YANG H,  SANGI M,  PARRISH J P,  HUI H C;  WO2013159064-A1   GILEAD SCI INC (GILE);  BABAOGLU K (BABA-Individual);  BRIZGYS G (BRIZ-Individual);  CHA J (CHAJ-Individual);  CHEN X (CHEN-Individual);  GUO H (GUOH-Individual);  HALCOMB R L (HALC-Individual);  HAN X (HANX-Individual);  HUANG R (HUAN-Individual);  LIU H (LIUH-Individual);  MCFADDEN R (MCFA-Individual);  MITCHELL M L (MITC-Individual);  QI Y (QIYY-Individual);  ROETHLE P A (ROET-Individual);  XU L (XULL-Individual);  YANG H (YANG-Individual)   BABAOGLU K,  BRIZGYS G,  CHA J,  CHEN X,  GUO H,  HALCOMB R L,  HAN X,  HUANG R,  LIU H,  MCFADDEN R,  MITCHELL M L,  QI Y,  ROETHLE P A,  XU L,  YANG H;  WO2013173488-A1   LINK J O (LINK-Individual);  COTTELL J J (COTT-Individual);  TREJO MARTIN T A (MART-Individual)   LINK J O,  COTTELL J J,  TREJO MARTIN T A;  WO2013173492-A1   LINK J O (LINK-Individual);  COTTELL J J (COTT-Individual);  TREJO M T A (TREJ-Individual)   LINK J O,  COTTELL J J,  TREJO M T A;  WO2013185090-A1   GILEAD SCI INC (GILE);  SELCIA LTD (SELC-Non-standard)   ACIRO C,  STEADMAN V A,  PETTIT S N,  POULLENNEC K G,  LAZARIDES L,  DEAN D K,  DUNBAR N A,  HIGHTON A J,  KEATS A J,  SIEGEL D S,  KARKI K K,  SCHRIER A J,  JANSA P,  MACKMAN R;  WO2013185093-A1   GILEAD SCI INC (GILE);  SELCIA LTD (SELC-Non-standard)   STEADMAN V A,  POULLENNEC K G,  LAZARIDES L,  ACIRO C,  DEAN D K,  KEATS A J,  SIEGEL D S,  SCHRIER A J,  MACKMAN R,  JANSA P;  WO2013185103-A1   GILEAD SCI INC (GILE);  SELCIA LTD (SELC-Non-standard)   ACIRO C,  STEADMAN V A,  PETTIT S N,  POULLENNEC K G,  LAZARIDES L,  DEAN D K,  DUNBAR N A,  HIGHTON A J,  KEATS A J,  SIEGEL D S,  KARKI K K,  SCHRIER A J,  JANSA P,  MACKMAN R;  WO2014008285-A1   GILEAD SCI INC (GILE)   BJORNSON K,  CANALES E,  COTTELL J J,  KARKI K K,  KATANA A A,  KATO D,  KOBAYASHI T,  LINK J O,  MARTINEZ R,  PHILLIPS B W,  PYUN H,  SANGI M,  SCHRIER A J,  SIEGEL D,  TAYLOR J G,  TRAN C V,  TREJO MARTIN T A,  VIVIAN R W,  YANG Z,  ZABLOCKI J,  ZIPFEL S;  WO2014028343-A1   HASHASH A (HASH-Individual);  WOLCKENHAUER S (WOLC-Individual);  SHI B (SHIB-Individual)   HASHASH A,  WOLCKENHAUER S,  SHI B;  WO2014055618-A1   BROWN B H (BROW-Individual);  CARRA E A (CARR-Individual);  WANG X (WANG-Individual)   BROWN B H,  CARRA E A,  WANG X;  WO2014070771-A1   RFS PHARMA LLC (RFSP-Non-standard);  UNIV EMORY (UEMR)   AMBLARD F,  COATS S J,  SCHINAZI R F;  WO2014070939-A1   GILEAD SCI INC (GILE)   BORNSTEIN J D,  ADAMKEWICZ J I,  SMITH V,  LYMAN S K,  CHIEN J,  LI X,  SHAO L;  WO2014074620-A1   CHENG G (CHEN-Individual);  DELANEY W E (DELA-Individual);  PENG B (PENG-Individual);  YU M (YUMM-Individual)   CHENG G,  DELANEY W E,  PENG B,  YU M;  WO2014099941-A1   PARSY C C (PARS-Individual);  ALEXANDRE F (ALEX-Individual);  DOUSSON C B (DOUS-Individual);  DUKHAN D (DUKH-Individual);  PIERRA C (PIER-Individual);  SURLERAUX D (SURL-Individual);  MAYES B A (MAYE-Individual);  MOUSSA A M (MOUS-Individual);  STEWART A J (STEW-Individual)   PARSY C C,  ALEXANDRE F,  DOUSSON C B,  DUKHAN D,  PIERRA C,  SURLERAUX D,  MAYES B A,  MOUSSA A M,  STEWART A J;  WO2014100323-A1   GILEAD SCI INC (GILE)   JIN H,  LAZERWITH S E,  MARTIN T A T,  BACON E M,  COTTELL J J,  CAI Z R,  PYUN H,  MORGANELLI P A,  JI M,  TAYLOR J G,  CHEN X,  MISH M R,  DESAI M C;  WO2014100500-A1   LINK J O (LINK-Individual);  COTTELL J J (COTT-Individual);  TREJO M T A (TREJ-Individual);  BACON E M (BACO-Individual)   LINK J O,  COTTELL J J,  TREJO M T A,  BACON E M;  WO2014100505-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  WANG G,  SMITH D B;  WO2014110296-A1   GILEAD SCI INC (GILE)   BONDY S S,  CANNIZZARO C E,  CHOU C,  HU Y E,  LINK J O,  LIU Q,  SCHROEDER S D,  TSE W C,  ZHANG J R;  WO2014110297-A1   GILEAD SCI INC (GILE)   BRIZGYS G,  CHOU C,  HALCOMB R L,  HU Y E,  LIU Q,  SOMOZA J R,  TSE W C,  ZHANG J R;  WO2014110298-A1   GILEAD SCI INC (GILE)   BONDY S S,  CANNIZZARO C E,  CHOU C,  LINK J O,  LIU Q,  SCHROEDER S D,  TSE W C,  ZHANG J R;  WO2014124430-A1   UNIV EMORY (UEMR)   LIOTTA D C,  PAINTER G R,  BLUEMLING G R;  WO2014145095-A1   GILEAD SCI INC (GILE)   BJORNSON K,  KARKI K K,  LINK J O,  PYUN H,  SCHRIER A J,  STEVENS K L,  TAYLOR J G,  VIVIAN R W,  ZABLOCKI J,  ZIPFEL S;  WO2014169278-A1   ACHILLION PHARM INC (ACHI)   DESHPANDE M,  WILES J A,  HASHIMOTO A,  PHADKE A;  WO2014186637-A1   RIBOSCIENCE LLC (RIBO-Non-standard)   KLUMPP K G,  SMITH M;  WO2014209979-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JIN Z;  WO2015023893-A1   GILEAD SCI INC (GILE)   DVORY-SOBOL H,  HEBNER C,  MO H,  XU S;  WO2015038596-A1   UNIV EMORY (UEMR)   LIOTTA D C,  PAINTER G R,  BLUEMLING G R,  DE LA ROSA A;  WO2015054465-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  WO2015069939-A1   CLARKE M O H (CLAR-Individual);  DOERFFLER E (DOER-Individual);  MACKMAN R L (MACK-Individual);  SIEGEL D (SIEG-Individual)   CLARKE M O H,  DOERFFLER E,  MACKMAN R L,  SIEGEL D;  WO2015099989-A1   CASTEEL M J (CAST-Individual);  DASHNER K (DASH-Individual);  JUNG H (JUNG-Individual);  SEO M S (SEOM-Individual);  SHI B (SHIB-Individual);  WANG F (WANG-Individual);  ZIA V (ZIAV-Individual)   CASTEEL M J,  DASHNER K,  JUNG H,  SEO M S,  SHI B,  WANG F,  ZIA V;  WO2015100144-A1   GILEAD SCI INC (GILE)   BRINGLEY D,  CHAN J,  FUNG P,  KEATON K,  LAPINA O,  MORRISON H,  PCION D;  WO2015108780-A1   HURLEY P B (HURL-Individual);  LAPINA O V (LAPI-Individual);  SHI B (SHIB-Individual);  WANG F (WANG-Individual);  WANG Z X (WANG-Individual);  WOO J C (WOOJ-Individual)   HURLEY P B,  LAPINA O V,  SHI B,  WANG F,  WANG Z X,  WOO J C;  WO2015120057-A1   BEGLEY R R (BEGL-Individual);  CUSTODIO J M (CUST-Individual);  KEARNEY B P (KEAR-Individual)   BEGLEY R R,  CUSTODIO J M,  KEARNEY B P;  WO2015130964-A1   GILEAD SCI INC (GILE)   BONDY S S,  CHOU C,  LINK J O,  TSE W C;  WO2015130966-A1   GILEAD SCI INC (GILE)   BONDY S S,  CHOU C,  LINK J O,  TSE W C;  WO2015179448-A1   GILEAD SCI INC (GILE)   BABAOGLU K,  MCFADDEN R,  MITCHELL M L;  WO2015191726-A1   CAI S (CAIS-Individual);  DU Z (DUZZ-Individual);  KIM M (KIMM-Individual);  LOYER-DREW J A (LOYE-Individual);  NADUTHAMBI D (NADU-Individual);  PATEL L (PATE-Individual);  PHILLIPS B W (PHIL-Individual);  PHILLIPS G (PHIL-Individual);  STEVENS K L (STEV-Individual);  TREIBERG J A (TREI-Individual);  VAN VELDHUIZEN J (VVEL-Individual);  WATKINS W J (WATK-Individual);  YEUNG S C (YEUN-Individual)   CAI S,  DU Z,  KIM M,  LOYER-DREW J A,  NADUTHAMBI D,  PATEL L,  PHILLIPS B W,  PHILLIPS G,  STEVENS K L,  TREIBERG J A,  VAN VELDHUIZEN J,  WATKINS W J,  YEUNG S C;  WO2015191743-A1   EVARTS J (EVAR-Individual);  KAPLAN J (KAPL-Individual);  PATEL L (PATE-Individual);  PERREAULT S (PERR-Individual);  PHILLIPS B W (PHIL-Individual);  PHILLIPS G (PHIL-Individual);  TREIBERG J A (TREI-Individual);  YEUNG S C (YEUN-Individual)   EVARTS J,  KAPLAN J,  PATEL L,  PERREAULT S,  PHILLIPS B W,  PHILLIPS G,  TREIBERG J A,  YEUNG S C;  WO2015191745-A1   DU Z (DUZZ-Individual);  EVARTS J (EVAR-Individual);  KAPLAN J (KAPL-Individual);  KIM M (KIMM-Individual);  NADUTHAMBI D (NADU-Individual);  PATEL L (PATE-Individual);  PERREAULT S (PERR-Individual);  PHILLIPS B W (PHIL-Individual);  PHILLIPS G (PHIL-Individual);  STEVENS K L (STEV-Individual);  TREIBERG J A (TREI-Individual);  VAN VELDHUIZEN J (VVEL-Individual);  WATKINS W J (WATK-Individual);  YEUNG S C (YEUN-Individual)   DU Z,  EVARTS J,  KAPLAN J,  KIM M,  NADUTHAMBI D,  PATEL L,  PERREAULT S,  PHILLIPS B W,  PHILLIPS G,  STEVENS K L,  TREIBERG J A,  VAN VELDHUIZEN J,  WATKINS W J,  YEUNG S C;  WO2015191752-A1   CAI S (CAIS-Individual);  DU Z (DUZZ-Individual);  KAPLAN J (KAPL-Individual);  LOYER-DREW J A (LOYE-Individual);  NADUTHAMBI D (NADU-Individual);  PHILLIPS B W (PHIL-Individual);  PHILLIPS G (PHIL-Individual);  VAN VELDHUIZEN J (VVEL-Individual);  YEUNG S C (YEUN-Individual)   CAI S,  DU Z,  KAPLAN J,  LOYER-DREW J A,  NADUTHAMBI D,  PHILLIPS B W,  PHILLIPS G,  VAN VELDHUIZEN J,  WATKINS W J,  YEUNG S C;  WO2015196137-A1   CARRA E A (CARR-Individual);  CHEN I (CHEN-Individual);  KEATON K A (KEAT-Individual);  ZIA V (ZIAV-Individual)   CARRA E A,  CHEN I,  KEATON K A,  ZIA V;  WO2015200205-A1   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  DYATKINA N (DYAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  DYATKINA N,  SMITH D B,  SYMONS J A;  WO2015200219-A1   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  SMITH D B,  SYMONS J A;  WO2016007765-A1   GELEZIUNAS R (GELE-Individual);  HESSELGESSER J E (HESS-Individual)   GELEZIUNAS R,  HESSELGESSER J E;  WO2016018697-A1   CLARKE M O H (CLAR-Individual);  MACKMAN R L (MACK-Individual);  SIEGEL D (SIEG-Individual)   CLARKE M O H,  MACKMAN R L,  SIEGEL D;  WO2016028866-A1   GILEAD SCI INC (GILE)   CLARKE M O H,  MACKMAN R L,  SIEGEL D;  WO2016033243-A1   GILEAD SCI INC (GILE)   BRIZGYS G,  CANALES E,  HALCOMB R L,  HU Y E,  KATO D,  LINK J O,  LIU Q,  SAITO R D,  TSE W C,  ZHANG J R;  WO2016036759-A1   GILEAD SCI INC (GILE)   BABUSIS D M,  RAY A S,  WANG J;  WO2016096116-A1   GILEAD SCI INC (GILE)   GEGE C,  KINZEL O,  KREMOSER C;  WO2016105532-A1   GILEAD SCI INC (GILE);  ORGANIC CHEM & BIOCHEM ACAD INST (CESK)   JANSA P,  KVASNICA M,  MACKMAN R L;  WO2016105534-A1   GILEAD SCI INC (GILE)   JANSA P,  MACKMAN R L,  HU Y E,  LANSDON E;  WO2016105564-A1   GILEAD SCI INC (GILE);  ORGANIC CHEM & BIOCHEM ACAD INST (CESK)   JANSA P,  SIMON T,  LANSDON E,  HU Y E,  BASZCZYNSKI O,  DEJMEK M,  MACKMAN R L;  WO2016106050-A1   UNIV EMORY (UEMR)   PAINTER G R,  GUTHRIE D B,  BLUEMLING G R,  NATCHUS M G;  WO2016106237-A1   GILEAD SCI INC (GILE)   BACON E M,  CAI Z R,  COTTELL J J,  JI M,  JIN H,  LAZERWITH S E,  MORGANELLI P A,  PYUN H;  WO2016134054-A1   ABBVIE INC (ABBI)   CHEN H J,  DEGOEY D A,  KALTHOD V,  KRUEGER A C,  WAGNER R,  RANDOLPH J T;  WO2016141092-A1   GILEAD SCI INC (GILE)   AKTOUDIANAKIS E,  CHIN G,  MACKMAN R L,  METOBO S E,  MISH M R,  PYUN H,  ZABLOCKI J;  WO2016161382-A1   GILEAD SCI INC (GILE)   CAI Z R,  JIN H,  LAZERWITH S E,  PYUN H;  WO2016168349-A1   GILEAD SCI INC (GILE)   AGUAYO E,  APPLEBY T,  BIRKUS G,  CHENG G,  DORNAN D,  KOBAYASHI T,  MELLO C C,  SCHMITZ U,  WILLKOM M,  YU M;  WO2016186967-A1   GILEAD SCI INC (GILE)   BARTLETT M J,  CODELLI J A,  CORKEY B K,  COSMAN J L,  ELBEL K,  LOYER-DREW J A,  SPERANDIO D,  VAN VELDHUIZEN J,  YANG H,  YEUNG S C;  WO2016205141-A1   GILEAD SCI INC (GILE)   SHI B,  SU Z,  WANG F;  WO2017004012-A1   GILEAD SCI INC (GILE);  JANSSEN SCI IRELAND UC (JOHJ)   KOZIARA J,  SPERGER D;  WO2017004244-A1   GILEAD SCI INC (GILE)   KOZIARA J M,  MCCALLISTER S;  WO2017035230-A1   GILEAD SCI INC (GILE)   BONDY S S,  MCFADDEN R;  WO2017040895-A1   ABBVIE INC (ABBI)   CHEN H J,  DEGOEY D A,  KALTHOD V,  KRUEGER A C,  RANDOLPH J T,  WAGNER R;  WO2017040896-A1   ABBVIE INC (ABBI)   CHEN H J,  DEGOEY D A,  KALTHOD V,  KRUEGER A C,  RANDOLPH J T,  WAGNER R;  WO2017048727-A1   GILEAD SCI INC (GILE)   GELEZIUNAS R,  HESSELGESSER J E,  KAUR J,  MURRY J P,  SLOAN D D;  WO2017049060-A1   GILEAD SCI INC (GILE)   CLARKE M O H,  FENG J Y,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  WO2017059120-A1   GILEAD SCI INC (GILE)   YU H,  CIHLAR T,  STEPAN G,  SLOAN D D,  MURRY J P,  HU Y E,  GRAUPE M;  WO2017083304-A1   GILEAD SCI INC (GILE)   HONG L,  COLLMAN B M;  WO2017106556-A1   GILEAD SCI INC (GILE)   DU Z,  DORNAN D,  GUERRERO J A,  KAPLAN J A,  KNOX J E,  NADUTHAMBI D,  PHILLIPS B W,  STINSON S Y,  VENKATARAMANI C,  WANG P,  WATKINS W J;  WO2017156380-A1   UNIV EMORY (UEMR)   PAINTER G R,  GUTHRIE D B,  BLUEMLING G R,  NATCHUS M R;  WO2017165489-A1   UNIV EMORY (UEMR)   SCHINAZI R F,  AMBLARD F,  COX B D,  BASSIT L,  ZHOU L,  GAVEGNANO C;  WO2017184668-A1   GILEAD SCI INC (GILE)   CLARKE M O H,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  WO2017205078-A1   GILEAD SCI INC (GILE)   GAGGAR A,  SUBRAMANIAN M G;  WO2017205115-A1   GILEAD SCI INC (GILE)   AKTOUDIANAKIS E,  CANALES E,  CHIN E,  CURRIE K S,  KATANA A A,  KATO D,  LINK J O,  METOBO S E,  SAITO R D,  YANG Z;  WO2017223020-A1   MERCK SHARP & DOHME CORP (MERI);  IDENIX PHARM LLC (INEM);  BOGEN S (BOGE-Individual);  DUKHAN D (DUKH-Individual);  ALEXANDRE F (ALEX-Individual);  RAHALI R (RAHA-Individual);  PARSY C C (PARS-Individual);  MILHAU J (MILH-Individual);  ROUVIERE C P (ROUV-Individual);  DOUSSON C B (DOUS-Individual)   BOGEN S,  DUKHAN D,  ALEXANDRE F,  RAHALI R,  PARSY C C,  MILHAU J,  ROUVIERE C P,  DOUSSON C B;  WO2017223268-A1   UNIV YALE (UYYA);  GILEAD SCI INC (GILE)   TURK B,  CALDERWOOD D,  SCHLESSINGER J,  SHI X,  BATES J,  BRECKENRIDGE D,  KUSAM S;  WO2019113462-A1   UNIV EMORY (UEMR)   PAINTER G R,  BLUEMLING G R,  NATCHUS M G,  GUTHRIE D;  WO2019173602-A1   UNIV EMORY (UEMR)   PAINTER G R,  PERRYMAN D,  BLUEMLING G R;  WO1994003467-A2   ;  WO1994024144-A2   ;  WO2003090691-A2   GILEAD SCI INC (GILE)   BIRKUS G,  CHEN J M,  CHEN X,  CIHLAR T,  EISENBERG E J,  HATADA M,  HE G,  KIM C U,  LEE W A,  MCDERMOTT M J,  SWAMINATHAN S;  WO2004005286-A2   LEUVEN RES&DEV (UYLN);  GILEAD SCI INC (GILE)   NEYTS J,  PUERSTINGER G,  DE CLERCQ E;  WO2004006843-A2   TRIANGLE PHARM INC (TRIA-Non-standard)   FURMAN P A;  WO2004031224-A2   GILEAD SCI INC (GILE)   DELANEY W E,  XIONG X;  WO2004035576-A2   GILEAD SCI INC (GILE)   CHEN J M,  CHEN X,  FARDIS M,  JIN H,  KIM C U,  SCHACHERER L N;  WO2004035577-A2   GILEAD SCI INC (GILE)   CHEN J M,  CHEN X,  FARDIS M,  JIN H,  KIM C U,  SCHACHERER L N;  WO2004050613-A2   TRIANGLE PHARM INC (TRIA-Non-standard)   SZNAIDMAN M,  PAINTER G R,  ALMOND M R,  CLEARY D G,  PESYAN A;  WO2004096286-A2   GILEAD SCI INC (GILE);  BOOJAMARA C G (BOOJ-Individual);  CANNIZZARO C E (CANN-Individual);  CHEN J M (CHEN-Individual);  CHEN X (CHEN-Individual);  CHO A (CHOA-Individual);  CHONG L S (CHON-Individual);  FARDIS M (FARD-Individual);  JIN H (JINH-Individual);  HIRSCHMANN R F (HIRS-Individual);  HUANG A X (HUAN-Individual);  KIM C U (KIMC-Individual);  KIRSCHBERG T A (KIRS-Individual);  LEE C P (LEEC-Individual);  LEE W A (LEEW-Individual);  MACKMAN R L (MACK-Individual);  MARKEVITCH D Y (MARK-Individual);  OARE D (OARE-Individual);  PRASAD V K (PRAS-Individual);  PYUN H (PYUN-Individual);  RAY A S (RAYA-Individual);  SHERLOCK R (SHER-Individual);  SWAMINATHAN S (SWAM-Individual);  WATKINS W (WATK-Individual);  ZHANG J R (ZHAN-Individual)   BOOJAMARA C G,  CANNIZZARO C E,  CHEN J M,  CHEN X,  CHO A,  CHONG L S,  FARDIS M,  JIN H,  HIRSCHMANN R F,  HUANG A X,  KIM C U,  KIRSCHBERG T A,  LEE C P,  LEE W A,  MACKMAN R L,  MARKEVITCH D Y,  OARE D,  PRASAD V K,  PYUN H,  RAY A S,  SHERLOCK R,  SWAMINATHAN S,  WATKINS W,  ZHANG J R;  WO2004096287-A2   WATKINS W (WATK-Individual);  ZHANG J R (ZHAN-Individual);  GILEAD SCI INC (GILE);  CANNIZZARO C E (CANN-Individual);  CHEN J M (CHEN-Individual);  CHEN X (CHEN-Individual);  CHO A (CHOA-Individual);  CHONG L S (CHON-Individual);  FARDIS M (FARD-Individual);  KIRSCHBERG T A (KIRS-Individual);  PYUN H (PYUN-Individual)   CANNIZZARO C E,  CHEN J M,  CHEN X,  CHO A,  CHONG L S,  FARDIS M,  KIRSCHBERG T A,  PYUN H,  WATKINS W,  ZHANG J R;  WO2004096818-A2   GILEAD SCI INC (GILE)   BIRKUS G,  CHEN J M,  CHEN X,  CIHLAR T,  EISENBERG E J,  HATADA M,  HE G,  KIM C U,  LEE W A,  MCDERMOTT M J,  SWAMINATHAN S;  WO2004100960-A2   NELSON P H (NELS-Individual);  OARE D (OARE-Individual);  PYUN H (PYUN-Individual);  RAY A S (RAYA-Individual);  SHERLOCK R (SHER-Individual);  SWAMINATHAN S (SWAM-Individual);  CANNIZZARO C E (CANN-Individual);  WATKINS W (WATK-Individual);  ZHANG J R (ZHAN-Individual);  CHEN J M (CHEN-Individual);  CHEN X (CHEN-Individual);  CHO A (CHOA-Individual);  CHONG L S (CHON-Individual);  FARDIS M (FARD-Individual);  GIBBS C (GIBB-Individual);  HIRSCHMANN R F (HIRS-Individual);  GILEAD SCI INC (GILE);  KIRSCHBERG T A (KIRS-Individual);  LEE C P (LEEC-Individual);  LIN K (LINK-Individual);  MACKMAN R L (MACK-Individual)   CANNIZZARO C E,  CHEN J M,  CHEN X,  CHO A,  CHONG L S,  FARDIS M,  GIBBS C,  HIRSCHMANN R F,  KIRSCHBERG T A,  LEE C P,  LIN K,  MACKMAN R L,  NELSON P H,  OARE D,  PYUN H,  RAY A S,  SHERLOCK R,  SWAMINATHAN S,  WATKINS W,  ZHANG J R;  WO2005002626-A2   GILEAD SCI INC (GILE)   BOOJAMRA C G,  CANNIZZARO C E,  CHEN J M,  CHEN X,  CHO A,  CHONG L S,  DESAI M,  FARDIS M,  GIBBS C S,  HIRSCHMANN R F,  HUANG A X,  JIN H,  KIM C U,  KIRSCHBERG T A,  KRAWCZYK S,  LEE C P,  LEE W A,  LIN K,  MACKMAN R L,  MARKEVITCH D Y,  NELSON P H,  OARE D A,  PRASAD V K,  PYUN H,  RAY A S,  SHERLOCK R,  SWAMINATHAN S,  WATKINS W J,  ZHANG J R,  ZHANG L;  WO2005012324-A2   GILEAD SCI INC (GILE)   KRAWCZYK S H;  WO2005039552-A2   GILEAD SCI INC (GILE);  CHO A (CHOA-Individual);  KIRSCHBERG T A (KIRS-Individual);  WATKINS W (WATK-Individual);  FARDIS M (FARD-Individual);  CHONG L S (CHON-Individual)   CHO A,  KIRSCHBERG T A,  WATKINS W,  FARDIS M,  CHONG L S;  WO2005047898-A2   GILEAD SCI INC (GILE)   MCDERMOTT M;  WO2005063744-A2   LEUVEN RES&DEV (UYLN);  GILEAD SCI INC (GILE);  PUERSTINGER G (PUER-Individual)   PUERSTINGER G,  BONDY S S,  DOWDY E D,  KIM C U,  OARE D A,  NEYTS J,  ZIA V;  WO2005070901-A2   GILEAD SCI INC (GILE)   JIN H,  KIM C U;  WO2005117904-A2   GILEAD SCI INC (GILE);  PASTOR R M (PAST-Individual);  CAI Z R (CAIZ-Individual);  CHEN X (CHEN-Individual);  FARDIS M (FARD-Individual);  JABRI S Y (JABR-Individual);  JIN H (JINH-Individual);  KIM C U (KIMC-Individual);  METOBO S E (METO-Individual);  MISH M R (MISH-Individual)   CAI Z R,  CHEN X,  FARDIS M,  JABRI S Y,  JIN H,  KIM C U,  METOBO S E,  MISH M R,  PASTOR R M;  WO2006015261-A2   GILEAD SCI INC (GILE)   BOOJAMRA C G,  LIN K,  MACKMAN R L,  MARKEVITCH D Y,  PETRAKOVSKY O V,  RAY A S,  ZHANG L;  WO2006017044-A2   GILEAD SCI INC (GILE)   DAHL T C;  WO2006020276-A2   GILEAD SCI INC (GILE)   CHAUDHARY K,  FLEURY M,  KIM C U,  MCMURTRIE D J,  SHENG X C;  WO2006047661-A2   GILEAD SCI INC (GILE);  WATKINS W J (WATK-Individual);  CHO A (CHOA-Individual)   WATKINS W J,  CHO A;  WO2006069193-A2   GILEAD SCI INC (GILE)   BONDY S S,  OARE D A,  TSE W C;  WO2006110157-A2   GILEAD SCI INC (GILE)   BOOJAMRA C G,  LIN K,  MACKMAN R L,  MARKEVITCH D Y,  PETRAKOVSKY O V,  RAY A S,  ZHANG L;  WO2006125048-A2   GILEAD SCI INC (GILE)   CAI Z R,  JABRI S Y,  JIN H,  KIM C U,  LANSDOWN R A,  METOBO S E,  MISH M R,  PASTOR R M;  WO2007009109-A2   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  SHENG X C;  WO2007014174-A2   GILEAD SCI INC (GILE);  LEUVEN RES&DEV (UYLN);  PUERSTINGER G (PUER-Individual)   BODDEKER N,  NEYTS J,  SHIH I,  VLIEGEN I,  ZHONG W;  WO2007014352-A2   GILEAD SCI INC (GILE)   CAI Z R,  JABRI S Y,  JIN H,  KIM C U,  METOBO S E,  MISH M R,  PASTOR R M;  WO2007126812-A2   GILEAD SCI INC (GILE)   CRAWFORD K R,  DOWDY E D,  GUTIERREZ A,  POLNIASZEK R P,  YU R H C;  WO2008003149-A2   GILEAD SCI INC (GILE)   HERDEWIJN P A M,  DE JONGHE S C A,  LEE W A,  WATKINS W J,  BONDY S S,  CHONG L S;  WO2008005519-A2   GILEAD SCI INC (GILE);  LEUVEN RES&DEV (UYLN);  PUERSTINGER G (PUER-Individual)   BONDY S S,  DAHL T C,  OARE D A,  OLIYAI R,  TSE W C,  ZIA V;  WO2008005542-A2   GILEAD SCI INC (GILE)   BOOJAMRA C G,  CHEN J M,  HUANG A X,  KIM C U,  LIN K,  MACKMAN R L,  OARE D A,  PERRY J K,  SAUNDERS O L,  SWAMINATHAN S,  ZHANG L;  WO2008009076-A2   GILEAD SCI INC (GILE)   HERDEWIJN P A M,  DE JONGHE S C A,  WATKINS W J,  CHONG L S,  ZHANG J;  WO2008009077-A2   GILEAD SCI INC (GILE)   GAO L,  HERDEWIJN P A M,  DE JONGHE S C A,  WATKINS W J,  CHONG L S;  WO2008009078-A2   GILEAD SCI INC (GILE)   GAO L,  HERDEWIJN P A M,  DE JONGHE S C A,  WATKINS W J,  CHONG L S;  WO2008009079-A2   GILEAD SCI INC (GILE)   HERDEWIJN P A M,  DE JONGHE S C A,  WATKINS W J,  CHONG L S;  WO2008010921-A2   ;  WO2008011116-A2   GILEAD SCI INC (GILE)   CANNIZZARO C E,  CHEN J M,  DESAI M C,  MITCHELL M L,  SWAMINATHAN S,  XU L;  WO2008011117-A2   GILEAD SCI INC (GILE)   CANNIZZARO C E,  YANG Z,  DESAI M C,  MITCHELL M L,  XU L,  SWAMINATHAN S,  CHEN J M;  WO2008016522-A2   GILEAD SCI INC (GILE);  KOREA RES INST CHEM TECHNOLOGY (KRIC)   GUO H,  KIM C U,  KIM H S,  LEE C,  LEE Y,  MITCHELL M L,  SON J C,  XU L;  WO2008100447-A2   GILEAD SCI INC (GILE)   CHEN J M,  HUANG A X,  MACKMAN R L,  PARRISH J P,  PERRY J K,  SAUNDERS O L,  SPERANDIO D;  WO2008133669-A2   BONDY S S (BOND-Individual);  OARE D A (OARE-Individual);  PUERSTINGER G (PUER-Individual)   BONDY S S,  OARE D A,  PUERSTINGER G;  WO2009005674-A2   GILEAD SCI INC (GILE);  KOREA RES INST CHEM TECHNOLOGY (KRIC)   GUO H,  KIM C U,  LEE I Y,  MITCHELL M L,  RHODES G,  SON J C,  XU L;  WO2009005676-A2   GILEAD SCI INC (GILE)   CHO A,  CLARKE M O H,  KIM C U,  LINK J O,  PYUN H,  SHENG X C,  WU Q;  WO2009005677-A2   GILEAD SCI INC (GILE)   COTTELL J J,  LINK J O,  SCHROEDER S D,  TAYLOR J,  TSE W C,  VIVIAN R W,  YANG Z;  WO2009005690-A2   GILEAD SCI INC (GILE)   CAI Z R,  CHO A,  KIM C U,  XU J;  WO2009058800-A2   HARVARD COLLEGE (HARD)   LEE S,  VERDINE G L;  WO2009105513-A2   GILEAD SCI INC (GILE)   BIRKUS G,  RAY A S,  TUMAS D,  WATKINS W J;  WO2011156610-A2   GILEAD SCI INC (GILE)   CAI Z R,  DU Z,  JI M,  JIN H,  KIM C U,  MISH M R,  PHILLIPS B W,  PYUN H,  SHENG X C,  WU Q,  ZONTE C S;  WO2012068234-A2   GILEAD SCI INC (GILE)   BACON E M,  COTTELL J J,  KATANA A A,  KATO D,  KRYGOWSKI E S,  LINK J O,  TAYLOR J,  TRAN C V,  TREJO MARTIN T A,  YANG Z,  ZIPFEL S;  WO2012142523-A2   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  KIRSCHBERG T A,  MISH M R,  SQUIRES N;  WO2013040492-A2   GILEAD SCI INC (GILE);  RAY A S (RAYA-Individual);  WATKINS W J (WATK-Individual);  LINK J O (LINK-Individual);  OLDACH D W (OLDA-Individual);  DELANEY W E (DELA-Individual)   RAY A S,  WATKINS W J,  LINK J O,  OLDACH D W,  DELANEY W E;  WO2014134566-A2   GILEAD SCI INC (GILE)   BRIZGYS G,  CANALES E,  CHOU C,  GRAUPE M,  HU Y E,  LINK J O,  LIU Q,  LU Y,  SAITO R D,  SCHROEDER S D,  SOMOZA J R,  TSE W C,  ZHANG J R;  WO2015084741-A2   DENNING J M (DENN-Individual);  MCHUTCHISON J G (MCHU-Individual);  SUBRAMANIAN G M (SUBR-Individual);  SYMONDS W T (SYMO-Individual)   DENNING J M,  MCHUTCHISON J G,  SUBRAMANIAN G M,  SYMONDS W T;  WO2015191526-A2   BACON E M (BACO-Individual);  COTTELL J J (COTT-Individual);  LINK J O (LINK-Individual);  TREJO M T A (TREJ-Individual);  ZIPFEL S (ZIPF-Individual)   BACON E M,  COTTELL J J,  LINK J O,  TREJO M T A,  ZIPFEL S;  WO2015191754-A2   KIM M (KIMM-Individual);  PERREAULT S (PERR-Individual);  YEUNG S C (YEUN-Individual)   KIM M,  PERREAULT S,  YEUNG S C;  WO2017059224-A2   GILEAD SCI INC (GILE);  ONO PHARM CO LTD (ONOY)   VENKATARAMAN S,  TUMAS D,  TANAKA K,  YASUHIRO T,  YOSHIZAWA T;  WO2017106346-A2   GILEAD SCI INC (GILE)   BALAKRISHNAN M,  CARR B A,  CORBIN J,  PACE C S,  THOMSEN N D,  ZHANG X;  WO2017184670-A2   GILEAD SCI INC (GILE)   CIHLAR T,  CLARKE M O N H,  JORDAN R,  MACKMAN R L,  SIEGEL D;  WO2002032920-A3   ;  WO2002100415-A3   ;  WO2003090690-A3   GILEAD SCI INC (GILE)   ARIMILLI M N,  BECKER M M,  BRYANT C,  CHEN J M,  CHEN X,  DASTGAH A,  FARDIS M,  HE G,  JIN H,  KIM C U,  LEE W A,  LEE C P,  LIN K,  LIU H,  MACKMAN R L,  MITCHELL M L,  NELSON P H,  PYUN H,  ROWE T D,  SPARACINO M,  SWAMINATHAN S,  TARIO J D,  WANG J,  WILLIAMS M A,  XU L,  YANG Z,  YU R H,  ZHANG J,  ZHANG L;  WO2007022268-A3   IRM LLC (IRMI);  SCRIPPS RES INST (SCRI)   OKRAM B,  REN P,  GRAY N S	WO2019113462-A1  MERTES ET AL.:          "Nucleic Acid Components and Their Analogues. Cxv.*          synthesis of n4 -hydroxy -6-azacytidine 5' -phosphate and          5' -diphosphate", COLLECTION OF CZECHOSLOVAK CHEMICAL          COMMUNICATIONS, vol. 33, no. 10, 1968, pages 3304 - 3312,          XP055616177, Retrieved from the Internet          &lt;URL:http://cccc.uochb.cas.cz/33/10/3304&gt;          [retrieved on 20190123],relevantClaims[3];  BROWN ET AL.:          "Mechanism of the Mutagenic Action of Hydroxylamine",          JOURNAL OF MOLECULAR BIOLOGY, vol. 11, no. 4, 1 April          1965 (1965-04-01), pages 663 - 671, XP026060291,          Retrieved from the Internet          &lt;URL:https://www.sciencedirect.com/sciancelarticlelpii/SO022283665800249&gt;          [retrieved on 20190123],relevantClaims[17, 18]CN111372592-A  D.M.BROWN ET AL.:          "Mechanism of the mutagenic action of hydroxylamine",          JOURNAL OF MOLECULAR          BIOLOGY,relevantClaims[1-4],relevantPassages[663-671]GB2581936-B            MERTES et al. Nucleic Acid Components and Their          Analogues. Cxv.*synthesis of n4-hydroxy-6-azacytidine          5'-phosphate and 5'-diphosphate, Collection of          Czechoslovak Chemical Communications, Vol.33, Issue.10,          1968 (retrieved on 23 January 2019). Retrieved from the          Internet;            Brown et al. Mechanism of the Mutagenic Action of          Hydroxylamine, Journal of Molecular Biology, Vol. 11, No.          4, 01 April 1965 (retrieved on 23 January 2019).          Retrieved from the Internet: &lt;URL:          https://www.sciencedirect.com/science/article/pii/SOO2283665800249&gt;          Pgs 663-671US11147826-B2            Bebenek, K.; Janion, C., Ability of base analogs to          induce the SOS response: effect of a dam mutation and          mismatch repair system. MGG, Mol. Gen. Genet. 1985, 201          (3), 519-24.;            Borodavkin, A. V.; Chekhov, V. O.; Dolin, Y. S.; Morozov,          Y. V.; Savin, F. A.; Budowskii, E. I.; Yakovlev, D. Y.,          Absorption UV spectroscopy and electronic structure of          ionic and tautomeric forms of hydroxy and methoxy          derivatives of cytosine and adenine, and of some          5-substituted analogs of pyrimidines. Int. J. Quantum          Chem. 1980, 17 (4), 803-11.;            Brown, D. M.; Schell, P., Nucleotides. XLVIII. The          reaction of hydroxylamine with cytosine and related          compounds. J. Chem. Soc. (Jan. 1965), 208-15.;            Budovskii, E. I.; Postnova, T. I., Mechanism of the          mutagenic action of hydroxylamine. X. Certain          specificities in the mutagenesis of N-hydroxy and          N-methoxy analogs of cytosine and adenine derivatives.          Mutat. Res. 1976, 37 (1), 11-17.;            Chekhov, V. O.; Budovskii, E. I.; Morozov, Y. V.; Savin,          F. A.; Yakovlev, D. Y., UV spectroscopy of fixed amino          and imino forms of cytidine and its N4-hydroxy and          N4-methoxy derivatives. Biofizika 1979, 24 (4), 772-3.          English Abstract Only.;            Chekhov, V. O.; Savin, F. A.; Morozov, Y. V.; Budovskii,          E. I.; Yakovlev, D. Y., Electron structure of some          hydroxy and methoxy derivatives of cytosine and adenine.          Biofizika 1979, 24 (4), 773-4. English Abstract          only.;            Chung, K. C.; Hayatsu, H., the reaction of hydroxylamine          with 4-thiouridine. Yongnam Taehakkyo Chonyonmul Hwahak          Yonguso Yongu Pogo 1976, 3, 31-6. English Abstract          Only.;  De          Serres, F. J.; Brockman, H. E., Comparison of the spectra          of genetic damage in N4-hydroxycytidine-induced ad-3          mutations between nucleotide excision repair-proficient          and -deficient heterokaryons of Neurospora crassa. Mutat.          Res., Fundam. Mol. Mech. Mutagen. 1993, 285 (2),          145-63.;            Fraenkel-Conrat, H.; Singer, B., Chemical basis for the          mutagenicity of hydroxylamine and methoxyamine. Biochim.          Biophys. Acta, Nucleic Acids Protein Synth. 1972, 262          (3), 264-8.;            Iida, S.; Chung, K. C.; Hayatsu, H., Reaction of          hydroxylamine with 4-thiouridine. Biochim. Biophys. Acta,          Nucleic Acids Protein Synth. 1973, 308 (2),          198-204.;            Janion, C., the efficiency and extent of mutagenic          activity of some new mutagens of the base-analog type.          Mutat. Res., Genet. Toxicol. Test. 1978, 56 (3),          225-34.;            Janion, C.; Bebenek, K.; Plewako, S., Are &lt;xhtml:i          &gt;Escherichia coli&lt;/xhtml:i&gt;dam- as          compared to dam+ hypermutable by base analogs? Acta          Biochim. Pol. 1987, 34 (2), 183-93.;            Janion, C.; Glickman, B. W., N4-Hydroxycytidine: a          mutagen specific for AT to GC transitions. Mutat. Res.          1980, 72 (1), 43-7.;            Janion, C.; Kajtaniak, E., Mutagenesis induced in amber          P22 phages by base analogs. Mutat. Res. 1979, 62 (1),          191-5.;            Janion, C.; Popowska, E., The reduction of          N4-hydroxycytidine to cytidine by Salmonella typhimurium          cells. Nucleic Acids Res., Spec. Publ. 1975, (III Symp.          on Chemistry of Nucleic Acids Components, Liblice Castle,          Czechoslovakia, Oct. 8-12, 1975), S159-S163.;            Janion, C.; Shugar, D., Mechanism of hydroxylamine          mutagenesis: complexing properties of copolymers of          hydroxycytidylic acid with cytidylic or uridylic acids.          Acta Biochim. Pol. 1969, 16 (2), 219-32.;            Krompholz, et al., The Mitochondrial Amidoxime Reducing          Component (mARC) Is Involved in Detoxification of          N-Hydroxylated Base Analogues. Chem. Res. Toxicol. 2012,          25 (11), 2443-2450.;            Levin, D. E.; Ames, B. N., Classifying mutagens as to          their specificity in causing the six possible transitions          and transversions: a simple analysis using the          &lt;xhtml:i          &gt;Salmonella&lt;/xhtml:i&gt;mutagenicity          assay. Environ. Mutagen. 1986, 8 (1), 9-28.;            Morozov, Y. V.; Savin, F. A.; Chekhov, V. O.; Budovskii,          E. I.; Yakovlev, D. Y., Photochemistry of          N6-methoxyadenosine and of N4-hydroxycytidine and its          methyl derivatives. I: Spectroscopic and quantum chemical          investigation of ionic and tautomeric forms: syn-anti          isomerization. J. Photochem. 1982, 20 (3),          229-52.;            Popowska, E.; Janion, C., N4-Hydroxycytidine. New mutagen          of a base analog type. Biochem. Biophys. Res. Commun.          1974, 56 (2), 459-66.;            Poslovina, A. S.; Vasyunina, E. A.; Andreeva, I. S.;          Salganik, R. I. In Effect of adenine and cytosine on the          mutagenic effect of hydroxylamine and study of the          mutagenic activity of the products of their modification          by hydroxylamine, Nauka: 1976; pp. 142-145. English          Abstract Only.;            Poslovina, A. S.; Vasyunina, E. A.; Andreeva, I. S.;          Salganik, R. I., Mutagenic effect of N4-HYDR oxycytidine,          the product of cytidine modification by hydroxylamine, in          &lt;xhtml:i &gt;Escherichia          coli&lt;/xhtml:i&gt;B. Genetika 1973, 9 (5),          76-81. English Abstract Only.;            Poslovina, A. S.; Vasyunina, E. A.; Andreeva, I. S. In          Mutagenic action of cytidine and adenosine derivatives          modified by hydroxylamine, Akad. Nauk SSSR, Sib. Otd.,          Inst. Tsitol. Genet.: 1974; pp. 7-8. English Abstract          Only.;            Salganik, R. I.; Vasyunina, E. A.; Poslovina, A. S.;          Andreeva, I. S., Mutagenic action of N4-hydroxycytidine          on &lt;xhtml:i &gt;Escherichia          coli&lt;/xhtml:i&gt;B cyt. Mutat. Res. 1973, 20          (1), 1-5.;            Sidwell, R.W., D.F. Smee, and D.L. Barnard 2006.          Development of antiviral drugs against avian (H5N1)          influenza virus. In: J.P. Wong (Ed.), Recent Developments          on the Avian Influenza (H5N1) Crisis. Transworld Research          Network, Kerala, India pp. 63-83.;            Singer, B., The effect of base modification on fidelity          in transcription. Jerusalem Symp. Quantum Chem. Biochem.          1980, 13 (Carcinog.: Fundam. Mech. Environ. Eff.),          91-102.;            Singer, B.; Spengler, S., Ambiguity and transcriptional          errors as a result of modification of exocyclic amino          groups of cytidine, guanosine, and adenosine.          Biochemistry 1981, 20 (5), 1127-32.;            Sledziewska, E.; Janion, C., Mutagenic specificity of          N4-hydroxycytidine. Mutat. Res. 1980, 70 (1),          11-16.;            Sledziewska-Gojska, E.; Janion, C., Do DNA repair systems          affect N4-hydroxycytidine-induced mutagenesis? Acta          Biochim. Pol. 1983, 30 (2), 149-57.;            Sledziewska-Gojska, E.; Janion, C., Effect of          proofreading and dam-instructed mismatch repair systems          on N4-hydroxycytidine-induced mutagenesis. MGG, Mol. Gen.          Genet. 1982, 186 (3), 411-18.;            Smrt, J., Homopolymers of N4-hydroxy- and          N4-methoxycytidylic acid and their interaction with          polyadenylic acid. Collect. Czech. Chem. Commun. 1970, 35          (8), 2314-23.;            Yakovlev, D. Y.; Simukova, N. A.; Budovskii, E. I.;          Chekhov, V. O.; Savin, F. A.; Morozov, Y. V.,          Photochemistry of N6-methoxyadenosine and of          N4-hydroxycytidine and its methyl derivatives. II:          Photoinduced rupture of the nitrogen-oxygen bond. J.          Photochem. 1982, 20 (3), 253-68.;            Examination report No. 1 issued for Australian          Application No. 2018378832, dated May 7, 2020.;            Examination report No. 2 issued for Australian          Application No. 2018378832, dated May 12, 2020.;            International Preliminary Report on Patentability issued          for Application No. PCT/US2018/064503, dated Jun. 18,          2020.;            Office Action issued for Eurasian Application No.          202091005, dated Jun. 26, 2020. English Translation          included.;            Office Action issued for Canadian Application No. 3, 082,          191, dated Jun. 29, 2020.;            Office Action issued for Korean Application No.          10-2020-7014737, dated Jun. 29, 2020. English Translation          included.;            Office Action issued for British Application No.          2008628.6, dated Jul. 10, 2020.;            Mertes et al., Nucleuic Acid Components and Their          Analogues. Cxv.* synthesis of n4 -hydroxy-6-azacylidine          5-phosphate and 5-diphosphate, Collection of Czechoslovak          Chemical Communications, vol. 33, Issue 10,          1968.;            Brown et al., Mechanism of the Mutagenic Action of          Hydroxylamine, J. Mol. Biol. (1965) 11,          663-671.;            International Search Report and Written Opinion for          International Application No. PCT/US2018/064503, dated          Feb. 7, 2019.;            Roy, Chad J., et al. Pathogenesis of aerosolized Eastern          Equine Encephalitis virus infection in guinea pigs.          Virology journal 6.1 (2009): 170.;            Stuyver, Lieven J., et al. Ribonucleoside analogue that          blocks replication of bovine viral diarrhea and hepatitis          C viruses in culture. Antimicrobial agents and          chemotherapy 47.1 (2003): 244-254.;            Costantini, Veronica P., et al. Antiviral activity of          nucleoside analogues against norovirus. Antiviral therapy          17.6 (2012): 981-991.;            Purohit, Meena K., et al. Novel cytidine-based          orotidine-5-monophosphate decarboxylase inhibitors with          an unusual twist. Journal of medicinal chemistry 55.22          (2012): 9988-9997.;            Ivanov, Maksim A., et al. New N 4-hydroxycytidine          derivatives: synthesis and antiviral activity. Collection          of Czechoslovak Chemical Communications 71.7 (2006):          1099-1106.;            Fox, Jack J., et al. Thiation of Nucleosides. II.          Synthesis of 5-Methyl-2-deoxycytidine and Related          Pyrimidine Nucleosides1. Journal of the American Chemical          Society 81.1 (1959): 178-187.;            Lam, Angela M., et al. PSI-7851, a pronucleotide of          -D-2-deoxy-2-fluoro-2-C-methyluridine monophosphate, is a          potent and pan-genotype inhibitor of hepatitis C virus          replication. Antimicrobial agents and chemotherapy 54.8          (2010): 3187-3196.;            Partial European Search Report issued for European Patent          Application No. 15874145.4, dated Aug. 15,          2018.;            Supplementary European Search Report issued for European          Patent Application No. 15874145.4, dated Jan. 1,          2019.;            Communication Pursuant to Article 94(3) EPC, Report          issued for European Patent Application No. 15874145.4,          dated May 6, 2020.;            Bonnac et. al., Structure Activity Relationships and          Design of Viral Mutagens and Application to Lethal          Mutagenesis J. Med Chem 2013, 56, 9403-9414.;            Reynard et. al., Identification of a New Ribonucleoside          Inhibitor of Ebola Virus Replication Viruses 2015,          6233-6240.;            International Search Report for PCT/US2015/066144, dated          Feb. 26, 2016.;            Pubchem-458 Date Created: Oct. 26, 2006 (Oct. 26, 2006)          Date Accessed: Feb. 9, 2016 (Feb. 9, 2016); p. 3,          compound.;            Pubchem-284 Date Created: Mar. 26, 2005 (Mar. 26, 2005)          Date Accessed: Feb. 9, 2016 (Feb. 9, 2016); p. 3,          compound.;            First Examination Report dated Feb. 25, 2020 for          Australian Application No. 2015370004.;            Translation of Office Action dated Nov. 12, 2019 for          Japanese Application No. 2017-534192.;            First Exam Report dated Dec. 20, 2019 for Indian          Application No. 201717025098.;            Falco, Elvira A., Elizabeth Pappas, and George H.          Hitchings. 1, 2, 4-Triazine analogs of the natural          pyrimidines. Journal of the American Chemical Society          78.9 (1956): 1938-1941.;            Vujjini, Satish Kumar, et al. An improved and scalable          process for the synthesis of 5-azacytidine: An          antineoplastic drug. Organic Process Research &          Development 17.2 (2013): 303-306.;            Barnard DL, et al. RW. 2004. Inhibition of severe acute          respiratory syndrome-associated coronavirus (SARSCoV) by          calpain inhibitors and -D-N4-hydroxycytidine Antivir Chem          Chemother 15:15-22.          https://doi.org/10.1177/095632020401500102.;            Urakova N, et al. 2017 -D-N4-Hydroxycytidine is a potent          anti-alphavirus compound that induces a high level of          mutations in the viral genome J Virol 92:e01965-17.          https://doi.org/10.1128/JVI.01965-17.;            Ehteshami, Maryam, et al. Characterization of          -d-N4-hydroxycytidine as a novel inhibitor of chikungunya          virus. Antimicrobial agents and chemotherapy 61.4 (2017):          e02395-16.          https://doi.org/10.1128/AAC.02395-16.;            Yoon J-J, et al., 2018. Orally efficacious broadspectrum          ribonucleoside analog inhibitor of influenza and          respiratory syncytial viruses. Antimicrob Agents          Chemother 62:1427.          https://doi.org/10.1128/AAC.00766-18.;            Reynard O, et al., 2015. Identification of a new          ribonucleoside inhibitor of Ebola virus replication.          Viruses 7:6233-6240.          https://doi.org/10.3390/v7122934.;            Suzuki, T.; Moriyama, K.; Otsuka, C.; Loakes, D.;          Negishi, K., Template properties of mutagenic cytosine          analogs in reverse transcription. Nucleic Acids Res.          2006, 34 (22), 6438-6449.;            Pyrc, K.; Bosch, B. J.; Berkhout, B.; Jebbink, M. F.;          Dijkman, R.; Rottier, P.; van der Hoek, L., Inhibition of          human coronavirus NL63 infection at early stages of the          replication cycle. Antimicrob. Agents Chemother. 2006, 50          (6), 2000-2008.;            Barnard, D. L.; Day, C. W.; Bailey, K.; Heiner, M.;          Montgomery, R.; Lauridsen, L.; Chan, P. K. S.; Sidwell,          R. W., Evaluation of immunomodulators, interferons and          known in vitro SARS-CoV inhibitors for inhibition of          SARS-CoV replication in BALB/c mice. Antiviral Chem.          Chemother. 2006, 17 (5), 275-284.;            Hollecker, L.; Choo, H.; Chong, Y.; Chu, C. K.; Lostia,          S.; McBrayer, T. R.; Stuyver, L. J.; Mason, J. C.; Du,          J.; Rachakonda, S.; Shi, J.; Schinazi, R. F.; Watanabe,          K. A., Synthesis of -enantiomers of          N4-hydroxy-3-deoxypyrimidine nucleosides and their          evaluation against bovine viral diarrhoea virus and          hepatitis C virus in cell culture. Antiviral Chem.          Chemother. 2004, 15 (1), 43-55.;            Hernandez-Santiago, B. I.; Beltran, T.; Stuyver, L.; Chu,          C. K.; Schinazi, R. F., Metabolism of the anti-hepatitis          C virus nucleoside -D-N4-hydroxycytidine in different          liver cells. Antimicrob. Agents Chemother. 2004, 48 (12),          4636-4642.;            Sledziewska-Gojska, E.; Grzesiuk, E.; Plachta, A.;          Janion, C., Mutagenesis of &lt;xhtml:i          &gt;Escherichia coli&lt;/xhtml:i&gt;: a          method for determining mutagenic specificity by analysis          of tRNA suppressors. Mutagenesis 1992, 7 (1),          41-6.;            Shugar, D.; Kierdaszuk, B., New light on tautomerism of          purines and pyrimidines and its biological and genetic          implications. J. Biosci. 1985, 8 (3-4), 657-68.;            Janion, C., Some problems of mutagenesis induced by base          analogues. Acta Biochim Pol 1984, 31 (1),          183-92.;            Janion, C., on the different response of &lt;xhtml:i          &gt;Salmonella          typhimurium&lt;/xhtml:i&gt;hisG46 and TA1530 to          the mutagenic action of base analogs. Acta Biochim. Pol.          1979, 26 (1-2), 171-7.;            Popowska, E.; Janion, C., The N4-hydroxycytidine          reduction system in toluenized cells of &lt;xhtml:i          &gt;Salmonella typhimurium&lt;/xhtml:i&gt;.          Acta Biochim. Pol. 1977, 24 (3), 197-205.;            Simukova, N. A.; Yakovlev, D. Y.; Budovskii, E. I.,          Mechanism of the mutagenic action of hydroxylamine. IX.          The uv-induced cleavage of the nitrogen-oxygen bond in          N4-hydroxy- and N4-methoxycytidine and          N6-methoxyadenosine. Nucleic Acids Res. 1975, 2 (12),          2269-78.;            Popowska, E.; Janion, C., Metabolism of          N4-hydroxycytidine, a mutagen for &lt;xhtml:i          &gt;Salmonella typhimurium&lt;/xhtml:i&gt;.          Nucleic Acids Res. 1975, 2 (7), 1143-51.;            Trimble, R. B.; Maley, F., Metabolism of          4-N-hydroxycytidine in &lt;xhtml:i          &gt;Escherichia coli&lt;/xhtml:i&gt;. J.          Bacteriol. 1971, 108 (1), 145-53.;            Notice of Intention to grant Office Action issued from          IPO issued in British Application No. 2008628.6, dated          Nov. 23, 2020.;            Office Action issued for Russian Application No.          2020116571, dated Nov. 2, 2020 and English Translation          included.;            Notice of Allowance issued for Japanese Application No.          2020544817, dated Oct. 27, 2020.;            English Translation of Office Action issued for Israeli          Application No. 274155, dated Oct. 23, 2020.;            Office Action issued for Indian Application No.          202017019418, dated Oct. 19, 2020 and English          Translation.;            Pre-Grant Opposition issued for Indian Application No.          201717025098, dated Mar. 22, 2021, 161 pages.;            Search and Examination Report issued for Application No.          GB2020498.8, dated Mar. 23, 2021.;            Pre-Grant Opposition issued for Indian Application No.          201717025098, dated Apr. 1, 2021, 172 pages.;            Office Action issued in Canadian Application No. 3, 082,          191 dated Nov. 12, 2020.;            English translation of Search Report issued in Chinese          Application No. 2018800732788 dated Dec. 25,          2020.;            English translation of First Office Action issued in          Chinese Application No. 2018800732788 dated Dec. 25,          2020.;            Agostini, Maria L., et al. Small-molecule antiviral          -d-N4-hydroxycytidine inhibits a proofreading-intact          coronavirus with a high genetic barrier to resistance.          Journal of virology 93.24 (2019).;            Beigel, John H., et al. Advances in respiratory virus          therapeuticsA meeting report from the 6th isirv Antiviral          Group conference. Antiviral research 167 (2019):          45-67.;            Cheng, Vincent CC, et al. Severe acute respiratory          syndrome coronavirus as an agent of emerging and          reemerging infection. Clinical microbiology reviews 20.4          (2007): 660-694.;            Cinatl Jr, Jindrich, et al. Development of antiviral          therapy for severe acute respiratory syndrome. Antiviral          research 66.2-3 (2005): 81-97.;            Day, Craig W., et al. A new mouse-adapted strain of          SARS-CoV as a lethal model for evaluating antiviral          agents in vitro and in vivo. Virology 395.2 (2009):          210-222.;  De          Clercq, Erik. Recent highlights in the development of new          antiviral drugs. Current opinion in microbiology 8.5          (2005): 552-560.;  De          Clercq, Erik. Status presens of antiviral drugs and          strategies: Part II: RNA Viruses (Except Retroviruses).          Advances in antiviral drug design 5 (2007):          59-112.;  De          Clercq, E. Viruses and viral diseases. Comprehensive          Medicinal Chemistry II (2007): 7.10:253-293.;            Dollinger, M. A., Burchenal, J. H., Kreis, W., and Fox,          J. J. Analogs of 1-f3-D-Arabinofuranosylcytosine. Studies          on Mechanisms of Action in Burkitt's Cell Culture and          Mouse Leukemia and in Vitro Deamination Studies. Biochem.          Pharmacol., 16: 689-706, 1967.;            Dooley, Andrea J., et al. From genome to drug lead:          identification of a small-molecule inhibitor of the SARS          virus. Bioorganic & medicinal chemistry letters 16.4          (2006): 830-833.;            Gaurav, Anand, and Mayasah Al-Nema. Polymerases of          coronaviruses: structure, function, and inhibitors. Viral          Polymerases. Academic Press, 2019. 271-300.;            Haagmans, Bart L., and Albert DME Osterhaus.          Coronaviruses and their therapy. Antiviral research          71.2-3 (2006): 397-403.;            Hampton, Tracy, New Flu Antiviral Candidate May Thwart          Drug Resistance JAMA Jan. 7, 2020 vol. 323, No. 1,          17.;            Kliger, Yossef, Erez Y. Levanon, and Doron Gerber. From          genome to antivirals: SARS as a test tube. Drug discovery          today 10.5 (2005): 345-352.;            Kumaki, Yohichi, et al. Inhibition of adenovirus serotype          14 infection by octadecyloxyethyl esters of          (S)-[(3-hydroxy-2-phosphonomethoxy) propyl]-nucleosides          in vitro. Antiviral research 158 (2018):          122-126.;            Law, Siukan, Albert Wingnang Leung, and Chuanshan Xu.          Severe acute respiratory syndrome (SARS) and coronavirus          disease-2019 (COVID-19): From causes to preventions in          Hong Kong. International Journal of Infectious Diseases          94 (2020): 156-163. doi:          https://doi.org/10.1016/j.ijid.2020.03.059.;            Matthes, E., and H. Buenger. Cellular Pharmacology of the          Anti-Hepatitis B Virus Agent -1-23-Didehydro-2,          3-Dideoxy-N4-Hydroxycytidine: Relevance for Activation in          HepG2 Cells. Antimicrobial agents and chemotherapy 54.1          (2010): 341-345.;            Memish, Ziad A., et al. Middle East respiratory syndrome.          The Lancet 395.10229 (2020): 1063-1077.;            Nichols, W. Garrett, Angela J. Peck Campbell, and Michael          Boeckh. Respiratory viruses other than influenza virus:          impact and therapeutic advances. Clinical microbiology          reviews 21.2 (2008): 274-290.;            Oxford, John S., et al. New antiviral drugs, vaccines and          classic public health interventions against SARS          coronavirus. Antiviral Chemistry and Chemotherapy 16.1          (2005): 13-21.;            Painter, George R., et al. The prophylactic and          therapeutic activity of a broadly active ribonucleoside          analog in a murine model of intranasal Venezuelan equine          encephalitis virus infection. Antiviral research 171          (2019): 104597.;            Pruijssers, Andrea J., and Mark R. Denison. Nucleoside          analogues for the treatment of coronavirus infections.          Current opinion in virology 35 (2019): 57-62.;            Rothan, Hussin A., and Siddappa N. Byrareddy. The          epidemiology and pathogenesis of coronavirus disease          (COVID-19) outbreak. Journal of autoimmunity 109 (2020):          102433.;            Sheahan, Timothy P., et al. An orally bioavailable          broad-spectrum antiviral inhibits SARS-CoV-2 in human          airway epithelial cell cultures and multiple          coronaviruses in mice. Science translational medicine          12.541 (2020), eabb5883.;            Shigeta, Shiro, and Toshihiro Yamase. Current status of          anti-SARS agents. Antiviral Chemistry and Chemotherapy          16.1 (2005): 23-31.;            Subissi, Lorenzo, et al. SARS-CoV ORF1b-encoded          nonstructural proteins 12-16: replicative enzymes as          antiviral targets. Antiviral research 101 (2014):          122-130.;            Tong, Tommy R. Therapies for coronaviruses. Part 2:          Inhibitors of intracellular life cycle. Expert opinion on          therapeutic patents 19.4 (2009): 415-431.;            Tong, Tommy R. Drug targets in severe acute respiratory          syndrome (SARS) virus and other coronavirus infections.          Infectious Disorders-Drug Targets (Formerly Current Drug          TargetsInfectious Disorders) 9.2 (2009):          223-245.;            Toots, Mart, et al. Characterization of orally          efficacious influenza drug with high resistance barrier          in ferrets and human airway epithelia. Science          translational medicine 11.515 (2019).;            Toots, Mart, et al. Quantitative efficacy paradigms of          the influenza clinical drug candidate EIDD-2801 in the          ferret model. Translational Research 218 (2020):          1628.;            Toots, Mart, and Richard K. Plemper. Next-generation          direct-acting influenza therapeutics. Translational          Research (2020).;            Van Der Hoek, Lia, Krzysztof Pyrc, and Ben Berkhout.          Human coronavirus NL63, a new respiratory virus. FEMS          microbiology reviews 30.5 (2006): 760-773.;            Van der Hoek, Lia. Human coronaviruses: what do they          cause?. Antiviral therapy 12.4 Pt B (2007):          651-658.;            Van der Hoek, L., et al. Inhibition of HCoV-NL63          infection at early stages of the replication cycle.          Journal of Clinical Virology 36 (2006): S35.;            Weiss, Susan R., and Sonia Navas-Martin. Coronavirus          pathogenesis and the emerging pathogen severe acute          respiratory syndrome coronavirus. Microbiology and          molecular biology reviews 69.4 (2005): 635-664.;            Wu, Yu-Shan, et al. Antiviral drug discovery against          SARS-CoV. Current medicinal chemistry 13.17 (2006):          2003-2020.;            Zhang, Xue Wu, Yee Leng Yap, and Ralf M. Altmeyer.          Generation of predictive pharmacophore model for          SARS-coronavirus main proteinase. European journal of          medicinal chemistry 40.1 (2005): 57-62.;            Zhuang, Min, et al. Procyanidins and butanol extract of          Cinnamomi Cortex inhibit SARS-CoV infection. Antiviral          research 82.1 (2009): 73-81.;            Second Examination Report dated Feb. 5, 2021 for          Australian Application No. 2015370004.;            Third Examination Report dated Feb. 24, 2021 for          Australian Application No. 2018378832.;            Translation of Office Action dated Oct. 20, 2020 for          Japanese Application No. 2017-534192.;            Office Action and Search Report issued for Brazilian          Application No. BR112017013858-1 dated Oct. 8, 2020.          English Translation included.;            Office Action issued for Chinese Application No.          201580076718.1, dated Aug. 24, 2020. English Translation          included.;            Office Action issued for Chinese Application No.          201580076718.1, dated Feb. 8, 2021. English Translation          included.;            Office Action issued for Chinese Application No.          201580076718.1, dated Aug. 15, 2019. English Translation          included.;            Office Action and search report issued in Russian          Application No. 2020116571, dated Apr. 1, 2021, and          English Language translation.;            Office Action issued in Philippine Application No.          1-2020-550607, dated Apr. 27, 2021.;            Office Action and search report issued in Eurasian          Application No. 202091005, dated Apr. 8, 2021, and          English Language translation.;            Pre-grant opposition issued in Indian Application No.          202017019418, dated Apr. 29, 2021 (253 pages).;            Pre-Grant Opposition for Indian Application No.          201717025098, dated Mar. 10, 2021.;            Communication Pursuant to Rule 114(2) EPC, issued for          Application No. 18886104.1, dated Jun. 30,          2021.;            Communication Pursuant to Rule 114(2) EPC, issued for          Application No. 18886104.1, dated Jun. 17,          2021.;            Office Action issued for Chinese Application No.          201880073278.8, dated Jun. 8, 2021.;            Written Opinion issue for Singaporean Application No.          11202004403Q, dated Jun. 18, 2021.;            Office Action issued for Eurasian Application No.          201791460, dated Jun. 23, 2021.;            Extended European Search Report issued for European          Application No. 18886104.1, dated Jul. 29, 2021, 8          pages.US11903959-B2            Chen, Y.L., et al. Inhibition of Dengue Virus by an ester          prodrug of an adenosine analog, Antimicrobial Agents and          Chemotherapy, 3255-3261, 2010.;            Opposition in Indian application 202017019418, dated Dec.          1, 2021.;            Opposition in Indian application 202017019418, dated Nov.          15, 2021.;            Third party observations in Philippine application          12020550607, dated Oct. 11, 2021.;            Third party observations in Eurasian Application          202091005, dated Nov. 8, 2021.;            Fujan, Li., et al., Prodrugs of nucleoside analogs for          improved oral absorption and tissue targeting, J. Pharm.          Sci. 97(3):1109-1134, 2008.;            Zhang, et al. Current prodrug strategies for improving          oral absorption of nucleoside analogs, Asian J. Pharm.          Sci. 9:65-74, 2014.;            Felczak, K., et al. 5-substituted          N4-hydroxy-2-deoxycytidines and their 5-monophosphates:          synthesis, conformation, interaction with tumor          thymidylate synthase, and in vitro antitumor activity, J.          Med. Chem. 43:4647-4656, 2000.;            Third Party Observation in Eurasian Application No.          202091005, dated Dec. 3, 2021.;            Mehellou, Youcef, Hardeep S. Rattan, and Jan Balzarini.          The ProTide Prodrug Technology: From the Concept to the          Clinic: Miniperspective. Journal of medicinal chemistry          61.6 (2017): 2211-2226.;            Dawadi, Surendra, et al. Synthesis and pharmacological          evaluation of nucleoside prodrugs designed to target          siderophore biosynthesis in Mycobacterium tuberculosis.          Bioorganic & medicinal chemistry 24.6 (2016):          1314-1321.;            Office Action issued for Chinese Application No.          201880073278.8, dated Oct. 15, 2021.;            Office Action and Search Report issued for Brazilian          Application No. BR112017013858-1 dated Sep. 16,          2021.;            Brown et al. Mechanism of the Mutagenic Action of          Hydroxylamine, Journal of Molecular Biology, vol. 11, n.          4, Apr. 1, 1965, p. 663-671.;            Mertes, M. P., and J. Smrt. Nucleic acid components and          their analogues. CXV. Synthesis of N          4-hydroxy-6-azacytidine 5-phosphate and 5-diphosphate.          Collection of Czechoslovak Chemical Communications 33.10          (1968): 3304-3312.;            International Search Report and Written Opinion for          International Application No. PCT/US2018/064503, dated          Feb. 7, 2019.;            Translation of Office Action issued for Brazilian          Application No. BR122021012627-5, dated Nov. 1,          2021.;            Translation of Objections of Third Party Observations in          connection to Eurasian Application No. EA202091005, dated          Dec. 6, 2021.;            Extended European Search Report issued for Application          No. 21178364.2, dated Nov. 30, 2021.;            Office Action issued for U.S. Appl. No. 16/921, 359,          dated Dec. 24, 2021.;            Office Action issued for U.S. Appl. No. 16/921, 359,          dated Mar. 21, 2022.;            Verrault, Daniel, et al. Evaluation of inhaled cidofovir          as postexposure prophylactic in an aerosol rabbitpox          model. Antiviral Research 93.1 (2012): 204-208.;            Barnard et al. Inhibition of severe acute respiratory          syndrome-associated coronavirus (SARSCoV) by calpain          inhibitors and Beta-D-N4 hydroxycytidine. Antiviral          Chemistry & Chemotherapy (2004), vol. 15, pp.          15-22.;            Office Action issued for Israeli Application No. 279663,          dated Jul. 14, 2021.;            Office Action issued for Chinese Application No.          201580076718.1, dated Jul. 28, 2021.;            Office Action issued for Japanese Application No.          2017-534192, dated Aug. 17, 2021.;            Office Action issued for Russian Application No.          2020116571, dated Aug. 27, 2021.;            Kummerer, Klaus. Pharmaceuticals in the environment.          Annual review of environment and resources 35          (2010):57-75.;            Examination report issued for Philippine Application No.          1-2020-550607, dated Sep. 7, 2021.;            Office Action issued for Philippine Application No.          2020550607, dated Dec. 14, 2021.;            Office Action issued for Eurasian Application No.          202091005, dated Dec. 24, 2021.;            Translation of the Official Notification issued for          Eurasian Application No. 202091005, dated Dec. 17,          2021.;            Rautio, Prodrugs and Targeted Delivery: Towards Better          ADME Properties, 2011, 6 pages.;            Kim, Dae-Kee, et al. Synthesis and evaluation of          2-amino-6-fluoro-9-(2-hydroxyethoxymethyl) purine esters          as potential prodrugs of acyclovir. Bioorganic &          medicinal chemistry 6.12 (1998): 2525-2530.;            Khimicheskiy entsiklopedicheskiy slovar (Chemical          Encyclopedic Dictionary), edited by I.L. Knunyants,          M.:Sovetskaya entsilopediya, 1983, p. 23.;            LL. Fizer, M. Fizer, Organicheskaya khimiya (Organic          Chemistry), M.: Khimiya, 1966, p. 445.;            Coats, Steven J., et al. Chutes and ladders in hepatitis          C nucleoside drug development. Antiviral research 102          (2014): 119-147.;            Iglesias, Luis E., et al. Biocatalytic approaches applied          to the synthesis of nucleoside prodrugs. Biotechnology          advances 33.5 (2015): 412-434.;            Rautio, Jarkko, et al. Prodrugs: design and clinical          applications. Nature reviews Drug discovery 7.3 (2008):          255-270.;            Cho, Seung-Ju, et al. Ibulocydine is a novel prodrug Cdk          inhibitor that effectively induces apoptosis in          hepatocellular carcinoma cells. Journal of Biological          Chemistry 286.22 (2011): 19662-19671.;            Agrawal, Vijay K., Ruchi Sharma, and P. V. Khadikar. QSAR          study on antiviral activity of ester prodrugs of          6-methoxypurine arabinosides. (2002). NISCAIR-CSIR,          India, 1163-1166.;            Brandl, Michael, et al. Physicochemical properties of the          nucleoside prodrug R1626 leading to high oral          bioavailability. Drug development and industrial pharmacy          34.7 (2008): 683-691.;            Nilsson, Magnus, et al. Discovery of          4-azido-2-deoxy-2-C-methyl cytidine and prodrugs thereof:          A potent inhibitor of Hepatitis C virus replication.          Bioorganic & medicinal chemistry letters 22.9 (2012):          3265-3268.;            Jonckers, Tim HM, et al.          2-Deoxy-2-spirocyclopropylcytidine revisited: a new and          selective inhibitor of the hepatitis C virus NS5B          polymerase. Journal of medicinal chemistry 53.22 (2010):          8150-8160.;            Kim, Dae-Kee, et al. Synthesis and evaluation of          2-amino-6-fluoro-9-(4-hydroxy-3-hydroxymethylbut-1-yl)          purine mono-and diesters as potential prodrugs of          penciclovir. Bioorganic & medicinal chemistry 7.3          (1999): 565-570.;            Roy, Chad J., et al. Pathogenesis of aerosolized Eastern          Equine Encephalitis virus infection in guinea pigs.          Virology journal 6.1 (2009): 170.;            Stuyver, Lieven J., et al. Ribonucleoside analogue that          blocks replication of bovine viral diarrhea and hepatitis          C viruses in culture. Antimicrobial agents and          chemotherapy 47.1 (2003): 244-254.;            Costantini, Veronica P., et al. Antiviral activity of          nucleoside analogues against norovirus. Antiviral therapy          17.6 (2012): 981-991.;            Purohit, Meena K., et al. Novel cytidine-based          orotidine-5-monophosphate decarboxylase inhibitors with          an unusual twist. Journal of medicinal chemistry 55.22          (2012): 9988-9997.;            Ivanov, Maksim A., et al. New N 4-hydroxycytidine          derivatives: synthesis and antiviral activity. Collection          of Czechoslovak Chemical Communications 71.7 (2006):          1099-1106.;            Fox, Jack J., et al. Thiation of Nucleosides. II.          Synthesis of 5-Methyl-2-deoxycytidine and Related          Pyrimidine Nucleosides1. Journal of the American Chemical          Society 81.1 (1959): 178-187.;            Lam, Angela M., et al. PSI-7851, a pronucleotide of          -D-2-deoxy-2-fluoro-2-C-methyluridine monophosphate, is a          potent and pan-genotype inhibitor of hepatitis C virus          replication. Antimicrobial agents and chemotherapy 54.8          (2010): 3187-3196.;            Partial European Search Report issued for European Patent          Application No. 15874145.4, dated Aug. 15,          2018.;            Supplementary European Search Report issued for European          Patent Application No. 15874145.4, dated Jan. 1,          2019.;            Communication Pursuant to Article 94(3) EPC, Report          issued for European Patent Application No. 15874145.4,          dated May 6, 2020.;            Bonnac et al., Structure Activity Relationships and          Design of Viral Mutagens and Application to Lethal          Mutagenesis J. Med Chem 2013, 56, 9403-9414.;            Reynard et. al., Identification of a New Ribonucleoside          Inhibitor of Ebola Virus Replication Viruses 2015,          6233-6240.;            International Search Report for PCT/US2015/066144, dated          Feb. 26, 2016.;            Pubchem-458 Date Created: Oct. 26, 2006 (Oct. 26, 2006)          Date Accessed: Feb. 9, 2016 (Feb. 9, 2016); p. 3,          compound.;            Pubchem-284 Date Created: Mar. 26, 2005 (Mar. 26, 2005)          Date Accessed: Feb. 9, 2016 (Feb. 9, 2016); p. 3,          compound.;            First Examination Report dated Feb. 25, 2020 for          Australian Application No. 2015370004.;            Translation of Office Action dated Nov. 12, 2019 for          Japanese Application No. 2017-534192.;            First Exam Report dated Dec. 20, 2019 for Indian          Application No. 201717025098.;            Falco, Elvira A., Elizabeth Pappas, and George H.          Hitchings. 1, 2, 4-Triazine analogs of the natural          pyrimidines. Journal of the American Chemical Society          78.9 (1956): 1938-1941.;            Vujjini, Satish Kumar, et al. An improved and scalable          process for the synthesis of 5-azacytidine: An          antineoplastic drug. Organic Process Research &          Development 17.2 (2013): 303-306.;            Barnard DL, et al. RW. 2004. Inhibition of severe acute          respiratory syndrome-associated coronavirus (SARSCoV) by          calpain inhibitors and -D-N4-hydroxycytidine Antivir Chem          Chemother 15:15-22.          https://doi.org/10.1177/095632020401500102.;            Urakova N, et al. 2017 -D-N4-Hydroxycytidine is a potent          anti-alphavirus compound that induces a high level of          mutations in the viral genome J Virol 92:e01965-17.          https://doi.org/10.1128/JVI.01965-17.;            Ehteshami, Maryam, et al. Characterization of          -d-N4-hydroxycytidine as a novel inhibitor of chikungunya          virus. Antimicrobial agents and chemotherapy 61.4 (2017):          e02395-16.          https://doi.org/10.1128/AAC.02395-16.;            Yoon J-J, et al., 2018. Orally efficacious broadspectrum          ribonucleoside analog inhibitor of influenza and          respiratory syncytial viruses. Antimicrob Agents          Chemother 62:1427.          https://doi.org/10.1128/AAC.00766-18.;            Reynard O, et al., 2015. Identification of a new          ribonucleoside inhibitor of Ebola virus replication.          Viruses 7:6233-6240.          https://doi.org/10.3390/v7122934.;            Suzuki, T.; Moriyama, K.; Otsuka, C.; Loakes, D.;          Negishi, K., Template properties of mutagenic cytosine          analogs in reverse transcription. Nucleic Acids Res.          2006, 34 (22), 6438-6449.;            Pyrc, K.; Bosch, B. J.; Berkhout, B.; Jebbink, M. F.;          Dijkman, R.; Rottier, P.; van der Hoek, L., Inhibition of          human coronavirus NL63 infection at early stages of the          replication cycle. Antimicrob. Agents Chemother. 2006, 50          (6), 2000-2008.;            Barnard, D. L.; Day, C. W.; Bailey, K.; Heiner, M.;          Montgomery, R.; Lauridsen, L.; Chan, P. K. S.; Sidwell,          R. W., Evaluation of immunomodulators, interferons and          known in vitro SARS-CoV inhibitors for inhibition of          SARS-CoV replication in BALB/c mice. Antiviral Chem.          Chemother. 2006, 17 (5), 275-284.;            Hollecker, L.; Choo, H.; Chong, Y.; Chu, C. K.; Lostia,          S.; McBrayer, T. R.; Stuyver, L. J.; Mason, J. C.; Du,          J.; Rachakonda, S.; Shi, J.; Schinazi, R. F.; Watanabe,          K. A., Synthesis of -enantiomers of          N4-hydroxy-3-deoxypyrimidine nucleosides and their          evaluation against bovine viral diarrhoea virus and          hepatitis C virus in cell culture. Antiviral Chem.          Chemother. 2004, 15 (1), 43-55.;            Hernandez-Santiago, B. I.; Beltran, T.; Stuyver, L.; Chu,          C. K.; Schinazi, R. F., Metabolism of the anti-hepatitis          C virus nucleoside -D-N4-hydroxycytidine in different          liver cells. Antimicrob. Agents Chemother. 2004, 48 (12),          4636-4642.;            Sledziewska-Gojska, E.; Grzesiuk, E.; Plachta, A.;          Janion, C., Mutagenesis of &lt;xhtml:i          &gt;Escherichia coli&lt;/xhtml:i&gt;: a          method for determining mutagenic specificity by analysis          of tRNA suppressors. Mutagenesis 1992, 7 (1),          41-6.;            Shugar, D.; Kierdaszuk, B., New light on tautomerism of          purines and pyrimidines and its biological and genetic          implications. J. Biosci. 1985, 8 (3-4), 657-68.;            Janion, C., Some problems of mutagenesis induced by base          analogues. Acta Biochim Pol 1984, 31 (1),          183-92.;            Janion, C., On the different response of &lt;xhtml:i          &gt;Salmonella          typhimurium&lt;/xhtml:i&gt;hisG46 and TA1530 to          the mutagenic action of base analogs. Acta Biochim. Pol.          1979, 26 (1-2), 171-7.;            Popowska, E.; Janion, C., The N4-hydroxycytidine          reduction system in toluenized cells of &lt;xhtml:i          &gt;Salmonella typhimurium&lt;/xhtml:i&gt;.          Acta Biochim. Pol. 1977, 24 (3), 197-205.;            Simukova, N. A.; Yakovlev, D. Y.; Budovskii, E. I.,          Mechanism of the mutagenic action of hydroxylamine. IX.          The uv-induced cleavage of the nitrogen-oxygen bond in          N4-hydroxy- and N4-methoxycytidine and          N6-methoxyadenosine. Nucleic Acids Res. 1975, 2 (12),          2269-78.;            Popowska, E.; Janion, C., Metabolism of          N4-hydroxycytidine, a mutagen for &lt;xhtml:i          &gt;Salmonella typhimurium&lt;/xhtml:i&gt;.          Nucleic Acids Res. 1975, 2 (7), 1143-51.;            Trimble, R. B.; Maley, F., Metabolism of          4-N-hydroxycytidine in &lt;xhtml:i          &gt;Escherichia coli&lt;/xhtml:i&gt;. J.          Bacteriol. 1971, 108 (1), 145-53.;            Bebenek, K.; Janion, C., Ability of base analogs to          induce the SOS response: effect of a dam mutation and          mismatch repair system. MGG, Mol. Gen. Genet. 1985, 201          (3), 519-24.;            Borodavkin, A. V.; Chekhov, V. O.; Dolin, Y. S.; Morozov,          Y. V.; Savin, F. A.; Budowskii, E. I.; Yakovlev, D. Y.,          Absorption UV spectroscopy and electronic structure of          ionic and tautomeric forms of hydroxy and methoxy          derivatives of cytosine and adenine, and of some          5-substituted analogs of pyrimidines. Int. J. Quantum          Chem. 1980, 17 (4), 803-11.;            Brown, D. M.; Schell, P., Nucleotides. XLVIII. The          reaction of hydroxylamine with cytosine and related          compounds. J. Chem. Soc. 1965, (Jan.), 208-15.;            Budovskii, E. I.; Postnova, T. I., Mechanism of the          mutagenic action of hydroxylamine. X. Certain          specificities in the mutagenesis of N-hydroxy and          N-methoxy analogs of cytosine and adenine derivatives.          Mutat. Res. 1976, 37 (1), 11-17.;            Chekhov, V. O.; Budovskii, E. I.; Morozov, Y. V.; Savin,          F. A.; Yakovlev, D. Y., UV spectroscopy of fixed amino          and imino forms of cytidine and its N4-hydroxy and          N4-methoxy derivatives. Biofizika 1979, 24 (4), 772-3.          English Abstract Only.;            Chekhov, V. O.; Savin, F. A.; Morozov, Y. V.; Budovskii,          E. I.; Yakovlev, D. Y., Electron structure of some          hydroxy and methoxy derivatives of cytosine and adenine.          Biofizika 1979, 24 (4), 773-4. English Abstract          only.;            Chung, K. C.; Hayatsu, H., The reaction of hydroxylamine          with 4-thiouridine. Yongnam Taehakkyo Chonyonmul Hwahak          Yonguso Yongu Pogo 1976, 3, 31-6. English Abstract          Only.;  De          Serres, F. J.; Brockman, H. E., Comparison of the spectra          of genetic damage in N4-hydroxycytidine-induced ad-3          mutations between nucleotide excision repair-proficient          and -deficient heterokaryons of Neurospora crassa. Mutat.          Res., Fundam. Mol. Mech. Mutagen. 1993, 285 (2),          145-63.;            Fraenkel-Conrat, H.; Singer, B., Chemical basis for the          mutagenicity of hydroxylamine and methoxyamine. Biochim.          Biophys. Acta, Nucleic Acids Protein Synth. 1972, 262          (3), 264-8.;            Iida, S.; Chung, K. C.; Hayatsu, H., Reaction of          hydroxylamine with 4-thiouridine. Biochim. Biophys. Acta,          Nucleic Acids Protein Synth. 1973, 308 (2),          198-204.;            Janion, C., The efficiency and extent of mutagenic          activity of some new mutagens of the base-analog type.          Mutat. Res., Genet. Toxicol. Test. 1978, 56 (3),          225-34.;            Janion, C.; Bebenek, K.; Plewako, S., Are &lt;xhtml:i          &gt;Escherichia coli&lt;/xhtml:i&gt;damas          compared to dam+ hypermutable by base analogs? Acta          Biochim. Pol. 1987, 34 (2), 183-93.;            Janion, C.; Glickman, B. W., N4-Hydroxycytidine: a          mutagen specific for AT to GC transitions. Mutat. Res.          1980, 72 (1), 43-7.;            Janion, C.; Kajtaniak, E., Mutagenesis induced in amber          P22 phages by base analogs. Mutat. Res. 1979, 62 (1),          191-5.;            Janion, C.; Popowska, E., The reduction of          N4-hydroxycytidine to cytidine by &lt;xhtml:i          &gt;Salmonella          typhimurium&lt;/xhtml:i&gt;cells. Nucleic Acids          Res., Spec. Publ. 1975, (III Symp. on Chemistry of          Nucleic Acids Components, Liblice Castle, Czechoslovakia,          Oct. 8-12, 1975), S159-S163.;            Janion, C.; Shugar, D., Mechanism of hydroxylamine          mutagenesis: complexing properties of copolymers of          hydroxycytidylic acid with cytidylic or uridylic acids.          Acta Biochim. Pol. 1969, 16 (2), 219-32.;            Krompholz, et al., The Mitochondrial Amidoxime Reducing          Component (mARC) is Involved in Detoxification of          N-Hydroxylated Base Analogues. Chem. Res. Toxicol. 2012,          25 (11), 2443-2450.;            Levin, D. E.; Ames, B. N., Classifying mutagens as to          their specificity in causing the six possible transitions          and transversions: a simple analysis using the          &lt;xhtml:i          &gt;Salmonella&lt;/xhtml:i&gt;mutagenicity          assay. Environ. Mutagen. 1986, 8 (1), 9-28.;            Morozov, Y. V.; Savin, F. A.; Chekhov, V. O.; Budovskii,          E. I.; Yakovlev, D. Y., Photochemistry of          N6-methoxyadenosine and of N4-hydroxycytidine and its          methyl derivatives. I: Spectroscopic and quantum chemical          investigation of ionic and tautomeric forms: syn-anti          isomerization. J. Photochem. 1982, 20 (3),          229-52.;            Popowska, E.; Janion, C., N4-Hydroxycytidine. New mutagen          of a base analog type. Biochem. Biophys. Res. Commun.          1974, 56 (2), 459-66.;            Poslovina, A. S.; Vasyunina, E. A.; Andreeva, I. S.;          Salganik, R. I. In Effect of adenine and cytosine on the          mutagenic effect of hydroxylamine and study of the          mutagenic activity of the products of their modification          by hydroxylamine, Nauka: 1976; pp. 142-145. English          Abstract Only.;            Poslovina, A. S.; Vasyunina, E. A.; Andreeva, I. S.;          Salganik, R. I., Mutagenic effect of N4-HYDR oxycytidine,          the product of cytidine modification by hydroxylamine, in          &lt;xhtml:i &gt;Escherichia          coli&lt;/xhtml:i&gt;B. Genetika 1973, 9 (5),          76-81. English Abstract Only.;            Poslovina, A. S.; Vasyunina, E. A.; Andreeva, I. S. In          Mutagenic action of cytidine and adenosine derivatives          modified by hydroxylamine, Akad. Nauk SSSR, Sib. Otd.,          Inst. Tsitol. Genet.: 1974; pp. 7-8. English Abstract          Only.;            Salganik, R. I.; Vasyunina, E. A.; Poslovina, A. S.;          Andreeva, I. S., Mutagenic action of N4-hydroxycytidine          on &lt;xhtml:i &gt;Escherichia          coli&lt;/xhtml:i&gt;B cyt. Mutat. Res. 1973, 20          (1), 1-5.;            Sidwell, R.W., D.F. Smee, and D.L. Barnard 2006.          Development of antiviral drugs against avian (H5N1)          influenza virus. In: J.P. Wong (Ed.), Recent Developments          on the Avian Influenza (H5N1) Crisis. Transworld Research          Network, Kerala, India pp. 63-83.;            Singer, B., The effect of base modification on fidelity          in transcription. Jerusalem Symp. Quantum Chem. Biochem.          1980, 13 (Carcinog.: Fundam. Mech. Environ. Eff.),          91-102.;            Singer, B.; Spengler, S., Ambiguity and transcriptional          errors as a result of modification of exocyclic amino          groups of cytidine, guanosine, and adenosine.          Biochemistry 1981, 20 (5), 1127-32.;            Sledziewska, E.; Janion, C., Mutagenic specificity of          N4-hydroxycytidine. Mutat. Res. 1980, 70 (1),          11-16.;            Sledziewska-Gojska, E.; Janion, C., Do DNA repair systems          affect N4-hydroxycytidine-induced mutagenesis? Acta          Biochim. Pol. 1983, 30 (2), 149-57.;            Sledziewska-Gojska, E.; Janion, C., Effect of          proofreading and dam-instructed mismatch repair systems          on N4-hydroxycytidine-induced mutagenesis. MGG, Mol. Gen.          Genet. 1982, 186 (3), 411-18.;            Smrt, J., Homopolymers of N4-hydroxy- and          N4-methoxycytidylic acid and their interaction with          polyadenylic acid. Collect. Czech. Chem. Commun. 1970, 35          (8), 2314-23.;            Yakovlev, D. Y.; Simukova, N. A.; Budovskii, E. I.;          Chekhov, V. O.; Savin, F. A.; Morozov, Y. V.,          Photochemistry of N6-methoxyadenosine and of          N4-hydroxycytidine and its methyl derivatives. II:          Photoinduced rupture of the nitrogen-oxygen bond. J.          Photochem. 1982, 20 (3), 253-68.;            Examination report No. 1 issued for Australian          Application No. 2018378832, dated May 7, 2020.;            Examination report No. 2 issued for Australian          Application No. 2018378832, dated May 12, 2020.;            International Preliminary Report on Patentability issued          for Application No. PCT/US2018/064503, dated Jun. 18,          2020.;            Office Action issued for Eurasian Application No.          202091005, dated Jun. 26, 2020. English Translation          included.;            Office Action issued for Canadian Application No. 3, 082,          191, dated Jun. 29, 2020.;            Office Action issued for Korean Application No.          10-2020-7014737, dated Jun. 29, 2020. English Translation          included.;            Office Action issued for British Application No.          2008628.6, dated Jul. 10, 2020.;            Notice of Intention to grant Office Action issued from          IPO issued in British Application No. 2008628.6, dated          Nov. 23, 2020.;            Office Action issued for Russian Application No.          2020116571, dated Nov. 2, 2020 and English Translation          included.;            Notice of Allowance issued for Japanese Application No.          2020544817, dated Oct. 27, 2020.;            English Translation of Office Action issued for Israeli          Application No. 274155, dated Oct. 23, 2020.;            Office Action issued for Indian Application No.          202017019418, dated Oct. 19, 2020 and English          Translation.;            Office Action issued in Canadian Application No. 3, 082,          191 dated Nov. 12, 2020.;            English translation of Search Report issued in Chinese          Application No. 2018800732788 dated Dec. 25,          2020.;            English translation of First Office Action issued in          Chinese Application No. 2018800732788 dated Dec. 25,          2020.;            Agostini, Maria L., et al. Small-molecule antiviral          -d-N4-hydroxycytidine inhibits a proofreading-intact          coronavirus with a high genetic barrier to resistance.          Journal of virology 93.24 (2019).;            Beigel, John H., et al. Advances in respiratory virus          therapeuticsA meeting report from the 6th isirv Antiviral          Group conference. Antiviral research 167 (2019):          45-67.;            Cheng, Vincent CC, et al. Severe acute respiratory          syndrome coronavirus as an agent of emerging and          reemerging infection. Clinical microbiology reviews 20.4          (2007): 660-694.;            Cinatl Jr, Jindrich, et al. Development of antiviral          therapy for severe acute respiratory syndrome. Antiviral          research 66.2-3 (2005): 81-97.;            Day, Craig W., et al. A new mouse-adapted strain of          SARS-CoV as a lethal model for evaluating antiviral          agents in vitro and in vivo. Virology 395.2 (2009):          210-222.;  De          Clercq, Erik. Recent highlights in the development of new          antiviral drugs. Current opinion in microbiology 8.5          (2005): 552-560.;  De          Clercq, Erik. Status presens of antiviral drugs and          strategies: Part II: RNA Viruses (Except Retroviruses).          Advances in antiviral drug design 5 (2007):          59-112.;  De          Clercq, E. Viruses and viral diseases. Comprehensive          Medicinal Chemistry II (2007): 7.10:253-293.;            Dollinger, M. A., Burchenal, J. H., Kreis, W., and Fox,          J. J. Analogs of 1-f3-D-Arabinofuranosylcytosine. Studies          on Mechanisms of Action in Burkitt's Cell Culture and          Mouse Leukemia and in Vitro Deamination Studies. Biochem.          Pharmacol., 16: 689-706, 1967.;            Dooley, Andrea J., et al. From genome to drug lead:          identification of a small-molecule inhibitor of the SARS          virus. Bioorganic & medicinal chemistry letters 16.4          (2006): 830-833.;            Gaurav, Anand, and Mayasah Al-Nema. Polymerases of          coronaviruses: structure, function, and inhibitors. Viral          Polymerases. Academic Press, 2019. 271-300.;            Haagmans, Bart L., and Albert DME Osterhaus.          Coronaviruses and their therapy. Antiviral research          71.2-3 (2006): 397-403.;            Hampton, Tracy, New Flu Antiviral Candidate May Thwart          Drug Resistance JAMA Jan. 7, 2020 vol. 323, No. 1,          17.;            Kliger, Yossef, Erez Y. Levanon, and Doron Gerber. From          genome to antivirals: SARS as a test tube. Drug discovery          today 10.5 (2005): 345-352.;            Kumaki, Yohichi, et al. Inhibition of adenovirus serotype          14 infection by octadecyloxyethyl esters of          (S)-[(3-hydroxy-2-phosphonomethoxy) propyl]-nucleosides          in vitro. Antiviral research 158 (2018):          122-126.;            Law, Siukan, Albert Wingnang Leung, and Chuanshan Xu.          Severe acute respiratory syndrome (SARS) and coronavirus          disease-2019 (COVID-19): From causes to preventions in          Hong Kong. International Journal of Infectious Diseases          94 (2020): 156-163. doi:          https://doi.org/10.1016/j.ijid.2020.03.059.;            Matthes, E., and H. Buenger. Cellular Pharmacology of the          Anti-Hepatitis B Virus Agent -1-2, 3-Didehydro-2,          3-Dideoxy-N4-Hydroxycytidine: Relevance for Activation in          HepG2 Cells. Antimicrobial agents and chemotherapy 54.1          (2010): 341-345.;            Memish, Ziad A., et al. Middle East respiratory syndrome.          The Lancet 395.10229 (2020): 1063-1077.;            Nichols, W. Garrett, Angela J. Peck Campbell, and Michael          Boeckh. Respiratory viruses other than influenza virus:          impact and therapeutic advances. Clinical microbiology          reviews 21.2 (2008): 274-290.;            Oxford, John S., et al. New antiviral drugs, vaccines and          classic public health interventions against SARS          coronavirus. Antiviral Chemistry and Chemotherapy 16.1          (2005): 13-21.;            Painter, George R., et al. The prophylactic and          therapeutic activity of a broadly active ribonucleoside          analog in a murine model of intranasal Venezuelan equine          encephalitis virus infection. Antiviral research 171          (2019): 104597.;            Pruijssers, Andrea J., and Mark R. Denison. Nucleoside          analogues for the treatment of coronavirus infections.          Current opinion in virology 35 (2019): 57-62.;            Rothan, Hussin A., and Siddappa N. Byrareddy. The          epidemiology and pathogenesis of coronavirus disease          (COVID-19) outbreak. Journal of autoimmunity 109 (2020):          102433.;            Sheahan, Timothy P., et al. An orally bioavailable          broad-spectrum antiviral inhibits SARS-CoV-2 in human          airway epithelial cell cultures and multiple          coronaviruses in mice. Science translational medicine          12.541 (2020), eabb5883.;            Shigeta, Shiro, and Toshihiro Yamase. Current status of          anti-SARS agents. Antiviral Chemistry and Chemotherapy          16.1 (2005): 23-31.;            Subissi, Lorenzo, et al. SARS-CoV ORF1b-encoded          nonstructural proteins 12-16: replicative enzymes as          antiviral targets. Antiviral research 101 (2014):          122-130.;            Tong, Tommy R. Therapies for coronaviruses. Part 2:          Inhibitors of intracellular life cycle. Expert opinion on          therapeutic patents 19.4 (2009): 415-431.;            Tong, Tommy R. Drug targets in severe acute respiratory          syndrome (SARS) virus and other coronavirus infections.          Infectious Disorders-Drug Targets (Formerly Current Drug          Targets-Infectious Disorders) 9.2 (2009):          223-245.;            Toots, Mart, et al. Characterization of orally          efficacious influenza drug with high resistance barrier          in ferrets and human airway epithelia. Science          translational medicine 11.515 (2019).;            Toots, Mart, et al. Quantitative efficacy paradigms of          the influenza clinical drug candidate EIDD-2801 in the          ferret model. Translational Research 218 (2020):          16-28.;            Toots, Mart, and Richard K. Plemper. Next-generation          direct-acting influenza therapeutics. Translational          Research (2020).;            Van Der Hoek, Lia, Krzysztof Pyrc, and Ben Berkhout.          Human coronavirus NL63, a new respiratory virus. FEMS          microbiology reviews 30.5 (2006): 760-773.;            Van der Hoek, Lia. Human coronaviruses: what do they          cause ?. Antiviral therapy 12.4 Pt B (2007):          651-658.;            Van der Hoek, L., et al. Inhibition of HCoV-NL63          infection at early stages of the replication cycle.          Journal of Clinical Virology 36 (2006): S35.;            Weiss, Susan R., and Sonia Navas-Martin. Coronavirus          pathogenesis and the emerging pathogen severe acute          respiratory syndrome coronavirus. Microbiology and          molecular biology reviews 69.4 (2005): 635-664.;            Wu, Yu-Shan, et al. Antiviral drug discovery against          SARS-CoV. Current medicinal chemistry 13.17 (2006):          2003-2020.;            Zhang, Xue Wu, Yee Leng Yap, and Ralf M. Altmeyer.          Generation of predictive pharmacophore model for          SARS-coronavirus main proteinase. European journal of          medicinal chemistry 40.1 (2005): 57-62.;            Zhuang, Min, et al. Procyanidins and butanol extract of          Cinnamomi Cortex inhibit SARS-CoV infection. Antiviral          research 82.1 (2009): 73-81.;            Second Examination Report dated Feb. 5, 2021 for          Australian Application No. 2015370004.;            Third Examination Report dated Feb. 24, 2021 for          Australian Application No. 2018378832.;            Translation of Office Action dated Oct. 20, 2020 for          Japanese Application No. 2017-534192.;            Office Action and Search Report issued for Brazilian          Application No. BR112017013858-1 dated Oct. 8, 2020.          English Translation included.;            Office Action issued for Chinese Application No.          201580076718.1, dated Aug. 24, 2020. English Translation          included.;            Office Action issued for Chinese Application No.          201580076718.1, dated Feb. 8, 2021. English Translation          included.;            Office Action issued for Chinese Application No.          201580076718.1, dated Aug. 15, 2019. English Translation          included.;            Pre-Grant Opposition issued for Indian Application No.          201717025098, dated Mar. 22, 2021.;            Search and Examination Report issued for Application No.          GB2020498.8, dated Mar. 23, 2021.;            Pre-Grant Opposition issued for Indian Application No.          201717025098, dated Apr. 1, 2021, 172 pages.;            Office Action and search report issued in Russian          Application No. 2020116571, dated Apr. 1, 2021, and          English Language translation.;            Office Action issued in Philippine Application No.          1-2020-550607, dated Apr. 27, 2021.;            Office Action and search report issued in Eurasian          Application No. 202091005, dated Apr. 8, 2021, and          English Language translation.;            Pre-grant opposition issued in Indian Application No.          202017019418, dated Apr. 29, 2021 (253 pages).;            Pre-Grant Opposition for Indian Application No.          201717025098, dated Mar. 10, 2021.;            Communication Pursuant to Rule 114(2) EPC, issued for          Application No. 18886104.1, dated Jun. 30,          2021.;            Communication Pursuant to Rule 114(2) EPC, issued for          Application No. 18886104.1, dated Jun. 17,          2021.;            Written Opinion issue for Singaporean Application No.          11202004403Q, dated Jun. 18, 2021.;            Office Action issued for Eurasian Application No.          201791460, dated Jun. 23, 2021.;            Extended European Search Report issued for European          Application No. 18886104.1, dated Jul. 29, 2021, 8          pages.;            English translation of Brazilian Office Action issued in          BR112020010581-3, dated Jan. 13, 2023.;            English translation of Brazilian Office Action issued in          BR122021012627-5, dated Jan. 10, 2023.;            English translation of Japanese Office Action issued in          JP 2021-106296 dated Jan. 11, 2023.;            English summary of Korean Office Action issued in Korean          Application No. 10-2017-7020692, dated Oct. 31,          2022.;            English translation of Brazilian Office Action issued in          BR122021015700-6, dated Feb. 7, 2023.;            Written Opinion issued in Singapore application No.          11202004403Q, dated Nov. 15, 2022.;            Office Action issued in Canadian application No. 2972259,          dated Feb. 20, 2023.;            English translation of Mexican Office Action issued in          MX/a/2020/005392, dated Dec. 16, 2022.;            English translation of Japanese Office Action issued in          JP 204082 dated Dec. 20, 2022.;            English translation of Brazilian Office Action issued in          BR112017013858-1, dated Dec. 20, 2022.;            Third Party Observation in Philippine Application No.          2020550607, dated Jan. 31, 2022.;            Office Action issued for Russian Application No.          2020116571, dated Jan. 25, 2022.;            Michael J Sofia; Nucleotide prodrugs for HCV therapy          Antiviral Chemistry & Chemotherapy 2011;          22:23-49.;            Office Action issued for Japanese Application No. 2020          195927, dated Jul. 6, 2022.;            Larsen C. S. et al., Textbook of Drug Design and          Discovery, Charpter 14, 2002, p. 460-514.;            Camille G.Wermuth et al., The Practice of Medicinal          Chemistry (Third edition), 2008, Chapter 36 pp.          721-746.;            Third Party Observation on Philippine application          12020550607 dated Feb. 3, 2022.;            Office Action issued for Eurasian Application No.          202091005, dated Mar. 28, 2022.;            Translation of Third Party Observation for Eurasian          Application No. 202091005, dated Apr. 20, 2022.;            Office Action issued for Canadian Application No. 2, 972,          259, dated Apr. 4, 2022.;            Office Action issued for Eurasian Application No.          201791460/28, dated Mar. 28, 2022.;            Examination Report issued for Australian Application No.          2021203840, dated Aug. 19, 2022.;            Office Action issued for Brazilian Application No.          BR112020010581-3, dated Jul. 12, 2022.;            Office Action issued for Brazilian Application No.          BR122021012627-5, dated Jul. 12, 2022.;            Office Action issued for Brazilian Application No.          BR122022008466-4, dated Jul. 12, 2022.;            Office Action issued for Brazilian Application No.          BR12202208542-3, dated Jul. 12, 2022.;            Official Action issued for Russian Application No.          2020116571/04, dated Sep. 23, 2022.;  H.          Musther et al. Animal versus human oral drug          bioavailability: Do they correlate? European Journal of          Pharmaceutical Sciences, 2014, 57(100),          280-291.;            English translation of Third Party          ObesrvationComplementary Subsidy to the Technical          Examination issued for Brazilian Patent Application No.          BR122021012627-5, dated Oct. 6, 2022.;            Notice of Allowance issued for U.S. Appl. No. 16/921,          359, dated Sep. 28, 2022.;            Official Action issued for Korean Application No.          10-2022-0077077, dated Oct. 14, 2022.;            Decision to Grant issued for Japanese Patent Application          No. 2020-195927, dated Oct. 19, 2022.;            Ehteshami, Nucleotide Substrate Specificity of Anti          Hepatitis C Virus Nucleoside Analogs for Human          Mitochondrial RNA Polymerase Antimicrobial agents and          chemotherapy vol. 61 Issue 8 pp. e00492-17.;            Foster, A.B., et al., Deuterium Isotope Effects in the          Metabolism of Drugs and Xenobiotics: Implications for          Drug Design, Advances in Drug Research, 1985, vol. 14,          pp. 1-40.;            Haraguchi et al., Ring Opening of 4, 5-Epoxynucleosides:          A Novel Stereoselective Entry to 4-C-Branched          Nucleosides, Org. Lett., vol. 5, No. 9,          1399-1402.;            Henderson et al., Lithium 2, 2, 2-Trifluoroethoxide,          Encyclopedia of Reagents for Organic Synthesis, 1-3,          2009.;            Ivanov et al., Synthesis and Biological Properties of          Pyrimidine 4- Fluoronucleosides and 4-Fluorouridine          5-OTriphosphate, Russian Journal of Bioorganic Chemistry          vol. 36, No. 4, 2010, pp. 488-496.;            Nowak et al., Selective Removal of the 2- and 3-O-Acyl          Groups from 2, 3, 5-Tri-Oacylribonucleoside Derivatives          with Lithium Trifluoroethoxide, J. Org. Chem. 2006, 71,          3077-3081.;            PUBCHEM database, prior reported chemical structures,          created before Jul. 12, 2017.;            Shimada et al., Nucleophilic substitution approach to          4-substituted thymidines by employing 4-benzenesulfonyl          leaving group, Tetrahedronm vol. 65, Jun. 3, 2009, pp.          6008-6016.;            Singh et al., Manipulation of enzyme regioselectivity by          solvent engineering: Enzymatic synthesis of          5-Oacylribonucleosides. Tetrahedron Letters.;            Sun et al., Synthesis, transport and pharmacokinetics of          5-amino acid ester prodrugs of          1-beta-D-arabinofuranosylcytosine, Molecular          Pharmaceutics, vol. 6, No. 1, 315-325, 2009.;            Ueda et al., Synthesis and Reaction of Pyrimidine          Nucleosides, Chemistry of Nucleosides and Nucleotides,          1988, pp. 1-112.;            Belikov V.G. Pharmaceutical Chemistry, textbook , 2007,          M, MEDpressinform, 624 pages, p. 27-29.;            Information of national phases of the application          PCT/US2018/064503 from the WIPO website          (PATENTSCOPE).;            First Examination Report dated Aug. 19, 2022, for          Australian Application No. 2021203840.;            First Examination Report for Australian Application No.          202106866 dated Apr. 17, 2023.;            Examination Report dated Jun. 30, 2023, for Australian          Application No. 2021203840.;            Office Action issued for Brazilian Application No.          BR112017013858-1 dated Nov. 25, 2022.;            Office Action issued in Brazilian Application No.          BR112020010581-3, dated Sep. 16, 2021.;            Office Action issued for Brazilian Application No.          BR112020010581-3, dated Feb. 1, 2022.;            Office Action issued for Brazilian Application No.          BR122021012627-5, dated Mar. 8, 2022.;            Office Action issued for Brazilian Application No.          BR122022008466-4 dated Apr. 11, 2023.;            Office Action issued for Brazilian Application No.          BR12202208542-3 dated Mar. 2, 2023.;            Office Action issued for Chinese Application No.          201880073278.8 dated Jun. 8, 2021.;            Reexamination Notice issued for Chinese Application No.          201580076718.1 dated May 24, 2023.;            Office Action issued for Eurasian Application No.          202091005, dated Mar. 16, 2022.;            Office Action issued for Eurasian Application No.          202091005, dated Apr. 21, 2022.;            Office Action issued in Eurasian Application No.          202091005 dated Nov. 25, 2022.;            English translation of Office Action issued for Eurasian          Application No. 202091005 dated Apr. 25, 2023.;            Office Action issued for Eurasian Application No.          201791460/28 dated Aug. 18, 2020.;            Office Action issued for Eurasian Application No.          201791460/28 dated Jan. 25, 2023.;            Communication issued in EP Application No. 21178364.2,          dated Apr. 4, 2023.;            Office Action issued for Japanese Application No.          2017-534192, dated Apr. 25, 2023.;            Re-Examination report issued for JP2021-017354, dated          Mar. 8, 2022.;            Pre-Grant Opposition issued in IN 202017019418, dated          Oct. 8, 2021.;            Pre-Grant Opposition issued in IN 201717025098, dated          Mar. 10, 2021.;            Pre-Grant Opposition issued in IN 201717025098, dated          Apr. 7, 2021.;            Pre-Grant Opposition issued in IN 201717025098, dated          Jun. 23, 2021.;            Pre-Grant Opposition issued in IN 201717025098, dated          Sep. 6, 2021.;            Office Action issued in Indian Application No.          201717025098 dated Feb. 16, 2023.;            Office Action for Israeli Application No. 252997 dated          Aug. 15, 2019.;            Office Action for Israeli Application No. 279663 dated          Feb. 16, 2022.;            Office Action for Israeli Application No. 296496 dated          Mar. 22, 2023.;            English summary of Korean Application No. 10-2017-7020692          dated Feb. 15, 2023.;            English summary of Korean Application No. 10-2017-7020692          dated May 30, 2023.;            English translation of Office Action for Korean          Application No. 10-2021-7012910 dated Jul. 3,          2023.;            English translation of Korean Notice of Preliminary          Rejection issued KR 10-2021-7012910 dated Dec. 22,          2022.;            Office Action for Russian Application No. 2020116571          dated Jan. 25, 2022.;            Office Action for Russian Application No. 2020116571          dated May 19, 2023.;            Office Action Issued for Singaporean Application No.          11201705069Y, dated Mar. 22, 2021.;            Office Action Issued for Singaporean Application No.          10202105371Y, dated Jul. 5, 2023.;            Search Report Issued for Singaporean Application No.          10202105371Y, dated Jul. 5, 2023.;            International Search Report and Written Opinion issued          for Application No. PCT/US2021/016984 dated Jun. 28,          2021.;            International Search Report and Written Opinion for          International Application No. PCT/US2019/021168 dated          Jul. 8, 2019, 12 pages.;            International Preliminary Report on Patentability issued          for Application No. PCT/US2019/021168, dated Sep. 17,          2020.;            Office Action dated Sep. 3, 2020, in U.S. Appl. No.          16/755, 779.;            Office Action dated Jan. 6, 2021, in U.S. Appl. No.          16/755, 779.;            Notice of Allowance issued for U.S. Appl. No. 16/755,          779, dated Apr. 28, 2021.;            Office Action issued in Philippine Application No.          1-2020-550607, dated Jan. 31, 2022.;            Third Party Observation in Philippine Application No.          2020550607, dated Feb. 3, 2022.;            Office Action for Philippines Application No.          1-2022-550371 dated Oct. 7, 2022.;            English translation of Indonesian Application No.          P00202003494 mailed Jun. 30, 2022.;            English summary of Substantive Examination for          Application No. 520412305 OA dated Feb. 25,          2022.;            Office Action for Saudi Arabian Application No. 522432673          dated May 22, 2023.;            Office Action with English translation for Georgian          Application No. 202116034 dated 5/10/223.;            English translation of Office Action for Mongolian          Application No. 10-2022-00681 dated Jan. 3,          2023.;            Office Action for Vietnamese Application No. 1-2022-01444          dated Sep. 13, 2022.;            Examination Report for Pakistan Application No. 115/2021          dated Mar. 1, 2022.;            Office Action for Korean Application No. 10-2021-7012910          dated Jul. 3, 2023.;            Office Action and Search Report for Malaysian Application          No. PI2022001117 dated Jun. 21, 2023.;            Office Action for Russian Application No. 20201165701          dated May 19, 2023.;            English translation of Office Action for Iranian          Application No. 140150140003003647, dated Jul. 12,          2023.;            Office Action for Sri Lankan Application No. 22215, dated          Jul. 20, 2023.;            Extended European Search Report issued in EP 21750787.0,          dated Aug. 2, 2023.;            Sheahan et al: An orally bioavailable broad-spectrum          antiviral inhibits SARS-CoV-2 and multiple endemic,          epidemic and bat coronavirus, bioRxiv, Mar. 20,          2020.;            Sheahan et al: An orally bioavailable broad-spectrum          antiviral inhibits SARS-CoV-2 in human airway epithelial          cell cultures and multiple coronaviruses in mice, Sci.          Transl. Med, Apr. 29, 2020 p. eabb5883.;            Al-Horani et al: Potential Anti-SARS-CoV-2 Therapeutics          That Target the Post-Entry Stages of the Viral Life          Cycle: A Comprehensive Review, Viruses, vol. 12, No. 10,          Sep. 26, 2020.;            Painter Wendy P. et al: Human Safety, Tolerability, and          Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral          Compound, Molnupiravir, with Activity Against SARS-CoV-2,          medRxiv, Dec. 14, 2020.;            Painter Wendy P. et al: Human Safety, Tolerability, and          Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum          Oral Antiviral Agent with Activity against SARS-CoV-2,          Antimicrobial Agents and Chemotherapy, vol. 65, No. 5,          Apr. 19, 2021.;            Wahl Angela et al: SARS-CoV-2 infection is effectively          treated and prevented by EIDD-2801, Nature, vol. 591, No.          7850, Feb. 9, 2021.;            Imran Mohd. et al: Discovery, Development, and Patent          Trends on Molnupiravir: A Prospective Oral Treatment for          COVID-19, Molecules, vol. 26, No. 19, Sep. 24,          2021.;            Notice of Acceptance issued in Australian Application No.          2021203840, dated Aug. 15, 2023.;            English translation of Office Action for Chilean          Application No. 2022-423, dated Aug. 3, 2023.;            English translation of Office Action for Indonesian          Application No. P00202211381, dated Aug. 23,          2023.;            English Translation of Office Action issued for          MX/a/2020/005392 dated Sep. 2, 2022.;            English translation of Office Action issued in Ukrainian          application No. a202203239, dated Sep. 27,          2023.;            English translation of Japanese Notice of Allowance          issued in JP2017-534192, dated Oct. 10, 2023.;            English translation of Eurasian Office Action issued in          Application No. 202291843, dated Oct. 11, 2023.;            English translation of Decision to Grant issued in KR          10-2021-7012910, dated Oct. 12, 2023.;            English summary of office action issued in Saudi Arabian          Application No. 520412305, dated Oct. 19, 2023.;            English summary of office action issued in Saudi Arabian          Application No. 522432673, dated Oct. 19, 2023.;            Substantive Examination Report issued in Philippines          Application No. 1/2020/550607, dated Nov. 13,          2023.;            English translation of Office Action issued in Indonesia          Application No. P00202201460, dated Oct. 20,          2023.;            Office Action issued in Canadian Application No. 297259,          dated Dec. 8, 2023.	 M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N; 11573-0-0-0 K M; 122573-0-0-0 K M; 444-0-0-0 	214883802 M N; 214883803 M N; 214883804 M N; 214883801 M N	00211; 00212; 41247	RCLL1G M N; RCLL1H M N; RCLL1I M N; RCLL1J M N; RCLL1K M N; RCLL1L M N; RCLL1M M N; RCLL1N M N; RCLL1O M N; RCLL1P M N; RCLL1Q M N; RCLL1R M N; RCLL1S M N; RCLL1T M N; RCLL1U M N; RCLL1V M N; RCLL1W M N; RCLL1X M N; RCLL1Y M N; RCLL1Z M N; RCLL20 M N; RCLL21 M N; RCLL22 M N; RCLL23 M N; RCLL24 M N; RCLL25 M N; RCLL26 M N; RCLL27 M N; RCLL28 M N; RCLL29 M N; RCLL2A M N; RCLL2B M N; RCLL2C M N; RCLL2D M N; RCLL2E M N; RCLL2F M N; RCLL2G M N; RCLL2H M N; RCLL2I M N; RCLL2J M N; RCLL2K M N; RCLL2L M N; RCLL2M M N; RCLL2N M N; RCLL2O M N; RCLL2P M N; RCLL2Q M N; RCLL2R M N; RCLL2S M N; RCLL2T M N; RCLL2U M N; RCLL2V M N; RCLL2W M N; RCLL2X M N; RCLL2Y M N; RCLL2Z M N; RCLL30 M N; RCLL31 M N; RCLL32 M N; RCLL33 M N; RCLL34 M N; RCLL35 M N; RCLL36 M N; RCLL37 M N; RCLL38 M N; RCLL39 M N; RCLL3A M N; RCLL3B M N; RCLL3C M N; RCLL3D M N; RCLL3E M N; RCLL3F M N; RCLL3G M N; RCLL3H M N; RCLL3I M N; RCLL3J M N; RCLL3K M N; RCLL3L M N; RCLL3M M N; RCLL3N M N; RCLL3O M N; RCLL3P M N; RCLL3Q M N; RCLL3R M N; RCLL3S M N; RCLL3T M N; RCLL3U M N; RCLL3V M N; RCLL3W M N; RCLL3X M N; RCLL3Y M N; RCLL3Z M N; RCLL40 M N; R16596 K M; R20290 K M; R00351 		RU2708891-C1	VACCINE FOR ROTA-, CORONAVIRAL INFECTION AND CATTLE COLIBACILLOSIS	SOKOLOVA N A;  MNIKOVA L A;  ISHKOVA T A;  GORBATOV A V;  LOSHCHININ M N;  SIMANOVA I N;  MAKAROVA V N;  BADEEVA O B;  KORYUKINA M V	AS RUSSIA EXPERIMENTAL VETERINARY MEDICI (ASEX-Non-standard)	202005213C	   NOVELTY - Invention refers to veterinary science, namely to virology, and can be used to produce a vaccine for rota-, coronaviral infection and cattle colibacillosis. Vaccine as an active substance contains a mixture of inactivated suspension of rotavirus strain RM, family Reoviridae, genus Rotavirus, inactivated suspension of the coronavirus KL-2 strain of the Coronaviridae family, of the genus Coronavirus, with activity of each of viral strains 105.5 - 106.5 TCDD50 in cm3 a vaccine grown in a transplantable cell culture of MDVK or LEC, and adhesive antigens K99, F41, Att25 of Escherichia coli bacteria; purification of adhesive antigens K99, F41, Att25 of Escherichia coli bacteria taken in equal ratio (1:1:1), with concentration 50100 ml of microbial cells in 1 cm3 vaccines are carried out with concentration of the solution of phosphate-urea buffer increased to 1.53.0 M.    USE - Veterinary medicine.    ADVANTAGE - Using the given invention enables to obtain an associated trivalent vaccine exhibiting high immunogenicity in association with adhesive Escherichia coli strains. 1 cl, 4 ex, 4 tbl 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-F10A3;  B04-F11B;  B14-A02;  B14-G01;  B14-S11A;  C04-F10A3;  C04-F11B;  C14-A02;  C14-G01;  C14-S11A;  D05-H07	A61K-039/108;  A61K-039/15;  A61K-039/215;  A61P-031/00	RU2708891-C1   12 Dec 2019   A61K-039/15   202006Pages: 0   Russian	RU2708891-C1    RU122231    19 Jun 2018		RU122231    19 Jun 2018			RU2708891-C1 -- RU2145236-C1   VETERINARY RES INST (VETE-Soviet Institute)   GAFFAROV KH Z,  SPIRIDONOV G N,  IVANOV A V,  ROMANOV E A,  KHABIBULLIN F SH;  RU2325183-C1   VETERINARY MED BIOTECHN INST STOCK CO (VETE-Soviet Institute)   STAVTSEVA L YA,  SUBBOTIN V V,  MELNIK N V,  KRYUKOV S V,  RAKHMANIN P P,  SOLOVEV B V;  RU2403063-C1   HUMAN&ANIMAL DISEASES DIAGNOSTICS INST (HUMA-Soviet Institute)   SERGEEV V A,  NEPOKLONOV E A,  ALIPER T I,  VERKHOVSKAYA A E,  KORITSKAYA M A,  DEMKINA M M,  PIROZHKOV M K;  RU2517733-C1   TOXICOLOGY RADIATION & BIOLOGICAL SAFET (TOXI-Non-standard)   GAFFAROV KH Z,  IVANOV A V,  DUPLEVA L SH,  JARULLIN A I;  UA45698-A   		200757-0-0-0 K M			RA00GT K M		WO2019147050-A1;  KR2019090301-A;  KR2020021494-A;  KR2145025-B1;  CN111902419-A;  EP3744726-A1;  US2021040135-A1;  JP2021511354-W;  EP3744726-A4;  JP7190494-B2;  US11655268-B2;  CN111902419-B	New pyrimidin-2-one derivative used in            pharmaceutical composition for preventing or treating            viral infection-related disease, where virus includes            coronavirus, picornavirus, phlebovirus, ebolavirus,            hepatitis B virus and hepatitis C virus	KIM K;  KIM M;  KIM U;  GO Y Y;  NAM H;  BANG H T;  SHIN J S;  YOON J;  JANG Y;  KIM M H;  TAE B H;  JIN Q;  JIN X;  GO Y;  NAN G;  FANG Y;  SHIN J;  ZHANG L;  BANG H	ST PHARM CO LTD (SPHA-Non-standard);  ST PHARM CO LTD (SPHA-Non-standard);  ST PHARM CO LTD (SPHA-Non-standard);  ST PHARM CO LTD (SPHA-Non-standard);  ST PHARM CO LTD (SPHA-Non-standard)	2019675262	   NOVELTY - A pyrimidin-2(1H)-one derivative (I) is                new.    USE - New pyrimidin-2(1H)-one derivative is used in                pharmaceutical composition for preventing or                treating viral infection-related disease. The virus                includes coronavirus, picornavirus, phlebovirus,                ebolavirus, alpha -virus, flavivirus, human                immunodeficiency virus, hepatitis B virus and                hepatitis C virus (all claimed).    ADVANTAGE - The pharmaceutical composition containing the                pyrimidin-2(1H)-one derivative is non-toxic, and                does not exhibit cytotoxicity.    DETAILED DESCRIPTION - A pyrimidin-2(1H)-one derivative of formula                (I) or its racemate, stereoisomer or salt is                new.    Y' = H, halo or -NHC(O)R3;    R1 = H, group of formula (i);    R2 = H or halo;    R3 = heteroaryl, H, heterocyclyl, halo, amino,                cyano, nitro, azido, thio, hydroxy, 1-6C                (halo)alkyl, 1-6c aminoalkyl, 1-6C hydroxyalkyl,                1-6C dihydroxyalkyl, 1-6C alkoxy, 1-6C cycloalkyl,                heterocyclyl, 1-3C alkoxy-1-3C alkyl or                aryl;and    R4-R6 = H, 1-6C alkyl, 1-6C haloalkyl, aryl or                heteroaryl.    (i) Heterocyclyl and Heteroaryl include one or                more heteroatoms chosen from N, O and S; (ii)                Cycloalkyl and heterocyclyl are optionally                substituted with 1-6C alkyl, hydroxy, oxo, 1-6C                hydroxyalkyl, halo, cyano, nitro, O-1-6C haloalkyl,                1-6C alkoxy, formyl, 1-6C alkylformyl, carboxy,                1-6C alkylcarboxy, amino, 1-6C alkylamino, di(1-6C                alkyl)amino, carbamoyl, 1-6C alkylcarbamoyl,                di(1-6C alkyl)carbamoyl or O-1-3C alkoxy-1-3C                alkyl; and (iii) Aryl and heteroaryl are optionally                substituted by 1-6C alkyl, 1-6C alkoxy, O-1-3C                alkoxy-1-3C alkyl, 1-6C hydroxyalkyl, halo, cyano,                pyrazinyl, hydroxy, oxo, nitro, formyl-1-6C                alkylformyl, carboxy, 1-6C alkylcarboxy, amino,                1-6C alkylamino, di(1-6C alkyl)amino, carbamoyl,                1-6C alkylcarbamoyl, di-(1-6C alkyl)carbamoyl or                O-1-6C alkylsulfonyl. 			B03 (Other heterocyclics.)	B04-B03D;  B04-B03E;  B14-A02	A61P-031/12;  A61P-031/16;  A61P-031/18;  C07H-019/067;  A61K-031/7068;  A61P-031/14;  A61P-031/20;  C07H-019/073;  C07H-019/06;  C07H-019/10	WO2019147050-A1   01 Aug 2019   C07H-019/067   201965Pages: 64   ;  KR2019090301-A   01 Aug 2019   C07H-019/067   201966   ;  KR2020021494-A   28 Feb 2020   C07H-019/067   202022   ;  CN111902419-A   06 Nov 2020   C07H-019/067   202094   Chinese;  EP3744726-A1   02 Dec 2020   C07H-019/067   202098   English;  US2021040135-A1   11 Feb 2021   C07H-019/067   202116   English;  JP2021511354-W   06 May 2021   C07H-019/067   202140Pages: 52   Japanese;  EP3744726-A4   26 Jan 2022   C07H-019/06   202209   English;  JP7190494-B2   15 Dec 2022   C07H-019/073   202203   Japanese;  US11655268-B2   23 May 2023   C07H-019/067   202343   English;  CN111902419-B   24 Nov 2023   C07H-019/067   202398   Chinese	WO2019147050-A1    WOKR001036    24 Jan 2019;   KR2019090301-A    KR009009    24 Jan 2018;   KR2020021494-A    KR021164    20 Feb 2020;   KR2145025-B1    KR021164    20 Feb 2020;   CN111902419-A    CN80021422    24 Jan 2019;   EP3744726-A1    EP743401    24 Jan 2019;   US2021040135-A1    US16963900    22 Jul 2020;   JP2021511354-W    JP540631    24 Jan 2019;   EP3744726-A4    EP743401    24 Jan 2019;   JP7190494-B2    JP540631    24 Jan 2019;   US11655268-B2    US16963900    22 Jul 2020;   CN111902419-B    CN80021422    24 Jan 2019	KR2020021494-A Div ex Application KR009009;   KR2145025-B1 Div ex Application KR009009;   CN111902419-A PCT application Application WOKR001036;   CN111902419-A Based on Patent WO2019147050;   EP3744726-A1 PCT application Application WOKR001036;   EP3744726-A1 Based on Patent WO2019147050;   US2021040135-A1 PCT application Application WOKR001036;   JP2021511354-W PCT application Application WOKR001036;   JP2021511354-W Based on Patent WO2019147050;   JP7190494-B2 PCT application Application WOKR001036;   JP7190494-B2 Based on Patent WO2019147050;   JP7190494-B2 Previous Publ. Patent JP2021511354;   US11655268-B2 PCT application Application WOKR001036;   US11655268-B2 Previous Publ. Patent US2021040135;   US11655268-B2 Based on Patent WO2019147050;   CN111902419-B PCT application Application WOKR001036;   CN111902419-B Previous Publ. Patent CN111902419;   CN111902419-B Based on Patent WO2019147050	KR009009    24 Jan 2018;  WOKR001036    24 Jan 2019;  KR021164    20 Feb 2020;  CN80021422    23 Sep 2020	WO2019147050-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP3744726-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      EP3744726-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR        		WO2019147050-A1 -- KR2015132879-A   ASAVI LLC (ASAV-Non-standard);  IVACHTCHENKO A V (IVAC-Individual)   IVACHTCHENKO A V;  US20160052952-A1   ;  WO2015134334-A1   SUO Z (SUOZ-Individual)   SUO Z,  TAGGART D J,  CAO S;  CN111902419-A -- CN101781283-A   ZENG H (ZENG-Individual)   ZENG H;  CN105263941-A   ASAVI LLC (ASAV-Non-standard);  IVACHTCHENKO A V (IVAC-Individual)   IVACHTCHENKO A V;  CN105792830-A   OHIO STATE INNOVATION FOUND (OHIS)   SUO Z,  VYAVHARE V P,  TAGGART D J;  CN106459130-A   SUO Z (SUOZ-Individual)   SUO Z,  TAGGART D J,  CAO S;  CN109153639-A   SPHAERA PHARMA PVT LTD (SPHA-Non-standard)   DUGAR S,  MAHAJAN D,  SEN S;  WO2015066053-A2   SYNTA PHARM CORP (SYPH)   CHIMMANAMADA D U,  YING W;  EP3744726-A4 -- CN101781283-A   ZENG H (ZENG-Individual)   ZENG H;  EP2977379-A1   ASAVI LLC (ASAV-Non-standard);  IVACHTCHENKO A V (IVAC-Individual)   IVACHTCHENKO A V;  US20160052952-A1   ;  WO2015134334-A1   SUO Z (SUOZ-Individual)   SUO Z,  TAGGART D J,  CAO S;  WO2017158621-A1   SPHAERA PHARMA PVT LTD (SPHA-Non-standard)   DUGAR S,  MAHAJAN D,  SEN S;  WO2015066053-A2   SYNTA PHARM CORP (SYPH)   CHIMMANAMADA D U,  YING W;  CN111902419-B -- CN101781283-A   ZENG H (ZENG-Individual)   ZENG H;  CN105263941-A   ASAVI LLC (ASAV-Non-standard);  IVACHTCHENKO A V (IVAC-Individual)   IVACHTCHENKO A V;  CN105792830-A   OHIO STATE INNOVATION FOUND (OHIS)   SUO Z,  VYAVHARE V P,  TAGGART D J;  CN106459130-A   SUO Z (SUOZ-Individual)   SUO Z,  TAGGART D J,  CAO S;  CN109153639-A   SPHAERA PHARMA PVT LTD (SPHA-Non-standard)   DUGAR S,  MAHAJAN D,  SEN S;  WO2015066053-A2   SYNTA PHARM CORP (SYPH)   CHIMMANAMADA D U,  YING W	WO2019147050-A1  WADA, T.:          "Synthesis and hybridization ability of          oligodeoxyribonucleotides incorporating          N-acyldeoxycytidine derivatives", EUROPEAN JOURNAL OF          ORGANIC CHEMISTRY, 2001, pages 4583 - 4593,          XP002595983,relevantClaims[1-5];  WALLIS, M. P.:          "Synthesis and anti-HIV activity of C4-modified          pyrimidine nucleosides", II FARMACO, vol. 54, 1999, pages          83 - 89, XP055107573,relevantClaims[1-9];  AKULA, H. K.:          "Facile functionalization at the C4 position of          pyrimidine nucleosides via amide group activation with          (benzotriazol-l-yloxy) tris (dimethylamino) phosphonium          hexafluorophosphate (BOP) and biological evaluations of          the products", ORGANIC & BIOMOLECULAR CHEMISTRY, vol.          15, 2017, pages 1130 - 1139,          XP055631274,relevantClaims[1-9]CN111902419-A  WADA, AKIO KOBORI:          "Synthesis and Hybridization Ability of          Oligodeoxyribonucleotides Incorporating          N-Acyldeoxycytidine Derivatives", EUROPEAN JOURNAL OF          ORGANIC          CHEMISTRY,relevantClaims[1-5],relevantPassages[4583-45934584scheme          1];  A. KRASZEWSKI :          "SYNTHESIS OF N4-MONO- AND DIALKYL-2"-DEOXYCYTIDINES AND          THEIR INSERTION INTO AN OLIGONUCLEOTIDE", TETRAHEDRON          LETTERS,relevantClaims[1-2],relevantPassages[861-864862          IIIk];  MARK P. WALLIS:          "Synthesis and anti-HIV activity of C4-modified          pyrimidine nucleosides", IL          FARMACO,relevantClaims[1-9],relevantPassages[83-8985Table          1 9885.2];  THOMAS R.WEBB:          "Hybridization triggered cross-Unking of          deoxyoligonudeotides", NUCLEIC ACIDS          RESEARCH,relevantClaims[1-2],relevantPassages[7661-76747662          1b];  HARI K.AKULA:          "acile functionalization at the C4 position of pyrimidine          nucleosides via amide group activation with          (benzotriazol-1-yloxy) tris(dimethylamino)phosphonium          hexafluorophosphate (BOP) and biological evaluations of          the products", ORGANIC & BIOMOLECULAR          CHEMISTRY,relevantClaims[1-9],relevantPassages[1130-11391136521b21c21dTable6];  HIRONORI KOMATSU:          "An Efficient Amination Method for Manufacturing          Cytidines", ORGANIC PROCESS RESEARCH &          DEVELOPMENT,relevantClaims[1-2],relevantPassages[564-567565          9];  DEYI ZHANG: "Facile          rearrangement of N4-(a-aminoacyl)cytidines to          N-(4-cytidinyl)amino acid amides", TETRAHEDRON          LETTERS,relevantClaims[1-2],relevantPassages[2052205520535h]US2021040135-A1            Zhang et al., Tetrahedron Letters, 2008, 49(13), pp          2052-2055. (Year: 2008)EP3744726-A4  MARK P WALLIS ET          AL: "Synthesis and anti-HIV activity of C4-modified          pyrimidine nucleosides", IL FARMACO, vol. 54, no. 1-2, 1          January 1999 (1999-01-01), pages 83 - 89, XP055107573,          ISSN: 0014-827X, DOI:          10.1016/S0014-827X(98)00107-4,relevantClaims[1,2,4-9],relevantPassages[&lt;pp&gt;85&lt;/pp&gt;&lt;compound&gt;9,          10&lt;/compound&gt;];  HARI K. AKULA ET          AL: "Facile functionalization at the C4 position of          pyrimidine nucleosides via amide group activation with          (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium          hexafluorophosphate (BOP) and biological evaluations of          the products", ORGANIC & BIOMOLECULAR CHEMISTRY, vol.          15, no. 5, 1 January 2017 (2017-01-01), pages 1130 -          1139, XP055631274, ISSN: 1477-0520, DOI:          10.1039/C6OB02334G,relevantClaims[1,2,7-9|4-6],relevantPassages[&lt;pp&gt;1136&lt;/pp&gt;&lt;figure&gt;5&lt;/figure&gt;&lt;compound&gt;21b,          21c, 21d&lt;/compound&gt;];  ZHANG ET AL:          "Facile rearrangement of N^4-(@a-aminoacyl)cytidines to          N-(4-cytidinyl)amino acid amides", TETRAHEDRON LETTERS,          ELSEVIER, AMSTERDAM , NL, vol. 49, no. 13, 8 February          2008 (2008-02-08), pages 2052 - 2055, XP022502896, ISSN:          0040-4039, DOI:          10.1016/J.TETLET.2008.02.015,relevantClaims[1,2],relevantPassages[&lt;pp&gt;2053&lt;/pp&gt;&lt;compound&gt;5h&lt;/compound&gt;];  KRASZEWSKI A. ET          AL: "Synthesis of 4-mono- and dialkyl-2'-deoxycytidines          and their insertion into an oligonucleotide", TETRAHEDRON          LETTERS, vol. 27, no. 7, 1 January 1986 (1986-01-01),          Amsterdam , NL, pages 861 - 864, XP055845473, ISSN:          0040-4039, DOI:          10.1016/S0040-4039(00)84121-0,relevantClaims[1,2],relevantPassages[&lt;pp&gt;862&lt;/pp&gt;&lt;compound&gt;IIIk&lt;/compound&gt;];  WEBB T R ET AL:          "HYRIDIZATION TRIGGERED CROSS-LINKING OF          DEOXYOLIGONUCLEOTIDES", NUCLEIC ACIDS RESEARCH, OXFORD          UNIVERSITY PRESS, GB, vol. 14, no. 19, 1 October 1986          (1986-10-01), pages 7661 - 7674, XP008035829, ISSN:          0305-1048,relevantClaims[1,2],relevantPassages[&lt;pp&gt;7662&lt;/pp&gt;&lt;compound&gt;1b&lt;/compound&gt;];  KOMATSU HIRONORI ET          AL: "An Efficient Amination Method for Manufacturing          Cytidines", ORGANIC PROCESS RESEARCH & DEVELOPMENT,          vol. 8, no. 4, 20 May 2004 (2004-05-20), US, pages 564 -          567, XP055845485, ISSN: 1083-6160, Retrieved from the          Internet          &lt;URL:https://pubs.acs.org/doi/pdf/10.1021/op0499371&gt;          DOI:          10.1021/op0499371,relevantClaims[1,2],relevantPassages[&lt;pp&gt;565&lt;/pp&gt;&lt;compound&gt;9&lt;/compound&gt;]CN111902419-B            Mark P. Wallis et al. Synthesis and anti-HIV activity of          C4-modified nucleosides; Ill Farmaco; 19990101; Volume 54          (1-2); page 83-89 see Table 1 Compound 9, page 85; page          88 5.2 Antiviral and Cytotoxicity Detection;            Hari K. Akula et al. acile function at the C4 position of          the nucleosides of the group activation with          (benzotri-1-yloxy) tris (+) (+) (+) (+) (+) (+) (+) (+)          (+) (+) (+) (+) and biological evaluations of the          products; Hari K.Akula and so on; Organic &          Biomolecular Chemistry; 20170207; Volume 15 (5); page          1130-1139, see page 1136, FIG. 5, compound 21b, 21c, 21d,          Table6;            Deyi Zhang and so on. Facile of N4 - (a-aminoacyl)          cytidines to N - (4-cytidinyl) amino acid amides, Deyi          Zhang and so on; (2) The compound of Formula (I) was          prepared in the following manner:;  A.          KRASZEWSKI et al. SYNTHESIS OF N4-MONO-AND FID-2 " -          DEOXYCYTIDINES AND THEIR INSERTION INTO AN          ALL-ROUND-OF-A-FID; KRASZEWSKI et al., Tetrahedron          Letters, 19860101, Vol. 127 (Phase 7), pages 861-864, see          page 862, compound IIIk.;            Thomas R. Webb, et al.. Hybrimultiple cross-cross-Unking          of deoxyB. deotides; "Nucleic Acids Research"; 19861001;          Vol. 14 (p. 19); p. 7661-7674, see p. 7662 compound          1b;            Hironori Komatsu et al. An effective AMethod for          Manufacturing Cytidines; Hironori Komatsu and so on;          "Organic Process Research & Development"; 20040520;          Volume 8 (Phase 4); p. 564-567, see compound 9, p.          565.;            Wada, Akio Kobori and so on. Synthesis and Hybrid Ability          of Oligodeoxyribonytidine Incorporating          N-Acyldeoxycytidine Derivatives; Wada, Akio Kobori and so          on; European Journal of Organic Chemistry; 20011119; Vol.          2001 (24); pages 4583-4593, see page 4584 scheme          1	 N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N	215868501 N		RCMSRY N; RCMSRZ N; RCMSS0 N; RCMSS1 N; RCMSS2 N; RCMSS3 N; RCMSS4 N; RCMSS5 N; RCMSS6 N; RCMSS7 N; RCMSS8 N; RCMSS9 N; RCMSSA N; RCMSSB N; RCMSSC N; RCMSSD N; RCMSSE N; RCMSSF N; RCMSSG N; RCMSSH N; RCMSSI N; RCMSSJ N; RCMSSK N; RCMSSL N; RCMSSM N; RCMSSN N; RCMSSO N; RCMSSP N; RCMSSQ N; RCMSSR N; RCMSSS N; RCMSST N; RCMSSU N; RCMSSV N; RCMSSW N; RCMSSX N; RCMSSY N; RCMSSZ N; RCMST0 N; RCMST1 N; RCMST2 N; RCMST3 N; RCMST4 N; RCMST5 N		US2019083569-A1	Composition used to treat viral infection e.g.            herpes simplex virus 2 infection and HIV infection            comprises electrospun fiber having surface and            biological adhesive moiety conjugated to surface of            electrospun fiber	STEINBACH-RANKINS J;  PALMER K	UNIV LOUISVILLE RES FOUND INC (ULSV-C)	201925847Y	   NOVELTY - Composition (C1), comprises an electrospun                fiber having a surface and a biological adhesive                moiety conjugated to the surface of the electrospun                fiber.    USE - The compositions are useful for treating a                viral infection in a subject, where the viral                infection comprises a herpes simplex virus 2                infection, a HIV infection, a hepatitis C virus                infection, a middle east respiratory virus syndrome                coronavirus infection, a severe acute respiratory                syndrome coronavirus infection, an Ebola virus                infection, a human papilloma virus infection, an                influenza virus infection, an enterovirus                infection, a measles virus infection, a simian                immunodeficiency virus infection, a human                T-lymphotrophic virus infection and a Japanese                encephalitis virus infection (all claimed). Test                details are described but no results given.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a                composition (C2), comprising a polymeric                nanoparticle having a surface and a biological                adhesive moiety conjugated to the surface of the                polymeric nanoparticle. 			B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B02 (Fused ring heterocyclics.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  A96 (Medical, dental, veterinary, cosmetic.)	B04-B03D;  B04-B03E;  B04-C03B;  B04-C03D;  B04-N03;  B04-Q;  B05-B01E;  B10-A20;  B10-C02;  B14-A02;  B14-C03;  B14-K01D;  B14-S18;  A12-V01;  A12-W05	A61K-031/522;  A61K-031/675;  A61K-038/16;  A61K-045/06;  A61K-047/59;  A61K-047/69	US2019083569-A1   21 Mar 2019   A61K-038/16   201924Pages: 44   English	US2019083569-A1    US043602    24 Jul 2018	US2019083569-A1 Provisional Application US174346P;   US2019083569-A1 Cont of Application US180963	US174346P    11 Jun 2015;  US043602    24 Jul 2018					86437-0-0-0 K M; 161137-1-0-0 K M; 162061-1-1-0 K M; 1014507-0-0-0 K M; 104374-0-0-0 K M; 1220805-0-0-0 K M; 104373-0-0-0 K M; 199410-0-0-0 K M; 104380-0-0-0 K M; 1911-0-0-0 ; 5938-0-0-0 ; 7447-0-0-0 ; 7560-0-0-0 ; 1220805-0-0-0 CL USE; 1014507-0-0-0 CL USE		00357	R04178 K M; RA04GU K M; RA0Z3O K M; RAF2EG K M; RAGKPQ K M; RA0B83 K M; RAXJLM K M; RB5U5N K M; RA0SC3 K M; RA0TPM K M; RA02L0 K M; RA037T K M; R00446 ; R01295 ; R00009 ; R00448 		CN110512027-A;  CN110512027-B	Quintuple real time (RT)-PCR detection method            useful for detecting porcine viral diarrhea disease, by            designing primer-specific sequences of 5 viruses,            preparing cDNA of sample, and detecting amplified            products	SU S;  ZHANG C;  PAN Z;  HE W;  DI X	UNIV NANJING AGRIC (UYNA-C)	2019A2756K	   NOVELTY - Quintuple real time (RT)-PCR detection method                involves (i) designing primer-specific sequences of                5 viruses for RT-PCR, (ii) preparing cDNA of the                sample to be tested by extracting total RNA in the                diarrhea stool sample or intestinal tissue and                reverse-transcribing into cDNA template, (iii)                using 5 pairs of RT-PCR primers for detection by                placing the primer pairs of porcine delta                coronavirus (PDCoV), porcine torovirus (PToV),                porcine epidemic diarrhea virus (PEDV), swine acute                diarrhea syndrome coronavirus (SADS-CoV), and                transmissible gastroenteritis virus (TGEV) in a PCR                reaction system and using cDNA as a template for                performing PCR amplification, and (iv) detecting                amplified products using agarose gel                electrophoresis and determining PDCoV (148 bp),                PToV (274 bp), PEDV (411 bp), Sads-CoV (574 bp) and                TGEV (833bp).    USE - The quintuple RT-PCR method is useful for                detecting porcine viral diarrhea disease.    ADVANTAGE - The detection sensitivity reaches initial                template concentration of 1x 103 copies/ mu l and                has good specificity and reproducibility that is                directly applied to the detection of clinical                samples.    DETAILED DESCRIPTION - Quintuple real time (RT)-PCR detection method                involves (i) designing primer-specific sequences of                5 viruses for RT-PCR, (ii) preparing cDNA of the                sample to be tested by extracting total RNA in the                diarrhea stool sample or intestinal tissue and                reverse-transcribing into cDNA template, (iii)                using 5 pairs of RT-PCR primers for detection by                placing the primer pairs of porcine delta                coronavirus (PDCoV), porcine torovirus (PToV),                porcine epidemic diarrhea virus (PEDV), swine acute                diarrhea syndrome coronavirus (SADS-CoV), and                transmissible gastroenteritis virus (TGEV) in a PCR                reaction system and using cDNA as a template for                performing PCR amplification, and (iv) detecting                amplified products using agarose gel                electrophoresis and determining PDCoV (148 bp),                PToV (274 bp), PEDV (411 bp), Sads-CoV (574 bp) and                TGEV (833bp). The primer-specific sequences of                PDCoV comprises upstream primer forward sequence                (F) having 5'-tacaacctaaggctaaccaac-3' and                downstream primer reverse sequence (R) having                5'-acaactttacctgccttacata-3'. The primer-specific                sequences of PToV comprises upstream primer F                having 5'-tcctcgtgacactttatctca-3' and downstream                primer R having 5'-ttcactaacatcctctaccaca-3'. The                primer-specific sequences comprises upstream primer                F having PEDV 5'-tgaagacttttgacaatccac-3' and                downstream primer R having                5-acacagcattaccatctac-3'. The primer-specific                sequences of Sads-CoV comprises upstream primer F                having 5'-gctcagtacatcttttcaact-3' and downstream                primer R having 5'-catagtcatactcgctacctt-3'. The                primer-specific sequences of TGEV comprises                upstream primer F having                5'-tacataccacctgcttatgcaa-3' and downstream primer                R having 5'-tacacaattgaccaatcaacac-3'. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B04B2;  B04-E01;  B04-E05;  B04-E99;  B04-F02;  B04-F11B;  B04-L04B;  B11-C08D1;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  C04-B04B2;  C04-E01;  C04-E05;  C04-E99;  C04-F02;  C04-F11B;  C04-L04B;  C11-C08D1;  C11-C08E3;  C11-C08F8;  C12-K04F;  C12-K04G1B;  D05-A02B;  D05-H06A;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/686;  C12Q-001/70;  C12R-001/93	CN110512027-A   29 Nov 2019   C12Q-001/70   202002Pages: 16   Chinese;  CN110512027-B   01 Apr 2022   C12Q-001/70   202231   Chinese	CN110512027-A    CN10794842    27 Aug 2019;   CN110512027-B    CN10794842    27 Aug 2019	CN110512027-B Previous Publ. Patent CN110512027	CN10794842    27 Aug 2019			CN110512027-A -- CN105420412-A   UNIV HENAN AGRIC (UYHR)   HAN L,  HU H,  ZHOU Y,  JIN X,  ZHANG L,  CAO B;  CN108754019-A   UNIV SOUTH CHINA AGRIC (USCG)   GUO X,  MO M,  KUANG Y;  CN108913812-A   SHANGHAI AGRIC SCI ACAD (SHNY)   LIU H,  TAO J,  LI B,  MA Y,  CHENG J,  SHI Y,  RAO B;  CN108950083-A   UNIV HENAN AGRIC (UYHR)   WANG C,  CHANG H,  WANG A,  CHEN L,  ZHOU F,  LI Y,  WANG X,  YANG X,  CUI D,  DU J,  LIU H,  ZHAO J;  KR617951-B1   REPUBLIC KOREA MANAGEMENT NAT FISHERIES (REPU-Non-standard)   KIM S H,  TARK D S,  CHO S D,  KWON J H;  CN110512027-B -- CN105420412-A   UNIV HENAN AGRIC (UYHR)   HAN L,  HU H,  ZHOU Y,  JIN X,  ZHANG L,  CAO B;  CN108754019-A   UNIV SOUTH CHINA AGRIC (USCG)   GUO X,  MO M,  KUANG Y;  CN108913812-A   SHANGHAI AGRIC SCI ACAD (SHNY)   LIU H,  TAO J,  LI B,  MA Y,  CHENG J,  SHI Y,  RAO B;  CN108950083-A   UNIV HENAN AGRIC (UYHR)   WANG C,  CHANG H,  WANG A,  CHEN L,  ZHOU F,  LI Y,  WANG X,  YANG X,  CUI D,  DU J,  LIU H,  ZHAO J;  KR617951-B1   REPUBLIC KOREA MANAGEMENT NAT FISHERIES (REPU-Non-standard)   KIM S H,  TARK D S,  CHO S D,  KWON J H	CN110512027-A  ZHICHAO XU:          "Isolation and characterization of A Highly Pathogenic          Strain of Porcine enteric alphacoronavirus Causing Watery          Diarrhea and High Mortality in Newborn Piglets",          TRANSBOUNDARY AND EMERGING          DISEASES,relevantClaims[1-6],relevantPassages[119-130];  ZHONGZHOU PAN:          "Development of a TaqMan-probe-based multiplex real-time          PCR for the simultaneous detection of emerging and          reemerging swine coronaviruses",          VIRULENCE,relevantClaims[1-6],relevantPassages[707-718];  : "PEDRT-PCR",          (),relevantClaims[1-6],relevantPassages[D050-306];  : "",          ,relevantClaims[1-6],relevantPassages[551-555]CN110512027-B  Li          Jianqiang and so on. The clone and characteristic          analysis of porcine source coronavirus polymerase gene,          Li Jianqiang and so on, China virology, 20061130, the 21          volume (6), 551-555 page;            Zhichao Xu. Isolation and characterization of A Highly          Pathogenic Strain of Porcine enteric alphacoronavirus          Causing Watery Diarrhea and High Mortality in Newborn          Piglets;Zhichao Xu;Transboundary and Emerging          Diseases;20180910;66(1);119-130;            Zhongzhou Pan. Development of a TaqMan-probe-based          multiplex real-time PCR for the simultaneous detection of          emerging and reemerging swine coronaviruses;Zhongzhou          Pan;Virulence;20200603;11(1);707-718;  "          Jiangsu salt city of a pig breeding company porcine          epidemic diarrhea (PED) of epidemiology survey and          porcine diarrhea virus quadrupPCR detection method of          establishing ; "China's Degree of Achiemeria Desertation          (Master's) Agricultural Science and Technology"; 20210815          (stage 08) D050-306	201562-0-0-0 D K M			RA0124 D K M		CN110157839-A;  CN110157839-B	Quadruple fluorescence quantitative detection kit            useful for simultaneously detecting four human            coronavirus (HCoV) i.e. HCoV-229E, HCoV-NL63, HCoV-OC43            or HCoV-HKUI comprises four sets of specific primer            pairs and probe	GENG H;  ZHU N;  CAI L;  SUN Y;  XU C;  YANG Z;  WANG S;  WU H;  TAN W	WUXI CUSTOMS PEOPLES REPUBLIC CHINA (WUXI-Non-standard);  CHINESE CENT DISEASE CONTROL & PREVENTIO (CCDC-C);  INST BEIJING VIRAL DISEASE CONTROL & PRE (CCDC-C)	201976418Y	   NOVELTY - Quadruple fluorescence quantitative detection                kit comprises four sets of specific primer pairs                and probe, positive control product and negative                control product. Each set of primer pairs and                probes comprises a pair of specific primer pair and                a probe sequence. The positive control substance is                specific synthetic target sequence. The negative                control substance is deionized water or sterile                water.    USE - The quadruple fluorescence quantitative                detection kit is useful for simultaneously                detecting four HCoV i.e. HCoV-229E, HCoV-NL63,                HCoV-OC43 or HCoV-HKUI (claimed).    ADVANTAGE - The kit simultaneously detects four human HCoV                in a single tube, has strong detection specificity,                high detection sensitivity and rapid action, avoids                cross-contamination and is cost-effective and                suitable for detection, prevention and control of                infectious diseases.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for method                for detecting human coronavirus (HCoV) using a                quadruple fluorescence quantitative detection kit,                which involves (a) subjecting sample to be detected                to nucleic acid extraction to obtain sample nucleic                acid, (b) formulating the specific primers and                probe sequences, 2? reaction solution, DNA                polymerase, reverse transcriptase (RT) and sample                nucleic acid obtained in step (a) to obtain                reaction system, arranging the positive control                product and the negative control product                respectively with a reaction system consistent with                the sample nucleic acid and subjecting the three                reaction systems to quantitative RT-PCR detection                and (c) adjusting the threshold of the highest                point of the fluorescent signal of the negative                control product, where the positive control product                has an S-type amplification curve in the four                detection channels and comparing the amplification                curve obtained from the sample nucleic acid with                the positive control product to interpret the                result. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E05;  B04-E99;  B04-F11B;  B04-L04A;  B04-L04B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  D05-A02B;  D05-H06A;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/686;  C12Q-001/70;  C12R-001/93	CN110157839-A   23 Aug 2019   C12Q-001/70   201973Pages: 16   Chinese;  CN110157839-B   20 Jun 2023   C12Q-001/70   202356   Chinese	CN110157839-A    CN10520198    17 Jun 2019;   CN110157839-B    CN10520198    17 Jun 2019	CN110157839-B Previous Publ. Patent CN110157839	CN10520198    17 Jun 2019			CN110157839-A -- CN101985665-A   UNIV FUDAN (UYFU);  UNITED GENE SHANGHAI HEALTHCARE MANAGEMENT                  SERVICE CO LTD (SHBD)   CHEN Q,  JIANG L,  LI Y,  QIU M,  XIAO H;  CN102732638-A   UNIV SUN YAT SEN (UYSY)   CAO K,  GUAN L,  CHANG Y,  FENG F,  HE X,  LI M,  WU J,  XU L,  ZHANG D,  WANG Z,  ZHENG Y,  XU S;  CN103993101-A   CUI S (CUIS-Individual)   CHEN M,  CUI S,  DAN W,  HUANG F,  SUN Y,  TIAN L,  WANG H,  ZHANG X,  ZHANG Y;  CN110157839-B -- CN101985665-A   UNIV FUDAN (UYFU);  UNITED GENE SHANGHAI HEALTHCARE MANAGEMENT                  SERVICE CO LTD (SHBD)   CHEN Q,  JIANG L,  LI Y,  QIU M,  XIAO H;  CN102732638-A   UNIV SUN YAT SEN (UYSY)   CAO K,  GUAN L,  CHANG Y,  FENG F,  HE X,  LI M,  WU J,  XU L,  ZHANG D,  WANG Z,  ZHENG Y,  XU S;  CN103993101-A   CUI S (CUIS-Individual)   CHEN M,  CUI S,  DAN W,  HUANG F,  SUN Y,  TIAN L,  WANG H,  ZHANG X,  ZHANG Y		201562-0-0-0 D K M; 204644-0-0-0 D K M			RA0124 D K M; RA031J D K M		CN110257357-A	Use of 3C-like proteases as            non-diagnostic/therapeutic target for deubiquitinating            enzymes and interferon antagonist and preparing            deubiquitinating enzyme medicine and interferon            antagonist medicine for treating interferon pathway            disease	XING Y;  CHEN Z;  XIE Q;  CHEN X	ACAD MILITARY MEDICAL SCI PLA (JSYX-C)	201991541S	   NOVELTY - Use of 3C-like proteases is claimed, as                non-diagnostic/therapeutic target for                deubiquitinating enzymes. The 3C-like protease is                substantially homologous to the full length                sequence having a 306 base pair sequence (SEQ ID                NO: 1) fully defined in the specification and is                derived from Middle East respiratory syndrome                coronavirus (MERS-CoV) and has protease catalytic                activity.    USE - The 3C-like proteases is used as                non-diagnostic/therapeutic target for                deubiquitinating enzyme and interferon antagonist                and preparing deubiquitinating enzyme medicine and                interferon, preferably type I interferon or                interferon beta antagonist medicine for treating                interferon pathway disease (interferonopathy),                preferably acquired immunodeficiency syndrome                (AIDS), Ankylosing spondylitis, arthritis,                dermatomyositis (DM), aplastic anemia, Behcet's                disease, diabetes, graft-versus-host disease,                Graves disease, hemolytic anemia,                hypogammaglobulinemia, high immunoglobin E (IgE)                syndrome, idiopathic thrombocytopenic purpura                (ITP), multiple sclerosis (MS), myasthenia gravis,                psoriasis and lupus (all claimed).    ADVANTAGE - The 3C-like proteases provides a theoretical                basis for the study of coronavirus and host                antiviral innate immunity and antiviral medicine                targeting viral proteases. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-E99;  B04-L05C;  B11-C08E3;  B14-C03;  B14-C09;  B14-F03;  B14-F08;  B14-G02;  B14-J05;  B14-L06;  B14-N11;  B14-N17;  B14-S01;  B14-S04;  D05-A02C;  D05-H09;  D05-H99;  S03-E09F;  S03-E14H5	C12N-009/48;  G01N-033/573	CN110257357-A   20 Sep 2019   C12N-009/48   201985Pages: 19   Chinese	CN110257357-A    CN10599247    04 Jul 2019		CN10599247    04 Jul 2019			CN110257357-A -- US20150050308-A1   ;  US6942865-B2   BAYLOR COLLEGE MEDICINE (BAYU)   ESTES M K,  JIANG X,  GRAHAM D Y	CN110257357-A  : "MERS3C",          ,relevantClaims[1-10],relevantPassages[4.1-4.4]						KR2019138413-A	Umbrella handle, comprises microphone body provided to allow user to hold by hand, microphone device is provided to convert sound into electrical signal and microphone control unit controls operation of microphone inside	HEE Y T	HEE Y T (HEEY-Individual)	2019A59270	   NOVELTY - The umbrella handle comprises a microphone body provided to allow a user to hold by hand and a microphone device is provided to convert sound into an electrical signal on an upper portion of the microphone body. A microphone control unit is provided to control the operation of the microphone inside the microphone body. A lower portion of the microphone body is included. The microphone is configured to wirelessly transmit the microphone signal to the muffler. The lower portion of the microphone element is provided with a moisturizing portion capable of supplying humidified air during use.    USE - Umbrella handle.    ADVANTAGE - The configuration of an umbrella handle prevents the handle from getting infected from pandemic disease. The battery portion minimizes the risk of electric shock to increase safety.    DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of an umbrella handle. 			D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  P24 (Hand, travelling articles, brushes (A45, A46).);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).);  Q74 (Heating, ranges, ventilating (F24));  X27 (Domestic Electric Appliances\n)	D09-A;  P24-A02;  P34-A01;  Q74-A02C;  X27-A02E;  X27-E01	A45B-003/00;  A45B-009/02;  A61L-009/012;  F24F-006/00	KR2019138413-A   13 Dec 2019   A45B-009/02   201999Pages: 6   	KR2019138413-A    KR064827    05 Jun 2018		KR064827    05 Jun 2018										RU2681473-C1	TEST SYSTEM FOR DETECTION OF THE VIRUS GENOME OF            PARAINFLUENZA 3 TYPES AT CATTLE WITH A MULTIPLEX            POLYMERASE CHAIN REACTION WITH FLUORESCENT DETECTION IN            REAL TIME MODE	CHERNYKH O YU;  BANNOV V A;  MALYSHEV D V;  DROBIN YU D;  DONNIK I M;  KLIMENKO A I;  DEVRISHOV D A;  LYSENKO A A;  KRIVONOS R A;  KOSHCHAEV A G;  KALOSHKINA I M;  ZABASHTA S N;  KULAKOVA A L	UNIV KUBAN AGRIC (UKUB-C)	2019289735	   NOVELTY - Invention relates to biotechnology, and in                particular to means of diagnosing parainfluenza                virus type 3 in animals. Test system for detecting                the genome of the causative agent of coronavirus                infection in animals using multiplex polymerase                chain reaction with fluorescence detection in real                time is proposed. Test system includes a buffer for                carrying out the polymerase chain reaction, primers                and fluorescent probes specific for Coronavirus A                and for the internal control sample, a mixture of                enzymes from DNA polymerase with antibodies                inhibiting enzyme activity, TAQ POLYMERASE and                reverse transcriptase MMLV REVERSE TRANSCRIPTASE,                buffer for diluting RNA in the form of deionized                water, internal control sample, negative control                sample, positive control sample, for internal                control sample bacteriophage MS2 suspension, and                for a positive control sample, a mixture of                recombinant plasmid DNA containing a fragment of                the BPI 3 virus genome and a fragment of the                bacteriophage genome is used.    USE - Biotechnology.    ADVANTAGE - Invention serves to extend the functionality                and obtain reliable diagnostics. 1 cl, 5 tbl, 1 ex 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-E01;  B04-E05;  B04-F11B;  B04-G08;  B04-L04A;  B04-L04B;  B11-C07A5;  B11-C08E3;  B11-C08F8;  B12-K04F;  C04-E99;  C04-E01;  C04-E05;  C04-F11B;  C04-G08;  C04-L04A;  C04-L04B;  C11-C07A5;  C11-C08E3;  C11-C08F8;  C12-K04F;  D05-H99;  D05-A02B;  D05-H06A;  D05-H09;  D05-H18B	C12Q-001/6806	RU2681473-C1   06 Mar 2019   C12Q-001/6806   201925Pages: 0   Russian	RU2681473-C1    RU101625    16 Jan 2018		RU101625    16 Jan 2018			RU2681473-C1 -- RU2421731-C2   ;  US9505807-B2   UNIV GEORGIA RES FOUND INC (UYGA);  HE B (HEBB-Individual)   HE B;  WO2017080500-A1   COYOTE BIOSCIENCE CO LTD (COYO-Non-standard)   LI X		1525931-1-0-0 K M; 1525931-1-0-0 CL USE			RARECG K M		WO2019136824-A1	New polypeptide compound useful in pharmaceutical composition for treating or preventing middle east respiratory syndrome coronavirus (MERS-CoV) infection related disease, preferably MERS-CoV	WANG C;  LIU K;  ZHANG P;  MENG G;  LIANG G	MILITARY MEDICAL SCI ACAD (JSYX-C)	2019634207	   NOVELTY - A polypeptide compound having at least 80% sequence homology to amino acid sequence, or their stereoisomer, mixture, salt and/or functional equivalent variant, is new.    USE - The polypeptide compound is useful in pharmaceutical composition and preparation of MERS-CoV fusion inhibitor for treating or preventing MERS-CoV infection related disease, preferably MERS-CoV (all claimed).    DETAILED DESCRIPTION - A polypeptide compound, is new. The polypeptide compound has at least 80% sequence homology to sequence of formula: R1-U-Leu-Asp-Leu-Thr-Tyr-Glu-Xa-Leu-X1-Leu-Gln-X2-Val-Val-Lys-X3-Leu-Asn-Glu-X4-Tyr-W-R2 (I) or their stereoisomer, mixture, salt and/or functional equivalent variant, where the Xa is an amino acid residue capable of generating hydrophobic interaction with middle east respiratory syndrome coronavirus (MERS-CoV) derived region (MERS-COV HR2), which is chosen from D-type or L-type hydrophobic amino acid: Ala, Val, Leu, Ile, Pro, Phe, Trp, n-Leu and Met, X1, X2, X3 and X4 are chosen from D-type or L-type amino acids, U and W do not exist or chosen from one or more additional D-type or L-type amino acids, R1 is chosen from H, polymer derived from polyethylene glycol optionally substituted with non-cyclic aliphatic group, alicyclic group, heterocyclyl group, heteroaralkyl group, aryl group, aralkyl group and R5-CO-, R5 is chosen from H optionally substituted with non-cyclic aliphatic group, alicyclic group, aryl group, aralkyl group, heterocyclyl group and heteroaralkyl group, preferably H, acetyl group, lauryl group, myristoyl group or palmitoyl group, R2 is chosen from -NR3R4, -OR3 and -SR3, preferably -NR3R4 and -OR3, R3 and R4 are chosen from H, polymer derived from polyethylene glycol optionally substituted with non-cyclic aliphatic group, alicyclic group, heterocyclyl group, heteroaralkyl group, aryl group and aralkyl group, preferably H, methyl group, ethyl group, hexyl group, dodecyl group and hexadecyl group, and R1 and R2 are not D-type or L-type amino acids. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  A96 (Medical, dental, veterinary, cosmetic.)	B04-E99;  B04-N04;  B14-A01;  B14-A02;  B14-A04;  A10-E01;  A12-V01	A61K-038/16;  A61P-031/14;  C07K-014/165	WO2019136824-A1   18 Jul 2019   C07K-014/165   201963Pages: 48   Chinese	WO2019136824-A1    WOCN079474    19 Mar 2018		CN10035685    15 Jan 2018	WO2019136824-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  		WO2019136824-A1 -- CN104072592-A   UNIV FUDAN (UYFU)   JIANG S,  LU L,  LIU Q;  CN107022008-A   UNIV FUDAN (UYFU)   JIANG S,  LU L,  XIA S,  WANG Q,  YU F		184611-0-0-0 N; 184616-0-0-0 N; 444-0-0-0 			RA00H1 N; RA00H3 N; R00351 		US2019154687-A1;  CN109799339-A;  KR2019056938-A;  JP2019095204-A;  JP6782218-B2;  JP2021036869-A;  US11169151-B2;  JP7050878-B2	Detection device for detecting human-infecting            strongly-virulent influenza, comprises sensor element,            and probe molecule immobilized at sensor element and            associated with receptor exposed at surface of            detection target	SUGIZAKI Y	TOSHIBA KK (TOKE-C);  TOSHIBA KK (TOKE-C);  TOSHIBA KK (TOKE-C);  TOSHIBA CORP (TOKE-C)	2019448013	   NOVELTY - Detection device comprises a sensor element;                and a probe molecule (21) immobilized at the sensor                element. The probe molecule associates with a                receptor exposed at a surface of a detection                target. The sensor element detects cleavage of the                receptor having associated with the probe                molecule.    USE - The device is useful for detecting                human-infecting strongly-virulent influenza.    ADVANTAGE - Detection device and detection method are                provided that rapidly and specifically detect                human-infecting strongly-virulent influenza that                threatens to cause a pandemic.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a                detection method which involves detecting cleavage                of a receptor exposed at a surface of a detection                target, the detection target being associated with                a probe molecule immobilized at a sensor element,                the detecting being performed by the sensor                element.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of                detection device.    Substrate (11)    Foundation film (12)    Graphene film (13)    Phospholipid film (14)    Probe molecule (21) 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-E05;  B04-F11B;  B04-N03K;  B11-C08F8;  B11-C08K;  B12-K04G1B;  D05-H09;  D05-H10;  S03-E09F;  S03-E14H	G01N-033/483;  G01N-033/559;  G01N-033/566;  G01N-033/569;  G01N-033/543;  G01N-033/68;  C12M-001/34;  C12Q-001/04;  C12Q-001/37;  G01N-021/41;  G01N-027/00;  G01N-027/414;  G01N-029/02;  G01N-033/53;  G01N-005/02;  C12N-009/50;  C12N-009/76;  C12Q-001/70	US2019154687-A1   23 May 2019   G01N-033/569   201944Pages: 24   English;  CN109799339-A   24 May 2019   G01N-033/569   201944   Chinese;  KR2019056938-A   27 May 2019   G01N-033/543   201944   ;  JP2019095204-A   20 Jun 2019   G01N-033/569   201946Pages: 19   Japanese;  JP6782218-B2   11 Nov 2020   G01N-033/569   202091Pages: 18   Japanese;  JP2021036869-A   11 Mar 2021   C12M-001/34   202122Pages: 20   Japanese;  US11169151-B2   09 Nov 2021   G01N-033/569   202192   English;  JP7050878-B2   08 Apr 2022   C12M-001/34   202237   Japanese	US2019154687-A1    US913946    07 Mar 2018;   CN109799339-A    CN10164966    28 Feb 2018;   KR2019056938-A    KR019268    19 Feb 2018;   JP2019095204-A    JP221876    17 Nov 2017;   JP6782218-B2    JP221876    17 Nov 2017;   JP2021036869-A    JP171359    09 Oct 2020;   US11169151-B2    US913946    07 Mar 2018;   JP7050878-B2    JP171359    09 Oct 2020	JP6782218-B2 Previous Publ. Patent JP2019095204;   JP2021036869-A Div ex Application JP221876;   US11169151-B2 Previous Publ. Patent US2019154687;   JP7050878-B2 Div ex Application JP221876;   JP7050878-B2 Previous Publ. Patent JP2021036869	JP221876    17 Nov 2017;  JP171359    09 Oct 2020			US2019154687-A1 -- US20150148265-A1   ;  US20160208883-A1   ;  WO2016111568-A1   UNIV YONSEI IND FOUND (UYIA);  KOREA RES INST BIOSCIENCE &                  BIOTECHNOLOG (KRIB)   HAAM S,  KIM H,  SONG D,  KIM J,  JANG E,  CHOI J;  CN109799339-A -- CN102119331-A   LIFE TECHNOLOGIES CORP (LITC)   BARTEL J,  IGNATIUS M,  MOLOKANOVA E,  SAVTCHENKO A,  TREADWAY J,  ZHAO W;  CN102154436-A   UNIV SOUTHEAST (UYSE)   ZHAO J,  ZHANG H,  WANG X,  WU X,  ZUO J,  CHANG H;  CN104436157-A   ALFENITO M R (AIFE-Individual);  BAER M (BAER-Individual);  BUCHER D (BUCH-Individual)   ALFENITO M R,  BAER M,  BUCHER D;  EP3244210-A1   UNIV YONSEI IND FOUND (UYIA);  KOREA RES INST BIOSCIENCE &                  BIOTECHNOLOG (KRIB)   HAAM S,  KIM H,  SONG D,  KIM J,  JANG E,  CHOI J;  US20140106469-A1   ;  US20150148265-A1   	CN109799339-A  ALEXANDER          B.ARTYUKHIN: "Functional One-Dimensional Lipid Bilayers          on Carbon Nanotube Templates",          J.AM.CHEM.SOC.,relevantClaims[1-10],relevantPassages[7538-7542];  BERND WHCKLEIN:          "Biomimetic Architectures for the Impedimetric          Discrimination of Influenza Virus Phenotypes", ADVANCED          FUNCTIONAL          MATERIALS,relevantClaims[2,6-9|13-5,10],relevantPassages[254-26216]	1562508-1-0-0 A K; 1562508-1-0-0 CL DET			RAS6IN A K		US10282378-B1	Tool for use by technical workers for developing technological innovations, comprises specially programmed computer that accesses predefined data store containing information about published technical documents	EUSEBI C A	EUSEBI C A (EUSE-Individual)	2019377169	   NOVELTY - The tool comprises a specially programmed computer that accesses a predefined data store containing an information about a published technical documents, where the data store organizes the published documents according to a predetermined set of different technical areas and includes the information reflecting dates of first publication of the technical documents. The computer detects the publication of documents, which emerges in a first technological area. The second technical area is identified by the computer for accessing a non-transitory computer readable memory storing a network representation of linkages among multiple different technical areas.    USE - Tool for use by technical workers for develop ing technological innovations and for forecasting integration of the technology with other technologies.    ADVANTAGE - The tool for develop ing technological innovations takes an epidemiological models as an analogy for pandemic spread and integration of technology, which helps in determin g an outbreak of a new technology.    DESCRIPTION OF DRAWING(S) - The drawing shows a logistic growth of a technology. 			T01 (Digital Computers)	T01-N01A2E;  T01-N02A3	G06F-016/00;  G06F-016/28;  G06F-016/335;  G06F-016/95;  G06Q-010/00	US10282378-B1   07 May 2019   G06F-016/00   201934Pages: 13   English	US10282378-B1    US249810    10 Apr 2014	US10282378-B1 Provisional Application US810286P	US810286P    10 Apr 2013;  US249810    10 Apr 2014		705/007110;  705/007420	US10282378-B1 -- US6104989-A   INT BUSINESS MACHINES CORP (IBMC)   KANEVSKY D,  YASHCHIN E;  US20010047254-A1   ;  US20030030637-A1   ;  US20030182310-A1   ;  US20040015481-A1   ;  US20060248055-A1   ;  US20070214186-A1   ;  US20100070448-A1   ;  US20100268714-A1   ;  US20120102033-A1   ;  US20120166180-A1   ;  US20130144605-A1   ;  US20130151525-A1   ;  US20130317994-A1   ;  US20140006332-A1   ;  US6360227-B1   INT BUSINESS MACHINES CORP (IBMC)   AGGARWAL C C,  GATES S C,  YU P S;  US7194483-B1   INTELLIGENXIA INC (INTE-Non-standard)   MOHAN R,  MOHAN U,  SHA D;  US8195426-B1   ANTANIES J (ANTA-Individual)   ANTANIES J;  US7085771-B2   VERITY INC (VERI-Non-standard)   CHUNG C Y,  LIU J,  LUK A,  MAO J,  TAANK S,  VUTUKURU V;  US7546278-B2   MICROSOFT CORP (MICT)   YANG H,  LIU T,  MA W;  US7716226-B2   BARNEY J A (BARN-Individual)   BARNEY J A;  US9177249-B2   ABERCROMBIE R K (ABER-Individual);  SCHLICHER B G (SCHL-Individual);  SHELDON F T (SHEL-Individual)   ABERCROMBIE R K,  SCHLICHER B G,  SHELDON F T;  US9183600-B2   INT BUSINESS MACHINES CORP (IBMC)   CHEN Y,  HE B,  HE Q,  JIN X,  SPANGLER W S;  US9256667-B2   KOUDAS N (KOUD-Individual);  BANSAL N (BANS-Individual)   KOUDAS N,  BANSAL N	US10282378-B1  Technology Futures Analysis Methods Working Group. Technology futures analysis: Toward integration of the field and new methods. Technological Forecasting and Social Change 71.3 (2004): 287-303.;  Eusebi, Christopher A., and Richard Silberglitt. Identification and Analysis of Technology Emergence Using Patent Classification. Rand National Defense Research Inst Santa Monica CA, 2014.;  Meyer, Martin. Patent citations in a novel field of technologywhat can they tell about interactions between emerging communities of science and technology?. Scientometrics 48.2 (2000): 151-178. (Year: 2000).;  Daim, Tugrul U., et al. Forecasting emerging technologies: Use of bibliometrics and patent analysis. Technological Forecasting and Social Change 73.8 (2006): 981-1012. (Year: 2006).;  Gerdsri, Nathasit, and Tugrul U. Daim. Generating intelligence on the research and development progress of emerging technologies using patent and publication information. Management of Innovation and Technology, 2008. ICMIT 2008. 4th IEEE International Conference on. IEEE, 2008. (Year: 2008).;  Spatial Preferential Attachment Networks: Power Laws and Clustering Coefficients, Emmanuel Jacob et al., Oct. 12, 2012, pp. 1-25.;  Multidimensional Networks and the Dynamics of Sociomateriality: Bringing Technology Inside the Network, Noshir S. Contractor, et al., 2011, 40 pages.;  Applied Actant-Network Theory: Toward the Automated Detection of Technoscientific Emergence from Full-Text Publications and Patents, David C. Brock, et al., 2012, pp. 8-16.;  Benchmarking Bayesian neural networks for time series forecasting, Rafael A. Calvo et al., 5 pages.;  Coauthorship and citation in scientific publishing, Travis Martin, et al., Apr. 1, 2013, 10 pages.;  How to Build Your Network, Harvard Business Review by Brian Uzzi and Shannon Dunlap, Dec. 2005, pp. 1-9.;  Patent Portfolios, Gideon Parchomovsky and R. Polk Wagner, 78 pages.;  Total Variation Error Bounds for Geometric Approximation, Erol Pekoez, Adrian Roellin and Nathan Ross, Jun. 23, 2011, pp. 1-29.;  Reviews of Modern Physics, vol. 74, Jan. 2002, Statistical mechanics of complex networks, Reka Albert and Albert-Laszlo Barabasi, Published Jan. 30, 2002, pp. 47-97.;  A Big Data Approach to Computational Creativity, Lav R. Varshney, Florian Pinel, Kush R. Varshney, Debarun Bhattacharjya, Angela Schoergendorfer and Yi-Min Chee, Nov. 5, 2013, pp. 1-16.;  Complex Adaptive Systems and the Diffusion of Innovations, Everett M. Rogers et al., The Innovation Journal: The Public Sector innovation Journal, vol. 10(3), article 30, pp. 1-26.;  Power-Law Distribgutions in Empirical Data, Aaron Clauset, Cosma Rohilla Shalizi and M.E.J. Newman, Feb. 2, 2009, pp. 1-43.;  Competition-Induced Critically in a Model of Meme Popularity, James P. Gleeson et al. Jan. 31, 2014, pp. 1-5.;  Hysteresis effects of changing parameters of noncooperative games, David H. Wolpert et al. Mar. 2, 2011, pp. 1-5.;  Robustness and complexity co-constructed in multimodal signalling networks, Nihat Ay et al. Jan. 11, 2007, pp. 441-447.;  Policing stabilizes construction of social niches in primates, Jessica C. Flack et al., vol. 439/26 Jan. 2006, pp. 426-429 and vol. 406/ Jul. 27, 2000, pp. 378-382.;  The Thin Red Line Between Success and Failure: Path Dependence in the Diffusion of Innovative Production Technologies, Henrich R. Greve et al. 2014, 22 pages.;  Towards Explanation of Scientific and Technological Emergence, James R. Michaelis et al., 7 pages.;  Bayesian Network Models of Portfolio Risk and Return, Chaterine Shenoy and Prakash P. Shenoy, 15 pages.						CN110578017-A;  CN110578017-B	New kit useful for synchronously detecting            twenty-three respiratory tract pathogens comprising            transcription and amplification primers, 2.5x Reaction            MIX, diethyl pyrocarbonate water, hot start tapase and            reverse transcriptase	CHE L;  WANG Y	SHENZHEN BM LIFE SCI CO LTD (SHEN-Non-standard);  DONGGUAN MAIDAO BIOTECHNOLOGY CO LTD (DONG-Non-standard)	202000089Q	   NOVELTY - Kit comprising transcription and amplification                primers, 2.5x Reaction MIX, diethyl pyrocarbonate                water, hot start tapase and reverse transcriptase,                is new. The transcription and amplification primers                include 17 kinds of RNA viruses, 2 kinds of DNA                viruses, and 4 kinds of respiratory pathogens and                gene sequences is same as specified in the tabular                column.    USE - The kit is useful for synchronously detecting                twenty-three respiratory tract pathogens                (claimed).    ADVANTAGE - The kit: has strong specificity, high                sensitivity, fast detection speed, transcription                amplification in a single tube, and is simple in                operation.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for                synchronous detection of twenty-three respiratory                tract pathogens, comprising (i) collecting samples                and extracting nucleic acids, collecting                nasopharyngeal swabs or sputum from patients with                respiratory tract infection, isolating culture and                extracting nucleic acids from the isolation                culture; (ii) grouping transcription and                amplification primers and labeling with different                fluorescent dyes respectively; (iii) extracting                nucleic acid from infected person as a sample by                reverse transcription and compound amplification,                and reaction conditions are comprises maintaining                thermal cycle temperature of 50 degrees C for 30                minutes, 95 degrees C for 5 minutes, 94 degrees C                for 5 seconds, 60 degrees C for 30 seconds and                running 28 cycles, 60 degrees C for 5 minutes and                storing at 4 degrees C; and (iv) using capillary                electrophoresis instrument to perform gene                sequencing on the amplification primers, comparing                map obtained by the software of the capillary                electrophoresis instrument with the standard map,                determining type of respiratory pathogens and                obtaining the detection result. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  T01 (Digital Computers)	B04-B04D2;  B04-E01;  B04-E05;  B04-E99;  B04-F01;  B04-F11;  B04-L04B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1C;  B12-K04G2G;  D05-A02B;  D05-H04;  D05-H05;  D05-H18B;  D05-H99;  A03-C01;  A10-E07C;  A10-E08A;  A10-E08B;  A12-V03C2;  A12-W11L;  T01-J13A	C12N-015/11;  C12Q-001/04;  C12Q-001/686;  C12Q-001/689;  C12Q-001/70;  C12R-001/01	CN110578017-A   17 Dec 2019   C12Q-001/70   202004Pages: 27   Chinese;  CN110578017-B   25 Jul 2023   C12Q-001/70   202362   Chinese	CN110578017-A    CN10696975    30 Jul 2019;   CN110578017-B    CN10696975    30 Jul 2019	CN110578017-B Previous Publ. Patent CN110578017	CN10696975    30 Jul 2019			CN110578017-A -- CN102839223-A   INST VIRUS PREVENTION & CONTROL CHINA                  DI (CCDC)   MA X,  TAN W,  XU W,  MAO N,  LI J;  CN103074448-A   HAI'ERSHI BIO-PHARM CO LTD (HAIE-Non-standard)   HUANG Y,  NA L,  WU Y;  CN103074451-A   HAI'ERSHI BIO-PHARM CO LTD (HAIE-Non-standard)   NA L,  HUANG Y,  WU Y;  CN103146841-A   HAI'ERSHI BIO-PHARM CO LTD (HAIE-Non-standard)   WU Y,  CHEN Y,  HUANG Y,  NA L;  CN103757110-A   WUXI AGCU SCI & TECHNOLOGY INC LTD (WUXI-Non-standard);  ZHEJIANG PROVINCIAL CENT DISEASE PREVENT (ZHEJ-Non-standard)   ZHANG Z,  JIN D,  LU Q,  ZHOU L,  LUO Y,  GE B,  GE H,  GUO Y;  CN105734168-A   NANJING MOKOBIO BIOTECHNOLOGY CO LTD (NANJ-Non-standard)   GUO T,  JIN X,  LI B,  LIU W;  CN107365876-A   NANJING LANYU BIOTECHNOLOGY CO LTD (NANJ-Non-standard)   CHEN J,  XU H,  YU P,  ZHANG R,  ZHU T;  CN109355437-A   SHANGHAI GENEODX BIOTECH CO LTD (SHAN-Non-standard)   XIA X,  CHENG L,  WANG Y,  QIN J,  DONG J,  SIMON G;  CN109439765-A   JIANGSU SUPERBIO MEDICAL TECHNOLOGY NANJ (JIAN-Non-standard);  JIANGSU SUPERBIO STOCK CO LTD (JIAN-Non-standard)   GE B,  HUANG C,  GAO Z,  ZHANG M,  ZHAO X,  SU X,  WANG Y;  CN109457053-A   CHINESE ACAD SCI SUZHOU NANO-TECH &                  NANO (CASZ)   LI J,  WANG N,  LIU S;  CN110578017-B -- CN102839223-A   INST VIRUS PREVENTION & CONTROL CHINA                  DI (CCDC)   MA X,  TAN W,  XU W,  MAO N,  LI J;  CN103074448-A   HAI'ERSHI BIO-PHARM CO LTD (HAIE-Non-standard)   HUANG Y,  NA L,  WU Y;  CN103074451-A   HAI'ERSHI BIO-PHARM CO LTD (HAIE-Non-standard)   NA L,  HUANG Y,  WU Y;  CN103146841-A   HAI'ERSHI BIO-PHARM CO LTD (HAIE-Non-standard)   WU Y,  CHEN Y,  HUANG Y,  NA L;  CN103757110-A   WUXI AGCU SCI & TECHNOLOGY INC LTD (WUXI-Non-standard);  ZHEJIANG PROVINCIAL CENT DISEASE PREVENT (ZHEJ-Non-standard)   ZHANG Z,  JIN D,  LU Q,  ZHOU L,  LUO Y,  GE B,  GE H,  GUO Y;  CN105734168-A   NANJING MOKOBIO BIOTECHNOLOGY CO LTD (NANJ-Non-standard)   GUO T,  JIN X,  LI B,  LIU W;  CN107365876-A   NANJING LANYU BIOTECHNOLOGY CO LTD (NANJ-Non-standard)   CHEN J,  XU H,  YU P,  ZHANG R,  ZHU T;  CN109355437-A   SHANGHAI GENEODX BIOTECH CO LTD (SHAN-Non-standard)   XIA X,  CHENG L,  WANG Y,  QIN J,  DONG J,  SIMON G;  CN109439765-A   JIANGSU SUPERBIO MEDICAL TECHNOLOGY NANJ (JIAN-Non-standard);  JIANGSU SUPERBIO STOCK CO LTD (JIAN-Non-standard)   GE B,  HUANG C,  GAO Z,  ZHANG M,  ZHAO X,  SU X,  WANG Y;  CN109457053-A   CHINESE ACAD SCI SUZHOU NANO-TECH &                  NANO (CASZ)   LI J,  WANG N,  LIU S		201562-0-0-0 D K M; 297125-0-0-0 K M; 444-0-0-0 ; 86886-0-0-0 			RA0124 D K M; RA20EO K M; R00351 ; R24039 		CN109735504-A;  CN109735504-B	New canine distemper virus attenuated vaccine            strain used for preparing drugs for treating,            preventing, diagnosing or detecting diseases	LIAO L;  WANG H;  CHEN C;  MAN K	BEIJING DABEINONG TECHNOLOGY GROUP CO (DBNO-C);  BEIJING DABEINONG SCI & TECHNOLOGY GROUP (DBNO-C);  JOFUNHWA BIOTECHNOLOGY NANJING CO LTD (JOFU-Non-standard);  BEIJING BIOMEDICAL TECHNOLOGY CENT BIOTE (BEIJ-Non-standard);  BEIJING KEMUFENG BIOLOGICAL PHARM CO LTD (DBNO-C);  JOFUNHWA BIOTECHNOLOGY FUZHOU CO LTD (JOFU-Non-standard)	201945155X	   NOVELTY - Canine distemper virus attenuated vaccine                strain (CGMCC No. 15036) is new.    USE - The canine distemper virus attenuated vaccine                strain is used for preparing drugs for treating,                preventing, diagnosing or detecting diseases                (claimed).    ADVANTAGE - The strain has stable heredity, lasting                immunity, good effect, safety and reliability and                long shelf life.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for                preparation of the canine distemper virus                attenuated vaccine strain comprising adopting                attenuated canine distemper vaccine strain with                immunogen, performing immunogenic immunization of                healthy animals to prepare canine distemper virus                high immune serum, extracting immunoglobulin (IgG)                from highly immune serum of canine distemper virus                and purifying IgG. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-B04C;  B04-B04D4;  B04-E99;  B04-F10A;  B04-F11;  B04-G08;  B04-G27G;  B11-C08E;  B12-K04G1B;  B14-A02A1;  B14-A02A9;  B14-A02B;  B14-G01;  B14-S11A;  B14-S11B1;  B14-S11D2;  C04-B04C;  C04-B04D4;  C04-E99;  C04-F10A;  C04-F11;  C04-G08;  C04-G27G;  C11-C08E;  C12-K04G1B;  D05-H06A;  D05-H07;  D05-H99;  S03-E09F;  S03-E14H	A61K-039/02;  A61K-039/155;  A61K-039/175;  A61K-039/205;  A61K-039/215;  A61K-039/23;  A61K-039/235;  A61K-039/295;  A61K-039/42;  A61P-031/04;  A61P-031/14;  A61P-031/20;  C07K-016/06;  C07K-016/10;  C12N-007/00;  C12R-001/93;  G01N-033/569	CN109735504-A   10 May 2019   C12N-007/00   201953Pages: 10   Chinese;  CN109735504-B   16 Apr 2021   C12N-007/00   202138   Chinese	CN109735504-A    CN11562008    20 Dec 2018;   CN109735504-B    CN11562008    20 Dec 2018	CN109735504-B Previous Publ. Patent CN109735504	CN11562008    20 Dec 2018			CN109735504-A -- CN1117081-A   GAO Y (GAOY-Individual)   ZHENG H,  YANG P,  GAO Y;  CN1876181-A   INST VETERINARY ACAD MILITARY MEDICAL                  SCI (JSYX)   XIA X,  HUANG G,  FAN Q,  ZHONG Z,  LI J,  HU G,  HE H,  QIAO J,  YU C,  YANG S,  WANG C,  GAO Y,  WANG T;  CN104383530-A   SPECIALTY RES INST CHINESE ACAD AGRIC SC (CAGS)   BAI X,  CHAI X,  HU B,  LIU H,  YAN X,  ZHANG H,  ZHAO J,  ZHANG L;  CN107158370-A   CHINESE ACAD AGRIC SCI SPECIAL ANIMAL                  & (CAGS)   HU B,  YAN X,  WANG Y,  LV S,  LIAN S,  LIU H,  ZHANG L,  BAI X,  LU R,  ZHANG H,  ZHAO J,  ZHU Y,  SHI N,  XUE X,  DENG X,  XU S;  CN108066758-A   CHINESE ACAD AGRIC SCI SPECIAL ANIMAL                  & (CAGS)   ZHAO Z,  YAN X,  HU B,  LU R,  LUO G,  CHENG Y,  ZHANG L,  LIU H,  DENG X,  SHI N,  CHAI X,  BAI X,  ZHANG H,  ZHAO J,  XU S;  EP2134742-B1   WYETH (AMHP)   GILL M A;  US3098011-A   BEHRINGWERKE AG (BEHW);  WO2014029702-A1   INTERVET INT BV (IVET);  INTERVET INC (MERI)   OCONNELL K,  QIAO Z;  CN109735504-B -- CN106399260-A   BEIJING DABEINONG TECHNOLOGY GROUP CO (DBNO);  BEIJING DABEINONG SCI & TECHNOLOGY                  GROUP (DBNO);  BEIJING KEMUFENG BIOLOGICAL PHARM CO LTD (DBNO);  FUZHOU DABEINONG BIOTECH CO LTD (FUZH-Non-standard)   WANG H,  LIAO L,  ZHAO R,  LIU F,  MA J,  WANG G,  ZHAO Y	CN109735504-A  : "",          ,relevantClaims[1-6],relevantPassages[23];  : " ",          ,relevantClaims[1-6],relevantPassages[111.11.92.4];  : "",          ,relevantClaims[1-6],relevantPassages[]						CN109378079-A	Fever symptom based infectious diseases monitoring            system, has data collecting analysis module for            analyzing information in abnormal personnel database to            monitor and prevent occurrence of infectious            diseases	JIANG C;  LI Y;  PU M;  ZHANG S	UNIV TONGJI (UYTJ-C)	201920203V	   NOVELTY - The system has a temperature identification                device (1) arranged in an area to obtain abnormal                body temperature of people. A human face                identifying device (2) performs human face                recognition. An abnormal personnel database (3) is                stored with abnormal body temperature information.                An infectious patient location tracking module (4)                determines infectious patients according to                identity information in the abnormal personnel                database. A data collecting analysis module (5)                analyzes information in the abnormal personnel                database to monitor and prevent occurrence of                infectious diseases.    USE - Fever symptom based infectious diseases                monitoring system.    ADVANTAGE - The system is simple to operate, realizes                epidemiological investigation and research in                infectious and non- pandemic periods, reduces                infectious diseases detection cost, and monitors                infection prevention effect.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a                fever symptom based infectious diseases monitoring                method.    DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram of a fever                symptom based infectious diseases monitoring                system. '(Drawing includes non-English language                text)'    Temperature identification device (1)    Human face identifying device (2)    Abnormal personnel database (3)    Infectious patient location tracking module                (4)    Data collecting analysis module (5) 			S03 (Scientific Instrumentation);  S05 (Electrical Medical Equipment);  T01 (Digital Computers);  T04 (Computer Peripheral Equipment)	S03-B01X;  S05-D01E;  S05-D07;  S05-G02G3;  S05-G02G9;  T01-J05B4P;  T01-J06A1;  T01-J10B2A;  T04-D07F1	G01K-011/00;  G06K-009/00;  G16H-050/80	CN109378079-A   22 Feb 2019   G16H-050/80   201930Pages: 7   Chinese	CN109378079-A    CN11134382    27 Sep 2018		CN11134382    27 Sep 2018			CN109378079-A -- CN104765759-A   TIANJIN RUIWEITUO NEW TECHNOLOGY DEV CO (TIAN-Non-standard)   SUN W;  CN105740615-A   UNIV SUN YAT-SEN (UYSY)   LIU R,  LU J,  SONG Z,  ZHANG K,  DU Y,  LI Z;  CN105852819-A   SHENZHEN YUNTIAN LIFEI TECHNOLOGY CO LTD (SZIF)   CHENG B,  TIAN D,  ZHANG Z,  YANG L;  CN108498080-A   ZHONGSHAN LKANG MEDICAL INFORMATION                  TECHNOLOGY SOFTWARE CO L (ZHON-Non-standard)   LIN J							CN110215456-A	Synergistic composition useful for treating feline            infectious peritonitis, comprises GC376 and            GS-441524	PENG G;  LIU Z	UNIV HUAZHONG AGRIC (UHZA-C)	2019796192	   NOVELTY - Composition comprises GC376 and                GS-441524.    USE - The composition is useful for treating feline                infectious peritonitis (claimed).    ADVANTAGE - The composition has synergistic effect, high                safety and no toxicity and side effects, and                reduces drug resistance. 			B03 (Other heterocyclics.);  B02 (Fused ring heterocyclics.);  C02 (Heterocyclic.);  C01 (Organophosphorus; organometallic - i.e. compounds containing other than H, C, N, O, S and halogen.)	B04-B03D;  B05-A01B;  B07-D03;  B14-A02;  B14-C03;  B14-L06;  B14-S09;  B14-S12;  B14-S18;  C04-B03D;  C05-A01B;  C07-D03;  C14-A02;  C14-C03;  C14-L06;  C14-S09;  C14-S12;  C14-S18	A61K-031/4015;  A61K-031/53;  A61P-031/14	CN110215456-A   10 Sep 2019   A61K-031/53   201981Pages: 10   Chinese	CN110215456-A    CN10554607    25 Jun 2019		CN10554607    25 Jun 2019				CN110215456-A  NIELS C PEDERSEN:          "Efficacy and safety of the nucleoside analog GS-441524          for treatment of cats with naturally occurring feline          infectious peritonitis", JOURNAL OF FELINE MEDICINE AND          SURGERY,relevantClaims[1-4],relevantPassages[271-281];  : "",          HTTPS://MP.WEIXIN.QQ.COM/S/CXGYVN5HL1J7PFXDHX2YEW,relevantClaims[1-4],relevantPassages[1-3]	2812375-1-1-0 K M; 2157647-1-0-0 K M; 2812375-1-1-0 CL USE; 2157647-1-0-0 CL USE		61435	RCO90X K M; RB4RFE K M		JP2019077681-A;  JP7217609-B2	Antiviral disinfectant used for reducing e.g.            smallpox virus, comprise monovalent copper compound            particle covered with covering layer, and dispersion            medium comprising water and/or lower alcohol, in which            particles are dispersed	FUKUYO A;  NAGAO T;  NAKAYAMA T	NBC MESHTEC INC (NISS-C);  NBC MESHTEC INC (NISS-C)	2019440195	   NOVELTY - Antiviral disinfectant comprise (a) monovalent                copper compound particles covered with a covering                layer comprising an inorganic oxide and an organic                compound, and (b) a dispersion medium comprising                water and/or a lower alcohol, in which the                monovalent copper compound particles are                dispersed.    USE - The antiviral disinfectant is useful for                reducing rhinovirus, poliovirus, foot and mouth                disease virus, rotavirus, norovirus, enterovirus,                hepatovirus, astrovirus, hepatitis A, B, C and E                virus, influenza C virus, human parainfluenza                virus, mumps virus, measles virus, human                metapneumovirus, human orthopneumovirus, Nipah                virus, hendra virus, yellow fever virus, dengue                virus, Japanese encephalitis virus, west nile                virus, eastern and western horses encephalitis                virus, O'nyong-nyong virus, rubella virus, Lassa                virus, junin virus, machupo virus, guanarito virus,                sabia virus, Crimean Congo hemorrhagic fever virus,                hantavirus, Sin nombre virus, rabies virus, Ebola                virus, marburg virus, Australian bat lyssavirus,                human T cell leukemia virus, human immunodeficiency                virus, human coronavirus, severe acute respiratory                syndrome (SARS)-related coronavirus, human                parvovirus, polyoma virus, human papillomavirus,                adenovirus, herpes virus, varicella-zoster virus,                cytomegalovirus, smallpox virus, Epstein-Barr                virus, cowpox virus, molluscipoxvirus, parapoxvirus                and zika virus. The disinfectant is useful as a                hand soap for killing and/or inactivating                Escherichia coli, Staphylococcus aureus,                S.epidermidis, Streptococcus, S.pneumonia,                Haemophilus influenzae, Bordetella pertussis,                Salmonella, S.enterica, Pseudomonas aeruginosa,                V.cholerae, Shigella, Bacillus anthracis,                Mycobacterium tuberculosis, Clostridium botulinum                and Clostridium tetani.    ADVANTAGE - The antiviral disinfectant is capable of                sustaining their performance. 			D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)	D08-B;  D09-A01	A01N-025/04;  A01N-025/26;  A01N-059/20;  A01P-001/00;  A01P-003/00	JP2019077681-A   23 May 2019   A01N-059/20   201942Pages: 15   Japanese;  JP7217609-B2   03 Feb 2023   A01N-059/20   202314   Japanese	JP2019077681-A    JP200899    25 Oct 2018;   JP7217609-B2    JP200899    25 Oct 2018	JP7217609-B2 Previous Publ. Patent JP2019077681	JP206541    25 Oct 2017										WO2019160261-A1	Filter useful in mask, comprises a substrate made            of porous material and a binder-containing composition            adsorbed on the substrate	KWAK J H	NANOMEDICA INC (NANO-Non-standard)	201973270N	   NOVELTY - Filter (1) comprises a substrate (100) made of                porous material and a binder-containing composition                (200) adsorbed on the substrate. The binder                includes a core and a reactor bonded to the surface                of the core. The reactor comprises a reactor                provided with sialic acid, sialylactose or their                derivatives.    USE - The filter is useful in mask (claimed).    ADVANTAGE - The filter prevents transmission of                respiratory diseases and pandemic caused by virus,                and does not penetrate into somatic cells of human                body or animal due to binding to the                conjugate.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) mask comprising a main body configured to                sequentially overlap the breathable inner member,                the filter, and the breathable outer member, and a                fixing member for bringing the main body close                contact with the respirator such that air drawn                through the respirator of the human body or animal                pass through the main body; and    (2) providing conjugate, comprising providing                a reactor comprising at least one of sialic acid,                sialylactose or their derivatives, dissolving                binder in designated solvent, dipping the object in                the solution in which the binder is dissolved, and                drying the object.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic representation                of the filter.    Filter (1)    Substrate (100)    Binder-containing composition (200) 			B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.);  A23 (Polyamides; polyesters. (including polycarbonates, polyesteramides); alkyds; other unsaturated polymers.);  P35 (Life-saving, fire-fighting (A62).)	B04-C02D;  B04-C02X;  B04-C03;  B04-E01;  B04-N03K;  B04-Q03;  B07-A02B;  B10-B02F;  B11-C04;  B14-A02;  B14-K01;  B14-S18;  D05-H06A;  A03-A00A;  A03-C;  A05-E02B;  A08-S02;  A11-C01C;  A12-A02;  A12-H04;  A12-V03C1;  A12-W;  P35-A03E1	A62B-018/02;  B01D-039/14	WO2019160261-A1   22 Aug 2019   B01D-039/14   201971Pages: 44   	WO2019160261-A1    WOKR001327    31 Jan 2019		KR018593    14 Feb 2018	WO2019160261-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  		WO2019160261-A1 -- JP2006320491-A   IRYO HOJIN KUWANO SEIKEI GEKA IIN (IRYO-Non-standard)   KUWANO S;  JP2011116692-A   TOKO YAKUHIN KOGYO KK (TOKO-Non-standard)   MORITA M,  NAKAMURA H;  KR2009036136-A   GLAXO GROUP LTD (GLAX);  SMITHKLINE BEECHAM CORP (SMIK)   BIEDERMANN K,  DENG F,  KING S,  MIDDLETON A;  KR2012107970-A   MARINOMED BIOTECHNOLOGIE GMBH (MARI-Non-standard)   GRASSAUER A,  PRIESCHL-GRASSAUER E,  MEIER C,  KOENIG-SCHUSTER M	WO2019160261-A1  LANDERS, JEFFERY J.          ET AL.: "Prevention of Influenza Pneumonitis by Sialic          Acid-Conjugated Dendritic Polymers", THE JOURNAL OF          INFECTIOUS DISEASES, vol. 186, no. 9, 8 October 2002          (2002-10-08), pages 1222 - 1230, XP008020077,          doi:10.1086/344316,relevantClaims[1-17],relevantPassages[.          Seepages 1222-1223 and Fig. 1.];  KWON, SEOK-JOON ET          AL.: "Nanostructured glycan architecture is important in          the inhibition of influenza A virus infection", NATURE          NANOTECHNOLOGY, vol. 12, 24 October 2016 (2016-10-24),          pages 48 - 54, XP055583759,          doi:10.1038/nnano.2016.181,relevantClaims[1-17],relevantPassages[.          See the entire document.]	104420-0-0-0 K M Q; 104422-0-0-0 K M Q; 104376-1-0-0 K M Q; 104427-0-0-0 K M Q; 104389-0-0-0 K M Q; 104413-0-0-0 K M Q; 1562508-1-0-0 K M Q; 107307-0-0-0 K M Q; 93605-0-0-0 K M Q; 105730-0-0-0 K M Q; 184597-0-0-0 K M Q;  K M Q; 1359078-6-0-0 K M Q; 2548435-1-0-0 K M Q; 2548436-1-0-0 K M Q; 2548437-1-0-0 K M Q; 26937-1-0-0 K M Q;  K M Q; 160570-1-0-0 K M Q; 5938-0-0-0 ; 133659-0-0-0 ; 7447-0-0-0 ; 8187-0-0-0 ; 192393-0-0-0 ; 133925-0-0-0 ; 104420-0-0-0 CL RCT USE; 104422-0-0-0 CL RCT USE; 104376-1-0-0 CL RCT USE; 104427-0-0-0 CL RCT USE; 104389-0-0-0 CL RCT USE; 104413-0-0-0 CL RCT USE; 1562508-1-0-0 CL RCT USE; 107307-0-0-0 CL RCT USE; 93605-0-0-0 CL RCT USE; 105730-0-0-0 CL RCT USE; 184597-0-0-0 CL RCT USE; 1359078-6-0-0 CL RCT USE; 2548435-1-0-0 CL RCT USE; 2548436-1-0-0 CL RCT USE; 2548437-1-0-0 CL RCT USE; 26937-1-0-0 CL RCT USE; 160570-1-0-0 CL RCT USE	216209202 K M Q; 216209203 K M Q; 216209204 K M Q; 216209201 K M Q		R24028 K M Q; RA0739 K M Q; RA030X K M Q; RA01KR K M Q; RA05GF K M Q; RA01KS K M Q; RAS6IN K M Q; R06725 K M Q; RA00NS K M Q; RA012P K M Q; RA14TW K M Q; RC28WQ K M Q; RBD3Y0 K M Q; RBD3Y4 K M Q; RBD3Y5 K M Q; RBD3Y6 K M Q; R10767 K M Q; R14670 K M Q; RCNCHC K M Q; RA58XM K M Q; R01295 ; R17298 ; R00009 ; R01655 ; R24090 ; R07226 	1866-S	CN110003303-A	Application of cholesterol transport inhibitors            for preparing reagent for inhibiting cell            clathrin-mediated viral endocytosis	CHU B;  WANG J;  YANG G;  LI G;  MING S	UNIV HENAN AGRIC (UYHR-C)	201963219F	   NOVELTY - A cholesterol transport inhibitors is used for                preparing reagent for inhibiting cell                clathrin-mediated viral endocytosis.    USE - Cholesterol transport inhibitors used for                preparing reagent for inhibiting cell                clathrin-mediated viral endocytosis comprising                orthomyxovirus, paramyxovirus, coronavirus, herpes                virus, arteritis virus, pox virus and influenza                virus, preferably vesicular stomatitis virus,                influenza virus, pseudorabies virus, porcine                reproductive and respiratory syndrome virus, and                herpes simplex virus, for biology and medical field                research, and preparing medicament for                anti-envelopic virus infection for mammal,                preferably pig or human subjects (claimed). 			B01 (Steroids - including systems containing carbocyclic and/or heterocyclic rings fused onto the basic steroidal ring structure.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.)	B04-E99;  B01-D02;  B04-N04;  B14-A02B;  B14-C03;  B14-D02A2;  B14-F02;  B14-S12;  C04-E99;  C01-D02;  C04-N04;  C14-A02B;  C14-C03;  C14-D02A2;  C14-F02;  C14-S12	A61K-031/56;  A61P-031/14;  A61P-031/16;  A61P-031/22;  C07J-041/00	CN110003303-A   12 Jul 2019   C07J-041/00   201965Pages: 27   Chinese	CN110003303-A    CN10375299    07 May 2019		CN10375299    07 May 2019			CN110003303-A -- CN102498404-A   INSERM (INRM);  AFFICHEM SAS (AFFI-Non-standard)   DE MEDINA P,  PAILLASSE M,  POIROT M,  SILVENTE P S;  CN103450351-A   UNIV CHINA AGRICULTURAL (UCAG)   WANG X;  WO2012055814-A1   INSERM INST NAT SANTE&RECH MEDICALE (INRM)   CHAPUY-REGAUD S,  IZOPET J,  POIROT M,  RECORD M;  WO2012103081-A1   UNIV YESHIVA EINSTEIN COLLEGE (YESH);  HARVARD COLLEGE (HARD);  WHITEHEAD INST BIOMEDICAL RES (WHED)   CHANDRAN K,  WHELAN S,  BRUMMELKAMP T,  CARETTE J,  RAABEN M	CN110003303-A  TOMOMI TAKANO :          "The cholesterol transport inhibitor U18666A inhibits          type I feline coronavirus infection", ANTIVIRAL          RESEARCH,relevantClaims[1-10],relevantPassages[96-102];  AHMED A. ELTOUKHY :          "Niemann-Pick C1 Affects the Gene Delivery Efficacy of          Degradable Polymeric Nanoparticles", ACS          NANO,relevantClaims[1-10],relevantPassages[7905-7913];  TAKASHI TAKANO :          "Augmentation of DHCR24 expression by hepatitis C virus          infection facilitates viral replication in hepatocytes",          JOURNAL OF          HEPATOLOGY,relevantClaims[1-10],relevantPassages[512-521];  MEE KIAN POH :          "U18666A, an intra-cellular cholesterol transport          inhibitor, inhibits dengue virus entry and replication",          ANTIVIRAL          RESEARCH,relevantClaims[1-10],relevantPassages[191-198];  CHARLES J.          SHOEMAKER : "Multiple Cationic Amphiphiles Induce a          Niemann-Pick C Phenotype and Inhibit Ebola Virus Entry          and Infection", PLOS          ONE,relevantClaims[1-10],relevantPassages[1-13];  SINEEWANLAYA WICHIT          : "Imipramine Inhibits Chikungunya Virus Replication in          Human Skin Fibroblasts through Interference with          Intracellular Cholesterol Trafficking", SCIENTIFIC          REPORTS,relevantClaims[1-10],relevantPassages[1-12];  FEIRAN LU :          "Identification of NPC1 as the target of U18666A, an          inhibitor of lysosomal cholesterol export and Ebola          infection",          ELIFE,relevantClaims[1-10],relevantPassages[1-16];  ANDREW S. HERBERT :          "Niemann-Pick C1 Is Essential for Ebolavirus Replication          and Pathogenesis In Vivo",          MBIO,relevantClaims[1-10],relevantPassages[1-12];  : "BmNPC1BmNPV",          ,relevantClaims[1-10],relevantPassages[1-130921021131147.3]	184616-0-0-0 K M; 99637-1-1-0 K M			RA00H3 K M; RB0T1F K M		CN110358865-A	Primer probe useful for detecting respiratory            virus for non-diagnostic purposes or assisting in the            detection of respiratory viruses	LU M;  PANG T;  WANG W;  MA M;  SUN J;  LI J	LANGFANG NUODAO ZHONGKE MEDICAL TEST LAB CO              LTD (LANG-Non-standard)	201989243L	   NOVELTY - Primer probe comprises (a) primer pair 1,                comprises a fully defined sequence of 25                nucleotides (SEQ ID NO: 1) as given in the                specification and comprises a fully defined                sequence of 22 nucleotides (SEQ ID NO: 2) as given                in the specification and a probe-1 comprises a                fully defined sequence of 20 nucleotides (SEQ ID                NO: 33) as given in the specification, (b) primer                pair-2, comprises a fully defined sequence of 28                nucleotides (SEQ ID NO: 3) as given in the                specification and comprises a fully defined                sequence of 22 nucleotides (SEQ ID NO: 4) as given                in the specification and a probe-2 comprises a                fully defined sequence of 30 nucleotides (SEQ ID                NO: 34) as given in the specification, (c) primer                pair-3, comprises a fully defined sequence of 22                nucleotides (SEQ ID NO: 5) as given in the                specification and comprises a fully defined                sequence of 25 nucleotides (SEQ ID NO: 6) as given                in the specification.    USE - The primer probe is useful for detecting                respiratory virus for non-diagnostic purposes or                assisting in the detection of respiratory viruses                (claimed).    ADVANTAGE - The primer has high sensitivity, can                simultaneously detect 16 kinds of respiratory                viruses, can realize batch detection of samples,                realizes multiple detections; and is quick and                convenient.    DETAILED DESCRIPTION - Primer probe comprises (a) primer pair 1,                comprising fully defined sequence of                5'-cacactaacaactgcaatcatacaa-3' (SEQ ID NO: 1) and                comprising fully defined sequence of                5'-aagctgattccaagctgggga-3' (SEQ ID NO: 2) and a                probe-1, comprising fully defined sequence of 5'-                atgcaacgaaccagatcaagaacacaacc-3' (SEQ ID NO: 33),                (b) primer pair-2, comprising fully defined                sequence of 5'-aaacataaccacttaccttactcaagt-3' (SEQ                ID NO: 3) and comprising fully defined sequence of                5'-gtttgtgtggattggtggtgtg-3' (SEQ ID NO: 4) and a                probe-2 represented by polynucleotide sequence,                comprising fully defined sequence of                5'-ccagaaagggttagcccatccaaac-3' (SEQ ID NO: 34),                (c) primer pair-3, comprising fully defined                sequence of 5'-ctaaagacaagaccaatcytg-3' (SEQ ID NO:                5) and comprising fully defined sequence of                5'-gacaaagcgtctacgctgcagtcc-3' (SEQ ID NO: 6) and                probe-3 represented by polynucleotide sequence,                comprising fully defined sequence of                5'-gctcactgggcacggtgagcgtga-3' (SEQ ID NO: 35),                primer pair-4 to primer pair-16 and probe-4 to                probe-16. An INDEPENDENT CLAIM is also included for                kit for detecting respiratory viruses, comprising                primer probe combination. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E05;  B04-E99;  B04-F11;  B04-L01;  B04-L04B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  D05-A02;  D05-H06A;  D05-H12D1;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/686;  C12Q-001/70	CN110358865-A   22 Oct 2019   C12Q-001/70   201988Pages: 30   Chinese	CN110358865-A    CN10677694    25 Jul 2019		CN10677694    25 Jul 2019			CN110358865-A -- CN107058622-A   DEBIQI BIOLOGICAL TECHNOLOGY XIAMEN CO (DEBI-Non-standard)   TONG C,  QIU Y;  CN107475446-A   JIANGSU MOLE BIOTECHNOLOGY CO LTD (JIAN-Non-standard);  UNIV FUDAN CHILDREN HOSPITAL (UYFU)   JIA R,  LI Y,  LIU P,  LU L,  WANG W,  XU J,  XU M,  ZHONG H;  CN109207639-A   NANTONG INT TRAVEL HEALTH CARE CLINIC (NANT-Non-standard)   CHEN F,  WU H,  YANG Q,  YANG G		201562-0-0-0 D K M			RA0124 D K M		CN110361542-A	Kit useful for detecting porcine deltacoronavirus            nucleocapsid (PDCoV-N) protein antigen, contains            enzyme-linked immunosorbent assay plate coated with            monoclonal antibody PDCoV-N-1A2, color developing            solution and washing solution	ZHANG X;  QIAN B;  WU Y;  GUO M;  ZHANG C;  CAO Y;  CHEN Y	UNIV YANGZHOU (UYYZ-C)	201988749A	   NOVELTY - Kit comprises enzyme-linked immunosorbent                assay (ELISA) plate coated with monoclonal antibody                porcine delta coronavirus nucleocapsid                (PDCoV-N)-1A2, positive and negative controls,                horseradish peroxidase (HRP)-labeled detection                antibody PDCoV-N-5C5, sample diluent, color                developing solution, and washing solution.    USE - The kit is useful for detecting PDCoV-N                protein antigen by double-antibody sandwich                ELISA.    ADVANTAGE - The kit provides new detection method for                clinical diagnosis and epidemiological                investigation of PDCoV infection. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-G08;  B04-G21;  B04-L03B;  B04-N03K;  B11-C07A4;  B12-K04G1B;  C04-G08;  C04-G21;  C04-L03B;  C04-N03K;  C11-C07A4;  C12-K04G1B;  D05-A02A;  D05-H09;  D05-H10;  S03-E09F;  S03-E14H5	G01N-033/558;  G01N-033/577;  G01N-033/68	CN110361542-A   22 Oct 2019   G01N-033/68   201993Pages: 13   Chinese	CN110361542-A    CN10674711    25 Jul 2019		CN10674711    25 Jul 2019			CN110361542-A -- CN101661042-A   UNIV CHINA AGRICULTURAL (UCAG)   CHEN Y,  GAI X,  GUO X,  LIU C,  YANG H,  ZHA Z;  CN109880843-A   UNIV YANGZHOU (UYYZ)   ZHANG X,  QIAN B,  WU Y,  GUO M,  ZHANG C,  CAO Y,  CHEN Y;  CN109913423-A   UNIV YANGZHOU (UYYZ)   ZHANG X,  QIAN B,  WU Y,  CHEN Y,  GUO M,  ZHANG C,  CAO Y;  WO2013117063-A1   SHANGHAI VETERINARY INST CHINESE ACAD AG (CAGS)   JI X,  LI X,  LI Z		97055-0-0-0 D K M			RA02YE D K M		US2019139217-A1	System for determining emotional inclination, has            analysis subsystem to receive recorded imaging data to            analyze imaging data to interpret subjects emotional            inclination based on analysis	SZU H	SZU H (SZUH-Individual)	201940137J	   NOVELTY - The system has an imaging subsystem detects a                dynamic vein map of a subject to actively                illuminate the dynamic vein map and to record                imaging data of the dynamic vein map. An analysis                subsystem receives the recorded imaging data to                analyze the recorded imaging data to interpret the                subject's emotional inclination based on the                analysis.    USE - System for determining emotional inclination                for covertly determining the mindset and intentions                of a subject through the use of a cellular                telephone.    ADVANTAGE - By identifying behavior of individuals that                indicate preparation for committing a suicide                bombing so that patterns of behavior is detected                that leads to increased scrutiny of a particular                person to thwart any violent crime before anyone is                hurt. The computational intelligence design is used                to help law enforcement personnel using a                smartphone to catch the brain internal state of a                suicide bomber or terrorist a few minutes early,                thus prevents senseless killing and someday to                eradicate the suicide terror pandemic entirely. The                deep learning implies multiple layers of neural                networks for multiple feature extraction to                increase the probability of detection of overly                stressed emotion intelligence and to reduce the                false alarm rate.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method                for determining emotional inclination.    DESCRIPTION OF DRAWING(S) - The drawing shows a graph illustrating the                increase in world-wide suicide terrorist                causalities over time. 			P31 (Diagnosis, surgery (A61B).);  S05 (Electrical Medical Equipment);  T01 (Digital Computers);  W01 (Telephone and Data Transmission Systems)	P31-A05;  S05-D;  T01-J10B2;  T01-N01A2;  T01-N01E;  W01-C01D3C;  W01-C01G8S	A61B-005/00;  A61B-005/024;  A61B-005/16;  G06Q-050/26;  G06T-007/00	US2019139217-A1   09 May 2019   G06T-007/00   201938Pages: 15   English	US2019139217-A1    US103885    14 Aug 2018	US2019139217-A1 Provisional Application US545421P	US545421P    14 Aug 2017;  US103885    14 Aug 2018										CN110093461-A;  CN110093461-B	New set of quadruple real-time polymerase chain            reaction detection primers comprises e.g. porcine            epidemic diarrhea virus detection primers, and porcine            transmissible gastroenteritis virus detection            primers	SUN P;  LI L;  ZHOU T;  QIN J;  LI J;  ZHAN S;  WANG J;  GAO Y	UNIV ANHUI AGRIC (UYAH-C)	201969841J	   NOVELTY - Set of quadruple real-time polymerase chain                reaction (RT-PCR) detection primers comprises                porcine epidemic diarrhea virus detection primers                PEDV F and PEDV R, porcine transmissible                gastroenteritis virus detection primers TGEV F and                TGEV R, porcine group A rotavirus detection primers                PoRV F and PoRV R, porcine delta coronavirus                detection primers PDCoV F and PDCoV R, is                new.    USE - Used as set of quadruple real-time polymerase                chain reaction detection primers.    ADVANTAGE - The primer has strong specificity,                repeatability, high sensitivity and high clinical                reliability.    DETAILED DESCRIPTION - Set of quadruple real-time polymerase chain                reaction (RT-PCR) detection primers comprises                porcine epidemic diarrhea virus detection primers                PEDV F and PEDV R, porcine transmissible                gastroenteritis virus detection primers TGEV F and                TGEV R, porcine group A rotavirus detection primers                PoRV F and PoRV R, porcine delta coronavirus                detection primers PDCoV F and PDCoV R, is new. The                PEDV F comprises sequence represented by                5'-accatactgggtttacctttcct-3' (SEQ ID NO: 1), the                PEDV R comprises sequence represented by                5'-gcgtctaactctgctttcttcac-3' (SEQ ID NO: 2), the                TGEV F comprises sequence represented by                5'-ctacgatttcataacagagcg-3' (SEQ ID NO: 3), the                TGEV R comprises sequence represented by                5'-atattgtcccaaccaccataa-3' (SEQ ID NO: 4), the                PDCoV-F comprises sequence represented by                5'-atggctactggctgcgttac-3' (SEQ ID NO: 5), the                PDCoV-R comprises sequence represented by                5'-gcgtttcctgggctgatt-3' (SEQ ID NO: 6), the PoRVF                comprises sequence represented by                5'-gaaccagattagctcgaca-3' (SEQ ID NO: 7), and the                PoRV R comprises sequence represented by                5'-aagaatcaagtccggcca-3' (SEQ ID NO: 8). An                INDEPENDENT CLAIM is also included for kit,                comprising primer, 2x Taq PCR MasterMix and                water. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E05;  B04-E99;  B04-F11B;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  C04-E01;  C04-E05;  C04-E99;  C04-F11B;  C11-C08E3;  C11-C08F8;  C12-K04F;  C12-K04G1B;  D05-H06A;  D05-H12D1;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/686;  C12Q-001/70;  C12R-001/93	CN110093461-A   06 Aug 2019   C12Q-001/70   201971Pages: 19   Chinese;  CN110093461-B   09 Mar 2021   C12Q-001/70   202123   Chinese	CN110093461-A    CN10510132    13 Jun 2019;   CN110093461-B    CN10510132    13 Jun 2019	CN110093461-B Previous Publ. Patent CN110093461	CN10510132    13 Jun 2019			CN110093461-A -- CN103409558-A   UNIV NORTHEAST AGRIC (UNEA)   TANG L,  LI Y,  WU Y,  QIAO X,  DU C,  YIN J;  CN108060269-A   UNIV NORTHEAST AGRIC (UNEA)   XU Y,  WANG Z,  WANG L,  JIANG Y,  TANG L,  LI Y;  CN108950083-A   UNIV HENAN AGRIC (UYHR)   WANG C,  CHANG H,  WANG A,  CHEN L,  ZHOU F,  LI Y,  WANG X,  YANG X,  CUI D,  DU J,  LIU H,  ZHAO J							WO2019079339-A1;  TW201927293-A;  EP3697404-A1;  US2020338032-A1;  CN111886008-A;  JP2021500400-W;  EP3697404-A4;  HK40038027-A0;  JP7466907-B2;  CN111886008-B	Treating viral infection comprises administering            antiviral compound to inhibit viral replication	LAU J Y;  YUAN S;  CHAN F W J;  CHU H;  YUEN K Y;  CHEN F;  ZHU X;  LIU Y;  YUAN G	AVALON FLAVIVIRAL THERAPEUTICS HK LTD (AVAL-Non-standard);  VERSITECH LTD (UYHK-C);  LAU J Y (LAUJ-Individual);  AVALON FLAVIVIRAL THERAPEUTICS HK LTD (AVAL-Non-standard);  VERSITECH LTD (UYHK-C);  AVALON FLAVIVIRAL THERAPEUTICS HK LTD (AVAL-Non-standard);  VERSITECH LTD (UYHK-C);  AVALON FLAVIVIRAL THERAPEUTICS HK LTD (AVAL-Non-standard);  VERSITECH LTD (UYHK-C);  AVALON FLAVIVIRAL THERAPEUTICS HK LTD (AVAL-Non-standard);  VERSITECH LTD (UYHK-C);  AVALON FLAVIVIRAL THERAPEUTICS HK LTD (AVAL-Non-standard);  LAU J Y (LAUJ-Individual);  VERSITECH LTD (UYHK-C)	201937021V	   NOVELTY - Treating a viral infection, comprises                administering an antiviral compound (I) to inhibit                viral replication, where (I) has an antiviral                activity against both an RNA virus and a DNA                virus.    USE - The methods are useful for treating a viral                infection, reducing an inflammatory process                associated with viral infection, modulating                lipogenesis in a cell and disrupting viral                replication in a host cell, where the RNA virus                comprises Coronoviridae, Picornaviridae,                Flaviviridae or Orthomyxoviridae, the RNA virus                comprises Middle East respiratory                syndrome-coronavirus (MERS-CoV), severe acute                respiratory syndrome-related coronavirus                (SARS-CoV), ZIKAV, influenza and enterovirus, the                DNA virus is an Adenoviridae or a human adenovirus,                the inflammatory process comprises interstitial                inflammation, alveolar damage or suppression of                viral induced activation of a pro-inflammatory                cytokine and the pro-inflammatory cytokine                comprises TNF- alpha , interleukin (IL)-1 beta or                IL-8 (all claimed).    ADVANTAGE - The methods: provide broad spectrum antiviral                therapy; utilize synergistic components; utilize                components with comprehensive safety profile; and                are effective. The ability of the synergistic                combination to treat viral infection was tested                against MERS-CoV by measuring FICI value using a                biological assay. The result showed that the                combination (comprised of AM580 and lopinavir in a                ratio of 1:10) exhibited an FICI value of 0.46                (units not described).    DETAILED DESCRIPTION - Treating a viral infection, comprises                administering an antiviral compound of formula (I)                to inhibit viral replication, where (I) has an                antiviral activity against both an RNA virus and a                DNA virus.    L1 = linking group; and    G1 = charged group.    INDEPENDENT CLAIMS are also included                for:    (1) reducing an inflammatory process                associated with viral infection, comprising                administering (I) to inhibit the inflammatory                process associated with viral infection;    (2) modulating lipogenesis in a cell,                comprising administering (I) to modulate a                lipogenesis process in the cell; and    (3) disrupting viral replication in a host                cell, comprising administering (I) to disrupt the                viral replication process in the host cell. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B02-Z;  B04-H02A;  B04-H02J;  B04-H08;  B10-C04C;  B14-A02;  B14-C01;  B14-C03;  B14-E06;  B14-L01;  B14-S09;  B14-S18;  B15-A00;  D05-H99;  D05-A04A	A61K-031/07;  A61K-031/192;  A61K-031/195;  A61K-045/06;  A61P-031/12;  A61K-045/00;  A61P-011/00;  A61P-029/00;  A61P-031/14;  A61P-031/16;  A61P-031/20;  A61P-043/00;  A61K-031/196	WO2019079339-A1   25 Apr 2019   A61K-031/195   201935Pages: 102   English;  TW201927293-A   16 Jul 2019   A61K-031/07   201976   Chinese;  EP3697404-A1   26 Aug 2020   A61K-031/195   202070   English;  US2020338032-A1   29 Oct 2020   A61K-031/192   202089   English;  CN111886008-A   03 Nov 2020   A61K-031/195   202094   Chinese;  JP2021500400-W   07 Jan 2021   A61K-031/192   202104Pages: 59   Japanese;  EP3697404-A4   21 Jul 2021   A61K-031/196   202160   English;  HK40038027-A0   18 Jun 2021   A61K-031/195   202200   English;  JP7466907-B2   15 Apr 2024   A61K-031/192   202434   Japanese;  CN111886008-B   31 May 2024   A61K-031/195   202447   Chinese	WO2019079339-A1    WOUS056138    16 Oct 2018;   TW201927293-A    TW136527    17 Oct 2018;   EP3697404-A1    EP867413    16 Oct 2018;   US2020338032-A1    US16757312    17 Apr 2020;   CN111886008-A    CN80080271    16 Oct 2018;   JP2021500400-W    JP542534    16 Oct 2018;   EP3697404-A4    EP867413    16 Oct 2018;   HK40038027-A0    HK6026716    04 Mar 2021;   JP7466907-B2    JP542534    16 Oct 2018;   CN111886008-B    CN80080271    16 Oct 2018	EP3697404-A1 PCT application Application WOUS056138;   EP3697404-A1 Based on Patent WO2019079339;   US2020338032-A1 PCT application Application WOUS056138;   US2020338032-A1 Provisional Application US573933P;   CN111886008-A PCT application Application WOUS056138;   CN111886008-A Based on Patent WO2019079339;   JP2021500400-W PCT application Application WOUS056138;   JP2021500400-W Based on Patent WO2019079339;   HK40038027-A0 PCT application Application WOUS056138;   HK40038027-A0 Based on Patent WO2019079339;   HK40038027-A0 Previous Publ. Patent CN111886008;   JP7466907-B2 PCT application Application WOUS056138;   JP7466907-B2 Previous Publ. Patent JP2021500400;   JP7466907-B2 Based on Patent WO2019079339;   CN111886008-B PCT application Application WOUS056138;   CN111886008-B Previous Publ. Patent CN111886008;   CN111886008-B Based on Patent WO2019079339	US573933P    18 Oct 2017;  CN80080271    16 Oct 2018;  WOUS056138    16 Oct 2018;  US16757312    17 Apr 2020;  CN80080271    12 Jun 2020	WO2019079339-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP3697404-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        EP3697404-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR        		WO2019079339-A1 -- US20040152073-A1   ;  US8536196-B2   EVOLVA SA (EVLO)   SORENSEN A S,  MEYER J,  ALBERTS P,  PRATHAMA M S,  CRAMERI M H;  WO2013159243-A1   NAT INST BIOLOGICAL SCI BEIJING (NABI-Non-standard)   LI W,  YAN H,  ZHONG G,  XU G,  HE W,  SUI J,  JING Z,  HUANG Y;  WO2015138354-A1   UNIV CORNELL (CORR);  GUDAS L J (GUDA-Individual);  TANG X (TANG-Individual);  OSEI-SARFO K (OSEI-Individual);  URVALEK A (URVA-Individual)   GUDAS L J,  TANG X,  OSEI-SARFO K,  URVALEK A;  WO2008017692-A2   INSERM INST NAT SANTE & RECH                  MEDICALE (INRM)   ANDRE P,  LOTTEAU V,  SCHOLTES C;  CN111886008-A -- WO2005120479-A1   GPC BIOTECH AG (GPCB-Non-standard)   HERGET T,  KLEBL B;  WO2014079709-A1   AB SCI (ABSC)   GROS L,  DUBREUIL P,  MOUSSY A,  AUDEBERT S,  MANSFIELD C;  EP3697404-A4 -- WO2005120479-A1   GPC BIOTECH AG (GPCB-Non-standard)   HERGET T,  KLEBL B;  WO2014079709-A1   AB SCI (ABSC)   GROS L,  DUBREUIL P,  MOUSSY A,  AUDEBERT S,  MANSFIELD C;  WO2015138354-A1   UNIV CORNELL (CORR);  GUDAS L J (GUDA-Individual);  TANG X (TANG-Individual);  OSEI-SARFO K (OSEI-Individual);  URVALEK A (URVA-Individual)   GUDAS L J,  TANG X,  OSEI-SARFO K,  URVALEK A;  WO2018054891-A1   UNIV HEIDELBERG RUPRECHT-KARLS (UYRH)   LEMPP F,  URBAN S,  NI Y,  NUSSBAUM L,  BINGQIAN Q;  CN111886008-B -- US20060151574-A1   ;  US20170007672-A1   ;  WO2005120479-A1   GPC BIOTECH AG (GPCB-Non-standard)   HERGET T,  KLEBL B;  WO2014079709-A1   AB SCI (ABSC)   GROS L,  DUBREUIL P,  MOUSSY A,  AUDEBERT S,  MANSFIELD C	WO2019079339-A1  KAST, H. R. ET AL.:          "Farnesoid X-activated receptor induces apolipoprotein          C-11 transcription: a molecular mechanism linking plasma          triglyceride levels to bile acids", MOLECULAR          ENDOCRINOLOGY, vol. 15, no. 10, 2001, pages 1720 - 1728,          XP001157555, DOI:          doi:10.1210/me.15.10.1720,relevantClaims[63-66,          75],relevantPassages[See abstract; page 1720, right          column; page 1721, left column.]CN111886008-A  BAO NGOC NGUYEN:          "Retinoid derivative Tp80 exhibits anti-hepatitis C virus          activity through restoration of GI-GPx expression",          JOURNAL OF MEDICAL          VIROLOGY,relevantClaims[1-20],relevantPassages[1-29]EP3697404-A4  NGUYEN BAO NGOC ET          AL: "Retinoid derivative Tp80 exhibits anti-hepatitis C          virus activity through restoration of GI-GPx expression",          JOURNAL OF MEDICAL VIROLOGY, vol. 89, no. 7, 28 March          2017 (2017-03-28), US, pages 1224 - 1234, XP055806129,          ISSN: 0146-6615, Retrieved from the Internet          &lt;URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jmv.24739&gt;          DOI:          10.1002/jmv.24739,relevantClaims[1-15],relevantPassages[&lt;pp&gt;1231&lt;/pp&gt;&lt;figure&gt;5&lt;/figure&gt;];  LU Y ET AL:          "Mechanism of inhibition of MMTV-neu and MMTV-wnt1          induced mammary oncogenesis by RAR[alpha] agonist AM580",          ONCOGENE, vol. 29, no. 25, 10 May 2010 (2010-05-10),          London, pages 3665 - 3676, XP055806205, ISSN: 0950-9232,          Retrieved from the Internet          &lt;URL:http://www.nature.com/articles/onc2010119&gt;          DOI:          10.1038/onc.2010.119,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  YUAN SHUOFENG ET          AL: "Broad-Spectrum Host-Based Antivirals Targeting the          Interferon and Lipogenesis Pathways as Potential          Treatment Options for the Pandemic Coronavirus Disease          2019 (COVID-19)", VIRUSES, vol. 12, no. 6, 10 June 2020          (2020-06-10), pages 628, XP055773673, Retrieved from the          Internet          &lt;URL:https://www.mdpi.com/1999-4915/12/6/628&gt;          DOI:          10.3390/v12060628,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            See also references of WO 2019079339A1CN111886008-B            Harry D Dawson et.al .. The Retinoic Acid Receptor-alpha          mediates human T-cell activation and Th2 and chemokine          "BMC Immunology". 2008, Volume 9 (phase 16),          1-14.;            Bao Ngoc Nguyen. Retinoid derivative Tp80 exhibits          anti-hepatitis C virus activity through restoration of          GI-GPx expression;Bao Ngoc Nguyen;Journal of Medical          Virology;20170328;89(7);1-29	97961-0-0-0 K M; 97929-0-0-0 K M; 109602-0-0-0 K M; 87103-0-0-0 K M; 87106-0-0-0 K M; 111298-0-0-0 K M; 184617-0-0-0 K M	214217801 K M		RA09LE K M; RA0MPN K M; RA06YS K M; RA2WZI K M; RA2WZH K M; RA0T83 K M; RA0HDM K M		US2019078060-A1;  US10954493-B2	Preparing influenza vaccine from influenza virus,            involves testing vaccine and/or culture for presence of            infectious agent that can grow in cell line but that            does not grow in embryonated hen eggs	GREGERSEN J	NOVARTIS AG (NOVS-C);  NOVARTIS AG (NOVS-C)	2021293240	   NOVELTY - Process (P1) for preparing an influenza                vaccine from influenza virus that has been grown in                a culture of a mammalian cell line, involves                testing the vaccine and/or the culture for the                presence of an infectious agent that can grow in                cell line but that does not grow in embryonated hen                eggs or treating the vaccine and/or the culture to                remove and/or inactivate an infectious agent that                can grow in the cell line but does not grow in                embryonated hen eggs.    USE - The process is useful for preparing an                influenza vaccine from influenza virus, which is                used for pediatric immunization (claimed) or                decreasing potential iatrogenic risks associated                with influenza vaccines or treating influenza virus                in children and adults.    ADVANTAGE - The process ensures safety and avoids                iatrogenic infections.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following: (1) a process (P2) for preparing an                influenza vaccine from influenza virus that has                been grown in a culture of a first mammalian cell                line, involves testing the vaccine and/or the                culture for the presence of an infectious agent                that can grow in the first cell line but that does                not grow in a second mammalian cell line, or                treating the vaccine and/or the culture to remove                and/or inactivate an infectious agent that can grow                in first cell line but does not grow in a second                mammalian cell line; (2) a process (P3) for                preparing an influenza vaccine from influenza virus                that has been grown in a culture of a mammalian                cell line or in hens eggs involves testing the                vaccine and/or the culture for the presence of a                pathogen chosen from parainfluenza viruses,                Herpesviridae, Adenoviridae, Mycoplasma, avian                circoviruses, avian Reoviridae, and Birnaviridae;                (3) an influenza vaccine (V1) that has been grown                in a culture of a mammalian cell line, where the                vaccine has been confirmed as free from the                presence of an infectious agent that can grow in                cell line but that does not grow in embryonated hen                eggs; (4) an influenza vaccine (V2) that has been                grown in a culture of a first mammalian cell line,                where the vaccine has been confirmed as free from                the presence of an infectious agent that can grow                in first cell line but that does not grow in a                second mammalian cell line; and (5) an influenza                vaccine (V3) in which mammalian reovirus is                undetectable by reverse transcription                (RT)-PCR. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-F02;  B04-F11B;  B11-C05;  B14-A02B2;  B14-G01;  B14-S11A;  B14-S11D1;  B14-S24;  C04-F02;  C04-F11B;  C11-C05;  C14-A02B2;  C14-G01;  C14-S11A;  C14-S11D1;  D05-H07;  S03-E09F;  S03-E14H	A61K-039/12;  A61K-039/145;  C12N-007/00;  C12Q-001/70;  G01N-033/569;  C12N-007/02	US2019078060-A1   14 Mar 2019   C12N-007/00   202130Pages: 9   English;  US10954493-B2   23 Mar 2021   C12N-007/00   202137   English	US2019078060-A1    US184482    08 Nov 2018;   US10954493-B2    US184482    08 Nov 2018	US2019078060-A1 Cont of Application US150214;   US2019078060-A1 Cont of Application US740100;   US2019078060-A1 Cont of Application US738929;   US2019078060-A1 Cont of Application US274285;   US2019078060-A1 Cont of Application US662481;   US2019078060-A1 Cont of Application WOIB003266;   US2019078060-A1 Cont of Patent US9220768;   US2019078060-A1 Cont of Patent US10155932;   US2019078060-A1 Cont of Patent US8119337;   US2019078060-A1 Cont of Patent US8460914;   US2019078060-A1 Cont of Patent US9358280;   US10954493-B2 Cont of Application US150214;   US10954493-B2 Cont of Application US740100;   US10954493-B2 Cont of Application US738929;   US10954493-B2 Cont of Application US274285;   US10954493-B2 Cont of Application US662481;   US10954493-B2 Cont of Application WOIB003266;   US10954493-B2 Cont of Patent US9220768;   US10954493-B2 Cont of Patent US10155932;   US10954493-B2 Cont of Patent US8460914;   US10954493-B2 Cont of Patent US9358280;   US10954493-B2 Cont of Patent US8119337;   US10954493-B2 Previous Publ. Patent US2019078060	EP255471    09 Sep 2004			US2019078060-A1 -- US8119337-B2   CHIRON BEHRING GMBH & CO (CHIR)   GREGERSEN J;  US8460914-B2   CHIRON BEHRING GMBH & CO (CHIR)   GREGERSEN J;  US9220768-B2   CHIRON BEHRING GMBH & CO (CHIR)   GREGERSEN J;  US9358280-B2   CHIRON BEHRING GMBH & CO (CHIR)   GREGERSEN J;  US10155932-B2   CHIRON BEHRING GMBH & CO (CHIR)   GREGERSEN J							CN110403941-A;  CN110403941-B	Use of            (1-methyl-5-(2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy)-1H-benzoimidazol-2-yl)-(4-trifluoromethyl-phenyl)-amine            in preparing broad-spectrum antiviral medicine or            composition for inhibiting virus infection	WANG X;  XUE Y;  LI C;  YANG D;  LU J	UNIV CHINA AGRICULTURAL (UCAG-C)	201994383J	   NOVELTY - Use of                (1-methyl-5-(2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy)-1H-benzoimidazol-2-yl)-(4-trifluoromethyl-phenyl)-amine                (RAF265) (I) or its salts in preparing                broad-spectrum antiviral medicine or composition,                is claimed.    USE - (I) are useful: in preparing antiviral                medicine or composition (claimed) for inhibiting                virus infection in host cells and mice; and in                aquaculture and biomedical fields.    ADVANTAGE - (I): have high-efficient antiviral activity                and low cytotoxicity (CC50/IC50 greater than 100);                has no toxic side effects on chicken embryos and                mice; reduces amount of virus in mice and symptoms                of infection; and provides kinase inhibitor which                can effectively resist variety of virus                infections.    DETAILED DESCRIPTION - Use of                (1-methyl-5-(2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy)-1H-benzoimidazol-2-yl)-(4-trifluoromethyl-phenyl)-amine                (RAF265) of formula (I) or its salts in preparing                broad-spectrum antiviral medicine or composition,                is claimed. 			B02 (Fused ring heterocyclics.);  C02 (Heterocyclic.)	B06-D05;  B14-A02;  B14-D06C;  B14-S12;  C06-D05;  C14-A02;  C14-D06C;  C14-S12	A61K-031/4439;  A61P-031/14;  A61P-031/22	CN110403941-A   05 Nov 2019   A61K-031/4439   201990Pages: 23   Chinese;  CN110403941-B   10 Jun 2022   A61K-031/4439   202251   Chinese	CN110403941-A    CN10664898    23 Jul 2019;   CN110403941-B    CN10664898    23 Jul 2019	CN110403941-B Previous Publ. Patent CN110403941	CN10664898    23 Jul 2019			CN110403941-A -- US20160101106-A1   ;  CN110403941-B -- US20160101106-A1   	CN110403941-A  TERESA E. WILLIAMS:          "Discovery of RAF265: A Potent mut-B-RAF Inhibitor for          the Treatment of Metastatic Melanoma", ACS MEDICINAL          CHEMISTRY          LETTERS,relevantClaims[2-4|1],relevantPassages[961-965];  YOUNGNAM KIM:          "Extracellular signal-regulated kinase (ERK) activation          is required for porcine epidemic diarrhea virus          replication",          VIROLOGY,relevantClaims[2-4],relevantPassages[181-193];  ZHILI CHU:          "Newcastle Disease Virus V Protein Promotes Viral          Replication in HeLa Cells through the Activation of          MEK/ERK Signaling",          VIRUSES,relevantClaims[2-4],relevantPassages[489];  : "ERK",          ,relevantClaims[2-4],relevantPassages[779-783]CN110403941-B            Teresa E. Williams, et al. Discovery of RAF265: A Potent          mut-B-RAF Inhibitor for the treatment of Metastatic          Melanoma, Teresa E. Williams, et al. ACS Medicinal          Chemistry Letters, 20150803, the sixth volume (ninth          period), 961-965;            Teresa E. Williams et al. Discovery of RAF265: A Potent          mut-B-RAF Inhibitor for the Treatment of Metastatic          Melanoma. ACS Medicinal Chemistry Letters. 2015, the          sixth volume (the ninth period), the 961-965          page.;            Luo Ling-chi and so on. cell ERK signal path for herpes          simplex virus II type the influence of the proliferation          replication, Luogel et al., Chinese Microbiology and          Immunology Magazine, 20070930, Vol (9), 779-783          page;            Chu, Chu. Newcastle disease Virus V Protein Promotes          Viral Replication in HeLa Cells through the Activation of          MEK/ERK Signaling, Chu Chu et al., "Viruses"; 20180912;          Section 10; pages 489;;            Young gnam Kim et al. Extracts signal-regulated kinase          (ERK) activation is required for the disease virus ;          Young gnam Kim et al., "Virology"; 20150623; No. 484;          pages 181-193; pages 181-193;	1325025-0-0-0 K U; 1325025-0-0-0 CL USE			RAQ5YH K U		WO2019121916-A1;  EP3727432-A1;  US2020376106-A1;  BR112020012483-A2;  CA3085535-A1;  JP2021506874-W;  US11744883-B2	Combination vaccine for preventing porcine            enzootic pneumonia, comprises one or more antigens of            Mycoplasma hyopneumoniae, one or more antigens of            porcine circovirus, and pharmaceutically acceptable            excipients and/or carriers	MONTANE GIRALT J;  PUIGVERT MOLAS E;  MOROS SANZ A;  SITJA ARNAU M;  MONTANE G J;  PUIGVERT M E;  MOROS S A;  SIT J A M;  GIRALT J M;  MOLAS E P;  SANZ A M;  ARNAU M S;  SITJA A M	HIPRA SCI SLU (HIPR-Non-standard);  HIPRA SCI SLU (HIPR-Non-standard);  HIPRA SCI SLU (HIPR-Non-standard);  HIPRA SCI SLU (HIPR-Non-standard);  HIPRA SCI SLU (HIPR-Non-standard)	201954067G	   NOVELTY - Combination vaccine comprises one or more                antigens of Mycoplasma hyopneumoniae, one or more                antigens of porcine circovirus, and                pharmaceutically acceptable excipients and/or                carriers, where vaccine is administered into dermis                of livestock to prevent and/or treat porcine                enzootic pneumonia and/or porcine                circovirus-associated diseases, where one or more                antigens of porcine circovirus comprises PCV2 ORF2                protein in an amount from 0.1-10pg/dose.    USE - Combination vaccine for preventing and/or                treating porcine enzootic pneumonia and/or porcine                circovirus-associated diseases, and for another                disease or pathological conditions affecting swine                (claimed).    ADVANTAGE - The combination vaccine contains antigen from                both pathogens in a single working composition,                which reduces rounds of administration and risk                associated to them.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) an intradermal combination vaccine, which                comprises one or more antigens of Mycoplasma                hyopneumoniae and one or more antigens of porcine                circovirus; and    (2) a vaccination kit, which comprises an                intradermal combination vaccine, a delivery device                for intradermal delivery of vaccines, and an                instructions for its use. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)	B04-N02;  B14-K01;  B14-S11D1;  B14-S11D2;  B14-S12;  C04-B04C1;  C14-K01;  C14-S11D1;  C14-S11D2;  C14-S12;  D05-H07;  A12-V01;  A12-V03C2	A61K-039/00;  A61K-039/02;  A61K-039/12;  A61K-039/39;  A61K-009/00;  A61P-031/20;  A61K-039/295;  A61P-031/04;  A61P-037/04	WO2019121916-A1   27 Jun 2019   A61K-039/00   201951Pages: 43   English;  EP3727432-A1   28 Oct 2020   A61K-039/00   202088   English;  US2020376106-A1   03 Dec 2020   A61K-039/02   202098   English;  BR112020012483-A2   24 Nov 2020   A61K-039/02   202002   English;  CA3085535-A1   27 Jun 2019   A61K-039/00   202004   English;  JP2021506874-W   22 Feb 2021   A61K-039/295   202118Pages: 35   Japanese;  US11744883-B2   05 Sep 2023   A61K-039/02   202372   English	WO2019121916-A1    WOEP085844    19 Dec 2018;   EP3727432-A1    EP833856    19 Dec 2018;   US2020376106-A1    US16955015    17 Jun 2020;   BR112020012483-A2    BR11012483    19 Dec 2018;   CA3085535-A1    CA3085535    19 Dec 2018;   JP2021506874-W    JP533815    19 Dec 2018;   US11744883-B2    US16955015    17 Jun 2020	EP3727432-A1 PCT application Application WOEP085844;   EP3727432-A1 Based on Patent WO2019121916;   US2020376106-A1 PCT application Application WOEP085844;   BR112020012483-A2 PCT application Application WOEP085844;   BR112020012483-A2 Based on Patent WO2019121916;   CA3085535-A1 PCT application Application WOEP085844;   CA3085535-A1 Based on Patent WO2019121916;   JP2021506874-W PCT application Application WOEP085844;   JP2021506874-W Based on Patent WO2019121916;   US11744883-B2 PCT application Application WOEP085844;   US11744883-B2 Previous Publ. Patent US2020376106;   US11744883-B2 Based on Patent WO2019121916	EP382893    22 Dec 2017;  CA3085535    11 Jun 2020;  BR11012483    19 Jun 2020	WO2019121916-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP3727432-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN            		WO2019121916-A1 -- WO2013152086-A1   ZOETIS W LLC (ZOET)   NITZEL G P,  GALVIN J E,  GARRETT J K,  KULAWIK J R,  RICKER T L,  SMUTZER M M;  WO2014182872-A1   PROTATEK INT INC (PROT-Non-standard)   MA S J,  SUI J;  WO2017116698-A1   MERIAL INC (BOEH)   WILSON K,  LAWRENCE P;  WO2017162741-A1   INTERVET INT BV (IVET);  INTERVET INC (MERI)   SNO M,  WITVLIET M H,  FACHINGER V;  WO2009126356-A2   BOEHRINGER INGELHEIM VETMEDICA INC (BOEH)   EICHMEYER M,  ROOF M;  WO2016102619-A1   HIPRA SCI SLU (HIPR-Non-standard)   FONT VENTURA M,  PUJOL PRAT M G,  PONS MOLL J C;  WO2014009586-A2   LAB HIPRA SA (HIPR-Non-standard)   GONZALEZ GONZALEZ L,  PINOL RIBAS J,  MONTANE GIRALT J,  CAMATS MALET M,  QUEROL MURILLO E,  SITJA ARNAU M;  US2020376106-A1 -- US9120859-B2   ZOETIS W LLC (ZOET)   GALVIN J E,  NITZEL G P,  GARRETT J K,  KULAWIK J R,  RICKER T L,  SMUTZER M M;  US11744883-B2 -- US5565205-A   SOLVAY ANIMAL HEALT (SOLV)   PETERSEN G R,  DAY,  DAYALU K;  US20090092636-A1   ;  US20200376106-A1   ;  US9120859-B2   ZOETIS W LLC (ZOET)   GALVIN J E,  NITZEL G P,  GARRETT J K,  KULAWIK J R,  RICKER T L,  SMUTZER M M;  WO2013152086-A1   ZOETIS W LLC (ZOET)   NITZEL G P,  GALVIN J E,  GARRETT J K,  KULAWIK J R,  RICKER T L,  SMUTZER M M;  WO2014079943-A1   KARLSRUHER INST TECHNOLOGIE (KARL);  AMCURE GMBH (AMCU-Non-standard)   MATZKE A,  ORIAN-ROUSSEAU V,  PONTA H;  WO2014182872-A1   PROTATEK INT INC (PROT-Non-standard)   MA S J,  SUI J;  WO2016102619-A1   HIPRA SCI SLU (HIPR-Non-standard)   FONT VENTURA M,  PUJOL PRAT M G,  PONS MOLL J C;  WO2017116698-A1   MERIAL INC (BOEH)   WILSON K,  LAWRENCE P;  WO2017162741-A1   INTERVET INT BV (IVET);  INTERVET INC (MERI)   SNO M,  WITVLIET M H,  FACHINGER V;  WO2009126356-A2   BOEHRINGER INGELHEIM VETMEDICA INC (BOEH)   EICHMEYER M,  ROOF M;  WO2014009586-A2   LAB HIPRA SA (HIPR-Non-standard)   GONZALEZ GONZALEZ L,  PINOL RIBAS J,  MONTANE GIRALT J,  CAMATS MALET M,  QUEROL MURILLO E,  SITJA ARNAU M	WO2019121916-A1  BOEHRINGER          INGELHEIM: "Ingelvac CircoFLEX -MycoFLEX(TM) MATERIAL          SAFETY DATA SHEET", 23 June 2008 (2008-06-23),          XP055306404, Retrieved from the Internet          &lt;URL:http://www.bi-vetmedica.com/content/dam/internet/ah/vetmedica/com_EN/MSDS/Ingelvac          CircoFlex-Mycoflex_msds.pdf&gt; [retrieved on          20160928],relevantClaims[13,14,16,17,20|1-12,15,18,19],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ANONYMOUS:          "One-Dose Vaccination Against Mycoplasma hyopneumoniae          and Porcine Circovirus Type 2", 27 July 2010          (2010-07-27), XP002781041, Retrieved from the Internet          &lt;URL:http://www.thepigsite.com/articles/3191/onedose-vaccination-against-mycoplasma-hyopneumoniae-and-porcine-circovirus-type-2/&gt;,relevantClaims[1-20],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ROMAN PEPOVICH ET          AL: "Clinical Testing of Combined Vaccine Against          Enzootic Pneumonia in Industrial Pig Farming in          Bulgaria", MACEDONIAN VETERINARY REVIEW, vol. 38, no. 2,          1 January 2015 (2015-01-01), XP055474403, DOI:          10.14432/j.macvetrev.2015.07.051,relevantClaims[1-20],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            SEGALES J. ET AL.: "PCV-2 genotype definition and          nomenclature", VET REC., vol. 162, no. 26, 2008, pages          867 - 8, XP009179386, DOI:          doi:10.1136/vr.162.26.867;            XIAO ET AL.: "Global molecular genetic analysis of          porcine circovirus type 2 (PCV2) sequences confirms the          presence of four main PCV2 genotypes and reveals a rapid          increase of PCV2d", J GEN VIROL, vol. 96, 2015, pages          1830 - 41, XP055415245, DOI:          doi:10.1099/vir.0.000100;            PALINSKI R. ET AL., A NOVEL PORCINE CIRCOVIRUS DISTANTLY          RELATED TO KNOWN CIRCOVIRUSES IS ASSOCIATED WITH PORCINE          DERMATITIS AND NEPHROPATHY SYNDROME AND REPRODUCTIVE          FAILURE, vol. 91, no. 1, 2016;            "GenBank", Database accession no. AAC35310;            "GenBank", Database accession no. AAC35331;            "GenBank", Database accession no. ABX71779;            MINION ET AL.: "The genome sequence of Mycoplasma          hyopneumoniae strain 232, the agent of swine          mycoplasmosis", J. BACTERIOL., vol. 186, no. 21, 2004,          pages 7123 - 7133, XP002443117, DOI:          doi:10.1128/JB.186.21.7123-7133.2004;            VASCONCELOS ET AL.: "Swine and poultry pathogens: the          complete genome sequences of two strains of Mycoplasma          hyopneumoniae and a strain of Mycoplasma synoviae", J.          BACTERIOL., vol. 187, no. 16, 2005, pages 5568 - 5577,          XP002513991, DOI:          doi:10.1128/JB.187.16.5568-5577.2005;            CARON ET AL.: "Diagnosis and differentiation of          Mycoplasma hyopneumoniae and Mycoplasma hyorhinis          infections in pigs by PCR amplification of the p36 and          p46 genes", J. CLIN. MICROBIOL., vol. 38, no. 4, 2000,          pages 1390 - 1396;            XIAO ET AL.: "Global molecular genetic analysis of          porcine circovirus type 2 (PCV2) sequences confirms the          presence of four main PCV2 genotypes and reveals a rapid          increase of PCV2d", J GEN VIROL, vol. 96, no. Pt 7, 2015,          pages 1830 - 41, XP055415245, DOI:          doi:10.1099/vir.0.000100US11744883-B2            Reddy et al. (Advanced Drug Delivery Reviews. 2009; 61:          1412-1426).;            Singh-Joy et al. (International journal of toxicology.          2008; 27: 93-128).;            International Search Report and Written Opinion dated          Feb. 15, 2019 for PCT Application No. PCT/EP2018/085844,          14 pages.;            Anonymous, One-Dose Vaccination Against Mycoplasma          hyopneumoniae and Porcine Circovirus Type 2, The Pig          Site; MSD Animal Health; XP002781041, 4 pages; URL:          HTTP:/thepigsite.com/articles/3191/onedose-vaccination-against-mycoplasma-hyopneumoniae-and-porcine-circovirus-type-2/          [retrieved Jul. 27, 2010], the whole document.;            Boehringer Ingelheim, Ingelvac CircoFLEX-MycoFLEX (TM)          Material Safety Data Sheet, Jun. 23, 2008, URL:          http://www.bi-vetmedica.com/content/dam/internet/ah/vetmedica/com_EN/MSDS/Ingelvac_CircoFlex-MycoFlex_msds.pdf          [retrieved Sep. 28, 2016] the whole document.;            Caron, et al., Diagnosis and differentiation of          &lt;xhtml:i &gt;Mycoplasma          hyopneumoniae&lt;/xhtml:i&gt;and &lt;xhtml:i          &gt;Mycoplasma          hyorhinis&lt;/xhtml:i&gt;infections in pigs by          PCR amplification of the p36 and p46 genes, Journal of          Clinical Microbiology Apr. 2000; vol. 38, No. 4, pp.          1390-1396.;            Minion, et al., The genome sequence of &lt;xhtml:i          &gt;Mycoplasma          hyopneumoniae&lt;/xhtml:i&gt;strain 232, the          agent of swine mycoplasmosis, Journal of Bacteriology          Nov. 2004; vol. 186, No. 21, pp. 7123-7133.;            Palinski, et al., A Novel Porcine Circovirus Distantly          Related to Known Circoviruses is Associated with Porcine          Dermatitis and Nephropathy Syndrome and Reproductive          Failure, Oct. 26, 2016; vol. 91, No. 1, 42          pages.;            Pepovich, et al., Clinical Testing of Combined Vaccine          against enzootic pneumonia in industrial pig farming in          Bulgaria, Macedonian Veterinary Review Jan. 1, 2015; vol.          38, No. 2, pp. 195-201; XP055474403; DOI:          10.14432.;            Segales, et al., PCV-2 genotype definition and          nomenclature, The Veterinary Record, Letters, Jun. 28,          2008, vol. 162, No. 26, pp. 867-868.;            Vasconcelos, et al., Swine and poultry pathogens: the          complete genome sequences of two strains of          &lt;xhtml:i &gt;Mycoplasma          hyopneumoniae&lt;/xhtml:i&gt;and a strain of          &lt;xhtml:i &gt;Mycoplasma          synoviae&lt;/xhtml:i&gt;, Journal of          Bacteriology, Aug. 2005, vol. 187, No. 16, pp.          5568-5577.;            Xiao, et al., Global molecular genetic analysis of          porcine circovirus type 2 (PCV2) sequences confirms the          presence of four main PCV2 genotypes and reveals a rapid          increase of PCV2d, Journal of General Virology, Feb. 23,          2015; vol. 96, Part 7, pp. 1830-1841.	184611-0-0-0 K U; 184616-0-0-0 K U; 483-0-0-0 			RA00H1 K U; RA00H3 K U; R00429 		WO2019191257-A1;  CN112189019-A;  EP3774884-A1;  US2021128715-A1;  JP2021519084-W;  US11576964-B2;  JP7329529-B2;  EP3774884-B1;  EP3774884-C0	Generating recombinant influenza hemagglutinin            polypeptide including consensus amino acids involves            selecting more than one influenza HA polypeptide            sequence and aligning sequences, and calculating            pairwise similarity/dissimilarity matrices	STRUGNELL T;  OLOO E;  OOMEN R;  VOGEL T;  KLEANTHOUS H	SANOFI PASTEUR INC (SNFI-C);  AVENTIS PASTEUR INC (AVET-C);  SANOFI PASTEUR INC (SNFI-C);  SANOFI PASTEUR INC (SNFI-C);  SANOFI PASTEUR INC (SNFI-C);  SANOFI PASTEUR INC (SNFI-C)	201983278T	   NOVELTY - Generating a recombinant influenza                hemagglutinin (HA) polypeptide including consensus                amino acids involves selecting more than one                influenza HA polypeptide sequence and aligning the                sequences, calculating pairwise                similarity/dissimilarity matrices, identifying and                creating clusters of similar sequences from the                pairwise similarity/dissimilarity matrices, within                each cluster, determining whether there is a                consensus amino acid for each position in the                sequence alignment using a pairwise alignment,                where if the frequency of the amino acid at a given                position is 50% or greater, that amino acid is                designated a consensus amino acid, and if the                frequency of the amino acid at a given position is                less than 50%, that amino acid is designated as a                variable amino acid.    USE - Method for generating a recombinant influenza                hemagglutinin (HA) polypeptide for immunizing a                subject against influenza virus (claimed).    DETAILED DESCRIPTION - Generating a recombinant influenza                hemagglutinin (HA) polypeptide including consensus                amino acids involves selecting more than one                influenza HA polypeptide sequence and aligning the                sequences, calculating pairwise                similarity/dissimilarity matrices, identifying and                creating clusters of similar sequences from the                pairwise similarity/dissimilarity matrices, within                each cluster, determining whether there is a                consensus amino acid for each position in the                sequence alignment using a pairwise alignment,                where if the frequency of the amino acid at a given                position is 50% or greater, that amino acid is                designated a consensus amino acid, and if the                frequency of the amino acid at a given position is                less than 50%, that amino acid is designated as a                variable amino acid. The first sequence comprising                consensus amino acids and variable amino acids is                generated for each cluster, if a multiple of                clusters is analyzed, comparing the first sequence                generated of a cluster with a first sequence                generated in another cluster or multiple clusters                by aligning the sequences generated for each                cluster, determining whether there is a consensus                amino acid for each position in the sequence                alignment using a pairwise alignment method, where                if the frequency of the amino acid at a given                position is 50% or greater, that amino acid is                designated a consensus amino acid, and if the                frequency of the amino acid at a given position is                less than 50%, that amino acid is designated as a                variable amino acid, and generating a second                sequence comprising consensus amino acids and                variable amino acids, within the first sequence                generated or the second sequence generated,                determining a consensus amino acid for each                variable amino acid position, by generating a set                of test sequences based on the first or second                sequence, where test amino acids are placed at the                variable amino acid positions, performing molecular                modeling for each of the test sequences;                determining a consensus amino acid for each                variable amino acid position by selecting amino                acids that result in a polypeptide having a                negative total energy value, and generating the                recombinant influenza HA polypeptide comprising the                consensus amino acids. INDEPENDENT CLAIMS are                included for the following:    (1) a recombinant influenza HA polypeptide,                which is generated using the method;    (2) a recombinant trimeric HA protein, which                comprises one or more of the recombinant HA                polypeptides;    (3) an isolated nucleic acid, which is                encoding the recombinant HA polypeptide or the                recombinant trimeric HA protein;    (4) a vector, which comprises the nucleic                acid;    (5) an isolated cell, which comprises the                vector;    (6) a fusion protein, which comprises the                recombinant HA polypeptide or the recombinant                trimeric HA protein;    (7) an influenza virus-like particle (VLP),                which comprises the recombinant HA polypeptide or                the recombinant trimeric HA protein;    (8) a pharmaceutical composition, which                comprises the recombinant HA polypeptide, the                recombinant trimeric HA protein, the fusion                protein, or the influenza VLP, and a                pharmaceutically acceptable carrier, excipient, or                adjuvant;    (9) a method for immunizing a subject against                influenza virus, which involves administering an                effective amount of the recombinant HA polypeptide,                the recombinant trimeric HA protein, the fusion                protein, the influenza VLP, or the pharmaceutical                composition to the subject; and    (10) a method for inducing an immune response                to influenza virus in a subject, which involves                administering an effective amount of the                recombinant HA polypeptide, the recombinant                trimeric HA protein, the fusion protein, or the                influenza VLP, or the pharmaceutical composition to                the subject. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  T01 (Digital Computers)	B04-C01;  B04-E02H;  B04-E08;  B04-E99;  B04-F0200E;  B04-H0100E;  B04-N03K0E;  B04-N0600E;  B04-N08;  B14-A02B2;  B14-G01;  D05-H12C;  D05-H12E;  D05-H14;  D05-H17A6;  D05-H99;  T01-J04C;  T01-J05B3;  T01-J06A	A61K-039/145;  C07K-014/005;  C07K-016/10;  A61P-031/16;  C07K-014/11;  A61K-039/39;  C07K-019/00;  C12N-015/44;  C12N-015/63;  C12N-005/10;  C12N-007/01;  C12P-021/02;  A61K-038/00;  A61K-039/00;  C12N-007/00	WO2019191257-A1   03 Oct 2019   C07K-016/10   201981Pages: 87   English;  CN112189019-A   05 Jan 2021   C07K-016/10   202106   Chinese;  EP3774884-A1   17 Feb 2021   C07K-016/10   202116   English;  US2021128715-A1   06 May 2021   A61K-039/145   202138   English;  JP2021519084-W   10 Aug 2021   C12N-015/44   202165Pages: 56   Japanese;  US11576964-B2   14 Feb 2023   A61K-039/145   202314   English;  JP7329529-B2   18 Aug 2023   C12P-021/02   202369   Japanese;  EP3774884-B1   06 Dec 2023   C07K-016/10   202399   English;  EP3774884-C0   06 Dec 2023   C07K-016/10   202415   English	WO2019191257-A1    WOUS024323    27 Mar 2019;   CN112189019-A    CN80033891    27 Mar 2019;   EP3774884-A1    EP719672    27 Mar 2019;   US2021128715-A1    US17041784    25 Sep 2020;   JP2021519084-W    JP551864    27 Mar 2019;   US11576964-B2    US17041784    25 Sep 2020;   JP7329529-B2    JP551864    27 Mar 2019;   EP3774884-B1    EP719672    27 Mar 2019;   EP3774884-C0    EP719672    27 Mar 2019	CN112189019-A PCT application Application WOUS024323;   CN112189019-A Based on Patent WO2019191257;   EP3774884-A1 PCT application Application WOUS024323;   EP3774884-A1 Based on Patent WO2019191257;   US2021128715-A1 PCT application Application WOUS024323;   US2021128715-A1 Provisional Application US649004P;   JP2021519084-W PCT application Application WOUS024323;   JP2021519084-W Based on Patent WO2019191257;   US11576964-B2 Provisional Application US649004P;   US11576964-B2 PCT application Application WOUS024323;   US11576964-B2 Previous Publ. Patent US2021128715;   US11576964-B2 Based on Patent WO2019191257;   JP7329529-B2 PCT application Application WOUS024323;   JP7329529-B2 Based on Patent WO2019191257;   JP7329529-B2 Previous Publ. Patent JP2021519084;   EP3774884-B1 PCT application Application WOUS024323;   EP3774884-B1 Based on Patent WO2019191257;   EP3774884-C0 PCT application Application WOUS024323;   EP3774884-C0 Based on Patent WO2019191257	US649004P    28 Mar 2018;  US17041784    25 Sep 2020;  CN80033891    19 Nov 2020	WO2019191257-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP3774884-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN          EP3774884-B1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  EP3774884-C0:      (Regional): AT;  BE;  BG;  DE;  DK;  EE;  FI;  FR;  IT;  LT;  LU;  LV;  MT;  NL;  PT;  SE;  SI  		;  CN112189019-A -- CN106995488-A   UNIV PITTSBURGH COMMONWEALTH SYSTEM HIGH (UPIT)   CREVAR C J,  GILES B M,  ROSS T M;  CN107074912-A   CRUCELL HOLLAND BV (CRUL)   IMPAGLIAZZO A,  MEIJBERG J W,  RADOSEVIC K,  WAGNER M,  DING Z;  CN107375919-A   ACAD SINICA (SNIC)   WONG C,  MA C,  WANG C,  CHEN J;  EP2831094-A1   UNIV PITTSBURGH COMMONWEALTH SYSTEM HIGH (UPIT)   CARTER D M,  CREVAR C J,  ROSS T M;  WO2012036993-A1   UNIV PITTSBURGH COMMONWEALTH SYSTEM HIGH (UPIT)   GILES B M,  ROSS T M;  WO2016196846-A2   SANOFI PASTEUR INC (SNFI)   STRUGNELL T,  OLOO E,  OOMEN R;  US11576964-B2 -- EP2831094-B1   UNIV PITTSBURGH COMMONWEALTH SYSTEM HIGH (UPIT)   CARTER D M,  CREVAR C J,  ROSS T M;  WO2012036993-A1   UNIV PITTSBURGH COMMONWEALTH SYSTEM HIGH (UPIT)   GILES B M,  ROSS T M;  WO2013148164-A1   UNIV PITTSBURGH COMMONWEALTH SYSTEM HIGH (UPIT)   CARTER D M,  CREVAR C J,  ROSS T M;  WO2010036970-A2   FRAUNHOFER USA INC (FRAU)   METT V,  MUSIYCHUK K,  YUSIBOV V;  WO2016196846-A2   SANOFI PASTEUR INC (SNFI)   STRUGNELL T,  OLOO E,  OOMEN R	CN112189019-A  : " ", , vol. 45,          no. 3, pages 66 - 70,relevantClaims[1-34];  ;;;: "", , vol. 23,          no. 2, pages 164 - 168,relevantClaims[1-34];  GHEDIN, E.ET AL.:          "hemagglutinin [Influenza A virus          (A/Memphis/2/1996(H1N1))]", GENBANK: ABM22257.1, pages          1,relevantClaims[89];  COREY J CREVAR ET          AL.: "Cocktail of H5N1 COBRA HA vaccines elicit          protective antibodies against H5N1 viruses from multiple          clades", HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol.          11, no. 3, pages 572, XP055384933, DOI:          10.1080/21645515.2015.1012013,relevantClaims[1-34];  BRENDAN M. GILES ET          AL.: "A computationally optimized broadly reactive          antigen (COBRA) based H5N1 VLP vaccine elicits broadly          reactive antibodies in mice and ferrets", VACCINE, vol.          29, no. 16, pages 3043, XP055267595, DOI:          10.1016/j.vaccine.2011.01.100,relevantClaims[1-34]US11576964-B2            Carter et al. (Journal of Virology, 2016, p. 4720-4734)          in IDS on Mar. 26, 2021.;            Giles et al. (Vaccine, 2011, p. 3042-3054) in IDS on Mar.          26, 2021.;            Carter et al., Design and Characterization of a          Computationally Optimized Broadly Reactive Hemagglutinin          Vaccine for H1N1 Influenza Viruses, Journal of Virology,          90(9), pp. 4720-4734 (Feb. 24, 2016).;            Giles et al., A computationally optimized broadly          reactive antigen (COBRA) based H5N1 VLP vaccine elicits          broadly Yeactive antibodies in mice and ferrets, Vaccine,          29(16), pp. 3043-3054 (Apr. 1, 2011).;            Notification of Transmittal of the International Search          Report and the Written Opinion of the International          Searching Authority, or the Declaration, issued in          International Application No. PCT/US2019/024323, dated          Jul. 31, 2019 (22 pages).;            Pessia et al., K-Pax2: Bayesian identification of          cluster-defining amino acid positions in large sequence          datasets, Microbial Genomics, 1(1) (Jul. 15, 2015) (1          page).	1562508-1-0-0 K M P Q; 1562508-1-0-0 CL PRD RCT USE			RAS6IN K M P Q		WO2019081750-A1;  CN111526886-A;  US2020268873-A1;  IN202017018291-A;  EP3700561-A1;  US11389525-B2	Nucleotide sequence used in nucleotide vaccine and            kit for preventing influenza infection, comprises            influenza genes encoding haemagglutinin and one or more            influenza genes encoding neuraminidase and influenza            genes are connected by linkers	POLACEK C;  FOMSGAARD A	STATENS SERUM INST (SSIN-C);  STATENS SERUM INST (SSIN-C);  STATENS SERUM INST (SSIN-C);  STATENS SERUM INST (SSIN-C);  STATENS SERUM INST (SSIN-C)	201937540S	   NOVELTY - Nucleotide sequence comprises one or more                influenza genes encoding haemagglutinin (HA) and                one or more influenza genes encoding neuraminidase                (NA), where the influenza genes are connected by                linkers each comprising one cleavage site.    USE - Nucleotide sequence used in nucleotide vaccine                and kit for preventing influenza infection                (claimed).    ADVANTAGE - The nucleotide sequence is more efficient                and/or less expensive for providing nucleotide                vaccines comprising multiple antigen-encoding                nucleic acids.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) nucleotide vaccine comprises a nucleotide                sequence;    (2) kit comprises effective amount of a                nucleotide sequence or effective amount of a                nucleotide vaccine and optionally, instructions for                use; and    (3) method for producing a nucleotide vaccine                involves multiple antigen- encoding nucleic acids,                involves providing a nucleotide sequence of at                least two genes encoding antigenic peptides or                proteins, where the two genes are connected by                linkers comprising at least one cleavage site, and                mixing the nucleotide sequence with a                pharmaceutical acceptable diluent, excipient and/or                adjuvant, for providing a nucleotide vaccine. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03B;  B04-E02;  B04-E03;  B04-E99;  B14-S11A;  C04-B03B;  C04-E02;  C04-E03;  C04-E99;  C14-S11A;  D05-H07;  D05-H99	A61K-039/12;  A61P-031/16;  A61K-039/145;  A61K-039/00	WO2019081750-A1   02 May 2019   A61K-039/12   201935Pages: 78   English;  CN111526886-A   11 Aug 2020   A61K-039/12   202067   Chinese;  US2020268873-A1   27 Aug 2020   A61K-039/145   202070   English;  IN202017018291-A   04 Sep 2020   A61K-039/12   202076   English;  EP3700561-A1   02 Sep 2020   A61K-039/12   202079   English;  US11389525-B2   19 Jul 2022   A61K-039/145   202258   English	WO2019081750-A1    WOEP079481    26 Oct 2018;   CN111526886-A    CN80080348    26 Oct 2018;   US2020268873-A1    US16758932    24 Apr 2020;   IN202017018291-A    IN17018291    29 Apr 2020;   EP3700561-A1    EP800527    26 Oct 2018;   US11389525-B2    US16758932    24 Apr 2020	CN111526886-A PCT application Application WOEP079481;   CN111526886-A Based on Patent WO2019081750;   US2020268873-A1 PCT application Application WOEP079481;   US2020268873-A1 Provisional Application US578406P;   IN202017018291-A PCT application Application WOEP079481;   IN202017018291-A Based on Patent WO2019081750;   EP3700561-A1 PCT application Application WOEP079481;   EP3700561-A1 Based on Patent WO2019081750;   US11389525-B2 PCT application Application WOEP079481;   US11389525-B2 Provisional Application US578406P;   US11389525-B2 Based on Patent WO2019081750;   US11389525-B2 Previous Publ. Patent US2020268873	DK000607    27 Oct 2017;  US578406P    28 Oct 2017;  CN80080348    12 Jun 2020	WO2019081750-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP3700561-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    		WO2019081750-A1 -- WO2016174408-A1   UCL BUSINESS PLC (UNLO)   PULE M,  CORDOBA S;  WO2018013704-A1   UNIV DUKE (UDUK)   HEATON N S,  HARDING A T,  HEATON B E;  WO2006053871-A2   CRUCELL HOLLAND BV (CRUL);  AERAS GLOBAL TB VACCINE FOUND (AERA-Non-standard)   HAVENGA M J E,  VOGELS R,  SADOFF J,  HONE D,  SKEIKY Y A W,  RADOSEVIC K;  WO2010060430-A2   STATENS SERUM INST (SSIN)   BRAGSTAD K,  FOMSGAARD A;  WO2016041562-A1   STATENS SERUM INST (SSIN)   FOMSGAARD A;  WO2008145129-A2   STATENS SERUM INST (SSIN)   FORMSGAARD A;  CN111526886-A -- CN1632124-A   HARBIN VETERINARY RES INST CAAS (CAGS)   CHEN H,  JIANG Y,  BU Z;  CN101624580-A   UNIV HUAZHONG AGRIC (UHZA)   CHEN H,  JIN M,  LI X,  QIAN P;  CN101877965-A   UNIV PENNSYLVANIA (UPEN);  VGX PHARM INC (IVIO)   DRAGHIA-AKLI R,  WEINER D B,  YAN J,  LADDY D;  CN102719479-A   UNIV JILIN (UYJI)   CONG Y,  DING Z,  GUO Y,  HAN M,  FAN J,  HUANG Z,  LIU H,  LI X,  YANG J,  ZHU L;  CN103421843-A   HARBIN VETERINARY RES INST CAAS (CAGS)   LI Y,  JIANG Y,  LIU J,  DENG G,  CHEN H,  SHI J,  WANG J,  CHEN P;  EP2358386-A2   STATENS SERUM INST (SSIN)   BRAGSTAD K,  FOMSGAARD A;  US20100160421-A1   ;  US20130280296-A1   ;  US11389525-B2 -- US20170246295-A1   ;  WO2016174408-A1   UCL BUSINESS PLC (UNLO)   PULE M,  CORDOBA S;  WO2018013704-A1   UNIV DUKE (UDUK)   HEATON N S,  HARDING A T,  HEATON B E;  WO2006053871-A2   CRUCELL HOLLAND BV (CRUL);  AERAS GLOBAL TB VACCINE FOUND (AERA-Non-standard)   HAVENGA M J E,  VOGELS R,  SADOFF J,  HONE D,  SKEIKY Y A W,  RADOSEVIC K;  WO2010060430-A2   STATENS SERUM INST (SSIN)   BRAGSTAD K,  FOMSGAARD A	WO2019081750-A1  ALFRED T. HARDING          ET AL: "Rationally Designed Influenza Virus Vaccines That          Are Antigenically Stable during Growth in Eggs", MBIO,          vol. 8, no. 3, 5 July 2017 (2017-07-05), US, pages e00669          - 17, XP055452815, ISSN: 2150-7511, DOI:          10.1128/mBio.00669-17,relevantClaims[1-3,6-9,19-22,25,33-36,38,39,42-44|4,5,10-18,23,24,26-32,37,40,41],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;&lt;figure&gt;1A,1F&lt;/figure&gt;|&lt;pp&gt;12&lt;/pp&gt;&lt;para&gt;l&lt;/para&gt;&lt;ppl&gt;13&lt;/ppl&gt;&lt;paral&gt;1&lt;/paral&gt;|&lt;pp&gt;4&lt;/pp&gt;&lt;para&gt;2&lt;/para&gt;|&lt;pp&gt;4&lt;/pp&gt;&lt;para&gt;l&lt;/para&gt;&lt;ppl&gt;7&lt;/ppl&gt;&lt;paral&gt;1&lt;/paral&gt;];  YUNG-YI C. MOSLEY          ET AL: "Eliciting specific humoral immunity from a          plasmid DNA encoding infectious bursal disease virus          polyprotein gene fused with avian influenza virus          hemagglutinin gene", JOURNAL OF VIROLOGICAL METHODS, vol.          211, 1 January 2015 (2015-01-01), NL, pages 36 - 42,          XP055532118, ISSN: 0166-0934, DOI:          10.1016/j.jviromet.2014.10.011,relevantClaims[43,44|1-42],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;&lt;figure&gt;1A&lt;/figure&gt;|&lt;pp&gt;40&lt;/pp&gt;&lt;column&gt;r&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;|&lt;pp&gt;37&lt;/pp&gt;&lt;column&gt;r&lt;/column&gt;&lt;para&gt;4&lt;/para&gt;];  DE FELIPE PABLO:          "Skipping the co-expression problem: the new 2A "CHYSEL"          technology", GENETIC VACCINES AND THERAPY, BIOMED          CENTRAL, LONDON, GB, vol. 2, no. 1, 13 September 2004          (2004-09-13), pages 13, XP021009743, ISSN: 1479-0556,          DOI:          10.1186/1479-0556-2-13,relevantClaims[19,20,23,24,27],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  JIAN'ER LIN ET AL:          "Impact of Signal Peptides on Furin-2A Mediated          Monoclonal Antibody Secretion in CHO Cells",          BIOTECHNOLOGY JOURNAL, vol. 12, no. 9, 1 September 2017          (2017-09-01), DE, pages 1700268, XP055533345, ISSN:          1860-6768, DOI:          10.1002/biot.201700268,relevantClaims[19-27],relevantPassages[&lt;pp&gt;1&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;1&lt;/para&gt;&lt;ppl&gt;2&lt;/ppl&gt;&lt;coll&gt;l&lt;/coll&gt;&lt;paral&gt;1&lt;/paral&gt;];  X-L GUO ET AL:          "Cleavage mechanism of the H5N1 hemagglutinin by trypsin          and furin", AMINO ACIDS ; THE FORUM FOR AMINO ACID AND          PROTEIN RESEARCH, SPRINGER-VERLAG, VI, vol. 35, no. 2, 31          January 2008 (2008-01-31), pages 375 - 382, XP019634514,          ISSN:          1438-2199,relevantClaims[1-44],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];            WILLIAMS JA, VACCINES, vol. 1, 2013, pages 225 -          249;            WILLIAMS J.: "Vector design for improved DNA vaccine          efficacy, safety and production", VACCINES, vol. 1, 2013,          pages 225 - 249, XP002713195, DOI:          doi:10.3390/vaccines1030225CN111526886-A  FREDDERIC KENDIRGI:          "Novel linear DNA vaccines induce protective immune          responses against lethal infection with influenza virus          type          A/H5N1",relevantClaims[1-27],relevantPassages[];  :          "2A",relevantClaims[1-27],relevantPassages[10426]US11389525-B2            Harding, Alfred, et al., Rationally Designed Influenza          Virus Vaccines That Are Antigenically Stable during          Growth in Eggs, mBio, E-pub Jun. 6, 2017, e00669-17, vol.          8, issue 3.;            Guo, X.-L., et al., Cleavage mechanism of the H5N1          hemagglutinin by trypsin and furin, Amino Acids, Jan. 31,          2008, 35: 375-382.;            Mosley YY, et al., Eliciting specific humoral immunity          from a plasmid DNA encoding infectious bursal disease          virus polyprotein gene fused with avian influenza virus          hemagglutinin gene, J. Virol Methods, E-pub Oct. 28,          2014, 211:36-42.;  De          Felipe, Pablo, Skipping the co-expression problem: the          new 2A CHYSEL technology, Genetic Vaccines and Therapy,          Sep. 13, 2004, 2:13 (pp. 1-6).;            Lin, Jian'er, et al.. Impact of Signal Peptides on          Furin-2A Mediated Monoclonal Antibody Secretion in CHO          Cells, Biotechnology Journal, First published Jul. 20,          2017, vol. 12, issue 9, p. 1700268.;            Ramanathan, M.P., et al., Development of a novel DNA          SynCon tetravalent dengue vaccine that elicits immune          responses against four serotypes, Vaccine, E-pub Jul. 4,          2009, 27(46):6444-53.	93605-0-0-0 K U; 105730-0-0-0 K U			RA00NS K U; RA012P K U		CN110302192-A	New antimicrobial agent containing lauroyl            arginine ethyl, prepared by heating lauroyl arginine            ethyl compound, adding organic acid salt solution,            mixing, reacting and cooling	YI Z;  GAO S;  SHAO T;  QIU W;  LIU M	UNIV EAST CHINA NORMAL (UYEN-C)	201995010E	   NOVELTY - Antimicrobial agent containing lauroyl                arginine ethyl (LAE) (I) is new.    USE - Antimicrobial agent containing lauroyl                arginine ethyl (LAE).    ADVANTAGE - The agent inhibits or kills virus and prevents                or reduces infection ability of the virus to                cells.    DETAILED DESCRIPTION - Antimicrobial agent containing lauroyl                arginine ethyl (LAE) of formula (I) is new. The                microorganism is envelope virus. The mass                percentage concentration of LAE in antimicrobial                agent is 0.0025-1%.    X=halogen or HSO4;    R1=straight chain saturated fatty acid with                8-14C or straight chain oxy acid with 8-14C;    R2=straight chain fatty acid group containing                1-18C, branched fatty acid containing 1-18C,                aromatic group containing 1-18C or straight chain                alkyl containing 1-4C;    R3=ammonia; and    n=0-4.    An INDEPENDENT CLAIM is included for                preparation of the (I). 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.)	B07-D09;  B10-A17;  B14-A01;  B14-A02;  B14-A04	A61K-031/194;  A61K-031/221;  A61K-031/465;  A61P-031/04;  A61P-031/10;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-031/18;  A61P-031/20;  A61P-031/22	CN110302192-A   08 Oct 2019   A61K-031/221   201988Pages: 19   Chinese	CN110302192-A    CN10548789    24 Jun 2019		CN10649068    22 Jun 2018			CN110302192-A -- CN101227884-A   LAB MIRET SA (MIRE-Non-standard)   MIRET CARCELLER J,  FIGUERAS ROCA S,  SEGRET PONS R;  CN101500552-A   LAB MIRET SA (MIRE-Non-standard)   ROCABAYERA BONVILA X,  FIGUERAS ROCA S,  SEGRET PONS R;  CN106565546-A   WUHAN JASON BIOTECH CO LTD (WUHA-Non-standard)   TANG Q,  WANG C,  LI J,  ZHANG J		497495-0-2-0 N P; 5781-0-0-0 K U V; 11-0-0-0 K U V; 842-0-0-0 K U V; 114043-0-0-0 K U V; 1-0-0-0 K U V; 107329-0-0-0 K U V; 407-0-0-0 K U V; 188963-0-0-0 K U V; 407-0-1-0 K U V; 407-0-2-0 K U V; 8440-0-0-0 K U V; 213126-0-1-0 K U V; 7447-0-0-0 K U V; 168-0-0-0 K U V; 311-0-0-0 K U V; 6354-0-0-0 K U V; 6354-0-1-0 K U V; 154284-0-2-0 K U V; 7658-0-0-0 K U V; 849-0-0-0 K U V; 849-0-6-0 K U V; 849-0-2-0 K U V; 849-0-3-0 K U V; 2623-0-0-0 K U V; 4073-0-0-0 K U V; 63-0-0-0 K U V; 107324-0-0-0 K U V; 95-0-0-0 K U V; 90034-0-0-0 K U V; 497495-0-2-0 CL NEW PRD; 114043-0-0-0 CL RGT USE; 107329-0-0-0 CL RGT USE; 188963-0-0-0 CL RGT USE; 213126-0-1-0 CL RGT USE; 6354-0-1-0 CL RGT USE; 154284-0-2-0 CL RGT USE; 107324-0-0-0 CL RGT USE; 90034-0-0-0 CL RGT USE	217174201 N P		RAANWI N P; R00291 K U V; R00246 K U V; R07340 K U V; R01355 K U V; R00247 K U V; RA0X4P K U V; R00445 K U V; R15584 K U V; R10382 K U V; R13202 K U V; R00832 K U V; RA09NJ K U V; R00009 K U V; R00258 K U V; R01333 K U V; RBNWXX K U V; R00903 K U V; R09194 K U V; R10128 K U V; R00902 K U V; R00419 K U V; R16811 K U V; R04004 K U V; RA00DB K U V; R06309 K U V; R12953 K U V; R00540 K U V; R01656 K U V; R01711 K U V; R01287 K U V; R01152 K U V; R13387 K U V	0291-U; 0246-U; 1355-U; 0247-U; 1081-U; 0445-U; 0832-U; 0009-U; 0258-U; 1333-U; 0903-U; 0902-U; 0419-U; 0540-U; 1656-U; 1711-U; 1287-U; 1152-U	CN109609692-A;  CN109609692-B	New nucleic acid reagent useful for preparing a            kit for detecting a respiratory infection            pathogen	LIN X;  WANG L;  WANG X;  ZHANG Z	BEIJING ZHUOCHENG HUISHENG BIOLOGICAL (BEIJ-Non-standard)	201936532R	   NOVELTY - Nucleic acid reagent comprising nucleic acid                reagent includes the primers of (SEQ ID NO: 1),                (SEQ ID NO: 2), (SEQ ID NO: 3), (SEQ ID NO: 4),                (SEQ ID NO: 5), (SEQ ID NO: 6), (SEQ ID NO: 7),                (SEQ ID NO: 8), (SEQ ID NO: 9), (SEQ ID NO: 10),                (SEQ ID NO: 11), (SEQ ID NO: 12), (SEQ ID NO: 13),                (SEQ ID NO: 14), (SEQ ID NO: 15), (SEQ ID NO: 16),                (SEQ ID NO: 17), (SEQ ID NO: 18), (SEQ ID NO: 19),                (SEQ ID NO: 20), (SEQ ID NO: 21), (SEQ ID NO: 22),                (SEQ ID NO: 23), (SEQ ID NO: 24) and probes of (SEQ                ID NO: 27), (SEQ ID NO: 28), (SEQ ID NO: 29), (SEQ                ID NO: 30), (SEQ ID NO: 31), (SEQ ID NO: 32), (SEQ                ID NO: 33), (SEQ ID NO: 34), (SEQ ID NO: 35), (SEQ                ID NO: 36), (SEQ ID NO: 37), (SEQ ID NO: 38), (SEQ                ID NO: 39), (SEQ ID NO: 40), (SEQ ID NO: 41), (SEQ                ID NO: 42), (SEQ ID NO: 43), (SEQ ID NO: 44), (SEQ                ID NO: 45) and storing separately or independently                mixing with each other, is new.    USE - The nucleic acid reagent/kit/system is useful                for preparing a kit for detecting a respiratory                infection pathogen, preferably influenza A virus,                influenza B virus, respiratory syncytial virus type                A, respiratory syncytial virus type B, adenovirus,                human parainfluenza type I virus, human                parainfluenza type II virus, human parainfluenza                Type III virus, human parainfluenza type IV virus,                human rhinovirus, human metapneumovirus, chlamydia                pneumoniae, mycoplasma pneumoniae, legionella                pneumophila, coronavirus NL63, coronavirus HKUI,                coronavirus 229E, coronavirus OC43 and bocavirus                (all claimed).    ADVANTAGE - The nucleic acid reagent/kit/system is capable                of achieving rapid, comprehensive, sensitive,                specific, and automated detection results.    DETAILED DESCRIPTION - Nucleic acid reagent comprising nucleic acid                reagent includes the primers fully defined                5'-tgagycttytaaccgaggtcga-3' nucleotides (SEQ ID                NO: 1), fully defined 5'-gacaaancgtctacgctgc-3'                nucleotides (SEQ ID NO: 2), fully defined                5'-tgaaggacattcaaagcc-3' nucleotides (SEQ ID NO:                3), fully defined 5'-ctggtgataatcggtgc-3'                nucleotides (SEQ ID NO: 4), fully defined                5'-aggatgcttcggagtac-3' nucleotides (SEQ ID NO: 5),                fully defined 5'-gggtttctaaacttgttccc-3'                nucleotides (SEQ ID NO: 6), fully defined                5'-gtgtaccgtagacacttagc-3' nucleotides (SEQ ID NO:                7), fully defined 5'-cagcacccaccctctaggctgt-3'                nucleotides (SEQ ID NO: 8), fully defined                5'-ttaactatttgcatcgtctt-3' nucleotides (SEQ ID NO:                9), fully defined 5'-ggctagtatcaaagtgataa-3'                nucleotides (SEQ ID NO: 10), fully defined                5'-ggataaagattgaaaatacactc-3' nucleotides (SEQ ID                NO: 11), fully defined 5'-caagttatcttaagagcatca-3'                nucleotides (SEQ ID NO: 12), fully defined                5'-gagtcctccggcccctgaa-3' nucleotides (SEQ ID NO:                13), fully defined 5'-gagtgtgtgccaacattctg-3'                nucleotides (SEQ ID NO: 14), fully defined                5'-atggcaataaccaccggggc-3 nucleotides (SEQ ID NO:                15), fully defined 5-ctgcccccgagggtggcttggaca-3                nucleotides (SEQ ID NO: 16), fully defined                5-gcgatagcatgtggtgtcccaacga-3' nucleotides (SEQ ID                NO: 17), fully defined 5'-tgatcaaatcattaattcgata-3'                nucleotides (SEQ ID NO: 18), fully defined                5'-tgaaaaaattattagaagagaa-3' nucleotides (SEQ ID                NO: 19), fully defined                5'-ctaacgacttttaagacgccgattt-3' nucleotides (SEQ ID                NO: 20), fully defined                5'-gcgtatgcgcagggggcaacgtgttg-3' nucleotides (SEQ                ID NO: 21), fully defined                5'-ctcaacaacagagagctctggaggcaa-3' nucleotides (SEQ                ID NO: 22), fully defined                5'-gcttcagtcarttcaacagaa-3' nucleotides (SEQ ID NO:                23), fully defined 5'-ctgcagatgtyggcatgt-3'                nucleotides (SEQ ID NO: 24) and probes fully                defined 5'-aggccccctcaaagccgagatcgcgcaga-3'                nucleotides (SEQ ID NO: 27), fully defined                5'-ccaattcgagcagctgaaactg-3' nucleotides (SEQ ID                NO: 28), fully defined 5'-acacctacttcagtatgg-3'                nucleotides (SEQ ID NO: 29), fully defined                5'-tgctgaaagcatggaagcagatgcctcc-3' nucleotides (SEQ                ID NO: 30), fully defined                5'-ataccagcttatagaactacaa-3' nucleotides (SEQ ID                NO: 31), fully defined 5'-atatcagcttatagttctacaa-3'                nucleotides (SEQ ID NO: 32), fully defined                5'-aagtcaacaccaagtgtgt-3' nucleotides (SEQ ID NO:                33), fully defined 5'-gcagttggaagcgggatctatca-3'                nucleotides (SEQ ID NO: 34), fully defined                5'-gatatggaggtcttgaacatcca-3' nucleotides (SEQ ID                NO: 35), fully defined 34 nucleotides (SEQ ID NO:                36), fully defined                5'-atccttattgattgcttatggtgacaatat-3' nucleotides                (SEQ ID NO: 37), fully defined                5'-tttccaacatcggcgtcggcctc-3' nucleotides (SEQ ID                NO: 38), fully defined 33 nucleotides (SEQ ID NO:                39), fully defined                5'-gcagtaaccctcgaagatgttcctgcagat-3' nucleotides                (SEQ ID NO: 40), fully defined                5'-taaggaaggtgctaaaactgttaata-3' nucleotides (SEQ                ID NO: 41), fully defined 33 nucleotides (SEQ ID                NO: 42), fully defined                5'-aatggtattttttctagagtaagaatact-3' nucleotides                (SEQ ID NO: 43), fully defined                5'-gtttgttgacaaaatcactgaattccaa-3' nucleotides (SEQ                ID NO: 44), fully defined 5'-tgcggcartcagacaatgc-3'                nucleotides (SEQ ID NO: 45) and storing separately                or independently mixing with each other, is new.                INDEPENDENT CLAIMS are also included for:    (1) kit for detecting respiratory infection                pathogens;    (2) system for detecting respiratory infection                pathogens; and    (3) detecting a pathogen of a respiratory                infection. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03B;  B04-E01A;  B04-E05;  B04-E99;  B04-F01;  B04-F11;  B04-L04A;  B04-L04B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B11-C11;  B12-K04F;  C04-B03B;  C04-E01A;  C04-E05;  C04-E99;  C04-F01;  C04-F11;  C04-L04A;  C04-L04B;  C11-C07B3;  C11-C08E3;  C11-C08F8;  C11-C11;  C12-K04F;  D05-H04;  D05-H05;  D05-H06;  D05-H18B;  D05-H99	C12M-001/34;  C12N-015/11;  C12Q-001/04;  C12Q-001/686;  C12Q-001/689;  C12Q-001/70	CN109609692-A   12 Apr 2019   C12Q-001/70   201953Pages: 36   Chinese;  CN109609692-B   13 Sep 2019   C12Q-001/70   201972   Chinese	CN109609692-A    CN11593412    25 Dec 2018;   CN109609692-B    CN11593412    25 Dec 2018	CN109609692-B Previous Publ. Patent CN109609692	CN11593412    25 Dec 2018			CN109609692-A -- CN102803512-A   BGI SHENZHEN CO LTD (BGIG);  INST MICROBIOLOGY & EPIDEMIOLOGY (JSYX);  BEIJING GBI BIOTECHNOLOGY CO LTD (BGIG)   CHEN W,  GUAN Y,  JIANG Y,  LIU L,  PIAO J,  YANG Y;  CN104561377-A   HUAMEI BIOLOGICAL ENG CO LTD (HUAM-Non-standard)   JIA X,  PENG Z,  ZHANG S,  WAN D;  CN105463129-A   SHENZHEN INT TRAVEL HEALTH CARE CENT (SHEN-Non-standard)   GUO Y,  LIU J,  SHI L,  XIN B,  XU Y,  YE Y,  YE J,  LEI X;  CN105734168-A   NANJING MOKOBIO BIOTECHNOLOGY CO LTD (NANJ-Non-standard)   GUO T,  JIN X,  LI B,  LIU W;  CN107058622-A   DEBIQI BIOLOGICAL TECHNOLOGY XIAMEN CO (DEBI-Non-standard)   TONG C,  QIU Y;  CN107090519-A   SUZHOU XIEYUN GENE TECHNOLOGY CO LTD (SUZH-Non-standard)   LIU Y,  WANG Y,  ZHANG X;  WO2012100370-A1   BGI SHENZHEN CO LTD (BGIG);  INST MICROBIOLOGY & EPIDEMIOLOGY (JSYX);  BEIJING GBI BIOTECHNOLOGY CO LTD (BGIG)   CHEN W,  GUAN Y,  JIANG Y,  LIU L,  PIAO J,  YANG Y		201562-0-0-0 D K M; 204644-0-0-0 D K M			RA0124 D K M; RA031J D K M		KR2019045050-A	Food composition useful for relieving and improving cold and cold symptoms including e.g. cough by inhibiting cold virus, comprises e.g. xylitol, vitamin C, Manuka honey, cnidii rhizoma, aurantii fructus immaturus and kalopanacis cortex	YU H J	YU H J (YUHJ-Individual);  YESKIN (YESK-Non-standard)	2019376736	   NOVELTY - Food composition comprises first composition comprising xylitol, vitamin C, Manuka honey, Boswellia, myrrh and propolis in powder, liquid or extract form, and second composition comprising cnidii rhizoma, aurantii fructus immaturus, kalopanacis cortex, coicis semen, maple syrup and bambusae caulis in liquamen in powder, liquid or extract form.    USE - The composition is useful for relieving and improving cold and cold symptoms (claimed) including runny nose, nasal congestion, neck pain, cough, and muscle pain by inhibiting cold virus e.g. rhinovirus, coronavirus and other flu viruses, and relieving and healing influenza, bird flu and swine flu. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)	B04-A08;  B04-A09;  B04-A10;  B04-A98;  B04-D01A;  B14-A02B2;  B14-A02B3;  B14-C01;  B14-K01B;  B14-K01E;  B14-N04;  B14-S12;  B14-S18;  D03-H01A;  D03-H01T2B;  D03-H01T2C	A23L-033/105;  A61K-031/047;  A61K-031/375;  A61K-035/644;  A61K-036/324;  A61K-036/328;  A61K-036/8994	KR2019045050-A   02 May 2019   A61K-036/8994   201938Pages: 10   	KR2019045050-A    KR107264    07 Sep 2018	KR2019045050-A Div ex Application KR137000	KR137000    22 Oct 2017;  KR107264    07 Sep 2018					114315-0-0-0 K M; 104823-0-0-0 K M			RA02A1 K M; RA0GRF K M		JP2019156807-A;  JP7064203-B2	New anti-human cluster of differentiation (CD)26 monoclonal antibody or its antigen-binding fragment, useful in composition for immunostaining human CD26 for e.g. diagnosing cancer cells	MORIMOTO I;  HATANO R;  YAMADA T;  ONUMA K	GH JUNTENDO (JUNT-Non-standard);  UNIV SAITAMA MEDICAL (SAIT-C);  UNIV JUNTENDO (UYJU-Non-standard);  UNIV SAITAMA MEDICAL (SAIT-C)	201981373T	   NOVELTY - An anti-human cluster of differentiation (CD)26 monoclonal antibody or its antigen-binding fragment binds to both human CD26 of cancer tissue treated for immunostaining and human CD26 of normal tissue treated for immunostaining.    USE - The anti-human CD26 monoclonal antibody or its antigen-binding fragment is useful in composition for immunostaining human CD26 (claimed) for diagnosing cancer cells and treating the human CD26 associated diseases such as cancer e.g. metastatic and infiltrative or non-infiltrative cancer, sarcoma, or mesothelioma, immune disease e.g. rheumatoid arthritis, multiple sclerosis, Basedow's disease, or graft versus host disease, viral disease e.g. coronavirus, metabolic disease e.g. diabetes, or inflammatory disease.    ADVANTAGE - The monoclonal antibody has high binding capacity. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-E99;  B04-G03;  B04-G21;  B04-G23;  B11-C07A1;  B12-K04G2A;  B14-A02;  B14-C03;  B14-C09B;  B14-G02C;  B14-G03;  B14-H01;  B14-N11;  B14-S01;  B14-S04;  B14-S13;  D05-H09;  D05-H11A;  D05-H99;  S03-E09F	C07K-016/28;  G01N-033/53;  B60K-017/28	JP2019156807-A   19 Sep 2019   C07K-016/28   201977Pages: 30   Japanese;  JP7064203-B2   10 May 2022   B60K-017/28   202242   Japanese	JP2019156807-A    JP049308    16 Mar 2018;   JP7064203-B2    JP049308    16 Mar 2018	JP7064203-B2 Previous Publ. Patent JP2019156807	JP049308    16 Mar 2018										CN109666766-A	New fluorescent RT-PCR primer set useful for            detecting SADS-CoV and preparing a reagent for            detecting SADS-CoV comprises e.g. upstream primer,            downstream primer and probe	LUO B;  LI R;  SU H;  DENG X;  HUANG Z;  ZHAO F;  LIAO X	TECH CENT INSPECTION & QUARANTINE ZHUHAI (TEIN-Non-standard)	201939951A	   NOVELTY - Fluorescent RT-PCR primer set comprises                upstream primer represented by the sequence (SEQ ID                NO: 1), downstream primer (SEQ ID NO: 2), and probe                represented by the sequence (SEQ ID NO: 3) is                new.    USE - The fluorescent RT-PCR primer is useful for                detecting swine acute diarrhea syndrome coronavirus                and preparing a reagent for detecting SADS-CoV (all                claimed).    ADVANTAGE - The method realizes purpose of rapidly                identifying SADS-CoV, has detection minimum                concentration of the order of 10 copies/ mu l, has                very stable detection results, high specificity,                high amplification efficiency and high                sensitivity.    DETAILED DESCRIPTION - The fluorescent RT-PCR primer set comprises                upstream primer comprises defined sequence of                5-'cagacaccacgtgaacaatacc-3' (SEQ ID NO: 1),                downstream primer comprises defined sequence o                5'-tccatagctcccaagtcaaat-3' (SEQ ID NO: 2), and                probe comprises defined sequence o                5'-tagctgtttcgcccattcacgttacg-3' (SEQ ID NO: 3). An                INDEPENDENT CLAIM is also included for detecting                swine acute diarrhea syndrome coronavirus                (SADS-CoV) comprising (i) synthesizing fluorescent                RT-PCR primer set for detecting SADS-CoV, (ii)                extracting total RNA of the sample to be testing,                using extracted total RNA as a template, performing                polymerase chain amplification reaction and                fluorescence detection using a fluorescent RT-PCR                primer set of SADS-CoV, and (iii) determining                results based on the PCR amplification reaction and                fluorescence value; and #use method of kit adding                RNA of the sample to be tested to reaction system,                performing PCR amplification and fluorescence                detection using one-step fluorescent RT-polymerase                chain reaction, where reaction system comprises                12.5 mu l 2x One Step RT-PCR buffer, 0.5 mu l                TaKaRa Ex Taq enzyme, 0.5 mu l PrimeScript RT                Enzyme Mix enzyme, 1 mu l of 10 mu mol/l SADS-CoV                upstream and downstream primers each, 1.0 mu l of                10 mu mol/l SADS-CoV probe, 5 mu l nucleic acid                template and making up to 25 mu l                diethylpyrocarbonate water, the reaction conditions                are: pre-denaturation at 42 degrees C for 5                minutes, denaturation at 95 degrees C for 10                seconds, carrying out cycle at 95 degrees C for 5                seconds, extending at 55 degrees C for 45 seconds,                performing 40 cycles, and collecting fluorescence                signal at 55 degrees C for 45 seconds. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01B;  B04-E05;  B04-E99;  B04-F11B;  B04-L04A;  B04-L04B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  B12-K04G2I;  C04-E01B;  C04-E05;  C04-E99;  C04-F11B;  C04-L04A;  C04-L04B;  C11-C07B3;  C11-C08E3;  C11-C08F8;  C12-K04F;  C12-K04G1B;  C12-K04G2I;  D05-A02B;  D05-H06A;  D05-H09;  D05-H12D1;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/686;  C12Q-001/70;  C12R-001/93	CN109666766-A   23 Apr 2019   C12Q-001/70   201944Pages: 10   Chinese	CN109666766-A    CN10089777    30 Jan 2019		CN10089777    30 Jan 2019			CN109666766-A -- CN103060474-A   JIANGSU AGRIC SCI INST (JSAS)   HE K,  LI B,  HU G,  NI Y,  LV L,  DU L,  WEN L,  ZHANG X,  YU Y,  ZHOU J,  WANG X,  GUO R,  ZHU H,  MAO A,  YU Z;  CN106755599-A   TECH CENT INSPECTION & QUARANTINE                  ZHUHAI (TEIN-Non-standard)   BAO Q,  LUO B,  LIAO X,  SHA C,  PENG Y,  ZHAO F,  SHAO J,  HUANG H;  CN107630109-A   UNIV SOUTH CHINA AGRIC (USCG)   JINGYUN M,  LING Z,  YUAN S;  CN108315490-A   XIANYANG VOCATIONAL & TECH COLLEGE (XIAN-Non-standard)   ZHU X,  WU X;  CN108384762-A   GUANDONG WENS FOOD GROUP CO LTD (GUAN-Non-standard)   TIAN X,  LI C,  PAN Y,  WANG D,  OUYANG H,  SONG Y;  CN108411040-A   UNIV ZHEJIANG (UYZH);  GUANGDONG LAB ANIMALS MONITORING INST (GUAN-Non-standard)   WANG H,  HUANG R,  CONG F,  ZENG F,  GUO P,  WANG Y;  US20070231801-A1   ;  WO2007095352-A2   MCLEAN HOSPITAL CORP (MCLE)   KIM K,  KIM C	CN109666766-A  LING ZHOU :          "Retrospective detection and phylogenetic analysis of          swine acute diarrhoea syndrome coronavirus in pigs in          southern China", TRANSBOUND EMERG          DIS,relevantClaims[1-35-6],relevantPassages[688268916942S1];  : "5",          ,relevantClaims[1-7],relevantPassages[61-64]	201562-0-0-0 D K M; 1525931-1-0-0 D K M; 1525931-1-0-0 CL USE			RA0124 D K M; RARECG D K M		US2019282694-A1;  US11123427-B2	New immunoprotective primary mesenchymal stems cells (IP-MSC) that episomally express immunoreactive polypeptides that specifically target a viral pathogen, used e.g. to treat or prevent infection caused by pathogen e.g. cytomegalovirus	GARRY R F;  BRANCO L M;  BUNNELL B A;  WILSON R B;  HOPKINS S E	TULANE EDUCATIONAL FUND (TULA-C);  AUTOIMMUNE TECHNOLOGIES LLC (AUTO-Non-standard);  AUTOIMMUNE TECHNOLOGIES INC (AUTO-Non-standard)	201980665P	   NOVELTY - Immunoprotective primary mesenchymal stems cells (IP-MSC) that episomally express immunoreactive polypeptides that specifically target a viral pathogen, where: the IP-MSC are adipose-derived mesenchymal stem cells transfected with at least one episomal vector encoding expressible immunoreactive polypeptides that specifically target the pathogen; the immunoreactive polypeptides comprise amino acid sequences from an antigen-binding region of a neutralizing antibody specific for the pathogen; the antigen-binding region amino acid sequences are arranged to specifically bind to and neutralize the pathogen; the viral pathogen is e.g. adenovirus and papillomavirus; the episomal vector includes an inducible apoptosis gene; the immunoreactive polypeptides comprise the complementarity determining regions of the antibody; and the episomal vectors are non-infective, non-integrative, circular episomal vectors, are new.    USE - The immunoprotective primary mesenchymal stems cells (IP-MSC) are useful for: treating or preventing an infection caused by the pathogen in a subject, where the pathogen is adenovirus, papillomavirus, hepadnavirus, parvovirus, pox virus, Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus, roseolovirus, varicella zoster virus, filovirus, paramyxovirus, orthomyxovirus, rhabdovirus, arenavirus, coronavirus, human enterovirus, hepatitis A virus, human rhinovirus, polio virus, retrovirus, rotavirus, flavivirus, hepacivirus or rubella virus, preferably CMV (all claimed), and the pathogen also includes bacterium or parasite; and for ameliorating deleterious effects of a toxin. Test details are described but no results given.    ADVANTAGE - The IP-MSC reduces undesirable long-term side effects.    DETAILED DESCRIPTION - Immunoprotective primary mesenchymal stems cells (IP-MSC) that episomally express immunoreactive polypeptides that specifically target a viral pathogen, where: the IP-MSC are adipose-derived mesenchymal stem cells transfected with at least one episomal vector encoding expressible immunoreactive polypeptides that specifically target the pathogen; the immunoreactive polypeptides comprise amino acid sequences from an antigen-binding region of a neutralizing antibody specific for the pathogen; the antigen-binding region amino acid sequences are arranged to specifically bind to and neutralize the pathogen; the viral pathogen is adenovirus, papillomavirus, hepadnavirus, parvovirus, pox virus, Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus, roseolovirus, varicella-zoster virus, filovirus, paramyxovirus, orthomyxovirus, rhabdovirus, arenavirus, coronavirus, human enterovirus, hepatitis A virus, human rhinovirus, polio virus, retrovirus, rotavirus, flavivirus, hepacivirus or rubella virus; the episomal vector includes an inducible apoptosis gene; the immunoreactive polypeptides comprise the complementarity determining regions of the antibody; and the episomal vectors are non-infective, non-integrative, circular episomal vectors, are new. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-E99;  B04-F02B0E;  B14-A01;  B14-A02;  B14-B02;  B14-M01;  B14-S21;  D05-H14B2;  D05-H99;  S03-E09;  S03-E14H	A61K-035/28;  A61K-039/42;  C07K-016/10;  C12N-005/0775;  G01N-033/68	US2019282694-A1   19 Sep 2019   A61K-039/42   201976Pages: 26   English;  US11123427-B2   21 Sep 2021   A61K-039/42   202177   English	US2019282694-A1    US426911    30 May 2019;   US11123427-B2    US426911    30 May 2019	US2019282694-A1 Cont of Application US802247;   US2019282694-A1 Cont of Application US826285;   US2019282694-A1 Cont of Patent US9101597;   US2019282694-A1 Cont of Patent US10357562;   US11123427-B2 Cont of Application US802247;   US11123427-B2 Cont of Application US826285;   US11123427-B2 Cont of Patent US9101597;   US11123427-B2 Cont of Patent US10357562;   US11123427-B2 Previous Publ. Patent US2019282694	US826285    14 Mar 2013;  US426911    30 May 2019			;  US11123427-B2 -- US9101597-B2   TULANE EDUCATIONAL FUND (TULA)   GARRY R F,  BRANCO L M,  BUNNELL B A,  WILSON R B,  HOPKINS S E;  US10357562-B2   AUTOIMMUNE TECHNOLOGIES LLC (AUTO-Non-standard);  TULANE EDUCATIONAL FUND (TULA)   GARRY R F,  BRANCO L M,  BUNNELL B A,  WILSON R B,  HOPKINS S E;  US20040039186-A1   ;  US20050053587-A1   ;  US20050058983-A1   ;  US20070160585-A1   ;  US20070196365-A1   ;  US20080014205-A1   ;  US20100226912-A1   ;  US20140178422-A1   ;  US7101704-B1   OSIRIS THERAPEUTICS INC (OSIR)   MOSCA J;  US8076102-B2   BIOFACTURA INC (BIOF-Non-standard)   BRANCO L,  SAMPEY D B;  WO2009129616-A1   TISSUE REGENERATION THERAPEUTICS INC (TISS-Non-standard)   DAVIES J E,  ENNIS J E,  TURNER J D	US11123427-B2  Abraham, E.J. et al., Human Pancreatic Islet-Derived Progenitor Cell Engraftment in Immunocompetent Mice, American Journal of Pathology, vol. 164 (3), 817-830 (2004).;  Balyasnikova et al., J. Tissue Eng. Regen Med 4, 247-258 (2010).;  Bao, C. et al., TNFR Gene-Modified Mesenchymal Stem Cells Attenuate Inflammation and Cardiac Dysfunction Following MI, Scandinavian Cardiovascular Journal 42, 56-62 (2008).;  Bhargava, A. et al., Dendritic Cell Engineering for Tumor Immunotherapy: From Biology to Clinical Translation, Immunotherapy 4 (7), 703-718 (2012).;  Cavenaugh, J.S. et al., Partially Randomized, Non-Blinded Trial of DNA and MVA Therapeutic Vaccines Based on Hepatitis B Virus Surface Protein for Chronic HBV Infection, PLoS One 6 (2), e14626 (2011).;  Choi, J.J. et al., Mesenchymal Stem Cells Overexpressing Interleukin-10 Attenuate Collagen-Induced Arthritis in Mice, Clinical and Experimental Immunology 153, 269-276 (2008).;  Compte, M. et al., Tumor Immunotherapy Using Gene-Modified Human Mesenchymal Stem Cells Loaded Into Synthetic Extracellular Matrix Scaffolds, Stem Cells, 27, 753-760 (2009).;  Frank, R.T., et al., Concise Review: Stem Cells as an Emerging Platform for Antibody Therapy of Cancer, Stem Cells, 28, 2084-2087 (2010).;  Gao, J. et al., The Dynamic In Vivo Distribution of Bone Marrow-Derived Mesenchymal Stem Cells After Infusion, Cells Tissues Organs 169, 12-20 (2001).;  Hagiwara et al., Human Gene Therapy 19, 807-819 (2008).;  Klinge, P.M. et al., Encapsulated Native and Glucagon-Like Peptide-1 Transfected Human Mesenchymal Stem Cells in a Transgenic Mouse Model of Alzheimer's Disease, Neuroscience Letters 497, 6-10 (2011).;  Kumar, S., et al. Therapeutic Potential of Genetically Modified Adult Stem Cells for Osteopenia, Gene Therapy 17, 105-116 (2010).;  Li, X. et al., In Vitro Effect of Adenovirus-Mediated Human Gamma Interferon Gene Transfer Into Human Mesenchymal Stem Cells for Chronic Myelogenous Leukemia, Hematological Oncology 24, 151-158 (2006).;  Loebinger M.R. et al., Stem Cells as Vectors for Antitumour Therapy, Thorax 65, 362-369 (2010).;  Logtenberg, T., Antibody Cocktails: Next Generation Biopharmaceuticals with Improved Potency, Trends in Biotechnology 25 (9), 390-394 (2007).;  Ohtaki H. et al., Stem/Progenitor Cells From Bone Marrow Decrease Neuronal Death in Global Ischemia by Modulation of Inflammatory/Immune Responses, PNAS 105 (38), 14638-14643 (2008).;  Palucka K. et al., Cancer Immunotherapy via Dendritic Cells, Nature Reviews/Cancer 12, 265-277 (2012).;  Jayne, N.L., et al., Early Intervention With Gene-Modified Mesenchymal Stem Cells Overexpressing Interleukin-4 Enhances Anti-Inflammatory Responses and Functional Recovery in Experimental Autoimmune Demyelination, Cell Adhesion & Migration 6 (3), 179-189 (2012).;  Porada, C.D. et al., Phenotypic Correction of Hemophilia A in Sheep by Postnatal Intraperitoneal Transplantation of FVIII-Expressing MSC, Exp. Hematol, 39 (12), 1124-1135 (2011).;  Prockop D.J., Repair of Tissues by Adult Stem/Progenitor Cells (MSCs): Controversies, Myths, and Changing Paradigms, Molecular Therapy 17 (6), 939-946 (2009).;  Ren, C. et al., Therapeutic Potential of Mesenchymal Stem Cells Producing IFN- in a Mouse Melanoma Lung Metastasis Model, Stem Cells, vol. 26 (9), 2332-2338 (2008).;  Sasaki, M. et al., BDNF-Hypersecreting Human Mesenchymal Stem Cells Promote Functional Recovery, Axonal Sprouting, and Protection of Corticospinal Neurons After Spinal Cord Injury, The Journal of Neuroscience 29 (47), 14932-14941 (2009).;  Song, Y.S. et al., Mesenchymal Stem Cells Overexpressing Hepatocyte Growth Factor (HGF) Inhibit Collagen Deposit and Improve Bladder Function in Rat Model of Bladder Outlet Obstruction, Cell Transplantation 21, 1641-1650 (2012).;  Stasi, A.D. et al., Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy, The New England Journal of Medicine 365, 1673-1683 (2011).;  Tomchuck, S. L. et al., Mesenchymal Stem Cells as a Novel Vaccine Platform, Frontiers in Cellular and Infection Microbiology, vol. 2, (140) 1-7 (2012).;  Vargas et al., Human Gene Therapy 15, 361-372 (2004).;  Wang, Y. et al., Human Serum Amyloid P Functions as a Negative Regulator of the Innate and Adaptive Immune Responses to DNA Vaccines, The Journal of Immunology 186, 2860-2870 (2011).;  Wei, H.J. et al., The Development of a Novel Cancer Immunotherapeutic Platform Using Tumor-Targeting Mesenchymal Stem Cells and a Protein Vaccine, Molecular Therapy, 1-8 (2011).;  Wikipedia, Papillomaviridae, 1-17 (2018).;  Yan, C. et al., Human Umbilical Cord Mesenchymal Stem Cells as Vehicles of CD20-Specific TRAIL Fusion Protein Delivery: A Double-Target Therapy Against Non-Hodgkin's Lymphoma, Molecular Pharmaceutics 10, 142-151 (2013).;  Yu, J. et al., Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences, Science 324, 797 (2009).	200757-0-0-0 N			RA00GT N		WO2019204571-A1;  KR2021005114-A;  US2021236622-A1;  US11389526-B2	Live, self-attenuated virus used as vaccine for            prevention of infectious diseases for post infection            treatment, comprises isolated virus comprising viral            genome that expresses one or more viral antigens and            artificial microRNA 30	ZENG M;  WEN K	UNIV TEXAS TECH SYSTEM (UTTS-C)	201988266D	   NOVELTY - Live, self-attenuated virus comprises an                isolated virus comprising a viral genome that                expresses one or more viral antigens and an                artificial microRNA 30 (amiR-30) or other microRNA                expression cassette inserted into a viral                neuraminidase (NA) or a viral non-structural (NS)                gene segment that expresses an amiR-30 or other                microRNA that specifically inhibits the expression                of a host gene essential for influenza virus                replication in host cells.    USE - Live, self-attenuated virus used as vaccine                for prevention of infectious diseases or as                therapeutic for post infection treatment                (claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a method for making a live,                self-attenuated virus, which involves obtaining                isolated virus comprising a viral genome that                expresses one or more viral antigens and an                artificial microRNA 30 (amiR-30) expression                cassette inserted into a viral neuraminidase (NA)                or a viral non-structural (NS) gene segment that                expresses an amiR-30 that specifically inhibits the                expression of a host gene essential for influenza                virus replication in host cells;    (2) a method for testing a live,                self-attenuated virus for making a vaccine, which                involves selecting a cell for propagation of a                virus that does not express a specific miRNA,                obtaining an isolated virus comprising a viral                genome that expresses one or more viral antigens,                inserting into the viral genome an artificial                microRNA 30 (amiR-30) expression cassette inserted                into a viral neuraminidase (NA) or a viral                non-structural (NS) gene segment that expresses an                amiR-30 that specifically inhibits the expression                of a host gene essential for influenza virus                replication in host cells and determining if the                virus propagates in the viral propagation cell but                is attenuated in the viral target species                cell;    (3) a live, self-attenuated therapeutic                vaccine, which comprises an isolated virus                comprising a viral genome that expresses one or                more viral antigens; an artificial microRNA 30                (amiR-30) or other microRNA expression cassette                inserted into a viral neuraminidase (NA) or a viral                non-structural (NS) gene segment that expresses an                amiR-30 or other microRNA that specifically                inhibits the expression of a host gene essential                for influenza virus replication in host cells and                optionally one or more adjuvants, excipients, or                buffers, where the therapeutic vaccine is adapted                for one of pulmonary, intraalveolar, nasal,                transcutaneous, or mucosal administration;                and    (4) a method for treating a patient with a                therapeutic vaccine, which involves identifying                that the patient is in need of prophylaxis or                treatment of an active viral infection and                providing the patient with a vaccine comprising a                live, attenuated virus that comprises an artificial                microRNA 30 (amiR-30) expression cassette inserted                into a viral neuraminidase (NA) or a viral                non-structural (NS) gene segment that expresses an                amiR-30 that specifically inhibits the expression                of a host gene essential for influenza virus                replication in host cells, in an amount effective                to provide prophylaxis against, or treatment of, an                active viral infection. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-F01;  B04-F1100E;  B11-C08E;  B11-C10;  B12-K04E;  B14-A02;  B14-D06C;  B14-L06;  B14-S11A;  B14-S11D2;  C04-E99;  C04-F01;  C04-F1100E;  C11-C08E;  C11-C10;  C12-K04E;  C14-A02;  C14-D06C;  C14-L06;  C14-S11A;  C14-S11D2;  D05-H06A;  D05-H07;  D05-H12F;  D05-H99	A61K-039/12;  A61K-039/145;  C12N-015/113;  A61K-039/00;  A61P-031/12;  C12N-007/00;  A61K-039/39	WO2019204571-A1   24 Oct 2019   A61K-039/145   201984Pages: 44   English;  KR2021005114-A   13 Jan 2021   C12N-007/00   202108   ;  US2021236622-A1   05 Aug 2021   A61K-039/145   202164   English;  US11389526-B2   19 Jul 2022   A61K-039/145   202258   English	WO2019204571-A1    WOUS028065    18 Apr 2019;   KR2021005114-A    KR733446    18 Apr 2019;   US2021236622-A1    US17048714    19 Oct 2020;   US11389526-B2    US17048714    19 Oct 2020	KR2021005114-A PCT application Application WOUS028065;   KR2021005114-A Based on Patent WO2019204571;   US2021236622-A1 Provisional Application US660327P;   US2021236622-A1 PCT application Application WOUS028065;   US11389526-B2 PCT application Application WOUS028065;   US11389526-B2 Provisional Application US660327P;   US11389526-B2 Based on Patent WO2019204571;   US11389526-B2 Previous Publ. Patent US2021236622	US660327P    20 Apr 2018;  US17048714    19 Oct 2020;  KR733446    19 Nov 2020	WO2019204571-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        		WO2019204571-A1 -- WO2016061200-A1   UNIV TEXAS TECH SYSTEM (UTTS)   ZENG M,  LI J;  WO2010110914-A2   ZIRUS INC (ZIRU-Non-standard)   MCDONALD N;  US11389526-B2 -- US10493146-B2   UNIV TEXAS TECH SYSTEM (UTTS)   ZENG M,  LI J;  US20170232097-A1   ;  US8883995-B2   MOUNT SINAI SCHOOL MEDICINE (MOUN)   TENOEVER B;  WO2016061200-A1   UNIV TEXAS TECH SYSTEM (UTTS)   ZENG M,  LI J;  WO2010110914-A2   ZIRUS INC (ZIRU-Non-standard)   MCDONALD N	WO2019204571-A1  LI, JUNWEI ET AL.:          "Generation of a safe and effective live viral vaccine by          virus self- attenuation using species-specific artificial          microRNA", JOURNAL OF CONTROLLED RELEASE, vol. 207, 2015,          pages 70 - 76, XP029226657, DOI:          10.1016/j.jconrel.2015.04.001,relevantClaims[1-2, 4-16,          34],relevantPassages[. Abstract; Figure 1; page 7, first          paragraph];  WU, LIHONG ET AL.:          "New cross-strain protective influenza vaccine using          self-attenuated influenza virus", JOURNAL OF IMMUNOLOGY,          vol. 196, no. 1, 2016,relevantClaims[1-2, 4-16,          34],relevantPassages[(Abstract). Abstract];  HAO, LINHUI ET AL.:          "Drosophila RNAi screen identifies host genes important          for influenza virus replication", NATURE, vol. 454, 2008,          pages 890 - 893, XP002629478, DOI:          10.1038/nature07151,relevantClaims[1-2, 4-16,          34],relevantPassages[. Abstract; page 4, first          paragraph];  YANG, CHEN ET AL.:          "Deliberate reduction of hemagglutinin and neuraminidase          expression of influenza virus leads to an ultraprotective          live vaccine in mice", PROCEEDINGS OF THE NATIONAL          ACADEMY OF SCIENCES, vol. 110, 2013, pages 9481 - 9486,          XP055287199, DOI:          10.1073/pnas.1307473110,relevantPassages[. Abstract; page          9483, Greatly Reduced Growth of (NA+HA) in the Lungs of          Vaccinated Mice]US11389526-B2            Seitz et al. Transfue Med. Hemother. May 2016, vol. 43          (3). pp. 203-222.;            Liang Hepatology, 2019, 49(5 Suppl): S13-S21.;            Abraham S et al. Long-term engraftment of human natural T          regulatory cells in NOD/SCID IL2rgammac(null) mice by          expression of human IL-2. PLoS One.          2012;7(12):e51832.;            Arevalo MT et al. Targeted Silencing of Anthrax Toxin          Receptors Protects against Anthrax Toxins. The Journal of          biological chemistry. 2014;289(22):15730-8.;            Boltz DA et al. Oseltamivir prophylactic regimens prevent          H5N1 influenza morbidity and mortality in a ferret model.          J Infect Dis. 2008;197(9):1315-23.;            Bouvier NM et al. Animal Models for Influenza Virus          Pathogenesis and Transmission. Viruses.          2010;2(8):1530-63.;            Cellerai C et al. Proliferation capacity and cytotoxic          activity are mediated by functionally and phenotypically          distinct virus-specific CD8 T cells defined by          interleukin-7R{alpha} (CD127) and perforin expression. J          Virol. 2010;84(8):3868-78.;            Corti D et al. Broadly neutralizing antiviral antibodies.          Annu Rev Immunol. 2013;31:705-42. doi:          10.1146/annurev-immunol-032712-095916.;            D'Cruz OJ et al. Intravaginal toxicity studies of a          gel-microemulsion formulation of spermicidal vanadocenes          in rabbits. Toxicol Appl Pharmacol.          2001;170(2):104-12.;            D'Cruz OJ et al. Mucosal toxicity studies of a gel          formulation of native pokeweed antiviral protein. Toxicol          Pathol. 2004;32(2):212-21.;            Donnelly S et al. Whole-cell but not acellular pertussis          vaccines induce convulsive activity in mice: evidence of          a role for toxin-induced interleukin-1beta in a new          murine model for analysis of neuronal side effects of          vaccination. Infect Immun. 2001;69(7):4217-23.;            Duan S et al. Oseltamivir-resistant pandemic H1N1/2009          influenza virus possesses lower transmissibility and          fitness in ferrets. PLoS pathogens.          2010;6(7):e1001022.;            Dugan VG et al. Update: Influenza ActivityUnited States,          Oct. 1-Nov. 25, 2017.;            Hao, Linhui, et al., &lt;xhtml:i          &gt;Drosophila&lt;/xhtml:i&gt;RNAi screen          identifies host genes important for influenza virus          replication, 2008, Nature, vol. 454, pp.          890-893.;            Harari A et al. Distinct profiles of cytotoxic granules          in memory CD8 T cells correlate with function,          differentiation stage, and antigen exposure. J Virol.          2009;83(7):2862-71.;            Harmon MW et al. Antibody response in humans to influenza          virus type B host-cell-derived variants after vaccination          with standard (egg-derived) vaccine or natural infection.          J Clin Microbiol. 1988;26(2):333-7.;            Hensley SE. Challenges of selecting seasonal influenza          vaccine strains for humans with diverse pre-exposure          histories. Current opinion in virology.          2014;8C:85-9.;            International Search Report [ISA/AU] PCT/US2019/028065          dated Jul. 29, 2019.;            Ison MG. Antivirals and resistance: influenza virus.          Current opinion in virology. 2011;1(6):563-73.;            Jackson LA et al. Immunogenicity of an inactivated          monovalent 2009 H1N1 influenza vaccine in pregnant women.          J Infect Dis. 2011;204(6):854-63.;            Jagger BW et al. An overlapping protein-coding region in          influenza A virus segment 3 modulates the host response.          Science (New York, NY). 2012;337(6091):199-204.;            Karlas A et al. Genome-wide RNAi screen identifies human          host factors crucial for influenza virus replication.          Nature. 2010;463(7282):818-22.;            Keitel WA et al. Safety and immunogenicity of          inactivated, Vero cell culture-derived whole virus          influenza A/H5N1 vaccine given alone or with aluminum          hydroxide adjuvant in healthy adults. Vaccine.          2009;27(47):6642-8.;            Kitano M et al. Efficacy of single intravenous injection          of peramivir against influenza B virus infection in          ferrets and cynomolgus macaques. Antimicrobial agents and          chemotherapy. 2011;55(11):4961-70.;            Konig R et al. Human host factors required for influenza          virus replication. Nature.          2010;463(7282):813-7.;            Layton RC et al. Delta inulin polysaccharide adjuvant          enhances the ability of split-virion H5N1 vaccine to          protect against lethal challenge in ferrets. Vaccine.          2011;29(37):6242-51.;            Layton RC et al. Enhanced immunogenicity, mortality          protection, and reduced viral brain invasion by alum          adjuvant with an H5N1 split-virion vaccine in the ferret.          PLoS One. 2011;6(6):e20641.;  Li          CK, et al. Correlates of protection against influenza          infection in humanson the path to a universal vaccine?          Current opinion in immunology.          2013;25(4):470-6.;  Li          J et al Generation of a safe and effective live viral          vaccine by virus self-attenuation using species-specific          artificial microRNA. J Control Release.          2015;207:70-6.;  Li          J et al. Intranasal immunization with influenza antigens          conjugated with cholera toxin subunit B stimulates broad          spectrum immunity against influenza viruses. Human          vaccines & immunotherapeutics.          2014;10(5):1211-20.;  Li          J et al. T-cell-mediated cross-strain protective immunity          elicited by prime-boost vaccination with a live          attenuated influenza vaccine. International journal of          infectious diseases : IJID : official publication of the          International Society for Infectious Diseases.          2014;27C:37-43.;            Music N et al. Influenza vaccination accelerates recovery          of ferrets from lymphopenia. PLoS One.          2014;9(6):e100926.;            Noah DL et ak. Qualification of the hemagglutination          inhibition assay in support of pandemic influenza vaccine          licensure. Clin Vaccine Immunol.          2009;16(4):558-66.;            Perez JT et al. MicroRNA-mediated species-specific          attenuation of influenza A virus. Nat Biotechnol.          2009;27(6):572-6.;            Reed LJ, Muench H. A simple method for estimating fifty          percent endpoints. Am J Hyg. 1938;27:493-7.;            Rimmelzwaan GF et al. Correlates of protection: novel          generations of influenza vaccines. Vaccine. 2008;26 Suppl          4:D41-4.;            Rimmelzwaan GF et al. Influenza virus-specific cytotoxic          T lymphocytes: a correlate of protection and a basis for          vaccine development. Curr Opin Biotechnol.          2007;18(6):529-36.;            Rowe T et al. Detection of antibody to avian influenza A          (H5N1) virus in human serum by using a combination of          serologic assays. J Clin Microbiol.          1999;37(4):937-43.;            Sasaki S et al. Influence of prior influenza vaccination          on antibody and B-cell responses. PLoS One.          2008;3(8):e2975.;            Schmid S, et al. A versatile RNA vector for delivery of          coding and noncoding RNAs. J Virol.          2014;88(4):2333-6.;            Sridhar S et al. Cellular immune correlates of protection          against symptomatic pandemic influenza. Nat Med.          2013;19(10):1305-12.;            Thangavel RR et al. Animal models for influenza virus          pathogenesis, transmission, and immunology. Journal of          immunological methods. 2014.;            Wu, Lihong, et al., New cross-strain protective influenza          vaccine using self-attenuated influenza virus, 2016,          Journal of Immunology, vol. 196, Supplement 1.;            Yang, Chen, et al. Deliberate reduction of hemagglutinin          and neuraminidase expression of influenza virus leads to          an ultraprotective live vaccine in mice, 2013,          Proceedings of the National Academy of Sciences, vol.          110, pp. 9481-9486.;            Yen HL et al. Changes in H5N1 influenza virus          hemagglutinin receptor binding domain affect systemic          spread. Proc Natl Acad Sci U S A.          2009;106(1):286-91.;            Yuhas Y et al. Involvement of tumor necrosis factor alpha          and interleukin-1beta in enhancement of          pentylenetetrazole-induced seizures caused by Shigella          dysenteriae. Infect Immun. 1999;67(3):1455-60.						CN110408726-A;  CN110408726-B	Complete set of primer probe useful in kit or            Taqman low density microfluidic chip for preparing            product used for e.g. identifying 29 respiratory            pathogens e.g. influenza A virus, comprises specific            sets of primer probe combination	LIU P;  JIANG Y;  LIU K;  LV Q;  ZHENG Y;  JIANG H;  KONG D	UNIV ARMY MEDICAL CHINESE PEOPLES LIBERA (UAMT-C);  UNIV ARMY MEDICAL CHINESE PEOPLES LIBERA (UAMT-C)	2019942764	   NOVELTY - Complete set of primer probe comprises 29 sets                of primer probe combination.    USE - The complete set of primer probe is useful in                kit or Taqman (RTM: Hydrolysis probes) low density                microfluidic chip for preparing product used for                identifying 29 respiratory pathogens, identifying                whether the pathogen is one of 29 respiratory                pathogens and identifying whether the test sample                is infected with one or more 29 respiratory                pathogens. The 29 respiratory pathogens are chosen                from Influenza A virus, Influenza B virus,                parainfluenza virus type 1, parainfluenza virus                type 2, parainfluenza virus type 3, human                metapneumovirus type A, human metapneumovirus type                B, rhinovirus, Enterovirus, adenovirus, respiratory                syncytial virus type A, respiratory syncytial virus                type B, Mycoplasma pneumoniae, chlamydia                pneumoniae, Streptococcus pneumoniae, tuberculosis,                human bocavirus, measles virus, rubella virus,                mumps virus, Rickettsia, human coronavirus 229E,                human coronavirus NL63, human coronavirus OC43,                human coronavirus KU1, Legionella pneumophila,                Haemophilus influenzae, Bordetella pertussis I and                B.pertussis II (all claimed).    ADVANTAGE - The product enables multi-target detection of                29 types of respiratory pathogens in one sample                within two hours, has good sensitivity and                specificity, and is fast and accurate.    DETAILED DESCRIPTION - Complete set of primer probe comprises 29 sets                of primer probe combination, where primer probe                combination 1 comprising primers of SEQ ID NOs: 1                and 2 and probe of SEQ ID NO: 3, primer probe                combination 2 comprising primers of SEQ ID NOs: 4                and 5 and probe of SEQ ID NO: 6, primer probe                combination 3 comprising primers of SEQ ID NOs: 7                and 8 and probe of SEQ ID NO: 9, primer probe                combination 4 comprising primers of SEQ ID NOs: 10                and 11 and probe of SEQ ID NO: 12, primer probe                combination 5 comprising primers of SEQ ID NOs: 13                and 14 and probe of SEQ ID NO: 15, primer probe                combination 6 comprising primers of SEQ ID NOs: 16                and 17 and probe of SEQ ID NO: 18, primer probe                combination 7 comprising primers of SEQ ID NO: 19                and a 33 base pair sequence (SEQ ID NO: 20) fully                defined in the specification and probe of SEQ ID                NO: 21, primer probe combination 8 comprising                primers of SEQ ID NOs: 22 and 23 and probe of SEQ                ID NO: 24, primer probe combination 9 comprising                primers of SEQ ID NOs: 25 and 26 and probe of SEQ                ID NO: 27, primer probe combination 10 comprising                primers of SEQ ID NOs: 28 and 29 and probe of SEQ                ID NO: 30, primer probe combination 11 comprising                primers of SEQ ID NOs: 31 and 32 and probe of SEQ                ID NO: 33, primer probe combination 12 comprising                primers of SEQ ID NOs: 34 and 35 and probe of SEQ                ID NO: 36, primer probe combination 13 comprising                primers of SEQ ID NOs: 37 and 38 and probe of SEQ                ID NO: 39, primer probe combination 14 comprising                primers of SEQ ID NOs: 40 and 41 and probe of SEQ                ID NO: 42, primer probe combination 15 comprising                primers of SEQ ID NOs: 43 and 44 and probe of SEQ                ID NO: 45, primer probe combination 16 comprising                primers of SEQ ID NOs: 46 and 47 and probe of SEQ                ID NO: 48, primer probe combination 17 comprising                primers of SEQ ID NOs: 49 and 50 and probe of SEQ                ID NO: 51, primer probe combination 18 comprising                primers of SEQ ID NOs: 52 and 53 and probe of SEQ                ID NO: 54, primer probe combination 19 comprising                primers of SEQ ID NOs: 55 and 56 and probe of SEQ                ID NO: 57, primer probe combination 20 comprising                primers of SEQ ID NOs: 58 and 59 and probe of SEQ                ID NO: 60, primer probe combination 21 comprising                primers of SEQ ID NOs: 61 and 62 and probe of SEQ                ID NO: 63, primer probe combination 22 comprising                primers of SEQ ID NOs: 64 and 65 and probe of SEQ                ID NO: 66, primer probe combination 23 comprising                primers of SEQ ID NOs: 67 and 68 and probe of SEQ                ID NO: 69, primer probe combination 24 comprising                primers of SEQ ID NOs: 70 and 71 and probe of SEQ                ID NO: 72, primer probe combination 25 comprising                primers of SEQ ID NOs: 73 and 74 and probe of SEQ                ID NO: 75, primer probe combination 26 comprising                primers of SEQ ID NOs: 76 and 77 and probe of SEQ                ID NO: 78, primer probe combination 27 comprising                primers of SEQ ID NOs: 79 and 80 and probe of SEQ                ID NO: 81, primer probe combination 28 comprising                primers of SEQ ID NOs: 82 and 83 and probe of SEQ                ID NO: 84, and primer probe combination 29                comprising primers of SEQ ID NOs: 85 and 86 and                probe of SEQ ID NO: 87. gacca/gatcctgtcacctctgac                (SEQ ID NO: 1), agggcattc/ttggacaaag/tcgtcta (SEQ                ID NO: 2), tgcagtcctcgctcact (SEQ ID NO: 3),                tgaat/cgatgtctgtttccaaagatc (SEQ ID NO: 4),                gggag/ctgtgcttcct/cgcaaa (SEQ ID NO: 5),                aaagagttggacttgaccct (SEQ ID NO: 6),                tgatttaaacccggtaatttctcat (SEQ ID NO: 7),                ccttgttcctgcagctattacaga (SEQ ID NO: 8),                acgacaacaggaaatc (SEQ ID NO: 9) and                aggactatgaaaaccatttacctaagtga (SEQ ID NO: 10).                INDEPENDENT CLAIMS are included for the following:                (1) kit comprising the above-mentioned primer probe                set; (2) method for preparing the kit involves                individually packing each primer probe set; and (3)                a Taqman (RTM: Hydrolysis probes) low density                microfluidic chip having primer probe set fixed on                the chip. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E05;  B04-E99;  B04-F10;  B04-F11;  B11-C07B3;  B11-C08C1;  B11-C08F8;  B12-K04F;  B12-K04G1B;  B12-K04G1C;  D05-H04;  D05-H06A;  D05-H09;  D05-H12D1;  D05-H99	C12N-015/11;  C12Q-001/04;  C12Q-001/6851;  C12Q-001/689;  C12Q-001/70	CN110408726-A   05 Nov 2019   C12Q-001/70   201995   Chinese;  CN110408726-B   04 Oct 2022   C12Q-001/70   202292   Chinese	CN110408726-A    CN10665493    23 Jul 2019;   CN110408726-B    CN10665493    23 Jul 2019	CN110408726-B Previous Publ. Patent CN110408726	CN10665493    23 Jul 2019			CN110408726-A -- CN101273143-A   US SEC OF NAVY (USNA)   LIN B,  BLANEY K M,  MALANOSKI A,  SCHNUR J M,  STENGER D A;  CN104561377-A   HUAMEI BIOLOGICAL ENG CO LTD (HUAM-Non-standard)   JIA X,  PENG Z,  ZHANG S,  WAN D;  CN105463129-A   SHENZHEN INT TRAVEL HEALTH CARE CENT (SHEN-Non-standard)   GUO Y,  LIU J,  SHI L,  XIN B,  XU Y,  YE Y,  YE J,  LEI X;  CN107937613-A   BEIJING ZHUOCHENG HUISHENG BIOLOGICAL (BEIJ-Non-standard)   LIN X,  LING M,  WANG L,  ZHANG Z;  WO2016170121-A1   PATHOFINDER BV (PATH-Non-standard)   REIJANS M G C,  DINGEMANS G J H,  SIMONS A F;  CN110408726-B -- CN101273143-A   US SEC OF NAVY (USNA)   LIN B,  BLANEY K M,  MALANOSKI A,  SCHNUR J M,  STENGER D A;  CN104561377-A   HUAMEI BIOLOGICAL ENG CO LTD (HUAM-Non-standard)   JIA X,  PENG Z,  ZHANG S,  WAN D;  CN105463129-A   SHENZHEN INT TRAVEL HEALTH CARE CENT (SHEN-Non-standard)   GUO Y,  LIU J,  SHI L,  XIN B,  XU Y,  YE Y,  YE J,  LEI X;  CN107937613-A   BEIJING ZHUOCHENG HUISHENG BIOLOGICAL (BEIJ-Non-standard)   LIN X,  LING M,  WANG L,  ZHANG Z;  WO2016170121-A1   PATHOFINDER BV (PATH-Non-standard)   REIJANS M G C,  DINGEMANS G J H,  SIMONS A F							CN109111405-A;  CN109111405-B	New aromatic thioether compounds useful in agricultural pesticides, fungicides, antiviral agents, treating Candida albicans and severe acute respiratory syndrome virus diseases	WANG J;  SONG G;  WU R	UNIV NANKAI (UNAN-C)	201903954P	   NOVELTY - Aromatic thioether compounds (A) i.e. e.g. 2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-6-fluorobenzonitrile (I), 2-chloro-6-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile (II), 2-bromo-6-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile (III), 2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-6-iodobenzonitrile (IV), 2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-5-fluorobenzonitrile (V), 5-chloro-2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile of (VI), 5-bromo-2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile (VII), 4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-3-fluorobenzonitrile (VIII), 3-chloro-4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile (IX), 3-bromo-4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile (X), 2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-5-fluorobenzoic acid (XI), 5-chloro-2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzoic acid (XII), 5-bromo-2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzoic acid (XIII) are new.    USE - (A) are useful in agricultural pesticides, fungicides, antiviral agents, treating Candida albicans and severe acute respiratory syndrome virus-infected drugs (all claimed).    DETAILED DESCRIPTION - Aromatic thioether compounds (A) i.e. 2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-6-fluorobenzonitrile of formula (I), 2-chloro-6-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile of formula (II), 2-bromo-6-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile of formula (III), 2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-6-iodobenzonitrile of formula (IV), 2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-5-fluorobenzonitrile of formula (V), 5-chloro-2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile of formula (VI), 5-bromo-2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile of formula (VII), 4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-3-fluorobenzonitrile of formula (VIII), 3-chloro-4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile of formula (IX), 3-bromo-4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile of formula (X), 2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-5-fluorobenzoic acid of formula (XI), 5-chloro-2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzoic acid of formula (XII), 5-bromo-2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzoic acid of formula (XIII), 4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-3-fluorobenzoic acid of formula (XIV), 3-chloro-4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzoic acid of formula (XV), 3-bromo-4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzoic acid of formula (XVI), 2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-5-fluorobenzoic acid of formula (XVII), 5-bromo-2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzoic acid of formula (XVIII), 4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-3-fluorobenzoic acid of formula (XIX), 4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-3-fluorobenzoic acid of formula (XX), 3-bromo-4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzoic acid of formula (XXI), 4-chloro-2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzonitrile of formula (XXII), 2-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-4-(trifluoromethyl)benzonitrile of formula (XXIII), 3-chloro-4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)benzoic acid of formula (XXIV), 4-(4,6-dimethoxy-1,3,5-triazin-2-ylthio)-2-(trifluoromethyl)benzoic acid of formula (XXV), 4-(4,6-dimethoxypyrimidin-2-ylthio)-2-(trifluoromethyl)benzoic acid of formula (XXVI), 2-(4,6-dimethoxypyrimidin-2-ylthio)-4-(trifluoromethyl)benzoic acid of formula (XXVII), 2-(4,6-dimethoxypyrimidin-2-ylthio)-5-(trifluoromethyl)benzonitrile of formula (XXVIII), 2-(4,6-dimethoxypyrimidin-2-ylthio)-5-(trifluoromethyl)benzoic acid of formula (XXIX), 4-(4,6-dimethoxypyrimidin-2-ylthio)isophthalic acid of formula (XXX), 4-(4,6-dimethoxypyrimidin-2-ylthio)-2-(trifluoromethyl)benzonitrile of formula (XXXI), 2-(4,6-dimethoxypyrimidin-2-ylthio)-5-(trifluoromethyl)benzonitrile of formula (XXXII), 4-(4,6-dimethoxypyrimidin-2-ylthio)-3-(trifluoromethyl)benzonitrile of formula (XXXIII) are new. An INDEPENDENT CLAIM is also included for agricultural insecticide, fungicide or antiviral agent comprising (A) and carrier. 			C02 (Heterocyclic.)	C07-D12;  C07-D13;  C14-A02B8;  C14-A06;  C14-B01;  C14-K01D	A01N-043/54;  A01N-043/66;  A01P-001/00;  A01P-003/00;  A01P-007/04;  A61K-031/505;  A61K-031/53;  A61P-031/04;  A61P-031/10;  A61P-031/14;  C07D-239/60;  C07D-251/38	CN109111405-A   01 Jan 2019   C07D-251/38   201920Pages: 25   Chinese;  CN109111405-B   30 Jul 2021   C07D-251/38   202164   Chinese	CN109111405-A    CN11226569    22 Oct 2018;   CN109111405-B    CN11226569    22 Oct 2018	CN109111405-B Previous Publ. Patent CN109111405	CN11226569    22 Oct 2018			CN109111405-A -- CN1052852-A   KUMIAI CHEM IND CO LTD (TSUB);  IHARA CHEM IND CO LTD (IHAR)   TAMARU M,  KAWAMURA N,  SATO M,  TACHIKAWA S,  YOSHIDA R,  TAKABE F;  CN105837480-A   UNIV NANJING SCI & TECHNOLOGY (UNSC)   LU G,  TIAN R,  XU X,  ZHANG X,  WU T;  EP346789-A   BASF AG (BADI)   RHEINHEIME J,  EICKEN K,  PLATH P,  PAUL G,  HARREUS A,  WESTPHALEN K O,  WUERZER B,  GROSSMANN K;  EP493321-A1   CIBA GEIGY AG (CIBA)   LUETHY C,  FISHER R;  KR90012909-A   ;  US5360913-A   BASF AG (BADI)   RHEINHEIMER J,  EICKEN K,  VOGELBACHE U J,  WESTPHALEN K O,  GERBER M,  WALTER H;  WO1993003017-A1   ;  WO2009075691-A1   ACADIA PHARM INC (ACAD)   BULOW A,  EK F,  OLSSON R,  OTTESEN L K;  CN109111405-B -- CN1052852-A   KUMIAI CHEM IND CO LTD (TSUB);  IHARA CHEM IND CO LTD (IHAR)   TAMARU M,  KAWAMURA N,  SATO M,  TACHIKAWA S,  YOSHIDA R,  TAKABE F;  CN105837480-A   UNIV NANJING SCI & TECHNOLOGY (UNSC)   LU G,  TIAN R,  XU X,  ZHANG X,  WU T;  EP346789-A   BASF AG (BADI)   RHEINHEIME J,  EICKEN K,  PLATH P,  PAUL G,  HARREUS A,  WESTPHALEN K O,  WUERZER B,  GROSSMANN K;  EP493321-A1   CIBA GEIGY AG (CIBA)   LUETHY C,  FISHER R;  KR199012909-A   ;  US5360913-A   BASF AG (BADI)   RHEINHEIMER J,  EICKEN K,  VOGELBACHE U J,  WESTPHALEN K O,  GERBER M,  WALTER H;  WO1993003017-A1   ;  WO2009075691-A1   ACADIA PHARM INC (ACAD)   BULOW A,  EK F,  OLSSON R,  OTTESEN L K		 N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N		00212	RCJPFM N; RCJPFN N; RCJPFO N; RCJPFP N; RCJPFQ N; RCJPFR N; RCJPFS N; RCJPFT N; RCJPFU N; RCJPFV N; RCJPFW N; RCJPFX N; RCJPFY N; RCJPFZ N; RCJPG0 N; RCJPG1 N; RCJPG2 N; RCJPG3 N; RCJPG4 N; RCJPG5 N; RCJPG6 N; RCJPG7 N; RCJPG8 N; RCJPG9 N; RCJPGA N; RCJPGB N		KR1960504-B1	Epidemic proliferation prediction modeling device            has diffusion model that is modeled according to            inter-area spreading probabilities calculated based on            number of populations of zone, number of infected            persons and network information	JANGYOON;  KIM S;  JUNGSUNGMIN	UNIV SEJONG IND ACAD COOP FOUND (UNSE-C)	201964597D	   NOVELTY - The device (100) has a processor (120) for                executing a program stored in a memory (110). A                protection model represents a result of inhibiting                diffusion by applying multiple protection policies                preset to a result of modeling a pandemic model,                and a diffusion model is modeled and output as a                simulation result. The diffusion model is modeled                according to inter-area spreading probabilities                calculated based on the number of populations of                each zone, the number of infected persons, network                information, and weather condition information. The                disease is spread so as to increase the number of                infections on the influenza model of the spreading                zone when the spread probability exceeds a                predetermined threshold value. The protection                policy comprises one of an isolation plan and a                vaccination plan.    USE - Epidemic proliferation prediction modeling                device.    ADVANTAGE - The users can set various predefined variables                for predicting infectious disease proliferation,                and can provide a visual analysis tool for                infectious disease prediction modeling that can be                compared and analyzed based on actual data. The                user can simulate in advance how the spread of the                disease takes place across multiple zones by using                the functions provided by the epidemic                proliferation prediction modeling device and                applying the attribute of disease to be predicted                and analyzed by the user. The effects of applying a                protection model to a spreading disease is                simulated, thus the user can quickly find out what                is the most appropriate protection model.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a method for modeling epidemic                proliferation prediction; and    (2) a computer-readable recording medium                storing program for modeling epidemic proliferation                prediction.    DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram of the                epidemic proliferation prediction modeling device.                (Drawing includes non-English language text)    Epidemic proliferation prediction modeling                device (100)    Memory (110)    Processor (120) 			T01 (Digital Computers)	T01-J04;  T01-N01A2;  T01-S03	G06F-017/10;  G06Q-050/10;  G06Q-050/26	KR1960504-B1   15 Jul 2019   G06Q-050/26   201957Pages: 22   	KR1960504-B1    KR174589    18 Dec 2017		KR174589    18 Dec 2017			KR1960504-B1 -- JP2015038708-A   UNIV TOKYO (UYTY)   TANAKA G,  AIHARA K,  URABE C;  KR2011056800-A   KOREA INST SCI & TECHNOLOGY                  INFORMATION (KIIN)   CHOI D H,  LEE J H;  KR1733652-B1   HAN I (HANI-Individual);  SOC SOFT INC (SOFT-Non-standard)   IL H							US2019023769-A1;  WO2019183228-A1;  US10829543-B2;  US2021002355-A1;  CN112203640-A;  EP3768239-A1;  EP3768239-A4;  CN112203640-B	Treating or preventing viral infection by virion            in subject involves by administering to subject,            recombinant antibody with specific affinity for virion,            and comprising human or humanized crystallizable            fragment (Fc) region	LAI S;  WANG Y;  KANNAN A;  NUNN K;  SUBRAMANI D B;  CONE R;  YANG B;  MCCALLEN J;  MCALEER J;  RAI S	UNIV NORTH CAROLINA (UNCR-C);  UNIV JOHNS HOPKINS (UYJO-C);  UNIV NORTH CAROLINA (UNCR-C);  UNIV NORTH CAROLINA (UNCR-C);  UNIV NORTH CAROLINA (UNCR-C)	2019077645	   NOVELTY - A viral infection by a virion is treated or                prevented in a subject by administering to the                subject, via an inhaled route, a recombinant                antibody with a specific affinity for the virion,                the recombinant antibody comprising a human or                humanized crystallizable fragment (Fc) region. The                recombinant antibody comprises an oligosaccharide                having a glycosylation pattern that enhances the                trapping potency of the recombinant antibody in                mucus, so that the recombinant antibody binds to                the virion to form an antibody/virion complex that                is trapped in the subject's mucus.    USE - The methods are useful for treating or                preventing viral infection by virion in subject;                where the virion is selected from Ebola virus,                respiratory syncytial virus (RSV) (preferred),                influenza virus, adenovirus, human rhinovirus,                coronavirus, human metapneumovirus, parainfluenza                virus, hantavirus, Middle Eastern respiratory                syndrome (MERS) coronavirus, Bocavirus, and Marburg                virus; for immobilizing respiratory virion in mucus                of subject's lung; and for blocking, preventing or                eliminating the proliferation, infiltration or                spreading of respiratory virion in mucus of a                subject's lung (all claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) immobilizing a respiratory virion in mucus                of a subject's lung, which involves administering                to the subject, via an inhaled route, a population                of recombinant antibodies with a specific affinity                for the virion, the recombinant antibodies                comprising a human or humanized Fc region, where                greater than or equal to 50% of the recombinant                antibodies comprise an oligosaccharide having a                glycosylation pattern comprising the biantennary                core glycan structure Man alpha 1-6(Man alpha                1-3)Man beta 1-4GlcNac beta 1-4GlcNAc beta 1 with                terminal N-acetylglucosamine on each branch to                enhance the trapping potency of the recombinant                antibody in mucus, so that the recombinant                antibodies bind to the virion to form an                antibody/virion complex that is trapped in the                subject's mucus, thus treating or preventing the                infection; and    (2) blocking, preventing or eliminating the                proliferation, infiltration or spreading of a                respiratory virion in mucus of a subject's lung,                which involves immobilizing the virion by                administering to the subject, via an inhaled route,                a recombinant antibody with a specific affinity for                the virion so that the recombinant antibody is                trapped in the subject's mucus, the recombinant                antibody comprising a human or humanized Fc region,                where the recombinant antibody comprises an                oligosaccharide having a glycosylation pattern that                enhances the trapping potency of the recombinant                antibody in mucus. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-C01;  B04-C02X;  B04-E99;  B04-G0800E;  B04-G2100E;  B04-G2300E;  B04-G27G0E;  B12-M01B;  B12-M12Z;  B14-A02;  B14-K01;  D05-H11A;  D05-H99	A61P-031/14;  A61P-031/22;  C07K-016/08;  C07K-016/10;  A61K-039/00;  A61K-039/395;  A61K-009/00;  A61P-031/12;  A61P-011/00;  C07K-016/12;  A61K-039/42	US2019023769-A1   24 Jan 2019   C07K-016/08   201909Pages: 60   English;  WO2019183228-A1   26 Sep 2019   A61K-009/00   201974   English;  US10829543-B2   10 Nov 2020   C07K-016/08   202091   English;  US2021002355-A1   07 Jan 2021   C07K-016/10   202104   English;  CN112203640-A   08 Jan 2021   A61K-009/00   202106   Chinese;  EP3768239-A1   27 Jan 2021   A61K-009/00   202110   English;  EP3768239-A4   19 Jan 2022   A61K-009/00   202211   English;  CN112203640-B   19 Apr 2024   A61K-009/00   202436   Chinese	US2019023769-A1    US138643    21 Sep 2018;   WO2019183228-A1    WOUS023174    20 Mar 2019;   US10829543-B2    US138643    21 Sep 2018;   US2021002355-A1    US16982682    21 Sep 2020;   CN112203640-A    CN80034722    20 Mar 2019;   EP3768239-A1    EP771963    20 Mar 2019;   EP3768239-A4    EP771963    20 Mar 2019;   CN112203640-B    CN80034722    20 Mar 2019	US2019023769-A1 Provisional Application US719689P;   US2019023769-A1 Provisional Application US646220P;   US2019023769-A1 CIP of Application US438511;   US2019023769-A1 CIP of Application WOUS067328;   US2019023769-A1 CIP of Patent US10100102;   US10829543-B2 Provisional Application US719689P;   US10829543-B2 Provisional Application US646220P;   US10829543-B2 CIP of Application US438511;   US10829543-B2 CIP of Application WOUS067328;   US10829543-B2 CIP of Patent US10100102;   US10829543-B2 Previous Publ. Patent US2019023769;   US2021002355-A1 PCT application Application WOUS023174;   US2021002355-A1 Provisional Application US646220P;   CN112203640-A PCT application Application WOUS023174;   CN112203640-A Based on Patent WO2019183228;   EP3768239-A1 PCT application Application WOUS023174;   EP3768239-A1 Based on Patent WO2019183228;   CN112203640-B PCT application Application WOUS023174;   CN112203640-B Previous Publ. Patent CN112203640;   CN112203640-B Based on Patent WO2019183228	US719689P    29 Oct 2012;  US646220P    21 Mar 2018;  US138643    21 Sep 2018;  WOUS023174    20 Mar 2019;  US16982682    21 Sep 2020;  CN80034722    23 Nov 2020	  WO2019183228-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP3768239-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  EP3768239-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR    		US2019023769-A1 -- US4501729-A   RESEARCH CORP (RESE)   BOUCHER R C,  GATZY J T,  KNOWLES M R;  US20150284451-A1   ;  US10100102-B2   UNIV NORTH CAROLINA (UNCR);  UNIV JOHNS HOPKINS (UYJO)   LAI S,  WANG Y,  KANNAN A,  NUNN K,  SUBRAMANI D B,  CONE R;  WO2019183228-A1 -- US20150284451-A1   ;  WO2011056697-A1   MEDIMMUNE LLC (ASTR)   RICHTER B,  SUZICH J;  WO2011056899-A2   LIGOCYTE PHARM INC (LIGO-Non-standard)   HAYNES J R;  WO2012006596-A2   CALMUNE CORP (CALM-Non-standard)   WILLIAMSON R A,  WADIA J,  PASCUAL G,  KEOGH E;  US2021002355-A1 -- US20130164338-A1   ;  US20150284451-A1   ;  US20170267780-A1   ;  US10100102-B2   UNIV NORTH CAROLINA (UNCR);  UNIV JOHNS HOPKINS (UYJO)   LAI S,  WANG Y,  KANNAN A,  NUNN K,  SUBRAMANI D B,  CONE R;  US10829543-B2   UNIV NORTH CAROLINA (UNCR);  UNIV JOHNS HOPKINS (UYJO)   LAI S,  WANG Y,  KANNAN A,  NUNN K,  SUBRAMANI D B,  CONE R,  YANG B,  MCCALLEN J;  CN112203640-A -- US20150284451-A1   ;  WO1992001473-A   ;  WO2011056697-A1   MEDIMMUNE LLC (ASTR)   RICHTER B,  SUZICH J;  CN112203640-B -- US20150284451-A1   ;  WO1992001473-A   ;  WO2011056697-A1   MEDIMMUNE LLC (ASTR)   RICHTER B,  SUZICH J	WO2019183228-A1  ROBBIE, G.J. ET          AL.: "A novel investigational Fc-modified humanized          monoclonal antibody, motavizumab-YTE, has an extended          half-life in healthy adults", ANTIMICROB. AGENTS          CHEMOTHER., vol. 57, no. 12, December 2013 (2013-12-01),          pages 6147 - 6153, XP055369674,          doi:10.1128/AAC.01285-13,relevantClaims[17,          18],relevantPassages[See abstract; page 6147.]CN112203640-A  : "", 30 November          2014,          ,relevantClaims[1-28],relevantPassages[334];  SHAMIR R.          JACOBINO,ET AL.: "Reformatting palivizumab and          motavizumab from IgG to human IgA impairs their efficacy          against RSV infection in vitro and in vivo",          MABS,relevantClaims[1-28],relevantPassages[453-462]CN112203640-B            Baichun, et al., size of atomized particles. "Modern          Respiratory." Fudan University Press, 2014, page          334.;            Shamir R. Jacobino, et al .. Resumed palivizumab and          motavizumab from IgG to human IgA impairs against RSV In          vitro and in vivo; Shamir R. Jacobino, et al.; MABS;          20180319; Volume 10 (Phase 3); 453-462;						RU2696007-C1	ASSOCIATED WITH PARAINFLUENZA-3 VACCINE,            INFECTIOUS RHINOTRACHEITIS, VIRAL DIARRHEA, ROTA- AND            CORONAVIRAL INFECTIONS OF CATTLE INACTIVATED            EMULSION	MAKAEV KH N;  GUMEROV V G;  SPIRIDONOV G N;  NIKITIN A I;  KARIMULLINA I G;  AGLYAMOV R N;  MAKHMUTOV A F	FEDERAL CENT TOXICOLOGICAL RADIATION (TOXI-Soviet Institute)	2019747394	   NOVELTY - Invention refers to veterinary virology and                biotechnology, particularly to                parainfluenza-3-associated vaccines, infectious                rhinotracheitis, viral diarrhea, rota- and                coronaviral infections in cattle. Vaccine contains,                as an active substance, a mixture of inactivated                and concentrated antigens of strain "PTK-45/86" of                parainfluenza-3, strain "TK-A (VIEV)-V2" of                infectious rhinotracheitis virus, strain "VK-1" of                viral diarrhea virus disease of mucous membranes of                cattle, strain "RM" of rotavirus and strain                2-"CL-2" of bovine coronavirus with activity of                each of strains not less than 8.0 Lg TCD 50/cm3,                taken in volume ratio of 1:1:1:1:1. As an adjuvant                contains a mixture of synthetic oil PES-3M and                lanolin anhydrous, taken in ratio 85:15, wherein                for preparing the series of the associated vaccine,                the oil adjuvant is mixed in a volume ratio of 1:1                with a mixture of concentrated viral                antigens.    USE - Veterinary medicine.    ADVANTAGE - Invention enables to preserve the biological                properties of vaccine for 12 months. 1 cl, 3 tbl, 8 ex 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B01B;  B04-B01C3;  B04-B04C1;  B14-A02A3;  B14-A02B;  B14-S11A;  B14-S11D1;  B14-S12;  C04-B01B;  C04-B01C3;  C04-B04C1;  C14-A02A3;  C14-A02B;  C14-S11A;  C14-S11D1;  C14-S12;  D05-H07	A61K-039/155;  A61K-039/215;  A61K-039/265;  A61K-047/10;  A61K-047/44;  A61P-031/00	RU2696007-C1   30 Jul 2019   A61K-039/155   201973Pages: 0   Russian	RU2696007-C1    RU132282    10 Sep 2018		RU132282    10 Sep 2018			RU2696007-C1 -- RU2111011-C1   ;  RU2261111-C1   	RU2696007-C1            -3, , . N: -1-4.8/02246 21.11.16 .;  ,          -3, , -, -, , N13-3-04/0703 20.03.2003 .	99130-0-0-0 K M			RA01SB K M		WO2019108877-A1;  US2020331948-A1;  US11254700-B2	New substituted (E)-1,3-diphenyl-propenone            compounds are glycogen synthase kinase-3beta inhibitors            useful for treating e.g. Alzheimer's disease, cancer,            obesity, diabetes, inflammatory or autoimmune disease            and cardiovascular disorder	LI Q X;  LIANG Z	UNIV HAWAII (UYHW-C);  UNIV HAWAII (UYHW-C)	2019503718	   NOVELTY - Substituted (E)-1,3-diphenyl-propenone                compounds (I) are new.    USE - (I) are useful for treating: cognitive,                neurodegenerative or neurological disease or                condition in a subject, where the cognitive,                neurodegenerative or neurological disease or                condition is Alzheimer's disease; and cancer,                obesity, diabetes, inflammatory or autoimmune                disease, cardiovascular disorder, metabolic                syndrome X, hair loss, severe acute respiratory                syndrome coronavirus, cocaine addiction, dental                caries, bone loss or glaucoma (all claimed).    DETAILED DESCRIPTION - Substituted (E)-1,3-diphenyl-propenone                compounds of formula (I) or their salts, solvates                or prodrugs are new.    n = 0 or 1-3;    m = 1-3;    R1 = H, OH, alkylamino or alkoxy;    R2 = alkyl, alkoxy, heterocyclyl, aryl,                heteroaryl (all optionally substituted), H or OH;                and    X1 = H or O, S or N bonded to 1 or 2 carbon                position forms 5- or 6-membered heteroaryl,                respectively, where (I) are not isoorientin,                isovitexin, orientin, luteolin or hispidol. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  B02 (Fused ring heterocyclics.)	B06-A01;  B06-B01;  B06-D01;  B06-D02;  B07-H;  B10-B03B;  B10-B04A;  B10-E02;  B10-F02;  B14-A02B5;  B14-C03;  B14-D06C;  B14-E12;  B14-F01;  B14-F02;  B14-G02D;  B14-H01;  B14-J01;  B14-K01D;  B14-M01C;  B14-N01;  B14-N03A;  B14-N06A;  B14-R02;  B14-S04;  B14-S13;  B14-S16	A61K-031/353;  C07D-311/32;  C07C-049/835;  C07H-007/06	WO2019108877-A1   06 Jun 2019   A61K-031/353   201946Pages: 93   English;  US2020331948-A1   22 Oct 2020   C07H-007/06   202086   English;  US11254700-B2   22 Feb 2022   C07H-007/06   202217   English	WO2019108877-A1    WOUS063208    30 Nov 2018;   US2020331948-A1    US16760700    30 Apr 2020;   US11254700-B2    US16760700    30 Apr 2020	US2020331948-A1 PCT application Application WOUS063208;   US2020331948-A1 Provisional Application US593500P;   US11254700-B2 PCT application Application WOUS063208;   US11254700-B2 Provisional Application US593500P;   US11254700-B2 Based on Patent WO2019108877;   US11254700-B2 Previous Publ. Patent US2020331948	US593500P    01 Dec 2017;  US16760700    30 Apr 2020	WO2019108877-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      		WO2019108877-A1 -- US20060276416-A1   ;  US20110183942-A1   ;  WO2011055561-A1   JAPAN SCI & TECHNOLOGY AGENCY (JSTA)   MIKOSHIBA K,  HAMADA K,  TERAUCHI A,  OZAKI S,  GOTO J,  EBISUI E,  SUZUKI A;  US11254700-B2 -- US20110183942-A1   ;  US20160009692-A1   ;  US20060276416-A1   	US11254700-B2            Wolff, Manfred E. Burger's Medicinal Chemistry, 5ed, Part          I, John Wiley & Sons, 1995, pp. 975-977 (Year:          1995).;            Banker, G.S. et al., Modern Pharmaceutics, 3ed., Marcel          Dekker, New York, 1996, p. 596 (Year: 1996).;            Luong et al., Helvetica Chimica Acta, 1980, vol. 63(1),          pp. 244-249 (Year: 1980).;            Sim et al., ChemMedChem, 2011, 6(4), pp. 713-724. (Year:          2011).;            Zhang et al., Biomedical Pharmacology, 1997, vol. 54(9),          pp. 1047-1053. (Year: 1997).;            Hsieh et al., Pharmaceutical Research, vol. 15(1), 1998,          pp. 39-46. (Year: 1998).;            International Preliminary Report on Patentability in          PCT/US2018/063208 dated Jun. 11, 2020.;            International Search Report and Written Opinion in          PCT/US2018/063208 dated Mar. 25, 2019.;            Liang, Z., B. Zhang, W.W. Su, P.G. Williams & Q.X. Li          (2016) C-Glycosylflavones Alleviate Tau Phosphorylation          and Amyloid Neurotoxicity through GSK3 Inhibition, ACS          Chem. Neurosci. 7(7):912-923.;            Song, Y, H.-D. Kim, M.-K. Lee, I.-H. Hong, C.-K. Won,          H.-W. Bai, S.S. Lee, S. Lee, B.Y. Chung & J.-H. Cho.          (2017) Maysin and Its Flavonoid Derivative from          Centipedegrass Attenuates Amyloid Plaques by Inducting          Humoral Immune Response with Th2 Skewed Cytokine Response          in the Tg (APPswe, PS1dE9) Alzheimer's Mouse Model, PLoS          ONE 12(1): e0169509.	65127-1-0-0 N; 1476523-0-0-0 N; 2854470-1-0-0 N;  N;  N; 1341553-2-0-0 N; 97036-1-0-0 N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N; 1476523-0-0-0 CL NEW; 2854470-1-0-0 CL NEW; 1341553-2-0-0 CL NEW	214786201 N; 214786202 N; 214786203 N; 214786204 N		RA41M6 N; RAQCMC N; RBJU8N N; RCLE9F N; RCLE9G N; RANGZM N; RASOK1 N; RAC2DO N; RCLE9H N; RCLE9I N; RCLE9J N; RCLE9K N; RCLE9L N; RCLE9M N; RCLE9N N; RCLE9O N; RCLE9P N; RCLE9Q N; RCLE9R N; RCLE9S N; RCLE9T N		WO2019199955-A1;  CA3096849-A1;  AU2019252112-A1;  KR2020142028-A;  CN112203683-A;  EP3773699-A1;  US2021162033-A1;  IN202027046148-A;  US11534486-B2;  US2023146032-A1;  US11925681-B2	Composition useful for increasing human's immune            response to non-Burkholderia immunogen, comprises            non-Burkholderia immunogen and outer membrane vesicles            derived from organisms of e.g. Burkholderia            pseudomallei, or Burkholderia mallei	MORICI L A;  MCLACHLAN J B;  DAVITT C J;  KURTZ J R;  DAVITT C J H	TULANE EDUCATIONAL FUND (TULA-C);  TULANE EDUCATIONAL FUND (TULA-C);  TULANE EDUCATIONAL FUND (TULA-C);  TULANE EDUCATIONAL FUND (TULA-C)	201986549D	   NOVELTY - Immunogenic composition comprises (a) a                non-Burkholderia immunogen and (b) several outer                membrane vesicles (OMVs) derived from one or more                organisms of the species B.pseudomallei, B.mallei,                B.oklahomensis, B.thailandensis, B.humptydooensis,                or Burkholderia spp. ciades A, B, or C                (B.pseudomallei complex or (Bpc)).    USE - The composition is useful for increasing                subject's immune response to a non-Burkholderia                immunogen. The immunogen is a killed or attenuated                pathogenic organism or is derived from a pathogenic                organism. The killed or attenuated pathogenic                organism or pathogenic organism or is derived is a                virus, fungus, or parasite. The killed or                attenuated pathogenic organism or pathogenic                organism is a bacterium. The bacterium is Bacillus,                Rickettsia, Chlamydia, Chlamydophila, Mycobacteria,                Salmonella, Shigella, Spirochete, Listeria, or                Mycoplasma. The bacterium is Mycobacterium                tuberculosis or B.anthracis. The virus is a rabies                virus, herpes simplex virus type 2, herpes simplex                virus type 1, human cytomegalovirus, Epstein-Barr                virus, varicella zoster virus, human                papillomavirus, human T-cell lymphotropic virus                type 1, rotavirus, norovirus, hepatitis A virus,                hepatitis B virus, hepatitis C virus, influenza                virus, polio virus, Japanese encephalitis virus,                measles virus, mumps virus, rubella virus, yellow                fever virus, varicella virus, dengue virus,                hantavirus, HIV-1, Ebola virus, Marburg virus,                Lassa virus, Lymphocytic choriomeningitis virus,                Nipah virus, Rift Valley fever virus, Middle East                Respiratory Syndrome Coronavirus, Severe acute                respiratory syndrome (SARS) coronavirus,                Crimean-Congo hemorrhagic fever virus, Zika virus,                or West Nile virus. The fungus is Aspergillus,                Pneumocystis, Histoplasma, Coccidioides,                Malassezia, Blastomyces, or Candida. The parasite                is Plasmodium, Schistosoma, Leishmania, helminths,                or Trypanosoma. The immunogen is derived from a                cancer cell. The immunogen derived from a cancer                cell is an activated oncogene, a fetal antigen, an                activation marker, an overexpressed growth factor,                or a neoantigen. The cancer cell is a cell of a                lymphoma, a leukemia, a prostate cancer, a breast                cancer, a pancreatic cancer, a small cell lung                cancer, a non-small cell lung cancer, a colon or                rectal cancer, a liposarcoma, a melanoma, a bladder                cancer, a liver or intrahepatic duct cancer, an                endometrial cancer, or an ovarian cancer. The                subject is a primate, an equine, a bovine, an                ovine, a porcine, a canine, a feline, or a camelid.                The primate is a human (all claimed). The                composition is also used for preventing or reducing                severity of a selected infectious disease, or                cancer.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method                of increasing subject's immune response to a                non-Burkholderia immunogen, which involves                co-administering (a) an amount a non-Burkholderia                immunogen and (b) an amount of OMVs of one or more                above-mentioned species to the subject. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B01C;  B04-F10A6;  B12-M11P;  B14-A01;  B14-A02;  B14-A04;  B14-B02;  B14-C03;  B14-C04;  B14-H01;  B14-K01D;  B14-S11B1;  C04-F10A6;  C14-A01;  C14-A02;  C14-A04;  C14-B02;  C14-C03;  C14-C04;  C14-H01;  C14-K01D;  C14-S11B1;  D05-H08A	A61K-039/02;  A61K-039/385;  C12N-001/20;  C12N-001/36;  C12R-001/01;  A61K-039/39;  A61P-037/04;  A61K-039/00;  A61K-039/04;  A61K-039/07;  A61K-039/112;  A61K-039/118;  A61K-039/12;  A61P-031/04;  A61P-031/14;  A61K-035/74;  A61K-039/104	WO2019199955-A1   17 Oct 2019   A61K-039/02   201983Pages: 68   English;  CA3096849-A1   17 Oct 2019   A61K-039/39   202090   English;  AU2019252112-A1   26 Nov 2020   A61K-039/02   202096   English;  KR2020142028-A   21 Dec 2020   A61K-039/02   202102   ;  CN112203683-A   08 Jan 2021   A61K-039/02   202106   Chinese;  EP3773699-A1   17 Feb 2021   A61K-039/02   202116   English;  US2021162033-A1   03 Jun 2021   A61K-039/02   202146   English;  IN202027046148-A   27 Aug 2021   A61K-039/00   202212   English;  US11534486-B2   27 Dec 2022   A61K-039/02   202204   English;  US2023146032-A1   11 May 2023   A61K-039/02   202339   English;  US11925681-B2   12 Mar 2024   A61K-039/02   202422   English	WO2019199955-A1    WOUS026769    10 Apr 2019;   CA3096849-A1    CA3096849    10 Apr 2019;   AU2019252112-A1    AU252112    10 Apr 2019;   KR2020142028-A    KR731979    10 Apr 2019;   CN112203683-A    CN80035165    10 Apr 2019;   EP3773699-A1    EP784543    10 Apr 2019;   US2021162033-A1    US17046723    09 Oct 2020;   IN202027046148-A    IN27046148    22 Oct 2020;   US11534486-B2    US17046723    09 Oct 2020;   US2023146032-A1    US088690    26 Dec 2022;   US11925681-B2    US088690    26 Dec 2022	CA3096849-A1 PCT application Application WOUS026769;   CA3096849-A1 Based on Patent WO2019199955;   AU2019252112-A1 PCT application Application WOUS026769;   AU2019252112-A1 Based on Patent WO2019199955;   KR2020142028-A PCT application Application WOUS026769;   KR2020142028-A Based on Patent WO2019199955;   CN112203683-A PCT application Application WOUS026769;   CN112203683-A Based on Patent WO2019199955;   EP3773699-A1 PCT application Application WOUS026769;   EP3773699-A1 Based on Patent WO2019199955;   US2021162033-A1 PCT application Application WOUS026769;   US2021162033-A1 Provisional Application US655667P;   IN202027046148-A PCT application Application WOUS026769;   IN202027046148-A Based on Patent WO2019199955;   US11534486-B2 Provisional Application US655667P;   US11534486-B2 PCT application Application WOUS026769;   US11534486-B2 Previous Publ. Patent US2021162033;   US11534486-B2 Based on Patent WO2019199955;   US2023146032-A1 Cont of Application WOUS026769;   US2023146032-A1 Cont of Application US046723;   US2023146032-A1 Provisional Application US655667P;   US2023146032-A1 Cont of Patent US11534486;   US11925681-B2 Cont of Application WOUS026769;   US11925681-B2 Cont of Application US046723;   US11925681-B2 Provisional Application US655667P;   US11925681-B2 Previous Publ. Patent US2023146032;   US11925681-B2 Cont of Patent US11534486	US655667P    10 Apr 2018;  CA3096849    09 Oct 2020;  US17046723    09 Oct 2020;  KR731979    05 Nov 2020;  CN80035165    25 Nov 2020;  US088690    26 Dec 2022	WO2019199955-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          EP3773699-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN            		WO2019199955-A1 -- US20140004178-A1   ;  US20150118263-A1   ;  CN112203683-A -- AU2006200732-A1   CHIRON SPA (CHIR)   PIZZA M,  RAPPUOLI R,  GIULIANI M;  CN102223876-A   NANOBIO CORP (NANO-Non-standard)   BAKER J R,  HAMOUDA T,  SUTCLIFFE J A;  CN104602702-A   NOVARTIS AG (NOVS)   GRANDI G,  MARGARIT Y R I,  CHIAROT E;  US20130195907-A1   ;  US20170065700-A1   ;  US20170333543-A1   ;  WO2016184860-A1   UNIV TRENTO (UYTR-Non-standard)   GRANDI G,  CAFARDI V,  FANTAPPIE L,  GRIFANTINI R,  GRANDI A;  WO2019030271-A1   GLAXOSMITHKLINE BIOLOGICALS SA (GLAX)   ALFINI R,  DI BENEDETTO R,  MICOLI F,  SAUL A J;  WO2012097185-A2   TULANE EDUCATIONAL FUND (TULA)   MORICI L A;  US11534486-B2 -- US20140004178-A1   ;  US20150118263-A1   ;  US9526775-B2   UNIV ALBERTA (UYAL)   FELDMAN M,  PRICE N,  GARCIA-QUINTANILLA F,  IELMINI M V;  US10639280-B2   STAAT NEDERLANDEN MIN VWS MIN VOLKS (NEVW-Non-standard)   SALVERDA M L M,  VAN DER LEY P A;  US11066453-B2   UNIV TRENTO (UYTR-Non-standard)   GRANDI G,  CAFARDI V,  FANTAPPIE L,  GRIFANTINI R,  GRANDI A;  WO2003051379-A1   MICROBIOLOGICAL RES AUTHORITY (MICR-Non-standard)   FOSTER K A,  GORRINGE A R,  HUDSON M J,  REDDIN K M,  ROBINSON A;  WO2010036938-A2   NANOBIO CORP (NANO-Non-standard)   BAKER J R,  HAMOUDA T,  SUTCLIFFE J A;  WO2012097185-A2   TULANE EDUCATIONAL FUND (TULA)   MORICI L A;  US2023146032-A1 -- US20140004178-A1   ;  US20150118263-A1   ;  US11534486-B2   TULANE EDUCATIONAL FUND (TULA)   MORICI L A,  MCLACHLAN J B,  DAVITT C J,  KURTZ J R;  US11925681-B2 -- US20140004178-A1   ;  US20150118263-A1   ;  US11534486-B2   TULANE EDUCATIONAL FUND (TULA)   MORICI L A,  MCLACHLAN J B,  DAVITT C J,  KURTZ J R;  US20170333543-A1   ;  US9526775-B2   UNIV ALBERTA (UYAL)   FELDMAN M,  PRICE N,  GARCIA-QUINTANILLA F,  IELMINI M V;  US10639280-B2   STAAT NEDERLANDEN MIN VWS MIN VOLKS (NEVW-Non-standard)   SALVERDA M L M,  VAN DER LEY P A;  US11066453-B2   UNIV TRENTO (UYTR-Non-standard)   GRANDI G,  CAFARDI V,  FANTAPPIE L,  GRIFANTINI R,  GRANDI A;  WO2003051379-A1   MICROBIOLOGICAL RES AUTHORITY (MICR-Non-standard)   FOSTER K A,  GORRINGE A R,  HUDSON M J,  REDDIN K M,  ROBINSON A;  WO2010036938-A2   NANOBIO CORP (NANO-Non-standard)   BAKER J R,  HAMOUDA T,  SUTCLIFFE J A;  WO2012097185-A2   TULANE EDUCATIONAL FUND (TULA)   MORICI L A	WO2019199955-A1  CHEN, DJ ET AL.:          "Delivery of foreign antigens by engineered outer          membrane vesicle vaccines", PROCEEDINGS OF THE NATIONAL          ACADEMY OF SCIENCES OF THE USA, vol. 107, no. 7, 27          January 2010 (2010-01-27), pages 3099 - 3104,          XP055035314, DOI:          10.1073/pnas.0805532107,relevantClaims[1-47],relevantPassages[;          abstract; page 3102, 1st column, 6th paragraph; DOI:          10.1073/pnas.0805532107];  PETERSEN, H ET AL.:          "Evaluation of a Burkholderia pseudomallei Outer Membrane          Vesicle Vaccine in Nonhuman Primates", PROCEDIA IN          VACCINOLOGY, vol. 8, 1 January 2014 (2014-01-01), pages          38 - 42, XP009512885, DOI:          10.1016/j.provac.2014.07.007,relevantClaims[1-47],relevantPassages[;          abstract; page 40, 1st paragraph; Figure 2; DOI:          10.1016/j.provac.2014.07.007];  BAKER, SM ET AL.:          "A Burkholderia pseudomallei Outer Membrane Vesicle          Vaccine Provides Cross Protection against Inhalational          Glanders in Mice and Non-Human Primates", VACCINES, vol.          5, no. 4, 9 December 2017 (2017-12-09), pages 1 - 17,          XP009513004, DOI:          10.3390/vaccines5040049,relevantClaims[1-47]CN112203683-A  MOHAMMAD REZA          AGHASADEGHI ET AL.: "Application of outer membrane          vesicle of Neisseria meningitidis serogroup B as a new          adjuvant to induce strongly Th1-oriented responses          against HIV-1", CURR HIV RES, vol. 9, no. 8, pages 630 -          635,relevantClaims[1-47];  MATTHIAS J H          GERRITZEN ET AL.: "Bioengineering bacterial outer          membrane vesicles as vaccine platform", BIOTECHNOL ADV,          vol. 35, no. 5, pages 565 - 574, XP085118072, DOI:          10.1016/j.biotechadv.2017.05.003,relevantClaims[1-47];  ROBERT C ALANIZ ET          AL.: "Membrane vesicles are immunogenic facsimiles of          Salmonella typhimurium that potently activate dendritic          cells, prime B and T cell responses, and stimulate          protective immunity in vivo", J IMMUNOL, vol. 179, no.          11, pages 7692 - 7701, XP002721554, DOI:          10.4049/jimmunol.179.11.7692,relevantClaims[1-47];  JAIKIN E HARRELL ET          AL.: "An Outer Membrane Vesicle-Adjuvanted Oral Vaccine          Protects Against Lethal, Oral Salmonella Infection",          PATHOGENS, vol. 10, no. 5, pages 1 -          14,relevantClaims[1-47];  WILDALIZ NIEVES ET          AL.: "A Burkholderia pseudomallei outer membrane vesicle          vaccine provides protection against lethal sepsis", CLIN          VACCINE IMMUNOL, vol. 21, no. 5, pages 747 - 754,          XP009512886, DOI:          10.1128/CVI.00119-14,relevantClaims[1-47];  DAVID J CHEN ET          AL.: "Delivery of foreign antigens by engineered outer          membrane vesicle vaccines", PROC NATL ACAD SCI U S A,          vol. 107, no. 7, pages 3101 -          3103,relevantClaims[1-47];  WILDALIZ NIEVES ET          AL.: "A naturally derived outer-membrane vesicle vaccine          protects against lethal pulmonary Burkholderia          pseudomallei infection", VACCINE, vol. 29, no. 46, pages          8381 - 8382,relevantClaims[1-47]US11534486-B2            Nieves et al (Vaccine (2011), 29(46),          8381-8389).;            Baker, SM, A Burkholderia pseudomallei Outer Membrane          Vesicle Vaccine Provides Cross Protection against          Inhalational Glanders. Vaccines, Dec. 9, 2017, p. 1-17,          v. 5(4).;            Chen, DJ, et al., Delivery of foreign antigens by          engineered outer membrane vesicles. Proc Natl Acad Sci          USA, Feb. 16, 2017, epub Jan. 2017, pp. 3099-3104, v.          107(7).;            Petersen, H, et al., Evaluation of a Burkholderia          pseudomallei Outer Membrane Vaccine in Nonhuman Primates,          Procedia Vaccinol, Jan. 1, 2014, pp. 38-42, v.          8.;            Thomas, S, Intl Search Report, ISA/US, PCT/US19/26769,          dated Jul. 18, 2019.;            Thomas, S, Written Opinion, ISA/US, PCT/US19/26769, dated          Jul. 18, 2019.;            Fateh et al., New Insight into the Application of Outer          Membrane Vesicles of Gram-negative bacteria, Vaccine Res,          Aug. 2015, pp. 93-96, vol. 2, No. 5.US11925681-B2            Shi, S., et al., Vaccine adjuvants: Understanding the          structure and mechanism of adjuvanticity, Vaccine, 2019,          p. 3167-3178.;            Baker, SM, A Burkholderia pseudomallei Outer Membrane          Vesicle Vaccine Provides Cross Protection Against          Inhalational Glanders, Vaccines, Dec. 9, 2017, pp. 1-17,          v. 5(4).;            Chen, DJ, et al., Delivery of foreign antigens by          engineered outer membrane vesicles, Proc Natl Acad Sci          USA, Feb. 16, 2017, epub Jan. 2017, pp. 3099-3104, v.          107(7).;            Petersen, H., et al., Evaluation of a Burkholderia          pseudomallei Outer Membrane Vaccine in Nonhuman Primates,          Procedia Vaccinol., Jan. 1, 2014, pp. 38-42, v.          8.;            Thomas, S., Intl Search Report, ISA/US, PCT/US19/26769,          dated Jul. 18, 2019.;            Thomas, S., Written Opinion, ISA/US, PCT/US19/26769,          dated Jul. 18, 2019.;            Nieves, W., et al., A naturally derived outer-membrane          vesicle vaccine protects agains lethal pulmonary          Burkholderia pseudomallei infection, 2011, pp. 8381-8389,          v. 29.;            Fateh, A., et al., New insight into the application of          outer membrane vesicles of Gram-negative bacteria,          Vaccine Res., Aug. 11, 2015, 93-9, v. 2(5).;            Tuanyok, A., et al., Burkholderia humptydooensis sp.          nov., a new species related to Burkholderia thailandensis          and ... , App and Environ Microbiol, Mar. 2017, pp1-10, v          83(5).;            Godoy, D., et al., Multilocus Sequence Typing and          Evolutionary Relationships among the causative agents of          Meliodosis ... , J Clin Microbiol, May 2003, pp.          2068-2079, v. 41(5).;            Hall, C., et al., Expanding the Burkholderia pseudomallei          Complex with the addition of two novel species:          Burkholderia, App. and Environ Microbiol, Jan. 2022, pp.          1-12, v 88(1).						US2019388465-A1;  WO2020005841-A1;  CA3103914-A1;  CN112351766-A;  EP3810067-A1;  US2021260107-A1;  EP3810067-A4	Inhibiting microbial infection, reducing            occurrence and/or microbial infections duration            involves delivering oral composition comprising first            and second components comprising Eh-raising and zinc            compounds respectively in specified amounts	BURCH A L	TRIUMPH PHARM INC (TRIU-Non-standard);  TRIUMPH PHARM INC (TRIU-Non-standard);  CUIANGFENG PHARM CO (CUIA-Non-standard);  TRIUMPH PHARM INC (TRIU-Non-standard)	2019A74140	   NOVELTY - Inhibiting a microbial infection and reducing                the occurrence and/or duration of microbial                infections suffered by an individual comprises                delivering an oral composition into an oral cavity                of a subject, the oral composition comprises a                first component comprising 0.1-3.0 wt/vol.% t least                one Eh-raising compound and a second component                comprising 0.02-0.2 wt/vol.% a zinc compound.    USE - The methods are useful for inhibiting a                microbial infection in a subject; and reducing the                occurrence and/or duration of microbial infections                suffered by an individual, where the microbial                infection comprises a bacterial infection or a                viral infection (preferred), the viral infection is                caused by a virus comprising rhinovirus                (preferred), influenza virus, parainfluenza virus,                coronavirus, respiratory syncytial virus (RSV),                poliovirus, picornavirus, foot-and-mouth disease                virus, mengovirus or herpes virus (all claimed).                Test details are described but no results                given.    ADVANTAGE - The method: reduces the occurrence of                microbial infections over the course of one year                (claimed). 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  B03 (Other heterocyclics.);  B06 (Inorganics - including fluorides for toothpastes etc.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C02 (Heterocyclic.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)	B05-A01B;  B05-A03A4;  B05-C02;  B05-C05;  B05-C07;  B05-C08;  B07-D04A;  B10-C03;  B10-C04D;  B10-C04E6;  B12-M12N;  B14-A01;  B14-A02;  B14-A04;  B14-S12;  B14-S18;  C05-A01B;  C05-A03A4;  C05-C02;  C05-C05;  C05-C07;  C05-C08;  C07-D04A;  C10-C04D;  C10-C04E6;  C10-D03;  C12-M12N;  C14-A01;  C14-A02;  C14-A04;  C14-S12;  C14-S18;  D03-H01T2B	A23L-033/16;  A61K-031/4425;  A61K-033/14;  A61K-033/30;  A61K-033/40;  A61K-009/00;  A61K-009/08;  A61P-031/16;  A61K-008/20;  A61K-008/27;  A23L-033/00;  A61K-031/44;  A61K-033/00;  A23L-033/10	US2019388465-A1   26 Dec 2019   A61K-033/30   202002Pages: 24   English;  WO2020005841-A1   02 Jan 2020   A61K-008/20   202003   English;  CA3103914-A1   02 Jan 2020   A61K-008/20   202106   English;  CN112351766-A   09 Feb 2021   A61K-008/20   202118   Chinese;  EP3810067-A1   28 Apr 2021   A61K-008/20   202136   English;  US2021260107-A1   26 Aug 2021   A61K-033/30   202170   English;  EP3810067-A4   13 Apr 2022   A61K-008/20   202232   English	US2019388465-A1    US450163    24 Jun 2019;   WO2020005841-A1    WOUS038746    24 Jun 2019;   CA3103914-A1    CA3103914    24 Jun 2019;   CN112351766-A    CN80042780    24 Jun 2019;   EP3810067-A1    EP827212    24 Jun 2019;   US2021260107-A1    US17253910    18 Dec 2020;   EP3810067-A4    EP827212    24 Jun 2019	US2019388465-A1 Provisional Application US689366P;   CA3103914-A1 PCT application Application WOUS038746;   CA3103914-A1 Based on Patent WO2020005841;   CN112351766-A PCT application Application WOUS038746;   CN112351766-A Based on Patent WO2020005841;   EP3810067-A1 PCT application Application WOUS038746;   EP3810067-A1 Based on Patent WO2020005841;   US2021260107-A1 PCT application Application WOUS038746;   US2021260107-A1 Provisional Application US689366P	US689366P    25 Jun 2018;  US450163    24 Jun 2019;  WOUS038746    24 Jun 2019;  CA3103914    14 Dec 2020;  US17253910    18 Dec 2020;  CN80042780    24 Dec 2020	  WO2020005841-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP3810067-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    EP3810067-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  		;  WO2020005841-A1 -- US20010006624-A1   ;  US20060045855-A1   ;  US20120034280-A1   ;  CN112351766-A -- CN1248155-A   UNIV NEW YORK STATE RES FOUND (UNYS)   KLEINBERG I,  CODIPILLY M;  CN1845877-A   OCULUS INNOVATIVE SCI INC (OCUL-Non-standard)   ALIMI H;  CN102481357-A   OCULUS INNOVATIVE SCI INC (OCUL-Non-standard)   ALIMI H,  THATCHER E;  CN103221031-A   UNIV NEW YORK STATE RES FOUND (UNYS)   COHEN M,  COHEN S,  FLYNN B;  CN105246332-A   HONBU SANKEI CO LTD (HONB-Non-standard)   GODA H;  US9072753-B1   BROWN A C (BROW-Individual)   BROWN A C;  EP3810067-A4 -- US20120034280-A1   ;  US20120148506-A1   ;  WO2009116944-A1   TANO K (TANO-Individual)   TANO K	WO2020005841-A1  GEIST, FC ET AL.:          "In Vitro Activity of Zinc Salts against Human          Rhinoviruses", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,          vol. 31, no. 4, 1987, pages 622 - 624,          XP002494070,relevantClaims[3-5, 21-23],relevantPassages[;          page 622, column 1, first - second paragraphs]EP3810067-A4  GEIST F C ET AL:          "In vitro activity of zinc salts against human          rhinoviruses", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,          AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 31, no. 4, 1          January 1987 (1987-01-01), pages 622 - 624, XP002494070,          ISSN:          0066-4804,relevantClaims[1-15],relevantPassages[&lt;table&gt;1-4&lt;/table&gt;];  NIMS RAYMOND W ET          AL: "Intra-family differences in efficacy of inactivation          of small, non-enveloped viruses", BIOLOGICALS, ACADEMIC          PRESS LTD., LONDON, GB, vol. 44, no. 5, 26 July 2016          (2016-07-26), pages 456 - 462, XP029718202, ISSN:          1045-1056, DOI:          10.1016/J.BIOLOGICALS.2016.05.005,relevantClaims[1-15],relevantPassages[&lt;table&gt;6&lt;/table&gt;];            See also references of WO 2020005841A1	2895-0-0-0 K M; 110843-0-0-0 K M; 110858-0-0-0 K M; 125-0-0-0 K M; 131724-0-0-0 K M; 133223-0-0-0 K M; 129375-0-0-0 K M; 209-0-0-0 K M; 107326-0-0-0 K M; 1461-0-0-0 K M			R04654 K M; R01703 K M; RA07Q2 K M; R01741 K M; RA046W K M; R05406 K M; R08968 K M; R09501 K M; R15440 K M; RBOAGA K M; R01774 K M; R01732 K M; R01754 K M; RACL56 K M	1036-S; 1741-S; 0247-S; 0009-S; 0291-S; 1774-S; 1732-S; 1754-S	WO2019173602-A1;  CA3093222-A1;  AU2019231725-A1;  CN112074506-A;  KR2020140274-A;  BR112020018209-A2;  EP3762372-A1;  SG11202008527-A1;  GB2589205-A;  VN76426-A;  JP2021517132-W;  PH12020551404-A1;  US2021308168-A1;  IN202017043621-A;  EP3762372-A4;  RU2020132881-A;  GB2611644-A;  IL277160-A;  GB2589205-B;  GB2611644-B;  JP7371931-B2;  JP2024009953-A;  RU2819040-C2;  US2024180948-A1;  ID202107952-A1;  AU2019231725-B2	Composition useful in pressurized container to            treat or prevent viral infection e.g. infection of            Eastern equine encephalitis virus and Western equine            encephalitis virus comprises excipient and 4-halo            containing nucleotide or nucleoside	PAINTER G R;  PERRYMAN D;  BLUEMLING G R;  PEINTER D R;  PERRIMAN D;  BLUMLING G R	UNIV EMORY (UEMR-C);  UNIV EMORY (UEMR-C);  UNIV EMORY (UEMR-C);  UNIV EMORY (UEMR-C)	2019788509	   NOVELTY - Composition comprises an excipient and a                4-halo containing nucleotide or nucleoside compound                (I).    USE - The composition is useful in a pressurized                container for treating or preventing a viral                infection in a subject, where the viral infection                is infection of Togaviridae, Coronaviridae, Eastern                equine encephalitis virus, Western equine                encephalitis virus, Venezuelan equine encephalitis                virus, Chikungunya virus, Ross River virus,                influenza A virus, influenza B virus, respiratory                syncytial virus, Orthomyxoviridae virus,                Pneumoviridae, Arenaviridae, human coronavirus,                severe acute respiratory syndrome coronavirus,                middle east respiratory syndrome coronavirus,                Tacaribe virus, Pichinde virus, Junin virus, Lassa                fever virus, Lymphocytic choriomeningitis virus,                Bunyaviridae, Rift Valley fever virus, Punta Toro                virus, La Crosse virus, Maporal virus, Heartland                virus, severe fever thrombocytopenia syndrome                virus, Flaviviridae, Zika virus, Dengue virus 1,                Dengue virus 2, Dengue virus 3, Dengue virus 4,                West Nile virus, Yellow fever virus, Japanese                encephalitis virus, Powassan virus, Usutu virus,                tick-borne encephalitis virus, Picornaviridae,                poliovirus, Coxsackie virus and enterovirus (all                claimed).    ADVANTAGE - The composition exhibits increased                bioavailability. The pharmacokinetic profile (Cmax)                of composition was tested in mouse using in vivo                assay. The result showed that the mouse orally                administered with 500 mg/kg composition exhibited a                Cmax value of                1-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione                of 76 plus minus 15.3 nmol/ml in blood.    DETAILED DESCRIPTION - Composition comprises an excipient and a                4-halo containing nucleotide or nucleoside compound                (I) of formula (Ia) or (Ib) or its stereoisomer or                salt.    X1 = CH2, CH(CH3), C(CH3)2, CHF, CF2 or                CD2;    U1 = O, S, NH, NR7, CH2, CHF, CF2, CCH2 or                CCF2 ;    Q1 = natural or unnatural nucleobase;    R1 = e.g. esters, branched esters, carbonates,                carbamates, thioesters, branched thioesters,                thiocarbonates, S-thiocarbonate, dithiocarbonates,                thiocarbamates, oxymethoxycarbonyl,                oxymethoxythiocarbonyl, oxymethylcarbonyl,                oxymethylthiocarbonyl, sulfenyl, imidate,                hydrazonate, oximyl, imidinyl, imidyl, aminal,                hemiaminal, acetal, hemiacetal, carbonimidate,                thiocarbonimidate, carbonimidyl, carbamimidate,                carbamimidyl, thioacetal, S-acyl-2-thioethyl,                bis-(acyloxybenzyl)esters, (acyloxybenzyl)esters                (all optionally substituted with at least one R10),                H, R5O-C(O)-C(CH3)-NH-P(=Y11)(Y2)-,                R5O-C(O)-C(CH3)-NH-P(=Y11)(Y2)-O-P(=Y11)(Y2)-,                HO-P(=O)(OH)-O-P(=Y11)(Y2)-,                HO-P(=O)(OH)-O-P(=O)(OH)-O-P(=Y11)(Y2)-, R6-C(O)-,                substituted cyclic phosphates of formula (z1)-(z5),                substituted amine of formula (z6) or (z7), L-amino                acid esters, D-amino acid esters, N-substituted                L-amino acid esters, N,N-disubstituted L-amino acid                esters, N-substituted D-amino acid esters,                N,N-disubstituted D-amino acid esters and                bis-(4-acyloxybenzyl)-esters;    Y11 = O or S;    Y1 = OH, OY3 or BH3-M+;    Y2 = OH or BH3-M+;    Y3 = aryl, heteroaryl or heterocyclyl (all                optionally substituted with at least one R10);                either    R2, R21, R3, R31 = H, D, alkyl, alkenyl,                alkynyl, allenyl, alkoxy, OH, thiol, amino, azido,                formyl, acyl, cyano, halo, aryl, heteroaryl,                heterocyclyl, carbocyclyl, heterocarbocyclyl,                sulfinyl, sulfamoyl or sulfonyl, where R2, R21, R3                and R31 are optionally substituted with at least                one R10; or    CR2R21, CR3R31 = ring (optionally substituted                with at least one R10);    R4 = H or D;    R5 = H, alkyl, alkenyl, alkynyl, carbocyclyl,                heterocarbocyclyl, aryl, heteroaryl, heterocyclyl,                cycloalkyl, cycloalkenyl, allenyl or lipid, where                R5 is optionally substituted with at least one                R10;    R6, R6a, R6b and R6c = H, D, OH, amino, azido,                thiol, acyl, formyl, halo, nitro, alkyl, alkenyl,                alkynyl, carbocyclyl, heterocarbocyclyl, aryl,                heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl,                alkoxy, carbocycloxy, heterocarbocycloxy, aryloxy,                heteroaryloxy, heterocycloxy, cycloalkoxy,                cycloalkenoxy, alkylamino, di(alkyl)amino,                carbocyclamino, heterocarbocyclamino, arylamino,                heteroarylamino, heterocyclamino, cycloalkamino,                cycloalkenamino, alkylthio, carbocyclylthio,                heterocarbocyclylthio, arylthio, heteroarylthio,                heterocyclylthio, cycloalkylthio, cycloalkenylthio,                sulfinyl, sulfamoyl, sulfonyl, allenyl, cyano, or                lipid, where R6, R6a, R6b and R6c can each be                optionally substituted with at least one R10;                either    R7, R71 = H or J1, where R7 is optionally                substituted with at least one R10; and    R8-R11 = J1, where R8 and R9 are optionally                substituted with at least one R10, and R10 is                optionally substituted with at least one R11;                or    R7R71, R8R9 = ring with the alpha -carbon                which they are attached to and the amino group                attached to the alpha -carbon, where the ring is                optionally substituted with at least one R10;                or    R7R71, R8R9 = ring with the alpha -carbon                which they are attached, where the ring is                optionally substituted with at least one R10;    J1 = D, OH, azido, thiol, amino, cyano, halo,                alkyl, alkenyl, alkynyl, carbocyclyl,                heterocarbocyclyl, aryl, heteroaryl, heterocyclyl,                cycloalkyl, cycloalkenyl, alkoxy, carbocycloxy,                heterocarbocycloxy, aryloxy, heteroaryloxy,                heterocycloxy, cycloalkoxy, cycloalkenoxy,                alkylamino, di(alkyl)amino, carbocyclamino,                heterocarbocyclamino, arylamino, heteroarylamino,                heterocyclamino, cycloalkamino, cycloalkenamino,                alkylthio, carbocyclylthio, heterocarbocyclylthio,                arylthio, heteroarylthio, heterocyclylthio,                cycloalkylthio, cycloalkenylthio, allenyl,                sulfinyl, sulfamoyl, sulfonyl, lipid, nitro or                carbonyl; and    lipid = 11-22C higher alkyl, 11-22C higher                alkoxy, polyethylene glycol or aryl substituted                with alkyl, or lipid.    An INDEPENDENT CLAIM is also included for a                pressurized container comprising the                composition. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-B03D;  B04-B03E;  B14-A02;  B14-C03;  B14-C04;  B14-F03;  B14-K01D;  C04-E99;  C04-B03D;  C04-B03E;  C14-A02;  C14-C03;  C14-C04;  C14-F03;  C14-K01D;  D05-H99;  D05-H	A61K-031/505;  C07D-239/10;  C07D-307/12;  C07D-405/04;  A61K-031/7072;  A61K-031/7088;  A61P-031/12;  A61P-031/14;  A61K-009/12;  A61P-031/16;  A61K-009/72;  A61P-031/20;  A61P-031/22;  A61P-043/00;  A61K-031/7068;  C07K-016/10;  C07H-019/10;  A61K-045/06;  C07H-019/06;  C07H-019/067;  C07H-019/20;  C07H-019/207;  C07H-019/213;  C07H-019/11;  C07H-019/14	WO2019173602-A1   12 Sep 2019   C07D-307/12   201975Pages: 591   English;  CA3093222-A1   12 Sep 2019   A61K-031/7072   202080   English;  AU2019231725-A1   08 Oct 2020   C07D-307/12   202082   English;  CN112074506-A   11 Dec 2020   C07D-307/12   202002   Chinese;  KR2020140274-A   15 Dec 2020   A61K-031/7072   202102   ;  BR112020018209-A2   29 Dec 2020   C07D-307/12   202105   English;  EP3762372-A1   13 Jan 2021   C07D-307/12   202106   English;  SG11202008527-A1   29 Oct 2020   C07D-307/12   202109   English;  GB2589205-A   26 May 2021   C07D-307/12   202145   English;  JP2021517132-W   15 Jul 2021   A61K-031/7072   202158Pages: 603   Japanese;  PH12020551404-A1   21 Jun 2021   A61K-031/505   202167   English;  US2021308168-A1   07 Oct 2021   A61K-031/7068   202182   English;  IN202017043621-A   24 Sep 2021   C07K-016/10   202183   English;  EP3762372-A4   08 Dec 2021   A61K-031/505   202100   English;  RU2020132881-A   12 Apr 2022   C07D-307/12   202272   Russian;  GB2611644-A   12 Apr 2023   A61K-031/7072   202332   English;  IL277160-A   29 Oct 2020   A61K-031/505   202341   English;  GB2589205-B   24 May 2023   A61K-031/7072   202343   English;  GB2611644-B   26 Jul 2023   A61K-031/7072   202361   English;  JP7371931-B2   31 Oct 2023   C07H-019/213   202390   Japanese;  JP2024009953-A   23 Jan 2024   A61K-031/7072   202410   Japanese;  RU2819040-C2   13 May 2024   C07D-307/12   202447   Russian;  US2024180948-A1   06 Jun 2024   A61K-031/7068   202447   English;  ID202107952-A1   27 Sep 2021   C07D-307/12   202447;  AU2019231725-B2   20 Jun 2024   C07D-307/12   202452   English	WO2019173602-A1    WOUS021168    07 Mar 2019;   CA3093222-A1    CA3093222    07 Mar 2019;   AU2019231725-A1    AU231725    07 Mar 2019;   CN112074506-A    CN80030574    07 Mar 2019;   KR2020140274-A    KR728655    07 Mar 2019;   BR112020018209-A2    BR11018209    07 Mar 2019;   EP3762372-A1    EP764729    07 Mar 2019;   SG11202008527-A1    SG11008527    07 Mar 2019;   GB2589205-A    GB015827    07 Mar 2019;   VN76426-A    VN005714    07 Mar 2019;   JP2021517132-W    JP546962    07 Mar 2019;   PH12020551404-A1    PH551404    07 Sep 2020;   US2021308168-A1    US16979108    08 Sep 2020;   IN202017043621-A    IN17043621    07 Oct 2020;   EP3762372-A4    EP764729    07 Mar 2019;   RU2020132881-A    RU132881    07 Mar 2019;   GB2611644-A    GB018405    07 Dec 2022;   IL277160-A    IL277160    07 Mar 2019;   GB2589205-B    GB015827    07 Mar 2019;   GB2611644-B    GB018405    07 Dec 2022;   JP7371931-B2    JP546962    07 Mar 2019;   JP2024009953-A    JP176993    12 Oct 2023;   RU2819040-C2    RU132881    07 Mar 2019;   US2024180948-A1    US359435    26 Jul 2023;   ID202107952-A1    IDP07314    07 Mar 2019;   AU2019231725-B2    AU231725    07 Mar 2019	CA3093222-A1 PCT application Application WOUS021168;   CA3093222-A1 Based on Patent WO2019173602;   AU2019231725-A1 PCT application Application WOUS021168;   AU2019231725-A1 Based on Patent WO2019173602;   CN112074506-A PCT application Application WOUS021168;   CN112074506-A Based on Patent WO2019173602;   KR2020140274-A PCT application Application WOUS021168;   KR2020140274-A Based on Patent WO2019173602;   BR112020018209-A2 PCT application Application WOUS021168;   BR112020018209-A2 Based on Patent WO2019173602;   EP3762372-A1 PCT application Application WOUS021168;   EP3762372-A1 Based on Patent WO2019173602;   SG11202008527-A1 PCT application Application WOUS021168;   SG11202008527-A1 Based on Patent WO2019173602;   GB2589205-A PCT application Application WOUS021168;   GB2589205-A Based on Patent WO2019173602;   VN76426-A PCT application Application WOUS021168;   VN76426-A Based on Patent WO2019173602;   JP2021517132-W PCT application Application WOUS021168;   JP2021517132-W Based on Patent WO2019173602;   PH12020551404-A1 PCT application Application WOUS021168;   PH12020551404-A1 Based on Patent WO2019173602;   US2021308168-A1 PCT application Application WOUS021168;   US2021308168-A1 Provisional Application US639725P;   IN202017043621-A PCT application Application WOUS021168;   IN202017043621-A Based on Patent WO2019173602;   RU2020132881-A PCT application Application WOUS021168;   RU2020132881-A Based on Patent WO2019173602;   GB2611644-A Div ex Application GB015827;   IL277160-A Based on Patent WO2019173602;   GB2589205-B PCT application Application WOUS021168;   GB2589205-B Based on Patent WO2019173602;   GB2611644-B Div ex Application GB015827;   JP7371931-B2 PCT application Application WOUS021168;   JP7371931-B2 Previous Publ. Patent JP2021517132;   JP7371931-B2 Based on Patent WO2019173602;   JP2024009953-A Div ex Application JP546962;   RU2819040-C2 PCT application Application WOUS021168;   RU2819040-C2 Based on Patent WO2019173602;   US2024180948-A1 Cont of Application WOUS021168;   US2024180948-A1 Cont of Application US979108;   US2024180948-A1 Provisional Application US639725P;   AU2019231725-B2 PCT application Application WOUS021168;   AU2019231725-B2 Based on Patent WO2019173602	US639725P    07 Mar 2018;  WOUS021168    07 Mar 2019;  BR11018209    04 Sep 2020;  CA3093222    04 Sep 2020;  US16979108    08 Sep 2020;  GB015827    06 Oct 2020;  KR728655    06 Oct 2020;  RU132881    07 Oct 2020;  CN80030574    05 Nov 2020;  US359435    26 Jul 2023	WO2019173602-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA            EP3762372-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN              EP3762372-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR                        		WO2019173602-A1 -- US20060014709-A1   ;  US20100189772-A1   ;  US20140294769-A1   ;  US20170253628-A1   ;  WO2017040896-A1   ABBVIE INC (ABBI)   CHEN H J,  DEGOEY D A,  KALTHOD V,  KRUEGER A C,  RANDOLPH J T,  WAGNER R;  WO2017223020-A1   MERCK SHARP & DOHME CORP (MERI);  IDENIX PHARM LLC (INEM);  BOGEN S (BOGE-Individual);  DUKHAN D (DUKH-Individual);  ALEXANDRE F (ALEX-Individual);  RAHALI R (RAHA-Individual);  PARSY C C (PARS-Individual);  MILHAU J (MILH-Individual);  ROUVIERE C P (ROUV-Individual);  DOUSSON C B (DOUS-Individual)   BOGEN S,  DUKHAN D,  ALEXANDRE F,  RAHALI R,  PARSY C C,  MILHAU J,  ROUVIERE C P,  DOUSSON C B;  WO2009058800-A2   HARVARD COLLEGE (HARD)   LEE S,  VERDINE G L;  CN112074506-A -- CN105829333-A   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  CN106573011-A   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  SMITH D B,  SYMONS J A;  TW201542578-A   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JIN Z;  US20150011497-A1   ;  US2021308168-A1 -- US20130315868-A1   ;  EP3762372-A4 -- WO2013092481-A1   HOFFMANN LA ROCHE&CO AG F (HOFF)   ZHANG J,  ZHANG Z;  WO2013177219-A1   MAYES B A (MAYE-Individual);  MOUSSA A M (MOUS-Individual);  STEWART A J (STEW-Individual)   MAYES B A,  MOUSSA A M,  STEWART A J;  WO2014100505-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  WANG G,  SMITH D B;  WO2014186637-A1   RIBOSCIENCE LLC (RIBO-Non-standard)   KLUMPP K G,  SMITH M;  WO2015054465-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  WO2015200205-A1   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  DYATKINA N (DYAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  DYATKINA N,  SMITH D B,  SYMONS J A;  WO2016100441-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  SMITH D B,  WANG G,  DYATKINA N;  WO2016134054-A1   ABBVIE INC (ABBI)   CHEN H J,  DEGOEY D A,  KALTHOD V,  KRUEGER A C,  WAGNER R,  RANDOLPH J T;  WO2017040892-A1   ABBVIE INC (ABBI)   CHEN H J,  DEGOEY D A,  KALTHOD V,  KRUEGER A C,  RANDOLPH J T,  WAGNER R;  WO1993017651-A2   ;  GB2589205-B -- US20060014709-A1   ;  US20100189772-A1   ;  US20120035115-A1   ;  US20140294769-A1   ;  US20170253628-A1   ;  WO2014186637-A1   RIBOSCIENCE LLC (RIBO-Non-standard)   KLUMPP K G,  SMITH M;  WO2014209979-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JIN Z;  WO2016134054-A1   ABBVIE INC (ABBI)   CHEN H J,  DEGOEY D A,  KALTHOD V,  KRUEGER A C,  WAGNER R,  RANDOLPH J T;  WO2017040896-A1   ABBVIE INC (ABBI)   CHEN H J,  DEGOEY D A,  KALTHOD V,  KRUEGER A C,  RANDOLPH J T,  WAGNER R;  WO2017165489-A1   UNIV EMORY (UEMR)   SCHINAZI R F,  AMBLARD F,  COX B D,  BASSIT L,  ZHOU L,  GAVEGNANO C;  WO2017223020-A1   MERCK SHARP & DOHME CORP (MERI);  IDENIX PHARM LLC (INEM);  BOGEN S (BOGE-Individual);  DUKHAN D (DUKH-Individual);  ALEXANDRE F (ALEX-Individual);  RAHALI R (RAHA-Individual);  PARSY C C (PARS-Individual);  MILHAU J (MILH-Individual);  ROUVIERE C P (ROUV-Individual);  DOUSSON C B (DOUS-Individual)   BOGEN S,  DUKHAN D,  ALEXANDRE F,  RAHALI R,  PARSY C C,  MILHAU J,  ROUVIERE C P,  DOUSSON C B;  WO1993017651-A2   ;  WO2009058800-A2   HARVARD COLLEGE (HARD)   LEE S,  VERDINE G L;  WO2015051169-A2   MODERNA THERAPEUTICS INC (MODR)   FRALEY A W,  ROY A,  STANTON M;  GB2611644-B -- US20120035115-A1   ;  WO2017165489-A1   UNIV EMORY (UEMR)   SCHINAZI R F,  AMBLARD F,  COX B D,  BASSIT L,  ZHOU L,  GAVEGNANO C;  WO1993017651-A2   ;  WO2015051169-A2   MODERNA THERAPEUTICS INC (MODR)   FRALEY A W,  ROY A,  STANTON M	WO2019173602-A1  HARAGUCHI K., ET          AL.: "Ring Opening of 4',5'-Epoxynucleosides: A Novel          Stereoselective Entry to 4'-C-Branched Nucleosides",          ORGANIC LETTERS, vol. 5, no. 9, May 2003 (2003-05-01),          pages 1399 - 1402, XP055635757,relevantClaims[1-4,          202-222],relevantPassages[, abstract and Supporting          Information Pgs. 1-11];  SHIMADA H., ET AL.:          "Nucleophilic substitution approach to 4'-substituted          thymidines by employing 4'-benzenesulfonyl leaving          group", TETRAHEDRON, vol. 65, no. 31, August 2009          (2009-08-01), pages 6008 - 6016,          XP055635765,relevantClaims[1-4, 202-222]US2021308168-A1            Sofia, M.J., Antiviral Chemistry & Chemotherapy,          2011, 22, p23-49. (Year: 2011)EP3762372-A4            See also references of WO 2019173602A1GB2589205-B            HARAGUCHI K., et al., "Ring Opening of          4',5'-Epoxynucleosides: A Novel Stereoselective Entry to          4'-C-Branched Nucleosides", Organic Letters, vol. 5, no.          9, 03 April 2003, pages 1399 - 1402, - abstract and          Supporting Information Pgs. 1-11 *;            SHIMADA H., et al., "Nucleophilic substitution approach          to 4'-substituted thymidines by employing          4'-benzenesulfonyl leaving group", Tetrahedron, vol. 65,          no. 31, 03 June 2009, pages 6008 - 6016,;            Journal of Organic Chemistry, Vol. 83(17), 2018          (published 2 July 2018), (Malek-Adamian, Elise et al),          pages 9839-9849, ISSN: 0022-3263.;            Journal of Organic Chemistry, Vol. 79(12), 2014,          (Martinez-Montero, Saul et al), pages 5627-5635, ISSN:          0022-3263.;            Russian Journal of Bioorganic Chemistry, Vol. 36(4),          2010, (Ivanov, M. A. et al), pages 488-496, ISSN:          1068-1620.;            Journal of Organic Chemistry, Vol. 80(6), 2015,          (Martinez-Montero, Saul et al), pages 3083-3091, ISSN:          0022-3263.	 K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U	216470401 K U; 216470402 K U; 216470403 K U; 216470404 K U	00211; 00212; 00218; 01528; 41247; 00265	RCNS7Y K U; RCNS7Z K U; RCNS80 K U; RCNS81 K U; RCNS82 K U; RCNS83 K U; RCNS84 K U; RCNS85 K U; RCNS86 K U; RCNS87 K U; RCNS88 K U; RCNS89 K U; RCNS8A K U; RCNS8B K U; RCNS8C K U; RCNS8D K U; RCNS8E K U; RCNS8F K U; RCNS8G K U; RCNS8H K U; RCNS8I K U; RCNS8J K U; RCNS8K K U; RCNS8L K U; RCNS8M K U; RCNS8N K U; RCNS8O K U; RCNS8P K U; RCNS8Q K U; RCNS8R K U; RCNS8S K U; RCNS8T K U; RCNS8U K U; RCNS8V K U; RCNS8W K U; RCNS8X K U; RCNS8Y K U; RCNS8Z K U; RCNS90 K U; RCNS91 K U; RCNS92 K U; RCNS93 K U; RCNS94 K U; RCNS95 K U; RCNS96 K U; RCNS97 K U; RCNS98 K U; RCNS99 K U; RCNS9A K U; RCNS9B K U; RCNS9C K U; RCNS9D K U; RCNS9E K U; RCNS9F K U; RCNS9G K U; RCNS9H K U; RCNS9I K U; RCNS9J K U; RCNS9K K U; RCNS9L K U; RCNS9M K U; RCNS9N K U; RCNS9O K U; RCNS9P K U; RCNS9Q K U; RCNS9R K U; RCNS9S K U; RCNS9T K U; RCNS9U K U; RCNS9V K U; RCNS9W K U; RCNS9X K U; RCNS9Y K U; RCNS9Z K U; RCNSA0 K U; RCNSA1 K U; RCNSA2 K U; RCNSA3 K U; RCNSA4 K U; RCNSA5 K U; RCNSA6 K U; RCNSA7 K U; RCNSA8 K U; RCNSA9 K U; RCNSAA K U; RCNSAB K U; RCNSAC K U; RCNSAD K U; RCNSAE K U; RCNSAF K U; RCNSAG K U; RCNSAH K U; RCNSAI K U; RCNSAJ K U; RCNSAK K U		WO2019022357-A1;  KR1944909-B1	Pharmaceutical composition, health functional food or anti-absorption agent useful for preventing or treating Middle East respiratory syndrome, contains 3-((3-methyl-1-((3-methylbutyl)carbamoyl)butyl)carbamoyl)oxirane-2-carboxylic acid	KIM S;  KIM J Y;  KIM I K;  KIM S H	UNIV ULSAN FOUND IND COOP (ULAS-C);  ASAN FOUND (ASFO-C)	201912244S	   NOVELTY - Pharmaceutical composition, health functional food or anti-absorption agent comprises 3-((3-methyl-1-((3-methylbutyl)carbamoyl)butyl)carbamoyl)oxirane-2-carboxylic acid (I) or dihydrotanshinone (II) and their salts or prodrugs as an active ingredient.    USE - The pharmaceutical composition or health functional food is useful for preventing or treating Middle East respiratory syndrome (MERS) and providing anti-viral effect against MERS coronavirus (CoV). The agent is useful in coating agent, detergent and spray for inhibiting absorption of MERS-CoV. The detergent includes automotive detergent, oral detergent or hand detergent. The spray includes eye spray, nasal spray or oral spray (all claimed). The agent is useful in human and animal foodstuffs, pharmaceutical products, veterinary products, cosmetics, mask or filter products, personal hygiene products and household articles.    ADVANTAGE - The composition does not cause cytotoxicity, and causes reduced side effects.    DETAILED DESCRIPTION - Pharmaceutical composition, health functional food or anti-absorption agent comprises 3-((3-methyl-1-((3-methylbutyl)carbamoyl)butyl)carbamoyl)oxirane-2-carboxylic acid of formula (I), dihydrotanshinone of formula (II) and their salts or prodrugs as an active ingredient. 			B03 (Other heterocyclics.);  B02 (Fused ring heterocyclics.);  C02 (Heterocyclic.);  D25 (Detergents - other than soap and used for cleaning (C11D));  ;  G02 (Inks, paints, polishes â€“ polymer-based paints and inks are also classified in Section A (C09D, F, G).)	B06-A03;  B07-A03;  B14-A02B5;  B14-E11;  B14-K01D;  B14-N03;  B14-R01;  B14-S12;  B14-S18;  C06-A03;  C07-A03;  C14-A02B5;  C14-E11;  C14-K01D;  C14-N03;  C14-R01;  C14-S12;  C14-S18;  D03-G;  D08-B09A2B;  D09-A01;  G02-A05	A23L-033/10;  A61K-031/336;  A61K-031/343;  A61K-008/49;  A61K-009/00;  A61Q-019/10	WO2019022357-A1   31 Jan 2019   A61K-031/336   201914Pages: 33   ;  KR1944909-B1   07 Feb 2019   A61K-031/336   201914   	WO2019022357-A1    WOKR005761    21 May 2018;   KR1944909-B1    KR095963    28 Jul 2017		KR095963    28 Jul 2017	WO2019022357-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    		WO2019022357-A1 -- KR2013071032-A   KOREA RES INST BIOSCIENCE & BIOTECHNOLOG (KRIB)   LEE W S,  RYU Y B,  KIM Y M,  PARK S J,  KWON H J,  RHO M C,  OH H M,  JUNG H J;  KR2017009276-A   IL YANG PHARM CO LTD (ILYA-Non-standard)   KIM D Y,  PARK M S,  CHO D J,  LEE G Y,  KIM H Y,  LEE H U,  AHN C A,  BANG H J,  SONG S E,  PARK J S;  US20070203073-A1   	WO2019022357-A1  HU , XIN ET AL.: "Kinetic, Mutational, and Structural Studies of the Venezuelan Equine Encephalitis Virus Nonstructural Protein 2 Cysteine Protease", BIOCHEMISTRY, vol. 55, no. 21, 2016, pages 3007 - 3019, XP055567283,relevantClaims[1-10],relevantPassages[See the entire document.];  PARK. JI-YOUNG ET AL.: "Tanshinones as Selective and Slow-binding Inhibitors for SARS-CoV Cysteine Proteases", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 20, no. 19, 2012, pages 5928 - 5935, XP055567436,relevantClaims[1-10],relevantPassages[See the entire document.]	93883-1-0-0 K M; 93228-1-0-0 K M		00012; 04645	RAAFVZ K M; RADF86 K M		WO2019053696-A1;  CA3075950-A1;  AU2018332540-A1;  SG11202002295-A1;  EP3684782-A1;  CN111542531-A;  KR2020098483-A;  US2020277321-A1;  IN202017016460-A;  BR112020005177-A2;  JP2020534361-W;  PH12020550114-A1;  VN74551-A;  US11149049-B2;  US2021395288-A1;  HK40034999-A0;  IL273341-A;  US11773126-B2;  AU2018332540-B2;  IN481446-B	New substituted            pyrrolo(2,1-f)(1,2,4)triazin-4-ylamine compounds used            to treat e.g. Picornaviridae viral infection,            Flaviviridae viral infection, Hepacivirus infection,            Pneumoviridae viral infection and Coronaviridae viral            infection	BEIGELMAN L;  DEVAL J;  PRHAVC M	ALIOS BIOPHARMA INC (JOHJ-C);  JANSSEN BIOPHARMA INC (JOHJ-C);  JANSSEN BIOPHARMA INC (JOHJ-C);  JANSSEN BIOPHARMA INC (JOHJ-C);  JANSSEN BIOPHARMA INC (JOHJ-C);  ALIOS BIOPHARMA INC (JOHJ-C);  JANSSEN PHARM INC (JANC-C)	201926118U	   NOVELTY - Substituted                pyrrolo(2,1-f)(1,2,4)triazin-4-ylamine compounds                (I) are new.    USE - (I) are useful for treating Picornaviridae                viral infection e.g. Rhinovirus infection,                Flaviviridae viral infection e.g. Dengue virus                infection, Hepacivirus infection and ebola virus                infection, Pneumoviridae viral infection e.g. human                respiratory syncytial virus infection,                Coronaviridae viral infection e.g. human alpha                -coronavirus viral infection, human beta                -coronavirus viral infection or panviral (all                claimed). The ability of (I) to treat viral                infection was tested in HeLa-OHIO cells using                Rhinovirus antiviral assay. The result showed that                (2R,3R,4S,5S)-2-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile                exhibited an EC50 value of 0.12 mu M.    ADVANTAGE - (I) has low toxicity.    DETAILED DESCRIPTION - Substituted                pyrrolo(2,1-f)(1,2,4)triazin-4-ylamine compounds of                formula (I) and their salts are new.    R1A = 1-4C alkyl (substituted with at least                one F or Cl), F, CN, azido, unsubstituted 2-4C                alkenyl, unsubstituted 2-4C alkynyl, unsubstituted                1-4C alkoxy or unsubstituted 1-4C alkyl;    R4A = 1-4C alkyl (substituted with at least                one F or Cl), F, CN, azido, an unsubstituted 2-4C                alkenyl, an unsubstituted 2-4C alkynyl, an                unsubstituted 1-4C alkoxy, an unsubstituted 1-4C                alkyl;    R2A, R3A, Ra1, Ra2 = H or D;    R5A = acyl, O-linked amino acid (both                optionally substituted), H, R6AO-P((=Z1A)(OR7A))-,                R8AO-P((=Z2A)(OR9A))- or R10AO-P((=Z3A)(OR11A))-;                either    R6A, R7A, R8A = e.g. 1-24C alkyl, 3-24C                alkenyl, 3-24C alkynyl, 3-6C cycloalkyl, 3-6C                cycloalkenyl, aryl, heteroaryl, aryl(1-6C alkyl),                -(CR15AR16A)p-O-1-24C alkyl, (CR17AR18A)q-O-1-24C                alkenyl (all optionally substituted), absent, H and                -C((R19A)(R20A))-C(O)-R21A; or    R6AR7A = e.g. -CH2-CH2-CH2-CH2-CH2-, where the                oxygen connected to R6A and R7A, the phosphorus and                the moiety form a 6-10 membered ring system;    R9A = 1-24C alkyl, 2-24C alkenyl, 2-24C                alkynyl, 3-6C cycloalkyl, 3-6C cycloalkenyl,                N-linked amino acid, N-linked amino acid ester                derivative (all optionally substituted) or                NR30AR31A;    R10A, R11A = N-linked amino acid or N-linked                amino acid ester derivative (both optionally                substituted);    R12A, R13A, R14A = absent or H;    R15A, R16A, R17A R18A = 1-24C alkyl                (optionally substituted), H or alkoxy;    R19A R20A = 1-24C alkyl, aryl (optionally                substituted) or H;    R21A = 1-24C alkyl, aryl, -O-1-24C alkyl,                -O-aryl, -O-heteroaryl, -O-monocyclic heterocyclyl                (all optionally substituted) or H; and    p, q = 1-3.    An INDEPENDENT CLAIM is also included for                substituted                (2R,3R,4S,5R)-2-(4-Amino-pyrrolo(2,1-f)(1,2,4)triazin-7-yl)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-carbonitrile                compounds of formula (II).    R4a = 1-4C alkyl (substituted by F or Cl), F,                CN or azido; and    R5a = e.g. H and                HO-P((=O)(OH))-O-P((O)(OH)-O-P((O)(OH))-. 			B02 (Fused ring heterocyclics.);  C02 (Heterocyclic.);  C01 (Organophosphorus; organometallic - i.e. compounds containing other than H, C, N, O, S and halogen.)	B04-B03A;  B04-B03B;  B04-B03D;  B04-B03E;  B14-A02;  B14-K01;  C04-B03A;  C04-B03B;  C04-B03D;  C04-B03E;  C14-A02;  C14-K01	A61P-031/12;  C07H-019/23;  A61K-031/7064;  A61P-031/14;  A61P-031/16;  C07H-007/06;  C07H-009/04;  A61K-031/53;  A61K-031/661;  A61K-031/7004;  C07D-487/04;  C07H-011/04;  C07H-003/02;  C07H-005/02	WO2019053696-A1   21 Mar 2019   C07H-019/23   201925Pages: 123   English;  CA3075950-A1   21 Mar 2019   C07H-019/23   202029   English;  AU2018332540-A1   30 Apr 2020   C07H-019/23   202037   English;  SG11202002295-A1   29 Apr 2020   C07H-019/23   202049   English;  EP3684782-A1   29 Jul 2020   C07H-019/23   202062   English;  CN111542531-A   14 Aug 2020   C07H-019/23   202069   Chinese;  KR2020098483-A   20 Aug 2020   C07H-019/23   202070   ;  US2020277321-A1   03 Sep 2020   C07H-007/06   202072   English;  IN202017016460-A   28 Aug 2020   C07H-019/23   202075   English;  BR112020005177-A2   15 Sep 2020   C07H-019/23   202081   English;  JP2020534361-W   26 Nov 2020   C07D-487/04   202096Pages: 113   Japanese;  PH12020550114-A1   07 Dec 2020   A61P-031/12   202107   English;  VN74551-A   25 Dec 2020   C07H-019/23   202118   ;  US11149049-B2   19 Oct 2021   C07H-007/06   202185   English;  US2021395288-A1   23 Dec 2021   C07H-007/06   202104   English;  HK40034999-A0   07 May 2021   C07H-019/23   202298   English;  IL273341-A   31 May 2020   C07H-019/23   202335   English;  US11773126-B2   03 Oct 2023   C07H-007/06   202382   English;  AU2018332540-B2   05 Oct 2023   C07H-019/23   202382   English;  IN481446-B   15 Dec 2023   C07H-019/23   202415   English	WO2019053696-A1    WOIB057188    18 Sep 2018;   CA3075950-A1    CA3075950    18 Sep 2018;   AU2018332540-A1    AU332540    18 Sep 2018;   SG11202002295-A1    SG11002295    18 Sep 2018;   EP3684782-A1    EP783113    18 Sep 2018;   CN111542531-A    CN80074579    18 Sep 2018;   KR2020098483-A    KR711130    18 Sep 2018;   US2020277321-A1    US16648405    18 Mar 2020;   IN202017016460-A    IN17016460    16 Apr 2020;   BR112020005177-A2    BR11005177    18 Sep 2018;   JP2020534361-W    JP537296    18 Sep 2018;   PH12020550114-A1    PH550114    22 Mar 2020;   PH12020550114-A1    PH550114    22 Mar 2020;   VN74551-A    VN002160    18 Sep 2018;   US11149049-B2    US16648405    18 Mar 2020;   US2021395288-A1    US446007    26 Aug 2021;   HK40034999-A0    HK6024371    27 Jan 2021;   IL273341-A    IL273341    18 Sep 2018;   US11773126-B2    US446007    26 Aug 2021;   AU2018332540-B2    AU332540    18 Sep 2018;   IN481446-B    IN17016460    16 Apr 2020	CA3075950-A1 PCT application Application WOIB057188;   CA3075950-A1 Based on Patent WO2019053696;   AU2018332540-A1 PCT application Application WOIB057188;   AU2018332540-A1 Based on Patent WO2019053696;   SG11202002295-A1 PCT application Application WOIB057188;   SG11202002295-A1 Based on Patent WO2019053696;   EP3684782-A1 PCT application Application WOIB057188;   EP3684782-A1 Based on Patent WO2019053696;   CN111542531-A PCT application Application WOIB057188;   CN111542531-A Based on Patent WO2019053696;   KR2020098483-A PCT application Application WOIB057188;   KR2020098483-A Based on Patent WO2019053696;   US2020277321-A1 PCT application Application WOIB057188;   US2020277321-A1 Provisional Application US560110P;   IN202017016460-A PCT application Application WOIB057188;   IN202017016460-A Based on Patent WO2019053696;   BR112020005177-A2 PCT application Application WOIB057188;   BR112020005177-A2 Based on Patent WO2019053696;   JP2020534361-W PCT application Application WOIB057188;   JP2020534361-W Based on Patent WO2019053696;   PH12020550114-A1 PCT application Application WOIB057188;   PH12020550114-A1 Based on Patent WO2019053696;   VN74551-A PCT application Application WOIB057188;   VN74551-A Based on Patent WO2019053696;   US11149049-B2 PCT application Application WOIB057188;   US11149049-B2 Provisional Application US560110P;   US11149049-B2 Based on Patent WO2019053696;   US11149049-B2 Previous Publ. Patent US2020277321;   US2021395288-A1 Provisional Application US560110P;   US2021395288-A1 Cont of Application US648405;   US2021395288-A1 Cont of Application WOIB057188;   US2021395288-A1 Cont of Patent US11149049;   HK40034999-A0 PCT application Application WOIB057188;   HK40034999-A0 Based on Patent WO2019053696;   HK40034999-A0 Previous Publ. Patent EP3684782;   IL273341-A Based on Patent WO2019053696;   US11773126-B2 Cont of Application WOIB057188;   US11773126-B2 Cont of Application US648405;   US11773126-B2 Provisional Application US560110P;   US11773126-B2 Previous Publ. Patent US2021395288;   US11773126-B2 Cont of Patent US11149049;   AU2018332540-B2 PCT application Application WOIB057188;   AU2018332540-B2 Based on Patent WO2019053696;   IN481446-B PCT application Application WOIB057188;   IN481446-B Based on Patent WO2019053696	US560110P    18 Sep 2017;  EP783113    18 Sep 2018;  WOIB057188    18 Sep 2018;  CA3075950    13 Mar 2020;  BR11005177    16 Mar 2020;  US16648405    18 Mar 2020;  PH550114    22 Mar 2020;  KR711130    17 Apr 2020;  CN80074579    18 May 2020;  US446007    26 Aug 2021	WO2019053696-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP3684782-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR                                		WO2019053696-A1 -- WO2012012776-A1   GILEAD SCI INC (GILE)   MACKMAN R L,  PARRISH J P,  RAY A S,  THEODORE D A;  WO2012040127-A1   ALIOS BIOPHARMA INC (JOHJ)   SMITH D B,  DEVAL J,  DYATKINA N,  BEIGELMAN L,  WANG G;  WO2015054465-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  WO2017049060-A1   GILEAD SCI INC (GILE)   CLARKE M O H,  FENG J Y,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  WO2005020884-A2   IDENIX CAYMAN LTD (MERI);  CENT NAT RECH SCI (CNRS);  UNIV CAGLIARI (UYCA-Non-standard)   SOMMADOSSI J,  GOSSELIN G,  LA COLLA P,  STORER R;  US5432272-A   BENNER S A (BENN-Individual)   BENNER S A;  US7125855-B2   MERCK&CO INC (MERI);  ISIS PHARM INC (ISSP)   CARROLL S S,  MACCOSS M,  OLSEN D B,  BHAT B,  BHAT N,  COOK P D,  ELDRUP A B,  PRAKASH T P,  PRHAVC M,  SONG Q;  CN111542531-A -- CN102015714-A   GILEAD SCI INC (GILE)   BUTLER T,  CHO A,  KIM C U,  SAUNDERS O L,  ZHANG L;  CN103209987-A   ALIOS BIOPHARMA INC (JOHJ)   SMITH D B,  DEVAL J,  DYATKINA N,  BEIGELMAN L,  WANG G;  CN105343098-A   GILEAD SCI INC (GILE)   MACKMAN R L,  PARRISH J P,  RAY A S,  THEODORE D A;  CN105829333-A   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  CN106573011-A   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  SMITH D B,  SYMONS J A;  CN106795199-A   MERCK SHARP & DOHME CORP (MERI)   GIRIJAVALLABHAN V M,  OLSEN D B,  ZHANG Z,  FU J,  TANG B;  CN107073005-A   GILEAD SCI INC (GILE)   CHUN B K,  CLARKE M O N H,  DOERFFLER E,  HUI H C,  JORDAN R,  MACKMAN R L,  PARRISH J P,  RAY A S,  SIEGEL D;  US20100035836-A1   ;  US20160176910-A1   ;  US20170071964-A1   ;  WO2017049060-A1   GILEAD SCI INC (GILE)   CLARKE M O H,  FENG J Y,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  US11149049-B2 -- US20150152116-A1   ;  US20150274767-A1   ;  US5432272-A   BENNER S A (BENN-Individual)   BENNER S A;  US7125855-B2   MERCK&CO INC (MERI);  ISIS PHARM INC (ISSP)   CARROLL S S,  MACCOSS M,  OLSEN D B,  BHAT B,  BHAT N,  COOK P D,  ELDRUP A B,  PRAKASH T P,  PRHAVC M,  SONG Q;  WO2012012776-A1   GILEAD SCI INC (GILE)   MACKMAN R L,  PARRISH J P,  RAY A S,  THEODORE D A;  WO2012040127-A1   ALIOS BIOPHARMA INC (JOHJ)   SMITH D B,  DEVAL J,  DYATKINA N,  BEIGELMAN L,  WANG G;  WO2015054465-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  WO2017049060-A1   GILEAD SCI INC (GILE)   CLARKE M O H,  FENG J Y,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  WO2005020884-A2   IDENIX CAYMAN LTD (MERI);  CENT NAT RECH SCI (CNRS);  UNIV CAGLIARI (UYCA-Non-standard)   SOMMADOSSI J,  GOSSELIN G,  LA COLLA P,  STORER R;  US2021395288-A1 -- US11149049-B2   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  PRHAVC M;  US11773126-B2 -- US11149049-B2   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  PRHAVC M;  CL2016001120-A1   ;  CN102015714-A   GILEAD SCI INC (GILE)   BUTLER T,  CHO A,  KIM C U,  SAUNDERS O L,  ZHANG L;  CN103209987-A   ALIOS BIOPHARMA INC (JOHJ)   SMITH D B,  DEVAL J,  DYATKINA N,  BEIGELMAN L,  WANG G;  CN105343098-A   GILEAD SCI INC (GILE)   MACKMAN R L,  PARRISH J P,  RAY A S,  THEODORE D A;  CN105829333-A   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  CN106573011-A   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  SMITH D B,  SYMONS J A;  CN106795199-A   MERCK SHARP & DOHME CORP (MERI)   GIRIJAVALLABHAN V M,  OLSEN D B,  ZHANG Z,  FU J,  TANG B;  CN107073005-A   GILEAD SCI INC (GILE)   CHUN B K,  CLARKE M O N H,  DOERFFLER E,  HUI H C,  JORDAN R,  MACKMAN R L,  PARRISH J P,  RAY A S,  SIEGEL D;  JP2013535453-A   GILEAD SCI INC (GILE)   MACKMAN R L,  PARRISH J P,  RAY A S,  THEODORE D A;  JP2017519780-A   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  DYATKINA N (DYAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  DYATKINA N,  SMITH D B,  SYMONS J A;  JP2017519784-A   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  SMITH D B,  SYMONS J A;  US5432272-A   BENNER S A (BENN-Individual)   BENNER S A;  US20100035836-A1   ;  US20120070415-A1   ;  US20150152116-A1   ;  US20150274767-A1   ;  US20160176910-A1   ;  US20170071964-A1   ;  US20200277321-A1   ;  US7125855-B2   MERCK&CO INC (MERI);  ISIS PHARM INC (ISSP)   CARROLL S S,  MACCOSS M,  OLSEN D B,  BHAT B,  BHAT N,  COOK P D,  ELDRUP A B,  PRAKASH T P,  PRHAVC M,  SONG Q;  WO2009132123-A1   GILEAD SCI INC (GILE)   CHO A,  KIM C U,  PARRISH J,  XU J;  WO2012012776-A1   GILEAD SCI INC (GILE)   MACKMAN R L,  PARRISH J P,  RAY A S,  THEODORE D A;  WO2012040127-A1   ALIOS BIOPHARMA INC (JOHJ)   SMITH D B,  DEVAL J,  DYATKINA N,  BEIGELMAN L,  WANG G;  WO2015054465-A1   ALIOS BIOPHARMA INC (JOHJ)   BEIGELMAN L,  DEVAL J,  JEKLE C A,  PRHAVC M,  SMITH D B,  WANG G;  WO2015069939-A1   CLARKE M O H (CLAR-Individual);  DOERFFLER E (DOER-Individual);  MACKMAN R L (MACK-Individual);  SIEGEL D (SIEG-Individual)   CLARKE M O H,  DOERFFLER E,  MACKMAN R L,  SIEGEL D;  WO2015143712-A1   MERCK SHARP & DOHME CORP (MERI)   GIRIJAVALLABHAN V M,  OLSEN D B,  ZHANG Z,  FU J,  TANG B;  WO2015200219-A1   BEIGELMAN L (BEIG-Individual);  BLATT L M (BLAT-Individual);  SMITH D B (SMIT-Individual);  SYMONS J A (SYMO-Individual)   BEIGELMAN L,  BLATT L M,  SMITH D B,  SYMONS J A;  WO2016069825-A1   GILEAD SCI INC (GILE)   AXT S D,  BADALOV P R,  BRAK K,  CAMPAGNA S,  CHTCHEMELININE A,  DOERFFLER E,  FRICK M M,  GAO D,  HEUMANN L V,  HOANG B,  LEW W,  MILBURN R R,  NEVILLE S T,  ROSS B,  RUEDEN E,  SCOTT R W,  SIEGEL D,  STEVENS A C,  TADEUS C,  VIEIRA T,  WALTMAN A W,  WANG X,  WHITCOMB M C,  WOLFE L,  YU C;  WO2017049060-A1   GILEAD SCI INC (GILE)   CLARKE M O H,  FENG J Y,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  WO2005020884-A2   IDENIX CAYMAN LTD (MERI);  CENT NAT RECH SCI (CNRS);  UNIV CAGLIARI (UYCA-Non-standard)   SOMMADOSSI J,  GOSSELIN G,  LA COLLA P,  STORER R	WO2019053696-A1            BIOCHEM., vol. 11, 1972, pages 942 - 944;  T.          W. GREENE; P. G. M. WUTS: "Protective Groups in Organic          Synthesis", 1999, JOHN WILEY & SONS;            J.F.W. MCOMIE: "Protective Groups in Organic Chemistry",          1973, PLENUM PRESS;            UCHIYAMA, M.; ASO, Y.; NOYORI, R.; HAYAKAWA, Y.:          "O-selective phosphorylation of nucleosides without          N-protection", J. ORG. CHEM., vol. 58, 1993, pages 373 -          379;            MCGUIGAN ET AL., J. MED. CHEM., vol. 48, no. 10, 2005,          pages 3504 - 3515US11149049-B2            International Search Report and Written Opinion dated          Nov. 28, 2018 for PCT Application No.          PCT/IB2018/057188.US11773126-B2            International Search Report and Written Opinion dated          Nov. 28, 2018 for PCT Application No. PCT/IB2018/057188,          18 pages.;            Greene, T.W. et al. (1999). Protective Groups in Organic          Synthesis, 3. Ed., John Wiley & Sons, Cover &          Contents pages, 20 pages.;            IUPAC-IUB. (1972). IUPAC-IUB Commission on Biochemical          Nomenclature Abbreviated Nomenclature of Synthetic          Polypeptides (Polymerized Amino Acids) Revised          Recommendations (1971) Biochemistry          11(5):942-944.;            McGuigan, C. et al. (May 19, 2005). Application of          Phosphoramidate Pronucleotide Technology to Abacavir          Leads to a Significant Enhancement of Antiviral Potency,          48(10):3504-3515. (Abstract Only).;            Mcomie, J. F. W. (1973) Protective Groups in Organic          Chemistry, Plenum Press, Cover & Contents pages only,          3 pages.;            Uchiyama, M. et al. (1993) O-Selective Phosphorylation of          Nucleosides Without N-Protection, J. Org. Chem.          58:373-379.	 N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N	213721501 N	61435	RCJZNH N; RCJZNI N; RCJZNJ N; RCJZNK N; RCJZNL N; RCJZNM N; RCJZNN N; RCJZNO N; RCJZNP N; RCJZNQ N; RCJZNR N; RCJZNS N		WO2019046664-A1	Pharmaceutical composition useful for prophylaxing            or treating infection in user, comprises targeted            antiviral component or targeted anti-bacterial, and            non-targeted anti-microbial or anti-inflammatory and            carrier, diluent or excipient	LATEFI N	APPLIED BIOLOGICAL LAB INC (BIOL-Non-standard)	201922941H	   NOVELTY - Pharmaceutical composition comprises (i) a                targeted antiviral component comprising one or more                active agents capable of binding to virions and/or                a targeted anti-bacterial, and (ii) a non-targeted                anti-microbial or anti-inflammatory and a carrier,                diluent and/or excipient.    USE - The pharmaceutical composition is useful for                prophylaxing and/or treating infection in a user                (claimed) or protecting upper respiratory                epithelial and mucous membranes of a subject from                infection by airborne or ingested pathogens, such                as viruses, bacteria, and fungi, and irritation                from undesirable airborne particles such as                allergens, irritants, or odorants. The subject is                mammal, preferably human.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a pharmaceutical product comprising (a) a                body configured to be inserted into a nasal passage                for dispensing a nasal spray composition through an                orifice, (b) a reservoir in fluid communication                with the orifice, and (c) a pump mechanism capable                of expelling the nasal spray composition through                the orifice in appropriate sized aerosolized                droplets capable of coating the nasal mucosa of a                user; and    (2) a method for prophylaxing and/or treating                infection in a user, involves applying the                pharmaceutical composition to the mucosa of the                user. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-A08;  B04-A10;  B04-A98;  B04-B01B;  B04-B01C1;  B04-B04D2;  B04-C02E1;  B04-D01A;  B04-F11;  B04-N02;  B04-N06;  B05-B01P;  B07-A02B;  B12-M01;  B12-M12Q;  B14-A01;  B14-A02;  B14-A04;  B14-D07C;  B14-S18;  B15-C00;  B15-E00;  C04-A08;  C04-A09;  C04-A10;  C04-A98;  C04-B04D2;  C04-C02E1;  C04-D01A;  C04-F11;  C04-N02;  C04-N06;  C05-B01P;  C07-A02B;  C12-M01;  C12-M12Q;  C14-A01;  C14-A02;  C14-A04;  C14-D07C;  C14-S18;  C15-C00;  C15-E00;  D05-A02C	A01N-043/90;  A01N-063/04	WO2019046664-A1   07 Mar 2019   A01N-043/90   201921Pages: 129   English	WO2019046664-A1    WOUS048985    30 Aug 2018		US552348P    30 Aug 2017	WO2019046664-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  		WO2019046664-A1 -- US6017880-A   US DEPT HEALTH&HUMAN SERVICES (USSH);  AMGEN INC (AMGE)   DRIPPS D J,  THOMPSON R C,  WAHL S M,  EISENBERG S;  US20010006939-A1   ;  US20070099055-A1   ;  US20120308579-A1   ;  WO2004024919-A1   REPLICOR INC (REPL-Non-standard)   VAILLANT A,  JUTEAU J		101373-0-0-0 K M; 184616-0-0-0 K M; 1669226-0-0-0 K M; 1816852-0-0-0 K M; 2166468-0-0-0 K M; 114315-0-0-0 K M; 106033-0-0-0 K M; 1135329-0-0-0 K M; 2889796-0-0-0 K M; 418022-0-0-0 K M; 101751-0-0-0 K M; 138286-1-0-0 K M; 4015-0-0-0 K M; 109110-0-0-0 K M; 109111-0-0-0 K M; 109113-0-0-0 K M; 109114-0-0-0 K M; 232701-0-0-0 K M; 96795-0-0-0 K M; 99094-0-0-0 K M; 1543621-0-0-0 K M; 1149809-0-0-0 K M; 96319-1-0-0 K M; 95883-1-0-0 K M; 40293-1-0-0 K M; 1669226-0-0-0 CL USE; 1816852-0-0-0 CL USE; 2166468-0-0-0 CL USE; 1135329-0-0-0 CL USE; 2889796-0-0-0 CL USE; 1543621-0-0-0 CL USE; 1149809-0-0-0 CL USE		06384	RA1DZT K M; RA00H3 K M; RAUHL3 K M; RAXN65 K M; RB4Y66 K M; RA02A1 K M; RA04BM K M; RAJ38G K M; RBKLEC K M; RA4ID3 K M; RA01PT K M; R00035 K M; R00179 K M; R14756 K M; R01163 K M; R00990 K M; RA0CPW K M; R01693 K M; RA0OIA K M; RA069A K M; RA0I5T K M; RARRXO K M; RAJEAW K M; R03492 K M; R16409 K M; RA0ICO K M; R06521 K M; RA0KCF K M; RA1F77 K M	0035-S; 0179-S; 1163-S; 0990-S; 1693-S	WO2019241213-A1;  US2021251942-A1;  US11679093-B2	New 2-naphthimidamide-based compound used in            pharmaceutical composition for treating or preventing            e.g. influenza A or B virus, excludes            amino(6-(3-methoxybenzamido)naphthalen-2-yl)methaniminium	BENAM K H	UNIV COLORADO (COLS-C);  UNIV COLORADO (COLS-C)	2019A6204P	   NOVELTY - A 2-naphthimidamide-based compound (I)                excluding                amino(6-(3-methoxybenzamido)naphthalen-2-yl)methaniminium,                is new.    USE - New 2-naphthimidamide-based compound is used                in pharmaceutical composition (claimed) for                treating or preventing influenza A or B virus, and                various strains of influenza infection, such as                drug-resistant viral mutants or viral infection                caused by an influenza virus or a coronavirus in                mammal, preferably human. The influenza virus is                chosen from influenza A virus and influenza B                virus.    DETAILED DESCRIPTION - A 2-naphthimidamide-based compound of formula                (I) or its salt, solvate, enantiomer,                diastereoisomer or tautomer excluding                amino(6-(3-methoxybenzamido)naphthalen-2-yl)methaniminium,                is new.    L1 = bond, or group chosen from groups of                formulae (i) and (ii);    L2 = bond or 1-6C alkylene;    R1 = group chosen from groups of formulae                (iii) and (iv);    Z = CH or N;    X = CR2 or N, with the proviso that 0-2 X                being N;    R2 = H, CN, OH, NRR, F, Cl, Br, I, or 1-6C                alkyl, 1-6C alkoxy, 3-8C cycloalkyl, phenyl,                heteroaryl or heterocyclyl (all optionally                substituted), (CH2)0-3C(=O)OR, (CH2)0-3C(=O)NRR,                (CH2)0-3NRRR, or N(R)-C(=N+RR)-NRR;and    R = H or 1-6C alkyl.    An INDEPENDENT CLAIM is included for                pharmaceutical composition, which comprises the                compound (I) and further comprises at least one                carrier. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C02 (Heterocyclic.)	B06-H;  B07-H;  B10-A15;  B10-A17;  B14-A02;  B14-A02B2;  B14-D07C;  C06-H;  C07-H;  C10-A15;  C10-A17;  C14-A02;  C14-D07C	A23L-033/10;  A61K-031/4245;  A61K-031/4439;  A61K-031/167;  A61K-031/422;  A61K-031/42;  A61K-031/194;  A61K-031/195;  A61K-031/4166;  C07D-261/08;  C07D-233/70;  C07C-257/18;  C07C-279/18;  A61K-045/06;  A61K-031/245;  A61K-031/472;  A61K-031/4725;  C07D-217/12;  C07D-217/26	WO2019241213-A1   19 Dec 2019   A23L-033/10   202002Pages: 54   English;  US2021251942-A1   19 Aug 2021   A61K-031/245   202168   English;  US11679093-B2   20 Jun 2023   C07C-257/18   202350   English	WO2019241213-A1    WOUS036499    11 Jun 2019;   US2021251942-A1    US17251070    10 Dec 2020;   US11679093-B2    US17251070    10 Dec 2020	US2021251942-A1 PCT application Application WOUS036499;   US2021251942-A1 Provisional Application US683480P;   US11679093-B2 Provisional Application US683480P;   US11679093-B2 PCT application Application WOUS036499;   US11679093-B2 Previous Publ. Patent US2021251942;   US11679093-B2 Based on Patent WO2019241213	US683480P    11 Jun 2018;  US17251070    10 Dec 2020	WO2019241213-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      		WO2019241213-A1 -- US5869501-A   YAMANOUCHI PHARM CO LTD (YAMA)   HIRAYAMA F,  KOSHIO H,  MATSUMOTO Y,  KAWASAKI T,  KAKU S,  YANAGISAWA I;  US6284796-B1   ABBOTT LAB (ABBO)   GEYER A G,  MCCLELLAN W J,  ROCKWAY T W,  STEWART K D,  WEITZBERG M,  WENDT M D;  US6596754-B1   DAIICHI PHARM CO LTD (DAUC)   HARA T,  FUJIWARA K	WO2019241213-A1  DATABASE PubChem 11          July 2005 (2005-07-11), Database accession no.          6347167,relevantClaims[1-9]	 M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N	217737001 M N; 217737002 M N	00096	RCPMYV M N; RCPMYW M N; RCPMYX M N; RCPMYY M N; RCPMYZ M N; RCPMZ0 M N; RCPMZ1 M N; RCPMZ2 M N; RCPMZ3 M N; RCPMZ4 M N; RCPMZ5 M N; RCPMZ6 M N; RCPMZ7 M N; RCPMZ8 M N; RCPMZ9 M N; RCPMZA M N; RCPMZB M N; RCPMZC M N; RCPMZD M N; RCPMZE M N; RCPMZF M N; RCPMZG M N; RCPMZH M N; RCPMZI M N; RCPMZJ M N; RCPMZK M N; RCPMZL M N; RCPMZM M N; RCPMZN M N; RCPMZO M N; RCPMZP M N; RCPMZQ M N; RCPMZR M N; RCPMZS M N; RCPMZT M N; RCPMZU M N; RCPMZV M N; RCPMZW M N; RCPMZX M N; RCPMZY M N; RCPMZZ M N		CN109355365-A	Detecting microorganisms by RNA capture small RNA sequencing comprises e.g. extracting total RNA in biological sample, carrying out enzyme digestion or physical breaking to obtain fragment RNA and hybridizing with DNA probe with marker	CHEN Z;  GAO S;  MI D;  YAO X;  ZHAO Q;  LIU Y;  WANG Q;  RUAN J	LANZHOU VETERINARY RES INST CHINA AGRIC (CAGS-C);  UNIV NANKAI (UNAN-C)	201919579P	   NOVELTY - Detecting microorganisms by RNA capture small RNA sequencing comprise e.g. extracting total RNA in biological sample, and carrying out enzyme digestion or physical breaking to obtain fragment RNA, hybridizing fragmented RNA with DNA probe with marker to obtain marked RNA-DNA hybridization product, mixing marked RNA-DNA hybrid product with magnetic bead having a ligand specifically combined with marker, where the magnetic beads adsorb marked RNA-DNA hybridization product, eluting and removing non-hybridized DNA probes and pollutants, heating of RNA-DNA hybrid product on magnetic beads, eluting and recovering RNA, and adding DNA enzyme degradation DNA fragment into recovered substance, connecting the joint to 3' end of RNA recovered to obtain RNA with the 3'end joint, annealing and hybridizing RNA with 3'end joint and reverse transcription primer to obtain RNA-primer hybrid product and ligating 5' end joint to 5'end of the RNA of the RNA-primer hybridization product.    USE - The method is useful for detecting microorganisms by RNA capture small RNA sequencing.    ADVANTAGE - The method detects thousands of microorganisms in sample at one time and achieves extremely high sensitivity.    DETAILED DESCRIPTION - Detecting microorganisms by RNA capture small RNA sequencing comprise (i) extracting total RNA in biological sample, and carrying out enzyme digestion or physical breaking to obtain fragment RNA, (ii) hybridizing fragmented RNA with DNA probe with marker to obtain marked RNA-DNA hybridization product, (iii) mixing marked RNA-DNA hybrid product with magnetic bead having a ligand specifically combined with marker, where the magnetic beads adsorb marked RNA-DNA hybridization product, eluting and removing non-hybridized DNA probes and pollutants, (iv) heating of RNA-DNA hybrid product on magnetic beads, eluting and recovering RNA, and adding DNA enzyme degradation DNA fragment into recovered substance, (v) connecting the joint to 3' end of RNA recovered to obtain RNA with the 3' end joint, (vi) annealing and hybridizing RNA with 3' end joint and reverse transcription primer to obtain RNA-primer hybrid product, (vii) ligating 5' end joint to 5' end of the RNA of the RNA-primer hybridization product to obtain RNA-primer hybrid product with 5' end joint, (viii) carrying out reverse transcription PCR with RNA fragment in primer hybrid product as template to obtain amplified cDNA fragment, and selecting cDNA fragment with length of 130-200 base pair, sequencing, where the sequencing length is over 50 base pairs, (ix) sequencing the sequenced joint at 3' end of sequence, removing the sequence with length less than 15 base pairs to obtain cleaned sequence and (x) using bowtie or Burrows-Wheeler Aligner software, comparing cleaned sequence with target microorganism genome sequence, determining cleaned sequence with at most 1 base different from target microorganism genome sequence as target small RNA sequence, comparing with sequence of target microorganism genome sequence, counting target small RNA sequence, counting the 5' end or the 3' end is compared with all the target small RNA sequences at the same position in the target microorganism genome sequence for one time, where if value of target small RNA sequence in sample exceeds specified threshold value, the detection result of the target microorganism in the sample is determined to be positive.    DESCRIPTION OF DRAWING(S) - The drawing shows a flow chart of the process of detecting microorganisms by RNA capture-small RNA sequencing. (Drawing includes non-English language text). 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E05;  B04-E99;  B04-F01;  B04-F09A;  B04-F10A;  B04-F11;  B04-L01;  B11-C08E3;  B11-C08F7A;  B11-C08F8;  B11-C11;  B12-K04F;  B12-K04G1;  D05-A02;  D05-H04;  D05-H05;  D05-H06A;  D05-H18;  D05-H99	C12Q-001/6869;  C12Q-001/689;  C12Q-001/6895;  C12Q-001/70	CN109355365-A   19 Feb 2019   C12Q-001/6869   201937Pages: 6   Chinese	CN109355365-A    CN11452689    25 Nov 2018		CN11452689    25 Nov 2018			CN109355365-A -- CN101835907-A   ROCHE NIMBLEGEN INC (HOFF)   RODESCH M,  ALBERT T;  CN103403186-A   UNIV RAMOT AT TEL AVIV LTD (UYTA)   ISAKOV O,  MODAI S,  SHOMRON N;  CN104212879-A   SHANGHAI PAISENNUO BIOTECHNOLOGY CO LTD (SHAN-Non-standard)   CHEN Y,  SUN Z;  CN106148502-A   CHINESE ACAD SCI SHANGHAI BIOLOGICAL INS (CABS)   CHU R,  LI J,  QIU H,  WANG H,  ZHAO R;  CN107488660-A   LANZHOU VETERINARY RES INST CHINA AGRIC (CAGS);  UNIV NANKAI (UNAN)   GAO S,  CHEN Z,  LIU G,  YAO X,  YIN H,  LUO J,  WANG Q,  WANG F,  REN Q;  CN107922971-A   KARIUS INC (KARI-Non-standard)   BLAUWKAMP T A,  CHRISTIANS F,  KERTESZ M,  SMITH S,  VILFAN I D	CN109355365-A  FANG WANG: "Using Small RNA Deep Sequencing Data to Detect Human Viruses", BIOMED RES INT,relevantClaims[1-6],relevantPassages[12];  MARCIN CIESLIK: "The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing", GENOME RES,relevantClaims[1-6],relevantPassages[];  QUAN NGUYEN: "Target-enrichment sequencing for detailed characterization of small RNAs", NAT PROTOC,relevantClaims[1-6],relevantPassages[];  TIM R MERCER: "Targeted sequencing for gene discovery and quantification using RNA CaptureSeq", NAT PROTOC,relevantClaims[1-6],relevantPassages[];  THOMAS BRIESE: "Virome Capture Sequencing Enables Sensitive Viral Diagnosis and Comprehensive Virome Analysis", MBIO,relevantClaims[1-6],relevantPassages[1-2]						WO2019086646-A1;  AU2018358077-A1;  WO2019086646-A8;  CA3080427-A1;  EP3706788-A1;  BR112020008957-A2;  JP2021501761-W;  US2021177961-A1;  US11311616-B2;  US2022211839-A1;  RU2020118586-A;  RU2784533-C2;  JP2023159327-A	Immunogenic composition for preventing disease due            to feline leukemia virus (FeLV), and for immunizing            feline against pathogenic FeLV, comprises alphavirus            RNA replicon particle that encodes FeLV antigen	TARPEY I;  IAN T	INTERVET INT BV (IVET-C);  INTERVET INC (MERI-C);  INTERVET INT BV (IVET-C);  INTERVET INT BV (IVET-C);  INTERVET INC (MERI-C);  INTERVET INC (MERI-C)	201940597Y	   NOVELTY - Immunogenic composition comprises an                alphavirus RNA replicon particle that encodes a                feline leukemia virus (FeLV) antigen.    USE - The composition or vaccine is useful for                preventing disease due to FeLV; and for immunizing                feline against pathogenic FeLV (all claimed).    ADVANTAGE - Improved, safe nonadjuvanted FeLV vaccine is                provided, which while not inducing feline                injection-site sarcomas still protects vaccinates                from the debilitating disease state caused by FeLV                infection as efficaciously as its inactivated                whole-virus adjuvanted vaccine counterpart.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) a vaccine to aid in the prevention of                disease due to FeLV comprising the immunogenic                composition and a carrier; and    (2) immunizing a feline against a pathogenic                FeLV which involves administering to the feline, an                immunological amount of the vaccine. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E02J;  B04-E03J;  B04-E99;  B14-A02;  B14-S03A;  B14-S11D1;  B14-S11D2;  B14-S12;  C04-E02J;  C04-E03J;  C04-E99;  C14-A02;  C14-S03A;  C14-S11D1;  C14-S11D2;  C14-S12;  D05-H07;  D05-H99	A61K-039/12;  A61K-039/118;  A61K-039/145;  A61K-039/21;  A61K-039/215;  A61K-039/23;  A61K-039/245;  A61K-048/00;  A61P-035/02;  A61P-037/04;  C12N-015/48;  C12N-015/86;  C12N-007/01;  A61P-031/14;  C12N-007/00;  A61K-039/00;  C07K-014/005;  C07K-014/18;  C07K-014/15;  C12N-015/867	WO2019086646-A1   09 May 2019   A61K-039/12   201938Pages: 39   English;  AU2018358077-A1   14 May 2020   A61K-039/12   202041   English;  WO2019086646-A8   04 Jun 2020   A61K-039/12   202046   English;  CA3080427-A1   09 May 2019   A61K-039/12   202048   English;  EP3706788-A1   16 Sep 2020   A61K-039/12   202076   English;  BR112020008957-A2   13 Oct 2020   A61K-039/12   202089   English;  JP2021501761-W   21 Jan 2021   A61K-039/21   202108Pages: 40   Japanese;  US2021177961-A1   17 Jun 2021   A61K-039/21   202151   English;  US11311616-B2   26 Apr 2022   C12N-015/86   202235   English;  US2022211839-A1   07 Jul 2022   A61K-039/21   202255   English;  RU2020118586-A   08 Dec 2021   A61K-039/12   202262   Russian;  RU2784533-C2   28 Nov 2022   A61K-039/12   202308   Russian;  JP2023159327-A   31 Oct 2023   A61K-039/12   202390   Japanese	WO2019086646-A1    WOEP080094    05 Nov 2018;   AU2018358077-A1    AU358077    05 Nov 2018;   WO2019086646-A8    WOEP080094    05 Nov 2018;   CA3080427-A1    CA3080427    05 Nov 2018;   EP3706788-A1    EP803572    05 Nov 2018;   BR112020008957-A2    BR11008957    05 Nov 2018;   JP2021501761-W    JP524369    05 Nov 2018;   US2021177961-A1    US16759927    28 Apr 2020;   US11311616-B2    US16759927    28 Apr 2020;   US2022211839-A1    US698205    18 Mar 2022;   RU2020118586-A    RU118586    05 Nov 2018;   RU2784533-C2    RU118586    05 Nov 2018;   JP2023159327-A    JP135272    23 Aug 2023	AU2018358077-A1 PCT application Application WOEP080094;   AU2018358077-A1 Based on Patent WO2019086646;   CA3080427-A1 PCT application Application WOEP080094;   CA3080427-A1 Based on Patent WO2019086646;   EP3706788-A1 PCT application Application WOEP080094;   EP3706788-A1 Based on Patent WO2019086646;   BR112020008957-A2 PCT application Application WOEP080094;   BR112020008957-A2 Based on Patent WO2019086646;   JP2021501761-W PCT application Application WOEP080094;   JP2021501761-W Based on Patent WO2019086646;   US2021177961-A1 PCT application Application WOEP080094;   US2021177961-A1 Provisional Application US582050P;   US11311616-B2 PCT application Application WOEP080094;   US11311616-B2 Provisional Application US599401P;   US11311616-B2 Provisional Application US582050P;   US11311616-B2 Provisional Application US596508P;   US11311616-B2 Based on Patent WO2019086646;   US11311616-B2 Previous Publ. Patent US2021177961;   US2022211839-A1 Provisional Application US582050P;   US2022211839-A1 Provisional Application US596508P;   US2022211839-A1 Provisional Application US599401P;   US2022211839-A1 Cont of Application US759927;   US2022211839-A1 Cont of Application WOEP080094;   US2022211839-A1 Cont of Patent US11311616;   RU2020118586-A PCT application Application WOEP080094;   RU2020118586-A Based on Patent WO2019086646;   RU2784533-C2 PCT application Application WOEP080094;   RU2784533-C2 Based on Patent WO2019086646;   JP2023159327-A Div ex Application JP524369	US582050P    06 Nov 2017;  US596508P    08 Dec 2017;  US599401P    15 Dec 2017;  CA3080427    27 Apr 2020;  US16759927    28 Apr 2020;  BR11008957    05 May 2020;  RU118586    08 Jun 2020;  US698205    18 Mar 2022	WO2019086646-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW    WO2019086646-A8:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP3706788-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                  		WO2019086646-A1 -- US20130064839-A1   ;  US8460913-B2   ALPHAVAX INC (ALPH-Non-standard)   KAMRUD K I,  SMITH J F,  MAUGHAN M;  US9441247-B2   ALPHAVAX INC (ALPH-Non-standard)   RAYNER J O,  SMITH J F,  HUBBY B,  REAP E A;  US11311616-B2 -- US20130064839-A1   ;  US7449323-B2   UNIV CALIFORNIA (REGC)   FOLEY J E,  HURLEY K,  PEDERSEN N C;  US8460913-B2   ALPHAVAX INC (ALPH-Non-standard)   KAMRUD K I,  SMITH J F,  MAUGHAN M;  US9441247-B2   ALPHAVAX INC (ALPH-Non-standard)   RAYNER J O,  SMITH J F,  HUBBY B,  REAP E A;  WO2017109045-A1   INTERVET INT BV (IVET);  INTERVET INC (MERI)   SHEHU E,  BHOGLE A S;  WO2001066568-A2   	WO2019086646-A1  M. PATEL ET AL:          "ABSTRACT", CLINICAL AND VACCINE IMMUNOLOGY, vol. 22, no.          7, 1 July 2015 (2015-07-01), US, pages 798 - 805,          XP055536768, ISSN: 1556-6811, DOI:          10.1128/CVI.00034-15,relevantClaims[1-19],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  KRISTIN STUKE ET          AL: "Efficacy of an inactivated FeLV vaccine compared to          a recombinant FeLV vaccine in minimum age cats following          virulent FeLV challenge", VACCINE, vol. 32, no. 22, 1 May          2014 (2014-05-01), AMSTERDAM, NL, pages 2599 - 2603,          XP055536766, ISSN: 0264-410X, DOI:          10.1016/j.vaccine.2014.03.016,relevantClaims[1-19],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  KASS PHILIP H ET          AL: "Epidemiologic evidence for a causal relation between          vaccination and fibrosarcoma tumorigenesis in cats",          JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION,          vol. 203, no. 3, 1993, pages 396 - 405, XP055536940,          ISSN:          0003-1488,relevantClaims[1-19],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  GROSENBAUGH D A ET          AL: "COMPARISON OF THE SAFETY AND EFFICACY OF A          RECOMBINANT FELINE LEUKEMIA VIRUS (FELV) VACCINE          DELIVERED TRANSDERMALLY AND AN INACTIVATED FELV VACCINE          DELIVERED SUBCUTANEOUSLY", VETERINARY THERAPEUTICS,          VETERINARY LEARNING SYSTEMS, TRENTON, NJ, US, vol. 5, no.          4, 21 December 2004 (2004-12-21), pages 258 - 262,          XP001536412, ISSN:          1528-3593,relevantClaims[1-19],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  RAYNER J O ET AL:          "ALPHAVIRUS VECTORS AND VACCINATION", REVIEWS IN MEDICAL          VIRO, CHICHESTER, GB, vol. 12, no. 5, 1 September 2002          (2002-09-01), pages 279 - 296, XP008035758, ISSN:          1052-9276, DOI:          10.1002/RMV.360,relevantClaims[1-19],relevantPassages[&lt;pp&gt;283&lt;/pp&gt;"Replicon          vectors"];  LJUNGBERG KARL ET          AL: "Self-replicating alphavirus RNA vaccines", EXPERT          REVIEW OF VACC, EXPERT REVIEWS LTD, GB, vol. 14, no. 2, 1          February 2015 (2015-02-01), pages 177 - 194, XP008175780,          ISSN: 1744-8395, DOI:          10.1586/14760584.2015.965690,relevantClaims[1-19],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ATKINS GREGORY J ET          AL: "Therapeutic and prophylactic applications of          alphavirus vectors", EXPERT REVIEWS IN MOLECULAR MEDI,          CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, vol. 10, no. 1, 1          December 2008 (2008-12-01), pages e33/1 - 18,          XP009116159, ISSN: 1462-3994, [retrieved on 20081111],          DOI:          10.1017/S1462399408000859,relevantClaims[1-19],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  VANDER VEEN RYAN L          ET AL: "Alphavirus replicon vaccines", ANIMAL HEALTH          RESEARCH REV, CAB INTERNATIONAL ; CAMBRIDGE : CAMBRIDGE          UNIVERSITY PRESS, UK, vol. 13, no. 1, 1 June 2012          (2012-06-01), pages 1 - 9, XP009166113, ISSN: 1475-2654,          DOI:          10.1017/S1466252312000011,relevantClaims[1-19],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  GUGLIELMO LUCCHESE          ET AL: "How a single amino acid change may alter the          immunological information of a peptide", FRONTIERS IN          BIOSCIENCE : ELITE EDITION, vol. 4, no. 5, 1 January 2012          (2012-01-01), US, pages 1843 - 1852, XP055467091, ISSN:          1945-0494, DOI:          10.2741/e506,relevantClaims[7,9],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];            PACITTI ET AL., VET REC, vol. 118, 1986, pages 381 -          384;            LEVY ET AL., J FELINE MED SURG, vol. 10, 2008, pages 300          - 316;            HOOVER ET AL., J AM VET MED ASSOC, vol. 199, 1991, pages          1287 - 1297;            LEVY; CRAWFORD: "Textbook of Veterinary Internal          Medicine", 2005, WB SAUNDERS;            HOSIE ET AL., VETERINARY RECORDS, vol. 128, 1989, pages          293 - 297;            BRALEY, FELINE PRACTICE, vol. 22, 1994, pages 25 -          29;            MALIK ET AL., AUSTRALIAN VETERINARY JOURNAL, vol. 75,          1997, pages 323 - 327;            ARJONA ET AL., JOURNAL OF CLINICAL MICROBIOLOGY, vol. 38,          2000, pages 3448 - 3449;            THOMSEN ET AL., JOURNAL OF GENERAL VIROLOGY, vol. 73,          1992, pages 1819 - 1824;            DENORONHA ET AL., VIROLOGY, vol. 85, 1978, pages 617 -          621;            NUNBERG ET AL., PNAS, vol. 81, 1983, pages 3675 -          3679;            MATHES ET AL., NATURE, vol. 274, 1978, pages 687 -          689;            FLYNN ET AL., J. VIROL., vol. 76, no. 5, 2002, pages 2306          - 2315;            ROJKO; KOCIBA, J AM VET MED ASSOC, vol. 199, 1991, pages          1305 - 1310;            SPARKES, J SMALL ANIM PRACT, vol. 38, 1997, pages 187 -          194;            HINES ET AL., J AM VET MED ASSOC, vol. 199, 1991, pages          1428 - 1430;            PEDERSEN, J VET INTERN MED, vol. 7, 1993, pages 34 -          39;            TORRES ET AL., VET IMMUNOL IMMUNOPATHOL, vol. 134, 2010,          pages 122 - 131;            STUKE ET AL., VACCINE, vol. 32, 2014, pages 2599 -          2603;            PATEL ET AL., CLINICAL AND VACCINE IMMUNOLOGY, vol. 22,          no. 7, 2015, pages 798 - 805;            KASS ET AL., J. AM VET MED ASSOC, vol. 203, no. 3, 1993,          pages 396 - 405;            AAFP FELINE ADVISORY PANEL, vol. 15, 2013, pages 785 -          808;            VANDER VEEN ET AL., ANIM HEALTH RES REV, vol. 13, no. 1,          2012, pages 1 - 9;            KAMRUD ET AL., J GEN VIROL., vol. 91, 2010, pages 1723 -          1727;            PUSHKO ET AL., VIROLOGY, vol. 239, 1997, pages 389 -          401;            BREDENBEEK ET AL., JOURNAL OF VIROLOGY, vol. 67, 1993,          pages 6439 - 6446;            LILJESTROM; GAROFF, BIOTECHNOLOGY (NY, vol. 9, 1991,          pages 1356 - 1361;            PUSHKO ET AL., VIROLOGY, vol. 239, no. 2, 1997, pages 389          - 401;            PATEL ET AL., CLIN VACCINE IMMUNOL, vol. 22, no. 7, 2015,          pages 798 - 808;            SHIPLEY ET AL., JAVMA, vol. 199, no. 10, 15 November 1991          (1991-11-15)US11311616-B2            Thomsen et al. Expression of feline leukaemia virus gp85          and gag proteins and assembly into virus-like particles          using the baculovrius expression vector system Journal of          General Virology, 1992, 73:1819-1824.;            Arjona, Alvaro et al., Seroepidemiological Survey of          Infection by Feline Leukemia Virus and Immunodeficiency          Virus in Madrid and Correlation with Some Clinical          Aspects, Journal of Clinical Microbiology, 2000,          3448-3449, 38.;            Atkins, GJ et al, Therapeutic and prophylactic          applications of alphavirus vectors, Expert Reviews in          Molecular Medicine, 2008, e33, 1-18, 10(1).;            Braley, JO, FeLV and FIV: Survey Shows Prevalence in the          United States and Europe, Feline PracticeInfectious          Disease, 1994, 25-29, 22.;            Bredenbeek, Peter J. et al., Sindbis Virus Expression          Vectors: Packaging of RNA Replicons by Using Defective          Helper RNAs, Journal of Virology, 1993, 6439-6446,          67(11).;  De          Noronha, F. et al., Influence of Antisera To Oncornavirus          Glycoprotein (gp71) on Infections of Cats with Feline          Leukemia Virus, Virology, 1978, 617-621, 85.;            Flynn, J. Norman et al., Longitudinal Analysis of Feline          Leukemia Virus-Specific Cytotoxic T Lymphocytes:          Correlation with Recovery from Infection, Journal of          Virology, 2002, 2306-2315, 76(5).;            Grosenbaugh, DA et al, Comparison of the Safety and          Efficacy of a Recombinant Feline Leukemia Virus (FeLV)          Vaccine Delivered Transdermally and an Inactivated FeLV          Vaccine Delivered Subcutaneously, Veterinary          Therapeutics, Veterinary Learning Systems, 2004, 258-262,          5(4).;            Hardy, Jr., William D. et al., Ten-year study comparing          enzyme-linked immunosorbent assay with the          immunofluorescent antibody test for detection of feline          leukemia virus infection in cats, JAVMA, 1991, 1365-1373,          199(10).;            Hines, David L. et al., Evaluation of efficacy and safety          of an inactivated virus vaccine against feline leukemia          virus infection, J. Am. Vet. Med. Assoc., 1991,          1428-1430, 199.;            Hoover, Edward A. et al., Feline leukemia virus infection          and diseases, J. Am. Vet. Med. Assoc., 1991, 1287-1297,          199.;            Hosie, M.J. et al., Prevalence of feline leukaemia virus          and antibodies to feline immunodeficiency virus in cats          in the United Kingdom, Veterinary Records, 1989, 293-297,          128.;            International Search Report for PCT/EP2018/080094 dated          Jan. 15, 2019, 16 pages.;            Kamrud, K.I. et al., Development and characterization of          promoterless helper RNAs for the production of alphavirus          replicon particle, Journal of General Virology, 2010,          1723-1727, 91(Pt 7).;            Kass, P et al, Epidemiologic evidence for a causal          relation between vaccination and fibrosarcoma          tumorigenesis in cats, Journal of the American Veterinary          Medical Association, 1993, 396-405, 203(3).;            Konopka, Jennifer L. et al., Acute Infection with          Venezuelan Equine Encephalitis Virus Replicon Particles          Catalyzes a Systemic Antiviral State and Protects from          Lethal Virus Challenge, Journal of Virology, 2009,          12432-12442, 83(29).;            Levy, Julie et al., 2008 American Association of Feline          Practitioners' feline retrovirus management guidelines,          Journal of Feline Medicine and Surgery, 2008, 300-316,          10.;            Liljestrom, P. et al., A new generation of animal cell          expression vectors based on the semliki forest virus          replicon, Biotechnology, 1991, pp. 1356-1361,          9.;            Liu, Chunguo et al., Complete Genome Sequence of Feline          Panleukopenia Virus Strain HRB-CS1, Isolated from a          Domestic Cat in Northeastern China, Genome Announcements,          2015, 1, 3(2):e01556-14.;            Ljungberg, K et al, Self-replicating alphavirus RNA          vaccines, Expert Review of Vaccines, 2015, 177-194,          14(2).;            Lucchese, G et al, How a single amino acid change may          alter the immunological information of a peptide,          Frontiers in Bioscience: Elite Edition, 2012, 1843-1852,          vol. 4, No. 5.;            Malik, R. et al., Prevalences of feline leukaemia virus          and feline immunodeficiency virus infections in cats in          Sydney, Australian Veterinary Journal, 1997, 323-327,          75.;            Mathes L.E. et al., Abrogation of lymphocyte          blastogenesis by a feline leukaemia virus protein,          Nature, 1978, 687-689, 274.;            Nunberg, J.H. et al., Method to map antigenic          determinants recognized by monoclonal antibodies:          Localization of a determinant of virus neutralization on          the feline leukemia virus envelope protein gp7O, Proc.          Natl. Acad. Sci. USA, 1984, 3675-3679, 81.;            Pacitti, A.M. et al., Transmission of feline leukaemia          virus in the milk of a non-viraemic cat, The Veterinary          Record, 1986, 381-384, 118.;            Patel, M et al, Comparative Efficacy of Feline Leukemia          Virus (FeLV) Inactivated Whole-Virus Vaccine and          Canarypox Virus-Vectored Vaccine during Virulent FeLV          Challenge and Immunosuppression, Abstract, Clinical and          Vaccine Immunology, 2015, 798-805, 22(7).;            Pedersen, Niels C., Immunogenicity and Efficacy of a          Commercial Feline Leukemia Virus Vaccine, J. Vet. Intern.          Med., 1993, 34-39, 7.;            Pushko, Peter et al., Replicon-Helper Systems from          Attenuated Venezuelan Equine Encephalitis Virus:          Expression of Heterologous Genes in Vitro and          Immunization against Heterologous Pathogens in Vivo,          Virology, 1997, 389-401, 239.;            Radford, Alan D. et al., Feline calicivirus. Vet. Res.,          2007, 319-335, 38(2).;            Rayner, JO et al., Alphavirus vectors and vaccination,          Reviews in Medical Virology, 2002, pp. 279-296,          12.;            Reed, DS et al, Combined Alphavirus Replicon Particle          Vaccine Induces Durable and Cross-Protective Immune          Responses against Equine Encephalitis Viruses, Journal of          Virology, 2014, 12077-12086, vol. 88, No. 20.;            Rojko, Jennifer L. et al., Pathogenesis of infection by          the feline leukemia virus, J Am Vet Med Assoc, 1991,          1305-1310, 199.;            Scherk, M.A., et al., 2013 AAFP Feline Vaccination          Advisory Panel Report, Journal of Feline Medicine and          Surgery, 2013, pp. 785-808, 15.;            Scott, Fred W et al., Long-term immunity in cats          vaccinated with an inactivated trivalent vaccine, Am. J.          Vet. Res., 1999, 652-658, 60.;            Segundo, Fayna Diaz-San et al., Venezuelan Equine          Encephalitis Replicon Particles Can Induce Rapid          Protection against Foot-and-Mouth Disease Virus, Journal          of Virology, 2013, 5447-5460, 87(10).;            Sosnovtsev, Stanislav V. et al., Identification and          Genomic Mapping of the ORF3 and VPg Proteins in Feline          Calicivirus Virions, Virology, 2000, 193-203,          277.;            Sparkes, A.H., Feline leukaentia virus: a revie-w of          immunity and vaccination, Journal of Small Animal          Practice, 1997, 187-194, 38.;            Stuke, K et al, Efficacy of an inactivated FeLV vaccine          compared to a recombinant FeLV vaccine in minimum age          cats following virulent FeLV challenge, Vaccine, 2014,          2599-2603, 32(22).;            Thomsen, Darrell R. et al., Expression of feline          leukaemia virus gp85 and gag proteins and assembly into          virus-like particles using the baculovirus expression          vector system, Journal of General Virology, 1992,          1819-1824, 73.;            Torres, Andrea N. et al., Feline leukemia virus immunity          induced by whole inactivated virus vaccination,          Veterinary Immunology and Immunopathology, 2010, 122-131,          134.;            Uematus, Y et al, Lack of Interference with          Immunogenicity of a Chimeric Alphavirus Replicon          Particle-Based Influenza Vaccine by Preexisting          Antivector Immunity, Clinical and Vaccine Immunology,          2012, 991-998, vol. 19, No. 7.;            Vander Veen, RL et al, Alphavirus replicon vaccines,          Animal Health Research Reviews, 2012, 1-9, vol. 13, No.          1.	105730-0-0-0 K M			RA012P K M		CN110101705-A;  CN110101705-B	Use of a BET family protein inhibitor for            preparing reagent for inhibiting cyst membrane of the            virus into the cell, and inhibiting cyst membrane virus            adsorption to cells	CHU B;  YANG G;  WANG J;  LI G;  MING S	UNIV HENAN AGRIC (UYHR-C)	2019707626	   NOVELTY - Use of a BET family protein inhibitor is                claimed for preparing reagent for inhibiting cyst                membrane of the virus into the cell.    USE - BET family protein inhibitor used for                preparing reagent for inhibiting cyst membrane of                the virus into the cell, and inhibiting cyst                membrane virus adsorption to cells (all                claimed).    ADVANTAGE - The BET family protein inhibitor has important                implications for biology, particularly viral                research and drug development. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.)	B04-E99;  B06-D17;  B06-E05;  B06-F05;  B14-A02;  B14-L06;  C04-E99;  C06-D17;  C06-E05;  C06-F05;  C14-A02	A61K-031/4745;  A61K-031/551;  A61P-031/14;  A61P-031/16;  A61P-031/20;  A61P-031/22	CN110101705-A   09 Aug 2019   A61K-031/551   201966Pages: 30   Chinese;  CN110101705-B   14 Jan 2022   A61K-031/551   202211   Chinese	CN110101705-A    CN10375300    07 May 2019;   CN110101705-B    CN10375300    07 May 2019	CN110101705-B Previous Publ. Patent CN110101705	CN10375300    07 May 2019			CN110101705-A -- CN106265679-A   UNIV FUDAN (UYFU)   ZHU H,  LU P,  QU X;  CN106551939-A   UNIV NANJING (UNAJ)   LI E,  REN K,  WANGZI R,  WANG J;  CN108472295-A   DANA FARBER CANCER INST INC (DAND);  BRADNER J E (BRAD-Individual)   BRADNER J E,  QI J,  TANAKA M,  ROBERTS J M;  CN109503618-A   HINOVA PHARM INC (HINO-Non-standard)   FAN L,  XU K,  CHEN K,  WANG F,  WU X,  LUO T,  ZHANG S,  LI X,  CHEN Y;  WO2013019710-A1   CHILDRENS HOSPITAL PHILADELPHIA (CHHP)   FINKEL T H,  WANG J,  BLOBEL G,  KADAUKE S;  WO2013148197-A1   GLADSTONE INST J DAVID (GLAN);  MOUNT SINAI SCHOOL MEDICINE (MOUN);  OTT M (OTTM-Individual);  VERDIN E M (VERD-Individual);  ZHOU M (ZHOU-Individual)   OTT M,  VERDIN E M,  ZHOU M;  WO2016196471-A1   COOPER HUMAN SYSTEMS LLC (COOI)   COOPER K G,  DE SOUZA M S,  EUBANKS K,  STARR D H,  KAPSON J D,  YANG H;  CN110101705-B -- CN106265679-A   UNIV FUDAN (UYFU)   ZHU H,  LU P,  QU X;  CN106551939-A   UNIV NANJING (UNAJ)   LI E,  REN K,  WANGZI R,  WANG J;  CN108472295-A   DANA FARBER CANCER INST INC (DAND);  BRADNER J E (BRAD-Individual)   BRADNER J E,  QI J,  TANAKA M,  ROBERTS J M;  CN109503618-A   HINOVA PHARM INC (HINO-Non-standard)   FAN L,  XU K,  CHEN K,  WANG F,  WU X,  LUO T,  ZHANG S,  LI X,  CHEN Y;  WO2013019710-A1   CHILDRENS HOSPITAL PHILADELPHIA (CHHP)   FINKEL T H,  WANG J,  BLOBEL G,  KADAUKE S;  WO2013148197-A1   GLADSTONE INST J DAVID (GLAN);  MOUNT SINAI SCHOOL MEDICINE (MOUN);  OTT M (OTTM-Individual);  VERDIN E M (VERD-Individual);  ZHOU M (ZHOU-Individual)   OTT M,  VERDIN E M,  ZHOU M;  WO2016196471-A1   COOPER HUMAN SYSTEMS LLC (COOI)   COOPER K G,  DE SOUZA M S,  EUBANKS K,  STARR D H,  KAPSON J D,  YANG H	CN110101705-A  SUDEEP BHUSHAL ET          AL.: "Cell Polarization and Epigenetic Status Shape the          Heterogeneous Response to Type III Interferons in          Intestinal Epithelial Cells", FRONT          IMMUNOL,relevantClaims[1-10],relevantPassages[1-18];  KRISTIN M. KECK ET          AL.: "Bromodomain and extraterminal inhibitors block the          Epstein-Barr virus lytic cycle at two distinct steps", J.          BIOL.          CHEM.,relevantClaims[2-10|1-10],relevantPassages[13284-13295];  PANPAN LU ET AL.:          "The BET inhibitor OTX015 reactivates latent HIV-1          through P-TEFb", SCIENTIFIC          REPORTS,relevantClaims[1-10],relevantPassages[1-13]CN110101705-B            Kristin M. Keck et al.. Bromodomain and extraterminal          inhibitors block the Epstein-Barr virus lytic cycle at          two distinct steps;Kristin M. Keck et al.;J. Biol.          Chem.;20170606;292(32);13284-13295;            Kristin M. Keck et al..Bromodomain and extraterminal          inhibitors block the Epstein-Barr virus lytic cycle at          two distinct steps.J. Biol.          Chem..2017,292(32),13284-13295.;            Sudeep Bhushal et al .. Cell Polarization and Epigenetic          Status Shape the Heterogeneous Response to Type III          Interferons in Intestinal Epithelial Cells; Sudeep          Bhushal et al.; " Front Immunol "; 20170612; the eighth          volume; the 1-18 page;            Panpan Lu et al .. The BET inhibitor OTX015 reactit HIV-1          through P-TEFb; Panpan Lu et al., " Scientific Reports,          20160412, 1-13	2585101-3-0-0 K U; 500201-1-0-0 K U; 2487506-1-0-0 K U; 2585101-3-0-0 CL USE; 2487506-1-0-0 CL USE		41383; 02763	RBE54P K U; RA67N6 K U; RBBS0C K U		US2019085024-A1	Amide derivative for treating calpain-mediated disorder in subject, comprises alpha-ketoamide linkage which is terminated on each end by amino acid	GREENBAUM D;  ADDIS R;  GABOURY J;  KULKAMI S;  MEINHARDT N	PHELIX THERAPEUTICS (PHEL-Non-standard)	201926023N	   NOVELTY - Amide derivative comprises alpha-ketoamide linkage which is terminated on each end by amino acid.    USE - Amide derivative for treating a calpain-mediated disorder in a subject, where calpain-mediated disorder is Alzheimer's disease, atherosclerosis, bacterial infection, cancer, cataract formation, diabetes, fibrotic disease, such as halogen/acid exposure injury, ischemia, muscular dystrophy, neurological injury, such as pulmonary fibrosis, scleroderma, cardiac fibrosis, renal fibrosis, liver fibrosis including nonalcoholic steatohepatitis (NASH), Crohn's disease, strabismus, or hypertrophic scarring, traumatic brain injury, stroke, Parkinson's disease, or spinal cord injury, parasite infection, reperfusion injury, osteoarthritis, Wolfram's syndrome, for treating cathepsin-L or cathepsin-S mediated disorder, where disorder is chronic pain, a coronavirus infection, such as middle east respiratory syndrome (MERS), ebola virus infection, a filovirus infection, marburg virus syndrome or osteoporosis (all claimed).    ADVANTAGE - The amide derivative inhibits calpain activity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:    (1) a method for inhibiting calpain activity, which involves administering compound of one or more compounds to a patient;    (2) a method for treating a calpain-mediated disorder in a subject, which involves administering subject with a therapeutically effective amount of compound;    (3) a method for inhibiting cathepsin-B, cathepsin-L, cathepsin-S, or cathepsin-L activity, which involves administering compound to a patient; and    (4) a method for treating a cathepsin-B, cathepsin-L, cathepsin-S, or cathepsin-L mediated disorder in a subject, which involves administering subject with a therapeutically effective amount of compound. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.)	B06-H;  B07-H;  B10-A13D;  B10-A17;  B10-A18;  B10-B02;  B10-C04C;  B10-C04E1;  B10-D01;  B10-D03;  B14-A02B;  B14-B02;  B14-C01;  B14-C03;  B14-C09A;  B14-D07C;  B14-F01;  B14-F02D;  B14-F05;  B14-F07;  B14-H01;  B14-J01;  B14-J05E;  B14-K01;  B14-N01A;  B14-N03;  B14-N10;  B14-N12;  B14-N16;  B14-S04;  B14-S16	C07K-005/062;  C07K-005/078;  C07C-271/18;  C07D-211/62;  C07D-205/04;  C07D-213/56;  C07C-237/22;  C07C-279/12;  C07D-209/20;  C07D-233/64;  C07C-275/24;  C07D-403/12	US2019085024-A1   21 Mar 2019   C07K-005/062   201924Pages: 131   English	US2019085024-A1    US132794    17 Sep 2018	US2019085024-A1 Provisional Application US559200P	US559200P    15 Sep 2017;  US132794    17 Sep 2018					 N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N	213703701 N; 213703702 N		RCJZ4A N; RCJZ4B N; RCJZ4C N; RCJZ4D N; RCJZ4E N; RCJZ4F N; RCJZ4G N; RCJZ4H N; RCJZ4I N; RCJZ4J N; RCJZ4K N; RCJZ4L N; RCJZ4M N; RCJZ4N N; RCJZ4O N; RCJZ4P N; RCJZ4Q N; RCJZ4R N; RCJZ4S N; RCJZ4T N; RCJZ4U N; RCJZ4V N; RCJZ4W N; RCJZ4X N; RCJZ4Y N; RCJZ4Z N; RCJZ50 N; RCJZ51 N; RCJZ52 N; RCJZ53 N; RCJZ54 N; RCJZ55 N; RCJZ56 N; RCJZ57 N; RCJZ58 N; RCJZ59 N; RCJZ5A N; RCJZ5B N; RCJZ5C N; RCJZ5D N; RCJZ5E N; RCJZ5F N; RCJZ5G N; RCJZ5H N; RCJZ5I N; RCJZ5J N; RCJZ5K N; RCJZ5L N; RCJZ5M N; RCJZ5N N; RCJZ5O N; RCJZ5P N; RCJZ5Q N; RCJZ5R N; RCJZ5S N; RCJZ5T N; RCJZ5U N; RCJZ5V N; RCJZ5W N; RCJZ5X N; RCJZ5Y N; RCJZ5Z N; RCJZ60 N; RCJZ61 N; RCJZ62 N; RCJZ63 N; RCJZ64 N; RCJZ65 N; RCJZ66 N; RCJZ67 N; RCJZ68 N; RCJZ69 N; RCJZ6A N; RCJZ6B N; RCJZ6C N; RCJZ6D N; RCJZ6E N; RCJZ6F N; RCJZ6G N; RCJZ6H N; RCJZ6I N; RCJZ6J N; RCJZ6K N; RCJZ6L N; RCJZ6M N; RCJZ6N N; RCJZ6O N; RCJZ6P N; RCJZ6Q N; RCJZ6R N; RCJZ6S N; RCJZ6T N; RCJZ6U N; RCJZ6V N; RCJZ6W N; RCJZ6X N; RCJZ6Y N		AU2019204604-A1	Treating a dog for canine diseases, where the canine diseases comprise one or more canine diseases caused by canine diseases virus, involves administering to the dog therapeutically effective amounts of vaccine	TUCKER C M;  HAWORTH J D	ZOETIS SERVICES LLC (ZOET-C)	201962527V	   NOVELTY - Treating a dog for canine diseases involves administering to the dog therapeutically effective amounts of vaccine, where the vaccine comprises viral antigens, a bacterin, or both, and where the vaccine is administered subcutaneously or orally in a first dose, orally in a second dose, orally in an optional third dose, and orally in one or more annual doses, and where the viral antigens comprise canine distemper (CD) virus, canine adenovirus type 2 (CAV-2), canine parainfluenza (CPI) virus, canine parvovirus (CPV), and canine coronavirus (CCV), and where the bacterin comprises one or more bacteria selected from Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae, Leptospira Pomona, Leptospira bratislava, and Bordetella bronchiseptica and any combination of viral antigens and bacteria.    USE - Method for treating a dog for canine diseases (CD), where the canine diseases comprise one or more CD caused by CD virus, infectious canine hepatitis caused by CAV-1, respiratory disease caused by CAV-2 or respiratory CCV, CPI caused by CPI virus, enteritis caused by CCV or CPV, leptospirosis caused by Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae, Leptospira Pomona, or L. Bratislava and infectious tracheobronchitis (kennel cough) caused by Bordetella bronchiseptica, CD caused by CD virus, infectious canine hepatitis caused by CAV-1, respiratory disease caused by CAV-2, CPI caused by CPI virus and canine parvoviral enteritis caused by CPV (all claimed). 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B04C1;  B04-F10A;  B11-C04;  B12-M12K;  B12-M12N;  B14-A01A;  B14-A02A1;  B14-A02A9;  B14-A02B2;  B14-A02B5;  B14-C03;  B14-E10C;  B14-K01;  B14-N12;  B14-S12;  C04-B04C1;  C04-F10A;  C11-C04;  C12-M12K;  C12-M12N;  C14-A01A;  C14-A02A1;  C14-A02A9;  C14-A02B2;  C14-A02B5;  C14-C03;  C14-E10C;  C14-K01;  C14-N12;  C14-S12;  D05-H07	A61K-039/02;  A61K-039/10;  A61K-039/12;  A61K-039/155;  A61K-039/175;  A61K-039/23;  A61K-039/295	AU2019204604-A1   18 Jul 2019   A61K-039/02   201959Pages: 28   English	AU2019204604-A1    AU204604    28 Jun 2019	AU2019204604-A1 Div ex Application AU203965	AU203965    13 Jun 2017;  AU204604    28 Jun 2019										WO2019222768-A2;  WO2019222768-A3;  CA3096850-A1;  AU2019269753-A1;  EP3773616-A2;  IN202017048438-A;  US2021196749-A1;  EP3773616-A4	Inactivation of infectious agent, e.g. resistant            virus or cancer-causing virus, by contacting infectious            agent with bufferless, electrolyzed, hypohalous acid            composition	TERRY D J;  WILLIAMS J F	BRIOTECH INC (BRIO-Non-standard);  BRIOTECH INC (BRIO-Non-standard);  BRIOTECH INC (BRIO-Non-standard);  BRIOTECH INC (BRIO-Non-standard)	201998225P	   NOVELTY - Inactivation of infectious agent, i.e.                resistant virus, cancer-causing virus,                chemically-resistant non-enveloped virus, or                infectious agent present in mucous membrane or                epithelial surface, comprises contacting infectious                agent with bufferless, electrolyzed, hypohalous                acid composition.    USE - The method is for inactivating infectious                agent, i.e. resistant virus, cancer-causing virus,                chemically-resistant non-enveloped virus, or                infectious agent present in mucous membrane or                epithelial surface, particularly infectious protein                such as self-replicating protein or prion that is                an agent of Creutzfeldt-Jakob disease, bovine                spongiform encephalopathy, chronic wasting disease,                scrapie, Alzheimer's disease, Parkinson's disease                and amyotrophic lateral sclerosis; Gram negative                bacteria including Acinetobacter baumannii,                Escherichia coli, Escherichia coli 0157,                Pseudomonas aeruginosa, Salmonella choleraesuis,                Shigella flexneri, E. coli NDM-1, Klebsiella                pneumoniae, Yersinia enterocolitica, Proteus                vulgaris, Neisseria, Chlamydia, or Listeria; Gram                positive bacteria including Bacillus subtilis,                Staphylococcus epidermidis, methicillin-resistant                S. aureus (MRSA), Enterobacter cloacae, or                Enterococcus such as vancomycin-resistant                enterococci (VRE); fungus such as Candida albicans                or Aspergillus niger; virus such as human                Coronavirus OC43, human Papillomavirus (HPV), or                MS-2; or protozoa (all claimed).    ADVANTAGE - The method achieves convenient,                cost-effective, entirely non-hazardous high-level                decontamination or inactivation of resistant forms                of agents that pose challenges for infectious                disease control measures today. The method does not                result in damage to surfaces, devices and                equipment, and does not require heat or prolonged                exposures to or immersion in toxic or corrosive                solutions or vapor. The aqueous composition is safe                and non-toxic to allow for application at full                strength to delicate and expensive medical or                dental instruments, contaminated environmental                surfaces, and human skin and mucosal surfaces that                are subject to localized infections. 			B06 (Inorganics - including fluorides for toothpastes etc.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B05-A01A;  B05-A01B;  B05-C07;  B14-A01;  B14-A02;  B14-A03;  B14-A04A;  B14-A04B;  B14-S18;  C05-A01;  C05-C07;  C14-A01;  C14-A02;  C14-A03;  C14-A04A;  C14-A04B;  C14-S18;  C14-Z;  D05-H08A	A61K-033/00;  C02F-001/467;  A61K-031/473;  A61K-033/20;  A61K-038/47;  A61K-047/14;  A61P-031/22;  A61P-031/00;  A61P-031/20	WO2019222768-A2   21 Nov 2019   A61K-033/00   201993Pages: 30   English;  WO2019222768-A3   26 Dec 2019   A61K-033/00   202001   English;  CA3096850-A1   21 Nov 2019   A61K-033/00   202090   English;  AU2019269753-A1   12 Nov 2020   A61K-033/00   202092   English;  EP3773616-A2   17 Feb 2021   A61K-033/00   202116   English;  IN202017048438-A   12 Feb 2021   A61K-033/20   202119   English;  US2021196749-A1   01 Jul 2021   A61K-033/20   202155   English;  EP3773616-A4   27 Jul 2022   A61K-033/20   202262   English	WO2019222768-A2    WOUS036722    12 Jun 2019;   WO2019222768-A3    WOUS036722    12 Jun 2019;   CA3096850-A1    CA3096850    12 Jun 2019;   AU2019269753-A1    AU269753    12 Jun 2019;   EP3773616-A2    EP804087    12 Jun 2019;   IN202017048438-A    IN17048438    05 Nov 2020;   US2021196749-A1    US17047054    12 Oct 2020;   EP3773616-A4    EP804087    12 Jun 2019	CA3096850-A1 PCT application Application WOUS036722;   CA3096850-A1 Based on Patent WO2019222768;   AU2019269753-A1 PCT application Application WOUS036722;   AU2019269753-A1 Based on Patent WO2019222768;   EP3773616-A2 PCT application Application WOUS036722;   EP3773616-A2 Based on Patent WO2019222768;   IN202017048438-A PCT application Application WOUS036722;   IN202017048438-A Based on Patent WO2019222768;   US2021196749-A1 PCT application Application WOUS036722;   US2021196749-A1 Provisional Application US656513P	US656513P    12 Apr 2018;  CA3096850    12 Jun 2019;  WOUS036722    12 Jun 2019;  CA3096850    09 Oct 2020;  US17047054    12 Oct 2020	WO2019222768-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2019222768-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP3773616-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      EP3773616-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  		;  WO2019222768-A3 -- US20080003171-A1   ;  US20120269904-A1   ;  US9833471-B1   REOXCYN DISCOVERIES GROUP INC (REOX-Non-standard)   RICHARDS K,  HOOVER A;  WO2017223361-A1   BRIOTECH INC (BRIO-Non-standard)   TERRY D J,  WILLIAMS J F;  EP3773616-A4 -- KR2009084798-A   DOLKI KOREA LTD (DOLK-Non-standard)   KIM C;  WO2017189792-A1   BIIOSMART TECHNOLOGIES LLC (BIIO-Non-standard)   ARENAS D A;  WO2017223361-A1   BRIOTECH INC (BRIO-Non-standard)   TERRY D J,  WILLIAMS J F;  WO2012150477-A2   APR NANOTECHNOLOGIES SA (APRN-Non-standard)   CHEN Y,  DE NONI R,  REINER G,  GALFETTI P	EP3773616-A4  ROBINS L ET AL:          "P483 EFFICACY TESTING OF HOCL AS A DISINFECTANT FOR          HIGH-RISK HPV", ANTIMICROBIAL RESISTANCE AND INFECTION          CONTROL, 10 September 2019 (2019-09-10), pages 1 - 2,          XP055928643, Retrieved from the Internet          &lt;URL:https://aricjournal.biomedcentral.com/articles/10.1186/s13756-019-0567-6&gt;          [retrieved on          20220607],relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]	2355-0-0-0 K M; 3225-0-0-0 K M; 127-0-0-0 K M; 99995-0-0-0 K M; 66-0-0-0 K M; 114-0-0-0 K M			R08430 K M; R17721 K M; R01678 K M; R01801 K M; R01947 K M; R01706 K M	1678-S; 1801-S; 1947-S; 1706-S	US2019119266-A1;  US10344027-B2	New            N-(4-methyl-3-4-5-(4-methyl-isoxazol-5-yl)-pyridin-3-yl-pyrimidin-2-ylamino-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide            useful for treating cancer or bacterial or viral            infection or cardiovascular abnormalities	WERNER M H;  KELLY T A	INHIBIKASE THERAPEUTICS INC (INHI-Non-standard)	2019367303	   NOVELTY - A                N-(4-methyl-3-(4-(5-(4-methyl-isoxazol-5-yl)-pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide                (I), or its salt, is new.    USE - The                N-(4-methyl-3-(4-(5-(4-methyl-isoxazol-5-yl)-pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide                (I) is useful for treating cancer or bacterial or                viral infection, or cardiovascular abnormalities                such as pulmonary arterial hypertension (PAH),                HIV-related Kaposi's sarcoma, idiopathic pulmonary                fibrosis (IPF), diffuse cutaneous systemic                sclerosis or rheumatoid arthritis. The bacterial                infection is caused by Pseudomonas aeruginosa,                Chlamydia trachomatis, Escherichia coli,                Helicobacter pylori, Listeria monocytogenes,                Salmonella typhimurium, Shigella flexneri, or                Mycobacterium tuberculosis. The viral infection is                caused by a vaccinia virus, a variola virus, a                polyoma virus, a pox virus, a herpes virus, a                cytomegalovirus (CMV), a HIV, simian virus 40                (SV40), Ebola virus, West Nile virus or                Coronavirus. The subject is a human.    DETAILED DESCRIPTION - A                N-(4-methyl-3-(4-(5-(4-methyl-isoxazol-5-yl)-pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide                of formula (I), or its salt, is new. An INDEPENDENT                CLAIM is included for a pharmaceutical composition,                which comprises the                N-(4-methyl-3-(4-(5-(4-methyl-isoxazol-5-yl)-pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide                (I) and an excipient. 			B03 (Other heterocyclics.)	B07-D04B;  B07-D11;  B07-D12;  B07-E01;  B14-A01;  B14-A02;  B14-C09B;  B14-H01;  B14-K01;  B14-N17	A61K-031/506;  A61K-045/06;  C07D-401/14;  C07D-403/14;  C07D-413/14;  C07D-417/14	US2019119266-A1   25 Apr 2019   C07D-417/14   201934Pages: 42   English;  US10344027-B2   09 Jul 2019   C07D-401/14   201953   English	US2019119266-A1    US169683    24 Oct 2018;   US10344027-B2    US169683    24 Oct 2018	US2019119266-A1 Provisional Application US182955P;   US2019119266-A1 Provisional Application US151659P;   US2019119266-A1 Cont of Application US805693;   US2019119266-A1 Cont of Application US136497;   US2019119266-A1 Cont of Patent US9828370;   US2019119266-A1 Cont of Patent US10118923;   US10344027-B2 Provisional Application US182955P;   US10344027-B2 Provisional Application US151659P;   US10344027-B2 Cont of Application US805693;   US10344027-B2 Cont of Application US136497;   US10344027-B2 Cont of Patent US9828370;   US10344027-B2 Cont of Patent US10118923;   US10344027-B2 Previous Publ. Patent US2019119266	US151659P    23 Apr 2015;  US169683    24 Oct 2018		514/252180;  544/295000	;  US10344027-B2 -- US20100249122-A1   ;  US9828370-B2   INHIBIKASE THERAPEUTICS INC (INHI-Non-standard)   WERNER M H,  KELLY T A;  US10118923-B2   INHIBIKASE THERAPEUTICS INC (INHI-Non-standard)   WERNER M H,  KELLY T A;  WO2014055938-A1   SPHAERA PHARMA PTE LTD (SPHA-Non-standard);  INHIBIKASE THERAPEUTICS INC (INHI-Non-standard)   DEOKAR R C,  DUGAR S,  MAHAJAN D,  WERNER M H;  WO2016172528-A1   INHIBIKASE THERAPEUTICS INC (INHI-Non-standard)   WERNER M H,  KELLY T A;  WO2018081251-A1   INHIBIKASE THERAPEUTICS INC (INHI-Non-standard)   WERNER M H,  KELLY T A;  WO2008070350-A2   UNIV TEXAS SYSTEM (TEXA);  UNIV RICE (RICV)   FERNANDEZ A,  BORNMANN W,  LOPEZ-BERESTEIN G,  SANGUINO A,  PENG Z;  WO2008079460-A2   UNIV EMORY (UEMR)   KALMAN D	US10344027-B2            Bosseray, et al., What's new in vaccines against herpes          simplex infections? Pathol Biol (Paris), 50(8): 483-492          (2002). (Abstract).;            Brahmachari et al., c-Abl and Parkinson's Disease:          Mechanisms and Therapeutic Potential, J Parkinsons Dis,          7(4):589-601 (2017).;            Douglas, Jr., Introduction to Viral Diseases, Cecil          Textbook of Medicine, 20(2): 1739-1747 (1996).;            Goff, Intracellular trafficking of retroviral genomes          during the early phase of infection: viral exploitation          of cellular pathways, J Gene Med, 3(6): 517-528 (2001).          (Abstract).;            Gura, Systems for Identifying New Drugs are Often Faulty,          Science, 278(5340): 1041-1042 (1997).;            Imam et al., Novel regulation of parkin function through          c-Abl-mediated tyrosine phosphorylation: implications for          Parkinson's disease, J Neurosci, 31(1):157-163          (2011).;            International Search Report and Written Opinion for          International Application No. PCT/US2017/058263 dated          Feb. 26, 2018.;            Johnson, et al., Relationships between drug activity in          NCI preclinical in vitro and in vivo models and early          clinical trials, Br J Cancer, 84(10): 1424-1431          (2001).;            Karuppagounder et al., The c-Abl inhibitor, nilotinib,          protects dopaminergic neurons in a preclinical animal          model of Parkinson's disease, Sci Rep, 4:4874          (2014).;            Lindholm et al., c-Abl inhibitors enable insights into          the pathophysiology and neuroprotection in Parkinson's          disease, Front Aging Neurosci, 8:254 (2016).;            Napier et al., Low Doses of Imatinib Induce Myelopoiesis          and Enhance Host Anti-microbial Immunity, Plos Pathog,          1-27 (Mar. 30, 2015).;            Pearce, et al., Failure modes in anticancer drug discover          and development, Cancer Drug Design and Discovery:          424-435 (2008).;            Razonable, et al., Herpesvirus infections in transplant          recipients: current challenges in the clinical management          of cytomegalovirus and Epstein-Barr virus infections,          Herpes, 10(3): 60-65 (2003). (Abstract).;            Simone, Oncology: Introduction, Cecil Textbook of          Medicine, 20(1): 1004-1010 (1996).	 N			RCKHFK N		WO2019240504-A1	New modified oligonucleotide that binds to target gene, in which a nucleotide of modified oligonucleotide is locked nucleic acid and oligonucleotide forms quadruplex upon binding to target gene, used to inhibit expression of target gene	KIM K H;  LEE A R;  KIM D H	AM SCI CO LTD (AMSC-Non-standard)	2019A6954Y	   NOVELTY - Modified oligonucleotide that binds to a target gene sequence (I), where at least one nucleotide of the modified oligonucleotide is a locked nucleic acid (LNA) and the modified oligonucleotide forms a quadruplex upon binding to the target gene sequence, is new.    USE - The modified oligonucleotide is useful: for inhibiting expression of a target gene, where the target gene sequence is a viral gene sequence, and is not a hepatitis B sequence, and the viral gene sequence is a sequence from a virus consisting of HIV-1, Herpes simplex virus (HSV)-1, Epstein-Barr virus, Kaposi's sarcoma-associated herpes virus, Human herpes virus 6 (HHV-6), Hepatitis C virus (HCV), Human papillomavirus (HPV), Zika virus (ZIKV), Severe acute respiratory syndrome-related coronavirus (SARS Co-V), Ebola virus (EBOV) or influenza virus (claimed); and as anti-viral agent. Test details are described but no results given.    DETAILED DESCRIPTION - Modified oligonucleotide that binds to a target gene sequence of formula ((A1)x-(G1)y-(B1)z) (I), where at least one nucleotide of the modified oligonucleotide is a locked nucleic acid (LNA) and the modified oligonucleotide forms a quadruplex upon binding to the target gene sequence, is new.    A1 = sense sequence to the target gene sequence;    x, z = 1-16;    G1 = guanine;    y = 4-6; and    B1 = sense sequence to the target gene sequence.    An INDEPENDENT CLAIM is also included for inhibiting expression of a target gene, comprising contacting the target gene sequence with the modified oligonucleotide, where the modified oligonucleotide comprises at least four consecutive guanines (gggg) and at least one LNA, and the modified oligonucleotide comprises a sense sequence to the target gene sequence and forms a G quadruplex upon binding to the target gene sequence resulting in target gene expression inhibition. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03F;  B04-E11;  B04-E99;  B14-A02;  B14-S03A;  C04-B03F;  C04-E11;  C04-E99;  C14-A02;  C14-S03A;  D05-H12D6;  D05-H99	A61K-031/7088;  A61P-031/12;  C12N-015/113	WO2019240504-A1   19 Dec 2019   C12N-015/113   202006Pages: 191   English	WO2019240504-A1    WOKR007112    12 Jun 2019		US684000P    12 Jun 2018	WO2019240504-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  		WO2019240504-A1 -- KR2010010509-A   COLEY PHARM GROUP INC (PFIZ);  COLEY PHARM GMBH (PFIZ)   KRIEG A M,  UHLMANN E,  VOLLMER J;  KR2013137156-A   MERCK SHARP & DOHME CORP (MERI)   BARTZ S,  BROWN D,  ROBINSON M;  KR2015022911-A   BLOCK T M (BLOC-Individual);  CHANG J (CHAN-Individual);  KINNEY W A (KINN-Individual);  GUO J (GUOJ-Individual)   BLOCK T M,  CHANG J,  KINNEY W A;  KR2018068320-A   AM SCI INC (AMSC-Non-standard)   KIM K H,  KIM D H,  PARK Y M;  US5856459-A   HOFFMANN LA ROCHE & CO AG F (HOFF);  HYBRIDON INC (HYBR)   CRAIG C J,  FRANK B L,  GOODCHILD J,  JUPP R,  KILKUSKIE R E,  MILLS J S,  ROBERTS N A,  ROBERTS P C,  SLADE A;  US20130288380-A1   ;  US20170016000-A1   ;  WO2018089914-A1   ALIOS BIOPHARMA INC (JOHJ)   GRYAZNOV S,  FITZGERALD M,  STOYCHEVA A D,  HONG J	WO2019240504-A1  HARRIS, L. M. ET AL.: "G-quadruplexes in pathogens: a common route to virulence control?", PLOS PATHOGENS, vol. 11, no. 2, 5 February 2015 (2015-02-05), pages 1 - 15, XP055211017,relevantClaims[1-80],relevantPassages[See the whole document.]	184610-0-0-0 N	217811201 N	01001	RA013I N		WO2019182947-A1;  US2021032227-A1;  US11542257-B2	New substituted arylnaphthalene compound useful in            pharmaceutical composition for treating viral            infection	DAVISSON V J;  LINDSTROM A R	PURDUE RES FOUND (PURD-C);  PURDUE RES FOUND (PURD-C);  PURDUE RES FOUND (PURD-C)	201982331J	   NOVELTY - A substituted arylnaphthalene compound (I), is                new.    USE - New substituted arylnaphthalene compound is                useful in pharmaceutical composition for treating                viral infection by flaviviridae viruses including                Dengue virus, West Nile virus, Yellow fever virus,                Japanese encephalitis virus, Powassan virus, Zika                virus and Usutu virus, respiratory viruses                including Middle East respiratory syndrome-related                (MERS) coronavirus, Influenza A H1N1 virus,                Respiratory syncytial virus, Arenaviridae virus                including Tacaribe virus, Pichinde virus, Junin                virus, Lassa fever virus, Lymphocytic                Choriomeningitis virus, Filoviridae virus,                including Ebola virus, Marburg virus, Togaviridae                virus including Venezuelan equine encephalitis                virus, Eastern equine encephalitis virus, Western                equine encephalitis virus, and Chikungunya virus,                Mayaro virus, and Hantavirus (all claimed). The                substituted arylnaphthalene compound is also used                for treating cancer e.g. prostate cancer, ovarian                cancer, lung cancer, or breast cancer.    DETAILED DESCRIPTION - A substituted arylnaphthalene compound of                formula (I) or its salt, is new.    A,X = C, C=O, CR, CH, CHR, O, S, N, NH, or                NR;    B' = H, D, or F;    Y' = O, CF2, CH2, CHR, S, NH, or NR;    R1 = H, or alkyl, alkylamido, alkylamino,                alkenyl, alkenylamido, alkenylamino, alkynyl,                alkynylamido, alkynylamino, heteroalkyl,                heteroalkenyl, heteroalkynyl, heterocyclyl,                cycloalkyl, cycloalkenyl, cycloheteroalkyl,                cycloheteroalkenyl, acyl, aryl, heteroaryl,                arylalkyl, arylalkenyl, or arylalkynyl (all                optionally substituted);    R2,R3,R = H, D, halo, azido, cyano, nitro,                hydroxy, amino, thio, carboxy, ester, amido, or                acyl, sulfoxy, sulfonyl, phosphato, phosphoryl,                alkyl, alkenyl, alkynyl, heteroalkyl,                heteroalkenyl, heteroalkynyl, heterocyclyl,                cycloalkyl, cycloalkenyl, cycloheteroalkyl,                cycloheteroalkenyl, aryl, heteroaryl, arylalkyl,                arylalkenyl, or arylalkynyl (all optionally                substituted);and    or (two R+C) = optionally substituted cyclyl                or heterocyclyl.    INDEPENDENT CLAIMS are included for the                following:    (1) treatment of patient with viral infection,                which involves administering specific amount of                compound(s) (I) in the form of nanoparticles, and                carriers, diluents and/or excipients;    (2) drug conjugate, which comprises                compound(s) (I). The conjugate confers cell-type or                tissue-type targeting or the conjugate targets                another pathway that synergizes the action of                compound(s) (I); and    (3) nanoparticles, which comprise compound(s)                (I) together with diluents, excipients and/or                carriers. 			B02 (Fused ring heterocyclics.)	B04-Q;  B05-A04A;  B05-B01E;  B05-B01M;  B06-A02;  B12-M11Q;  B14-A02;  B14-C03;  B14-C04;  B14-D07;  B14-H01	A61K-031/352;  A61K-031/365;  A61P-031/14;  A61K-009/14;  A61P-031/12;  C07D-405/04;  C07D-405/14;  C07D-407/04;  C07D-409/14;  C07D-413/14	WO2019182947-A1   26 Sep 2019   A61K-031/352   201978Pages: 74   English;  US2021032227-A1   04 Feb 2021   C07D-405/14   202115   English;  US11542257-B2   03 Jan 2023   C07D-405/14   202302   English	WO2019182947-A1    WOUS022695    18 Mar 2019;   US2021032227-A1    US16982354    18 Sep 2020;   US11542257-B2    US16982354    18 Sep 2020	US2021032227-A1 PCT application Application WOUS022695;   US2021032227-A1 Provisional Application US644637P;   US11542257-B2 Provisional Application US644637P;   US11542257-B2 PCT application Application WOUS022695;   US11542257-B2 Previous Publ. Patent US2021032227;   US11542257-B2 Based on Patent WO2019182947	US644637P    19 Mar 2018;  US16982354    18 Sep 2020	WO2019182947-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      		WO2019182947-A1 -- US4486445-A   DU PONT DE NEMOURS & CO E I (DUPO)   PATEL N G,  WANG C L J;  US20040044069-A1   ;  US20100119483-A1   ;  US20110105423-A1   ;  US20150336938-A1   ;  US11542257-B2 -- WO2008058897-A2   NORDIC BIOSCIENCE AS (NORD-Non-standard)   SORENSEN M G,  HENRIKSEN K,  KARSDAL M A;  US4486445-A   DU PONT DE NEMOURS & CO E I (DUPO)   PATEL N G,  WANG C L J;  US20040044069-A1   ;  US20100119483-A1   ;  US20110105423-A1   ;  US20150336938-A1   	WO2019182947-A1  DATABASE PUBCHEM          compound [online] 30 November 2012 (2012-11-30),          "9-(1,3-Benzodioxol-5-yl)-4-hydroxy-6,7-dimethoxy2,3-dihydrocyclopenta[b]naphthalen-1-one",          XP055638679, retrieved from NCBI Database accession no.          67198177,relevantClaims[1, 3],relevantPassages[; page 2,          formula]US11542257-B2            Kostova et al., CAPLUS Abstract 132:345480          (2000).;  Yu          et al., Synthesis and bioevaluation of novel analogues of          justicidin A, Med Chem Res. 19, pp. 71-76          (2010).;            Zhao et al., Synthesis, Cytotoxicity and Pro-apoptosis of          Novel Benzisoindolin Hydrazones as Anticancer Agents,          Chem. Pharm. Bull. 58(10), pp. 1324-1327          (2010).;            Fan et al., CAPLUS Abstract 160:158962 (2013).;            Bosseray et al., PubMed Abstract (Pathol Biol (Paris)          50(8): 483-92), 2002.;            Douglas, Jr., Introduction to Viral Diseases, Cecil          Textbook of Medicine, 20th Edition, vol. 2, pp. 1739-1747          (1996).;            Goff, PubMed Abstract (J Gene Med 3(6): 517-28),          2001.;            Razonable et al., PubMed Abstract (Herpes 10(3): 60-5),          2003.;            PCT_ISR-WO, Jul. 2019.;            Lindstrom, A., et al., Phenotypic Prioritization of          Diphyllin Derivatives That Block Filoviral Cell Entry by          Vacuolar (H+)-ATPase Inhibition, ChemMedChem 2018, 13,          2664-2676.	1929821-0-0-0 N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N; 1929821-0-0-0 CL NEW	216719101 N	03010; 02923; 02677; 02678; 02708; 02782; 02833; 02921; 03009; 03057; 03058; 03125; 44879; 51455	RAZZYJ N; RCO0F8 N; RCO0FK N; RCO0F9 N; RCO0FA N; RCO0FB N; RCO0FC N; RCO0FD N; RCO0FE N; RCO0FF N; RCO0FG N; RCO0FH N; RCO0FI N; RCO0FJ N		WO2019180688-A2;  WO2019180688-A3;  CA3094903-A1;  AU2019240293-A1;  US2021008028-A1;  EP3768095-A2;  JP2021519344-W	Composition used for treating diarrheal disease            e.g. cholera, comprises polyphenol-rich extract of            mixture of blueberry or bilberry from Vaccinium            cyanococcus or Vaccinium myrtillis, and sloe berry from            Prunus spinosa	KRAVTSOV D;  KVOCHINA L I;  GRAY N;  SAINZ A S	VANESSA RES INC (VANE-Non-standard);  VANESSA RES INC (VANE-Non-standard);  VANESSA RES INC (VANE-Non-standard);  VANESSA RES INC (VANE-Non-standard)	201982385D	   NOVELTY - Composition comprises a polyphenol-rich                extract of a mixture of (A) 80-20 wt.% blueberry or                bilberry from Vaccinium cyanococcus spp. and/or                V.myrtillis spp., and (B) 20-80 wt.% sloe berry                from Prunus spinosa spp..    USE - The composition is used for treating diarrheal                disease (all claimed) such as cholera, travelers'                diarrhea, Escherichia coli diarrhea, Vibrio cholera                diarrheas, Clostridium difficile diarrhea,                Klebsiella pneumoniae diarrhea, Rotavirus diarrhea,                adenovirus diarrhea, parvovirus diarrhea, norwalk                virus (norovirus) diarrhea, Giardia diarrhea,                astrovirus diarrhea, calicivirus diarrhea, Shigella                diarrhea, Salmonella diarrhea, Staphylococcus                related diarrhea, Campylobacter related diarrhea,                Yersinia related diarrhea, Aeromonas related                diarrhea, Pseudomonas related diarrhea, Torovirus                related diarrhea, Coronavirus related diarrhea,                Picobirnavirus related diarrhea, Pestivirus related                diarrhea, AIDS-related diarrhea, and inflammatory                diarrheal disorders, such as inflammatory bowel                disease, Crohn's disease and irritable bowel                syndrome.    ADVANTAGE - The composition is safe and efficient.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method                for making a polyphenol-rich extract, comprising                (i) mixing 50-70% alcohol with a blueberry,                bilberry, sloe berry, or chokeberry to form a                mixture, (ii) incubating the mixture at room                temperature for 1 hour to 90 days while rotating                daily to form an incubated mixture, (iii) filtering                or centrifuging solid matter out of the incubated                mixture, and collecting flow-through of the                incubated mixture, (iv) optionally, combining the                flow-through from the step (iii) with a berry                powder to form a second mixture, (v) optionally,                incubating the second mixture for 1-3 hours at room                temperature to form a second incubated mixture,                (vi) optionally, filtering or centrifuging solid                matter out of the second incubated mixture and                collecting supernatant, and (vii) evaporating                alcohol under vacuum from the flow-through from the                step (iii) or the supernatant from the step (iv) at                40 degrees C to a desired alcohol concentration,                such as 20% or less to form the polyphenol-rich                extract. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  A96 (Medical, dental, veterinary, cosmetic.)	B04-A08G2;  B04-A10;  B04-A98;  B06-A01;  B09-D01;  B10-A07A;  B10-A07E;  B10-C03;  B14-A01A9;  B14-C03;  B14-E02;  B14-E10C;  B14-G01B;  B14-S18;  A12-V01	A61K-036/736;  A23K-020/121;  A23K-050/10;  A61K-031/353;  A23L-033/105;  A61K-036/45;  A61K-036/73;  A61P-001/12;  A61K-031/352;  A61K-031/7048	WO2019180688-A2   26 Sep 2019   A61K-036/736   201977Pages: 35   English;  WO2019180688-A3   31 Oct 2019   A23K-020/121   201984   English;  CA3094903-A1   26 Sep 2019   A61K-036/45   202084   English;  AU2019240293-A1   15 Oct 2020   A23K-020/121   202084   English;  US2021008028-A1   14 Jan 2021   A61K-031/353   202106   English;  EP3768095-A2   27 Jan 2021   A23K-020/121   202110   English;  JP2021519344-W   10 Aug 2021   A61K-036/45   202165Pages: 25   Japanese	WO2019180688-A2    WOIB052371    23 Mar 2019;   WO2019180688-A3    WOIB052371    23 Mar 2019;   CA3094903-A1    CA3094903    23 Mar 2019;   AU2019240293-A1    AU240293    23 Mar 2019;   US2021008028-A1    US17040749    23 Sep 2020;   EP3768095-A2    EP772259    23 Mar 2019;   JP2021519344-W    JP500370    23 Mar 2019	CA3094903-A1 PCT application Application WOIB052371;   CA3094903-A1 Based on Patent WO2019180688;   AU2019240293-A1 PCT application Application WOIB052371;   AU2019240293-A1 Based on Patent WO2019180688;   US2021008028-A1 PCT application Application WOIB052371;   US2021008028-A1 Provisional Application US647622P;   EP3768095-A2 PCT application Application WOIB052371;   EP3768095-A2 Based on Patent WO2019180688;   JP2021519344-W PCT application Application WOIB052371;   JP2021519344-W Based on Patent WO2019180688	US647622P    23 Mar 2018;  CA3094903    23 Sep 2020;  US17040749    23 Sep 2020	WO2019180688-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2019180688-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP3768095-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    		;  WO2019180688-A3 -- US20150328258-A1   ;  US20170080015-A1   ;  WO2017112953-A1   VANESSA RES INC (VANE-Non-standard)   GRAY N,  KRAVTSOV D;  US2021008028-A1 -- WO2010003472-A2   MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFT (MART-Non-standard)		95854-2-0-0 K M Q; 91937-0-0-0 K M Q; 92514-0-1-0 K M Q; 95854-1-0-0 K M Q; 104714-2-0-0 K M Q; 95853-1-0-0 K M Q; 159573-1-0-0 K M Q; 7650-0-0-0 K M Q; 196455-0-0-0 K M Q; 196509-7-0-0 K M Q;  K M Q; 8767-1-0-0 K M Q; 196909-5-0-0 K M Q; 1177433-0-0-0 K M; 1713214-0-0-0 K M;  K M; 2035532-0-0-0 K M; 747985-0-0-0 K M; 1177433-0-0-0 CL USE; 1713214-0-0-0 CL USE; 2035532-0-0-0 CL USE; 95854-2-0-0 CL RCT USE; 91937-0-0-0 CL RCT USE; 92514-0-1-0 CL RCT USE; 95854-1-0-0 CL RCT USE; 104714-2-0-0 CL RCT USE; 95853-1-0-0 CL RCT USE; 196455-0-0-0 CL RCT USE; 196509-7-0-0 CL RCT USE; 196909-5-0-0 CL RCT USE		03619	R07947 K M Q; RAB6H6 K M Q; R09597 K M Q; R09596 K M Q; RASOKF K M Q; R19452 K M Q; RA00TN K M Q; R00038 K M Q; R01170 K M Q; RACTRE K M Q; RA64CM K M Q; RAHRZY K M Q; RA1BYB K M Q; RADS46 K M Q; RAJZ9L K M; RAVFKA K M; RCCXAK K M; RB26E6 K M; RAB2B5 K M	0038-S; 1170-S	WO2019133712-A1;  CA3087192-A1;  EP3732180-A1;  CN111971284-A;  IN202047030171-A;  US2021060051-A1;  EP3732180-A4;  IN476949-B	New substituted nucleosides compounds are NADPH            oxidase (NOX) inhibitors, used for treating or            preventing HIV, reducing biological activity of            infection with HIV and treating or preventing viral            infection e.g. Arenavirus and Herpesviridae	SCHINAZI R F;  AMBLARD F;  GAVEGNANO C;  COX B;  MENGSHETTI S	SCHINAZI R F (SCHI-Individual);  AMBLARD F (AMBL-Individual);  GAVEGNANO C (GAVE-Individual);  COX B (COXB-Individual);  MENGSHETTI S (MENG-Individual);  UNIV EMORY (UEMR-C);  UNIV EMORY (UEMR-C);  SCHINAZI R F (SCHI-Individual);  AMBLARD F (AMBL-Individual);  GAVEGNANO C (GAVE-Individual);  COX B (COXB-Individual);  MENGSHETTI S (MENG-Individual)	201957882X	   NOVELTY - Substituted nucleosides compounds (I) are                new.    USE - (I) are useful for treating or preventing HIV,                reducing the biological activity of an infection                with HIV and treating (M3) or preventing a viral                infection, where the viral infection comprises                Arenavirus, Herpesviridae, Filoviridae,                Rhabdoviridae, Coronaviridae, Paramyxoviridae,                Polyomaviridae, Picornaviridae, Bunyaviridae,                Caliciviridae, Flaviviridae, Hepadnaviridae,                Orthomyxoviridae, Retroviridae or Togaviridae                families, the Arenavirus comprises Junin, Machupo,                Guanarito, Lassa or Lujo viruses, the Herpesviridae                virus comprises human Herpesvirus 1, 2, 3, 4, 5, 6,                7 or 8, the Filoviridae virus comprises Ebola virus                or Marburg virus, the Rhabdoviridae comprises                rabies virus or the Australian bat Lyssavirus, the                Coronaviridae virus comprises human Coronavirus                229E or human Coronavirus NL63, the Paramyxoviridae                virus comprises Mumps rubulavirus, the                Polyomaviridae virus comprises Influenza A virus or                the BK virus, the Picornaviridae virus comprises                Foot-and-mouth disease virus, Enterovirus-68,                Enterovirus-71, Enterovirus C (poliovirus) or                Rhinovirus, the Bunyaviridae virus comprises Hanta                virus, Rift Valley fever virus or Crimean-congo                hemorrhagic fever virus, the Caliciviridae virus                comprises Norwalk virus or Norovirus, the                Flaviviridae virus comprises Dengue virus,                Deer-tick encephalitis virus, Japanese encephalitis                virus, Murray Valley encephalitis virus, omsk                hemorrhagic fever virus, Powassan virus, St. Louis                encephalitis virus, Tick-borne encephalitis virus,                West Nile virus, Yellow fever virus, Zika virus or                hepatitis C, the Hepadnaviridae virus comprises                hepatitis B, the Orthomyxoviridae virus comprises                influenza A, influenza B, or influenza C, the                Retroviridae virus comprises HIV-1, HIV-2 or human                T-lymphotrophic virus, or the Togaviridae virus                comprises Chikungunya virus, Mayaro virus, Sindbis                virus or Venezuelan equine encephalitis virus (all                claimed).    DETAILED DESCRIPTION - Substituted nucleosides compounds (I) of                formula (IA) and (IB) or their salts or prodrugs                are new.    Y1 = H, 1-6C alkyl, 1-6C haloalkyl, 2-6C                alkenyl or 2-6C alkynyl;    R = e.g. 1-6C alkyl, 2-6C alkenyl, 2-6C                alkynyl, 3-6C cycloalkyl (all optionally                substituted by at least one of halo, OH, NH2,                alkyl-NH2, aryl-NH2, alkoxy, aryloxy, NO2, CN,                sulfonic acid, sulfate, phosphonic acid, phosphate,                or phosphonate), H, 1-6C haloalkyl, 1-6C alkoxy,                aryl, heteroaryl, heterocyclic, alkylaryl,                arylalkyl, OH, NO2, CN, CN-alkyl, azido,                azidoalkyl, formyl and hydrazino; either    R1, R1A = H, CH3, CH2F, CHF2 or CF3, when R1                is Me, C to which it is attached may be wholly or                partially R or S; or    R1R1A = 3-7C cycloalkyl ring; and    R1B = 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl                (all optionally substituted by 1-3 of halo, OH,                nitrile, NH2, alkylamino, arylamino, alkoxy,                thioalkoxy, aryloxy, NO2, CN, sulfonic acid,                sulfate, phosphonic acid, phosphate or                phosphonate), H, acyl, alkyl, 1-6C alkyl, 2-6C                alkenyl, 2-6C alkynyl or 3-6C cycloalkyl.    Full definitions are given in the DEFINITIONS                (Full Definitions) Field. INDEPENDENT CLAIMS are                also included for:    (1) a composition comprising (I) and a carrier                or excipient;    (2) treating (M1) or preventing HIV,                comprising administering (I) to a patient;    (3) treating (M2) or preventing HIV,                comprising administering 6 compounds e.g.                substituted heterocyclic compounds of formulae (IX)                and (X) to a patient, where the compounds are                preferably 94 compounds e.g.                2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazol                (4,3-c)pyridine-3,6(2H,5H)-dione,                2-(2-chlorophenyl)-4-(2,6-difluorophenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo(4,3-c)                pyridine-3,6(2H,5H)-dione,                4-(2-fluoro-5-methoxyphenyl)-2-(2-methoxyphenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo(4,3-c)pyridine-3,6-(2H,5H)-dione,                2-(2-chlorophenyl)-4-(2,5-difluorophenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo(4,3-c)pyridine-3,6-(2H,5H)-dione                and                2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-((1-methyl-1H-pyrazol-3-yl)methyl)-1H-pyrazolo(4,3-c)pyridine-3,6-(2H,5H)-dione;                and    (4) treating (M3) or preventing a viral                infection, where the virus targets the macrophage,                comprising administering a nicotinamide adenine                dinucleotide phosphate oxidase (NADPH Oxidase, NOX)                modulator to a patient.    A = monocyclic or bicyclic aromatic or                non-aromatic ring having 5-12 atoms in the ring,                where the ring optionally has at least one of C, O,                S and/or N;    R111 = H, OH, halo, alkyl, alkoxy, aryl,                alkylaryl, heteroaryl, alkylheteroaryl,                heterocyclyl or alkyl heterocyclyl;    R222 = halo, azide, alkyl, aralkyl, alkenyl,                alkynyl, cycloalkyl, hydroxyl, alkoxy, NH2, NO2,                sulfhydryl, imino, amido, phosphonate, phosphinate,                carbonyl, carboxy, ether, alkylthio, sulfonyl,                sulfonamido, ketone, aldehyde, ester, heterocyclyl,                aromatic or heteroaromatic moieties, -CF3 or                -CN;    Base = substituted heterocyclic moieties of                formula (II)-(VIII);    X = O, S or NR3a;    R3a = aryl (optionally substituted), OH or                alkyl;    Y1a = C, O, N, NR4a, S and Se;    Q = alky, hydroxy, ether, ester, carboxylic                acid, NR4a, SR5 or Se; and    R4a = H, alkyl, or L-glutathione. 			B03 (Other heterocyclics.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C02 (Heterocyclic.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03D;  B04-B03E;  B04-E99;  B05-A04A;  B05-B01D;  B05-B01J;  B05-B01K;  B05-B01L;  B05-B01M;  B05-B01N;  B05-B01P;  B06-H;  B07-H;  B14-A02;  B14-C03;  B14-C04;  B14-S18;  C04-B03D;  C04-B03E;  C04-E99;  C05-A04A;  C05-B01D;  C05-B01J;  C05-B01K;  C05-B01L;  C05-B01M;  C05-B01N;  C05-B01P;  C06-H;  C07-H;  C14-A02;  C14-C03;  C14-C04;  C14-S18;  D05-H99	C07D-487/04;  C07H-019/14;  A61K-031/12;  A61K-031/17;  A61K-031/41;  A61K-031/428;  A61K-031/437;  A61K-031/45;  A61K-031/519;  A61K-031/5415;  A61K-031/69;  A61K-031/7072;  A61K-031/7076;  A61K-045/06;  A61P-031/14;  A61P-031/16;  A61P-031/18;  A61P-031/22;  C07C-275/40;  C07D-275/04;  C07D-279/20;  C07D-417/04;  C07D-471/04;  C07H-019/10;  C07H-019/16;  A61K-031/706;  A61K-031/7064;  A61K-031/7068;  A61P-031/12;  C07H-019/06;  C07H-019/20;  A61P-031/00	WO2019133712-A1   04 Jul 2019   C07D-487/04   201956Pages: 153   English;  CA3087192-A1   04 Jul 2019   C07D-487/04   202062   English;  EP3732180-A1   04 Nov 2020   C07D-487/04   202090   English;  CN111971284-A   20 Nov 2020   C07D-487/04   202097   Chinese;  IN202047030171-A   02 Oct 2020   C07D-487/04   202108   English;  US2021060051-A1   04 Mar 2021   A61K-031/7076   202122   English;  EP3732180-A4   11 May 2022   C07H-019/10   202244   English;  IN476949-B   08 Dec 2023   A61P-031/00   202409   English	WO2019133712-A1    WOUS067674    27 Dec 2018;   CA3087192-A1    CA3087192    27 Dec 2018;   EP3732180-A1    EP894881    27 Dec 2018;   CN111971284-A    CN80090352    27 Dec 2018;   IN202047030171-A    IN47030171    15 Jul 2020;   US2021060051-A1    US16958572    26 Jun 2020;   EP3732180-A4    EP894881    27 Dec 2018;   IN476949-B    IN47030171    15 Jul 2020	CA3087192-A1 PCT application Application WOUS067674;   CA3087192-A1 Based on Patent WO2019133712;   EP3732180-A1 PCT application Application WOUS067674;   EP3732180-A1 Based on Patent WO2019133712;   CN111971284-A PCT application Application WOUS067674;   CN111971284-A Based on Patent WO2019133712;   IN202047030171-A PCT application Application WOUS067674;   IN202047030171-A Based on Patent WO2019133712;   US2021060051-A1 PCT application Application WOUS067674;   US2021060051-A1 Provisional Application US610841P;   EP3732180-A4 PCT application Application WOUS067674;   IN476949-B PCT application Application WOUS067674;   IN476949-B Based on Patent WO2019133712	US610841P    27 Dec 2017;  CA3087192    26 Jun 2020;  US16958572    26 Jun 2020;  CN80090352    27 Aug 2020	WO2019133712-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP3732180-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR        EP3732180-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR    		WO2019133712-A1 -- US20160002252-A1   ;  WO2010015637-A1   NOVARTIS AG (NOVS)   CHEN Y,  DURAISWAMY J,  KONDREDDI R R,  YIN Z;  CN111971284-A -- CN101287472-A   ROCHE PALO ALTO LLC (SYNT)   KLUMPP K,  MARTIN J A,  MCGUIGAN C,  SMITH D B;  CN106795199-A   MERCK SHARP & DOHME CORP (MERI)   GIRIJAVALLABHAN V M,  OLSEN D B,  ZHANG Z,  FU J,  TANG B;  US20020022722-A1   ;  US20160002252-A1   ;  US20160220595-A1   ;  US20170037078-A1   ;  WO2000069876-A1   ;  WO2010015637-A1   NOVARTIS AG (NOVS)   CHEN Y,  DURAISWAMY J,  KONDREDDI R R,  YIN Z;  WO2015038596-A1   UNIV EMORY (UEMR)   LIOTTA D C,  PAINTER G R,  BLUEMLING G R,  DE LA ROSA A;  US2021060051-A1 -- US20020022722-A1   ;  US20130034521-A1   	CN111971284-A  EI-ICHI KODAMA ET          AL.: "49-Ethynyl Nucleoside Analogs: Potent Inhibitors of          Multidrug-Resistant Human Immunodeficiency Virus Variants          In Vitro", ANTIMICROBIAL AGENTS AND          CHEMOTHERAPY,relevantClaims[1-47],relevantPassages[1539-1546];  MICHAEL O. CLARKE          ET AL.: "Discovery of          -D-20-deoxy-20--uoro-40--cyano-5-aza-7,9-dideaza          adenosine as a potent nucleoside inhibitor of respiratory          syncytial virus with excellent selectivity over          mitochondrial RNA and DNA polymerases", BIOORGANIC &          MEDICINAL CHEMISTRY          LETTERS,relevantClaims[1-4891117],relevantPassages[2-3]US2021060051-A1            Nomura, Journal of Medicinal Chemistry, 1999, vol. 42,          No. 15. (Year: 1999);            Shi, Bioorganic & Medicinal Chemistry Letters 21          (2011) 7094-7098. (Year: 2011);            Wagner, Current HIV Research, 2011, 9, 209-222. (Year:          2011);            Thenin-Houssier, Antimicrobial Agents and Chemotherapy          April 2016, Volume 60, Number 4, pp 2195-2208. (Year:          2016)	 M N;  M N; 4078726-1-0-0 M N; 4078678-1-0-0 M N; 4078719-1-0-0 M N; 4078672-1-0-0 M N; 4078671-1-0-0 M N; 4078668-1-0-0 M N; 4078650-1-0-0 M N; 4078651-1-0-0 M N; 4078681-1-0-0 M N; 4078680-1-0-0 M N; 4078683-1-0-0 M N; 4078703-1-0-0 M N; 4078690-1-0-0 M N; 4078724-1-0-0 M N; 4078707-1-0-0 M N; 4078706-1-0-0 M N; 4078682-1-0-0 M N; 4078720-1-0-0 M N; 4078721-1-0-0 M N; 4078677-1-0-0 M N; 4078663-1-0-0 M N; 4078700-1-0-0 M N; 4078684-1-0-0 M N; 4078685-1-0-0 M N; 4078695-1-0-0 M N; 4078689-1-0-0 M N; 4078654-1-0-0 M N; 4078701-1-0-0 M N; 4078656-1-0-0 M N; 4078657-1-0-0 M N; 4078704-1-0-0 M N; 4078697-1-0-0 M N; 4078698-1-0-0 M N; 4078648-1-0-0 M N; 4078728-1-0-0 M N; 4078715-1-0-0 M N; 4078718-1-0-0 M N; 4078713-1-0-0 M N; 4078675-1-0-0 M N; 4078687-1-0-0 M N; 4078686-1-0-0 M N; 4078705-1-0-0 M N; 4078659-1-0-0 M N; 4078679-1-0-0 M N; 4078662-1-0-0 M N; 4078727-1-0-0 M N; 4078708-1-0-0 M N; 4078729-1-0-0 M N; 4078722-1-0-0 M N; 4078676-1-0-0 M N; 4078688-1-0-0 M N; 4078661-1-0-0 M N; 4078702-1-0-0 M N; 4078712-1-0-0 M N; 4078716-1-0-0 M N; 4078714-1-0-0 M N; 4078731-1-0-0 M N; 4078710-1-0-0 M N; 4078699-1-0-0 M N; 4078649-1-0-0 M N; 4078673-1-0-0 M N; 4078693-1-0-0 M N; 4078725-1-0-0 M N; 4078653-1-0-0 M N; 4078723-1-0-0 M N; 4078694-1-0-0 M N; 4078730-1-0-0 M N; 4078646-1-0-0 M N; 4078717-1-0-0 M N; 4078660-1-0-0 M N; 4078674-1-0-0 M N; 4078658-1-0-0 M N; 4078664-1-0-0 M N; 4078647-1-0-0 M N; 4078666-1-0-0 M N; 4078709-1-0-0 M N; 4078667-1-0-0 M N; 4078696-1-0-0 M N; 4078655-1-0-0 M N; 4078652-1-0-0 M N; 4078691-1-0-0 M N; 4078692-1-0-0 M N; 4078711-1-0-0 M N; 4078669-1-0-0 M N; 4078665-1-0-0 M N; 4078670-1-0-0 M N; 4078732-1-0-0 M N; 970635-0-0-0 K M; 2132724-0-0-0 K M; 1530637-1-0-0 K M;  K M; 106758-0-0-0 K M; 102516-2-0-0 K M; 76849-0-0-0 K M; 97854-0-0-0 K M; 4078726-1-0-0 CL NEW USE; 4078678-1-0-0 CL NEW USE; 4078719-1-0-0 CL NEW USE; 4078672-1-0-0 CL NEW USE; 4078671-1-0-0 CL NEW USE; 4078668-1-0-0 CL NEW USE; 4078650-1-0-0 CL NEW USE; 4078651-1-0-0 CL NEW USE; 4078681-1-0-0 CL NEW USE; 4078680-1-0-0 CL NEW USE; 4078683-1-0-0 CL NEW USE; 4078703-1-0-0 CL NEW USE; 4078690-1-0-0 CL NEW USE; 4078724-1-0-0 CL NEW USE; 4078707-1-0-0 CL NEW USE; 4078706-1-0-0 CL NEW USE; 4078682-1-0-0 CL NEW USE; 4078720-1-0-0 CL NEW USE; 4078721-1-0-0 CL NEW USE; 4078677-1-0-0 CL NEW USE; 4078663-1-0-0 CL NEW USE; 4078700-1-0-0 CL NEW USE; 4078684-1-0-0 CL NEW USE; 4078685-1-0-0 CL NEW USE; 4078695-1-0-0 CL NEW USE; 4078689-1-0-0 CL NEW USE; 4078654-1-0-0 CL NEW USE; 4078701-1-0-0 CL NEW USE; 4078656-1-0-0 CL NEW USE; 4078657-1-0-0 CL NEW USE; 4078704-1-0-0 CL NEW USE; 4078697-1-0-0 CL NEW USE; 4078698-1-0-0 CL NEW USE; 4078648-1-0-0 CL NEW USE; 4078728-1-0-0 CL NEW USE; 4078715-1-0-0 CL NEW USE; 4078718-1-0-0 CL NEW USE; 4078713-1-0-0 CL NEW USE; 4078675-1-0-0 CL NEW USE; 4078687-1-0-0 CL NEW USE; 4078686-1-0-0 CL NEW USE; 4078705-1-0-0 CL NEW USE; 4078659-1-0-0 CL NEW USE; 4078679-1-0-0 CL NEW USE; 4078662-1-0-0 CL NEW USE; 4078727-1-0-0 CL NEW USE; 4078708-1-0-0 CL NEW USE; 4078729-1-0-0 CL NEW USE; 4078722-1-0-0 CL NEW USE; 4078676-1-0-0 CL NEW USE; 4078688-1-0-0 CL NEW USE; 4078661-1-0-0 CL NEW USE; 4078702-1-0-0 CL NEW USE; 4078712-1-0-0 CL NEW USE; 4078716-1-0-0 CL NEW USE; 4078714-1-0-0 CL NEW USE; 4078731-1-0-0 CL NEW USE; 4078710-1-0-0 CL NEW USE; 4078699-1-0-0 CL NEW USE; 4078649-1-0-0 CL NEW USE; 4078673-1-0-0 CL NEW USE; 4078693-1-0-0 CL NEW USE; 4078725-1-0-0 CL NEW USE; 4078653-1-0-0 CL NEW USE; 4078723-1-0-0 CL NEW USE; 4078694-1-0-0 CL NEW USE; 4078730-1-0-0 CL NEW USE; 4078646-1-0-0 CL NEW USE; 4078717-1-0-0 CL NEW USE; 4078660-1-0-0 CL NEW USE; 4078674-1-0-0 CL NEW USE; 4078658-1-0-0 CL NEW USE; 4078664-1-0-0 CL NEW USE; 4078647-1-0-0 CL NEW USE; 4078666-1-0-0 CL NEW USE; 4078709-1-0-0 CL NEW USE; 4078667-1-0-0 CL NEW USE; 4078696-1-0-0 CL NEW USE; 4078655-1-0-0 CL NEW USE; 4078652-1-0-0 CL NEW USE; 4078691-1-0-0 CL NEW USE; 4078692-1-0-0 CL NEW USE; 4078711-1-0-0 CL NEW USE; 4078669-1-0-0 CL NEW USE; 4078665-1-0-0 CL NEW USE; 4078670-1-0-0 CL NEW USE; 4078732-1-0-0 CL NEW USE; 2132724-0-0-0 CL USE; 1530637-1-0-0 CL USE	215262801 M N; 215262802 M N	00152; 01261; 59042; 61435; 00061; 70379; 01156	RCM4O9 M N; RCM4OA M N; RC9W3C M N; RC9W20 M N; RC9W35 M N; RC9W1U M N; RC9W1T M N; RC9W1Q M N; RC9W18 M N; RC9W19 M N; RC9W23 M N; RC9W22 M N; RC9W25 M N; RC9W2P M N; RC9W2C M N; RC9W3A M N; RC9W2T M N; RC9W2S M N; RC9W24 M N; RC9W36 M N; RC9W37 M N; RC9W1Z M N; RC9W1L M N; RC9W2M M N; RC9W26 M N; RC9W27 M N; RC9W2H M N; RC9W2B M N; RC9W1C M N; RC9W2N M N; RC9W1E M N; RC9W1F M N; RC9W2Q M N; RC9W2J M N; RC9W2K M N; RC9W16 M N; RC9W3E M N; RC9W31 M N; RC9W34 M N; RC9W2Z M N; RC9W1X M N; RC9W29 M N; RC9W28 M N; RC9W2R M N; RC9W1H M N; RC9W21 M N; RC9W1K M N; RC9W3D M N; RC9W2U M N; RC9W3F M N; RC9W38 M N; RC9W1Y M N; RC9W2A M N; RC9W1J M N; RC9W2O M N; RC9W2Y M N; RC9W32 M N; RC9W30 M N; RC9W3H M N; RC9W2W M N; RC9W2L M N; RC9W17 M N; RC9W1V M N; RC9W2F M N; RC9W3B M N; RC9W1B M N; RC9W39 M N; RC9W2G M N; RC9W3G M N; RC9W14 M N; RC9W33 M N; RC9W1I M N; RC9W1W M N; RC9W1G M N; RC9W1M M N; RC9W15 M N; RC9W1O M N; RC9W2V M N; RC9W1P M N; RC9W2I M N; RC9W1D M N; RC9W1A M N; RC9W2D M N; RC9W2E M N; RC9W2X M N; RC9W1R M N; RC9W1N M N; RC9W1S M N; RC9W3I M N; RAFO3W K M; RB48BW K M; RB6U95 K M; RC292E K M; R09785 K M; R20748 K M; R04816 K M; RA022K K M		CN109970851-A;  CN109970851-B	Monoclonal antibody of the CCV virus M protein            comprises a pair of hybridoma cell lines against the            CCV virus M protein, where the first and second            hybridoma cell line is preserved at	GAN J;  TIAN X;  LV H;  LIU X	UNIV YANGZHOU (UYYZ-C)	2019605103	   NOVELTY - Monoclonal antibody of the CCV virus M protein                comprises a pair of hybridoma cell lines against                the CCV virus M protein, where the first hybridoma                cell line is named 2H11, and is preserved at (CGMCC                NO: 17287), and the second hybridoma cell line is                named 2G3, and is preserved at China General                Microbiological Culture Collection Center (CGMCC                NO:17288).    USE - Monoclonal antibody of the CCV virus M                protein.    ADVANTAGE - The monoclonal antibody of the CCV virus M                protein has strong specificity, high sensitivity,                simple operation and low cost, and is suitable for                clinical and field detection, and is used for CCV                pathogenic diagnosis, epidemiological investigation                and rapid diagnosis of animal hospitals.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) a method for preparing a monoclonal                antibody of a CCV virus M protein, which comprises                preparing a CCV monoclonal antibody by using an                isolated and purified CCV inactivated virus; and                preparing a CCV monoclonal antibody by a monoclonal                antibody technique; using the western blot to                identify the M protein, and then the gene encoding                the CCV virus M protein is cloned into the                linearized pCDNA3.1 vector by recombinant enzyme                ExnaseTM II technology; transfecting the 293T cells                into M protein expression; verifing the monoclonal                antibody and the expressed M protein by IFA                identification; and obtaining the two CCV virus M                protein-specific monoclonal antibodies 2H11 and                2G3; and    (2) a method for preparing an immunocolloidal                gold test strip, which comprises labeling the                monoclonal antibody 2H11 on colloidal gold;                spraying the colloidal gold onto the glass fiber to                form a gold standard pad; spraying a rabbit                anti-mouse IgG and the monoclonal antibody 2G3                together on a nitrocellulose membrane to prepare a                control line and a detection line; and assembling                the sample pad, the colloidal gold pad, the                nitrocellulose membrane, and the absorbent paper on                the PVC board from bottom to top, and then cutting                into test strips, where the sample mat is a blank                glass cellulose membrane. 			A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	A03-A03;  A04-E02E;  A05-H03;  A12-E13;  A12-V;  B04-E99;  B04-F04B1A;  B04-F04B1E;  B04-G08;  B04-G0800E;  B04-G21;  B04-G2100E;  B04-G27G;  B11-C07A6;  B12-K04G1B;  C04-E99;  C04-F04B1A;  C04-F04B1E;  C04-G08;  C04-G0800E;  C04-G21;  C04-G2100E;  C04-G27G;  C11-C07A6;  C12-K04G1B;  D05-C12;  D05-H09;  D05-H11A1;  D05-H17A1;  D05-H99;  S03-E09F;  S03-E14H5	C07K-016/10;  G01N-033/52;  G01N-033/558;  G01N-033/569	CN109970851-A   05 Jul 2019   C07K-016/10   201967Pages: 21   Chinese;  CN109970851-B   06 Dec 2022   C07K-016/10   202201   Chinese	CN109970851-A    CN10257290    01 Apr 2019;   CN109970851-B    CN10257290    01 Apr 2019	CN109970851-B Previous Publ. Patent CN109970851	CN10257290    01 Apr 2019			CN109970851-A -- CN103687615-A   DECARO N (DECA-Individual);  MARTELLA V (MART-Individual);  ELIA G (ELIA-Individual);  BUONAVOGLIA C (BUON-Individual)   DECARO N,  MARTELLA V,  ELIA G,  BUONAVOGLIA C	CN109970851-A  GABRIELLAELIA ET          AL.: "Recombinant M protein-based ELISA test for          detection of antibodies to canine coronavirus", JOURNAL          OF VIROLOGICAL          METHODS,relevantClaims[1,2,5],relevantPassages[1401-1415];  : "", ()          (),relevantClaims[1,2,5],relevantPassages[132241-331];  : "AGV2VP3",          ,relevantClaims[1-7],relevantPassages[];  : "SARSM",          ,relevantClaims[1-7],relevantPassages[];  : "ELISA",          ,relevantClaims[1-7],relevantPassages[]	133921-0-0-0 ; 444-0-0-0 ; 621-0-0-0 			R01861 ; R00351 ; R00338 		WO2019175606-A1;  US2021061887-A1	New fusion polypeptide useful in pharmaceutical            composition or as medicament for preventing or treating            autoimmune disease, comprises domain derived from            immunoglobulin heavy chain constant region, and hinge            regions	PLEASS R;  BLUNDELL P	LIVERPOOL SCHOOL TROPICAL MEDICINE (LIVE-Non-standard);  LIVERPOOL SCHOOL TROPICAL MEDICINE (LIVE-Non-standard)	2019808000	   NOVELTY - A fusion polypeptide comprising a domain                derived from an immunoglobulin (Ig) heavy chain                constant region, and several hinge regions derived                from IgG hinge sequences, is new.    USE - The fusion polypeptide is useful in                pharmaceutical composition or as medicament (all                claimed) for preventing or treating an autoimmune                disease.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a protein comprising at least two fusion                polypeptides;    (2) a nucleic acid encoding the fusion                polypeptide; and    (3) a method of producing fusion                polypeptide. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B04C;  B04-C01;  B04-E02H;  B04-E99;  B04-G0100E;  B04-G2300E;  B04-G27G0E;  B04-H0100E;  B04-K0100E;  B04-N0400E;  B04-N08;  B04-N14;  B14-G02D;  D05-C12;  D05-H11;  D05-H12C;  D05-H17C1;  D05-H99	A61K-038/04;  C07K-016/00	WO2019175606-A1   19 Sep 2019   A61K-038/04   201977Pages: 58   English;  US2021061887-A1   04 Mar 2021   C07K-016/00   202122   English	WO2019175606-A1    WOGB050745    15 Mar 2019;   US2021061887-A1    US16981131    15 Sep 2020	US2021061887-A1 PCT application Application WOGB050745	GB004243    16 Mar 2018	WO2019175606-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    		WO2019175606-A1 -- WO1999015549-A2   ;  WO2002072608-A2   ;  WO2008151088-A2   UNIV MARYLAND BALTIMORE (UMBA)   STROME S E,  SCHULZE D H,  BLOCK D S	WO2019175606-A1  FARNOUSH JAFARI          IRI-SOFLA ET AL: "Nanobody-based chimeric receptor gene          integration in Jurkat cells mediated by PhiC31          integrase", EXPERIMENTAL CELL RESEARCH, ELSEVIER,          AMSTERDAM, NL, vol. 317, no. 18, 22 August 2011          (2011-08-22), pages 2630 - 2641, XP028307301, ISSN:          0014-4827, [retrieved on 20110828], DOI:          10.1016/J.YEXCR.2011.08.015,relevantClaims[1-3,10-16,18,43-46|8,26-33,41],relevantPassages[&lt;figure&gt;1&lt;/figure&gt;|&lt;pp&gt;2639&lt;/pp&gt;&lt;column&gt;2&lt;/column&gt;]	184587-0-0-0 M N P Q; 184587-0-0-0 CL NEW PRD RCT USE			RA00C8 M N P Q		CN109276563-A;  TW650120-B1;  TW201907912-A;  CN109276563-B	Medicinal composition useful in preparing medicine for treating or preventing an individual infected with a virus including e.g. H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, H5N2, H5N3, H5N6, H5N8, H6N1, H7N9 and H10N8	LI S;  WU Z;  LI Q;  YANG S;  ZHENG Y;  LEE S H;  WU C J;  LEE C K;  YANG S H;  JHENG Y S;  LEE S;  WU C;  LEE C;  JHENG Y	ZHUHAI XINZHAN BIOTECHNOLOGY CO LTD (ZHUH-Non-standard);  POWER NATURE (POWE-Non-standard)	201915566J	   NOVELTY - Medicinal composition comprises active ingredient, where active ingredient includes 1,2,3,4-tetramethoxy-5-toluene, 1,2-dimethoxybenzene, 1,2,3-trimethoxybenzene, 2,3,4-trimethoxy-6-methylphenol, 3,4-dimethoxy-6-toluene-1,2-diol, 3,4-dimethoxy-5-toluene-1,2-diol, 2,4-dimethoxy-6-toluene-1,3-diol, 3,6-dimethoxy-4-toluene-1,2-diol, 4,5-dimethoxy-7-methylbenzo(d)(1,3)dioxole, 4,5-dimethoxy-6- methylbenzo(d)(1,3)dioxole, 4,7-dimethoxy-5-methylbenzo(d)(1,3)dioxole, 5-iodo-4,7-dimethoxy-6-methylbenzo(d)(1,3)dioxole, 1-iodo-2,3,4,5-tetramethoxy-6-toluene, 1,2,3,4-tetramethoxy-5-methyl-6-(3-methylbut-3-en-1-yn-1-yl)benzene, 4,7-Dimethoxy-5-methyl-6-(3-methylbut-3-en-1-yn-1-yl)benzo(d)(1,3)dioxole, 1,2,4-trimethoxybenzene, 1-iodo-2,4,5-trimethoxybenzene, 3,4-dimethoxyphenol, 4,5-dimethoxy-2-methylphenol, 2,5-dimethoxyphenol and/or 2,4-dimethoxyphenol.    USE - The medicinal composition is useful in preparing medicine for treating or preventing an individual infected with a virus including H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, H5N2, H5N3, H5N6, H5N8, H6N1, H7N9, H10N8, chicken infectious anemia virus (CAV), Newcastle disease virus (NDV), avian infectious bursal virus (IBDV), porcine reproductive and respiratory syndrome virus (PRRSV), the second pig ring virus (PCV2), classical swine fever virus (CSFV), porcine respiratory coronavirus virus (PRCV), porcine parvovirus virus (PPV) or porcine transmissible gastroenteritis virus (TGEV), in reducing the individual lung infection virus number, reducing the individual pulmonary lung injury caused by virus infection, reducing cell inflammation reaction, reducing the expression of neutravidin (IL-6), tumor necrosis factor (TNF) and medium echinocandins -1 beta (IL-1 beta ).    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for preparing anisole compounds of formula (I) comprising reacting 1,2,4-trimethoxybenzene compounds of formula (II) with methylene chloride in presence of aluminum chloride under argon atmosphere to obtain (I).    R7, R8 = H, methoxy, hydroxy or methyl; and    R1, R2, R3, R4 = H, methyl, methoxy or hydroxy. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C02 (Heterocyclic.)	B06-A02;  B10-E02;  B10-H01;  B14-A02;  B14-C03;  B14-L07;  B14-S18;  C06-A02;  C10-E02;  C10-H01;  C14-A02;  C14-C03;  C14-L07;  C14-S18	A61K-031/09;  A61K-031/36;  A61P-031/16;  C07C-041/22;  C07C-041/26;  C07C-041/30;  C07C-043/215;  C07C-043/225;  C07C-043/23;  C07D-317/64;  A61K-031/357;  A61P-031/12;  C07C-043/205	CN109276563-A   29 Jan 2019   A61K-031/09   201938Pages: 31   Chinese;  TW650120-B1   11 Feb 2019   A61K-031/09   201938   Chinese;  TW201907912-A   01 Mar 2019   A61K-031/09   201941   Chinese;  CN109276563-B   09 Apr 2021   A61K-031/09   202134   Chinese	CN109276563-A    CN10994334    23 Oct 2017;   TW650120-B1    TW124631    21 Jul 2017;   TW201907912-A    TW124631    21 Jul 2017;   CN109276563-B    CN10994334    23 Oct 2017	CN109276563-B Previous Publ. Patent CN109276563	TW124631    21 Jul 2017			CN109276563-A -- CN101214238-A   GUODING BIOLOGICAL CO LTD (GUOD-Non-standard)   LIU S,  WEN W,  ZOU W;  CN102755355-A   NEW BELLUS ENTERPRISE CO LTD (NEWB-Non-standard)   HUANG J,  LAI Z,  YE S,  ZHONG Y;  CN103012358-A   YOU J (YOUJ-Individual)   CHEN B,  LI Q,  LUO J,  QIU T,  YOU J,  ZHONG W;  CN101243031-B   DSM IP ASSETS BV (STAM)   AQUINO F,  BONRATH W,  BOHRER P,  HUGENTOBLER M,  NETSCHER T,  RADSPIELER A;  US3930862-A   FUJI PHOTO FILM CO LTD (FUJF);  US20080103195-A1   ;  US20120322807-A1   ;  US9044467-B2   NEW BELLUS ENTERPRISES CO LTD (NEWB-Non-standard)   YEH W,  HUANG C	CN109276563-A  GEORGE BUCHI ET AL.: "A synthesis of gymnomitrol", J. AM. CHEM. SOC.,relevantClaims[9-10],relevantPassages[6767];  PI-YU CHEN ET AL.: "Isolation and Synthesis of a Bioactive Benzenoid Derivative from the Fruiting Bodies of Antrodia camphorata", MOLECULES,relevantClaims[9-10|9],relevantPassages[6700-7608]	 K M P; 75216-0-0-0 K M P;  K M P; 23780-0-0-0 K M P;  K M P; 73371-0-0-0 K M P; 2632974-0-0-0 K M P;  K M P;  K M P;  K M P; 1731582-0-0-0 K M P;  K M P;  K M P;  K M P;  K M P;  K M P;  K M P;  K M P; 11516-0-0-0 K M P; 11482-0-0-0 K M P; 62482-0-0-0 K M P; 27-0-0-0 K U V; 61-0-0-0 K U V	214277401 K M P		RC8GLG K M P; RA6H47 K M P; RCKOMC K M P; RA3RPK K M P; RCKOM2 K M P; RA18K4 K M P; RBF1UV K M P; RCKOM3 K M P; RCKOM4 K M P; RCKOM5 K M P; RAVUES K M P; RCKOM6 K M P; RCKOM7 K M P; RCKOM8 K M P; RCKOM9 K M P; RCKOMA K M P; RCKOMB K M P; RCKOMD K M P; RA2XGL K M P; R00576 K M P; RAAQK3 K M P; R00345 K U V; R01677 K U V	0576-P; 0345-U; 1677-U	CN110596396-A;  CN110596396-B	Detecting protein by incubating target, labeled            antibody and complex, passing mixture through detection            and quality control zones, and determining target            protein content based on signal strength of detection            and quality control zones	LIU X;  ZHU Y	TIANJIN YIAN BIOTECHNOLOGY CO LTD (TIAN-Non-standard);  TIANJIN YIAN BIOTECHNOLOGY CO LTD (TIAN-Non-standard)	2020012884	   NOVELTY - Method for detecting protein involves (a)                incubating the target to be detected, labeled                antibody, and complex to obtain a mixture, (b)                passing the mixture through the detection zone and                quality control zone in sequence, and (c)                determining content of the target protein in the                target to be detected based on signal strength of                detection area and quality control area, where the                labeled antibody is a specific antibody to a target                protein and labeled with a signal substance, and                the complex is a complex formed by a specific                antibody of a target protein and a recognition                element, the detection zone is fixedly provided                with a specific antibody of the recognition                element, and the quality control region is fixedly                provided with a secondary antibody of the target                protein.    USE - The method, protein detection test strip or                protein detection kit is useful for detecting                protein. The target protein is Canine coronavirus,                C-reactive protein, bovine beta -casein, skeletal                muscle troponin, beta -conglycinin, symmetrical                dimethylarginine and asymmetric dimethylarginine,                preferably C-reactive protein and/or symmetric                dimethylarginine (all claimed).    ADVANTAGE - The method detects protein in a rapid manner                with high sensitivity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) protein detection test strip comprising a                sample pad, a water absorption pad, and a bottom                plate fixed with a nitrocellulose membrane provided                with a detection area and a quality control area,                where the sample pad and water absorption pad are                provided on the bottom plate and located on                opposite sides of the bottom plate, where the                sample pad is used to carry an incubation of a test                target, a labeled antibody, and a complex, the                labeled antibody is a specific antibody of a target                protein and is labeled with a signal substance, the                complex is a complex formed by the specific                antibody of the target protein and a recognition                element, the detection area is fixed with a                specific antibody of the recognition element, and                the quality control region is fixedly provided with                a secondary antibody of the target protein;                and    (2) protein detection kit comprising the                protein detection test strip, an incubation                solution, and Standard curve chart card for                optional target protein. 			A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	A03-A03;  A03-C01;  A12-E13;  A12-L04B;  A12-W11A;  B04-B04D2;  B04-C02A3;  B04-C03C;  B04-L01;  B04-N02;  B04-N03K;  B04-N06;  B11-C07A;  B11-C08E;  B11-C12;  B12-K04;  C04-C02A3;  C04-C03C;  C04-L01;  C04-N02;  C04-N03K;  C04-N06;  C11-C07A;  C11-C08E;  C11-C12;  C12-K04;  D05-A02;  D05-H09;  D05-H10;  S03-E09F;  S03-E14H5	G01N-033/533;  G01N-033/543;  G01N-033/58;  G01N-033/68	CN110596396-A   20 Dec 2019   G01N-033/68   202010Pages: 10   Chinese;  CN110596396-B   19 Jul 2022   G01N-033/68   202264   Chinese	CN110596396-A    CN10717982    05 Aug 2019;   CN110596396-B    CN10717982    05 Aug 2019	CN110596396-B Previous Publ. Patent CN110596396	CN10717982    05 Aug 2019					687349-0-0-0 A K; 1528510-1-0-0 A K; 90158-0-0-0 A K; 91832-0-0-0 A K; 102901-0-0-0 K M; 297125-0-0-0 K M; 900-0-0-0 K M; 133921-0-0-0 ; 444-0-0-0 ; 1528510-1-0-0 CL DET			RAAIAM A K; RARGCO A K; R24040 A K; RA1GG5 A K; RA0BDE K M; RA20EO K M; R02044 K M; RA0GM6 K M; R01861 ; R00351 	2044-S	CN110272480-A;  CN110272480-B	New duck-alpha interferon useful in preparation of            medicament or agent for preventing and/or treating duck            viral disease including duck virus hepatitis, and duck            plague, comprises specific amino acid sequence	YI Y;  WANG P;  SHEN X;  TANG S;  HU X;  WEI Z;  ZENG Z	UNIV JIANGSU SCI & TECHNOLOGY (UYJG-C)	201984570M	   NOVELTY - A duck- alpha interferon comprising 191 amino                acid sequence (SEQ ID NO: 1) fully defined in the                specification, is new. The polynucleotide sequence                encoding the gene is chosen from (a) polynucleotide                sequence comprising 576 base pair sequence (SEQ ID                NO: 2) fully defined in the specification, (b)                polynucleotide sequence capable of hybridizing to                complementary sequence comprising a base pair                sequence of SEQ ID NO: 2 under stringent                hybridization conditions, where the protein encoded                by the polynucleotide still having the function or                activity of the interferon, and (c) polynucleotide                sequence having at least 80% homology to the                polynucleotide sequence of SEQ ID NO: 2, where the                protein encoded by the polynucleotide still has the                function or activity of the interferon.    USE - The duck- alpha interferon is useful in                preparation of medicament or agent for preventing                and/or treating duck viral disease including duck                virus hepatitis, duck plague, gosling plague,                muscovy duck parvovirus disease, young muscovy duck                gosling pheasant, duck epidemic hemorrhagic                disease, duck liver disease, duck viral                encephalitis, duck reovirus infection, duck                adenovirus infection, infectious cyst of duck, duck                paramyxovirus, duck coronavirus infection and duck                flu (all claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) duck alpha -interferon mutant comprising                191 amino acid sequence (SEQ ID NO: 3) fully                defined in the specification, and nucleotide                sequence of the coding gene comprising 576 base                pair sequence (SEQ ID NO: 4) fully defined in the                specification;    (2) recombinant vector or recombinant host                cell comprising the coding gene for duck- alpha                interferon or the gene encoding the duck alpha                -interferon mutant;    (3) method for preparing duck- alpha                interferon, involves cloning the coding gene of                duck alpha -interferon or the coding gene into                baculovirus transfer vector to construct                recombinant transfer vector, co-transforming the                recombinant transfer vector with the baculovirus                DNA to obtain a recombinant baculovirus, infecting                an insect cell or an insect host with the                recombinant baculovirus, culturing the infected                insect cell or the insect host to express the                corresponding protein, and purifying protein;                and    (4) use of duck alpha -interferon or the duck                alpha -interferon mutant, in preparation of                medicament or agent for preventing and/or treating                duck viral disease. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-C01G;  B04-E08;  B04-E99;  B04-H05A;  B04-H05A0E;  B14-A02;  B14-S12;  C04-C01G;  C04-E08;  C04-E99;  C04-H05A;  C04-H05A0E;  C14-A02;  C14-S12;  D05-C12;  D05-H12E;  D05-H17B2;  D05-H99	A61K-038/21;  A61P-031/14;  A61P-031/16;  A61P-031/20;  C07K-014/56;  C12N-015/21;  C12N-015/866	CN110272480-A   24 Sep 2019   C07K-014/56   201987Pages: 37   Chinese;  CN110272480-B   22 Jul 2022   C07K-014/56   202263   Chinese	CN110272480-A    CN10510526    13 Jun 2019;   CN110272480-B    CN10510526    13 Jun 2019	CN110272480-B Previous Publ. Patent CN110272480	CN10510526    13 Jun 2019			;  CN110272480-B -- CN1861796-A   UNIV DONGBEI AGRIC (UYDO-Non-standard)   WANG J,  REN G,  XU L,  LI H		97855-0-0-0 N P; 97855-0-0-0 CL NEW PRD			RA02SP N P		CN109913584-A	New four porcine enterovirus multiplex fluorescent            reverse transcription polymerase chain reaction kit            comprises e.g. four pairs of primers and corresponding            four TaqMan probes	SHI K;  WANG R;  SU Y;  LI Z;  YIN Y;  LU W;  QU S;  FENG S	GUANGXI ZHUANG AUTONOMOUS REGION INST (GUAG-C)	2019572448	   NOVELTY - Four porcine enterovirus multiplex fluorescent                reverse transcription polymerase chain reaction                (RT-PCR) kit comprises four pairs of primers and                corresponding four TaqMan probes are directed                against four porcine enteroviruses: porcine                epidemic diarrhea virus (PEDV), transmissible                gastroenteritis virus or transmissible                gastroenteritis coronavirus (TGEV), porcine                deltacoronavirus (PDCoV) and porcine rotavirus                (PRoV), is new.    USE - Used as four porcine enterovirus multiplex                fluorescent reverse transcription polymerase chain                reaction kit.    DETAILED DESCRIPTION - Four porcine enterovirus multiplex fluorescent                reverse transcription polymerase chain reaction                (RT-PCR) kit comprises four pairs of primers and                corresponding four TaqMan probes are directed                against four porcine enteroviruses: PEDV, TGEV,                PDCoV and PRoV. The four pairs of primers are: a                primer for detecting PEDV: PEDV-N-F:                5'-ctggaatgagcaaattcgctg-3' (SEQ ID NO: 1), and the                size is 140 base pairs, PEDV-N-R:                5'-ctgagggtgttttctgggttg-3' (SEQ ID NO: 2), size                140 base pairs, primer for detecting TGEV:                TGEV-M-F: 5'-gcaattctttgcgttagtgcat-3' (SEQ ID NO:                3), size 102 base pairs, TGEV-M-R:                5'-agcgtacaaattccctgaaagc-3' (SEQ ID NO: 4), size                102 base pairs, primer for detecting PDCoV:                PDCoV-M-F: 5'-atcgaccacatggctccaa-3' (SEQ ID NO:                5), size 72 base pairs, PDCoV-M-R:                5'-cagctcttgcccatgtagctt-3' (SEQ ID NO: 6), size 72                base pairs, primer for detecting PRoV: PRoV-VP6-F:                5'-aatatgacaccagcagttgcaaa-3' (SEQ ID NO: 7), size                107 base pairs, PRoV-VP6-R:                5'-acagattcacaaactgcagattcaa-3' (SEQ ID NO: 8),                size 107 base pairs. The four TaqMan probes are:                TaqMan probe for detecting PEDV: PEDV-N-P:                JOE-5'-agcgaattgaacaaccttccaattggca-3'-BHQ1 (SEQ ID                NO: 9), the size is 140 base pairs, TaqMan probe                for detecting TGEV: TGEV-M-P: Texas                Red-5'-cttcctctcgaaggtgtgccaactgg-3'-BHQ2 (SEQ ID                NO: 10), size 102 base pairs, TaqMan probe for                detecting PDCoV: PDCoV-M-P:                6-FAM-5'-cacaccagtcgttaagcatggcaagct-3'-BHQ1 (SEQ                ID NO: 11), size 72 base pairs, TaqMan probe for                detection of PRoV: PRoV-VP6-P:                Cy5-5'-caagcaccgccatttatatttcatgctaca-3'-BHQ3 (SEQ                ID NO: 12), size 107 base pairs. An INDEPENDENT                CLAIM is also included for detecting porcine                enterovirus multiplex fluorescent RT-PCR,                comprising simultaneous detection of multiple                porcine enteroviruses of PEDV, TGEV, PDCoV and PRoV                by multiple TaqMan quantitative RT-PCR. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E05;  B04-E99;  B04-F11B;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B11-C11;  B12-K04F;  C04-E01;  C04-E05;  C04-E99;  C04-F11B;  C11-C07B3;  C11-C08E3;  C11-C08F8;  C11-C11;  C12-K04F;  D05-H06A;  D05-H18B;  D05-H99	C12Q-001/686;  C12Q-001/70;  C12R-001/93	CN109913584-A   21 Jun 2019   C12Q-001/70   201965Pages: 23   Chinese	CN109913584-A    CN10120378    18 Feb 2019		CN10120378    18 Feb 2019			CN109913584-A -- CN105483291-A   UNIV HENAN AGRIC (UYHR)   HU H,  LIANG X,  WEI Z,  ZHENG L,  ZHANG J,  ZHOU Y,  CAO B;  CN107557494-A   UNIV HUAZHONG AGRIC (UHZA)   FANG L,  XIAO S,  SUN Z,  LIU H,  LIU K,  WANG D;  CN108715906-A   UNIV GUANGXI (UYGU)   OUYANG K,  ZHONG L,  HUANG W,  WANG R,  LU Y,  WU Y,  LIU X;  CN108866243-A   LANZHOU VETERINARY RES INST CHINA AGRIC (CAGS)   LIU G,  CHEN J,  HUANG X;  CN108950083-A   UNIV HENAN AGRIC (UYHR)   WANG C,  CHANG H,  WANG A,  CHEN L,  ZHOU F,  LI Y,  WANG X,  YANG X,  CUI D,  DU J,  LIU H,  ZHAO J;  CN109234465-A   SHANDONG NEW HOPE LIUHE GROUP CO LTD (NEHO)   LI X,  QIN L,  CHEN T,  SUN A,  WEI X	CN109913584-A  : "DeltaRT-PCR",          ,relevantClaims[1],relevantPassages[1911]						CN110396559-A	Kit useful detecting target nucleic acid sequence            of several pneumonia-associated pathogenic            microorganisms in sample, contains storage device            comprising amplification primer set and internal            quantitative standard nucleic acids		MERIEUX DIAGNOSTIC PROD SHANGHAI CO LTD (MERI-Non-standard)	201995184E	   NOVELTY - Kit capable of detecting target nucleic acid                sequence of several pneumonia-associated pathogenic                microorganisms in a sample. The kit has a housing                comprising first storage device, which comprises                first amplification primer set and internal                quantitative standard nucleic acids, first reaction                vessel for performing a first stage amplification                reaction, several second storage device, which                comprises second set of amplification primers and                internal quantitative standard nucleic acids,                several second reaction vessels for performing a                second stage amplification reaction, several other                second reaction containers for storing or accepting                a second quantitative standard primer pair of each                of the quantitative standard nucleic acids from the                second reservoir and channel connecting the first                reaction vessel, the second reaction vessel, the                first storage device, and second storage device,                where channel allows liquid to flow between the                first and second reaction vessels and the storage                device.    USE - The kit is useful for detecting target nucleic                acid sequence of several pneumonia-associated                pathogenic microorganisms in a sample.    DETAILED DESCRIPTION - Kit capable of detecting target nucleic acid                sequence of several pneumonia-associated pathogenic                microorganisms in a sample. The detection method                involves (a) providing a first amplification primer                set for several target nucleic acids to circulating                amplification reaction mixture containing the                sample, which comprises amplification primer pairs                each having a target nucleic acid as a template,                where each primer pair comprises corresponding                specific upstream outer primer and downstream outer                primer for amplifying first amplicon of each target                nucleic acid, providing circulating amplification                reaction mixture containing the sample with one or                more combinations of internal quantitative standard                nucleic acids having different known                concentrations, where each internal quantitative                standard nucleic acid comprises first quantitative                standard primer pair that amplifies the first                amplicon of each quantitative standard nucleic acid                and performing several cyclic amplification on the                cyclic amplification reaction mixture to perform a                first-stage amplification reaction, where the first                stage amplification reaction is carried out in the                same reaction vessel and in the same reaction time                period, (b) dividing the amplification product                mixture obtained in the step (a) into several                fractions, and performing the second-stage                amplification reaction, where a portion of the                amplification product mixture is used in the second                stage amplification reaction of the several target                nucleic acids, a second set of amplification                primers for the several target nucleic acids is                provided to the reaction mixture, which comprises                an amplification primer pair of each target nucleic                acid with its first amplicon as a template, each                primer pair includes a corresponding specific                upstream inner primer and a downstream inner for                amplifying a second amplicon of each target nucleic                acid, several additional portions of the                amplification product mixture in the second stage                amplification reaction with one or more                combinations of internal quantitative standard                nucleic acids having different known                concentrations, which comprises first amplicon as a                template for each of the quantitative standard                nucleic acids is provided to the reaction mixture                for amplifying asecond amplicon of each                quantitative standard nucleic acid, where the                second amplicon of each of the quantitative                standard nucleic acids has a specified quantitative                standard cycle threshold (Ct) and the second stage                amplification reaction of several internal                quantitative standard nucleic acids is carried out                in different reaction vessels and (c) performing                quantitative or semi-quantitative analysis of the                second amplicon of the target nucleic acid based on                a specified quantitative standard Ct of the second                amplicon of each of the quantitative standard                nucleic acids measured in the different reaction                vessel. The kit has a housing comprising first                storage device, which comprises first amplification                primer set and internal quantitative standard                nucleic acids, first reaction vessel for performing                a first stage amplification reaction, several                second storage device, which comprises second set                of amplification primers and internal quantitative                standard nucleic acids, several second reaction                vessels for performing a second stage amplification                reaction, several other second reaction containers                for storing or accepting a second quantitative                standard primer pair of each of the quantitative                standard nucleic acids from the second reservoir                and channel connecting the first reaction vessel,                the second reaction vessel, the first storage                device, and second storage device, where channel                allows liquid to flow between the first and second                reaction vessels and the storage device. An                INDEPENDENT CLAIM is included for method for                detecting several target nucleic acid sequences in                a sample, which involves performing the                above-mentioned detection method. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E02;  B04-E03;  B04-E05;  B04-E08;  B04-F10A;  B04-F11;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1C;  D05-H04;  D05-H06A;  D05-H09;  D05-H18B	C12Q-001/04;  C12Q-001/06;  C12Q-001/10;  C12Q-001/14;  C12Q-001/6848;  C12Q-001/6851;  C12Q-001/689;  C12Q-001/70;  C12R-001/93	CN110396559-A   01 Nov 2019   C12Q-001/70   201991Pages: 22   Chinese	CN110396559-A    CN10440047    24 May 2019		CN10440047    24 May 2019										EP3431099-A1;  EP3431099-B1	Attenuated virus for preventing subject from            becoming afflicted with virus-associated disease            comprises viral genome including modified protein            encoding sequence having codon pair bias less than            codon pair bias of parent protein sequence	WIMMER E;  SKIENA S;  MUELLER S;  FUTCHER B;  PAPAMICHAIL D;  COLEMAN J R;  CELLO J	UNIV NEW YORK STATE RES FOUND (UNYS-C);  UNIV NEW YORK STATE RES FOUND (UNYS-C)	2019074251	   NOVELTY - Attenuated virus comprises a viral genome                including a modified protein encoding sequence                having a codon pair bias less than the codon pair                bias of a parent protein encoding sequence from                which it is derived.    USE - Attenuated virus for preventing a subject from                becoming afflicted with a virus-associated disease                (Claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a method for making an attenuated viral                genome, which involves obtaining the nucleotide                sequence of a protein encoding region of a parent                virus, rearranging the codons of the nucleotide                sequence to obtain a mutated nucleotide sequence                that encodes the same amino acid sequence as the                coding region of the parent virus and has a reduced                codon pair bias compared to the coding region of                the parent virus, and substituting all or portions                of the mutated nucleotide sequence into the                nucleotide sequence of the parent virus;    (2) a vaccine composition for inducing a                protective immune response in a subject, which                comprises the attenuated virus and a                pharmaceutically acceptable carrier;    (3) a method for eliciting a protective immune                response in a subject, which involves administering                a prophylactically or therapeutically effective                dose of the vaccine composition to the                subject;    (4) a method for preventing a subject from                becoming afflicted with a virus-associated disease,                which involves administering a prophylactically                effective dose of the vaccine composition to the                subject; and    (5) a method for delaying the onset of, or                slowing the rate of progression of, a                virus-associated disease in a virus-infected                subject, which involves administering a                therapeutically effective dose of the vaccine                composition to the subject. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E99;  B04-F11;  B04-F1100E;  B14-A02;  B14-G01;  B14-S11A;  B14-S11D2;  B14-S11D3;  C04-E01;  C04-E99;  C04-F11;  C04-F1100E;  C14-A02;  C14-G01;  C14-S11A;  C14-S11D2;  C14-S11D3;  D05-H07;  D05-H99	A61K-039/12;  A61K-039/13	EP3431099-A1   23 Jan 2019   A61K-039/13   201909Pages: 211   English;  EP3431099-B1   03 Jan 2024   A61K-039/13   202402   English	EP3431099-A1    EP177156    31 Mar 2008;   EP3431099-B1    EP177156    31 Mar 2008	EP3431099-A1 Div ex Application EP799746;   EP3431099-A1 Div ex Patent EP2139515;   EP3431099-B1 Div ex Application EP799746;   EP3431099-B1 Div ex Patent EP2139515	US909389P    30 Mar 2007;  US068666    07 Mar 2008	EP3431099-A1:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MT;  NL;  NO;  PL;  PT;  RO;  SE;  SI;  SK;  TR;  AL;  BA;  MK;  RS  EP3431099-B1:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MT;  NL;  NO;  PL;  PT;  RO;  SE;  SI;  SK;  TR;  AL;  BA;  MK;  RS  		EP3431099-A1 -- WO2002095363-A2   ;  WO2006042156-A2   US DEPT HEALTH & HUMAN SERVICES (USSH)   KEW O M,  BURNS C C,  SHAW J,  CAMPAGNOLI R,  QUAY J	EP3431099-A1  BURNS CARA CARTHEL          ET AL: "Modulation of poliovirus replicative fitness in          HeLa cells by deoptimization of synonymous codon usage in          the capsid region", JOURNAL OF VIROLOGY, vol. 80, no. 7,          April 2006 (2006-04-01), pages 3259 - 3272,          XP002633525,relevantClaims[1-8,11-16],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  MUELLER STEFFEN ET          AL: "Reduction of the rate of poliovirus protein          synthesis through large-scale codon deoptimization causes          attenuation of viral virulence by lowering specific          infectivity.", JOURNAL OF VIROLOGY, vol. 80, no. 19,          October 2006 (2006-10-01), pages 9687 - 9696,          XP002633526, ISSN:          0022-538X,relevantClaims[1-8,11-16],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  DATABASE EMBL          [online] 10 September 2007 (2007-09-10), "Synthetic          construct capsid protein P1-Min gene, partial cds.",          XP002633527, retrieved from EBI accession no.          EM_SY:EU095953 Database accession no.          EU095953,relevantClaims[1-16],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  COLEMAN J ROBERT ET          AL: "Virus attenuation by genome-scale changes in codon          pair bias.", SCIENCE, vol. 320, no. 5884, 27 June 2008          (2008-06-27), pages 1784 - 1787, XP002633528, ISSN:          1095-9203,relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  TOYODA HIDEMI ET          AL: "Oncolytic treatment and cure of neuroblastoma by a          novel attenuated poliovirus in a novel          poliovirus-susceptible animal model.", CANCER RESEARCH,          vol. 67, no. 6, 15 March 2007 (2007-03-15), pages 2857 -          2864, XP002633529, ISSN:          0008-5472,relevantClaims[1-16],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  GU WANJUN ET AL:          "Analysis of synonymous codon usage in SARS Coronavirus          and other viruses in the Nidovirales.", VIRUS RESEARCH,          vol. 101, no. 2, May 2004 (2004-05-01), pages 155 - 161,          XP002633530, ISSN:          0168-1702,relevantClaims[1-16],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ZHOU T ET AL:          "Analysis of synonymous codon usage in H5N1 virus and          other influenza A viruses", BIOSYSTEMS, vol. 81, no. 1, 1          July 2005 (2005-07-01), NORTH-HOLLAND, AMSTERDAM, NL,          pages 77 - 86, XP004905562, ISSN: 0303-2647, DOI:          10.1016/J.BIOSYSTEMS.2005.03.002,relevantClaims[1-16],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  WIMMER ECKARD ET          AL: "Synthetic viruses: a new opportunity to understand          and prevent viral disease", NATURE BIOTECHNOLOGY, vol.          27, no. 12, December 2009 (2009-12-01), pages 1163 -          1172, XP002633531, ISSN:          1087-0156,relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  STEFFEN MUELLER ET          AL: "Live attenuated influenza virus vaccines by          computer-aided rational design", NATURE BIOTECHNOLOGY,          vol. 28, no. 7, 13 June 2010 (2010-06-13), pages 723 -          726, XP055451664, ISSN: 1087-0156, DOI:          10.1038/nbt.1636,relevantPassages[&lt;pp&gt;A&lt;/pp&gt;&lt;figure&gt;S1&lt;/figure&gt;];            REED, L. J.; M. MUENCH, AM. J. HYG., vol. 27, 1938, pages          493 - 497;            GUTMAN; HATFIELD, PROC. NATL. ACAD. SCI. USA, vol. 86,          1989, pages 3699 - 3703;            ALEXANDER, H.E.; G. KOCH; I.M. MOUNTAIN; K. SPRUNT; O.          VAN DAMME: "Infectivity of ribonucleic acid of poliovirus          on HeLa cell mono-layers", VIROLOGY, vol. 5, 1958, pages          172 - 3;            ALTMEYER, R.; A.D. MURDIN; J.J. HARBER; E. WIMMER:          "Construction and characterization of          poliovirus/rhinovirus antigenic hybrid", VIROLOGY, vol.          184, 1991, pages 636 - 44, XP023056138, DOI:          doi:10.1016/0042-6822(91)90433-C;            ANSARDI, D.C.; D.C. PORTER; C.D. MORROW: "Complementation          of a poliovirus defective genome by a recombinant          vaccinia virus which provides poliovirus PI capsid          precursor in trans", J. VIROL., vol. 67, 1993, pages 3684          - 3690;            BELOV, G.A.; L.I. ROMANOVA; E.A. TOLSKAYA; M.S.          KOLESNIKOVA; Y.A. LAZEBNIK; V.I. AGOL.: "The major          apoptotic pathway activated and suppressed by          poliovirus", J. VIROL., vol. 77, 2003, pages 45 -          56;            BUCHAN, J.R.; L.S. AUCOTT; I. STANSFIELD: "tRNA          properties help shape codon pair preferences in open          reading frames", NUCL. ACIDS RES., vol. 34, 2006, pages          1015 - 27;            BURNS, C. C.; J. SHAW; R. CAMPAGNOLI; J. JORBA; A.          VINCENT; J. QUAY; O. KEW: "Modulation of poliovirus          replicative fitness in HeLa cells by deoptimization of          synonymous codon usage in the capsii region", J. VIROL.,          vol. 80, 2006, pages 3259 - 72, XP002633525, DOI:          doi:10.1128/JVI.80.7.3259-3272.2006;            CAO, X.; R. J. KUHN; E. WIMMER: "Replication of          poliovirus RNA containing two VPg coding sequences leads          to a specific deletion event", J. VIROL., vol. 67, 1993,          pages 5572 - 5578;            CARLINI, D.B.; W. STEPHAN: "In vivo introduction of          unpreferred synonymous codons into the Drosophila Adh          gene results in reduced levels of ADH protein", GENETICS,          vol. 163, 2003, pages 239 - 243;            CELLO, J.; A.V. PAUL; E. WIMMER: "Chemical synthesis of          poliovirus cDNA: generation of infectious virus in the          absence of natural template", SCIENCE, vol. 297, 2002,          pages 1016 - 1018, XP002438834, DOI:          doi:10.1126/science.1072266;            CHENG, L.; E. GOLDMAN: "Absence of effect of varying          Thr-Leu codon pairs on protein synthesis in a T7 system",          BIOCHEMISTRY, vol. 40, 2001, pages 6102 - 6;            COHEN, B.; S. SKIENA: "Natural selection and algorithmic          design of mRNA", J. COMPUT BIOL., vol. 10, 2003, pages          419 - 432;            "Current Protocols in Immunology", 1994, WILEY &          SONS, INC.;            CORPET, F.: "Multiple sequence alignment with          hierarchical clustering", NUCL. ACIDS RES., vol. 16,          1988, pages 10881 - 90;            CRAM, P.; S.G. BLITZ; A. MONTE; A.M. FENDRICK:          "Influenza. Cost of illness and consideration in the          economic evaluation of new and emerging therapies",          PHARMACOECONOMICS, vol. 19, 2001, pages 223 -          30;            CROTTY, S.; C.E. CAMERON; R. ANDINO: "RNA virus error          catastrophe: direct molecular test by using ribavirin",          PROC. NATL. ACAD. SCI. U.S.A., vol. 98, 2001, pages 6895          - 6900, XP002378245, DOI:          doi:10.1073/pnas.111085598;            CURRAN, J.F.; E.S. POOLE; W.P. TATE; B.L. GROSS:          "Selection of aminoacyl-tRNAs at sense codons: the size          of the tRNA variable loop determines whether the          immediate 3' nucleotide to the coder has a context          effect", NUCL. ACIDS RES., vol. 23, 1995, pages 4104 -          8;            DOMA, M.K.; R. PARKER: "Endonucleolytic cleavage of          eukaryotic mRNAs with stalls in translation elongation",          NATURE, vol. 440, 2006, pages 561 - 4;            DOVE, A.W.; V.R. RACANIELLO: "Cold-adapted poliovirus          mutants bypass a postentry replication block", J. VIROL.,          vol. 71, 1997, pages 4728 - 4735, XP002733377;            ENAMI, M.; W. LUYTJES; M. KRYSTAL; P. PALESE:          "Introduction of site-specific mutations into the genome          of influenza virus", PROC. NATL. ACAD. SCI. U.S.A., vol.          87, 1990, pages 3802 - 5;            FARABAUGH, P.J.: "Programmed translational          frameshifting", MICROBIOL REV., vol. 60, 1996, pages 103          - 34;            FEDOROV, A.; S. SAXONOV; W. GILBERT: "Regularities of          context-dependent codon bias in eukaryotic genes", NUCL.          ACIDS RES., vol. 30, 2002, pages 1192 - 7;            FODOR, E.; L. DEVENISH; O.G. ENGELHARDT; P. PALESE; G.G.          BROWNLEE; A. GARCIA-SASTRE: "Rescue of influenza A virus          from recombinant DNA", J VIROL., vol. 73, 1999, pages          9679 - 82;            GABOW, H.: "Ph.D. thesis", 1973, STANFORD          UNIVERSITY;            GARCIA-SASTRE, A.; P. PALESE: "Genetic manipulation of          negative-strand RNA virus genomes", ANNU. REV.          MICROBIOL., vol. 47, 1993, pages 765 - 90, XP000600723,          DOI: doi:10.1146/annurev.mi.47.100193.004001;            GEORGESCU, M.M.; J. BALANANT; A. MACADAM; D. OTELEA; M.          COMBIESCU; A.A. COMBIESCU; R. CRAINIC; F. DELPEYROUX:          "Evolution of the Sabin type 1 poliovirus in humans:          characterization of strains isolated from patients with          vaccine-associated paralytic poliomyelitis", J. VIROL.,          vol. 71, 1997, pages 7758 - 68;            GERBER, K.; E. WIMMER; A.V. PAUL: "Biochemical and          genetic studies of the initiation of human rhinovirus 2          RNA replication: identification of a cis-replicating          element in the coding sequence of 2A(pro", J. VIROL.,          vol. 75, 2001, pages 10979 - 10990;            GIRARD, S.; T. COUDERC; J. DESTOMBES; D. THIESSON; F.          DELPEYROUX; B. BLONDEL: "Poliovirus induces apoptosis in          the mouse central nervous system", J. VIROL., vol. 73,          1999, pages 6066 - 6072;            GOODFELLOW, I.; Y. CHAUDHRY; A. RICHARDSON; J. MEREDITH;          J.W. ALMOND; W. BARCLAY; D.J. EVANS: "Identification of a          cis-acting replication element within the poliovirus          coding region", J. VIROL., vol. 74, 2000, pages 4590 -          600;            GREVE, J.M.; G. DAVIS; A.M. MEYER; C.P. FORTE; S.C. YOST;          C.W. MARLOR; M.E. KAMARCK; A. MCCLELLAND: "The major          human rhinovirus receptor is ICAM-1", CELL, vol. 56,          1989, pages 839 - 47, XP023884491, DOI:          doi:10.1016/0092-8674(89)90688-0;            GUSTAFSSON, C.; S. GOVINDARAJAN; J. MINSHULL: "Codon bias          and heterologous protein expression", TRENDS BIOTECHNOL,          vol. 22, 2004, pages 346 - 353;            GUTMAN, G.A.; G.W. HATFIELD: "Nonrandom utilization of          codon pairs in Escherichia coli", PROC. NATL. ACAD. SCI.          U. S. A., vol. 86, 1989, pages 3699 - 703, XP002460057,          DOI: doi:10.1073/pnas.86.10.3699;            HE, Y.; V.D. BOWMAN; S. MUELLER; C.M. BATOR; J. BELLA; X.          PENG; T.S. BAKER; E. WIMMER; R.J. KUHN; M.G. ROSSMANN:          "Interaction of the poliovirus receptor with poliovirus",          PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 79 - 84,          XP055184241, DOI: doi:10.1073/pnas.97.1.79;            HENDLEY, J. O.: "Clinical virology of rhinoviruses", ADV          VIRUS RES, vol. 54, 1999, pages 453 - 66;            HEROLD, J.; R. ANDINO: "Poliovirus requires a precise 5'          end for efficient positive-strand RNA synthesis", J.          VIROL., vol. 74, 2000, pages 6394 - 400;            HOEKEMA, A.; R.A. KASTELEIN; M. VASSER; H.A. DE BOER:          "Codon replacement in the PGKI gene of Saccharomyces          cerevisiae: experimental approach to study the role of          biased codon usage in gene expression", MOL. CELL. BIOL.,          vol. 7, 1987, pages 2914 - 2924, XP008035184;            HOFER, F.; M. GRUENBERGER; H. KOWALSKI; H. MACHAT; M.          HUETTINGER; E. KUECHLER; D. BLAAS: "Members of the low          density lipoprotein receptor family mediate cell entry of          a minor-group common cold virus", PROC. NATL. ACAD. SCI.          U.S.A., vol. 91, 1994, pages 1839 - 42;            HOFFMANN, E.; G. NEUMANN; Y. KAWAOKA; G. HOBOM; R. G.          WEBSTER: "A DNA transfection system for generation of          influenza: A virus from eight plasmids", PROC. NATL.          ACAD. SCI. U.S.A., vol. 97, 2000, pages 6108 - 13,          XP008131838, DOI: doi:10.1073/pnas.100133697;            HOGLE, J. M.: "Poliovirus cell entry: common structural          themes in viral cell entry pathways", ANNU. REV.          MICROBIOL., vol. 56, 2002, pages 677 - 702;            HOLLAND, J.J.; E. DOMINGO; J.C. DE LA TORRE; D.A.          STEINHAUER: "Mutation frequencies at defined single codon          sites in vesicular stomatitis virus and poliovirus can be          increased only slightly by chemical mutagenesis", J.          VIROL., vol. 64, 1990, pages 3960 - 3962;            HSIAO, L.L.; F. DANGOND; T. YOSHIDA; R. HONG; R.V.          JENSENET: "A compendium of gene expression in normal          human tissues", PHYSIOL. GENOMICS, vol. 7, 2001, pages 97          - 104, XP002904791;            IRWIN, B.; J. D. HECK; G. W. HATFIELD: "Codon pair          utilization biases influence translational elongation          step times", J. BIOL CHEM., vol. 270, 1995, pages 22801 -          6, XP002406003, DOI:          doi:10.1074/jbc.270.39.22801;            JANG, S.K.; M.V. DAVIES; R.J. KAUFMAN; E. WIMMER:          "Initiation of protein synthesis by internal entry of          ribosomes into the 5' nontranslated region of          encephalomyocarditis virus RNA in vitro", J. VIROL., vol.          63, 1989, pages 1651 - 1660, XP002322705;            JAYARAJ, S.; R. REID; D.V. SANTI: "GeMS: an advanced          software package for designing synthetic genes", NUCL.          ACIDS RES., vol. 33, 2005, pages 3011 - 3016,          XP002438837, DOI: doi:10.1093/nar/gki614;            JOHANSEN, L.K.; C.D. MORROW: "The RNA encompassing the          internal ribosome entry site in the poliovirus 5'          nontranslated region enhances the encapsidation of          genomic RNA", VIROLOGY, vol. 273, 2000, pages 391 - 399,          XP004436243, DOI: doi:10.1006/viro.2000.0433;            JOKLIK, W.; J. DARNELL: "The adsorption and early fate of          purified poliovirus in HeLa cells", VIROLOGY, vol. 13,          1961, pages 439 - 447, XP026424664;            "Influenza Report", 2006, FLYING PUBLISHER;            KAPLAN, G.; V.R. RACANIELLO: "Construction and          characterization of poliovirus subgenomic replicons", J.          VIROL., vol. 62, 1988, pages 1687 - 96;            KARLIN, S.; W. DOERFLER; L.R. CARDON: "Why is CpG          suppressed in the genomes of virtually al small          eukaryotic viruses but not in those of large eukaryotic          viruses?", J VIROL, vol. 68, 1994, pages 2889 -          97;            "Concepts and procedures for laboratory-based influenza          surveillance", 1982, WORLD HEALTH ORGANIZATION          COLLABORATING CENTERS;            KEW, O.; V. MORRIS-GLASGOW; M. LANDAVERDE; C. BURNS; J.          SHAW; Z. GARIB; J. ANDRE; E. BLACKMAN; C.J. FREEMAN; J.          JORBA: "Outbreak of poliomyelitis in Hispaniola          associated with circulating type 1 vaccine-derived          poliovirus", SCIENCE, vol. 296, 2002, pages 356 -          9;            KILBOURNE, E.D.: "Influenza pandemics of the 20th          century", EMERG. INFECT. DIS., vol. 12, 2006, pages 9 -          14;            KITAMURA, N.; B.L. SEMLER; P.G. ROTHBERG; G.R. LARSEN;          C.J. ADLER; A.J. DORNER; E.A. EMINI; R. HANECAK; J. LEE;          S. VAN DER WELL: "Primary structure, gene organization          and polypeptide expression of poliovirus RNA", NATURE,          vol. 291, 1981, pages 547 - 553, XP002029775, DOI:          doi:10.1038/291547a0;            KOIKE, S.; C. TAYA; T. KURATA; S. ABE; I. ISE; H.          YONEKAWA; A. NOMOTO: "Transgenic mice susceptible to          poliovirus", PROC. NATL. ACAD. SCI. U.S.A., vol. 88,          1991, pages 951 - 955;            LANDSTEINER, K.; E. POPPER: "Ubertragung der          Poliomyelitis acuta auf Affen", Z. IMMUNNITATSFORSCH          ORIG, vol. 2, 1909, pages 377 - 90;            LAVNER, Y.; D. KOTLAR: "Codon bias as a factor in          regulating expression via translation rate in the human          genome", GENE, vol. 345, 2005, pages 127 - 38,          XP004877084, DOI:          doi:10.1016/j.gene.2004.11.035;            LEDFORD, R.M.; N.R. PATEL; T.M. DEMENCZUK; A. WATANYAR;          T. HERBERTZ; M.S. COLLETT; D.C. PEVEAR: "VP1 sequencing          of all human rhinovirus serotypes: insights into genus          phylogeny and susceptibility to antiviral capsid-binding          compounds", J. VIROL., vol. 78, 2004, pages 3663 - 74,          XP002575100, DOI:          doi:10.1128/JVI.78.7.3663-3674.2004;            LUYTJES, W.; M. KRYSTAL; M. ENAMI; J. D. PAVIN; P.          PALESE: "Amplification, expression, and packaging of          foreign gene by influenza virus", CELL, vol. 59, 1989,          pages 1107 - 13, XP027461606, DOI:          doi:10.1016/0092-8674(89)90766-6;            MCKNIGHT, K.L.: "The human rhinovirus internal cis-acting          replication element (cre) exhibits disparate properties          among serotypes", ARCH. VIROL., vol. 148, 2003, pages          2397 - 418;            MOLLA, A.; A.V. PAUL; E. WIMMER: "Cell-free, de novo          synthesis of poliovirus", SCIENCE, vol. 254, 1991, pages          1647 - 1651;            MUELLER, S.; D. PAPAMICHAIL; J.R. COLEMAN; S. SKIENA; E.          WIMMER: "Reduction of the Rate of Poliovirus Protein          Synthesis through Large-Scale Codon Deoptimization Causes          Attenuation of Viral Virulence by lowering specific          infectivity", J. VIROL., vol. 80, 2006, pages 9687 -          9696, XP002722711, DOI:          doi:10.1128/JVI.00738-06;            MUELLER, S.; E. WIMMER; J. CELLO: "Poliovirus and          poliomyelitis: a tale of guts, brains, and an accidental          event", VIRUS RES, vol. 111, 2005, pages 175 - 193,          XP004962565, DOI:          doi:10.1016/j.virusres.2005.04.008;            MURDIN, A.D.; E. WIMMER: "Construction of a poliovirus          type 1/type 2 antigenic hybrid by manipulation of          neutralization antigenic site I", J. VIROL., vol. 63,          1989, pages 5251 - 5257;            NEUMANN, G.; T. WATANABE; H. ITO; S. WATANABE; H. GOTO;          P. GAO; M. HUGHES; D. R. PEREZ; R. DONIS; E. HOFFINANN:          "Generation of influenza A viruses entirely from clone          cDNAs", PROC. NATL. ACAD. SCI. U.S.A., vol. 96, 1999,          pages 9345 - 50;            NEZNANOV, N.; K.M. CHUMAKOV; L. NEZNANOVA; A. ALMASAN;          A.K. BANERJEE; A.V. GUDKOV: "Proteolytic cleavage of the          p65-RelA subunit of NF-kappaB during poliovirus          infection", J. BIOL. CHEM., vol. 280, 2005, pages 24153 -          24158;            PALESE, P.; M. L. SHAW: "Fields virology", 2007,          LIPPINCOTT WILLIAMS & WILKINS, article          "Orthomyxoviridae: the viruses and their replication",          pages: 1647 - 1689;            PARK, S.; X. YANG; J. G. SAVEN: "Advances in          computational protein design", CURR OPIN STRUCT BIOL,          vol. 14, 2004, pages 487 - 94, XP027347977;            PAUL, A. V.; J.A. MUGAVERO; A. MOLLA; E. WIMMER:          "Internal ribosomal entry site scanning of the poliovirus          polyprotein: implications for proteolytic processing",          VIROLOGY, vol. 250, 1998, pages 241 - 253, XP004445636,          DOI: doi:10.1006/viro.1998.9376;            PELLETIER, J.; N. SONENBERG: "Internal initiation of          translation of eukaryotic mRNA directed by; sequence          derived from poliovirus RNA", NATURE, vol. 334, 1988,          pages 320 - 325, XP002059536, DOI:          doi:10.1038/334320a0;            PFISTER, T.; E. WIMMER: "Characterization of the          nucleoside triphosphatase activity of poliovirus protein          2C reveals a mechanism by which guanidine inhibits          poliovirus replication", J. BIOL. CHEM., vol. 274, 1999,          pages 6992 - 7001;            PLOTKIN, J.B.; H. ROBINS; A.J. LEVINE: "Tissue-specific          codon usage and the expression of human genes", PROC.          NATL. ACAD. SCI. U.S.A., vol. 101, 2004, pages 12588 -          12591, XP002382913, DOI:          doi:10.1073/pnas.0404957101;            RACANIELLO, V. R.; D. BALTIMORE: "Cloned poliovirus          complementary DNA is infectious in mammalian cells",          SCIENCE, vol. 214, 1981, pages 916 - 9, XP001057398, DOI:          doi:10.1126/science.6272391;            REED, L. J.; M. MUENCH: "A simple method for estimating          fifty percent endpoints", AM. J. HYG., vol. 27, 1938,          pages 493 - 497;            RICHARDSON, S. M.; S. J. WHEELAN; R. M. YARRINGTON; J. D.          BOEKE: "GeneDesign: rapid, automated design of          multikilobase synthetic genes", GENOME RES., vol. 16,          2006, pages 550 - 556, XP002509763, DOI: doi:10.1101/          GR.4431306;            ROBINSON, M.; R. LILLEY; S. LITTLE; J.S. EMTAGE; G.          YARRONTON; P. STEPHENS; A. MILLICAN; M. EATON; G.          HUMPHREYS: "Codon usage can affect efficiency of          translation of genes in Escherichia coli", NUCL. ACIDS          RES., vol. 12, 1984, pages 6663 - 6671;            ROTHBERG, E., WMATCH: A C PROGRAM TO SOLVE MAXIMUM-WEIGHT          MATCHING, 1985;            RUECKERT, R. R.: "Fields virology", vol. 1, 1985, RAVEN          PRESS, article "Picornaviruses and their replication",          pages: 705 - 738;            RUSSELL, C. J.; R. G. WEBSTER: "The genesis of a pandemic          influenza virus", CELL, vol. 123, 2005, pages 368 -          371;            SAMBROOK, J.; E.F. FRITSCH; T. MANIATIS: "Molecular          Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR          LABORATORY PRESS;            SANCHEZ, G.; A. BOSCH; R.M. PINTO: "Genome variability          and capsid structural constraints of hepatitis A virus",          J. VIROL., vol. 77, 2003, pages 452 - 459, XP002576154,          DOI: doi:10.1128/JVI.77.1.452-459.2003;            SAVOLAINEN, C.; S. BLOMQVIST; T. NOVI: "Human          rhinoviruses", PAEDIATR. RESPIR. REV., vol. 4, 2003,          pages 91 - 98;            SCHWERDT, C.; J. FOGH: "The ratio of physical particles          per infectious unit observed for poliomyelitis viruses",          VIROLOGY, vol. 4, 1957, pages 41 - 52, XP023052383, DOI:          doi:10.1016/0042-6822(57)90042-9;            SHIMIZU, H.; B. THORLEY; F.J. PALADIN; K.A. BRUSSEN; V.          STAMBOS ET AL.: "Circulation of type 1 vaccine-derived          poliovirus in the Philippines in 2001", J. VIROL., vol.          78, 2004, pages 13512 - 13521;            SIMONSEN, L.; T. A. REICHERT; C. VIBOUD; W. C.          BLACKWELDER; R. J. TAYLOR; M. A. MILLER: "Impact of          influenza vaccination on seasonal mortality in the US          elderly population", ARCH. INTERN. MED., vol. 165, 2005,          pages 265 - 272;            SKIENA, S. S., DESIGNING BETTER PHAGES BIOINFORMATICS,          vol. 17, no. 1, 2001, pages 5253 - 61;            STEINHAUER, D.A.; J.J. SKEHEL: "Genetics of influenza          viruses", ANNU. REV. GENET., vol. 36, 2002, pages 305 -          332;            STEPHENSON, I.; J. DEMOCRATIS: "Influenza: current threat          from avian influenza", BR. MED. BULL., vol. 75-76, 2006,          pages 63 - 80, XP002467263, DOI:          doi:10.1093/bmb/ldh063;            SVITKIN, Y.V.; G.A. ALPATOVA; G.A. LIPSKAYA; S.V.          MASLOVA; V.I. AGOL; O. KEW; K. MEEROVITCH; N. SONENBERG:          "Towards development of an in vitro translation test for          poliovirus neurovirulence", DEV. BIOL. STAND, vol. 78,          1993, pages 27 - 32;            SVITKIN, Y.V.; S.V. MASLOVA; V.I. AGOL: "The genomes of          attenuated and virulent poliovirus strains differ in          their in vitro translation efficiencies", VIROLOGY, vol.          147, 1985, pages 243 - 252, XP023052695, DOI:          doi:10.1016/0042-6822(85)90127-8;            TALON, J.; M. SALVATORE; R.E. O'NEILL; Y. NAKAYA; H.          ZHENG; T. MUSTER; A. GARCIA-SASTRE; P. PALESE: "Influenza          A and B viruses expressing altered NS1 proteins: A          vaccine approach", PROC. NATL. ACAD. SCI. U.S.A., vol.          97, 2000, pages 4309 - 4314, XP002985464, DOI:          doi:10.1073/pnas.070525997;            THOMPSON, W.W.; D. K.SHAY; E. WEINTRAUB; L. BRAMMER; N.          COX; L.J. ANDERSON; K. FUKUDA: "Mortality associated with          influenza and respiratory syncytial virus in the United          States", JAMA, vol. 289, 2003, pages 179 - 186,          XP055181478, DOI: doi:10.1001/jama.289.2.179;            TIAN, J.; H. GONG; N. SHANG; X. ZHOU; E. GULARI; X. GAO;          G. CHURCH: "Accurate multiplex gene synthesis from          programmable DNA microchips", NATURE, vol. 432, 2004,          pages 1050 - 1054, XP002371017, DOI:          doi:10.1038/nature03151;            TOLSKAYA, E.A.; L.I. ROMANOVA; M.S. KOLESNIKOVA; T.A.          IVANNIKOVA; E.A. SMIRNOVA; N.T. RAIKHLIN; V.I. AGOL:          "Apoptosis-inducing and apoptosis-preventing functions of          poliovirus", J. VIROL., vol. 69, 1995, pages 1181 -          1189;            TOYODA, H.; J. YIN; S. MUELLER; E. WIMMER; J. CELLO:          "Oncolytic treatment and cure of neuroblastoma by a novel          attenuated poliovirus in a novel poliovirus-susceptible          animal model", CANCER RES., vol. 67, 2007, pages 2857 -          64, XP002633529, DOI:          doi:10.1158/0008-5472.CAN-06-3713;            VAN DER WERT, S.; J. BRADLEY; E. WIMMER; F.W. STUDIER;          J.J. DUNN: "Synthesis of infectious poliovirus RNA by          purified T7 RNA polymerase", PROC. NATL. ACAD. SCI.          U.S.A., vol. 78, 1986, pages 2330 - 2334, XP000916849,          DOI: doi:10.1073/pnas.83.8.2330;            WAHBY, A. F.: "Combined cell culture enzyme-linked          immunosorbent assay for quantification of poliovirus          neutralization- relevant antibodies", CLIN. DIAGN. LAB.          IMMUNOL., vol. 7, 2000, pages 915 - 9;            WANG, B.; D. PAPAMICHAIL; S. MUELLER; S. SKIENA: "Two          Proteins for the Price of One: The Design of Maximally          Compressed Coding Sequences Natural Computing. Eleventh          International Meeting on DNA Based Computers (DNA11",          LECTURE NOTES IN COMPUTER SCIENCE (LNCS, vol. 3892, 2005,          pages 387 - 398;            ZHAO, W.D.; E. WIMMER: "Genetic analysis of a          poliovirus/hepatitis C virus chimera: new structure for          domain II of the internal ribosomal entry site of          hepatitis C virus", J. VIROL., vol. 75, 2001, pages 3719          - 3730;            ZHOU, J.; W.J. LIU; S.W. PENG; X.Y. SUN; I. FRAZER:          "Papillomavirus capsid protein expression level depends          on the match between codon usage and tRNA availability",          J. VIROL., vol. 73, 1999, pages 4972 - 4982,          XP002164427;            ZOLOTUKHIN, S.; M. POTTER; W.W. HAUSWIRTH; J. GUY; N.          MUZYCZKA: "A ''humanized'' green fluorescent protein cDNA          adapted for high-level expression in mammalian cells", J.          VIROL., vol. 70, 1996, pages 4646 - 4654,          XP002030427	200757-0-0-0 M N P; 200757-0-0-0 CL NEW PRD USE			RA00GT M N P		CN110283938-A;  CN110283938-B	Dual reverse-transcription recombinase aided            amplification primer set useful for detecting porcine            epidemic diarrhea virus and porcine deltacoronavirus,            comprises PEDV-forward primer and PEDV-reverse primer            and PDCoV-F and PDCoV-R	HE D;  LI G;  SU D	UNIV SOUTH CHINA AGRIC (USCG-C)	201984108L	   NOVELTY - Dual reverse-transcription recombinase aided                amplification (RT-RAA) primer set comprises primers                porcine epidemic diarrhea virus (PEDV)-forward                primer (F) and PEDV-reverse primer (R) and porcine                deltacoronavirus (PDCoV)-F and PDCoV-R.    USE - The dual RT-RAA primer set or kit is useful                for detecting PEDV and PDCoV (claimed).    ADVANTAGE - The dual RT-RAA kit has high specificity,                sensitivity, repeatability and stability, is                suitable for the diagnosis of pathogens, pathogen                purification and epidemiological investigations,                such as laboratory, entry and exit sites, farms,                etc., compared with traditional testing methods and                provides accurate and reliable detection technology                for the rapid differential diagnosis of porcine                epidemic diarrhea virus and porcine delta                coronavirus.    DETAILED DESCRIPTION - Dual reverse-transcription recombinase aided                amplification (RT-RAA) primer set comprises primers                porcine epidemic diarrhea virus (PEDV)-forward                primer (F) having                5'-tcaagatggctattctatggatactttgg-3' (SEQ ID NO: Not                defined), and PEDV-reverse primer (R) having                5'-gtagtgagaagcgcgtcagtttcaggattg-3' (SEQ ID NO:                Not defined) and porcine deltacoronavirus (PDCoV)-F                having (SEQ ID NO: Nor defined) and PDCoV-R having                5'-gactccaatctgttccgtacctatcatcac-3' (SEQ ID NO:                Not defined). INDEPENDENT CLAIMS are included for                the following:    (1) dual RT-RAA kit comprising the primer set                of PEDV and PDCoV; and    (2) use of dual RT-RAA kit in detecting PEDV                and PDCoV, where PEDV and PDCoV is detected by (a)                preparing a reverse transcription reaction system                using the sample RNA to be tested as a template,                and random primer as amplification primer and                performing reverse transcription reaction of sample                RNA to obtain cDNA, (b) preparing double RT-RAA                reaction system using the cDNA of the reverse                transcription reaction product prepared in the step                (a) as a template, and mixed primers PEDV-F,                PEDV-R, PDCoV-F and PDCoV-R as amplification                primers and performing dual RT-RAA reaction, (c)                performing the agarose gel electrophoresis                detection on the double PCR reaction product                obtained in the step (b), determining s result by                determining determination of the target band at 226                bp to be PEDV-positive amplification, the                determination of the target band at 321 bp to be                PDCoV-positive amplification, the determination                that the target band did not appear at 226 bp is                PEDV-negative amplification, and absence of the                target band at 321 bp is judged to be PDCoV                negative amplification. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03B;  B04-E01;  B04-E05;  B04-E99;  B04-F11B;  B11-C08D1;  B11-C08E3;  B11-C08F8;  B12-K04F;  C04-B03B;  C04-E01;  C04-E05;  C04-E99;  C04-F11B;  C11-C08D1;  C11-C08E3;  C11-C08F8;  C12-K04F;  D05-H06A;  D05-H12D1;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/6844;  C12Q-001/70;  C12R-001/93	CN110283938-A   27 Sep 2019   C12Q-001/70   201983Pages: 26   Chinese;  CN110283938-B   08 Aug 2023   C12Q-001/70   202367   Chinese	CN110283938-A    CN10539507    20 Jun 2019;   CN110283938-B    CN10539507    20 Jun 2019	CN110283938-B Previous Publ. Patent CN110283938	CN10539507    20 Jun 2019			CN110283938-A -- CN105420412-A   UNIV HENAN AGRIC (UYHR)   HAN L,  HU H,  ZHOU Y,  JIN X,  ZHANG L,  CAO B;  CN107299156-A   HEBEI INSPECTION & QUARANTINE SCI &                  TECHNOLOGY INST (HEBE-Non-standard)   DAN R,  LIU L,  NA H,  WANG J;  CN108715906-A   UNIV GUANGXI (UYGU)   OUYANG K,  ZHONG L,  HUANG W,  WANG R,  LU Y,  WU Y,  LIU X;  CN109593889-A   GUANGZHOU DONGBAI BIOTECHNOLOGY CO LTD (GUAN-Non-standard);  UNIV ZHEJIANG (UYZH)   CONG X,  WANG H,  YANG Z,  YANG Y;  CN109868331-A   UNIV YANGTZE (UYYT)   LIU G,  CHANG X,  LIU Y,  LIU M,  HU L,  ZENG P;  CN110283938-B -- CN105420412-A   UNIV HENAN AGRIC (UYHR)   HAN L,  HU H,  ZHOU Y,  JIN X,  ZHANG L,  CAO B;  CN105483291-A   UNIV HENAN AGRIC (UYHR)   HU H,  LIANG X,  WEI Z,  ZHENG L,  ZHANG J,  ZHOU Y,  CAO B;  CN106676197-A   UNIV HENAN AGRIC (UYHR)   HU H,  WEI F,  ZHANG L,  CAO B,  WANG L,  DING Q,  YUAN T,  ZHANG X,  GAO G,  HUANG D,  FENG W,  ZHANG Y;  CN107299156-A   HEBEI INSPECTION & QUARANTINE SCI &                  TECHNOLOGY INST (HEBE-Non-standard)   DAN R,  LIU L,  NA H,  WANG J;  CN108715906-A   UNIV GUANGXI (UYGU)   OUYANG K,  ZHONG L,  HUANG W,  WANG R,  LU Y,  WU Y,  LIU X;  CN109593889-A   GUANGZHOU DONGBAI BIOTECHNOLOGY CO LTD (GUAN-Non-standard);  UNIV ZHEJIANG (UYZH)   CONG X,  WANG H,  YANG Z,  YANG Y;  CN109868331-A   UNIV YANGTZE (UYYT)   LIU G,  CHANG X,  LIU Y,  LIU M,  HU L,  ZENG P	CN110283938-A  LEI MA :          "Point-of-care diagnostic assay for rapid detection of          porcine deltacoronavirus using the recombinase polymerase          amplification method", TRANSBOUND EMERG          DIS,relevantClaims[13-5],relevantPassages[-13282];  : "RPA",          ,relevantClaims[13-5],relevantPassages[-343611]CN110283938-B            The establishment of the real-time fluorescence RPA          isothermal detection method for porcine epidemic diarrhea          virus. "Chinese Animal Veterinary". 2017, Vol. 44 (Phase          12)						US2019314372-A1;  US10786502-B2	New pyrimidine compounds containing acidic groups are toll-like receptor 7 modulators used to treat e.g. cancer, viral infection including common cold, and infection due to respiratory syncytial virus and influenza and conjunctivitis	WU T Y	APROS THERAPEUTICS INC (APRO-Non-standard)	2019861994	   NOVELTY - Pyrimidine compounds containing acidic groups (I) are new.    USE - (I) are useful for treating a condition associated with TLR7 modulation in a subject, where the condition is viral infection or cancer and treating hepatitis B virus infection (claimed) where the viral infection including common cold, and infection due to respiratory syncytial virus, influenza, coronavirus and adenovirus and e.g. conjunctivitis, nephritis, allograft rejection and erythematosus.    DETAILED DESCRIPTION - Pyrimidine compounds containing acidic groups of formula (I), and their salts are new.    R1a = H, 1-4C alkyl, -NH2, -NHAc, -COOH, -SO2CH3, -SCH3, -OCH3, and where the alkyl is optionally substituted with -OH, -NH2, -NHAc, -COOH, -SO2CH3, -SCH3, -OCH3, 2H-tetrazole-5-yl or A;    R1b = 2-5C alkyl;    X = H or 1-4C alkyl, where the alkyl is optionally substituted with A, -OH, or -C(CH3)2OH;    L1 = a bond, -CH2-, -CF2-, -O-, -S-, -SO2-, -NH-, -C(CH3)2-, cyclopropyl or -CH2CH2-;    Y1 = 1-3C alkyl, aryl, and heteroaryl, where the alkyl, aryl, and heteroaryl are optionally substituted with 1-5 A, 1-3C alkyl, or 1-3C alkoxy;    A = e.g. L2-C(=O)OH, L2-P(=O)(OH)2, L2-S(=O)2OH, or L2-B(OH)2;    L2 = e.g. bond, -(CH2)n-, -C(O)NH(CH2)n, -(O(CH2CH2))n-, -(O(1-4C alkylene))-, -(O(CH2CH2)) n-OCH2CH2CF2-, -C(O)NHCH2CH2-(O(CH2CH2)) m- or -C(O)NHCH2CH2-(O(CH2CH2))m-OCH2CH2CF2-;    m = zero to four; and    n = one to four where the compound is substituted with at least one A and when X is -CH3, L1 is -CH2-, Y1 is aryl substituted with A and L2 is -CH2-, then A is not -L2-COOH, except when R1a comprises -COOH or -SO2CH3 and when X is -CH3, L1 is -CH2-, Y1 is aryl substituted with A, L2 is -CH2-, -O-(CH2)2-O(CH2)2-, or -O-(CH2)2-or O(CH2)2(CF2)- and A is L2-P(=O)(OH)2 then A and L1 are not in a para position with respect to each other.    INDEPENDENT CLAIMS are also included for:    (1) composition comprising (I) and carrier;    (2) treating hepatitis B virus infection in a subject comprising administering (I) in combination with an antiviral nucleoside; and    (3) treating cancer in a subject, comprising administering (I) in combination with a PD-1 antibody or PD-L1 antibody. 			B03 (Other heterocyclics.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C02 (Heterocyclic.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B03A;  B04-G21;  B05-B01A;  B05-B01E;  B05-B01J;  B06-H;  B07-D12;  B14-A02;  B14-C03;  B14-G02C;  B14-H01;  B14-L01;  B14-L06;  B14-N03;  B14-N10;  B14-N17;  B14-S18;  C04-B03A;  C04-G21;  C05-B01A;  C05-B01E;  C05-B01J;  C06-H;  C07-D12;  C14-A02;  C14-C03;  C14-G02C;  C14-H01;  C14-L01;  C14-L06;  C14-N03;  C14-N10;  C14-N17;  C14-S18;  D05-H11	A61K-031/505;  A61K-031/506;  A61K-031/675;  A61K-031/69;  A61K-031/7052;  A61K-039/395;  C07D-239/49;  C07D-403/10;  C07D-403/12;  C07F-005/02;  C07F-009/6512;  C07D-239/48	US2019314372-A1   17 Oct 2019   A61K-031/506   201983Pages: 188   English;  US10786502-B2   29 Sep 2020   A61K-031/505   202079   English	US2019314372-A1    US364053    25 Mar 2019;   US10786502-B2    US364053    25 Mar 2019	US2019314372-A1 Provisional Application US532230P;   US2019314372-A1 Provisional Application US430183P;   US2019314372-A1 CIP of Application US831131;   US2019314372-A1 CIP of Patent US10287253;   US10786502-B2 Provisional Application US532230P;   US10786502-B2 Provisional Application US430183P;   US10786502-B2 Cont of Application US831131;   US10786502-B2 Cont of Patent US10287253;   US10786502-B2 Previous Publ. Patent US2019314372	US430183P    05 Dec 2016;  US364053    25 Mar 2019		514/275000;  544/323000	;  US10786502-B2 -- US8268990-B2   ASTRAZENECA AB (ASTR);  DAINIPPON SUMITOMO PHARMA CO LTD (SUMU)   BENNETT N J,  MCINALLY T,  MOCHEL T,  THOM S,  TIDEN A;  US4689338-A   RIKER LAB INC (RIKL)   GERSTER J F;  US20180155298-A1   ;  US20190365756-A1   ;  US10287253-B2   APROS THERAPEUTICS INC (APRO-Non-standard)   WU T Y;  WO1997022596-A1   ;  WO1997030035-A1   ;  WO1997032856-A1   ;  WO1998001448-A1   ;  WO1998013354-A1   ;  WO1998035985-A1   ;  WO1999002166-A1   ;  WO2000040529-A1   ;  WO2000047212-A1   ;  WO2001032651-A1   ;  WO2001092224-A1   ;  WO2001094341-A1   ;  WO2002004434-A1   ;  WO2002008213-A1   ;  WO2009067081-A1   ASTRAZENECA AB (ASTR);  DAINIPPON SUMITOMO PHARMA CO LTD (SUMU)   BENNETT N J,  MCINALLY T,  MOCHEL T,  THOM S,  TIDEN A;  WO2010133885-A1   ASTRAZENECA AB (ASTR);  ASTRAZENECA UK LTD (ASTR);  DAINIPPON SUMITOMO PHARMA CO LTD (SUMU)   BENNETT N J,  MCINALLY T,  THOM S;  WO2012031140-A1   NOVARTIS AG (NOVS);  IRM LLC (IRMI)   SINGH M,  SKIBINSKI D A G,  WU T Y,  LI Y,  CORTEZ A,  ZHANG X,  ZOU Y,  HOFFMAN T Z,  PAN J,  YUE K;  WO2012066336-A1   ASTRAZENECA AB (ASTR);  ASTRAZENECA UK LTD (ASTR);  DAINIPPON SUMITOMO PHARMA CO LTD (SUMU)   HASEGAWA F,  HORI S,  MCINALLY T,  MOCHEL T;  WO2013172479-A1   ASTRAZENECA AB (ASTR);  DAINIPPON SUMITOMO PHARMA CO LTD (SUMU)   HASEGAWA F,  HORI S,  KUREBAYASHI H,  URABE D;  WO2014128189-A1   JANSSEN R & D IRELAND (JOHJ)   MC GOWAN D C,  RABOISSON P J B,  JONCKERS T H M;  WO2018106606-A1   APROS THERAPEUTICS INC (APRO-Non-standard)   WU T Y;  WO2001060814-A2   ;  WO2000041669-A3   ;  WO1999028321-A9   	US10786502-B2  Lombardo et al., Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays, J. Med. Chem. 47(27): 6658-6661 (2004).;  McGowan et al., Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus, J. Med. Chem. 59(17):7936-7949.;  Oballa et al., Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia, J. Med. Chem. 54(14):5082-5096 (2011).;  Pfefferkorn et al., Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl) propanamido) nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus, J. Med. Chem., 2012, 55(3):1318-1333 (2012).;  Stern et al., Overview of monoclonal antibodies in cancer therapy: present and promise, Crit Rev Oncol Hematol. 54(1):11-29 (2005).;  Tu et al., Medicinal Chemistry Design Principles for Liver Targeting Through OATP Transporters, Current Topics in Medicinal Chemistry 13(7): 857-866 (2013).;  International Search Report and Written Opinion issue by the International Searching Authority for Application No. PCT/US2017/064541, dated Mar. 2, 5018, 17 pages.;  Santarpia et al., Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role, Transl. Lung Cancer Res 2015; 4(6): 728-742.;  Flyleaf of Introduction to Organic Chemistry, Clayton Heathcock and Andrew Streitweiser, MacMillan Publishing Co., Inc., 1976.;  International Search Report and Written Opinion issued by the International Searching Authority for Application No. PCT/US2019/035247, dated Jul. 31, 2019, 13 pages.	184587-0-0-0 K M; 184608-0-0-0 K M;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N	216923801 M N	00061	RA00C8 K M; RA0HFE K M; RCBFEQ M N; RCBFER M N; RCOFXZ M N; RCBFET M N; RCOFY0 M N; RCBFEV M N; RCBFEY M N; RCOFY1 M N; RCBFEZ M N; RCOFY2 M N; RCBFF0 M N; RCBFF1 M N; RCBFF2 M N; RCBFF3 M N; RCBFF4 M N; RCBFF5 M N; RCBFF6 M N; RCBFF7 M N; RCBFF8 M N; RCOFY3 M N; RCOFY4 M N; RCOFY5 M N; RCOFY6 M N; RCOFY7 M N; RCOFY8 M N; RCOFY9 M N; RCOFYA M N; RCBFFH M N; RCOFYB M N; RCBFFJ M N; RCOFYC M N; RCBFFG M N; RCOFYD M N; RCOFYE M N; RCOFYF M N; RCOFYG M N; RCBFFQ M N; RCOFYH M N; RCBFFS M N; RCOFYI M N; RCOFYJ M N; RCBFFU M N; RCBFFV M N; RCOFYK M N; RCOFYL M N; RCBFFX M N; RCBFFY M N; RCOFYM M N; RCBFG0 M N; RCBFG1 M N; RCBFG2 M N; RCBFG3 M N		WO2019110486-A1;  AU2018379121-A1;  CA3082959-A1;  CN111432835-A;  US2020289634-A1;  EP3720489-A1;  BR112020011041-A2;  JP2021505560-W;  RU2020120941-A;  RU2785620-C2;  JP2023145681-A;  US11883476-B2;  AU2018379121-B2;  US2024181027-A1	Immunogenic composition comprises alphavirus RNA            replicon particles each encoding Borrelia burgdorferi            antigens or antigenic fragments, where one alphavirus            RNA replicon particle encodes Borrelia burgdorferi            outer surface protein A	LAFLEUR R L;  DANT J C;  MOGLER M A;  CALLISTER S M;  XU Z;  LAFLEUR R;  LAFLER R L;  DANT Y S;  MOGLER M;  XU ZH;  XU Z C	INTERVET INT BV (IVET-C);  INTERVET INC (MERI-C);  INTERVET INT BV (IVET-C);  INTERVET INC (MERI-C);  INTERVET INT BV (IVET-C);  INTERVET INC (MERI-C);  INTERVET INC (MERI-C)	201950955P	   NOVELTY - Immunogenic composition comprises two or more                alphavirus RNA replicon particles each individually                encoding one or more Borrelia burgdorferi antigens                or antigenic fragments, where one alphavirus RNA                replicon particle encodes a one or more Borrelia                burgdorferi outer surface protein A (OspA) or an                antigenic fragment, and where another alphavirus                RNA replicon particle encodes one or more Borrelia                burgdorferi outer surface protein C (OspC) or an                antigenic fragment.    USE - Immunogenic composition used for canine Lyme                disease.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a vaccine to aid in the prevention of                disease due to Borrelia burgdorferi infection                comprises the immunogenic composition and a                pharmaceutically acceptable carrier; and    (2) a method for immunizing a mammal against a                pathogenic Borrelia genospecies, which involves                administering to the mammal an immunologically                effective amount of the vaccine. 			B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E02J;  B04-E03J;  B04-E99;  B04-F06;  B04-F10A;  B04-F11;  B14-A01A2;  B14-A01A4;  B14-A02A1;  B14-A02A9;  B14-A02B3;  B14-A02B5;  B14-G01;  B14-S11A;  B14-S11B1;  B14-S11B3;  B14-S11D2;  C04-E02J;  C04-E03J;  C04-E99;  C04-F06;  C04-F10A;  C04-F11;  C14-A01A2;  C14-A01A4;  C14-A02A1;  C14-A02A9;  C14-A02B3;  C14-A02B5;  C14-G01;  C14-S11A;  C14-S11B1;  C14-S11B3;  C14-S11D2;  D05-H07;  D05-H99	A61K-039/00;  A61K-039/02;  A61K-039/193;  A61K-009/10;  A61P-031/00;  A61P-031/12;  A61P-031/16;  C07K-014/20;  A61P-031/04;  A61K-035/76;  A61K-048/00;  A61P-037/06;  A61P-043/00;  C07K-014/08;  C07K-014/705;  C07K-019/00;  C12N-015/31;  C12N-015/38;  C12N-015/62;  A61K-039/008;  A61K-039/145;  A61K-039/155;  A61K-039/175;  A61K-039/205;  A61K-039/215;  A61K-039/23;  A61K-039/235;  A61P-037/04;  C12N-015/86	WO2019110486-A1   13 Jun 2019   A61K-039/193   201949Pages: 39   English;  AU2018379121-A1   21 May 2020   C07K-014/20   202042   English;  CA3082959-A1   13 Jun 2019   A61K-039/193   202052   English;  CN111432835-A   17 Jul 2020   A61K-039/193   202060   Chinese;  US2020289634-A1   17 Sep 2020   A61K-039/02   202076   English;  EP3720489-A1   14 Oct 2020   A61K-039/193   202084   English;  BR112020011041-A2   17 Nov 2020   A61K-009/10   202002   English;  JP2021505560-W   18 Feb 2021   A61K-039/02   202116Pages: 33   Japanese;  RU2020120941-A   13 Jan 2022   A61K-039/193   202293   Russian;  RU2785620-C2   09 Dec 2022   A61K-039/193   202309   Russian;  JP2023145681-A   11 Oct 2023   A61K-039/02   202385   Japanese;  US11883476-B2   30 Jan 2024   A61K-039/02   202410   English;  AU2018379121-B2   02 May 2024   A61K-039/193   202437   English;  US2024181027-A1   06 Jun 2024   A61K-039/02   202448   English	WO2019110486-A1    WOEP083306    03 Dec 2018;   AU2018379121-A1    AU379121    03 Dec 2018;   CA3082959-A1    CA3082959    03 Dec 2018;   CN111432835-A    CN80077939    03 Dec 2018;   US2020289634-A1    US16767715    28 May 2020;   EP3720489-A1    EP815595    03 Dec 2018;   BR112020011041-A2    BR11011041    03 Dec 2018;   JP2021505560-W    JP530359    03 Dec 2018;   RU2020120941-A    RU120941    03 Dec 2018;   RU2785620-C2    RU120941    03 Dec 2018;   JP2023145681-A    JP126448    02 Aug 2023;   US11883476-B2    US16767715    28 May 2020;   AU2018379121-B2    AU379121    03 Dec 2018;   US2024181027-A1    US539997    14 Dec 2023	AU2018379121-A1 PCT application Application WOEP083306;   AU2018379121-A1 Based on Patent WO2019110486;   CA3082959-A1 PCT application Application WOEP083306;   CA3082959-A1 Based on Patent WO2019110486;   CN111432835-A PCT application Application WOEP083306;   CN111432835-A Based on Patent WO2019110486;   US2020289634-A1 PCT application Application WOEP083306;   US2020289634-A1 Provisional Application US594342P;   EP3720489-A1 PCT application Application WOEP083306;   EP3720489-A1 Based on Patent WO2019110486;   BR112020011041-A2 PCT application Application WOEP083306;   BR112020011041-A2 Based on Patent WO2019110486;   JP2021505560-W PCT application Application WOEP083306;   JP2021505560-W Based on Patent WO2019110486;   RU2785620-C2 PCT application Application WOEP083306;   RU2785620-C2 Based on Patent WO2019110486;   JP2023145681-A Div ex Application JP530359;   US11883476-B2 Provisional Application US594342P;   US11883476-B2 PCT application Application WOEP083306;   US11883476-B2 Previous Publ. Patent US2020289634;   US11883476-B2 Based on Patent WO2019110486;   AU2018379121-B2 PCT application Application WOEP083306;   AU2018379121-B2 Based on Patent WO2019110486;   US2024181027-A1 Cont of Application WOEP083306;   US2024181027-A1 Cont of Application US767715;   US2024181027-A1 Provisional Application US594342P;   US2024181027-A1 Cont of Patent US11883476	US594342P    04 Dec 2017;  CA3082959    19 May 2020;  US16767715    28 May 2020;  BR11011041    01 Jun 2020;  CN80077939    01 Jun 2020;  RU120941    06 Jul 2020;  US539997    14 Dec 2023	WO2019110486-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          EP3720489-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                  		WO2019110486-A1 -- EP1939294-A1   BROOKHAVEN SCI ASSOC LLC (BRKH);  UNIV NEW YORK STATE RES FOUND (UNYS)   LUFT B J,  DUNN J J;  WO2005007689-A1   ALPHAVAX INC (ALPH-Non-standard)   CHULAY J D,  DRYGA S,  REAP E A,  OLMSTED R A,  MORRIS J S;  WO2007047749-A1   NOVARTIS VACCINES & DIAGNOSTICS INC (NOVS)   VAJDY M;  WO2013006834-A1   NOVARTIS AG (NOVS)   BRITO L,  CHAN M,  GEALL A,  OHAGAN D,  SINGH M,  O'HAGAN D;  WO2013116770-A1   SANOFI PASTEUR BIOLOGICS LLC (SNFI)   PUGACHEV K V;  WO2014005958-A1   NOVARTIS AG (NOVS)   BANNERJEE K,  BARNETT S,  OTTEN G,  GEALL A;  WO2013158818-A2   ZOETIS LLC (ZOET)   LOHSE R M,  MEEUS P F M,  MILLERSHIP J J,  XU Z;  US6210676-B1   GUNDERSEN LUTHERAN MEDICAL FOUND INC (GUND-Non-standard)   CALLISTER S N,  LOVRICH S D,  SCHELL R F,  JOBE D A;  US6316005-B1   SOLVAY ANIMAL HEALTH INC (SOLV)   KORSHUS J B,  RUNNELS P L,  SHARPEE R L,  SCHELL R F,  CALLISTER S M;  US6464985-B1   GUNDERSEN LUTHERAN MEDICAL FOUND INC (GUND-Non-standard)   CALLISTER S N,  LOVRICH S D,  SCHELL R F,  JOBE D A;  US6872550-B1   IMMUNO AG (IMMO)   LIVEY I,  CROWE B,  DORNER F;  US8137678-B2   SCHERING-PLOUGH LTD (SCHE)   CALLISTER S M,  LAFLEUR R,  WASMOEN T L;  US8414901-B2   SCHERING-PLOUGH LTD (SCHE)   CALLISTER S M,  LAFLEUR R,  WASMOEN T L;  US8460913-B2   ALPHAVAX INC (ALPH-Non-standard)   KAMRUD K I,  SMITH J F,  MAUGHAN M;  US9441247-B2   ALPHAVAX INC (ALPH-Non-standard)   RAYNER J O,  SMITH J F,  HUBBY B,  REAP E A;  CN111432835-A -- CN104379164-A   ZOETIS LLC (ZOET)   LOHSE R M,  MEEUS P F M,  MILLERSHIP J J,  XU Z;  EP1939294-A1   BROOKHAVEN SCI ASSOC LLC (BRKH);  UNIV NEW YORK STATE RES FOUND (UNYS)   LUFT B J,  DUNN J J;  WO2007047749-A1   NOVARTIS VACCINES & DIAGNOSTICS INC (NOVS)   VAJDY M;  WO2013116770-A1   SANOFI PASTEUR BIOLOGICS LLC (SNFI)   PUGACHEV K V;  US2020289634-A1 -- US6451769-B1   PASTEUR MERIEUX SERUMS & VACCINS SA (INMR);  VICAL INC (VICA-Non-standard);  UNIV TEXAS SYSTEM (TEXA)   HUEBNER R C,  NORMAN J A,  LIANG X,  CARNER K R,  BARBOUR A G,  LUKE C J;  US11883476-B2 -- US20080181916-A1   ;  US20120141530-A1   ;  US20120142023-A1   ;  US20140314801-A1   ;  US20200289634-A1   ;  US20200323975-A1   ;  US20160083435-A9   ;  US6451769-B1   PASTEUR MERIEUX SERUMS & VACCINS SA (INMR);  VICAL INC (VICA-Non-standard);  UNIV TEXAS SYSTEM (TEXA)   HUEBNER R C,  NORMAN J A,  LIANG X,  CARNER K R,  BARBOUR A G,  LUKE C J;  US8414901-B2   SCHERING-PLOUGH LTD (SCHE)   CALLISTER S M,  LAFLEUR R,  WASMOEN T L;  US9238065-B2   WYETH (AMHP)   CHU H,  LI W,  XU Z;  US9562079-B2   ZOETIS LLC (ZOET)   LOHSE R M,  MEEUS P F M,  MILLERSHIP J J,  XU Z;  US10983121-B2   QIAGEN SCI LLC (QIAG);  BIOPEPTIDES CORP (BIOP-Non-standard);  GUNDERSEN LUTHERAN MEDICAL FOUND INC (GUND-Non-standard)   CALLISTER S M,  BOYLE J,  MIYAMASU M,  DATTWYLER R J,  ARNABOLDI P M;  CN104379164-A   ZOETIS LLC (ZOET)   LOHSE R M,  MEEUS P F M,  MILLERSHIP J J,  XU Z;  EP1939294-A1   BROOKHAVEN SCI ASSOC LLC (BRKH);  UNIV NEW YORK STATE RES FOUND (UNYS)   LUFT B J,  DUNN J J;  JP2015514776-A   ;  US6210676-B1   GUNDERSEN LUTHERAN MEDICAL FOUND INC (GUND-Non-standard)   CALLISTER S N,  LOVRICH S D,  SCHELL R F,  JOBE D A;  US6316005-B1   SOLVAY ANIMAL HEALTH INC (SOLV)   KORSHUS J B,  RUNNELS P L,  SHARPEE R L,  SCHELL R F,  CALLISTER S M;  US6464985-B1   GUNDERSEN LUTHERAN MEDICAL FOUND INC (GUND-Non-standard)   CALLISTER S N,  LOVRICH S D,  SCHELL R F,  JOBE D A;  US6872550-B1   IMMUNO AG (IMMO)   LIVEY I,  CROWE B,  DORNER F;  US8137678-B2   SCHERING-PLOUGH LTD (SCHE)   CALLISTER S M,  LAFLEUR R,  WASMOEN T L;  US8460913-B2   ALPHAVAX INC (ALPH-Non-standard)   KAMRUD K I,  SMITH J F,  MAUGHAN M;  US9441247-B2   ALPHAVAX INC (ALPH-Non-standard)   RAYNER J O,  SMITH J F,  HUBBY B,  REAP E A;  WO2005007689-A1   ALPHAVAX INC (ALPH-Non-standard)   CHULAY J D,  DRYGA S,  REAP E A,  OLMSTED R A,  MORRIS J S;  WO2007047749-A1   NOVARTIS VACCINES & DIAGNOSTICS INC (NOVS)   VAJDY M;  WO2013006834-A1   NOVARTIS AG (NOVS)   BRITO L,  CHAN M,  GEALL A,  OHAGAN D,  SINGH M,  O'HAGAN D;  WO2013116770-A1   SANOFI PASTEUR BIOLOGICS LLC (SNFI)   PUGACHEV K V;  WO2014005958-A1   NOVARTIS AG (NOVS)   BANNERJEE K,  BARNETT S,  OTTEN G,  GEALL A;  WO2013158818-A2   ZOETIS LLC (ZOET)   LOHSE R M,  MEEUS P F M,  MILLERSHIP J J,  XU Z	WO2019110486-A1  GIPSON C L ET AL:          "Evaluation of Venezuelan Equine Encephalitis (VEE)          replicon-based Outer surface protein A (OspA) vaccines in          a tick challenge mouse model of Lyme disease", VAC,          ELSEVIER, AMSTERDAM, NL, vol. 21, no. 25-26, 8 September          2003 (2003-09-08), pages 3875 - 3884, XP004446163, ISSN:          0264-410X, DOI:          10.1016/S0264-410X(03)00307-4,relevantClaims[1-21],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;3883&lt;/pp&gt;&lt;column&gt;1&lt;/column&gt;&lt;coll&gt;2&lt;/coll&gt;&lt;figure&gt;1,4&lt;/figure&gt;page          3876, column 2, item 2.3];  DUSTIN BRISSON ET          AL: "Biodiversity of Borrelia burgdorferi Strains in          Tissues of Lyme Disease Patients", PLOS ONE, 1 January          2011 (2011-01-01), United States, pages e22926,          XP055555910, Retrieved from the Internet          &lt;URL:https://www.zoetisus.com/products/dogs/vanguard-crlyme/resources/vanguard-crlyme-tech-bulletin.pdf&gt;          DOI:          10.1371/journal.pone.0022926,relevantClaims[1-21],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  R. L. LAFLEUR ET          AL: "Bacterin That Induces Anti-OspA and Anti-OspC          Borreliacidal Antibodies Provides a High Level of          Protection against Canine Lyme Disease", CLINICAL AND          VACCINE IMMUNOLOGY, vol. 16, no. 2, 1 February 2009          (2009-02-01), pages 253 - 259, XP055177097, ISSN:          1556-6811, DOI:          10.1128/CVI.00373-08,relevantClaims[1-21],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;256&lt;/pp&gt;&lt;column&gt;2&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;&lt;ppl&gt;258&lt;/ppl&gt;&lt;coll&gt;1&lt;/coll&gt;];            BARANTON ET AL., INT. J. SYS. BACTERIOL., vol. 42, 1992,          pages 378 - 383;            HOVIUS ET AL., J. CLIN. MICROBIOL., vol. 38, 2000, pages          2611 - 2621;            JACOBSON ET AL., SEMIN. VET. MED. SURG., vol. 11, 1996,          pages 172 - 182;            SUMMERS ET AL., J. COMP. PATH., vol. 133, 2005, pages 1 -          13;            HANINKOVA ET AL., EMERG. INFECT. DIS., vol. 12, 2006,          pages 604 - 610;            DAMBACH ET AL., VET PATHOL, vol. 34, 1997, pages 85 -          96;            LITTMAN ET AL., J VET INTERN MED., vol. 20, 2006, pages          422 - 434;            SCHWAN, BIOCHEM. SOC. TRANS., vol. 31, 2003, pages 108 -          112;            TOKARZ ET AL., INFECT. IMMUN., vol. 72, 2004, pages 5419          - 5432;            CAINE ET AL., INFECT IMMUN, vol. 83, 2015, pages 3184 -          3194;            CHU ET AL., JAVMA, vol. 201, 1992, pages 403 -          411;  MA          ET AL., VACCINE, vol. 14, 1996, pages 1366 -          1374;            WIKLE ET AL., INTERN. J. APPL. RES. VET. MED., vol. 4,          2006, pages 23 - 28;            STRAUBINGER ET AL., VACCINE, vol. 20, 2002, pages 181 -          193;            JOBE ET AL., J. CLIN. MICROBIOL., vol. 32, 1994, pages          618 - 622;            LOVRICH ET AL., INFECT. IMMUN., vol. 63, 1995, pages 2113          - 2119;            FIKRIG ET AL., INFECT. IMMUN., vol. 63, 1995, pages 1658          - 1662;            OHNISHI ET AL., PROC. NATL. ACAD. SCI., vol. 98, 2001,          pages 670 - 675;            ORNSTEIN ET AL., J. CLIN. MICROBIOL., vol. 39, 2001,          pages 1294 - 1298;            PAL ET AL., J CLIN INVEST, vol. 106, 2000, pages 561 -          569;            SCHWAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995,          pages 2909 - 2913;            ROUSSELLE ET AL., J. INFECT. DIS., vol. 178, 1998, pages          733 - 741;            IKUSHIMA ET AL., FEMS IMMUNOL. MED. MICROBIOL., vol. 29,          2000, pages 15 - 21;            ING-NANG ET AL., GENETICS, vol. 151, 1999, pages 15 -          30;            BUCKLES ET AL., CLIN. VACC. IMMUNOL., vol. 13, 2006,          pages 1162 - 1165;            JOBE ET AL., CLIN. DIAGN. LAB. IMMUNO., vol. 10, 2003,          pages 573 - 578;            LOVRICH ET AL., CLIN. DIAGN. LAB. IMMUNOL., vol. 12,          2005, pages 746 - 751;            LAFLEUR ET AL., CLIN VACCINE IMMUNOL, vol. 16, 2009,          pages 253 - 259;            LAFLEUR ET AL., CLIN VACC IMMUNOL, vol. 17, 2010, pages          870 - 874;            LAFLEUR ET AL., CLIN VACC IMMUNOL, vol. 22, 2015, pages          836 - 839;            EARNHARDT ET AL., CLIN VACCINE IMMUNOL, vol. 14, 2007,          pages 628 - 634;            RHODES ET AL., VET J, 2013, pages 198;            FROLOV ET AL., PNAS, vol. 93, 1996, pages 11371 -          11377;            VANDER VEEN ET AL., ANIM HEALTH RES REV., vol. 13, no. 1,          2012, pages 1 - 9;            KAMRUD ET AL., J GEN VIROL., vol. 91, 2010, pages 1723 -          1727;            PUSHKO ET AL., VIROLOGY, vol. 239, 1997, pages 389 -          401;            BREDENBEEK ET AL., JOURNAL OF VIROLOGY, vol. 67, 1993,          pages 6439 - 6446;            LILJESTROM; GAROFF, BIOTECHNOLOGY (NY, vol. 9, 1991,          pages 1356 - 1361;            PUSHKO ET AL., VIROLOGY, vol. 239, no. 2, 1997, pages 389          - 401;            GIPSON ET AL., VACCINE, vol. 21, no. 25-26, 2003, pages          3875 - 84;  G.          BARANTON ET AL., INTERNATIONAL J. OF SYSTEMATIC          BACTERIOLOGY, vol. 42, 1992, pages 378 - 383;            CALLISTER ET AL.: "Current Protocols in Cytometry", vol.          26, 2003, JOHN WILEY AND SONS, INC., article "Detection          of Borreliacidal Antibodies by Flow Cytometry";            CALLISTER ET AL., CLINICAL AND DIAGNOSTIC LABORATORY          IMMUNOLOGY, vol. 3, no. 4, 1996, pages 399 -          4021;            "American Type Culture Collection", 30 July 1999,          UNIVERSITY BOULEVARD MANASSAS;            BARBOUR ET AL., J. CLIN. MICROBIOL., vol. 52, 1985, pages          478 - 484;            LEE ET AL., VACCINE, vol. 24, no. 47-48, 2006, pages 6886          - 6892;            LILJESTROM; GAROFF, BIOTECHNOLOGY, vol. 9, 1991, pages          1356 - 1361;            CALLISTER ET AL., ARCH. INTERN. MED., vol. 154, 1994,          pages 1625 - 1632;            CALLISTER, ARCH. INTERN. MED., vol. 154, 1994, pages 1625          - 1632CN111432835-A  CLAY L. GIPSON:          "Evaluation of Venezuelan Equine Encephalitis (VEE)          replicon-based Outer surface protein A (OspA) vaccines in          a tick challenge mouse model of Lyme disease", VACCINE,          vol. 21, pages 3875, XP085648375, DOI:          10.1016/S0264-410X(03)00307-4,relevantClaims[1-15]US2020289634-A1            Ellis (Vaccines, W.B. Saunders Company, Chapter 29, 1988,          pages 568-574);            Boslego et al (Vaccines and Immunotherapy, 1991, Chapter          17);            Skolnick et al. (Trends in Biotechnology 18: 34-39,          2000)US11883476-B2            Ellis (Vaccines, W.B. Saunders Company, Chapter 29, 1988,          pp. 568-574).;            Boslego et al (Vaccines and Immunotherapy, 1991, Chapter          17).;            Skolnick et al. (Trends in Biotechnology 18: 34-39,          2000).;            Servin-Blanco (Human Vaccines and Immunotherapeutics vol.          12 No. 10, pp. 2640-2648).;            Baranton, Guy et al., Delineation of Borrelia burgdorferi          Sensu Stricto, &lt;xhtml:i &gt;Borrelia          garinii&lt;/xhtml:i&gt;sp. nov., and Group VS461          Associated with Lyme Borreliosis, International Journal          of Systematic Bacteriology, 1992, 378-383,          42(3).;            Barbour, Alan G. et al., Heterogeneity of Major Proteins          in Lyme Disease Borreliae: A Molecular Analysis of North          American and European Isolates, The Journal of Infectious          Diseases, 1985, 478-484, 152(3).;            Bredenbeek, Peter J. et al., Sindbis Virus Expression          Vectors: Packaging of RNA Replicons by Using Defective          Helper RNAs, Journal of Virology, 1993, 6439-6446,          67(11).;            Brisson, D et al., Biodiversity of Borrelia burgdorferi          Strains in Tissues of Lyme Disease Patients, PloS One,          2011, e22926, pp. 1-5, vol. 6, Issue 8.;            Buckles, Eric L. et al., Analysis of Antibody Response in          Humans to the Type A OspC Loop 5 Domain and Assessment of          the Potential Utility of the Loop 5 Epitope in Lyme          Disease Vaccine Development, Clinical and Vaccine          Immunology, 2006, 1162-1165, 13(10).;            Caine, Jennifer A. et al.., A Short-Term Borrelia          burgdorferi Infection Model Identifies Tissue Tropisms          and Bloodstream Survival Conferred by Adhesion Proteins,          Infection and Immunity, 2015, 3184-3194, 83(8).;            Callister, Steven M. et al., Detection of Borreliacidal          Antibodies by Flow Cytometry, Arch. Intern. Med., 1994,          1625-1632, 154.;            Callister, Steven M. et al., Sensitivity and Specificity          of the Borreliacidal-Antibody Test during Early Lyme          Disease: a Gold Standard?, Clinical and Diagnostic          Laboratory Immunology, 1996, 399-402, 3(4).;            Chu, Hsien-Jue et al., Immunogenicity and efficacy study          of a commercial Borrelia burgdorferi bacterin, JAVMA,          1992, 403-411, 201.;            Dambach, D.M. et al., Morphologic, Immunohistochemical,          and Ultrastructural Characterization of a Distinctive          Renal Lesion in Dogs Putatively Associated with Borrelia          burgdorf eri Infection: 49 Cases (1987-1992), Vet Pathol,          1997, 85-96, 34.;            Earnhart, Christopher G. et al., OspC Phylogenetic          Analyses Support the Feasibility of a Broadly Protective          Polyvalent Chimeric Lyme Disease Vaccine, Clinical and          Vaccine Immunology, 2007, 628-634, 14(5).;            Fikrig, Erol et al., Selection of Variant Borrelia          burgdorferi Isolates from Mice Immunized with Outer          Surface Protein A or B, Infection and Immunity, 1995,          1658-1662, 63(5).;            Frolov, Ilya et al., Alphavirus-based expression vectors:          Strategies and applications, Proc. Natl. Acad. Sci. USA,          1996, 11371-11377, 93.;            Gipson, CL et al., Evaluation of Venezuelan Equine          Encephalitis (VEE) replicon-based Outer surface protein A          (OspA) vaccines in a tick challenge mouse model of Lyme          disease, Vaccine, 2003, 3875-3884, vol. 21, No.          25-26.;            Hanincova, Klara et al., Epidemic Spread of Lyme          Borreliosis, Northeastern United States, Emerging          Infectious Diseases, 2006, 604-610, 12(4).;            Heikkilae, Tero et al., Recombinant BBK32 Protein in          Serodiagnosis of Early and Late Lyme Borreliosis, Journal          of Clinical Microbiology, 2002, 1174-1180,          40(4).;            Hovius, Joppe W.R. et al., Antibodies against Specific          Proteins of and Immobilizing Activity against Three          Strains of Borrelia burgdorferi Sensu Lato Can Be Found          in Symptomatic but Not in Infected Asymptomatic Dogs,          Journal of Clinical Microbiology, 2000, 2611-2621,          38(7).;            Ikushima, Masako et al., Specic immune response to a          synthetic peptide derived from outer surface protein C of          Borrelia burgdorferi predicts protective borreliacidal          antibodies, FEMS Immunology and Medical Microbiology,          2000, 15-21, 29.;            International Search Report of PCT/EP2018/083306, dated          Feb. 25, 2019, 17 pages.;            Jacobson, Richard H. et al., Lyme Disease: Laboratory          Diagnosis of Infected and Vaccinated Symptomatic Dogs,          Seminars in Veterinary Medicine and Surgery (Small          Animal), 1996, 172-182, 11(3).;            Jobe, Dean A. et al., Ability of Canine Lyme Disease          Vaccine to Protect Hamsters against Infection with          Several Isolates of Borrelia burgdorferi, Journal of          Clinical Microbiology, 1994, 618-622, 32(3).;            Jobe, Dean A. et al., C-Terminal Region of Outer Surface          Protein C Binds Borreliacidal Antibodies in Sera from          Patients with Lyme Disease, Clinical and Diagnostic          Laboratory Immunology, 2003, 573-578, 10(4).;            Kamrud, K.I. et al., Development and characterization of          promoterless helper RNAs for the production of alphavirus          replicon particle, Journal of General Virology, 2010,          1723-1727, 91(Pt 7).;            Lafleur, Rhonda L. et al., One-Year Duration of Immunity          Induced by Vaccination with a Canine Lyme Disease          Bacterin, Clinical and Vaccine Immunology, 2010, 870-874,          17(5).;            Lafleur, Rhonda L. et al., Vaccination with the ospA- and          ospB-Negative Borrelia burgdorferi Strain 50772 Provides          Significant Protection against Canine Lyme Disease,          Clinical and Vaccine Immunology, 2015, 836-839,          22(7).;            Lafleur, RL et al., Bacterin That Induces Anti-OspA and          Anti-OspC Borreliacidal Antibodies Provides a High Level          of Protection against Canine Lyme Disease, Clinical and          Vaccine Immunology, 2009, 253-259, vol. 16, No.          2.;            Lagal, Vanessa et al., Genetic Diversity among Borrelia          Strains Determined by Single-Strand Conformation          Polymorphism Analysis of the ospC Gene and its          Association with Invasiveness, Journal of Clinical          Microbiology, 2003, 5059-5065, 41(11).;            Lee, John S. et al., Multiagent vaccines vectored by          Venezuelan equine encephalitis virus replicon elicits          immune responses to Marburg virus and protection against          anthrax and botulinum neurotoxin in mice, Vaccine, 2006,          6886-6892, 24.;            Liljestrom, P. et al., A new generation of animal cell          expression vectors based on the semliki forest virus          replicon, Biotechnology, 1991, pp. 1356-1361,          9.;            Littman, Meryl P. et al., ACVIM Small Animal Consensus          Statement on Lyme Disease in Dogs: Diagnosis, Treatment,          and Prevention, J Vet Intern Med, 2006, 422-434,          20.;            Lovrich, S.D. et al., Abilities of OspA Proteins from          Different Seroprotective Groups of Borrelia burgdorferi          to Protect Hamsters from Infection, Infection and          Immunity, 1995, 2113-2119, 63(6).;            Lovrich, Steven D. et al., Borreliacidal OspC Antibodies          Specific for a Highly Conserved Epitope are          Immunodominant in Human Lyme Disease and Do Not Occur in          Mice or Hamsters, Clinical and Diaganostic Laboratory          Immunology, 2005, 746-751, 12(6).;            Ma, Jianneng et al., Safety, efficacy, and immunogenicity          of a recombinant Osp subunit canine Lyme disease vaccine,          Vaccine, 1996, 1366-1374, 14(14).;            Ohnishi, Jun et al., Antigenic and genetic heterogeneity          of Borrelia burgdorferi populations transmitted by ticks,          Proc. Natl. Acad. Sci. USA, 2001, 670-675,          98(2).;            Ornstein, Katharina et al., Characterization of Lyme          Borreliosis Isolates from Patients with Erythema Migrans          and Neuroborreliosis in Southern Sweden, Journal of          Clinical Microbiology, 2001, 1294-1298, 39(4).;            Pal, Utpal et al., Attachment of Borrelia burgdorferi          within Ixodes scapularis mediated by outer surface          protein A, Journal of Clinical Investigation, 2000,          561-569, 106.;            Pushko, Peter et al., Replicon-Helper Systems from          Attenuated Venezuelan Equine Encephalitis Virus:          Expression of Heterologous Genes in Vitro and          Immunization against Heterologous Pathogens in Vivo,          Virology, 1997, 389-401, 239.;            Rhodes, D.V.L. et al., Identification of Borrelia          burgdorferi ospC genotypes in canine tissue following          tick Infestation: Implications for Lyme disease vaccine          and diagnostic assay design, Vet. J., 2013, 1-15,          198(2).;            Rousselle, Jill C. et al., Borreliacidal Antibody          Production against Outer Surface Protein C of Borrelia          burgdorferi, J. Infect. Dis., 1998, 733-741,          178.;            Schwan, T.G., Temporal regulation of outer surface          proteins of the Lyme-disease spirochaete Borrelia          burgdorferi, Biochemical Society Transactions, 2003,          108-112, 31(1).;            Schwan, Tom G. et al., Induction of an outer surface          protein on Borrelia burgdorferi during tick feeding,          Proc. Natl. Acad. Sci. USA, 1995, 2909-2913,          92.;            Straubinger, Reinhard K. et al., Protection against          tick-transmitted Lyme disease in dogs vaccinated with a          multiantigenic vaccine, Vaccine, 2002, 181-193,          20.;            Summers, B. A. et al., Histopathological Studies of          Experimental Lyme Disease in the Dog, J. Comp. Path.,          2005, 1-13, 133.;            Tokarz, Rafal et al., Combined Effects of Blood and          Temperature Shift on Borrelia burgdorferi Gene Expression          as Determined by Whole Genome DNA Array, Infection and          Immunity, 2004, 5419-5432, 72(9).;            Vander Veen, RL et al., Alphavirus replicon vaccines,          Animal Health Research Reviews, 2012, 1-9, vol. 13, No.          1.;            Wang, Ing-Nang et al., Genetic Diversity of ospC in a          Local Population of Borrelia burgdorferi sensu stricto,          Genetics, 1999, 15-30, 151.;            Wikle, R.E.et al., Canine Lyme Disease: One-Year Duration          of Immunity Elicited With a Canine OspA Monovalent Lyme          Vaccine, Intern J Appl Res Vet Med, 2006, 23-28,          4(1).;            Day, M.J. et al., Guidelines for the Vaccination of Dogs          and Cats, Vaccination Guidelines Group (VGG) of the World          Small Animal Veterinary Association (WSAVA), 2016, 1-11,          57.;            Day, M.J. et al., Guidelines for the Vaccination of Dogs          and Cats, Vaccination Guidelines Group (VGG) of the World          Small Animal Veterinary Association (WSAVA), 2016, 1-14,          57, English translation.;            Probert, William Scott et al., Immunization with Outer          Surface Protein (Osp) A, but Not OspC, Provides          Cross-Protection of Mice Challenged with North American          Isolates of Borrelia burgdorferi, The Journal of          Infectious Diseases, 1997, 400-405, 175.;            Wallich, Reinhard et al., DNA Vaccines Expressing a          Fusion Product of Outer Surface Proteins A and C from          Borrelia burgdorferi Induce Protective Antibodies          Suitable for Prophylaxis but Not for Resolution of Lyme          Disease, Infection and Immunity, 2001, 2130-2136,          69(4).	105730-0-0-0 K M; 93605-0-0-0 K M; 200757-0-0-0 K P			RA012P K M; RA00NS K M; RA00GT K P		CN109206509-A;  CN109206509-B	New variable region sequence specifically binding            to pseudorabies virus gD protein useful for preventing            and/or treating disease associated with pseudorabies            virus infection	TIAN K;  WANG Y	LUOYANG PULAIKE WANTAI BIOLOGICAL TECHNOLOGY (LUOY-Non-standard);  LUOYANG PUTAI BIOTECHNOLOGY CO LTD (LUOY-Non-standard)	201908078Y	   NOVELTY - Variable region sequence specifically binding                to pseudorabies virus gD protein including variable                region sequence of murine monoclonal antibody 3B6                and heavy chain variable region amino acid sequence                including fully defined 119 amino acid sequence                (SEQ ID No: 2) or conservative variant obtained by                adding, deleting, replacing or modifying at least                one fully defined 107 amino acids (SEQ ID No: 4),                light chain variable region amino acid sequence                include or conservative variant obtained by adding,                deleting, replacing or modifying at least one amino                acids of (SEQ ID No: 4) and/or variable region                sequence of the murine monoclonal antibody 5G7,                where amino acid sequence of heavy chain variable                region is the amino acid sequence including fully                defined 119 amino acids (SEQ ID No: 6) or                conservative variant obtained by adding, deleting,                replacing or modifying at least one amino acids of                (SEQ ID No: 6). The light chain variable region                amino acid sequence including (SEQ ID No: 8), is                new.    USE - The medicinal composition is useful for                preventing and/or treating disease associated with                pseudorabies virus infection and ELISA detection                kit is useful for quantitatively detecting                expression level of pseudorabies virus gD protein                and antibody useful for detecting pseudorabies                virus for non-diagnostic purposes (all                claimed).    ADVANTAGE - The ELISA test kit containing antibody                overcomes technical problem that PRVgD protein                cannot be accurately quantified after serial                expression or fusion expression with other proteins                and expected expression effect cannot be verified                and key problem of formulating the vaccine is                solved and medicinal composition containing                antibody has a broad spectrum.    DETAILED DESCRIPTION - Variable region sequence specifically binding                to pseudorabies virus gD protein including variable                region sequence of murine monoclonal antibody 3B6                and heavy chain variable region amino acid sequence                including fully defined 119 amino acid sequence                (SEQ ID No: 2) or conservative variant obtained by                adding, deleting, replacing or modifying at least                one fully defined 107 amino acids (SEQ ID No: 4),                light chain variable region amino acid sequence                include (SEQ ID No: 4) or conservative variant                obtained by adding, deleting, replacing or                modifying at least one amino acids of (SEQ ID No:                4) and/or variable region sequence of the murine                monoclonal antibody 5G7, where amino acid sequence                of heavy chain variable region is the amino acid                sequence including fully defined 119 amino acids                (SEQ ID No: 6) or conservative variant obtained by                adding, deleting, replacing or modifying at least                one amino acids of (SEQ ID No: 6). The light chain                variable region amino acid sequence including fully                defined 107 amino acids (SEQ ID No: 8) or                conservative variant obtained by adding, deleting,                replacing or modifying at least one of amino acid                of (SEQ ID No: 8), is new. INDEPENDENT CLAIMS are                also included for: (I) antibody that binds to                pseudorabies virus gD protein, comprising heavy                chain variable region amino acid sequence of murine                monoclonal antibody 3B6 and/or light chain variable                region amino acid sequence, preferably, antibody is                a monoclonal antibody and/or a genetically                engineered antibody. The genetically engineered                antibody is at least one of single chain antibody,                single chain antibody fragment, chimeric monoclonal                antibody, chimeric monoclonal antibody fragment,                modified monoclonal antibody, modified monoclonal                antibody fragment, pig monoclonal antibody or pig                monoclonal antibody fragment, further preferably,                antibody is murine monoclonal antibody 3B6; (II)                medicinal composition, comprising immunological                amount of antibody and medicinally acceptable                carrier. The antibody is at least one of                antibodies, one of single chain antibody prepared                from the heavy chain variable region amino acid                sequence of the murine monoclonal antibody 5G7 and                light chain variable region amino acid sequence of                the murine monoclonal antibody 3B6, preferably,                antibody is at least one of single chain antibody                prepared from the heavy chain variable region amino                acid sequence of the murine monoclonal antibody 5G7                and light chain variable region amino acid sequence                of the murine monoclonal antibody 3B6, preferably,                antibody is a murine monoclonal antibody 5G7 and/or                single-chain antibody prepared from the heavy chain                variable region amino acid sequence and light chain                variable region amino acid sequence of the murine                monoclonal antibody 5G7, more preferably,                composition further comprises other pathogen                antigens, including pathogen antigens that infect                pigs or pathogen antigens that infect dogs, where,                pathogen antigen of infected pig includes swine                fever virus antigen, porcine circovirus antigen,                Haemophilus parasuis antigen, Streptococcus suis                antigen, swine influenza virus antigen, porcine                contagious pleuropneumoniae antigen, porcine                contagious pleuropneumoniae antigen, porcine                antigen, porcine reproductive and respiratory                syndrome virus antigen, Salmonella choleraesuis                antigen, porcine parvovirus antigen and/or porcine                Japanese encephalitis virus antigen, pathogen                antigen of infected dog is at least one of canine                parvovirus antigen, canine distemper virus antigen,                canine adenovirus type I antigen, canine adenovirus                type II antigen, canine leptospira antigen, canine                coronavirus antigen, canine parainfluenza virus                antigen , rabies virus antigen, canine influenza                virus antigen, canine reovirus antigen, canine                rotavirus antigen, canine herpes virus antigen,                canine viral papillomavirus antigen, canine                parvovirus antigen, canine mumps virus antigen,                canine lymphocytic choriomeningitis virus antigen,                meningitis dog lymphocytic choriomeningitis virus                antigen and Bordetella bronchiseptica antigen,                preferably, pathogen antigen of infected dog is                canine parvovirus antigen, canine distemper virus                antigen, canine coronavirus antigen, canine                parainfluenza virus antigen, canine adenovirus type                I antigen, canine adenovirus type II antigen,                Leptospira antigen, rabies virus antigen and/or                canine influenza virus antigen; (III) use of                medicinal composition for preventing and/or                treating disease associated with pseudorabies virus                infection, comprising pseudorabies virus                infection-related diseases include pseudorabies                caused by classical strain of pseudorabies virus                and pseudorabies caused by pseudorabies virus                variant strain, preferably, pseudorabies includes                pig pseudorabies and canine pseudorabies; (IV)                ELISA detection kit, comprising antibody, detecting                reagent and pseudorabies virus gD protein standard                substance, preferably antibody comprises mouse                monoclonal antibody 3B6 and murine monoclonal                antibody 5G7. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  S03 (Scientific Instrumentation)	B04-B04C1;  B04-C01G;  B04-E99;  B04-G08;  B04-G0800E;  B04-G21;  B04-G2100E;  B04-G23;  B04-G2300E;  B04-N03K0E;  B04-N08;  B11-C07A4;  B11-C07A5;  B12-K04G1B;  B14-A02A3;  B14-S12;  C04-B04C1;  C04-C01G;  C04-E99;  C04-G08;  C04-G0800E;  C04-G21;  C04-G2100E;  C04-G23;  C04-G2300E;  C04-N03K0E;  C04-N08;  C11-C07A4;  C11-C07A5;  C12-K04G1B;  C14-A02A3;  C14-S12;  D05-A01A4;  D05-A01B;  D05-H06A;  D05-H11A;  D05-H99;  J04-B01;  J04-B03;  S03-E09F;  S03-E14H5	A61K-039/42;  A61P-031/22;  C07K-016/08;  G01N-033/535;  G01N-033/569;  G01N-033/577;  G01N-033/68	CN109206509-A   15 Jan 2019   C07K-016/08   201928   Chinese;  CN109206509-B   20 Jul 2021   C07K-016/08   202162   Chinese	CN109206509-A    CN10514485    29 Jun 2017;   CN109206509-B    CN10514485    29 Jun 2017	CN109206509-B Previous Publ. Patent CN109206509	CN10514485    29 Jun 2017			CN109206509-A -- CN102747044-A   ZHENGZHOU HOUYI PHARM CO LTD (ZHEN-Non-standard)   SUN F,  WANG W,  WU H,  HASITONGLAGA;  CN104459121-A   LUOYANG PULAIKE WANTAI BIOLOGICAL TECHNOLOGY                  CO LTD (LUOY-Non-standard)   TIAN K,  WANG Y;  CN104561374-A   ANIMAL DISEASE CONTROL & PREVENTION (ANIM-Non-standard)   CAO W,  FANG X,  JIN D,  LIU M,  LIU X,  WANG S,  WANG Y,  WU Z,  YAN R,  ZHANG P,  ZHAO S,  ZHAO X,  SONG H,  YAN Z,  YU Z;  CN106366188-A   GUANGDONG HAIDA ANIMAL HUSBANDRY &                  VETER (GUAN-Non-standard)   JIA A,  WANG G,  LIU Q,  ZHOU R,  GAN Z;  DE102013111487-A1   THALLER A (THAL-Individual)   THALLER A;  EP2657333-A1   KUO T (KUOT-Individual);  CHEN H C G (CHEN-Individual);  WU C (WUCC-Individual);  CHEN H (CHEN-Individual)   KUO T,  CHEN H C G,  WU C,  CHEN H;  CN109206509-B -- CN102747044-A   ZHENGZHOU HOUYI PHARM CO LTD (ZHEN-Non-standard)   SUN F,  WANG W,  WU H,  HASITONGLAGA;  CN104459121-A   LUOYANG PULAIKE WANTAI BIOLOGICAL TECHNOLOGY                  CO LTD (LUOY-Non-standard)   TIAN K,  WANG Y;  CN104561374-A   ANIMAL DISEASE CONTROL & PREVENTION (ANIM-Non-standard)   CAO W,  FANG X,  JIN D,  LIU M,  LIU X,  WANG S,  WANG Y,  WU Z,  YAN R,  ZHANG P,  ZHAO S,  ZHAO X,  SONG H,  YAN Z,  YU Z;  CN106366188-A   GUANGDONG HAIDA ANIMAL HUSBANDRY &                  VETER (GUAN-Non-standard)   JIA A,  WANG G,  LIU Q,  ZHOU R,  GAN Z;  DE102013111487-A1   THALLER A (THAL-Individual)   THALLER A;  EP2657333-A1   KUO T (KUOT-Individual);  CHEN H C G (CHEN-Individual);  WU C (WUCC-Individual);  CHEN H (CHEN-Individual)   KUO T,  CHEN H C G,  WU C,  CHEN H	CN109206509-A  : "gDgE",          ,relevantClaims[1-10],relevantPassages[D050-146]CN109206509-B            Guo Li-jing. prokaryotic expression of porcine          pseudorabies virus gD and gE gene and development of          monoclonal antibody; Guo Li-jing, "China's outstanding          master's degree thesis database agricultural science and          technology"; D050-146;						WO2019092153-A1;  CN111511924-A;  EP3707271-A1;  IN202017017705-A;  SG11202003247-A1;  JP2021502079-W;  US2022144877-A1;  RU2020117848-A;  IL274442-A;  US11692002-B2;  US2024150386-A1	Modifying retention time of RNA on chromatographic            column, where RNA used in vaccine, composition, and            kit, involves adapting the RNA sequence by altering            number of adenine and/or uracil nucleotides in original            RNA sequence	HEINZ S;  ROOS T;  VAHRENHORST D;  CONZELMANN M;  ROS T;  FARENHORST D;  CONCELMAN M	CUREVAC AG (CUEV-C);  CUREVAC GMBH (CUEV-C);  CUREVAC AG (CUEV-C);  CUREVAC AG (CUEV-C);  CUREVAC AG (CUEV-C);  CUREVAC SE (CUEV-C)	201943568H	   NOVELTY - Modifying retention time of RNA on                chromatographic column involves adapting the RNA                sequence by altering the number of adenine (A)                and/or uracil (U) nucleotides in the RNA sequence                with respect to the number of A and/or U                nucleotides in the original RNA sequence.    USE - Method for modifying retention time of RNA on                chromatographic column, where RNA used in vaccine,                composition, and kit.    ADVANTAGE - The method enables to modify retention time of                RNA on chromatographic columnprovides major                importance to public health, and allow fast                exchange of (one or multiple) antigens (such as for                seasonal adaptations of the vaccine, pandemic                scenario) without changing the conditions for key                processes of production (such as purification,                analysis etc.) by multivalent/polyvalent influenza                RNA vaccine.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) Method for purifying RNA species from a                mixture of two RNA species, involves adapting the                sequence of the one RNA species by altering the                number of A and/or U nucleotides with respect to                the number of A and/or U nucleotides in the                original sequence; performing chromatography where                the adapted RNA species is separated from one other                RNA species;    (2) Method for co-purifying two RNA species                from a mixture comprising two RNA species, involves                adapting the sequence of one RNA species by                altering the number of A and/or U nucleotides in                the RNA sequence with respect to the number of A                and/or U nucleotides in the original RNA sequence;                and performing chromatography, where one RNA                species having an adapted sequence and one further                RNA species are co-purified;    (3) method for harmonizing the numbers of A                and/or U nucleotides in the sequences of two RNA                species, the method comprising adapting the                sequence of one RNA species by altering the number                of A and/or U nucleotides in the RNA sequence with                respect to the number of A and/or U nucleotides in                the original RNA sequence;    (4) method for synthesizing a mixture                comprising two harmonized RNA species, involves                harmonizing the numbers of A and/or U nucleotides                in the sequences of two RNA species, where the                sequence of one RNA species is adapted by altering                the number of A and/or U nucleotides in the RNA                sequence with respect to the number of A and/or U                nucleotides in the original RNA sequence; and                synthesizing the two harmonized RNA species;    (5) Vector comprising a nucleic acid sequence                corresponding to the RNA or encoding the RNA                according;    (6) composition comprising two RNA species,                where the sequence of one RNA species is adapted by                altering the number of A and/or U nucleotides in                the sequence of the one RNA species with respect to                the number of A and/or U nucleotides in the                original RNA sequence;    (7) Vaccine comprises the RNA or the                composition;    (8) Kit comprises the RNA, composition, or the                vaccine, optionally a liquid vehicle for                solubilising, and optionally technical instructions                providing information on administration and dosage                of the components; and    (9) Method for providing an adapted RNA,                involves determining the total number of                nucleotides in an original RNA sequence;                determining the number of A and/or U nucleotides in                the original RNA sequence; determining the codons                in the original RNA sequence that can be replaced                with one alternative codon without changing the                encoded amino acid sequence; and adjusting the                number of A and/or U nucleotides in the RNA                sequence to a pre-set number of A and/or U                nucleotides by replacing one original codon with an                alternative codon, where the alternative codon                encodes the same amino acid as the original codon                and is further characterized in a higher content of                A and/or U nucleotides; and optionally, producing                the RNA, preferably via in vitro                transcription. 			A96 (Medical, dental, veterinary, cosmetic.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	A04-C02E;  A12-L04A;  A12-V00V;  A12-V01;  A12-W11L;  B04-E01B;  B04-E08;  B04-E99;  B11-B03A;  B14-S11D3;  D05-C07;  D05-H12E;  D05-H13;  D05-H99	A61K-031/7105;  C12N-015/10;  C12P-019/34;  A61K-035/76;  A61K-038/02;  A61K-039/00;  A61K-039/145;  A61K-039/295;  A61K-039/39;  A61K-047/56;  A61K-047/61;  A61K-047/62;  A61K-048/00;  A61K-009/08;  A61K-009/127;  A61K-009/14;  A61P-031/12;  A61P-031/16;  C12N-015/11;  C12N-015/44;  C12N-015/63;  A61K-031/713;  C07H-001/06;  A61K-031/7088;  C12Q-001/68	WO2019092153-A1   16 May 2019   C12P-019/34   201942Pages: 122   English;  CN111511924-A   07 Aug 2020   C12P-019/34   202066   Chinese;  EP3707271-A1   16 Sep 2020   C12P-019/34   202076   English;  IN202017017705-A   04 Sep 2020   C12P-019/34   202076   English;  SG11202003247-A1   28 May 2020   C12P-019/34   202081   English;  JP2021502079-W   28 Jan 2021   C12N-015/10   202110Pages: 107   Japanese;  US2022144877-A1   12 May 2022   C07H-001/06   202241   English;  RU2020117848-A   08 Dec 2021   C12P-019/34   202262   Russian;  IL274442-A   30 Jun 2020   A61K-031/7088   202335   English;  US11692002-B2   04 Jul 2023   C07H-001/06   202355   English;  US2024150386-A1   09 May 2024   C07H-001/06   202440   English	WO2019092153-A1    WOEP080692    08 Nov 2018;   CN111511924-A    CN80072222    08 Nov 2018;   EP3707271-A1    EP796481    08 Nov 2018;   IN202017017705-A    IN17017705    24 Apr 2020;   SG11202003247-A1    SG11003247    08 Nov 2018;   JP2021502079-W    JP524754    08 Nov 2018;   US2022144877-A1    US16762081    06 May 2020;   RU2020117848-A    RU117848    08 Nov 2018;   IL274442-A    IL274442    08 Nov 2018;   US11692002-B2    US16762081    06 May 2020;   US2024150386-A1    US320598    19 May 2023	CN111511924-A PCT application Application WOEP080692;   CN111511924-A Based on Patent WO2019092153;   EP3707271-A1 PCT application Application WOEP080692;   EP3707271-A1 Based on Patent WO2019092153;   IN202017017705-A PCT application Application WOEP080692;   IN202017017705-A Based on Patent WO2019092153;   SG11202003247-A1 PCT application Application WOEP080692;   SG11202003247-A1 Based on Patent WO2019092153;   JP2021502079-W PCT application Application WOEP080692;   JP2021502079-W Based on Patent WO2019092153;   US2022144877-A1 PCT application Application WOEP080692;   RU2020117848-A PCT application Application WOEP080692;   RU2020117848-A Based on Patent WO2019092153;   IL274442-A Based on Patent WO2019092153;   US11692002-B2 PCT application Application WOEP080692;   US11692002-B2 Previous Publ. Patent US2022144877;   US11692002-B2 Based on Patent WO2019092153;   US2024150386-A1 Cont of Application WOEP080692;   US2024150386-A1 Cont of Application US762081;   US2024150386-A1 Cont of Patent US11692002	WOEP078647    08 Nov 2017;  CN80072222    07 May 2020;  RU117848    08 Jun 2020	WO2019092153-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP3707271-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                  		WO2019092153-A1 -- CN106442827-A   UNIV BEIJING TECHNOLOGY (UYBT)   HAN Z,  LU L,  WANG X;  US20020153312-A1   ;  US20100048883-A1   ;  US20160235864-A1   ;  WO2016193206-A1   CUREVAC AG (CUEV)   FUNKNER A,  DORNER S,  SEWING S,  KAMM J,  BROGHAMMER N,  KETTERER T,  MUTZKE T;  US20100324120-A1   ;  US20110256175-A1   ;  US20120027803-A1   ;  US20120128760-A1   ;  US8158601-B2   ALNYLAM PHARM INC (ALNY);  AKINC A (AKIN-Individual);  DORKIN J R (DORK-Individual);  QIN X (QINX-Individual);  CANTLEY W (CANT-Individual);  MANOHARAN M (MANO-Individual);  RAJEEV K G (RAJE-Individual);  NARAYANANNAIR J K (NARA-Individual);  JAYARAMAN M (JAYA-Individual)   CHEN J,  ANSELL S,  AKINC A,  DORKIN J R,  QIN X,  CANTLEY W,  MANOHARAN M,  RAJEEV K G,  NARAYANANNAIR J K,  JAYARAMAN M;  WO2008077592-A1   CUREVAC GMBH (CUEV)   KETTERER T,  REIDEL L,  MUTZKE T,  VON DER MUELBE F;  WO2009030481-A1   CUREVAC GMBH (CUEV)   BAUMHOF P,  FOTIN-MLECZEK M;  WO2009086558-A1   TEKMIRA PHARM CORP (TEKM-Non-standard);  UNIV BRITISH COLUMBIA (UYBR);  ALNYLAM PHARM INC (ALNY)   CHEN J,  CIUFOLINI M A,  CULLIS P R,  HOPE M J,  KALLANTHOTTATHIL R G,  MADDEN T D,  MANOHARAN M,  MUI B,  SEMPLE S C,  WONG K F;  WO2009127060-A1   PROTIVA BIOTHERAPEUTICS INC (PRTO)   LAM K,  MACLACHLAN I,  YAWORSKI E;  WO2009144230-A1   UNIV ZUERICH (UYZU)   KNUTH A,  PASCOLO S;  WO2010037539-A1   CUREVAC GMBH (CUEV)   FOTIN-MLECZEK M,  VOSS S;  WO2010054406-A1   ALNYLAM PHARM INC (ALNY)   MANOHARAN M,  RAJEEV K G,  BUTLER D,  NARAYANANNAIR J K,  JAYARAMAN M,  ELTEPU L;  WO2010129709-A1   ALNYLAM PHARM INC (ALNY);  MANOHARAN M (MANO-Individual);  RAJEEV K G (RAJE-Individual);  JAYARAMAN M (JAYA-Individual);  BUTLER D (BUTL-Individual);  JUNG M E (JUNG-Individual)   MANOHARAN M,  RAJEEV K G,  JAYARAMAN M,  BUTLER D,  JUNG M E;  WO2011015347-A1   BIONTECH AG (BNTC);  UNIV MAINZ GUTENBERG JOHANNES (UMGJ);  UNIV WARSZAWSKI (UWAR)   SAHIN U,  KUHN A,  DARZYNKIEWICZ E,  JEMIELITY J,  KOWALSKA J;  WO2011026641-A1   CUREVAC GMBH (CUEV)   BAUMHOF P,  SCHLAKE T;  WO2011069586-A1   CUREVAC GMBH (CUEV)   MUTZKE T;  WO2012013326-A1   CUREVAC GMBH (CUEV)   BAUMHOF P,  VOSS S,  KRAMPS T,  KALLEN K;  WO2012019780-A1   CUREVAC GMBH (CUEV)   THESS A,  SCHLAKE T,  PROBST J;  WO2012113513-A1   CUREVAC GMBH (CUEV)   BAUMHOF P,  KALLEN K,  FOTIN-MLECZEK M;  WO2013059475-A1   LIFE TECHNOLOGIES CORP (LITC)   KORE A,  MUTHIAN S,  GEE K;  WO2015024667-A1   CUREVAC GMBH (CUEV)   BAUMHOF P;  WO2015062738-A1   CUREVAC GMBH (CUEV)   SCHLAKE T,  THESS A;  WO2015101415-A1   CUREVAC GMBH (CUEV)   GRUND S,  SCHLAKE T;  WO2015188933-A1   CUREVAC AG (CUEV)   WOCHNER A,  ROOS T,  KETTERER T;  WO2016091391-A1   CUREVAC AG (CUEV)   THESS A,  SCHLAKE T,  GRUND S;  WO2016107877-A1   CUREVAC AG (CUEV)   GRUND S,  SCHLAKE T;  WO2016165825-A1   CUREVAC AG (CUEV)   MUTZKE T,  KREUZ M,  SEWING S,  EBER F J,  WAGNER W,  SONNTAG M,  WIGGENHORN M,  KOLLAND K;  WO2016165831-A1   CUREVAC AG (CUEV)   KETTERER T,  MUTZKE T,  WIGGENHORN M,  SCHAUBHUT F,  VON DER MULBE F;  WO2016174271-A1   CUREVAC AG (CUEV)   ROOS T,  YAZDAN PANAH B,  CONZELMANN M,  WAGNER V;  WO2016180430-A1   CUREVAC AG (CUEV)   VON DER MUELBE F,  REIDEL L,  KETTERER T;  WO2016184575-A1   CUREVAC AG (CUEV)   EBER F J,  YAZDAN PANAH B,  SEWIG S,  KETTERER T,  MUTZKE T,  ROOS T,  SONNTAG M,  WIGGENHORN M,  KOLLAND K;  WO2016193226-A1   CUREVAC AG (CUEV)   ROOS T,  YAZDAN PANAH B,  CONZELMANN M,  THESS A,  BUOB D,  KUNZE M,  WAGNER V;  WO2016203025-A1   CUREVAC AG (CUEV)   HIPP M,  HEIDENREICH R,  FOTIN-MLECZEK M,  BAUMHOF P,  LUTZ J,  KOWALCZYK A;  WO2017036580-A1   CUREVAC AG (CUEV)   SCHLAKE T,  GRUND S;  WO2017066781-A1   MODERNATX INC (MODR)   BUTORA G,  STANTON M,  STEELE T;  WO2017066782-A1   MODERNATX INC (MODR)   BUTORA G,  STANTON M,  MIRACCO E J;  WO2017066789-A1   MODERNATX INC (MODR)   BUTORA G,  STANTON M,  STEELE T;  WO2017066791-A1   MODERNATX INC (MODR)   BUTORA G,  STANTON M,  STEELE T;  WO2017066793-A1   MODERNATX INC (MODR)   BUTORA G,  STANTON M,  STEELE T;  WO2017066797-A1   MODERNATX INC (MODR)   BUTORA G,  STANTON M,  MIRACCO E J;  WO2017109134-A1   CUREVAC AG (CUEV)   ROOS T,  KUNZE M,  YAZDAN PANAH B,  YILMAZ S,  CONZELMANN M;  WO2017109161-A1   CUREVAC AG (CUEV)   YAZDAN PANAH B,  WOCHNER A,  ROOS T,  FUNKNER A,  KUNZE M;  WO2017191258-A1   CUREVAC AG (CUEV)   JASNY E,  RAUCH S,  SCHMIDT K E,  PETSCH B,  SLOBOD K;  WO2017191264-A1   CUREVAC AG (CUEV)   RAUCH S,  SCHMIDT K E,  PETSCH B;  WO2017212006-A1   CUREVAC AG (CUEV)   BAUMHOF P,  THIELE C;  WO2017212007-A1   CUREVAC AG (CUEV)   BAUMHOF P,  THIELE C;  WO2017212009-A1   CUREVAC AG (CUEV)   BAUMHOF P,  THIELE C;  WO2018078053-A1   CUREVAC AG (CUEV);  ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   BAUMHOF P,  FOTIN-MLECZEK M,  HEIDENREICH R,  HOPE M J,  JASNY E,  LAZZARO S,  LIN P J C,  LUTZ J,  MUI B,  PETSCH B,  RAUCH S,  SCHMIDT K E,  TAM Y;  WO2018172556-A1   CUREVAC AG (CUEV)   CHEVESSIER-TUENNESEN F,  POENISCH M,  SCHLAKE T;  WO2002098443-A2   ;  WO2008014979-A2   CUREVAC GMBH (CUEV)   HOERR I,  PROBST J,  KETTERER T,  SCHEEEL B;  WO2008016473-A2   APPLERA CORP (APLR)   KORE A R,  SHANMUGASUNDARAM M;  WO2008157688-A2   UNIV LOUISIANA STATE & AGRIC & MECH                  COLL (LOUU)   JEMIELITY J,  GRUDZIEN-NOGALSKA E M,  KOWALSKA J,  DARZYNKIEWICZ E,  RHOADS R E;  WO2009095226-A2   CUREVAC GMBH (CUEV)   HOERR I,  KRAMPS T,  PROBST J,  VOSS S;  WO2009149253-A2   UNIV WARSZAWSKI (UWAR);  UNIV LOUISIANA STATE & AGRIC & MECH                  COLL (LOUU)   DARZYNKIEWICZ E,  JEMIELITY J,  KOWALSKA J,  LUKASZEWICZ M,  RHOADS R E,  ZUBEREK J;  WO2010048536-A2   ALNYLAM PHARM INC (ALNY)   MANOHARAN M,  RAJEEV K G,  JAYARAMAN M;  WO2010088537-A2   ALNYLAM PHARM INC (ALNY)   AKINC A,  QUERBES W,  WONG F,  DORKIN J R,  QIN X,  CANTLEY W,  BORODOVSKY A,  DE S,  MANOHARAN M,  JAYARAMAN M,  RAJEEV K G;  WO2011153493-A2   ALNYLAM PHARM INC (ALNY)   MANOHARAN M,  MAIER M,  JAYARAMAN M,  MATSUDA S,  JAYAPRAKASH N K,  RAJEEV K G;  WO2013143700-A2   CUREVAC GMBH (CUEV)   THESS A;  WO2015101414-A2   CUREVAC GMBH (CUEV)   THESS A;  WO2016184576-A2   CUREVAC AG (CUEV)   EBER F J,  YAZDAN PANAH B,  SEWIG S,  KETTERER T,  MUTZKE T,  ROOS T,  SONNTAG M,  WIGGENHORN M,  KOLLAND K;  US11692002-B2 -- CN106442827-B   UNIV BEIJING TECHNOLOGY (UYBT)   HAN Z,  LU L,  WANG X;  RU2595374-C2   RUSSIAN FEDERATION MIN DEFENCE EDUCATION (RUDE);  MOLECULAR BIOLOGY INST (MOLE-Non-standard)   GRYADUNOV D A,  MIKHAYLOVICH V M,  ZASEDATELEV A S,  KHODAKOV D A,  MAMAEV D D,  DEMENTYEVA E I;  US20020153312-A1   ;  US20050032730-A1   ;  US20050059624-A1   ;  US20050250723-A1   ;  US20060188490-A1   ;  US20080025944-A1   ;  US20080267873-A1   ;  US20090324584-A1   ;  US20100048883-A1   ;  US20100189729-A1   ;  US20100203076-A1   ;  US20100291156-A1   ;  US20100305196-A1   ;  US20110053829-A1   ;  US20110054005-A1   ;  US20110250225-A1   ;  US20120021043-A1   ;  US20120258046-A1   ;  US20130129754-A1   ;  US20130142818-A1   ;  US20130259879-A1   ;  US20130280283-A1   ;  US20130295043-A1   ;  US20130336998-A1   ;  US20150037326-A1   ;  US20150050302-A1   ;  US20150057340-A1   ;  US20150093413-A1   ;  US20150118183-A1   ;  US20150118264-A1   ;  US20150165006-A1   ;  US20150184195-A1   ;  US20150218554-A1   ;  US20150306249-A1   ;  US20150320847-A1   ;  US20160130345-A1   ;  US20160166668-A1   ;  US20160166678-A1   ;  US20160166710-A1   ;  US20160166711-A1   ;  US20160168207-A1   ;  US20160168227-A1   ;  US20160235864-A1   ;  US20160304883-A1   ;  US20160304938-A1   ;  US20160326575-A1   ;  US20160331844-A1   ;  US20170014496-A1   ;  US20170029847-A1   ;  US20170114378-A1   ;  US20170252430-A1   ;  US20170326225-A1   ;  US20180044687-A1   ;  US20180125952-A1   ;  US20180126003-A1   ;  US20180142275-A1   ;  US20180147146-A1   ;  US20180148727-A1   ;  US20180201967-A1   ;  US20180208957-A1   ;  US20180214537-A1   ;  US20180237786-A1   ;  US20180237817-A1   ;  US20180243219-A1   ;  US20180296663-A1   ;  US20180298372-A1   ;  US20180312545-A1   ;  US20180371392-A1   ;  US20190010485-A1   ;  US20190017100-A1   ;  US20190024096-A1   ;  US20190040378-A1   ;  US20190049414-A1   ;  US20190083602-A1   ;  US20190100784-A1   ;  US20190125857-A1   ;  US20190133950-A1   ;  US20190160164-A1   ;  US20190177714-A1   ;  US20190185859-A1   ;  US20190194760-A1   ;  US20190225971-A1   ;  US20190241633-A1   ;  US20190249219-A1   ;  US20190336608-A1   ;  US20190336611-A1   ;  US20190343933-A1   ;  US20190343942-A1   ;  US20190351044-A1   ;  US20190351047-A1   ;  US20190351048-A1   ;  US20190381180-A1   ;  US20200023076-A1   ;  US20200085852-A1   ;  US20200085944-A1   ;  US20200149026-A1   ;  US20200163878-A1   ;  US20200179526-A1   ;  US20200318097-A1   ;  US20200392572-A1   ;  US20210030864-A1   ;  US20210069315-A1   ;  US20210162037-A1   ;  US20210170017-A1   ;  US20210180106-A1   ;  US20210205434-A1   ;  US20210260178-A1   ;  US20210261897-A1   ;  US20210361761-A1   ;  US20210379181-A1   ;  US20210403925-A1   ;  US20220040281-A1   ;  US20220073962-A1   ;  WO2016193206-A1   CUREVAC AG (CUEV)   FUNKNER A,  DORNER S,  SEWING S,  KAMM J,  BROGHAMMER N,  KETTERER T,  MUTZKE T;  WO2018211038-A1   CUREVAC AG (CUEV)   HEINZ S,  ROOS T;  WO2019077001-A1   CUREVAC AG (CUEV)   SCHLAKE T,  THESS A,  THRAN M,  CHEVESSIER-TUENNESEN F,  POENISCH M;  WO2019092153-A1   CUREVAC AG (CUEV)   HEINZ S,  ROOS T,  VAHRENHORST D,  CONZELMANN M;  WO2020161342-A1   CUREVAC AG (CUEV)   REJMAN J,  BAUMHOF P;  WO2020254535-A1   CUREVAC AG (CUEV)   RAUCH S,  ROIER S,  PETSCH B;  WO2021028439-A1   CUREVAC AG (CUEV)   THESS A,  CHEVESSIER-TUENNESEN F,  LUTZ J,  SCHLAKE T;  WO2020123300-A2   LILLY & CO ELI (ELIL)   AGGARWAL A,  FIEDLER K,  GNAD-VOGT U,  HEIDENREICH R,  KONERU M,  PLOWMAN G D;  WO2021239880-A9   CUREVAC AG (CUEV)   OOSTVOGELS C,  PETSCH B,  RAUCH S,  SCHWENDT K E	WO2019092153-A1  MORELLE G ET AL:          "Restructuring the translation initiation region of the          human parathyroid hormone gene for improved expression in          Escherichia coli", BIOCHIMICA ET BIOPHYSICA ACTA . GENE          STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, vol.          1089, no. 3, 23 July 1991 (1991-07-23), pages 320 - 324,          XP027202154, ISSN: 0167-4781, [retrieved on          19910723],relevantClaims[53,54,67|24-28,35-52,55-66,68-70],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  LUYEN THI VU ET AL:          "C-to-U editing and site-directed RNA editing for the          correction of genetic mutations", BIOSCIENCE TRENDS, vol.          11, no. 3, June 2017 (2017-06-01), pages 243 - 253,          XP002779778,relevantClaims[24-28,35-37,53-56,67|38-56,68-70],relevantPassages[&lt;pp&gt;244&lt;/pp&gt;&lt;column&gt;1&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;&lt;ppl&gt;246&lt;/ppl&gt;&lt;coll&gt;2&lt;/coll&gt;&lt;paral&gt;2&lt;/paral&gt;abstract];  AZARANI A ET AL:          "RNA analysis by ion-pair reversed-phase high performance          liquid chromatography", NUCLEIC ACIDS RESEARCH,          INFORMATION RETRIEVAL LTD, vol. 29, no. 2, 15 January          2001 (2001-01-15), pages E7 - 1, XP002474349, ISSN:          0305-1048, DOI:          10.1093/NAR/29.2.E7,relevantClaims[1-23],relevantPassages[&lt;pp&gt;2&lt;/pp&gt;&lt;column&gt;2&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;|&lt;pp&gt;6&lt;/pp&gt;&lt;column&gt;2&lt;/column&gt;&lt;line&gt;18-25&lt;/line&gt;&lt;para&gt;2&lt;/para&gt;];            KARLIN ET AL., PNAS USA, vol. 90, 1993, pages 5873 -          5877;            ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages          3389 - 3402;            DAVILA LOPEZ, M.; SAMUELSSON, T., RNA, vol. 14, no. 1,          2008US2022144877-A1            Azarani et al. Nucleic Acids Research Vol.29, No.2 e7,          2001.US11692002-B2            Azarani et al. Nucleic Acids Research vol. 29, No. 2 e7,          2001.;            Morelle et al., Restructuring the translation initiation          region of the human parathyroid hormone gene for improved          expression in &lt;xhtml:i &gt;Escherichia          coli&lt;/xhtml:i&gt;, &lt;xhtml:i          &gt;Biochim Biophys Acta&lt;/xhtml:i&gt;.,          1089(3):320-324, 1991.;            PCT International Search Report and Written Opinion          issued in International Application No.          PCT/EP2018/080692, dated Dec. 17, 2018.;  Vu          et al., C-to-U editing and site-directed RNA editing for          the correction of genetic mutations, &lt;xhtml:i          &gt;Bioscience Trends&lt;/xhtml:i&gt;,          11(3):243-253, 2017.	91481-0-0-0 ; 368-0-0-0 			R24034 ; R00708 		WO2019147831-A1;  US2019300625-A1;  EP3638698-A1;  AU2019211406-A1;  CA3089377-A1;  KR2020115576-A;  SG11202006898-A1;  CN111936517-A;  EP3638698-B1;  US10941213-B2;  BR112020015112-A2;  JP2021511058-W;  US2021230303-A1;  ES2864529-T3;  US2022081489-A9;  ZA202004494-A;  HK40027684-A0;  US11603413-B2;  TR2021006133-T4;  IL276164-A;  US2023265216-A1;  JP2024009962-A	Human antigen-binding protein for treating or            preventing cancer which is prostate cancer, colon            cancer, lung cancer, pancreas cancer, urinary tract            cancer, ovarian cancer, prostate adenocarcinoma, that            specifically binds to human TMPRSS2	PURCELL L;  PURCELL L A	REGENERON PHARM INC (REGN-C);  REGENERON PHARM INC (REGN-C);  REGENERON PHARM INC (REGN-C);  REGENERON PHARM INC (REGN-C)	2019675190	   NOVELTY - Human antigen-binding protein that                specifically binds to human TMPRSS2, which is an                antibody or antigen-binding fragment.    USE - Human antigen-binding protein for treating or                preventing cancer which is prostate cancer, colon                cancer, lung cancer, pancreas cancer, urinary tract                cancer, breast cancer, ovarian cancer, prostate                adenocarcinoma, renal cell carcinoma, colorectal                adenocarcinoma, lung adenocarcinoma, lung squamous                cell carcinoma and/or pleural mesothelioma                (claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) an antigen-binding protein, which competes                with an antigen-binding protein, for binding to                TMPRSS2 and/or binds to the same or an overlapping                epitope on TMPRSS2;    (2) a complex, which comprises an                antigen-binding protein bound to a TMPRSS2                polypeptide;    (3) a method for making an antigen-binding                protein or immunoglobulin chain, which comprises                introducing one or more polynucleotides encoding an                immunoglobulin chain of antigen-binding protein;                culturing the host cell under conditions favorable                to expression of the polynucleotide; and isolating                the antigen-binding protein or immunoglobulin chain                from the host cell and/or medium in which the host                cell is grown;    (4) an antigen-binding protein or                immunoglobulin chain;    (5) a polypeptide, which comprises CDR1 ,                CDR2, and CDR3 of a VH domain of an immunoglobulin                chain that comprises the amino acid sequence set                forth in (SEQ ID NO: 2), given in the                specification, or CDR1 , CDR2, and CDR3 of a VL                domain of an immunoglobulin chain that comprises                the amino acid sequence set forth in (SEQ ID NO:                4), given in the specification;    (6) a polynucleotide encoding the                polypeptide;    (7) a vector, which comprises the                polynucleotide;    (8) a host cell, which comprises the                antigen-binding protein or immunoglobulin chain or                polypeptide or polynucleotide or vector;    (9) a composition or kit, which comprises the                antigen-binding protein and is association with a                further therapeutic agent;    (10) a pharmaceutical composition, which                comprises the antigen-binding protein and                pharmaceutically acceptable carrier and,                optionally, a further therapeutic agent;    (11) A vessel or injection device, which                comprises the antigen-binding protein or                composition;    (12) a method for treating or preventing                cancer or infection with an influenza virus,                coronavirus, SARS-Co virus, MERS-Co virus,                parainfluenza virus, human metapneumovirus or                hepatitis C virus (HCV), in a subject, which                comprises administering a therapeutically effective                amount of antigen-binding protein; and    (13) a method for administering an                antigen-binding protein into the body of a subject,                which comprises injecting the antigen-binding                protein into the body of the subject. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E02A;  B04-E03A;  B04-E08;  B04-E99;  B04-F0100E;  B04-G03;  B04-G23;  B04-G24;  B11-C04C;  B11-C06;  B12-M12C;  B14-A02B;  B14-D07C;  B14-H01;  B14-S11A;  B14-S11C;  D05-H11;  D05-H12A;  D05-H12E;  D05-H14;  D05-H99	A61K-039/395;  A61P-031/16;  C07K-016/10;  C07K-016/28;  C07K-016/40;  A61K-009/00;  C12N-009/64;  A61K-039/00;  C07K-001/00;  C07K-016/00;  C12P-021/08;  A61K-039/215;  A61K-045/00;  A61P-031/12;  A61P-031/14;  A61P-037/04;  C12M-001/00;  C12N-001/15;  C12N-001/19;  C12N-001/21;  C12N-015/13;  C12N-015/63;  C12N-005/10;  A61K-000/00;  A61P-000/00;  C07K-000/00;  A61K-039/42;  C07K-014/435;  A61P-001/16;  A61P-035/00;  A61P-043/00;  C12N-015/62	WO2019147831-A1   01 Aug 2019   C07K-016/28   201961Pages: 115   English;  US2019300625-A1   03 Oct 2019   C07K-016/40   201976   English;  EP3638698-A1   22 Apr 2020   C07K-016/28   202033   English;  AU2019211406-A1   13 Aug 2020   C07K-016/28   202066   English;  CA3089377-A1   01 Aug 2019   C07K-016/28   202068   English;  KR2020115576-A   07 Oct 2020   C07K-016/40   202083   ;  SG11202006898-A1   28 Aug 2020   C07K-016/28   202095   English;  CN111936517-A   13 Nov 2020   C07K-016/28   202095   Chinese;  US10941213-B2   09 Mar 2021   C07K-016/00   202123   English;  BR112020015112-A2   06 Apr 2021   C07K-016/28   202138   English;  JP2021511058-W   06 May 2021   C12N-015/13   202140Pages: 89   Japanese;  US2021230303-A1   29 Jul 2021   C07K-016/40   202163   English;  ES2864529-T3   14 Oct 2021   C07K-016/28   202198   Spanish;  US2022081489-A9   17 Mar 2022   C07K-016/40   202224   English;  ZA202004494-A   25 May 2022   A61K-000/00   202247   English;  HK40027684-A0   22 Jan 2021   C07K-016/28   202288   English;  US11603413-B2   14 Mar 2023   C07K-014/435   202323   English;  TR2021006133-T4   21 Apr 2021   C07K-016/28   202335;  IL276164-A   30 Sep 2020   A61K-009/00   202340   English;  US2023265216-A1   24 Aug 2023   C07K-016/40   202369   English;  JP2024009962-A   23 Jan 2024   C12N-015/13   202410   Japanese	WO2019147831-A1    WOUS014978    24 Jan 2019;   US2019300625-A1    US256560    24 Jan 2019;   EP3638698-A1    EP701428    24 Jan 2019;   AU2019211406-A1    AU211406    24 Jan 2019;   CA3089377-A1    CA3089377    24 Jan 2019;   KR2020115576-A    KR724526    24 Jan 2019;   SG11202006898-A1    SG11006898    24 Jan 2019;   CN111936517-A    CN80021929    24 Jan 2019;   EP3638698-B1    EP701428    24 Jan 2019;   US10941213-B2    US256560    24 Jan 2019;   BR112020015112-A2    BR11015112    24 Jan 2019;   JP2021511058-W    JP540397    24 Jan 2019;   US2021230303-A1    US153684    20 Jan 2021;   US2022081489-A9    US153684    20 Jan 2021;   ZA202004494-A    ZA004494    21 Jul 2020;   HK40027684-A0    HK6017391    09 Oct 2020;   US11603413-B2    US153684    20 Jan 2021;   TR2021006133-T4    TR006133    24 Jan 2019;   IL276164-A    IL276164    24 Jan 2019;   US2023265216-A1    US159827    26 Jan 2023;   JP2024009962-A    JP177262    13 Oct 2023	US2019300625-A1 Provisional Application US622292P;   EP3638698-A1 PCT application Application WOUS014978;   EP3638698-A1 Based on Patent WO2019147831;   AU2019211406-A1 PCT application Application WOUS014978;   AU2019211406-A1 Based on Patent WO2019147831;   CA3089377-A1 PCT application Application WOUS014978;   CA3089377-A1 Based on Patent WO2019147831;   KR2020115576-A PCT application Application WOUS014978;   KR2020115576-A Based on Patent WO2019147831;   SG11202006898-A1 PCT application Application WOUS014978;   SG11202006898-A1 Based on Patent WO2019147831;   CN111936517-A PCT application Application WOUS014978;   CN111936517-A Based on Patent WO2019147831;   EP3638698-B1 PCT application Application WOUS014978;   EP3638698-B1 Based on Patent WO2019147831;   US10941213-B2 Provisional Application US622292P;   US10941213-B2 Previous Publ. Patent US2019300625;   BR112020015112-A2 PCT application Application WOUS014978;   BR112020015112-A2 Based on Patent WO2019147831;   JP2021511058-W PCT application Application WOUS014978;   JP2021511058-W Based on Patent WO2019147831;   US2021230303-A1 Div ex Application US256560;   US2021230303-A1 Provisional Application US622292P;   US2021230303-A1 Div ex Patent US10941213;   ES2864529-T3 PCT application Application WOUS014978;   ES2864529-T3 EP application Application EP701428;   ES2864529-T3 Based on Patent WO2019147831;   ES2864529-T3 Based on Patent EP3638698;   US2022081489-A9 Provisional Application US622292P;   US2022081489-A9 Div ex Application US256560;   US2022081489-A9 Div ex Patent US10941213;   US2022081489-A9 Previous Publ. Patent US2021230303;   HK40027684-A0 PCT application Application WOUS014978;   HK40027684-A0 Based on Patent WO2019147831;   HK40027684-A0 Previous Publ. Patent EP3638698;   US11603413-B2 Div ex Application US256560;   US11603413-B2 Provisional Application US622292P;   US11603413-B2 Previous Publ. Patent US2022081489;   US11603413-B2 Previous Publ. Patent US2021230303;   US11603413-B2 Div ex Patent US10941213;   TR2021006133-T4 EP application Application EP701428;   TR2021006133-T4 Based on Patent EP3638698;   IL276164-A Based on Patent WO2019147831;   US2023265216-A1 Div ex Application US256560;   US2023265216-A1 Cont of Application US153684;   US2023265216-A1 Provisional Application US622292P;   US2023265216-A1 Cont of Patent US11603413;   US2023265216-A1 Div ex Patent US10941213;   JP2024009962-A Div ex Application JP540397	US622292P    26 Jan 2018;  EP701428    24 Jan 2019;  US256560    24 Jan 2019;  CA3089377    22 Jul 2020;  BR11015112    24 Jul 2020;  KR724526    25 Aug 2020;  CN80021929    24 Sep 2020;  US153684    20 Jan 2021;  US159827    26 Jan 2023	WO2019147831-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP3638698-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                                      		WO2019147831-A1 -- US20130273070-A1   ;  WO2002004953-A2   ;  WO2008076379-A2   REGENERON PHARM INC (REGN)   PAPADOPOULOS N J,  MARTIN J H,  SMITH E,  NOGUERA-TROISE I,  THURSTON G;  WO2018175749-A2   CHILDRENS MEDICAL CENT (CHLD)   WATNICK R S;  US2019300625-A1 -- CA2672622-A1   REGENERON PHARM INC (REGN)   PAPADOPOULOS N J,  MARTIN J H,  SMITH E,  NOGUERA-TROISE I,  THURSTON G;  WO2013158516-A1   REGENERON PHARM INC (REGN)   PURCELL N L A;  US10941213-B2 -- CA2672622-C   REGENERON PHARM INC (REGN)   PAPADOPOULOS N J,  MARTIN J H,  SMITH E,  NOGUERA-TROISE I,  THURSTON G;  WO2013158516-A1   REGENERON PHARM INC (REGN)   PURCELL N L A;  US20130273070-A1   ;  US9498529-B2   REGENERON PHARM INC (REGN)   PURCELL N L A;  WO2008127347-A1   DIADEXUS INC (DEXU)   DIEDRICH G,  MILLER P L,  PAPKOFF J,  STRELOW A;  WO2017151453-A1   REGENERON PHARM INC (REGN)   PURCELL L,  MUJICA A O,  TANG Y;  WO2018175749-A3   CHILDRENS MEDICAL CENT (CHLD)   WATNICK R S;  WO2002004953-A8   ;  WO2008076379-A8   REGENERON PHARM INC (REGN)   PAPADOPOULOS N J,  MARTIN J H,  SMITH E,  NOGUERA-TROISE I,  THURSTON G;  US11603413-B2 -- CA2672622-C   REGENERON PHARM INC (REGN)   PAPADOPOULOS N J,  MARTIN J H,  SMITH E,  NOGUERA-TROISE I,  THURSTON G;  US20130273070-A1   ;  US9498529-B2   REGENERON PHARM INC (REGN)   PURCELL N L A;  WO2008127347-A1   DIADEXUS INC (DEXU)   DIEDRICH G,  MILLER P L,  PAPKOFF J,  STRELOW A;  WO2013158516-A1   REGENERON PHARM INC (REGN)   PURCELL N L A;  WO2017151453-A1   REGENERON PHARM INC (REGN)   PURCELL L,  MUJICA A O,  TANG Y;  WO2018175749-A3   CHILDRENS MEDICAL CENT (CHLD)   WATNICK R S;  WO2002004953-A8   ;  WO2008076379-A8   REGENERON PHARM INC (REGN)   PAPADOPOULOS N J,  MARTIN J H,  SMITH E,  NOGUERA-TROISE I,  THURSTON G	WO2019147831-A1  DE NARDIS CAMILLA          ET AL: "Recombinant Expression of the Full-length          Ectodomain of LDL Receptor-related Protein 1 (LRP1)          Unravels pH-dependent Conformational Changes and the          Stoichiometry of Binding with Receptor-associated Protein          (RAP).", THE JOURNAL OF BIOLOGICAL CHEMISTRY 20 01 2017,          vol. 292, no. 3, 20 January 2017 (2017-01-20), pages 912          - 924, XP002790847, ISSN:          1083-351X,relevantClaims[1,8,10,12,14,18,23],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  WILSON SUSAN ET AL:          "The membrane-anchored serine protease, TMPRSS2,          activates PAR-2 in prostate cancer cells.", THE          BIOCHEMICAL JOURNAL 15 JUN 2005, vol. 388, no. Pt 3, 15          June 2005 (2005-06-15), pages 967 - 972, XP002790848,          ISSN:          1470-8728,relevantClaims[8,10,12,14,18,23],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  SHEN LI WEN ET AL:          "TMPRSS2: A potential target for treatment of influenza          virus and coronavirus infections", BIOCHIMIE, vol. 142, 1          August 2017 (2017-08-01), pages 1 - 10, XP085244550,          ISSN: 0300-9084, DOI:          10.1016/J.BIOCHI.2017.07.016,relevantClaims[1-30],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  DATABASE UniParc          [online] UniParc; 12 March 2003 (2003-03-12), "UniParc -          UPI00001178DF", XP002790849, Database accession no.          UPI00001178DF,relevantClaims[15-18],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]US10941213-B2            Bertram et al., TMPRSS2 and TMPRSS4 facilitate          trypsin-independent spread of influenza virus in Caco-2          cells. Journal of Virology. 84, 10016-10025          (2010).;            Bonkhoff, Estrogen receptor signaling in prostate cancer:          Implications for carcinogenesis and tumor progression,          Prostate 78(1): 2-10 (2018).;            Bottcher et al., Proteolytic Activation of Influenza          Viruses by Serine Proteases TMPRSS2 and HAT from Human          Airway Epithelium. Journal of Virology. Oct.          2006;80(19):9896-8.;            Boettcher-Friebertshaeuser et al., Inhibition of          influenza virus infection in human airway cell cultures          by an antisense peptide-conjugated morpholino oligomer          targeting the hemagglutinin-activating protease TMPRSS2.          Journal of Virology. 85, 1554-1562 (2011).;            Database UniParc [Online] UniParc; (Mar. 12,          2003).;  De          Nardis Camilla et al., Recombinant Expression of the          Full-length Ectodomain of LDL Receptor-related Protein 1          (LRP1) Unravels pH-dependent Conformational Changes and          the Stoichiometry of Binding with Receptor-associated          Protein (RAP). The Journal of Biological Chemistry (Jan.          1, 2017) vol. 292, No. 3.;            Reinke et al., Different residues in the SARS-CoV spike          protein determine cleavage and activation by the host          cell protease TMPRSS2. PLoS One. 12, e0179177          (2017).;            Shen et al. TMPRSS2: A potential target for treatment of          influenza virus and coronavirus infections. Biochimie          142: 1-10 (2017).;            Shirato et al. Clinical Isolates of Human Coronavirus          229E Bypass the Endosome for Cell Entry. Journal of          Virology. 91, e01387-16 (2017).;            Tarnow et al., TMPRSS2 is a host factor that is essential          for pneumotropism and pathogenicity of H7N9 influenza A          virus in mice. Journal of Virology 88(9):4744-51          (2014).;            Wilson Susan et al., The membrane-anchored serine          protease, TMPRSS2, activates PAR-2 in prostate cancer          cells., The Biochemical Journal (Jun. 15, 2005) vol. 388,          No. Pt. 3.;            Zhou et al., Protease inhibitors targeting coronavirus          and filovirus entry. Antiviral Research. 116, 76-84          (2015).;            Zmora et al. TMPRSS2 Isoform 1 Activates Respiratory          Viruses and Is Expressed in Viral Target Cells. PLoS One.          10, e0138380 (2015)).;            Zmora et al., Non-human primate orthologues of TMPRSS2          cleave and activate the influenza virus hemagglutinin.          PLoS One. 12, e0176597 (2017).US11603413-B2            Bertram et al. (2010) TMPRSS2 and TMPRSS4 Facilitate          Trypsin-Independent Spread of Influenza Virus in Caco-2          Cells, Journal of Virology, 84, 10016-10025.;            Bonkhoff (2018) Estrogen Receptor Signaling in Prostate          Cancer: Implications for Carcinogenesis and Tumor          Progression, Prostate, 78(1): 2-10.;            Bottcher et al. (2006) Proteolytic Activation of          Influenza Viruses by Serine Proteases TMPRSS2 and HAT          from Human Airway Epithelium, Journal of Virology,          80(19):9896-8.;            Bottcher-Friebertsauser et al. (2011) Inhibition of          Influenza Virus Infection in Human Airway Cell Cultures          by an Antisense Peptide-Conjugated Morpholino Oligomer          Targeting the Hemagglutinin-Activating Protease TMPRSS2,          Journal of Virology, 85, 1554-1562.;            Database UniParc [Online] UniParc; (Mar. 12,          2003).;  De          Nardis Camilla et al. (2017) Recombinant Expression of          the Full-length Ecto domain of LDL Receptor-related          Protein 1 (LRP1) Unravels pH dependent Conformational          Changes and the Stoichiometry of Binding with          Receptor-associated Protein (RAP), The Journal of          Biological Chemistry, vol. 292, No. 3.;            Reinke et al. (2017) Different Residues in the SARS-CoV          Spike Protein Determine Cleavage and Activation by the          Host Cell Protease TMPRSS2, PLoS ONE, 12,          e0179177.;            Shen et al. (2017) TMPRSS2: A Potential Target for          Treatment of Influenza Virus and Coronavirus Infections,          Biochimie, 142: 1-10.;            Shirato et al. (2017) Clinical Isolates of Human          Coronavirus 229E Bypass the Endosome for Cell Entry,          Journal of Virology, 91, e01387-16.;            Tarnow et al. (2014) TMPRSS2 is a Host Factor That is          Essential for Pneumotropism and Pathogenicity of H7N9          Influenza A Virus in Mice, Journal of Virology,          88(9):4744-51.;            Wilson et al. (2005) The Membrane-Anchored Serine          Protease, TMPRSS2, Activates PAR-2 in Prostate Cancer          Cells, The Biochemical Journal, vol. 388, No. Pt.          3.;            Zhou et al. (2015) Protease Inhibitors Targeting          Coronavirus and Filo Virus Entry, Antiviral Research,          116, 76-84.;            Zmora et al. (2015) TMPRSS2 Isoform 1 Activates          Respiratory Viruses and IsExpressed in Viral Target          Cells, PLoS ONE, 10, e0138380.;            Zmora et al. (2017) Non-human Primate Orthologues of          TMPRSS2 Cleave and Activate the Influenza Virus          Hemagglutinin, PLoS ONE, 12, e0176597.;            International Search Report and Written Opinion for          International Application No. PCTUS2019/014978 dated May          10, 2019, 21 pages.						WO2019137463-A1;  CN110028501-A;  CA3088303-A1;  AU2019207140-A1;  KR2020108451-A;  EP3738962-A1;  US2021078985-A1;  JP2021510383-W;  EP3738962-A4;  CN110028501-B;  EP3738962-B1;  JP7318956-B2	New 4-methoxy-1H-indazole containing compound            useful as pharmaceutical composition for treating            chemokine receptor 4-mediated disease e.g. respiratory            diseases, inflammation of bones and joints, psoriasis            and inflammatory skin diseases	ZHAO H F;  ZHAO H	MEDSPRING INT LTD (MEDS-Non-standard);  MEDSPRING INT LTD (MEDS-Non-standard);  MEDSPRING INT LTD (MEDS-Non-standard);  MEDSPRING INT LTD (MEDS-Non-standard)	201963518A	   NOVELTY - A 4-methoxy-1H-indazole containing compound                (I) or its salt, solvate or prodrug, is new.    USE - The 4-methoxy-1H-indazole containing compound                is useful in pharmaceutical composition for                treating chemokine receptor-4 (CCR4)-mediated                disease in a patient. The CCR4-mediated disease                includes (i) respiratory diseases such as airway                obstructive diseases (asthma, preferably bronchial                asthma, allergic asthma, endogenous asthma,                exogenous asthma, exercise-induced asthma,                drug-induced (aspirin and NSAID-induced) asthma and                dust-induced asthma, intermittent asthma and                persistent asthma), chronic obstructive pulmonary                disease (COPD), bronchitis (infectious bronchitis                and eosinophilic bronchitis) emphysema,                bronchiectasis, cystic fibrosis, hypersensitivity                pneumonia, pulmonary fibrosis, cryptogenic fibrotic                alveolitis, idiopathic interstitial pneumonia,                anti-tumor therapy and fibrosis complicated by                chronic infection, vasculitis and thrombotic                diseases of pulmonary vessels and pulmonary                hypertension, rhinitis, acute rhinitis and chronic                rhinitis (drug-induced rhinitis, vasomotor                rhinitis, perennial allergic rhinitis, neurogenic                rhinitis and seasonal allergic rhinitis), and acute                viral infections (common cold and infections caused                by respiratory syncytial virus, influenza,                coronavirus and adenovirus), (ii) inflammation of                bones and joints such as arthritis of bones and                joints, cervical and lumbar spondylitis and low                back pain and neck pain, osteoporosis, rheumatoid                arthritis, acute and chronic synovitis, urate                deposition, calcium pyrophosphate deposition and                calcium apatite-related sputum, bursa and synovial                inflammation, inflammatory myopathy                (dermatomyositis and polymyositis), rheumatic                polymyalgia, juvenile arthritis (idiopathic                inflammatory arthritis and associated syndrome and                rheumatic fever and systemic complications in any                joint), drug-induced joint pain, tendinitis, and                myopathy, (iii) psoriasis and inflammatory skin                diseases such as dermatitis, eczema, atopic                dermatitis, allergic contact dermatitis, rubella                and pruritus, (iv) orbital inflammation and                ophthalmia such as conjunctivitis (perennial                allergic conjunctivitis or spring allergic                conjunctivitis), iritis, anterior uveitis and                posterior uveitis, choroiditis, degenerative or                inflammatory disease affecting the retina,                sympathetic ophthalmia, sarcoidosis, and infection                (including ophthalmitis of viral, fungal and                bacterial infections), and (v) other diseases                associated with CCR4 such as gastrointestinal                inflammation, genitourinary system inflammation,                and immune system inflammation (all claimed).    ADVANTAGE - The 4-methoxy-1H-indazole containing compound                has enhanced solubility and bioavailability.    DETAILED DESCRIPTION - A 4-methoxy-1H-indazole containing compound of                formula (I) or its salt, solvate or prodrug, is                new.    M = monovalent alkali metal.    INDEPENDENT CLAIMS are included for the                following:    (1) method for treating chemokine receptor 4                (CCR4)-mediated disease, involves administering                4-methoxy-1H-indazole containing compound, or its                salt, solvate or prodrug to a patient; and    (2) method for preparing 4-methoxy-1H-indazole                containing compound. 			B02 (Fused ring heterocyclics.)	B05-A01A;  B05-A01B;  B06-D05;  B14-A01;  B14-A02;  B14-A04;  B14-C01;  B14-C03;  B14-C04;  B14-C06;  B14-C09;  B14-E10C1;  B14-F02;  B14-F04;  B14-G02A;  B14-G02B;  B14-H01;  B14-J05;  B14-K01;  B14-L06;  B14-N01A;  B14-N03;  B14-N04;  B14-N17;  B14-S14;  B14-S16	A61K-031/416;  A61P-011/06;  A61P-011/08;  A61P-029/00;  A61P-037/08;  C07D-409/12;  A61P-001/00;  A61P-011/00;  A61P-015/00;  A61P-017/00;  A61P-019/00;  A61P-019/02;  A61P-019/06;  A61P-019/10;  A61P-027/02;  A61P-031/00;  A61P-031/04;  A61P-031/10;  A61P-031/12;  A61P-031/16;  A61P-035/00;  A61P-007/02;  A61P-043/00;  A61P-011/02;  A61P-037/02;  A61P-017/06;  A61P-021/00	WO2019137463-A1   18 Jul 2019   C07D-409/12   201959Pages: 35   Chinese;  CN110028501-A   19 Jul 2019   C07D-409/12   201959   Chinese;  CA3088303-A1   18 Jul 2019   C07D-409/12   202064   English;  AU2019207140-A1   03 Sep 2020   C07D-409/12   202073   English;  KR2020108451-A   18 Sep 2020   C07D-409/12   202077   ;  EP3738962-A1   18 Nov 2020   C07D-409/12   202094   English;  US2021078985-A1   18 Mar 2021   C07D-409/12   202125   English;  JP2021510383-W   22 Apr 2021   C07D-409/12   202134Pages: 33   Japanese;  EP3738962-A4   16 Jun 2021   C07D-409/12   202150   English;  CN110028501-B   22 Feb 2022   C07D-409/12   202221   Chinese;  EP3738962-B1   02 Aug 2023   C07D-409/12   202363   English;  JP7318956-B2   01 Aug 2023   C07D-409/12   202364   Japanese	WO2019137463-A1    WOCN071315    11 Jan 2019;   CN110028501-A    CN10032410    12 Jan 2018;   CA3088303-A1    CA3088303    11 Jan 2019;   AU2019207140-A1    AU207140    11 Jan 2019;   KR2020108451-A    KR723106    11 Jan 2019;   EP3738962-A1    EP738948    11 Jan 2019;   US2021078985-A1    US16961690    12 Jul 2020;   JP2021510383-W    JP558674    11 Jan 2019;   EP3738962-A4    EP738948    11 Jan 2019;   CN110028501-B    CN10032410    12 Jan 2018;   EP3738962-B1    EP738948    11 Jan 2019;   JP7318956-B2    JP558674    11 Jan 2019	CA3088303-A1 PCT application Application WOCN071315;   CA3088303-A1 Based on Patent WO2019137463;   AU2019207140-A1 PCT application Application WOCN071315;   AU2019207140-A1 Based on Patent WO2019137463;   KR2020108451-A PCT application Application WOCN071315;   KR2020108451-A Based on Patent WO2019137463;   EP3738962-A1 PCT application Application WOCN071315;   EP3738962-A1 Based on Patent WO2019137463;   US2021078985-A1 PCT application Application WOCN071315;   JP2021510383-W PCT application Application WOCN071315;   JP2021510383-W Based on Patent WO2019137463;   CN110028501-B Previous Publ. Patent CN110028501;   EP3738962-B1 PCT application Application WOCN071315;   EP3738962-B1 Based on Patent WO2019137463;   JP7318956-B2 PCT application Application WOCN071315;   JP7318956-B2 Based on Patent WO2019137463;   JP7318956-B2 Previous Publ. Patent JP2021510383	CN10032410    12 Jan 2018;  WOCN071315    11 Jan 2019;  CA3088303    13 Jul 2020;  KR723106    11 Aug 2020	WO2019137463-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          EP3738962-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      EP3738962-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR    EP3738962-B1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR    		WO2019137463-A1 -- CN102388039-A   HODGSON S T (HODG-Individual);  LACROIX Y M (LACR-Individual);  PROCOPIOU P A (PROC-Individual)   HODGSON S T,  LACROIX Y M,  PROCOPIOU P A;  CN110028501-A -- WO2010097395-A1   HODGSON S T (HODG-Individual);  LACROIX Y M (LACR-Individual);  PROCOPIOU P A (PROC-Individual)   HODGSON S T,  LACROIX Y M,  PROCOPIOU P A;  EP3738962-A4 -- EP2401270-A1   HODGSON S T (HODG-Individual);  LACROIX Y M (LACR-Individual);  PROCOPIOU P A (PROC-Individual)   HODGSON S T,  LACROIX Y M,  PROCOPIOU P A;  CN110028501-B -- WO2010097395-A1   HODGSON S T (HODG-Individual);  LACROIX Y M (LACR-Individual);  PROCOPIOU P A (PROC-Individual)   HODGSON S T,  LACROIX Y M,  PROCOPIOU P A;  EP3738962-B1 -- CN101370793-A   ASTRAZENECA AB (ASTR)   CHESHIRE D,  KINDON N,  METE A,  ROBERTS B;  CN102388039-A   HODGSON S T (HODG-Individual);  LACROIX Y M (LACR-Individual);  PROCOPIOU P A (PROC-Individual)   HODGSON S T,  LACROIX Y M,  PROCOPIOU P A	WO2019137463-A1  PROCOPIOU, P.A. ET          AL.: "Lead Optimisation of the N1 Substituent of a Novel          Series of Indazole Arylsulfonamides as CCR4 Antagonists          and Identification of a Candidate for Clinical          Investigation", BIOORGANIC & MEDICINAL CHEMISTRY          LETTERS, vol. 22, no. 8, 7 March 2012 (2012-03-07), pages          2730 - 2733, XP055625236, ISSN:          0960-894X,relevantClaims[1-10]CN110028501-A  PROCOPIOUPANAYIOTIS          A.: "Lead optimisation of the N1 substituent of a novel          series of indazole arylsulfonamides as CCR4 antagonists          and identification of a candidate for clinical          investigation", BIOORGANIC & MEDICINAL CHEMISTRY          LETTERS,relevantClaims[1-10],relevantPassages[2730-2733]EP3738962-A4            See also references of WO 2019137463A1CN110028501-B            Profile ou, Panayiotis A. et al., Lead-in-Lead-on-the N1          - (+) - type of a novel series of Along-series of (R) -          CCR4 and identification of a candidate for the field,          Procopiou, Panayiotis A, etc.; "Bioorganic &          Medicinal Chemistry Letters"; 20130307; No. 22 (No. 8);          pages 2730-2733EP3738962-B1            Christine AP et al. J. Biol. Chem. 1995, 270 (8):          19495-19500;            Sadatoshi Maeda et al., Veterinary Immunology and          Immunology 2002 (90): 145-154;            Han WL et al., Biochem J. 2001, 357 (Pt1):          127-135;            Pharmacopoeia 2010 editi	2345747-0-0-0 K S; 2345747-0-0-0 CL RCT	215479501 N P		RB8R6J K S		WO2019011293-A1;  CN109248170-A;  GB2578390-A;  US2020163983-A1;  JP2020526594-W;  GB2578390-B;  US11464795-B2;  CN109248170-B	Use of saponin compound or its salt, prodrug and            solvate in preparation of medicament for targeting            programmed cell death protein 1	LI H;  XIAO W;  ZHU L;  QUAN L;  LI Q;  DIAO Y;  ZHAO Z;  JIANG H	UNIV EAST CHINA SCI & TECHNOLOGY (UYEC-C);  UNIV YUNNAN (UYUN-C);  SHANGHAI INST MATERIA MEDICA CAS (CAMM-C);  UNIV YUNNAN (UYUN-C);  CAS SHANGHAI MATERIA MEDICA INST (CAMM-C);  UNIV EAST CHINA SCI & TECHNOLOGY (UYEC-C);  UNIV YUNNAN (UYUN-C);  CHINESE ACAD SCI SHANGHAI MATERIA MEDIC (CAMM-C);  UNIV EAST CHINA SCI & TECHNOLOGY (UYEC-C);  CAS SHANGHAI MATERIA MEDICA INST (CAMM-C);  CHINESE ACAD SCI SHANGHAI MATERIA MEDI (CAMM-C);  SHANGHAI INST MATERIA MEDICA CAS (CAMM-C);  CHINESE ACAD SCI SHANGHAI MATERIA MEDIC (CAMM-C)	201907091Q	   NOVELTY - Use of saponin compound (I) or (II) or its                salt, prodrug and solvate in preparation of                medicament for targeting programmed cell death                protein 1, is claimed.    USE - Use of saponin compound or its salt, prodrug                and solvate in preparation of medicament and in                pharmaceutical composition for targeting programmed                cell death protein 1, and for treating disease by                inhibiting binding of programmed cell death protein                1 to its ligand, preferably tumor, infection caused                by bacterium, virus or fungus, or inflammatory                disease. The tumor is melanoma, lung cancer, kidney                cancer, ovarian cancer, prostate cancer, breast                cancer, colon cancer, bone cancer, pancreatic                cancer, skin cancer, head and neck cancer, uterine                cancer, rectal cancer, anal cancer, stomach cancer,                testicular cancer, fallopian tube cancer,                endometrial cancer, cervical cancer, vaginal                cancer, vulvar cancer, Hodgkin's disease,                non-Hodgkin's lymphoma, esophageal cancer, small                intestine cancer, endocrine system cancer, thyroid                cancer, parathyroid carcinoma, adrenal cancer, soft                tissue sarcoma, urethral cancer, penile cancer,                acute myeloid leukemia, chronic myeloid leukemia,                acute lymphocytic leukemia, chronic lymphocytic                leukemia, pediatric solid tumor, lymphocytic                lymphoma, bladder cancer, renal or ureteral cancer,                renal pelvic cancer, central nervous system (CNS)                tumor, primary CNS lymphoma, spinal axial tumor,                brainstem glioma, pituitary adenoma, Kaposi                sarcoma, epidermoid carcinoma, squamous cell                carcinoma, or T-cell lymphoma, ankylosing                spondylitis, autoimmune hemolytic anemia,                arthritis, myasthenia gravis, systemic lupus                erythematosus, rheumatoid arthritis, pernicious                anemia, or polymyositis. The virus includes                hepatitis virus, herpes virus, influenza virus,                adenovirus, coronavirus measles virus, dengue                virus, poliovirus, or rabies virus. The bacterium                includes Chlamydia, Rickettsia, Mycobacterium,                Staphylococcus, Pneumococcus, Vibrio cholerae, or                Clostridium tetanus. The fungus includes Candida,                Aspergillus, and dermatitis. The lung cancer                includes non-small cell lung cancer. The hepatitis                virus includes hepatitis A, B or C virus (all                claimed).    DETAILED DESCRIPTION - Use of saponin compound of formula (I) or (II)                or its salt, prodrug and solvate in preparation of                medicament for targeting programmed cell death                protein 1, is claimed.    R1 = H, or group chosen from groups of                formulae (i)-(vi);    R2,R3 = H, optionally substituted 1-6C alkyl,                OH, hydroxy-optionally substituted 1-6C                alkylene;    R4 = H, OH, optionally substituted 1-6C                alkoxy, or -OC(O)R11;    R11 = H or optionally substituted 1-6C alkyl,                preferably optionally substituted 1-3C alkyl;    R5,R6 = H or optionally substituted 1-6C                alkyl;    R7 = H or OH;    R8 = H, 1-3C carboxy, optionally substituted                2-7C ester, or group of formula (vii);and    R9,R10 = H, optionally substituted 1-6C alkyl,                or OH.    An INDEPENDENT CLAIM is included for method                for inhibiting binding of programmed cell death                protein 1 to its ligand, which involves using                compound (I) or (II). 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.)	B08-B;  B14-A01;  B14-A02B;  B14-A04;  B14-C03;  B14-C09;  B14-F03;  B14-G02D;  B14-H01;  B14-J05;  B14-L06;  B14-N17	A61K-031/352;  A61K-031/56;  A61K-031/704;  A61K-031/7056;  A61P-019/02;  A61P-031/00;  A61P-035/00;  A61P-019/08;  A61P-021/00;  A61P-021/04;  A61P-029/00;  A61P-031/04;  A61P-031/10;  A61P-031/12;  A61P-031/14;  A61P-031/20;  A61P-035/02;  A61P-007/06;  A61P-031/16;  A61P-031/22;  A61P-037/02	WO2019011293-A1   17 Jan 2019   A61K-031/56   201914Pages: 49   Chinese;  CN109248170-A   22 Jan 2019   A61K-031/704   201914   Chinese;  GB2578390-A   06 May 2020   A61K-031/56   202039   English;  US2020163983-A1   28 May 2020   A61K-031/704   202044   English;  JP2020526594-W   31 Aug 2020   A61K-031/56   202072Pages: 42   Japanese;  GB2578390-B   31 Aug 2022   A61K-031/56   202273   English;  US11464795-B2   11 Oct 2022   A61K-031/704   202284   English;  CN109248170-B   03 Oct 2023   A61K-031/704   202388   Chinese	WO2019011293-A1    WOCN095426    12 Jul 2018;   CN109248170-A    CN10763960    12 Jul 2018;   GB2578390-A    GB000501    12 Jul 2018;   US2020163983-A1    US16630309    10 Jan 2020;   JP2020526594-W    JP523480    12 Jul 2018;   GB2578390-B    GB000501    12 Jul 2018;   US11464795-B2    US16630309    10 Jan 2020;   CN109248170-B    CN10763960    12 Jul 2018	GB2578390-A PCT application Application WOCN095426;   GB2578390-A Based on Patent WO2019011293;   US2020163983-A1 PCT application Application WOCN095426;   JP2020526594-W PCT application Application WOCN095426;   JP2020526594-W Based on Patent WO2019011293;   GB2578390-B PCT application Application WOCN095426;   GB2578390-B Based on Patent WO2019011293;   US11464795-B2 PCT application Application WOCN095426;   US11464795-B2 Previous Publ. Patent US2020163983;   US11464795-B2 Based on Patent WO2019011293;   CN109248170-B Previous Publ. Patent CN109248170	CN10570889    13 Jul 2017;  CN10763960    12 Jul 2018;  GB000501    14 Jan 2020	WO2019011293-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA                		WO2019011293-A1 -- CN106581006-A   UNIV HONG KONG POLYTECHNIC SHENZHEN RES (UYKP)   LI X,  DONG X,  ZHAO Q,  ZHANG H;  CN106619816-A   JINAN HAOYU QINGTIAN MEDICAL TECHNOLOGY (JINA-Non-standard);  CN106727854-A   JINAN HAOYU QINGTIAN MEDICAL TECHNOLOGY (JINA-Non-standard);  CN106749488-A   JIANGXI HERBFINE HI TECH CO LTD (UJXT)   FANG Y,  JIN Y,  FENG Y,  OU Y,  YANG S;  CN106822206-A   JINAN HAOYU QINGTIAN MEDICAL TECHNOLOGY (JINA-Non-standard);  CN109248170-A -- CN105708847-A   UNIV CHENGDU (UYUD)   FU J,  GUO X,  HU Y,  LI W,  ZHAO J,  YANG L,  ZHANG J,  ZHAO G,  ZOU L,  YU T;  GB2578390-B -- CN102657660-A   SHANGHAI INST PHARM IND (CNPG);  UNIV SHANGHAI JIAO TONG MEDICINE SCHOOL (USJT)   CHEN H,  FANG C,  LIN M,  LU Q,  YANG G,  YANG Y,  YU D,  WANG Q,  ZHAO M,  ZHU W;  CN105998032-A   UNIV GUIZHOU MEDICAL (UGZM)   CHEN R,  DU K,  LI W,  TANG L,  WU H,  ZHANG J;  CN105998033-A   UNIV FUZHOU (UFZU)   SHAO J,  ZHENG G,  LIU Y,  JIANG K;  CN106038571-A   UNIV FUZHOU (UFZU)   SHAO J,  ZHENG G,  JIANG K;  CN106581006-A   UNIV HONG KONG POLYTECHNIC SHENZHEN RES (UYKP)   LI X,  DONG X,  ZHAO Q,  ZHANG H;  CN106619816-A   JINAN HAOYU QINGTIAN MEDICAL TECHNOLOGY (JINA-Non-standard);  CN106727854-A   JINAN HAOYU QINGTIAN MEDICAL TECHNOLOGY (JINA-Non-standard);  CN106749488-A   JIANGXI HERBFINE HI TECH CO LTD (UJXT)   FANG Y,  JIN Y,  FENG Y,  OU Y,  YANG S;  CN106822206-A   JINAN HAOYU QINGTIAN MEDICAL TECHNOLOGY (JINA-Non-standard);  KR2003092170-A   UNIV HANDONG GLOBAL (UYHA-Non-standard)   JUNG M J,  KIM J B,  LEE G B,  SONG G S,  YOO Y C;  WO2015171598-A1   UNIV TEXAS SYSTEM (TEXA)   SLAGA T J,  JUNCO J,  LIANG H,  REYNA S;  US11464795-B2 -- US20030108628-A1   ;  CN102657660-A   SHANGHAI INST PHARM IND (CNPG);  UNIV SHANGHAI JIAO TONG MEDICINE SCHOOL (USJT)   CHEN H,  FANG C,  LIN M,  LU Q,  YANG G,  YANG Y,  YU D,  WANG Q,  ZHAO M,  ZHU W;  CN105769889-A   JIAN SHENGLIYUAN BIOTECHNOLOGY DEV CO (JIAN-Non-standard)   XIAO Y,  ZHANG N;  CN105998032-A   UNIV GUIZHOU MEDICAL (UGZM)   CHEN R,  DU K,  LI W,  TANG L,  WU H,  ZHANG J;  CN105998033-A   UNIV FUZHOU (UFZU)   SHAO J,  ZHENG G,  LIU Y,  JIANG K;  CN106038571-A   UNIV FUZHOU (UFZU)   SHAO J,  ZHENG G,  JIANG K;  CN106581006-A   UNIV HONG KONG POLYTECHNIC SHENZHEN RES (UYKP)   LI X,  DONG X,  ZHAO Q,  ZHANG H;  CN106619816-A   JINAN HAOYU QINGTIAN MEDICAL TECHNOLOGY (JINA-Non-standard);  CN106727854-A   JINAN HAOYU QINGTIAN MEDICAL TECHNOLOGY (JINA-Non-standard);  CN106749488-A   JIANGXI HERBFINE HI TECH CO LTD (UJXT)   FANG Y,  JIN Y,  FENG Y,  OU Y,  YANG S;  CN106822206-A   JINAN HAOYU QINGTIAN MEDICAL TECHNOLOGY (JINA-Non-standard);  JP04005235-A   ;  KR2003092170-A   UNIV HANDONG GLOBAL (UYHA-Non-standard)   JUNG M J,  KIM J B,  LEE G B,  SONG G S,  YOO Y C;  WO2015171598-A1   UNIV TEXAS SYSTEM (TEXA)   SLAGA T J,  JUNCO J,  LIANG H,  REYNA S;  CN109248170-B -- CN105708847-A   UNIV CHENGDU (UYUD)   FU J,  GUO X,  HU Y,  LI W,  ZHAO J,  YANG L,  ZHANG J,  ZHAO G,  ZOU L,  YU T	WO2019011293-A1  LI, SAINAN ET AL.:          "Extraction and in Vitro Screening of Potential          Acetylcholinesterase Inhibitors from the Leaves of Panax          Japonicus", JOURNAL OF CHROMATOGRAPHY B, vol. 1061 -10,          12 July 2017 (2017-07-12), pages 139 - 145,          XP085183280,relevantClaims[10];  SHIN, Y.K. ET AL.:          "Macelignan Inhibits Bee Pathogenic Fungi Ascophaera Apis          Growth Through H0G1 Pathway", BRAZILIAN JOURNAL OF          MEDICAL AND BIOLOGICAL RESEARCH, vol. 49, no. 7, 31          December 2016 (2016-12-31), pages e5313,          XP055565327,relevantClaims[10];  JANG, W.J. ET AL.:          "SB365, Pulsatilla Saponin D, Suppresses the Growth of          Gefitinib-Resistant NSCLC Cells with Met Amplification",          ONCOLOGY REPORTS, vol. 32, 31 December 2014 (2014-12-31),          pages 2612 - 2618,          XP055565331,relevantClaims[10];  SINGH, T.R. ET AL.:          "Study of Hypoglycemic Effect of Corosolic Acid & Its          Comparative Evaluation with Standard Drug Glibenclamide          in Alloxan Induced Diabetes in Female Albino Mice", THE          PHARMA INNOVATION JOURNAL, vol. 5, no. 10, 31 December          2016 (2016-12-31), pages 56 - 59,          XP055565333,relevantClaims[1-10]GB2578390-B            LI, SAINAN et al., "Extraction and in Vitro Screening of          Potential Acetylcholinesterase Inhibitors from the Leaves          of Panax Japonicus", Journal of Chromatography B,          (20170712), vol. 1061 -1062, pages 139 - 145,;            SHIN, Y.K. et al., "Macelignan Inhibits Bee Pathogenic          Fungi Ascophaera Apis Growth Through H0G1 Pathway",          Brazilian Journal of Medical and Biological Research,          (20161231), vol. 49, no. 7, page e5313,;            JANG, W.J. et al., "SB365, Pulsatilla Saponin D,          Suppresses the Growth of Gefitinib-Resistant NSCLC Cells          with Met Amplification", Oncology Reports, (20141231),          vol. 32, pages 2612 - 2618,;            SINGH, T.R. et al., "Study of Hypoglycemic Effect of          Corosolic Acid & Its Comparative Evaluation with          Standard Drug Glibenclamide in Alloxan Induced Diabetes          in Female Albino Mice", The Pharma Innovation Journal,          (20161231), vol. 5, no. 10, pages 56 - 59,US11464795-B2            Zarganes-Tzitzikas, T., Konstantinidou, M., Gao, Y.,          Krzemien, D., Zak, K., Dubin, G., . . . & Doemling,          A. (2016). Inhibitors of programmed cell death 1 (PD-1):          a patent review (2010-2015). Expert opinion on          therapeutic patents, 26(9), 973-977. (Year:          2016).;            Gong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia,          R. (2018). Development of PD-1 and PD-L1 inhibitors as a          form of cancer immunotherapy: a comprehensive review of          registration trials and future considerations. Journal          for immunotherapy of cancer, 6(1), 1-18. (Year:          2018).;            Skalniak, L., Zak, K. M., Guzik, K., Magiera, K.,          Musielak, B., Pachota, M., . . . & Holak, T. A.          (2017). Small-molecule inhibitors of PD-1/PD-L1 immune          checkpoint alleviate the PD-L1-induced exhaustion of          T-cells. Oncotarget, 8(42), 72167. (Year:          2017).;            English Translation of the International Search Report          corresponding to PCT/CN2018/095426 dated Sep. 27, 2018; 4          pages.;            Jang, Won-Jun et al., SB365 &lt;xhtml:i          &gt;Pulsatilla&lt;/xhtml:i&gt;saponin D,          suppresses the growth of gefitinib-resistant NSCLC cells          with Met amplification, &lt;xhtml:i &gt;Oncology          Reports&lt;/xhtml:i&gt;(Dec. 31, 2014)          32:2612-2618.;            Li, Sainan et al., Extraction and in vitro screening of          potential acetylcholinesterase inhibitors from the leaves          of &lt;xhtml:i &gt;Panax japonicas, Journal of          Chromatography B&lt;/xhtml:i&gt;; Accepted          manuscript (Jul. 12, 2017) vol. 1061-1062; pp. 139-145          (submission is 23 pages).;            Shin, Y. K. et al., Macelignan inhibits bee pathogenic          fungi &lt;xhtml:i &gt;Ascophaera          apis&lt;/xhtml:i&gt;growth through HOG1 pathway,          &lt;xhtml:i &gt;Brazilian Journal of Medical and          Biological Research&lt;/xhtml:i&gt;(Dec. 31,          2016) 49(7):e5313, pp. 1-9.;            Singh, Thakur Rohit et al., Study of hypoglycemic effect          of corosolic acid & its comparative evaluation with          standard drug glibenclamide in alloxan induced diabetes          in female albino mice, &lt;xhtml:i &gt;The Pharma          Innovation Journal&lt;/xhtml:i&gt;(Dec. 31, 2016)          5(10):56-59.;            First Examination Report dated Nov. 19, 2021          corresponding to GB2000501.3; 6 pages.;            Second Examination Report dated Feb. 4, 2022          corresponding to GB2000501.3; 2 pages.;            Avato et al., Antimicrobial Activity of Saponins from          &lt;xhtml:i          &gt;Medicago&lt;/xhtml:i&gt;sp.:Structure-Activity          Relationship, Phytotherapy Research, 20, 454-457, 2006, 5          pages.;            Choi et al., Anti-Rheumatoid Arthritis Effect of the          Kochia scoparia Fruits and Activity Comparison of          Momordin Ic, its Prosapogenin and Sapogenin, Archives of          Pharmacal Research, vol. 25, No. 3, 336-342, Mar. 5,          2002, 8 pages.;            Kashyap et al., Ursolic Acid and Oleanolic Acid:          Pentacycluc Terpenoids with Promising Anti-Inflammatory          Activities, Recent Patents on Inglammation & Allergy          Drug Discovery, vol. 10, No. 1, Jul. 3, 2016, 15          pages.;            Kim et al., Hederagenin Supplementation Alleviates the          Pro-Inflammatory and Apoptotic Response to Alcohol in          Rats, Nutrients, 9, 41, Jan. 6, 2017, 14 pages.;            Kong et al., Oleanolic acid and ursolic acid: Novel          hepatitis C virus antivirals that inhibit NS5B activity,          Antiviral Research, 98, 2013, 44-53.;            Liu et al., Hederagenin from the leaves of ivy (Hedera          helix L.) induces apoptosis in human LoVo colon cells          through the mitochondrial pathway, Bio Med Central          Complementary and Alternative Medicine, 14:412, 2014, 11          pages.;            Lucio et al., Oleanolic Acid Initiates Apoptosis in          Non-Small Cell Lung Cancer Cell Lines and Reduces          Metastasis of a B16F10 Melanoma Model In Vivo, PLoS One,          e28596, vol. 6, Issue 12, Dec. 2011, 11 pages.;            Luo et al., Triterpenoid saponins of Sanguisorba          Officinalis and their anti-inflammatory activity, Chinese          Journal of Medicinal Chemistry, vol. 18, No. 2, School of          Traditional Chinese Materia Medica, Shanyang          Pharmaceutical University, Shenyang 110016, China, Apr.          2008, 138-141, 5 pages.;            Reyes-Zurita et al., The natural triterpene maslinic acid          induces apoptosis in HT29 colon cancer cells by a          JNK-p53-dependent mechanism, BioMed Central Cancer,          11:154, 2011.;            Ryu et al., Antiviral Activity of Triterpenoid          Derivatives, Archives of Pharmacal Research, vol. 16, No.          4, 1993, 339-342, 5 pages.;  Wu          et al., Momordin Ic, a new natural SENP1 inhibitor,          inhibits prostate cancer cell proliferation, Oncotarget,          vol. 7, No. 37, 58995-59005, Jul. 16, 2016, 12          pages.;            Yanaki et al., In Vivo Antitumor Effects of MK615 Led by          PD-LI Downregulation, Integrative Cance Therapies, vol.          17(3), 2018, 646-653, 10 pages.;            Zhu et al., Ziyuglycoside II induces cell cycle arrest          and apoptosis through activation of ROS/JNK pathway in          human breast cancer cells, Key Laboratory of Nuclear          Medicine, Ministry of Health, Jiangsu Key Laboratory of          Molecular Nuclear Medicine, Jiangsu Institute of Nuclear          Medicine, Wuxi 214063, Jiangsu Province, China Toxicology          Letters 227 (2014) 65-73, 10 pages.	 K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U	212996802 K U; 212996801 K U	06384	RCJ6WN K U; RCJ6WO K U; RCJ6WP K U; RCJ6WQ K U; RCJ6WR K U; RCJ6WS K U; RCJ6WT K U; RCJ6WU K U; RCJ6WV K U; RCJ6WW K U; RCJ6WX K U; RCJ6WY K U; RCJ6WZ K U		WO2019043201-A1	Use of polypeptide comprising specific amino acid sequence as medicament to treat dyslipidemia or disease associated with dyslipidemia i.e. cardiovascular disease	LE GOFF W;  TREGOUET D;  CARRIE A;  COUVERT P	UNIV SORBONNE (USRB-C);  ASSISTANCE PUBLIQUE-HOPITAUX PARIS (ASSI-C);  INSERM NAT SANTE & RECH MEDICALE INST (INRM-C)	201923036K	   NOVELTY - Use of a polypeptide comprising amino acid sequence SEQ ID NO: 1 (comprising a fully defined sequence of 626 amino acids as given in the specification) or its homologous amino acid sequence, as a medicament, where the homologous amino acid sequence is defined as showing at least 80% identity with respect to SEQ ID NO: 1, while keeping the property of decreasing the hepatic expression of all four cholesteryl ester transfer protein (CETP), phospholipid transfer protein (Pltp), ATP-binding cassette sub-family G member 1 (Abcg1) and lipoprotein lipase (Lpl) genes when administered to a mammal subject, is claimed.    USE - The polypeptide is useful for treating a dyslipidemia or a disease associated with dyslipidemia, preferably where the disease associated with dyslipidemia is a cardiovascular disease (claimed). Test details are described but no results given.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:    (1) a nucleic acid for use as a medicament, where the nucleic acid encodes the polypeptide;    (2) a vector for use as a medicament, where the vector comprises the nucleic acid which encodes the polypeptide and preferably the vector is a viral vector and preferably the vector comprises a lentivirus, HIV, Simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), EAIV, canine influenza virus (CIV), alpha -virus, adenovirus, adeno associated virus, baculovirus, herpes simplex virus (HSV), coronavirus, bovine papilloma virus or Mo-murine leukemia virus (MLV);    (3) an agent for use in treating dyslipidemia or a disease associated with dyslipidemia in a subject, where the agent decreases the expression, preferably the hepatic expression of all four CETP, Pltp, Abcg1 and Lpl genes;    (4) an in vitro method for determining the likelihood for a subject to respond to a treatment with a CETP inhibitor, comprising identifying, in a biological sample of the subject, the presence of an alteration in the genetic sequence of the ZNF471 gene locus or in the ZNF471 expression or ZNF471 protein activity, where the presence of the alteration is indicative of a subject being likely to respond to the treatment; and    (5) an in vitro method for determining or adjusting the dosage or regimen of a CETP inhibitor in treating a subject afflicted with a dyslipidemia or a disease associated with dyslipidemia, comprising identifying, in a biological sample of the subject, the presence of an alteration in the genetic sequence of the ZNF471 gene locus or in the ZNF471 expression or ZNF471 protein activity, where a patient for whom an alteration in the genetic sequence of the ZNF471 gene locus or in the ZNF471 expression or ZNF471 protein activity is identified requires a higher dosage of the CETP inhibitor than a patient for whom such alteration is not detected. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-C01G;  B04-E02F;  B04-E03F;  B04-E08;  B04-E09;  B04-E99;  B04-F1100E;  B04-N02A;  B04-N11;  B11-C08E;  B12-K04E3;  B12-K04F;  B12-Q01A;  B14-D07A;  B14-F01;  B14-F02;  B14-F06A;  B14-L06;  D05-H09;  D05-H12A;  D05-H12E;  D05-H99	A61P-009/10;  C07K-014/47	WO2019043201-A1   07 Mar 2019   C07K-014/47   201921Pages: 50   English	WO2019043201-A1    WOEP073545    31 Aug 2018		EP306129    01 Sep 2017	WO2019043201-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  		WO2019043201-A1 -- US20150316566-A1   ;  WO2002059260-A2   ;  US20070184015-A1   	WO2019043201-A1  SERGI SAYOLS-BAIXERAS: "Materials and Methods Epigenome-Wide Association Study Approach", ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1 March 2017 (2017-03-01), pages 567 - 569, XP055417698, Retrieved from the Internet &lt;URL:http://atvb.ahajournals.org/content/atvbaha/37/3/567.full.pdf?download=true&gt; [retrieved on 20171020], DOI: 10.1161/ATVBAHA.116.308831,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  KANNEL ET AL., ANN INTERN MED., vol. 74, 1971, pages 1 - 12;  FERENCE ET AL., EUROPEAN HEART JOURNAL, vol. 0, 2017, pages 1 - 14;  KO ET AL., J AM COLL CARDIOL., vol. 68, no. 19, 2016, pages 2073 - 2083;  FREDERICKSON; LEE, CIRCULATION, vol. 31, 1965, pages 321 - 7;  NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453;  SMITH; WATERMAN: "Comparison of biosequences", ADV. APPL. MATH, vol. 2, 1981, pages 482, XP000869556, DOI: doi:10.1016/0196-8858(81)90046-4;  ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389;  WALENSKY ET AL., SCIENCE, vol. 305, 2004, pages 1466 - 1470;  SAMBROOK J; RUSSELL D: "Molecular cloning: a laboratory manual", 2001, COLD SPRING HARBOR;  WU, Z, MOL THER, vol. 14, 2006, pages 316 - 27;  CHOI, VW, J VIROL, vol. 79, 2005, pages 6801 - 07;  HOWARTH, CELL BIOL TOXICOL, vol. 26, 2010, pages 1 - 10;  PARRA ET AL., ARTERIOSCLERTHROMB, vol. 12, 1992, pages 701 - 707;  LARREDE ET AL., ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 29, 2009, pages 1930 - 1936;  DICK ET AL., LANCET, vol. 383, 2014, pages 1990 - 1998;  GERMAIN ET AL., AMERICAN JOURNAL OF HUMAN GENETICS, vol. 96, 2015, pages 532 - 542;  TREGOUET ET AL., ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 24, 2004, pages 775 - 781;  CORBEX ET AL., GENETIC EPIDEMIOLOGY, vol. 19, 2000, pages 64 - 80;  KHERA ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 364, 2011, pages 127 - 135;  GUAY ET AL., EPIGENETICS, vol. 9, 2014, pages 718 - 729;  SAMANI ET AL.: "Genomewide association analysis of coronary artery disease", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 357, 2007, pages 443 - 453;  HEINIG ET AL.: "A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk", NATURE, vol. 467, 2010, pages 460 - 464, XP055039900, DOI: doi:10.1038/nature09386;  DICK ET AL.: "DNA methylation and body-mass index: A genome-wide analysis", LANCET, vol. 383, 2014, pages 1990 - 1998						WO2019027670-A1;  CA3070102-A1;  US2020164055-A1;  BR112020001014-A2	Immunogenic composition for reducing the incidence            of or severity of a clinical sign or symptom of            infection by a tick-borne pathogen, comprises an            inactivated hole cell bacteria, e.g. Rickettsia,            Ehrlichia, and Anaplasma	GANTA R R	UNIV KANSAS STATE RES FOUND (UNIV-C);  UNIV KANSAS STATE RES FOUND (UNIV-C)	201913900G	   NOVELTY - An immunogenic composition comprises an                inactivated whole cell bacteria selected from                Rickettsia rickettsii, Ehrlichia chaffeensis,                Ehrlichia canis, Ehrlichia ruminantium, Anaplasma                marginale, Anaplasma phagocytophilum, and their                combination; and an adjuvant.    USE - The immunogenic composition, vaccine and                methods are used for reducing the incidence of or                severity of a clinical sign or symptom of infection                by a tick-borne pathogen; and reducing the                bacterial load of a tick-borne pathogen in a canine                or human. The clinical symptom or clinical sign is                caused by infection by R. rickettsia and is                selected from fever, headache, nausea, vomiting,                muscle pain, lack of appetite, rash, and death. The                clinical symptom or clinical sign is caused by                infection by E. chaffeensis and is selected from                fever, chills, headache, malaise, low-back pain,                conjuctival injection, rash, gastrointestinal                symptoms, myalgias, arthralgias, coughing,                pharyngitis, diarrhea, vomiting, abdominal pain,                and changes in mental status. The clinical symptom                or clinical sign is caused by infection by E. canis                and is selected from fever, lethargy, depression,                weight loss, swelling of lymph nodes or spleen,                decline in thrombocytes, anorexia, edema of the                limbs or scrotum, cough, splenomegaly,                glomerulonephritis, renal failure, interstitial                pneumonitis, anterior uveitis, meningitis with                associated cerebellar ataxia, paresis, and                hyperesthesia. The clinical symptom or clinical                sign is caused by infection by A. phagocytophilum                and is selected from loss of appetite, lethargy,                lameness, reluctance to move, neck pain, neurologic                signs, fever, chills, severe headache, muscle                aches, nausea, vomiting, diarrhea, respiratory                failure, bleeding problems, organ failure, and                death (all claimed).    ADVANTAGE - The vaccines are highly effective against                tick-borne diseases.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: (1) a                method of reducing the incidence of or severity of                a clinical sign or symptom of infection by a                tick-borne pathogen selected from R. rickettsii, E.                chaffeensis, E. canis, E. ruminantium, A.                marginale, A. phagocytophilum, and their                combination by administering a dose of an                immunogenic composition or vaccine comprising                inactivated whole cell bacteria selected from R.                rickettsii, E. chaffeensis, E. canis, E.                ruminantium, A. marginale, A. phagocytophilum, and                their combination, together with an adjuvant to an                animal; and (2) a method of reducing the bacterial                load of a tick-borne pathogen in a canine or human                by administering an immunogenic composition or                vaccine comprising inactivated tick-borne pathogens                selected from R. rickettsii, E. chaffeensis, E.                canis, E. ruminantium, A. marginale, A.                phagocytophilum, or their combination and an                adjuvant to a canine or human. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B14-C01;  B14-C03;  B14-C04;  B14-E02;  B14-E05;  B14-E11A;  B14-F08;  B14-J01;  B14-J05;  B14-K01;  B14-N03;  B14-N05B;  B14-N10;  B14-N15;  B14-N16;  B14-N17;  B14-S11D1;  C14-A01A7;  C14-C01;  C14-C03;  C14-C04;  C14-E02;  C14-E05;  C14-E11A;  C14-F08;  C14-J01;  C14-J05;  C14-K01;  C14-N03;  C14-N05B;  C14-N10;  C14-N15;  C14-N16;  C14-N17;  C14-S11D1;  D05-H08A	A61K-039/00;  A61K-039/02;  A61K-039/39;  A61K-047/06;  A61P-031/04	WO2019027670-A1   07 Feb 2019   A61K-039/00   201913Pages: 46   English;  CA3070102-A1   07 Feb 2019   A61K-039/00   202012   English;  US2020164055-A1   28 May 2020   A61K-039/02   202044   English;  BR112020001014-A2   14 Jul 2020   A61K-039/00   202061   English	WO2019027670-A1    WOUS042496    17 Jul 2018;   CA3070102-A1    CA3070102    17 Jul 2018;   US2020164055-A1    US16631964    17 Jan 2020;   BR112020001014-A2    BR11001014    17 Jul 2018	CA3070102-A1 PCT application Application WOUS042496;   CA3070102-A1 Based on Patent WO2019027670;   US2020164055-A1 PCT application Application WOUS042496;   US2020164055-A1 Provisional Application US533550P;   BR112020001014-A2 PCT application Application WOUS042496;   BR112020001014-A2 Based on Patent WO2019027670	US533550P    31 Jul 2017;  CA3070102    15 Jan 2020;  BR11001014    16 Jan 2020;  US16631964    17 Jan 2020	WO2019027670-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        		WO2019027670-A1 -- US20050202046-A1   ;  US20070237782-A1   ;  US20100239613-A1   ;  US20120045475-A1   ;  US2020164055-A1 -- US20100239613-A1   ;  US20120045475-A1   	WO2019027670-A1  GONG ET AL.:          "Chloroform-Methanol Residue of Coxiella bumetii Markedly          Potentiated the Specific Immunoprotection Elicited by a          Recombinant Protein Fragment rOmpB-4 Derived from Outer          Membrane Protein B of Rickettsia rickettsii in C3H/HeN          Mice", PLOS ONE, vol. 10, no. 4, 24 April 2015          (2015-04-24), pages 1 - 18,          XP055571296,relevantClaims[10],relevantPassages[. entire          document]US2020164055-A1            Mahan et al. Journal of Veterinary Research, vol.72,          pp.115-129, 2005. (Year: 2005);            Stun et al. Acta. Vet. Scand. 57-40 2015. (Year:          2015);            Thomas et al. PLoS One, vol.4, issue 11, 2011. (Year:          2011)	200757-0-0-0 K M			RA00GT K M		WO2019191261-A1;  CN112153981-A;  EP3773709-A1;  US2021046176-A1;  JP2021519085-W;  JP7329530-B2	Generating recombinant influenza neuraminidase            polypeptide, by calculating pair-wise matrices,            identifying and creating clusters of similar sequences,            comparing and determining consensus amino acid, and            generating influenza polypeptide	STRUGNELL T;  OLOO E;  OOMEN R;  VOGEL T;  SAELENS X;  JOB E;  OHMAN R	SANOFI PASTEUR INC (SNFI-C);  VIB VZW (VIBV-C);  UNIV GENT (UGNT-C);  AVENTIS PASTEUR INC (AVET-C);  VIB VZW (VIBV-C);  UNIV GENT (UGNT-C);  SANOFI PASTEUR INC (SNFI-C);  VIB VZW (VIBV-C);  UNIV GENT (UGNT-C);  SANOFI PASTEUR INC (SNFI-C);  VIB VZW (VIBV-C);  UNIV GENT (UGNT-C);  SANOFI PASTEUR INC (SNFI-C)	201983278S	   NOVELTY - Method for generating recombinant influenza                neuraminidase (NA) polypeptide comprising consensus                amino acids, involves (a) selecting more than one                influenza NA polypeptide sequence and aligning the                sequences, (b) calculating pair-wise                similarity/dissimilarity matrices, (c) identifying                and creating clusters of similar sequences from the                pair-wise similarity/dissimilarity matrices, (d)                determining whether there is a consensus amino acid                for each position in the sequence alignment using a                pair-wise alignment method within each cluster, (e)                generating a first sequence comprising consensus                amino acids and variable amino acids for each                cluster, (f) optionally, comparing the first                sequence generated in step (e) of a cluster with a                first sequence generated in another cluster or                multiple clusters, (g) determining a consensus                amino acid for each variable amino acid position,                and (h) generating the recombinant influenza NA                polypeptide comprising the consensus amino                acids.    USE - The method is useful for (a) generating                recombinant influenza NA polypeptide, (b)                immunizing a subject against influenza virus, (c)                inducing an immune response by producing antibodies                against one or more influenza virus strains, types,                or subtypes to influenza virus in a subject, or (d)                eliciting an immune response against one or more                influenza strains, types, and/or subtypes. The                influenza virus is a seasonal or pandemic influenza                virus. The subject is a mammal, preferably human                (all claimed).    ADVANTAGE - The method provides long-lasting protection                against influenza viruses including mismatched                strains.    DETAILED DESCRIPTION - Method for generating recombinant influenza                neuraminidase (NA) polypeptide comprising consensus                amino acids, involves (a) selecting more than one                influenza NA polypeptide sequence and aligning the                sequences, (b) calculating pair-wise                similarity/dissimilarity matrices, (c) identifying                and creating clusters of similar sequences from the                pair-wise similarity/dissimilarity matrices, (d)                determining whether there is a consensus amino acid                for each position in the sequence alignment using a                pair-wise alignment method within each cluster,                where if the frequency of the amino acid at a given                position is 50% or greater, that amino acid is                designated a consensus amino acid, and if the                frequency of the amino acid at a given position is                less than 50%, that amino acid is designated as a                variable amino acid, (e) generating a first                sequence comprising consensus amino acids and                variable amino acids for each cluster, (f)                optionally, comparing the first sequence generated                in step (e) of a cluster with a first sequence                generated in another cluster or multiple clusters                by (i) aligning the sequences generated in step (e)                for each cluster, (ii) determining whether there is                a consensus amino acid for each position in the                sequence alignment using a pair-wise alignment                method, where if the frequency of the amino acid at                a given position is 50% or greater, that amino acid                is designated a consensus amino acid, and if the                frequency of the amino acid at a given position is                less than 50%, that amino acid is designated as a                variable amino acid, and (iii) generating a second                sequence comprising consensus amino acids and                variable amino acids if clusters are analyzed, (g)                determining a consensus amino acid for each                variable amino acid position, by (i) generating a                set of test sequences based on the first or second                sequence, where test amino acids are placed at the                variable amino acid positions, (ii) performing                molecular modeling for each of the test sequences,                and (iii) determining a consensus amino acid for                each variable amino acid position by selecting                amino acid(s) that result in a polypeptide having a                negative total energy value within the first                sequence generated in step (e) or the second                sequence generated in step (f) (iii), and (h)                generating the recombinant influenza NA polypeptide                comprising the consensus amino acids. INDEPENDENT                CLAIMS are included for the following:    (1) a recombinant influenza NA polypeptide                generated using the method;    (2) a recombinant tetrameric NA protein                comprising one or more of the recombinant NA                polypeptides;    (3) an isolated nucleic acid encoding the                recombinant HA polypeptide or the recombinant                tetrameric NA protein;    (4) a vector comprising the nucleic                acid;    (5) an isolated cell comprising the                vector;    (6) a fusion protein comprising the                recombinant NA polypeptide or the recombinant                tetrameric NA protein;    (7) an influenza virus-like particle (VLP)                comprising the recombinant NA polypeptide or the                recombinant tetrameric NA protein; and    (8) a pharmaceutical composition comprising                the recombinant NA polypeptide, the recombinant                tetrameric NA protein, the fusion protein, or the                influenza VLP, and a carrier, excipient, or                adjuvant. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  T01 (Digital Computers)	B04-C01;  B04-E02H;  B04-E08;  B04-E99;  B04-F0100E;  B04-F0200E;  B04-L05B0E;  B04-N03K0E;  B04-N08;  B11-C11;  B14-A02B2;  B14-G01;  D05-H12C;  D05-H12E;  D05-H14;  D05-H17C;  D05-H99;  T01-J04C;  T01-J05B3;  T01-J06A	A61K-039/00;  A61K-039/12;  A61K-039/145;  C12N-007/00;  C12N-009/24;  G16B-015/20;  G16B-030/10;  A61P-031/16;  A61P-037/04;  C12N-015/44;  C12N-015/49;  C12N-015/56;  C12N-015/85;  C12N-005/07;  C12N-005/09;  C12N-005/10;  C07K-014/11;  C12P-021/02	WO2019191261-A1   03 Oct 2019   A61K-039/12   201981Pages: 123   English;  CN112153981-A   29 Dec 2020   A61K-039/12   202105   Chinese;  EP3773709-A1   17 Feb 2021   A61K-039/12   202116   English;  US2021046176-A1   18 Feb 2021   A61K-039/145   202120   English;  JP2021519085-W   10 Aug 2021   C12N-015/56   202165Pages: 70   Japanese;  JP7329530-B2   18 Aug 2023   C12P-021/02   202369   Japanese	WO2019191261-A1    WOUS024327    27 Mar 2019;   CN112153981-A    CN80033797    27 Mar 2019;   EP3773709-A1    EP777329    27 Mar 2019;   US2021046176-A1    US17041792    25 Sep 2020;   JP2021519085-W    JP551865    27 Mar 2019;   JP7329530-B2    JP551865    27 Mar 2019	CN112153981-A PCT application Application WOUS024327;   CN112153981-A Based on Patent WO2019191261;   EP3773709-A1 PCT application Application WOUS024327;   EP3773709-A1 Based on Patent WO2019191261;   US2021046176-A1 PCT application Application WOUS024327;   US2021046176-A1 Provisional Application US718527P;   US2021046176-A1 Provisional Application US649002P;   JP2021519085-W PCT application Application WOUS024327;   JP2021519085-W Based on Patent WO2019191261;   JP7329530-B2 PCT application Application WOUS024327;   JP7329530-B2 Based on Patent WO2019191261;   JP7329530-B2 Previous Publ. Patent JP2021519085	US649002P    28 Mar 2018;  US718527P    14 Aug 2018;  US17041792    25 Sep 2020;  CN80033797    19 Nov 2020	WO2019191261-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP3773709-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        		WO2019191261-A1 -- US20090175909-A1   ;  WO2016196846-A2   SANOFI PASTEUR INC (SNFI)   STRUGNELL T,  OLOO E,  OOMEN R;  CN112153981-A -- US20110229518-A1   ;  WO2016196846-A2   SANOFI PASTEUR INC (SNFI)   STRUGNELL T,  OLOO E,  OOMEN R	CN112153981-A            ALONSO-PADILLA JULIO ET AL.: "Computer-Aided Design of an          Epitope-Based Vaccine against Epstein-Barr Virus",          JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2017, pages 1 - 15,          XP055861714, DOI:          10.1155/2017/9363750,relevantClaims[1-35]	101849-0-0-0 K M P Q; 1562508-1-0-0 K M P Q; 101849-0-0-0 CL PRD RCT USE; 1562508-1-0-0 CL PRD RCT USE			RA0PTU K M P Q; RAS6IN K M P Q		WO2019196937-A1;  CN110372664-A;  CN112119070-A;  EP3782993-A1;  KR2021023814-A;  US2021179598-A1;  JP2021521214-W;  EP3782993-A4;  CN112119070-B	New pyridine compounds used in preparing medicine            for treating disease mediated by janus kinase-2            inhibitor including e.g. myelodysplastic syndrome and            tumor, inflammatory diseases, bacterial infection,            viral infection and fungal infection	LI H;  XU Y;  ZHAO Z;  ZHU L;  WANG W;  QI T;  SHI Y	UNIV EAST CHINA SCI & TECHNOLOGY (UYEC-C);  UNIV EAST CHINA SCI & TECHNOLOGY (UYEC-C);  UNIV EAST CHINA SCI & TECHNOLOGY (UYEC-C);  UNIV EAST CHINA SCI & TECHNOLOGY (UYEC-C)	201986514P	   NOVELTY - Pyridine compounds (I) or their salts,                stereoisomers, optical isomers, prodrugs or                solvates are new.    USE - (I) is useful in preparing medicine for                treating disease mediated by JAK2, including                myelodysplastic syndrome (MDS), cutaneous infection                caused by granulocytosis, tumor (including bone                marrow proliferation cancer (MPN), melanoma, lung                cancer, renal cancer, ovarian cancer, prostate                cancer, breast cancer, colon cancer, bone cancer,                pancreatic cancer, skin cancer, head and neck                cancer, uterine cancer, rectal cancer, anal cancer,                gastric cancer, testicular cancer, fallopian tube                carcinoma, endometrial carcinoma, cervical                carcinoma, vaginal cancer, vulva cancer, Hodgkin's                disease, non-Hodgkin's lymphoma, esophageal cancer,                small intestine cancer, endocrine system cancer,                thyroid cancer, parathyroid cancer, adrenal cancer,                soft tissue sarcoma, urethral cancer, penile                cancer, acute myeloid leukemia, chronic myeloid                leukemia, acute lymphoblastic leukemia, chronic                lymphocytic leukemia, pediatric solid tumor,                lymphocytic lymphoma, bladder cancer, kidney or                ureter cancer, renal pelvis cancer, cancer of the                central nervous system (CNS) tumor, primary CNS                lymphoma, tumor angiogenesis, spinal axis tumor,                brain stem glioma, pituitary adenoma, Kaposi's                sarcoma, epidermoid carcinoma, squamous cell                cancer, T-cell lymphoma, inflammatory diseases                (including rheumatoid arthritis, ankylosing                spondylitis, autoimmune hemolytic anemia,                arthritis, myasthenia gravis, systemic lupus                erythematosus, pernicious anemia or multiple                myositis), bacterial infection including chlamydia,                pneumococcus, cholera or tetanus caused by                Rickettsial, Mycobacterium, Staphylococcus aureus),                viral infection (including hepatitis C (influenza                A, B and C), herpes simplex, influenza caused by                Adenovirus, coronavirus, measles virus, dengue                fever virus, poliomyelitis virus or rabies virus),                or fungal infection i.e. candida caused by                Aspergillus or dermatitis bud yeast (all                claimed).    DETAILED DESCRIPTION - Pyridine compounds of formula (I) or their                salts, stereoisomers, optical isomers, prodrugs or                solvates are new.    R1 = H, halo, 1-10C alkyl, halogenated 1-10C                alkyl, 1-10C alkoxy, halogenated 1-10C alkoxy,                phenyl, benzyl, cyano, (-R7-O-R8), 5- or 6-membered                heterocyclic ring, 9- or 10-membered heterocyclic                ring, four- to six-membered ring group containing                nitrogen, oxygen and/or sulfur (optionally                substituted with oxo group (=O)), or                -NR5(R6);    R5 = H or 1-4C alkyl;    R6 = 1-10C alkyl, halogenated 1-10C alkyl,                cyano, halo, phenyl, benzyl, 5- or 6-membered                heterocyclic ring containing nitrogen, 9- or                10-membered heterocyclic ring;    R7 = 1-6C alkylene;    R8 = 1-6C alkyl, halogenated 1-6C alkyl, or                4-6 membered ring group containing oxygen, sulfur                and/or nitrogen;    R2 = phenyl, pyridyl, pyrimidinyl or 5-7C                cycloalkyl (optionally substituted with H, halo,                1-3C alkyl, halogenated 1-3C alkyl, 1-3C alkoxy or                halogenated 1-3C alkoxy);    R3 = H, halo, 1-10C alkyl, halogenated 1-10C                alkyl, hydroxy or 1-10C alkoxy;    R4 = H, 1-10C alkyl or 1-10C acyl; and    X = CH2, O, NH, S, SO or SO2 (optionally                substituted with 1-4C alkyl, 1-4C haloalkyl or                halo).    An INDEPENDENT CLAIM is also included for                medicinal composition comprising (I). 			B03 (Other heterocyclics.);  B02 (Fused ring heterocyclics.);  C02 (Heterocyclic.)	B06-H;  B07-D04B;  B14-A01;  B14-A02;  B14-A04;  B14-C03;  B14-C09;  B14-D06C;  B14-F03;  B14-G01;  B14-G02;  B14-H01;  B14-J05;  B14-N17;  C06-H;  C07-D04B;  C14-A01;  C14-A02;  C14-A04;  C14-C03;  C14-C09;  C14-D06C;  C14-F03;  C14-G01;  C14-G02;  C14-H01;  C14-J05;  C14-N17	A61K-031/4427;  C07D-213/73;  C07D-401/14;  A61K-031/4439;  A61K-031/444;  A61K-031/4545;  A61K-031/496;  A61P-019/02;  A61P-021/04;  A61P-029/00;  A61P-031/04;  A61P-031/10;  A61P-031/12;  A61P-031/14;  A61P-031/20;  A61P-035/00;  A61P-035/02;  A61P-007/06;  C07D-401/04;  C07D-401/10;  C07D-405/14;  A61K-031/519;  A61K-031/5377;  A61P-031/00;  C07D-401/12;  C07D-413/10;  C07D-417/04;  C07D-471/04;  C07D-487/04;  A61K-031/437;  A61K-031/506;  A61P-017/04;  A61P-021/00;  A61P-031/16;  A61P-037/02;  A61P-043/00;  C07D-213/74;  C07D-407/14;  C07D-413/04	WO2019196937-A1   17 Oct 2019   C07D-401/14   201984Pages: 53   Chinese;  CN110372664-A   25 Oct 2019   C07D-401/04   201985   Chinese;  CN112119070-A   22 Dec 2020   C07D-401/14   202102   Chinese;  EP3782993-A1   24 Feb 2021   C07D-401/14   202118   English;  KR2021023814-A   04 Mar 2021   C07D-401/14   202122   ;  US2021179598-A1   17 Jun 2021   C07D-413/10   202151   English;  JP2021521214-W   26 Aug 2021   C07D-213/74   202170Pages: 80   Japanese;  EP3782993-A4   08 Jun 2022   C07D-401/14   202248   English;  CN112119070-B   17 Feb 2023   C07D-401/14   202316   Chinese	WO2019196937-A1    WOCN082496    12 Apr 2019;   CN110372664-A    CN10331657    13 Apr 2018;   CN112119070-A    CN80025717    12 Apr 2019;   EP3782993-A1    EP784682    12 Apr 2019;   KR2021023814-A    KR732819    12 Apr 2019;   US2021179598-A1    US17046996    12 Oct 2020;   JP2021521214-W    JP556321    12 Apr 2019;   EP3782993-A4    EP784682    12 Apr 2019;   CN112119070-B    CN80025717    12 Apr 2019	CN112119070-A PCT application Application WOCN082496;   CN112119070-A Based on Patent WO2019196937;   EP3782993-A1 PCT application Application WOCN082496;   EP3782993-A1 Based on Patent WO2019196937;   KR2021023814-A PCT application Application WOCN082496;   KR2021023814-A Based on Patent WO2019196937;   US2021179598-A1 PCT application Application WOCN082496;   JP2021521214-W PCT application Application WOCN082496;   JP2021521214-W Based on Patent WO2019196937;   CN112119070-B PCT application Application WOCN082496;   CN112119070-B Previous Publ. Patent CN112119070;   CN112119070-B Based on Patent WO2019196937	CN10331657    13 Apr 2018;  WOCN082496    12 Apr 2019;  CN80025717    13 Oct 2020;  KR732819    13 Nov 2020	WO2019196937-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP3782993-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        EP3782993-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR    		WO2019196937-A1 -- CN103087050-A   SHANDONG XUANZHU PHARM CO LTD (SDXZ)   LIU Z;  CN104230890-A   XINNOUKAI BEIJING CHEM CO LTD (XINN-Non-standard);  US20130196952-A1   ;  WO2006021886-A1   PFIZER INC (PFIZ)   CUI J J,  FUNK L A,  JIA L,  KUNG P,  MENG J J,  NAMBU M D,  PAIRISH M A,  SHEN H,  TRAN-DUBE M B;  CN110372664-A -- CN103087050-A   SHANDONG XUANZHU PHARM CO LTD (SDXZ)   LIU Z;  CN103265477-A   SUGEN INC (PFIZ)   CUI J J;  CN104230890-A   XINNOUKAI BEIJING CHEM CO LTD (XINN-Non-standard);  CN107001317-A   XUANZHU PHARMA CO LTD (SDXZ)   WU F;  US20140051708-A1   ;  US20140271543-A1   ;  WO2006021886-A1   PFIZER INC (PFIZ)   CUI J J,  FUNK L A,  JIA L,  KUNG P,  MENG J J,  NAMBU M D,  PAIRISH M A,  SHEN H,  TRAN-DUBE M B;  WO2015003658-A1   BETTA PHARM CO LTD (BTTA)   HU S,  LIU X,  BAI J,  LONG W;  CN112119070-A -- CN103087050-A   SHANDONG XUANZHU PHARM CO LTD (SDXZ)   LIU Z;  CN104016979-A   HEC PHARM CO LTD (SUSN);  JIATUO SCI CO (JIAT-Non-standard)   WANG L,  XI N,  WANG R;  CN104230890-A   XINNOUKAI BEIJING CHEM CO LTD (XINN-Non-standard);  US20130196952-A1   ;  WO2006021886-A1   PFIZER INC (PFIZ)   CUI J J,  FUNK L A,  JIA L,  KUNG P,  MENG J J,  NAMBU M D,  PAIRISH M A,  SHEN H,  TRAN-DUBE M B;  WO2014146486-A1   ZHEJIANG DTRM BIOPHARMA CO LTD (ZHJA)   HE W;  US2021179598-A1 -- WO2006021881-A2   PFIZER INC (PFIZ)   CUI J J,  FUNK L A,  JIA L,  KUNG P,  MENG J J,  NAMBU M D,  PAIRISH M A,  SHEN H,  TRAN-DUBE M B;  EP3782993-A4 -- CN104230890-A   XINNOUKAI BEIJING CHEM CO LTD (XINN-Non-standard);  WO2014146486-A1   ZHEJIANG DTRM BIOPHARMA CO LTD (ZHJA)   HE W;  CN112119070-B -- CN103087050-A   SHANDONG XUANZHU PHARM CO LTD (SDXZ)   LIU Z;  CN104016979-A   HEC PHARM CO LTD (SUSN);  JIATUO SCI CO (JIAT-Non-standard)   WANG L,  XI N,  WANG R;  CN104230890-A   XINNOUKAI BEIJING CHEM CO LTD (XINN-Non-standard);  US20130196952-A1   ;  WO2006021886-A1   PFIZER INC (PFIZ)   CUI J J,  FUNK L A,  JIA L,  KUNG P,  MENG J J,  NAMBU M D,  PAIRISH M A,  SHEN H,  TRAN-DUBE M B;  WO2014146486-A1   ZHEJIANG DTRM BIOPHARMA CO LTD (ZHJA)   HE W	WO2019196937-A1  MAY-DRACKA, TRICIA          L. ET AL.: "Investigating small molecules to inhibit ger-          minal center kinase-like kinase (GLK/MAP4K3) upstream of          PKC theta phosphoryla- tion: Potential therapy to          modulate T cell dependent immunity", BIOORGANIC &          MEDICINAL CHEMISTRY LETTERS, vol. 28, no. 10, 1 June 2018          (2018-06-01), pages 1964 - 1971,          XP055644699,relevantClaims[1-8,          9],relevantPassages[,];  LEE, JOO YUN ET          AL.: "3D-QSAR Studies on Chemical Features of 3-          (benzo[d]oxazol-2-yl)pyridine-2-amines in the External          Region of c-Met Active Site", BULL. KOREAN CHEM. SOC.,          vol. 34, no. 12, 20 December 2013 (2013-12-20), pages          3553 - 3558, XP055331232,relevantClaims[1-8,          9],relevantPassages[,];  HUANG, QINHUA ET          AL.: "Design of Potent and Selective Inhibitors to          Overcome Clinical Anaplastic Lymphoma Kinase Mutations          Resistant to Crizotinib", J. MED. CHEM., vol. 57, no. 4,          27 February 2014 (2014-02-27), pages 1170 - 1187,          XP055331233,relevantClaims[1-8,          9],relevantPassages[,]CN110372664-A  TRICIA L.          MAY-DRACKA,ET AL.: "Investigating small molecules to          inhibit germinal center kinase-like kinase (GLK/MAP4K3)          upstream of PKCh phosphorylation: Potential therapy to          modulate T cell dependent immunity", BIOORGANIC &          MEDICINAL CHEMISTRY          LETTERS,relevantClaims[1-12|1-5],relevantPassages[1965Fig.          1Table 11966Table 2-31968Table 5-6197111];  COLUMBUS, OHIO, US          REGISTRY[ONLINE]: "STN", STN          REGISTRY,relevantClaims[1-5],relevantPassages[1-41];  :          "P-JAK2/P-STAT3p53",          ,relevantClaims[1-12],relevantPassages[221-225]CN112119070-A  QINHUA HUANG :          "Design of Potent and Selective Inhibitors to Overcome          Clinical Anaplastic Lymphoma Kinase Mutations Resistant          to Crizotinib", JOURNAL OF MEDICINAL          CHEMISTRY,relevantClaims[1-4,6-9],relevantPassages[1173Table          2];  TRICIA L.          MAY-DRACKA : "Investigating small molecules to inhibit          germinal center kinase-like kinase (GLK/MAP4K3) upstream          of PKC phosphorylation: Potential therapy to modulate T          cell dependent immunity", BIOORGANIC & MEDICINAL          CHEMISTRY          LETTERS,relevantClaims[1-4,6-9],relevantPassages[1966Table          21965Fig. 1197111];  WANQI WANG :          "Design, synthesis and structure-activity relationship          study of aminopyridine derivatives as novel inhibitors of          Janus kinase 2", BIOORGANIC & MEDICINAL CHEMISTRY          LETTERS,relevantClaims[1-14],relevantPassages[1509-1510Table          115072151211];  JOO YUN LEE :          "3D-QSAR Studies on Chemical Features of          3-(benzo[d]oxazol-2-yl)pyridine-2-amines in the External          Region of c-Met Active Site", BULL. KOREAN CHEM.          SOC.,relevantClaims[1-4,6-9],relevantPassages[3554Table          1]EP3782993-A4  LU XIAOYUN ET AL:          "Novel Anaplastic Lymphoma Kinase Inhibitors Targeting          Clinically Acquired Resistance", JOURNAL OF MEDICINAL          CHEMISTRY, vol. 57, no. 4, 27 February 2014 (2014-02-27),          US, pages 1167 - 1169, XP055870556, ISSN: 0022-2623,          Retrieved from the Internet          &lt;URL:https://pubs.acs.org/doi/pdf/10.1021/jm500178r&gt;          DOI:          10.1021/jm500178r,relevantClaims[1-9],relevantPassages[&lt;compound&gt;1a&lt;/compound&gt;];            See also references of WO 2019196937A1CN112119070-B            Wanqi Wang and so on. Design, synthesis and          structure-activity study of aminonesas Janus kinase 2,          Wanqi Wang et al., Bioorganic & Medicinal Chemistry          Letters, 20190406, No. 29, pp. 1509-1510 Table 1, 1507          page right column 2 section, 1512 page left column last 1          section to the right column 1 section;            Tricia L. May-Dracka et al. The invention claims a method          for controlling the production of the kinase-like kinase          (GLK/MAP4K3), wherein the method comprises the following          steps: Potential therapy to T cell dependent, Tricia L          May-Dracka and so on, Bioorganic & Medicinal          Chemistry Letters, 20180326, 28, 1966 page Table 2, 1965          page. 1. No. 1971 References 11.;            Joo Yun Lee et al. on 3D-QSAR external Region of c-Met,          Active Site; Joo Yun Lee et al., " Bull. Chem. Soc. ",          20131231, Voluth 34 (No. 12), Table 1, page 3554, page          1,;            Qinhua Huang and so on. Design of Potent and Selective          Inhibitors to Overcome Clinical Anaplastic Lymphoma          Kinase Mutations Residual Crizotinib, Qinhua Huang et          al., Journal of Medicinal Chemistry, 20140116, No. 57,          No. 1173 Table 2	 N;  N;  N;  N;  N; 1269739-1-0-0 N;  N;  N; 1269739-0-0-0 N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N; 1269748-0-0-0 N; 1269739-1-0-0 CL NEW; 1269739-0-0-0 CL NEW; 1269748-0-0-0 CL NEW	216994201 N	01199; 01183; 01268; 00044; 00094; 01269; 01272	RBSMYH N; RCOIGI N; RCOIF2 N; RCOIF3 N; RCOIF4 N; RAM1WO N; RCOIF5 N; RCOIF6 N; RALWNK N; RCOIF7 N; RCOIF8 N; RCOIF9 N; RCOIFA N; RCOIFB N; RCOIFC N; RCOIFD N; RCOIFE N; RCOIFF N; RCOIFG N; RCOIFH N; RCOIFI N; RCOIFJ N; RCOIFK N; RCOIFL N; RCOIFM N; RCOIFN N; RCOIFO N; RCOIFP N; RCOIFQ N; RCOIFR N; RCOIFS N; RCOIFT N; RCOIFU N; RCOIFV N; RCOIFW N; RCOIFX N; RCOIFY N; RCOIFZ N; RCOIG0 N; RCOIG1 N; RCOIG2 N; RCOIG3 N; RCOIG4 N; RCOIG5 N; RCOIG6 N; RCOIG7 N; RCOIG8 N; RCOIG9 N; RCOIGA N; RCOIGB N; RCOIGC N; RCOIGD N; RCOIGE N; RCOIGF N; RCOIGG N; RCOIGJ N; RCOIGH N; RALWNT N		CN110093458-A	New nested PCR primer useful in kit for performing non-diagnostic and therapeutic detection of atypical porcine pestivirus, comprises external primer and internal primer comprising base pair sequences	HE D;  WEI L;  SU D;  XIE Y;  LI J;  LIANG W;  SI G	UNIV SOUTH CHINA AGRIC (USCG-C)	2019701994	   NOVELTY - A nested PCR primer designed based on highly conserved specific sequences for detection of atypical porcine pestivirus, comprising external primer comprising a forward primer comprising a base pair sequence of SEQ ID NO: 1 and a reverse primer comprising a base pair sequence of SEQ ID NO: 2, and internal primer comprising a forward primer comprising a base pair sequence of SEQ ID NO: 3 and a reverse primer comprising a base pair sequence of SEQ ID NO: 4, is new.    USE - The nested PCR primer is useful in kit for performing non-diagnostic and therapeutic detection of atypical porcine pestivirus (all claimed).    ADVANTAGE - The nested PCR primer detects atypical porcine pestivirus with high sensitivity and specificity in a cost-effective manner, and with reduced requirements for operation level of the detection equipment and personnel. The kit detects a minimum of 10 copies/ mu l of atypical porcine pestivirus and does not detect one or more of Seneca Valley virus (SVV), swine delta -coronavirus, porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV), and porcine reproductive and respiratory syndrome (PRRSV).    DETAILED DESCRIPTION - A nested PCR primer designed based on highly conserved specific sequences for detection of atypical porcine pestivirus, comprising external primer comprising a forward primer comprising a base pair sequence of SEQ ID NO: 1 and a reverse primer comprising a base pair sequence of SEQ ID NO: 2, and internal primer comprising a forward primer comprising a base pair sequence of SEQ ID NO: 3 and a reverse primer comprising a base pair sequence of SEQ ID NO: 4, is new. accaat/catccccaaccaaag (SEQ ID NO: 1), tcataa/ggtgat/ccttg/cacctttttctt (SEQ ID NO: 2), tgcca/caaaaatgagaaaaga/ggat/cg (SEQ ID NO: 3), and tggt/cttccagat/cccct/caagtaagtc (SEQ ID NO: 4). INDEPENDENT CLAIMS are included for the following: (1) nested PCR method for detecting atypical porcine pestivirus, involves (a) extracting a nucleic acid template from the sample to be tested, (b) adding the external primer of the nested PCR primer to the first round reaction system of the nested PCR to amplify nucleic acid template and obtain a first round of PCR amplification product, (c) subjecting the first round of PCR amplification product to second round PCR amplification using internal primer, and amplifying to obtain second round of PCR amplification product, and (d) subjecting the second round of amplification products to agarose gel electrophoresis to obtain detection results; and (2) kit comprising the nested PCR primer, first-round reaction system comprising external primer, PrimeScript (RTM: Highly optimized premix reagents) 1 Step Enzyme Mix, 2x 1 Step buffer (Dye Plus), RNA of sample to be tested and RNase free distilled water, and the second-round amplification reaction system comprising first-round PCR amplification product, internal primer, deoxyribonucleotide triphosphate mixture, PCR buffer (added with magnesium ion), TaKaRaTaq (RTM: Highly purified, recombinant, thermostable, 94 kDa DNA polymerase) and RNase free distilled water. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E05;  B04-E99;  B04-F11B;  B04-L04A0E;  B11-C08D1;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  C04-E01;  C04-E05;  C04-E99;  C04-F11B;  C04-L04A0E;  C11-C08D1;  C11-C08E3;  C11-C08F8;  C12-K04F;  C12-K04G1B;  D05-A02B;  D05-H06A;  D05-H12D1;  D05-H18B;  D05-H99	C12N-015/11;  C12Q-001/686;  C12Q-001/70;  C12R-001/93	CN110093458-A   06 Aug 2019   C12Q-001/70   201971Pages: 18   Chinese	CN110093458-A    CN10454968    29 May 2019		CN10454968    29 May 2019			CN110093458-A -- CN104830994-A   ZHANGJIAKOU ANIMAL DISEASE PREVENTION (ZHAN-Non-standard)   YANG R;  CN106929606-A   UNIV SOUTH CHINA AGRIC (USCG)   SUN Y,  MA J,  LAN T,  MAI K	CN110093458-A  SEUNG-CHAI KIM : "Detection of atypical porcine pestivirus (APPV) from a case of congenital tremor in Korea", KOREAN J VET SERV,relevantClaims[1-10],relevantPassages[]	204644-0-0-0 D K M			RA031J D K M		CN110317256-A;  CN110317256-B	New duck-gamma interferon useful in preparation of medicament for preventing and/or treating duck viral disease e.g. duckling viral hepatitis, duck viral enteritis and gosling plague, comprises specific amino acid sequence	LIU X;  ZHANG Z;  HU X;  LI Y;  YI Y;  WANG P	CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS-C)	201987562G	   NOVELTY - A duck- gamma interferon comprising 164 amino acid sequence (SEQ ID NO: 1) fully defined in the specification, is new.    USE - The duck- gamma interferon is useful in preparation of medicament for preventing and/or treating duck viral disease. The duck viral disease is chosen from duckling viral hepatitis, duck plague or duck viral enteritis, gosling plague, muscovy duck parvovirus disease, young muscovy duck gosling plague, duck epidemic hemorrhagic or black feather disease, duck liver disease, duck viral encephalitis, duck reovirus infection, duck adenovirus infection, duck infectious cyst disease, duck paramyxovirus disease or duck Newcastle disease, duck coronavirus infection or duck flu (all claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) duck interferon- gamma mutant comprising 164 amino acid sequence (SEQ ID NO: 3) fully defined in the specification, where the nucleotide sequence of the coding gene comprises 495 base pair sequence (SEQ ID NO: 4) fully defined in the specification; (2) recombinant vector or recombinant host cell comprising the coding gene for duck- gamma interferon or the gene encoding the duck- gamma interferon mutant; (3) use of duck- gamma interferon, in preparation of medicament for preventing and/or treating duck viral disease; (4) method of preparing the duck- gamma interferon, involves cloning the coding gene of the duck- gamma interferon or the coding gene of the duck- gamma interferon mutant, involves constructing recombinant transfer vector, co-transfecting the constructed recombinant transfer vector with baculovirus DNA into insect cell to obtain recombinant baculovirus, infecting the baculovirus to infect an insect cell or an insect host, culturing the infected insect cell or the insect host to express the corresponding protein, and purifying protein, where the baculovirus transfer vector is chosen from AcRP23-lacZ, AcRP6-SC, AcUWl-lacZ, BacPAK6, Bac to Pac, Bacmid, BlucBacII (pETL), p2Bac, p2Blue, p89B310, pAc360, pAc373, pAcAB3, pAcAB4 , PAcAS3, pAcC129, pAcC4, DZI, pAcGP67, pAcIEl, pAcJPl, pAcMLF2, pAcMLF7, pAcMLF8, pAcMPl, pAcMP2, pAcRP23, pAcRP25, pAcRW4, pAcsMAG, pAcUWl, pAcUW21, pAcUW2A, pAcUW2B, pAcUW3, pAcUW31, pAcUW41, pAcUW42, pAcUW43, pAcUW51, pAcVC2, pAcVC3, pAcYMl, pAcJcC5, pBacl, pBac2, pBlueBacIII, pBlueBaSWis, pEV55, mXIV, pIEINeo, pJVETL, pJVNhel, pJVP10, pJVrsMAG, pMBac, pP10, pPAK1, pPBac, pSHONEX1.1, pSYN XIV VI+, pSYNVI Any of +wp, pSYNXIV VI-, pVL1391, pVL 1392, pVL 1393, pVL941, pVL 945, pVL 985, pVTBac, pBM030 or pUAC-5, the baculovirus parent strain is chosen from Bombyx mori, Baculovirus BmBacmid, BmNPV, AcMNPV, any one ApNPV, HaNPV, HzNPV, LdMNPV, MbMNPV, OpMNPV, SlMNPV, SeMNPV or SpltNPV, the insect host is chosen from B.mori, B.mandarina, P.cynthia, Dictyoploca japanica, Philosamia cynthiapryeri, Antheraea pernyi, Japanese tussah, Antheraea polyphymus, Atographa califorica, Ectropis obliqua, Mamestra brassicae, Spodoptera littoralis, S.frugiperda, Triswoplusia, Thaumetopoea wilkinsoni and Heliothis armigera, the infection is recombinant baculovirus infecting 1-5 year old insect larvae or carcasses by swallowing or permeating the epidermis. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-C01G;  B04-E08;  B04-E99;  B04-F0100E;  B04-H05C;  B04-H05C0E;  B14-A01A;  B14-A02;  B14-C03;  B14-E10C;  B14-F08;  B14-N12;  B14-N16;  B14-N17;  B14-S12;  C04-C01G;  C04-E08;  C04-E99;  C04-F0100E;  C04-H05C;  C04-H05C0E;  C14-A01A;  C14-A02;  C14-C03;  C14-E10C;  C14-F08;  C14-N12;  C14-N16;  C14-N17;  C14-S12;  D05-C12;  D05-H12E;  D05-H14;  D05-H17B2;  D05-H99	A61K-038/21;  A61P-031/12;  C07K-014/57;  C12N-015/23;  C12N-015/866	CN110317256-A   11 Oct 2019   C07K-014/57   201989Pages: 26   Chinese;  CN110317256-B   19 Feb 2021   C07K-014/57   202118   Chinese	CN110317256-A    CN10503365    11 Jun 2019;   CN110317256-B    CN10503365    11 Jun 2019	CN110317256-B Previous Publ. Patent CN110317256	CN10503365    11 Jun 2019			CN110317256-A -- CN108329390-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   ZHANG Z,  LI Y,  HU X,  ZHAO Z,  YI Y,  SHAO L,  YANG X,  LIU X,  ZHAO L,  MEHBOOB A;  CN108484750-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   LI Y,  ZHANG Z,  HU X,  YI Y,  LIU X,  SONG H,  YANG X,  DU M,  ZHANG W;  CN108707194-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   ZHANG Z,  LI Y,  HU X,  YI Y,  LIU X,  WANG X,  ZHAO L,  ZHAO Z,  WANG P;  US6642032-B2   COMMONWEALTH SCI & IND RES ORG (CSIR)   LOWENTHAL J W,  YORK J J,  ONEIL T E,  RHODES S,  DIGBY M R;  CN110317256-B -- CN108329390-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   ZHANG Z,  LI Y,  HU X,  ZHAO Z,  YI Y,  SHAO L,  YANG X,  LIU X,  ZHAO L,  MEHBOOB A;  CN108484750-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   LI Y,  ZHANG Z,  HU X,  YI Y,  LIU X,  SONG H,  YANG X,  DU M,  ZHANG W;  CN108707194-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   ZHANG Z,  LI Y,  HU X,  YI Y,  LIU X,  WANG X,  ZHAO L,  ZHAO Z,  WANG P;  US6642032-B2   COMMONWEALTH SCI & IND RES ORG (CSIR)   LOWENTHAL J W,  YORK J J,  ONEIL T E,  RHODES S,  DIGBY M R	CN110317256-A  : "", ,relevantClaims[89],relevantPassages[64-93];  ZHUANG,Y: "KF746069.1, Anas poecilorhyncha interferon gamma mRNA, complete cds", GENBANK:KF746069.1,relevantClaims[8-10|1-27],relevantPassages[FEATURESORIGIN];  GAO P: "Recombinant duck interferon gamma inhibits H5N1 influenza virus replication in vitro and in vivo", J INTERFERON CYTOKINE RES.,relevantClaims[1-10],relevantPassages[]CN110317256-B  Zhuang, Y and so on. KF746069.1, Anas poecilorhyncha interferon gamma mRNA, cds, Zhuang, Y and so on; GenBank: KF746069.1, 20140128, FEATURES and ORIGIN part;  Zhuang, Y and so on. KF746069.1, Anas poecilorhyncha interferon gamma mRNA, complete cds. GenBank: KF746069.1. 2014;  Gao Pei, and so on. duck interferon research progress and application, high and so on, breeding poultry and poultry disease prevention, 20160205, summary, 6 page 4-ninth page 3 section;  Gao P and so on. The invention claims a method for using the method of the invention, wherein the method comprises the following steps: (a), (a), (a), (a), (a), (a), (a), (a), Interferon Cytokine Res. " 20180731, Volute 38 (Phase 7);	97914-0-0-0 N P			R12268 N P; RA03HS N P		EP3546580-A1	Preparing mutant strain of Mycoplasma            hyopneumoniae (Mhyo) by transforming a strain of Mhyo            by using transposon vector comprising DNA sequence            coding for transposase, and exogenous DNA sequence            comprising marker gene	GONZALEZ GONZALEZ L;  PINOL RIBAS J;  MONTAGE GIRALT J;  CAMATS MALET M;  QUEROL MURILLO E;  SITJA ARNAU M	HIPRA SCI SLU (HIPR-Non-standard)	201983154C	   NOVELTY - Preparing a mutant strain of Mycoplasma                hyopneumoniae (Mhyo), involves transforming a                strain of Mhyo by using a transposon vector                comprising exogenous DNA sequence, that sequence                being under the control of a DNA sequence having a                degree of identity of greater than or equal to 80%                with a promoter region of Mhyo. The transposon                vector comprises: (1) a DNA sequence coding for a                transposase, (2) an exogenous DNA sequence                comprising a marker gene, and (3) optionally, an                additional exogenous DNA sequence. DNA sequence                coding for a transposase and at least one of the                exogenous DNA sequences are under the control of a                DNA sequence having a degree of identity of greater                than or equal to 80% with a promoter region of                Mhyo.    USE - The method or transposon vector is useful for                preparing mutant strain of Mhyo. The mutant strain                of Mhyo is useful for preparing a vaccine against                porcine enzootic pneumonia caused by Mhyo, and                optionally against another disease or additional                pathological conditions affecting pigs, where the                another disease or additional pathological                conditions affecting pigs is caused by a                microorganism, which is selected from                Actinobacillus sp., Brachyspira sp., Pasteurella                multocida, Salmonella sp., Streptococcus sp.,                Isospora sp., Erysipelothrix rhusiopathiae,                Leptospira sp., Staphylococcus sp., Haemophilus                parasuis, Bordetella bronchiseptica, Clostridium                sp., Mycoplasma sp., Lawsonia intracellularis,                Escherichia coli, porcine reproductive and                respiratory syndrome virus, swine influenza virus,                contagious gastroenteritis virus, porcine                parvovirus, encephalomyocarditis virus,                coronavirus, rotavirus, porcine circovirus, porcine                periweaning failure to thrive syndrome agent,                classical swine fever virus, African swine fever                virus, calicivirus and torque teno virus                (TTV).    ADVANTAGE - The exogenous DNA sequences can be stably                introduced into the cytoplasm or into the genome of                a strain of Mhyo.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) a transposon vector comprising: (1) a DNA                sequence coding for a transposase, (2) an exogenous                DNA sequence comprising a marker gene, and (3)                optionally, an additional exogenous DNA sequence,                where the DNA sequence coding for a transposase and                at least one of the exogenous DNA sequences are                under the control of a DNA sequence having a degree                of identity of greater than or equal to 80% with a                promoter region of Mhyo;    (2) a mutant strain of Mhyo, comprising the                transposon vector; or a mutant strain of Mhyo,                which is a mutant strain of Mhyo deposited at                Leibniz-Institute DSMZ and selected from a mutant                strain of Mhyo with the accession number DSM 26020;                a mutant strain of Mhyo with the accession number                DSM 26027; a mutant strain of Mhyo with the                accession number DSM 26033; a mutant strain of Mhyo                with the accession number DSM 26034; and a mutant                strain of Mhyo with the accession number DSM                26049;    (3) a vaccine for protecting pigs against                porcine enzootic pneumonia caused by Mhyo, and                optionally against another disease or additional                pathological conditions affecting pigs, comprising                an immunologically effective amount of the mutant                strain of Mhyo; and    (4) a vaccination kit for vaccinating pigs                against an infection or disease caused by Mhyo, and                optionally against another disease or pathological                conditions caused by microorganisms affecting pigs,                comprising a container comprising an                immunologically effective amount of the mutant                strain of Mhyo. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-E08;  B04-F10A4E;  B14-A01A4;  B14-A02B;  B14-S11D3;  B14-S12;  C04-E99;  C14-A01A4;  C14-A02B;  C14-S11D3;  C14-S12;  D05-H99;  D05-H07;  D05-H12E;  D05-H14A1	A61K-039/02;  C12N-015/74;  C12R-001/35	EP3546580-A1   02 Oct 2019   C12N-015/74   201978Pages: 61   English	EP3546580-A1    EP174710    09 Jul 2013	EP3546580-A1 Div ex Application EP766387;   EP3546580-A1 Div ex Patent EP2873733	EP382277    10 Jul 2012	EP3546580-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME  		EP3546580-A1 -- WO2011143706-A1   BIOPROPERTIES PTY LTD (BIOP-Non-standard)   YOUIL R,  ABS EL-OSTA Y;  WO2014174257-A2   ROYAL VETERINARY COLLEGE (ROYA-Non-standard)   RYCROFT A N,  MAGLENNON G A;  WO2010132932-A1   UNIV MELBOURNE (UYME);  BIOPROPERTIES PTY LTD (BIOP-Non-standard)   ABS EL-OSTA Y,  BROWNING G,  MARKHAM P,  YOUIL R	EP3546580-A1  BEATRIZ MACHADO          TERRA LOPES: "CONSTRUCAO DE VETOR ORIC DE MYCOPLASMA          HYOPNEUMONIAE - UMA FERRAMENTA PARA ESTUDOS GENETICOS DO          AGENTE DA PNEUMONIA ENZOOTICA SUINA", 2007, Porto Alegre,          XP002689217, Retrieved from the Internet          &lt;URL:http://www.lume.ufrgs.br/bitstream/handle/10183/11473/000613564.pdf?sequence=1&locale=en&gt;          [retrieved on          20121214],relevantClaims[1-21],relevantPassages[section          1.14 (p.23)];  HEDREYDA C T ET AL:          "Transformation of Mycoplasma pneumoniae with Tn4001 by          Electroporation", PLASMID, NEW YORK,NY, US, vol. 30, no.          2, 1 September 1993 (1993-09-01), pages 170 - 175,          XP024799159, ISSN: 0147-619X, [retrieved on 19930901],          DOI:          10.1006/PLAS.1993.1047,relevantClaims[1-21],relevantPassages[p.170-171;          Fig.1];  HALBEDEL ET AL:          "Tools for the genetic analysis of Mycoplasma",          INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, URBAN UND          FISCHER, DE, vol. 297, no. 1, 26 January 2007          (2007-01-26), pages 37 - 44, XP005863125, ISSN:          1438-4221, DOI:          10.1016/J.IJMM.2006.11.001,relevantClaims[1-21],relevantPassages[Section          "Transposons"];  ZIMMERMAN C U ET          AL: "Synthesis of a small, cysteine-rich, 29 amino acids          long peptide in Mycoplasma pneumoniae", FEMS MICROBIOLOGY          LETTERS, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 253,          no. 2, 15 December 2005 (2005-12-15), pages 315 - 321,          XP027871759, ISSN: 0378-1097, [retrieved on          20051215],relevantClaims[1-21],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  REDDY SHANKER P ET          AL: "Isolation and characterization of transposon          Tn4001-generated, cytadherence-deficient transformants of          Mycoplasma pneumoniae and Mycoplasma genitalium", FEMS          IMMUNOLOGY AND MEDICAL MICROBIOLOGY, vol. 15, no. 4,          1996, pages 199 - 211, XP002721523, ISSN:          0928-8244,relevantClaims[1-21],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  VASCONCELOS ANA          TEREZA R ET AL: "Swine and poultry pathogens: the          complete genome sequences of two strains of Mycoplasma          hyopneumoniae and a strain of Mycoplasma synoviae",          JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR          MICROBIOLOGY, WASHINGTON, DC; US, vol. 187, no. 16, 1          August 2005 (2005-08-01), pages 5568 - 5577, XP002513991,          ISSN: 0021-9193, DOI:          10.1128/JB.187.16.5568-5577.2005,relevantClaims[1-21],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  WEBER SHANA DE          SOUTO ET AL: "Unveiling Mycoplasma hyopneumoniae          Promoters: Sequence Definition and Genomic Distribution",          DNA RESEARCH, vol. 19, no. 2, April 2012 (2012-04-01),          pages 103 - 115,          XP002689218,relevantClaims[1-21],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            MINION ET AL.: "The Genome Sequence of Mycoplasma          hyopneumoniae Strain 232, the Agent of Swine          Mycoplasmosis", J. BACTERIOL., vol. 186, no. 21, 2004,          pages 7123 - 7133, XP002443117, DOI:          doi:10.1128/JB.186.21.7123-7133.2004;            MADSEN ET AL.: "Transcriptional Profiling of Mycoplasma          hyopneumoniae during Heat Shock Using Microarrays",          INFECT. IMMUN., vol. 74, no. 1, 2006, pages 160 -          166;            PICH ET AL.: "Comparative analysis of antibiotic          resistance marker genes in Mycoplasma genitalium:          application to studies of the minimal gene complement",          MICROBIOLOGY, vol. 152, 2006, pages 519 - 527;  B.          MACHADO, CONSTRUGAO DE VETOR ORIC DE MYCOPLASMA          HYOPNEUMONIAE - UMA FERRAMENTA PARA ESTUDOS GENETICOS DO          AGENTE DA PNEUMONIA ENZOTICA SULNA, 2007;  M.          CALCUTT: "Development of genetic manipulation protocols          for Mycoplasma hyopneumoniae clade of animal pathogens",          UNIVERSITY OF MISSOURI;            BROWNING ET AL.: "Developing attenuated vaccines to          control mycoplasmoses", MICROBIOLOGY, 2011, pages 121 -          122;            MABONI ET AL.: "Mycoplasma hyopneumoniae Transcription          Unit Organization: Genome Survey and Prediction", DNA          RESEARCH, vol. 18, 2011, pages 413 - 422, XP055104237,          DOI: doi:10.1093/dnares/dsr028;            DYBVIG ET AL., J. BACTERIOL, vol. 182, 2000, pages 4343 -          4347;            CHOW ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 45, no.          10, 2001, pages 2691 - 2694;            MINION ET AL., J. BACTERIOL., vol. 186, no. 21, 2004,          pages 7123 - 7133;            VASCONCELOS ET AL., J. BACTERIOL., vol. 187, no. 16,          2005, pages 5568 - 5577;            CARON ET AL., J. CLIN. MICROBIOL., vol. 38, no. 4, 2000,          pages 1390 - 1396;            "GenBank", Database accession no. AE017243;            SAMBROOKRUSSELL: "Molecular Cloning", 2001, COLD SPRING          HARBOR LABORATORY PRESS, COLD SPRING HARBOR;            "GenBank", Database accession no. AAC61864;            CAO ET AL., J. BACTERIOL., vol. 176, no. 14, 1994, pages          4459 - 4462;            "GenBank", Database accession no. AE017332;            "Remington The Science and Practice of Pharmacy", 2000,          LIPPINCOTT WILLIAMS & WILKINS;            R.C. ROWE ET AL.: "Handbook of Pharmaceutical          Excipients", 2003, PHARMACEUTICAL PRESS;            SAMBROOKRUSSELL: "Molecular Cloning", 2001, COLD SPRING          HARBOR LABORATORY PRESS;            AUSUBEL ET AL.: "Current Protocols In Molecular Biology",          1998, JOHN WILEY AND SONS, INC.;            PICH ET AL., MICROBIOLOGY, vol. 152, 2006, pages 519 -          527;            "GenBank", Database accession no. AE017332.1;            QUINTANA ET AL., VETERINARY RECORD, vol. 149, 2001, pages          357 - 361;            OLVERA ET AL., J. VIROL. METH., vol. 10, no. 117, 2004,          pages 75 - 80;            FORT ET AL., VET. IMMUNOL. IMMUNOPATHOL., vol. 137, 2010,          pages 226 - 234;            CHRISTENSEN ET AL.: "Diseases of the respiratory system.          In: Diseases of Swine", 1999, IOWA STATE UNIVERSITY          PRESS, pages: 914	200757-0-0-0 K P			RA00GT K P		WO2019191295-A1;  US2019300592-A1;  US2019359672-A1;  US10787494-B2;  AU2019244091-A1;  CA3094112-A1;  AR115024-A1;  KR2020136453-A;  CN112154153-A;  BR112020018709-A2;  SG11202009017-A1;  EP3774861-A1;  IN202017047059-A;  TW202003551-A;  JP2021519094-W;  US11359000-B2;  US2022348625-A1;  HK40036999-A0;  IL277288-A;  AU2019244091-B2;  AU2023270286-A1;  JP7464530-B2	New fusion protein comprising first polypeptide            comprising interleukin-2 (IL2) polypeptide and second            polypeptide comprising extracellular domain of IL-2            receptor alpha polypeptide having fewer glycosylation            used to	STRUTHERS M;  DAVIS J H;  DOYLE M L;  MADIA P A;  SINHAROY M S	BRISTOL-MYERS SQUIBB CO (BRIM-C);  BRISTOL-MYERS SQUIBB CO (BRIM-C);  BRISTOL-MYERS SQUIBB CO (BRIM-C);  BRISTOL MYERS SQUIBB CO (BRIM-C);  BRISTOL MYERS SQUIBB CO (BRIM-C)	2019837095	   NOVELTY - Fusion protein comprising a first polypeptide                comprising an interleukin-2 (IL2) polypeptide and a                second polypeptide comprising an extracellular                domain of an IL-2 receptor alpha (IL2R alpha )                polypeptide, is new, where the extracellular domain                of the IL2R alpha polypeptide has at least one                fewer glycosylation compared to the extracellular                domain of native IL2R alpha (SEQ ID NO: 7                comprising fully defined sequence of 219 amino                acids as given in the specification) and/or the IL2                polypeptide has at least one fewer glycosylation                compared to native IL2 (SEQ ID NO: 2 comprising                fully defined sequence of 133 amino acids as given                in the specification), and the fusion protein has                IL2 activity.    USE - The fusion protein is useful for treating a                disease or disorder, where the disease or disorder                is cancer e.g. bladder cancer, breast cancer,                uterine cancer, endometrial carcinoma, ovarian                cancer, colorectal cancer, colon cancer, head and                neck cancer, lung cancer, stomach cancer, germ cell                cancer, bone cancer, squamous cell cancer, skin                cancer, neoplasm of the CNS, lymphoma, leukemia,                sarcoma, small-cell lung cancer, non-small cell                lung cancer, gastrointestinal cancer, Hodgkin's or                non-Hodgkin's lymphoma, pancreatic cancer,                glioblastoma and/or glioma, an inflammatory disease                or an autoimmune disease consisting of type 1                diabetes, multiple sclerosis, rheumatoid arthritis,                celiac disease, systemic lupus erythematosus, lupus                nephritis, cutaneous lupus, juvenile idiopathic                arthritis, Crohn's disease, ulcerative colitis or                systemic sclerosis, graft versus host disease,                psoriasis, alopecia areata, HCV induced vasculitis,                Sjogren's syndrome, pemphigus, ankylosing                spondylitis, Behcet's disease, Wegener's                granulomatosis, Takayasu's disease, autoimmune                hepatitis, sclerosing cholangitis, Gougerot-Sjogren                syndrome or macrophage activation syndrome, an                infectious disease caused by a pathogenic virus                (consisting of HIV, hepatitis A-C, herpes virus,                adenovirus, influenza virus, flaviviruses,                echovirus, rhinovirus, coxsackie virus,                coronavirus, respiratory syncytial virus, mumps                virus, rotavirus, measles virus, rubella virus,                parvovirus, vaccinia virus, human T-lymphotropic                (HTL) virus, dengue virus, papillomavirus,                molluscum virus, poliovirus, rabies virus, John                Cunningham (JC) virus or arboviral encephalitis                virus) or bacteria (consisting of Chlamydia,                rickettsial bacteria, mycobacteria, staphylococci,                streptococci, pneumococci, meningococci and                gonococci, Klebsiella, Proteus, Serratia,                Pseudomonas, Legionella, diphtheria, Salmonella,                bacilli, cholera, tetanus, botulism, anthrax,                plague, leptospirosis and Lymes disease bacteria),                fungi (consisting of Candida albicans, Candida                krusei, Candida glabrata, Candida tropicalis,                etc.), Cryptococcus neoformans, Aspergillus                fumigatus, Aspergillus niger, etc.), Genus                Mucorales (Mucor, Absidia, Rhizopus), Sporothrix                schenckii, Blastomyces dermatitidis,                Paracoccidioides brasiliensis, Coccidioides immitis                and Histoplasma capsulatum), parasite (consisting                of Entamoeba histolytica, Balantidium coli,                Naegleria fowleri, Acanthamoeba sp. Giardia                lamblia, Cryptosporidium sp., Pneumocystis carinii,                Plasmodium vivax, Babesia microti, Trypanosoma                brucei, Trypanosoma cruzi, Leishmania donovani,                Toxoplasma gondii and Nippostrongylus brasiliensis)                (all claimed).    ADVANTAGE - The fusion protein exhibits: at least one                property consisting of increased thermodynamic                stability, increased TM, increased resistant to                degradation, increased resistance to modifications                and/or increased stability in vivo compared to a                reference protein; at least one pharmacokinetic                property consisting of an increased or extended                half-life, increased Cmax, increased AUC, increased                Cmin, decreased clearance and/or improved                bioavailability, compared to the pharmacokinetic                property of the polypeptide consisting of SEQ ID                NO: 2 or SEQ ID NO: 13, where the extended                half-life is at least 1.5 fold, preferably at least                22 fold compared to the half-life of a polypeptide                of SEQ ID NO: 2 or SEQ ID NO: 13.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) a nucleic acid that encodes the fusion                protein;    (2) a vector comprising the nucleic                acid;    (3) a host cell comprising the nucleic                acid;    (4) a kit comprising the fusion protein, the                nucleic acid, the vector, or the host cell and                instructions for administering the fusion protein                to a subject;    (5) producing the fusion protein; and    (6) treating a disease or disorder, comprising                administering the fusion protein, the nucleic acid,                the vector or the host cell. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.);  A25 (Polyurethanes; polyethers.)	B04-B04D2;  B04-C01G;  B04-E02H;  B04-E08;  B04-E99;  B04-F0100E;  B04-G01;  B04-G04;  B04-G27G0E;  B04-H02B0E;  B04-K01G0E;  B04-N0400E;  B14-A01;  B14-A02B;  B14-C03;  B14-C09;  B14-E08;  B14-E10C;  B14-F02;  B14-G02;  B14-H01;  B14-N10;  B14-N12;  B14-N16;  B14-N17;  B14-R02;  B14-S01;  B14-S03A;  B14-S04;  B14-S11A;  B14-S16;  B14-S21;  D05-H12C;  D05-H12E;  D05-H14;  D05-H17C;  D05-H99;  A10-E01;  A11-C03;  A12-V01;  A12-W11L	A61K-038/20;  C07K-014/55;  C07K-014/715;  A61K-047/65;  A61P-037/04;  C07K-016/28;  A61K-038/00;  A61K-038/17;  C12N-015/62;  C12N-015/13;  C12N-015/85;  C12N-005/10;  A61P-031/00;  A61P-035/00;  A61K-031/17;  A61K-031/196;  A61K-031/4164;  A61K-031/436;  A61K-031/454;  A61K-031/4745;  A61K-031/475;  A61K-031/573;  A61K-031/675;  A61K-031/69;  A61K-031/704;  A61K-031/7088;  A61K-033/24;  A61K-035/12;  A61K-038/14;  A61K-038/16;  A61K-039/395;  A61K-045/00;  A61K-047/60;  A61K-047/64;  A61K-047/68;  A61P-001/04;  A61P-001/16;  A61P-013/12;  A61P-017/00;  A61P-017/06;  A61P-017/14;  A61P-019/02;  A61P-025/00;  A61P-029/00;  A61P-003/10;  A61P-031/04;  A61P-031/10;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-031/18;  A61P-031/20;  A61P-031/22;  A61P-033/00;  A61P-033/02;  A61P-033/04;  A61P-033/06;  A61P-035/02;  A61P-037/02;  C07K-019/00;  C12N-001/19;  C12N-001/21;  C12N-015/26;  C12N-015/63;  C12P-021/02;  C07D-401/04;  C07D-471/04;  C07D-498/18;  C07D-519/04;  C07H-015/252;  C07J-005/00;  C07K-014/495;  C07K-014/57	WO2019191295-A1   03 Oct 2019   C07K-014/55   201981Pages: 153   English;  US2019300592-A1   03 Oct 2019   C07K-014/55   201981   English;  US2019359672-A1   28 Nov 2019   C07K-014/55   201992   English;  US10787494-B2   29 Sep 2020   A61K-038/20   202080   English;  AU2019244091-A1   08 Oct 2020   C07K-014/55   202082   English;  CA3094112-A1   03 Oct 2019   C07K-014/55   202083   English;  AR115024-A1   18 Nov 2020   C07K-014/55   202095   Spanish;  KR2020136453-A   07 Dec 2020   C07K-014/55   202001   ;  CN112154153-A   29 Dec 2020   C07K-014/55   202107   Chinese;  BR112020018709-A2   05 Jan 2021   C07K-014/55   202110   English;  SG11202009017-A1   29 Oct 2020   C07K-014/55   202110   English;  EP3774861-A1   17 Feb 2021   C07K-014/55   202117   English;  IN202017047059-A   12 Feb 2021   C07K-014/55   202119   English;  TW202003551-A   16 Jan 2020   C07K-014/55   202136   Chinese;  JP2021519094-W   10 Aug 2021   C12N-015/62   202165Pages: 131   Japanese;  US11359000-B2   14 Jun 2022   C07K-014/55   202249   English;  US2022348625-A1   03 Nov 2022   C07K-014/55   202289   English;  HK40036999-A0   04 Jun 2021   C07K-014/55   202200   English;  IL277288-A   29 Oct 2020   A61K-038/00   202340   English;  AU2019244091-B2   07 Dec 2023   C07K-014/55   202399   English;  AU2023270286-A1   01 Feb 2024   C07K-014/55   202411   English;  JP7464530-B2   09 Apr 2024   C12N-015/62   202432   Japanese	WO2019191295-A1    WOUS024376    27 Mar 2019;   US2019300592-A1    US366838    27 Mar 2019;   US2019359672-A1    US435420    07 Jun 2019;   US10787494-B2    US435420    07 Jun 2019;   AU2019244091-A1    AU244091    27 Mar 2019;   CA3094112-A1    CA3094112    27 Mar 2019;   AR115024-A1    AR100781    27 Mar 2019;   KR2020136453-A    KR730629    27 Mar 2019;   CN112154153-A    CN80033780    27 Mar 2019;   BR112020018709-A2    BR11018709    27 Mar 2019;   SG11202009017-A1    SG11009017    27 Mar 2019;   EP3774861-A1    EP719678    27 Mar 2019;   IN202017047059-A    IN17047059    28 Oct 2020;   TW202003551-A    TW110805    27 Mar 2019;   JP2021519094-W    JP552003    27 Mar 2019;   US11359000-B2    US366838    27 Mar 2019;   US2022348625-A1    US663384    13 May 2022;   HK40036999-A0    HK6026377    26 Feb 2021;   IL277288-A    IL277288    27 Mar 2019;   AU2019244091-B2    AU244091    27 Mar 2019;   AU2023270286-A1    AU270286    23 Nov 2023;   AU2023270286-A1    AU270286    23 Nov 2023;   JP7464530-B2    JP552003    27 Mar 2019	US2019300592-A1 Provisional Application US649379P;   US2019359672-A1 Provisional Application US649379P;   US2019359672-A1 Cont of Application US366838;   US10787494-B2 Provisional Application US649379P;   US10787494-B2 Cont of Application US366838;   US10787494-B2 Previous Publ. Patent US2019359672;   AU2019244091-A1 PCT application Application WOUS024376;   AU2019244091-A1 Based on Patent WO2019191295;   CA3094112-A1 PCT application Application WOUS024376;   CA3094112-A1 Based on Patent WO2019191295;   KR2020136453-A PCT application Application WOUS024376;   KR2020136453-A Based on Patent WO2019191295;   CN112154153-A PCT application Application WOUS024376;   CN112154153-A Based on Patent WO2019191295;   BR112020018709-A2 PCT application Application WOUS024376;   BR112020018709-A2 Based on Patent WO2019191295;   SG11202009017-A1 PCT application Application WOUS024376;   SG11202009017-A1 Based on Patent WO2019191295;   EP3774861-A1 PCT application Application WOUS024376;   EP3774861-A1 Based on Patent WO2019191295;   IN202017047059-A PCT application Application WOUS024376;   IN202017047059-A Based on Patent WO2019191295;   JP2021519094-W PCT application Application WOUS024376;   JP2021519094-W Based on Patent WO2019191295;   US11359000-B2 Provisional Application US649379P;   US11359000-B2 Previous Publ. Patent US2019300592;   US2022348625-A1 Provisional Application US649379P;   US2022348625-A1 Div ex Application US366838;   US2022348625-A1 Div ex Patent US11359000;   HK40036999-A0 PCT application Application WOUS024376;   HK40036999-A0 Based on Patent WO2019191295;   HK40036999-A0 Previous Publ. Patent EP3774861;   IL277288-A Based on Patent WO2019191295;   AU2019244091-B2 PCT application Application WOUS024376;   AU2019244091-B2 Based on Patent WO2019191295;   AU2023270286-A1 Div ex Application AU244091;   JP7464530-B2 PCT application Application WOUS024376;   JP7464530-B2 Previous Publ. Patent JP2021519094;   JP7464530-B2 Based on Patent WO2019191295	US649379P    28 Mar 2018;  AU244091    27 Mar 2019;  EP719678    27 Mar 2019;  US366838    27 Mar 2019;  US435420    07 Jun 2019;  BR11018709    14 Sep 2020;  CA3094112    15 Sep 2020;  KR730629    23 Oct 2020;  CN80033780    19 Nov 2020;  US663384    13 May 2022;  AU270286    23 Nov 2023	WO2019191295-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA                      EP3774861-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                      		WO2019191295-A1 -- WO2013184942-A1   ALKERMES INC (AMES)   ALVAREZ J,  CHAMOUN J;  WO2016022671-A1   UNIV MIAMI (UYMI)   MALEK T;  WO2016100788-A1   ALKERMES INC (AMES)   ALVAREZ J,  MOUSTAKAS D T,  BRODKIN H R,  MCSWEENEY L A;  WO2010020766-A2   ASTERION LTD (ASTE-Non-standard)   ARTYMIUK P,  ROSS R;  WO2011123683-A2   UNIV ROCHESTER (UYRP)   FRELINGER J G,  PUSKAS J,  KIM B,  SULLIVAN M;  WO2017201432-A2   JOUNAIDI Y (JOUN-Individual);  FORMAN S (FORM-Individual);  MILLER K (MILL-Individual);  COTTEN J F (COTT-Individual)   JOUNAIDI Y,  FORMAN S,  MILLER K,  COTTEN J F;  US4179337-A   DAVIS F F (DAVI-Individual)   DAVIS F F,  VANES T,  PALCZUK N C,  VAN ES T;  US4522811-A   SYNTEX (USA) (SYNT)   EPPSTEIN D A,  FRASERSMIT E B,  MATTHEWS T R,  FRASER-SMITH E B;  US4683195-A   CETUS CORP (CETU)   MULLIS K B,  ARNHEIM N,  SAIKI R K,  ERLICH H A,  HORN G T,  SCHARF S J;  US4683202-A   CETUS CORP (CETU)   MULLIS K B,  ARNHEIM N,  SAIKI R K,  ERLICH H A,  HORN G T,  SCHARF S J;  US4704362-A   GENENTECH INC (GETH)   ITAKURA K,  RIGGS A D;  US4800159-A   CETUS CORP (CETU)   MULLIS K B,  ARNHEIM N,  SAIKI R K,  ERLICH H A,  HORN G T,  SCHARF S J;  US4965188-A   CETUS CORP (CETU)   ERLICH H A,  HORN G,  SAIKI R K,  STOFFEL S,  MULLIS K B,  LAWYER F C,  GELFAND D H;  US5643575-A   ENZON INC (ENZO-Non-standard)   GREENWALD R B,  MARTINEZ A;  US5648260-A   MEDICAL RES COUNCIL (MRCX)   WINTER G P,  DUNCAN A R,  BURTON D R;  US5736137-A   IDEC PHARM CORP (BIOJ)   ANDERSON D R,  RASTETTER W H,  HANNA N,  LEONARD J E,  NEWMAN R A,  REFF M E;  US5739277-A   GENENTECH INC (GETH)   SNEDECOR B R,  PRESTA L G;  US5811097-A   UNIV CALIFORNIA (REGC)   ALLISON J P,  LEACH D R,  KRUMMEL M F;  US5834250-A   GENENTECH INC (GETH)   CUNNINGHAM B C,  WELLS J A;  US5837243-A   MEDAREX INC (BRIM)   SOMASUNDARAM C,  GRAZIANO R,  DEO Y M,  GOLDSTEIN J;  US5846951-A   SCHOOL OF PHARMACY (SCHO-Non-standard)   GREGORIADIS G;  US5869046-A   GENENTECH INC (GETH)   PRESTA L G,  SNEDECOR B R;  US5922845-A   MEDAREX INC (BRIM)   DEO Y M,  GRAZIANO R,  KELER T;  US6030613-A   BRIGHAM & WOMENS HOSPITAL (BGHM);  UNIV BRANDEIS (UYEB)   BLUMGERG R S,  SIMISTER N E,  LENCER W I;  US6086875-A   BRIGHAM & WOMENS HOSPITAL (BGHM);  UNIV BRANDEIS (UYEB)   BLUMBERG R S,  SIMISTER N E,  LENCER W I;  US6096871-A   GENENTECH INC (GETH)   PRESTA L G,  SNEDECOR B R;  US6121022-A   GENENTECH INC (GETH)   PRESTA L G,  SNEDECOR B R;  US6159730-A   IDEC PHARM CORP (BIOJ)   REFF M E;  US20030069395-A1   ;  US20030235536-A1   ;  US20060160187-A1   ;  US20060269515-A1   ;  US20070191597-A1   ;  US20070231329-A1   ;  US20070237765-A1   ;  US20070237766-A1   ;  US20070237767-A1   ;  US20070243188-A1   ;  US20070248603-A1   ;  US20070286859-A1   ;  US20080004206-A1   ;  US20080057056-A1   ;  US20080153751-A1   ;  US20080161243-A1   ;  US20080194481-A1   ;  US20080261877-A1   ;  US20090058322-A1   ;  US20100239554-A1   ;  US20100292130-A1   ;  US20100323956-A1   ;  US20110046060-A1   ;  US20110046061-A1   ;  US20110077199-A1   ;  US20110172146-A1   ;  US20150218260-A1   ;  US20170210777-A1   ;  US20170327555-A1   ;  US20170334954-A1   ;  US20180037624-A1   ;  US20180125941-A1   ;  US6193980-B1   UNIV CAMBRIDGE TECH SERVICES LTD (UYCA)   EFSTATHIOU S,  LACHMANN R H;  US6194551-B1   GENENTECH INC (GETH)   IDUSOGIE E E,  PRESTA L G,  MULKERRIN M G;  US6242195-B1   GENENTECH INC (GETH)   IDUSOGIE E E,  MULKERRIN M G,  PRESTA L G,  SHIELDS R L;  US6277375-B1   UNIV TEXAS SYSTEM (TEXA)   WARD E S;  US6413777-B1   IDEC PHARM CORP (BIOJ)   REFF M E,  BARNETT R S,  MCLACHLAN K R;  US6485726-B1   BRIGHAM & WOMENS HOSPITAL INC (BGHM);  UNIV BRANDEIS (UYEB)   BLUMBERG R S,  SIMISTER N E,  LENCER W I;  US6528624-B1   GENENTECH INC (GETH)   IDUSOGIE E E,  MULKERRIN M G,  PRESTA L G,  SHIELDS R L;  US6538124-B1   GENENTECH INC (GETH)   IDUSOGIE E E,  PRESTA L G,  MULKERRIN M G;  US6737056-B1   GENENTECH INC (GETH)   PRESTA L G;  US6998253-B1   GENENTECH INC (GETH)   PRESTA L G,  SNEDECOR B R;  US6696245-B2   MEDICAL RES COUNCIL (MRCX)   TOMLINSON I,  WINTER G;  US6821505-B2   UNIV TEXAS SYSTEM (TEXA)   WARD E S;  US7083784-B2   MEDIMMUNE INC (ASTR)   DALLACQUA W,  JOHNSON L S,  WARD E S;  US7317091-B2   XENCOR (XENC)   LAZAR G A,  CHIRINO A J,  DANG W,  DESJARLAIS J R,  DOBERSTEIN S K,  HAYES R J,  KARKI S B,  VAFA O;  US7348004-B2   SYNTONIX INC (BIOJ)   PETERS R T,  MEZO A R,  RIVERA D S,  BITONTI A J,  STATTEL J M,  LOW S C;  US7371371-B2   UNIV SOUTHERN CALIFORNIA (USCA)   EPSTEIN A L,  HU P;  US7404956-B2   SYNTONIX INC (BIOJ)   PETERS R T,  MEZO A R,  RIVERA D S,  BITONTI A J,  STATTEL J M,  LOW S C;  US7569215-B2   MASSACHUSETTS INST TECHNOLOGY (MASI)   WITTRUP K D,  RAO B M,  LAUFFENBURGER D A;  US7862820-B2   SYNTONIX INC (BIOJ)   PETERS R T,  MEZO A R,  RIVERA D S,  BITONTI A J,  STATTEL J M,  LOW S C;  US7951360-B2   MASSACHUSETTS INST TECHNOLOGY (MASI)   WITTRUP K D,  RAO B M,  LAUFFENBURGER D A;  US8349311-B2   MASSACHUSETTS INST TECHNOLOGY (MASI)   WITTRUP K D,  RAO B M,  LAUFFENBURGER D A;  US8759486-B2   CIM CENT IMMUNOLOGIA MOLECULAR (IMML)   LEON MONZON K,  CARMENATE PORTILLA T,  GARCIA MATINEZ K,  LAGE DAVILA A B,  PEREZ RODRIGUEZ S,  GONZALEZ ROCHE D,  MARQUEZ PERERA G;  US8906356-B2   MASSACHUSETTS INST TECHNOLOGY (MASI)   LIU D V,  WITTRUP K D;  US9266938-B2   ROCHE GLYCART AG (HOFF)   AST O,  BRUENKER P,  FREIMOSER-GRUNDSCHOBER A,  HERTER S,  HOFER T U,  HOSSE R,  KLEIN C,  MOESSNER E,  NICOLINI V G,  UMANA P;  US9580486-B2   AMGEN INC (AMGE)   KANNAN G;  US9616105-B2   AICURIS GMBH & CO KG (AIUC)   BRAY D,  BRUNNER N,  PAULSEN D;  US9732134-B2   AMGEN INC (AMGE)   GAVIN M A,  LI L;  US9932380-B2   AMGEN INC (AMGE)   KANNAN G;  WO1988007089-A   ;  WO1996014339-A1   ;  WO1998005787-A1   ;  WO1998023289-A1   ;  WO1999051642-A1   ;  WO1999058572-A1   ;  WO1999060128-A1   ;  WO2000032767-A1   ;  WO2004044859-A1   WILSON G M (WILS-Individual);  WILSON P A (WILS-Individual)   WILSON G M,  WILSON P A;  WO2005070963-A1   APPLIED MOLECULAR EVOLUTION INC (MOLE-Non-standard)   ALLAN B W,  MARQUIS D M,  TANG Y,  WATKINS J D;  WO2006019447-A1   XENCOR INC (XENC)   LAZAR G A,  DANG W,  DESJARLAIS J R,  KARKI S B,  VAFA O,  HAYES R;  WO2006074199-A1   SYNTONIX PHARM INC (BIOJ)   PETERS R T,  MEZO A R,  RIVERA D S,  BITONTI A J;  WO2008155134-A1   UNIV MUENCHEN TECH (MUEN)   SKERRA A,  THEOBALD I,  SCHLAPSCHY M;  WO2010091122-A1   AMUNIX PHARM INC (AMUN-Non-standard)   SCHELLENBERGER V,  SILVERMAN J,  WANG C,  SPINK B,  STEMMER W P,  GEETHING N,  TO W,  CLELAND J L;  WO2010144508-A1   AMUNIX OPERATING INC (SNFI)   SCHELLENBERGER V,  SILVERMAN J,  STEMMER W P,  WANG C,  GEETHING N;  WO2011028228-A1   AMUNIX OPERATING INC (SNFI)   SCHELLENBERGER V,  SILVERMAN J,  STEMMER W P,  WANG C,  SPINK B,  GEETHING N C,  TO W;  WO2011028229-A1   AMUNIX OPERATING INC (SNFI)   SCHELLENBERGER V,  SILVERMAN J,  STEMMER W P,  WANG C,  SPINK B,  GEETHING N C,  TO W;  WO2011070024-A1   HOFFMANN LA ROCHE&CO AG F (HOFF)   DIMOUDIS N,  FERTIG G,  FIDLER A,  KALUZA K,  PICKL M,  RIES C,  SEEBER S,  LANZENDOERFER M;  WO2011107553-A1   HOFFMANN LA ROCHE&CO AG F (HOFF)   FERTIG G,  FIDLER A,  KALUZA K,  PICKL M,  RIES C,  SEEBER S;  WO2011131407-A1   HOFFMANN LA ROCHE&CO AG F (HOFF)   FERTIG G,  FIDLER A,  KALUZA K,  PICKL M,  RIES C,  SEEBER S;  WO2013087699-A1   HOFFMANN LA ROCHE&CO AG F (HOFF)   FERTIG G,  FIDLER A,  KALUZA K,  RIES C,  SEEBER S,  THOMAS M;  WO2013119716-A1   GENENTECH INC (GETH);  HOFFMANN LA ROCHE & CO AG F (HOFF)   MA X,  CHEN Y,  STAWICKI S,  WU Y,  MARTIN F,  LIN W Y,  STARVASNIK M A;  WO2013132044-A1   HOFFMANN LA ROCHE & CO AG F (HOFF)   CANNARILE M,  RIES C,  RUETTINGER D,  WARTHA K;  WO2013169264-A1   FIVE PRIME THERAPEUTICS INC (FPTI)   WONG B,  MASTELLER E,  WONG J,  LIN H;  WO2014036357-A1   FIVE PRIME THERAPEUTICS INC (FPTI)   WONG B,  MASTELLER E,  REEDQUIST K,  ZANGHI J A,  HAMBLETON J,  BAKER K;  WO2016025385-A1   DELINIA INC (DELI-Non-standard)   GREVE J;  WO2017069158-A1   PROTENOVA CO LTD (PROT-Non-standard)   MAJIMA E,  SHIMA A;  WO2018091003-A1   CENT IMMUNOLOGIA MOLECULAR (IMML)   ROJAS DORANTES G,  LEON MONZON K,  CARMENATE PORTILLA T;  WO2000009560-A2   ;  WO2000042072-A2   ;  WO2001087922-A2   ;  WO2002044215-A2   ;  WO2002060919-A2   ;  WO2002092780-A2   ;  WO2003074569-A2   IMMUNOMEDICS INC (IMMD);  MCCALL J D (MCCA-Individual)   QU Z,  HANSEN H,  GOLDENBERG D M;  WO2003074679-A2   XENCOR (XENC)   LAZAR G A,  DESJARLAIS J R,  MARSHALL S A,  DAHIYAT B;  WO2003077834-A2   BRIGHAM & WOMENS HOSPITAL INC (BGHM)   BLUMBERG R S,  LENCER W I,  SIMISTER N E,  BITONTI A J;  WO2004016750-A2   MACROGENICS INC (MACC)   KOENIG S,  VERI M;  WO2004029207-A2   XENCOR (XENC)   LAZAR G A,  CHIRINO A J,  DANG W,  DESJARLAIS J R,  DOBERSTEIN S K,  HAYES R J,  KARKI S B,  VAFA O;  WO2004035752-A2   PROTEIN DESIGN LABS INC (PROT-Non-standard)   HINTON P R,  TSURUSHITA N,  TSO Y J,  VASQUEZ M;  WO2004063351-A2   MACROGENICS INC (MACC)   STAVENHAGEN J,  VIJH S;  WO2004074455-A2   WATKINS J D (WATK-Individual);  ALLAN B (ALLA-Individual)   WATKINS J D,  ALLAN B;  WO2004099249-A2   XENCOR (XENC)   LAZAR G A,  CHIRINO A J,  DANG W,  DESJARLAIS J R,  DOBERSTEIN S K,  HAYES R J,  KARKI S B,  VAFA O;  WO2004101740-A2   SYNTONIX PHARM INC (BIOJ)   RIVERA D S,  PETERS R T,  BITONTI A J;  WO2005040217-A2   UNIV CAMBRIDGE TECH SERVICES LTD (UYCA);  ARMOUR K L (ARMO-Individual);  CLARK M R (CLAR-Individual)   ARMOUR K L,  CLARK M R;  WO2005047327-A2   BIOGEN IDEC MA INC (BIOJ)   FARRINGTON G K,  LUGOVSKOY A A,  ELDREDGE J K,  GARBER E;  WO2005077981-A2   XENCOR INC (XENC)   LAZAR G A;  WO2005092925-A2   XENCOR INC (XENC)   LAZAR G A,  KARKI S B;  WO2005123780-A2   PROTEIN DESIGN LABS INC (PROT-Non-standard)   HINTON P R,  TSURUSHITA N,  TSO Y J,  VASQUEZ M;  WO2006047350-A2   XENCOR INC (XENC)   LAZAR G A,  DAHIYAT B I,  DANG W,  KARKI S B,  VAFA O;  WO2006085967-A2   XENCOR INC (XENC)   LAZAR G A,  DANG W,  DESJARLAIS J J,  KARKI S B,  VAFA O,  HAYES R;  WO2010144502-A2   AMUNIX OPERATING INC (SNFI)   SCHELLENBERGER V,  SILVERMAN J,  STEMMER W P,  WANG C,  GEETHING N;  WO2011028344-A2   AMUNIX OPERATING INC (SNFI)   SCHELLENBERGER V,  SILVERMAN J,  STEMMER W P,  WANG C,  GEETHING N,  SPINK B,  TO W,  CLELAND J L;  WO2011140249-A2   FIVE PRIME THERAPEUTICS INC (FPTI)   WONG J,  VASQUEZ M;  WO2016164937-A2   AMGEN INC (AMGE)   BUTZ E A,  THOMSON C A,  GAVIN M A,  FOLTZ I N,  XIA D,  ALCORN D N,  LIM A C,  KETCHEM R R,  MANCHULENKO K,  SEKIROV L,  BERRY K A,  DE IMUS C C C,  AGRAWAL N J,  KANNAN G,  LI L;  US10787494-B2 -- WO2016022671-A1   UNIV MIAMI (UYMI)   MALEK T;  EP75444-A   GENENTECH INC (GETH)   DEBOER H A,  SEEBURG P H,  HEYNEKER H L;  JP2008545397-A   UNIV CONNECTICUT (UCNT)   LEFRANCOIS L,  STOKLASEK T A;  JP10511846-W   UNIV KENTUCKY (KENT)   CHATTERJEE M,  KOHLER H,  CHATTERJEE S K,  FOON K A;  US4522811-A   SYNTEX (USA) (SYNT)   EPPSTEIN D A,  FRASERSMIT E B,  MATTHEWS T R,  FRASER-SMITH E B;  US4873192-A   US DEPT HEALTH & HUMAN SERVICE (USSH)   KUNKEL T A;  US5250296-A   TAKEDA CHEM IND LTD (TAKE)   OOTSU K;  US5605793-A   AFFYMAX TECHNOLOGIES NV (GLAX)   STEMMER W P C,  CRAMERI A;  US5837458-A   MAXYGEN INC (MAXY)   MINSHULL J,  STEMMER W P C;  US20040265272-A1   ;  US20060160187-A1   ;  US20060263857-A1   ;  US20060269515-A1   ;  US20130336924-A1   ;  US20170233448-A1   ;  US20190300592-A1   ;  US6967092-B1   SEARLE & CO G D (SEAR)   MCWHERTER C A,  FENG Y,  MCKEARN J P,  SUMMERS N L,  STATEN N R,  STREETER P R,  MINNERLY J C,  MINSTER N I,  WOULFE S L;  US9359415-B2   ALKERMES INC (AMES)   ALVAREZ J,  MCSWEENEY L A;  WO1999060128-A1   ;  WO2003029475-A1   DNAVEC RES INC (DNAV)   IWAMOTO A,  TACHIKAWA A;  WO2013184942-A1   ALKERMES INC (AMES)   ALVAREZ J,  CHAMOUN J;  WO2014023752-A1   ROCHE GLYCART AG (HOFF)   HOSSE R,  KLEIN C,  MOESSNER E,  PETERSON L B,  UMANA P,  WICKER L;  WO2016100788-A1   ALKERMES INC (AMES)   ALVAREZ J,  MOUSTAKAS D T,  BRODKIN H R,  MCSWEENEY L A;  WO1996020277-A2   ;  WO2010020766-A2   ASTERION LTD (ASTE-Non-standard)   ARTYMIUK P,  ROSS R;  WO2011123683-A2   UNIV ROCHESTER (UYRP)   FRELINGER J G,  PUSKAS J,  KIM B,  SULLIVAN M;  WO2017201432-A2   JOUNAIDI Y (JOUN-Individual);  FORMAN S (FORM-Individual);  MILLER K (MILL-Individual);  COTTEN J F (COTT-Individual)   JOUNAIDI Y,  FORMAN S,  MILLER K,  COTTEN J F;  WO2007001677-A9   UNIV CONNECTICUT (UCNT)   LEFRANCOIS L,  STOKLASEK T A;  CN112154153-A -- CN101148477-A   UNIV SOUTH MEDICAL (UNSM)   GAO J,  HU Z,  ZHOU M;  CN103492411-A   ROCHE GLYCART AG (HOFF)   AST O,  BRUENKER P,  FREIMOSER-GRUNDSCHOBER A,  HERTER S,  HOFER T U,  HOSSE R,  KLEIN C,  MOESSNER E,  NICOLINI V G,  UMANA P;  CN105143253-A   AMGEN INC (AMGE)   GAVIN M A,  KANNAN G,  LI L,  PEARSON J T,  KAROW M;  US20110243947-A1   ;  WO2016022671-A1   UNIV MIAMI (UYMI)   MALEK T;  US11359000-B2 -- US5223408-A   GENENTECH INC (GETH)   GOEDDEL D V,  RICE G C,  LEUNG D W H;  WO2016022671-A1   UNIV MIAMI (UYMI)   MALEK T;  EP75444-A   GENENTECH INC (GETH)   DEBOER H A,  SEEBURG P H,  HEYNEKER H L;  JP2008545397-A   UNIV CONNECTICUT (UCNT)   LEFRANCOIS L,  STOKLASEK T A;  JP10511846-W   UNIV KENTUCKY (KENT)   CHATTERJEE M,  KOHLER H,  CHATTERJEE S K,  FOON K A;  US4522811-A   SYNTEX (USA) (SYNT)   EPPSTEIN D A,  FRASERSMIT E B,  MATTHEWS T R,  FRASER-SMITH E B;  US4873192-A   US DEPT HEALTH & HUMAN SERVICE (USSH)   KUNKEL T A;  US5250296-A   TAKEDA CHEM IND LTD (TAKE)   OOTSU K;  US5605793-A   AFFYMAX TECHNOLOGIES NV (GLAX)   STEMMER W P C,  CRAMERI A;  US5837458-A   MAXYGEN INC (MAXY)   MINSHULL J,  STEMMER W P C;  US20040265272-A1   ;  US20060160187-A1   ;  US20060263857-A1   ;  US20060269515-A1   ;  US20130336924-A1   ;  US20170233448-A1   ;  US20190300592-A1   ;  US6967092-B1   SEARLE & CO G D (SEAR)   MCWHERTER C A,  FENG Y,  MCKEARN J P,  SUMMERS N L,  STATEN N R,  STREETER P R,  MINNERLY J C,  MINSTER N I,  WOULFE S L;  US9359415-B2   ALKERMES INC (AMES)   ALVAREZ J,  MCSWEENEY L A;  WO1999060128-A1   ;  WO2003029475-A1   DNAVEC RES INC (DNAV)   IWAMOTO A,  TACHIKAWA A;  WO2013184942-A1   ALKERMES INC (AMES)   ALVAREZ J,  CHAMOUN J;  WO2014023752-A1   ROCHE GLYCART AG (HOFF)   HOSSE R,  KLEIN C,  MOESSNER E,  PETERSON L B,  UMANA P,  WICKER L;  WO2016100788-A1   ALKERMES INC (AMES)   ALVAREZ J,  MOUSTAKAS D T,  BRODKIN H R,  MCSWEENEY L A;  WO1996020277-A2   ;  WO2010020766-A2   ASTERION LTD (ASTE-Non-standard)   ARTYMIUK P,  ROSS R;  WO2011123683-A2   UNIV ROCHESTER (UYRP)   FRELINGER J G,  PUSKAS J,  KIM B,  SULLIVAN M;  WO2017201432-A2   JOUNAIDI Y (JOUN-Individual);  FORMAN S (FORM-Individual);  MILLER K (MILL-Individual);  COTTEN J F (COTT-Individual)   JOUNAIDI Y,  FORMAN S,  MILLER K,  COTTEN J F;  WO2007001677-A9   UNIV CONNECTICUT (UCNT)   LEFRANCOIS L,  STOKLASEK T A	WO2019191295-A1  JOHN PUSKAS ET AL:          "Development of an attenuated interleukin-2 fusion          protein that can be activated by tumour-expressed          proteases", IMMUNOLOGY, vol. 133, no. 2, 23 June 2011          (2011-06-23), pages 206 - 220, XP055073392, ISSN:          0019-2805, DOI:          10.1111/j.1365-2567.2011.03428.x,relevantClaims[1-5,59,60],relevantPassages[&lt;pp&gt;207&lt;/pp&gt;&lt;ppl&gt;209&lt;/ppl&gt;];            JUO, PEI-SHOW: "Concise Dictionary of Biomedicine and          Molecular Biology", 2002, CRC PRESS;            "The Dictionary of Cell and Molecular Biology", 1999,          ACADEMIC PRESS;            "Oxford Dictionary Of Biochemistry And Molecular          Biology", 2000, OXFORD UNIVERSITY PRESS;            "GenBank", Database accession no. Q7JFM2;            "GenBank", Database accession no.          NP_001030597.1;            "GENBANK", Database accession no.          NP_001028089.1;            "GENBANK", Database accession no.          NM_001003211.1;            "GENBANK", Database accession no. NP_776783.1;            "GENBANK", Database accession no. NP_032393.3;            "GENBANK", Database accession no. NP _037295.1;            ROBB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988,          pages 5654 - 5658;            MEI ET AL., BLOOD, vol. 116, 2010, pages 270 -          79;            JEFFERIS ET AL., MABS, vol. 1, 2009, pages 1;            BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 -          1187;            KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999,          pages 879 - 884;            BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997,          pages 412 - 417;  E.          MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 -          17;            NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages          444 - 453;            ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403          - 10;            ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17,          1997, pages 3389 - 3402;  F.          AUSUBEL ET AL.: "Current Protocols in Molecular Biology",          1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;            KABAT ET AL.: "Sequences of Proteins of Immunological          Interest", 1991, U. S. DEPARTMENT OF PUBLIC          HEALTH;            STORY ET AL., J. EXP. MED., vol. 180, 1994, pages          2377;            MALEK ET AL., IMMUNITY, vol. 33, no. 2, 2010, pages 153 -          65;            CARMENATE ET AL., J IMMUNOL, vol. 200, no. 10, 2018,          pages 3475 - 3484;            EPSTEIN ET AL., BLOOD, vol. 101, no. 12, 2003, pages 4853          - 61;            WITTRUP ET AL., J IMMUNOTHER., vol. 32, no. 9, 2009,          pages 887 - 94;            WITTRUP ET AL., JLMMUNOTHER., vol. 32, no. 9, 2009, pages          887 - 94;            WITTRUP ET AL., BIOCHEMISTRY, vol. 44, no. 31,          2005;            SHANAFELT ET AL., NAT BIOTECHNOL., vol. 18, no. 11, 2000,          pages 1197 - 202;            "GENBANK", Database accession no. NP_037295.1;            JANEWAY ET AL.: "Immunobiology", 2001, GARLAND          PUBLISHING;            "PCR Protocols: A Guide to Methods and Applications",          1990, ACADEMIC PRESS;  HO          ET AL., GENE, vol. 77, 1989, pages 51;            HORTON ET AL., METHODS ENZYMOL., vol. 217, 1993, pages          270;            BENHAR; PASTAN: "Protein Engineering", vol. 7, 1994,          pages: 1509;            RUBERTI, F. ET AL., J. IMMUNOL. METHODS, vol. 173, 1994,          pages 33;            LARRICK ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 160,          1989, pages 1250;            CAPON ET AL., NATURE, vol. 337, 1989, pages 525;            ROUTLEDGE ET AL., TRANSPLANTATION, vol. 60, 1995, pages          847;            FRIEND ET AL., TRANSPLANTATION, vol. 68, 1999, pages          1632;            SHIELDS ET AL., J. BIOL. CHEM., vol. 276, 1995, pages          6591;            SHIELDS ET AL., J. BIOL. CHEM., vol. 276, 2001, pages          6591;            WARD; GHETIE, THERAPEUTIC IMMUNOLOGY, vol. 2, 1995, pages          77;            ARMOUR ET AL., EUR. J. IMMUNOL., vol. 29, 1999, pages          2613;            KONIG, T.; SKERRA, A., J. IMMUNOL. METHODS, vol. 218,          1998, pages 73 - 83;            DENNIS ET AL., J. BIOL. CHEM., vol. 277, 2002, pages          35035 - 35043;            "GenBank", Database accession no. NM001063;            "GENBANK", Database accession no. XM002793;            "GENBANK", Database accession no. M12530;            "GENBANK", Database accession no. XM039845;            "GENBANK", Database accession no. XM 039847;            "GENBANK", Database accession no. S95936;            MORPURGO ET AL., APPL. BIOCHEM. BIOTECHNOL., vol. 56,          1996, pages 59 - 72;            VOROBJEV ET AL., NUCLEOSIDES NUCLEOTIDES, vol. 18, 1999,          pages 2745 - 2750;            CALICETI ET AL., BIOCONJUG. CHEM., vol. 10, 1999, pages          638 - 646;            DELGADO ET AL., CRIT. REV. THERA. DRUG CARRIER SYS., vol.          9, 1992, pages 249 - 304;            SOMMERMEYER ET AL., KRANKENHAUSPHARMAZIE, vol. 8, no. 8,          1987, pages 271 - 278;            WEIDLER ET AL., ARZNEIM.-FORSCHUNG/DRUG RES., vol. 41,          1991, pages 494 - 498;            ROTH J. ET AL.: "Polysialic Acid: From Microbes to Man",          1993, BIRKHAUSER VERLAG, pages: 335 - 348;            CHO; TROY, P.N.A.S., USA, vol. 91, 1994, pages 11427 -          11431;            AMAU ET AL., PROT EXPR AND PURIF, vol. 48, 2006, pages 1          - 13;            DELANO WL ET AL., SCIENCE, vol. 287, 2000, pages 1279 -          1283;            HASE ET AL., J. BIOCHEM., vol. 95, 1984, pages          197;            "GenBank", Database accession no. AAA26738.1;            KUTMEIER G ET AL., BIOTECHNIQUES, vol. 17, 1994, pages          242 - 6;            LANGER, SCIENCE, vol. 249, 1990, pages 1527 -          33;            TREAT ET AL.: "Liposomes in the Therapy of Infectious          Disease and Cancer", 1989, LISS, pages: 353 -          65;            SEFTON, CRIT. REV. BIOMED. ENG., vol. 14, 1987, pages 201          - 40;            BUCHWALD ET AL., SURGERY, vol. 88, 1980, pages 507 -          16;            SAUDEK ET AL., N ENGL. J MED., vol. 321, 1989, pages 574          - 79;            LEVY ET AL., SCIENCE, vol. 228, 1985, pages 190 -          92;            DURING ET AL., ANN. NEURAL., vol. 25, 1989, pages 351 -          56;            HOWARD ET AL., J NEUROSURG., vol. 71, 1989, pages 105 -          12;            SAMBROOK ET AL.: "Molecular Cloning: A Laboratory          Manual", 1989;            "Current Protocols in Molecular Biology", vol. I-III,          1994;            "Cell Biology: A Laboratory Handbook", vol. I-III,          1994;            "Current Protocols in Immunology", vol. I-III,          1994;            "Oligonucleotide Synthesis", 1984;            "Nucleic Acid Hybridization", 1985;            "Transcription And Translation", 1984;            "Animal Cell Culture", 1986;            "Immobilized Cells And Enzymes", 1986, IRL          PRESS;  B.          PERBAL, A PRACTICAL GUIDE TO MOLECULAR CLONING,          1984;  HE          ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 -          28;            ROSENBERG, S.: "ASCO Educational Book Spring", 2000,          article "Development of Cancer Vaccines", pages: 60 -          62;            LOGOTHETIS, C, ASCO EDUCATIONAL BOOK SPRING, 2000, pages          300 - 302;            KHAYAT, D., ASCO EDUCATIONAL BOOK SPRING, 2000, pages 414          - 428;            FOON, K., ASCO EDUCATIONAL BOOK SPRING, 2000, pages 730 -          738;            RESTIFO, N.; SZNOL, M. ET AL.: "Cancer Vaccines", 1997,          article "Cancer: Principles and Practice of Oncology",          pages: 3023 - 3043;            DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90,          1993, pages 3539 - 43;            ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 -          7;            KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 -          2013;            SUOT; SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 -          1588;            TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 -          120;            NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 -          332;            KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 -          336;            KEHRL ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 -          1050;            HOWARD; O'GARRA, IMMUNOLOGY TODAY, vol. 13, 1992, pages          198 - 200;            HAHNE ET AL., SCIENCE, vol. 274, 1996, pages 1363 -          1365;            RIDGE ET AL., NATURE, vol. 393, 1998, pages 474 -          478;            WEINBERG ET AL., IMMUNOL, vol. 164, 2000, pages 2160 -          2169;            MELERO ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 -          685;            HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 262 -          266;            GREENBERG; RIDDELL, SCIENCE, vol. 285, 1999, pages 546 -          51;            HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993,          pages 6444 - 6448;            POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 -          1123;            TANSEY, DRUG DISCOVERY TODAY, 2009, pages 1;            TSAI ET AL., J. VIROLOGY, 8 February 2017          (2017-02-08);            FULDA ET AL., NAT MED, vol. 8, 2002, pages 808 -          15;            HYER ET AL., CANCER RESEARCH, vol. 65, 2005, pages 4799 -          808;            "Molecular Cloning A Laboratory Manual", 1989, COLD          SPRING HARBOR LABORATORY PRESS;            "Molecular Cloning: A Laboratory Manual", 1992, COLD          SPRINGS HARBOR LABORATORY;            "DNA Cloning", vol. I; II, 1985;            "Nucleic Acid Hybridization", 1984;            FRESHNEY: "Culture Of Animal Cells", 1987, ALAN R. LISS,          INC.;            PERBAL: "Methods In Enzymology", 1984, ACADEMIC PRESS,          INC., article "A Practical Guide To Molecular Cloning;          the treatise";            "Gene Transfer Vectors For Mammalian Cells", 1987, COLD          SPRING HARBOR LABORATORY;            "Methods In Enzymology", vol. 154; 155;            "Immunochemical Methods In Cell And Molecular Biology",          1987, ACADEMIC PRESS;            "Handbook Of Experimental Immunology", vol. I-IV,          1986;            "Manipulating the Mouse Embryo", 1986, COLD SPRING HARBOR          LABORATORY PRESS;            CROOKS: "Antisense drug Technology: Principles,          strategies and applications", 2007, CRC PRESS;            AUSUBEL ET AL.: "Current Protocols in Molecular Biology",          1989, JOHN WILEY AND SONS;            LIPAROTO, S.F.; MYSZKA, D.G.; WU, Z.; GOLDSTEIN, B.;          LAUE, T.M.; CIARDELLI, T.L., BIOCHEMISTRY, vol. 41, 2002,          pages 2543 - 51US10787494-B2            Office action dated Mar. 8, 2019 in U.S. Appl. No.          15/501, 392, inventor Malek, T., int'l filed Aug. 6,          2015, 10 pages.;            Office action dated Aug. 27, 2018 in U.S. Appl. No.          15/501, 392, inventor Malek, T., int'l filed Aug. 6,          2015, 13 pages.;            Rao, B., et al., High-Affinity CD25-Binding IL-2 Mutants          Potently Stimulate Persistent T Cell Growth, Biochemistry          44:10696-10701, American Chemical Society, United States          (2007).;            Office action dated Mar. 5, 2020, in U.S. Appl. No.          15/501, 392, inventor Malek, T., int'l filed Aug. 6,          2015, 13 pages.;            Buchwald, H., et al., Long-term, Continuous Intravenous          Heparin Administration by an Implantable Infusion Pump in          Ambulatory Patients with Recurrent Venous Thrombosis,          Surgery 88(4):507-516, Mosby, United States          (1980).;            Centers for Disease Control and Prevention (CDC)., FDA          Approval for Infants of a Haemophilus Influenzae Type B          Conjugate and Hepatitis B (Recombinant) Combined Vaccine,          MMWR. Morbidity and Mortality Weekly Report          46(5):107-109, Centers for Disease Control, United States          (1997).;            Crameri, A., DNA Shuffling of a Family of Genes from          Diverse Species Accelerates Directed Evolution, Nature          391(6664):288-291, Nature America Publishing, United          States (1998).;            Crameri, A., Molecular Evolution of an Arsenate          Detoxification Pathway by DNA Shuffling, Nature          Biotechnology 15(5):436-438, Nature America Publishing,          United States (1997).;            During, M.J., et al., Controlled Release of Dopamine From          a Polymeric Brain Implant: in Vivo Characterization,          Annals of Neurology 25(4):351-356, Wiley-Liss, United          States (1989).;            Gait., et al., Oligonucleotide Synthesis: A Practical          Approach, IRL Press, MRC Laboratory of Molecular          Biology(1984).;            Genbank, Canis lupus familiaris interleukin 2 receptor,          alpha (IL2RA), mRNA, accession No. NM_001003211.1,          accessed at          https://www.ncbi.nlm.nih.gov/nuccore/NM_001003211.1, Feb.          2014.;            Genbank, interleukin-2 receptor subunit alpha precursor          [Bos taurus], accession No. NP_776783.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/NP_776783.1, Jun.          2018.;            Genbank, interleukin-2 receptor subunit alpha precursor          [Macaca mulatta], accession No. NP_001028089.1, accessed          at https://www.ncbi.nlm.nih.gov/protein/NP_001028089.1,          Nov. 2017.;            Genbank, interleukin-2 receptor subunit alpha precursor          [Mus musculus], accession No. NP_032393.3, accessed at          https://www.ncbi.nlm.nih.gov/protein/NP_032393.3, Jun.          2018.;            Genbank, interleukin-2 receptor subunit alpha precursor          [Pan troglodytes], accession No. NP_001030597.1, accessed          at https://www.ncbi.nlm.nih.gov/protein/78486568/, Nov.          2017.;            Genbank, interleukin-2 receptor subunit alpha precursor          [Rattus norvegicus], accession No. NP_037295.1, accessed          at https://www.ncbi.nlm.nih.gov/protein/NP_037295.1, Aug.          2018.;            Howard, M.A. 3rd., Intracerebral Drug Delivery in Rats          With Lesion-induced Memory Deficits, Journal of          Neurosurgery 71(1):105-112, American Association of          Neurological Surgeons, United States (1989).;            International Preliminary Report on Patentability,          European Patent Office, PCT/US2015/043792, dated Feb. 7,          2017.;            International Search Report and Written Opinion of the          International Search Authority, European Patent Office,          PCT/US2015/043792, dated Nov. 20, 2015.;            Kunkel, T.A., et al., Rapid and Efficient Site-specific          Mutagenesis Without Phenotypic Selection, Methods in          Enzymology 154:367-382, Academic Press, United States          (1987).;            Kunkel, T.A., Rapid and Efficient Site-Specific          Mutagenesis Without Phenotypic Selection, Proceedings of          the National Academy of Sciences USA 82(2):488-492,          National Academy of Sciences, United States          (1985).;            Langer, R., New Methods of Drug Delivery, Science          249(4976):1527-1533, American Association for the          Advancement of Science, United States (1990).;            Levy, R.J., et al., Inhibition of Calcification of          Bioprosthetic Heart Valves by Local Controlled-release          Diphosphonate, Science 228(4696):190-192, American          Association for the Advancement of Science, United States          (1985).;            Lowenthal, J.W., et al., Contrasting Interleukin 2          Binding Properties of the Alpha (P55) and Beta (P70)          Protein Subunits of the Human High-Affinity Interleukin 2          Receptor, Journal of Experimental Medicine,          166(4):1156-1161, Rockefeller University Press, United          States (1987).;            Malek, T.R and Castro, I., Interleukin-2 Receptor          Signaling: at the Interface Between Tolerance and          Immunity, Immunity 33(2):153-165, Cell Press, United          States (2010).;            Malek, T.R and Korty, P.E., The Murine Interleukin 2          Receptor. IV. Biochemical Characterization, Journal of          Immunology 136(11):4092-4098, American Association of          Immunologists, United States (1986).;            Melder, R.J., et al. Pharmacokinetics and in Vitro and in          Vivo Anti-tumor Response of an Interleukin-2-Human Serum          Albumin Fusion Protein in Mice, Cancer Immunology,          Immunotherapy, 54(6):535-547, Springer Verlag, Germany          (2005).;            Millington, T., et al. Effects of an Agonist          Interleukin-2/FC Fusion Protein, a Mutant Antagonist          Interleukin-15/FC Fusion Protein, and Sirolimus on          Cardiac Allograft Survival in Non-Human Primates, The          Journal of Heart and Lung Transplantation, 31(4):427-435,          Elsevier, United States (2012).;            Nikaido, T., et al., Molecular Cloning of cDNA Encoding          Human Interleukin-2 Receptor, Nature, 311(5987):631-635,          Nature Publishing Group, England (1984).;            Wang, H.M and Smith, K.A., The Interleukin 2 Receptor.          Functional Consequences of its Bimolecular Structure,          Journal of Experimental Medicine, 166(4):1055-1069,          Rockefeller University Press, United States          (1987).;            Puskas, J., et al. Development of an Attenuated          Interleukin-2 Fusion Protein That Can Be Activated by          Tumour-expressed Proteases, Immunology, 133(2):206-220,          Blackwell Scientific Publications, England          (2011).;            Robb, R.J., et al., Structure-function Relationships for          the Interleukin 2 Receptor: Location of Ligand and          Antibody Binding Sites on the Tac Receptor Chain by          Mutational Analysis, Proceedings of the National Academy          of Sciences of the United States of America          85(15):5654-5658, National Academy of Sciences, United          States (1988).;            Zhang, J.H., Directed Evolution of a Fucosidase From a          Galactosidase by DNA Shuffling and Screening, Proceedings          of the National Academy of Sciences of the United States          of America 94(9):4504-4509, National Academy of Sciences,          United States (1997).;            Saudek, C.D., et al., A Preliminary Trial of the          Programmable Implantable Medication System for Insulin          Delivery, The New England Journal of Medicine          321(9):574-579, Massachusetts Medical Society, United          States (1989).;            Sefton, M.V., Implantable Pumps, Critical Reviews in          Biomedical Engineering 14(3):201-240, Begell House,          United States (1987).;            Speck, L.M and Tyring, S.K., Vaccines for the Prevention          of Human Papillomavirus Infections, Skin Therapy Letter          11(6):1-3, International Skin Therapy Newsletter, Canada          (2006).;            Stemmer, W.P., DNA Shuffling by Random Fragmentation and          Reassembly: in Vitro Recombination for Molecular          Evolution, Proceedings of the National Academy of          Sciences of the United States of America          91(22):10747-10751, National Academy of Sciences, United          States (1994).;            Stoklasek, T.A., et al. Combined IL-15/IL-15 Ralpha          Immunotherapy Maximizes IL-15 Activity in Vivo, Journal          of Immunology, 177(9):6072-6080, American Association of          Immunologists, United States (2006).;            UniProtKB, RecName: Full=Interleukin-2; Short=IL-2;          AltName: Full=T-cell growth factor; Short=TCGF; Flags:          Precursor, accession No. P05016.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/P05016, Nov.          2017.;            UniProtKB, RecName: Full=Interleukin-2; Short=IL-2;          AltName: Full=T-cell growth factor; Short=TCGF; Flags:          Precursor, accession No. P36835.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/P36835, Nov.          2017.;            UniProtKB, RecName: Full=Interleukin-2; Short=IL-2;          AltName: Full=T-cell growth factor; Short=TCGF; Flags:          Precursor, accession No. p37997.2, accessed at          https://www.ncbi.nlm.nih.gov/protein/P37997, May          2018.;            UniProtKB, RecName: Full=Interleukin-2; Short=IL-2;          AltName: Full=T-cell growth factor; Short=TCGF; Flags:          Precursor, accession No. Q29416.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/Q29416, May          2018.;            UniProtKB, RecName: Full=Interleukin-2; Short=IL-2;          AltName: Full=T-cell growth factor; Short=TCGF; Flags:          Precursor, accession No. Q7JFM2.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/61213128/, Nov.          2017.;            UniProtKB, RecName: Full=Interleukin-2; Short=IL-2;          AltName: Full=T-cell growth factor; Short=TCGF; Flags:          Precursor, accession No. Q7JFM5.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/Q7JFM5, May          2018.;            Wilkinson, I.R., et al. A Ligand-receptor Fusion of          Growth Hormone Forms a Dimer and is a Potent Long-acting          Agonist, Nature Medicine, 13(9):1108-1113, Nature          Publishing Company, United States (2007).;            Rickert, M., et al., The structure of interleukin-2          complexed with its alpha receptor, Science;          308(5727):1477-80, United States (2005).;            Fehniger, T.A., et al., Interleukin 15: biology and          relevance to human disease, Blood;97(1):14-32 United          States (2001).;            Girt, J.G., et al., IL-15, a novel T cell growth factor          that shares activities and receptor components with IL-2,          J Leukoc Biol.;57(5):763-6, United States          (1995).;            Rubinstein, M.P., et al. Converting IL-15 to a          superagonist by binding to soluble IL-15R{alpha}, Proc          Natl Acad Sci U S A.;103(24):9166-71, United States          (2006).;            Co-Pending U.S. Appl. No. 16/366, 838, inventor          Struthers, M., et al., filed Mar. 27, 2019          (Unpublished).;            International Search Report and Written Opinion of the          International Search Authority, European Patent Office,          PCT/US2019/024376, dated Jun. 13, 2019.CN112154153-A  ZHAOHUI WANG:          "Ontak-like human IL-2 fusion toxin", JOURNAL          IMMUNOLOGICAL METHODS, vol. 448, pages 51 - 58,          XP085153338, DOI:          10.1016/j.jim.2017.05.008,relevantClaims[1-114]US11359000-B2            Shental-Bechor et al., Proc. Nat'l. Acad. Sci. U.S.A.,          2008, vol. 105(24):8256-8261.;            Buchwald, H., et al., Long-term, Continuous Intravenous          Heparin Administration by an Implantable Infusion Pump in          Ambulatory Patients with Recurrent Venous Thrombosis,          Surgery 88(4):507-516, Mosby, United States          (1980).;            Centers for Disease Control and Prevention (CDC)., FDA          Approval for Infants of a Haemophilus Influenzae Type B          Conjugate and Hepatitis B (Recombinant) Combined Vaccine,          MMWR. Morbidity and Mortality Weekly Report 46(5):          107-109, Centers for Disease Control, United States          (1997).;            Crameri, A., DNA Shuffling of a Family of Genes from          Diverse Species Accelerates Directed Evolution, Nature          391(6664):288-291, Nature America Publishing, United          States (1998).;            Crameri, A., Molecular Evolution of an Arsenate          Detoxification Pathway by DNA Shuffling, Nature          Biotechnology 15(5):436-438, Nature America Publishing,          United States (1997).;            During, M.J., et al., Controlled Release of Dopamine From          a Polymeric Brain Implant: in Vivo Characterization,          Annals of Neurology 25(4):351-356, Wiley-Liss, United          States (1989).;            Gait., et al., Oligonucleotide Synthesis: A Practical          Approach, IRL Press, MRC Laboratory of Molecular          Biology(1984).;            Genbank, Canis lupus familiaris interleukin 2 receptor,          alpha (IL2RA), mRNA, accession No. NM_001003211.1,          accessed at          https://www.ncbi.nlm.nih.gov/nuccore/NM_001003211.1, Feb.          2014.;            Genbank, interleukin-2 receptor subunit alpha precursor          [&lt;xhtml:i &gt;Bos          taurus&lt;/xhtml:i&gt;], accession No.          NP_776783.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/NP_776783.1, Jun.          2018.;            Genbank, interleukin-2 receptor subunit alpha precursor          [&lt;xhtml:i &gt;Macaca          mulatta&lt;/xhtml:i&gt;], accession No.          NP_001028089.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/NP_001028089.1, Nov.          2017.;            Genbank, interleukin-2 receptor subunit alpha precursor          [&lt;xhtml:i &gt;Mus          musculus&lt;/xhtml:i&gt;], accession No.          NP_032393.3, accessed at          https://www.ncbi.nlm.nih.gov/protein/NP_032393.3, Jun.          2018.;            Genbank, interleukin-2 receptor subunit alpha precursor          [&lt;xhtml:i &gt;Pan          troglodytes&lt;/xhtml:i&gt;], accession No.          NP_001030597.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/78486568/, Nov.          2017.;            Genbank, interleukin-2 receptor subunit alpha precursor          [&lt;xhtml:i &gt;Rattus          norvegicus&lt;/xhtml:i&gt;], accession No.          NP_037295.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/NP_037295.1, Aug.          2018.;            Howard, M.A. 3rd., Intracerebral Drug Delivery in Rats          With Lesion-induced Memory Deficits, Journal of          Neurosurgery 71(1):105-112, American Association of          Neurological Surgeons, United States (1989).;            International Preliminary Report on Patentability,          European Patent Office, PCT/US2015/043792, dated Feb. 7,          2017.;            International Search Report and Written Opinion of the          International Search Authority, European Patent Office,          PCT/US2015/043792, dated Nov. 20, 2015.;            Kunkel, T.A., et al., Rapid and Efficient Site-specific          Mutagenesis Without Phenotypic Selection, Methods in          Enzymology 154:367-382, Academic Press, United States          (1987).;            Kunkel, T.A., Rapid and Efficient Site-Specific          Mutagenesis Without Phenotypic Selection, Proceedings of          the National Academy of Sciences USA 82(2):488-492,          National Academy of Sciences, United States          (1985).;            Langer, R., New Methods of Drug Delivery, Science          249(4976):1527-1533, American Association for the          Advancement of Science, United States (1990).;            Levy, R.J., et al., Inhibition of Calcification of          Bioprosthetic Heart Valves by Local Controlled-release          Diphosphonate, Science 228(4696):190-192, American          Association for the Advancement of Science, United States          (1985).;            Lowenthal, J.W., et al., Contrasting Interleukin 2          Binding Properties of the Alpha (P55) and Beta (P70)          Protein Subunits of the Human High-Affinity Interleukin 2          Receptor, Journal of Experimental Medicine,          166(4):1156-1161, Rockefeller University Press, United          States (1987).;            Malek, T.R and Castro, I., Interleukin-2 Receptor          Signaling: at the Interface Between Tolerance and          Immunity, Immunity 33(2):153-165, Cell Press, United          States (2010).;            Malek, T.R and Korty, P.E., The Murine Interleukin 2          Receptor. IV. Biochemical Characterization, Journal of          Immunology 136(11):4092-4098, American Association of          Immunologists, United States (1986).;            Melder, R.J., et al., Pharmacokinetics and in Vitro and          in Vivo Anti-tumor Response of an Interleukin-2-Human          Serum Albumin Fusion Protein in Mice, Cancer Immunology,          Immunotherapy, 54(6):535-547, Springer Verlag, Germany          (2005).;            Millington, T., et al., Effects of an Agonist          Interleukin-2/FC Fusion Protein, a Mutant Antagonist          Interleukin-15/FC Fusion Protein, and Sirolimus on          Cardiac Allograft Survival in Non-Human Primates, The          Journal of Heart and Lung Transplantation, 31(4):427-435,          Elsevier, United States (2012).;            Nikaido, T., et al., Molecular Cloning of cDNA Encoding          Human Interleukin-2 Receptor, Nature, 311(5987):631-635,          Nature Publishing Group, England (1984).;            Wang, H.M and Smith, K.A., The Interleukin 2 Receptor.          Functional Consequences of its Bimolecular Structure,          Journal of Experimental Medicine, 166(4):1055-1069,          Rockefeller University Press, United States          (1987).;            Puskas, J., et al., Development of an Attenuated          Interleukin-2 Fusion Protein That Can Be Activated by          Tumour-expressed Proteases, Immunology, 133(2):206-220,          Blackwell Scientific Publications, England          (2011).;            Robb, R.J., et al., Structure-function Relationships for          the Interleukin 2 Receptor: Location of Ligand and          Antibody Binding Sites on the Tac Receptor Chain by          Mutational Analysis, Proceedings of the National Academy          of Sciences of the United States of America          85(15):5654-5658, National Academy of Sciences, United          States (1988).;            Zhang, J.H., Directed Evolution of a Fucosidase From a          Galactosidase by DNA Shuffling and Screening, Proceedings          of the National Academy of Sciences of the United States          of America 94(9):4504-4509, National Academy of Sciences,          United States (1997).;            Saudek, C.D., et al., A Preliminary Trial of the          Programmable Implantable Medication System for Insulin          Delivery, The New England Journal of Medicine          321(9):574-579, Massachusetts Medical Society, United          States (1989).;            Sefton, M.V., Implantable Pumps, Critical Reviews in          Biomedical Engineering 14(3):201-240, Begell House,          United States (1987).;            Speck, L.M and Tyring, S.K., Vaccines for the Prevention          of Human Papillomavirus Infections, Skin Therapy Letter          11(6):1-3, International Skin Therapy Newsletter, Canada          (2006).;            Stemmer, W.P., DNA Shuffling by Random Fragmentation and          Reassembly: in Vitro Recombination for Molecular          Evolution, Proceedings of the National Academy of          Sciences of the United States of America          91(22):10747-10751, National Academy of Sciences, United          States (1994).;            Stoklasek, T.A., et al., Combined IL-15/IL-15 Ralpha          Immunotherapy Maximizes IL-15 Activity in Vivo, Journal          of Immunology, 177(9):6072-6080, American Association of          Immunologists, United States (2006).;            UniprotKB, RecName: Full=Interleukin-2; Short=IL-2;          AltName: Full=T-cell growth factor; Short=TCGF; Flags:          Precursor, accession No. P05016.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/P05016, Nov.          2017.;            UniprotKB, RecName: Full=Interleukin-2; Short=IL-2;          AltName: Full=T-cell growth factor; Short=TCGF; Flags:          Precursor, accession No. P36835.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/P36835, Nov.          2017.;            UniprotKB, RecName: Full=Interleukin-2; Short=IL-2;          AltName: Full=T-cell growth factor; Short=TCGF; Flags:          Precursor, accession No. P37997.2, accessed at          https://www.ncbi.nlm.nih.gov/protein/P37997, May          2018.;            UniprotKB, RecName: Full=Interleukin-2; Short=IL-2;          AltName: Full=T-cell growth factor; Short=TCGF; Flags:          Precursor, accession No. Q29416.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/Q29416, May          2018.;            UniprotKB, RecName: Full=Interleukin-2; Short=IL-2;          AltName: Full=T-cell growth factor; Short=TCGF; Flags:          Precursor, accession No. Q7JFM2.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/61213128/, Nov.          2017.;            UniprotKB, RecName: Full=Interleukin-2; Short=IL-2;          AltName: Full=T-cell growth factor; Short=TCGF; Flags:          Precursor, accession No. Q7JFM5.1, accessed at          https://www.ncbi.nlm.nih.gov/protein/Q7JFM5, May          2018.;            Wilkinson, I.R., et al., A Ligand-receptor Fusion of          Growth Hormone Forms a Dimer and is a Potent Long-acting          Agonist, Nature Medicine, 13(9):1108-1113, Nature          Publishing Company, United States (2007).;            Rickert, M., et al., The structure of interleukin-2          complexed with its alpha receptor, Science;          308(5727):1477-80, United States (2005).;            Fehniger, T.A., et al., Interleukin 15: biology and          relevance to human disease, Blood;97(1):14-32 United          States (2001).;            Giri, J.G., et al., IL-15, a novel T cell growth factor          that shares activities and receptor components with IL-2,          J Leukoc Biol.;57(5):763-6, United States          (1995).;            Rubinstein, M.P., et al. Converting IL-15 to a          superagonist by binding to soluble IL-15R{alpha}, Proc          Natl Acad Sci U S A.;103(24):9166-71, United States          (2006).;            Co-Pending U.S. Appl. No. 16/435, 420, inventor          Struthers, M., et al., filed Jun. 7, 2019          (Unpublished).;            International Search Report and Written Opinion of the          International Search Authority, European Patent Office,          PCT/US2019/024376, dated Jun. 13, 2019.;            Office Action dated Mar. 8, 2019 in U.S. Appl. No.          15/501, 392, inventor Malek, T., filed Aug. 5, 2015          (371(c) dated Feb. 2, 2017), 9 pages.;            Office Action dated Aug. 27, 2018 in U.S. Appl. No.          15/501, 392, inventor Malek, T., filed Aug. 5, 2015          (371(c) dated Feb. 2, 2017), 12 pages.;            Rao, B., et al., High-affinity CD25-binding IL-2 mutants          potently stimulate persistent T cell growth,          &lt;xhtml:i          &gt;Biochemistry&lt;/xhtml:i&gt;44(31):10696-10701,          American Chemical Society, United States (Aug.          2005).;            Office Action dated Mar. 5, 2020, in U.S. Appl. No.          15/501, 392, inventor Malek, T., filed Aug. 5, 2015          (371(c) dated Feb. 2, 2017), 13 pages.;            Office Action dated Oct. 16, 2020, in U.S. Appl. No.          15/501, 392, inventor Malek, T., filed Aug. 5, 2015          (371(c) dated Feb. 2, 2017), 9 pages.	97946-0-0-0 M N P Q; 444-0-0-0 ; 97946-0-0-0 CL NEW PRD RCT USE			R06364 M N P Q; R16207 M N P Q; R00351 		CN110256552-A;  CN110256552-B	New duck interferon-lambda useful in preparation            of medicament for preventing or treating duck viral            disease e.g. duck viral hepatitis and duck viral            enteritis, comprises specific base pair sequence	HU X;  ZHANG Z;  LIU X;  YI Y;  LI Y;  WANG P	CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS-C);  CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS-C)	2019915434	   NOVELTY - A duck interferon- lambda comprising 185 base                pair sequence (SEQ ID NO: 1) fully defined in the                specification, is new.    USE - The duck interferon- lambda is useful in                preparation of medicament for preventing or                treating duck viral disease. The duck viral disease                comprises duck viral hepatitis, duck viral                enteritis, gosling plague, muscovy parvovirus                disease, young muscovy duck gosling, duck epidemic                hemorrhagic or black feather disease, duck liver                disease, duck viral encephalitis, duck reovirus                infection, duck adenovirus infection, duck                infectious cyst disease, duck paramyxovirus disease                or duck Newcastle disease, One or more of duck                coronavirus infection or duck flu (all                claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following: (1) coding gene for duck interferon                comprising polynucleotide sequence chosen from (a)                polynucleotide sequence comprising 558 base pair                sequence (SEQ ID NO: 2) fully defined in the                specification, (b) polynucleotide sequence capable                of hybridizing to the complementary sequence of SEQ                ID NO: 2 under stringent hybridization conditions,                where the protein encoded by the polynucleotide                still has function or activity of the interferon,                and (c) polynucleotide sequence having at least 80%                homology with the polynucleotide sequence of SEQ ID                NO: 2, and the protein encoded by the                polynucleotide still has the function or activity                of the interferon; (2) conserved amino acid                sequence of duck interferon- lambda , comprising                185 amino acid sequence (SEQ ID NO: 3) fully                defined in the specification, and polynucleotide                sequence encoding the gene comprising 558 base pair                sequence (SEQ ID NO: 4) fully defined in the                specification; (3) duck interferon- lambda mutant                comprising amino acid sequence of duck interferon-                lambda comprising amino acid sequence of SEQ ID NO:                3, mutant obtained by single-point mutation of an                amino acid unit of I95V, D104H, F117L, G126D,                Q136K, H143Y, S158G, V166L or H173N; (4)                recombinant vector or recombinant host cell                comprising the gene encoding duck alpha                -interferon; (5) use of duck lambda -interferon or                conservative amino acid sequence of duck interferon                alpha , in preparation of medicament for preventing                or treating duck viral disease; and (6) method for                producing duck alpha -interferon, the conservative                amino acid sequence of duck interferon- lambda ,                involves cloning coding gene of the duck lambda                -interferon encoding gene, constructing a                recombinant transfer vector into a baculovirus                transfer vector, co-transfecting the recombinant                transfer vector with the baculovirus DNA to obtain                a recombinant baculovirus, recombinant baculovirus                infected insect cells or insect host, cultured                insect cells infected insect host or expression of                the corresponding protein, where the baculovirus                transfer vector is chosen from AcRP23-lacZ,                AcRP6-SC, AcUWl-lacZ, BacPAK6, Bac to Pac, Bacmid,                BlucBacII (pETL), p2Bac, p2Blue, p89B310, pAc360,                pAc373, pAcAB3, pAcAB4 , PAcAS3, pAcC129, pAcC4,                DZI, pAcGP67, pAcIEl, pAcJPl, pAcMLF2, pAcMLF7,                pAcMLF8, pAcMPl, pAcMP2, pAcRP23, pAcRP25, pAcRW4,                pAcsMAG, pAcUWl, pAcUW21, pAcUW2A, pAcUW2B, pAcUW3,                pAcUW31, pAcUW41, pAcUW42, pAcUW43 , pAcUW51,                pAcVC2, pAcVC3, pAcYMl, pAcJcC5, pBacl, pBac2,                pBlueBacIII, pBlueBaSWis, pEV55, mXIV, pIEINeo,                pJVETL, pJVNhel, pJVP10, pJVrsMAG, pMBac, pP10,                pPAK1, pPBac, pSHONEX1.1, pSYN XIV VI+, pSYNVI +wp,                pSYNXIV VI-, pVL1391, pVL 1392, pVL 1393, pVL941,                pVL 945, pVL 985, pVTBac, pBM030 or pUAC-5;                Preferably, the baculovirus parent strain is chosen                from baculovirus BmBacmid, BmNPV, AcMNPV, ApNPV,                HaNPV, HzNPV, LdMNPV, MbMNPV, OpMNPV, SlMNPV,                SeMNPV or SpltNPV, the insect host is chosen from                Bombyx mori, B.mandarina, Philosamia cynthia,                Dictyoploca japanica, P.cynthiapryeri, Antheraea                pernyi, Japanese tussah, A.polyphymus, Atographa                califorica, Ectropis obliqua, Mamestra brassicae,                Spodoptera littoralis, S.frugiperda, Triswoplusia,                Thaumetopoea wilkinsoni and Heliothis                armigera. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-C01G;  B04-E02B;  B04-E03B;  B04-E08;  B04-F0100E;  B04-H05;  B04-H0500E;  B14-A02;  B14-S12;  C04-E99;  C04-C01G;  C04-E02B;  C04-E03B;  C04-E08;  C04-H0500E;  C14-A02;  C14-S12;  D05-H99;  D05-H12;  D05-H14	A61K-038/21;  A61P-031/12;  C07K-014/555;  C12N-015/20;  C12N-015/866	CN110256552-A   20 Sep 2019   C07K-014/555   201985Pages: 24   Chinese;  CN110256552-B   19 Feb 2021   C07K-014/555   202118   Chinese	CN110256552-A    CN10503363    11 Jun 2019;   CN110256552-B    CN10503363    11 Jun 2019	CN110256552-B Previous Publ. Patent CN110256552	CN10503363    11 Jun 2019			CN110256552-A -- CN104788554-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   CHEN X,  LI Y,  LI H,  ZHANG Z,  YI Y,  HU X,  LIU X;  CN108276486-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   HU X,  LI Y,  ZHANG Z,  LI H,  LIU X,  YI Y,  CHEN X;  CN108314724-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   HU X,  LI Y,  ZHANG Z,  LI H,  LIU X,  YI Y,  CHEN X;  CN108329390-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   ZHANG Z,  LI Y,  HU X,  ZHAO Z,  YI Y,  SHAO L,  YANG X,  LIU X,  ZHAO L,  MEHBOOB A;  CN108484750-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   LI Y,  ZHANG Z,  HU X,  YI Y,  LIU X,  SONG H,  YANG X,  DU M,  ZHANG W;  CN108676083-A   ZHEJIANG SHANCE HEQISHI BIOTECHNOLOGY CO                  LTD (ZHEJ-Non-standard)   CHENG Q,  ZHANG Z,  LI Y;  CN108707194-A   CHINESE ACAD AGRIC SCI BIOTECHNOLOGY RES (CAGS)   ZHANG Z,  LI Y,  HU X,  YI Y,  LIU X,  WANG X,  ZHAO L,  ZHAO Z,  WANG P;  CN108840921-A   ZHEJIANG SHANCE HEQISHI BIOTECHNOLOGY CO                  LTD (ZHEJ-Non-standard)   CHENG Q,  LI Y,  ZHANG Z	CN110256552-A  : " 2", 31 August          2012,relevantClaims[1-10],relevantPassages[212-217];  YAO Q: "NCBI          Reference Sequence:NM_001310792.1, Anas platyrhynchos          interferon lambda-3-like (LOC101795406),mRNA",          GENBANK:NM_001310792.1,relevantClaims[8-10|1-47],relevantPassages[FEATURESORIGIN];  YAO Q: "interferon          lambda-3-like precursor [Anas platyrhynchos]",          GENBANK:NP_001297721.1,relevantClaims[8-10|1-47],relevantPassages[FEATURESORIGIN];  : "",          ,relevantClaims[8-9],relevantPassages[64-93]	97854-0-0-0 N			RA022K N		US2019330572-A1;  US11060052-B2	Formulating a cleaning composition for preventing            and/or decontaminating a surface from pathogen by            coating a granular absorbent material with coating            agent, and mixing coated absorbent material with            sanitation agent	HAWKINS W;  REYNOLDS S W;  LILLARD J W	MOREHOUSE SCHOOL MEDICINE (MORE-Non-standard);  DEVMAR PROD LLC (DEVM-Non-standard);  INNOVATIVE ENVIRONMENTAL CO (INNO-Non-standard)	201990128M	   NOVELTY - A cleaning composition is formulated by                coating a granular absorbent material with a                coating agent to produce a coated absorbent                material; and mixing the coated absorbent material                with a sanitation agent where the coated absorbent                material absorbs the sanitation agent to faun the                cleaning composition.    USE - Formulation of cleaning composition for                preventing and/or decontaminating a surface from                pathogen (claimed).    ADVANTAGE - The cleaning composition imparts chemical                disinfection, deodorizing chemicals or blanketing                effect on the affected area to reduce the spread of                microbe into the open air.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) preventing and/or decontaminating a                surface from a pathogen which involves applying an                effective amount of cleaning composition on surface                where cleaning composition comprises an granular                absorbent material coated with a biocide and a                sanitation agent absorbed in granular absorbent                material;    (2) cleaning composition comprising a granular                absorbent material coated with a biocide; and                sanitation agent absorbed in granular absorbent                material;    (3) sanitation process which involves applying                an effective amount of cleaning composition to a                surface in need of sanitation; and removing the                cleaning composition after;    (4) cleaning kit comprising cleaning                composition and instructions on how to use the                cleaning composition; and    (5) making a cleaning composition which                involves coating a high surface area solid with                non-toxic biostatic film. 			A97 (Miscellaneous goods not specified elsewhere - including papermaking, gramophone records, detergents, food and oil well applications.);  G02 (Inks, paints, polishes â€“ polymer-based paints and inks are also classified in Section A (C09D, F, G).);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.)	A03-A05;  A12-W12B;  G02-A03B;  C04-C02D;  C04-C03;  C12-M15	A01N-025/26;  C11D-011/00;  C11D-017/00;  C11D-003/48	US2019330572-A1   31 Oct 2019   C11D-017/00   201986Pages: 14   English;  US11060052-B2   13 Jul 2021   C11D-017/00   202158   English	US2019330572-A1    US448059    21 Jun 2019;   US11060052-B2    US448059    21 Jun 2019	US2019330572-A1 Provisional Application US495274P;   US2019330572-A1 Cont of Application US696480;   US2019330572-A1 Cont of Patent US10370625;   US11060052-B2 Provisional Application US495274P;   US11060052-B2 Cont of Application US135568;   US11060052-B2 Cont of Application US696480;   US11060052-B2 Cont of Patent US10370625;   US11060052-B2 Cont of Patent US10457901;   US11060052-B2 Previous Publ. Patent US2019330572	US495274P    08 Sep 2016;  US448059    21 Jun 2019			;  US11060052-B2 -- US20200190444-A1   ;  US20200199502-A1   ;  US10370625-B2   MOREHOUSE SCHOOL MEDICINE (MORE-Non-standard);  DEVMAR PROD LLC (DEVM-Non-standard);  INNOVATIVE ENVIRONMENTAL CO (INNO-Non-standard)   HAWKINS W,  HE Q,  JONES H M,  LILLARD J W,  REYNOLDS S W;  US10457901-B2   MOREHOUSE SCHOOL MEDICINE (MORE-Non-standard);  DEVMAR PROD LLC (DEVM-Non-standard);  INNOVATIVE ENVIRONMENTAL CO (INNO-Non-standard)   HAWKINS W,  REYNOLDS S W,  LILLARD J W;  US10704012-B2   MOREHOUSE SCHOOL MEDICINE (MORE-Non-standard);  DEVMAR PROD LLC (DEVM-Non-standard);  INNOVATIVE ENVIRONMENTAL CO (INNO-Non-standard)   HAWKINS W,  REYNOLDS S W,  LILLARD J W,  HE Q,  JONES H M;  CN1425039-A   THC PTY LTD (THCT-Non-standard)   TOMLINSON D J,  LINKLATER W J;  JP2004204085-A   LION CORP (LIOY)   HANIWARA K,  NAGAAI Y;  JP2006151907-A   LION CORP (LIOY)   SUZUKI A,  HASEGAWA T,  SUZUKI Y,  FUJIMURA S,  SONODA A;  JP2007008976-A   LION CORP (LIOY)   ARITA K,  NAKANO S,  ONO M,  HASEGAWA T,  TOBE S;  JP2008007494-A   NIPPON SODA CO (NIPS)   MUTO K,  TAKAHASHI Y,  YOSHIDA M;  US4497869-A   TOYOTA CENT RES & DEV LAB (TOYW);  US20030143187-A1   ;  US20070065475-A1   ;  US20070179079-A1   ;  US20120308626-A1   ;  US20140326192-A1   ;  US20180066216-A1   ;  US20180265822-A1   ;  US20190017000-A1   ;  US6905698-B1   CROSFIELD LTD (CROS-Non-standard)   ALDCROFT D,  JONES H,  TURNER D,  EDGE M,  ROBINSON J,  SEAL K;  US8758503-B2   ANDERSON T L (ANDE-Individual);  BERKE N S (BERK-Individual)   ANDERSON T L,  BERKE N S;  WO2001079341-A1   ;  WO2014149052-A1   EMPIRE TECHNOLOGY DEV LLC (EMTD)   ADAM G A,  SJONG A,  CARLSON W B,  WAN F,  LONDERGAN T M	US11060052-B2            Notification of Reason(s) for Refusal, Japanese Patent          Application No. 2019-151276, dated Oct. 1,          2019.;            Notification of the First Office Action, Chinese Patent          Application No. 201780054902.5, dated Oct. 11,          2019.;            Ye, R. et al., Preparation, Mechanical and Thermal          Properties of Cement Board with Expanded Perlite Based          Composite Phase Change Material for Improving Buildings          Thermal Behavior, Materials, Nov. 13, 2015, vol. 8(11),          pp. 7702-7713.;            Gerba, C. P., Quaternary Ammonium Biocides: Efficacy in          Application, Applied and Environmental Microbiology, Jan.          2015, vol. 81(2), pp. 464-469.;            International Search Report and Written Opinion of the          International Searching Authority of International          Application No. PCT/US17/50337 dated Dec. 4,          2017.;            Perlite as an Absorbent or Carrier, Perlite Institute,          Inc., pp. 1-2, Feb. 1, 2001date provided by Google Search          9see p. 3 of 4) (total pages: 4) (Year 2001).;            Kim, S. et al. A Study for the Removal of Phosphorous          Using Coated Exfoliated Vermiculite, Journal of the          Korean Geo-Environmental Society, 15 (12); 5-13, Dec.          2014 (year: 2014).;            File History of U.S. Appl. No. 15/696, 480, filed Sep. 6,          2017.;            File History of U.S. Appl. No. 16/004, 954, filed Jun.          11, 2018.;            File History of U.S. Appl. No. 16/005, 740, filed Jun.          11, 2018.;            File History of U.S. Appl. No. 16/135, 568, filed Sep.          19, 2018.	184613-0-0-0 K M; 133912-0-0-0 			RA00I9 K M; R01835 		EP3460053-A1;  WO2019057953-A1;  EP3688146-A1	Isolated porcine astrovirus comprises nucleotide            sequence, or the complementary strand, an ORF2 nucleic            acid sequence, ORF2 nucleic acid sequence encoding an            ORF2 polypeptide, ORF1a nucleic acid sequence, or            complementary strand	BOROS A;  REUTER G K;  ALBERT M;  PANKOVICS P	CEVA SANTE ANIMALE (CEVA-C);  CEVA SANTE ANIMALE (CEVA-C)	2019276733	   NOVELTY - Isolated porcine astrovirus comprises a                nucleotide sequence having 6393, 6393, 6394, or                2265 nucleobases (SEQ ID NOs: 1-4), given in the                specification, or the complementary strand, an ORF2                nucleic acid sequence selected from nucleotide                residues nucleotide residues 4075-6339 of anyone of                (SEQ ID NOs: 1-4), or the complementary strand, an                ORF2 nucleic acid sequence encoding an ORF2                polypeptide comprising the amino acid sequence                having 754 aminobases (SEQ ID NOs: 5-8), given in                the specification, or the complementary strand, an                ORF1a nucleic acid sequence selected from                nucleotide residues 31-2559 of anyone of (SEQ ID                NOs:1-3) or the complementary strand, an ORF1a                nucleic acid sequence encoding an ORF1a polypeptide                comprising the amino acid sequence having 842 amino                bases (SEQ ID NOs: 9-11), given in the                specification, or the complementary strand, an                ORFlab nucleic acid sequence selected from                nucleotide residues 31-4085 of anyone of (SEQ ID                NOs:1-3) or the complementary strand.    USE - Isolated porcine astrovirus used for                propagating is host cell, where the combination is                used for vaccinating porcine, to treat or prevent                porcine astrovirus associated disease (all                claimed).    DETAILED DESCRIPTION - Isolated porcine astrovirus further comprises                an ORFlab nucleic acid sequence encoding an ORFlab                polypeptide comprising or consisting of the                aminoacid sequence having 1351 amino bases (SEQ ID                NOs: 12-14), given in the specification, or the                complementary strand, an ORF1b nucleic acid                sequence selected from nucleotide residues                2559-4085 of anyone of (SEQ ID NOs:1-3) or the                complementary strand, an ORF1b nucleic acid                sequence encoding an ORF1b polypeptide comprising                the aminoacid sequence having 508 amino bases (SEQ                ID NOs: 15-17), given in the specification, or the                complementary strand, and a nucleotide sequence                having a homology of 87-99% to a nucleotide                sequences, and a variant sequence within the                degeneration of the genetic code. INDEPENDENT                CLAIMS are included for the following:    (1) a method for preparing a vaccine, which                involves attenuating or killing a virus, and,                formulating the attenuated or inactivated virus in                a suitable excipient;    (2) a host cell containing a virus;    (3) a method of producing a porcine                astrovirus, which involves seeding a competent host                cell with a seed of culture of a virus, growing the                cells under suitable conditions in a manner                allowing production of the virus, and harvesting                the porcine astrovirus from the cells;    (4) a nucleic acid molecule comprises a                nucleotide sequence having (SEQ ID NO: 1-4), a                nucleotide sequence comprising nucleotide residues                4075-6339 having (SEQ IDNOs: 1-3), nucleotide                residues 31-2559 of (SEQ ID NOs: 1-3), nucleotide                residues 31-4085 of (SEQ ID NOs: 1-3), nucleotide                residues 2559-4085 of (SEQ ID NOs: 1-3), or the                complementary strand, a nucleic acid sequence                encoding a polypeptide comprising the amino acid                sequence of (SEQ ID NO: 5-17), or the complementary                strand, a nucleotide sequence having a homology of                87-99% to a nucleotide sequence, a variant sequence                within the degeneration of the genetic code, or a                fragment of a sequence of 10 consecutive                nucleotides;    (5) a polypeptide encoded by a nucleic acid                molecule;    (6) a vector, virus, plasmid or host cell                comprises a nucleic acid molecule;    (7) a composition comprises a virus, a                subunit, a polypeptide, a vector, virus, plasmid or                host cell, a cell, and a veterinary acceptable                vehicle or excipient;    (8) a container comprises an immunologically                effective amount the composition;    (9) a kit comprises the container and an                instruction manual including information for the                administration of the immunologically effective                amount of the composition into pigs for treating                and/or preventing porcine astrovirus-associated                diseases;    (10) a nucleic acid probe or primer                characteristic of a nucleotide sequence or a                fragmen;    (11) an antibody or a derivative which is                capable of binding to a virus or sub-units;                and    (12) a method for diagnosing the presence of a                virus in an animal, which involves contacting a                tissue or fluid sample with a probe, primer or                antibody, and detecting the presence of a                virus. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E02F;  B04-E03F;  B04-E05;  B04-E08;  B04-E99;  B04-F0100E;  B04-F11B;  B04-F11B0E;  B04-G01;  B04-G08;  B11-C07A;  B11-C08F8;  B12-K04F;  B12-K04G;  B14-A02B;  B14-G01;  B14-S11A;  C04-E02F;  C04-E03F;  C04-E05;  C04-E08;  C04-E99;  C04-F0100E;  C04-F11B;  C04-F11B0E;  C04-G01;  C04-G08;  C11-C07A;  C11-C08F8;  C12-K04F;  C12-K04G;  C14-A02B;  C14-G01;  C14-S11A;  D05-H06A;  D05-H07;  D05-H09;  D05-H11;  D05-H12A;  D05-H12D1;  D05-H12E;  D05-H12F;  D05-H14;  D05-H99	C07K-014/005;  C12N-007/00	EP3460053-A1   27 Mar 2019   C12N-007/00   201924Pages: 108   English;  WO2019057953-A1   28 Mar 2019   C12N-007/00   201924   English;  EP3688146-A1   05 Aug 2020   C12N-007/00   202064   English	EP3460053-A1    EP306260    25 Sep 2017;   WO2019057953-A1    WOEP075738    24 Sep 2018;   EP3688146-A1    EP773446    24 Sep 2018	EP3688146-A1 PCT application Application WOEP075738;   EP3688146-A1 Based on Patent WO2019057953	EP306260    25 Sep 2017	EP3460053-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  MA;  MD  WO2019057953-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP3688146-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  		EP3460053-A1 -- CN103146846-A   GUANGZHOU VIPOTION BIOTECH CO LTD (GUAN-Non-standard)   CHEN Y,  HUANG C,  HUANG J,  LIAO J,  LIU J,  MO H,  WANG B,  XU D,  XU G,  YE Y,  ZHOU M;  WO2014153168-A2   UNIV COLUMBIA NEW YORK (UYCO);  UNIV IOWA STATE RES FOUND INC (IOWA);  UNIV KANSAS STATE RES FOUND (UNIV);  ZOETIS LLC (ZOET)   FIRTH C,  HALBUR P G,  HARDHAM J M,  HESSE R A,  LIPKIN W I,  MARX J G,  OPRIESSNIG T I,  REDDY S K;  US4745051-A   UNIV TEXAS A & M SYSTEM (UTAM)   SMITH G E,  SUMMERS M D;  WO2019057953-A1 -- CN103146846-A   GUANGZHOU VIPOTION BIOTECH CO LTD (GUAN-Non-standard)   CHEN Y,  HUANG C,  HUANG J,  LIAO J,  LIU J,  MO H,  WANG B,  XU D,  XU G,  YE Y,  ZHOU M;  WO2014153168-A2   UNIV COLUMBIA NEW YORK (UYCO);  UNIV IOWA STATE RES FOUND INC (IOWA);  UNIV KANSAS STATE RES FOUND (UNIV);  ZOETIS LLC (ZOET)   FIRTH C,  HALBUR P G,  HARDHAM J M,  HESSE R A,  LIPKIN W I,  MARX J G,  OPRIESSNIG T I,  REDDY S K;  US4745051-A   UNIV TEXAS A & M SYSTEM (UTAM)   SMITH G E,  SUMMERS M D	EP3460053-A1  HANKE D ET AL:          "Porcine Epidemic Diarrhea in Europe: In-Detail Analyses          of Disease Dynamics and Molecular Epidemiology", VIRUSES,          vol. 9, no. 7, 6 July 2017 (2017-07-06), CH, pages 177,          XP055492371, ISSN: 1999-4915, DOI:          10.3390/v9070177,relevantClaims[1,3,7-11,13-15|1,3-15],relevantPassages[table          2; sequences;];  ITO M ET AL: "Whole          genome analysis of porcine astroviruses detected in          Japanese pigs reveals genetic diversity and possible          intra-genotypic recombination", INFECTION, GENETICS AND          EVOLUTION, ELSEVIER, AMSTERDAM, NL, vol. 50, 9 February          2017 (2017-02-09), pages 38 - 48, XP029958046, ISSN:          1567-1348, DOI:          10.1016/J.MEEGID.2017.02.008,relevantClaims[1,3,7-11,13,14|1,3-15],relevantPassages[abstract;          table 2; sequences];  BOROS A ET AL:          "Outbreaks of Neuroinvasive Astrovirus Associated with          Encephalomyelitis, Weakness, and Paralysis among Weaned          Pigs, Hungary", EMERGING INFECTIOUS DISEASES, vol. 23,          no. 12, 1 December 2017 (2017-12-01), US, pages 1982 -          1993, XP055492382, ISSN: 1080-6040, DOI:          10.3201/eid2312.170804,relevantClaims[1-15];            "Program Manual for the Wisconsin Package", GENETICS          COMPUTER GROUP, vol. 575, 8 August 1996 (1996-08-08),          pages 53711;            NEEDLEMAN, S.B.; WUNSCH, C.D., JOURNAL OF MOLECULAR          BIOLOGY, vol. 48, 1970, pages 443 - 453;  "A          Laboratory Manual", 1988, COLD SPRING HARBOR          LABORATORYWO2019057953-A1  HANKE D ET AL:          "Porcine Epidemic Diarrhea in Europe: In-Detail Analyses          of Disease Dynamics and Molecular Epidemiology", VIRUSES,          vol. 9, no. 7, 6 July 2017 (2017-07-06), CH, pages 177,          XP055492371, ISSN: 1999-4915, DOI:          10.3390/v9070177,relevantClaims[1,3,7-11,13-17,24|1-28],relevantPassages[table          2; sequences;];  ITO M ET AL: "Whole          genome analysis of porcine astroviruses detected in          Japanese pigs reveals genetic diversity and possible          intra-genotypic recombination", INFECTION, GENETICS AND          EVOLUTION, ELSEVIER, AMSTERDAM, NL, vol. 50, 9 February          2017 (2017-02-09), pages 38 - 48, XP029958046, ISSN:          1567-1348, DOI:          10.1016/J.MEEGID.2017.02.008,relevantClaims[1,3,7-11,13,14,16,17,24|1-28],relevantPassages[abstract;          table 2; sequences];  BOROS A ET AL:          "Outbreaks of Neuroinvasive Astrovirus Associated with          Encephalomyelitis, Weakness, and Paralysis among Weaned          Pigs, Hungary", EMERGING INFECTIOUS DISEASES, vol. 23,          no. 12, 1 December 2017 (2017-12-01), US, pages 1982 -          1993, XP055492382, ISSN: 1080-6040, DOI:          10.3201/eid2312.170804,relevantClaims[1-28],relevantPassages[abstract,          materials and methods; results; discussion;];  CHU D K W ET AL:          "Novel Astroviruses in Insectivorous Bats", JOURNAL OF          VIROLOGY., vol. 82, no. 18, 15 September 2008          (2008-09-15), US, pages 9107 - 9114, XP055518273, ISSN:          0022-538X, DOI:          10.1128/JVI.00857-08,relevantClaims[26,28],relevantPassages[abstract;          materials and methods;];  ULLOA J C ET AL:          "Identification of Two Immunoreactive Peptides Useful for          the Detection of Porcine Astrovirus", INTERVIROLOGY.,          vol. 55, no. 4, 1 January 2012 (2012-01-01), CH, pages          127 - 133, XP055517839, ISSN: 0300-5526, DOI:          10.1159/000328277,relevantClaims[27,28],relevantPassages[abstract;          page 316, left-hand column, paragraph 4 - right-hand          column, paragraph 3;];            NEEDLEMAN, S.B.; WUNSCH, C.D., JOURNAL OF MOLECULAR          BIOLOGY, vol. 48, 1970, pages 443 - 453;  "A          Laboratory Manual", 1988, COLD SPRING HARBOR          LABORATORY						WO2019099868-A2;  WO2019099868-A3;  CN111372585-A;  EP3710002-A2;  EP3710002-A4;  US2022251061-A1;  HK40035124-A0;  US11524949-B2;  US2023357180-A1	New substituted amine compound useful in            pharmaceutical composition for treating human with            medical disorder e.g. abnormal cellular proliferation,            tumor, cancer, immune disorder, autoimmune disorder,            arthritis, and lupus	PHILLIPS A J;  NASVESCHUK C G;  HENDERSON J A;  HE M;  LAZARSKI K	C4 THERAPEUTICS INC (CFOU-Non-standard);  C4 THERAPEUTICS INC (CFOU-Non-standard);  C4 THERAPEUTICS INC (CFOU-Non-standard)	2019458215	   NOVELTY - A substituted amine compound chosen from                compounds (I)-(IV), is new.    USE - New substituted amine compound is useful in                pharmaceutical composition for treating human with                medical disorder. The medical disorder is chosen                from abnormal cellular proliferation, tumor,                cancer, immune disorder, autoimmune disorder,                arthritis, lupus, diabetes, cardiovascular disease,                infectious disease, or inflammatory condition. The                infectious disease is chosen from HIV, hepatitis B                virus (HBV), HCV, herpes simplex virus (HSV), human                papillomavirus (HPV), respiratory syncytial virus                (RSV), cytomegalovirus (CMV), Ebola, Flavivirus,                Pestivirus, Rotavirus, Influenza, Coronavirus,                Epstein-Barr virus (EBV), viral pneumonia,                drug-resistant viruses, Bird flu, RNA virus, DNA                virus, adenovirus, poxvirus, Picornavirus,                Togavirus, Orthomyxovirus, Retrovirus,                Hepadnavirus, a Gram-negative bacterium, a                Gram-positive bacterium, atypical bacterium,                Staphylococcus, Streptococcus, Escherichia coli,                Salmonella, Helicobacter pylori, meningitis,                gonorrhea, Chlamydiaceae, fungus, protozoa,                helminths, worms, prion or parasite. The cancer is                chosen from squamous-cell carcinoma, basal cell                carcinoma, adenocarcinoma, hepatocellular                carcinoma, renal cell carcinoma, bladder cancer,                bowel cancer, cervical cancer, colon cancer,                esophageal cancer, head and neck cancer, kidney                cancer, liver cancer, lung cancer, ovarian cancer,                pancreatic cancer, prostate cancer, stomach cancer,                leukemia, lymphoma, Burkitt's lymphoma,                Non-Hodgkin's lymphoma, melanoma,                myeloproliferative disease, sarcoma,                hemangiosarcoma, Kaposi's sarcoma, liposarcoma,                myxosarcoma, peripheral neuroepithelioma, synovial                sarcoma, glioma, astrocytoma, oligodendroglioma,                ependymoma, glioblastoma, neuroblastoma,                ganglioneuroma, ganglioglioma, medulloblastoma,                pineal cell tumor, meningioma, meningeal sarcoma,                neurofibroma, Schwannoma, breast cancer, uterine                cancer, testicular cancer, thyroid cancer,                astrocytoma, carcinosarcoma, Hodgkin's disease,                Wilms tumor, and teratocarcinoma (all                claimed).    DETAILED DESCRIPTION - A substituted amine compound chosen from                compounds of formulae (I)-(IV) or its salt,                L-oxide, isotopic derivative, or prodrug, is                new.    W1 = CR6R7, C=O, C=S, C=CH2, SO2, S(O),                P(O)OH, or P(O)NH2;    W2 = CR8R9, C=O, C=S, C=CH2, SO2, S(O),                P(O)OH, or P(O)NH2;    X = NH, NR2, O, S(O), S(O)2, or S;    R2 = H, alkyl, heteroalkyl, aliphatic group,                heteroaliphatic group, heterocyclyl, aryl,                heteroaryl, -C(O)H, -C(O)OH, -C(O)alkyl,                -C(O)O-alkyl, -C(O)(aliphatic group, aryl,                heteroaliphatic group, or heteroaryl),                -C(O)O(aliphatic group, aryl, heteroaliphatic                group, or heteroaryl), alkenyl, or alkynyl;    R4 = H, aliphatic group, heterocyclyl, or                heteroaliphatic group;    R5 = e.g. H, alkyl, C(O)R4', aryl, aryloxy,                heterocyclyl, heteroaryl, arylalkyl, O-arylalkyl,                nitro, nitroso, sulfonyl, sulfoxide, thioalkyl,                thio, or cycloalkyl;    R6-R11 = H, alkyl, aliphatic group,                heteroaliphatic group, carbocyclyl, heterocyclyl,                aryl, heteroaryl, halo, azido, cyano, hydroxy,                alkoxy, amino, -NH(aliphatic), or                -N(aliphatic)2;    or (R10+R11+C), (R13+R14+C) = 3-6-membered                spirocarbocyclyl, or 4-6-membered spiroheterocyclyl                comprising N, O, and/or S;    R13,R14 = H, alkyl, alkenyl, alkynyl, alkoxy,                haloalkoxy, hydroxy, amino, -NH-alkyl, or                -N(alkyl)2;    R15 = e.g. H or aliphatic group;    R16 = group chosen from groups of formulae                (i-1)-(i-29);    R17 = R'17a, R'17b, or R'17c;    R'17a = group chosen from groups of formulae                (ii-1)-(ii-27);    R'17b = group chosen from groups of formulae                (iii-1)-(iii-28);    R'17c = group chosen from groups of formulae                (iv-1)-(iv-29);    R4' = e.g. H or alkyl;    Y' = N, CH, or CR5;    Z1 = CH2, CHR2, C(R2)2, NR2, O, or S;    Z2 = NH, O, S, NR2, C=O, S=O, or SO2;    R12 = -(Linker)'-Targeting Ligand or                -(Linker)";    (Linker)' = bivalent chemical group;    (Linker)" = monovalent chemical                group;and    Targeting Ligand = molecule that binds to                Target Protein which is mediator of disease in                human or other mammal.    Full definitions are given in the DEFINITIONS                (Full Definitions) Field. An INDEPENDENT CLAIM is                included for a treatment of human with medical                disorder i.e. treated by degrading target protein                that binds to targeting ligand, by or binding to                the protein cereblon in vivo, which involves                administering compound (I), or its salt, optionally                in carrier. 			B03 (Other heterocyclics.);  B02 (Fused ring heterocyclics.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B05-B01M;  B06-H;  B07-D11;  B07-E03;  B07-F03;  B14-A01;  B14-A02;  B14-A04;  B14-C03;  B14-C09;  B14-F01;  B14-F02;  B14-F03;  B14-G02D;  B14-G03;  B14-H01;  B14-H05;  B14-K01;  B14-N16;  B14-S04;  D05-H	A61K-031/53;  A61K-031/454;  A61K-047/50;  C07D-401/14;  C07D-211/88;  C07D-403/04;  C07D-413/04;  C07D-417/04;  C07D-471/04;  C07D-401/04	WO2019099868-A2   23 May 2019   A61K-031/53   201947Pages: 823   English;  WO2019099868-A3   27 Jun 2019   A61K-031/454   201948   English;  CN111372585-A   03 Jul 2020   A61K-031/454   202057   Chinese;  EP3710002-A2   23 Sep 2020   A61K-031/454   202079   English;  EP3710002-A4   07 Jul 2021   A61K-031/454   202156   English;  US2022251061-A1   11 Aug 2022   C07D-401/04   202265   English;  HK40035124-A0   07 May 2021   A61K-031/454   202298   English;  US11524949-B2   13 Dec 2022   C07D-401/04   202200   English;  US2023357180-A1   09 Nov 2023   C07D-401/04   202391   English	WO2019099868-A2    WOUS061573    16 Nov 2018;   WO2019099868-A3    WOUS061573    16 Nov 2018;   CN111372585-A    CN80074388    16 Nov 2018;   EP3710002-A2    EP878359    16 Nov 2018;   EP3710002-A4    EP878359    16 Nov 2018;   US2022251061-A1    US874475    14 May 2020;   HK40035124-A0    HK6024709    02 Feb 2021;   US11524949-B2    US874475    14 May 2020;   US2023357180-A1    US079815    12 Dec 2022	CN111372585-A PCT application Application WOUS061573;   CN111372585-A Based on Patent WO2019099868;   EP3710002-A2 PCT application Application WOUS061573;   EP3710002-A2 Based on Patent WO2019099868;   US2022251061-A1 Provisional Application US587303P;   US2022251061-A1 Cont of Application WOUS061573;   HK40035124-A0 PCT application Application WOUS061573;   HK40035124-A0 Based on Patent WO2019099868;   HK40035124-A0 Previous Publ. Patent EP3710002;   US11524949-B2 Provisional Application US587303P;   US11524949-B2 Cont of Application WOUS061573;   US11524949-B2 Previous Publ. Patent US2022251061;   US2023357180-A1 Cont of Application WOUS061573;   US2023357180-A1 Cont of Application US874475;   US2023357180-A1 Provisional Application US587303P;   US2023357180-A1 Cont of Patent US11524949	US587303P    16 Nov 2017;  EP878359    16 Nov 2018;  WOUS061573    16 Nov 2018;  US874475    14 May 2020;  CN80074388    15 May 2020;  US079815    12 Dec 2022	WO2019099868-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2019099868-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP3710002-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  EP3710002-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR          		;  WO2019099868-A3 -- US20160058872-A1   ;  WO2017161119-A1   MOFFITT CANCER CENT & RES INST INC H                  LEE (MOFF)   BURNETTE P,  LAWRENCE H,  LAWRENCE N J;  WO2017197046-A1   C4 THERAPEUTICS INC (CFOU-Non-standard)   HE M,  HENDERSON J A,  LAZARSKI K,  LIANG Y,  NASVESCHUK C G,  PHILLIPS A J,  VEITS G K,  VORA H U;  WO2017197055-A1   C4 THERAPEUTICS INC (CFOU-Non-standard)   FITZGERALD M E,  HE M,  HENDERSON J A,  LIANG Y,  MICHAEL R E,  NASVESCHUK C G,  PHILLIPS A J;  CN111372585-A -- CN104736569-A   GLAXOSMITHKLINE INTELLECTUAL PROPERTY (GLAX);  UNIV YALE (UYYA);  UNIV CAMBRIDGE ENTERPRISE LTD CAMBRIDGE (UYCA)   BUCKLEY D,  CAMPOS S A,  CIULLI A,  CREWS C M,  GAREISS P C,  GUSTAFSON J,  HARLING J D,  HOYER D W,  JORGENSEN W,  LE J,  MIAH A H,  MICHEL J,  MOLLE I V,  ROTH A G,  SMITH I E D,  TAE H;  US20160272639-A1   ;  WO2017161119-A1   MOFFITT CANCER CENT & RES INST INC H                  LEE (MOFF)   BURNETTE P,  LAWRENCE H,  LAWRENCE N J;  EP3710002-A4 -- US2763652-A   ;  US2948723-A   ;  US11524949-B2 -- BR201100318-A2   UNIV ESTADUAL PAULISTA UNESP (UYES-Non-standard)   DOS SANTOS J L,  CHIN C M;  CN103421061-A   UNIV CHINA PHARM (UYCP)   XU Y,  LIU K,  ZHUANG Y,  DONG J,  LOU Y;  US2763652-A   ;  US2948723-A   ;  US5635517-A   CELGENE CORP (CGEN)   CHEN R S,  MULLER G W,  STIRLING D I;  US6045501-A   CELGENE CORP (CGEN)   WILLIAMS B,  ELSAYED M;  US20060069067-A1   ;  US20130190340-A1   ;  US20140302523-A1   ;  US20140356322-A1   ;  US20150119435-A1   ;  US20150274738-A1   ;  US20150291562-A1   ;  US20160016966-A1   ;  US20160022642-A1   ;  US20160045607-A1   ;  US20160046661-A1   ;  US20160058872-A1   ;  US20160176916-A1   ;  US20160214972-A1   ;  US20160272639-A1   ;  US20170008904-A1   ;  US20170037004-A1   ;  US20170065719-A1   ;  US20180015087-A1   ;  US20180085465-A1   ;  US20200140456-A1   ;  US20200207733-A1   ;  US20200207764-A1   ;  US20200207783-A1   ;  US20200308171-A1   ;  US20200361930-A1   ;  US20210009559-A1   ;  US20210032245-A1   ;  US6306663-B1   PROTEINIX INC (PROT-Non-standard)   KENTEN J H,  ROBERTS S F,  LEBOWITZ M S;  US6315720-B1   CELGENE CORP (CGEN)   WILLIAMS B A,  KAMINSKI J K;  US6395754-B1   CELGENE CORP (CGEN);  MULLER G W (MULL-Individual);  STIRLING D I (STIR-Individual);  CHEN R S (CHEN-Individual)   MULLER G W,  STIRLING D I,  CHEN R S;  US10905768-B1   C4 THERAPEUTICS INC (CFOU-Non-standard)   FITZGERALD M E,  HE M,  HENDERSON J A,  LIANG Y,  MICHAEL R E,  NASVESCHUK C G,  PHILLIPS A J;  US6561976-B2   ELSAYED M (ELSA-Individual);  WILLIAMS B (WILL-Individual)   ELSAYED M,  WILLIAMS B;  US6561977-B2   CELGENE CORP (CGEN)   WILLIAMS B A,  KAMINSKI J K;  US6755784-B2   WILLIAMS B A (WILL-Individual);  KAMINSKI J K (KAMI-Individual)   WILLIAMS B A,  KAMINSKI J K;  US6869399-B2   CELGENE CORP (CGEN)   WILLIAMS B A,  KAMINSKI J K;  US6908432-B2   CELGENE CORP (CGEN)   ELSAYED M,  WILLIAMS B;  US7041298-B2   CALIFORNIA INST OF TECHNOLOGY (CALY);  UNIV YALE (UYYA);  UNIV CALIFORNIA (REGC)   DESHAIES R J,  CREWS C,  SAKAMOTO K M;  US7141018-B2   CELGENE CORP (CGEN)   WILLIAMS B A,  KAMINSKI J K;  US7208157-B2   CALIFORNIA INST OF TECHNOLOGY (CALY);  UNIV YALE (UYYA);  UNIV CALIFORNIA (REGC)   DESHAIES R J,  CREWS C,  SAKAMOTO K M;  US7230012-B2   CELGENE CORP (CGEN)   D'ANGIO P;  US7820697-B2   CELGENE CORP (CGEN)   MAN H,  MULLER G W;  US7874984-B2   CELGENE CORP (CGEN)   ELSAYED M,  WILLIAMS B;  US7959566-B2   CELGENE CORP (CGEN)   WILLIAMS B A,  KAMINSKI J K;  US8204763-B2   ELSAYED M (ELSA-Individual);  WILLIAMS B (WILL-Individual)   ELSAYED M,  WILLIAMS B;  US8315886-B2   WILLIAMS B A (WILL-Individual);  KAMINSKI J K (KAMI-Individual)   WILLIAMS B A,  KAMINSKI J K;  US8589188-B2   CELGENE CORP (CGEN)   ELSAYED M,  WILLIAMS B;  US8626531-B2   WILLIAMS B A (WILL-Individual);  KAMINSKI J K (KAMI-Individual)   WILLIAMS B A,  KAMINSKI J K;  US8673939-B2   CELGENE CORP (CGEN)   ZELDIS J B;  US8735428-B2   CELGENE CORP (CGEN)   ZELDIS J B;  US8741929-B2   CELGENE CORP (CGEN)   ZELDIS J B;  US8828427-B2   CELGENE CORP (CGEN)   TUTINO A,  KELLY M T;  US9056120-B2   CELGENE CORP (CGEN)   ZELDIS J B;  US9101621-B2   CELGENE CORP (CGEN)   ZELDIS J B;  US9101622-B2   CELGENE CORP (CGEN)   ZELDIS J B;  US9125915-B2   MITSUBISHI TANABE PHARMA CORP (MTSB)   MIYOSHI S,  OOIKE S,  IWATA K,  HIKAWA H,  SUGAHARA K;  US9249161-B2   CONSTELLATION PHARM (MORY)   ALBRECHT B K,  AUDIA J E,  COTE A,  GEHLING V S,  HARMANGE J,  HEWITT M C,  NAVESCHUK C G,  TAYLOR A M,  VASWANI R G;  US10351568-B2   HARVARD COLLEGE (HARD)   FINLEY D,  KING R W,  LEE B,  LEE M J,  GAHMAN T C;  US10646575-B2   C4 THERAPEUTICS INC (CFOU-Non-standard)   FITZGERALD M E,  HE M,  HENDERSON J A,  LIANG Y,  MICHAEL R E,  NASVESCHUK C G,  PHILLIPS A J;  US10660968-B2   C4 THERAPEUTICS INC (CFOU-Non-standard)   HENDERSON J A,  LAZARSKI K,  LIANG Y,  MICHAEL R E,  NASVESCHUK C G,  PHILLIPS A J;  US10849982-B2   C4 THERAPEUTICS INC (CFOU-Non-standard)   HE M,  HENDERSON J A,  LAZARSKI K,  LIANG Y,  NASVESCHUK C G,  PHILLIPS A J,  VEITS G K,  VORA H U;  WO1998011111-A1   ;  WO2002059106-A1   ;  WO2007031791-A1   ARROW THERAPEUTICS LTD (ARRO-Non-standard)   WHEELHOUSE C J,  THOMAS A J F,  BUSHNELL D J,  LUMLEY J,  SALTER J I,  CARTER M C,  MATHEWS N,  PILKINGTON C J,  ANGELL R M;  WO2008033567-A1   CELGENE CORP (CGEN)   MULLER G W,  CHEN R S C;  WO2008122038-A1   HARVARD COLLEGE (HARD);  CAMBRIDGE ENTERPRISE LTD (UYCA);  DANA FARBER CANCER INST (DAND)   BRADNER J E,  SHEN J P,  PERLSTEIN E O,  RUBINSZTEIN D,  SARKAR S,  SCHREIBER S L;  WO2009042177-A1   CELGENE CORP (CGEN)   MAN H,  MULLER G W;  WO2009139880-A1   CELGENE CORP (CGEN)   CHEN R S C,  MULLER G W;  WO2009145899-A1   CELGENE CORP (CGEN)   CHEN R S C,  MULLER G W,  RUCHELMAN A L;  WO2010053732-A1   CELGENE CORP (CGEN)   MULLER G W,  RUCHELMAN A L;  WO2010107485-A1   UNIV COLUMBIA NEW YORK (UYCO)   STOCKWELL B R,  HERMAN A;  WO2011097218-A1   UNIV WAYNE STATE (UYWY)   BURGER A M,  WESTWELL A;  WO2012079022-A1   CONCERT PHARM INC (CNPH)   LIU J F,  TUNG R D;  WO2013059215-A1   BIOTHERYX INC (BIOT-Non-standard)   CHAN K W H,  MERCURIO F,  STIRLING D I;  WO2013089278-A1   TAIHO PHARM CO LTD (TAIH)   FUKASAWA K,  ISHIDA K;  WO2013170147-A1   UNIV YALE (UYYA)   CREWS C,  GUSTAFSON J,  ROTH A G,  TAE H S,  BUCKLEY D,  NEKLESA T;  WO2014023081-A1   CHINESE ACAD SCI SHANGHAI BIOLOGICAL SCI                  INST (CABS);  SHANGHAI INST MATERIA MEDICA CAS (CAMM)   CHEN K,  GONG N,  LI X,  LIU H,  LIU Y,  WANG H,  ZHANG X,  ZHOU Y;  WO2014145887-A1   WHITEHEAD INST BIOMEDICAL RES (WHED);  MASSACHUSETTS INST TECHNOLOGY (MASI)   LINQUIST S L,  BUCHWALD S L,  TARDIFF D,  JUI N;  WO2016065139-A1   FL THERAPEUTICS LLC (FLTH-Non-standard)   SUN Q;  WO2016105518-A1   DANA FARBER CANCER INST INC (DAND)   BRADNER J,  BUCKLEY D,  WINTER G;  WO2016118666-A1   ARVINAS INC (ARVI-Non-standard)   JIN M,  CREW A P,  DONG H,  WANG J,  SIU K,  FERRARO C,  CHEN X,  QIAN Y;  WO2016146985-A1   UNIV DUNDEE (UDUN)   CIULLI A,  ZENGERLE M,  CHAN K;  WO2016149668-A1   ARVINAS INC (ARVI-Non-standard);  UNIV YALE (UYYA)   CREW A P,  CREWS C M,  CHEN X,  DONG H,  FERRARO C,  QIAN Y,  SIU K,  WANG J,  JIN M,  BERLIN M,  ZIMMERMANN K,  SNYDER L;  WO2016169989-A1   GLAXOSMITHKLINE INTELLECTUAL PROPERTY (GLAX)   HARLING J D,  SMITH I E D;  WO2016191178-A1   BIOTHERYX INC (BIOT-Non-standard)   CHAN K W H,  FUNG L,  SULLIVAN R,  ERDMAN P E,  MERCURIO F;  WO2016197032-A1   ARVINAS INC (ARVI-Non-standard)   CREW A P,  CREWS C,  DONG H,  WANG J,  QIAN Y,  SIU K,  JIN M;  WO2016197114-A1   ARVINAS INC (ARVI-Non-standard);  CREW A P (CREW-Individual);  WANG J (WANG-Individual);  DONG H (DONG-Individual);  QIAN Y (QIAN-Individual);  SIU K (SIUK-Individual);  FERRARO C (FERR-Individual);  CREWS C M (CREW-Individual)   CREW A P,  WANG J,  DONG H,  QIAN Y,  SIU K,  FERRARO C,  CREWS C M;  WO2017007612-A1   DANA FARBER CANCER INST INC (DAND)   BRADNER J,  BUCKLEY D,  WINTER G;  WO2017024318-A1   DANA FARBER CANCER INST INC (DAND)   BRADNER J,  ROBERTS J,  NABET B,  WINTER G,  PHILLIPS A J,  HEFFERNAN T P,  BUCKLEY D;  WO2017024319-A1   DANA FARBER CANCER INST INC (DAND)   BUCKLEY D,  WINTER G,  PHILLIPS A J,  HEFFERNAN T,  BRADNER J,  ROBERTS J,  NABET B;  WO2017030814-A1   ARVINAS INC (ARVI-Non-standard);  UNIV YALE (UYYA)   QIAN Y,  DONG H,  WANG J,  BERLIN M,  SIU K,  CREW A P,  CREWS C M;  WO2017046036-A1   GLAXOSMITHKLINE INTELLECTUAL PROPERTY (GLAX)   HARLING J D,  NEIPP C E,  PENDRAK I,  SMITH I E D,  TERRELL L R,  YOUNGMAN M;  WO2017079267-A1   UNIV YALE (UYYA)   CREWS C,  TOURE M,  KO E,  JAIME-FIGUEROA S;  WO2017161119-A1   MOFFITT CANCER CENT & RES INST INC H                  LEE (MOFF)   BURNETTE P,  LAWRENCE H,  LAWRENCE N J;  WO2017176708-A1   ARVINAS INC (ARVI-Non-standard)   WANG J,  CREW A P,  DONG H,  NEKLESA T,  HAMMAN B;  WO2017176957-A1   UNIV MICHIGAN (UNMI)   WANG S,  LI Y,  YANG J,  AGUILAR A,  ZHOU B,  HU J,  XU F,  REJ R,  HAN X;  WO2017176958-A1   UNIV MICHIGAN (UNMI)   WANG S,  LI Y,  AGUILAR A,  ZHOU B,  HU J,  XU F,  QIN C,  HU Y,  XIANG W,  REJ R,  YANG J,  HAN X,  BAI L,  YANG C;  WO2017180417-A1   UNIV MICHIGAN (UNMI)   WANG S,  ZHOU B,  XU F,  HU J,  BAI L,  YANG C;  WO2017197036-A1   C4 THERAPEUTICS INC (CFOU-Non-standard)   HENDERSON J A,  LAZARSKI K,  LIANG Y,  MICHAEL R E,  NASVESCHUK C G,  PHILLIPS A J;  WO2017197046-A1   C4 THERAPEUTICS INC (CFOU-Non-standard)   HE M,  HENDERSON J A,  LAZARSKI K,  LIANG Y,  NASVESCHUK C G,  PHILLIPS A J,  VEITS G K,  VORA H U;  WO2017197051-A1   C4 THERAPEUTICS INC (CFOU-Non-standard)   CHEN C,  DUPLESSIS M,  HE M,  HENDERSON J A,  LAZARSKI K,  LIANG Y,  NASVESCHUK C G,  PHILLIPS A J;  WO2017197055-A1   C4 THERAPEUTICS INC (CFOU-Non-standard)   FITZGERALD M E,  HE M,  HENDERSON J A,  LIANG Y,  MICHAEL R E,  NASVESCHUK C G,  PHILLIPS A J;  WO2017197056-A1   C4 THERAPEUTICS INC (CFOU-Non-standard)   FITZGERALD M E,  HENDERSON J A,  LIANG Y,  MICHAEL R E,  NASVESCHUK C G,  PHILLIPS A J;  WO2017197240-A1   UNIV MICHIGAN (UNMI)   GREMBECKA J,  CIERPICKI T,  ROGAWSKI D,  BORKIN D,  KLOSSOWSKI S,  ZHUANG J,  MONTGOMERY D,  DENG J,  SZEWCZYK M,  LI H;  WO2017201069-A1   BIOTHERYX INC (BIOT-Non-standard)   CHAN K W H,  FUNG L,  SULLIVAN R,  ERDMAN P E,  MERCURIO F,  TORRES E;  WO2017201449-A1   GENENTECH INC (GETH);  HOFFMANN LA ROCHE & CO AG F (HOFF)   PILLOW T,  SADOWSKY J,  STABEN L,  STABEN S,  WEI B,  WERTZ I,  ADHIKARI P,  BLAQUIERE N,  DRAGOVICH P,  FAIRBROTHER W;  WO2018023029-A1   MAYO FOUND MEDICAL EDUCATION & RES (MAYO)   CAULFIELD T R,  FIESEL F C,  SPRINGER W;  WO2018051107-A1   UNIV DUNDEE (UDUN)   CIULLI A,  TESTA A;  WO2018052945-A1   UNIV MICHIGAN (UNMI)   WANG S,  HU Y,  QIN C,  XU F,  HU J,  ZHOU B,  CHEN Z,  FERNANDEZ-SALAS E,  BAI L,  MCEACHERN D;  WO2018052949-A1   UNIV MICHIGAN (UNMI)   WANG S,  HU Y,  QIN C,  XU F,  HU J,  XIANG W,  ZHOU B;  WO2018053354-A1   ARVINAS INC (ARVI-Non-standard)   CREW A P,  QIAN Y,  DONG H,  WANG J,  CREWS C M;  WO2018071606-A1   ARVINAS INC (ARVI-Non-standard)   CREW A P,  HORNBERGER K R,  SNYDER L B,  ZIMMERMANN K,  WANG J,  BERLIN M,  CREWS C M,  DONG H;  WO2018085247-A1   UNIV CORNELL (CORR);  DANA FARBER CANCER INST INC (DAND);  CHILDRENS MEDICAL CENT (CHLD)   MELNICK A M,  GABAS L F,  US I,  CASALENA G,  GRAY N S,  SCOTT D A,  HATCHER J,  DU G,  WU H,  QIAO Q;  WO2018102725-A1   ARVINAS INC (ARVI-Non-standard)   CREW A P,  QIAN Y,  DONG H,  WANG J,  HORNBERGER K R,  CREWS C M;  WO2018118598-A1   ARVINAS INC (ARVI-Non-standard);  UNIV YALE (UYYA)   CREW A P,  HORNBERGER K R,  CREWS C M,  BURSLEM G;  WO2018118947-A1   BIOTHERYX INC (BIOT-Non-standard)   CHAN K W H,  ERDMAN P E,  FUNG L,  MERCURIO F,  SULLIVAN R,  TORRES E;  WO2018119357-A1   ARVINAS INC (ARVI-Non-standard)   CREW A P,  SNYDER L B,  WANG J,  DONG H,  QIAN Y,  BERLIN M;  WO2018119441-A1   ARVINAS INC (ARVI-Non-standard);  UNIV YALE (UYYA)   GREW A P,  ZIMMERMANN K,  WANG J,  BERLIN M,  DONG H,  ISHCHENKO A,  QIAN Y,  CREWS C M,  JAIME-FIGUEROA S,  BURSLEM G;  WO2018119448-A1   ARVINAS INC (ARVI-Non-standard);  UNIV YALE (UYYA)   CREW A P,  HORNBERGER K R,  WANG J,  DONG H,  QIAN Y,  CREWS C M,  JAIME-FIGUEROA S;  WO2018140809-A1   ARVINAS OPERATIONS INC (ARVI-Non-standard)   QIAN Y,  CREW A P,  CREWS C M,  DONG H,  HORNBERGER K R,  WANG J;  WO2018144649-A1   ARVINAS OPERATIONS INC (ARVI-Non-standard)   CREW A P,  BERLIN M,  DONG H,  HOMBERGER K R,  QIAN Y,  SNYDER L B,  WANG J,  ZIMMERMANN K;  WO2018169777-A1   BIOTHERYX INC (BIOT-Non-standard)   CHAN K W H,  ERDMAN P E,  FUNG L,  MERCURIO F,  SULLIVAN R;  WO2018183411-A1   UNIV MICHIGAN (UNMI)   WANG S,  ZHOU H,  LU J,  LIU L,  SUN Y,  BERNARD D;  WO2018189554-A1   UNIV DUNDEE (UDUN)   CIULLI A,  MANIACI C,  HUGHES S J,  TESTA A;  WO2018191199-A1   UNIV MICHIGAN (UNMI)   WANG S,  ZHOU H,  LU J,  LIU L,  STUCKEY J,  RUI L,  SUN Y;  WO2019060693-A1   KYMERA THERAPEUTICS INC (KYME-Non-standard)   MAINOLFI N,  JI N,  ZHANG Y,  WEISS M M;  WO2019060742-A1   KYMERA THERAPEUTICS INC (KYME-Non-standard)   MAINOLFI N,  JI N,  ZHANG Y,  WEISS M M;  WO2019140387-A1   KYMERA THERAPEUTICS INC (KYME-Non-standard)   MAINOLFI N,  JI N,  KLUGE A F;  WO2019152440-A1   FOGHORN THERAPEUTICS INC (FOGH-Non-standard)   ZHOU Q,  BOCKER M,  MILLAN D S,  CHAN H M,  SOARES L,  NETHERTON M R,  RUPPEL S K,  YANG Z,  LOWE J T,  BRUCELLE F;  WO2019165229-A1   DANA FARBER CANCER INST INC (DAND);  ANDERSON K C (ANDE-Individual);  WU L (WULL-Individual)   ANDERSON K C,  WU L,  QI J,  SONG Y,  PARK P,  CHAUHAN D;  WO2019199816-A1   ARVINAS INC (ARVI-Non-standard)   CREW A P,  CREWS C M,  DONG H,  HORNBERGER K R,  WANG J,  QIAN Y,  ZIMMERMANN K,  BERLIN M,  SNYDER L B;  WO2019213005-A1   DANA FARBER CANCER INST INC (DAND)   FISCHER E,  GRAY N,  NOWAK R,  DONOVAN K,  ZHANG T,  LIU Y;  WO2020006262-A1   DANA FARBER CANCER INST INC (DAND)   GRAY N,  ZHANG T,  FISCHER E,  VERANO A,  HE Z,  DU G,  DONOVAN K,  NOWAK R,  YUAN C;  WO2020006264-A1   DANA FARBER CANCER INST INC (DAND)   GRAY N,  ZHANG T,  FISCHER E,  VERANO A,  HE Z,  DU G,  DONOVAN K,  NOWAK R,  YUAN C;  WO2020006265-A1   DANA FARBER CANCER INST INC (DAND)   GRAY N,  ZHANG T,  FISCHER E,  VERANO A,  HE Z,  DU G,  DONOVAN K,  NOWAK R,  YUAN C;  WO2020010227-A1   KYMERA THERAPEUTICS INC (KYME-Non-standard)   JI N,  KLUGE A F,  WEISS M M,  ZHANG Y;  WO2020023851-A1   UNIV YALE (UYYA);  ARVINAS OPERATIONS INC (ARVI-Non-standard)   CREWS C M,  CROMM P M,  CREW A P;  WO2020041331-A1   ARVINAS OPERATIONS INC (ARVI-Non-standard)   CREW A P,  DONG H,  BERLIN M,  SPARKS S M;  WO2020051564-A1   ARVINAS OPERATIONS INC (ARVI-Non-standard);  UNIV YALE (UYYA)   CREW A P,  HORNBERGER K R,  WANG J,  CREWS C M,  JAIME-FIGUEROA S,  DONG H,  QIAN Y,  ZIMMERMAN K;  WO2020081450-A1   NURIX THERAPEUTICS INC (NURI-Non-standard)   ROBBINS D W,  SANDS A T,  MCINTOSH J,  MIHALIC J,  WU J,  KATO D,  WEISS D,  PENG G;  WO2006102557-A2   HARVARD COLLEGE (HARD);  DANA FARBER CANCER INST INC (DAND)   ANDERSON K C,  BRADNER J E,  GREENBERG E F,  HIDESHIMA T,  KWIATKOWSKI N P,  MAZITSCHEK R,  SCHREIBER S L,  SHAW J;  WO2008027542-A2   CELGENE CORP (CGEN)   MULLER G W,  CHEN R S C,  RUCHELMAN A L;  WO2008039489-A2   CELGENE CORP (CGEN)   MULLER G W,  MAN H;  WO2008115516-A2   CELGENE CORP (CGEN)   RUCHELMAN A L,  MULLER G W,  MAN H;  WO2011143669-A2   DANA FARBER CANCER INST INC (DAND)   BRADNER J E,  QI J;  WO2012178208-A2   STEVENS INST TECHNOLOGY (STEV-Non-standard);  DANA FARBER CANCER INST INC (DAND)   ABEYWICKRAMA C,  BRADNER J E,  PONNALA S;  WO2013106646-A2   GLAXOSMITHKLINE INTELLECTUAL PROPERTY (GLAX);  UNIV YALE (UYYA);  UNIV CAMBRIDGE ENTERPRISE LTD CAMBRIDGE (UYCA)   BUCKLEY D,  CAMPOS S A,  CIULLI A,  CREWS C M,  GAREISS P C,  GUSTAFSON J,  HARLING J D,  HOYER D W,  JORGENSEN W,  LE J,  MIAH A H,  MICHEL J,  MOLLE I V,  ROTH A G,  SMITH I E D,  TAE H;  WO2015160845-A2   CREW A P (CREW-Individual);  CREWS C (CREW-Individual);  DONG H (DONG-Individual);  WANG J (WANG-Individual);  QIAN Y (QIAN-Individual);  SIU K (SIUK-Individual);  FERRARO C (FERR-Individual);  JIN M (JINM-Individual);  CHEN X (CHEN-Individual)   CREW A P,  CREWS C,  DONG H,  WANG J,  QIAN Y,  SIU K,  FERRARO C,  JIN M,  CHEN X;  WO2017024317-A2   DANA FARBER CANCER INST INC (DAND)   BRADNER J,  BUCKLEY D,  WINTER G;  WO2018102067-A2   ARVINAS INC (ARVI-Non-standard)   CREW A P,  BERLIN M,  FLANAGAN J J,  DONG H,  ISHCHENKO A	WO2019099868-A3  DATABASE          PUBCHEM-CID 9 February 2007 (2007-02-09), Database          accession no.          14872634,relevantClaims[24-26],relevantPassages[pages          1-7. pg 2, structure]CN111372585-A  PUBCHEM:          "pubchem-CID:14872634",          PUBCHEM,relevantClaims[28],relevantPassages[1-3]EP3710002-A4  M. SAKAMOTO ET.          AL.: "Solid State Photochemical Reaction of          N-(alpha-beta-Unsaturated Carbonyl)-Benzoylformamides.",          JOURNAL OF ORGANIC CHEMISTRY, vol. 62, no. 18, 5          September 1997 (1997-09-05), pages 6298 - 6308,          XP002803003, DOI:          10.1021/jo9704974,relevantClaims[1-5],relevantPassages[&lt;pp&gt;6299&lt;/pp&gt;&lt;figure&gt;1&lt;/figure&gt;];  "Synthesis and          aromatase inhibitory activity of novel          1-(4-aminophenyl)-3-azabicyclo[3.1.0] hexane and -[3.1.1]          heptane-2,4-diones.", JOURNAL OF MEDICINAL CHEMISTRY,          vol. 34, no. 4, 1 April 1991 (1991-04-01), pages 1329 -          1334, XP002803004, DOI:          10.1021/jm00108a013,relevantClaims[1-5],relevantPassages[page          1330, Scheme IV, compound 2a]US11524949-B2            Shi. Nature Reviews: Genetics, 2007, 8, 829-833 (Year:          2007).;            Lau. Journal of Cell Science, 2012, 125(12), 2815-2824          (Year: 2012).;            Yu. Mediators of Inflammation, 2014, article ID 950742,          1-10 (Year: 2014).;            Bornemann. Journal of Organic Chemistry, 2005, 70,          5862-5968. (Year: 2005).;            Burns.Archives of Toxicology, 2012, 86, 1491-1504 (Year:          2012).;            Shukla. Andrology, 2016, 4, 366-381 (Year:          2016).;            U.S. Appl. No. 16/882, 236, filed May 22, 2020, Phillips          et al.;            U.S. Appl. No. 17/103, 621, filed Nov. 24, 2020,          Nasveschuk et al.;            U.S. Appl. No. 17/107, 781, filed Nov. 30, 2020, Phillips          et al.;            U.S. Appl. No. 17/121, 389, filed Dec. 14, 2020, Phillips          et al.;            U.S. Appl. No. 17/164, 446, filed Feb. 1, 2021, Phillips          et al.;            Sakamoto, et al.; Solid State Photochemical Reaction of          N-(, -Unsaturated carbonyl) benzoylformamides; Journal of          Organic Chemistry, vol. 62, p. 6298-6308          (1997).;            Stanek, et al.; Synthesis and Aromatase Inhibitory          Activity of Novel          1-(4-Aminophenyl)-3-azabicyclo[3.1.0]heptane-2, 4-diones;          Journal of Medicinal Chemistry, vol. 34, p. 13291334          (1991).;            Agafonov Roman et al., Poster Presentation titled          Quantitative and high throughput method for measuring          complex formation between target proteins and E3          ubiquitin ligase, EMBO, Sep. 16, 2017.;            Bartlett, et al., The evolution of thalidomide and its          IMiD derivatives as anticancer agents. Nat Rev Cancer          2004, 4(4):312-322.;            Berndsen et al., New insights into ubiquitin E3 ligase          mechanism Nat. Struct. Mol. Biol. 2014,          21:301-307.;            Bondeson et al., Catalytic in vivo protein knockdown by          small-molecule PROTACs Nature Chemical Biology 2015,          11:611-617.;            Buckley et al., HaloPROTACS: Use of Small Molecule          PROTACS to Induce Degradation of HaloTag Fusion Proteins          ACS Chemical Biology 2015, 10:1831-1837.;            Buckley et al., Small-Molecule Control of Intracellular          Protein Levels through Modulation of the Ubiquitin          Proteasome System Angewandte Reviews, 2014,          53:2312-2330.;            Buckley et al., Targeting the Von Hippel-Lindau E3          Ubiquitin Ligase Using Small Molecules to Disrupt the          Vhl/Hif-1 alpha Interaction J. Am. Chem. Soc. 2012,          134:4465-4468.;            Burkhard et al., Synthesis and Stability of Oxetane          Analogs of Thalidomide and Lenalidomide Organic Letters          2013, 15(7):4312-4315.;            Chamberlain et al., Structure of the human          cereblon-DDB1-lenalidomide complex reveals basis for          responsiveness to thalidomide analogs Nature Structural          and Molecule Biology, 2014, 21(9):803-809.;            Chang, X. and Stewart, K. A., What is the functional role          of the thalidomide binding protein cereblon? Int J          Biochem Mol Bio. 2011, 2(3):287-294.;            Contino-Pepin, et al., Preliminary biological evaluations          of new thalidomide analogues for multiple sclerosis          application, Bioorganic & Medicinal Chemistry          Letters, 2009, 19(3), 878-881.;            Corson et al., Design and applications of bifunctional          small molecules: Why two heads are better than one ACS          Chemical Biology 2008, 3(11): 677-692.;            Crews, C. M., Targeting the undruggable proteome: the          small molecules of my dreams Chemistry and Biology 2010,          17(6):551-555.;            Deshaies et al., Ring domain E3 ubiquitin ligases. Ann.          Rev. Biochem. 2009, 78:399-434.;            Elam W.A., et al., Poster Presentation titled Application          of Biophysical Techniques to the Targeted Protein          Degradation Therapeutic Strategy, Sep. 24,          2017.;            Faden et al., Generic tools for conditionally altering          protein abundance and phenotypes on demain Biol. Chem.          2014, 395(7-8):737-762.;            Fischer et al., Structure of the DDB1-CRBN E3 ubiquitin          ligase in complex with thalidomide Nature 2014,          512:49-53.;            Fischer et al., The Molecular Basis of CRL4DDB2/CSA          Ubiquitin Ligase Architecture, Targeting, and Activation,          Cell 2011, 147:1024-1039.;            Fisher et al., Targeted protein degradation and the          enzymology of degraders, Current Opinion of Chemical          Biology, 2018, 44, 47-55.;            Grant, Johnathan W. et al., Toward the Development of a          Cephalosporin-Based Dual-Release Prodrug for Use in          ADEPT, Journal of Organic Chemistry, vol. 69, No. 23,          Nov. 1, 2004, pp. 7965-7970. XP55639681, US ISSN:          0022-3263, DOI: 10.1021/jo048970i          *5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,          3-[[[[[4-[(3R)-ethyl-2,          6-dioxo-3-piperidinyl)phenyl]amino]-8-oxo-,          diphenylmethyl ester, (6R, 7E)*.;            Gosink et al., Redirecting the Specificity of          Ubiquitination by Modifying Ubiquitin-Conjugating Enzymes          Proc. Natl. Acad. Sci. USA 1995, 92:9117-9121.;            Gustafson et al., Small-Molecule-Mediated Degradation of          the Androgen Receptor through Hydrophobic Tagging          Angewandte Chemie, 2015, 54:9659-9662.;            Hines et al., Posttranslational protein knockdown couple          to receptor tyrosine kinase activation with          phosphoPROTACs PNAS 2013, 110(22):8942-8947.;            International Search Report and Written Opinion for          PCT/US2018/61573 dated May 3, 2019.;            Henderson C., Presentation titled Development of          AchillesTAG degradation systems and their application to          control CAR-T activity, ChemBio in the hub, Cambridge,          MA. Oct. 22, 2018.;            Ito et al., Identification of a Primary Target of          Thalidomide Teratogenicity Science 2010,          327(5971):1345-1350.;            Itoh et al., Protein knockdown using methyl          bestatin-ligand hybrid molecules: design and synthesis of          inducers of ubiquitination-mediated degradation of          cellular retinoic acid-binding proteins Journal of the          American Chemical Society 2010, 132(16),          5820-5826.;            Jacques et al., Differentiation of anti-inflammatory and          antitumorigenic properties of stabilized enantiomers of          thalidomide analogs PNAS 2015, 112:E1471-E1479.;            Jarman, M. et al., Selective inhibition of cholesterol          side-chain cleavage by potential pro-drug forms of          aminoglutethimide, Anti-Cancer Drug Design, vol. 3, 1988,          pp. 185-190, XPOO9517051, *N-{4-{3-ethyl-2,          6-dioxo-3-piperidinyl)-4-methyl-4-(4-methylphenyl)-2,          5-dioxo-1-imidazolidineacetamide*.;            Kronke et al., Lenalidomide Causes Selective Degradation          of IKZF1 and IKZF3 in Multiple Myeloma Cells Science          2014, 343(6168):301-305.;            Kronke et al., Lenalidomide induces ubiquitination and          degradation of CDK1[alpha] in del(5q) MDS Nature 2015,          523(7559):183-188.;            Lai et al., Modular PROTAC Design for the Degradation of          Oncogenic BCR-ABL Angewandte Chemie International Edition          2016, 55:807-810.;            Lee et al., Targeted Degradation of the Aryl Hydrocarbon          Receptor by the PROTAC Approach: A Useful Chemical          Genetic Tool ChemBioChem 2007, 8:2058-2062.;  Li          et al., Genome-wide and functional annotation of human E3          ubiquitin ligases identifies MULAN, a mitochondrial E3          that regulates the organelle's dynamics and signaling          PLOS One 2008, 3:1487.;            Liu et al., Design and biological characterization of          hybrid compounds of curcumin and thalidomide for multiple          myeloma Organic and Biomolecular Chemistry, 2013,          11:4757.;  Lu          et al., Hijacking the E3 Ubiquitin Ligase Cereblon to          Efficiently Target BRD4 Chemistry and Biology 2015,          22(6):755-763.;  Lu          et al., The myeloma drug lenalidomide promotes the          cereblon-dependent destruction of Ikaros proteins          Science, 2014, 343:305-309.;            Martiniani, R. et al., Biological activity of          lenalidomide and its underlying therapeutic effects in          multiple myeloma, Adv Hematol, 2012,          2012:842945.;            Nasveschuk C., Presentation titled Advances in the          Medicinal Chemistry of Targeted Protein Degradation, Aug.          7, 2018.;            Nawaz et al., Proteasome-Dependent Degradation of the          Human Estrogen Receptor Proc. Natl. Acad. Sci. USA 1999,          96:1858-1862.;            Neklesa et al., Small-molecule hydrophobic          tagging-induced degradation of HaloTag fusion proteins.          Nat Chem Biol 2011, 7(8):538-543.;            Patel, J., Poster Presentation titled Diverse Utility of          Targeted Protein Degradation at C4 Therapeutics, Sep. 17,          2017.;            Phillips A., Presentation titled Targeted Protein          Degradation, Applied Pharmaceutical Chemistry, Cambridge,          MA. Apr. 5, 2018.;            Phillips A., Presentation titled Small molecule driven          targeted protein degradation, ChemBio in the hub,          Cambridge, MA. Oct. 22, 2018.;            PubChem-CID: 14872634 Create Date Feb. 9, 2007, pp. 1-7,          structure 2.;            Raina et al., Chemical Inducers of Targeted Protein          Degradation Journal of Biological Chemistry 2010,          285:11057-11060.;            Rodriguez-Gonzalez et al., Targeting steroid hormone          receptors for ubiquitination and degradation in breast          and prostate cancer Oncogene, 2008,          27:7201-7211.;            Ruchelman et al., Isosteric analogs of lenalidomide and          pomalidomide: Synthesis and biological activity,          Bioorganic and Medicinal Chemistry Letters, 2012,          23:360-365.;            Sakamoto et al., Development of Protacs to Target          Cancer-Promoting Proteins for Ubiquitination and          Degradation Molecular and Cellular Proteomics, 2003,          2(12):1350-1357.;            Sakamoto et al., Protacs: chimeric molecules that target          proteins to the Skp1-Cullin-F box complex for          ubiquitination and degradation PNAS, 2001,          98(15):8554-8559.;            Schneekloth et al., Chemical approaches to controlling          intracellular protein degradation Chembiochem., 2005,          6(1):40-46.;            Schneekloth et al., Chemical Genetic Control of Protein          Levels: Selective in Vivo Targeted Degradation Journal of          the American Chemical Society, 2004,          126(12):3748-3754.;            Schneekloth et al., Targeted Intracellular Protein          Degradation Induced by a Small Molecule: En Route to          Chemical Proteomics Bioorganic and Medicinal Chemistry          Letters, 2008, 18:5904-5908.;            Shoji, et al., Modified DNA Aptamer That Binds the          (R)-Isomer of a Thalidomide Derivative with High          Enantioselectivity, J. Am. Chem. Soc., 2007, 129,          1456-1464.;            Smith et al., Targeted Intracellular Protein Degradation          Induced by a Small Molecule: En Route to Chemical          Proteomics Bioorg. Med. Chem. Lett. 2008,          18(22):5904-5908.;            Spratt et al., RBR E3 ubiquitin ligases: new structures,          new insights, new questions. Biochem. 2014,          458:421-437.;            Terpos, E. et al., Pomalidomide: a novel drug to treat          relapsed and refractory multiple myeloma, Oncotargets and          Therapy, 2013, 6:531.;            Toure et al., Small-Molecule PROTACs: New Approaches to          Protein Degradation Angewandte Chemie International          Edition 2016, 55:1966-1973.;            Vassilev et al., In Vivo Activation of the P53 Pathway by          Small-Molecule Antagonists of MDM2 Science, 2004,          303:844-848.;            Vieux Ellen et al., Poster Presentation titled Measuring          Small Molecule Induced Ubiquitination of Proteins, EMBO,          Sep. 18, 2017.;            Wang et al., Roles of F-box proteins in cancer. Nat. Rev.          Cancer 2014, 14:233-347.;            Winter et al., Phthalimide conjugation as a strategy for          in vivo target protein degradation, Science 2015,          348(6241):1376-1381.;            Zeid Rhamy Presentation titled Targeted protein          degradation as a novel therapeutic approach, Gordon          Research Conference, Jun. 26, 2017.;            Zengerle et al., Selective Small Molecule Induced          Degradation of the BET Bromodomain Protein BRD4 ACS Chem.          Biol. 2015, 10:1770-1777.;            Zhou et al., Harnessing the Ubiquitination Machinery to          Target the Degradation of Specific Cellular Proteins          Molecular Cell 2000, 6:751-756.;            US, 2020/0207764, A1, U.S. Appl. No. 16/809, 325,          Norcross et al., Jul. 2, 2020.;            US, 2020/0207783, A1, U.S. Appl. No. 16/809, 336,          Norcross et al., Jul. 2, 2020.;            US, 2020/0207733, A1, U.S. Appl. No. 16/809, 345,          Norcross et al., Jul. 2, 2020.;            US, 2021/0009559, A1, U.S. Appl. No. 17/031, 550,          Henderson et al., Jan. 14, 2021.;            US, 2020/0140456, A1, U.S. Appl. No. 16/721, 650,          Phillips et al., May 7, 2020.;            US, 2021/0032245, A1, U.S. Appl. No. 17/072, 896,          Nasveschuk et al., Feb. 4, 2021.;            US, 2021/0070763, A1, U.S. Appl. No. 17/103, 621,          Nasveschuk et al, Mar. 11, 2021.;            US, 2021/0106688, A1, U.S. Appl. No. 16/882, 236,          Phillips et al., Apr. 15, 2021.;            US, 2021/0198256, A1, U.S. Appl. No. 17/192, 634,          Nasveschuk et al, Jul. 1, 2021.;            U.S. Appl. No. 17/351, 935, filed Jun. 18, 2021, Phillips          et al.	 N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N	214683504 N; 214683501 N; 214683503 N; 214683502 N	00826; 49755; 59469; 59470; 00094; 01200	RCLGE7 N; RCLGE8 N; RCLGE9 N; RCLGEA N; RCLGEB N; RCLGEC N; RCLGED N; RCLGEE N; RCLGEF N; RCLGEG N; RCLGEH N; RCLGEI N; RCLGEJ N; RCLGEK N; RCLGEL N; RCLGEM N; RCLGEN N; RCLGEO N; RCLGEP N; RCLGEQ N		US2019142792-A1	Acceleration of healing of genital warts by            applying highly purified epicatechin oligomers from            Theobroma cacao	PRESTON D;  MURPHY R B	CACAO BIO-TECHNOLOGIES LLC (CACA-Non-standard)	201942115M	   NOVELTY - Acceleration of healing of genital warts                comprises applying highly purified epicatechin                oligomers from Theobroma cacao. Healing is                accelerated by combination of antiviral and                antioxidant properties of highly purified                epicatechin oligomers.    USE - Method for accelerating healing of genital                warts.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for                inhibition of virus replication in mammal by                administering antiviral epicatechin oligomer. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  P31 (Diagnosis, surgery (A61B).)	B04-E99;  B02-A;  B02-C04;  B02-D;  B02-G;  B02-K;  B02-M;  B02-N;  B02-P;  B02-S;  B02-T;  B02-Z;  B04-B03A;  B04-B03D;  B04-B03E;  B04-C01G;  B04-C03C;  B04-E01;  B04-H05A;  B05-B01G;  B05-B01M;  B06-A01;  B07-H;  B09-D01;  B10-A17;  B10-B02F;  B10-B03B;  B10-C04C;  B10-E04D;  B14-A01;  B14-A02;  B14-N17;  B14-S08;  B14-S18;  B15-E00;  P31-A01	A61B-018/02;  A61B-018/04;  A61B-018/12;  A61B-018/20;  A61K-031/353;  A61K-031/355;  A61K-036/185;  A61K-045/06	US2019142792-A1   16 May 2019   A61K-031/353   201939Pages: 20   English	US2019142792-A1    US255071    23 Jan 2019	US2019142792-A1 Provisional Application US311317P;   US2019142792-A1 Cont of Application US334895;   US2019142792-A1 Cont of Application US202103;   US2019142792-A1 Cont of Application US039760	US311317P    06 Mar 2010;  US255071    23 Jan 2019					332237-0-0-0 K M; 111470-1-0-0 K M; 104371-0-0-0 K M; 88707-2-0-0 K M; 104714-2-0-0 K M; 4015-0-0-0 K M; 109110-0-0-0 K M; 109111-0-0-0 K M; 109113-0-0-0 K M; 109114-0-0-0 K M; 109117-0-0-0 K M; 91190-1-0-0 K M; 88182-1-0-0 K M; 107860-1-0-0 K M; 109093-1-0-0 K M; 101842-1-0-0 K M; 98579-1-0-0 K M; 96010-1-0-0 K M; 87202-1-0-0 K M; 94336-2-0-0 K M; 101051-1-0-0 K M; 142657-1-0-0 K M; 91066-0-0-0 K M; 99570-0-0-0 K M; 94229-0-0-0 K M; 28954-0-0-0 K M; 91082-0-0-0 K M; 102303-0-0-0 K M; 81119-0-0-0 K M; 95245-0-0-0 K M; 90334-1-0-0 K M; 90327-1-0-0 K M; 143959-1-0-0 K M; 90308-1-0-0 K M; 90336-1-0-0 K M; 90343-1-0-0 K M; 90344-1-0-0 K M; 106154-1-0-0 K M; 90314-1-0-0 K M; 143938-1-0-0 K M; 99601-1-0-0 K M; 90329-3-0-0 K M; 90317-1-0-0 K M; 90310-1-0-0 K M; 90313-1-0-0 K M; 90346-1-0-0 K M; 90322-1-0-0 K M; 90276-1-0-0 K M; 88192-1-0-0 K M; 90283-1-0-0 K M; 97728-1-0-0 K M; 104084-1-0-0 K M; 88183-0-0-0 K M; 100969-1-0-0 K M; 90006-0-0-0 K M; 108920-1-0-0 K M; 87346-1-0-0 K M; 12910-0-0-0 K M; 92977-1-0-0 K M; 91382-1-0-0 K M; 102915-1-0-0 K M; 106535-1-0-0 K M; 86228-1-0-0 K M; 105670-1-0-0 K M; 105621-1-0-0 K M; 1320477-0-0-0 K M; 104316-1-0-0 K M; 112385-0-0-0 K M; 223554-1-0-0 K M; 89253-0-0-0 K M; 160569-1-0-0 K M; 101892-0-0-0 K M; 157540-1-0-0 K M; 101277-0-0-0 K M; 161989-1-0-0 K M; 88470-1-0-0 K M; 97483-2-0-0 K M; 99051-1-0-0 K M; 97733-0-0-0 K M; 81257-1-0-0 K M; 100639-1-0-0 K M; 97501-1-0-0 K M; 352021-0-0-0 K M; 6512-0-0-0 K M; 95875-0-0-0 K M; 95549-0-0-0 K M; 221899-1-0-0 K M; 94878-0-0-0 K M; 135583-1-0-0 K M; 95660-1-0-0 K M; 120177-1-0-0 K M; 93958-1-0-0 K M; 93616-0-0-0 K M; 92990-1-0-0 K M; 92506-0-0-0 K M; 182803-1-0-0 K M; 97073-1-0-0 K M; 833290-2-0-0 K M; 1182837-0-0-0 K M; 1320477-0-0-0 CL USE; 1182837-0-0-0 CL USE		00534; 54107; 02806; 01683; 03279; 00211; 00061; 00810; 00042; 41252; 03624; 00096; 00085; 04205; 00083; 67767; 00133; 02763; 57265; 00998; 00690	RA2Q7B K M; RA2GQN K M; RAAWUD K M; R00222 K M; R19452 K M; R00179 K M; R14756 K M; R01163 K M; R00990 K M; RA0CPW K M; R01693 K M; RA00RW K M; R21291 K M; RA00N3 K M; R00149 K M; R02067 K M; R09105 K M; R03878 K M; RA01IY K M; R03012 K M; R00210 K M; R04156 K M; R01382 K M; R04490 K M; R11682 K M; R11683 K M; R04553 K M; R04552 K M; R10124 K M; R04550 K M; R01243 K M; R18337 K M; R09263 K M; R09524 K M; R21436 K M; R21876 K M; RA00I0 K M; R10571 K M; R03876 K M; R12516 K M; RA04L6 K M; R07901 K M; R13720 K M; RA092G K M; RA1R6R K M; RA092F K M; R21437 K M; R14028 K M; R09260 K M; R13721 K M; R04389 K M; R04556 K M; R20865 K M; RB2MJ0 K M; R01180 K M; R15097 K M; R03877 K M; R09271 K M; R09259 K M; R12518 K M; R01634 K M; R07290 K M; R02055 K M; R00289 K M; R07291 K M; R00225 K M; R00265 K M; RA0H1C K M; RA02DL K M; R07589 K M; R04428 K M; RAN0P1 K M; RA65BL K M; RA43SM K M; RA0HKQ K M; R21048 K M; RA01FU K M; RA0F4H K M; RA0AIB K M; RA22UN K M; RA17MV K M; RA0AI9 K M; R00167 K M; R19582 K M; RA0AIC K M; R19961 K M; R00084 K M; RA53NN K M; RA0WVE K M; RADR2U K M; R07688 K M; R06407 K M; R07687 K M; R14569 K M; RA0GA7 K M; RA061M K M; RA26J1 K M; RA1HN4 K M; RA0AIJ K M; R10039 K M; R10126 K M; R04625 K M; RA0AIE K M; RA1C6R K M; RA0Z3N K M; RACU4Q K M; RAQ7CV K M; RB7QK5 K M	0222-S; 0179-S; 1163-S; 0990-S; 1693-S; 0149-S; 2067-S; 0210-S; 1382-S; 1243-S; 1180-S; 1634-S; 2055-S; 0289-S; 0225-S; 0265-S; 0167-S; 0084-S	WO2019110213-A1;  AU2018380582-A1;  CA3080430-A1;  EP3706789-A1;  US2020338186-A1;  JP2021505529-W;  BR112020008958-A2;  US11229699-B2;  RU2020118606-A;  JP2023159325-A;  JP7374893-B2;  RU2792898-C2	Immunogenic composition used to immunize feline            against pathogenic feline calicivirus (FCV) comprises            alpha virus RNA replicon particle that encodes FCV            antigen	TARPEY I;  IAN T	INTERVET INT BV (IVET-C);  INTERVET INC (MERI-C);  INTERVET INT BV (IVET-C);  INTERVET INT BV (IVET-C);  INTERVET INC (MERI-C);  INTERVET INC (MERI-C)	201950957D	   NOVELTY - Immunogenic composition, comprises an alpha                virus RNA replicon particle that encodes a feline                calicivirus (FCV) antigen.    USE - The composition is useful for immunizing a                feline against a pathogenic FCV (claimed). Test                details are described but no results given.    ADVANTAGE - The composition: is safe; and produces no                adverse reactions.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) a vaccine to aid in the prevention of                disease due to FCV, comprising the immunogenic                composition and a carrier; and    (2) immunizing a feline against a pathogenic                FCV, comprising administering to the vaccine. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B04C1;  B04-E99;  B04-F11B;  B04-N03K;  B14-A02B0;  B14-G01;  B14-S11A;  B14-S11D1;  B14-S11D2;  B14-S12;  C04-B04C1;  C04-E99;  C04-F11B;  C04-N03K;  C14-A02B0;  C14-G01;  C14-S11A;  C14-S11D1;  C14-S11D2;  C14-S12;  D05-H99	A61K-039/12;  C12N-007/00;  A01K-067/027;  A61K-031/7105;  A61K-039/00;  A61K-048/00;  A61K-009/16;  A61P-031/12;  A61P-037/04;  A61P-043/00;  C12N-007/01;  A61K-039/118;  A61K-039/295;  C12N-015/41;  C12N-015/86;  C12N-015/33	WO2019110213-A1   13 Jun 2019   A61K-039/12   201947Pages: 48   English;  AU2018380582-A1   07 May 2020   A61K-039/12   202038   English;  CA3080430-A1   13 Jun 2019   A61K-039/12   202048   English;  EP3706789-A1   16 Sep 2020   A61K-039/12   202076   English;  US2020338186-A1   29 Oct 2020   A61K-039/12   202089   English;  JP2021505529-W   18 Feb 2021   A61K-039/12   202116Pages: 44   Japanese;  BR112020008958-A2   11 May 2021   A61K-039/12   202145   English;  US11229699-B2   25 Jan 2022   A61K-039/12   202209   English;  RU2020118606-A   08 Dec 2021   A61K-039/12   202262   Russian;  JP2023159325-A   31 Oct 2023   A61K-039/12   202390   Japanese;  JP7374893-B2   07 Nov 2023   A61K-039/12   202391   Japanese	WO2019110213-A1    WOEP080096    05 Nov 2018;   AU2018380582-A1    AU380582    05 Nov 2018;   CA3080430-A1    CA3080430    05 Nov 2018;   EP3706789-A1    EP803573    05 Nov 2018;   US2020338186-A1    US16759945    28 Apr 2020;   JP2021505529-W    JP524368    05 Nov 2018;   BR112020008958-A2    BR11008958    05 Nov 2018;   US11229699-B2    US16759945    28 Apr 2020;   RU2020118606-A    RU118606    05 Nov 2018;   JP2023159325-A    JP135198    23 Aug 2023;   JP7374893-B2    JP524368    05 Nov 2018;   RU2792898-C2    RU118606    05 Nov 2018	AU2018380582-A1 PCT application Application WOEP080096;   AU2018380582-A1 Based on Patent WO2019110213;   CA3080430-A1 PCT application Application WOEP080096;   CA3080430-A1 Based on Patent WO2019110213;   EP3706789-A1 PCT application Application WOEP080096;   EP3706789-A1 Based on Patent WO2019110213;   US2020338186-A1 PCT application Application WOEP080096;   US2020338186-A1 Provisional Application US582050P;   US2020338186-A1 Provisional Application US581955P;   US2020338186-A1 Provisional Application US599401P;   US2020338186-A1 Provisional Application US596508P;   JP2021505529-W PCT application Application WOEP080096;   JP2021505529-W Based on Patent WO2019110213;   BR112020008958-A2 PCT application Application WOEP080096;   BR112020008958-A2 Based on Patent WO2019110213;   US11229699-B2 PCT application Application WOEP080096;   US11229699-B2 Provisional Application US581955P;   US11229699-B2 Provisional Application US599401P;   US11229699-B2 Provisional Application US596508P;   US11229699-B2 Provisional Application US582050P;   US11229699-B2 Based on Patent WO2019110213;   US11229699-B2 Previous Publ. Patent US2020338186;   RU2020118606-A PCT application Application WOEP080096;   RU2020118606-A Based on Patent WO2019110213;   JP2023159325-A Div ex Application JP524368;   JP7374893-B2 PCT application Application WOEP080096;   JP7374893-B2 Previous Publ. Patent JP2021505529;   JP7374893-B2 Based on Patent WO2019110213;   RU2792898-C2 PCT application Application WOEP080096;   RU2792898-C2 Based on Patent WO2019110213	US581955P    06 Nov 2017;  US582050P    06 Nov 2017;  US596508P    08 Dec 2017;  US599401P    15 Dec 2017;  CA3080430    27 Apr 2020;  US16759945    28 Apr 2020;  BR11008958    05 May 2020;  RU118606    08 Jun 2020	WO2019110213-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP3706789-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                		WO2019110213-A1 -- US9441247-B2   ALPHAVAX INC (ALPH-Non-standard)   RAYNER J O,  SMITH J F,  HUBBY B,  REAP E A;  WO2017109045-A1   INTERVET INT BV (IVET);  INTERVET INC (MERI)   SHEHU E,  BHOGLE A S;  WO2001066568-A2   ;  US7449323-B2   UNIV CALIFORNIA (REGC)   FOLEY J E,  HURLEY K,  PEDERSEN N C;  US8460913-B2   ALPHAVAX INC (ALPH-Non-standard)   KAMRUD K I,  SMITH J F,  MAUGHAN M;  US11229699-B2 -- US20150159143-A1   ;  US20150299728-A1   ;  US8685412-B2   HUANG C (HUAN-Individual);  HESS J (HESS-Individual)   HUANG C,  HESS J;  WO2017109045-A1   INTERVET INT BV (IVET);  INTERVET INC (MERI)   SHEHU E,  BHOGLE A S;  WO2004083390-A3   UNIV CALIFORNIA (REGC)   FOLEY J E,  HURLEY K,  PEDERSEN N C,  POLAND A;  US20130064839-A1   ;  US7449323-B2   UNIV CALIFORNIA (REGC)   FOLEY J E,  HURLEY K,  PEDERSEN N C;  US8460913-B2   ALPHAVAX INC (ALPH-Non-standard)   KAMRUD K I,  SMITH J F,  MAUGHAN M;  US9441247-B2   ALPHAVAX INC (ALPH-Non-standard)   RAYNER J O,  SMITH J F,  HUBBY B,  REAP E A;  WO2001066568-A2   	WO2019110213-A1  LJUNGBERG KARL ET          AL: "Self-replicating alphavirus RNA vaccines", EXPERT          REVIEW OF VACC, EXPERT REVIEWS LTD, GB, vol. 14, no. 2, 1          February 2015 (2015-02-01), pages 177 - 194, XP008175780,          ISSN: 1744-8395, DOI:          10.1586/14760584.2015.965690,relevantClaims[1-21],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  VANDER VEEN RYAN L          ET AL: "Alphavirus replicon vaccines", ANIMAL HEALTH          RESEARCH REV, CAB INTERNATIONAL ; CAMBRIDGE : CAMBRIDGE          UNIVERSITY PRESS, UK, vol. 13, no. 1, 1 June 2012          (2012-06-01), pages 1 - 9, XP009166113, ISSN: 1475-2654,          DOI:          10.1017/S1466252312000011,relevantClaims[1-21],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|In          particular, "Protective immunity" and];  ATKINS GREGORY J ET          AL: "Therapeutic and prophylactic applications of          alphavirus vectors", EXPERT REVIEWS IN MOLECULAR MEDI,          CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, vol. 10, no. 1, 1          December 2008 (2008-12-01), pages e33/1 - 18,          XP009116159, ISSN: 1462-3994, [retrieved on 20081111],          DOI:          10.1017/S1462399408000859,relevantClaims[1-21],relevantPassages[&lt;pp&gt;7&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;last&lt;/para&gt;&lt;ppl&gt;8&lt;/ppl&gt;&lt;coll&gt;r&lt;/coll&gt;&lt;paral&gt;1&lt;/paral&gt;];  GUGLIELMO LUCCHESE          ET AL: "How a single amino acid change may alter the          immunological information of a peptide", FRONTIERS IN          BIOSCIENCE : ELITE EDITION, vol. 4, no. 5, 1 January 2012          (2012-01-01), US, pages 1843 - 1852, XP055467091, ISSN:          1945-0494, DOI:          10.2741/e506,relevantClaims[11-21],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  RAYNER J O ET AL:          "ALPHAVIRUS VECTORS AND VACCINATION", REVIEWS IN MEDICAL          VIRO, CHICHESTER, GB, vol. 12, no. 5, 1 September 2002          (2002-09-01), pages 279 - 296, XP008035758, ISSN:          1052-9276, DOI:          10.1002/RMV.360,relevantClaims[1-21],relevantPassages[&lt;pp&gt;283&lt;/pp&gt;"Replicon          vectors"];  YASUSHI UEMATSU ET          AL: "ABSTRACT", CLINICAL AND VACCINE IMMUNOLOGY, vol. 19,          no. 7, 23 May 2012 (2012-05-23), US, pages 991 - 998,          XP055552702, ISSN: 1556-6811, DOI:          10.1128/CVI.00031-12,relevantClaims[7,9,11-21],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  D. S. REED ET AL:          "Combined Alphavirus Replicon Particle Vaccine Induces          Durable and Cross-Protective Immune Responses against          Equine Encephalitis Viruses", JOURNAL OF VIROLOGY., vol.          88, no. 20, 13 August 2014 (2014-08-13), US, pages 12077          - 12086, XP055427114, ISSN: 0022-538X, DOI:          10.1128/JVI.01406-14,relevantClaims[7,9,11-21],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];            SCOTT ET AL., AM. J. VET. RES, vol. 60, 1999, pages 652 -          658;            RADFORD ET AL., VET RES., vol. 38, no. 2, 2007, pages 319          - 335;            SOSNOVTSEV; GREEN, VIROLOGY, vol. 277, 2000, pages 193 -          203;            VANDER VEEN ET AL., ANIM HEALTH RES REV., vol. 13, no. 1,          2012, pages 1 - 9;            KAMRUD ET AL., J GEN VIROL., vol. 91, 2010, pages 1723 -          1727;            PUSHKO ET AL., VIROLOGY, vol. 239, 1997, pages 389 -          401;            BREDENBEEK ET AL., JOURNAL OF VIROLOGY, vol. 67, 1993,          pages 6439 - 6446;            LILJESTROM; GAROFF, BIOTECHNOLOGY, vol. 9, 1991, pages          1356 - 1361;            PUSHKO ET AL., VIROLOGY, vol. 239, no. 2, 1997, pages 389          - 401;            AAFP FELINE ADVISORY PANEL, vol. 15, 2013, pages 785 -          808;            LILJESTROM; GAROFF, BIOTECHNOLOGY (NY, vol. 9, 1991,          pages 1356 - 1361US11229699-B2            Alignment of SEQ ID 2 with Geneseq db access No. BEB26323          in WO 2017109045 Aug. 2017 by Shehu et al.;            Alignment of SEQ ID 4 with Geneseq db access No. BEB26324          in WO 2017109045 Jun. 2017 by Shehu et al.;            Carroll et al. (Vaccine. 2011; 29: 931-940).;            Arjona, Alvaro et al., Seroepidemiological Survey of          Infection by Feline Leukemia Virus and Immunodeficiency          Virus in Madrid and Correlation with Some Clinical          Aspects, Journal of Clinical Microbiology, 2000,          3448-3449, 38.;            Atkins, GJ et al, Therapeutic and prophylactic          applications of alphavirus vectors, Expert Reviews in          Molecular Medicine, 2008, e33, 1-18, 10(1).;            Braley, Jo, FeLV and FIV: Survey Shows Prevalence in the          United States and Europe, Feline PracticeInfectious          Disease, 1994, 25-29, 22.;            Bredenbeek, Peter J. et al., Sindbis Virus Expression          Vectors: Packaging of RNA Replicons by Using Defective          Helper RNAs, Journal of Virology, 1993, 6439-6446,          67(11).;  De          Noronha, F. et al., Influence of Antisera To Oncornavirus          Glycoprotein (gp71) on Infections of Cats with Feline          Leukemia Virus, Virology, 1978, 617-621, 85.;            Flynn, J. Norman et al., Longitudinal Analysis of Feline          Leukemia Virus-Specific Cytotoxic T Lymphocytes:          Correlation with Recovery from Infection, Journal of          Virology, 2002, 2306-2315, 76(5).;            Grosenbaugh, Da et al, Comparison of the Safety and          Efficacy of a Recombinant Feline Leukemia Virus (FeLV)          Vaccine Delivered Transdermally and an Inactivated FeLV          Vaccine Delivered Subcutaneously, Veterinary          Therapeutics, Veterinary Learning Systems, 2004, 258-262,          5(4).;            Hardy, Jr., William D. et al., Ten-year study comparing          enzyme-linked immunosorbent assay with the          immunofluorescent antibody test for detection of feline          leukemia virus infection in cats, JAVMA, 1991, 1365-1373,          199 (10).;            Hines, David L. et al., Evaluation of efficacy and safety          of an inactivated virus vaccine against feline leukemia          virus infection, J. Am. Vet. Med. Assoc., 1991,          1428-1430, 199.;            Hoover, Edward A. et al., Feline leukemia virus infection          and diseases, J. Am. Vet. Med. Assoc., 1991, 1287-1297,          199.;            Hosie, M.J. et al., Prevalence of feline leukaemia virus          and antibodies to feline immunodeficiency virus in cats          in the United Kingdom, Veterinary Records, 1989, 293-297,          128.;            International Search Report for PCT/EP2018080096 dated          Feb. 19, 2019, 18 pages.;            Kamrud, K.I. et al., Development and characterization of          promoterless helper RNAs for the production of alphavirus          replicon particle, Journal of General Virology, 2010,          1723-1727, 91(Pt 7).;            Kass, P et al, Epidemiologic evidence for a causal          relation between vaccination and fibrosarcoma          tumorigenesis in cats, Journal of the American Veterinary          Medical Association, 1993, 396-405, 203(3).;            Konopka, Jennifer L. et al., Acute Infection with          Venezuelan Equine Encephalitis Virus Replicon Particles          Catalyzes a Systemic Antiviral State and Protects from          Lethal Virus Challenge, Journal of Virology, 2009,          12432-12442, 83(29).;            Levy, Julie et al., 2008 American Association of Feline          Practitioners' feline retrovirus management guidelines,          Journal of Feline Medicine and Surgery, 2008, 300-316,          10.;            Liljestrom, P. et al., A new generation of animal cell          expression vectors based on the semliki forest virus          replicon, Biotechnology, 1991, pp. 1356-1361,          9.;            Liu, Chunguo et al., Complete Genome Sequence of Feline          Panleukopenia Virus Strain HRB-CS1, Isolated from a          Domestic Cat in Northeastern China, Genome Announcements,          2015, 1, 3(2):e01556-14.;            Ljungberg, K et al, Self-replicating alphavirus RNA          vaccines, Expert Review of Vaccines, 2015, 177-194,          14(2).;            Lucchese, G et al, How a single amino acid change may          alter the immunological information of a peptide,          Frontiers in Bioscience: Elite Edition, 2012, 1843-1852,          vol. 4, No. 5.;            Malik, R. et al., Prevalences of feline leukaemia virus          and feline immunodeficiency virus infections in cats in          Sydney, Australian Veterinary Journal, 1997, 323-327,          75.;            Mathes L.E. et al., Abrogation of lymphocyte          blastogenesis by a feline leukaemia virus protein,          Nature, 1978, 687-689, 274.;            Nunberg, J.H. et al., Method to map antigenic          determinants recognized by monoclonal antibodies:          Localization of a determinant of virus neutralization on          the feline leukemia virus envelope protein gp7O, Proc.          Natl. Acad. Sci. USA, 1984, 3675-3679, 81.;            Pacitti, A.M. et al., Transmission of feline leukaemia          virus in the milk of a non-viraemic cat, The Veterinary          Record, 1986, 381-384, 118.;            Patel, M et al, Comparative Efficacy of Feline Leukemia          Virus (FeLV) Inactivated Whole-Virus Vaccine and          Canarypox Virus-Vectored Vaccine during Virulent FeLV          Challenge and Immunosuppression, Abstract, Clinical and          Vaccine Immunology, 2015, 798-805, 22(7).;            Pedersen, Niels C., Immunogenicity and Efficacy of a          Commercial Feline Leukemia Virus Vaccine, J. Vet. Intern.          Med., 1993, 34-39, 7.;            Pushko, Peter et al., Replicon-Helper Systems from          Attenuated Venezuelan Equine Encephalitis Virus:          Expression of Heterologous Genes in Vitro and          Immunization against Heterologous Pathogens in Vivo,          Virology, 1997, 389-401, 239.;            Radford, Alan D. et al., Feline calicivirus. Vet. Res.,          2007, 319-335, 38(2).;            Rayner, Jo et al., Alphavirus vectors and vaccination,          Reviews in Medical Virology, 2002, pp. 279-296,          12.;            Reed, DS et al, Combined Alphavirus Replicon Particle          Vaccine Induces Durable and Cross-Protective Immune          Responses against Equine Encephalitis Viruses, Journal of          Virology, 2014, 12077-12086, vol. 88, No. 20.;            Rojko, Jennifer L. et al., Pathogenesis of infection by          the feline leukemia virus, J Am Vet Med Assoc, 1991,          1305-1310, 199.;            Scherk, M.A., et al., 2013 AAFP Feline Vaccination          Advisory Panel Report, Journal of Feline Medicine and          Surgery, 2013, pp. 785-808, 15.;            Scott, Fred W et al., Long-term immunity in cats          vaccinated with an inactivated trivalent vaccine, Am. J.          Vet. Res., 1999, 652-658, 60.;            Segundo, Fayna Diaz-San et al., Venezuelan Equine          Encephalitis Replicon Particles Can Induce Rapid          Protection against Foot-and-Mouth Disease Virus, Journal          of Virology, 2013, 5447-5460, 87(10).;            Sosnovtsev, Stanislav V. et al., Identification and          Genomic Mapping of the ORF3 and VPg Proteins in Feline          Calicivirus Virions, Virology, 2000, 193-203,          277.;            Sparkes, A.H., Feline leukaentia virus: a revie-w of          immunity and vaccination, Journal of Small Animal          Practice, 1997, 187-194, 38.;            Stuke, K et al, Efficacy of an inactivated FeLV vaccine          compared to a recombinant FeLV vaccine in minimum age          cats following virulent FeLV challenge, Vaccine, 2014,          2599-2603, 32(22).;            Thomsen, Darrell R. et al., Expression of feline          leukaemia virus gp85 and gag proteins and assembly into          virus-like particles using the baculovirus expression          vector system, Journal of General Virology, 1992,          1819-1824, 73.;            Torres, Andrea N. et al., Feline leukemia virus immunity          induced by whole inactivated virus vaccination,          Veterinary Immunology and Immunopathology, 2010, 122-131,          134.;            Uematus, Y et al, Lack of Interference with          Immunogenicity of a Chimeric Alphavirus Replicon          Particle-Based Influenza Vaccine by Preexisting          Antivector Immunity, Clinical and Vaccine Immunology,          2012, 991-998, vol. 19, No. 7.;            Vander Veen, RL et al, Alphavirus replicon vaccines,          Animal Health Research Reviews, 2012, 1-9, vol. 13, No.          1.	200757-0-0-0 K M			RA00GT K M		WO2019147604-A2;  WO2019147604-A3;  EP3743083-A2;  US2021030860-A1;  EP3743083-A4;  US11696943-B2	New genetically modified T cell useful for            increasing engraftment of adoptively transferred T            cells or providing long-term delivery of antigen to            human, or increasing engraftment of adoptively            transferred T cells	ONEIL R T;  WILSON M H	UNIV VANDERBILT (UVAN-C);  UNIV VANDERBILT (UVAN-C);  UNIV VANDERBILT (UVAN-C)	201967521B	   NOVELTY - A genetically modified T cell is new, where                the T cell is modified to express T cell receptor                specific for an antigen of interest, where the T                cell comprises a vector encoding the antigen of                interest or therapeutic peptide.    USE - The genetically modified T cell is useful for                (a) increasing engraftment of adoptively                transferred T cells, or providing long-term                delivery of an antigen to a subject, (b) increasing                engraftment of adoptively transferred T cells, (c)                treating, inhibiting, reducing, or preventing                cancer, (d) treating chronic kidney disease, (e)                treating diabetes, or (f) treating, inhibiting,                reducing, or preventing a viral or bacterial                infection in a subject. The T cell is a memory T                cell (all claimed). The subject is mammal,                preferably human.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a method (M1) of increasing engraftment of                adoptively transferred T cells, or providing                long-term delivery of an antigen to a subject,                involves administering the modified T cells to a                subject, or administering a genetically modified T                cell to a subject, where the T cell is modified to                express a vector encoding the antigen of                interest;    (2) a method (M2) of increasing engraftment of                adoptively transferred T cells, involves                administering a first T cell genetically modified                to express a T cell receptor specific for an                antigen of interest and a second T cell genetically                modified to express a vector encoding the antigen                of interest to a subject;    (3) a method (M3) of treating, inhibiting,                reducing, or preventing cancer, involves                administering a genetically modified T cell to a                subject with a cancer, where the T cell is modified                to express T cell receptor specific for a tumor                antigen of interest and the T cell comprises a                vector encoding the tumor antigen of                interest;    (4) a method (M4) of treating chronic kidney                disease, involves administering a genetically                modified T cell to a subject with chronic kidney                disease, where the T cell is modified to express a                T cell receptor specific for erythropoietin (EPO),                where the T cell comprises a vector encoding                EPO;    (5) a method (M5) of treating diabetes,                involves administering a genetically modified T                cell to a subject with diabetes, where the T cell                is modified to express a T cell receptor specific                for insulin, where the T cell comprises vector                encoding insulin; and    (6) a method (M6) of treating, inhibiting,                reducing, or preventing a viral or bacterial                infection in a subject, involves administering a                first genetically modified T cell to a subject in                risk of the infection, where the first T cell has                been modified to express a T cell receptor specific                for a bacterial or viral antigen of interest, where                the antigen of interest is an antigen from the                bacterium or virus from which immunological                protection is sought, and the T cell further                comprises a vector encoding the antigen of                interest. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E99;  B04-F04B1A;  B04-F04B1E;  B14-A01;  B14-A02;  B14-H01;  B14-N10;  B14-S04;  B14-S21;  D05-H14B2;  D05-H99	A61K-039/02;  A61K-035/17;  C07K-014/725;  C07K-016/30;  C07K-019/00;  C12N-005/0783;  A61K-039/12;  A61K-039/00	WO2019147604-A2   01 Aug 2019   A61K-039/02   201963Pages: 61   English;  WO2019147604-A3   09 Apr 2020   A61K-035/17   202031   English;  EP3743083-A2   02 Dec 2020   A61K-035/17   202098   English;  US2021030860-A1   04 Feb 2021   A61K-039/02   202115   English;  EP3743083-A4   03 Nov 2021   A61K-035/17   202190   English;  US11696943-B2   11 Jul 2023   A61K-039/00   202356   English	WO2019147604-A2    WOUS014652    23 Jan 2019;   WO2019147604-A3    WOUS014652    23 Jan 2019;   EP3743083-A2    EP743772    23 Jan 2019;   US2021030860-A1    US16964007    22 Jul 2020;   EP3743083-A4    EP743772    23 Jan 2019;   US11696943-B2    US16964007    22 Jul 2020	EP3743083-A2 PCT application Application WOUS014652;   EP3743083-A2 Based on Patent WO2019147604;   US2021030860-A1 PCT application Application WOUS014652;   US2021030860-A1 Provisional Application US620736P;   US11696943-B2 Provisional Application US620736P;   US11696943-B2 PCT application Application WOUS014652;   US11696943-B2 Previous Publ. Patent US2021030860;   US11696943-B2 Based on Patent WO2019147604	US620736P    23 Jan 2018;  WOUS014652    23 Jan 2019;  US16964007    22 Jul 2020	WO2019147604-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2019147604-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP3743083-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    EP3743083-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR    		;  WO2019147604-A3 -- US20040241851-A1   ;  US20150079025-A1   ;  US20170158749-A1   ;  US20170224798-A1   ;  US20170240612-A1   ;  EP3743083-A4 -- WO2017192924-A1   HUTCHINSON CANCER RES CENT FRED (CANC)   RIDDELL S R,  VEATCH J;  WO2014186469-A2   UNIV TEXAS SYSTEM (TEXA)   COOPER L J N,  WANG-JOHANNING F,  TORIKAI H,  HULS H,  HURTON L,  KRISHNAMURTHY J,  OLIVARES S,  ZHANG L;  US11696943-B2 -- US20040241851-A1   ;  US20150079025-A1   ;  US20170158749-A1   ;  US20170224798-A1   ;  US20170240612-A1   	WO2019147604-A3  O'NEIL ET AL.:          "Transposon-modified antigen-specific T lymphocytes for          sustained therapeutic protein delivery in vivo", NAT          COMMUN, vol. 9, 1325, 10 April 2018 (2018-04-10), pages 1          - 10, XP055700102,relevantClaims[1-28],relevantPassages[.          entire document];  NAKAZAWA ET AL.:          "PiggyBac-mediated cancer immunotherapy using          EBV-specific cytotoxic T-cells expressing HER2-specific          chimeric antigen receptor", MOL THER, vol. 19, 19 July          2011 (2011-07-19), pages 2133 - 2143, XP055282256, DOI:          10.1038/mt.2011.131,relevantClaims[1-28],relevantPassages[.          entire document];  RUSSO ET AL.:          "Lymphocytes genetically modified to express tumor          antigens target DCs in vivo and induce antitumor          immunity", THE JOURNAL OF CLINICAL INVESTIGATION, vol.          17, no. 10, 1 October 2007 (2007-10-01), pages 3087 -          3096, XP055700106,relevantClaims[1-28],relevantPassages[.          entire document];  KUEBERUWA ET AL.:          "CCR7+ selected gene -modified T cells maintain a central          memory phenotype and display enhanced persistence in          peripheral blood in vivo", J IMMUNOTHER CANCER, vol. 5,          no. 14, 21 February 2017 (2017-02-21), pages 1 - 14,          XP021242385, DOI:          10.1186/s40425-017-0216-7,relevantClaims[1-28],relevantPassages[.          entire document];  MOHAMMED ET AL.:          "Improving Chimeric Antigen Receptor-Modified T Cell          Function by Reversing the Immunosuppressive Tumor          Microenvironment of Pancreatic Cancer", MOLECULAR          THERAPY, vol. 25, no. 1, 4 January 2017 (2017-01-04),          pages 249 - 258, XP055695458, DOI:          10.1016/j.ymthe.2016.10.016,relevantClaims[1-28],relevantPassages[.          entire document];  TSAI ET AL.:          "Producer T cells: Using genetically engineered T cells          as vehicles to generate and deliver therapeutics to          tumors", ONCOLMMUNOLOGY, vol. 5, no. 5, 15 January 2016          (2016-01-15), pages 1 - 10,          XP055700109,relevantClaims[1-28],relevantPassages[.          entire document]EP3743083-A4  PALLAVI V. RAJA          MANURI ET AL: "piggyBac Transposon/Transposase System to          Generate CD19-Specific T Cells for the Treatment of          B-Lineage Malignancies", HUMAN GENE THERAPY, vol. 21, no.          4, 1 April 2010 (2010-04-01), pages 427 - 437,          XP055181368, ISSN: 1043-0342, DOI:          10.1089/hum.2009.114,relevantClaims[1,2,4-8,10,13,14|1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|Materials          and methods];  SARIDEY SAI K ET          AL: "PiggyBac Transposon-based Inducible Gene Expression          In Vivo After Somatic Cell Gene Transfer", MOLECULAR          THERAPY, vol. 17, no. 12, 6 October 2009 (2009-10-06),          US, pages 2115 - 2120, XP055844358, ISSN: 1525-0016, DOI:          10.1038/mt.2009.234,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|Materials          and methods];  RICHARD T. O'NEIL          ET AL: "Transposon-modified antigen-specific T          lymphocytes for sustained therapeutic protein delivery in          vivo", NATURE COMMUNICATIONS, vol. 9, no. 1, 10 April          2018 (2018-04-10), XP055700102, DOI:          10.1038/s41467-018-03787-8,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|Methods]US11696943-B2            Babitt JL & Lin HY (2012) Mechanisms of anemia in          CKD. &lt;xhtml:i &gt;Journal of the American          Society of Nephrology&lt;/xhtml:i&gt;,          23(10):1631-1634.;            Bear AS, Cruz CR, & Foster AE (2011) T cells as          vehicles for cancer vaccination. &lt;xhtml:i          &gt;Journal of          biomedicine&lt;/xhtml:i&gt;& &lt;xhtml:i          &gt;biotechnology&lt;/xhtml:i&gt;2011:417403.;            Bertino P, et al. (2014) Vaccination with a piggyBac          plasmid with transgene integration potential leads to          sustained antigen expression and CD8(+) T cell responses.          &lt;xhtml:i          &gt;Vaccine&lt;/xhtml:i&gt;32(15):1670-1677.;            Besarab A, et al. (1998) The effects of normal as          compared with low hematocrit values in patients with          cardiac disease who are receiving hemodialysis and          epoetin. &lt;xhtml:i &gt;N Engl J          Med&lt;/xhtml:i&gt;339(9):584-590.;            Blum S, et al. (2017) TARGT Gene Therapy Platform for          Correction of Anemia in End-Stage Renal Disease.          &lt;xhtml:i &gt;N Engl J          Med&lt;/xhtml:i&gt;376(2):189-191.;            Clarke SR, et al. (2000) Characterization of the          ovalbumin-specific TCR transgenic line OT-I: MHC elements          for positive and negative selection. &lt;xhtml:i          &gt;Immunology and cell          biology&lt;/xhtml:i&gt;78(2):110-117.;  Di          Stasi A, et al. (2011) Inducible apoptosis as a safety          switch for adoptive cell therapy. &lt;xhtml:i          &gt;N Engl J          Med&lt;/xhtml:i&gt;365(18):1673-1683.;            Doherty JE, et al. (2012) Hyperactive piggyBac Gene          Transfer in Human Cells and In Vivo. &lt;xhtml:i          &gt;Human Gene          Therapy&lt;/xhtml:i&gt;23(3):311-320.;            Doherty JE, Woodard LE, Bear AS, Foster AF, & Wilson          MH (2013) An adaptable system for improving          transposon-based gene expression in vivo via transient          transgene repression. &lt;xhtml:i &gt;FASEB          J&lt;/xhtml:i&gt;. 27(9):3753-3762.;            Drueke TB, et al. (2006) Normalization of hemoglobin          level in patients with chronic kidney disease and anemia.          &lt;xhtml:i          &gt;N.Engl.J.Med&lt;/xhtml:i&gt;.          355(20):2071-2084.;            Fesnak AD, June CH, & Levine BL (2016) Engineered T          cells: the promise and challenges of cancer          immunotherapy. &lt;xhtml:i &gt;Nature reviews.          Cancer&lt;/xhtml:i&gt;16(9):566-581.;            Foster AE, et al. (2008) Antitumor activity of          EBV-specific T lymphocytes transduced with a dominant          negative TGF-beta receptor. &lt;xhtml:i          &gt;Journal of          immunotherapy&lt;/xhtml:i&gt;31(5):500-505.;            Galvan DL, et al. (2015) Anti-Tumor Effects after          Adoptive Transfer of IL-12 Transposon-Modified Murine          Splenocytes in the OT-I-Melanoma Mouse Model.          &lt;xhtml:i &gt;PLoS          One&lt;/xhtml:i&gt;10(10):e0140744.;            Gao G, et al. (2004) Erythropoietin gene therapy leads to          autoimmune anemia in macaques. &lt;xhtml:i          &gt;Blood&lt;/xhtml:i&gt;103(9):3300-3302.;            Heslop HE (2009) How I treat EBV lymphoproliferation.          &lt;xhtml:i          &gt;Blood&lt;/xhtml:i&gt;114(19):4002-4008.;            Heslop HE, et al. (1996) Long-term restoration of          immunity against Epstein-Barr virus infection by adoptive          transfer of gene-modified virus-specific T lymphocytes.          &lt;xhtml:i &gt;Nat          Med&lt;/xhtml:i&gt;2(5):551-555.;            Hoppe PS, Coutu DL, & Schroeder T (2014) Single-cell          technologies sharpen up mammalian stem cell research.          &lt;xhtml:i &gt;Nature cell          biology&lt;/xhtml:i&gt;16(10):919-927.;            Johnston J, et al. (2003) Regulated expression of          erythropoietin from an AAV vector safely improves the          anemia of beta-thalassemia in a mouse model.          &lt;xhtml:i &gt;Molecular          therapy&lt;/xhtml:i&gt;, 7(4):493-497.;            Kahlig KM, et al. (2010) Multiplexed transposon-mediated          stable gene transfer in human cells. &lt;xhtml:i          &gt;Proceedings of the National Academy of Sciences          of the United States of          America&lt;/xhtml:i&gt;107(4):1343-1348.;            Kebriaei P, et al. (2016) Phase I trials using Sleeping          Beauty to generate CD19-specific CAR T cells.          &lt;xhtml:i &gt;The Journal of clinical          investigation&lt;/xhtml:i&gt;126(9):3363-3376.;            Koury MJ & Haase VH (2015) Anaemia in kidney disease:          harnessing hypoxia responses for therapy. &lt;xhtml:i          &gt;Nature reviews.          Nephrology&lt;/xhtml:i&gt;11(7):394-410.;            Mocini D, Leone T, Tubaro M, Santini M, & Penco M          (2007) Structure, production and function of          erythropoietin: implications for therapeutical use in          cardiovascular disease. &lt;xhtml:i          &gt;Curr.Med.Chem&lt;/xhtml:i&gt;.          14(21):2278-2287.;            Nakazawa Y, et al. (2009) Optimization of the PiggyBac          transposon system for the sustained genetic modification          of human T lymphocytes. &lt;xhtml:i &gt;Journal          of          immunotherapy&lt;/xhtml:i&gt;32(8):826-836.;            Nakazawa Y, et al. (2013) Evaluation of Long-term          Transgene Expression in piggyBac-Modified Human T          Lymphocytes. &lt;xhtml:i &gt;Journal of          Immunotherapy&lt;/xhtml:i&gt;36(1):3-10.;            Osada S, et al. (1999) Gene therapy for renal anemia in          mice with polycystic kidney using an adenovirus vector          encoding the human erythropoietin gene. &lt;xhtml:i          &gt;Kidney          Int&lt;/xhtml:i&gt;55(4):1234-1240.;            Pfeffer MA, et al. (2009) A trial of darbepoetin alfa in          type 2 diabetes and chronic kidney disease.          &lt;xhtml:i          &gt;N.Engl.J.Med&lt;/xhtml:i&gt;.          361(21):2019-2032.;            Rooney CM, et al. (1998) Infusion of cytotoxic T cells          for the prevention and treatment of Epstein-Barr          virus-induced lymphoma in allogeneic transplant          recipients. &lt;xhtml:i          &gt;Blood&lt;/xhtml:i&gt;92(5):1549-1555.;            Russo V, et al. (2007) Lymphocytes genetically modified          to express tumor antigens target DCs in vivo and induce          antitumor immunity. &lt;xhtml:i &gt;The Journal          of clinical          investigation&lt;/xhtml:i&gt;117(10):3087-3096.;            Saridey SK, et al. (2009) PiggyBac Transposon-based          Inducible Gene Expression In Vivo After Somatic Cell Gene          Transfer. &lt;xhtml:i &gt;Molecular          Therapy&lt;/xhtml:i&gt;17(12):2115-2120.;            Scholler J, et al. (2012) Decade-long safety and function          of retroviral-modified chimeric antigen receptor T cells.          &lt;xhtml:i &gt;Sci Transl          Med&lt;/xhtml:i&gt;4(132):132ra153.;            Shapir N, et al. (2015) Preclinical and Preliminary          Clinical Evaluation of Genetically Transduced Dermal          Tissue Implants for the Sustained Secretion of          Erythropoietin and Interferon alpha. &lt;xhtml:i          &gt;Human gene therapy. Clinical          development&lt;/xhtml:i&gt;26(4):216-227.;            Skali H, et al. (2011) Stroke in patients with type 2          diabetes mellitus, chronic kidney disease, and anemia          treated with Darbepoetin Alfa: the trial to reduce          cardiovascular events with Aranesp therapy (TREAT)          experience. &lt;xhtml:i          &gt;Circulation&lt;/xhtml:i&gt;124(25):2903-2908.;            Smith CA, et al. (1995) Production of genetically          modified Epstein-Barr virus-specific cytotoxic T cells          for adoptive transfer to patients at high risk of          EBV-associated lymphoproliferative disease.          &lt;xhtml:i &gt;Journal of          hematotherapy&lt;/xhtml:i&gt;4(2):73-79.;            Takacs K, et al. (2004) The regulated long-term delivery          of therapeutic proteins by using antigen-specific B          lymphocytes. &lt;xhtml:i &gt;Proc Natl Acad Sci U          S A&lt;/xhtml:i&gt;101(46):16298-16303.;            Woodard LE & Wilson MH (2015) piggyBac-ing models and          new therapeutic strategies. &lt;xhtml:i          &gt;Trends          Biotechnol&lt;/xhtml:i&gt;33(9):525-533.;            International Preliminary Report on Patentability issued          for Application No. PCT/US2019/014652, dated Aug. 6,          2020.;            International Search Report and Written Opinion dated          Apr. 19, 2019, from International Application No.          PCT/US2019/014652, 13 pages.;            O'Neil, R.T. et al. Transposon-modified antigen-specific          T lymphocytes for sustained therapeutic protein delivery          in vivo. Nature Communications, (2018), 9:1325.;            Nakazawa, Y. et al. PiggyBac-mediated Cancer          Immunotherapy Using EBV-specific Cytotoxic T-cells          Expressing HER2-specific Chimeric Antigen Receptor, The          American Society of Gene & Cell Therapy, Molecular          Therapy, vol. 19, No. 12, 2133-2143, Dec. 2011.;            Russo, V. et al. Lymphoctyes genetically modified to          express tumor antigens target DCs in vivo and induce          antitumor immunity, The Journal of Clinical          Investigation, vol. 117, No. 10, Oct. 2007.;            Kueberuwa, G. et al. CCR7+ selected gene-modified T cells          maintain a central memory phenotype and display enhanced          persistence in peripheral blood in vivo, Journal for          Immunotherapy of Cancer, (2017)5:14.;            Mohammed, S. et al. Improving Chimeric Antigen          Receptor-Modified T Cell Function by Reversing the          Immunosuppressive Tumor Microenvironment of Pancreatic          Cancer, Molecular Therapy, vol. 25, No. 1, Jan.          2017.;            Tsai, A. et al. Producer T cells: Using genetically          engineered T cells as vehicles to generate and deliver          therapeutics to tumors, OncoImmunology, 2016, vol. 5, No.          5.	200757-0-0-0 N			RA00GT N		WO2019079671-A1;  TW201922778-A;  CN111465409-A;  EP3697437-A1;  US2021070843-A1;  EP3697437-A4;  TW728272-B1;  US11434277-B2	Screening neutralizing antibody specific to virus,            by exposing phage-displayed single-chain variable            fragment (scFv) library to viral antigen, selecting            phages, exposing to virus, and selecting soluble scFv            exhibiting superior efficacy	YANG A;  CHEN I;  CHIU Y;  YU C;  LEE C;  TUNG C;  TSOU Y;  HUANG Y;  LIN C;  CHEN H;  WANG H;  CHEN Y;  QIU Y;  YU Z;  LI Z;  DONG Z;  ZOU Y;  LIN J	ACAD SINICA (SNIC-C);  YANG A (YANG-Individual);  ACAD SINICA (SNIC-C);  ACAD SINICA (SNIC-C);  ACAD SINICA (SNIC-C)	2019370129	   NOVELTY - Method (M1) for high-throughput screening of a                neutralizing antibody specific to a virus, involves                (a) providing a phage-displayed single-chain                variable fragment (scFv) library that comprises                phage-displayed scFvs, (b) exposing the                phage-displayed scFv library of the step (a) to a                viral antigen derived from the virus, (c) selecting                phages that express scFvs exhibiting binding                affinity to the viral antigen under an acidic                condition from the phage-displayed scFv library of                the step (b), (d) respectively enabling the phages                selected in the step (c) to express soluble scFvs,                (e) exposing the soluble scFvs of the step (d) to                the virus, (f) determining the respective                neutralizing efficacy of the soluble scFvs in the                step (e), and (g) selecting one soluble scFv that                exhibits superior efficacy over the other soluble                scFvs of the soluble scFvs as the neutralizing                antibody based on the results determined in the                step (f).    USE - The method is useful for (a) screening a                neutralizing antibody specific to a virus, (b)                producing a recombinant antibody, or (c) treating                or preventing a virus infection in a subject. The                virus is influenza virus, measles virus,                coronavirus, mumps virus, Marburg virus, Ebola                virus, rubella virus, rhinovirus, poliovirus,                hepatitis virus, smallpox virus, varicella-zoster                virus, severe acute respiratory syndrome virus,                retrovirus, rotavirus, adenoviruses,                adeno-associated virus or alpha -virus. The virus                is influenza virus. The subject is a human (all                claimed).    ADVANTAGE - The method achieves high-throughput screening                of neutralizing antibody specific to a virus.    DETAILED DESCRIPTION - Method (M1) for high-throughput screening of a                neutralizing antibody specific to a virus, involves                (a) providing a phage-displayed single-chain                variable fragment (scFv) library that comprises                phage-displayed scFvs, where the heavy chain                variable (VH) domain of each phage-displayed scFvs                has a binding affinity to protein A, and the light                chain variable (VL) domain of each phage-displayed                scFvs has a binding affinity to protein L, (b)                exposing the phage-displayed scFv library of the                step (a) to a viral antigen derived from the virus,                (c) selecting phages that express scFvs exhibiting                binding affinity to the viral antigen under an                acidic condition from the phage-displayed scFv                library of the step (b), (d) respectively enabling                the phages selected in the step (c) to express                soluble scFvs, (e) exposing the soluble scFvs of                the step (d) to the virus, (f) determining the                respective neutralizing efficacy of the soluble                scFvs in the step (e), and (g) selecting one                soluble scFv that exhibits superior efficacy over                the other soluble scFvs of the soluble scFvs as the                neutralizing antibody based on the results                determined in the step (f). INDEPENDENT CLAIMS are                included for the following:    (1) a neutralizing antibody, comprising a VL                domain has the amino acid sequence at least 85%                identical to any of SEQ ID NOs: 1-28, and a VH                domain has the amino acid sequence at least 85%                identical to any of SEQ ID NOs: 29-56;    (2) a method (M2) of producing a recombinant                antibody, involves (a) selecting a neutralizing                antibody, (b) extracting a phagemid DNA from                corresponding to the phage that expresses the                neutralizing antibody of the step (a), (c)                respectively amplifying a first nucleic acid                sequence that encodes a VL domain, and a second                nucleic acid sequence that encodes a VH domain by                PCR using the phagemid DNA of the step (b) as a                template, (d) inserting the first and second                nucleic acid sequences into an expression vector                that comprises a third and a fourth nucleic acid                sequences, where the third nucleic acid sequence                encodes the light chain constant (CL) domain of an                immunoglobulin, and the fourth nucleic acid                sequence encodes the heavy chain constant (CH)                domain of the immunoglobulin, and (e) transfecting                a host cell with the expression vector of the step                (d) that comprises the first, second, third, and                fourth nucleic acid sequences so as to produce the                recombinant antibody; and    (3) a recombinant antibody, comprising a VL                domain, a CL domain, a VH domain and a CH domain,                where the VL domain has the amino acid sequence at                least 85% identical to any of SEQ ID NOs: 1-28, and                the VH domain has the amino acid sequence at least                85% identical to any of SEQ ID NOs: 29-56.    Sequences not defined here may be found at                ftp://ftp.wipo.int/pub/published_pct_sequences/publication. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B04C1;  B04-E99;  B04-F11;  B04-G08;  B04-G0800E;  B04-G23;  B04-L05B;  B04-N03K;  B11-C07A;  B11-C10A;  B11-C10D;  B12-K04E1;  B14-A02;  D05-H09;  D05-H11;  D05-H99	A61K-039/00;  C12N-015/10;  A61K-039/395;  A61P-035/00;  C07K-016/08;  C40B-030/04;  C07K-016/10;  A61P-031/16;  C07K-016/00	WO2019079671-A1   25 Apr 2019   A61K-039/00   201935Pages: 43   English;  TW201922778-A   16 Jun 2019   C07K-016/08   201967   Chinese;  CN111465409-A   28 Jul 2020   A61K-039/00   202064   Chinese;  EP3697437-A1   26 Aug 2020   A61K-039/00   202070   English;  US2021070843-A1   11 Mar 2021   C07K-016/10   202124   English;  EP3697437-A4   13 Oct 2021   A61P-031/16   202184   English;  TW728272-B1   21 May 2021   C07K-016/08   202198   Chinese;  US11434277-B2   06 Sep 2022   C07K-016/00   202272   English	WO2019079671-A1    WOUS056627    19 Oct 2018;   TW201922778-A    TW136858    19 Oct 2018;   CN111465409-A    CN80068162    19 Oct 2018;   EP3697437-A1    EP868719    19 Oct 2018;   US2021070843-A1    US16757460    20 Apr 2020;   EP3697437-A4    EP868719    19 Oct 2018;   TW728272-B1    TW136858    19 Oct 2018;   US11434277-B2    US16757460    20 Apr 2020	CN111465409-A PCT application Application WOUS056627;   CN111465409-A Based on Patent WO2019079671;   EP3697437-A1 PCT application Application WOUS056627;   EP3697437-A1 Based on Patent WO2019079671;   US2021070843-A1 PCT application Application WOUS056627;   US2021070843-A1 Provisional Application US574884P;   TW728272-B1 Previous Publ. Patent TW201922778;   US11434277-B2 PCT application Application WOUS056627;   US11434277-B2 Provisional Application US574884P;   US11434277-B2 Previous Publ. Patent US2021070843;   US11434277-B2 Based on Patent WO2019079671	US574884P    20 Oct 2017;  WOUS056627    19 Oct 2018;  CN80068162    20 Apr 2020;  US16757460    20 Apr 2020	WO2019079671-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP3697437-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    EP3697437-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR      		WO2019079671-A1 -- US20080014205-A1   ;  WO2016137992-A2   YANG A (YANG-Individual);  ACAD SINICA (SNIC)   YANG A,  CHEN H,  CHEN I,  TUNG C,  HOU S,  YU C,  YANG C,  CHIU Y;  CN111465409-A -- CN101607995-A   UNIV XIAMEN (UYXI);  YANG SHENG TANG CO LTD (YANG-Non-standard)   CHEN Y,  LUO W,  ZHANG J,  XIA N,  GUAN Y,  CHEN H;  CN107056938-A   SHENZHEN PLANNED SCI & TECHNOLOGY CO                  LTD (SHEN-Non-standard)   YANG Z;  TW201712031-A   ACAD SINICA (SNIC)   YANG A,  CHEN I,  TUNG C,  YU C;  WO2016137992-A2   YANG A (YANG-Individual);  ACAD SINICA (SNIC)   YANG A,  CHEN H,  CHEN I,  TUNG C,  HOU S,  YU C,  YANG C,  CHIU Y;  EP3697437-A4 -- WO2016137992-A2   YANG A (YANG-Individual);  ACAD SINICA (SNIC)   YANG A,  CHEN H,  CHEN I,  TUNG C,  HOU S,  YU C,  YANG C,  CHIU Y;  US11434277-B2 -- WO2016137992-A2   YANG A (YANG-Individual);  ACAD SINICA (SNIC)   YANG A,  CHEN H,  CHEN I,  TUNG C,  HOU S,  YU C,  YANG C,  CHIU Y;  TW201632547-A   YANG A (YANG-Individual);  ACAD SINICA (SNIC)   YANG A,  CHEN H,  CHEN I,  TUNG C,  HOU S,  YU C,  YANG C,  CHIU Y;  US20080014205-A1   	CN111465409-A  CHAO-PING TUNG:          "Discovering neutralizing antibodies targeting the stem          epitope of H1N1 influenza hemagglutinin with synthetic          phage-displayed antibody libraries", SCIENTIFIC          REPORTS,relevantClaims[1-610-13],relevantPassages[1-1635]EP3697437-A4  TUNG CHAO-PING ET          AL: "Discovering neutralizing antibodies targeting the          stem epitope of H1N1 influenza hemagglutinin with          synthetic phage-displayed antibody libraries", SCIENTIFIC          REPORTS, vol. 5, no. 1, 1 December 2015 (2015-12-01),          XP055807656, Retrieved from the Internet          &lt;URL:https://www.nature.com/articles/srep15053.pdf&gt;          DOI:          10.1038/srep15053,relevantClaims[1-6,10-13],relevantPassages[&lt;pp&gt;3&lt;/pp&gt;&lt;para&gt;5&lt;/para&gt;];  CHAI NING ET AL:          "Two Escape Mechanisms of Influenza A Virus to a Broadly          Neutralizing Stalk-Binding Antibody", PLOS PATHOGENS,          vol. 12, no. 6, 28 June 2016 (2016-06-28), US, pages          e1005702, XP055807854, ISSN: 1553-7366, DOI:          10.1371/journal.ppat.1005702,relevantClaims[1-6,10-13],relevantPassages[&lt;figure&gt;5&lt;/figure&gt;&lt;table&gt;1&lt;/table&gt;];  AKERSTROM B ET AL:          "On the interaction between single chain Fv antibodies          and bacterial immunoglobulin-binding proteins", JOURNAL          OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS          B.V.,AMSTERDAM, NL, vol. 177, no. 1-2, 28 December 1994          (1994-12-28), pages 151 - 163, XP023992162, ISSN:          0022-1759, [retrieved on 19941228], DOI:          10.1016/0022-1759(94)90152-X,relevantClaims[1-6,10-13],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            See also references of WO 2019079671A1US11434277-B2            Ing-Chien Chen et al; High throughput discovery of          influenza virus neutralizing antibodies from          phage-displayed synthetic antibody libraries.; published          on Oct. 31, 2017, Scientific Reports 7, Article No.          14455; pp. 1-17.;            Chao-Ping Tung; Discovering neutralizing antibodies          targeting the stem epitope of H1N1 influenza          hemagglutinin with synthetic phage-displayed antibody          libraries; Scientific Reports | 5:15053 | DOI:          10.1038/srep15053; www.nature.com/scientificreports; Oct.          12, 2015. (pp. 16).	1562508-1-0-0 D K M; 101849-0-0-0 D K M			RAS6IN D K M; RA0PTU D K M		WO2019178188-A1;  US2020087709-A1	System useful for detecting pathogens and/or            antimicrobial resistance in sample, comprises detection            module comprising fluid handling system for performing            recombinase polymerase assay on sample, and data            analysis and processing module	BRACHT J;  NELSON M;  BELLOWS W;  WALTERS-CONTE K	MICROINVESTIGATE LLC (MICR-Non-standard);  MICROINVESTIGATE LLC (MICR-Non-standard)	201981180W	   NOVELTY - System comprises a detection module, and a                data analysis and processing module, where the                detection module comprises a fluid handling system                for performing recombinase polymerase assay (RPA)                on the sample.    USE - The system is useful for detecting pathogens                and/or antimicrobial resistance in a sample or                detecting both mecA and mef(A), preferably mef(A).                The sample is bodily fluid chosen from blood, or                its component, urine, or saliva (all                claimed). 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-B03C;  B04-E01;  B04-E05;  B04-E99;  B04-F10;  B04-F11;  B11-C08E3;  B11-C08F8;  B11-C08K;  B11-C11C1;  B12-K04F;  B12-K04G1A;  C04-B03C;  C04-E05;  C04-E99;  C04-F10;  C04-F11;  C11-C08E3;  C11-C08F8;  C11-C08K;  C11-C11C1;  C12-K04F;  C12-K04G1A;  D05-H04;  D05-H05;  D05-H06;  D05-H10;  D05-H18B;  D05-H99;  S03-E09F;  S03-E14H1;  S03-E14H2	G01N-033/53;  G01N-033/539;  G01N-033/566;  C12Q-001/6844;  C12Q-001/689	WO2019178188-A1   19 Sep 2019   G01N-033/53   201977Pages: 70   English;  US2020087709-A1   19 Mar 2020   C12Q-001/689   202024   English	WO2019178188-A1    WOUS021988    13 Mar 2019;   US2020087709-A1    US352083    13 Mar 2019	US2020087709-A1 Provisional Application US642107P	US642107P    13 Mar 2018;  US352083    13 Mar 2019	WO2019178188-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    		WO2019178188-A1 -- US20110171649-A1   ;  US20140323710-A1   ;  US20150111760-A1   ;  US20170016048-A1   ;  US20170218455-A1   ;  US20180335424-A1   	WO2019178188-A1  NELSON ET AL.:          "Rapid Molecular Detection of Macrolide Resistance", BMC          INFECTIOUS DISEASES, vol. 19, no. 1, 12 February 2019          (2019-02-12), pages 1 - 12, XP021271095,          doi:10.1186/s12879-019-3762-4,relevantClaims[1-5,          9-14],relevantPassages[. entire document]						CN110305215-A;  TW202003851-A;  CN110305215-B;  TW833738-B1	New isolated antibody polypeptide comprising heavy            chain variable domain that specifically binds to            lymphocyte activation gene 3 useful for treating e.g.            glioblastoma, malaria and allergy and detecting LAG-3            in human	CHEN Y;  LI J	CSTONE PHARM (CSTO-Non-standard);  CSTONE PHARM SUZHOU CO LTD (CSTO-Non-standard);  CSTONE PHARM SHANGHAI CO LTD (CSTO-Non-standard);  WUXI BIOLOGICS SHANGHAI CO LTD (WUXI-Non-standard);  CSTONE PHARM (CSTO-Non-standard)	2019950404	   NOVELTY - An isolated antibody polypeptide (I), is new.                The isolated antibody polypeptide comprises a heavy                chain variable domain that specifically binds to                lymphocyte activation gene 3 (LAG3), where the                heavy chain variable domain comprises                complementarity-determining region (CDR)1, CDR2 and                CDR3. The CDR1 has a amino acid sequence of SEQ ID                NO: 1 or its homologous sequence having at least                80% sequence homology. The CDR2 has a amino acid                sequence of SEQ ID NO: 33 or its homologous                sequence having at least 75% sequence homology. The                CDR3 has a amino acid sequence of SEQ ID NO: 34 or                its homologous sequence having at least 75%                sequence homology.    USE - The isolated antibody polypeptide is useful in                preparation of a medicament for treating a LAG-3                associated disease or condition and a diagnostic                reagent for diagnosis of a LAG-3 related disease or                condition and kit for detecting LAG-3 in human. The                disease or condition is cancer, autoimmune disease                or infectious disease. The cancer includes                glioblastoma, hematological tumors, metastatic                melanoma, Burkitt's lymphoma (BL), multiple myeloma                (MM), B cell chronic lymphocytic leukemia (CLL),                B-cell and T-cell acute lymphocytic leukemia (ALL),                T-cell lymphoma (TCL), hairy cell leukemia (HCL),                Hodgkin's lymphoma (HL), melanoma, mesothelioma,                renal cancer, prostate cancer, breast cancer, colon                cancer, colorectal cancer, lung cancer, bone                cancer, pancreatic cancer, hepatocellular cancer,                skin cancer and head and neck cancer. The                autoimmune disease is Alzheimer's disease, allergy,                asthma, Celiac disease, Crohn's disease, Graves                disease, inflammatory bowel disease (IBD), lupus,                multiple sclerosis, myasthenia gravis, rheumatic                polymyalgia, rheumatoid arthritis, type I diabetes                and vasculitis. The infectious disease is caused by                HIV, hepatitis (A, B and C), human papilloma virus                (HPV), lymphocytic choriomeningitis meningitis                virus (LCMV), simian immunodeficiency virus (SIV),                influenza, herpes, Giardia, Leishmania,                Staphylococcus aureus, Pseudomonas aeruginosa,                flaviviruses, echovirus, rhinovirus,                Coxsackievirus, coronavirus, respiratory syncytial                virus, mumps virus, rotavirus, measles virus,                rubella virus, parvovirus, vaccinia, human T-cell                leukemia-lymphoma virus (HTLV) virus, dengue virus,                papillomavirus, molluscum virus, poliovirus, rabies                virus, John Cunningham virus, arboviral                encephalitis virus, Rickettsia, mycobacteria,                staphylococci, streptococci, Streptococcus                pneumoniae, Neisseria meningitidis and                N.gonorrhoeae, Klebsiella, Proteus, Serratia,                Pseudomonas, Legionella, Salmonella, bacilli,                botulinum, Clostridium, Entamoeba histolytica,                Balantidium coli, Naegleria fowleri, Acanthamoeba,                Giardia lamblia, Cryptosporidium, Pneumocystis                carinii, Plasmodium vivax, Babesia, Trypanosoma                brucei, Trypanosoma cruzi, Leishmania, Toxoplasma                gondii and Brazilian nematode and malaria,                Chlamydia, cholera, tetanus, diphtheria, anthrax,                plague, leptospirosis and Lyme disease (all                claimed).    DETAILED DESCRIPTION - An isolated antibody polypeptide (I), is new.                The isolated antibody polypeptide comprises a heavy                chain variable domain that specifically binds to                lymphocyte activation gene 3 (LAG3), where the                heavy chain variable domain comprises                complementarity-determining region (CDR)1, CDR2 and                CDR3. The CDR1 has a amino acid sequence of SEQ ID                NO: 1 or its homologous sequence having at least                80% sequence homology. The CDR2 has a amino acid                sequence of                Ala-Ile-His-Trp-Thr-Ser-Ser-Val-Thr-Asp-Tyr-Ala-Asp-Ser-Val-X1-Gly                (SEQ ID NO: 33) or its homologous sequence having                at least 75% sequence homology. The CDR3 has a                amino acid sequence of                Thr-X2-Tyr-Tyr-Thr-His-Arg-Gly-X3-Phe-Asp-Tyr (SEQ                ID NO: 34) or its homologous sequence having at                least 75% sequence homology.    X1 = Lys, Tyr, Met, Asp or Arg;    X2 = His or Trp;and    X3 = Ser or Pro.    Gly-Leu-Thr-Leu-Ser-Gln-Tyr-Thr-Met-Gly (SEQ                ID NO: 1). INDEPENDENT CLAIMS are included for the                following:    (1) an antibody polypeptide (II) competes for                same epitope as antibody polypeptide (I);    (2) a isolated polynucleotide encoding the                antibody polypeptide;    (3) a vector comprising the isolated                polynucleotide;    (4) a host cell comprising the vector;    (5) a method for expressing an antibody                polypeptide involves culturing the host cell under                suitable conditions;    (6) a method for detecting presence or amount                of LAG-3 in a sample involves contacting the sample                with antibody polypeptide and determining presence                or amount of LAG-3 in the sample; and    (7) a method for diagnosing a disease or                condition associated with LAG-3 involves (a)                contacting a sample with the antibody polypeptide,                (b) determining presence or amount of LAG-3 in the                sample and (c) correlating presence or amount of                the LAG-3 with presence or state of the LAG-3                related disease or condition. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-C01;  B04-E01;  B04-E02A;  B04-E03A;  B04-E08;  B04-E99;  B04-F01;  B04-F0100E;  B04-G01;  B04-G0100E;  B04-G23;  B04-G27G;  B04-L01;  B04-N02;  B11-C07A;  B12-K04G;  B14-A01;  B14-A02;  B14-A03B;  B14-A04;  B14-C03;  B14-C09B;  B14-D09;  B14-E10C1;  B14-F02;  B14-G02A;  B14-G02D;  B14-H01;  B14-J01A4;  B14-J05;  B14-K01A;  B14-L06;  B14-N11;  B14-N12;  B14-N16;  B14-S01;  B14-S04;  B14-S11A;  B14-S25;  C04-C01;  C04-E01;  C04-E02A;  C04-E03A;  C04-E08;  C04-E99;  C04-F01;  C04-G01;  C04-G0100E;  C04-G23;  C04-G27G;  C04-L01;  C04-N02;  C11-C07A;  C12-K04G;  C14-A01;  C14-A02;  C14-A03B;  C14-A04;  C14-B02;  C14-C03;  C14-C09B;  C14-D09;  C14-E10C1;  C14-F02;  C14-G02A;  C14-G02D;  C14-H01;  C14-J01A4;  C14-J05;  C14-K01A;  C14-L06;  C14-N11;  C14-N12;  C14-N16;  C14-S01;  C14-S04;  C14-S11A;  C14-S25;  D05-H09;  D05-H11;  D05-H12A;  D05-H12E;  D05-H14;  D05-H17A1;  D05-H99;  S03-E09F;  S03-E14H	A61K-039/395;  A61P-031/00;  A61P-035/00;  A61P-037/02;  C07K-016/28;  C12N-015/13;  C12N-015/85;  C12N-005/10;  G01N-033/574;  G01N-033/68	CN110305215-A   08 Oct 2019   C07K-016/28   201989Pages: 93   Chinese;  TW202003851-A   16 Jan 2020   C12N-015/13   202148   Chinese;  CN110305215-B   03 Nov 2023   C07K-016/28   202393   Chinese;  TW833738-B1   01 Mar 2024   C12N-015/13   202441   Chinese	CN110305215-A    CN10199182    15 Mar 2019;   TW202003851-A    TW108992    15 Mar 2019;   CN110305215-B    CN10199182    15 Mar 2019;   TW833738-B1    TW108992    15 Mar 2019	CN110305215-B Previous Publ. Patent CN110305215;   TW833738-B1 Previous Publ. Patent TW202003851	WOCN079682    20 Mar 2018;  CN10730302    05 Jul 2018			CN110305215-A -- CN107428836-A   ANAPTYSBIO INC (ANAP-Non-standard)   JUN H T,  KEHRY M,  BOWERS P,  KING D J;  US20150259420-A1   ;  WO2017219995-A1   JIANGSU HENGRUI MEDICINE CO LTD (JSHR);  SHANGHAI HENGRUI PHARM CO LTD (JSHR)   CAO Z,  FU Y,  HU Q,  TAO W,  ZHANG L,  SUN P;  CN110305215-B -- CN107428836-A   ANAPTYSBIO INC (ANAP-Non-standard)   JUN H T,  KEHRY M,  BOWERS P,  KING D J;  US20150259420-A1   ;  WO2017219995-A1   JIANGSU HENGRUI MEDICINE CO LTD (JSHR);  SHANGHAI HENGRUI PHARM CO LTD (JSHR)   CAO Z,  FU Y,  HU Q,  TAO W,  ZHANG L,  SUN P	CN110305215-A  PETER C FRIDY: "A          robust pipeline for rapid production of versatile          nanobody repertoires", NATURE          METHODS,relevantClaims[1-37],relevantPassages[1253-1260]CN110305215-B            Peter C Fridy. A robust pipeline for rapid production of          versatile nanobody repertoires;Peter C Fridy;Nature          Methods;20141102;11(12);1253-1260	184611-0-0-0 M N; 93605-0-0-0 M N; 105730-0-0-0 M N; 184611-0-0-0 CL NEW USE; 93605-0-0-0 CL NEW USE; 105730-0-0-0 CL NEW USE	217150101 M N		RA00H1 M N; RA00NS M N; RA012P M N		WO2019042470-A1;  CN109422726-A;  CN109422726-B	Use of 1,4-dihydroquinoline-based compound in            pharmaceutical composition and for manufacturing            medicine for blocking interaction of signal regulatory            protein with cluster of differentiation 47 and            inhibiting tumors	LI H;  ZHU L;  XU Y;  ZHAO Z;  QUAN L;  WANG W;  WEN D;  LI W;  WANG Y	UNIV EAST CHINA SCI & TECHNOLOGY (UYEC-C);  UNIV EAST CHINA SCI & TECHNOLOGY (UYEC-C)	2019230095	   NOVELTY - Use of 1,4-dihydroquinoline-based compound (I)                or its salt, prodrug or solvate for manufacturing                medicament for blocking interaction of signal                regulatory protein (SIRP( alpha )) with cluster of                differentiation 47 (CD47), is claimed.    USE - Use of 1,4-dihydroquinoline-based compound in                pharmaceutical composition and for preparing                medicine for blocking interaction of sirp alpha                protein with CD47, inhibiting tumors, preferably                melanoma, lung cancer e.g. non-small cell lung                cancer, kidney cancer, ovarian cancer, prostate                cancer, breast cancer, colon cancer, bone cancer,                pancreatic cancer, skin cancer, head and neck                cancer, uterine cancer, rectal cancer, anal cancer,                stomach cancer, testicular cancer, fallopian tube                cancer, endometrial cancer, cervical cancer,                vaginal cancer, vulvar cancer, Hodgkin's disease,                non-Hodgkin's lymphoma, esophageal cancer, small                bowel cancer, endocrine system cancer, thyroid                cancer, parathyroid carcinoma, adrenal cancer, soft                tissue sarcoma, urethral cancer, penile cancer,                acute myeloid leukemia, chronic myeloid leukemia,                acute lymphocytic leukemia, chronic lymphocytic                leukemia, pediatric solid tumor, lymphocytic                lymphoma, bladder cancer, renal and ureteral                cancer, renal pelvic cancer, central nervous system                (CNS) tumor, primary CNS lymphoma, tumor                angiogenesis, spinal axis tumor, brain stem glioma,                pituitary adenoma, Kaposi's sarcoma, epidermoid                carcinoma, squamous cell carcinoma and T-cell                lymphoma, preventing and treating infections caused                by bacteria, e.g. Chlamydia, Rickettsia,                Mycobacterium, Staphylococcus, Pneumococci, Vibrio                cholerae and Clostridium tetanus, viruses such as                hepatitis viruses (types A, B and C), herpesvirus,                influenza virus, adenovirus, coronavirus, measles                virus, dengue virus, poliovirus, rabies virus and                fungus e.g. Candida, Aspergillus and dermatitis and                inflammatory diseases e.g. ankylosing spondylitis,                autoimmune hemolytic anemia, arthritis, myasthenia                gravis, systemic lupus erythematosus, rheumatoid                arthritis, xenograft immune rejection, pernicious                anemia, and polymyositis and disease mediated by                CD47/SIRP alpha interaction (all claimed).    DETAILED DESCRIPTION - Use of 1,4-dihydroquinoline-based compound of                formula (I) or its salt, prodrug or solvate for                manufacturing medicament for blocking interaction                of signal regulatory protein (SIRP( alpha )) with                cluster of differentiation 47 (CD47), is                claimed.    X = CH2, CHOH, C=O or C=S;    Y' = N or C;    R3 = absent when Y' is N;    R1 = H, halo, nitro, CN or 1-10F alkyl, 1-10C                alkoxy, 6-10C aryl or benzyl (all optionally                substituted);    R2 = H, 1-10C alkyl or cycloalkyl, halo, 1-10C                alkoxy, optionally substituted 6-10C aryl, NR'aR'b,                or group chosen from groups of formulae                (i)-(xiii);    R'a,R'b = H, or optionally substituted 1-6C                alkyl;    R-1+R2 = groups of formula (xiv);    n = 1-3;    R3 = H, halo, or 1-10C alkoxy or alkylthio                (both optionally substituted);    R4 = H, or 1-10C alkyl, 3-10C cycloalkyl,                6-10C aryl or benzyl (all optionally                substituted);    R3+R4 = 6-membered ring, or oxygen-containing                or sulfur-containing 6-membered heterocyclyl (both                optionally substituted);    R5 = H, halo, or optionally substituted 1-10C                alkyl;    R6 = H, R'c-COOH, R'c-COOR'd, R'c-CONR8R9, or                optionally substituted hydroxy-1-3C alkyl;    R'c = absent or optionally substituted                -(CH2)m-;    m = 1-3;    R'd = optionally substituted 1-3C alkyl;    R8,R9 = H, or 1-10C alkyl or 6-10C aryl (both                optionally substituted);and    R7 = H, halo, amino or optionally substituted                1-10C alkyl.    INDEPENDENT CLAIMS are included for the                following:    (1) 1,4-dihydroquinoline-based compound of                formula (II);    (2) pharmaceutical composition, which                comprises the compound (II); and    (3) method of blocking the binding of (SIRP(                alpha )) to CD47, which involves blocking the                binding of (SIRP( alpha )) to CD47using the                compound (I) or the pharmaceutical                composition.    R'1 = H, cyano, halo, preferably F or Cl, or                1-10C alkyl or 6-10C aryl (both optionally                substituted);    R'2 = optionally substituted phenyl, butyl,                morpholinyl, piperidinyl, piperazinyl or                NR''aR''b;    R''a,R''b = H, or optionally substituted 1-6C                6 alkyl;    R'4 = 3-8C, preferably cyclohexyl, 1-6C alkyl,                preferably butyl, -(CH2)o-optionally substituted                phenyl or group chosen from groups of formulae                (a)-(c);    o = 0-2;    R'6 = COOH, C(O)-O-1-4C alky, preferably                COOCH3 or COOCH2CH3, CONR8R9, CONHC6H5 or                CH2OH;    X' = CH2, CH2CH3, CHOH, C=O or C=S;and    R'8,R'9 = H, 1-10C alkyl or 6-10C aryl (both                optionally substituted), preferably phenyl. 			B02 (Fused ring heterocyclics.);  C02 (Heterocyclic.)	B06-D02;  B06-D06;  B14-A01;  B14-A02B;  B14-C03;  B14-C09;  B14-F03;  B14-G02C;  B14-G02D;  B14-H01;  B14-J05;  B14-N12;  B14-N17;  C06-D02;  C06-D06;  C14-A01;  C14-A02B;  C14-C03;  C14-C09;  C14-F03;  C14-G02C;  C14-G02D;  C14-H01;  C14-J05;  C14-N12;  C14-N17	A61P-031/00;  A61P-031/10;  A61P-035/00;  C07D-498/00;  A61K-031/4375;  A61K-031/47;  A61K-031/4709;  A61K-031/4741;  A61K-031/496;  A61K-031/5377;  A61K-031/5383;  A61K-031/55;  A61P-019/02;  A61P-021/04;  A61P-029/00;  A61P-031/04;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-031/20;  A61P-031/22;  A61P-035/02;  A61P-037/06;  A61P-007/06;  C07D-215/56;  C07D-401/04;  C07D-455/04;  C07D-471/04;  C07D-491/056;  C07D-498/06	WO2019042470-A1   07 Mar 2019   C07D-498/00   201922Pages: 51   Chinese;  CN109422726-A   05 Mar 2019   C07D-401/04   201922   Chinese;  CN109422726-B   28 Oct 2022   C07D-401/04   202289   Chinese	WO2019042470-A1    WOCN103974    04 Sep 2018;   CN109422726-A    CN10785796    04 Sep 2017;   CN109422726-B    CN10785796    04 Sep 2017	CN109422726-B Previous Publ. Patent CN109422726	CN10785796    04 Sep 2017	WO2019042470-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      		WO2019042470-A1 -- CN86103954-A   ;  CN109422726-A -- CN86103954-A   ;  CN106467541-A   UNIV JINAN SHANDONG (UNJN);  CHINESE ACAD SCI SHANGHAI MATERIA MEDIC (CAMM)   AI J,  DING J,  DING K,  GAO D,  GENG M,  LU X,  REN X,  TAN L,  TU Z,  ZHANG D,  ZHANG Z;  US4959363-A   STERLING DRUG INC (STER)   WENTLAND M P;  US20060142295-A1   ;  WO2014160183-A1   US DEPT HEALTH & HUMAN SERVICES (USSH)   ROBERTS D D,  SOTO PANTOJA D R;  CN109422726-B -- CN86103954-A   ;  CN106467541-A   UNIV JINAN SHANDONG (UNJN);  CHINESE ACAD SCI SHANGHAI MATERIA MEDIC (CAMM)   AI J,  DING J,  DING K,  GAO D,  GENG M,  LU X,  REN X,  TAN L,  TU Z,  ZHANG D,  ZHANG Z;  US4959363-A   STERLING DRUG INC (STER)   WENTLAND M P;  US20060142295-A1   ;  WO2014160183-A1   US DEPT HEALTH & HUMAN SERVICES (USSH)   ROBERTS D D,  SOTO PANTOJA D R	WO2019042470-A1  F. J.          MORALES-GUTIERREZ: "High-resolution Mass Spectrometry          Applied to the Identification of Transformation Products          of Quinolones from Stability Stu- dies and New          Metabolites of Enrofloxacin in Chicken Muscle Tissues",          JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol.          92, 24 January 2014 (2014-01-24), pages 165 - 176,          XP028620672, ISSN:          0731-7085,relevantClaims[8-9],relevantPassages[,];  DANIEL: "Synthesis          and Structure-Activity Relationships of Novel          Arylfluoroquinolone Antibacterial Agents", JOURNAL OF          MEDICINAL CHEMISTRY, vol. 28, no. 11, 1 November 1985          (1985-11-01), pages 1558 - 1564, XP001061840, ISSN:          0022-2623, DOI:          doi:10.1021/jm00149a003,relevantClaims[8-9],relevantPassages[,];  SHEU, JIAYUH ET AL:          "Synthesis and Antibacterial Activity of          1-(Substituted-ben- zyl)-6-fluoro-1,          4-dihydro-4-oxoquinoline-3-carboxylic Acids and their 6,          8- Difluoro Analogs", JOURNAL OF HETEROCYCLIC CHEMISTRY,          vol. 35, no. 4, 31 August 1998 (1998-08-31), pages 955 -          964, XP055579097, ISSN:          0022-152X,relevantClaims[8-9],relevantPassages[,]CN109422726-A  ACS:          "RN:888069-76-9 et al.", STN REGISTRY          ,relevantClaims[9],relevantPassages[2-3];  DANIEL T. W. CHU:          "Synthesis and structure-activity relationships of novel          arylfluoroquinolone antibacterial agents", JOURNAL OF          MEDICINAL          CHEMISTRY,relevantClaims[9],relevantPassages[1560 3,1561          4];  GEORG          HILTENSPERGER: "Synthesis and Structure-Activity          Relationships of New Quinolone-Type Molecules against          Trypanosoma brucei", J. MED.          CHEM.,relevantClaims[8],relevantPassages[2545];  JIA-YUH SHEU:          "Synthesis and antibacterial activity of          1-(substituted-benzyl)-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic          acids and their 6,8-difluoro analogs", JOURNAL OF          HETEROCYCLIC          CHEMISTRY,relevantClaims[8-9],relevantPassages[9582,960-961          3];  LINKE GE: "Aquatic          Photochemistry of Fluoroquinolone Antibiotics: Kinetics,          Pathways, and Multivariate Effects of Main Water          Constituents", ENVIRON. SCI.          TECHNOL.,relevantClaims[9],relevantPassages[2403          3]CN109422726-B            Georg Hiltensperger et al. Synthesis and          Structure-Activity Relationship of New Quinolone-Type          Molecules against Trypanosoma brucei, Georg Hiltensperger          and so on, " J. Med. Chem., 20120301; No. 55; page 2545;          left column;            Jia-Yuh Sheu and so on. Synthesis and activity of          activity of 1 - (ted-benzyl) -6-fluoro-1,          4-dihydro-4-oxoquinoline-3-carboxylic 8-difluoro and 6, ,          Jia-Yuh Sheu et al., Journal of Heterocyclic Chemistry,          19980831, No. 35, No. 958 page table 2, page 960-961 page          table 3;            Daniel T. W. Chu, et al. Synthesis and structure-activity          of novel arylfluoroquinolone; Daniel T. W. Chu et al.,          Journal of Medicinal Chemistry, 19851231, Voluan 28          (Phase 11), page 1560, page 3, page 1561, page          4,;            ACS. RN: 888069-76-9 et al, ACS; " STN Registry database          ", 20060618, 2-3;            Linke Ge and so on. Aquatic Photochemistry of          Fluoroquinolone Antibiotics: Kinetics, Pathways, and          Multi-Main Water, Linke Ge and so on; " Environ. Sci. No.          20100305; No. 44 (No. 7); No. 2403	93096-0-0-0 K U; 588223-1-0-0 K U; 91233-0-0-0 K U;  K U; 1196540-1-0-0 K U; 171256-1-0-0 K U; 87100-0-0-0 K U; 99570-0-0-0 K U; 159480-2-0-0 K U; 102303-0-0-0 K U; 106041-0-0-0 K U; 103004-0-0-0 K U;  K U; 107484-0-0-0 K U;  K U; 81119-0-0-0 K U; 95323-0-0-0 K U; 101567-0-0-0 K U; 28954-1-0-0 K U; 28954-0-0-0 K U; 108231-1-0-0 K U; 1526139-0-0-0 K U; 2541434-0-0-0 K U;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N; 1196540-1-0-0 CL USE; 1526139-0-0-0 CL USE; 2541434-0-0-0 CL USE	213601802 K U; 213601801 N	01279; 02809; 01683; 03493; 03279; 03425; 40059; 44093; 44284; 65268	R19472 K U; RA81DC K U; RA1YB4 K U; RCJUJF K U; RAKDIZ K U; RA81DD K U; RA0YXC K U; R11682 K U; R11683 K U; RAMT0L K U; R04550 K U; R20836 K U; R01980 K U; RCJUJG K U; R19726 K U; RC5XW3 K U; R01243 K U; R06710 K U; RA1IG6 K U; RA1IG3 K U; R04552 K U; R22800 K U; RAREI9 K U; RBCX6P K U; RCJUIT N; RCJUIU N; RCJUIV N; RCJUIW N; RCJUIX N; RCJUIY N; RCJUIZ N; RCJUJ0 N; RCJUJ1 N; RCJUJ2 N; RCJUJ3 N; RCJUJ4 N; RCJUJ5 N; RCJUJ6 N; RCJUJ7 N; RCJUJ8 N; RCJUJ9 N; RCJUJA N; RCJUJB N; RCJUJC N; RCJUJD N; RCJUJE N	1980-U; 1243-U	WO2019175436-A1;  EP3765454-A1;  US2021070737-A1;  EP3765454-B1;  US11814366-B2;  EP3765454-C0	New substituted 1H-pyrrole compounds used for            destabilizing viral envelope for treating viral disease            caused by enveloped virus e.g. HIV-1, Herpes 1 virus,            Herpes 2 virus, influenza virus, respiratory syncytial            virus and cytomegalovirus	BOTTA M;  CANDUCCI F;  CAGNO V;  LEMBO D;  TINTORI C;  BRAI A;  PALOMBI N	UNIV SIENA (UYSI-Non-standard);  UNIV SIENA (UYSI-Non-standard);  UNIV SIENA (UYSI-Non-standard);  UNIV SIENA (UYSI-Non-standard)	201980801R	   NOVELTY - Substituted 1H-pyrrole compounds (I) are                new.    USE - (I) are useful for destabilizing a viral                envelope for treating a viral disease caused by an                enveloped virus comprising HIV-1, Herpes 1 virus                (HSV-1), Herpes 2 virus (HSV-2), influenza virus                (H1N1), respiratory syncytial virus (RSV),                cytomegalovirus, Zika virus (ZKV), Dengue virus                (Dengue Virus Type 2), vesicular stomatitis virus                (all preferred), HIV-2, West Nile virus, Lassa                virus, Ebola virus, Lloviu virus, Bundibugyo virus,                Reston virus, Sudan virus, Tai Forest virus,                Marburg virus, Ravn virus, Pneumovirus, Junin                virus, Rift Valley fever virus, La Crosse virus,                porcine reproductive and respiratory syndrome                virus, Poxvirus, Bovine viral diarrhea norovirus,                severe acute respiratory syndrome coronavirus,                Chikunguya virus, hepatitis C virus, hepatitis B                virus, Schmallenberg virus, African swine fever                virus, Eastern Equine Encephalitis virus, Cowpox                virus, Western Equine Encephalitis virus, Nipah                virus, Omsk hemorrhagic fever virus, Venezuelan                Equine Encephalitis virus, human parainfluenza                viruses, Japanese Encephalitis virus, Tick Borne                Encephalitis virus, Russian spring-summer                encephalitis virus, Yellow Fever virus, Newcastle                virus, bovine viral diarrhea virus, parainfluenza                virus type 5, border disease virus of sheep,                classical swine fever virus or HSV-2 acyclovir                resistant (all claimed). The ability of (I) to                treat HIV-1 was tested against HIV strain AD8 using                in vivo assay. The result showed that                4-(5-(4,6-dioxo-2-thioxo-tetrahydro-pyrimidin-5-ylidenemethyl)-1H-pyrrol-2-yl)-2-hydroxy-benzoic                acid exhibited an EC50 value of 76 nM.    ADVANTAGE - (I) exhibit increased bioavailability and act                as broad spectrum antiviral agent.    DETAILED DESCRIPTION - Substituted 1H-pyrrole compounds of formula                (I) and their salts, solvates or stereoisomers are                new.    Y1, Z1 = C or N, when Y1 is N, R1 is a lone                pair and when Z1 is N, R4 is a lone pair;    R1-R7 = 1-6C alkyl, 2-6C alkenyl, 2-6C                alkynyl, aryl, heteroaryl (all optionally                unsubstituted by at least one halo, OR1A, COOR1B,                OC(=O)R1B, NR1AR1B, OP(=O)(OR1A)2, OC(=O)NR1AR1B,                NHC(=O)OR1A, NHC(=O)R1A, CONR1AR1B or optionally                substituted phenyl), H, halo, alkoxy, OR1A, SR1A,                S(=O)(=O)-R1A, SO2NHR1A, COOR1B, OC(=O)R1B,                NR1AR1B, OP(O)(OR1A)2, NHC(O)R1A, CONR1AR1B, NO2,                CN or 2H-tetrazol-5-yl;    A1 = heterocyclyl moiety of formula                (x1);    X1 = -C(=O)-N(K1)- or S;    R8 = 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl,                aryl (all optionally substituted by at least one                halo, OR1A, COOR1B, OC(=O)R1B, NR1AR1B,                OP(=O)(OR1A)2, OC(=O)NR1AR1B, NHC(=O)OR1A,                NHC(=O)R1A, CONR1AR1B or optionally substituted                phenyl) or H; either    R1A, R1B = H, 1-6C alkyl, haloalkyl or                optionally substituted aralkyl; or    R1AR1B (when together with N, S or O) = 4-7                membered saturated or partially unsaturated ring                optionally containing at least one additional N, S                or O (optionally substituted by at least one halo,                1-6C alkyl, haloalkyl, OH or alkoxy); and    B1, K1 = 1-10C alkyl, phenyl (both optionally                substituted by at least one halo, 3-10C cycloalkyl,                3-10C heterocycloalkyl, OR1A, COOR1B, OC(=O)R1B,                NR1AR1B, OP(=O)(OR1A)2, OC(=O)NR1AR1B, NHC(=O)OR1A,                NHC(=O)R1A, COONR1AR1B, or optionally substituted                phenyl or heteroaryl), H, 2-10C alkenyl or 2-10C                alkynyl.    Provided that: (I) are not                1-allyl-5-(1-(3,5-diphenyl-1H-pyrrol-2-yl)-meth-(E)-ylidene)-2-thioxo-dihydro-pyrimidine-4,6-dione,                1-(4-chloro-phenyl)-5-(1-(3,5-diphenyl-1H-pyrrol-2-yl)-meth-(Z)-ylidene)-2-thioxo-dihydro-pyrimidine-4,6-dione,                5-(1-(3,5-diphenyl-1H-pyrrol-2-yl)-meth-(Z)-ylidene)-1-(4-phenoxy-phenyl)-2-thioxo-dihydro-pyrimidine-4,6-dione,                5-(1-(5-phenyl-1H-pyrrol-2-yl)-meth-(Z)-ylidene)-2-thioxo-thiazolidin-4-one,                4-(5-(1-(3,5-diphenyl-1H-pyrrol-2-yl)-meth-(Z)-ylidene)-4-oxo-2-thioxo-thiazolidin-3-yl)-butyric                acid,                2-chloro-5-(5-(4-oxo-2-thioxo-3-(3-trifluoromethyl-phenyl)-thiazolidin-(5Z)-ylidenemethyl)-1H-pyrrol-2-yl)-benzoic                acid,                2-fluoro-3-(5-(4-oxo-2-thioxo-3-(3-trifluoromethyl-phenyl)-thiazolidin-(5Z)-ylidenemethyl)-1H-pyrrol-2-yl)-benzoic                acid,                2-fluoro-5-(5-(4-oxo-2-thioxo-3-(3-trifluoromethyl-phenyl)-thiazolidin-(5Z)-ylidenemethyl)-1H-pyrrol-2-yl)-benzoic                acid,                2-methoxy-3-(5-(4-oxo-2-thioxo-3-(3-trifluoromethyl-phenyl)-thiazolidin-(5Z)-ylidenemethyl)-1H-pyrrol-2-yl)-benzoic                acid and                3-(5-(4-oxo-2-thioxo-3-(3-trifluoromethyl-phenyl)-thiazolidin-(5Z)-ylidenemethyl)-1H-pyrrol-2-yl)-benzoic                acid; and when A1 is substituted                4-oxo-2-thioxo-oxazolidin-(5E)-ylidenemethyl of                formula (x2), B1 is not norbornane or adamantane.                An INDEPENDENT CLAIM is also included for a                composition comprising at least one compound (I)                and at least one excipient and/or diluent. 			B03 (Other heterocyclics.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C02 (Heterocyclic.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.)	B04-A01;  B04-B03D;  B04-B03E;  B04-H05A;  B05-B01E;  B05-B01M;  B06-H;  B07-D02;  B07-H;  B09-B;  B10-B02F;  B12-M12B;  B14-A02;  B14-A02B1;  B14-A02X;  B14-C03;  B14-C04;  B14-D06A;  B14-D06B;  B14-D07C;  B14-K01D;  B14-S18;  C04-A01;  C04-B03D;  C04-B03E;  C04-H05A;  C05-B01E;  C05-B01M;  C06-H;  C07-D02;  C07-H;  C09-B;  C10-B02F;  C12-M12B;  C14-A02;  C14-A02B1;  C14-A02X;  C14-C03;  C14-C04;  C14-D06A;  C14-D06B;  C14-D07C;  C14-K01D;  C14-S18	A61K-031/427;  A61K-031/515;  A61P-031/12;  C07D-403/06;  C07D-417/06;  A61K-031/513;  A61K-045/06;  A61P-031/14;  A61P-031/16;  A61P-031/18;  A61P-031/22	WO2019175436-A1   19 Sep 2019   C07D-403/06   201975Pages: 84   English;  EP3765454-A1   20 Jan 2021   C07D-403/06   202108   English;  US2021070737-A1   11 Mar 2021   C07D-403/06   202125   English;  EP3765454-B1   08 Nov 2023   C07D-403/06   202390   English;  US11814366-B2   14 Nov 2023   C07D-403/06   202393   English;  EP3765454-C0   08 Nov 2023   C07D-403/06   202407   English	WO2019175436-A1    WOEP056717    18 Mar 2019;   EP3765454-A1    EP711363    18 Mar 2019;   US2021070737-A1    US16981346    16 Sep 2020;   EP3765454-B1    EP711363    18 Mar 2019;   US11814366-B2    US16981346    16 Sep 2020;   EP3765454-C0    EP711363    18 Mar 2019	EP3765454-A1 PCT application Application WOEP056717;   EP3765454-A1 Based on Patent WO2019175436;   US2021070737-A1 PCT application Application WOEP056717;   EP3765454-B1 PCT application Application WOEP056717;   EP3765454-B1 Based on Patent WO2019175436;   US11814366-B2 PCT application Application WOEP056717;   US11814366-B2 Previous Publ. Patent US2021070737;   US11814366-B2 Based on Patent WO2019175436;   EP3765454-C0 PCT application Application WOEP056717;   EP3765454-C0 Based on Patent WO2019175436	IT00003680    16 Mar 2018	WO2019175436-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP3765454-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    EP3765454-B1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR    EP3765454-C0:      (Regional): AT;  BE;  BG;  DE;  DK;  EE;  FI;  FR;  IT;  LT;  LU;  LV;  MT;  NL;  PT;  SE;  SI  		WO2019175436-A1 -- US3917645-A   PFIZER INC (PFIZ);  WO2003074497-A1   PINTEX PHARM INC (PINT-Non-standard)   MCKEE T D,  SUTO R K,  TIBBITTS T,  SOWADSKI J;  WO2004028535-A1   PINTEX PHARM INC (PINT-Non-standard)   MCKEE T D,  SUTO R K,  TIBBITTS T,  SOWADSKI J;  WO2004093803-A2   PINTEX PHARM INC (PINT-Non-standard)   BAO L,  KIMZEY A;  WO2011160024-A2   UAB RES FOUND (UABR);  FUZIANS BIOMEDICALS INC (FUZI-Non-standard)   LUO M,  WANG G,  YANG Z;  US2021070737-A1 -- US20050049267-A1   ;  EP3765454-B1 -- WO2003074497-A1   PINTEX PHARM INC (PINT-Non-standard)   MCKEE T D,  SUTO R K,  TIBBITTS T,  SOWADSKI J;  WO2011160024-A3   UAB RES FOUND (UABR);  FUZIANS BIOMEDICALS INC (FUZI-Non-standard)   LUO M,  WANG G,  YANG Z;  US11814366-B2 -- US20050049267-A1   ;  US3917645-A   PFIZER INC (PFIZ);  WO2003074497-A1   PINTEX PHARM INC (PINT-Non-standard)   MCKEE T D,  SUTO R K,  TIBBITTS T,  SOWADSKI J;  WO2004028535-A1   PINTEX PHARM INC (PINT-Non-standard)   MCKEE T D,  SUTO R K,  TIBBITTS T,  SOWADSKI J;  WO2004093803-A2   PINTEX PHARM INC (PINT-Non-standard)   BAO L,  KIMZEY A;  WO2011160024-A2   UAB RES FOUND (UABR);  FUZIANS BIOMEDICALS INC (FUZI-Non-standard)   LUO M,  WANG G,  YANG Z	WO2019175436-A1  DATABASE CA          [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;          2003, MCKEE, TIMOTHY D. ET AL: "Pin1-modulating compounds          and methods of use thereof", XP002790749, retrieved from          STN Database accession no.          2003:719458,relevantClaims[1-20],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  DATABASE CA          [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;          1974, ALTHUIS, THOMAS H.:          "2-(Methylthio)-3-(2-pyrrolyl)acrylates", XP002790750,          retrieved from STN Database accession no.          1974:551989,relevantClaims[1-20],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  DATABASE CA          [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;          2004, MCKEE, TIMOTHY D. ET AL: "Pin1-modulating compounds          and methods of use for the treatment of Pin1-associated          diseases, including cancer", XP002790751, retrieved from          STN Database accession no.          2004:291950,relevantClaims[1-20],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  DATABASE CA          [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;          2004, BAO, LERE ET AL: "Pin1-modulating compounds and          methods of use for the treatment of Pin1-associated          diseases, including cancer", XP002790752, retrieved from          STN Database accession no.          2004:927010,relevantClaims[1-20],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  DATABASE CA          [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;          2010, JIANG, SHIBO ET AL: "Design, synthesis, and          biological activity of novel          5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-          (trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1          fusion inhibitors targeting gp41", XP002790753, retrieved          from STN Database accession no.          2010:1633976,relevantClaims[1-20],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];            SANDRA T. COOPER; PAUL L. MCNEIL, MEMBRANE REPAIR:          MECHANISMS AND PATHOPHYSIOLOGY PHYSIOL REV., vol. 95, no.          4, October 2015 (2015-10-01), pages 1205 - 1240;            HOLLMANN, A.; CASTANHO, M. A. R. B.; LEE, B.; SANTOS, N.          C.: "Singlet Oxygen Effects on Lipid Membranes:          Implications for the Mechanism of Action of          Broad-Spectrum Viral Fusion Inhibitors", BIOCHEM. J.,          vol. 459, no. 1, 2014, pages 161 - 170;            CAGNO, V.; TINTORI, C.; CIVRA, A.; CAVALLI, R.; TIBERI,          M.; BOTTA, L.; BRAI, A.; POLI, G.; TAPPAREL, C.; LEMBO,          D. ET AL., NOVEL BROAD SPECTRUM VIRUCIDAL MOLECULES          AGAINST ENVELOPED VIRUSES, 2018;            BERGE S. M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages          1 - 19;            GOULD P. L., INT. J. PHARM, vol. 33, 1986, pages 201 -          217;            BIGHLEY ET AL.: "Encyclopedia of Pharmaceutical          Technology", vol. 13, 1996, MARCEL DEKKER INC, pages: 453          - 497;            REMINGTON: "The Science and Practice of Pharmacy", 2000,          LIPPINCOTT WILLIAMS & WILKINS;            DRUG OF TODAY, vol. 19, no. 9, 1983, pages 499 -          538;            "Topics in Chemistry", pages: 306 - 316;  H.          BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER;            REMINGTON: "Remington ''The Science and Practice of          Pharmacy", 2000, LIPPINCOTT WILLIAMS &          WILKINS;            DONALISIO M; NANA HM; NGANE RAN; GATSING D; TCHINDA AT;          ROVITO R ET AL.: "In vitro anti-Herpes simplex virus          activity of crude extract of the roots of Nauclea          latifolia Smith (Rubiaceae", BMC COMPLEMENT ALTERN MED.,          vol. 13, 2013, pages 266, XP021163987, Retrieved from the          Internet          &lt;URL:https://doi.org/10.1186/1472-6882-13-266&gt;          DOI: doi:10.1186/1472-6882-13-266;  V.          CAGNO ET AL.: "In vitro evaluation of the antiviral          properties of Shilajit and investigation of its          mechanisms of action", J ETHNOPHARMACOL., vol. 166, 2015,          pages 129 - 134;  V.          CAGNO ET AL.: "The agmatine-containing poly(amidoamine)          polymer AGMA1 binds cell surface heparan sulfates and          prevents attachment of mucosal human papillomaviruses",          ANTIMICROB. AGENTS CHEMOTHER., vol. 59, 2015, pages 5250          - 5259;            BOON-HUAT BAY; YUAN-KUN LEE; BENNY KWONG-HUAT TAN;          ENG-ANG LING: "Lipid peroxidative stress and          antioxidative enzymes in brains of milk-supplemented          rats", NEUROSCIENCE LETTERS, vol. 277, 1999, pages 127 -          130;            TINTORI C; CORRADI V; MAGNANI M; MANETTI F; BOTTA M:          "Targets looking for drugs: a multistep computational          protocol for the development of structure-based          pharmacophores and their applications for hit discovery",          J CHEMLNF MODEL., vol. 48, no. 11, November 2008          (2008-11-01), pages 2166 - 79, XP055032344, DOI:          doi:10.1021/ci800105p;            RINALDI M; TINTORI C; FRANCHI L; VIGNAROLI G; INNITZER A;          MASSA S; ESTE JA; GONZALO E; CHRIST F; DEBYSER Z: "A          versatile and practical synthesis toward the development          of novel HIV-1 integrase inhibitors", CHEMMEDCHEM., vol.          6, no. 2, 7 February 2011 (2011-02-07), pages 343 -          52;            TIBERI M; TINTORI C; CERESOLA ER; FAZI R; ZAMPERINI C;          CALANDRO P; FRANCHI L; SELVARAJ M; BOTTA L; SAMPAOLO M:          "2-Aminothiazolones as anti-HIV agents that act as          gp120-CD4 inhibitors", ANTIMICROB AGENTS CHEMOTHER., vol.          58, no. 6, June 2014 (2014-06-01), pages 3043 -          52;            ANTHONY, S. J. ET AL.: "A Strategy To Estimate Unknown          Viral Diversity in Mammals", MBIO 4, 2013, pages e00598 -          13;            AROURI, A.; MOURITSEN, O. G.: "Membrane-perturbing effect          of fatty acids and lysolipids", PROG. LIPID RES., vol.          52, 2013, pages 130 - 140;            POLLOCK, S. ET AL.: "Polyunsaturated liposomes are          antiviral against hepatitis B and C viruses and HIV by          decreasing cholesterol levels in infected cells", PROC.          NATL. ACAD. SCI. U.S.A., vol. 107, 2010, pages 17176 -          17181;            SAMPLE, C. J. ET AL.: "A mastoparan-derived peptide has          broad-spectrum antiviral activity against enveloped          viruses", PEPTIDES, vol. 48, 2013, pages 96 - 105,          XP028729574, DOI:          doi:10.1016/j.peptides.2013.07.014;  M.          DONALISIO ET AL.: "The AGMA1 poly(amidoamine) inhibits          the infectivity of herpes simplex virus in cell lines, in          human cervicovaginal histocultures, and in vaginally          infected mice", BIOMATERIALS, vol. 85, 2016, pages 40 -          53, XP029423184, DOI:          doi:10.1016/j.biomaterials.2016.01.055;  V.          CAGNO ET AL.: "Highly sulfated K5 Escherichia coli          polysaccharide derivatives inhibit respiratory syncytial          virus infectivity in cell lines and human          tracheal-bronchial histocultures", ANTIMICROB. AGENTS          CHEMOTHER., vol. 58, 2014, pages 4782 - 4794;  A.          CIVRA ET AL.: "Identification of Equine          Lactadherin-derived Peptides That Inhibit Rotavirus          Infection via Integrin Receptor Competition", J. BIOL.          CHEM., vol. 290, 2015, pages 12403 - 12414;  S.          PFAENDER ET AL.: "Inactivation of Zika virus in human          breast milk by prolonged storage or pasteurization",          VIRUS RESEARCH., vol. 228, 2017, pages 58 - 60;            BOON-HUAT BAY; YUAN-KUN LEE; BENNY KWONG-HUAT TAN:          "Eng-Ang Ling, Lipid peroxidative stress and          antioxidative enzymes in brains of milk-supplemented          rats", NEUROSCIENCE LETTERS, vol. 277, 1999, pages 127 -          130EP3765454-B1            Sandra T. Cooper and Paul L. McNeil Membrane Repair:          Mechanisms and Pathophysiology Physiol Rev. 2015 Oct;          95(4): 1205-1240;            Hollmann, A.; Castanho, M. A. R. B.; Lee, B.; Santos, N.          C. Singlet Oxygen Effects on Lipid Membranes:          Implications for the Mechanism of Action of          Broad-Spectrum Viral Fusion Inhibitors. Biochem. J. 2014,          459 (1), 161-170;            Cagno, V.; Tintori, C.; Civra, A.; Cavalli, R.; Tiberi,          M.; Botta, L.; Brai, A.; Poli, G.; Tapparel, C.; Lembo,          D.; et al. Novel Broad Spectrum Virucidal Molecules          against Enveloped Viruses. 2018;            Berge S. M. et al., J. Pharm. Sci. 1977, 66,          1-19;            Gould P. L. Int. J. Pharm 1986, 33, 201-217;            Bighley et al. Encyclopedia of Pharmaceutical Technology,          Marcel Dekker Inc, New York 1996, Volume 13, page          453-497;            Remington "The Science and Practice of Pharmacy",          Lippincott Williams & Wilkins, 2000;            Drug of Today, Volume 19, Number 9, 1983, pp          499-538;            Topics in Chemistry, Chapter 31, pp 306-316;            Design of Prodrugs" by H. Bundgaard, Elsevier, 1985,          Chapter 1;            Remington Remington "The Science and Practice of          Pharmacy", Lippincott Williams & Wilkins,          2000;            Donalisio M, Nana HM, Ngane RAN, Gatsing D, Tchinda AT,          Rovito R, et al. In vitro anti-Herpes simplex virus          activity of crude extract of the roots of Nauclea          latifolia Smith (Rubiaceae). BMC Complement Altern Med.          2013; 13:266. https://doi.org/10.1186/1472-6882-13-266          PMID: 2413191618;  V.          Cagno et al., In vitro evaluation of the antiviral          properties of Shilajit and investigation of its          mechanisms of action. J Ethnopharmacol. 166, 129-134          (2015;  V.          Cagno et al., The agmatine-containing poly(amidoamine)          polymer AGMA1 binds cell surface heparan sulfates and          prevents attachment of mucosal human papillomaviruses.          Antimicrob. Agents Chemother. 59, 5250-5259          (2015;            Neuroscience Letters 277 (1999) 127-130;            Tintori C, Corradi V, Magnani M, Manetti F, Botta M.          Targets looking for drugs: a multistep computational          protocol for the development of structure-based          pharmacophores and their applications for hit discovery.          J Chemlnf Model. 2008 Nov;48(11):2166-79;            Rinaldi M, Tintori C, Franchi L, Vignaroli G, Innitzer A,          Massa S, Este JA, Gonzalo E, Christ F, Debyser Z, Botta          M. A versatile and practical synthesis toward the          development of novel HIV-1 integrase          inhibitors.ChemMedChem. 2011 Feb 7;6(2):343-52;            Tiberi M, Tintori C, Ceresola ER, Fazi R, Zamperini C,          Calandro P, Franchi L, Selvaraj M, Botta L, Sampaolo M,          Saita D, Ferrarese R, Clementi M, Canducci F, Botta M.          2-Aminothiazolones as anti-HIV agents that act as          gp120-CD4 inhibitors. Antimicrob Agents Chemother. 2014          Jun;58(6):3043-52;            Anthony, S. J. et al. A Strategy To Estimate Unknown          Viral Diversity in Mammals. mBio 4, e00598-13          (2013;            Arouri, A. & Mouritsen, O. G. Membrane-perturbing          effect of fatty acids and lysolipids. Prog. Lipid Res.          52, 130-140 (2013;            Pollock, S. et al. Polyunsaturated liposomes are          antiviral against hepatitis B and C viruses and HIV by          decreasing cholesterol levels in infected cells. Proc.          Natl. Acad. Sci. U.S.A. 107, 17176-17181 (2010;            Sample, C. J. et al. A mastoparan-derived peptide has          broad-spectrum antiviral activity against enveloped          viruses. Peptides 48, 96-105 (2013;  M.          Donalisio et al., The AGMA1 poly(amidoamine) inhibits the          infectivity of herpes simplex virus in cell lines, in          human cervicovaginal histocultures, and in vaginally          infected mice. Biomaterials. 85, 40-53 (2016;  V.          Cagno et al., Highly sulfated K5 Escherichia coli          polysaccharide derivatives inhibit respiratory syncytial          virus infectivity in cell lines and human          tracheal-bronchial histocultures. Antimicrob. Agents          Chemother. 58, 4782-4794 (2014;  A.          Civra et al., Identification of Equine          Lactadherin-derived Peptides That Inhibit Rotavirus          Infection via Integrin Receptor Competition. J. Biol.          Chem. 290, 12403-12414 (2015;  S.          Pfaender et al., Inactivation of Zika virus in human          breast milk by prolonged storage or pasteurization. Virus          Research. 228, 58-60 (2017;            Boon-Huat Bay, Yuan-Kun Lee, Benny Kwong-Huat Tan,          Eng-Ang Ling, Lipid peroxidative stress and antioxidative          enzymes in brains of milk-supplemented rats, Neuroscience          Letters 277 (1999) 127-130US11814366-B2            McKee et al., Pin1-modulating compounds and methods of          use thereof, Chemical Abstracts Service, XP002790749,          2003, Database accession No. 2003:719458, pp.          1-2.;            Althuis et al., 2-(Methylthio)-3-(2-pyrrolyl)acrylates,          Chemical Abstracts Service, XP002790750, 1974, Database          accession No. 1974:551989, pp. 1-2.;            McKee et al., Pin1-modulating compounds and methods of          use for the treatment of Pin1-associated diseases,          including cancer Chemical Abstracts Service, XP002790751,          2004, Database accession No. 2004:291950, pp.          1-2.;            Bao et al., Pin1-modulating compounds and methods of use          for the treatment of Pin1-associated diseases, including          cancer, Chemical Abstracts Service, XP002790752, 2004,          Database accession No. 2004:927010, pp. 1-2.;            Jiang et al., Design, synthesis, and biological activity          of novel          5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones          as HIV-1 fusion inhibitors targeting gp41, Chemical          Abstracts Service, XP002790753, 2010, Database accession          No. 2010:1633976, pp. 1-4.;            International Search Report and Written Opinion for          International Application No. PCT/EP2019/056717, (17          Pages) (dated May 21, 2019).	97855-0-0-0 K M;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N; 86437-0-0-0 K M; 105621-1-0-0 K M; 496893-1-0-0 K M; 89216-1-0-0 K M; 94878-0-0-0 K M; 89253-0-0-0 K M; 95875-0-0-0 K M; 87119-0-0-0 K M; 105670-1-0-0 K M; 160569-1-0-0 K M; 111368-1-0-0 K M; 8823-1-0-0 K M; 92990-1-0-0 K M; 88470-1-0-0 K M; 95660-1-0-0 K M; 93037-1-0-0 K M; 120177-1-0-0 K M; 101892-0-0-0 K M; 288707-0-0-0 K M; 687706-0-0-0 K M; 161137-1-0-0 K M; 1320477-0-0-0 K M; 2241465-1-0-0 K M; 1196540-1-0-0 K M; 833290-2-0-0 K M; 538791-1-0-0 K M; 2246321-1-0-0 K M; 2413902-1-0-0 K M; 2611702-1-0-0 K M; 2013118-0-0-0 K M; 1883980-3-0-0 K M; 111889-1-0-0 K M; 1704576-3-0-0 K M; 1320477-0-0-0 CL USE; 2241465-1-0-0 CL USE; 1196540-1-0-0 CL USE; 2246321-1-0-0 CL USE; 2413902-1-0-0 CL USE; 2611702-1-0-0 CL USE; 2013118-0-0-0 CL USE; 1883980-3-0-0 CL USE; 1704576-3-0-0 CL USE	216525501 M N; 216525502 M N	00061; 03624; 00096; 00133; 67767; 00085; 00690; 00993; 71558; 00691; 00994	RA02SP K M; RCNQAV M N; RCNQAW M N; RCNQAX M N; RCNQAY M N; RCNQAZ M N; RCNQB0 M N; RCNQB1 M N; RCNQB2 M N; RCNQB3 M N; RCNQB4 M N; RCNQB5 M N; RCNQB6 M N; RCNQB7 M N; RCNQB8 M N; RCNQB9 M N; RCNQBA M N; RCNQBB M N; RCNQBC M N; RCNQBD M N; RCNQBE M N; RCNQBF M N; RCNQBG M N; RCNQBH M N; RCNQBI M N; R04178 K M; RA04GU K M; R04428 K M; RA6558 K M; RAUQ1X K M; R04821 K M; RA061M K M; R21048 K M; R06407 K M; R01452 K M; R07589 K M; RA01FU K M; RA36PU K M; R04437 K M; R07682 K M; R04625 K M; RA0AI9 K M; RA1HN4 K M; R11606 K M; RA0AIJ K M; RA0F4H K M; RA1UDN K M; RAA0EL K M; RA0Z3O K M; RAN0P1 K M; RBARPZ K M; RAKDIZ K M; RACU4Q K M; RAQ7CV K M; RA70NZ K M; RB6N5A K M; RBA78U K M; RBELH8 K M; RB1PTD K M; RB8E3N K M; RA08UL K M; RB0ACK K M	1452-S	US2019298752-A1;  WO2019191026-A2;  WO2019191026-A3;  EP3773604-A2;  US10946034-B2;  JP2021519315-W;  HK40041244-A0;  JP7242696-B2;  EP3773604-B1;  JP2023071933-A;  EP4226971-A1;  HK40041244-A1;  ES2949441-T3	Treating, managing or preventing an RNA            virus-related disease or condition caused by RNA virus            e.g. Coronaviridae family virus and Pneumoviridae            family virus comprises administering 5'-adenosine            diphosphate ribose	SHALWITZ R;  RUEHLMANN A K	INVIRSA INC (INVI-Non-standard);  INVIRSA INC (INVI-Non-standard);  INVIRSA INC (INVI-Non-standard);  INVIRSA INC (INVI-Non-standard)	201983243G	   NOVELTY - Treating, managing or preventing an RNA                virus-related disease or condition in a patient,                comprises administering 5'-adenosine diphosphate                ribose (ADPR) or their salts, solvates, hydrates,                tautomers, stereoisomers, isotopologues or                polymorphs, where the patient has or is at risk of                developing an RNA virus-related disease or                condition.    USE - The methods are useful for: treating, managing                or preventing an RNA virus-related disease or                condition in a patient, where the RNA virus-related                disease or condition is caused by an RNA virus, and                the RNA virus is a Coronaviridae family virus, a                Pneumoviridae family virus, a Paramyxoviridae                family virus, a Picornaviridae family virus or an                Orthomyxoviridae family virus, the Coronaviridae                family virus is Coronavirus or severe acute                respiratory syndrome (SARS), the Pneumoviridae                family virus is human respiratory syncytial virus                (HRSV), the Paramyxoviridae family virus is human                parainfluenza virus, measles virus or mumps virus,                the Picornaviridae family virus is rhinovirus and                the Orthomyxoviridae family virus is influenza                virus, preferably the RNA virus is a Pneumoviridae                family virus or HRSV, the RNA virus-related disease                or condition is epi-bulbar disease, conjunctivitis,                keratitis, kerato-conjunctivitis, corneal abrasion,                ulcerative infectious keratitis, epithelial                keratitis, stromal keratitis, uveitis, acute                glaucoma, blepharitis, otitis media, otitis                externa, gingivitis, mucositis, pharyngitis,                tonsillitis, rhinitis, sinusitis, laryngitis,                croup, tracheitis, bronchitis, bronchiolitis,                bronchiolar pneumonia, pneumonia, exacerbation of                asthma, exacerbation of chronic obstructive                pulmonary disease, exacerbation of emphysema, or                exacerbation of a chronic lung disease; treating,                managing or preventing a disease or condition                associated with Sirt6 deficiency in a patient,                where the disease or condition is a viral disease,                disease due to aging, diabetes mellitus, type 2                diabetes mellitus, respiratory disorder, chronic                lung disease, chronic obstructive pulmonary                disease, asthma, idiopathic pulmonary fibrosis,                cystic fibrosis, ocular disorder, diabetic                retinopathy, retinal disease, retinal detachment,                adult macular degeneration, glaucoma, liver                disease, non-alcoholic steatohepatitis, chronic                hepatitis infection, neurodegenerative disorder                (e.g. Alzheimer's disease), disorder resulting in                cognitive decline, trauma resulting in brain or                spinal cord injury, cancer, chemotherapy-induced                neuropathy, neuropathy associated with an ischemic                or traumatic event, an autoimmune disorder,                disorder associated with excessive inflammation,                dental pulpitis, mitochondrial disease or disorder,                cardiovascular disease, stroke, disorder associated                with stress, arthritis, osteoarthritis, preterm                labor, disorder that would benefit from decreased                cellular glycolytic activity, muscle tissue damage                associated with hypoxia or ischemia, blood                coagulation disorder, fungal infection, ischemia,                chronic pain associated with brain and/or spinal                cord disease and/or hypertension; treating,                managing, or preventing a herpes virus-related                disease or condition in a patient, where the herpes                virus-related disease or condition is caused by a                herpes virus comprising herpes simplex virus 1                (HSV1) or herpes simplex virus 2 (HSV2); treating,                managing or preventing a disease or condition                associated with Pax6 deficiency in a patient, where                the disease or condition is aniridia, aniridia                related eye disease, aniridia related keratopathy,                keratoconus, uveitis, diabetic retinopathy, retinal                disease, retinal detachment, acute retinal                necrosis, Gillespie syndrome, Peters anomaly, WAGR                syndrome, dry eye, presbyopia, myopia, glaucoma,                congenital glaucoma, cataracts, corneal injury or                infection, keratitis, keratoconjunctivitis, adult                macular degeneration, diabetic retinopathy,                post-operative recovery from eye or brain surgery,                limbal stem cell deficiency, diabetes mellitus,                type 2 diabetes mellitus, neurodegenerative disease                (e.g. Alzheimer's disease, Parkinson's disease, and                others), disorder resulting in cognitive decline,                cerebellar ataxia, reduced olfaction, nystagmus,                impaired auditory processing, impaired memory,                autism, mental retardation, trauma resulting in                brain or spinal cord injury and/or stroke;                increasing the concentration of p53 by inhibiting                MDM2 in a patient; treating, managing, or                preventing a disease or condition associated with                p53 deficiency in a patient, where the disease or                condition e.g. viral disease, disease due to aging,                liver disease, cancer, autoimmune disorder,                arthritis, osteoarthritis (all claimed). Test                details are described but no results given.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) treating, managing or preventing a disease                or condition associated with Sirt6 deficiency in a                patient, comprising administering the ADPR, where                the patient has or is at risk of developing a                disease or condition associated with Sirt6                deficiency;    (2) treating, managing or preventing a herpes                virus-related disease or condition in a patient                comprising administering the ADPR, where the                patient has or is at risk of developing a herpes                virus-related disease or condition;    (3) treating, managing or preventing a disease                or condition associated with Pax6 deficiency in a                patient, comprising administering ADPR, where the                patient has or is at risk of developing a disease                or condition associated with Pax6 deficiency;    (4) increasing the concentration of p53 by                inhibiting MDM2 in a patient, comprising                administering the ADPR; and    (5) treating, managing or preventing a disease                or condition associated with p53 deficiency in a                patient, comprising administering the ADPR, where                the patient has or is at risk of developing a                disease or condition associated with p53                deficiency. 			B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B02 (Fused ring heterocyclics.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.)	B04-B03B;  B14-A02;  B14-A04;  B14-C01;  B14-C03;  B14-C09;  B14-F01;  B14-F02;  B14-F04;  B14-G01;  B14-G02D;  B14-H01E5;  B14-J01;  B14-J05;  B14-K01;  B14-N02;  B14-N03;  B14-N04;  B14-N05B;  B14-N06;  B14-N12;  B14-N16;  B14-N17;  B14-S04A;  B14-S16	A61K-031/7056;  A61K-031/7076;  A61K-047/02;  A61K-009/00;  A61P-011/00;  A61P-031/14;  A61P-031/22;  A61P-031/12;  A01N-043/04;  A61K-031/70;  A61K-045/00;  A61P-001/02;  A61P-001/16;  A61P-019/02;  A61P-021/00;  A61P-025/00;  A61P-025/28;  A61P-027/02;  A61P-029/00;  A61P-003/10;  A61P-035/00;  A61P-043/00;  A61P-009/00;  A61K-009/08;  A61K-009/10;  A61K-009/12;  A61K-009/20;  A61K-009/70;  A61K-009/72;  A61P-001/04;  A61P-011/02;  A61P-011/04;  A61P-011/06;  A61P-027/06;  A61P-027/16;  A61P-001/00;  A61P-025/16	US2019298752-A1   03 Oct 2019   A61K-031/7076   201980Pages: 37   English;  WO2019191026-A2   03 Oct 2019   A61K-031/7076   201981   English;  WO2019191026-A3   05 Dec 2019   A61K-031/7076   201995   English;  EP3773604-A2   17 Feb 2021   A61K-031/7076   202116   English;  US10946034-B2   16 Mar 2021   A01N-043/04   202124   English;  JP2021519315-W   10 Aug 2021   A61K-031/7076   202165Pages: 51   Japanese;  HK40041244-A0   13 Aug 2021   A61K-031/7076   202303   English;  JP7242696-B2   20 Mar 2023   A61K-031/7076   202325   Japanese;  EP3773604-B1   19 Apr 2023   A61K-031/7076   202333   English;  JP2023071933-A   23 May 2023   A61K-031/7076   202350   Japanese;  EP4226971-A1   16 Aug 2023   A61P-025/16   202368   English;  HK40041244-A1   10 Nov 2023   A61K-031/7076   202412   English;  ES2949441-T3   28 Sep 2023   A61K-031/7076   202426   Spanish	US2019298752-A1    US364760    26 Mar 2019;   WO2019191026-A2    WOUS023977    26 Mar 2019;   WO2019191026-A3    WOUS023977    26 Mar 2019;   EP3773604-A2    EP726521    26 Mar 2019;   US10946034-B2    US364760    26 Mar 2019;   JP2021519315-W    JP551992    26 Mar 2019;   HK40041244-A0    HK6031001    13 May 2021;   JP7242696-B2    JP551992    26 Mar 2019;   EP3773604-B1    EP726521    26 Mar 2019;   JP2023071933-A    JP035224    08 Mar 2023;   EP4226971-A1    EP168073    26 Mar 2019;   HK40041244-A1    HK6031001    13 May 2021	US2019298752-A1 Provisional Application US648585P;   US2019298752-A1 Provisional Application US693021P;   EP3773604-A2 PCT application Application WOUS023977;   EP3773604-A2 Based on Patent WO2019191026;   US10946034-B2 Provisional Application US648585P;   US10946034-B2 Provisional Application US693021P;   US10946034-B2 Previous Publ. Patent US2019298752;   JP2021519315-W PCT application Application WOUS023977;   JP2021519315-W Based on Patent WO2019191026;   HK40041244-A0 PCT application Application WOUS023977;   HK40041244-A0 Based on Patent WO2019191026;   HK40041244-A0 Previous Publ. Patent EP3773604;   JP7242696-B2 PCT application Application WOUS023977;   JP7242696-B2 Based on Patent WO2019191026;   JP7242696-B2 Previous Publ. Patent JP2021519315;   EP3773604-B1 PCT application Application WOUS023977;   EP3773604-B1 Based on Patent WO2019191026;   JP2023071933-A Div ex Application JP551992;   EP4226971-A1 Div ex Application EP726521;   EP4226971-A1 Div ex Patent EP3773604;   HK40041244-A1 PCT application Application WOUS023977;   HK40041244-A1 Based on Patent WO2019191026;   HK40041244-A1 Previous Publ. Patent EP3773604;   ES2949441-T3 PCT application Application WOUS023977;   ES2949441-T3 EP application Application EP726521;   ES2949441-T3 Based on Patent WO2019191026;   ES2949441-T3 Based on Patent EP3773604	US648585P    27 Mar 2018;  US693021P    02 Jul 2018;  EP726521    26 Mar 2019;  US364760    26 Mar 2019	  WO2019191026-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2019191026-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP3773604-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN          EP3773604-B1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR    EP4226971-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR      		;  WO2019191026-A3 -- US20050276762-A1   ;  WO2003099297-A1   ABBOTT LAB (ABBO)   SHALWITZ R A,  JOHNS P W,  DAS T,  LEACH J L;  WO2015073319-A1   MASSACHUSETTS INST TECHNOLOGY (MASI)   CHANG P,  TODOROVA T,  BOCK F J;  WO2017143113-A1   INVIRSA INC (INVI-Non-standard)   SHALWITZ R;  US10946034-B2 -- EP2647382-A1   YERXA B R (YERX-Individual);  DOUGLASS J G (DOUG-Individual);  SHAVER S R (SHAV-Individual);  PETERSON W M (PETE-Individual);  BROWN E G (BROW-Individual);  CREAN C S (CREA-Individual)   YERXA B R,  DOUGLASS J G,  SHAVER S R,  PETERSON W M,  BROWN E G,  CREAN C S;  EP701562-B1   MERRELL DOW PHARM INC (RICH)   CASARA P,  NAVE J,  HALAZY S;  EP1948215-B1   CNRS CENT NAT RECH SCI (CNRS)   HAMICHE A;  JP07247210-A   ;  US20020052338-A1   ;  US20030008834-A1   ;  US20030236217-A1   ;  US20050009777-A1   ;  US20050276762-A1   ;  US20070212395-A1   ;  US20080081796-A1   ;  US20080305994-A1   ;  US20110217262-A1   ;  US20130116284-A1   ;  US20150038473-A1   ;  US6331529-B1   INSPIRE PHARM INC (INPM)   YERXA B R,  RIDEOUT J L,  JONES A C;  US6436910-B1   INSPIRE PHARM INC (INPM)   YERXA B R,  RIDEOUT J L,  JONES A C;  US6528042-B1   GALILEO LAB INC (GALI-Non-standard)   BROWN L A,  MILLER G;  US6989260-B2   ICOS CORP (ELIL)   CHRISTENSON E,  DEMAGGIO A J,  GOLDMAN P S,  MCELLIGOTT D L;  US7115585-B2   YERXA B R (YERX-Individual);  DOUGLASS J G (DOUG-Individual);  SHAVER S R (SHAV-Individual);  PETERSON W M (PETE-Individual);  BROWN E G (BROW-Individual);  CREAN C S (CREA-Individual)   YERXA B R,  DOUGLASS J G,  SHAVER S R,  PETERSON W M,  BROWN E G,  CREAN C S;  WO2003072067-A1   YERXA B R (YERX-Individual);  DOUGLASS J G (DOUG-Individual);  SHAVER S R (SHAV-Individual);  PETERSON W M (PETE-Individual);  BROWN E G (BROW-Individual);  CREAN C S (CREA-Individual)   YERXA B R,  DOUGLASS J G,  SHAVER S R,  PETERSON W M,  BROWN E G,  CREAN C S;  WO2003099297-A1   ABBOTT LAB (ABBO)   SHALWITZ R A,  JOHNS P W,  DAS T,  LEACH J L;  WO2005123030-A1   DAS T (DAST-Individual);  SHALWITZ R A (SHAL-Individual)   DAS T,  SHALWITZ R A;  WO2007054814-A1   CNRS CENT NAT RECH SCI (CNRS)   HAMICHE A;  WO2015073319-A1   MASSACHUSETTS INST TECHNOLOGY (MASI)   CHANG P,  TODOROVA T,  BOCK F J;  WO2017143113-A1   INVIRSA INC (INVI-Non-standard)   SHALWITZ R;  WO2006127987-A2   SIRTRIS PHARM INC (GLAX)   MILBURN M,  WESTPHAL C H,  LIVINGSTON D J,  LAMBERT P,  NORMINGTON K D,  ELLIOTT P;  WO1999012951-A8   ;  EP3773604-B1 -- US20050276762-A1   ;  WO2003099297-A1   ABBOTT LAB (ABBO)   SHALWITZ R A,  JOHNS P W,  DAS T,  LEACH J L;  WO2015073319-A1   MASSACHUSETTS INST TECHNOLOGY (MASI)   CHANG P,  TODOROVA T,  BOCK F J;  WO2017143113-A1   INVIRSA INC (INVI-Non-standard)   SHALWITZ R;  EP4226971-A1 -- WO2017143113-A1   INVIRSA INC (INVI-Non-standard)   SHALWITZ R	WO2019191026-A3  PAUL JOHNS ET AL:          "Cytoprotective Agent in Lactobacillus bulgaricus          Extracts", CURRENT MICROBIOLOGY, SPRINGER-VERLAG, NE,          vol. 54, no. 2, 5 January 2007 (2007-01-05), pages 131 -          135, XP019473020, ISSN: 1432-0991, DOI:          10.1007/S00284-006-0256-6,relevantClaims[1-28],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  SWAPNIL SUBHASH          BAWAGE ET AL: "Recent Advances in Diagnosis, Prevention,          and Treatment of Human Respiratory Syncytial Virus",          ADVANCES IN VIROLOGY, vol. 2013, 1 January 2013          (2013-01-01), US, pages 1 - 26, XP055574610, ISSN:          1687-8639, DOI:          10.1155/2013/595768,relevantClaims[1-28],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|&lt;pp&gt;14&lt;/pp&gt;&lt;ppl&gt;18&lt;/ppl&gt;];  BLUMBERG E A ET AL:          "Herpes zoster", CLINICS IN DERMATOLOGY, J.B. LIPPINCOTT,          PHILADELPHIA, PA, US, vol. 7, no. 1, 1 January 1989          (1989-01-01), pages 37 - 48, XP026208152, ISSN:          0738-081X, [retrieved on 19890101], DOI:          10.1016/0738-081X(89)90027-8,relevantClaims[32,33],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  NIKKELS A F ET AL:          "RECOGNITION AND TREATMENT OF SHINGLES", DRUGS, ADIS          INTERNATIONAL LTD, NZ, vol. 48, no. 4, 1 October 1994          (1994-10-01), pages 528 - 548, XP000567542, ISSN:          0012-6667, DOI:          10.2165/00003495-199448040-00004,relevantClaims[32,33],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  HAILE JANUARY D ET          AL: "The activity of an ancient atypical protein kinase          is stimulated by ADP-ribose in vitro.", ARCHIVES OF          BIOCHEMISTRY AND BIOPHYSICS JUL 2011, vol. 511, no. 1-2,          July 2011 (2011-07-01), pages 56 - 63, XP002794776, ISSN:          1096-0384,relevantClaims[37-39],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  MALANGA M ET AL:          "Poly(ADP-ribose) binds to specific domains of p53 and          alters its DNA binding functions.", THE JOURNAL OF          BIOLOGICAL CHEMISTRY 08 MAY 1998, vol. 273, no. 19, 8 May          1998 (1998-05-08), pages 11839 - 11843, XP002794777,          ISSN:          0021-9258,relevantClaims[37-39],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]US10946034-B2            Griffiths et al. Clinical Microbiology Reviews (2017),          vol. 30, pp. 277-319.;            Blumberg et al., 1989, Herpes Zoster, Clinics in          Dermatology, 7(1):37-48.;            Nikkels et al., 1994, Recognition and Treatment of          Shingles, Drugs, 48(4):529-548.;            Haile et al., 2011, The Activity of an Ancient Atypical          Protein Kinase is Stimulated by ADP-Ribose in vitro,          Archives of Biochemistry & Biophysics,          511:56-63.;            Malanga et al., 1998, Polu(ADP-Ribose) Binds to Specific          Domains of p53 and Alters its DNA Binding Functions,          Journal of Biological Chemistry,          273(19):11839-11843.;            International Search Report dated Oct. 28, 2019 of          International Application No.          PCT/US2019/023977.;            Written Opinion dated Oct. 28, 2019 of International          Application No. PCT/US2019/023977.;            Bawage et al., 2013, Recent Advances in Diagnosis,          Prevention, and Treatment of Human Respiratory Synctial          Virus, Advances in Virology, 203:1-26.;            Aleo et al., 1996, Enzymatic activites affecting          exogenous nicotinamide adenine dinucleotide in human skin          fibroblasts, J Cell Physiol, 167:173-176.;            Braun, 2014, A novel disease connection for TRPM2          channels, Channels, 8(6):475-476.;            Clement et al., 2011, Clinical and antiviral efficacy of          an ophthalmic formulation of dexamethasone          povidone-iodone in a rabbit model of adenoviral          keratoconjunctivitis, Investigative Ophthalmology &          Visual Science, 52(1):339-344;            Gil-Fernandez et al., 1987, Antiviral activity of uridine          5-diphosphate glucose analogues against some enveloped          viruses in cell culture, Antiviral Research,          8:299-310.;            Hottiger, 2015, SnapShot: ADP-ribosylation signaling,          Molecular Cell, 58:1134.;            Houlsby et al., 1986, Antimicrobial activity of          borate-buffered solutions, Antimicrobial Agents and          Chemotherapy, 29(5):803-806.;            Huang et al., 2014, Extracellular ADP-ribose induces          [Ca2+] pathway in pulmonary artery smooth muscle cells,          FASEB J, 28(1):Suppl 1175.4.;  Im          and Hoopes, 1989, Improved skin flap survival with          nicotinic acid and nicotinamide in rats, J Surg Res,          47:453-455.;            International Search Report dated May 29, 2017 of          International Application No.          PCT/US2017/018253.;            Johns et al., 2007, Cytoprotective agent in lactobacillus          bulgaricus extracts, Current Microbiology,          54(2):131-135.;            Lin et al., 2012, Niacinamide mitigated the acute lung          injury induced by phorbol myristate acetate in isolated          rat's lungs, J Biomed Sci, 19(27):1-13.;            Lion, 2014, Adenovirus infections in immunocompetent and          immunocompromised patients, Clin Microbiol Rev,          27(3):441-462.;            Martinez-Aguado et al., 2015, Antiadenovirus drug          discovery: potential targets and evaluation          methodologies, Drug Discovery Today,          20(10):1235-1242.;            Neurath et al., 1970, Disruption of adenovirus type 7 by          lithium iodide resulting in the release of viral          deoxyribonucleic acid, J Virol, 5(2):173-178.;            Paoletti et al., 2012, Multifaceted roles of purinergic          receptors in viral infection, Microbes and Infection,          14(14):1278-1283.;            Van Groeningen et al., 1992, Modulation of fluorouracil          toxicity with uridine, Seminars in Oncology, 19(2)Suppl          3:148-154.;            Virag and Szabo, 2002, The therapeutic potential of poly          (ADP-ribose) polymerase inhibitors, Phamacol Rev,          54(3):375-429.;            Wright et al., 2016, ADP-ribose-derived nuclear ATP          synthesis by NUDIX5 is required for chromatin remodeling,          Science, 352(6290):1221-1225.;            Written Opinion dated May 29, 2017 of International          Application No. PCT/US2017/018253.;            Budayeva et al., 2015, The intricate roles of mammalian          sirtuins in defense against viral pathogens, J. Virol.,          90(1):5-8.;            Chen et al., 2013, Pax6 Downregulation Mediates Abnormal          Lineage Commitment of the Ocular Surface Epithelium in          Aqueous-Deficient Dry Eye Disease, PLoS One,          8(10):e77286.;            Koyuncu et al., 2014, Sirtuins Are Evolutionarily          Conserved Viral Restriction Factors, Mbio,          5(6):e02249-14.;  Li          et al., 2008, Down-regulation of Pax6 is associated with          abnormal differentiation of corneal epithelial cells in          severe ocular surface diseases, J. Pathol.,          214(1):114-122.;            McNamara et al., 2014, Establishing PAX6 as a Biomarker          to Detect Early Loss of Ocular Phenotype in Human          Patients With Sjogren's Syndrome, Invest. Ophthalmol Vis.          Sci., 55:7079-7084.;            Pan et al., 2011, Structure and Biochemical Functions of          SIRT6, J. Biol. Chem., 286(16):14575-14587.;            Khan et al., 2006, Use of Substrate Analogs and          Mutagenesis to Study Substrate Binding and Catalysis in          the Sir2 Family of NAD-dependent Protein Deacetylases, J.          Biol. Chem., 281(17): 11702-11711.;            Priest et al., 2010, Deconstructing nucleotide binding          activity of the Mdm2 RING domain, Nucleic Acids Res.,          38(21):7587-7598.;            Poyurovsky et al., 2003, Nucleotide Binding by the MDM2          Ring Domain Facilitates Arf-Independent MDM2 Nucleolar          Localization, Mol. Cell, 12(4):875-887.;            Zhang et al., 2014, Aberrant activation of p53 due to          loss of MDM2 or MDMX causes early lens dysmorphogenesis,          Dev. Biol., 396(1):19-30.;            Thirumurthi et al., 2014, MDM2-mediated degradation of          SIRT6 phosphorylated by AKT1 promotes tumorigenesis and          trastuzumab resistance in breast cancer, Sci. Signal,          7(336):ra71.EP3773604-B1            Hall et al., 2009, N. Engl. J. Med.,          360(6):588-598;            Iwane et al., 2013, J. Infect. Dis., 208(Suppl. 3):          2-3;            Rose et al., 2018, Respiratory Syncytial Virus          Seasonality - United States, 2014-2017, MMWR Morb. Mortal          Wkly. Rep., 67:71-76;            Falsey et al., 2005, N. Engl. J. Med.,          352(17):1749-1759;            Kroeber et al., 2010, Human Molecular Genetics,          19(17):3332-3342;            Shaham et al., 2012, Progress in Retinal and Eye          Research, 31(5):351-376;            Swisa et al., Journal of Clinical Investigation,          127(1):230-243;            Osumi et al., 2008, Stem Cells, 26(7):1663-1672;  Li          et al., 2015, Journal of Cellular Physiology,          230(10):2318-2327;            Munoz-Fontela et al., 2016, Nature Reviews Immunology,          16(12):741-750;            Haupt et al., 1997, Nature, 387(6630):296-299;            Shangary and Wang, 2009, Annual Review of Pharmacology          and Toxicology, 49:223-241;            Roxburgh et al., 2012, Carcinogenesis,          33(4):791-798;            Madenspacher et al., 2013, The Journal of Experimental          Medicine, 210(5):891-904;            Wiley et al., 2011, Disease Models & Mechanisms,          4(4):484-495;            Tabas, 2001, Circulation Research,          88(8):747-749;            Hirota et al., 2010, Journal of Clinical Investigation,          120(3):803-815;            Madsen et al., 2016, J. Biol. Chem.,          291(13):7128-7141;            Johns et al. (2007, Curr. Microb., 54: 131-135;            Bawage et al. (2013, Adv. Virol., doi:          10.1155/2013/595768;            Blumberg and Molavi (1989, Clinics in Dermatology,          Chapter 5, 7(1): 37-48;            Nikkels and Pierard (1994, Recognition and Treatment of          Shingles, 48(4): 528-548;            Haile and Kennelly (2011, Arch. of Biochem. and Biophys.,          511(1-2): 56-63;            Malanga et al. (1998, J. of biological Chemistry,          273(19): 11839-11849;            Pan et al., 2011, J. Biol. Chem.,          286(16):14575-14587;            Michishita et al., 2008, Nature,          452(7186):492-496;            Khan and Lewis, 2005, J. Biol. Chem., 281(17),          11702-11711;            Heiner, 2006, Biochem. J., 398(2):225-232;            Rahnasto-Rilla, 2016, Methods Mol. Biol.,          1436:259-269;            Poyurovsky et al., 2003, Molecular Cell, 12(4),          875-887;            Priest et al., 2010, Nucleic Acids Research, 38(21),          7587-7598;            Grosdidier et al., 2011, Nucleic Acids Research,          39(SUPPL. 2), 270-277;            Linke et al., 2008, Cell Death and Differentiation,          15(5), 841-848;            Grasberger et al., 2005, Journal of Medicinal Chemistry,          48(4), 909-912EP4226971-A1  HAILE JANUARY D ET          AL: "The activity of an ancient atypical protein kinase          is stimulated by ADP-ribose in vitro", ARCHIVES OF          BIOCHEMISTRY AND BIOPHYSICS MAY 2012,, vol. 511, no. 1-2,          1 July 2011 (2011-07-01), pages 56 - 63, XP002794776,          ISSN: 1096-0384, DOI:          10.1016/J.ABB.2011.04.006,relevantClaims[1-15],relevantPassages[&lt;figure&gt;2,6&lt;/figure&gt;|&lt;pp&gt;A&lt;/pp&gt;];  MALANGA M ET AL:          "Poly(ADP-ribose) binds to specific domains of p53 and          alters its DNA binding functions", JOURNAL OF BIOLOGICAL          CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND          MOLECULAR BIOLOGY, US, vol. 273, no. 19, 8 May 1998          (1998-05-08), pages 11839 - 11843, XP002794777, ISSN:          0021-9258, DOI:          10.1074/JBC.273.19.11839,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            HALL ET AL., N. ENGL. J. MED., vol. 360, no. 6, 2009,          pages 588 - 598;            IWANE ET AL., J. INFECT. DIS., vol. 208, 2013, pages 2 -          3;            ROSE ET AL.: "Respiratory Syncytial Virus Seasonality -          United States, 2014-2017", MMWRMORB. MORTAL WKLY. REP.,          vol. 67, 2018, pages 71 - 76;            FALSEY ET AL., N. ENGL. J. MED., vol. 352, no. 17, 2005,          pages 1749 - 1759;            KROEBER ET AL., HUMAN MOLECULAR GENETICS, vol. 19, no.          17, 2010, pages 3332 - 3342;            SHAHAM ET AL.: "31", PROGRESS IN RETINAL AND EYE          RESEARCH, no. 5, 2012, pages 351 - 376;            HIROTA ET AL., JOURNAL OF CLINICAL INVESTIGATION, vol.          120, no. 3, 2010, pages 803 - 815;            OSUMI ET AL., STEM CELLS, vol. 26, no. 7, 2008, pages          1663 - 1672;  LI          ET AL., JOURNAL OF CELLULAR PHYSIOLOGY, vol. 230, no. 10,          2015, pages 2318 - 2327;            MUNOZ-FONTELA ET AL., NATURE REVIEWS IMMUNOLOGY, vol. 16,          no. 12, 2016, pages 741 - 750;            HAUPT ET AL., NATURE, vol. 387, no. 6630, 1997, pages 296          - 299;            SHANGARYWANG, ANNUAL REVIEW OF PHARMACOLOGY AND          TOXICOLOGY, vol. 49, 2009, pages 223 - 241;            ROXBURGH ET AL., CARCINOGENESIS, vol. 33, no. 4, 2012,          pages 791 - 798;            MADENSPACHER ET AL., THE JOURNAL OF EXPERIMENTAL          MEDICINE, vol. 210, no. 5, 2013, pages 891 -          904;            WILEY ET AL., DISEASE MODELS & MECHANISMS, vol. 4,          no. 4, 2011, pages 484 - 495;            ABAS, CIRCULATION RESEARCH, vol. 88, no. 8, 2001, pages          747 - 749;            MADSEN ET AL., J. BIOL. CHEM., vol. 291, no. 13, 2016,          pages 7128 - 7141;            PAN ET AL., J. BIOL. CHEM., vol. 286, no. 16, 2011, pages          14575 - 14587;            MICHISHITA ET AL., NATURE, vol. 452, no. 7186, 2008,          pages 492 - 496;            KHANLEWIS, J. BIOL. CHEM., vol. 281, no. 17, 2005, pages          11702 - 11711;            HEINER, BIOCHEM. J., vol. 398, no. 2, 2006, pages 225 -          232;            RAHNASTO-RILLA, METHODS MOL. BIOL., vol. 1436, 2016,          pages 259 - 269;            POYUROVSKY ET AL., MOLECULAR CELL, vol. 12, no. 4, 2003,          pages 875 - 887;            PRIEST ET AL., NUCLEIC ACIDS RESEARCH, vol. 38, no. 21,          2010, pages 7587 - 7598;            CIROSDIDIER ET AL., NUCLEIC ACIDS RESEARCH, vol. 39,          2011, pages 270 - 277;            LINKE ET AL., CELL DEATH AND DIFFERENTIATION, vol. 15,          no. 5, 2008, pages 841 - 848;            CIRASBERGER ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol.          48, no. 4, 2005, pages 909 - 912	824218-1-0-0 K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U			RAERFE K U; RCO3AC K U; RCO3AD K U; RCO3AE K U; RCO3AF K U; RCO3AG K U; RCO3AH K U; RCO3AI K U; RCO3AK K U; RCO3AL K U; RCO3AJ K U		WO2019179365-A1;  EP3768720-A1;  JP2021518166-W;  EP3768720-A4;  US2022169722-A1;  US11661452-B2;  JP7438180-B2	New isolated antibody polypeptide comprising heavy            chain variable domain that specifically binds to            lymphocyte-activation gene 3, useful for e.g. treating            disease including cancer, autoimmune disorder, and            infectious disease	CHEN Y;  LI J	WUXI BIOLOGICS IRELAND LTD (WUXI-Non-standard);  CSTONE PHARM (CSTO-Non-standard);  CSTONE PHARM SUZHOU CO LTD (CSTO-Non-standard);  CSTONE PHARM SHANGHAI CO LTD (CSTO-Non-standard);  WUXI BIOLOGICS IRELAND LTD (WUXI-Non-standard);  CSTONE PHARM (CSTO-Non-standard);  CSTONE PHARM SUZHOU CO LTD (CSTO-Non-standard);  CSTONE PHARM SHANGHAI CO LTD (CSTO-Non-standard);  WUXI BIOLOGICS IRELAND LTD (WUXI-Non-standard);  CSTONE PHARM (CSTO-Non-standard);  CSTONE PHARM SUZHOU CO LTD (CSTO-Non-standard);  CSTONE PHARM SHANGHAI CO LTD (CSTO-Non-standard);  CSTONE PHARM SHANGHAI CO LTD (CSTO-Non-standard);  CSTONE PHARM SUZHOU CO LTD (CSTO-Non-standard);  CSTONE PHARM (CSTO-Non-standard);  WUXI BIOLOGICS IRELAND LTD (WUXI-Non-standard);  CSTONE PHARM (CSTO-Non-standard);  WUXI BIOLOGICS SHANGHAI CO LTD (WUXI-Non-standard)	2019893494	   NOVELTY - Isolated antibody polypeptide (P1) comprising                a heavy chain variable domain that specifically                binds to lymphocyte-activation gene 3 (LAG-3), is                new. The heavy chain variable domain comprises                complementarity-determining region (CDR) 1, CDR2                and CDR3, where the CDR1 comprises the amino acid                sequence of SEQ ID NO: 1 or its homologous sequence                of at least 80% sequence identity, the CDR2                comprises the amino acid sequence SEQ ID NO: 33 or                its homologous sequence of at least 75% sequence                identity, and the CDR3 comprises the amino acid                sequence of SEQ ID NO:34 or its homologous sequence                of at least 75% sequence identity.    USE - The antibody polypeptide is useful for:                treating a disease or condition in a subject that                would benefit from modulation of LAG-3 activity,                where the disease or condition is a LAG-3 related                disease or condition, the disease or condition is                cancer (including e.g. glioblastoma, a hematologic                neoplasm, metastatic melanoma, Burkitt's lymphoma,                multiple myeloma, B chronic lymphocytic leukemia, B                and T acute lymphocytic leukemia, T cell lymphoma,                hairy cell leukemia, Hodgkin's lymphoma, melanoma,                mesothelioma, Wilm's cancer, renal cancer, prostate                cancer, breast cancer, colon cancer, colorectal                cancer, lung cancer, bone cancer, pancreatic                cancer, hepatic cell carcinoma, skin cancer,                endometrial cancer, carcinoid cancer, cancer of the                head or neck, cutaneous or intraocular malignant                melanoma, uterine cancer, ovarian cancer, rectal                cancer, cancer of the anal region, stomach cancer,                testicular cancer, carcinoma of the fallopian                tubes, carcinoma of the endometrium, and carcinoma                of the cervix), autoimmune disease (including                Alzheimer's disease, allergy, asthma, celiac                disease, Crohn's disease, Grave's disease,                inflammatory bowel disease (IBD), lupus, multiple                sclerosis, Myasthenia Gravis, polymyalgia                rheumatica, rheumatoid arthritis, type I diabetes,                and vasculitis), or infectious disease (including                HIV, hepatitis (A, B, and C), human papilloma                virus, lymphocytic choriomeningitis virus and                simian immunodeficiency virus, Influenza, Herpes,                Giardia, Malaria, Leishmania, Staphylococcus                aureus, Pseudomonas aeruginosa, Flaviviruses,                echovirus, rhinovirus, coxsackie virus,                coronavirus, respiratory syncytial virus, mumps                virus, rotavirus, measles virus, rubella virus,                parvovirus, vaccinia virus, human T-lymphotropic                virus, dengue virus, papillomavirus, molluscum                virus, poliovirus, rabies virus, John Cunningham                virus, arboviral encephalitis virus, chlamydia,                rickettsial bacteria, mycobacteria, staphylococci,                streptococci, pneumonococci, meningococci and                gonococci, Klebsiella, Proteus, Serratia,                Pseudomonas, Legionella, Diphtheria, Salmonella,                bacilli, cholera, tetanus, botulism, anthrax,                plague, leptospirosis, Lyme disease bacteria,                Entamoeba histolytica, Balantidium coli, Naegleria                fowleri, Acanthamoeba species, Giardia lamblia,                Cryptosporidium species, Pneumocystis carinii,                Plasmodium vivax, Babesia microti, Trypanosoma                brucei, Trypanosoma cruzi, Leishmania donovani,                Toxoplasma gondii, and Nippostrongylus                brasiliensis), and the subject is human; modulating                LAG-3 activity in a LAG-3-expressing cell;                detecting presence or amount of LAG-3 in a sample;                and diagnosing a Lag-3 related disease or condition                in a subject (all claimed).    ADVANTAGE - The antibody polypeptide: is capable of                specifically binding to human LAG-3 at a KD value                of not greater than 5x 10-9, 2x 10-10, 2.5x 10-12 M                as measured by surface plasmon resonance; and is                capable of specifically binding to human LAG-3                expressed on a cell surface at a KD value of not                greater than 10-9, 5x 10-10, 6x 10-11 M as measured                by flow cytometry (claimed).    DETAILED DESCRIPTION - Isolated antibody polypeptide (P1) comprising                a heavy chain variable domain that specifically                binds to lymphocyte-activation gene 3 (LAG-3), is                new. The heavy chain variable domain comprises                complementarity-determining region (CDR) 1, CDR2                and CDR3, where the CDR1 comprises the amino acid                sequence of Gly-Leu-Thr-Leu-Ser-Gln-Tyr-Thr-Met-Gly                (SEQ ID NO: 1) or its homologous sequence of at                least 80% sequence identity, the CDR2 comprises the                amino acid sequence of formula                (Ala-Ile-His-Trp-Thr-Ser-Ser-Val-Thr-Asp-Tyr-Ala-Asp-Ser-Val-X1-Gly)                (I) (SEQ ID NO: 33) or its homologous sequence of                at least 75% sequence identity, and the CDR3                comprises the amino acid sequence of formula                (Thr-X2-Tyr-Tyr-Thr-His-Arg-Gly-X3-Phe-Asp-Tyr)                (II) (SEQ ID NO:34) or its homologous sequence of                at least 75% sequence identity.    X1 = Lys, Tyr, Met, Asp, or Arg;    X2 = His or Trp; and    X3 = Ser or Pro.    INDEPENDENT CLAIMS are also included                for:    (1) an antibody polypeptide (P2), which                competes for the same epitope with the antibody                polypeptide (P1);    (2) an isolated polynucleotide encoding the                antibody polypeptide (P1) or (P2);    (3) a vector comprising the isolated                polynucleotide;    (4) a host cell comprising the vector;    (5) expressing (M1) the antibody                polypeptide;    (6) detecting (M2) presence or amount of LAG-3                in a sample, comprising contacting the sample with                the antibody polypeptide (P1) or (P2), and                determining the presence or the amount of LAG-3 in                the sample;    (7) diagnosing (M3) a Lag-3 related disease or                condition in a subject, comprising contacting a                sample obtained from the subject with the antibody                polypeptide, determining presence or amount of                LAG-3 in the sample, and correlating the presence                or the amount of LAG-3 to existence or status of                the LAG-3 related disease or condition in the                subject; and    (8) a kit comprising the antibody polypeptide                useful in detecting LAG-3. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E01;  B04-E08;  B04-E99;  B04-G01C;  B04-G27G;  B05-A03;  B11-C07A;  B11-C07B3;  B11-C07B4;  B12-K04E;  B14-A01;  B14-A02;  B14-A03B;  B14-A04;  B14-C03;  B14-C09B;  B14-D09;  B14-E10C;  B14-G02A;  B14-G02D;  B14-H01;  B14-J01A4;  B14-J05;  B14-K01A;  B14-L01;  B14-L06;  B14-N11;  B14-N12;  B14-S01;  B14-S04;  B14-S11A;  B14-S16;  B14-S25;  C04-E01;  C04-E08;  C04-E99;  C04-G01C;  C04-G27G;  C05-A03;  C11-C07A;  C11-C07B3;  C11-C07B4;  C12-K04E;  C14-A01;  C14-A02;  C14-A03B;  C14-A04;  C14-B02;  C14-C03;  C14-C09B;  C14-D09;  C14-E10C;  C14-E10C1;  C14-G02A;  C14-G02D;  C14-H01;  C14-J01A4;  C14-J05;  C14-K01A;  C14-L06;  C14-N11;  C14-N12;  C14-S01;  C14-S04;  C14-S11A;  C14-S16;  C14-S18;  C14-S25;  D05-H09;  D05-H11;  D05-H12E;  D05-H99	A61K-039/395;  A61P-035/00;  C07K-016/28;  A61K-045/00;  A61K-047/68;  A61K-049/00;  A61P-001/04;  A61P-011/06;  A61P-019/02;  A61P-021/00;  A61P-021/04;  A61P-025/00;  A61P-025/28;  A61P-029/00;  A61P-003/10;  A61P-031/00;  A61P-031/04;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-031/18;  A61P-031/20;  A61P-031/22;  A61P-033/02;  A61P-033/06;  A61P-035/02;  A61P-035/04;  A61P-037/02;  A61P-037/08;  A61P-009/00;  C07K-016/46;  C12N-001/15;  C12N-001/19;  C12N-001/21;  C12N-015/13;  C12N-015/63;  C12N-005/10;  C12P-021/02;  C12P-021/08;  G01N-033/536;  G01N-033/543;  G01N-033/574;  G01N-033/68;  A61K-039/00;  C07H-021/04;  C07K-016/00;  C12N-001/20;  C12N-015/00;  C12N-005/02;  C12Q-001/68	WO2019179365-A1   26 Sep 2019   C07K-016/28   201983Pages: 107   English;  EP3768720-A1   27 Jan 2021   C07K-016/28   202110   English;  JP2021518166-W   02 Aug 2021   C12N-015/13   202163Pages: 72   Japanese;  EP3768720-A4   05 Jan 2022   C07K-016/28   202207   English;  US2022169722-A1   02 Jun 2022   C07K-016/28   202245   English;  US11661452-B2   30 May 2023   A61K-039/395   202345   English;  JP7438180-B2   26 Feb 2024   C12N-015/13   202419   Japanese	WO2019179365-A1    WOCN078315    15 Mar 2019;   EP3768720-A1    EP770447    15 Mar 2019;   JP2021518166-W    JP500326    15 Mar 2019;   EP3768720-A4    EP770447    15 Mar 2019;   US2022169722-A1    US16982605    21 Sep 2020;   US11661452-B2    US16982605    21 Sep 2020;   JP7438180-B2    JP500326    15 Mar 2019	EP3768720-A1 PCT application Application WOCN078315;   EP3768720-A1 Based on Patent WO2019179365;   JP2021518166-W PCT application Application WOCN078315;   JP2021518166-W Based on Patent WO2019179365;   US2022169722-A1 PCT application Application WOCN078315;   US11661452-B2 PCT application Application WOCN078315;   US11661452-B2 Previous Publ. Patent US2022169722;   US11661452-B2 Based on Patent WO2019179365;   JP7438180-B2 PCT application Application WOCN078315;   JP7438180-B2 Previous Publ. Patent JP2021518166;   JP7438180-B2 Based on Patent WO2019179365	WOCN079682    20 Mar 2018;  WOCN078315    15 Mar 2019	WO2019179365-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP3768720-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR    EP3768720-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR        		WO2019179365-A1 -- CN104411723-A   BRISTOL-MYERS SQUIBB CO (BRIM)   LONBERG N,  SRINIVASAN M;  CN105793287-A   BRISTOL-MYERS SQUIBB CO (BRIM)   FONTANA D J,  GUTIERREZ A A,  KORMAN A J,  LEWIS K E,  LONBERG N,  SELBY M J;  CN105992595-A   BRISTOL-MYERS SQUIBB CO (BRIM)   GROSSO J,  GUTIERREZ A A,  HILL C M,  LEWIS K E,  SELBY M;  WO2017037203-A1   IMMUTEP SAS (IMMU-Non-standard)   TRIEBEL F,  BRIGNONE C;  WO2017149143-A1   AGENCY SCI TECHNOLOGY & RES (SGST);  CLEGG R I (CLEG-Individual)   LEE C Y,  OH H L J,  WANG C,  YEO S P;  WO2018034227-A1   UNIV HOKKAIDO NAT CORP (UHOK)   KONNAI S,  OHASHI K,  MURATA S,  OKAGAWA T,  NISHIMORI A,  MAEKAWA N,  SUZUKI Y,  NAKAJIMA C;  US2022169722-A1 -- US20180200378-A1   ;  WO2015116539-A1   BRISTOL-MYERS SQUIBB CO (BRIM)   GROSSO J,  GUTIERREZ A A,  HILL C M,  LEWIS K E,  SELBY M;  US11661452-B2 -- US20180200378-A1   ;  US20220213192-A1   ;  WO2015116539-A1   BRISTOL-MYERS SQUIBB CO (BRIM)   GROSSO J,  GUTIERREZ A A,  HILL C M,  LEWIS K E,  SELBY M;  CN104411723-A   BRISTOL-MYERS SQUIBB CO (BRIM)   LONBERG N,  SRINIVASAN M;  CN105793287-A   BRISTOL-MYERS SQUIBB CO (BRIM)   FONTANA D J,  GUTIERREZ A A,  KORMAN A J,  LEWIS K E,  LONBERG N,  SELBY M J;  CN105992595-A   BRISTOL-MYERS SQUIBB CO (BRIM)   GROSSO J,  GUTIERREZ A A,  HILL C M,  LEWIS K E,  SELBY M;  CN107428836-A   ANAPTYSBIO INC (ANAP-Non-standard)   JUN H T,  KEHRY M,  BOWERS P,  KING D J;  JP2016516681-A   GLAXOSMITHKLINE INTELLECTUAL PROPERTY (GLAX)   HAMBLIN P A,  LEWIS A P,  WEBB T M;  JP2017516489-A   BLATTLER W A (BLAT-Individual);  BRIGNONE C (BRIG-Individual);  CHANG H W (CHAN-Individual);  FREY G J (FREY-Individual);  IMMUTEP SA (IMMU-Non-standard);  MATARAZA J M (MATA-Individual);  NOVARTIS AG (NOVS);  SABATOS-PEYTON C A (SABA-Individual);  TRIEBEL F (TRIE-Individual)   BLATTLER W A,  BRIGNONE C,  CHANG H W,  FREY G J,  MATARAZA J M,  SABATOS-PEYTON C A,  TRIEBEL F;  JP2017532059-A   MERCK SHARP & DOHME CORP (MERI);  LIANG L (LIAN-Individual);  FAYADAT-DILMAN L (FAYA-Individual);  MALEFYT R D W (MALE-Individual);  RAGHUNATHAN G (RAGH-Individual)   LIANG L,  FAYADAT-DILMAN L,  MALEFYT R D W,  RAGHUNATHAN G;  TW201540727-A   BLATTLER W A (BLAT-Individual);  BRIGNONE C (BRIG-Individual);  CHANG H W (CHAN-Individual);  FREY G J (FREY-Individual);  IMMUTEP SA (IMMU-Non-standard);  MATARAZA J M (MATA-Individual);  NOVARTIS AG (NOVS);  SABATOS-PEYTON C A (SABA-Individual);  TRIEBEL F (TRIE-Individual)   BLATTLER W A,  BRIGNONE C,  CHANG H W,  FREY G J,  MATARAZA J M,  SABATOS-PEYTON C A,  TRIEBEL F;  TW201613979-A   MERCK SHARP & DOHME CORP (MERI);  LIANG L (LIAN-Individual);  FAYADAT-DILMAN L (FAYA-Individual);  MALEFYT R D W (MALE-Individual);  RAGHUNATHAN G (RAGH-Individual)   LIANG L,  FAYADAT-DILMAN L,  MALEFYT R D W,  RAGHUNATHAN G;  TW201726740-A   BOWMAN E (BOWM-Individual);  BEAUMONT M (BEAU-Individual);  BUYSE M (BUYS-Individual);  BOUTTON C (BOUT-Individual);  DOMBRECHT B (DOMB-Individual);  VLERICK D (VLER-Individual)   BOWMAN E,  BEAUMONT M,  BUYSE M,  BOUTTON C,  DOMBRECHT B,  VLERICK D;  US4560655-A   IMMUNEX CORP (IMMV)   BAKER P E;  US4657866-A   KUMAR S (KUMA-Individual)   KUMAR S;  US4767704-A   COLUMBIA UNIV (UYCO-Non-standard)   CLEVELAND W L,  ERLANGER B F;  US4927762-A   CELL ENTERPRISES (CELL-Non-standard)   DARFLER F J;  US5122469-A   GENENTECH INC (GETH)   MATHER J P,  TSAO M C;  US5624821-A   MEDICAL RES COUNCIL (MRCX)   WINTER G P,  DUNCAN A R,  BURTON D R;  US5648260-A   MEDICAL RES COUNCIL (MRCX)   WINTER G P,  DUNCAN A R,  BURTON D R;  US5731168-A   GENENTECH INC (GETH)   CARTER P J,  PRESTA L G,  RIDGWAY J B;  US6005079-A   CASTERMAN C (CAST-Individual);  HAMERS R (HAME-Individual)   CASTERMAN C,  HAMERS R;  US20110150892-A1   ;  US20150259420-A1   ;  US20170101472-A1   ;  US6248516-B1   MEDICAL RES COUNCIL (MRCX)   WINTER G P,  GUSSOW D,  WARD E S;  US30985-E   CARTAYA O A (CART-Individual)   CARTAYA O A;  WO1987000195-A   ;  WO1990003430-A   ;  WO1994004678-A1   ;  WO1994025591-A1   ;  WO1999051642-A1   ;  WO2014183052-A1   INST NACIONAL TECNOLOGIA AGROPECUARIA (NATE-Non-standard);  US DEPT HEALTH & HUMAN SERVICES (USSH)   AGUILAR A P,  BOK K,  BOK M,  GARAICOECHEA L L,  GREEN L K,  PARRENO V,  SOSNOVTSEV S V;  WO2015138920-A1   BLATTLER W A (BLAT-Individual);  BRIGNONE C (BRIG-Individual);  CHANG H W (CHAN-Individual);  FREY G J (FREY-Individual);  IMMUTEP SA (IMMU-Non-standard);  MATARAZA J M (MATA-Individual);  NOVARTIS AG (NOVS);  SABATOS-PEYTON C A (SABA-Individual);  TRIEBEL F (TRIE-Individual)   BLATTLER W A,  BRIGNONE C,  CHANG H W,  FREY G J,  MATARAZA J M,  SABATOS-PEYTON C A,  TRIEBEL F;  WO2017037203-A1   IMMUTEP SAS (IMMU-Non-standard)   TRIEBEL F,  BRIGNONE C;  WO2017149143-A1   AGENCY SCI TECHNOLOGY & RES (SGST);  CLEGG R I (CLEG-Individual)   LEE C Y,  OH H L J,  WANG C,  YEO S P;  WO2017198212-A1   SUZHOU ALPHAMAB CO LTD (SUZH-Non-standard);  ZHANG X (ZHAN-Individual)   BAI Y,  CHU Q,  GAO L,  LI J,  WANG X,  WU H,  XU T;  WO2017219995-A1   JIANGSU HENGRUI MEDICINE CO LTD (JSHR);  SHANGHAI HENGRUI PHARM CO LTD (JSHR)   CAO Z,  FU Y,  HU Q,  TAO W,  ZHANG L,  SUN P;  WO2018034227-A1   UNIV HOKKAIDO NAT CORP (UHOK)   KONNAI S,  OHASHI K,  MURATA S,  OKAGAWA T,  NISHIMORI A,  MAEKAWA N,  SUZUKI Y,  NAKAJIMA C;  WO2018220225-A1   ABLYNX NV (ABLY);  MERCK PATENT GMBH (MERE)   STEFFENSEN S,  BESTE G,  HERMANS G,  GUEHRING H,  LADEL C,  TOLEIKIS L;  WO1994029351-A2   ;  WO2006034488-A2   GENENTECH INC (GETH)   EIGENBROT C W,  JUNUTULA J R,  LOWMAN H,  RAAB H E,  VANDLEN R;  WO2017087589-A2   BOWMAN E (BOWM-Individual);  BEAUMONT M (BEAU-Individual);  BUYSE M (BUYS-Individual);  BOUTTON C (BOUT-Individual);  DOMBRECHT B (DOMB-Individual);  VLERICK D (VLER-Individual)   BOWMAN E,  BEAUMONT M,  BUYSE M,  BOUTTON C,  DOMBRECHT B,  VLERICK D	WO2019179365-A1  SASO C. ET AL.: "T          cell activation and anti-tumor efficacy of anti-LAG-3          antibodies is independent of LAG-3-MHCII blocking          capacity", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 3,          no. 2, 4 November 2015 (2015-11-04), pages 1 83,          XP021235237,          doi:10.1186/2051-1426-3-S2-P183,relevantClaims[1-37]US11661452-B2            Liu et al. Liver sinusoidal endothelial cell lectin          inhibits CTL-dependent virus clearance in mouse models of          viral hepatitis. J Immunol 2013;190:4185-95. (Year:          2013).;            Bae et al. Targeting LAG3/GAL-3 to overcome          immunosuppression and enhance anti-tumor immune responses          in multiple myeloma. Leukemia vol. 36, pp. 138-154 (2022)          (Year: 2022).;            Lauder et al. Enhanced antitumor immunity through          sequential targeting of PI3K and LAG3. J Immunother          Cancer 2020;8(2):1-13. (Year: 2020).;            Richards, J. O. et al., Optimization of antibody binding          to Fc RIIa enhances macrophage phagocytosis of tumor          cells, Mol. Cancer Ther. (Aug. 2008), vol. 7(8), pp.          2517-2527.;            Shields, R. L. et al., Lack of Fucose on Human IgG1          N-Linked Oligosaccharide Improves Binding to Human          FcyRIII and Antibody-dependent Cellular Toxicity, The          Journal of Biological Chemistry (Jul. 2002), vol.          277(30), pp. 26733-26740.;            Shinkawa, T. et al., The absence of fucose but not the          presence of galactose or bisecting N-acetylglucosamine of          human IgG1 complex-type oligosaccharides shows the          critical role of enhancing antibody-dependent cellular          cytotoxicity, The Journal of Biological Chemistry (2003),          vol. 278(5), pp. 3466-3473.;            Duncan, A. R. et al., The binding site for C1q on IgG,          Nature (Apr. 1988), vol. 332, pp. 738-740.;            Batzer, M. A. et al., Enhanced evolutionary PCR using          oligonucleotides with inosine at the 3-terminus, Nucleic          Acids Research (1991), vol. 19(18), pp. 5081.;            Ohtsuka, E. et al., An alternative approach to          deoxyoligonucleotides as hybridization probes by          insertion of deoxyinosine at ambiguous codon positions,          The Journal of Biological Chemistry (1985), vol. 260(5),          pp. 2605-2608.;            Rossolini, G. M. et al., Use of deoxyinosine-containing          primers vs degenerate primers for polymerase chain          reaction based on ambiguous sequence information,          Molecular and Cellular Probes (1994), vol. 8, pp.          91-98.;            Urlaub, G. et al., Isolation of Chinese hamster cell          mutants deficient in dihydrofolate reductase activity,          Proc. Natl. Acad. Sci. USA (1980), vol. 77(7), pp.          4216-4220.;            Mather, J. P., Establishment and Characterization of Two          Distinct Mouse Testicular Epithelial Cell Lines, Biology          of Reproduction (1980), vol. 23, pp. 243-252.;            Mather, J. P. et al., Culture of Testicular Cells in          Hormone-Supplemented Serum-Free Medium, Annals New York          Academy of Sciences (1982), vol. 383, pp.          44-68.;            Ham, R. G. et al. , [5] Media and growth requirements,          Methods in Enzymology (1979), vol. LVIII, pp.          44-93.;            Barnes, D. et al., Methods for growth of cultured cells          in serum-free medium, Analytical Biochemistry (1980),          vol. 102, pp. 255-270.;            Carter, P. et al., High Level &lt;xhtml:i          &gt;Escherichia          coli&lt;/xhtml:i&gt;Expression and Production of          a Bivalent Humanized Antibody Fragment, Nature          Biotechnology (Feb. 1992), vol. 10, pp.          163-167.;            Lindmark, R. et al., Binding of immunoglobulins to          protein A and immunoglobulin levels in mammalian sera,          Journal of Immunological Methods (1983), vol. 62, pp.          1-13.;            Guss, B. et al., Structure of the IgG-binding regions of          streptococcal protein G, The EMBO Journal (1986), vol.          5(7), pp. 1567-1575.;            Lymphocyte activation gene 3 protein precursor          [&lt;xhtml:i &gt;Homo          sapiens&lt;/xhtml:i&gt;], Genbank Accession No.          NP_002277.4.;            Predicted: lymphocyte activation gene 3 protein [Macaca          fascicularis], Genbank Accession No.          XP_005570011.1.;            Lymphocyte activation gene 3 protein precursor          [&lt;xhtml:i &gt;Mus          musculus&lt;/xhtml:i&gt;], Genbank Accession No.          XP_032505.1.;            Saso Cemerski et al., T cell activation and anti-tumor          efficacy of anti-LAG-3 antibodies is independent of          LAG-3-MHCII blocking capacity, Journal for Immuno Therapy          of Cancer, vol. 3, No. Suppl 2, Nov. 4, 2015 (Nov. 4,          2015), p. 183.;            International Search Report of PCT Application No.          PCT/CN2019/078315, dated Jun. 21, 2019.;            Koch-Nolte, F. et al., Single domain antibodies from          llama effectively and specifically block T cell          ecto-ADP-ribosyltransferase ART2.2 in vivo, The FASEB          Journal (Nov. 2007), vol. 21, pp. 3490-3498.;            Verhoeyen, M. et al., Reshaping human antibodies:          grafting an antilysozyme activity, Science (1988), vol.          239, pp. 1534-1536.;            Peter, C. F. et al., A robust pipeline for rapid          production of versatile nanobody repertoires, Nature          Methods (Nov. 2, 2014), vol. 11, No. 12, pp.          1253-1260.;            Dijkstra, J. M. et al., Identification and          characterization of a second CD4-like gene in teleost          fish, Molecular Immunology (2006), vol. 43, pp.          410-419.;            Huard, B. et al., CD4/major histocompatibility complex          class II interaction analyzed with CD4- and lymphocyte          activation gene-3 (LAG-3)-Ig fusion proteins, Eur. J.          Immunol. (1995), vol. 25, pp. 2718-2721.;            Baixeras, E. et al., Characterization of the lymphocyte          activation gene 3-encoded protein A new ligand for human          leukocyte antigen class II antigens , J. Exp. Med.          (1992), vol. 176, pp. 327-337.;            Andrews, L. P. et al., LAG3 (CD223) as a cancer          immunotherapy target, Immunological Reviews (2017), vol.          276, pp. 80-96.;            Andreae, S. et al., Maturation and Activation of          Dendritic Cells Induced by Lymphocyte Activation Gene-3          (CD223), The Journal of Immunology (2002), vol. 168, pp.          3874-3880.;            Goldberg, M. V. et al., LAG-3 in cancer immunotherapy,          Current Topics in Microbiology and Immunology (2011),          344, pp. 269-278.;            Workman, C. J. et al., Negative Regulation of T Cell          Homeostasis by Lymphocyte Activation Gene-3 (CD223), The          Journal of Immunology (2005), vol. 174, pp.          688-695.;            Harmsen, M. M. et al., Properties, production, and          applications of camelid single-domain antibody fragments,          Appl. Microbiol. Biotechnol. (2007), vol. 77, pp.          13-22.;            Al-Lazikani, B. et al., Standard conformations for the          canonical structures of immunoglobulins, J.Mol.Biol.          (1997), vol. 273, pp. 927-948.;            Chothia, C. et al., Domain association in immunoglobulin          molecules, J.Mol.Biol. (1985), vol. 186, pp.          651-663.;            Chothia, C. et al., Canonical structures for the          hypervariable regions of immunoglobulins, J.Mol.Biol.          (1987), vol. 196, pp. 901-917.;            Chothia, C. et al., Conformations of immunoglobulin          hypervariable regions, Nature (Dec. 1989), vol. 342, pp.          877-883.;            Lefranc, M.-P. et al., IMGT unique numbering for          immunoglobulin and T cell receptor variable domains and          Ig superfamily V-like domains. Developmental and          Comparative Immunology (2003), vol. 27, pp.          55-77.;            Lefranc, M.-P. et al., IMGT, the international          ImMunoGeneTics information system: a standardized          approach for immunogenetics and immunoinformatics,          Immunome Research(2005), vol. 1(3), pp. 1-11.;            Lefranc, M.-P. et al., IMGT Immunoglobulin Repertoire          Analysis and Antibody Humanization, Molecular Biology of          B Cells (2015), chapter 26, pp. 481-514.;            Hamers-Casterman, C. et al., Naturally occurring          antibodies devoid of light chains, Nature (Jun. 1993),          vol. 363, pp. 446-448.;            Riechmann, L. et al., Single domain antibodies:          comparison of camel VH and camelised human VH domains,          Journal of Immunological Methods (1999), vol. 231, pp.          25-38.;            Muyldermans, S., Single domain camel antibodies: current          status, Reviews in Molecular Biotechnology (2001), vol.          74, pp. 277-302.;            Nguyen, V. K. et al., Heavy-chain antibodies in          Camelidae; a case of evolutionary innovation,          Immunogenetics (2002), vol. 54, pp. 39-47.;            Nguyen, V. K. et al., Heavy-chain only antibodies derived          from dromedary are secreted and displayed by mouse B          cells, Immunology (2003), vol. 109, pp. 93-101.;            LAG-3 protein, partial [&lt;xhtml:i &gt;Homo          sapiens&lt;/xhtml:i&gt;], Genbank accession No.          GI: 4379038, CAA73914.1.;            Lymphocyte-activation gene 3 [Mus musculus], Genbank          accession No. GI: 111308743, AAI20592.1.;            LAG-3 [Rattus norvegicus], Genbank accession No. GI:          37921547, AAP57397.1.;            Altschul, S. F. et al., Basic local alignment search          tool, J.Mol.Biol. (1990), vol. 215, pp.          403-410.;            Altschul, S. F. et al., Gapped BLAST and PSI-BLAST: a new          generation of protein database search programs, Nucleic          Acids Research(1997), vol. 25, No. 17, p.          3389-3402.;            Higgins, D.G. et al., Using CLUSTAL for Multiple Sequence          Alignments, Methods in Enzymology(1996), vol. 266, p.          383-402.;            Larkin, M.A. et al., Clustal W and Clustal X version 2.0,          Bioinformatics (2007), vol. 23, No. 21, p.          2947-2948.;            Tonegawa, S., Somatic generation of antibody diversity,          Nature (1983), vol. 302, pp. 575-581.;            Xu, J. L. et al., Diversity in the CDR3 Region of VH Is          Sufficient for Most Antibody Specificities, Immunity          (Jul. 2000), vol. 13, pp. 37-45.;            Schier, R. et al., Isolation of picomolar affinity          anti-c-erbB-2 single-chain Fv by molecular evolution of          the complementarity determining regions in the center of          the antibody binding site, J. Mol. Biol.(1996), vol. 263,          pp. 551-567.;            Jones, P.T. et al., Replacing the          complementarity-determining regions in a human antibody          with those from a mouse, Nature (May 1986), vol. 321, pp.          522-525.;            Riechmann, L. et al., Reshaping human antibodies for          therapy, Nature (Mar. 1988), vol. 332, pp.          323-327.;            Carter, P. et al., Humanization of an anti-p185HER2          antibody for human cancer therapy, Proc. Natl. Acad. Sci.          USA (May 1992), vol. 89, pp. 4285-4289.;            Cunningham, B. C. et al., High-resolution epitope mapping          of hGH-receptor interactions by alanine-scanning          mutagenesis, Science (1989), vol. 244, pp.          1081-1085.;            Vaughn, D. E. et al., Structural basis of pH-dependent          antibody binding by the neonatal Fc receptor, Structure          (1998), vol. 6(1), pp. 63-73.;            Yeung, Y. A. et al., A Therapeutic Anti-VEGF Antibody          with Increased Potency Independent of Pharmacokinetic          Half-life. Cancer Research (2010), vol. 70(8), pp.          3269-3277.;            Hinton, P.R. et al., An Engineered Human IgG1 Antibody          with Longer Serum Half-Life, The Journal of Immunology          (2006), vol. 176, pp. 346-356.;            Shields, R. L. et al., High Resolution Mapping of the          Binding Site on Human IgG1 for FcyRI, FcyRII, FcyRIII,          and FcRn and Design of IgG1 Variants with Improved          Binding to the FcyR, The Journal of Biological Chemistry          (2001), vol. 276(9), pp. 6591-6604.;            Idusogie, E. E et al., Mapping of the C1q Binding Site on          Rituxan, a Chimeric Antibody with a Human IgG1 Fc, The          Journal of Immunology (2000), vol. 164, pp.          4178-4184.;            Steurer, W. et al., Ex vivo coating of islet cell          allografts with murine CTLA4/Fc promotes graft tolerance,          The Journal of Immunology (1995), vol. 155, pp.          1165-1174.;            Idusogie, E. E. et al., Engineered Antibodies with          Increased Activity to Recruit Complement, The Journal of          Immunology (2001), vol. 166, pp. 2571-2575.;            Lazar, G. A. et al., Engineered antibody Fc variants with          enhanced effector function, PNAS (Mar. 2006), vol.          103(11), pp. 4005-4010.;            Ryan, M. C. et al., Antibody targeting of B-cell          maturation antigen on malignant plasma cells, Molecular          Cancer Therapeutics (Nov. 2007), vol. 6, pp.          3009-3018.	93605-0-0-0 N; 105730-0-0-0 N; 184587-0-0-0 A N P Q; 1013903-0-0-0 A N P Q; 184587-0-0-0 CL DET NEW PRD RCT; 1013903-0-0-0 CL DET NEW PRD RCT	216693801 A N P Q; 216693802 A N P Q; 216693803 A N P Q; 216693804 A N P Q; 216693805 A N P Q; 216693806 A N P Q		RA00NS N; RA012P N; RA00C8 A N P Q; R90348 A N P Q		EP3502698-A1	Media useful for detecting antigenic exposure or            assessing level of antigenic exposure in human            following antigenic exposure, comprises reduction of            contaminating pre-existing plasma antibodies relative            to whole blood or plasma	LEE F E;  DAISS J L	MICROBPLEX INC (MICR-Non-standard)	201952572Y	   NOVELTY - Media elaborated with non-pre-existing                antibodies secreted from plasmablasts actively                responding to an ongoing antigenic insult,                expressing the nuclear proliferation antigen Ki67                and circulating in the blood, comprises at least                106 or 107-fold reduction of contaminating                pre-existing plasma antibodies relative to whole                blood or plasma.    USE - The media is useful for (a) detecting                antigenic exposure or assessing the level of                antigenic exposure in a subject following antigenic                exposure, (b) assessing the efficacy of a vaccine                in a subject, (c) separating pre-existing                antibodies from antibodies derived from antigenic                exposure, or (d) diagnosing presence of a disease                or exposure to an antigen in a subject. The disease                is a viral disease chosen from viruses such as                Herpes Simplex virus-1, Herpes Simplex virus-2,                Varicella-Zoster virus, Epstein-Barr virus,                Cytomegalovirus, Human Herpes virus-6, Variola                virus, Vesicular stomatitis virus, Hepatitis A                virus, Hepatitis B virus, Hepatitis C virus,                Hepatitis D virus, Hepatitis E virus, Rhinovirus,                Coronavirus, Influenza virus A, Influenza virus B,                Measles virus, Polyomavirus, Human Papillomavirus,                Respiratory syncytial virus, Adenovirus, Coxsackie                virus, Dengue virus, Mumps virus, Poliovirus,                Rabies virus, Rous sarcoma virus, Reovirus, Yellow                fever virus, Ebola virus, Marburg virus, Lassa                fever virus, Eastern Equine Encephalitis virus,                Japanese Encephalitis virus, St. Louis Encephalitis                virus, Murray Valley fever virus, West Nile virus,                Rift Valley fever virus, Rotavirus A, Rotavirus B,                Rotavirus C, Sindbis virus, Simian Immunodeficiency                virus, Human T-cell Leukemia virus type-1,                Hantavirus, Rubella virus, Simian Immunodeficiency                virus, HIV type-1, and HIV type-2. The disease is a                bacterial disease chosen from bacteria such as                Mycobacterium tuberculosis, M.bovis, M.bovis strain                BCG, BCG substrains, M.avium, M.intracellulare,                M.africanum, M.kansasii, M.marinum, M.ulcerans,                M.avium subsp. paratuberculosis, Nocardia                asteroides, other Nocardia sp., Legionella                pneumophila, other Legionella sp., Salmonella                typhi, other Salmonella sp., Shigella sp., Yersinia                sp., Pasteurella haemolytica, P.multocida, other                Pasteurella sp., Actinobacillus pleuropneumoniae,                Listeria monocytogenes, L.ivanovii, Brucella                abortus, other Brucella sp., Cowdria ruminantium,                Chlamydia pneumoniae, C.trachomatis, C.psittaci,                Coxiella burnetti, other Rickettsia sp., Ehrlichia                sp., Staphylococcus aureus, S.epidermidis,                Streptococcus pyogenes, S.agalactiae, Bacillus                anthracis, Escherichia coli, Vibrio cholerae,                Campylobacter sp., Neisseria meningitidis,                N.gonorrhoeae, Pseudomonas aeruginosa, other                Pseudomonas sp., Haemophilus influenzae, H.ducreyi,                other Haemophilus sp., Clostridium tetani,                C.difficile, other Clostridium sp.,                Y.enterocolitica, and other Yersinia sp.. The                antigen is a vaccine, bio-warfare agent, or toxin                chosen from abrin, conotoxins, diacetoxyscirpenol,                bovine spongiform encephalopathy agent, ricin,                saxitoxin, tetrodotoxin, i-toxin, botulinum                neurotoxins, shiga toxin, Staphylococcal                enterotoxins, T-2 toxin, diphtheria toxin, tetanus                toxoid, and pertussis toxin (all claimed). The                subject is human.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a method (M1) of isolating cell-free media                elaborated with non-pre-existing antibodies                secreted from plasmablasts actively responding to                an ongoing antigenic insult, and expressing the                nuclear proliferation antigen Ki67;    (2) a method (M2) of detecting antigenic                exposure or assessing the level of antigenic                exposure in a subject following antigenic                exposure;    (3) a method (M3) of assessing the efficacy of                a vaccine in a subject, involves separating                plasmablasts actively responding to an ongoing                antigenic insult, and expressing the nuclear                proliferation antigen Ki67 from the plasma of PBMC                or whole blood obtained from the subject of 3-15                days following administration of a vaccine, washing                the plasmablasts until the washed plasmablasts                comprise at least 106-fold reduction of                contaminating pre-existing plasma antibodies                relative to plasma or whole blood, culturing the                plasmablasts in media conducive to antibody                production and expression, measuring the vaccine                specific antibodies in the media, and comparing the                number of antibodies to a standard or control,                where an increase of vaccine specific antibodies in                the media relative to a standard or control                indicates an efficacious vaccine;    (4) a method (M4) for separating pre-existing                antibodies from antibodies derived from antigenic                exposure, involves obtaining plasmablasts actively                responding to an ongoing antigenic insult, and                expressing the nuclear proliferation antigen Ki67                from whole blood or PBMC obtained from a subject,                separating the plasmablasts from the plasma,                washing the plasmablasts until the washed                plasmablasts comprise at least 106-fold reduction                of contaminating pre-existing plasma antibodies                relative to plasma or whole blood, and incubating                the plasmablasts in a media for stimulating                antibody production in the plasmablasts; and    (5) a method (M5) of diagnosing the presence                of a disease or exposure to an antigen in a                subject, involves separating plasmablasts actively                responding to an ongoing antigenic insult, and                expressing the nuclear proliferation antigen Ki67                from the plasma of whole blood or PBMC obtained                from the subject of 3-15 days following infection                or vaccination, washing the plasmablasts until the                washed plasmablasts comprise at least 106-fold                reduction of contaminating pre-existing plasma                antibodies relative to plasma or whole blood, and                measuring antibodies from the plasmablasts specific                for an antigen, where the presence of antibodies                specific for the antigen indicates the subject has                an ongoing infection with the source of the                antigen. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)	B04-B04C;  B04-B04D4;  B04-C01;  B04-G01;  B04-N01;  B04-N03;  B04-N04;  B06-A03;  B06-D17;  B06-E05;  B11-B03A;  B11-C07A;  B12-K04E3;  B12-K04G1B;  B14-S11;  B14-S18;  C04-B04C;  C04-B04D4;  C04-C01;  C04-G01;  C04-N01;  C04-N03;  C04-N04;  C06-A03;  C06-D17;  C06-E05;  C11-C07A;  C12-K04E3;  C12-K04G1B;  C14-S11;  C14-S18;  D05-H09;  S03-E09F;  S03-E14H1	A61K-039/00;  G01N-033/569	EP3502698-A1   26 Jun 2019   G01N-033/569   201951Pages: 73   English	EP3502698-A1    EP155473    05 May 2015	EP3502698-A1 Div ex Application EP166489;   EP3502698-A1 Div ex Patent EP2942627	US988517P    05 May 2014	EP3502698-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  		EP3502698-A1 -- US20110229914-A1   ;  WO2009035738-A2   UNIV ROCHESTER (UYRP)   FALSEY A R,  HALLILEY J,  LEE F E,  SANZ I,  WALSH E;  US3817837-A   SYVA CORP (SYNT);  US3850752-A   AKZONA INC (ALKU);  ORGANON NV (ORGA);  US3939350-A   UNIV STANFORD (STRD)   KRONICK M N,  LITTLE W A;  US3996345-A   SYVA CO (SYNT);  US4275149-A   SYVA CO (SYNT);  US4277437-A   SYVA CO (SYNT)   MAGGIO E T;  US4342566-A   SCRIPPS CLINIC & RES FOUND (SCRI)   THEOFILOPO A N,  DIXON F J;  US4366241-A   SYVA CO (SYNT)   TOM H K,  ROWLEY G L;  US4376110-A   HYBRITECH INC (HYBR-Non-standard)   DAVIS G S,  GREENE H E;  US4452901-A   CIBA GEIGY AG (CIBA)   GORDON J,  STAEHELIN T,  TOWBIN H;  US4704692-A   LADNER R C (LADN-Individual);  GENEX CORP (GEMX);  GENTEX CORP (GENX)   LADNER R C;  US4816567-A   GENENTECH INC (GETH);  CITY OF HOPE (CITY)   CABILLY S,  HOLMES W E,  WETZEL R B,  HEYNEKER H L,  RIGGS A D;  US5424000-A   WEST AGRO INC (WAGR-Non-standard)   WINICOV E L,  LENAHAN E L,  GRIFFITH M W;  WO1994004679-A1   ;  WO1994029348-A2   	EP3502698-A1  HALLILEY J L ET AL:          "Peak frequencies of circulating human influenza-specific          antibody secreting cells correlate with serum antibody          response after immunization", VACCINE, ELSEVIER LTD, GB,          vol. 28, no. 20, 30 April 2010 (2010-04-30), pages 3582 -          3587, XP027000083, ISSN: 0264-410X, [retrieved on          20100316],relevantClaims[1-15],relevantPassages[&lt;pp&gt;3583&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;1,          2&lt;/para&gt;|&lt;pp&gt;3583&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;3&lt;/para&gt;|&lt;pp&gt;3583&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;5&lt;/para&gt;];  KYU S Y ET AL:          "Frequencies of human influenza-specific antibody          secreting cells or plasmablasts post vaccination from          fresh and frozen peripheral blood mononuclear cells",          JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE          PUBLISHERS B.V.,AMSTERDAM, NL, vol. 340, no. 1, 1 January          2009 (2009-01-01), pages 42 - 47, XP025991298, ISSN:          0022-1759, [retrieved on 20081106], DOI:          10.1016/J.JIM.2008.09.025,relevantClaims[1-15],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;43&lt;/pp&gt;&lt;column&gt;1&lt;/column&gt;&lt;ppl&gt;44&lt;/ppl&gt;&lt;coll&gt;2&lt;/coll&gt;|Discussion];  XIAO-SONG HE ET AL:          "Plasmablast-derived polyclonal antibody response after          influenza vaccination", JOURNAL OF IMMUNOLOGICAL METHODS,          ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 365,          no. 1, 13 December 2010 (2010-12-13), pages 67 - 75,          XP028141187, ISSN: 0022-1759, [retrieved on 20101221],          DOI:          10.1016/J.JIM.2010.12.008,relevantClaims[1-15],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|Material          and Methods];  FRANCES E H LEE ET          AL: "Novel Method For Diagnosing Microbial Infections          With A Blood Antibody Secreting Cell Assay: The          'MicroBspot'", INTERNET CITATION, 1 January 2010          (2010-01-01), pages A6845, XP009186122, Retrieved from          the Internet          &lt;URL:http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A6845&gt;          [retrieved on          20150915],relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  CZERKINSKY C C ET          AL: "A solid-phase enzyme-linked immunospot (ELISPOT)          assay for enumeration of specific antibody-secreting          cells", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER          SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 65, no. 1-2,          16 December 1983 (1983-12-16), pages 109 - 121,          XP023973707, ISSN: 0022-1759, [retrieved on 19831216],          DOI:          10.1016/0022-1759(83)90308-3,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            MAGGIO ET AL., ENZYME-IMMUNOASSAY, 1987;            NAKAMURA ET AL.: "Handbook of Experimental Immunology",          vol. 1, 1986, article "Enzyme Immunoassays: Heterogeneous          and Homogeneous Systems", pages: 27.1 - 27.20;            O'FARRELL, P.H.: "High Resolution Two-dimensional          Electrophoresis of Proteins", J. BIOL. CHEM., vol. 250,          1975, pages 4007 - 4021, XP008005139;            ANDERSON, L; ANDERSON, NG: "High resolution          two-dimensional electrophoresis of human plasma          proteins", PROC. NATL. ACAD. SCI., vol. 74, 1977, pages          5421 - 5425;            ORNSTEIN, L.: "Disc electrophoresis", L. ANN. N.Y. ACAD.          SCI., vol. 121, 1964, pages 321349;            NATURE, vol. 227, 1970, pages 680;            D.M. BOLLAG ET AL.: "Protein Methods", 1996;  E.          HARLOW; D. LANE, ANTIBODIES, A LABORATORY MANUAL,          1988;            ORNSTEIN L.: "Disc electrophoresis - I: Background and          theory", ANN. NY ACAD. SCI., vol. 121, 1964, pages 321 -          349;            MATSUDIARA, PT; DR BURGESS: "SDS microslab linear          gradient polyacrylamide gel electrophoresis", ANAL.          BIOCHEM., vol. 87, 1987, pages 386 - 396, XP024819922,          DOI: doi:10.1016/0003-2697(78)90688-7;            NEUHOFF ET AL., ELECTROPHORESIS, vol. 6, 1985, pages 427          - 448;            NEUHOFF ET AL., ELECTROPHORESIS, vol. 9, 1988, pages 255          - 262;            VOLLER, A. ET AL., J. CLIN. PATHOL., vol. 31, 1978, pages          507 - 520;            BUTLER, J. E., METH. ENZYMOL., vol. 73, 1981, pages 482 -          523;            "Enzyme Immunoassay", 1980, CRC PRESS;            BUTLER, J. E.; VAN REGENMORTEL, M.: "Structure of          Antigens", vol. 1, 1992, CRC PRESS, pages: 209 -          259;            BUTLER, J. E. ET AL.: "Immunochemistry", 1994, MARCEL          DEKKER, INC., pages: 759 - 803;            "Immunochemistry of Solid-Phase Immunoassay", 1991, CRC          PRESS;            CROWTHER: "Methods in Molecule Biology", vol. 42, 1995,          HUMANA PRESS, article "ELISA: Theory and          Practice";            KABAT E. A. ET AL.: "Sequences of Proteins of          Immunological Interest", 1987, NATIONAL INSTITUTES OF          HEALTH;            HARLOW; LANE: "Antibodies, A Laboratory Manual", 1988,          COLD SPRING HARBOR PUBLICATIONS;            JONES ET AL., NATURE, vol. 321, 1986, pages 522 -          525;            RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 -          327;            PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593          - 596;            VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 -          1536;            SIMS ET AL., J. IMMUNOL., vol. 151, 1993, pages          2296;            CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages          901;            CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992,          pages 4285;            PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages          2623;            MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81,          1984, pages 6851 - 6855;            KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages          495;            KILPATRICK KE ET AL.: "Gene gun delivered DNA-based          immunizations mediate rapid production of murine          monoclonal antibodies to the Flt-3 receptor", HYBRIDOMA,          vol. 17, no. 6, December 1998 (1998-12-01), pages 569 -          76;            KILPATRICK KE ET AL.: "High-affinity monoclonal          antibodies to PED/PEA-15 generated using 5 microg of          DNA", HYBRIDOMA, vol. 19, no. 4, August 2000          (2000-08-01), pages 297 - 302;            GODING: "Monoclonal Antibodies: Principles and Practice",          1986, ACADEMIC PRESS, pages: 59 - 103;            KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001;            BRODEUR ET AL.: "Monoclonal Antibody Production          Techniques and Applications", 1987, MARCEL DEKKER, INC.,          pages: 51 - 63;            HARLOW; LANE: "Antibodies, A Laboratory Manul", 1988,          COLD SPRING HARBOR PUBLICATIONS;            GRANT GA: "Synthetic Peptides: A User Guide", 1992, W.H.          FREEMAN AND CO.;            "Principles of Peptide Synthesis", 1993, SPRINGER-VERLAG          INC.;            ABRAHMSEN L ET AL., BIOCHEMISTRY, vol. 30, 1991, pages          4151;            DAWSON ET AL.: "Synthesis of Proteins by Native Chemical          Ligation", SCIENCE, vol. 266, 1994, pages 776 - 779,          XP002064666, DOI: doi:10.1126/science.7973629;            BAGGIOLINI M ET AL., FEBS LETT., vol. 307, 1992, pages 97          - 101;            CLARK-LEWIS I ET AL., J.BIOL.CHERN., vol. 269, 1994,          pages 16075;            CLARK-LEWIS I ET AL., BIOCHEMISTRY, vol. 30, 1991, pages          3128;            RAJARATHNAM K ET AL., BIOCHEMISTRY, vol. 33, 1994, pages          6623 - 30;            SCHNOLZER, M ET AL., SCIENCE, vol. 256, 1992, pages          221;            DELISLE MILTON RC ET AL.: "Techniques in Protein          Chemistry IV", 1992, ACADEMIC PRESS, pages: 257 -          267;            NEW ENGLAND BIOLABS PRODUCT CATALOG, 1996, pages          164;            ZOLLER MJ ET AL., NUCL. ACIDS RES., vol. 10, 1982, pages          6487 - 500;            MUNSON ET AL., ANAL. BIOCHEM., vol. 107, 1980, pages          220	108666-1-0-0 K M; 87454-1-0-0 K M; 106581-1-0-0 K M; 105641-0-0-0 K M; 184611-0-0-0 K M; 184587-0-0-0 K M; 86266-0-0-0 K M		40690; 00012; 40466; 40467; 49856	R18707 K M; R17076 K M; R21860 K M; RA0DRF K M; RA00H1 K M; RA00C8 K M; RA0DRG K M		CN110404064-A;  CN110404064-B	Adjuvant composition useful for vaccine            composition for poultry, comprises vitamin E and/or            sucrose fatty acid ester, polyoxyethylene hydrogenated            castor oil, and acrylic polymer	TIAN K;  LIU Y;  ZHANG X	LUOYANG SAIWEI BIOTECHNOLOGY CO LTD (LUOY-Non-standard)	2019943815	   NOVELTY - Adjuvant composition comprises vitamin E                and/or sucrose fatty acid ester having HLB value of                less than or equal to 5, polyoxyethylene                hydrogenated castor oil, and acrylic polymer.    USE - The adjuvant composition is useful for vaccine                composition for poultry (all claimed).    ADVANTAGE - The adjuvant composition: can actively                stimulates immune response in chicken body; will                not produces white oil residue and ensures chicken                meat quality.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for                vaccine composition comprising antigen and adjuvant                composition mentioned above, the amount of the                adjuvant composition is 30-70 Wt.%/vol.%. 			A96 (Medical, dental, veterinary, cosmetic.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C02 (Heterocyclic.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	A12-V;  B04-C03B;  B04-C03C;  B07-A02;  B14-S11;  B14-S12;  B15-E00;  C04-C03B;  C04-C03C;  C07-A02;  C14-S11;  C14-S12;  C15-E00;  D05-H07	A61K-039/145;  A61K-039/17;  A61K-039/39;  A61P-031/14;  A61P-031/16;  A61P-037/04	CN110404064-A   05 Nov 2019   A61K-039/39   201993Pages: 17   Chinese;  CN110404064-B   16 Jun 2023   A61K-039/39   202354   Chinese	CN110404064-A    CN10395103    27 Apr 2018;   CN110404064-B    CN10395103    27 Apr 2018	CN110404064-B Previous Publ. Patent CN110404064	CN10395103    27 Apr 2018			CN110404064-A -- CN1171053-A   SOLVAY SA (SOLV)   HILGERS L,  STREBELLE M;  CN101820903-A   FRAUNHOFER USA INC (FRAU)   YUSIBOV V;  CN104147599-A   UNIV HUAZHONG SCI & TECHNOLOGY (UYHZ)   LIANG K,  LIU W,  WAN J,  XU Q,  YANG X;  CN105879025-A   LI S (LISS-Individual)   LI S;  CN106267183-A   PULIKE BIOLOGICAL ENG INC (PULI-Non-standard)   ZHANG X,  SUN J,  ZHANG H,  TIAN K;  CN107375922-A   UNIV NANJING AGRIC (UYNA)   JIANG P,  BAI J,  ZHU X,  WANG X;  CN110404065-A   LUOYANG SAIWEI BIOTECHNOLOGY CO LTD (LUOY-Non-standard)   TIAN K,  YAN Z,  ZHANG X;  US20100310593-A1   ;  US20140205633-A1   ;  CN110404064-B -- CN102245201-A   MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  BRIGHAM & WOMENS HOSPITAL INC (BGHM)   ALEXIS F,  IANNACONE M,  SHI J,  BASTO P,  MOSEMAN A,  VON ANDRIAN U,  LANGER R,  FAROKHZAD O C,  TONTI E;  CN105879025-A   LI S (LISS-Individual)   LI S	CN110404064-A  FRANK WEGMANN: "The          Carbomer-Lecithin Adjuvant Adjuplex Has Potent          Immunoactivating Properties and Elicits Protective          Adaptive Immunity against Influenza Virus Challenge in          Mice", CLINICAL AND VACCINE          IMMUNOLOGY,relevantClaims[1-10],relevantPassages[1004-1012];  STEPHANE          ASCARATEIL: "Surfactants in vaccine adjuvants:          description and perspectives",          VACCINE,relevantClaims[1-10],relevantPassages[S83-S85];  L.A.THHILGERS:          "Effect of various adjuvants on secondary immune response          in chickens", VETERINARY IMMUNOLOGY AND          IMMUNOPATHOLOGY,relevantClaims[1-10],relevantPassages[159-171];  : "",          ,relevantClaims[1-10],relevantPassages[95-97+100]	4015-0-0-0 K M; 109110-0-0-0 K M; 109113-0-0-0 K M; 593220-1-0-0 K M; 2327058-1-0-0 K M; 593222-1-0-0 K M; 593224-1-0-0 K M; 107961-1-0-0 K M;  K M;  K M; 104431-0-0-0 K M; 104379-0-0-0 K M; 19200-0-0-0 K M; 465933-0-0-0 K M; 1911-0-0-0 ; 8781-0-0-0 ; 10151-0-0-0 ; 444-0-0-0 ; 2327058-1-0-0 CL USE			R00179 K M; R14756 K M; R01163 K M; RA0CPW K M; RA852V K M; RB8CVF K M; RA852X K M; RA852Z K M; RA0J5S K M; RCP4F3 K M; RCP4F4 K M; RA07AE K M; RA035M K M; R00657 K M; RA5I5U K M; R00446 ; R00444 ; R00460 ; R00351 	0179-S; 1163-S; 0657-S	WO2019217967-A1;  US2021162039-A1	Immunogenic composition ofr reducing incidence of            or severity of clinical sign or symptom of infection by            porcine epidemic disease virus (PEDV) or            enterotoxigenic Escherichia coli (ETEC), comprises            recombinant protein from PEDV or ETEC	ZHANG W;  FANG Y	UNIV KANSAS STATE RES FOUND (UNIV-C);  UNIV KANSAS STATE RES FOUND (UNIV-C)	201995994G	   NOVELTY - Immunogenic composition comprises a component                selected from recombinant protein from porcine                epidemic disease virus (PEDV) or enterotoxigenic                Escherichia coli (ETEC); nucleic acid sequence from                PEDV inserted into a bacterial strain expressing                the inserted nucleic acid sequence; nucleic acid                sequence from ETEC inserted into a vector                expressing the inserted nucleic acid sequence; and                combination.    USE - The composition is useful for reducing                incidence of or severity of clinical sign or                symptom of infection by PEDV or ETEC, where the                clinical sign is selected from diarrhea, vomiting,                anorexia death, dehydration, and any combination                for PEDV; or the clinical sign is selected from                diarrhea, vomiting, dehydration, roughened hair                coat, subnormal body temperature, shivering, death,                neonatal septicemia and polyserositis, lesions,                excess watery fluid in the small intestine and/or                colon, a distended and/or gas-filled small                intestine and/or colon, mild reddening and                congestion of the stomach, congestion of the                gastrointestinal tract, coliforms adhered to                microvilli of intestinal epithelial cells, necrosis                of villi, microvascular thrombosis in the lamina                propria, fibrinous polyserositis, arthritis, and                combination for ETEC (all claimed).    ADVANTAGE - The incidence of or severity of clinical sign                is reduced by greater than or equal to 10% in                comparison to an animal not receiving an                administration of the immunogenic composition. The                method provides safe but effective vaccines or                immunogenic compositions against clinical signs,                symptoms, and losses attributable to or caused by                infection with PEDV and/or ETEC.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) reducing the incidence of or severity of                clinical sign or symptom of infection by PEDV or                ETEC which involves administering the immunogenic                composition to an animal;    (2) making the immunogenic composition which                involves inserting a sequence encoding a protein                selected from a spike protein of PEDV; the LTA                subunit of ETEC; the K88 FaeG subunit of ETEC; the                F18 adhesin subunit of ETEC; and combination into a                vector; and    (3) a kit comprising a component selected from                recombinant protein from PEDV or ETEC; nucleic acid                sequence from PEDV inserted into a bacterial strain                expressing the inserted nucleic acid sequence;                nucleic acid sequence from ETEC inserted into a                vector expressing the inserted nucleic acid                sequence; and combination; and a set of                instructions for administration to an animal. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E02F;  B04-E03F;  B04-E08;  B04-E99;  B04-F10A3E;  B04-N03J;  B04-N03K;  B04-N08;  B14-C09;  B14-E02;  B14-E05;  B14-E11A;  B14-F04;  B14-G03;  B14-K01E;  B14-S06;  B14-S11D2;  B14-S11D3;  B14-S12;  B14-S13;  C04-E02F;  C04-E03F;  C04-E08;  C04-E99;  C04-F10A3E;  C04-N03J;  C04-N03K;  C04-N08;  C14-C09;  C14-E02;  C14-E05;  C14-E11A;  C14-F04;  C14-G03;  C14-K01E;  C14-S06;  C14-S12;  C14-S13;  D05-H07;  D05-H99	A61K-039/00;  A61K-039/108;  A61K-039/225;  C07K-014/165	WO2019217967-A1   14 Nov 2019   A61K-039/00   201991Pages: 66   English;  US2021162039-A1   03 Jun 2021   A61K-039/225   202146   English	WO2019217967-A1    WOUS032029    13 May 2019;   US2021162039-A1    US17250020    04 Nov 2020	US2021162039-A1 PCT application Application WOUS032029;   US2021162039-A1 Provisional Application US670126P	US670126P    11 May 2018;  US17250020    04 Nov 2020	WO2019217967-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    		WO2019217967-A1 -- US20120269842-A1   ;  US20150283229-A1   ;  US20150328307-A1   ;  WO2007114878-A2   US SEC OF NAVY (USNA)   SAVARINO S J,  HOLMES R K,  JOBLING M G;  US2021162039-A1 -- US20150283229-A1   		184616-0-0-0 K M Q; 93605-0-0-0 K M; 105730-0-0-0 K M; 184616-0-0-0 CL RCT USE			RA00H3 K M Q; RA00NS K M; RA012P K M		WO2019039863-A2;  WO2019039863-A3;  KR2020064064-A;  KR2275304-B1	Producing aptamer used for treating influenza            virus infection by contacting surrogate virus            expressing target protein on envelope of virus with            nucleic acid library by modified systematic evolution            of ligands by exponential enrichment	JANG S K;  KIM K;  SHIN E;  KWON J;  HAN M J;  NARAYAN C;  RYU S H;  KIM G S;  SIN U;  HAN M	APTAMER SCI INC (APTA-Non-standard);  POSTECH ACAD-IND FOUND (UYPO-C)	201919804S	   NOVELTY - Method for producing aptamer involves                contacting a surrogate virus expressing a target                protein on envelope of virus with a nucleic acid                library by performing a modified systematic                evolution of ligands by exponential enrichment                (SELEX).    USE - The method is useful for producing aptamer,                which is used in influenza virus detecting                composition, kit or pharmaceutical composition for                diagnosing, preventing and treating influenza virus                infection (all claimed).    ADVANTAGE - The method produces aptamer having excellent                binding affinity and specificity in a simple                manner, accurately detects influenza virus, and                exhibits rapid and maximized therapeutic effect                even at reduced dosage and does not cause adverse                side effects, and reduces administration frequency                of the compositions.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) aptamer produced by (a) contacting                surrogate virus expressing target protein to the                envelope of the virus with nucleic acid library,                (b) optionally (i) using a gene expression system                using a virus, bacteria, or eukaryotic cell,                contacting the separately isolated and purified                target protein with the surrogate virus and                contacting the selected nucleic acid library, or                (ii) contacting the target protein with a selected                nucleic acid library in contact with the surrogate                virus, (c) selectively separating only the binding                to the target protein from the construct bound by                the contact, (d) selectively removing only those                not bound to the target protein among the                structures bound by the contact, and (e) isolating                and amplifying the nucleic acid from the                selectively separated construct, where the steps                (a)-(e) are repeated for one or more times, and the                aptamer specifically binding to an influenza virus                comprises at least one nucleic acid sequence chosen                from SEQ ID NOs: 1-9;    (2) composition comprising the nucleic acid                sequence of SEQ ID NOs: 1-9, which specifically                binds to the influenza H3N2 virus;    (3) kit comprising the aptamer; and    (4) pharmaceutical composition comprising the                nucleic acid sequence of SEQ ID NOs: 1-9 which                specifically binds to the influenza H3N2                virus.    Sequences not defined here may be found at                ftp://ftp.wipo.int/pub/published_pct_sequences/publication. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.);  S03 (Scientific Instrumentation)	B04-E07F;  B04-E99;  B04-F11B;  B11-C08E;  B14-A02B2;  C04-E07F;  C04-E99;  C04-F11B;  C11-C08E;  C14-A02B2;  D05-C23;  D05-H06A;  D05-H09;  D05-H99;  A11-C01C;  A11-C03;  A12-E13;  A12-V01;  A12-V03C2;  A12-W11L;  S03-E09F;  S03-E14H3;  S03-E14H5	A61K-031/7088;  A61P-031/16;  C12N-015/10;  C12N-015/115;  G01N-033/558;  G01N-033/569	WO2019039863-A2   28 Feb 2019   C12N-015/10   201920Pages: 46   ;  WO2019039863-A3   11 Jul 2019   C12N-015/10   201953   ;  KR2020064064-A   05 Jun 2020   C12N-015/10   202048   	WO2019039863-A2    WOKR009662    22 Aug 2018;   WO2019039863-A3    WOKR009662    22 Aug 2018;   KR2020064064-A    KR706933    22 Aug 2018;   KR2275304-B1    KR706933    22 Aug 2018	KR2020064064-A PCT application Application WOKR009662;   KR2020064064-A Based on Patent WO2019039863;   KR2275304-B1 PCT application Application WOKR009662;   KR2275304-B1 Based on Patent WO2019039863	US548989P    23 Aug 2017;  KR706933    09 Mar 2020	WO2019039863-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2019039863-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    		;  WO2019039863-A3 -- KR2016019573-A   UNIV KOOKMIN IND ACAD COOP FOUND (UYKO)   YONG J J,  JIN M L,  HYE M W	WO2019039863-A3  YUAN, S. ET AL.:          "Cross-Protection of Influenza A Virus Infection by a DMA          Aptamer Targeting the PA Endonuclease Domain",          ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 59, no. 7, 31          July 2015 (2015-07-31), pages 4082 - 4093,          XP055618679,relevantClaims[1-38],relevantPassages[See          abstract; page 4083.];  PAREKH, P. ET AL.:          "Aptamers recognizing glycosylated hemagglutinin          expressed on the surface of vaccinia virus-infected          cells", ANALYTICAL CHEMISTRY, vol. 82, no. 20, 27          September 2010 (2010-09-27) - 15 October 2010          (2010-10-15), pages 8642 - 8649,          XP055618684,relevantClaims[1-38],relevantPassages[See          abstract; pages 2-3.];  WONGPHATCHARACHAI,          M. ET AL.: "Neutralizing DNA Aptamers against Swine          Influenza H3N2 Viruses", JOURNAL OF CLINICAL          MICROBIOLOGY, vol. 51, no. 1, 17 October 2012          (2012-10-17) - 31 January 2013 (2013-01-31), pages 46 -          54, XP055618688,relevantClaims[1-38],relevantPassages[See          abstract; pages 47-48.];  STOLTENBURG, R. ET          AL.: "SELEX-A (r)evolutionary method to generate          high-affinity nucleic acid ligands", BIOMOLECULAR          ENGINEERING, vol. 24, 2007, pages 381 - 403, XP022251573,          doi:10.1016/j.bioeng.2007.06.001,relevantClaims[1-38],relevantPassages[See          pages 382-384; figure 2.]	92818-0-0-0 ; 107779-0-0-0 ; 97115-1-0-0 ; 90356-0-0-0 			R01857 ; R01863 ; R03231 ; R01852 		WO2019010422-A1;  EP3648781-A1;  US2020165594-A1;  EP3648781-A4	Use of class 2, type VI clustered regularly            interspaced short palindromic repeats system for            treating, preventing, suppressing, or alleviating viral            pathogenesis, infection, propagation and/or replication            in mammalian subject	ZHANG F;  GOOTENBERG J S;  ABUDAYYEH O O;  SABETI P;  MYHRVOLD C;  FREIJE C A	BROAD INST INC (BROD-C);  MASSACHUSETTS INST TECHNOLOGY (MASI-C);  HARVARD COLLEGE (HARD-C);  BROAD INST INC (BROD-C);  MASSACHUSETTS INST TECHNOLOGY (MASI-C);  HARVARD COLLEGE (HARD-C);  BROAD INST INC (BROD-C);  MASSACHUSETTS INST TECHNOLOGY (MASI-C);  HARVARD COLLEGE (HARD-C);  MASSACHUSETTS TECHNOLOGY INST (MASI-C)	201904655J	   NOVELTY - Use of class 2, type VI clustered regularly                interspaced short palindromic repeats (CRISPR)                system is claimed, for treating, preventing,                suppressing, and/or alleviating viral pathogenesis,                infection, propagation and/or replication in a                subject, where the system comprises (a) a class 2,                type VI CRISPR effector protein and/or a                polynucleic acid encoding the effector protein and                (b) one or more guide RNAs and/or one or more                polynucleic acids encoding the guide RNAs designed                to bind to one or more target molecules of a                virus.    USE - The CRISPR system is useful for treating,                preventing, suppressing, and/or alleviating viral                pathogenesis, infection, propagation and/or                replication in a subject, performing immunization                in a subject, or reducing viremia or viral load in                a subject. The subject is a human or animal                subject. The subject is a mammalian subject (all                claimed). 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  A96 (Medical, dental, veterinary, cosmetic.);  T01 (Digital Computers)	B04-E99;  B04-E02;  B04-E03;  B04-E13;  B04-L05A2;  B04-N04;  B14-A02;  B14-G01;  B14-S11A;  C04-E99;  C04-E02;  C04-E03;  C04-E13;  C04-L05A2;  C04-N04;  C14-A02;  C14-G01;  C14-S11A;  A12-V01;  T01-J06A	A61K-035/76;  C12N-015/10;  C12N-015/113;  C12N-009/22	WO2019010422-A1   10 Jan 2019   A61K-035/76   201908Pages: 302   English;  EP3648781-A1   13 May 2020   A61K-035/76   202040   English;  US2020165594-A1   28 May 2020   C12N-015/10   202044   English;  EP3648781-A4   19 May 2021   A61K-035/76   202142   English	WO2019010422-A1    WOUS041099    06 Jul 2018;   EP3648781-A1    EP828493    06 Jul 2018;   US2020165594-A1    US16629310    07 Jan 2020;   EP3648781-A4    EP828493    06 Jul 2018	EP3648781-A1 PCT application Application WOUS041099;   EP3648781-A1 Based on Patent WO2019010422;   US2020165594-A1 PCT application Application WOUS041099;   US2020165594-A1 Provisional Application US530029P	US530029P    07 Jul 2017;  WOUS041099    06 Jul 2018;  US16629310    07 Jan 2020	WO2019010422-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP3648781-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    EP3648781-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  		WO2019010422-A1 -- US20160208243-A1   ;  US20160340660-A1   ;  US2020165594-A1 -- US20170362644-A1   ;  EP3648781-A4 -- WO2016205764-A1   ABUDAYYEH O O (ABUD-Individual);  BROAD INST INC (BROD);  GOOTENBERG J S (GOOT-Individual);  HARVARD COLLEGE (HARD);  JOUNG J (JOUN-Individual);  KONERMANN S (KONE-Individual);  KOONIN E (KOON-Individual);  LANDER E S (LAND-Individual);  MAKAROVA K S (MAKA-Individual);  MASSACHUSETTS INST TECHNOLOGY (MASI);  MINAKHIN L (MINA-Individual);  SEMENOVA E (SEME-Individual);  SEVERINOV K (SEVE-Individual);  SHMAKOV S (SHMA-Individual);  UNIV RUTGERS STATE NEW JERSEY (RUTF);  WOLF Y I (WOLF-Individual);  ZHANG F (ZHAN-Individual);  SKOLKOVO SCI & TECHNOLOGY INST (SKOL-Non-standard)   ABUDAYYEH O O,  GOOTENBERG J S,  JOUNG J,  KONERMANN S,  KOONIN E,  LANDER E S,  MAKAROVA K S,  MINAKHIN L,  SEMENOVA E,  SEVERINOV K,  SHMAKOV S,  WOLF Y I,  ZHANG F	EP3648781-A4  L. CONG ET AL:          "Multiplex Genome Engineering Using CRISPR/Cas Systems",          SCIENCE, vol. 339, no. 6121, 15 February 2013          (2013-02-15), pages 819 - 823, XP055067741, ISSN:          0036-8075, DOI:          10.1126/science.1231143,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  CHYLINSKI K ET AL:          "Classification and evolution of type II CRISPR-Cas          systems", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL          LTD, vol. 42, no. 10, 1 June 2014 (2014-06-01), pages          6091 - 6105, XP002760958, ISSN: 0305-1048, [retrieved on          20140411], DOI:          10.1093/NAR/GKU241,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  CARYN R. HALE ET          AL: "Target RNA capture and cleavage by the Cmr type          III-B CRISPR-Cas effector complex", GENES &          DEVELOPMENT, vol. 28, no. 21, 1 November 2014          (2014-11-01), US, pages 2432 - 2443, XP055247605, ISSN:          0890-9369, DOI:          10.1101/gad.250712.114,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  CARYN R. HALE ET          AL: "RNA-Guided RNA Cleavage by a CRISPR RNA-Cas Protein          Complex", CELL, vol. 139, no. 5, 25 November 2009          (2009-11-25), Amsterdam NL, pages 945 - 956, XP055038712,          ISSN: 0092-8674, Retrieved from the Internet          &lt;URL:http://www.cell.com/cell/fulltext/S0092-8674(09)00977-5&gt;          DOI:          10.1016/j.cell.2009.07.040,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            See also references of WO 2019010422A1	93605-0-0-0 K U; 105730-0-0-0 K U			RA00NS K U; RA012P K U		WO2019087092-A1;  AU2018360389-A1;  CA3081675-A1;  KR2020084333-A;  CN111386128-A;  EP3706798-A1;  IN202047023713-A;  US2020289477-A1;  JP2021503446-W;  US11497735-B2;  HK40036191-A0;  US2023081191-A1;  JP7378395-B2;  JP2023182597-A	Modulating immune response in human, involves            contacting human with inhibitor of V-domain            immunoglobulin (Ig) suppressor of T cell activation            pathway and T-cell Ig and mucin-domain containing-3            pathway	SASIKUMAR P G N;  RAMACHANDRA M;  RAMACHANDRA R K;  LAZORCHAK A S;  WYANT T L	AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY-C);  CURIS INC (CURS-C);  AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY-C);  CURIS INC (CURS-C);  AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY-C);  CURIS INC (CURS-C);  AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY-C);  CURIS INC (CURS-C);  AURIGENE ONCOLOGY LTD (REDY-C)	201940532L	   NOVELTY - Method (M1) of modulating an immune response                in a subject, involves contacting the subject with                an inhibitor of V-domain immunoglobulin (Ig)                suppressor of T cell activation (VISTA) pathway and                an inhibitor of T-cell Ig and mucin-domain                containing-3 (TIM-3) pathway.    USE - The method is useful for (a) modulating an                immune response in a subject, (b) treating cancer                or infectious disease in a subject, or (c)                inhibiting growth of tumor cells and/or metastasis.                The subject is suffering from a disease or disorder                chosen from cancer, immune disorders,                immunodeficiency disorders, inflammatory disorders,                infectious diseases, and transplant rejection. The                tumor cells are from a cancer chosen from small                cell lung cancer, multiple myeloma, bladder                carcinoma, primary ductal carcinoma, ovarian                carcinoma, Hodgkin's lymphoma, gastric carcinoma,                acute myeloid leukemia, and pancreatic cancer. The                tumor cells are from a cancer chosen from 64                cancers including blastoma, breast cancer,                epithelial cancer, colon cancer, lung cancer,                melanoma, prostate cancer, renal cancer, bone                cancer, pancreatic cancer, skin cancer, cancer of                the head or neck, uterine cancer, ovarian cancer,                colorectal cancer, rectal cancer, cancer of the                anal region, cancer of the peritoneum, stomach                cancer, testicular cancer and environmentally                induced cancers. The infectious disease is                bacterial infection, viral infection, fungal                infection or parasitic infection. The infectious                disease is chosen from at least one bacterium                chosen from 42 bacterium including Bordetella,                Borrelia, Brucella, Burkholderia, Campylobacter,                Chlamydia, Clostridium, Conococcus,                Corynebacterium, Enterobacter, Enterococcus,                Erwinia, Listeria, Mycobacterium, Mycoplasma,                Neisseria, Pasteurella, Pelobacter, Proteus,                Pseudomonas, Rickettsia, Salmonella, Serratia,                Shigella, Staphylococcus, Streptococcus, tetanus,                Treponema, Vibrio, Yersinia, andXanthomonas, at                least one virus chosen from arboviral encephalitis                virus, adenovirus, herpes simplex type I, herpes                simplex type 2, Varicella-zoster virus,                Epstein-barr virus, cytomegalovirus, herpesvirus                type 8, papillomavirus, BK virus, coronavirus,                echovirus, smallpox, hepatitis B, bocavirus,                parvovirus B19, astrovirus, Norwalk virus,                coxsackievirus, hepatitis A, poliovirus,                rhinovirus, severe acute respiratory syndrome                virus, hepatitis C, yellow fever, dengue virus,                West Nile virus, rubella, hepatitis E, HIV, human                T-cell lymphotropic virus (HTLV), influenza,                guanarito virus, Junin virus, Lassa virus, Machupo                virus, Sabia virus, Crimean-Congo hemorrhagic fever                virus, Ebola virus, Marburg virus, measles virus,                molluscum virus, mumps virus, parainfluenza,                respiratory syncytial virus, human metapneumovirus,                Nipah virus, rabies, hepatitis D, rotavirus                orbivirus, coltivirus, vaccinia virus, and Banna                virus, at least one fungal infection chosen from                thrush, sporotrichosis, zygomycosis,                chromoblastomycosis, lobomycosis, mycetoma,                onychomycosis, Aspergillus fumigatus, A.niger,                Blastomyces dermatitidis, Candida albicans,                C.krusei, C.glabrata, C.tropicalis, Coccidioides                immitis, Cryptococcus neoformans, Histoplasma                capsulatum, Paracoccidioides brasiliensis, and                Sporothrix schenckii, and at least one parasite                chosen from 43 parasites including Acanthamoeba,                Babesia microti, Balantidium coli, Entamoeba                histolytica, Giardia lamblia, Cryptosporidium                muris, Trypanosoma gambiense, T.rhodesiense,                T.brucei, T.cruzi, and Leishmania mexicana (all                claimed). The subject is mammal, preferably                human.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a pharmaceutical composition comprising a                carrier or an excipient and at least one                2-(methyl((methyl(1-(3-(1-methyl-1-(methylamino)ethyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)carbonyl)amino)propanoic                acid of formula (I), or its salt, and at least one                N-(1-(3-(1-amino-1-methylethyl)-1,2,4-oxadiazol-5-yl)ethyl)-N,N-dimethylamine                of formula (II), or its salt; and    (2) a method (M2) of treating or preventing                cancer or infectious in a subject, involves                conjointly administering a compound that inhibits                the VISTA pathway, and TIM-3 pathway to the                subject.    G = H or (1-6C)alkyl;    Ra = (1-6C)alkyl optionally substituted with                -OH, -C(O)NRxRy, -NRxRy, guanidino, carboxylic                acid, heteroaryl or aryl-OH;    Ra' = H;    Ra,Ra' = taken together with the atom to which                they are attached form 5- to 6-membered ring;    Rb = (1-6C)alkyl, optionally substituted with                -OH, -C(O)NRxRy, -NRxRy, carboxylic acid or                heteroaryl, where the heteroaryl is optionally                substituted with hydroxy;    Rc = H;    Rb,Rc = taken together with the atoms to which                they are attached form 5- to 6-membered ring;    Rd = H, (1-6C)alkyl optionally substituted                with -OH, -NRxRy or carboxylic acid;    Re = H;    Rd,Re = taken together with the atoms to which                they are attached form 5- to 6-membered ring                optionally containing 1-3 heteroatoms chosen from                O, NH or S;    Rx,Ry = H, (1-6C)alkyl, (2-6C)acyl or                (1-6C)cycloalkyl;    Z = -OH or -NH-G';    G' = H or (1-6C)alkyl;    Y' = H or group of formula (a);    Ra" = (1-6C)alkyl optionally substituted with                -OH, -NRxRy, -SRx, carboxylic acid, guanidino or                aryl, where the aryl group is optionally                substituted with hydroxy;    Ra,G = together with the atom to which they                are attached form 5- to 6-membered ring containing                1-3 heteroatoms chosen from O, N or S;    Ra'" = H;    Ra",Ra'" = taken together with the atom to                which they are attached form 5- to 6-membered ring,                optionally comprising 1-3 heteroatoms chosen from                O, N or S;    Rb' = (1-6C)alkyl, optionally substituted with                -C(O)NRxRy', -NRxRy or carboxylic acid;    Rc' = H;    Rb',Rc' = taken together with the atoms to                which they are attached form 5- to 6-membered ring                containing 1-3 heteroatoms chosen from O, N or S,                where the 5- to 6-membered ring is optionally                substituted with hydroxy;    Rd' = (1-6C)alkyl, optionally substituted with                -ORx', carboxylic acid or aryl-OH;    Re' = H;    Rd',Re' = taken together with the atoms to                which they are attached form 5- to 6-membered ring                containing 1-3 heteroatoms chosen from O, N or                S;and    Rx',Ry' = H, (1-6C)alkyl or (2-6C)acyl. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.)	B01-A02;  B01-B02;  B01-C01;  B02-A;  B02-B;  B02-C01;  B02-D;  B02-M;  B04-A07A1;  B04-B03A;  B04-C01;  B04-G01A;  B04-G21;  B04-H02;  B04-H04A;  B04-H05;  B04-J07;  B05-A03B3;  B05-B01A;  B05-B01G;  B05-C01;  B06-H;  B07-E04;  B07-H;  B09-D02;  B10-A09B;  B10-A12C;  B10-A13D;  B10-B01A;  B10-B02J;  B10-C02;  B14-A01;  B14-A02;  B14-A04;  B14-B02;  B14-C03;  B14-G01;  B14-G02C;  B14-H01;  B14-S18;  B15-A00A	A61K-031/4245;  A61K-045/06;  A61P-035/00;  A61P-031/00;  A61K-031/5377;  A61K-045/00;  A61P-031/04;  A61P-031/10;  A61P-031/12;  A61P-033/00;  A61P-035/02;  A61P-035/04;  A61P-037/02;  A61P-043/00	WO2019087092-A1   09 May 2019   A61K-045/06   201938Pages: 146   English;  AU2018360389-A1   07 May 2020   A61K-045/06   202038   English;  CA3081675-A1   09 May 2019   A61K-045/06   202049   English;  KR2020084333-A   10 Jul 2020   A61K-031/4245   202059   ;  CN111386128-A   07 Jul 2020   A61K-045/06   202059   Chinese;  EP3706798-A1   16 Sep 2020   A61K-045/06   202076   English;  IN202047023713-A   28 Aug 2020   A61K-045/06   202076   English;  US2020289477-A1   17 Sep 2020   A61K-031/4245   202076   English;  JP2021503446-W   12 Feb 2021   A61K-045/06   202114Pages: 113   Japanese;  US11497735-B2   15 Nov 2022   A61K-031/4245   202292   English;  HK40036191-A0   21 May 2021   A61K-045/06   202298   English;  US2023081191-A1   16 Mar 2023   A61K-031/4245   202323   English;  JP7378395-B2   13 Nov 2023   A61K-031/4245   202394   Japanese;  JP2023182597-A   26 Dec 2023   A61K-045/06   202402   Japanese	WO2019087092-A1    WOIB058533    31 Oct 2018;   AU2018360389-A1    AU360389    31 Oct 2018;   CA3081675-A1    CA3081675    31 Oct 2018;   KR2020084333-A    KR714821    31 Oct 2018;   CN111386128-A    CN80076269    31 Oct 2018;   EP3706798-A1    EP822129    31 Oct 2018;   IN202047023713-A    IN47023713    05 Jun 2020;   US2020289477-A1    US16761964    06 May 2020;   JP2021503446-W    JP526264    31 Oct 2018;   US11497735-B2    US16761964    06 May 2020;   HK40036191-A0    HK6026193    24 Feb 2021;   US2023081191-A1    US960586    05 Oct 2022;   JP7378395-B2    JP526264    31 Oct 2018;   JP2023182597-A    JP146295    08 Sep 2023	AU2018360389-A1 PCT application Application WOIB058533;   AU2018360389-A1 Based on Patent WO2019087092;   CA3081675-A1 PCT application Application WOIB058533;   CA3081675-A1 Based on Patent WO2019087092;   KR2020084333-A PCT application Application WOIB058533;   KR2020084333-A Based on Patent WO2019087092;   CN111386128-A PCT application Application WOIB058533;   CN111386128-A Based on Patent WO2019087092;   EP3706798-A1 PCT application Application WOIB058533;   EP3706798-A1 Based on Patent WO2019087092;   IN202047023713-A PCT application Application WOIB058533;   IN202047023713-A Based on Patent WO2019087092;   US2020289477-A1 PCT application Application WOIB058533;   JP2021503446-W PCT application Application WOIB058533;   JP2021503446-W Based on Patent WO2019087092;   US11497735-B2 PCT application Application WOIB058533;   US11497735-B2 Based on Patent WO2019087092;   US11497735-B2 Previous Publ. Patent US2020289477;   HK40036191-A0 PCT application Application WOIB058533;   HK40036191-A0 Based on Patent WO2019087092;   HK40036191-A0 Previous Publ. Patent EP3706798;   US2023081191-A1 Cont of Application WOIB058533;   US2023081191-A1 Cont of Application US761964;   US2023081191-A1 Cont of Patent US11497735;   JP7378395-B2 PCT application Application WOIB058533;   JP7378395-B2 Previous Publ. Patent JP2021503446;   JP7378395-B2 Based on Patent WO2019087092;   JP2023182597-A Div ex Application JP526264	IN41039497    06 Nov 2017;  EP822129    31 Oct 2018;  CA3081675    04 May 2020;  KR714821    22 May 2020;  CN80076269    26 May 2020	WO2019087092-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          EP3706798-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                  		;  US11497735-B2 -- US10781189-B2   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S;  US10961205-B2   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY);  SASIKUMAR P G N (SASI-Individual);  RAMACHANDRA M (RAMA-Individual);  NAREMADDEPALLI S S S (NARE-Individual)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S;  WO2018073754-A1   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S;  WO2019087087-A1   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S,  GOWDA N;  JP2016539662-A   INTELLIGENT GROWTH SOLUTIONS LTD (INTE-Non-standard)   AYKROYD H R G,  MARRIOTT L J,  TYRRELL P M;  KR2016081897-A   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S S;  US3227725-A   UNION CARBIDE CORP (UNIC);  US5387585-A   HOFFMANN LA ROCHE & CO AG F (HOFF)   BORER R,  GASSNER W,  GERECKE M,  KYBURZ E;  US5665718-A   HOFFMANN LA ROCHE & CO AG F (HOFF)   GODEL T,  HUNKELER W,  STADLER H,  WIDMER U;  US20050272779-A1   ;  US20070197522-A1   ;  US20070225332-A1   ;  US20090099227-A1   ;  US20110275673-A1   ;  US20130022629-A1   ;  US20140199334-A1   ;  US20140235620-A1   ;  US20150073042-A1   ;  US20200061030-A1   ;  US20200239422-A1   ;  US20200247766-A1   ;  US20200289477-A1   ;  US20200368210-A1   ;  US20210380544-A1   ;  US20220048875-A1   ;  US8735553-B1   BEIGENE LTD (BEIG)   LI K,  ZHANG T,  SONG J,  XU L,  LIU Q,  PENG H;  US9771338-B2   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY);  SASIKUMAR P G N (SASI-Individual);  RAMACHANDRA M (RAMA-Individual);  NAREMADDEPALLI S S S (NARE-Individual)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S S;  US10173989-B2   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY);  SASIKUMAR P G N (SASI-Individual);  RAMACHANDRA M (RAMA-Individual);  NAREMADDEPALLI S S S (NARE-Individual)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S;  US10590093-B2   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY);  SASIKUMAR P G N (SASI-Individual);  RAMACHANDRA M (RAMA-Individual);  NAREMADDEPALLI S S S (NARE-Individual)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S;  US11040948-B2   CURIS INC (CURS)   YU S;  US11136300-B2   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  NAREMADDEPALLI S;  WO2001014557-A1   ;  WO2002079499-A1   ;  WO2003070711-A1   BRITISH BIOTECH PHARM LTD (BRBI);  LAB SERONO SA (ISTF)   AYSCOUGH A P,  DAVIES S J,  PAIN G,  GILLON J;  WO2004004771-A1   ONO PHARM CO LTD (ONOY);  HONJO T (HONJ-Individual)   HONJO T,  MINATO N,  IWAI Y,  SHIBAYAMA S;  WO2004056875-A1   WYETH (AMHP);  CAMBRIDGE ANTIBODY TECHNOLOGY (ASTR)   COLLINS M,  WOOD C,  CARRENO B,  VALGE-ARCHER V,  LUXENBERG D,  JUSSIF J,  RUSSELL C,  CARTER L L,  BENNETT F,  ANDREWS J;  WO2006121168-A1   ONO PHARM CO LTD (ONOY);  MEDAREX INC (BRIM)   KORMAN A J,  SRINIVASAN M,  WANG C,  SELBY M J,  CHEN B,  CARDARELLI J M;  WO2008156712-A1   ORGANON NV (ORGA)   CARVEN G J,  VAN EENENNAAM H,  DULOS G J;  WO2009059162-A1   HUTCHISON MEDIPHARMA ENTERPRISES LTD (HTCH)   CAI Y,  DENG W,  DUAN J,  SU W;  WO2009105712-A1   IRM LLC (IRMI)   CHIANELLI D,  LIU X,  LI X,  LOREN J,  MOLTENI V,  NABAKKA J,  YEH V;  WO2010051447-A1   ELIXIR PHARM INC (ELIX-Non-standard)   SAUNDERS J O;  WO2010077634-A1   GENENTECH INC (GETH)   CHEUNG J,  CHIU H,  IRVING B,  LEHAR S M,  MAECKER H,  MARIATHASAN S,  WU Y;  WO2011066389-A1   AMGEN BRITISH COLUMBIA (AMGE);  ASTRAZENECA AB (ASTR);  HAMMOND S (HAMM-Individual);  MEDIMMUNE LLC (ASTR);  MORROW M (MORR-Individual);  QUEVA C (QUEV-Individual);  MEDIMMUNE LTD (ASTR)   ALIMZHANOV M,  BABCOCK J,  BOYLE M,  CHODORGE M,  FOLTZ I,  HAMMOND S,  KANG J S,  MORROW M,  QUEVA C,  SEKIROV L;  WO2011137587-A1   HUTCHISON MEDIPHARMA LTD (HTCH)   SU W,  DENG W,  CAI Y,  DUAN J;  WO2012168944-A1   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G,  RAMACHANDRA M,  VADLAMANI S K,  SHRIMALI K R,  SUBBARAO K;  WO2013132317-A1   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   POTTAYIL GOVINDAN NAIR S,  RAMACHANDRA M,  NAREMADDEPALLI SEETHARAMAIAH S;  WO2013144704-A1   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  RAMACHANDRA M;  WO2014100079-A1   MERCK SHARP & DOHME CORP (MERI)   PIERCE R H,  BOURNE P,  LIANG L,  BIGLER M;  WO2014110298-A1   GILEAD SCI INC (GILE)   BONDY S S,  CANNIZZARO C E,  CHOU C,  LINK J O,  LIU Q,  SCHROEDER S D,  TSE W C,  ZHANG J R;  WO2014141104-A1   NOVARTIS AG (NOVS)   CAFERRO T R,  CHEN Z,  CHO Y S,  COSTALES A Q,  LEVELL J R,  LIU G,  MANNING J R,  SENDZIK M,  SHAFER C,  SHULTZ M D,  SUTTON J,  WANG Y,  ZHAO Q;  WO2014147586-A1   NOVARTIS AG (NOVS)   CHO Y S,  LEVELL J R,  SHAFER C,  SHULTZ M D;  WO2015033299-A1   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S S;  WO2015033301-A1   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S;  WO2016073470-A1   UNIV KANSAS (UNIV)   WALLACE D P,  DAS B C;  WO2016142833-A1   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S;  WO2016142852-A1   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S;  WO2018047143-A1   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  RAMACHANDRA M,  NAREMADDEPALLI S;  WO2019067678-A1   CURIS INC (CURS)   YU S;  WO2002086083-A2   ;  WO2003042402-A2   DANA FARBER CANCER INST INC (DAND);  BRIGHAM & WOMENS HOSPITAL (BGHM)   FREEMAN G J,  SHARPE A H,  BUHLMAN J,  MANDELBROT D;  WO2005056550-A2   BRISTOL-MYERS SQUIBB CO (BRIM)   LUO G,  CHEN L,  DEGNAN A P,  DUBOWCHIK G M,  MACOR J E,  TORA G O,  CHATURVEDULA P V;  WO2006133216-A2   SMITHKLINE BEECHAM CORP (SMIK)   TURNBULL P S,  CADILLA R,  LARKIN A L,  STEWART E L,  STETSON K;  WO2007075749-A2   MERCK & CO INC (MERI)   IMBRIGLIO J,  COLLETTI S L,  TATA J R,  BERESIS R T,  MARLEY D,  RAGHAVAN S,  SCHMIDT D R,  LINS A R,  SMENTON A L,  CHEN W,  SHEN H,  DING F,  BODNER R;  WO2008011557-A2   KAHRAMAN M (KAHR-Individual);  BORCHARDT A J (BORC-Individual);  COOK T G (COOK-Individual);  DAVIS R L (DAVI-Individual);  GARDINER E M M (GARD-Individual);  MALECHA J W (MALE-Individual);  NOBLE S A (NOBL-Individual);  PRINS T J (PRIN-Individual)   KAHRAMAN M,  BORCHARDT A J,  COOK T G,  DAVIS R L,  GARDINER E M M,  MALECHA J W,  NOBLE S A,  PRINS T J;  WO2008039431-A2   PTC THERAPEUTICS INC (PTCT)   ALMSTEAD N G,  HWANG P S,  MOON Y;  WO2009006555-A2   YU M (YUMM-Individual);  WO2011082400-A2   HARVARD COLLEGE (HARD)   SHARPE A H,  BUTTE M J,  OYAMA S;  WO2011161699-A2   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  RAMACHANDRA M,  VADLAMANI S K,  VEMULA K R,  SATYAM L K,  SUBBARAO K,  SHRIMALI K R,  KANDEPU S;  WO2012129564-A2   MOFFITT CANCER CENT & RES INST INC H                  LEE (MOFF)   LAWRENCE H R,  SEBTI S M,  OZCAN S;  WO2014055897-A2   DANA FARBER CANCER INST INC (DAND)   MARASCO W A,  SUI J;  WO2014059173-A2   SANGAMO BIOSCIENCES INC (SAGM)   GREGORY P D,  HOLMES M C;  WO2016142886-A2   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G N,  RAMACHANDRA M,  PRASAD A,  NAREMADDEPALLI S	US11497735-B2            Dempke; European Journal of Cancer 2017, 74, 55-72.          http://dx.doi.org/10.1016/j.ejca.2017.01.001 (Year:          2017).;            Reitz; J. Med. Chem. 2021, 64, 19, 14757-14772.          https://doi.org/10.1021/acs.jmedchem.1c01336 (Year:          2021).;            Wu; RSC Med. Chem., 2021, 12, 1672-1679.          https://doi.org/10.1039/D1MD00185J (Year:          2021).;            Anderson et al., Lag-3, Tim-3, and TIGIT: Co-inhibitory          Receptors with Specialized Functions in Immune          Regulation, Immunity, 44(5): 989-1004 (2016).;            Ardestani et al., Cell death features induced in          Leishmania major by 1, 3, 4-thiadiazole derivatives, Exp          Parasitol, 132(2): 116-122 (2012).;            Borg et al., 1, 2, 4-Oxadiazole Derivatives of          Phenylalnine: Potential Inhibitors of Substance P          Endopeptidase, Eur. J. Med. Chem., 28(10):801-810          (1993).;            Brittain. Polymorphism in pharmaceutical solids, edited          by H.G Brittain, D.J.W. Grant (chapter 1) p. 1-10 and          J.K. Guillory (Chapter 5) p. 183-226 (1999).;            Byrn et al., Pharmaceutical Solids: A Strategic Approach          to Regulatory Considerations, Pharmaceutical Research,          12(7):945-954 (1995).;            CAS Registry No. 1252104-30-5 (2013).;            CAS Registry No. 1356744-17-6 (2012).;            CAS Registry No. 146429-76-5 (2013).;            CAS Registry No. 1494629-78-5 (2013).;            CAS Registry No. 1496514-97-6 (2013).;            CAS Registry No. 1496518-51-4 (2013).;            CAS Registry No. 1557852-63-7 (2014).;            CAS Registry No. 1848907-06-1 (2016).;            CAS Registry No. 1848909-97-6 (2016).;            CAS Registry No. 1857027-85-0 (2016).;            CAS Registry No. 1868314-35-5 (2016).;            CAS Registry No. 1868388-36-6 (2016).;            CAS Registry No. 1868393-26-3 (2016).;            CAS Registry No. 1869758-25-7 (2016).;            CAS Registry No. 1870159-31-1 (2016).;            CAS Registry No. 1875311-16-2 (2016).;            CAS Registry No. 1875758-09-0 (2016).;            CAS Registry No. 1878569-90-4 (2016).;            CAS Registry No. 876710-85-9 (2006).;            Database Registry Chemical Abstracts, STN Accession No.          172410-37-6. (1995).;            Database Registry Chemical Abstracts, STN Accession No.          197083-27-5. (1996).;            Extended European Search Report for EP Application No.          16761169.8 dated Jul. 2, 2019.;            Extended European Search Report for EP Application No.          16761184 dated Jun. 26, 2018.;            Extended European Search Report for European Application          No. 18162983.3 dated Jun. 27, 2018.;            Graham, Clinical Trials of HIV Vaccines, HIV Molecular          Immunology Database 2000. Edited by: Korber BT, Brander          C, Haynes BF, Koup R, Kuiken C, Moore JP, Walker BD, and          Watkins D. Published by: Theoretical Biology and          Biophysics Group, Los Alamos National Laboratory, Los          Alamos, NM, pp. 1-20-38.;            Guo et al., Design of oxobenzimidazoles and oxindoles as          novel androgen receptor antagonists, Bioorg Med Chem          Letts 22(7):2572-2578 (2012).;            Harvey, Immunologic and Clinical Effects of Targeting          PD-1 in Lung Cancer, Nature, 96: 214-223          (2014).;            International Preliminary Reporton Patentability for          International Application No. PCT/IB2018/058526 dated May          14, 2020.;            International Search Report and Written Opinion for          International Application No. PCT/CN2017/104485 dated          Jun. 29, 2018.;            International Search Report and Written Opinion for          International Application No. PCT/IB2014/064279 dated          Dec. 12, 2014.;            International Search Report and Written Opinion for          International Application No. PCT/IB2016/051266 dated          Jul. 8, 2016.;            International Search Report and Written Opinion for          International Application No. PCT/IB2016/051343 dated          Jul. 28, 2016.;            International Search Report and Written Opinion for          International Application No. PCT/IB2017/056462 dated          Jan. 10, 2018.;            International Search Report Written Opinion for          International Application No. PCT/US2018/053052 dated          Jan. 29, 2019.;            Jin, Role of PD-1 in Regulating T-Cell Immunity, Current          Topics in Microbiology and Immunology, 350: 17-37          (2010).;            Lazorchak et al., Abstract A36: CA-170, an oral small          molecule PD-L1 and VISTA immune checkpoint antagonist,          promotes T cell immune activation and inhibits tumor          growth in pre-clinical models of cancer, Cancer          Immunology Research, 5(S3):A36 (2017).;            Luo et al., Principles of Cancer Therapy: Oncogene and          Non-oncogene Addiction, Cell, 136(5): 823-837          (2009).;            Marechal et al., 1, 2, 4-oxadiazoles identified by          virtual screening and their non-covalent inhibition of          the human 20S proteasome, Curr Med Chem 20(18):2351-2362          (2013).;            Moussebois et al., Synthese de Deux Nouveaux Acides          Amines Phenoliques Comportant un Cycle 1, 2,          4-Oxadiazole, Helv. Chim. ACTA, 60(1):237-242          (1977).;            Ozcan et al., Oxadiazole-Isopropylamieds as Potent and          Noncovalent Proteasome Inhibitors, J. Med. Chem.,          56(10):3783-3805 (2013).;            Palazzo et al., 1, 2, 4-OxadiazolesIV. Synthesis and          Pharmacological Properties of a Series of Substituted          Aminoalkyl1, 2, 4-Oxadiazoles, J. Med. Chem., 351-367          (1961).;            Patwardhan et al., Structure-Activity Relationship          Studies and in Vivo Activity of Guanidine-Based          Sphingosine Kinase Inhibitors: Discovery of SphK1- and          SphK2Selective Inhibitors, J. Med. Chem., 58(4):1879-1899          (2015).;            Pedoeem et al., Programmed Death-1 Pathway in Cancer and          Autoimmunity, Clinical Immunology, 153: 145-152          (2014).;            Shi et al., The Role of PD-1 and PD-L1 in T-cell Immune          Suppression in Patients with Hematological Malignancies,          Journal of Hematology & Oncology, 6(74): 1-6          (2013).;            Sureshbabu et al., Synthesis of 1, 2, 4-oxadiazole-linked          Orthogonally Urethane-Protected Dipeptide Mimetics,          Tetrahedron Letters, 49(35): 5133-5136 (2008).;            Waldmann, Effective Cancer Therapy Through          Immunomodulation, T Annu Rev Med, 57: 65-81          (2006).;            Censi et al., Polymorph Impact on the Bioavailability and          Stability of Poorly Soluble Drugs, Molecules, 20(10):          18759-18776 (2015).;            Extended European Search Report for EP Application No.          17862427.6 dated Jun. 5, 2020.;            Extended European Search Report for EP Application No.          EP/US18/18863750 dated May 31, 2021.;            Lee, A practical guide to pharmaceutical polymorph          screening & selection, Asian J Pharm Sci, 9(4):          163-175 (2014).;            Liu et al., Immune-checkpoint proteins VISTA and PD-1          nonredundantly regulate murine T-cell responses, PNAS,          112(21): 6682-6687 (2015).;            Newman, Specialized Solid Form Screening Techniques, Org          Process Res Dev, 13(3): 457-471 (2012).;            Sasikumar et al., PD-1 derived CA-170 is an oral immune          checkpoint inhibitor that exhibits preclinical anti-tumor          efficacy, Communications Biology, 4: 12 pages          (2021).	 K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M; 94334-2-0-0 K M; 86312-0-0-0 K M; 86450-1-0-0 K M; 198180-0-0-0 K M; 111183-0-0-0 K M; 10897-5-0-0 K M; 87064-0-0-0 K M; 36113-0-0-0 K M; 87373-0-0-0 K M; 97610-0-0-0 K M; 366778-0-0-0 K M; 2132724-0-0-0 K M; 88446-1-0-0 K M; 88573-0-0-0 K M; 88888-0-0-0 K M; 128531-1-0-0 K M; 430273-0-0-0 K M; 860745-2-0-0 K M; 114047-1-0-0 K M; 174605-1-0-0 K M; 90035-0-0-0 K M; 90038-0-0-0 K M; 1316181-1-0-0 K M; 90088-0-0-0 K M; 90091-0-0-0 K M; 92292-1-0-0 K M; 92411-1-0-0 K M; 1595957-1-0-0 K M; 92536-0-0-0 K M; 94106-1-0-0 K M; 94239-0-0-0 K M; 94324-0-0-0 K M; 8769-2-0-0 K M; 1597883-1-0-0 K M; 143138-0-0-0 K M; 94866-0-0-0 K M; 95044-0-0-0 K M; 9095-1-0-0 K M; 95299-1-0-0 K M; 95467-1-0-0 K M; 111136-0-0-0 K M; 95563-0-0-0 K M; 33517-0-0-0 K M; 97647-1-0-0 K M; 97676-0-0-0 K M; 97746-0-0-0 K M; 1919660-1-0-0 K M; 99262-0-0-0 K M; 108645-2-0-0 K M; 106545-2-0-0 K M; 100528-0-0-0 K M; 26073-0-0-0 K M; 60080-1-0-0 K M; 194358-1-0-0 K M; 116849-0-0-0 K M; 108818-0-0-0 K M; 110145-1-0-0 K M; 110156-1-0-0 K M; 110868-1-0-0 K M; 110927-1-0-0 K M; 277196-0-0-0 K M; 88666-1-0-0 K M; 271577-0-0-0 K M; 137571-0-0-0 K M; 88971-1-0-0 K M; 95160-0-0-0 K M; 3008375-1-0-0 K M; 97854-0-0-0 K M; 166620-0-0-0 K M; 86524-1-0-0 K M; 90216-1-0-0 K M; 131634-2-0-0 K M; 89101-2-0-0 K M; 88752-2-0-0 K M; 95307-1-0-0 K M; 2132724-0-0-0 CL USE; 1316181-1-0-0 CL USE; 1595957-1-0-0 CL USE; 1597883-1-0-0 CL USE; 1919660-1-0-0 CL USE; 3008375-1-0-0 CL USE	214355801 K M; 214355802 K M	00083; 68515; 00996; 00212; 00096; 01261; 61435; 01941; 41300; 03487; 00012; 01200; 08295; 61102; 07746; 00904; 12848; 02763; 11065; 13275; 72272; 66218; 11946	RBUQ95 K M; RBUQ96 K M; RBUQ9J K M; RBUQ9G K M; RBUQ9C K M; RBUQ9H K M; RBUQ9E K M; RBUQ9I K M; RBUQ98 K M; RBUQ97 K M; RBUQ9Q K M; RBUQ9N K M; RBUQ9L K M; RBUQ9M K M; RBUQ9K K M; RBUQ9F K M; RBUQ9P K M; RBUQ9O K M; RBUQ9B K M; RBUQ9A K M; RBUQ9D K M; RBUQ99 K M; R18653 K M; RA22UL K M; R18816 K M; RA4TIV K M; RAC7F4 K M; R19810 K M; RA2WZB K M; RABA2C K M; R14101 K M; R12329 K M; R18845 K M; RA0GCS K M; RA3G48 K M; RB48BW K M; RA0S13 K M; RACDI6 K M; RA657D K M; RA4ACO K M; RACGRY K M; RAPFW4 K M; RA13WI K M; R06061 K M; R11768 K M; R18171 K M; RAX3LY K M; RAXNUO K M; R13082 K M; R08219 K M; R06570 K M; RA1EER K M; RB2I2J K M; R09334 K M; R22621 K M; RAMGG0 K M; RAWZHG K M; RA0EH2 K M; RASY1X K M; RABOJL K M; R21471 K M; RA0GCO K M; R18969 K M; R00037 K M; RA0CGV K M; RAVPUM K M; RAR70K K M; RA2EBG K M; R11605 K M; R08029 K M; R08228 K M; R17555 K M; RAZS9G K M; RA0GCP K M; R15080 K M; R01166 K M; R06247 K M; RA0T7D K M; R14399 K M; RB2MJB K M; R00180 K M; R03874 K M; RA65YP K M; R00062 K M; R04079 K M; R00125 K M; RA13WH K M; R18418 K M; RA44DH K M; RA1QSX K M; RA1I2G K M; RA1M7P K M; RA01T5 K M; RA1JOS K M; RBN527 K M; RA022K K M; RA1VLZ K M; RA169M K M; RAE7QA K M; RA2I30 K M; RAGKX1 K M; R00002 K M; R06696 K M	0037-S; 1166-S; 0180-S; 0062-S; 0125-S; 0002-S	US2019359629-A1;  US10906916-B2	New thienopyrimidinones derivatives are            ubiquitin-specific protease 7 inhibitors used to treat            e.g. cancer, neurodegenerative diseases, immunological            and inflammatory disorders, cardiovascular diseases and            viral and bacterial infections	IOANNIDIS S;  TALBOT A C;  FOLLOWS B;  BUCKMELTER A J;  WANG M;  CAMPBELL A;  LANCIA D R	FORMA THERAPEUTICS INC (FOMA-C);  VALO EARLY DISCOVERY INC (VALO-Non-standard)	201999590X	   NOVELTY - Thienopyrimidinones derivatives (I) are                new.    USE - (I) are useful for treating cancer,                neurodegenerative diseases, immunological                disorders, inflammatory disorders, cardiovascular                diseases, ischemic diseases, viral infections and                diseases or bacterial infections and diseases,                metastasis, diabetes, bone and joint diseases,                osteoporosis, arthritis inflammatory disorders,                where the cancer e.g. neuroblastoma, glioblastoma,                bladder cancer, oropharyngeal, nasopharyngeal                carcinoma, Hodgkin lymphoma or diffuse large B-cell                lymphoma, where the infections hepatitis A,                hepatitis C, severe acute respiratory                syndrome-related coronavirus infection and disease,                Epstein-Barr virus, rhinoviral infections and                diseases, adenoviral infections and diseases or                poliomyelitis, where the inflammatory disorders                type II diabetes, insulin resistance cardiovascular                disease, arrhythmia, atherosclerosis, coronary                artery disease, hypertriglyceridemia, dyslipidemia,                retinopathy, nephropathy, neuropathy or macular                edema.    DETAILED DESCRIPTION - Thienopyrimidinones derivatives of formula (I)                and their salts are new.    R2=1-6C alkyl or 6-14C aryl (both optionally                substituted by at least one R8); either    R6=1-6C alkyl or 6-14C aryl (both optionally                substituted by at least one R14), or H;    R7=1-6C alkyl or 6-14C aryl (both optionally                substituted by at least one R16) or H; or    R6R7=1-6C cycloalkyl optionally substituted by                at least one R16;either    R8=D, 1-6C alkyl, 1-6C alkoxy, 1-6C haloalkyl,                1-6C haloalkoxy, halo, CN, -1-3C alkylene-O-(1-6C)                alkyl, -(0-4C)-alkylene-aryl,                -(0-4C)-alkylene-heteroaryl, (3-10C) cycloalkyl,                heterocycloalkyl, -(0-4C)-alkylene-O-aryl,                -(0-4C)-alkylene-O-heteroaryl, -O-(3-8C)cycloalkyl,                -S-heteroaryl, -C(O)R21, -CO(O)R21, -C(O)NR21R22,                S(O)qR21, S(O)qNR21 R22, -NR21S(O)qR22,                -(0-3C)-alkylene-NR21R22, -NR21C(O)R22, P(O)((1-6C)                alkyl)2a, P(O)(aryl)2a, SiMe3, SF5 or -OR21, where                the alkyl, alkylene, aryl, heteroaryl, cycloalkyl                or heterocycloalkyl are optionally substituted by                at least one R9; or    2R8=3-8C cycloalkyl, heterocycloalkyl ring,                aryl ring or heteroaryl ring (all optionally                substituted by at least one R9);    R9=1-6C alkyl, 1-6C alkoxy, 1-6C haloalkyl,                1-6C haloalkoxy, halo, 3-8C cycloalkyl,                heterocycloalkyl, 6-14C aryl, heteroaryl, -NHP2,                -OH, -C(O)R23, -C(O)NR23R24, -NR23C(O)R24,                -NR23R24, -S(O)qR23, S(O)qNR23R24, NR23S(O)qR24,                oxo, -P(O)((1-6C)alkyl)2, -P(O)(aryl)2, -SiMe3,                -SF5, -O-aryl, CN, or -O-heteroaryl, where the                alkyl, aryl, heteroaryl, cycloalkyl or                heterocycloalkyl are optionally substituted by at                least one R26; either    R10, R11=(1-6C) alkyl, (6-14C) aryl,                heteroaryl, (5-8C) cycloalkyl or heterocycloalkyl                where the alkyl, aryl, heteroaryl, cycloalkyl or                heterocycloalkyl are optionally substituted by at                least one R18 or H; or    NR10R11=heterocycloalkyl ring optionally                substituted by at least one R18;    R14=(1-5C) alkyl, (1-6C) alkoxy, (1-6C)                haloalkyl, (1-6C) haloalkoxy, halo, CN, -C(O)(1-6C)                alkyl, S(O)q(1-6C) alkyl, -NH2, (1-6C) alkylamino,                di(1-6C) alkylamino, (6-14C) aryl, heteroaryl,                (5-8C) cycloalkyl or heterocycloalkyl, where the                alkyl, aryl, heteroaryl, cycloalkyl or                heterocycloalkyl are optionally substituted by at                least one R15; either    R15=(1-6C) alkyl, (1-6C) alkoxy, (Cr-C5)                haloalkyl, (1-6C) haloalkoxy, halo, -C(O)(1-6C),                S(O)q(1-6C) alkyl, -NH2, (1-6C)alkylamino, di(1-6C)                alkylamino, OH, CN,(6-14C) aryl, heteroaryl, (5-8C)                cycloalkyl or heterocycloalkyl, where the alkyl,                aryl, heteroaryl, cycloalkyl or heterocycloalkyl                are optionally substituted by at least one                R17;    R17=(1-6C) alkyl, (1-6C) alkoxy, (1-6C)                haloalkyl, (1-6C) haloalkoxy, halo, -C(O)(1-6C)                alkyl, S(O)q(1-6C) alkyl, -NH2, (1-6C) alkylamino,                di(1-6C) alkylamino, -OH or CN;    R18=(1-6C) alkyl, (1-6C) alkoxy, (C(-C6)                haloalkyl, (1-6C) haloalkoxy, halo, (1-6C)                hydroxyalkyl,-OH, CN, -C(O)(1-6C) alkyl,                S(O)q(1-6C) alkyl, -NH2, (1-6C) alkylamino,                di(1-6C) alkylamino, (6-14C) aryl, heteroaryl,                (5-8C) cycloalkyl or heterocycloalkyl, where the                alkyl, aryl, heteroaryl, cycloalkyl or                heterocycloalkyl are optionally substituted by at                least one R19;    R19=(1-6C) alkyl, (1-6C) alkoxy, (1-6C)                haloalkyl, (1-6C) haloalkoxy, halo, -C(O)(1-6C)                alkyl, S(O)q(1-6C) alkyl, NH2, (1-6C) alkylamino,                di(1-6C) alkylamino,-OH, or CN;    R21, R22=H, (1-6C) alkyl, (2-6C) alkenyl,                (2-6C) alkynyl, (6-14C) aryl, heteroaryl, (5-8C)                cycloalkyl, or heterocycloalkyl, where alkyl,                alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or                heterocycloalkyl are optionally substituted with at                least one R25;    R23, R24=H, (1-6C) alkyl, (2-6C) alkenyl,                (2-6C) alkynyl, (6-14C aryl, heteroaryl, (5-8C)                cycloalkyl, or heterocycloalkyl, where the alkyl,                aryl, heteroaryl, cycloalkyl or heterocycloalkyl                are optionally substituted by at least one                R25;    R25=(1-6C) alkyl, (1-6C) alkoxy, (1-6C)                haloalkyl, (1-6C) haloalkoxy, halo, -NH2, (1-6C)                alkylamino, di(1-6C) alkylamino, OH or CN;    R26=(1-6C) alkyl, C1-C5) alkoxy, (1-6C)                haloalkyl, (1-6C) haloalkoxy, halo, -NR27C(O)R28,                -NR27S(O)qR28, -C(O)R27, -C(O)NR27R28, -NR27R28,                S(O)qR27S(O)qNR27R28, -P(O)((1-6C)alkyl)2a,                -P(O)(aryl)2a, -SiMe3, -OH or CN;    R27, R28=(1-6C) alkyl, (2-6C) alkenyl, (2-6C)                alkynyl, (6-10C) aryl, heteroaryl, (5-8C)                cycloalkyl or heterocycloalkyl (all optionally                substituted by at least one (1-6C) alkyl, (1-6C)                (1-6C) haloalkyl (1-6C) haloalkoxy, NH2, (1-6C)                alkylamino or di(1-6C) alkylamino) or H; and    q=0-2. 			B02 (Fused ring heterocyclics.)	B05-A04A;  B05-B01B;  B05-B01E;  B05-B01F;  B05-B01G;  B05-B01J;  B05-B01K;  B05-B01L;  B05-B01M;  B05-B01N;  B05-B01P;  B06-F03;  B14-A01;  B14-A02;  B14-C03;  B14-C09;  B14-D07C;  B14-F01;  B14-F02;  B14-F06;  B14-F07;  B14-H01;  B14-J01;  B14-N01;  B14-N03;  B14-N10;  B14-S04A;  B14-S14;  B14-S16	A61K-031/519;  C07D-495/04	US2019359629-A1   28 Nov 2019   C07D-495/04   201993Pages: 36   English;  US10906916-B2   02 Feb 2021   C07D-495/04   202115   English	US2019359629-A1    US515194    18 Jul 2019;   US10906916-B2    US515194    18 Jul 2019	US2019359629-A1 Provisional Application US112482P;   US2019359629-A1 Cont of Application US909200;   US2019359629-A1 Cont of Application US015563;   US2019359629-A1 Cont of Patent US9932351;   US2019359629-A1 Cont of Patent US10377767;   US10906916-B2 Provisional Application US112482P;   US10906916-B2 Cont of Application US909200;   US10906916-B2 Cont of Application US015563;   US10906916-B2 Cont of Patent US9932351;   US10906916-B2 Cont of Patent US10377767;   US10906916-B2 Previous Publ. Patent US2019359629	US112482P    05 Feb 2015;  US515194    18 Jul 2019			US2019359629-A1 -- US9932351-B2   FORMA THERAPEUTICS INC (FOMA)   IOANNIDIS S,  TALBOT A C,  FOLLOWS B,  BUCKMELTER A J,  WANG M,  CAMPBELL A,  LANCIA D		 N;  N	217421701 N	01340	RC1P2E N; RC1P2D N		CN109651488-A	Preparing porcine deltacoronavirus recombinant N            protein comprises e.g. carrying out amplification of            PDCoV N gene fragment performing reverse transcribing            cDNA of PDCoV, and amplifying the PDCoV N gene            PCR	QIN Y;  LIU L;  LU B;  LI B;  ZHOU Y;  DUAN Q;  HE Y;  ZHAO W;  LIANG J;  JIANG D;  LU J	GUANGXI ZHUANG AUTONOMOUS REGION INST (GUAG-C)	201939143G	   NOVELTY - Preparing porcine deltacoronavirus (PDCoV)                recombinant N protein comprises e.g. (i) carrying                out amplification of PDCoV N gene fragment                performing reverse transcribing cDNA of PDCoV to                obtain cDNA, and amplifying the PDCoV N gene PCR by                specific primers N-P1 and N-P2, (ii) constructing                of prokaryotic expression plasmid pET32a-N by                ligating PCR-amplified PDCoV N gene fragment into                the pMD18-T cloning vector and transformed into DH5                alpha competent cells to obtain the pMD18-N cloning                plasmid, double digesting pMD18-N cloning plasmid                and pET-32a(+) to recover N. Gene and pET-32a (+)                vector, pET-32a (+) and N gene were ligated                overnight and transformed into DH5 alpha competent                cells by T4 ligase, and extracting the plasmid to                obtain prokaryotic expression plasmid pET32a-N,                (iii) carrying out acquisition of recombinant N                protein, transforming prokaryotic expression                plasmid pET32a-N into BL21 competent cells,                inducing by IPTG, lysing, centrifuging, and                collecting the supernatant and precipitate.    USE - The method is useful for preparing porcine                deltacoronavirus (PDCoV) recombinant N                protein.    DETAILED DESCRIPTION - Preparing porcine deltacoronavirus (PDCoV)                recombinant N protein comprises (i) carrying out                amplification of PDCoV N gene fragment performing                reverse transcribing cDNA of PDCoV to obtain cDNA,                and amplifying the PDCoV N gene PCR by specific                primers N-P1 and N-P2, where the specific primers                N-P1 and N-P2 have the base sequences comprising                fully defined 5'-cgcggatccatggctgcaccagtagtcc-3'                nucleotide sequence (SEQ ID NO:1) as given in the                specification and comprising fully defined                5'-ccaagcttctacgctgctgattcctgc-3' nucleotide                sequence (SEQ ID NO:2) as given in the                specification, (ii) constructing of prokaryotic                expression plasmid pET32a-N by ligating                PCR-amplified PDCoV N gene fragment into the                pMD18-T cloning vector and transformed into DH5                alpha competent cells to obtain the pMD18-N cloning                plasmid, double digesting pMD18-N cloning plasmid                and pET-32a(+) to recover N. Gene and pET-32a (+)                vector, pET-32a (+) and N gene were ligated                overnight and transformed into DH5 alpha competent                cells by T4 ligase, and extracting the plasmid to                obtain prokaryotic expression plasmid pET32a-N,                (iii) carrying out acquisition of recombinant N                protein, transforming prokaryotic expression                plasmid pET32a-N into BL21 competent cells,                inducing by IPTG, ultrasonically lysing,                centrifuging, and collecting the supernatant and                precipitate, SDS-PAGE electrophoresis confirmed                that the recombinant N protein was mainly expressed                in the supernatant, according to Kang Wei Century                Company His Purification method of tag protein                purification kit to obtain recombinant N                protein. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E05;  B04-E08;  B04-E99;  B04-F0100E;  B04-L08;  B04-N03K0E;  C04-E05;  C04-E08;  C04-E99;  C04-F0100E;  C04-L08;  C04-N03K0E;  D05-A02F;  D05-H17A;  D05-H99	C07K-014/165;  C07K-016/10;  C12N-015/70	CN109651488-A   19 Apr 2019   C07K-014/165   201955Pages: 16   Chinese	CN109651488-A    CN11572375    21 Dec 2018		CN11572375    21 Dec 2018			CN109651488-A -- CN101962644-A   UNIV NORTHWEST A & F (UNAF)   ZHANG D,  JIANG P;  CN105924525-A   UNIV GUANGXI (UYGU)   LUO T,  LI X,  TAO Q,  YING X,  ZHAO Q,  JIANG B;  CN106518989-A   JIANGSU AGRIC SCI INST (JSAS)   LI B,  PANG F,  HE K,  GUO R,  FAN B,  YU Z,  MAO A,  WEN L,  NI Y,  YUAN W,  WANG J;  WO2018140766-A2   BOEHRINGER INGELHEIM VETMEDICA INC (BOEH)   ACKERMAN S,  HERMANN J R,  HERNANDEZ L A,  HOBBS L A,  IYER A V,  OCONNER S,  PATTERSON A R,  VAUGHN E M,  VICTORIA J G	CN109651488-A  : "", 30 June 2013,          ,relevantClaims[1-8],relevantPassages[23];  : "", 30 November          2004,          ,relevantClaims[1-8],relevantPassages[169];  FATEN OKDA:          "Development of monoclonal antibodies and serological          assays including indirect ELISA and fluorescent          microsphere immunoassays for diagnosis of porcine          deltacoronavirus", BMC VETERINARY          RESEARCH,relevantClaims[1-5|6-8],relevantPassages[3Methods82];  : "MNN",          ,relevantClaims[1-5],relevantPassages[2.1.1-2.4.51]	184616-0-0-0 K P			RA00H3 K P		WO2019222349-A1;  EP3793539-A1;  US2021230101-A1;  EP3793539-A4	Treating or preventing viral infection e.g.            hepatitis B, fulminant viral hepatitis, or severe acute            respiratory syndrome in human involves administering            (cyclohexa-1,3-dien-1-ylmethyl)benzene derivative	YANG P L;  GRAY N S;  JANG J;  WANG J;  KWIATKOWSKI N P;  LIAN W;  LI Z	DANA FARBER CANCER INST INC (DAND-C);  HARVARD COLLEGE (HARD-C);  DANA FARBER CANCER INST INC (DAND-C);  HARVARD COLLEGE (HARD-C);  HARVARD COLLEGE (HARD-C);  DANA FARBER CANCER INST INC (DAND-C)	201998231X	   NOVELTY - Method (M1) for treating or preventing a viral                infection in a subject involves administering                (cyclohexa-1,3-dien-1-ylmethyl)benzene derivative                (I) or (II) or their salts, solvates, hydrates,                polymorphs, co-crystals, tautomers, stereoisomers,                isotopically labeled derivatives, or                prodrugs.    USE - The method is useful for (a) treating or                preventing a viral infection in a subject, (b)                inhibiting entry of a virus into a cell or                inhibiting an envelope glycoprotein of a virus and                (c) inhibiting fusion between the envelope of the                virus and the membrane of the cell. The cell or                virus is in vitro. The viral infection is Dengue                fever, Dengue hemorrhagic fever (DHF) or Dengue                shock syndrome (DSS). The viral infection is yellow                fever, West Nile encephalitis, West Nile fever,                Japanese encephalitis, or Zika fever. The viral                infection is hepatitis B, hepatitis C, fulminant                viral hepatitis, severe acute respiratory syndrome                (SARS), viral myocarditis, influenza A virus                infection, influenza B virus infection,                parainfluenza virus infection, measles virus                infection, vesicular stomatitis virus infection,                rabies virus infection, Ebola virus infection,                Junin virus infection, human cytomegalovirus                infection, herpes simplex virus 1 infection,                poliovirus infection, Marburg virus infection,                Lassa fever virus infection, Venezuelan equine                encephalitis, Rift Valley fever virus infection,                Korean hemorrhagic fever virus infection,                Crimean-Congo hemorrhagic fever virus infection,                HIV infection, Saint Louise encephalitis, Kyasanur                forest disease, Murray Valley encephalitis,                tick-borne encephalitis, Theiler's disease,                hepatocellular carcinoma, Kyasanur Forest disease                (KFD), Alkhurma disease, Omsk hemorrhagic fever,                Rocio encephalitis, Wesselsbron disease, Powassan                disease, Israeli turkey meningoencephalitis,                Central European tick-borne fever, Louping ill,                California encephalitis, Border disease, bovine                viral diarrhea-mucosal disease, classical swine                fever, or bovine hemorrhagic syndrome. The virus is                of the Flaviviridae family. The virus is of the                Flavivirus genus. The virus is Dengue virus 2                (DENV2), DENV1, DENV3, DENV4, or Kedougou virus                (KEDV). The virus is yellow fever virus, West Nile                virus, Japanese encephalitis virus, or Zika virus.                The subject is a mammal, preferably human (all                claimed).    DETAILED DESCRIPTION - Method (M1) for treating or preventing a viral                infection in a subject involves administering                (cyclohexa-1,3-dien-1-ylmethyl)benzene derivative                of formula (I) or (II) or their salts, solvates,                hydrates, polymorphs, co-crystals, tautomers,                stereoisomers, isotopically labeled derivatives, or                prodrugs.    ring A = phenyl or 6,5-fused bicyclic                heteroaryl (both optionally substituted);    Z = O, NR'n, S, C(R'c)2, OC(=O), C(=O)O,                C(=O)NR'n, NR'nC(=O), NR'nS(=O)2 and                S(=O)2NR'n;    Y' = O, NR'n, S and C(R'c)2;    X1,X2 (change in skc also) = H, halo, or                optionally substituted alkyl;    G1 = C-R3 or N;    R2,R3 = H, halo, CN, NO2, N3, or alkyl, aryl,                heteroaryl, carbocyclyl, heterocyclyl or acyl (all                optionally substituted), OR'o, N(R'n)2 or                SR's;    m = 0-3;    n = 0-4;    R'c = H, halo, CN, or alkyl or acyl (both                optionally substituted);    R'o = H, or alkyl or acyl (both optionally                substituted), or oxygen protecting group;    R'n = H, or alkyl or acyl (both optionally                substituted), or nitrogen protecting group;    or (R'n+R'n+N) = heterocyclyl or heteroaryl                (both optionally substituted);and    R's = H, or alkyl or acyl (both optionally                substituted), or sulfur protecting group.    INDEPENDENT CLAIMS are included for the                following:    (1) a method (M2) of inhibiting entry of a                virus into a cell or inhibiting an envelope                glycoprotein of a virus involves contacting the                cell or virus with the compound (I) or (II), or                their salts, solvates, hydrates, polymorphs,                co-crystals, tautomers, stereoisomers, isotopically                labeled derivatives, or prodrugs;    (2) a 1,4-dibenzylbenzene derivative of                formula (III) or (IV) or their salts, solvates,                hydrates, polymorphs, co-crystals, tautomers,                stereoisomers, isotopically labeled derivatives, or                prodrugs; and    (3) a pharmaceutical composition comprising                the compound, or their salts, and an                excipient.    R1 = -OR'o or -N(R'n)2;     = 1-3;    r = 0-5;and    R4 = H, halo, -CN, -NO2, -N3, or alkyl, aryl,                heteroaryl, carbocyclyl, heterocyclyl, or acyl (all                optionally substituted), -OR'o, -N(R'n)2, or                -SR's. 			B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C02 (Heterocyclic.)	B06-H;  B07-H;  B10-A08;  B10-A15;  B10-D03;  B14-A02;  B14-C03;  B14-F01B;  B14-H01;  B14-K01D;  B14-N16;  C06-H;  C07-H;  C10-A08;  C10-A15;  C10-D03;  C14-A02;  C14-C03;  C14-F01B;  C14-H01;  C14-K01D;  C14-N16	A61K-031/165;  A61K-031/404;  A61P-031/12;  A61P-031/14;  C07C-233/75;  C07C-255/44;  C07C-323/31;  C07D-209/08;  C07D-213/65;  C07D-235/08;  C07D-295/03	WO2019222349-A1   21 Nov 2019   A61K-031/165   201993Pages: 127   English;  EP3793539-A1   24 Mar 2021   A61K-031/165   202126   English;  US2021230101-A1   29 Jul 2021   C07C-233/75   202162   English;  EP3793539-A4   02 Mar 2022   A61K-031/165   202220   English	WO2019222349-A1    WOUS032418    15 May 2019;   EP3793539-A1    EP802703    15 May 2019;   US2021230101-A1    US17055366    13 Nov 2020;   EP3793539-A4    EP802703    15 May 2019	EP3793539-A1 PCT application Application WOUS032418;   EP3793539-A1 Based on Patent WO2019222349;   US2021230101-A1 Provisional Application US671871P;   US2021230101-A1 PCT application Application WOUS032418	US671871P    15 May 2018;  WOUS032418    15 May 2019;  US17055366    13 Nov 2020	WO2019222349-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP3793539-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    EP3793539-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  		WO2019222349-A1 -- US9353051-B2   SIGA TECHNOLOGIES INC (SGTE)   BYRD C M,  JORDAN R,  DAI D,  BOLKEN T,  HRUBY D E;  WO2012138377-A2   UNIV PENNSYLVANIA (UPEN);  ADVAXIS (ADVA-Non-standard)   HARN D A,  PATERSON Y;  EP3793539-A4 -- WO2016038035-A1   ANTIBIOTX APS (ANTI-Non-standard)   DELAVENNE E F A,  SIMON D J J,  SOMMER M O A,  TOFT-KEHLER R V;  WO2018213365-A1   DANA FARBER CANCER INST INC (DAND);  HARVARD COLLEGE (HARD)   YANG P L,  LIAN W L,  GRAY N S,  KWIATKOWSKI N P,  WANG J,  JANG J	WO2019222349-A1  DATABASE PUBCHEM 27          March 2005 (2005-03-27), Database accession no. CID          520487,relevantClaims[1-2, 23, 83-85,          87],relevantPassages[pages 1-19. pg 2,          structure.];  SHUM ET AL.:          "High-Content Assay to Identify Inhibitors of Dengue          Virus Infection", ASSAY AND DRUG DEVELOPMENT          TECHNOLOGIES, vol. 8, no. 5, 2010, pages 553 - 570,          XP009154193, DOI:          10.1089/adt.2010.0321,relevantClaims[1-2, 23, 83-85,          87],relevantPassages[. abstract; pg 567-568, Table 3; pg          561, Fig 4];  DATABASE Pubchem 26          March 2005 (2005-03-26), Database accession no. CID          31475,relevantClaims[1-2, 23, 83-85,          87],relevantPassages[pages 1-20; pg 2,          structure]EP3793539-A4  LIU Y ET AL:          "Identification of halosalicylamide derivatives as a          novel class of allosteric inhibitors of HCV NS5B          polymerase", BIOORGANIC & MEDICINAL CHEMISTRY          LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 18, no. 11, 1 June          2008 (2008-06-01), pages 3173 - 3177, XP022711191, ISSN:          0960-894X, [retrieved on 20080501], DOI:          10.1016/J.BMCL.2008.04.068,relevantClaims[1,4-9,11|1-15],relevantPassages[&lt;table&gt;1&lt;/table&gt;&lt;compound&gt;9,10&lt;/compound&gt;];  KRATKY M. ET AL:          "Antiviral Activity of Substituted Salicylanilides - A          Review", MINI-REVIEWS IN MEDICINAL CHEMISTRY, vol. 11,          no. 11, 1 October 2011 (2011-10-01), NL, pages 956 - 967,          XP055882482, ISSN: 1389-5575, DOI:          10.2174/138955711797068382,relevantClaims[1,4-9,11|1-15],relevantPassages[&lt;figure&gt;8&lt;/figure&gt;];  LIAN WENLONG ET AL:          "Discovery of Immunologically Inspired Small Molecules          That Target the Viral Envelope Protein", ACS INFECTIOUS          DISEASES, vol. 4, no. 9, 14 September 2018 (2018-09-14),          US, pages 1395 - 1406, XP055882493, ISSN: 2373-8227,          Retrieved from the Internet          &lt;URL:https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.8b00127&gt;          DOI:          10.1021/acsinfecdis.8b00127,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            See also references of WO 2019222349A1	 K U; 91361-0-0-0 K U; 105372-0-0-0 K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U	217382001 K U; 217382002 K U; 217382003 K U; 217382004 K U; 217382005 K U; 217382006 K U; 217382007 K U; 217382008 K U		RCP3J2 K U; R10456 K U; R10457 K U; RCP3J3 K U; RCP3J4 K U; RCP3J5 K U; RCP3J6 K U; RCP3J7 K U; RCP3J8 K U; RCP3J9 K U; RCP3JA K U; RCP3JB K U; RCP3JC K U; RCP3JD K U; RCP3JE K U; RCP3JF K U		US2019040370-A1	New nucleic acid molecule encoding two-component            RNA targeting system comprising nucleic acid sequence            encoding truncated nuclease-inactive RNA-targeted Cas9            polypeptide and single guide RNA sequence used to treat            disease e.g. cancer	YEO G;  NELLES D A;  FANG M;  BATRA R	UNIV CALIFORNIA (REGC-C)	2019138146	   NOVELTY - Nucleic acid molecule (N1) encoding a                2-component RNA targeting system comprising (a)                nucleic acid sequence encoding a truncated                nuclease-inactive RNA-targeted Cas9 (RCas9)                polypeptide, where the truncated nuclease-inactive                RCas9 polypeptide lacks all or part of its HNH                domain compared to a wild-type (WT) Cas9 protein                and (b) a single guide RNA (sgRNA) sequence                comprising on its 5' end, an RNA sequence that                hybridizes to or binds to a target RNA sequence and                on its 3' end, an RNA sequence capable of binding                to or associating with the truncated                nuclease-inactive RCas9 polypeptide, where the RNA                sequence capable of binding to or associating with                the truncated nuclease-inactive RCas9 polypeptide                comprises or is derived from a wild type guide RNA                of an archaeal or a bacterial organism from which                the truncated nuclease-inactive RCas9 is derived                and the 2-component RNA targeting system recognizes                and alters the target RNA in a cell in the absence                of a PAMmer, is new.    USE - The nucleic acid molecule is useful for                treating a disease, condition or infection                associated with an RNA microsatellite repeat                expansion in a patient, where the disease,                condition or infection comprises myotonic                dystrophy, Huntington's disease, familial                amyotrophic lateral sclerosis (ALS), cancer, spinal                muscular atrophy, spinocerebellar ataxia, fragile                X-associated tremor/ataxia syndrome, spinal-bulbar                muscular dystrophy, oculopharyngeal muscular                dystrophy, a viral infection, a bacterial                infection, a Herpesviridae or herpes simplex virus                infection, a human immunodeficiency virus                infection, an Epstein Barr virus infection, a                hepatitis virus infection, a hepatitis A infection,                a hepatitis B infection, a hepatitis C infection, a                hepatitis D infection, a hepatitis E infection, a                Zika virus infection, an enterovirus infection, a                human papillomavirus (HPV) infection, an influenza                virus infection, a Marburg virus infection, an                Ebola virus infection, a mumps virus infection, a                cytomegalovirus infection, a rotavirus infection, a                rubella virus infection, a varicella zoster virus                infection, a severe acute respiratory syndrome                (SARS) infection, a coronavirus infection, a                Paramyxoviridae or measles virus infection, a West                Nile virus infection, a Yellow fever virus                infection or a Dengue fever virus infection (all                claimed). Test details are described but no results                given.    DETAILED DESCRIPTION - Nucleic acid molecule (N1) encoding a                2-component RNA targeting system comprising (a)                nucleic acid sequence encoding a truncated                nuclease-inactive RNA-targeted Cas9 (RCas9)                polypeptide, where the truncated nuclease-inactive                RCas9 polypeptide lacks all or part of its HNH                domain compared to a wild-type (WT) Cas9 protein                and (b) a single guide RNA (sgRNA) sequence                comprising on its 5' end, an RNA sequence that                hybridizes to or binds to a target RNA sequence                comprising a repeat sequence comprising cug, ccug,                cag, and ggggcc and on its 3' end, an RNA sequence                capable of binding to or associating with the                truncated nuclease-inactive RCas9 polypeptide,                where the RNA sequence capable of binding to or                associating with the truncated nuclease-inactive                RCas9 polypeptide comprises or is derived from a                wild type guide RNA of an archaeal or a bacterial                organism from which the truncated nuclease-inactive                RCas9 is derived and the 2-component RNA targeting                system recognizes and alters the target RNA in a                cell in the absence of a PAMmer, is new.                INDEPENDENT CLAIMS are also included for: (1)                recognizing and altering target RNA in a cell                comprising contacting the cell with the nucleic                acid molecule (N1), where the nucleic acid molecule                encodes an RNA targeting system which recognizes                and alters target RNA in the cell in the absence of                a PAMmer; (2) treating a disease, condition or                infection associated with an RNA microsatellite                repeat expansion in a patient, comprising                administering the nucleic acid molecule (N1), where                the nucleic acid molecule encodes an RNA targeting                system which recognizes and alters target RNA                corresponding to the RNA microsatellite repeat                expansion; (3) a cell or tissue comprising the                nucleic acid molecule; (4) a nucleic acid molecule                (N2) encoding a 2-component RNA targeting system                comprising (a1) nucleic acid sequence encoding a                Campylobacter jejune Rcas9 polypeptide and (b1) an                sgRNA sequence comprising on its 5' end, an RNA                sequence that hybridizes to or binds to a target                RNA sequence comprising a repeat sequence                comprising cug, ccug, cag or ggggcc and on its 3'                end, an RNA sequence capable of binding to or                associating with the Campylobacter jejune Rcas9                polypeptide, where the RNA sequence capable of                binding to or associating with the Campylobacter                jejune Rcas9 polypeptide comprises or is derived                from a wild type guide RNA of a Campylobacter                jejune organism from which the Campylobacter jejune                RCas9 is derived, the sequences of (a1) and (b1)                are in a single vector and the 2-component RNA                targeting system recognizes and alters the target                RNA in the absence of a PAMmer; and (5) a nucleic                acid molecule (N3) encoding a 2-component RNA                targeting system comprising (a2) nucleic acid                sequence encoding an Rcas9 polypeptide and (b2) an                sgRNA sequence comprising on its 5' end, an RNA                sequence that hybridizes to or binds to a target                RNA sequence comprising a repeat sequence                comprising cug, ccug, cag or ggggcc and on its 3'                end, an RNA sequence capable of binding to or                associating with the RCas9 polypeptide, where the                RNA sequence capable of binding to or associating                with the RCas9 polypeptide comprises or is derived                from a wild type guide RNA of an archaeal or a                bacterial organism from which the RCas9 is derived,                the sequences of (a2) and (b2) are in a single                vector, the sequences of (a2) and (b2) are a size                of less than 4.5 kb or a size of less than 4.7 kb                and the 2-component RNA targeting system recognizes                and alters the target RNA in a cell in the absence                of a PAMmer. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E02K;  B04-E03K;  B04-E13;  B04-E99;  B04-F0100E;  B04-L05A2;  B14-A01;  B14-A02;  B14-F01;  B14-H01;  B14-J01;  B14-J05;  B14-K01D;  B14-N03;  B14-N16;  C04-E02K;  C04-E03K;  C04-E13;  C04-E99;  C04-F0100E;  C04-L05A2;  C14-A01;  C14-A02;  C14-F01;  C14-H01;  C14-J01;  C14-J05;  C14-K01D;  C14-N03;  C14-N16;  D05-H14;  D05-H19C;  D05-H99	A61K-038/46;  A61K-048/00;  C12N-015/11;  C12N-015/113;  C12N-009/22	US2019040370-A1   07 Feb 2019   C12N-009/22   201913Pages: 67   English	US2019040370-A1    US054298    03 Aug 2018	US2019040370-A1 Provisional Application US259014P;   US2019040370-A1 Cont of Application US359567	US259014P    23 Nov 2015;  US054298    03 Aug 2018					93605-0-0-0 N; 105730-0-0-0 N			RA00NS N; RA012P N		WO2019035972-A1	Generating broadly neutralizing antibodies against            a virus, comprises sequentially administering viral            antigen from virus for which protection is sought over            at least two administration round	WANG B;  MOHAN T	UNIV GEORGIA STATE RES FOUND (UYGA-C)	201917950J	   NOVELTY - Generating (M1) broadly neutralizing                antibodies against a virus, comprises (a)                sequentially administering at least one viral                antigen from a virus for which protection is sought                over at least two administration round, where each                successive administration round provides a                different clade variant of the antigens than any                preceding administration round.    USE - The method is useful for: generating broadly                neutralizing antibodies against a virus; immunizing                a subject against a viral infection; and generating                mucosal antibodies against a virus (all claimed).                Test details are described but no results                given.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) immunizing (M2) a subject against a viral                infection, comprising step (a) as above per                se;    (2) generating (M3) mucosal antibodies against                a virus, comprising step (a) as above per se;    (3) a viral immunization strategy comprising                the sequential administration of the antigens to a                subject over at least 2 administration rounds,                where each successive administration round provides                to the subject a different clade variant of the                antigens than any preceding administration round;                and    (4) a kit for immunizing a subject against HIV                comprising at least two clade variants of at least                one HIV antigen. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-B04C1;  B04-L04A;  B04-N03K;  B04-N03K0E;  B04-N06;  B04-N08;  B04-N1200E;  B14-A02;  B14-G01;  B14-S11A;  C04-B04C1;  C04-L04A;  C04-N03K;  C04-N03K0E;  C04-N06;  C04-N08;  C04-N1200E;  C14-A02;  C14-G01;  C14-S11A;  D05-H07	A61K-039/42;  A61K-045/06;  C07K-016/10	WO2019035972-A1   21 Feb 2019   C07K-016/10   201916Pages: 76   English	WO2019035972-A1    WOUS000247    16 Aug 2018		US546350P    16 Aug 2017	WO2019035972-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  		WO2019035972-A1 -- CN101569745-A   SUZHOU IND ZONE WEIKEDA BIO TECHN CO LTD (SUZH-Non-standard)   XU J;  US20010053368-A1   ;  US20110045017-A1   ;  US20110189230-A1   ;  US20130101617-A1   ;  US7179468-B1   CORNELL RES FOUND INC (CORR)   LU M,  JI H	WO2019035972-A1  LI ET AL.: "Control          of expression, glycosylation, and secretion of HIV-1          gp120 by homologous and heterologous signal sequences",          VIROLOGY, vol. 204, no. 1, 1 October 1994 (1994-10-01),          pages 266 - 278,          XP002126663,relevantClaims[11-12],relevantPassages[.          Especially Abstract; page 267, col 1, para 2; page 270,          col 1, para 1]	184602-0-0-0 K M Q; 184602-0-0-0 CL RCT USE			RA02DV K M Q		WO2019202285-A1;  GB2573649-A;  GB2573649-B	Pharmaceutical composition for treating disease,            e.g. Middle East respiratory syndrome, in animal,            comprises 1st formulation comprising bioactive            component, and solubility modifier, and 2nd formulation            comprising bioactive component	WILLIAMSON E D;  MOORE B D;  NEW R R C	UK SEC FOR DEFENCE (MINA-C);  PROXIMA CONCEPTS LTD (PROX-Non-standard);  UNIV STRATHCLYDE (UYST-C)	201988205L	   NOVELTY - Pharmaceutical composition for use as a                medicament for preventing or treating disease in an                animal, comprises a 1st formulation comprising a                bioactive component, microcrystal excipient and                solubility modifier; and a 2nd formulation                comprising a bioactive component, amphiphile and                oil-based excipient. The 1st formulation and 2nd                formulation are sequentially aciministered to the                animal via a parenteral route and an oral route                respectively.    USE - The pharmaceutical composition or kit is                useful as medicament for preventing or treating                disease, e.g. MERS, or plague in animal, e.g. human                (all claimed).    ADVANTAGE - The pharmaceutical products provide a safe,                reliable and effective stimulation of immunity in                animals, in particular the pharmaceutical products                can be deployed to outbreaks considered emergency                situations and/or associated with low-to-middle                income countries, and which require minimal cold                chain to ease the logistic burden of administering                such products to individuals.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a                pharmaceutical kit comprising the pharmaceutical                composition. 			B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B02 (Fused ring heterocyclics.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)	B04-E99;  B04-B01B;  B04-B01C3;  B04-B04C1;  B04-C01;  B04-C02;  B04-C03C;  B04-E01;  B04-N03J;  B04-N03K;  B04-N04;  B05-A01B;  B05-B01P;  B05-B02A3;  B06-D17;  B07-A02B;  B07-D09;  B10-A09B;  B10-B02J;  B10-E04D;  B10-G02;  B10-J02;  B12-M12N;  B14-A01A;  B14-A02B5;  B14-G01;  B14-K01D;  B14-S11;  B14-S18;  B15-A00;  B15-A00A;  B15-D00;  B15-E00;  D05-H99;  D05-H12;  A12-V01	A61K-039/00;  A61K-039/02;  A61K-039/12;  A61K-009/00;  A61P-031/04;  A61P-031/14;  C07K-016/10;  A61K-039/215;  A61K-009/107;  A61K-009/16	WO2019202285-A1   24 Oct 2019   A61K-009/00   201987Pages: 76   English;  GB2573649-A   13 Nov 2019   A61K-039/02   201988   English;  GB2573649-B   05 Oct 2022   A61K-039/02   202281   English	WO2019202285-A1    WOGB000061    23 Apr 2019;   GB2573649-A    GB005509    18 Apr 2019;   GB2573649-B    GB005509    18 Apr 2019		GB006460    20 Apr 2018	WO2019202285-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      		;  GB2573649-B -- WO2012152709-A1   VAXCINE LTD (VAXC-Non-standard)   NEW R;  WO2009077732-A2   UNIV STRATHCLYDE (UYST)   BRADLEY L,  MOORE B D,  PARTRIDGE J,  VOS J	GB2573649-B            International Journal of Pharmaceutics (2005) 296 117-121          Murdan 'Immobilisation of vaccines onto micro-crystals          for enhanced thermal stability';            Advanced Drug Delivery Reviews (1997) 25 59-69 New          'Solubilisation of hydrophilic drugs in oily          formulations';            Vaccine (2005) 23 1957-1965 Glynn 'Effect of homologous          and heterologous prime-boost on the immune response to          recombinant plague antigens';            Vaccine (2016) 34 2982-2987 Modjarrad 'MERS-CoV vaccine          candidates in development: The current          landscape';            Vaccine (2019) 37 4094 - 4102 New 'Antibody-mediated          protection against MERS-CoV in the murine          model'	95972-0-0-0 K M; 103242-0-0-0 K M; 184611-0-0-0 K M; 184616-0-0-0 K M; 184614-0-0-0 K M; 93605-0-0-0 K M; 105730-0-0-0 K M; 90862-0-0-0 K M; 20225-2-0-0 K M; 97733-0-0-0 K M; 99222-0-0-0 K M; 4464-0-1-0 K M; 109254-1-0-0 K M; 10897-1-0-0 K M; 109324-0-0-0 K M; 129481-5-0-0 K M; 129496-0-0-0 K M; 103967-1-0-0 K M; 105509-5-0-0 K M; 133363-1-0-0 K M; 6103-1-0-0 K M; 20225-3-0-0 K M; 4015-0-0-0 K M; 109110-0-0-0 K M; 109111-0-0-0 K M; 109113-0-0-0 K M; 109114-0-0-0 K M; 4015-1-1-0 K M; 196441-0-0-0 K M; 1108348-1-0-0 K M; 51640-0-0-0 K M; 444-0-0-0 ; 1108348-1-0-0 CL USE	216999102 K M; 216999103 K M; 216999101 K M	01391; 02763	R24033 K M; RA0218 K M; RA00H1 K M; RA00H3 K M; RA0121 K M; RA00NS K M; RA012P K M; RA0AMJ K M; RA09C1 K M; R19961 K M; R01833 K M; RA00JW K M; R07617 K M; R10400 K M; R06064 K M; R01211 K M; R10826 K M; R01757 K M; RA00D3 K M; R01636 K M; R00115 K M; R16828 K M; R00282 K M; R14908 K M; R00007 K M; R00276 K M; R00179 K M; R14756 K M; R01163 K M; R00990 K M; RA0CPW K M; R01693 K M; RALFO2 K M; RA04FP K M; RAIIWI K M; R03875 K M; R00351 	1833-S; 1211-S; 1757-S; 1636-S; 0115-S; 0282-S; 0007-S; 0276-S; 0179-S; 1163-S; 0990-S; 1693-S	WO2019210175-A1;  US2020236914-A1;  AU2019257776-A1;  CA3096283-A1;  KR2021005661-A;  BR112020021476-A2;  CN112313330-A;  VN77218-A;  PH12020551629-A1;  JP2021521844-W;  RU2020133923-A	Livestock animal or offspring or animal cell            comprises one modified chromosomal sequence in gene            encoding an aminopeptidase N protein	PRATHER R S;  WELLS K D;  WHITWORTH K M;  PRATER R S;  UELLS K D;  UITUORT K M	UNIV MISSOURI (UMOR-C);  UNIV MISSOURI (UMOR-C);  UNIV MISSOURI (UMOR-C)	201990406D	   NOVELTY - Livestock animal or offspring or an animal                cell comprises one modified chromosomal sequence in                a gene encoding an aminopeptidase N (ANPEP)                protein.    USE - Livestock animal or offspring or animal                cell.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a method for producing a non-human animal                or a lineage of non-human animals having reduced                susceptibility to infection by a pathogen, which                involves modifying an oocyte or a sperm cell to                introduce a modified chromosomal sequence in a gene                encoding an aminopeptidase N (ANPEP) protein into                one of the oocyte and the sperm cell, and                fertilizing the oocyte with the sperm cell to                create a fertilized egg containing the modified                chromosomal sequence in the gene encoding a ANPEP                protein, or modifying a fertilized egg to introduce                a modified chromosomal sequence in a gene encoding                an ANPEP protein into the fertilized egg,                transferring the fertilized egg into a surrogate                female animal, where gestation and term delivery                produces a progeny animal, screening the progeny                animal for susceptibility to the pathogen, and                selecting progeny animals that have reduced                susceptibility to the pathogen as compared to                animals that do not comprise a modified chromosomal                sequence in a gene encoding an ANPEP protein;    (2) a method for increasing a livestock animal                s resistance to infection with a pathogen, which                involves modifying one chromosomal sequence in a                gene encoding an aminopeptidase N (ANPEP) protein,                so that ANPEP protein production or activity is                reduced, as compared to ANPEP protein production or                activity in a livestock animal that does not                comprise a modified chromosomal sequence in a gene                encoding an ANPEP protein;    (3) a population of livestock animals, which                comprises two or more livestock animals and/or                offspring; and    (4) a nucleic acid molecule, which comprises a                nucleotide sequence selected from the group                consisting of a nucleotide sequence having 80%                sequence identity to the sequence of (SEQ ID NO:                135), where the nucleotide sequence comprises one                substitution, insertion, or deletion relative to                (SEQ ID NO: 135), a nucleotide sequence having 80%                sequence identity to the sequence of (SEQ ID NO:                132), where the nucleotide sequence comprises one                substitution, insertion, or deletion relative to                (SEQ ID NO: 132), not given in the specification,                and a cDNA. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E02E;  B04-E03E;  B04-E13;  B04-E99;  B04-F02;  B04-F0200E;  B04-L05A2E;  B04-P01;  B04-P0100E;  B14-A02B;  B14-S12;  C04-C02E;  C04-E03E;  C04-E13;  C04-E99;  C04-F02;  C04-F0200E;  C04-L05A2E;  C04-P01;  C04-P0100E;  C14-A02B;  C14-S12;  D05-H12A;  D05-H12B;  D05-H14B2;  D05-H16A;  D05-H19C;  D05-H99	A61K-039/00;  C12N-009/48;  A01K-067/027;  C07K-014/705;  C12N-015/90;  C12N-015/09;  C12N-015/57;  C12N-005/10	WO2019210175-A1   31 Oct 2019   C12N-009/48   201986Pages: 280   English;  US2020236914-A1   30 Jul 2020   A01K-067/027   202062   English;  AU2019257776-A1   22 Oct 2020   C12N-009/48   202086   English;  CA3096283-A1   31 Oct 2019   C12N-009/48   202089   English;  KR2021005661-A   14 Jan 2021   A01K-067/027   202107   ;  BR112020021476-A2   19 Jan 2021   C12N-009/48   202112   English;  CN112313330-A   02 Feb 2021   C12N-009/48   202114   Chinese;  VN77218-A   26 Apr 2021   C12N-009/48   202149   ;  PH12020551629-A1   12 Jul 2021   A61K-039/00   202167   English;  JP2021521844-W   30 Aug 2021   C12N-015/57   202171Pages: 203   Japanese;  RU2020133923-A   27 May 2022   C12N-009/48   202276   Russian	WO2019210175-A1    WOUS029356    26 Apr 2019;   US2020236914-A1    US16614116    15 Nov 2019;   AU2019257776-A1    AU257776    26 Apr 2019;   CA3096283-A1    CA3096283    26 Apr 2019;   KR2021005661-A    KR733628    26 Apr 2019;   BR112020021476-A2    BR11021476    26 Apr 2019;   CN112313330-A    CN80041749    26 Apr 2019;   VN77218-A    VN006609    26 Apr 2019;   PH12020551629-A1    PH551629    02 Oct 2020;   JP2021521844-W    JP560234    26 Apr 2019;   RU2020133923-A    RU133923    26 Apr 2019	US2020236914-A1 PCT application Application WOUS029356;   US2020236914-A1 Provisional Application US663495P;   AU2019257776-A1 PCT application Application WOUS029356;   AU2019257776-A1 Based on Patent WO2019210175;   CA3096283-A1 PCT application Application WOUS029356;   CA3096283-A1 Based on Patent WO2019210175;   KR2021005661-A PCT application Application WOUS029356;   KR2021005661-A Based on Patent WO2019210175;   BR112020021476-A2 PCT application Application WOUS029356;   BR112020021476-A2 Based on Patent WO2019210175;   CN112313330-A PCT application Application WOUS029356;   CN112313330-A Based on Patent WO2019210175;   VN77218-A PCT application Application WOUS029356;   VN77218-A Based on Patent WO2019210175;   PH12020551629-A1 PCT application Application WOUS029356;   PH12020551629-A1 Based on Patent WO2019210175;   JP2021521844-W PCT application Application WOUS029356;   JP2021521844-W Based on Patent WO2019210175;   RU2020133923-A PCT application Application WOUS029356;   RU2020133923-A Based on Patent WO2019210175	US663495P    27 Apr 2018;  US16614116    15 Nov 2019;  CA3096283    05 Oct 2020;  BR11021476    20 Oct 2020;  KR733628    23 Nov 2020;  RU133923    27 Nov 2020;  CN80041749    21 Dec 2020	WO2019210175-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA                      		WO2019210175-A1 -- CN107034218-A   UNIV ZHEJIANG (UYZH)   ZHANG K,  WANG S;  WO2015153647-A1   WEST J (WEST-Individual)   WEST J;  CN112313330-A -- CN103687482-A   UNIV MISSOURI (UMOR)   PRATHER R S;  CN105112450-A   UNIV MISSOURI (UMOR)   PRATHER R S;  CN107034218-A   UNIV ZHEJIANG (UYZH)   ZHANG K,  WANG S;  CN107937345-A   SHANDONG LANSI SEEDS IND CO LTD (SHAN-Non-standard)   LI K,  MOU Y,  LIU Z,  LI J,  XU K,  WEI Y,  GE C,  CAI X,  WANG L,  CHEN Q,  QIU Y;  WO2017023337-A1   UNIV MISSOURI (UMOR)   PRATHER R S,  WELLS K D,  WHITWORTH K M	CN112313330-A  XINYU ZHU:          "Contribution of porcine aminopeptidase N to porcine          deltacoronavirus infection", EMERG MICROBES INFECT, vol.          7, pages 65,relevantClaims[15-29|1-1427-28];  WENTAO LI:          "Aminopeptidase N is not required for porcine epidemic          diarrhea virus cell entry", VIRUS RESEARCH, vol. 235,          pages 6 - 13, XP085001367, DOI:          10.1016/j.virusres.2017.03.018,relevantClaims[1-35]	200757-0-0-0 K P; 93605-0-0-0 K U; 105730-0-0-0 K U; 184598-0-0-0 K U			RA00GT K P; RA00NS K U; RA012P K U; RA00GC K U		WO2019173756-A1;  CA3092961-A1;  AU2019231889-A1;  US2021000929-A1;  EP3762505-A1;  JP2021517168-W;  EP3762505-A4;  IL277182-A	Treating Parkinson's disease in human, involves            administering composition comprising population of            pluripotent cells that express transgene encoding            glucocerebrosidase to human	MASON C;  VAN TIL N P;  COOPER O;  VAN T N P	AVROBIO INC (AVRO-Non-standard);  AVROBIO INC (AVRO-Non-standard);  AVROBIO INC (AVRO-Non-standard);  AVROBIO INC (AVRO-Non-standard)	201979194A	   NOVELTY - Method of treating Parkinson's disease in a                subject, involves administering a composition                comprising a population of pluripotent cells that                express a transgene encoding glucocerebrosidase                (GBA) to the subject.    USE - The method is useful for treating Parkinson's                disease in a subject. The Parkinson's disease is                GBA-associated Parkinson's disease. The subject is                a human (all claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a composition comprising a population of                pluripotent cells that express (i) a first                transgene encoding non-secreted GBA, and (ii) one                or more transgenes that each encode an M2-promoting                agent, or a population of pluripotent cells that                express (i) a first transgene encoding secreted                GBA, and (ii) one or more transgenes that each                encode an M2-promoting agent; and    (2) a kit comprising the composition and a                package insert. 			B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)	B04-C02C;  B04-C03E;  B04-E13;  B04-E99;  B04-F0200E;  B04-L05A2;  B05-A01B;  B05-B01G;  B05-B02A3;  B06-D05;  B10-A09B;  B10-B03B;  B14-J01A3;  B14-S21;  D05-H08B;  D05-H14B2;  D05-H19C;  D05-H99;  A12-V01;  A12-W11L	A61K-035/28;  A61K-048/00;  C12Q-001/34;  A61K-031/138;  A61K-031/4439;  A61K-031/505;  A61K-038/20;  A61K-038/47;  A61K-009/00;  A61P-025/16;  C07K-014/54;  C07K-014/65;  C07K-014/775;  C07K-014/81;  C12N-015/113;  C12N-015/86;  C12N-009/38;  A01K-067/027;  A61K-035/545;  A61K-035/76;  A61P-043/00;  C12N-015/09;  C12N-015/12;  C12N-015/15;  C12N-015/16;  C12N-015/19;  C12N-015/24;  C12N-015/56;  C12N-015/62;  C12N-015/861;  C12N-015/863;  C12N-015/864;  C12N-015/867;  C12N-015/869;  C12N-015/87;  C12N-015/88;  C12N-005/0789;  C12N-005/10	WO2019173756-A1   12 Sep 2019   C12Q-001/34   201974Pages: 97   English;  CA3092961-A1   12 Sep 2019   C12Q-001/34   202079   English;  AU2019231889-A1   01 Oct 2020   C12Q-001/34   202081   English;  US2021000929-A1   07 Jan 2021   A61K-038/47   202104   English;  EP3762505-A1   13 Jan 2021   C12Q-001/34   202106   English;  JP2021517168-W   15 Jul 2021   A61K-035/28   202158Pages: 97   Japanese;  EP3762505-A4   01 Dec 2021   C12Q-001/34   202198   English;  IL277182-A   29 Oct 2020   C12Q-001/34   202341   English	WO2019173756-A1    WOUS021422    08 Mar 2019;   CA3092961-A1    CA3092961    08 Mar 2019;   AU2019231889-A1    AU231889    08 Mar 2019;   US2021000929-A1    US16979378    09 Sep 2020;   EP3762505-A1    EP764359    08 Mar 2019;   JP2021517168-W    JP571336    08 Mar 2019;   EP3762505-A4    EP764359    08 Mar 2019;   IL277182-A    IL277182    08 Mar 2019	CA3092961-A1 PCT application Application WOUS021422;   CA3092961-A1 Based on Patent WO2019173756;   AU2019231889-A1 PCT application Application WOUS021422;   AU2019231889-A1 Based on Patent WO2019173756;   US2021000929-A1 PCT application Application WOUS021422;   US2021000929-A1 Provisional Application US641012P;   EP3762505-A1 PCT application Application WOUS021422;   EP3762505-A1 Based on Patent WO2019173756;   JP2021517168-W PCT application Application WOUS021422;   JP2021517168-W Based on Patent WO2019173756;   IL277182-A Based on Patent WO2019173756	US641012P    09 Mar 2018;  WOUS021422    08 Mar 2019;  CA3092961    02 Sep 2020;  US16979378    09 Sep 2020	WO2019173756-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP3762505-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    EP3762505-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME    		WO2019173756-A1 -- US20140112896-A1   ;  US20150133496-A1   ;  US2021000929-A1 -- WO1998024924-A1   ;  EP3762505-A4 -- WO2012094321-A1   AVM BIOTECHNOLOGY LLC (AVMB-Non-standard)   DEISHER T A;  WO2016179497-A1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU);  MCLEAN HOSPITAL CORP (MCLE)   PARK Y H,  ISACSON O;  WO2017103612-A1   UCL BUSINESS PLC (UNLO)   GASPAR B,  THRASHER A,  ANTONIOU M,  MONTIEL-EQUIHUA C;  WO2017106363-A1   PARKINSON'S INST (PARK-Non-standard)   LANGSTON J W,  SCHULE B,  REES L,  NICHOLS R J,  BARLOW C	EP3762505-A4  BAHNSON A B ET AL:          "Transduction of CD34+ enriched cord blood and Gaucher          bone marrow cells by a retroviral vector carrying the          glucocerebrosidase gene", GENE THERAPY, vol. 1, no. 3, 1          May 1994 (1994-05-01), pages 176 - 184, XP055853772,          Retrieved from the Internet          &lt;URL:http://www.ncbi.nlm.nih.gov/pubmed/7584079&gt;,relevantClaims[1-15],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;178&lt;/pp&gt;&lt;figure&gt;3&lt;/figure&gt;];            See also references of WO 2019173756A1	299826-0-0-0 K M; 173429-0-0-0 K M; 89522-0-0-0 K M; 109265-0-0-0 K M; 91275-0-0-0 K M; 1249038-0-0-0 K M; 1925956-0-0-0 K M; 2493206-0-0-0 K M; 109324-0-0-0 K M; 97408-0-0-0 K M; 1606-0-0-0 ; 92818-0-0-0 ; 107779-0-0-0 ; 1249038-0-0-0 CL USE; 1925956-0-0-0 CL USE; 2493206-0-0-0 CL USE		01272	RA22EE K M; R14108 K M; R08220 K M; RA1QEQ K M; RBXVDD K M; RALH3O K M; RAZX0W K M; RBBWES K M; R01757 K M; RA00D3 K M; R23652 K M; R01176 ; R01857 ; R01863 	1757-S	WO2019118480-A1;  EP3723771-A1;  US2020399323-A1;  EP3723771-A4;  HK40039661-A0;  US11773142-B2	Isolated polynucleotide or its complement used for            treating subject having disease, where disease is            acquired immune deficiency syndrome, cancer,            tuberculosis, leprosy, typhoid fever, comprises            nucleotide sequence encoding hexon protein	BAROUCH D H;  ABBINK P;  IAMPIETRO M J;  HAVENGA M J E	BETH ISRAEL DEACONESS MEDICAL CENT (BEIS-C);  BETH ISRAEL DEACONESS MEDICAL CENT (BEIS-C);  BETH ISRAEL DEACONESS MEDICAL CENT (BEIS-C)	2019517943	   NOVELTY - Isolated polynucleotide or its complement                comprises nucleotide sequence encoding a hexon                protein, where nucleotide sequence encoding the                hexon protein has 93% sequence identity over entire                sequence of nucleobases (SEQ ID NOS: 55, 58, 59,                61, 62, 64, 65, and 67), not given in the                specification.    USE - Isolated polynucleotide or its complement used                for treating a subject having a disease, where                disease is acquired immune deficiency syndrome                (AIDS), cancer, tuberculosis, leprosy, typhoid                fever, pneumonia, meningitis, staphylococcal                scalded skin syndrome (SSSS), Ritter's disease,                tularemia (rabbit fever), brucellosis, Glanders                disease, bubonic plague, septicemic plague,                pneumonic plague, diphtheria, pertussis (whooping                cough), tetanus, anthrax, hepatitis, smallpox,                monkeypox, measles, mumps, rubella, chicken pox,                polio, rabies, Japanese encephalitis, herpes,                mononucleosis, influenza, ebola virus disease,                hemorrhagic fever, yellow fever, Zika fever,                Marburg virus disease, toxoplasmosis, malaria,                trypanosomiasis, legionellosis, aspergillosis,                blastomycosis, candidiasis, coccidioidomycosis,                cryptococcosis, histoplasmosis,                paracoccidioidomycosis, sporotrichosis, or                sinus-orbital zygomycosis (all claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a recombinant vector, which comprises the                isolated polynucleotide or its complement;    (2) a recombinant adenovirus, which comprises                isolated polynucleotide or its complement or                recombinant vector;    (3) a method for treating a subject having a                disease, which involves administering isolated                polynucleotide or its complement, recombinant                vector, or recombinant adenovirus to subject;    (4) a method for inducing an immune response                in a subject, which involves administering isolated                polynucleotide or its complement, recombinant                vector, or recombinant adenovirus to subject;                and    (5) a method for producing a recombinant                adenovirus, which involves transfecting a cell with                isolated polynucleotide or its complement or                recombinant vector; culturing cell in a suitable                medium to allow replication of polynucleotide or                vector in cell; and harvesting recombinant                adenovirus from cell and/or from medium. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	B04-E02F;  B04-E03F;  B04-E08;  B04-E99;  B04-F0100E;  B04-F0300E;  B04-F0800E;  B04-F1000E;  B04-F11A1E;  B04-N03J;  B04-N03K;  B14-A01;  B14-A02;  B14-A03;  B14-A04;  B14-C03;  B14-C04;  B14-G01;  B14-G02;  B14-H01;  B14-K01;  B14-N12;  B14-N16;  B14-N17;  B14-S03A;  B14-S16;  C04-E02F;  C04-E03F;  C04-E08;  C04-E99;  C04-F0100E;  C04-F0300E;  C04-F0800E;  C04-F1000E;  C04-F11A1E;  C04-N03J;  C04-N03K;  C14-A01;  C14-A02;  C14-A03;  C14-A04;  C14-C03;  C14-C04;  C14-G01;  C14-G02;  C14-H01;  C14-K01;  C14-N12;  C14-N16;  C14-N17;  C14-S03A;  C14-S16;  D05-H12;  D05-H99	A61K-031/7088;  A61K-035/76;  A61K-035/761;  A61K-039/12;  A61K-039/235;  C12N-015/09;  C12N-015/861;  C12N-007/00;  C07K-014/075;  C07K-014/54	WO2019118480-A1   20 Jun 2019   A61K-031/7088   201951Pages: 249   English;  EP3723771-A1   21 Oct 2020   A61K-031/7088   202086   English;  US2020399323-A1   24 Dec 2020   C07K-014/075   202004   English;  EP3723771-A4   06 Apr 2022   A61K-031/7088   202230   English;  HK40039661-A0   16 Jul 2021   A61K-031/7088   202203   English;  US11773142-B2   03 Oct 2023   C07K-014/075   202380   English	WO2019118480-A1    WOUS064978    11 Dec 2018;   EP3723771-A1    EP889863    11 Dec 2018;   US2020399323-A1    US16772045    11 Jun 2020;   EP3723771-A4    EP889863    11 Dec 2018;   HK40039661-A0    HK6029633    20 Apr 2021;   US11773142-B2    US16772045    11 Jun 2020	EP3723771-A1 PCT application Application WOUS064978;   EP3723771-A1 Based on Patent WO2019118480;   US2020399323-A1 PCT application Application WOUS064978;   US2020399323-A1 Provisional Application US607288P;   US2020399323-A1 Provisional Application US597268P;   US2020399323-A1 Provisional Application US641774P;   HK40039661-A0 PCT application Application WOUS064978;   HK40039661-A0 Based on Patent WO2019118480;   HK40039661-A0 Previous Publ. Patent EP3723771;   US11773142-B2 Provisional Application US607288P;   US11773142-B2 Provisional Application US641774P;   US11773142-B2 Provisional Application US597268P;   US11773142-B2 PCT application Application WOUS064978;   US11773142-B2 Previous Publ. Patent US2020399323;   US11773142-B2 Based on Patent WO2019118480	US597268P    11 Dec 2017;  US607288P    18 Dec 2017;  US641774P    12 Mar 2018;  EP889863    11 Dec 2018;  WOUS064978    11 Dec 2018;  US16772045    11 Jun 2020	WO2019118480-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP3723771-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    EP3723771-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR      		WO2019118480-A1 -- US20150291935-A1   ;  US20170119872-A1   ;  US9718863-B2   OKAIROS AG (GLAX)   AMBROSIO M,  AMMENDOLA V,  COLLOCA S,  CORTESE R,  NICOSIA A;  EP3723771-A4 -- WO2003046124-A2   UNIV PENNSYLVANIA (UPEN)   WILSON J M,  GAO G,  ROY S;  WO2008010864-A2   UNIV PENNSYLVANIA (UPEN)   SOUMITRA R,  WILSON J M;  WO2011057248-A2   GENVEC INC (GVEC)   GALL J,  BROUGH D,  KAHL C,  MCVEY D;  WO2012024351-A2   SALK BIOLOGICAL STUDIES INST (SALK)   OSHEA C,  POWERS C;  WO2014078688-A2   BETH ISRAEL DEACONESS MEDICAL CENT (BEIS);  UNIV WASHINGTON ST LOUIS (UNWL)   BAROUCH D H,  VIRGIN H,  ABBINK P;  US11773142-B2 -- EP1944043-A1   UNIV PENNSYLVANIA (UPEN)   WILSON J M,  GAO G,  ROY S;  US4695623-A   APPLIED MOLECULAR GENETICS INC (AMGE);  AMGEN (AMGE)   ALTON N K,  PETERS M A,  STABINSKY Y,  SNITMAN D L;  US20040136963-A1   ;  US20050232900-A1   ;  US20100034774-A1   ;  US20110000480-A1   ;  US20110306090-A1   ;  US20120027788-A1   ;  US20120076812-A1   ;  US20140348791-A1   ;  US20150291935-A1   ;  US20170119872-A1   ;  US20190136205-A1   ;  US7247472-B2   UNIV PENNSYLVANIA (UPEN)   WILSON J M,  GAO G,  ROY S;  US9718863-B2   OKAIROS AG (GLAX)   AMBROSIO M,  AMMENDOLA V,  COLLOCA S,  CORTESE R,  NICOSIA A;  US10106781-B2   BETH ISRAEL DEACONESS MEDICAL CENT (BEIS);  UNIV WASHINGTON ST LOUIS (UNWL)   BAROUCH D H,  VIRGIN H,  ABBINK P;  WO1997000326-A1   ;  WO2000070071-A1   ;  WO2001002607-A1   ;  WO2011129468-A1   MOGAM BIOTECHNOLOGY RES INST (MOGA)   LEE K,  YUN S,  KOH D,  LEE H,  JO E;  WO2002022080-A2   ;  WO2002040665-A2   ;  WO2003046124-A2   UNIV PENNSYLVANIA (UPEN)   WILSON J M,  GAO G,  ROY S;  WO2007104792-A2   CRUCELL HOLLAND BV (CRUL);  BETH ISRAEL DEACONESS MEDICAL CENT (BEIS)   BAROUCH D H,  HAVENGA M J E;  WO2008010864-A2   UNIV PENNSYLVANIA (UPEN)   SOUMITRA R,  WILSON J M;  WO2011057248-A2   GENVEC INC (GVEC)   GALL J,  BROUGH D,  KAHL C,  MCVEY D;  WO2011057254-A2   US DEPT HEALTH & HUMAN SERVICES (USSH);  GENVEC INC (GVEC)   NABEL G J,  CHENG C,  KO S,  GALL J G D,  KONG W,  BROUGH D E,  MCVEY D L,  KAHL C,  WEI C;  WO2012021730-A2   GENVEC INC (GVEC)   GALL J G D;  WO2012024351-A2   SALK BIOLOGICAL STUDIES INST (SALK)   OSHEA C,  POWERS C;  WO2014078688-A2   BETH ISRAEL DEACONESS MEDICAL CENT (BEIS);  UNIV WASHINGTON ST LOUIS (UNWL)   BAROUCH D H,  VIRGIN H,  ABBINK P	WO2019118480-A1  ABBINK, P ET AL.:          "Rapid Cloning of Novel Rhesus Adenoviral Vaccine          Vectors", JOURNAL OF VIROLOGY, vol. 96, no. 6, 15 March          2018 (2018-03-15), pages e01924-17, XP055618139, DOI:          10.1128/JVI.01924-17,relevantClaims[1-4,          20-24],relevantPassages[; entire document; DOI:          10.1128/JVI.01924-17]US2020399323-A1  Wu          et al. Flexibility of the Adenovirus Fiber Is Required          for Efficient Receptor Interaction. JOURNAL OF VIROLOGY,          July 2003, p. 72257235, Vol. 77, No. 13.EP3723771-A4  PETER ABBINK ET AL:          "ABSTRACT", JOURNAL OF VIROLOGY, vol. 89, no. 3, 19          November 2014 (2014-11-19), US, pages 1512 - 1522,          XP055551986, ISSN: 0022-538X, DOI:          10.1128/JVI.02950-14,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  KOVACS GABOR M ET          AL: "Complete genome sequence of simian adenovirus 1: an          Old World monkey adenovirus with two fiber genes",          JOURNAL OF GENERAL VIROLOGY,, vol. 86, no. Part 6, 1 June          2005 (2005-06-01), pages 1681 - 1686, XP009175224, ISSN:          0022-1317, DOI:          10.1099/VIR.0.80757-0,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  PANTO LAURA ET AL:          "Taxonomy proposal for Old World monkey adenoviruses:          characterisation of several non-human, non-ape primate          adenovirus lineages", ARCHIVES OF VIROLOGY, SPRINGER          WIEN, AT, vol. 160, no. 12, 14 September 2015          (2015-09-14), pages 3165 - 3177, XP035888451, ISSN:          0304-8608, [retrieved on 20150914], DOI:          10.1007/S00705-015-2575-Z,relevantClaims[1-15],relevantPassages[&lt;table&gt;1,          4&lt;/table&gt;];            See also references of WO 2019118480A1US11773142-B2  Wu          et al. Flexibility of the Adenovirus Fiber Is Required          for Efficient Receptor Interaction. Journal of Virology,          Jul. 2003, p. 7225-7235, vol. 77, No. 13.;            Morris et al. Simian adenoviruses as vaccine vectors.          Future Virol. (2016) 11(9), 649-659.;            GenBank: KP329562.1. Simian adenovirus 11 strain P-10,          complete genome. Dated Jan. 29, 2016.;            Awasthi et al. Genital Herpes by Using Glycoprotein C and          D Subunit Antigens to Induce Potent Antibody Responses          and Adenovirus Vectors Containing Capsid and Tegument          Proteins as T Cell Immunogens. J. Virol, 2015,          89:8497-8509.;            Communication Pursuant to 164(1) EPC for European Patent          Application No. 18889863.9, dated Nov. 3, 2021 (22          pages).;            GenBank Accession No. KM591901.1, Rhesus adenovirus 51,          complete genome, retrieved from          &lt;https://www.ncbi.nlm.nih.gov/nuccore/KM591901.1&gt;,          dated Apr. 21, 2015 (11 pages).;            GenBank Accession No. KM591902.1, Rhesus adenovirus 52,          complete genome, retrieved from          &lt;https://www.ncbi.nlm.nih.gov/nuccore/KM591902&gt;,          dated Apr. 21, 2015 (11 pages).;            GenBank Accession No. KM591903.1, Rhesus adenovirus 53,          complete genome, retrieved from          &lt;https://www.ncbi.nlm.nih.gov/nuccore/KM591903&gt;,          dated Apr. 21, 2015 (11 pages).;            UniProtKB-Q5C8P9, UniProtKB, retrieved from          &lt;https://www.uniprot.org/uniprot/Q5C8P9&gt;          (2005) (7 pages).;            UniProt: A0A0M5L3Y8, UniProt (2015) (2 pages).;            Extended European Search Report for European Patent          Application No. 18889863.9, dated Mar. 10, 2022 (24          pages).;            Panto et al., Taxonomy Proposal for Old World Monkey          Adenoviruses: Characterisation of Several Non-Human,          Non-Ape Primate Adenovirus Lineages, Arch Virol. 160:          3165-77 (2015) (14 pages).;            Sequence alignment results, EMBOSS Needle/Pairwise          Sequence Alignment/EMBLE-EBI web site,          &lt;www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html&gt;,          retrieved on Feb. 15, 2019 (10 pages).;            Abbink et al., Comparative seroprevalence and          immunogenicity of six rare serotype recombinant          adenovirus vaccine vectors from subgroups B and D, J          Virol. 81(9):4654-63 (2007).;            Abbink et al., Construction and Evaluation of Novel          Rhesus Monkey Adenovirus Vaccine Vectors, J Virol.          89(3):1512-22 (2015) (11 pages).;            Abbink et al., Development of Novel Simian Adenovirus          Based Vaccine Vectors. Poster, 2013.          &lt;epostersonline.s3.amazonaws.com&gt;.          Retrieved on Apr. 16, 2014 (1 page).;            Abbink et al. Rapid Cloning of Novel Rhesus Adenoviral          Vaccine Vectors, J Virol. 92(6):e01924-17 (2018) (11          pages).;            Bangari et al. Development of nonhuman adenoviruses as          vaccine vectors, Vaccine 24(7):849-62 (2006) (21          pages).;            Barouch et al. Immunogenicity of recombinant adenovirus          serotype 35 vaccine in the presence of pre-existing          anti-Ad5 immunity, J Immunol. 172(10):6290-7 (2004) (9          pages).;            Barouch et al. International seroepidemiology of          adenovirus serotypes 5, 26, 35, and 48 in pediatric and          adult populations, Vaccine. 29(32):5203-9 (2011) (14          pages).;            Communication Pursuant to 94(3) EPC for European Patent          Application No. 13854932.4, dated Sep. 28, 2017 (8          pages).;            Communication pursuant to Article 94(3) EPC for European          Application No. 1979450.2, dated May 13, 2020 (5          pages).;            Communication Pursuant to Rules 70(2) and 70a(2) EPC for          European Patent Application No. 13854932.4, dated Jul. 5,          2016 (6 pages).;            Dicks et al. A novel chimpanzee adenovirus vector with          low human seroprevalence: improved systems for vector          derivation and comparative immunogenicity, PLoS One          7(7):e40385 (2012) (12 pages).;            EMBOSS Needle, Pairwise Sequence Alignment (Nucleotide),          www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html,          retrieved Feb. 28, 2019 (10 pages).;            EMBOSS Needle, Pairwise Sequence Alignment (Protein),          www.ebi.ac.uk/Tools/psa/emboss_needle/, retrieved Aug.          18, 2017 (40 pages).;            Examination Report for Australian Patent Application No.          2018229561, dated Jun. 21, 2019 (4 pages).;            Examination Review Report for Singaporean Patent          Application No. 11201503864T, dated Apr. 22, 2019 (4          pages).;            Extended European Search Report for European Patent          Application No. 13854932.4, dated Jun. 17, 2016 (8          pages).;            Extended European Search Report for European Patent          Application No. 19179450.2, dated Oct. 9, 2019 (7          pages).;            Finkbeiner, et al., Metagenomic analysis of human          diarrhea: viral detection and discovery, PLoS Pathog.          4(2):e1000011 (2008) (9 pages).;            First Examination Report for New Zealand Patent          Application No. 708144, dated Mar. 13, 2019 (5          pages).;            Foy et al. Probable Non-Vector-borne Transmission of Zika          Virus, Colorado, USA, Emerg Infect Dis. 17(5):880-2          (2011) (7 pages).;            Geisbert et al. Recombinant adenovirus serotype 26 (Ad26)          and Ad35 vaccine vectors bypass immunity to Ad5 and          protect nonhuman primates against ebolavirus challenge, J          Virol. 85(9):4222-33 (2011).;            GenBank Accession No. AF326321.1. Retrieved on Apr. 16,          2014 (3 pages).;            GenBank Accession No. AY771780. Retrieved Oct. 24, 2017          (17 pages).;            GenBank Accession No. AY771780.1. Retrieved on Apr. 16,          2014 (15 pages).;            GenBank Accession No. AZ111781.1. Retrieved on Jul. 13,          2016 (2 pages).;            GenBank Accession No. AZI11781.1. Retrieved Jan. 7, 2020          (2 Pages).;            GenBank Accession No. JA453575.1. Retrieved on Jul. 13,          2016 (8 pages).;            Handley et al., Pathogenic simian immunodeficiency virus          infection is associated with expansion of the enteric          virome, Cell. 151(2):253-66 (2012).;            Hayes, Zika virus outside Africa, Emerg Infect Dis.          15(9):1347-50 (2009).;            Holterman et al., Novel replication-incompetent vector          derived from adenovirus type 11 (Ad11) for vaccination          and gene therapy: low seroprevalence and          non-cross-reactivity with Ad5, J Virol. 78(23):13207-15          (2004).;            International Preliminary Report on Patentability for          International Application No. PCT/US2018/064978, dated          Jun. 16, 2020 (9 pages).;            International Preliminary Report on Patentability for          International Patent Application No. PCT/US2013/070353,          dated May 19, 2015 (8 pages).;            International Search Report and Written Opinion for          International Application No. PCT/US2018/064978 dated          Apr. 24, 2019 (20 pages).;            International Search Report and Written Opinion for          International Patent Application No. PCT/US13/70353,          dated May 12, 2014 (17 pages).;            Kass-Eisler et al., Circumventing the immune response to          adenovirus-mediated gene therapy, Gene Ther. 3(2):154-62          (1996) (10 pages).;            Kass-Eisler et al., The Impact of Developmental Stage,          Route of Administration and the Immune System on          Adenovirus-Mediated Gene Transfer, Gene Ther.          1(6):395-402 (1994).;            Kovacs et al., Complete genome sequence of simian          adenovirus 1: an Old World monkey adenovirus with two          fiber genes, Journal of General Virology. 86(6): 1681-6          (2005).;            Kubo, The Task of Isolating and Identifying Human          Pathogenic Viruses, Seikatsu Eisei. 50(5):381-6 (2006)          (English language abstract included).;            Kuno et al., Full-length sequencing and genomic          characterization of Bagaza, Kedougou, and Zika viruses,          Arch Virol. 152(4):687-96 (2007).;            Larocca et al., Vaccine protection against Zika virus          from Brazil, Nature. 536(7617):474-8 (2016) (15          pages).;            Lemckert et al., Immunogenicity of heterologous          prime-boost regimens involving recombinant adenovirus          serotype 11 (Ad11) and Ad35 vaccine vectors in the          presence of anti-ad5 immunity, J Virol. 79(15):9694-701          (2005).;            Letvin et al., Prospects for vaccine protection against          HIV-1 infection and AIDS, Annu Rev Immunol. 20:73-99          (2002).;            Liu et al., Modulation of DNA vaccine-elicited          CD8&lt;xhtml:sup &gt;+          &lt;/xhtml:sup&gt;T-lymphocyte epitope          immunodominance hierarchies, J Virol. 80(24):11991-7          (2006).;            Notice of Reasons for Rejection for Japanese Patent          Application No. 2015-542833, dated Sep. 5, 2017 (20          pages).;            Office Action for Chinese Patent Application No.          201380068078.0, dated Apr. 4, 2018 (5 pages).;            Office Action for Israeli Patent Application No. 238847,          dated May 27, 2019 (5 pages).;            Office Action for Japanese Patent Application No.          2015-542833, dated Apr. 22, 2020 (4 pages).;            Office Action for Japanese Patent Application No.          2015-542833, dated Aug. 7, 2018 (8 pages).;            Office Action for Japanese Patent Application No.          2018-038380, dated Mar. 10, 2020 (16 pages).;            Office Action for Japanese Patent Application No.          2018-038380, dated Mar. 12, 2019 (28 pages).;            Ostapchuk et al., Pseudopackaging of adenovirus type 5          genomes into capsids containing the hexon proteins of          adenovirus serotypes B, D, or E, J Virol. 75(1):45-51          (2001).;            Poland et al., Development of vaccines against Zika          virus, Lancet Infect Dis. 18(7):e211-e219 (2018) (9          pages).;            Search Report for Singaporean Application No.          11201503864T, dated Feb. 29, 2016 (3 pages).;            Setoguchi et al., Intraperitoneal In Vivo Gene Therapy to          Deliver alpha1-Antitrypsin to the Systemic Circulation,          Am J Respir Cell Mol Biol. 10(4):369-77 (1994).;            Shiver et al., Recent advances in the development of          HIV-1 vaccines using replication-incompetent adenovirus          vectors, Annu Rev Med. 55:355-72 (2004).;            Shiver et al., Replication-incompetent adenoviral vaccine          vector elicits effective anti-immunodeficiency-virus          immunity, Nature. 415(6869):331-5 (2002).;            Sprangers et al., Quantifying adenovirus-neutralizing          antibodies by luciferase transgene detection: addressing          preexisting immunity to vaccine and gene therapy vectors,          J Clin Microbiol. 41(11):5046-52 (2003).;            Sumida et al., Neutralizing antibodies to adenovirus          serotype 5 vaccine vectors are directed primarily against          the adenovirus hexon protein, J Immunol. 174(11):7179-85          (2005).;            Tripp et al., Development of a Zika vaccine, Expert Rev          Vaccines. 15(9):1083-5 (2016).;            Vogels et al., Replication-deficient human adenovirus          type 35 vectors for gene transfer and vaccination:          efficient human cell infection and bypass of preexisting          adenovirus immunity, J Virol. 77(15):8263-71          (2003).;            Wodrich et al., Switch from capsid protein import to          adenovirus assembly by cleavage of nuclear transport          signals, EMBO J. 22(23):6245-55 (2003).;            Written Opinion for Singaporean Application No.          11201503864T, dated Apr. 1, 2016 (6 pages).;            Yei et al., Adenovirus-mediated Gene Transfer for Cystic          Fibrosis: Quantitative Evaluation of Repeated in Vivo          Vector Administration to the Lung, Gene Ther.          1(3):192-200 (1994).;            Zabner et al., Safety and efficacy of repetitive          adenovirus-mediated transfer of CFTR cDNA to airway          epithelia of primates and cotton rats, Nat Genet.          6(1):75-83 (1994).	93605-0-0-0 M N; 105730-0-0-0 M N; 200757-0-0-0 M N; 184616-0-0-0 K M; 93605-0-0-0 CL NEW USE; 105730-0-0-0 CL NEW USE; 200757-0-0-0 CL NEW USE			RA00NS M N; RA012P M N; RA00GT M N; RA00H3 K M		WO2019071051-A1;  CA3076518-A1;  AU2018346530-A1;  KR2020074102-A;  EP3692146-A1;  US2020254443-A1;  CN111630162-A;  BR112020006757-A2;  JP2020537121-W;  EP3692146-A4;  RU2020115264-A;  HK40036719-A0;  US11633732-B2;  IL273360-A;  KR2628577-B1	Lateral flow device for detecting target nucleic            acid in sample, comprises substrate, clustered            regularly interspaced short palindromic repeat effector            system, detection construct, and capture regions            comprising binding agents	ZHANG F;  GOOTENBERG J;  ABUDAYYEH O;  GOOTENBERG Y;  GOOTENBERG J S;  ABUDAYYEH O O	BROAD INST INC (BROD-C);  MASSACHUSETTS INST TECHNOLOGY (MASI-C);  HARVARD COLLEGE (HARD-C);  BROAD INST INC (BROD-C);  MASSACHUSETTS INST TECHNOLOGY (MASI-C);  HARVARD COLLEGE (HARD-C);  BROAD INST INC (BROD-C);  MASSACHUSETTS INST TECHNOLOGY (MASI-C);  HARVARD COLLEGE (HARD-C);  BROAD INST INC (BROD-C);  MASSACHUSETTS INST TECHNOLOGY (MASI-C);  HARVARD COLLEGE (HARD-C)	201933034D	   NOVELTY - Lateral flow device comprises a substrate                comprising a 1st end, where the 1st end comprises a                sample loading portion and a 1st region loaded with                a detectable ligand, a clustered regularly                interspaced short palindromic repeat (CRISPR)                effector system, a detection construct, a 1st                capture region comprising a 1st binding agent, and                a 2nd capture region comprising a 2nd binding                agent. The CRISPR effector system comprises a                CRISPR effector protein and guide sequences. Each                guide sequence is configured to bind target                molecules.    USE - The device is useful for detecting a target                nucleic acid in a sample (claimed).    ADVANTAGE - The device and method have high specificity                and sensitivity at low cost.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for detecting                a target nucleic acid in a sample, which involves                contacting a sample with the 1st end of the lateral                flow device comprising the sample loading portion;                where the sample flows from the sample loading                portion of the substrate towards the 1st and 2nd                capture regions and generates a detectable                signal. 			A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	A09-C;  B04-E99;  B04-A0800E;  B04-E01;  B04-E02;  B04-E03;  B04-E05;  B04-E13;  B04-G01;  B04-L05A2;  B04-N04;  B11-C07A5;  B11-C08D2;  B11-C08E3;  B11-C08F8;  B11-C08K;  B11-C12;  B12-K04;  C04-E99;  C04-A0800E;  C04-E01;  C04-E02;  C04-E03;  C04-E05;  C04-E13;  C04-G01;  C04-L05A2;  C04-N04;  C11-C07A5;  C11-C08D2;  C11-C08E3;  C11-C08F8;  C11-C08K;  C11-C12;  C12-K04;  D05-H99;  D05-H09;  D05-H10;  D05-H18B;  D05-H19C	C12N-015/09;  C12N-015/10;  C12N-015/11;  C12N-009/22;  C12N-009/96;  B01L-003/00;  C12Q-001/6816;  C12Q-001/70;  C12M-001/00;  C12N-015/115;  C12Q-001/6844;  C12Q-001/6851;  C12Q-001/686;  G01N-033/53;  G01N-033/543;  C12Q-001/68	WO2019071051-A1   11 Apr 2019   C12N-009/22   201930Pages: 366   English;  CA3076518-A1   11 Apr 2019   C12N-009/22   202031   English;  AU2018346530-A1   30 Apr 2020   C12N-009/22   202036   English;  KR2020074102-A   24 Jun 2020   B01L-003/00   202052   ;  EP3692146-A1   12 Aug 2020   C12N-009/22   202066   English;  US2020254443-A1   13 Aug 2020   B01L-003/00   202066   English;  CN111630162-A   04 Sep 2020   C12N-009/22   202076   Chinese;  BR112020006757-A2   06 Oct 2020   C12N-009/22   202088   English;  JP2020537121-W   17 Dec 2020   G01N-033/543   202002Pages: 223   Japanese;  EP3692146-A4   30 Jun 2021   C12Q-001/6816   202156   English;  RU2020115264-A   08 Nov 2021   C12N-009/22   202256   Russian;  HK40036719-A0   28 May 2021   C12N-009/22   202298   English;  US11633732-B2   25 Apr 2023   C12Q-001/68   202334   English;  IL273360-A   31 May 2020   B01L-003/00   202335   English;  KR2628577-B1   23 Jan 2024   G01N-033/543   202408   	WO2019071051-A1    WOUS054472    04 Oct 2018;   CA3076518-A1    CA3076518    04 Oct 2018;   AU2018346530-A1    AU346530    04 Oct 2018;   KR2020074102-A    KR710078    04 Oct 2018;   EP3692146-A1    EP864541    04 Oct 2018;   US2020254443-A1    US16753896    06 Apr 2020;   CN111630162-A    CN80078358    04 Oct 2018;   BR112020006757-A2    BR11006757    04 Oct 2018;   JP2020537121-W    JP519256    04 Oct 2018;   EP3692146-A4    EP864541    04 Oct 2018;   RU2020115264-A    RU115264    04 Oct 2018;   HK40036719-A0    HK6026696    04 Mar 2021;   US11633732-B2    US16753896    06 Apr 2020;   IL273360-A    IL273360    04 Oct 2018;   KR2628577-B1    KR710078    04 Oct 2018	CA3076518-A1 PCT application Application WOUS054472;   CA3076518-A1 Based on Patent WO2019071051;   AU2018346530-A1 PCT application Application WOUS054472;   AU2018346530-A1 Based on Patent WO2019071051;   KR2020074102-A PCT application Application WOUS054472;   KR2020074102-A Based on Patent WO2019071051;   EP3692146-A1 PCT application Application WOUS054472;   EP3692146-A1 Based on Patent WO2019071051;   US2020254443-A1 PCT application Application WOUS054472;   US2020254443-A1 Provisional Application US610144P;   US2020254443-A1 Provisional Application US623529P;   US2020254443-A1 Provisional Application US630787P;   US2020254443-A1 Provisional Application US568309P;   CN111630162-A PCT application Application WOUS054472;   CN111630162-A Based on Patent WO2019071051;   BR112020006757-A2 PCT application Application WOUS054472;   BR112020006757-A2 Based on Patent WO2019071051;   JP2020537121-W PCT application Application WOUS054472;   JP2020537121-W Based on Patent WO2019071051;   RU2020115264-A PCT application Application WOUS054472;   RU2020115264-A Based on Patent WO2019071051;   HK40036719-A0 PCT application Application WOUS054472;   HK40036719-A0 Based on Patent WO2019071051;   HK40036719-A0 Previous Publ. Patent CN111630162;   US11633732-B2 Provisional Application US623529P;   US11633732-B2 Provisional Application US630787P;   US11633732-B2 Provisional Application US568309P;   US11633732-B2 Provisional Application US610144P;   US11633732-B2 PCT application Application WOUS054472;   US11633732-B2 Previous Publ. Patent US2020254443;   US11633732-B2 Based on Patent WO2019071051;   IL273360-A Based on Patent WO2019071051;   KR2628577-B1 PCT application Application WOUS054472;   KR2628577-B1 Based on Patent WO2019071051	US568309P    04 Oct 2017;  US610144P    22 Dec 2017;  US623529P    29 Jan 2018;  US630787P    14 Feb 2018;  CN80078358    04 Oct 2018;  WOUS054472    04 Oct 2018;  CA3076518    19 Mar 2020;  BR11006757    03 Apr 2020;  US16753896    06 Apr 2020;  KR710078    07 Apr 2020;  RU115264    06 May 2020;  CN80078358    03 Jun 2020	WO2019071051-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP3692146-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN          EP3692146-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR            	435/006100	WO2019071051-A1 -- US20130224729-A1   ;  US9399793-B2   AJ INNUSCREEN GMBH (AJIN-Non-standard);  WO2015109255-A1   GENISPHERE LLC (GENI-Non-standard)   CASTA L J,  KADUSHIN J M,  CLEMENTE A;  WO2016022872-A1   ORTHO CLINICAL DIAGNOSTICS INC (ORTH)   DING Z,  HOSIMER P C,  SCALICE E R,  SALOTTO D P,  HEAVNER D A;  WO2016205711-A1   BROAD INST INC (BROD);  MASSACHUSETTS TECHNOLOGY INST (MASI);  HARVARD COLLEGE (HARD)   ZHANG F,  ZETSCHE B,  GOOTENBERG J,  ABUDAYYEH O,  SLAYMAKER I;  WO2017106657-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  ZHANG F (ZHAN-Individual);  ZETSCHE B (ZETS-Individual);  RAN F (RANF-Individual);  DAHLMAN J E (DAHL-Individual)   ZHANG F,  ZETSCHE B,  RAN F,  DAHLMAN J E;  WO2017219027-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  ZHANG F (ZHAN-Individual);  ABUDAYYEH O O (ABUD-Individual);  GOOTENBERG J (GOOT-Individual);  LANDER E S (LAND-Individual)   ZHANG F,  ABUDAYYEH O O,  GOOTENBERG J,  LANDER E S;  WO2018170340-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  ABUDAYYEH O (ABUD-Individual);  GOOTENBERG J (GOOT-Individual);  LANDER E S (LAND-Individual);  SABETI P (SABE-Individual);  FREIJE C A (FREI-Individual);  MYHRVOLD C (MYHR-Individual)   ABUDAYYEH O,  GOOTENBERG J,  LANDER E S,  SABETI P,  FREIJE C A,  MYHRVOLD C,  COLLINS J J,  ZHANG F;  WO2016028843-A2   HARVARD COLLEGE (HARD)   CHURCH G M,  VIGNEAULT F,  MIR K U;  CN111630162-A -- WO2015109255-A1   GENISPHERE LLC (GENI-Non-standard)   CASTA L J,  KADUSHIN J M,  CLEMENTE A;  WO2016022872-A1   ORTHO CLINICAL DIAGNOSTICS INC (ORTH)   DING Z,  HOSIMER P C,  SCALICE E R,  SALOTTO D P,  HEAVNER D A;  WO2016028843-A2   HARVARD COLLEGE (HARD)   CHURCH G M,  VIGNEAULT F,  MIR K U;  EP3692146-A4 -- WO2017218573-A1   UNIV CALIFORNIA (REGC)   DOUDNA C J H,  DOUDNA J A,  EAST-SELETSKY A,  KNIGHT S C,  OCONNELL M R;  WO2018107129-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  WO2020028185-A1   TOKITAE LLC (TKTE)   BAUGHMAN T A,  MADAN D,  NALEFSKI E,  LE NY A M;  WO2020028729-A1   MAMMOTH BIOSCI INC (MAMM-Non-standard);  CHEN J S (CHEN-Individual);  TEHRANCHI A (TEHR-Individual);  LANE A B (LANE-Individual);  BROUGHTON J P (BROU-Individual);  HARRINGTON L B (HARR-Individual);  TSALOGLOU M (TSAL-Individual);  MIAO X (MIAO-Individual);  FASCHING C L (FASC-Individual);  SINGH J (SING-Individual);  GALARZA P P D (GALA-Individual)   CHEN J S,  TEHRANCHI A,  LANE A B,  BROUGHTON J P,  HARRINGTON L B,  TSALOGLOU M,  MIAO X,  FASCHING C L,  SINGH J,  GALARZA P P D;  WO2019126577-A2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ZHANG F,  ZETSCHE B,  GOOTENBERG J,  ABUDAYYEH O;  US11633732-B2 -- US20190062724-A1   ;  US20190177775-A1   ;  WO2016028843-A2   HARVARD COLLEGE (HARD)   CHURCH G M,  VIGNEAULT F,  MIR K U;  JP2016535282-A   MOLOGIC LTD (MOLO-Non-standard)   DAVIS P,  PAREKH G,  SCHOUTEN J;  US20130224729-A1   ;  US20150152398-A1   ;  US20170211142-A1   ;  US9399793-B2   AJ INNUSCREEN GMBH (AJIN-Non-standard);  WO2015109255-A1   GENISPHERE LLC (GENI-Non-standard)   CASTA L J,  KADUSHIN J M,  CLEMENTE A;  WO2016022872-A1   ORTHO CLINICAL DIAGNOSTICS INC (ORTH)   DING Z,  HOSIMER P C,  SCALICE E R,  SALOTTO D P,  HEAVNER D A;  WO2016205711-A1   BROAD INST INC (BROD);  MASSACHUSETTS TECHNOLOGY INST (MASI);  HARVARD COLLEGE (HARD)   ZHANG F,  ZETSCHE B,  GOOTENBERG J,  ABUDAYYEH O,  SLAYMAKER I;  WO2017070605-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  ZHANG F (ZHAN-Individual);  SMARGON A (SMAR-Individual);  PYZOCHA N (PYZO-Individual);  COX D B T (COXD-Individual);  LANDER E S (LAND-Individual)   ZHANG F,  SMARGON A,  PYZOCHA N,  COX D B T,  LANDER E S;  WO2017106657-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  ZHANG F (ZHAN-Individual);  ZETSCHE B (ZETS-Individual);  RAN F (RANF-Individual);  DAHLMAN J E (DAHL-Individual)   ZHANG F,  ZETSCHE B,  RAN F,  DAHLMAN J E;  WO2017218573-A1   UNIV CALIFORNIA (REGC)   DOUDNA C J H,  DOUDNA J A,  EAST-SELETSKY A,  KNIGHT S C,  OCONNELL M R;  WO2017219027-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  ZHANG F (ZHAN-Individual);  ABUDAYYEH O O (ABUD-Individual);  GOOTENBERG J (GOOT-Individual);  LANDER E S (LAND-Individual)   ZHANG F,  ABUDAYYEH O O,  GOOTENBERG J,  LANDER E S;  WO2018035250-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  UNIV RUTGERS STATE NEW JERSEY (RUTF);  US DEPT HEALTH & HUMAN SERVICES (USSH)   COX D,  KOONIN E V,  MAKAROVA K S,  PYZOCHA N,  SCOTT D,  SEVERINOV K,  SHMAKOV S,  SMARGON A,  WOLF Y I,  YAN W,  ZHANG F;  WO2018107129-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  WO2018170340-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  ABUDAYYEH O (ABUD-Individual);  GOOTENBERG J (GOOT-Individual);  LANDER E S (LAND-Individual);  SABETI P (SABE-Individual);  FREIJE C A (FREI-Individual);  MYHRVOLD C (MYHR-Individual)   ABUDAYYEH O,  GOOTENBERG J,  LANDER E S,  SABETI P,  FREIJE C A,  MYHRVOLD C,  COLLINS J J,  ZHANG F;  WO2019005866-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ZHANG F,  ABUDAYYEH O O,  COX D B T,  GOOTENBERG J S;  WO2019071051-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ZHANG F,  GOOTENBERG J,  ABUDAYYEH O;  WO2020028185-A1   TOKITAE LLC (TKTE)   BAUGHMAN T A,  MADAN D,  NALEFSKI E,  LE NY A M;  WO2020028729-A1   MAMMOTH BIOSCI INC (MAMM-Non-standard);  CHEN J S (CHEN-Individual);  TEHRANCHI A (TEHR-Individual);  LANE A B (LANE-Individual);  BROUGHTON J P (BROU-Individual);  HARRINGTON L B (HARR-Individual);  TSALOGLOU M (TSAL-Individual);  MIAO X (MIAO-Individual);  FASCHING C L (FASC-Individual);  SINGH J (SING-Individual);  GALARZA P P D (GALA-Individual)   CHEN J S,  TEHRANCHI A,  LANE A B,  BROUGHTON J P,  HARRINGTON L B,  TSALOGLOU M,  MIAO X,  FASCHING C L,  SINGH J,  GALARZA P P D;  WO2014093622-A2   BROAD INST INC (BROD);  MASSACHUSETTS TECHNOLOGY INST (MASI);  ZHANG F (ZHAN-Individual);  HEIDENREICH M (HEID-Individual);  RAN F (RANF-Individual);  SWIECH L (SWIE-Individual)   ZHANG F,  HEIDENREICH M,  RAN F,  SWIECH L;  WO2019126577-A2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ZHANG F,  ZETSCHE B,  GOOTENBERG J,  ABUDAYYEH O;  WO2018107129-A8   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S	WO2019071051-A1  ABUDAYYEH ET AL.:          "C2c2 is a single-component programmable RNA-guided          RNA-targeting CRISPR effector", SCIENCE, vol. 353, no.          6299, 2 June 2016 (2016-06-02), pages 1 - 11,          XP055314442,relevantClaims[62],relevantPassages[. entire          document];  ABUDAYYEH ET AL.:          "RNA targeting with CRISPR-Cas13a", NATURE, vol. 550, no.          7675, 4 October 2017 (2017-10-04), pages 280 - 284,          XP055529736, DOI:          doi:10.1038/nature24049,relevantClaims[1-68],relevantPassages[.          entire document];  GOOTENBERG ET AL.:          "Multiplexed and portable nucleic acid detection platform          with Cas13, Cas12a, and Csm6", SCIENCE, vol. 360, no.          6387, 15 February 2018 (2018-02-15), pages 439 - 444,          XP055538780, DOI:          doi:10.1126/science.aaq0179,relevantClaims[1-68],relevantPassages[.          entire document]CN111630162-A  HUI YANG ET AL.:          "PAM-dependent Target DNA Recognition and Cleavage by          C2c1 CRISPR-Cas Endonuclease", CELL, vol. 167, no. 7,          XP029850724, DOI:          10.1016/j.cell.2016.11.053,relevantClaims[24-2568];  ALEXANDRA          EAST-SELETSKY ET AL.: "Two Distinct RNase Activities of          CRISPR-C2c2 Enable Guide RNA Processing and RNA          Detection", NATURE, vol. 538, no. 7624, pages 270 - 273,          XP055719305, DOI:          10.1038/nature19802,relevantClaims[1-75];  JONATHAN S.          GOOTENBERG ET AL.: "Nucleic acid detection with          CRISPR-Cas13a/C2c2", SCIENCE, vol. 356, no. 6336, pages          1,relevantClaims[25-68]EP3692146-A4  JONATHAN S.          GOOTENBERG ET AL: "Nucleic acid detection with          CRISPR-Cas13a/C2c2", SCIENCE, vol. 356, no. 6336, 28          April 2017 (2017-04-28), US, pages 438 - 442,          XP055481345, ISSN: 0036-8075, DOI:          10.1126/science.aam9321,relevantClaims[1,7],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  ALEXANDRA          EAST-SELETSKY ET AL: "Two distinct RNase activities of          CRISPR-C2c2 enable guide-RNA processing and RNA          detection", NATURE, vol. 538, no. 7624, 26 September 2016          (2016-09-26), London, pages 270 - 273, XP055719305, ISSN:          0028-0836, DOI:          10.1038/nature19802,relevantClaims[1,7],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  BRITTANY A. ROHRMAN          ET AL: "A Lateral Flow Assay for Quantitative Detection          of Amplified HIV-1 RNA", PLOS ONE, vol. 7, no. 9, 21          September 2012 (2012-09-21), pages e45611, XP055385687,          DOI:          10.1371/journal.pone.0045611,relevantClaims[1-15],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  JANICE S. CHEN ET          AL: "CRISPR-Cas12a target binding unleashes          indiscriminate single-stranded DNase activity", SCIENCE,          vol. 360, no. 6387, 27 April 2018 (2018-04-27), US, pages          436 - 439, XP055615609, ISSN: 0036-8075, DOI:          10.1126/science.aar6245,relevantClaims[1,7],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  CAMERON MYHRVOLD ET          AL: "Field-deployable viral diagnostics using          CRISPR-Cas13", SCIENCE, vol. 360, no. 6387, 27 April 2018          (2018-04-27), US, pages 444 - 448, XP055718928, ISSN:          0036-8075, DOI:          10.1126/science.aas8836,relevantClaims[1,7],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];            See also references of WO 2019071051A1US11633732-B2            East-Seletsky et al., Two distinct RNase activities of          CRISPR-C2c2 enable guide-RNA processing and RNA          detection, Nature. Oct. 13, 2016;538(7624):270-273. doi:          10.1038/nature19802. Epub Sep. 26, 2016.;            Gootenberg et al, Nucleic acid detection with          CRISPR-Cas13a/C2c2, Science. Apr. 28,          2017;356(6336):438-442. doi: 10.1126/science.aam9321.          Epub Apr. 13, 2017.;            Smirnov, et al., CRISPR/Cas9, a universal tool for          genomic engineering, Vavilov Journal of Genetics and          Breeding, vol. 20, No. 4 (2016), all enclosed pages          cited.;            Office Action from corresponding Russian application No.          2020115264 dated Feb. 24, 2022, all enclosed pages          cited.;            Office Action and translation from corresponding Japanese          application No. 2020-519256 dated Oct. 4, 2022, all          enclosed pages cited.;            International Preliminary Report on Patentability issued          in International Application No. PCT/US2018/054472, dated          Apr. 16, 2020, 17 pages.;            International Search Report and Written Opinion issued in          International Application No. PCT/US2018/054472, dated          Dec. 27, 2018, 20 pages.;            Abudayyeh et al., C2C2 is a Single-Component Programmable          RNA-Guided RNA-Targeting CRISPR Effector, Science, vol.          353, No. 6299, Aug. 5, 2016, 23 pages.;            Abudayyeh et al., RNA Targeting with CRISPR-Cas13a,          Nature, vol. 550, No. 7675, Oct. 4, 2017, 30          pages.;            Barletta et al., Lowering the Detection Limits of HIV-1          Viral Load Using Real-Time Immuno-PCR for HIV-1 p24          Antigen, American Journal of Clinical Pathology, vol.          122, 2004, 20-27.;            Barzon et al., Zika Virus: from Pathogenesis to Disease          Control, FEMS Microbiol Letters, vol. 363, No. 18, 2016,          43 pages.;            Bettegowda et al., Detection of Circulating Tumor DNA in          Farly- and Late-Stage Human Malignancies, Science          Translational Medicine, vol. 6, No. 224, Feb. 2014,          1-25.;            Chavez et al., Comparative Analysis of Cas9 Activators          Across Multiple Species, Nature Methods, vol. 13, No. 7,          Jul. 2016, 563-567.;            Compton, J., Nucleic Acid Sequence-based Amplification,          Nature, vol. 350, No. 6313, 1991, 91-92.;            Dejnirattisai et al., Dengue Virus Sero-cross-reactivity          Drives Antibody-dependent Enhancement of Infection with          Zika Virus, Nature Immunology, vol. 17, No. 9, Sep. 2016,          18 pages.;  Du          et al., Reservoir Computing using Dynamic Memristors for          Temporal Information Processing, Nature Communications,          vol. 8, No. 2204, Dec. 19, 2017, 10 pages.;            East-Seletsky et al., Two Distinct RNase Activities of          CRISPR-C2c2 Enable Guide-RNA Processing and RNA          Detection, Nature, vol. 538, No. 7624, Oct. 13, 2016, 17          pages.;            Emmadi et al., Molecular Methods and Platforms for          Infectious Diseases Testing a Review of FDA-Approved and          Cleared Assays, The Journal of Molecular Diagnostics,          vol. 13, No. 6, Nov. 2011, 583-604.;            Eriksson et al., Web-Based, Participant-Driven Studies          Yield Novel Genetic Associations for Common Traits, PLOS          Genetics, vol. 6, No. 6, Jun. 2010, 20 pages.;            Gootenberg et al., Multiplexed and Portable Nucleic Acid          Detection Platform with Cas13, Cas12a, and Csm6, Science,          vol. 360, No. 6387, Apr. 27, 2018, 14 pages.;            Gootenberg et al., Nucleic Acid Detection with          CRISPR-Cas13a/C2c2, Science, vol. 356, No. 6336, Apr. 28,          2017, 6 pages.;            Gourinat et al., Detection of Zika Virus in Urine,          Emerging Infectious Diseases, vol. 21, No. 1, Jan. 2015,          34-86.;            Green et al., Toehold Switches: De-Novo-Designed          Regulators of Gene Expression, Cell, vol. 159, No. 4,          Nov. 6, 2014, 28 pages.;            Guan et al., Visual and Rapid Detection of Two          Genetically Modified Soybean Events Using Loop-mediated          sothermal Amplification Method, Food Analytical Methods,          vol. 3, Issue 4, Mar. 26, 2010, 313-320.;            Gupta et al., Carbapenem-Resistant Enterobacteriaceae:          Epidemiology and Prevention, Clinical Infectious          Diseases, vol. 53, No. 1, Jul. 2011, 60-67.;            Lanciotti et al., Genetic and Serologic Properties of          Zika Virus Associated with an Epidemic, Yap State,          Micronesia, 2007, Emerging Infectious Disease, vol. 14,          No. 8, Aug. 2008, 1232-1239.;            Lewis et al., Building the Class 2 CRISPR-Cas Arsenal,          Molecular Cell, vol. 65, No. 3, Feb. 2, 2017,          377-379.;            Maheswaran et al., Detection of Mutations in EGFR in          Circulating Lung-Cancer Cells, The New England Journal of          Medicine, vol. 359, No. 4, Jul. 24, 2008, 19          pages.;            Kazlauskiene et al., A Cyclic Oligonucleotide Signaling          Pathway in type III CRISPR-Cas Systems, Science, vol.          357, No. 6351, Aug. 11, 2017, 6 pages.;  Li          et al., Engineering CRISPR-Cpf1 CrRNAS and MRNAs to          Maximize Genome Editing Efficiency, Nature Biomedical          Engineering, vol. 1, No. 5, May 2017, 21 pages.;            Millipore, Merck, Rapid Lateral Flow Test Strips, 2013,          36 pages.;            Nagrath et al., Isolation of Rare Circulating Tumour          Cells in Cancer Patients by Microchip Technology, Nature,          vol. 450, No. 7173, Dec. 20, 2007, 11 pages.;            Newman et al., An Ultrasensitive Method for Quantitating          Circulating Tumor DNA with Broad Patient Coverage, Nature          Medicine, vol. 20, No. 5, May 2014, 22 pages.;            Pardee et al., Paper-Based Synthetic Gene Networks, Cell,          vol. 159, No. 4, Nov. 6, 2014, 28 pages.;            Pardee et al., Rapid, Low-Cost Detection of Zika Virus          Using Programmable Biomolecular Components, Cell, vol.          165, May 19, 2016, 24 pages.;            Piepenburg et al., DNA Detection Using Recombination          Proteins, PLOS Biology, vol. 4, Issue 7, Jun. 13, 2006,          1115-1121.;            Qin et al., YAP Induces Human Naive Pluripotency, Cell          Reports, vol. 14, Mar. 15, 2016, 28 pages.;            Rissin et al., Single-Molecule Enzyme-Linked          Immunosorbent Assay Detects Serum Proteins at          Subfemtomolar Concentrations, Nature Biotechnology, vol.          28, No. 6, Jun. 2010, 21 pages.;            Rouillon et al., Structure of the CRISPR Interference          Complex CSM Reveals Key Similarities with Cascade,          Molecular Cell, vol. 52, No. 1, Oct. 10, 2013,          124-134.;            Shmakov et al., The CRISPR Spacer Space is Dominated by          Sequences from Species-Specific Mobilomes, American          Society for Microbiology, vol. 8, Issue 5, Sep./Oct.          2017, 18 pages.;            Smargon et al., Cas 13B is a Type VI-B CRISPR-Associated          RNA-Guided RNAse Differentially Regulated by Accessory          Proteins Csx27 and Csx28, Molecular Cell, vol. 65, No. 4,          Feb. 16, 2017, 30 pages.;            Song, Cohabiting Family Members share Microbiota with one          Another and with their Dogs, Elife, vol. 2, Apr. 16,          2013, 22 pages.;            Niewoehner et al., Structural Basis for the          Endoribonuclease Activity of the Type III-A          CRISPR-Associated Protein Csm6, Cold Spring Harbor          Laboratory Press, vol. 22, No. 3, 2016,          318-329.;            Urdea et al., Requirements for High Impact Diagnostics in          the Developing World, Nature, vol. 444, 2006,          73-79.;            Wang et al., Detection of Roundup Ready Soybean by          Loop-mediated Isothermal Amplification combined with a          Lateral-flow Dipstick, Food Control, vol. 29, Issue 1,          Jan. 2013, 213-220.;            Wang et al., Instant, Visual, and Instrument-Free Method          for On-Site Screening of GTS 40-3-2 Soybean Based on          Body-Heat Triggered Recombinase Polymerase Amplification,          Analytical Chemistry, vol. 89, No. 8, Mar. 27, 2017, 7          pages.;  Wu          et al., Personalized Targeted Therapy for Lung Cancer,          International Journal of Molecular Sciences, vol. 13, No.          9, Sep. 13, 2012, 11471-11496.;  Ye          et al., Primer-BLAST: A Tool to Design Target-Specific          Primers for Polymerase Chain Reaction, BMC          Bioinformatics, vol. 13, No. 134, 2012, all enclosed          pages cited.;            Zetsche et al., Cpf1 is a Single RNA-Guided Endonuclease          of a Class 2 CRISPR-Cas System, Cell, vol. 163, No. 3,          Oct. 22, 2015, 759-771.;            Shmakov et al., Discovery and Functional Characterization          of Diverse Class 2 CRISPR-Cas Systems, Molecular Dell,          vol. 60, No. 3, Nov. 5, 2015, 385-397.;            Kumar, P., et al., Loop-Mediated Isothermal Amplification          Assay for Rapid and Sensitive Diagnosis of Tuberculosis,          Journal of Infection 69 (2014), pp. 607-615.;            Olmedillas Lopez, S., et al., KRAS G12V Mutation          Detection by Droplet Digital PCR in Circulating Cell-Free          DNA of Colorectal Cancer Patients, International Journal          of Molecular Sciences 17 (2016), all enclosed pages          cited.;            Office Action and translation from corresponding Saudi          Arabian application No. 520411686 dated Sep. 14, 2022,          all enclosed pages cited.;            Rohrman, et al., A lateral flow assay for quantitative          detection of HIV-1 RNA, PLOS One, vol. 7, No. 9, Sep. 21,          2012, all enclosed pages cited.;            Shen, et al., CRISPR-Cas12a target binding unleashes          indiscriminate single-stranded DNase activity, Science,          vol. 360, No. 6387, Apr. 27, 2018, all enclosed pages          cited.;            Mlyhrvold, et al., Field-deployable viral diagnostics          using CRISPR-Cas 13, Science, vol. 360, No. 6387, Apr.          27, 2018, all enclosed pages cited.;            Extended Search Report and Written Opinion of          corresponding European application No. 18/864, 541 0          dated Jun. 1, 2021, all enclosed pages cited.						WO2019018439-A1;  CA3069880-A1;  AU2018304194-A1;  EP3655001-A1;  US2020164008-A1;  CN111225677-A;  BR112020000995-A2;  JP2020530834-W;  EP3655001-A4;  HK40031530-A0;  JP2023179414-A	Treating subject in need of treatment for disease            caused by a loss of function or activity of a protein,            involves removing, reducing, depleting, inhibiting,            inactivating or capturing adeno-associated virus            binding antibodies	WRIGHT J F;  CARR M E;  CARR M E J;  MARCUS EUGENE CARR J	SPARK THERAPEUTICS INC (HOFF-C);  SPARK THERAPEUTICS INC (HOFF-C);  SPARK THERAPEUTICS INC (HOFF-C);  SPARK THERAPEUTICS INC (HOFF-C)	201909599J	   NOVELTY - Treating a subject in need of treatment                involves removing, reducing, depleting, inhibiting,                inactivating or capturing adeno-associated virus                (AAV) binding antibodies from a blood product                obtained from the subject by a process comprising                apheresis, and administering an amount of a                recombinant adeno-associated virus (rAAV) vector                comprising a heterologous polynucleotide that                encodes a protein or peptide that provides or                supplements a function or activity of the                protein.    USE - Method for treating subject in need of                treatment for disease caused by a loss of function                or activity of a protein.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method                for treating a subject in need of treatment for a                disease caused by a gain of function, activity or                expression, of a protein, which involves:    (A) removing, reducing, depleting, inhibiting,                inactivating or capturing AAV binding antibodies                from a blood product obtained from the subject by a                process comprising apheresis; and    (B) administering an amount of a recombinant                adeno-associated virus (rAAV) vector comprising a                heterologous polynucleotide that is transcribed                into a nucleic acid that inhibits, decreases or                reduces expression of the gain of function,                activity or expression of the protein. 			B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)	B04-E08;  B04-E13;  B04-E99;  B04-F11A1E;  B04-G08;  B04-G23;  B04-G27A;  B04-G27D;  B04-G27E;  B04-G27G;  B04-G27M;  B04-L05A2;  B14-A01;  B14-A02;  B14-A04;  B14-C03;  B14-F02;  B14-F02D1;  B14-F03;  B14-F04;  B14-F08;  B14-F11;  B14-H01;  B14-J01;  B14-J07;  B14-K01;  B14-L01;  B14-L06;  B14-N03;  B14-N10;  B14-N12;  B14-N16;  B14-S03;  B14-S04;  B14-S13;  B14-S16;  D05-H10;  D05-H19C;  D05-H99;  A12-V01	A61K-035/761;  A61K-039/235;  A61K-048/00;  C12N-015/86;  C12N-015/861;  C12N-007/00;  A61K-035/16;  A61K-035/76;  A61M-001/16;  A61M-001/34;  A61M-001/36;  C07K-014/005;  C07K-016/08;  C12N-015/11;  C12N-009/22;  G01N-033/68;  A61P-025/00;  A61P-025/14;  A61P-025/28;  A61P-043/00;  A61P-007/00;  A61P-007/04;  A61P-007/06;  C07K-014/01;  C07K-016/42;  C12N-015/09;  C12N-015/113;  C12N-015/12;  C12N-015/55;  C12N-015/864;  C07K-014/015	WO2019018439-A1   24 Jan 2019   A61K-035/761   201912Pages: 55   English;  CA3069880-A1   24 Jan 2019   A61K-035/761   202012   English;  AU2018304194-A1   27 Feb 2020   A61K-035/761   202018   English;  EP3655001-A1   27 May 2020   A61K-035/761   202044   English;  US2020164008-A1   28 May 2020   A61K-035/76   202044   English;  CN111225677-A   02 Jun 2020   A61K-035/761   202049   Chinese;  BR112020000995-A2   08 Sep 2020   A61K-039/235   202081   English;  JP2020530834-W   29 Oct 2020   A61K-035/76   202089Pages: 43   Japanese;  EP3655001-A4   28 Apr 2021   A61K-035/761   202136   English;  HK40031530-A0   12 Mar 2021   A61K-035/761   202290   English;  JP2023179414-A   19 Dec 2023   A61K-035/76   202402   Japanese	WO2019018439-A1    WOUS042553    17 Jul 2018;   CA3069880-A1    CA3069880    17 Jul 2018;   AU2018304194-A1    AU304194    17 Jul 2018;   EP3655001-A1    EP835932    17 Jul 2018;   US2020164008-A1    US16631692    16 Jan 2020;   CN111225677-A    CN80060309    17 Jul 2018;   BR112020000995-A2    BR11000995    17 Jul 2018;   JP2020530834-W    JP502112    17 Jul 2018;   EP3655001-A4    EP835932    17 Jul 2018;   HK40031530-A0    HK6021063    27 Nov 2020;   JP2023179414-A    JP135227    23 Aug 2023	CA3069880-A1 PCT application Application WOUS042553;   CA3069880-A1 Based on Patent WO2019018439;   AU2018304194-A1 PCT application Application WOUS042553;   AU2018304194-A1 Based on Patent WO2019018439;   EP3655001-A1 PCT application Application WOUS042553;   EP3655001-A1 Based on Patent WO2019018439;   US2020164008-A1 PCT application Application WOUS042553;   US2020164008-A1 Provisional Application US533579P;   CN111225677-A PCT application Application WOUS042553;   CN111225677-A Based on Patent WO2019018439;   BR112020000995-A2 PCT application Application WOUS042553;   BR112020000995-A2 Based on Patent WO2019018439;   JP2020530834-W PCT application Application WOUS042553;   JP2020530834-W Based on Patent WO2019018439;   HK40031530-A0 PCT application Application WOUS042553;   HK40031530-A0 Based on Patent WO2019018439;   HK40031530-A0 Previous Publ. Patent EP3655001;   JP2023179414-A Div ex Application JP502112	US533579P    17 Jul 2017;  EP835932    17 Jul 2018;  WOUS042553    17 Jul 2018;  CA3069880    13 Jan 2020;  BR11000995    16 Jan 2020;  US16631692    16 Jan 2020;  CN80060309    17 Mar 2020	WO2019018439-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP3655001-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN          EP3655001-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR      		WO2019018439-A1 -- US5817528-A   THERASORB MEDIZINISCHE SYSTEME GMBH (THER-Non-standard)   SPAETHE R,  KRAUS C,  BOEHM W,  MUELLER-DERLICH J,  BERNHARD M,  BIEBER F A,  BARCLAY A;  US20150023924-A1   ;  WO2016055437-A1   ARTHROGEN BV (ARTH-Non-standard)   FINN J D,  VERVOORDELDONK M J,  TAK P;  WO2016128408-A1   INSERM INST NAT SANTE & RECH                  MEDICALE (INRM);  UNIV NANTES (UNNT);  CHU NANTES (CHUN-Non-standard);  ASSOC FR CONTRE MYOPATHIES (ASFR-Non-standard)   BRUMENT N;  US2020164008-A1 -- US20110201986-A1   ;  US20130068691-A1   ;  US20180093032-A1   ;  US20180169273-A1   ;  US20210317474-A1   ;  US7744883-B2   ADVANCED EXTRAVASCULAR SYSTEMS (ADEX-Non-standard)   BRISTOW D K;  US9434928-B2   NATIONWIDE CHILDREN'S HOSPITAL INC (CDHP)   MENDELL J R,  CHICOINE L,  RODINO-KLAPAC L,  CLARK K R,  PRESTON T J;  US9546112-B2   ASSOC INST MYOLOGIE (ASMY-Non-standard);  GENETHON III (GNTN);  CENT NAT RECH SCI (CNRS);  UNIV CURIE PARIS VI P & M (UPMC);  INSERM INST NAT SANTE & RECH                  MEDICALE (INRM)   VOIT T,  GARCIA L,  DENARD J,  SVINARTCHOUK F;  CN111225677-A -- CN104520428-A   PHILADELPHIA CHILDRENS HOSPITAL (CHHP)   HIGH K A,  MINGOZZI F,  SUN J,  JOHNSON P;  CN105579465-A   HIGH K (HIGH-Individual);  YAZICIOGLU M (YAZI-Individual);  ANGUELA X (ANGU-Individual)   HIGH K,  YAZICIOGLU M,  ANGUELA X;  CN107002096-A   ARTHROGEN BV (ARTH-Non-standard)   FINN J D,  VERVOORDELDONK M J,  TAK P;  US20150111955-A1   ;  WO2016055437-A1   ARTHROGEN BV (ARTH-Non-standard)   FINN J D,  VERVOORDELDONK M J,  TAK P;  EP3655001-A4 -- WO2018109207-A1   UNIQURE IP BV (UNIQ-Non-standard)   FERREIRA V;  WO2000020041-A2   ;  WO2001017537-A2   	WO2019018439-A1  CHICOINE ET AL.:          "Plasmapheresis eliminates the negative impact of AAV          antibodies on microdystrophin gene expression following          vascular delivery", MOLECULAR THERAPY : THE JOURNAL OF          THE AMERICAN SOCIETY OF GENE THERAPY,, vol. 22, no. 2, 23          October 2013 (2013-10-23), pages 338 - 347,          XP055367763,relevantClaims[1|2-4],relevantPassages[.          entire document];  HAJJAR ET AL.:          "1R01HL131404-01A1: Anti-AAV Antibodies as an Obstacle to          Cardiac AAV Gene Therapy", NIH RESEARCH PORTFOLIO ONLINE          REPORTING TOOLS (REPORT), 2016, pages 1 - 2, Retrieved          from the Internet          &lt;URL:https://projectreporter.nih.gov/project_info_description.cfm?aid=9176405&icde=41616913&gt;          [retrieved on 20181015],relevantClaims[70, 84, 85|3, 4,          71-78, 83, 86, 87],relevantPassages[. entire          document];  HURLBUT ET AL.:          "Preexisting immunity and low expression in primates          highlight translational challenges for liver-directed          AAV8-mediated gene therapy", MOLECULAR THERAPY : THE          JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 18,          no. 11, 24 August 2010 (2010-08-24), pages 1983 - 1994,          XP055563305,relevantClaims[1-4, 70-87],relevantPassages[.          entire document];  LOUIS JEUNE ET AL.:          "Pre-existing anti-adeno-associated virus antibodies as a          challenge in AAV gene therapy", HUMAN GENE THERAPY          METHODS, vol. 24, no. 2, 3 April 2013 (2013-04-03), pages          59 - 67, XP055563307,relevantClaims[1-4,          70-87],relevantPassages[. entire document];  MONTEILHET ET AL.:          "A 10 patient case report on the impact of plasmapheresis          upon neutralizing factors against adeno-associated virus          (AAV) types 1, 2, 6, and 8", MOLECULAR THERAPY : THE          JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 19,          no. 11, 31 May 2011 (2011-05-31), pages 2084 - 2091,          XP055367781,relevantClaims[1-4, 70-87],relevantPassages[.          entire document]US2020164008-A1            Bertin B, Veron P, Leborgne C, Deschamps JY, Moullec S,          Fromes Y, Collaud F, Boutin S, Latournerie V, van          Wittenberghe L, Delache B, Le Grand R, ET. AL.          Capsid-specific removal of circulating antibodies to          adeno-associated virus vectors. Sci Rep. 2020 Jan          21;10(1):864. (Year: 2020);            Tzartos SJ, Bitzopoulou K, Gavra I, Kordas G, Jacobson L,          Kostelidou K, Lagoumintzis G, Lazos O, Poulas K, Sideris          S, Sotiriadis A, Trakas N, Zisimopoulou P.          Antigen-specific apheresis of pathogenic autoantibodies          from myasthenia gravis sera. Ann N Y Acad Sci.          2008;1132:291-9. (Year: 2008);            Rydberg L, Bengtsson A, Samuelsson O, Nilsson K, Breimer          ME. In vitro assessment of a new ABO immunosorbent with          synthetic carbohydrates attached to sepharose. Transpl          Int. 2005 Jan;17(11):666-72. Epub 2004 Nov 17. (Year:          2004)CN111225677-A  LG CHICOINE:          "Plasmapheresis eliminates the negative impact of AAV          antibodies on microdystrophin gene expression following          vascular          delivery",relevantClaims[1-66],relevantPassages[]EP3655001-A4  F. MINGOZZI ET AL:          "Immune responses to AAV vectors: overcoming barriers to          successful gene therapy", BLOOD, vol. 122, no. 1, 17          April 2013 (2013-04-17), pages 23 - 36, XP055175008,          ISSN: 0006-4971, DOI:          10.1182/blood-2013-01-306647,relevantClaims[1-18],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;figure&gt;1-3,6&lt;/figure&gt;&lt;table&gt;1-3&lt;/table&gt;];  MINGOZZI FEDERICO          ET AL: "Overcoming preexisting humoral immunity to AAV          using capsid decoys", SCIENCE TRANSLATIONAL MEDICINE,          AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE (A A          A S), US, vol. 5, no. 194, 17 July 2013 (2013-07-17),          pages - 130, XP009183093, ISSN: 1946-6242, DOI:          10.1126/SCITRANSLMED.3005795,relevantClaims[1-18],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;126&lt;/pp&gt;&lt;column&gt;2&lt;/column&gt;&lt;para&gt;4&lt;/para&gt;&lt;figure&gt;1&lt;/figure&gt;];  GRIMM D ET AL:          "Novel tools for production and purification of          recombinant adenoassociated virus vectors", HUMAN GENE          THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, GB, vol. 9,          no. 18, 10 December 1998 (1998-12-10), pages 2745 - 2760,          XP002093963, ISSN:          1043-0342,relevantClaims[1-18],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;&lt;figure&gt;8&lt;/figure&gt;];  HINMAN C L ET AL:          "Affinity chromatographic purification of antibody          subsets depends on the mode of cross-linking of antigen          to the affinity matrix", MOLECULAR IMMUNOLOGY, PERGAMON,          GB, vol. 22, no. 6, 1 June 1985 (1985-06-01), pages 681 -          688, XP023852709, ISSN: 0161-5890, [retrieved on          19850601], DOI:          10.1016/0161-5890(85)90098-7,relevantClaims[1-18],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];            See also references of WO 2019018439A1	105730-0-0-0 K M; 93605-0-0-0 K M; 184587-0-0-0 K M			RA012P K M; RA00NS K M; RA00C8 K M		WO2019126577-A2;  WO2019126577-A3;  AU2018392709-A1;  CA3086550-A1;  KR2020111180-A;  EP3728613-A2;  CN111836903-A;  BR112020012696-A2;  JP2021508460-W;  US2021108267-A1;  RU2020124203-A;  HK40037199-A0;  IL275597-A	Nucleic acid detection system comprises two or            more clustered regularly interspaced short palindromic            repeats systems, each clustered regularly interspaced            short palindromic repeats system comprising Cas protein            and guide molecule	ZHANG F;  ZETSCHE B;  GOOTENBERG J;  ABUDAYYEH O;  ZETZCHE B;  GOOTENBERG Y;  GOOTENBERG J S;  ABUDAYYEH O O	BROAD INST INC (BROD-C);  MASSACHUSETTS INST TECHNOLOGY (MASI-C);  HARVARD COLLEGE (HARD-C);  BROAD INST INC (BROD-C);  MASSACHUSETTS INST TECHNOLOGY (MASI-C);  HARVARD COLLEGE (HARD-C);  BROAD INST INC (BROD-C);  MASSACHUSETTS INST TECHNOLOGY (MASI-C);  HARVARD COLLEGE (HARD-C);  MASSACHUSETTS TECHNOLOGY INST (MASI-C);  MASSACHUSETTS TECHNOLOGY INST (MASI-C)	201953991P	   NOVELTY - Nucleic acid detection system comprises two or                more clustered regularly interspaced short                palindromic repeats (CRISPR) systems, each CRISPR                system comprising a Cas protein and a guide                molecule comprising a guide sequence capable of                binding a corresponding target molecule, and                designed to form a complex with the Cas protein,                and a set of detection constructs, each detection                construct comprising a cutting motif sequence that                is preferentially cut by one of the Cas proteins,                where Cas protein of each CRISPR system exhibits                collateral nucleic acid cleavage activity and                preferentially cleaves the cutting motif sequence                of one or more of the set of detection                constructs.    USE - Nucleic acid detection system.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a system for detecting the presence of two                or more target polypeptides in an in vitro sample,                which comprises set of detection contructs, each                detection construct comprising cutting motif                sequence that is preferentially cut by one of the                Cas proteins,set of detection aptamers, each                designed to bind to one of the two or more target                polypeptides, and each detection aptamer comprising                a cutting motif sequence that is preferentially cut                by a Cas protein of one of the two or more CRISPR                Systems; a masked RNA polymerase promoter binding                site or a masked primer binding site; and a trigger                sequence template, encoding a trigger sequence, two                or more CRISPR systems, each CRISPR system                comprising a Cas protein and a guide polynucleotide                comprising a guide sequence capable of binding the                trigger sequence encoded by the trigger sequence                template, where the Cas protein exhibits collateral                nucleic acid cleavage activity and cleaves the                non-target sequence of the nucleic acid-based                masking construct once activated by the trigger                sequence;    (2) a diagnostic device, which comprises one                or more individual discrete volumes, each                individual discrete volume comprising a CRISPR                system;    (3) a method for detecting target nucleic                acids in samples, which involves distributing a                sample or set of samples into one or more                individual discrete volumes, the individual                discrete volumes comprising a CRISPR system,                incubating sample or set of samples under                conditions sufficient to allow binding of the one                or more guide molecules to one or more target                molecules, activating the CRISPR Cas protein via                binding of the one or more guide molecules to the                one or more target molecules, where activating the                CRISPR Cas protein results in modification of the                RNA-based masking construct such that a detectable                positive signal is generated, and detecting one or                more detectable positive signal, where detection of                the one or more detectable positive signal                indicates a presence of one or more target                molecules in the sample;    (4) a method for detecting polypeptides in                samples, which involves distributing a sample or                set of samples into a set of individual discrete                volumes, the individual discrete volumes comprising                peptide detection aptamers, a CRISPR system,                incubating sample or set of samples under                conditions sufficient to allow binding of the                peptide detection aptamers to the one or more                target molecules, activating the RNA Cas protein by                binding of the one or more guide molecules to the                trigger RNA, detecting the detectable positive                signal;    (5) a method for detecting target nucleic                acids in samples, which involves contacting one or                more samples with two or more CRISPR systems and                set of detection constructs, each detection                construct comprising a cutting motif sequence that                is preferentially cut by one of the Cas proteins,                detecting a signal from cleavage of the cutting                motif sequence of the detection construct,                detecting the one or more target nucleic acid                sequences in the sample;    (6) a method for detecting target nucleic                acids in samples, which involves contacting one or                more samples with set of detection contructs, each                detection construct comprising cutting motif                sequence that is preferentially cut by one of the                Cas proteins, two or more CRISPR systems, each                CRISPR system comprising a Cas protein and a guide                polynucleotide comprising a guide sequence capable                of binding the trigger sequence encoded by the                trigger sequence template, and detecting a signal                from cleavage of the cutting motif sequence of the                detection construct, detecting the one or more                target nucleic acid sequences in the sample;    (7) a method for detecting a target nucleic                acid in a sample, which involves contacting a                sample with a nucleic acid detection system,                applying contacted sample to a lateral flow                immunochromatographic assay; and    (8) a lateral flow device, which comprises                substrate comprising a first end, where the first                end comprises a sample loading portion and a first                region loaded with a detectable ligand, two or more                CRISPR Cas systems, two or more detection                constructs, one or more first capture regions, each                comprising a first binding agent, two or more                second capture regions, each comprising a second                binding agent, where each of the two or more CRISPR                Cas systems comprises a CRISPR Cas protein and one                or more guide sequences, each guide sequence                configured to bind one or more target                molecules. 			A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)	A12-V03C2;  A12-W11L;  B04-E01;  B04-E02;  B04-E03;  B04-E05;  B04-E07F;  B04-E09;  B04-E13;  B04-E99;  B04-G01;  B04-L05A2;  B04-L05A2E;  B04-N04;  B04-N08;  B11-C07A;  B11-C07B3;  B11-C08D2;  B11-C08E;  B11-C12;  B12-K04F;  B12-K04G;  C04-E01;  C04-E02;  C04-E03;  C04-E05;  C04-E07F;  C04-E09;  C04-E13;  C04-E99;  C04-G01;  C04-L05A2;  C04-L05A2E;  C04-N04;  C04-N08;  C11-C07A;  C11-C07B3;  C11-C08D2;  C11-C08E;  C11-C12;  C12-K04F;  C12-K04G;  D05-H09;  D05-H18B;  D05-H19C;  D05-H99	C12Q-001/68;  C12N-015/10;  C12N-015/11;  C12N-015/90;  C12N-009/22;  C12Q-001/6804;  C12Q-001/6823;  C12Q-001/6844;  G01N-033/53;  G01N-033/68;  G06F-019/20;  C12M-001/00;  C12N-015/09;  C12N-015/115;  C12Q-001/34;  C12Q-001/37;  C12Q-001/6827;  G01N-033/50;  G01N-033/543;  C12Q-001/6876	WO2019126577-A2   27 Jun 2019   C12Q-001/68   201952Pages: 417   English;  WO2019126577-A3   08 Aug 2019   C12N-015/90   201960   English;  AU2018392709-A1   16 Jul 2020   C12N-015/90   202059   English;  CA3086550-A1   27 Jun 2019   C12Q-001/68   202060   English;  KR2020111180-A   28 Sep 2020   C12Q-001/6823   202080   ;  EP3728613-A2   28 Oct 2020   C12N-015/90   202088   English;  CN111836903-A   27 Oct 2020   C12Q-001/6844   202091   Chinese;  BR112020012696-A2   24 Nov 2020   C12N-015/90   202003   English;  JP2021508460-W   11 Mar 2021   C12Q-001/34   202122Pages: 266   Japanese;  US2021108267-A1   15 Apr 2021   C12Q-001/6876   202133   English;  RU2020124203-A   24 Jan 2022   C12N-015/90   202266   Russian;  HK40037199-A0   04 Jun 2021   C12N-015/90   202200   English;  IL275597-A   31 Aug 2020   C12N-009/22   202340   English	WO2019126577-A2    WOUS066940    20 Dec 2018;   WO2019126577-A3    WOUS066940    20 Dec 2018;   AU2018392709-A1    AU392709    20 Dec 2018;   CA3086550-A1    CA3086550    20 Dec 2018;   KR2020111180-A    KR720622    20 Dec 2018;   EP3728613-A2    EP890190    20 Dec 2018;   CN111836903-A    CN80089710    20 Dec 2018;   BR112020012696-A2    BR11012696    20 Dec 2018;   JP2021508460-W    JP534965    20 Dec 2018;   US2021108267-A1    US16955380    18 Jun 2020;   RU2020124203-A    RU124203    20 Dec 2018;   HK40037199-A0    HK6027186    15 Mar 2021;   IL275597-A    IL275597    20 Dec 2018	AU2018392709-A1 PCT application Application WOUS066940;   AU2018392709-A1 Based on Patent WO2019126577;   CA3086550-A1 PCT application Application WOUS066940;   CA3086550-A1 Based on Patent WO2019126577;   KR2020111180-A PCT application Application WOUS066940;   KR2020111180-A Based on Patent WO2019126577;   EP3728613-A2 PCT application Application WOUS066940;   EP3728613-A2 Based on Patent WO2019126577;   CN111836903-A PCT application Application WOUS066940;   CN111836903-A Based on Patent WO2019126577;   BR112020012696-A2 PCT application Application WOUS066940;   BR112020012696-A2 Based on Patent WO2019126577;   JP2021508460-W PCT application Application WOUS066940;   JP2021508460-W Based on Patent WO2019126577;   US2021108267-A1 PCT application Application WOUS066940;   US2021108267-A1 Provisional Application US623546P;   US2021108267-A1 Provisional Application US630814P;   US2021108267-A1 Provisional Application US741501P;   US2021108267-A1 Provisional Application US610066P;   HK40037199-A0 PCT application Application WOUS066940;   HK40037199-A0 Based on Patent WO2019126577;   HK40037199-A0 Previous Publ. Patent EP3728613;   IL275597-A Based on Patent WO2019126577	US610066P    22 Dec 2017;  US623546P    29 Jan 2018;  US630814P    14 Feb 2018;  US741501P    04 Oct 2018;  EP890190    20 Dec 2018;  US16955380    18 Jun 2020;  CA3086550    19 Jun 2020;  BR11012696    22 Jun 2020;  KR720622    15 Jul 2020;  CN80089710    19 Aug 2020	WO2019126577-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2019126577-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP3728613-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                		;  WO2019126577-A3 -- WO2017184768-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  ZHANG F (ZHAN-Individual);  ZETSCHE B (ZETS-Individual);  GAO L (GAOL-Individual);  SLAYMAKER I (SLAY-Individual);  COX D B T (COXD-Individual)   ZHANG F,  ZETSCHE B,  GAO L,  SLAYMAKER I,  COX D B T;  WO2017184786-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  ZHANG F (ZHAN-Individual);  ZETSCHE B (ZETS-Individual);  YAN W (YANW-Individual);  SANJANA N E (SANJ-Individual);  JONES S (JONE-Individual)   ZHANG F,  ZETSCHE B,  YAN W,  SANJANA N E,  JONES S;  WO2017219027-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  ZHANG F (ZHAN-Individual);  ABUDAYYEH O O (ABUD-Individual);  GOOTENBERG J (GOOT-Individual);  LANDER E S (LAND-Individual)   ZHANG F,  ABUDAYYEH O O,  GOOTENBERG J,  LANDER E S;  CN111836903-A -- US20170211142-A1   ;  US2021108267-A1 -- US11174515-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S,  REGEV A;  WO2017219027-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  ZHANG F (ZHAN-Individual);  ABUDAYYEH O O (ABUD-Individual);  GOOTENBERG J (GOOT-Individual);  LANDER E S (LAND-Individual)   ZHANG F,  ABUDAYYEH O O,  GOOTENBERG J,  LANDER E S	WO2019126577-A3  EAST-SELETSKY ET          AL.: "RNA Targeting by Functionally Orthogonal Type VI-A          CRISPR-Cas Enzymes", MOL CELL ., vol. 66, no. 3, 4 May          2017 (2017-05-04), pages 373 - 383, XP029999996,          doi:10.1016/j.molcel.2017.04.008,relevantClaims[1, 3,          5/(1,3), (6-9)/5(1,3), 28, 88|2, 4, 5/(2,4),          (6-9)/5/(2,4), 89],relevantPassages[; Grapgic Abstract;          pg 375, col 1; pg 376, Fig its legend; pg 379, Fig 5 and          its legend; pg 380, col 2; pg 382, col 1; Supplementary          Materials, pg e2, pg 3];  DATABASE PROTEIN          [online] 22 November 2017 (2017-11-22), ANONYMOUS:          "RecName: Full=CRISPR-associated endoribonuclease Cas13a;          AltName: Full=CRISPR-associated endoribonuclease C2c2;          Short=EndoRNase; AltName: Full=LseC2c2", XP055628115,          retrieved from NCBI Database accession no. CS          13A_LISSS,relevantClaims[7-9],relevantPassages[; in          entirety, especially amino acids 1016-1021];  IYER ET AL.:          "Thrombin-Mediated Transcriptional Regulation Using DNA          Aptamers inDNA-Based Cell -Free Protein Synthesis", ACS          SYNTHETIC BIOLOGY, vol. 3, no. 6, 20 September 2013          (2013-09-20) - 2014, pages 340 - 346,          XP055628164,relevantClaims[2, 4, 5, (6-9)/5/(2,4),          89],relevantPassages[; Abstract, pg 341, Fig 1 and its          legend];  GOOTENBERG ET AL.:          "Nucleic acid detection with CRISPR-Cas13a/C2c2",          SCIENCE, vol. 356, no. 6336, 28 April 2017 (2017-04-28),          pages 438 - 442, XP055481345,          doi:10.1126/science.aam9321,relevantClaims[2, 4, 5,          (6-9)/5/(2,4), 89],relevantPassages[; Abstract, pg 1          [according to the posted document], Fig 1 and its legend;          pg 1, col 2 to pg 2, col 1];  LI ET AL.:          "CRISPR-Cas12a has both cis- and trans-cleavage          activities on single-stranded DNA", CELL RES., vol. 28,          no. 4, 12 March 2018 (2018-03-12), pages 491 - 493,          XP036483066,relevantClaims[21-24],relevantPassages[; in          entirety]CN111836903-A  ALEXANDRA          EAST-SELETSKY: "RNA targeting by functionally orthogonal          Type VI-A CRISPR-Cas enzymes", MOL CELL, vol. 66, no. 3,          XP029999996, DOI:          10.1016/j.molcel.2017.04.008,relevantClaims[1-128];  JONATHAN S.          GOOTENBERG: "Nucleic acid detection with          CRISPR-Cas13a/C2c2", SCIENCE, vol. 356, no. 6336,          XP055781069, DOI:          10.1126/science.aam9321,relevantClaims[1-128]US2021108267-A1            Patella et al., Biochemia et Biophysica Acta,          1861:1429-1447, (Year: 2017)						